PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Hammond, FM; Hart, T; Bushnik, T; Corrigan, JD; Sasser, H				Hammond, FM; Hart, T; Bushnik, T; Corrigan, JD; Sasser, H			Change and predictors of change in communication, cognition, and social function between 1 and 5 years after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognition; communication; function; Functional Independence Measure; memory; outcome; prediction; problem solving; social	SEVERE HEAD-INJURY; QUALITY-OF-LIFE; INDEPENDENCE MEASURE; FOLLOW-UP; SYSTEMATIC BIAS; RETURN; WORK; DISCOURSE; RECOVERY; MODERATE	Objective: To study cognitive, communication, and social changes experienced by individuals between I and 5 years after traumatic brain injury (TBI). Design: Prospective cohort. Setting and Participants: TBI Model System Database with 927 eligible subjects using a cohort with complete 1- and 5-year data (N = 292). Main Outcome Measures: Change in Functional Independence Measure(TM)-Cognitive (FIM-Cog) items from Year I to Year 5 postinjury. Results: On the FIM-Cog Total score, 26% individuals improved, 61% stayed the same, and 14% worsened by more than I point from Year I to Year 5. On the 2 FIM Communication items, 19% individuals improved, 68% stayed the same, and 13% worsened by greater than I point. On the FIM Social Interaction item, 12% individuals improved, 76% stayed the same, and 11% worsened. On the FIM Memory and Problem Solving items, 34% individuals improved, 48% stayed the same, and 19% worsened. Several variables predicted this improvement and worsening, some of which were available at the time of injury and most were those available at I year postinjury. The Memory and Problem Solving items, taken together, showed fewer participants at ceiling at Year I and more change between Year 1 and Year 5 compared to the Communication and Social Interaction items. Conclusions: Many individuals did not demonstrate meaningful change on FIM-Cog and its component items from Year I to Year 5. In particular, a high proportion of improvement was observed in Memory/Problem Solving, and worsening in Social Interaction. Demographic and functional indicators present at I year postinjury may be predictive of subsequent change.	Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, R Stuart Dickson Inst Hlth Studies, Charlotte, NC 28203 USA; Moss Rehabil Res Inst, TBI Clin Res Lab, Philadelphia, PA USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH USA	Hammond, FM (corresponding author), Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, R Stuart Dickson Inst Hlth Studies, 1100 Blythe Blvd, Charlotte, NC 28203 USA.	Flora.hammond@carolinashealthcare.org	Corrigan, John D./E-2921-2011	Bushnik, Tamara/0000-0003-3328-257X			Braakman R, 1986, Acta Neurochir Suppl (Wien), V36, P112; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2003, PROBLEMATIC SUBSTANC; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DITUNNO JF, 1995, SPINAL CORD INJURY C; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; HEATON RK, 1981, COMPREHENSIVE NORMS; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1976, LANCET, V1, P1031; Johansson U, 2001, DISABIL REHABIL, V23, P474; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; *NAT I DIS REH RES, 1998, TRAUM BRAIN INJ MOD; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; *SAS I INC, 1995, PROGR APPR COUR NOT; Smith A., 1982, SYMBOL DIGIT MODALIT; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; [US Department of Health and Human Services and US Department of Agriculture US Department of Health and Human Services and US Department of Agriculture], 1990, NUTR YOUR HLTH DIET; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WILSON BA, 1997, J REHABILITATION OUT, V1, P60	55	74	74	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2004	19	4					314	328		10.1097/00001199-200407000-00006			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	839CB	WOS:000222759800006	15263859				2021-06-18	
J	Ratzliff, ADH; Howard, AL; Santhakumar, V; Osapay, I; Soltesz, I				Ratzliff, ADH; Howard, AL; Santhakumar, V; Osapay, I; Soltesz, I			Rapid deletion of mossy cells does not result in a hyperexcitable dentate gyrus: Implications for epileptogenesis	JOURNAL OF NEUROSCIENCE			English	Article						epilepsy; mossy cell; hyperexcitability; hilar cell loss; dentate gyrus; dormant basket cell hypothesis	TEMPORAL-LOBE EPILEPSY; RECEPTOR SUBUNIT EXPRESSION; GRANULE CELLS; HIPPOCAMPAL INTERNEURONS; INHIBITORY INTERNEURONS; SYNAPTIC CONNECTIONS; MOLECULAR LAYER; IN-VIVO; RAT; NEURONS	Loss of cells from the hilus of the dentate gyrus is a major histological hallmark of human temporal lobe epilepsy. Hilar mossy cells, in particular, are thought to show dramatic numerical reductions in pathological conditions, and one prominent theory of epileptogenesis is based on the assumption that mossy cell loss directly results in granule cell hyperexcitability. However, whether it is the disappearance of hilar mossy cells from the dentate gyrus circuitry after various insults or the subsequent synaptic - cellular alterations ( e. g., reactive axonal sprouting) that lead to dentate hyperexcitability has not been rigorously tested, because of the lack of available techniques to rapidly remove specific classes of nonprincipal cells from neuronal networks. We developed a fast, cell-specific ablation technique that allowed the targeted lesioning of either mossy cells or GABAergic interneurons in horizontal as well as axial ( longitudinal) slices of the hippocampus. The results demonstrate that mossy cell deletion consistently decreased the excitability of granule cells to perforant path stimulation both within and outside of the lamella where the mossy cell ablation took place. In contrast, ablation of interneurons caused the expected increase in excitability, and control aspirations of the hilar neuropil or of interneurons in the presence of GABA receptor blockers caused no alteration in granule cell excitability. These data do not support the hypothesis that loss of mossy cells from the dentate hilus after seizures or traumatic brain injury directly results in hyperexcitability.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	isoltesz@uci.edu	Santhakumar, Vijayalakshmi/M-4192-2013; Santhakumar, Viji/K-4856-2019	Santhakumar, Viji/0000-0001-6278-4187; Ratzliff, Anna/0000-0002-6654-8007	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035915, R37NS035915, R29NS035915] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37 NS035915, NS35915, R01 NS035915, R29 NS035915] Funding Source: Medline		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; AMARAL DG, 1978, J COMP NEUROL, V182, P851, DOI 10.1002/cne.901820508; Andersen P, 2000, BRAIN RES, V886, P165, DOI 10.1016/S0006-8993(00)02991-7; Arabadzisz D, 1999, NEUROSCIENCE, V92, P27, DOI 10.1016/S0306-4522(98)00736-2; Bernard C, 1998, EPILEPSY RES, V32, P93, DOI 10.1016/S0920-1211(98)00043-6; BlascoIbanez JM, 1997, HIPPOCAMPUS, V7, P307, DOI 10.1002/(SICI)1098-1063(1997)7:3<307::AID-HIPO6>3.0.CO;2-H; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brooks-Kayal AR, 2001, J NEUROCHEM, V77, P1266, DOI 10.1046/j.1471-4159.2001.00329.x; Buckmaster PS, 1996, J COMP NEUROL, V366, P270, DOI 10.1002/(SICI)1096-9861(19960304)366:2<270::AID-CNE7>3.0.CO;2-2; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Buckmaster PS, 1999, J NEUROPHYSIOL, V81, P712; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; FROTSCHER M, 1991, J COMP NEUROL, V312, P145, DOI 10.1002/cne.903120111; GAUGAIN B, 1978, BIOCHEMISTRY-US, V17, P5078, DOI 10.1021/bi00617a002; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; Hajos N, 1997, J NEUROSCI, V17, P8427; HAUGHLAND RP, 1996, MOL PROBES HDB, P366; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; Houser C R, 1999, Adv Neurol, V79, P743; Ishizuka S, 1998, NEUROREPORT, V9, P193, DOI 10.1097/00001756-199801260-00004; Kapur GK, 2000, SLOAN MANAGE REV, V41, P6; Kotti T, 1996, EUR J NEUROSCI, V8, P2371, DOI 10.1111/j.1460-9568.1996.tb01200.x; Kraushaar U, 2000, J NEUROSCI, V20, P5594; Lechner HAE, 2002, J NEUROSCI, V22, P5287; Leranth C, 1996, NEUROSCIENCE, V70, P631, DOI 10.1016/S0306-4522(96)83003-X; Liu KS, 1999, NEURON, V23, P325, DOI 10.1016/S0896-6273(00)80783-7; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Monette R, 1998, BRAIN RES PROTOC, V2, P99, DOI 10.1016/S1385-299X(97)00020-2; PATTON PE, 1995, HIPPOCAMPUS, V5, P245, DOI 10.1002/hipo.450050402; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Ratzliff ADH, 2001, NEUROSCIENCE, V103, P337, DOI 10.1016/S0306-4522(01)00013-6; RIBAK CE, 1986, J NEUROSCI, V6, P3492; RIBAK CE, 1985, J NEUROCYTOL, V14, P835, DOI 10.1007/BF01170832; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1991, J NEUROSCI, V11, P1660; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179; Shah Eliza Mountcastle, 1993, Current Opinion in Neurobiology, V3, P738, DOI 10.1016/0959-4388(93)90146-P; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SOLTESZ I, 1993, NEUROSCIENCE, V57, P555, DOI 10.1016/0306-4522(93)90005-Z; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Toth Z, 1997, J NEUROSCI, V17, P8106; Wang X, 2003, NEUROSCIENCE, V117, P485, DOI 10.1016/S0306-4522(02)00659-0; Wenzel HJ, 1997, HIPPOCAMPUS, V7, P559; Westbrook GL, 2000, PRINCIPLES NEURAL SC, P910; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067; Zappone CA, 2001, J COMP NEUROL, V441, P324, DOI 10.1002/cne.1415	55	74	78	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 3	2004	24	9					2259	2269		10.1523/JNEUROSCI.5191-03.2004			11	Neurosciences	Neurosciences & Neurology	780PX	WOS:000189391500019	14999076	Green Published, Other Gold			2021-06-18	
J	Rismanchi, N; Floyd, CL; Berman, RF; Lyeth, BG				Rismanchi, N; Floyd, CL; Berman, RF; Lyeth, BG			Cell death and long-term maintenance of neuron-like state after differentiation of rat bone marrow stromal cells: a comparison of protocols	BRAIN RESEARCH			English	Article						differentiation; neuron; astrocyte; NeuN; GFAP; cell death	TRAUMATIC BRAIN INJURY; STEM-CELLS; IN-VITRO; THERAPEUTIC BENEFIT; CEREBRAL-ISCHEMIA; SPINAL-CORD; TRANSPLANTATION; REGENERATION; PROGENITORS; CULTURES	Recent literature suggests that bone marrow stromal cells (BMSCs) may be differentiated into neuron-like and/or glia-like cells, implying that differentiated BMSCs may have potential use in cell replacement therapy for central nervous system disorders. However, many questions remain concerning the nature of BMSCs differentiated to express CNS antigens. For example, how long after differentiation do cells express CNS markers, and do differentiation procedures alter cell viability? This study compared neuronal differentiation methods in sister cell preparations, evaluating cell death and maintenance of the CNS antigen positivity after the Deng or Woodbury methods. Rat BMSCs were harvested, passaged, differentiated, placed in growth or maintenance media, and processed for cell viability or immunocytochemistry for NeuN and GFAP post-differentiation. We report that the Woodbury differentiation protocol produced maximally 51% neuron-like cells, yet also produced significant cell death. The Deng differentiation method produced 13% neuron-like cells and without marked cell death. No significant increases in GFAP immunoreactivity (IR) were seen after differentiation by either protocol. Following both protocols, removal of cells from the maintenance media significantly decreased expression of NeuN. Thus, differentiation procedures may be substantially affected BMSC potential, and maintenance of immunoreactivity to neuronal antigens was dependent on specific, nonphysiological environmental conditions. (C) 2003 Elsevier B.V. All rights reserved.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29995, NS43085] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS043085, R01NS029995] Funding Source: NIH RePORTER		Akiyama Y, 2002, J NEUROSCI, V22, P6623; ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FRESHNEY IR, 1994, CULTURE ANIMAL CELLS, V3, P335; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MOUTON PR, 2000, STEREOLOGER HDB SYST; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.3.CO;2-#; Prockop DJ, 2000, BIOCHEM SOC T, V28, P341, DOI 10.1042/0300-5127:0280341; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Tremain N, 2001, STEM CELLS, V19, P408, DOI 10.1634/stemcells.19-5-408; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C	31	74	93	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 21	2003	991	1-2					46	55		10.1016/j.brainres.2003.07.004			10	Neurosciences	Neurosciences & Neurology	742QU	WOS:000186530200005	14575875				2021-06-18	
J	Geijerstam, JLA; Britton, M				Geijerstam, JLA; Britton, M			Mild head injury - mortality and complication rate: meta-analysis of findings in a systematic literature review	ACTA NEUROCHIRURGICA			English	Article						mild head injury; computed tomography; in-hospital observation; clinical management; meta-analysis	CRANIAL COMPUTED-TOMOGRAPHY; SIGNIFICANT INTRACRANIAL INJURY; TRAUMATIC BRAIN INJURY; NEUROLOGIC EXAMINATION; CLINICAL PREDICTORS; PEDIATRIC-PATIENTS; SKULL FRACTURE; CT-SCANS; MANAGEMENT; CHILDREN	Background. Whether the strategy for care of mild head injury should be in-hospital observation or computed tomography (CT) investigation and home care has been discussed lately. A necessary requirement for guidelines and the design of clinical trials would be knowledge about the risks of the condition. These have not been reliably summarised. The study aims to estimate as accurately as possible the mortality, the complication rates, and the frequency of pathological findings on CT in patients with mild head injury. Methods. Mild head injury was defined as head trauma involving loss of consciousness or amnesia, but where neurological findings on arrival at hospital are normal (GCS 15). Large databases were searched to find relevant scientific literature, and the retrieved studies were critically appraised. Findings were used from all representative patient data sets that met predefined standards for minimum quality. Meta-analysis using the random-effects model was performed on the data collected. Findings. The search yielded 24 studies on 24249 patients fulfilling the requirements. The mean mortality of patients was low, 0.1% (Cl 0.05-0.15). Complications, mostly requiring surgery, occurred in 0.9% (Cl 0.6-1.2) of the cases. In approximately 8% (Cl 6.1-9.5), pathological CT findings, dominated by haemorrhages, were identified in the acute phase. Conclusions. Of 1000 patients arriving at hospital with mild head injury, 1 will die, 9 will require surgery or other intervention, and about 80 will show pathological findings on CT. At least these 8% of patients will probably need in-hospital care.	Karolinska Hosp, Dept Med N4 01, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden; SBU, Swedish Council Technol Assessment Hlth Care, Stockholm, Sweden	Geijerstam, JLA (corresponding author), Karolinska Hosp, Dept Med N4 01, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden.						Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; af Geijerstam JL, 2000, EUR J SURG, V166, P526; AFGEIJERSTAM JL, 2003, IN PRESS EMERG MED J; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Ingebrigtsen T., 1995, Tidsskrift for den Norske Laegeforening, V115, P1601; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MIKHAIL MG, 1992, AM J EMERG MED, V10, P24, DOI 10.1016/0735-6757(92)90119-I; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; PELOSO LC, 2003, BRAIN INJ S, V17, P29; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V51, P526, DOI 10.1136/jnnp.51.4.526; SERVADEI F, 1993, SURG NEUROL, V39, P269, DOI 10.1016/0090-3019(93)90003-J; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STIELL IG, 2001, ACAD EMERG MED, V8, P455; STIELL IG, 2001, ACAD EMERG MED, V8, P453; *SWED COUNC TECHN, 2001, MILD HEAD INJ IN HOS; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Vilke GM, 2000, AM J EMERG MED, V18, P159, DOI 10.1016/S0735-6757(00)90009-3; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026	60	74	75	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	OCT	2003	145	10					843	850		10.1007/s00701-003-0115-1			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	739AW	WOS:000186320900001	14577005				2021-06-18	
J	Ewing-Cobbs, L; Barnes, MA; Fletcher, JM				Ewing-Cobbs, L; Barnes, MA; Fletcher, JM			Early brain injury in children: Development and reorganization of cognitive function	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Conference on Biological and Social Determinants of Child Development	JAN 18-21, 2000	HOUSTON, TX				CLOSED-HEAD-INJURY; EARLY-ONSET HYDROCEPHALUS; DEVELOPING AGE PEERS; YOUNG-CHILDREN; SPINA-BIFIDA; COMPREHENSION SKILL; NARRATIVE DISCOURSE; SPEECH ACTS; FOLLOW-UP; ADOLESCENTS	Children who sustain congenital or acquired brain injury typically experience a diffuse insult that impacts many areas of the brain. Yet research has only recently begun to examine the development of these children, who often provide excellent examples of the presence or absence of neural plasticity. Development and recovery after such injuries reflects both restoration and reorganization of cognitive functions. To understand these processes, research should focus on questions and assessment paradigms oriented toward the acquisition (rather than the recovery) of cognitive functions. Outcomes may appear similar across types of insults, even when the sources of difficulties and their neural correlates are different. Comparisons of outcomes involving intellectual functions, memory and learning, reading, and language/discourse in children who sustain congenital injury (spina bifida meningomyelocele) and acquired injury (traumatic brain injury) illustrate these principles and the value of research on diffuse brain injury in children.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,UCT 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu	fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 27957] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 21889, R01 NS 29462, R01 NS046308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462, R01NS046308, R01NS021889] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Aram DM, 1999, CHANGING NERVOUS SYSTEM, P254; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BACKMAN J, 1999, J INT NEUROPSYCHOLOG, V5; BARKOVICH AJ, 1995, PEDIAT NEUROIMAGING; Barnes MA, 1996, READING COMPREHENSION DIFFICULTIES, P251; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnes MA, 1998, BRAIN LANG, V61, P309, DOI 10.1006/brln.1998.1843; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Barnes MA, 2001, BRAIN LANG, V76, P35, DOI 10.1006/brln.2000.2389; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BARNES MA, 2002, UNPUB READING WRITIN; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Brewer VR, 2001, NEUROPSYCHOLOGY, V15, P185, DOI 10.1037//0894-4105.15.2.185; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Brookshire BL, 1995, CHILD NEUROPSYCHOL, V1, P106, DOI 10.1080/09297049508402242; BROOKSHIRE BL, 1995, J PEDIATR PSYCHOL, V20, P785, DOI 10.1093/jpepsy/20.6.785; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; Cain K, 2001, MEM COGNITION, V29, P850, DOI 10.3758/BF03196414; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Delis D, 1994, CALIFORNIA VERBAL LE; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1994, BRAIN LANG, V46, P129, DOI 10.1006/brln.1994.1008; DENNIS M, 1981, ARCH NEUROL-CHICAGO, V38, P607, DOI 10.1001/archneur.1981.00510100035004; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P723, DOI 10.1080/01688638708405213; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; DENNIS M, 1993, J PEDIATR PSYCHOL, V18, P639, DOI 10.1093/jpepsy/18.5.639; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P593, DOI 10.1080/01688638708410771; DENNIS M, 1990, DISCOURSE ABILITY BR, P1969; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DONDERS J, 1992, J CHILD NEUROL, V7, P375, DOI 10.1177/088307389200700408; DONDERS J, 1993, CLIN NEUROPSYCHOL, V7, P430, DOI 10.1080/13854049308401533; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, IN PRESS DEV NEUROPS; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1992, ARCH NEUROL-CHICAGO, V49, P818, DOI 10.1001/archneur.1992.00530320042010; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; Fletcher JM, 1996, ARCH NEUROL-CHICAGO, V53, P549, DOI 10.1001/archneur.1996.00550060093022; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P53, DOI 10.1080/87565649609540640; FLETCHER JM, 1994, ATYPICAL COGNITIVE D, P297; FLETCHER JM, 1995, J PEDIATR PSYCHOL, V20, P765; FLETCHER JM, 1995, SYNDROME NONVERBAL L, P206; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GOLDMANRAKIC PS, 1994, ATYPICAL COGNITIVE D, P3; Halliday Michael A. K., 1976, COHESION ENGLISH; HALLIWELL MD, 1980, Z KINDERCHIR, V31, P375; HAMM RJ, 2000, CEREBRAL REORGANIZAT, P46; Hannay HJ, 1999, CHANGING NERVOUS SYSTEM, P149; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HOLMBECK GN, 1995, J PEDIATR PSYCHOL, V20, P817, DOI 10.1093/jpepsy/20.6.817; Holmbeck GN, 1997, J PEDIATR PSYCHOL, V22, P167; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Kintsch W., 1974, REPRESENTATION MEANI; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LANDRY SH, 2001, J INT NEUROPSYCH SOC, V7, P246; LENNEBERG EH, 1967, BIOL FORMULATIONS LA; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MCCULLOUGH D, 1990, HYDROCEPHALUS, P180; MCDONOUGH SC, 1988, EARLY IDENTIFICATION, P318; MORROW JD, 1992, DEV MED CHILD NEUROL, V34, P488; MURDOCH BE, 1990, ACQUIRED NEUROLOGICA, P216; NORMAN MC, 1995, CONGENITAL MALFORMAT; PARSONS JG, 1969, DEV MED CHILD NEUROL, VS, P75; PENNINGTON BF, 1994, MAC FDN MEN, P243; Povlishock J T, 2000, Clin Neurosurg, V46, P113; REIGEL DH, 1994, PEDIAT NEUROSURGERY, P51; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SATZ P, 1981, ACQUIRED APHASIA, P399; Scott MA, 1998, NEUROPSYCHOLOGY, V12, P578, DOI 10.1037/0894-4105.12.4.578; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SOARE PL, 1977, AM J DIS CHILD, V131, P199, DOI 10.1001/archpedi.1977.02120150081017; St James-Roberts I, 1979, Adv Child Dev Behav, V14, P253, DOI 10.1016/S0065-2407(08)60116-0; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; WAGNER RK, 1994, DEV PSYCHOL, V30, P73, DOI 10.1037/0012-1649.30.1.73; Wechsler D., 1974, MANUAL WECHSLER INTE; WILLS KE, 1993, J CLIN CHILD PSYCHOL, V22, P247, DOI 10.1207/s15374424jccp2202_11; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WOLF LS, 1992, PEDIAT PHYSICAL THER, P12; Wolf M, 1999, J EDUC PSYCHOL, V91, P415, DOI 10.1037/0022-0663.91.3.415; WOODS BT, 1978, ANN NEUROL, V3, P273, DOI 10.1002/ana.410030315; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YEATES KO, 1995, J PEDIATR PSYCHOL, V20, P801, DOI 10.1093/jpepsy/20.6.801	116	74	77	0	27	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2003	24	2-3					669	704		10.1207/S15326942DN242&3_08			36	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	738LF	WOS:000186288600008	14561566				2021-06-18	
J	Townend, WJ; Guy, MJ; Pani, MA; Martin, B; Yates, DW				Townend, WJ; Guy, MJ; Pani, MA; Martin, B; Yates, DW			Head injury outcome prediction in the emergency department: a role for protein S-100B?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; RANDOMIZED CONTROLLED TRIAL; ROUTINE FOLLOW-UP; COMPUTED-TOMOGRAPHY; SERUM; SCALE; DAMAGE; SURGERY; MARKERS; EPIDEMIOLOGY	Background: Biochemical markers released after head injury may reflect the degree of brain damage, which is related to subsequent disability. If the serum level of a marker were found to be related to outcome, then earlier identification and intervention would be possible. Objective: To investigate the potential of the serum marker S-100B protein to predict the outcome after head injury. Methods: Blood samples for S-100B concentrations were taken from 148 adults within six hours of a head injury (initial Glasgow coma score 4-15). Patients were recruited from the emergency departments of four hospitals in Greater Manchester, United Kingdom. Outcome was assessed in 119 patients (80%) at one month using the extended Glasgow outcome scale (GOSE). Results: A significant inverse correlation between serum S-100B level and GOSE was found (Spearman's p = -0.349, p < 0.0001). A serum S-100B concentration of > 0.32 mug/l predicted severe disability (GOSE < 5) at one month with a sensitivity of 93% (95% confidence interval 68% to 100%), a specificity of 72% (54% to 79%), and a negative predictive value of 99% (93% to 100%). Conclusion: Serum S-100B concentration can be used in the emergency department to identify patients with head injury who are most likely to have a poor outcome at one month.	Univ Manchester, Hope Hosp, Emergency Dept, Salford M6 8HD, Lancs, England; Univ Manchester, Hope Hosp, Dept Biochem, Salford M6 8HD, Lancs, England; Univ Hosp, Dept Internal Med, Frankfurt, Germany	Townend, WJ (corresponding author), Univ Manchester, Hope Hosp, Emergency Dept, Salford M6 8HD, Lancs, England.						ALTMAN DG, 2000, STAT CONFIDENCE, P110; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hodgkinson D W, 1994, Eur J Emerg Med, V1, P9, DOI 10.1097/00063110-199403000-00003; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; *ROY COLL SURG, 1999, REP WORK PART MAN PA; Sapsed-Byrne S, 1997, PERFUSION-UK, V12, P167, DOI 10.1177/026765919701200304; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; USUI A, 1989, CLIN CHEM, V35, P1942; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	30	74	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2002	73	5					542	546		10.1136/jnnp.73.5.542			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	612UK	WOS:000179093700017	12397148	Green Published, Bronze			2021-06-18	
J	Hadley, M				Hadley, M			Blood pressure management after acute spinal cord injury	NEUROSURGERY			English	Article							POST-TRAUMATIC ISCHEMIA; BRAIN; FLOW		Univ Alabama, Div Neurol Surg, Birmingham, AL 35294 USA	Hadley, M (corresponding author), Univ Alabama, Div Neurol Surg, 516 Med Educ Bldg,1813 6th Ave S, Birmingham, AL 35294 USA.						Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DOLAN EJ, 1982, J NEUROSURG, V56, P350, DOI 10.3171/jns.1982.56.3.0350; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; FLOHR H, 1971, BRAIN BLOOD FLOW, P406; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; KINDT GW, 1971, BRAIN BLOOD FLOW, P401; King BS, 2000, SURG CLIN N AM, V80, P855, DOI 10.1016/S0039-6109(05)70100-6; Kobrine A I, 1975, Clin Neurosurg, V22, P573; KOBRINE AI, 1976, J NEUROSURG, V44, P12, DOI 10.3171/jns.1976.44.1.0012; LEDSOME JR, 1981, AM REV RESPIR DIS, V124, P41; LEHMANN KG, 1987, J AM COLL CARDIOL, V10, P46, DOI 10.1016/S0735-1097(87)80158-4; LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; Piepmeier J M, 1985, Cent Nerv Syst Trauma, V2, P153; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; Tator C H, 1984, J Neurosurg Sci, V28, P115; Tator C H, 1996, J Spinal Cord Med, V19, P206; TATOR CH, 1992, J NEUROTRAUM, V9, P139, DOI 10.1089/neu.1992.9.139; TATOR CH, 1984, CAN J SURG, V27, P289; TATOR CH, 1994, NEUROBIOLOGY CENTRAL, P209; Turnbull I M, 1973, Clin Neurosurg, V20, P56; TURNBULL IM, 1971, J NEUROSURG, V35, P141, DOI 10.3171/jns.1971.35.2.0141; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; WALLACE MC, 1987, NEUROSURGERY, V20, P710; WOLF A, 1991, J NEUROSURG, V75, P883, DOI 10.3171/jns.1991.75.6.0883; Zach G A, 1976, Paraplegia, V14, P58	29	74	80	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAR	2002	50	3		S			S58	S62					5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	527VU	WOS:000174209300020					2021-06-18	
J	Benson, BW; Rose, MS; Meeuwisse, WH				Benson, BW; Rose, MS; Meeuwisse, WH			The impact of face shield use on concussions in ice hockey: a multivariate analysis	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; HEAD; SPORT; MANAGEMENT; PLAYERS; NECK	Objective: To identify specific risk factors for concussion severity among ice hockey players wearing full face shields compared with half face shields (visors). Methods: A prospective cohort study was conducted during one varsity hockey season (1997-1998) with 642 male ice hockey players (median age 22 years) from 22 teams participating in the Canadian Inter-University Athletics Union. Half of the teams wore full face shields, and half wore half shields (visors) for every practice and game throughout the season. Team therapists and doctors recorded on structured forms daily injury, participation, and information on face shield use for each athlete. The main outcome measure was any traumatic brain injury requiring assessment or treatment by a team therapist or doctor, categorised by time lost from subsequent participation and compared by type of face shield worn. Results: Players who wore half face shields missed significantly more practices and games per concussion (2.4 times) than players who wore full face shields (4.07 sessions (95% confidence interval (CI) 3,48 to 4.74) v 1.71 sessions (95% Cl 1.32 to 2.18) respectively). Significantly more playing time was lost by players wearing half shields during practices and games, and did not depend on whether the athletes were forwards or defence, rookies or veterans, or whether the concussions were new or recurrent. In addition, players who wore half face shields and no mouthguards at the time of concussion missed significantly more playing time (5.57 sessions per concussion; 95% Cl 4.40 to 6.95) than players who wore half shields and mouthguards (2.76 sessions per concussion; 95% Cl 2.14 to 3.55). Players who wore full face shields and mouthguards at the time of concussion lost no playing time compared with 1.80 sessions lost per concussion (95% Cl 1.38 to 2.34) for players wearing full face shields and no mouthguards. Conclusions: The use of a full face shield compared with half face shield by intercollegiate ice hockey players significantly reduced the playing time lost because of concussion, suggesting that concussion severity may be reduced by the use of a full face shield.	Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB T2N 1N4, Canada	Benson, BW (corresponding author), Univ Calgary, Sport Med Ctr, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.						Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; BISHOP PJ, 1979, PHYSICIAN SPORTSMED, V7, P97; Brukner P, 1996, Aust Fam Physician, V25, P1445; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; CANTU RC, 1991, ADOLESC MED, V2, P141; CASTALDI CR, 1993, SAFETY ICE HOCKEY, P164; CLARKE J, 1994, HEAD NECK INJURIES S, P3; Dixon J. L., 1989, SAFETY ICE HOCKEY, P207; GOODWINGERBERIC.S, 1987, CHILD NERV SYST, V3, P59; Hennekens CH, 1987, EPIDEMIOLOGY MED; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; MASTRANGELO FA, 1989, SAFETY ICE HOCKEY, P52; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Parayre R., 1989, SAFETY ICE HOCKEY, P37; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; Tellier A, 1999, BRAIN INJURY, V13, P463; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; 1997, MMWR MORB MORTAL WKL, V46, P224	29	74	75	1	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	FEB	2002	36	1					27	32		10.1136/bjsm.36.1.27			6	Sport Sciences	Sport Sciences	521YU	WOS:000173869600011	11867489	Bronze, Green Published			2021-06-18	
J	Sherer, M; Novack, TA; Sander, AM; Struchen, MA; Alderson, A; Thompson, RN				Sherer, M; Novack, TA; Sander, AM; Struchen, MA; Alderson, A; Thompson, RN			Neuropsychological assessment and employment outcome after traumatic brain injury: A review	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; REHABILITATION; PREDICTION; VARIABLES; RETURN; TESTS	While there may be many reasons for obtaining neuropsychological assessment after traumatic brain injury (TBI), prediction of real world functioning is generally a key goal. The present paper reviews 23 studies concerning the relationship between neuropsychological test results and employment outcome after TBI. The review was conducted in accordance with guidelines developed by the Committee on Empirically Supported Practice of Division 40 (Neuropsychology) of the American Psychological Association. Results of the review support a Category A (strongly supported) recommendation for the use of early neuropsychological assessment to predict late employment outcome. Studies of late neuropsychological assessment and subsequent employment outcome and studies of concurrent neuropsychological assessment and employment outcome were inconclusive regarding either support or contraindication for neuropsychological assessment to predict employment outcome. Almost all studies conducted at these late or concurrent time points had significant limitations with regard to study type or adequacy of methodology. However, there is no conceptual basis for believing that neuropsychological findings obtained closer in time to assessment of employment outcome should be less predictive of this outcome than neuropsychological findings obtained at an earlier time.	Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Alabama Birmingham, Spain Rehabil Ctr, Birmingham, AL USA; Baylor Coll Med, Inst Rehabil & Res, Houston, TX 77030 USA; Shepard Ctr, Atlanta, GA USA	Sherer, M (corresponding author), ABPP Cn, Neuopsychol, Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980035, H133A980010, H133A970015] Funding Source: Medline		BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Hanlon RE, 1999, BRAIN INJURY, V13, P873; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HEATON RK, 2002, NEWSLETTER, V40, P36; Horn L.J., 1999, PHYSICAL MED REHABIL, P1281; Isaki E, 2000, BRAIN INJURY, V14, P441; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Long CJ., 1996, ECOLOGICAL VALIDITY; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MELAMED S, 1985, SCAND J REHABIL MED, P21; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHERER M, IN PRESS DEMONSTRATI; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	36	74	74	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2002	16	2					157	178		10.1076/clin.16.2.157.13238			22	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	588KH	WOS:000177700300005	12221479				2021-06-18	
J	Cruz, J; Minoja, G; Okuchi, K				Cruz, J; Minoja, G; Okuchi, K			Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: A randomized trial	NEUROSURGERY			English	Article						acute subdural hematoma; arteriojugular lactate difference; cerebral extraction of oxygen; head injury; intracranial pressure; mannitol	CEREBRAL BLOOD-FLOW; ACUTE BRAIN INJURY; ACUTE HEAD-INJURY; COMATOSE PATIENTS; INTRACRANIAL HYPERTENSION; OXYGEN-CONSUMPTION; ACUTE ANEMIA; METABOLISM; HYPERVENTILATION; HYPEREMIA	OBJECTIVE: To evaluate clinical outcomes and postoperative physiological findings for comatose patients with acute subdural hematomas who received preoperative high-dose mannitol (HDM) versus conventional-dose mannitol treatment. METHODS: One hundred seventy-eight adult patients with non-missile, traumatic, acute, subdural hematomas were prospectively and randomly assigned to receive emergency, preoperative, intravenous HDM treatment (91 patients), compared with a control group treated with a lower preoperative mannitol dose (87 patients). RESULTS: Preoperative improvement of abnormal pupillary widening was significantly more frequent in the study group than in the control group of patients (P < 0.0001). Preoperative HDM treatment was also associated with significantly better clinical outcomes at 6-month follow-up evaluations (P < 0.01). Postoperative physiological findings revealed statistically significant between-group differences, with higher intracranial pressure and lower cerebral extraction of oxygen (relative cerebral hyperperfusion) in the control group, compared with the HDM group. Postoperative global brain ischemia (abnormally low arteriojugular lactate difference values) was rare and was detected in 2.2 and 3.4% of the patients in the study and control groups, respectively. CONCLUSION: Emergency preoperative HDM administration was associated with improved clinical outcomes for patients with acute subdural hematomas. Preoperative improvement of abnormal pupillary widening and better postoperative control of intracranial hypertension and associated relative cerebral hyperperfusion seemed to be relevant factors associated with improved outcomes.	CICNEM, Comprehens Int Ctr Neuroemergencies, BR-04093970 Sao Paulo, SP, Brazil; Univ Sao Paulo, BR-05508 Sao Paulo, Brazil; Univ Insubria, Dept Anesthesiol & Crit Care Med, Varese, Italy; Nara Med Univ, Dept Emergency & Crit Care Med, Nara, Japan	Cruz, J (corresponding author), CICNEM, Comprehens Int Ctr Neuroemergencies, POB Cx Postal 57011, BR-04093970 Sao Paulo, SP, Brazil.						Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1994, J NEUROSURG, V80, P143, DOI 10.3171/jns.1994.80.1.0143; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1998, NEUROLOGIC NEUROSURG, P405; FINNERTY FA, 1954, J CLIN INVEST, V33, P1227, DOI 10.1172/JCI102997; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LANGFITT TW, 1968, JOHNS HOPKINS MED J, V122, P261; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TEASDALE G, 1974, LANCET, V2, P81	25	74	74	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	OCT	2001	49	4					864	871					8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	477JD	WOS:000171279600023	11564247				2021-06-18	
J	Dora, C; Leunig, M; Beck, M; Rothenfluh, D; Ganz, R				Dora, C; Leunig, M; Beck, M; Rothenfluh, D; Ganz, R			Entry point soft tissue damage in antegrade femoral nailing: A cadaver study	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						femoral nailing; soft tissue damage; medial femoral circumflex artery	AVASCULAR NECROSIS; SHAFT FRACTURES; HEAD; FEMUR; ADOLESCENT; STRENGTH	Introduction: Little attention is paid to insertion site morbidity associated with antegrade femoral nailing. However, residual peritrochanteric pain after nailing is not uncommon. Additionally, the end branches of the medial femoral circumflex artery (m.f.c.a.) supplying the femoral head are in close proximity to the insertion site of the nail, and the occurrence of avascular necrosis of the femoral epiphysis after nailing in adolescents is rather frequent. Objective: The aim of this study was to assess iatrogenic soft tissue injuries at the site of nail insertion. Materials and Methods: Nailing with a reamed AO universal femoral nail was performed on sixteen adult cadavers followed by dissection of the proximal part of the femur to assess possible damage to the soft tissues. Three entry portals were defined. (A) entry portal lateral to the junction of the neck and the greater trochanter; (B) entry portal at the base of the greater trochanter anterior to a line along the longitudinal axis of the femoral neck; and (C) entry portal at the base of the greater trochanter posterior to a line along the axis of the femoral neck (at the piriformis fossa). Results: In Group A, partial avulsion of the piriformis and the obturator internus tendon were present in four and in one of five specimens, respectively. Group B showed injuries to the piriformis tendon in two and to the gluteus minimus tendon in one of four cases. In Group C, partial avulsion of the piriformis, obturator internus, and obturator externus tendon were encountered in five, six, and two of seven specimens, respectively. Anterior branches of the ramus profundus of the m.f.c.a. within the synovial fold were damaged in all of these cases. Conclusion: To select the best nail entry portal, the ease of nail insertion must be weighed against the resulting soft tissue damage at the site of insertion. The nail entry portal at the piriformis fossa, although geometrically ideal and most recommended, causes the most significant damage to muscle and tendons as well as to the blood supply to the femoral head. Therefore, even if reported only once, the occurrence of avascular necrosis of the femoral head after nailing in adults is a possible complication of this nail entry portal. The authors therefore prefer to avoid this entry portal in every case. The nail entry portal anterior to the longitudinal axis of the femoral neck, as in group B, although better with respect to the soft tissue damage, has the worst geometric and biomechanical disadvantages. The results of the current study favor the nail entry portal lateral at the greater trochanter as in Group A, which is equal to the entry portal B with respect to the soft tissue damage but allows introduction of the nail into the medullar cavity without difficulties.	Univ Zurich, Balgrist Hosp, Dept Orthopaed Surg, CH-8008 Zurich, Switzerland; Univ Bern, Inselspital, Dept Orthopaed Surg, CH-3010 Bern, Switzerland	Dora, C (corresponding author), Univ Zurich, Dept Orthopaed, Balgrist,Forchstr 340, CH-8008 Zurich, Switzerland.		Leunig, Michael/E-7951-2017	Leunig, Michael/0000-0002-2036-5416; Beck, Martin/0000-0003-0697-946X			ASTION DJ, 1995, J BONE JOINT SURG AM, V77A, P1092, DOI 10.2106/00004623-199507000-00018; Bain GI, 1997, J ORTHOP TRAUMA, V11, P93, DOI 10.1097/00005131-199702000-00004; BEATY JH, 1994, J PEDIATR ORTHOPED, V14, P178, DOI 10.1097/01241398-199403000-00009; BEDNAR DA, 1993, CAN J SURG, V36, P464; Bonnevialle P, 1999, REV CHIR ORTHOP, V85, P397; BROWNER BD, 1986, CLIN ORTHOP RELAT R, P192; BRUMBACK RJ, 1990, J BONE JOINT SURG AM, V72A, P1067, DOI 10.2106/00004623-199072070-00017; BUCHOLZ RW, 1991, J BONE JOINT SURG AM, V73A, P1561, DOI 10.2106/00004623-199173100-00015; CHUNG SMK, 1976, J BONE JOINT SURG AM, V58, P961, DOI 10.2106/00004623-197658070-00011; DANCKWARDTLILLIESTROM G, 1976, ACTA ORTHOP SCAND, V47, P101, DOI 10.3109/17453677608998980; Dodenhoff RM, 1997, J BONE JOINT SURG BR, V79B, P738, DOI 10.1302/0301-620X.79B5.7345; Gautier E, 2000, J BONE JOINT SURG BR, V82B, P679, DOI 10.1302/0301-620X.82B5.10426; HARPER MC, 1987, CLIN ORTHOP RELAT R, P155; Hernigou P, 1995, REV CHIR ORTHOP, V81, P622; JACOBS LGH, 1989, J BONE JOINT SURG AM, V71A, P1239, DOI 10.2106/00004623-198971080-00018; JOHNSON KD, 1987, J ORTHOP TRAUMA, V14, P1; KAWEBLUM M, 1993, CLIN ORTHOP RELAT R, P193; KEMPF I, 1985, J BONE JOINT SURG AM, V67A, P709, DOI 10.2106/00004623-198567050-00005; LINHART W, 1984, Z ORTHOP GRENZGEB, V122, P766, DOI 10.1055/s-2008-1045064; MARKS PH, 1988, J TRAUMA, V28, P1207, DOI 10.1097/00005373-198808000-00012; MILESKI RA, 1995, J PEDIATR ORTHOPED, V15, P24, DOI 10.1097/01241398-199501000-00006; MILLER SD, 1993, J BONE JOINT SURG BR, V75, P202; Muller M, 1991, MANUAL INTERNAL FIXA, VThird; NICHOLS PJR, 1963, J BONE JOINT SURG BR, V45, P96; OMALLEY DE, 1995, J PEDIATR ORTHOPED, V15, P21, DOI 10.1097/01241398-199501000-00005; Orler R, 1998, UNFALLCHIRURG, V101, P495, DOI 10.1007/s001130050301; ROSS PM, 1980, CLIN ORTHOP RELAT R, P131; SEVITT S, 1965, J Bone Joint Surg Br, V47, P560; SIMONIAN PT, 1994, J BONE JOINT SURG BR, V76B, P293; THOMETZ JG, 1995, J BONE JOINT SURG AM, V77, P1423, DOI 10.2106/00004623-199509000-00019; TRUETA J, 1957, J BONE JOINT SURG BR, V39, P358; Wolinsky PR, 1999, J TRAUMA, V46, P392, DOI 10.1097/00005373-199903000-00007; Yang KH, 1998, J BONE JOINT SURG BR, V80B, P673, DOI 10.1302/0301-620X.80B4.8406	33	74	81	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	SEP-OCT	2001	15	7					488	493		10.1097/00005131-200109000-00005			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	484YF	WOS:000171716600005	11602831				2021-06-18	
J	Bogner, JA; Corrigan, JD; Mysiw, WJ; Clinchot, D; Fugate, L				Bogner, JA; Corrigan, JD; Mysiw, WJ; Clinchot, D; Fugate, L			A comparison of substance abuse and violence in the prediction of long-term rehabilitation outcomes after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; substance abuse; violence	COMMUNITY INTEGRATION QUESTIONNAIRE; HEAD-INJURY; EMPLOYMENT; RETURN; WORK; ALCOHOL	Objective: To determine the relative contributions of substance abuse history and violent etiology to the prediction of outcomes for individuals who sustained a traumatic brain injury (TBI) requiring inpatient rehabilitation. Design: Longitudinal study of outcomes 1 year postdischarge from rehabilitation. Setting: Specialized TBI acute rehabilitation unit. Participants: Three hundred fifty-one individuals consecutively admitted for rehabilitation. Interventions: Gathered data from patients' medical records (including etiology of injury, initial Glasgow Coma Scale scores, and FIM(TM) instrument scores at discharge), demographic details, and history of substance abuse; phone and mail survey data from individuals (Satisfaction with Life Scale [SWLS]; Community Integration Questionnaire [CIQ]). Main Outcome Measures: CIQ and SWLS; relative contributions of injury etiology, demographic and injury-related dependent variables, and substance abuse history to predictive model. Results: Almost 80% of persons with injuries from violence-related causes had a history of substance abuse. Substance abuse was found to contribute to the prediction of life satisfacton and productivity, while violent etiology was not a significant contributor to predictive models. Conclusion: Substance abuse history proved to be a strong predictor of long-term outcomes, while violent etiology of injury was less influential. The results of this study emphasize the need to include substance abuse history in all studies of outcomes after TBI, and to increase prevention efforts to limit the effects of such a history.	Ohio State Univ, Dept Phys Med & Rehabil, Ohio Reg Traumat Brain Injury Model Syst, Columbus, OH USA	Bogner, JA (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.	bogner.1@osu.edu	Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Clinchot, Daniel/0000-0002-2810-7227			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P8; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; Drubach D A, 1993, Md Med J, V42, P989; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HOFFMANN NG, 1993, PSYCHIAT CLIN N AM, V16, P127; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET, V1, P480; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; MCCRADY BS, 1986, ALCOHOL CLIN EXP RES, V10, P145, DOI 10.1111/j.1530-0277.1986.tb05061.x; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHUCKIT MA, 1986, AM J PSYCHIAT, V143, P140; Sherer M, 1999, BRAIN INJURY, V13, P973; Substance Abuse and Mental Health Services Administration, 1999, SUMM FIND 1998 NAT H; *SUNY BUFF, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; TELLIER A, 1990, J CONSULT CLIN PSYCH, V58, P531; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	39	74	74	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2001	82	5					571	577		10.1053/apmr.2001.22340			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	429RR	WOS:000168531200001	11346830				2021-06-18	
J	Banaclocha, MM				Banaclocha, MM			Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases	MEDICAL HYPOTHESES			English	Article							ALPHA-INDUCED APOPTOSIS; TRAUMATIC BRAIN INJURY; COMPLEX I DEFICIENCY; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; FRIEDREICHS-ATAXIA; CYTOCHROME-C; CELL-DEATH; OXIDATIVE-PHOSPHORYLATION	Increasing lines of evidence suggest a key role for mitochondrial damage in neurodegenerative diseases. Brain aging, Parkinson's disease, Alzheimer's disease, Huntington's disease and Friedreich's ataxia have been associated with several mitochondrial alterations including impaired oxidative phosphorylation. Mitochondrial impairment can decrease cellular bioenergetic capacity, which will then increase the generation of reactive oxygen species resulting in oxidative damage and programmed cell death. This paper reviews the mechanisms of N-acetylcysteine action at the cellular level, and the possible usefulness of this antioxidant for the treatment of age-associated neurodegenerative diseases. First, this thiol can act as a precursor for glutathione synthesis as well as a stimulator of the cytosolic enzymes involved in glutathione regeneration. Second, N-acetylcysteine can act by direct reaction between its reducing thiol group and reactive oxygen species. Third, it has been shown that N-acetylcysteine can prevent programmed cell death in cultured neuronal cells. And finally, N-acetylcysteine also increases mitochondrial complex I and IV specific activities both in vitro and in vivo in synaptic mitochondrial preparations from aged mice. In view of the above, and because of the ease of its administration and lack of toxicity in humans, the potential usefulness of N-acetylcysteine in the treatment of age-associated mitochondrial neurodegenerative diseases deserves investigation. (C) 2001 Harcourt Publishers Ltd.	Hosp La Paz, Dept Pathol, Madrid, Spain	Banaclocha, MM (corresponding author), Urb San Blas 31, Valencia, Spain.	marbanacl@latinmail.com	Martinez-Banaclocha, Marcos/AAG-5626-2020	Martinez-Banaclocha, Marcos/0000-0003-2639-7205			ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Banaclocha MM, 1999, BRAIN RES, V842, P249, DOI 10.1016/S0006-8993(99)01819-3; Banaclocha MM, 2000, BRAIN RES, V859, P173, DOI 10.1016/S0006-8993(00)02005-9; Banaclocha MM, 1997, BRAIN RES, V762, P256, DOI 10.1016/S0006-8993(97)00493-9; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; BENECKE R, 1992, ANN NEUROL, V32, P683, DOI 10.1002/ana.410320512; BLANCHARD BJ, 1993, NEUROREPORT, V4, P799, DOI 10.1097/00001756-199306000-00051; BORGSTROM L, 1986, EUR J CLIN PHARMACOL, V31, P217, DOI 10.1007/BF00606662; BORLONGAN CV, 1995, BRAIN RES, V697, P254, DOI 10.1016/0006-8993(95)00901-2; BRENNAN WA, 1985, J NEUROCHEM, V44, P1948, DOI 10.1111/j.1471-4159.1985.tb07192.x; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; Brown ASC, 1999, GREEN CHEM, V1, P17, DOI 10.1039/a807963c; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; DECARO L, 1989, ARZNEIMITTEL-FORSCH, V39-1, P382; DEFLORA S, 1991, AM J MED, V91, pS122, DOI 10.1016/0002-9343(91)90295-9; DONNELLY PJ, 1994, ARCH TOXICOL, V68, P110, DOI 10.1007/s002040050043; DUGAN LL, 1995, J NEUROSCI, V15, P6377; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FERRARI G, 1995, J NEUROSCI, V15, P2857; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Hanna MG, 1997, CURR OPIN NEUROL, V10, P351, DOI 10.1097/00019052-199708000-00012; HARMAN D, 1984, AGE, V7, P111, DOI 10.1007/BF02431866; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HAUGAARD N, 1969, BIOCHIM BIOPHYS ACTA, V172, P198, DOI 10.1016/0005-2728(69)90063-2; Helveston W, 1996, CLIN NEUROPHARMACOL, V19, P271, DOI 10.1097/00002826-199619030-00010; HOLDINESS MR, 1991, CLIN PHARMACOKINET, V20, P123, DOI 10.2165/00003088-199120020-00004; Hurd RW, 1996, NEUROLOGY, V47, P1264, DOI 10.1212/WNL.47.5.1264; HUSTLER VT, 1999, CELL DEATH DIFFER, V6, P342; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W; JONES DP, 1995, METHOD ENZYMOL, V252, P3; Kaplan J, 1999, P NATL ACAD SCI USA, V96, P10948, DOI 10.1073/pnas.96.20.10948; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; LARSSON A, 1983, FUNCTION GLUTATHIONE; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin KT, 1997, BIOCHEM BIOPH RES CO, V230, P115, DOI 10.1006/bbrc.1996.5897; Malorni W, 1998, AIDS RES HUM RETROV, V14, P1589, DOI 10.1089/aid.1998.14.1589; MANN VM, 1990, LANCET, V336, P749, DOI 10.1016/0140-6736(90)92242-A; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Martinez M, 2000, BRAIN RES, V855, P100, DOI 10.1016/S0006-8993(99)02349-5; MARTINEZ M, 1994, NEUROSCI LETT, V170, P121, DOI 10.1016/0304-3940(94)90254-2; Martinez M, 1999, LIFE SCI, V64, P1253, DOI 10.1016/S0024-3205(98)00472-X; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; Melkova Z, 1997, FEBS LETT, V403, P273, DOI 10.1016/S0014-5793(97)00065-3; MIQUEL J, 1995, EUR J PHARM-ENVIRON, V292, P333, DOI 10.1016/0926-6917(95)90041-1; MIZUNO Y, 1994, ANN NEUROL, V35, P204, DOI 10.1002/ana.410350212; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1146/annurev.neuro.22.1.123; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PERRY EK, 1980, NEUROSCI LETT, V18, P105, DOI 10.1016/0304-3940(80)90220-7; Priller J, 1997, ANN NEUROL, V42, P265, DOI 10.1002/ana.410420222; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; Reed D. J., 1984, PHARMACOL REV, V36, P255; Sawa A, 1999, NAT MED, V5, P1194; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Schapira AHV, 1997, ANN NEUROL, V41, P556, DOI 10.1002/ana.410410421; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Selwa LM, 1999, NEUROLOGY, V52, P426, DOI 10.1212/WNL.52.2.426; SHEFFNER AL, 1966, BIOCHEM PHARMACOL, V15, P1523, DOI 10.1016/0006-2952(66)90197-3; SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299; SIMONIAN NA, 1994, J NEUROPATH EXP NEUR, V53, P508, DOI 10.1097/00005072-199409000-00010; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; WHARTON DC, 1962, ARCH BIOCHEM BIOPHYS, V96, P103, DOI 10.1016/0003-9861(62)90458-7; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; YAGI T, 1984, BIOCHEMISTRY-US, V23, P2449, DOI 10.1021/bi00306a020; Yan CYI, 1998, J NEUROSCI, V18, P4042; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	94	74	76	0	4	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	APR	2001	56	4					472	477		10.1054/mehy.2000.1194			6	Medicine, Research & Experimental	Research & Experimental Medicine	428LF	WOS:000168462600011	11339849				2021-06-18	
J	Sachdev, P; Smith, JS; Cathcart, S				Sachdev, P; Smith, JS; Cathcart, S			Schizophrenia-like psychosis following traumatic brain injury: a chart-based descriptive and case-control study	PSYCHOLOGICAL MEDICINE			English	Article							HEAD-INJURY; DISEASE; ONSET	Background. Head injury has been reported to increase the likelihood of the development of schizophrenia-like psychosis (SLP), but its features and risk factors have been insufficiently investigated. Method. Between 1987 and 1997, we examined 45 referred patients with SLP following brain trauma. These subjects were matched with 45 head-injured subjects without SLP on age (current and at injury) and gender, and their case records reviewed systematically. The groups were compared and logistic regression analyses performed. Results. The psychoses had a mean age of onset of 26.3 years, a mean latency of 54.7 months after head injury, usually a gradual onset and a subacute or chronic course. Prodromal symptoms were common and depression often present at onset. Paranoid delusions and auditory hallucinations were the predominant features, with formal thought disorder, catatonic features and negative symptoms being uncommon. The SLP group had more widespread brain damage on neuroimaging, especially in the left temporal and right parietal regions, and were more impaired cognitively. Fewer (non-significantly) SLP subjects had epilepsy which was more likely to be well-controlled in this group. On regression analysis, a positive family history of psychosis and duration of loss of consciousness were the best predictors of SLP. Conclusions. Head injury-related psychosis is usually paranoid-hallucinatory and subacute or chronic in its presentation. A genetic predisposition to schizophrenia and severity of injury with significant brain damage and cognitive impairment may be vulnerability factors.	Prince Wales Hosp, NPI, Randwick, NSW 2031, Australia; Univ New S Wales, Sch Psychiat, Randwick, NSW, Australia	Sachdev, P (corresponding author), Prince Wales Hosp, NPI, Randwick, NSW 2031, Australia.		Sachdev, Perminder/ABC-1137-2020	Sachdev, Perminder/0000-0002-9595-3220			ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Australian Bureau of Statistics, 1997, AUSTR STAND CLASS OC, V2nd; BUCKLEY P, 1993, AM J PSYCHIAT, V150, P146; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; CUTTING J, 1987, BRIT J PSYCHIAT, V151, P324, DOI 10.1192/bjp.151.3.324; Dalman C, 1999, ARCH GEN PSYCHIAT, V56, P234, DOI 10.1001/archpsyc.56.3.234; DAVIS JC, 1969, ADV MAGN RESON, V4, P1; DEMOL J, 1987, ARCH PSICOLOGIA NEUR, V48, P336; FEINSTEIN A, 1990, PSYCHOL MED, V20, P793, DOI 10.1017/S0033291700036485; FRITH CD, 1988, BRIT J PSYCHIAT, V153, P437, DOI 10.1192/bjp.153.4.437; GUREJE O, 1994, AM J PSYCHIAT, V151, P368; HAFNER H, 1993, BRIT J PSYCHIAT, V162, P80, DOI 10.1192/bjp.162.1.80; HILLBOM E, 1951, ACTA PSYCHIAT NEUROL, V60, P36; JOHNSTONE EC, 1987, PSYCHOL MED, V17, P371, DOI 10.1017/S0033291700024922; Lewis S. W., 1995, P324; LEZAK MD, 1997, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LISHMAN WA, 1998, ORGANIC PSYCHIAT PSY; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; *SPSS INC, 1999, STAT PACK SOC SCI VE; VONKRAFFTEBING R, 1918, DURCH GEHIRNERSCHUTT; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	26	74	79	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0033-2917			PSYCHOL MED	Psychol. Med.	FEB	2001	31	2					231	239		10.1017/S0033291701003336			9	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	402TM	WOS:000167004300005	11232911				2021-06-18	
J	Ylvisaker, M; Todis, B; Glang, A; Urbanczyk, B; Franklin, C; DePompei, R; Feeney, T; Maxwell, NM; Pearson, S; Tyler, JS				Ylvisaker, M; Todis, B; Glang, A; Urbanczyk, B; Franklin, C; DePompei, R; Feeney, T; Maxwell, NM; Pearson, S; Tyler, JS			Educating students with TBI: Themes and recommendations	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; children; policy; research; schools; teacher training; traumatic brain injury	TRAUMATIC BRAIN INJURY; HEAD-INJURIES; CHILDREN; REHABILITATION; CHILDHOOD; RECOVERY; STATES; SCALE	Ten educational consultants and researchers. each with extensive experience working with children with traumatic brain injury (TBI) in school settings, identified seven themes related to serving this population in public schools. These themes are discussed under the headings (1) incidence of TBI and prevalence of per sistent educational disability (2) diversity and central tendencies within the population, (3) assessment, (4) intervention and support in school settings. (5) training and support for educators, (6) intervention and support for families, and (7) systems change and flexibility. For each theme. a set of recommendations is provided, forming an educational research and policy agenda for pediatric TBI.	Coll St Rose, Dept Commun Disorders, Albany, NY USA; Western Oregon State Coll, Teaching Res Div, Eugene, OR USA; Metropolitan Nashville Publ Sch, Nashville, TN USA; Vanderbilt Univ, Dept Hearing & Speech Sci, Nashville, TN USA; Univ Akron, Sch Speech Language Pathol & Audiol, Dept Communicat Disorders, Akron, OH 44325 USA; Wildwood Inst, Schenectady, NY USA; Wildwood Behav Resource Project, Schenectady, NY USA; Springs Union Free Sch Dist, Dept Special Educ, E Hampton, NY USA; Iowa Dept Educ, Iowa City, IA USA; Univ Kansas, Med Ctr, Dept Special Educ, Neurol Disabil Support Project, Kansas City, KS 66103 USA	Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.						ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BORKOWSKI JG, IN PRESS ISSUES MEAS; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; Carr E.G., 1999, POSITIVE BEHAV SUPPO; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DEPOMPEI R, 1995, SURVEY OHIO SPECIAL, P4; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DROTAR D, 1997, J PEDIAT PSYCHOL; Elmore RF, 1996, HARVARD EDUC REV, V66, P1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FOREST M, 1989, ED ALL STUDENTS MAIN; FOX TJ, 1980, QUALITY ED SEVERELY; Fullan M., 1999, CHANGE FORCES SEQUEL; GLANG A, 1997, CHILDREN ACQUIRED BR; Hostler SL, 1999, J HEAD TRAUMA REHAB, V14, P384, DOI 10.1097/00001199-199908000-00007; JOYCE B, 1980, EDUC LEADERSHIP, V37, P379; JOYCE B, 1982, EDUC LEADERSHIP, V40, P4; Joyce B., 1995, STUDENT ACHIEVEMENT; KATSIYANNIS A, 1994, REM SPEC EDUC, V15, P319, DOI 10.1177/074193259401500507; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kolb B., 1995, BRAIN PLASTICITY BEH; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; LENZ BK, 1987, LEARN DISABILITY Q, V10, P53, DOI 10.2307/1510755; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Pressley M.P., 1995, COGNITIVE STRATEGY I, V2nd; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Robinson TR, 1999, J EDUC PSYCHOL, V91, P195, DOI 10.1037/0022-0663.91.2.195; Schumaker J. B., 1992, CONT INTERVENTION RE; SHOWERS B, 1987, EDUC LEADERSHIP, V45, P77; SINGER GHS, 1997, CHILDREN ACQUIRED BR; SINGER GHS, 1996, REDEFINING FAMILY SU; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Swanson H. L., 1999, INTERVENTIONS STUDEN; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TOWNER E, 1996, HLTH PROMOTION CHILD; Tyler J. S., 1997, STUDENTS ACQUIRED BR, P323; *US DEP ED, 1999, IMPL IND DIS ED ACT; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; Wittrock, 1986, HDB RES TEACHING, P376; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P221; ZIRPOLI TJ, 1989, J ASSOC PERS SEVERE, V14, P163	52	74	75	0	10	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					76	93		10.1097/00001199-200102000-00009			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100011	11277852				2021-06-18	
J	Li, S; Stys, PK				Li, S; Stys, PK			Na+-K+-ATPase inhibition and depolarization induce glutamate release via reverse Na+-dependent transport in spinal cord white matter	NEUROSCIENCE			English	Article						excitotoxicity; alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate; calcium; L-trans-pyrrolidine-2,4-dicarboxylic acid; myelin; Na+-Ca2+ exchange	RAT OPTIC-NERVE; ANOXIC INJURY; GLIAL-CELLS; NA+-CA2+ EXCHANGER; MULTIPLE-SCLEROSIS; MYELINATED AXONS; BRAIN ISCHEMIA; TISSUE LOSS; IN-VITRO; EXCITOTOXICITY	Excitotoxic mechanisms involving alpha -amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA)/kainate receptors play an important role in mediating cellular damage in spinal cord injury. However. the precise cellular mechanisms of glutamate release from non-synaptic white matter are not well understood. We examined how the collapse of transmembrane Na+ and K+ gradients induces reverse operation of Na+-dependent glutamate transporters. leading to glutamate efflux and injury to rat spinal dorsal columns in vitro. Compound action potentials were irreversibly reduced to 43% or control after ouabain/high K+/low Na+ exposure (500 muM ouabain for 30 min to increase [Na+](i), followed by 1 h ouabain+high K+ (129 mM)/low Na+ (27 mM), to further reverse transmembrane ion gradients) followed by a 2 h wash. Ca2+-free perfusate was very protective (compound action potential amplitude recovered to 87% vs. 43%). The broad spectrum glutamate antagonist kynurenic acid (I mM) or the selective AMPA antagonist GYKI52466 (30 VM) were partially protective (68% recovery). Inhibition of Na+-dependent glutamate transport with L-trans-pyrrolidine-2,4-dicarboxylic acid (I mM) also provided significant protection (71% recovery), similar to that seen with glutamate receptor antagonists. Blocking reverse Na+-Ca2+ exchange with KB-R7943 (10 muM) however, was ineffective in this paradigm (49% recovery). Semiquantitative glutamate immunohistochemistry revealed that levels of this amino acid were significantly depleted in axon cylinders and, to a lesser degree, in oligodendrocytes (but not in astrocytes) by ouabain/high K+/low Na+. which was largely prevented by glutamate transport inhibition. Our data show that dorsal column white matter contains the necessary glutamate pools and release mechanisms to induce significant injury. When Na+ and K+ gradients are disrupted, even in the absence of reduced cellular energy reserves, reverse operation of Na-dependent glutamate transport will release enough endogenous glutamate to activate AMPA receptors and cause substantial Ca2+-dependent injury. This mechanism likely plays an important role during ischemic and traumatic white matter injury. where collapse of transmembratic Na+ and K+ gradients occurs. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa Hosp, Ottawa, ON K1Y 4K9, Canada	Stys, PK (corresponding author), Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa Hosp, Civic Campus,725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.						Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Basarsky TA, 1999, J NEUROSCI, V19, P6439; Brown AM, 2001, J NEUROPHYSIOL, V85, P900; Choi I, 1997, GLIA, V20, P184, DOI 10.1002/(SICI)1098-1136(199707)20:3<184::AID-GLIA2>3.3.CO;2-U; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; David JC, 1996, J NEUROSCI, V16, P200; Domercq M, 1999, MOL BRAIN RES, V67, P296, DOI 10.1016/S0169-328X(99)00072-8; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FERN R, 1995, J NEUROPHYSIOL, V74, P369; GarciaBarcina JM, 1996, EUR J NEUROSCI, V8, P2379, DOI 10.1111/j.1460-9568.1996.tb01201.x; Gegelashvili G, 1998, BRAIN RES BULL, V45, P233, DOI 10.1016/S0361-9230(97)00417-6; GEMBA T, 1994, NEUROSCIENCE, V63, P789, DOI 10.1016/0306-4522(94)90523-1; GRIFFITHS R, 1994, BIOCHEM PHARMACOL, V47, P267, DOI 10.1016/0006-2952(94)90016-7; Imaizumi T, 1999, BRAIN RES, V817, P84, DOI 10.1016/S0006-8993(98)01214-1; Imaizumi T, 1997, J NEUROTRAUM, V14, P299, DOI 10.1089/neu.1997.14.299; JENSEN AM, 1993, J NEUROSCI, V13, P1664; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LEES GJ, 1995, NEUROSCI LETT, V188, P113, DOI 10.1016/0304-3940(95)11413-Q; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Li S, 1999, J Neurosci, V19, pRC16; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; LoPachin RM, 1999, J NEUROPHYSIOL, V82, P2143; LOPACHIN RM, 1995, J NEUROSCI, V15, P6735; Matute C, 1998, P NATL ACAD SCI USA, V95, P10229, DOI 10.1073/pnas.95.17.10229; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; McAdoo DJ, 2000, BRAIN RES, V865, P283, DOI 10.1016/S0006-8993(00)02296-4; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Omar AI, 2000, NEUROSCIENCE, V95, P73; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rutledge EM, 1996, J NEUROSCI, V16, P7803; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Steffensen I, 1997, BRAIN RES, V776, P1, DOI 10.1016/S0006-8993(97)00868-8; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; Stys P. K., 1999, J NEUROTRAUM, V16, P984; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; STYS PK, 1992, J NEUROSCI, V12, P430; STYS PK, 1994, SCI COMPUT AUTOMATIO, V10, P19; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Takahashi M, 1997, J EXP BIOL, V200, P401; Teng YD, 1997, J NEUROSCI, V17, P4359; TRAPP BD, 1988, J NEUROCHEM, V51, P859, DOI 10.1111/j.1471-4159.1988.tb01822.x; Vandenberg RJ, 1998, CLIN EXP PHARMACOL P, V25, P393, DOI 10.1111/j.1440-1681.1998.tb02221.x; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Yoshioka A, 1996, J NEUROSCI RES, V46, P427; YOSHIOKA A, 1995, J NEUROCHEM, V64, P2442; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	58	74	74	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2001	107	4					675	683		10.1016/S0306-4522(01)00385-2			9	Neurosciences	Neurosciences & Neurology	501AV	WOS:000172661600013	11720790				2021-06-18	
J	McIntosh, AS; McCrory, P				McIntosh, AS; McCrory, P			Impact energy attenuation performance of football headgear	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						football; headgear; helmet; head; concussion	INJURY	Objectives-Commercially available football head protectors were tested to determine their impact energy attenuation performance and ability to reduce the likelihood of concussion. Methods-Prospective study using standardised impact test methods with both rigid (magnesium) and Hybrid III headforms. Results-Eight commercially available head protectors from six manufacturers were tested. The magnitude of the headform accelerations increased as the drop height was increased, ranging ti om a minimum of 64 g from a height of 0.2 m to a maximum of 1132 g from a height of 0.6 m. The head injury criterion and maximum headform acceleration values followed a similar trend. A steep increase was noted in the magnitude of maximum headform acceleration and head injury criterion when the drop height was increased from 0.4 to 0.5 m. This indicates that the foam material was completely compressed at an impact energy above about 20 J and therefore offers little protection against impacts of greater severity. Repeated tests using a drop height of 0.3 m showed that some helmets exhibit a "memory" effect, whereby impact performance is reduced by up to 50% with repeated impacts. Conclusions-Laboratory tests indicate that current commercially available football headgear performance will not reduce the likelihood of concussion. The absence of internationally recognised standards for soft headgear designed to ameliorate concussion is a major deficiency in sports injury prevention.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Dept Neurol, Austin & Repatriat Med Ctr, Heidelberg, Vic 3084, Australia; Olymp Pk Sports Med Ctr, Melbourne, Vic 3004, Australia	McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.		McCrory, Paul/Q-8688-2019				*AUSTR S, 1999, 251211 ASNZS; *AUSTR S, 1998, 25122 ASNZS; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; HARDY WN, 1993, ACCIDENTAL INJURY BI, P12; *IRB, 1996, LAWS GAM RUGB; McCrory P, 1998, SPORTS NEUROLOGY, P441; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McIntosh AS, 1993, 37 STAPP CAR CRASH C, P43; McIntosh AS, 1995, 39 STAPP CAR CRASH C, P111; NEWMAN J, 1978, P AM ASS AUT MED 22, P279; OMMAYA A, 1990, SPORTS NEUROLOGY, P84; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005	17	74	74	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2000	34	5					337	341		10.1136/bjsm.34.5.337			5	Sport Sciences	Sport Sciences	363XR	WOS:000089863400009	11049142	Green Published, Bronze			2021-06-18	
J	Malec, JF; Buffington, ALH; Moessner, AM; Degiorgio, L				Malec, JF; Buffington, ALH; Moessner, AM; Degiorgio, L			A medical/vocational case coordination system for persons with brain injury: An evaluation of employment outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; vocational; employment; case management	CLOSED-HEAD-INJURY; FOLLOW-UP; SUPPORTED EMPLOYMENT; EARLY INTERVENTION; SOCIAL-ADJUSTMENT; REHABILITATION; RECOVERY; RETURN; WORK; TRAUMA	Objective: To evaluate initial placement and 1-year employment outcomes of a Medical/Vocational Case Coordination System (MVCCS) for persons with brain injury (BI) that provides: (1) early case identification and coordination, (2) appropriate medical and vocational rehabilitation interventions, (3) work trials, and (4) supported employment interventions including job coaching. Participants: One hundred fourteen Minnesota residents, ages 18 to 65 years, with acquired BI. Main Outcome Measures: Outcome: Five levels of Vocational Independence Scale (VIS). Predictor: Preinjury employment status (VIS) and years of education, severity of initial injury, time since injury, current impairment/disaibility as measured by the Rasch-analyzed Staff Mayo-Portland Adaptability Inventory (MPAI), and impaired self-awareness measured by staff rating and the difference between Staff MPAI and Survivor MPAI. Results: At placement, 46% in independent work; 25% in transitional placements; 9% in long-term supported employ ment; 10% in sheltered work; and 10% not placed. At 1-year follow-up (n = 101), 53% in independent work; 19% in transitional placement; 9% in supported work; 6% in sheltered work; and 13% unemployed. Regression analyses showed time since injury and Rasch Staff MPAI predicted VIS at placement; only VIS at placement independently predicted VIS at I-year follow-up; Rasch Staff MPAI and preinjury education level predicted time to placement. Conclusions: The MVCCS optimized vocational outcome after BI. Time since injury and impairment/disability best predicted Vocational placement. Level of initial placement best predicted employment status at follow-up. Persons with greater disability required more extended time and more extensive rehabilitation services before placement.	Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	Malec, JF (corresponding author), Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA.						Adey C, 1967, Bristol Med Chir J, V82, P58; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BRUCKNER FE, 1972, RHEUMATOL PHYS MED, V2, P344; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; EVANS RW, 1991, J INSUR MED, V3, P192; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FAHY TJ, 1967, LANCET, V2, P475; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; Gjone R, 1972, Scand J Rehabil Med, V4, P2; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HPAY H, 1971, INT S HEAD INJ 1970, P110; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Kreutzer J S, 1991, Int Disabil Stud, V13, P162; LEWIN W, 1959, P ROY SOC MED, V52, P880; LEWIN W, 1967, P ROY SOC MED, V60, P1208, DOI 10.1177/003591576706011P204; LEWIN W, 1976, BRIT MED J, V2, P1234, DOI 10.1136/bmj.2.6046.1234; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LONDON P S, 1967, Annals of the Royal College of Surgeons of England, V41, P460; MACIVER IN, 1958, LANCET, V2, P544; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MALEC J, 1992, NEUROREHABILITATION, V2, P1; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; MALEC JF, IN PRESS REHABIL PSY; MATHESON JM, 1982, AUSTR APPROACHES REH, P32; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLER H, 1965, LANCET, V1, P225; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; RICHARDSON JC, 1971, INT S HEAD INJ 1970, P127; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWBOTHAM GF, 1954, BRIT MED J, V1, P726, DOI 10.1136/bmj.1.4864.726; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUSK H A, 1969, Medical Clinics of North America, V53, P677; RUSK HA, 1966, CLIN NEUROSURG, V12, P312; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN P, 1993, COMMUNITY BASED EMPL; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wright B. D., 1982, RATING SCALE ANAL RA; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	79	74	75	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2000	81	8					1007	1015		10.1053/apmr.2000.6980			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	349JJ	WOS:000089041700001	10943747				2021-06-18	
J	Natale, JE; Joseph, JG; Helfaer, MA; Shaffner, DH				Natale, JE; Joseph, JG; Helfaer, MA; Shaffner, DH			Early hyperthermia after traumatic brain injury in children: Risk factors, influence on length of stay, and effect on short-term neurologic status	CRITICAL CARE MEDICINE			English	Article						pediatric intensive care; length of stay; Glasgow Coma Scale; secondary brain injury; hyperthermia; multiple logistic regression; traumatic brain injury; resource utilization	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; ACUTE STROKE; TEMPERATURE; RATS; COMA; PATIENT; HYPOXIA; DAMAGE	Objectives: a) To determine the risk factors for early hyperthermia after traumatic brain injury in children; b) to identify the contribution of early hyperthermia to neurologic status at pediatric intensive care unit (PICU) discharge and to PICU length of stay in head-injured children. Study Design: Observational cohort study. Setting: PICU at a tertiary care, university medical center. Patients: Children (n = 117) admitted to a PICU from July 1995 to May 1997 with traumatic brain injury. These children had a median age of 5.4 yrs (3 wks to 15.2 yrs old), and 33.4% were girls. Measurements and Main Results: Early hyperthermia (temperature >38.5 degrees C within the first 24 hrs of admission) occurred in 29.9% of patients admitted to the PICU with traumatic brain injury. Risk factors predicting early hyperthermia included Glasgow Coma Scale score in the emergency department less than or equal to 8, pediatric trauma score less than or equal to 8, cerebral edema or diffuse axonal injury on initial head computed tomography scan, admission blood glucose >150 mg/dL (8.2 mmol/L), admission white cell count >14,300 cells/mm3 (14.3 x 10(9) cells/L), and systolic hypotension. The presence of early hyperthermia significantly increased the risk for Glasgow Coma Scale score <13 at PICU discharge (odds ratio [OR] 9.7, 95% confidence interval [CI] 2.8, 24.4) and PICU stay greater than or equal to 3 days (OR 13.8, GI 5.1, 37.5). When we used multiple logistic regression models including injury severity and hypotension, early hyperthermia remained an independent predictor of lower Glasgow Coma Scale score at PICU discharge (OR 4.7, CI 1.4, 15.6) and longer PICU length of stay (OR 8.5, CI 2.8, 25.6). Conclusions: Early hyperthermia is independently associated with a measure of early neurologic status and resource utilization in children with traumatic brain injury serious enough to require PICU admission. These results support the prevention of hyperthermia in the management of traumatic brain injury in children. Further research is required to understand the mechanisms of this response and to identify appropriate preventive or therapeutic interventions.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; George Washington Univ, Sch Med, Ctr Hlth Serv & Clin Res, Childrens Natl Med Ctr, Washington, DC USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Natale, JE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.			SHAFFNER, DONALD/0000-0001-5530-0746			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; Bullock MR, 1996, J NEUROTRAUM, V13, P653; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Guyer B, 1997, PEDIATRICS, V100, P905, DOI 10.1542/peds.100.6.905; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; LINDSAY JT, 1998, J NEUROTRAUM, V15, P573; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; RUDY TA, 1979, THERMOREGULATORY MEC, P75; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	30	74	74	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUL	2000	28	7					2608	2615		10.1097/00003246-200007000-00071			8	Critical Care Medicine	General & Internal Medicine	336QW	WOS:000088315300065	10921603				2021-06-18	
J	Allen, JW; Knoblach, SM; Faden, A				Allen, JW; Knoblach, SM; Faden, A			Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro	CELL DEATH AND DIFFERENTIATION			English	Article						metabotropic glutamate receptor; apoptosis; necrosis; neuronal death	TRAUMATIC BRAIN INJURY; CEREBELLAR GRANULE CELLS; NMDA-RECEPTORS; 1-AMINOINDAN-1,5-DICARBOXYLIC ACID; GLUCOSE DEPRIVATION; ANTAGONIST; AGONIST; CULTURE; NEUROTOXICITY; MODEL	Glutamate released during acute CNS insults acts at metabotropic glutamate receptors (mGluR), including group I mGluR, Blockade of group I mGluR during in vitro neuronal trauma provides neuroprotection, whereas activation exacerbates such injury. However, the effects of group I mGluR agonists or antagonists have been primarily studied in in vitro models characterized by necrotic cell death. We examined the role of group I mGluR in the modulation of neuronal injury induced during oxygen-glucose deprivation (OGD), a well-studied model of necrosis, and by application of two well established pro-apoptotic agents: staurosporine and etoposide. Inhibition of group I mGluR attenuated necrosis induced by OGD, whereas selective activation of group 1 mGluR exacerbated such injury. In contrast, activation of group I mGluR, including selective activation of mGluR5, significantly attenuated apoptotic cell death induced by both staurosporine and etoposide, This effect was completely reversed by coapplication of a group I mGluR antagonist. Thus, group I mGluR appear to exhibit opposite effects on necrotic and apoptotic neuronal cell death. Our findings suggest that activation of mGluR1 exacerbates neuronal necrosis whereas both mGluR1 and mGluR5 play a role in attenuation of neuronal apoptosis.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Faden, A (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 1999, FASEB J, V13, P1875; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHAVIS P, 1995, J NEUROSCI, V15, P135; COPANI A, 1995, J NEUROCHEM, V64, P101; COPANI A, 1995, MOL PHARMACOL, V47, P890; Copani A, 1998, EUR J NEUROSCI, V10, P2173, DOI 10.1046/j.1460-9568.1998.00230.x; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; ITO I, 1992, NEUROREPORT, V3, P1013, DOI 10.1097/00001756-199211000-00017; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; MALESE K, 1999, NEUROSCI LETT, V264, P17; MANZONI OJJ, 1991, EUR J PHARM-MOLEC PH, V207, P231; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Riedel G, 1996, PROG NEURO-PSYCHOPH, V20, P1253, DOI 10.1016/S0278-5846(96)00110-8; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; YUZAKI M, 1992, J NEUROSCI, V12, P4253	39	74	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	MAY	2000	7	5					470	476		10.1038/sj.cdd.4400678			7	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	310MV	WOS:000086832700006	10800080	Bronze			2021-06-18	
J	Kohen, R; Vellaichamy, E; Hrbac, J; Gati, I; Tirosh, O				Kohen, R; Vellaichamy, E; Hrbac, J; Gati, I; Tirosh, O			Quantification of the overall reactive oxygen species scavenging capacity of biological fluids and tissues	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						invasive and noninvasive techniques; cyclic voltammetry; total antioxidant capacity; free radicals; antioxidant profile; oxidative stress; low-molecular weight antioxidants	CLOSED-HEAD INJURY; RADICAL ABSORBENCY CAPACITY; TOTAL ANTIOXIDANT STATUS; CYCLIC VOLTAMMETRY; OXIDATIVE STRESS; IN-VIVO; PLASMA; SAMPLES; POWER; ASSAY	A method has been developed for measuring and evaluating the overall antioxidant activity derived from the low-molecular weight antioxidants (scavengers). The principle governing this method is based on a common chemical characteristic of the scavengers, their reducing properties. It was hypothesized and then demonstrated that an evaluation of the overall reducing power of a biological sample correlates with the overall scavenging activity of the sample. In order to quantify the total reducing power, the cyclic voltammetry methodology was applied. The resulting measurements correlated with the antioxidant activity of both hydrophilic and lipophilic scavengers. The method is suitable for use in biological fluids and in tissue homogenates, and can supply information concerning the type of antioxidants and their total concentration without having to determine specific compounds. A noninvasive procedure for determining skin overall scavenging activity is also described. This method is based on a well containing an extraction solution that is attached to the skin's surface. Following incubation time the extraction solution is analyzed using the cyclic voltammeter instrument and other methods. We have found these methods suitable for evaluating the reducing capacity status in various clinical conditions such as diabetes, ionizing and nonionizing irradiation, brain degenerative diseases, head trauma, and inflammatory bowel diseases. This method is also an efficient tool for evaluating the overall antioxidant capacity of mixtures of antioxidant preparations in vitro. The measurements themselves are simple and rapid. Furthermore, they do not require manipulation of the samples. (C) 2000 Elsevier Science Inc.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	Kohen, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel.		Hrbac, Jan/A-1007-2009				Bard A. J., 1980, ELECTROCHEMICAL METH; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Benzie IFF, 1999, METHOD ENZYMOL, V299, P15; Blau S, 1999, MOL CELL BIOCHEM, V194, P185, DOI 10.1023/A:1006994800272; BLAU S, 2000, IN PRESS DIGEST DIS; CAO GH, 1993, FREE RADICAL BIO MED, V14, P303, DOI 10.1016/0891-5849(93)90027-R; Cao GH, 1999, METHOD ENZYMOL, V299, P50; Chevion S, 1997, FREE RADICAL BIO MED, V22, P411, DOI 10.1016/S0891-5849(96)00337-1; Chevion S, 1999, BIOCHEM MOL BIOL INT, V47, P1019; COOPER MJ, 1991, CLIN CHIM ACTA, V202, P105, DOI 10.1016/0009-8981(91)90261-A; Elangovan V, 2000, FREE RADICAL RES, V32, P125, DOI 10.1080/10715760000300131; GHISELLI A, 1995, FREE RADICAL BIO MED, V18, P29, DOI 10.1016/0891-5849(94)00102-P; HALLIWELL B, 1995, FOOD CHEM TOXICOL, V33, P601, DOI 10.1016/0278-6915(95)00024-V; Halliwell B., 1989, FREE RADICAL BIOL ME; Heineman W. R., 1984, LAB TECHNIQUES ELECT; KISSINGER PT, 1973, BRAIN RES, V55, P209, DOI 10.1016/0006-8993(73)90503-9; Kohen R, 1999, BIOMED PHARMACOTHER, V53, P181, DOI 10.1016/S0753-3322(99)80087-0; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kohen R, 1997, REDOX REP, V3, P253, DOI 10.1080/13510002.1997.11747118; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; KOHEN R, 1993, INT S ANT DIS PREV S; LISSI E, 1995, FREE RADICAL BIO MED, V18, P153, DOI 10.1016/0891-5849(94)00117-3; MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; O'Neill RD, 1998, CRIT REV NEUROBIOL, V12, P69, DOI 10.1615/CritRevNeurobiol.v12.i1-2.40; Ornoy A, 1999, TERATOLOGY, V60, P376, DOI 10.1002/(SICI)1096-9926(199912)60:6<376::AID-TERA10>3.0.CO;2-Q; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; WHITE JA, 1992, J PROPUL POWER, V8, P257, DOI 10.2514/3.23471	34	74	75	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAR 15	2000	28	6					871	879		10.1016/S0891-5849(00)00191-X			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	311PN	WOS:000086893200006	10802217				2021-06-18	
J	Jaworski, DM; Kelly, GM; Hockfield, S				Jaworski, DM; Kelly, GM; Hockfield, S			Intracranial injury acutely induces the expression of the secreted isoform of the CNS-specific hyaluronan-binding protein BEHAB brevican	EXPERIMENTAL NEUROLOGY			English	Article						BEHAB; brevican; extracellular matrix; GFAP; hyaluronan; migration; nestin; PCNA; proliferation; proteoglycan; reactive gliosis	CHONDROITIN SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; TRAUMATIC BRAIN INJURY; CELL NUCLEAR ANTIGEN; REACTIVE ASTROCYTES; NEURITE OUTGROWTH; RAT-BRAIN; EXTRACELLULAR-MATRIX; INHIBITORY MOLECULES; HEPARAN-SULFATE	Hyaluronan (HA) plays an important role in tissue reorganization in response to injury. The mechanisms by which HA participates in these processes are likely to include HA-binding proteins. Previously, we reported the cloning and initial characterization of a central nervous system (CNS)-specific HA-binding protein, BEHAB (brain enriched hyaluronan binding), which was independently cloned in another laboratory and named brevican. BEHAB/brevican mRNA is expressed in the ventricular zone coincident with the initial proliferation and migration of glial cells and in surgical samples of human glioma, where glial-derived cells proliferate and migrate. To determine whether BEHAB/brevican is also expressed during the cellular proliferation and migration associated with CNS injury, we have examined BEHAB/brevican expression during reactive gliosis. BEHAB/brevican occurs as secreted and cell-surface, glycosylphosphatidylinositol (GPI)-anchored, isoforms. The secreted, but not the GPI-anchored, isoform is up-regulated in response to a stab wound to the adult rat brain. The temporal regulation and spatial distribution of BEHAB/brevican expression parallel the gliotic response and the expression of the intermediate filament protein nestin. The up-regulation of BEHAB/brevican in response to CNS injury suggests a role for this extracellular matrix molecule in reactive gliosis. Glial process extension, a central element in the glial response to injury, may require the reexpression of both cytoskeletal and matrix elements that are normally expressed during the glial motility seen in the immature brain. (C) 1999 Academic Press.	Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA	Jaworski, DM (corresponding author), Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA.				NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY06511] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35874] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035874] Funding Source: NIH RePORTER		ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; Burke E J, 1994, Acta Neurol (Napoli), V16, P103; Canning DR, 1996, INT J DEV NEUROSCI, V14, P153, DOI 10.1016/0736-5748(96)00004-4; CARBONETTO S, 1983, J NEUROSCI, V3, P2324; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; DELPECH B, 1993, EUR J CANCER, V29A, P1012, DOI 10.1016/S0959-8049(05)80214-X; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FAWCETT JW, 1990, DEVELOPMENT, V109, P59; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HOKE A, 1994, PERSPECT DEV NEUROBI, V2, P269; JAWORSKI DM, 1995, J NEUROSCI, V15, P1352; Jaworski DM, 1996, CANCER RES, V56, P2293; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; KITAMURA T, 1978, ACTA NEUROPATHOL, V44, P31, DOI 10.1007/BF00691636; KNUDSON CB, 1993, FASEB J, V7, P1233; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MIYAKE T, 1992, BRAIN RES, V590, P300, DOI 10.1016/0006-8993(92)91109-R; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROSEN GD, 1994, DEV BRAIN RES, V82, P127, DOI 10.1016/0165-3806(94)90155-4; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 1998, EUR J NEUROSCI, V10, P1621, DOI 10.1046/j.1460-9568.1998.00166.x; SMITH GM, 1993, J NEUROCHEM, V60, P1453, DOI 10.1111/j.1471-4159.1993.tb03308.x; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; Toole B.P., 1991, CELL BIOL EXTRACELLU, P305; TUSZYNSKI MH, 1995, MOL NEUROBIOL, V10, P151, DOI 10.1007/BF02740673; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yang HY, 1997, EXP NEUROL, V146, P199, DOI 10.1006/exnr.1997.6518; Zhang H, 1998, J NEUROSCI, V18, P2370; ZHANG LR, 1995, CANCER RES, V55, P428	57	74	77	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUN	1999	157	2					327	337		10.1006/exnr.1999.7062			11	Neurosciences	Neurosciences & Neurology	202LD	WOS:000080653000010	10364444				2021-06-18	
J	Fox, GB; LeVasseur, RA; Faden, AI				Fox, GB; LeVasseur, RA; Faden, AI			Behavioral responses of C57BL/6, FVB/N, and 129/SvEMS mouse strains to traumatic brain injury: Implications for gene targeting approaches to neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						Barnes maze; behavior differences; mouse; strain C57BL/6; strain FVB N; strain 129/SvEMS; water maze	CONTROLLED CORTICAL IMPACT; INBRED MICE; NICOTINE; MODEL; MAZE; SUSCEPTIBILITY; ISCHEMIA; GENOTYPE; ETHANOL	Recent studies have suggested that mouse models of traumatic brain injury may be useful for evaluating the role of single gene products in brain trauma. In the present study, we report that three background strains (C57BL/6, FVB/N, and 129/SvEMS), commonly used in genetically altered mice, exhibit significantly different behavioral responses when subjected to sham surgery (n = 9 per group) or moderate controlled cortical impact (CCI) injury (n = 12 per group), Injured animals from all three strains showed delayed recovery of pedal withdrawal and righting reflexes compared to sham-operated controls. Significant deficits in both a forepaw contraflexion and rotarod task were evident for up to 7 days after injury, with no significant difference among strains. Sham-operated C57BL/6 mice performed significantly better than FVB/N and 129/SvEMS sham controls in a beam walking task up to 4 weeks after surgery, However, CCI-injured FVB/N mice outperformed injured animals from both other strains in this same task, Significant impairment of place learning in the Morris water maze and Barnes circular maze was observed at 7-10 days and 21-24 days after injury, respectively, in C57BL/6 mice when compared with sham controls. Sham-operated FVB/N and 129/SvEMS mice were unable to learn either task, and performance did not differ significantly from respective CCI injured animals. Our results suggest that background strain should be carefully considered with experiments involving genetically altered mice, especially when planning behavioral outcome measures after CNS injury.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Rm EP-04, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Deutsch SI, 1997, PHARMACOL BIOCHEM BE, V57, P315, DOI 10.1016/S0091-3057(96)00347-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Goelz MF, 1998, LAB ANIM SCI, V48, P34; Laghmouch A, 1997, BEHAV GENET, V27, P67, DOI 10.1023/A:1025667426222; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; LUO YH, 1994, ALCOHOL, V11, P167, DOI 10.1016/0741-8329(94)90059-0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MELISKA CJ, 1995, PHARMACOL BIOCHEM BE, V50, P619, DOI 10.1016/0091-3057(94)00354-8; Montkowski A, 1997, BRAIN RES, V762, P12, DOI 10.1016/S0006-8993(97)00370-3; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; PICK CG, 1989, BEHAV GENET, V19, P315, DOI 10.1007/BF01065913; Robinson SF, 1996, PSYCHOPHARMACOLOGY, V124, P332, DOI 10.1007/BF02247438; ROULLET P, 1995, PHYSIOL BEHAV, V58, P1189, DOI 10.1016/0031-9384(95)02066-7; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SEALE TW, 1984, PHARMACOL BIOCHEM BE, V20, P567, DOI 10.1016/0091-3057(84)90306-X; SEALE TW, 1984, PHARMACOL BIOCHEM BE, V21, P237, DOI 10.1016/0091-3057(84)90221-1; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Zaharia MD, 1996, PSYCHOPHARMACOLOGY, V128, P227, DOI 10.1007/s002130050130	26	74	74	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					377	389		10.1089/neu.1999.16.377			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200004	10369558				2021-06-18	
J	Brooks, J; Fos, LA; Greve, KW; Hammond, JS				Brooks, J; Fos, LA; Greve, KW; Hammond, JS			Assessment of executive function in patients with mild traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; mild traumatic brain injury; neuropsychology; cognitive testing; executive function	MINOR HEAD-INJURY; STEM RESPONSES; SYMPTOMS; POPULATION; CONCUSSION; RECOVERY; TASK	Background: The nature of functional deficit after mild traumatic brain injury (TBI) defined by Glasgow Coma Score of 13-15 is not fully described. This study explored the sensitivity of several neuropsychological tests to identify sequelae of mild traumatic brain injury (TBI). Methods: Eleven adult patients with mild TBI admitted to a Level 1 trauma center were studied. The battery of tests included the Wechsler Intelligence Scale for Children-Revised: Mazes Subtest, Trails A and B, the Boston Naming Test, The Multilingual Aphasia Examination: Controlled Oral Word Association Test, and the Paced Auditory Serial Addition Task. Results: Control subjects performed significantly better than patients with mild TBI on Trails A and B, the Controlled Oral Word Association Test, and Paced Auditory Serial Addition Task (subtests 2-4). No significant differences in performances between patients and controls was found for the Wechsler Intelligence Scale for Children-Revised: Mazes Subtest, Boston Naming Test, and Paced Auditory Serial Addition Task Subtest Conclusion: The results suggest that tests of specific frontal lobe executive functions are valuable in diagnosing and monitoring recovery from mild TBI.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA; Univ New Orleans, New Orleans, LA 70148 USA	Hammond, JS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, 1 Robert Wood Johnson Pl,POB 19, New Brunswick, NJ 08903 USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; *AM PSYCH ASS, 1992, AM PSYCHOL, V47, P1597, DOI DOI 10.1037/0003-066X.47.12.1597; BARON JB, 1979, INT J NEUROL, V12, P237; Benton AL, 1983, MULTILINGUAL APHASIA; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1990, HORM METAB RES, V22, P508, DOI 10.1055/s-2007-1004958; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; CLARK E, 1992, CURR PSYCHOL RES REV, V11, P21, DOI 10.1007/BF02686825; Cullum C, 1991, FORENSIC NEUROPSYCHO, P141; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Halstead WC, 1985, HALSTEAD REITAN NEUR; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1982, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MENDELSON G, 1982, MED J AUSTRALIA, V2, P132, DOI 10.5694/j.1326-5377.1982.tb124267.x; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MINDERHOUD JM, 1984, TRAUMATISCHE HERSENT; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P670; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SYMONDS C, 1962, LANCET, V1, P1; TAYLOR AR, 1966, LANCET, V2, P178; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D., 1974, WISCR MANUAL WECHSLE; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	34	74	75	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1999	46	1					159	163		10.1097/00005373-199901000-00027			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	160DE	WOS:000078214400036	9932700				2021-06-18	
J	Signorini, DF; Andrews, PJD; Jones, PA; Wardlaw, JM; Miller, JD				Signorini, DF; Andrews, PJD; Jones, PA; Wardlaw, JM; Miller, JD			Adding insult to injury: the prognostic value of early secondary insults for survival after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; prognosis; survival; secondary insults; adults	SEVERE HEAD-INJURY; INTENSIVE-CARE; INTRACRANIAL HYPERTENSION; MODELS; UNIT	Objectives-To assess the prognostic value of summary measures of secondary physiological insult in addition to baseline clinical variables for patients with traumatic brain injury. Methods-A series of 110 patients with traumatic brain injury had data on intracranial pressure (ICP), arterial blood pressure (ABP), cerebral perfusion pressure (CPP), arterial O-2 saturation (SaO(2)), temperature in degrees C (Temp), and heart rate in beats/min (HRT) monitored and recorded every minute. Secondary insults were defined according to the Edinburgh University secondary insult grading system. The prognostic value of summary measures of these secondary insults was assessed by adding them to a prognostic model for survival at 1 year after controlling for baseline clinical variables using a previously validated model. Results-Of the eight secondary insults measured, only ICP added significantly to the prediction of survival in the first 72 hours after injury. The particular type of summary measure did not seem to influence the results. After the addition of ICP to the model, none of the other secondary insult measures could improve the predictive power of the model significantly. Conclusions-Early intracranial hypertension is confirmed as a sign of poor prognosis in patients with traumatic brain injury, even after controlling for baseline clinical variables. The value or otherwise of treating such secondary insults, however, can only be definitively established in the context of prospective randomised controlled trials. The specific pathophysiological evolution of secondary insults is still the subject of much research, and a clear understanding will be necessary before the development of specific treatments is feasible.	Univ Edinburgh, Dept Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Dept Anaesthet, Edinburgh EH8 9YL, Midlothian, Scotland	Signorini, DF (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Bramwell Dott Bldg,Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; CORRIE J, 1993, BRIT J INT CARE, V3, P225; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; MIDGLEY S, 1994, ANAESTHESIA INTENSIV, P373; Miller A, 1990, SUBSET SELECTION REG; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PIPER IR, 1991, BR J INTENS CARE, V1, P73; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SIGNORINI DF, 1997, CRIT CARE MED, V25; STOLL M, 1992, BIOMED TECH, V37, P37, DOI 10.1515/bmte.1992.37.3.37	22	74	81	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	1999	66	1					26	31		10.1136/jnnp.66.1.26			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	154DC	WOS:000077872500008	9886446	Green Published, Bronze			2021-06-18	
J	Murai, H; Pierce, JES; Raghupathi, R; Smith, DH; Saatman, KE; Trojanowski, JQ; Lee, VMY; Loring, JF; Eckman, C; Younkin, S; McIntosh, TK				Murai, H; Pierce, JES; Raghupathi, R; Smith, DH; Saatman, KE; Trojanowski, JQ; Lee, VMY; Loring, JF; Eckman, C; Younkin, S; McIntosh, TK			Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						traumatic brain injury; Alzheimer's disease; beta-amyloid peptides; amyloid plaques	FAMILIAL ALZHEIMERS-DISEASE; CONTROLLED CORTICAL IMPACT; RAT-BRAIN; SENILE PLAQUES; SECRETED FORMS; DOWNS-SYNDROME; HEAD-INJURY; EXPRESSION; DEFICITS; GENE	By using transgenic mice that overexpress human beta-amyloid precursor proteins (APPs) at levels twofold higher than endogenous APPs, following introduction of the human APP gene in a yeast artificial chromosome (YAC), we examined the effects of controlled cortical impact (CCI) brain injury on neuromotor/cognitive dysfunction and the development of Alzheimer's disease (AD)-like neuropathology. Neuropathological analyses included Nissl-staining and immunohistochemistry to detect APPs, beta-amyloid (A beta), neurofilament proteins, and glial fibrillary acidic protein, whereas A beta levels were measured in brain homogenates from mice subjected to CCI and control mice by using a sensitive sandwich enzyme-linked immunosorbent assay. Twenty APP-YAC transgenic mice and 17 wild type (WT) littermate controls were anesthetized and subjected to CCI (velocity, 5 m/second; deformation depth, 1 mm). Sham (anesthetized but uninjured) controls (n = 10 APP-YAC; n = 8 WT) also were studied. Motor function was evaluated by using rotarod, inclined-plane, and forelimb/hindlimb flexion tests. The Morris water maze was used to assess memory. Although CCI induced significant motor dysfunction and cognitive deficits, no differences were observed between brain-injured APP-YAC mice and WT mice at 24 hours and 1 week postinjury. By 1 week postinjury, both cortical and hippocampal CA3 neuron loss as well as extensive astrogliosis were observed in all injured animals, suggesting that overexpression of human APPs exhibited no neuroprotective effects. Although AD-like pathology (including amyloid plaques) was not observed in either sham or brain-injured animals, a significant decrease in brain concentrations of only A beta terminating at amino acid 40 (APx-40) was observed following brain injury in APP-YAC mice (P < 0.05 compared with sham control levels). Our data show that the APP-YAC mice do. not develop AD-like neuropathology following traumatic brain injury. This may be because this injury does not induce elevated levels of the more amyloidogenic forms of human A beta (i.e., A beta x-42/43) in these mice. (C) 1998 Wiley-Liss, Inc.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Mol Dynam, Sunnyvale, CA 94043 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@eniac.seas.upenn.edu	smith, douglas/A-1321-2007; Loring, Jeanne/A-1620-2011	Loring, Jeanne/0000-0001-6226-9767	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG11542] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DIXON CE, 1991, J NEUROSCI METH, V39, P1; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1997, MOL MECH DEMENTIA, P39; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Loring JF, 1996, NEUROBIOL AGING, V17, P173, DOI 10.1016/0197-4580(95)02076-4; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Pierce JES, 1996, J NEUROSCI, V16, P1083; PRICE DL, 1994, ANNU REV MED, V45, P435; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.ne.17.030194.002421; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SMITH DH, 1993, J NEUROTRAUMA S, V10, pS62; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281; TOPPER R, 1995, ACTA NEUROPATHOL, V89, P23; WALLACE WC, 1991, MOL BRAIN RES, V10, P173, DOI 10.1016/0169-328X(91)90108-A; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; YAMAGUCHI F, 1991, NEUROREPORT, V2, P781, DOI 10.1097/00001756-199112000-00013	62	74	75	0	7	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	MAR 23	1998	392	4					428	438		10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2			11	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	YZ711	WOS:000072283200002	9514508				2021-06-18	
J	Bell, MJ; Kochanek, PM; Carcillo, JA; Mi, ZC; Schiding, JK; Wisniewski, SR; Clark, RSB; Dixon, CE; Marion, DW; Jackson, E				Bell, MJ; Kochanek, PM; Carcillo, JA; Mi, ZC; Schiding, JK; Wisniewski, SR; Clark, RSB; Dixon, CE; Marion, DW; Jackson, E			Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						ATP; cAMP; contusion; head injury; microdialysis; purines	PIAL ARTERIOLAR DIAMETER; HIPPOCAMPAL SLICES; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; NEWBORN PIGLET; CYCLIC-AMP; HYPOXIA; RELEASE; HYPOGLYCEMIA; THEOPHYLLINE	Adenosine is a putative neuroprotectant in ischemia, but its role after traumatic brain injury (TBI) is not clear. Metabolites of adenosine, particularly inosine and hypoxanthine, are markers of ischemia and energy failure. Adenosine triphosphate (ATP) breakdown early after injury and metabolism of cyclic adenosine monophosphate (cAMP) are potential sources of adenosine. Further delineation of the magnitude, location, time course, and source of production of adenosine after TBI is needed. We measured adenosine, inosine, and hypoxanthine in brain interstitial fluid after controlled cortical impact (CCI) in the rat. Rats (n = 15) were prepared for TBI induced by CCI. A microdialysis probe was placed in the cortex, and samples were collected every 10 min. After 3 h of equilibration, the catheter was removed, CCI was performed (4 m/sec, depth 2.5 mm), and the catheter was replaced. In the shams, the catheter was removed and replaced without CCI. The injury group included rats (n = 10) subjected to CCI. Within the injury group, the microdialysis probe was placed in the center of the eventual contusion (center, n = 5) or in the penumbral region (penumbra, n = 5). Purine metabolites were measured using ultraviolet-based high-pressure liquid chromatography. Adenosine, inosine, and hypoxanthine were dramatically increased after injury (61-fold, 37-fold, and 16-fold, respectively sham, all p < 0.05, two-way analysis of variance for repeated measures). No changes in cAMP were observed (p = 0.62 vs. sham). Adenosine peaked in the first 20 min and returned to near baseline 40 min, whereas inosine and hypoxanthine peaked at 30 min and remained increased for 40 min after CCI. Interstitial brain adenosine, inosine, and hypoxanthine were increased early after CCI in rats in the contusion and penumbra. ATP breakdown is a potential source of adenosine in this early period while metabolism of cAMP does not appear to play a role. Confirmation of these data in humans may suggest new strategies targeting this important metabolic pathway.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Neurosurg, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Wisniewski, Stephen/0000-0002-3877-9860			ANGELLO DA, 1991, AM J PHYSIOL, V260, pH193; BOWERY NG, 1988, BRIT J PHARMACOL, V93, P944, DOI 10.1111/j.1476-5381.1988.tb11484.x; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; DONAGHY KM, 1994, BRAIN RES, V656, P174, DOI 10.1016/0006-8993(94)91380-3; FASTBOM J, 1987, NEUROSCIENCE, V22, P813, DOI 10.1016/0306-4522(87)92961-7; FOWLER JC, 1993, NEUROSCI LETT, V157, P83, DOI 10.1016/0304-3940(93)90648-5; GEIGER JD, 1997, PURINERGIC APPROACHE, P59; GIDDAY JM, 1995, PEDIATR RES, V38, P306, DOI 10.1203/00006450-199509000-00006; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HENDRICH KS, 1997, J CEREB BLOOD FLOW M, V17, pS76; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; JARVIS MF, 1989, BRAIN RES, V484, P111, DOI 10.1016/0006-8993(89)90353-3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LAUDIGNON N, 1990, J APPL PHYSIOL, V68, P1534; MENO JR, 1993, J CEREBR BLOOD F MET, V13, P214, DOI 10.1038/jcbfm.1993.26; MENO JR, 1991, J CEREBR BLOOD F MET, V11, P986, DOI 10.1038/jcbfm.1991.165; MI ZC, 1995, J PHARMACOL EXP THER, V273, P728; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; MORI M, 1992, NEUROSCIENCE, V46, P301, DOI 10.1016/0306-4522(92)90052-4; MORII S, 1986, J CEREBR BLOOD F MET, V6, P34, DOI 10.1038/jcbfm.1986.5; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PEDATA F, 1993, J NEUROCHEM, V61, P284, DOI 10.1111/j.1471-4159.1993.tb03566.x; PHILLIS JW, 1994, BRAIN RES, V652, P353, DOI 10.1016/0006-8993(94)90248-8; PHILLIS JW, 1975, EUR J PHARMACOL, V30, P125, DOI 10.1016/0014-2999(75)90214-9; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; RUDOLPHI KA, 1987, J CEREBR BLOOD F MET, V7, P74, DOI 10.1038/jcbfm.1987.11; RUTH VJ, 1993, AM J PHYSIOL, V265, pH1762; SEGAL M, 1982, EUR J PHARMACOL, V79, P193, DOI 10.1016/0014-2999(82)90625-2; SIGGINS GR, 1981, NEUROSCI LETT, V23, P55, DOI 10.1016/0304-3940(81)90186-5; TOMINAGA K, 1992, NEUROSCI LETT, V145, P67, DOI 10.1016/0304-3940(92)90205-L; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; VANWYLEN DGL, 1988, AM J PHYSIOL, V24, pH1211; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V263, P59, DOI 10.1016/0014-2999(94)90523-1; WALLMANJOHANSSON A, 1994, LIFE SCI, V55, P721, DOI 10.1016/0024-3205(94)00680-6; WINN HR, 1981, AM J PHYSIOL, V241, pH235; ZHOU JG, 1994, J CEREBR BLOOD F MET, V14, P166, DOI 10.1038/jcbfm.1994.22	39	74	75	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					163	170		10.1089/neu.1998.15.163			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500001	9528916				2021-06-18	
J	Durkin, MS; Hasan, ZM; Hasan, KZ				Durkin, MS; Hasan, ZM; Hasan, KZ			Prevalence and correlates of mental retardation among children in Karachi, Pakistan	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						child development; developing countries; developmental disabilities; mental retardation; prevalence	10 QUESTIONS SCREEN; CHILDHOOD DISABILITY; BANGLADESH	This paper reports estimates of the prevalence of mental retardation and associated factors based on a population survey of 2- to 9-year-old children in Greater Karachi, Pakistan. A two-phase survey was implemented during the years 1988-1989, In the first phase, a cluster sample of 6,365 children (5,748 from urban areas and 617 from rural areas) was screened for disabilities using a parental report known as the Ten Questions instrument, In the second phase, all children with positive screening results and a 10% sample of those with negative results were referred for structured medical and psychological assessments, Estimates of the prevalence of mental retardation were 19.0/1,000 children (95% confidence interval (CI) 13.5-24.4) for serious retardation and 65.3/1,000 children (95% CI 48.9-81.8) for mild retardation. Both estimates were considerably higher than respective prevalence estimates obtained in industrialized countries and in selected less developed countries. In this population, lack of maternal education was strongly associated with the prevalence of both serious (odds ratio = 3.26, 95% CI 1.26-8.43) and mild (odds ratio = 3.08, 95% CI 1.85-5.14) retardation. Other factors that were independently associated with mental retardation in Karachi included histories of perinatal difficulties, neonatal infections, postnatal brain infections, and traumatic brain injury, as well as current malnourishment. Further research is needed to assess the contribution of consanguineous marriage, improvements in child survival, and other factors to the unusually high prevalence of mental retardation in this population.	Columbia Univ, Gertrude H Sergievsky Ctr, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; New York State Psychiat Inst, New York, NY 10032 USA; Jinnah Postgrad Med Ctr, Dept Neuropsychiat, Karachi, Pakistan; Jinnah Med Coll, Karachi, Pakistan	Durkin, MS (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, Coll Phys & Surg, 630 W 168 St, New York, NY 10032 USA.		Durkin, Maureen/B-7834-2015		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27971-01-05] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027971] Funding Source: NIH RePORTER		Belmont L., 1986, SCI TECHNOLOGY MENTA, P389; BHUSHAN V, 1993, PEDIATRICS, V91, P1094; CHEN JH, 1993, CHILD CARE HLTH DEV, V19, P71, DOI 10.1111/j.1365-2214.1993.tb00715.x; DARR A, 1988, J MED GENET, V25, P186, DOI 10.1136/jmg.25.3.186; DRILLIEN CM, 1966, ARCH DIS CHILD, V41, P528, DOI 10.1136/adc.41.219.528; Durkin M S, 1992, Paediatr Perinat Epidemiol, V6, P166, DOI 10.1111/j.1365-3016.1992.tb00758.x; DURKIN MS, 1994, EPIDEMIOLOGY, V5, P283, DOI 10.1097/00001648-199405000-00005; DURKIN MS, 1995, J CLIN EPIDEMIOL, V48, P657, DOI 10.1016/0895-4356(94)00163-K; DURKIN MS, 1995, J EPIDEMIOL COMMUN H, V49, P431, DOI 10.1136/jech.49.4.431; DURKIN MS, IN PRESS PUBLIC HLTH; EYMAN RK, 1990, NEW ENGL J MED, V323, P584, DOI 10.1056/NEJM199008303230906; FOEGE W, 1994, JAMA-J AM MED ASSOC, V271, P1704, DOI 10.1001/jama.271.21.1704; FULLER WA, 1989, PC CARP; HASNA Z, 1981, INT J MENT HLTH, V10, P23; HASNA ZM, 1988, 8 WORLD C INT ASS SC; Hosmer DW, APPL LOGISTIC REGRES, P89; ISLAM S, 1993, MENT RETARD, V31, P412; KIELY M, 1987, EPIDEMIOL REV, V9, P194, DOI 10.1093/oxfordjournals.epirev.a036302; LEMESHOW S, 1988, SAMPLING TECHNIQUES; NARAYANAN HS, 1981, INT J MENT HEALTH, V10, P28, DOI 10.1080/00207411.1981.11448873; Reddy MA, 1996, STAT ABSTRACT WORLD; ROBERTS DF, 1969, ANN HUM GENET, V32, P407, DOI 10.1111/j.1469-1809.1969.tb00093.x; SHAMI SA, 1989, J MED GENET, V26, P267, DOI 10.1136/jmg.26.4.267; SHROUT PE, 1989, BIOMETRICS, V45, P549, DOI 10.2307/2531496; STEIN Z, 1984, STRESS DISABILITY CH, P21; Thorburn M J, 1992, Disabil Rehabil, V14, P122; Thorndike RL., 1986, STANFORD BINET INTEL, V4; Stein ZA, 1992, ASSESSMENT PEOPLE ME, P12	28	74	75	0	1	JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH	BALTIMORE	111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	FEB 1	1998	147	3					281	288					8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	YX150	WOS:000072011400014	9482503				2021-06-18	
J	Bellander, BM; vonHolst, H; Fredman, P; Svensson, M				Bellander, BM; vonHolst, H; Fredman, P; Svensson, M			Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat	JOURNAL OF NEUROSURGERY			English	Article						microglia; astroglia; complement factor C3d and C9; clusterin; rat	SULFATED GLYCOPROTEIN-2 SGP-2; FIBRILLARY ACIDIC PROTEIN; PERIPHERAL-NERVE INJURY; HYPOGLOSSAL NUCLEUS; ALZHEIMERS-DISEASE; NEURONAL SURVIVAL; GENE-EXPRESSION; MESSENGER-RNA; MICROGLIA; SYSTEM	The aim of the present study was to examine the glial cell response and the possible involvement of the complement cascade following a cerebral cortical contusion. The lesion was produced using a standardized weight-drop technique in adult rats. The blood-brain barrier was damaged, as demonstrated by a decrease of immunoreactivity for a tight junction protein normally expressed by endothelial cells of small vessels in the central nervous system. Increased immunoreactivity for microglial (OX42) and astroglial cells (glial fibrillary acidic protein), as well as macrophages expressing ED1-immunoreactivity (IR) were found in the vicinity of the lesion at all postoperative survival times (2-14 days). In the present study complement factor C3d- and C9-IR was found around the lesion, indicating that activation of the complement cascade had taken place. Furthermore, immunoreactivity for the putative complement inhibitor clusterin (sulfated glycoprotein-2) was found in some of the injured neurons. The contralateral hemisphere showed no evidence of the reaction found in the ipsilateral hemisphere. The balance between complement activation and complement inhibitors may have an impact on the degenerative components in the brain following traumatic injury and in particular on the events leading to nerve cell death.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT CLIN NEUROSCI,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT NEUROSCI,NEUROSURG SECT,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT NEUROSCI,SECT ANAT,S-10401 STOCKHOLM,SWEDEN; GOTHENBURG UNIV,CENT HOSP MOLNDAL,DEPT CLIN NEUROSCI,MOLNDAL,SWEDEN			Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003			AGOSTONI A, 1992, INT J IMMUNOPATH PH, V5, P123, DOI 10.1177/039463209200500207; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BRUCK W, 1991, J NEUROL SCI, V103, P182, DOI 10.1016/0022-510X(91)90162-Z; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CAVANAGH JB, 1970, J ANAT, V106, P471; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DAY JR, 1990, MOL ENDOCRINOL, V4, P1995, DOI 10.1210/mend-4-12-1995; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HANSCH GM, 1992, IMMUNOPHARMACOLOGY, V24, P107, DOI 10.1016/0162-3109(92)90017-7; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JONES J, 1990, COMPLEMENT INFLAMMAT, V7, P42, DOI 10.1159/000463125; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KONIGSMARK BW, 1963, J NEUROPATH EXP NEUR, V22, P643; LACHMANN PJ, 1991, IMMUNOL TODAY, V12, P312, DOI 10.1016/0167-5699(91)90005-E; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; LING EA, 1981, ADV CELL NEUROBIOL, V2, P33; LIU L, 1995, NEUROSCIENCE, V68, P167, DOI 10.1016/0306-4522(95)00103-P; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCNEILL T H, 1990, Society for Neuroscience Abstracts, V16, P1291; MICHEL D, 1992, SYNAPSE, V11, P105, DOI 10.1002/syn.890110203; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; NICHOLS NR, 1990, MOL BRAIN RES, V7, P1, DOI 10.1016/0169-328X(90)90066-M; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PASINETTI GM, 1991, NEUROSCI LETT, V130, P1, DOI 10.1016/0304-3940(91)90213-D; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; ROSEN H, 1990, J LEUKOCYTE BIOL, V48, P465; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; STOLL G, 1991, ANN NEUROL, V30, P147, DOI 10.1002/ana.410300205; SVENSSON M, 1993, J NEUROSCI RES, V35, P373, DOI 10.1002/jnr.490350404; SVENSSON M, 1995, MOL CHEM NEUROPATHOL, V24, P53, DOI 10.1007/BF03160112; SVENSSON M, 1992, J NEUROCYTOL, V21, P222, DOI 10.1007/BF01194980; SVENSSON M, 1992, J NEUROIMMUNOL, V40, P99, DOI 10.1016/0165-5728(92)90217-9; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; THANOS S, 1993, J NEUROSCI, V13, P455; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; TODD NV, 1990, ACT NEUR S, V51, P296; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	56	74	78	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1996	85	3					468	475		10.3171/jns.1996.85.3.0468			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VD347	WOS:A1996VD34700017	8751634				2021-06-18	
J	Lee, AJ; Garraway, WM				Lee, AJ; Garraway, WM			Epidemiological comparison of injuries in school and senior club rugby	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						prevention; rugby football injuries; schoolboys; senior club players	CONCUSSION; FOOTBALL; PLAYERS	Objective-To determine the frequency, nature, circumstances, and outcome of schoolboy rugby injuries and to compare these injuries with those occurring in senior rugby clubs. Methods-The study was a prospective cohort study, conducted on 1705 (98%) of 1736 eligible players from nine Edinburgh schools and 1169 (96%) of 1216 eligible players from all 26 senior Scottish Rugby Union clubs (South District) who provided personal details before the 1993-1994 rugby season. Adult linkpersons were appointed to notify the circumstances of all injury episodes occurring in matches or in rugby related training. Results-154 school players (9%) experienced 210 separate injuries in 186 injury episodes, 80% of which arose in matches. The prevalence rate of schoolboy match injuries was 86.8 (95% confidence interval 73.4 to 100.2) per 1000 player-seasons. Senior club match injury prevalence was much higher at 367.0 (339.4 to 394.6) per 1000 player-seasons. Club players had a higher rate of match injury than schoolboys for all injury types. One third of schoolboy match injury episodes occurred in September and the majority of match injury episodes were associated with tackling (40%) or with being tackled (24%). Nine per cent of schoolboy match injury episodes were classified as severe, compared to 13% for clubs. Sixteen per cent (n = 23) of all schoolboy match injury episodes resulted in missed school attendance compared with 27% (n = 117) of all senior club match injury episodes which involved loss of employment or education. Conclusions-Schoolboy rugby is much safer than senior club rugby and the outcome of injuries that do occur is less disruptive. The relatively high rate of match injury in September might be reduced by a more intensive period of preseason training.		Lee, AJ (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,SCH MED,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.						Dalley D., 1989, NZ J SPORTS MED, V20, P2; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; DIXON G, 1993, NZ J SPORTS MED, V2, P18; GARRAWAY M, 1995, LANCET, V345, P1485; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; HOSKINS T, 1979, PRACTICE MED, V223, P265; JANE JA, 1989, MILD MODERATE HEAD I; KEW T, 1991, S AFR MED J, V80, P127; MCQUILLAN R, 1992, IRISH MED J, V85, P72; MYERS PT, 1980, MED J AUSTRALIA, V2, P17, DOI 10.5694/j.1326-5377.1980.tb131804.x; NATHAN M, 1983, S AFR MED J, V64, P132; O'Brien C, 1992, Br J Sports Med, V26, P243; ROUX CE, 1987, S AFR MED J, V71, P307; ROY SP, 1974, S AFR MED J, V48, P2321; SCHER AT, 1991, AM J SPORT MED, V19, P485, DOI 10.1177/036354659101900511; *SCOTT RUGB UN, 1995, COACH MED MAN 1, P22; Silver J R, 1992, Br J Sports Med, V26, P253; Sparks J P, 1981, Br J Sports Med, V15, P30; Sugerman S, 1983, AUST J SPORTS MED EX, V15, P5; WATSON AWS, 1981, J SPORT MED PHYS FIT, V21, P417; 1995, IRFB HDB, P106	24	74	75	0	15	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	SEP	1996	30	3					213	217		10.1136/bjsm.30.3.213			5	Sport Sciences	Sport Sciences	VJ620	WOS:A1996VJ62000010	8889113	Bronze, Green Published			2021-06-18	
J	Cargill, RS; Thibault, LE				Cargill, RS; Thibault, LE			Acute alterations in [Ca2+]i in NG108-15 cells subjected to high strain rate deformation and chemical hypoxia: An in vitro model for neural trauma	JOURNAL OF NEUROTRAUMA			English	Article						hypoxia; injury; mechanical injury; NG108-15; TBI	BRAIN INJURY; HEAD-INJURY; INTRACRANIAL-PRESSURE; PATHO-PHYSIOLOGY; CALCIUM; CULTURE; INVITRO; DAMAGE; MITOCHONDRIA; GENERATION	The short-term (less than 2 min) alterations in the intracellular free calcium concentration in differentiated NG108-15 (neuroblastoma cross glioma) cells exposed to dynamic mechanical deformation with and without superimposed chemical hypoxia were determined, A previously developed device, modified for these studies, was used to apply deformations at a magnitude and rate representative of those experienced by neural tissue in Traumatic Brain Injury, Chemical hypoxia was imposed using a combination of 2-deoxy-D-glucose and salicylate, anaerobic and aerobic metabolic blockers, respectively, Real time measurement of intracellular free calcium concentration using Fura-2 and a custom epifluorescence microscopy system provided a quantitative index of cell response, At high rates of deformation (similar to 10 sec(-1)), increases in intracellular free calcium concentration were exponentially related to the magnitude of the applied deformation, Chemical hypoxia had no effect on this acute response, At low rates of deformation, small increases in intracellular free calcium concentration were independent of the magnitude of the deformation, These findings indicate that strategies for seducing severity of TBI should focus on minimizing the rate of deformation of neural cells, Together with data from animal, physical, and finite element models, these data can be employed in the development of physiologic injury tolerance criteria for the whole head.	UNIV PENN,DEPT BIOENGN,PHILADELPHIA,PA 19104					NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL034005] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 34005] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR304684] Funding Source: Medline		AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; BALENTINE JD, 1988, LAB INVEST, V58, P93; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; BOOCK RJ, 1993, ANN BIOMED ENG, V21, P645, DOI 10.1007/BF02368644; BOOCK RJ, 1990, INT C BIOM IMP LY FR; BOUMA G, 1992, NEUROTRAUMA, V9, pS333; BRODY TM, 1956, J PHARMACOL EXP THER, V117, P39; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; CUNARRO J, 1975, BIOCHIM BIOPHYS ACTA, V387, P234, DOI 10.1016/0005-2728(75)90106-1; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FUNG YC, 1993, BIOMECHANICS; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTKNECHT J, 1990, J MEMBRANE BIOL, V115, P253, DOI 10.1007/BF01868640; HAAS R, 1985, BIOCHEM PHARMACOL, V34, P900; HUNG CT, 1993, J BIOMECH, V27, P227; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KONGSAMUT S, 1985, BIOCHEM BIOPH RES CO, V130, P141, DOI 10.1016/0006-291X(85)90393-6; KURZINGER K, 1980, EUR J BIOCHEM, V103, P597, DOI 10.1111/j.1432-1033.1980.tb05985.x; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MEANEY DF, 1990, INT C BIOM IMP LY FR; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; NICHOLLS DG, 1985, MOL MECH ISCHEMIC BR, P97; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; OHKUMA S, 1994, MOL BRAIN RES, V22, P166, DOI 10.1016/0169-328X(94)90044-2; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SEARLES CD, 1988, BRAIN RES, V448, P373, DOI 10.1016/0006-8993(88)91280-2; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; THIBAULT LE, 1990, INT C BIOM IMP LY FR; THIBAULT LE, 1982, 35 ACEMB PHIL PENNS; THIBAULT LE, 1987, STAPP CAR CRASH C NE; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WATSON PA, 1991, FASEB J, V5, P2013; WHITEHOUSE MW, 1964, BIOCHEM PHARMACOL, V13, P319, DOI 10.1016/0006-2952(64)90148-0; WILLIAMS JL, 1992, J BIOMECH ENG-T ASME, V114, P377, DOI 10.1115/1.2891398; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861	47	74	75	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1996	13	7					395	407		10.1089/neu.1996.13.395			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VB732	WOS:A1996VB73200005	8863195				2021-06-18	
J	Sinson, G; Voddi, M; McIntosh, TK				Sinson, G; Voddi, M; McIntosh, TK			Combined fetal neural transplantation and nerve growth factor infusion: Effects on neurological outcome following fluid-percussion brain injury in the rat	JOURNAL OF NEUROSURGERY			English	Article						fluid-percussion injury; nerve growth factor; neural transplantation; cognitive dysfunction; traumatic brain injury	FRONTAL-CORTEX ABLATION; CAT SPINAL-CORD; ADULT-RATS; PARKINSONS-DISEASE; CAUDATE-NUCLEUS; LESIONS; TISSUE; GRAFTS; RECOVERY; NEURONS	This study was designed to evaluate the histological and behavioral impact of fetal neural transplantation with and without neurotrophin infusion in rats subjected to traumatic brain injury using a clinically relevant model of lateral fluid-percussion brain injury. Adult male Sprague-Dawley rats received lateral fluid-percussion brain injury of moderate severity (2.1-2.3 aim). Twenty-four hours after injury, minced fetal cortical grafts (E16) were stereotactically transplanted into the site of injury cavity formation (in 32 rats). Ten control animals received injections of saline. A third group of 29 animals that received transplants also underwent placement of a miniosmotic pump (immediately after transplantation) to continuously infuse nerve growth factor (NGF) directly into the region of graft placement for the duration of the experiment. A fourth group of eight animals underwent transplantation of fetal cortical cells that had been dissociated and placed in suspension. Animals were evaluated at 72 hours, 1 week, and 2 weeks after injury for cognitive function (using the Morris water maze), posttraumatic motor dysfunction, and transplant survival and morphology (using Nissl and modified Palmgren's silver staining techniques). Robust survival of whole-tissue transplants was seen in 65.6% of animals and was not increased in animals receiving NGF infusion. Animals receiving transplants of cell suspension had no surviving grafts. Brain-injured animals receiving transplants showed significant cognitive improvements compared with controls at the 2-week evaluation. Significantly improved memory scores were seen at all evaluation times in animals receiving both NGF and transplants compared with injured controls and compared with animals receiving transplants alone at the 72-hour and 1-week evaluations. Neurological motor function scores were significantly improved in animals receiving transplants alone and those receiving transplants with NGF infusion. Histological evaluation demonstrated differentiation of grafted cells, decreased glial scarring around transplants when compared with control animals, and the presence of neuronal fibers bridging the interface between graft and host. This study demonstrates that fetal cortical cells transplanted into the injured cortex of the adult rat can improve both posttraumatic cognitive and motor function and interact with the injured host brain.	UNIV PENN, SCH MED, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R55NS026818, P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline		Aguayo A. J., 1985, SYNAPTIC PLASTICITY, P457; ANDERSON DK, 1991, RESTOR NEUROL NEUROS, V2, P309, DOI 10.3233/RNN-1991-245621; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P1; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DUNNETT SB, 1987, BEHAV NEUROSCI, V101, P489, DOI 10.1037/0735-7044.101.4.489; DUNNETT SB, 1986, BRAIN RES, V378, P357, DOI 10.1016/0006-8993(86)90939-X; FINE A, 1985, NEUROSCIENCE, V16, P769, DOI 10.1016/0306-4522(85)90093-4; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREEMAN TB, 1994, NEUROL TRANSPL, V1, P29; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GIACOBINI MMJ, 1991, EXP BRAIN RES, V86, P73; GONZALEZ MF, 1988, EXP NEUROL, V99, P154, DOI 10.1016/0014-4886(88)90135-5; GOSHGARIAN HG, 1977, EXP NEUROL, V57, P296, DOI 10.1016/0014-4886(77)90065-6; HADANI M, 1992, J NEUROTRAUM, V9, P107, DOI 10.1089/neu.1992.9.107; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HUDSON JL, 1994, J NEUROSCI, V14, P283; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; JACOBS SE, 1994, J NEUROSCI, V14, P697; JAKEMAN LB, 1991, J COMP NEUROL, V307, P311, DOI 10.1002/cne.903070211; KESSLAK JP, 1986, EXP NEUROL, V94, P615, DOI 10.1016/0014-4886(86)90241-4; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; KIMBLE DP, 1986, BRAIN RES, V363, P358, DOI 10.1016/0006-8993(86)91023-1; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOUTON PR, 1993, ACTA NEUROL SCAND, V87, P376; NETTO CA, 1993, BEHAV BRAIN RES, V58, P107, DOI 10.1016/0166-4328(93)90095-8; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; Obukhova G P, 1992, Neurosci Behav Physiol, V22, P1, DOI 10.1007/BF01186660; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALMGREN AXEL, 1960, ACTA ZOOL [STOCKHOLM], V41, P239; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; REIER PJ, 1992, EXP NEUROL, V115, P177, DOI 10.1016/0014-4886(92)90245-L; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; RIDLEY RM, 1991, EXP BRAIN RES, V83, P533; RUTHERFORD A, 1987, NEUROSCI LETT, V83, P275, DOI 10.1016/0304-3940(87)90099-1; SANTUCCI AC, 1993, DEMENTIA, V4, P273, DOI 10.1159/000107333; SCHULZ MK, 1993, EXP BRAIN RES, V96, P480; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; SOARES H, 1995, IN PRESS J NEUROTRAU; Soares HD, 1995, J NEUROSCI, V15, P8223; SOTELO C, 1994, J NEUROSCI, V14, P124; SOTELO C, 1987, NATURE, V327, P421, DOI 10.1038/327421a0; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; TARRICONE BJ, 1993, BRAIN RES, V632, P41, DOI 10.1016/0006-8993(93)91136-G; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; TUSZYNSKI MH, 1990, NEUROSCIENCE, V36, P33, DOI 10.1016/0306-4522(90)90349-9; WAYNE DB, 1990, DEV BIOL, V138, P473, DOI 10.1016/0012-1606(90)90213-3; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403	59	74	81	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	1996	84	4					655	662		10.3171/jns.1996.84.4.0655			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UC211	WOS:A1996UC21100016	8613859				2021-06-18	
J	Dixon, CE; Bao, JL; Long, DA; Hayes, RL				Dixon, CE; Bao, JL; Long, DA; Hayes, RL			Reduced evoked release of acetylcholine in the rodent hippocampus following traumatic brain injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						brain injury; acetylcholine; microdialysis; scopolamine; rat	NUCLEUS BASALIS MAGNOCELLULARIS; CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; EXTRACELLULAR ACETYLCHOLINE; MEMORY IMPAIRMENT; PLACE NAVIGATION; RAT; MICRODIALYSIS; LESIONS; DEAFFERENTATION	The chronic effects of traumatic brain injury on acetylcholine release were evaluated by using in vivo microdialysis. Acetylcholine release was measured in the hippocampus of anesthetized rats 2 weeks after lateral controlled cortical impact (n = 10) or sham surgery (n = 10). Prior to microdialysis, behavioral assessments of motor and spatial memory were performed. Cortical impact (6 meter/s, 2 mm deformation) produced beam balance deficits that persisted for 1 day and beam walking deficits that persisted for 3 days after injury. In addition, spatial memory, as measured by swim latencies in a Morris water maze, was compromised between 10-14 days after injury. Immediately following behavioral testing, the animals were anesthetized with halothane, and a microdialysis probe was placed into the dorsal hippocampus. After a 160 min equilibration period, extracellular levels of acetylcholine were measured prior to and after an intraperitoneal administration of scopolamine (1 mg/kg), which evokes acetylcholine release by blocking autoreceptors. Prior to scopolamine administration, there were no differences in extracellular levels of acetylcholine between injured and sham animals. However, there was a significant reduction of hippocampal acetylcholine release evoked by scopolamine in injured animals as compared to sham controls. In separate control groups, saline administration alone did not change hippocampal acetylcholine release in injured(n = 5) or sham (n = 5) animals. This study represents the first application of in vivo microdialysis to evaluate chronic neurotransmission deficits following TBI. The present study demonstrates that a magnitude of traumatic brain injury (TBI) sufficient to produce spatial memory deficits can result in a reduction in scopolamine-evoked release of acetylcholine within the hippocampus. The data further suggest that presynaptic mechanisms mediating release of acetylcholine could play a significant role in cholinergic neurotransmission deficits following TBI.		Dixon, CE (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,6431 FANNIN ST,SUITE 7147,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49-CCR303547] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, P01, NS31998] Funding Source: Medline		AMMASSARITEULE M, 1993, BEHAV BRAIN RES, V54, P145, DOI 10.1016/0166-4328(93)90073-Y; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; DAMSMA G, 1988, LIFE SCI, V43, P1161, DOI 10.1016/0024-3205(88)90475-4; DAMSMA G, 1991, LIFE SCI, V48, P2469, DOI 10.1016/0024-3205(91)90383-M; Dixon C. E., 1992, Society for Neuroscience Abstracts, V18, P171; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1995, J NEUROTRAUM, V12, P971; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GREANEY MD, 1993, J CHROMATOGR-BIOMED, V622, P125, DOI 10.1016/0378-4347(93)80258-6; HAGAN JJ, 1988, BEHAV BRAIN RES, V27, P9, DOI 10.1016/0166-4328(88)90105-2; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HUFF FJ, 1988, DRUG DEVELOP RES, V12, P271; JAMES MK, 1987, J PHARMACOL EXP THER, V240, P203; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; KILBINGER H, 1984, EUR J PHARMACOL, V103, P313, DOI 10.1016/0014-2999(84)90492-8; LEANZA G, 1993, BRAIN RES, V615, P147, DOI 10.1016/0006-8993(93)91126-D; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MIYAMOTO M, 1987, BRAIN RES, V419, P19, DOI 10.1016/0006-8993(87)90564-6; MIZUNO T, 1991, NEUROSCIENCE, V44, P607, DOI 10.1016/0306-4522(91)90081-X; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; MORTIMER JA, 1991, INT J EPIDEMIOL S2, V20, P528; NILSSON OG, 1993, ANN NY ACAD SCI, V695, P267, DOI 10.1111/j.1749-6632.1993.tb23065.x; NORTH RA, 1986, TRENDS PHARM SCI S, V7, P19; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OGANE N, 1990, NEUROSCI LETT, V114, P95, DOI 10.1016/0304-3940(90)90434-B; Pepeu G, 1973, Prog Neurobiol, V2, P259, DOI 10.1016/0301-0082(73)90009-9; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCINTO LFM, 1994, SCIENCE, V266, P1051, DOI 10.1126/science.7973660; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STARKE K, 1989, PHYSIOL REV, V69, P864; STILLMAN MJ, 1993, BRAIN RES BULL, V32, P385, DOI 10.1016/0361-9230(93)90204-O; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1985, PSYCHOPHARMACOLOGY, V87, P247, DOI 10.1007/BF00431817; SUTHERLAND RJ, 1982, J COMP PHYSIOL PSYCH, V96, P563, DOI 10.1037/h0077914; SZERB JC, 1977, BRAIN RES, V128, P285, DOI 10.1016/0006-8993(77)90995-7; TOIDE K, 1993, EUR J PHARMACOL, V233, P21, DOI 10.1016/0014-2999(93)90344-H	47	74	74	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	MAR	1996	53	3					679	686		10.1016/0091-3057(95)02069-1			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	TX845	WOS:A1996TX84500029	8866972				2021-06-18	
J	Massagli, TL; Michaud, LJ; Rivara, FP				Massagli, TL; Michaud, LJ; Rivara, FP			Association between injury indices and outcome after severe traumatic brain injury in children	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; RECOVERY; ADOLESCENTS; MANAGEMENT; DISABILITY; MOTOR	Objectives: (1) To determine whether indices of traumatic brain injury (TBI) in children are associated with outcome at hospital discharge and 5 to 7 years later; (2) to describe persisting disabilities. Design: Retrospective, uncontrolled study of a cohort of children with severe, nonpenetrating TBI. Setting: Consecutive admissions to a level 1 trauma center over 2 years. Subjects: Seventy-five children younger than 17 years old were previously studied to identify predictors of disability at acute care discharge. Thirty-three of the 50 survivors (66%) were enrolled. Main Outcome Measures: A database of variables abstracted from medical records was available from the previous study. Subjects were surveyed about premorbid problems, school, employment, and current function, and school records were reviewed. Using all information, a Glasgow Outcome Scale (GOS) score was assigned 5 to 7 years after TBI. Associations between database variables and GOS score at discharge and follow-up were examined using nonparametric analyses. The odds ratio for good recovery was calculated for all significant associations. Results: Late GOS was good recovery for 27%, moderate disability for 55%, and severe disability for 18%. Discharge GOS scores were related (p less than or equal to .01) to the head Abbreviated Injury Scale score, Injury Severity Scale score, Glasgow Coma Scale (GCS) score measured in the field and at 6, 24, and 72 hours, the length of coma, and initial discharge site. Late GOS scores were related (p less than or equal to .01) to the same variables except the field and 6-hour GCS scores, as well as pupillary responses in the field and the discharge GOS. At follow-up, 64% were independent in mobility, 70% in self-care, and 24% in cognitive items on the Functional Independence Measure. Seventy percent of children received special education services. Employment histories were poor. Most subjects were not receiving neurological or rehabilitation follow-up. Conclusions: Early and late outcome after severe TBI are related to variables measured at and after injury. Subjects had long-term educational and vocational problems but often did not utilize the medical model of neurorehabilitation. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of physical Medicine and Rehabilitation.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; CHILDRENS HOSP PHILADELPHIA,CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA; UNIV PENN,DEPT REHABIL MED,PHILADELPHIA,PA; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; WASHINGTON UNIV,DEPT EPIDEMIOL,SEATTLE,WA; WASHINGTON UNIV,HARBORVIEW INJURY PREVENT & RES CTR,SEATTLE,WA	Massagli, TL (corresponding author), CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,CH-71,POB 5371,SEATTLE,WA 98105, USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; Dean AG., 1994, EPI INFO VERSION 6 W; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Epstein J. C., 1977, QUALITY SCH LIFE SCA; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NORUSIS MJ, 1986, SPSS PC PLUS IBM PCX; RAPHAELY RC, 1980, PEDIATR CLIN N AM, V27, P715; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; ROSNER B, 1986, FUNDAMENTALS BIOSTAT; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; 1989, GUIDE USE FUNCTIONAL	40	74	74	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1996	77	2					125	132		10.1016/S0003-9993(96)90156-2			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TU541	WOS:A1996TU54100003	8607735				2021-06-18	
J	Johnstone, B; Callahan, CD; Kapila, CJ; Bouman, DE				Johnstone, B; Callahan, CD; Kapila, CJ; Bouman, DE			The comparability of the WRAT-R reading test and NAART as estimates of premorbid intelligence in neurologically impaired patients	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							WAIS-R	A study by Wiens, Bryan, and Crossen (1993) suggests the Wide Range Achievement Test-Revised (WRAT-R) Reading subtest and North American Adult Reading Test (NAART) are adequate predictors of Wechsler Adult Intelligence Scale-Revised (WAIS-R) IQ scores for a normal population. Although it is common practice to use reading scores to estimate premorbid IQ in clinical populations, the WRAT-R and NAART have not been compared using individuals with brain dysfunction The current study cross-validated the Wiens et al. (1993) study using neurologically impaired populations: traumatic brain injury (n = 118), dementia (n = 37), and other neurologic impairments (n = 77). The results were generally consistent across all three groups: (a) the WRAT-R and NAART were equivalent and accurate estimates of average VIQ levels; (b) the WRAT-R and NAART were equivalent but underestimates of higher intelligence ranges: and (c) the WRAT-R is a more accurate estimate for lower VIQ ranges, although both are overestimates. This third finding is in contrast to Wiens et al.'s (1993) results that suggest the WRAT-R is an accurate estimate of lower Ie ranges for normals. It is concluded that the WRAT-R is the preferred measure of premorbid verbal intelligence for psychometric and clinical reasons.	UNIV MISSOURI,SCH MED,COLUMBIA,MO; MEM MED CTR,DEPT PSYCHOL,SPRINGFIELD,IL 62781; DRAKE CTR,DEPT PSYCHOL,CINCINNATI,OH				Johnstone, Brick/0000-0001-8845-9649			BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BERRY DTR, 1994, ARCH CLIN NEUROPSYCH, V9, P239, DOI 10.1016/0887-6177(94)90029-9; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BUTTERS N, 1990, J CLIN EXP NEUROPSYC, V12, P963, DOI 10.1080/01688639008401035; Christensen H., 1991, J CONSULT CLIN PSYCH, V3, P147, DOI DOI 10.1037/1040-3590.3.2.147; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC; JSTAK S, 1984, WRAT R WIDE RANGE AC; KARAKEN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P147; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Nelson H., 1982, NATIONAL ADULT READI; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P18, DOI 10.1080/13854049008401493; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889	14	74	75	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	6					513	519		10.1016/0887-6177(96)82330-4			7	Psychology, Clinical; Psychology	Psychology	VF792	WOS:A1996VF79200005	14588456	Bronze			2021-06-18	
J	GUTLING, E; GONSER, A; IMHOF, HG; LANDIS, T				GUTLING, E; GONSER, A; IMHOF, HG; LANDIS, T			EEG REACTIVITY IN THE PROGNOSIS OF SEVERE HEAD-INJURY	NEUROLOGY			English	Article							SOMATOSENSORY-EVOKED-POTENTIALS; POST-TRAUMATIC COMA; BRAIN-FUNCTION; CONDUCTION; PREDICTION	We compared reactivity of EEG to external stumuli-an easily and quickly available measure-with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head injury (SHI), and with the initial Glasgow Coma Scale (GCS) score. In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years. Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups. GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability. EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS. When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method.	UNIV HOSP, DEPT NEUROL, GENEVA, SWITZERLAND	GUTLING, E (corresponding author), UNIV ZURICH HOSP, DEPT NEUROL, NEUROL KLIN, EEG UNIT, CH-8091 ZURICH, SWITZERLAND.						BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; Courjon J, 1971, Rev Electroencephalogr Neurophysiol Clin, V1, P133, DOI 10.1016/S0370-4475(71)80054-0; FISCHGOLD H, 1946, SEM HOP PARIS, V22, P1245; FISCHGOLD H, 1955, PRESSE MED, V63, P1231; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JASPER H, 1949, ELECTROEN CLIN NEURO, V1, P405, DOI 10.1016/0013-4694(49)90213-8; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; MATHIS P, 1957, ELECTROENCEPHALOGR C, V6, P453; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; MOULTON RJ, 1988, CAN J NEUROL SCI, V15, P82, DOI 10.1017/S0317167100027244; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P420, DOI 10.1016/0013-4694(83)90224-9; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989	20	74	86	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY	1995	45	5					915	918		10.1212/WNL.45.5.915			4	Clinical Neurology	Neurosciences & Neurology	QY820	WOS:A1995QY82000012	7746406				2021-06-18	
J	ETCOFF, NL; FREEMAN, R; CAVE, KR				ETCOFF, NL; FREEMAN, R; CAVE, KR			CAN WE LOSE MEMORIES OF FACES - CONTENT SPECIFICITY AND AWARENESS IN A PROSOPAGNOSIC	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							POSTERIOR CEREBRAL-LESIONS; ASSOCIATIVE VISUAL AGNOSIA; MENTAL-IMAGERY; FACIAL RECOGNITION; REPRESENTATION; ORGANIZATION; KNOWLEDGE; DISORDERS; IDENTITY; CONTOURS	Prosopagnosia is a neurological syndrome in which patients cannot recognize faces. Recently it has been shown that some prosopagnosics give evidence of "covert" recognition: they show greater autonomic responses to familar faces than to unfamiliar ones, and respond differently to familiar faces in learning and interference tasks. Although some patients do not show covert recognition, this has usually been attributed to an "apperceptive" deficit that impairs perceptual analysis of the input. The implication is that prosopagnosia is a deficit in access to, or awareness of, memories of faces: the inducing brain injury does not destroy the memories themselves. We present a case study that challenges this view. LH suffers from prosopagnosia as the result of a closed head injury. He cannot recognize familiar faces or report that they are familiar, nor answer questions about the faces from memory, though he can (1) recognize common objects and subtly varying shapes, (2) match faces while ignoring irrelevant information such as emotional expression or angle of view, (3) recognize sex, age, and likeability from faces, and (4) recognize people by a number of nonfacial channels. The only other categories of shapes that he has marked trouble recognizing are animals and emotional expressions, though even these impairments were not as severe as the one for faces. Three measures (sympathetic skin response, pupil dilation, and learning correct and incorrect names of faces) failed to show any signs of covert face recognition in LH, though the measures were sensitive enough to reflect autonomic reactions in LH to stimuli other than faces, and face familiarity in normal controls. Thus prosopagnosia cannot always be attributed to a mere absence of awareness (i.e., preserved information about faces whose output is disconnected from conscious congnitive processing), to an apperceptive deficit (i.e., preserved information about faces that cannot be accessed due to improperly analyzed perceptual input), or to an inability to recognize complex or subtly varying shapes (i.e., loss or degradation of shape memory in general). We conclude that it is possible for brain injury to eliminate the storage of information about familiar faces and certain related shapes.	MASSACHUSETTS GEN HOSP,NEUROPSYCHOL LAB,BOSTON,MA 02114; BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DIV NEUROL,BOSTON,MA 02215; UNIV CALIF SAN DIEGO,DEPT PSYCHOL,SAN DIEGO,CA 92103	ETCOFF, NL (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E10-237A,CAMBRIDGE,MA 02139, USA.						ALBERT ML, 1975, NEUROLOGY, V25, P322, DOI 10.1212/WNL.25.4.322; ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; Bauer R. M., 1986, ASPECTS FACE PROCESS, P253, DOI 10.1007/978-94-009-4420-6_27.; BAUER RM, 1984, NEUROPSYCHOLOGIA, V22, P457, DOI 10.1016/0028-3932(84)90040-X; Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BODAMER J, 1947, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V118, P6, DOI 10.1007/BF00352849; BORNSTEIN B, 1963, PROBLEMS DYNAMIC NEU; BRUYER R, 1983, BRAIN COGNITION, V2, P257, DOI 10.1016/0278-2626(83)90014-3; CAREY S, 1982, U SHAPED BEHAVIORAL; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1986, ASPECTS FACE PROCESS, P279; De Renzi E., 1986, ASPECTS FACE PROCESS, P243, DOI [10.1007/978-94-009-4420-6_26, DOI 10.1007/978-94-009-4420-6_26]; DEHAAN EHF, 1987, COGN NEUROPSYCHOL, V4, P385, DOI 10.1080/02643298708252045; Ekman P., 1975, PICTURES FACIAL AFFE; ETCOFF NL, 1984, NEUROPSYCHOLOGIA, V22, P281, DOI 10.1016/0028-3932(84)90075-7; ETCOFF NL, 1991, INT NEUROPSYCHOLOGIC; FARAH MJ, 1988, COGNITIVE PSYCHOL, V20, P439, DOI 10.1016/0010-0285(88)90012-6; FERRO JM, 1984, CORTEX, V20, P121, DOI 10.1016/S0010-9452(84)80029-5; FINKE RA, 1989, COGNITIVE SCI, V13, P51, DOI 10.1016/0364-0213(89)90011-6; GARNER WR, 1974, PROCESSING INFORMATI; HECAEN H, 1974, NEUROPSYCHOLOGIA, V12, P447, DOI 10.1016/0028-3932(74)90075-X; Hess E.H., 1972, HDB PSYCHOPHYSIOLOGY, P491, DOI DOI 10.3758/BF03204445; Hooper H.E., 1958, HOOPER VISUAL ORG TE; KANIZSA G, 1976, SCI AM, V234, P48, DOI 10.1038/scientificamerican0476-48; Kanizsa G., 1979, ORG VISION ESSAYS GE; Kanizsa G., 1982, ORG REPRESENTATION P, P167; LANDIS T, 1986, CORTEX, V22, P243, DOI 10.1016/S0010-9452(86)80048-X; LEVINE DN, 1980, PSYCHOL RES-PSYCH FO, V41, P217, DOI 10.1007/BF00308658; LEVINE DN, 1985, NEUROLOGY, V35, P1010, DOI 10.1212/WNL.35.7.1010; LEVINE DN, 1989, BRAIN COGNITION, V10, P149, DOI 10.1016/0278-2626(89)90051-1; Lissauer H, 1890, ARCH PSYCHIATRIE NER, V21, P222, DOI [10.1007/BF02226765, DOI 10.1007/BF02226765]; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; Marr D., 1982, VISION; MARSLENWILSON WD, 1975, NEUROPSYCHOLOGIA, V13, P347; MCCARTHY RA, 1986, J NEUROL NEUROSUR PS, V49, P1233, DOI 10.1136/jnnp.49.11.1233; MICHEL F, 1986, REV NEUROL, V142, P545; NEWCOMBE F, 1989, NEUROPSYCHOLOGIA, V27, P179, DOI 10.1016/0028-3932(89)90170-X; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PINKER S, 1984, COGNITION, V18, P1, DOI 10.1016/0010-0277(84)90021-0; POSNER MI, 1970, J EXP PSYCHOL, V83, P304, DOI 10.1037/h0028558; POSNER MI, 1968, J EXP PSYCHOL, V77, P353, DOI 10.1037/h0025953; RENAULT B, 1989, NEUROPSYCHOLOGIA, V27, P905, DOI 10.1016/0028-3932(89)90066-3; SCHACTER D, 1988, THOUGHT LANGUAGE; SERGENT J, 1989, BRAIN, V112, P975, DOI 10.1093/brain/112.4.975; SHAHANI BT, 1984, J NEUROL NEUROSUR PS, V47, P536, DOI 10.1136/jnnp.47.5.536; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; TARR MJ, 1989, COGNITIVE PSYCHOL, V21, P233, DOI 10.1016/0010-0285(89)90009-1; TARR MJ, 1989, THESIS MIT; TEUBER HL, 1968, ANAL BEHAVIORAL CHAN; THOMPSON P, 1980, PERCEPTION, V9, P483, DOI 10.1068/p090483; TRANEL D, 1985, SCIENCE, V228, P1453, DOI 10.1126/science.4012303; TRANEL D, 1988, BEHAV BRAIN RES, V30, P235, DOI 10.1016/0166-4328(88)90166-0; VANLANCKER D, 1987, NEUROPSYCHOLOGIA, V25, P829, DOI 10.1016/0028-3932(87)90120-5; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; WARRINGTON E K, 1973, Cortex, V9, P152; WARRINGTON EK, 1978, PERCEPTION, V7, P695, DOI 10.1068/p070695; YOUNG AW, 1988, Q J EXP PSYCHOL-A, V40, P561, DOI 10.1080/02724988843000087; YOUNG AW, 1989, BRAIN COGNITION, V9, P16, DOI 10.1016/0278-2626(89)90042-0; YOUNG AW, 1988, THOUGHT LANGUAGE, V78	60	74	74	0	16	MIT PRESS	CAMBRIDGE	55 HAYWARD ST JOURNALS DEPT, CAMBRIDGE, MA 02142	0898-929X			J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	WIN	1991	3	1					25	41		10.1162/jocn.1991.3.1.25			17	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	FC735	WOS:A1991FC73500004	23964803				2021-06-18	
J	PARASURAMAN, R; MUTTER, SA; MOLLOY, R				PARASURAMAN, R; MUTTER, SA; MOLLOY, R			SUSTAINED ATTENTION FOLLOWING MILD CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							AUTOMATIC COGNITIVE-PROCESSES; MEMORY; VIGILANCE; PERFORMANCE; CONCUSSION; EFFORTFUL; RECOVERY; DEMENTIA; MODELS; TASKS	The sustained-attention performance of patients with mild closed-head injury (CHI) was examined within one month of injury using a high-event rate, digit-discrimination vigilance task with two levels of stimulus degradation (undegraded, highly degraded). Under undegraded stimulus conditions, vigilance performance for mild CHI subjects, uninjured case-matched control subjects, and college students was highly accurate and remained so across the entire task period. When stimuli were presented in degraded fashion, however, all three groups showed a similar decline over time (i.e., vigilance decrement) in hit rates and d' scores. Although mild CHI did not lead to a greater rate of deterioration in vigilance performance in the degraded stimulus condition, it did produce lower overall levels of sensitivity (d') in target detection. These results suggest that, during the first month after mild CHI, vigilance performance is unimpaired under normal task conditions, but may fall short under task conditions that require sustained effortful processing. These findings join a growing body of evidence showing that mild CHI can lead to measurable deficits in cognitive functioning.		PARASURAMAN, R (corresponding author), CATHOLIC UNIV AMER, DEPT PSYCHOL, WASHINGTON, DC 20064 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR302583-0] Funding Source: Medline		ASTONJONES G, 1985, PHYSIOL PSYCHOL, V13, P118; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO, P372; Conkey RC, 1938, ARCH PSYCHOL, P5; CRAIG A, 1987, HUM FACTORS, V29, P645; Davies D.R., 1982, PSYCHOL VIGILANCE; DENCKER SJ, 1958, ACTA PSYCHIATRI S122, V33; DUSOIR AE, 1975, PERCEPT PSYCHOPHYS, V17, P167, DOI 10.3758/BF03203882; ERWIN CW, 1978, J STUD ALCOHOL, V39, P505, DOI 10.15288/jsa.1978.39.505; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FISK AD, 1981, HUM FACTORS, V23, P737; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HANNAY H J, 1982, Journal of Clinical Neuropsychology, V4, P117; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JERISON HJ, 1964, SCIENCE, V143, P970, DOI 10.1126/science.143.3609.970; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; Levin HS, 1984, NEUROPSYCHOLOGY MEMO, P247; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MATTHEWS G, 1990, J PERS SOC PSYCHOL, V59, P150, DOI 10.1037/0022-3514.59.1.150; MCDONALD RD, 1964, J NEUROL NEUROSUR PS, V27, P206, DOI 10.1136/jnnp.27.3.206; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MUNRO SA, 1990, COGNITIVE NEUROPSYCH, V7, P329; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NESTOR PG, 1991, DEV NEUROPSYCHOL, V7, P243, DOI 10.1080/87565649109540491; NUECHTERLEIN KH, 1983, SCIENCE, V220, P327, DOI 10.1126/science.6836276; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1979, NEURAL TRAUMA, P371; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; PARASURAMAN R, 1987, PERCEPT PSYCHOPHYS, V41, P17, DOI 10.3758/BF03208208; PARASURAMAN R, 1989, PSYCHOL AGING, V4, P339, DOI 10.1037/0882-7974.4.3.339; PARASURAMAN R, 1984, VARIETIES ATTENTION, P243; Parasuraman R., 1985, ATTENTION PERFORM, P493; PARASURAMAN R, 1986, ENERGETICS HUMAN INF, P395; Parasuraman R., 1984, VARIETIES ATTENTION; Parasuraman R., 1977, VIGILANCE THEORY OPE, P559; POSNER MI, 1985, ATTENTION PERFORMANC, V11; POULTON EC, 1977, VIGILANCE THEORY OPE, P423; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROHRBAUGH JW, 1988, PSYCHOPHARMACOLOGY, V96, P442, DOI 10.1007/BF02180021; ROYBYRNE PP, 1986, ARCH GEN PSYCHIAT, V43, P265; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Ruesch J, 1944, J NEUROSURG, V1, P243, DOI 10.3171/jns.1944.1.4.0243; Ruff R.M., 1989, MILD HEAD INJURY, P176; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SWETS JA, 1986, PSYCHOL BULL, V99, P100, DOI 10.1037/0033-2909.99.1.100; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P75; Warm J. S., 1984, SUSTAINED ATTENTION; WARM JS, 1985, INT REV RES MENT RET, V13, P1, DOI 10.1016/S0074-7750(08)60231-1; WARM JS, 1987, J GEN PSYCHOL, V114, P423, DOI 10.1080/00221309.1987.9711080; Warm JS, 1984, SUSTAINED ATTENTION, P15; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1984, PSYCHIAT RES, V11, P223, DOI 10.1016/0165-1781(84)90071-4	69	74	74	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	SEP	1991	13	5					789	811		10.1080/01688639108401090			23	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	GK476	WOS:A1991GK47600012	1955532				2021-06-18	
J	EWERT, J; LEVIN, HS; WATSON, MG; KALISKY, Z				EWERT, J; LEVIN, HS; WATSON, MG; KALISKY, Z			PROCEDURAL MEMORY DURING POSTTRAUMATIC AMNESIA IN SURVIVORS OF SEVERE CLOSED HEAD-INJURY - IMPLICATIONS FOR REHABILITATION	ARCHIVES OF NEUROLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D73,GALVESTON,TX 77550; DEL ORO HOSP,MED CTR,DEPT PHYS MED & REHABIL,HOUSTON,TX; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77004					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; CUMMINGS JL, 1984, NEUROLOGY, V34, P679, DOI 10.1212/WNL.34.5.679; EISENBERG HM, 1988, 1988 M AM ASS NEUR S; ESLINGER PJ, 1986, J NEUROSCI, V6, P3006; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; Goodglass H., 1983, ASSESSMENT APHASIA R; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GREEN DM, 1966, SIGNAL DETECTION THE; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HEINDEL WC, 1988, BEHAV NEUROSCI, V102, P141, DOI 10.1037/0735-7044.102.1.141; Holbourn AHS, 1943, LANCET, V2, P438; JENNETT WB, 1969, BRIT J PSYCHIAT, P40; KIHLSTROM JF, 1987, SCIENCE, V237, P1445, DOI 10.1126/science.3629249; LEINER HC, 1986, BEHAV NEUROSCI, V100, P443, DOI 10.1037/0735-7044.100.4.443; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MAUK MD, 1987, BRAIN RES, V403, P89, DOI 10.1016/0006-8993(87)90126-0; NISSEN MJ, 1987, NEUROLOGY, V37, P789, DOI 10.1212/WNL.37.5.789; Porteus S. D., 1959, MAZE TEST CLIN PSYCH; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SHIMAMURA AP, 1984, J EXP PSYCHOL GEN, V113, P556, DOI 10.1037/0096-3445.113.4.556; SQUIRE LR, 1984, NEUROPSYCHOLOGIA, V22, P145, DOI 10.1016/0028-3932(84)90057-5; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; Thorndike EL., 1944, TEACHERS WORD BOOK 3	34	74	74	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	AUG	1989	46	8					911	916		10.1001/archneur.1989.00520440105027			6	Clinical Neurology	Neurosciences & Neurology	AJ310	WOS:A1989AJ31000025	2757532				2021-06-18	
J	Steyerberg, EW; Wiegers, E; Sewalt, C; Buki, A; Citerio, G; De Keyser, V; Ercole, A; Kunzmann, K; Lanyon, L; Lecky, F; Lingsma, H; Manley, G; Nelson, D; Peul, W; Stocchetti, N; von Steinbuchel, N; Vande Vyvere, T; Verheyden, J; Wilson, L; Maas, AIR; Menon, DK				Steyerberg, Ewout W.; Wiegers, Eveline; Sewalt, Charlie; Buki, Andras; Citerio, Giuseppe; De Keyser, Veronique; Ercole, Ari; Kunzmann, Kevin; Lanyon, Linda; Lecky, Fiona; Lingsma, Hester; Manley, Geoffrey; Nelson, David; Peul, Wilco; Stocchetti, Nino; von Steinbuechel, Nicole; Vande Vyvere, Thijs; Verheyden, Jan; Wilson, Lindsay; Maas, Andrew I. R.; Menon, David K.		CENTER-TBI Participants Investigat	Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study	LANCET NEUROLOGY			English	Article							NEUROTRAUMA EFFECTIVENESS RESEARCH; QUALITY-OF-LIFE; SCALE; MORTALITY; ALCOHOL	Background The burden of traumatic brain injury (TBI) poses a large public health and societal problem, but the characteristics of patients and their care pathways in Europe are poorly understood. We aimed to characterise patient case-mix, care pathways, and outcomes of TBI. Methods CENTER-TBI is a Europe-based, observational cohort study, consisting of a core study and a registry. Inclusion criteria for the core study were a clinical diagnosis of TBI, presentation fewer than 24 h after injury, and an indication for CT. Patients were differentiated by care pathway and assigned to the emergency room (ER) stratum (patients who were discharged from an emergency room), admission stratum (patients who were admitted to a hospital ward), or intensive care unit (ICU) stratum (patients who were admitted to the ICU). Neuroimages and biospecimens were stored in repositories and outcome was assessed at 6 months after injury. We used the IMPACT core model for estimating the expected mortality and proportion with unfavourable Glasgow Outcome Scale Extended (GOSE) outcomes in patients with moderate or severe TBI (Glasgow Coma Scale [GCS] score <= 12). The core study was registered with ClinicalTrials.gov , number NCT02210221, and with Resource Identification Portal (RRID: SCR_015582). Findings Data from 4509 patients from 18 countries, collected between Dec 9,2014, and Dec 17,2017, were analysed in the core study and from 22782 patients in the registry. In the core study, 848 (19%) patients were in the ER stratum, 1523 (34%) in the admission stratum, and 2138 (47%) in the ICU stratum. In the ICU stratum, 720 (36%) patients had mild TBI (GCS score 13-15). Compared with the core cohort, the registry had a higher proportion of patients in the ER (9839 [43%]) and admission (8571138%1) strata, with more than 95% of patients classified as having mild TBI. Patients in the core study were older than those in previous studies (median age 50 years [IQR 30-66], 1254 128%1 aged >65 years), 462 (11%) had serious comorbidities, 772 (18%) were taking anticoagulant or antiplatelet medication, and alcohol was contributory in 1054 (25%) TBIs. MRI and blood biomarker measurement enhanced characterisation of injury severity and type. Substantial inter-country differences existed in care pathways and practice. Incomplete recovery at 6 months (GOSE <8) was found in 207 (30%) patients in the ER stratum, 665 (53%) in the admission stratum, and 1547 (84%) in the ICU stratum. Among patients with moderate-to-severe TBI in the ICU stratum, 623 (55%) patients had unfavourable outcome at 6 months (GOSE <5), similar to the proportion predicted by the IMPACT prognostic model (observed to expected ratio 1.06 [95% CI 0.97-1-14]), but mortality was lower than expected (0.70 [0.62-0.76]). Interpretation Patients with TBI who presented to European centres in the core study were older than were those in previous observational studies and often had comorbidities. Overall, most patients presented with mild TBI. The incomplete recovery of many patients should motivate precision medicine research and the identification of best practices to improve these outcomes. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Steyerberg, Ewout W.; Wiegers, Eveline; Sewalt, Charlie; Lingsma, Hester] Univ Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands; [Buki, Andras] Univ Pecs, Dept Neurosurg, Med Sch, Pecs, Hungary; [Buki, Andras] Univ Pecs, Neurotrauma Res Grp, Janos Szentegothai Res Ctr, Pecs, Hungary; [Citerio, Giuseppe] ASST Monza, NeuroIntens Care, Monza, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [De Keyser, Veronique; Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Vande Vyvere, Thijs] Antwerp Univ Hosp, Dept Radiol, Edegem, Belgium; [Ercole, Ari; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Kunzmann, Kevin] Univ Cambridge, MRC Biostat Unit, Cambridge, England; [Lanyon, Linda] Karolinska Inst, Int Neuroinformat Coordinating Facil, Stockholm, Sweden; [Nelson, David] Karolinska Inst, Dept Physiol & Pharmacol, Sect Perioperat Med & Intens Care, Stockholm, Sweden; [Lecky, Fiona] Univ Sheffield, Hlth Serv Res Sect, Sch Hlth & Related Res, Ctr Urgent & Emergency Care Res, Sheffield, S Yorkshire, England; [Manley, Geoffrey] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Peul, Wilco] Leiden Univ, Med Ctr, The Hague, Netherlands; [Peul, Wilco] Leiden Univ, Med Ctr, Leiden, Netherlands; [Peul, Wilco] Univ Neurosurg Ctr Holland, Haaglanden Med Ctr, The Hague, Netherlands; [Peul, Wilco] Univ Neurosurg Ctr Holland, Haaglanden Med Ctr, Leiden, Netherlands; [Stocchetti, Nino] Milan Univ, Dept Pathophysiol & Transplantat, Milan, Italy; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosci Intens Care Unit, Milan, Italy; [von Steinbuechel, Nicole] Univ Med Gottingen, Inst Med Psychol & Med Sociol, Gottingen, Germany; [Vande Vyvere, Thijs; Verheyden, Jan] Icometrix, Leuven, Belgium; [Wilson, Lindsay] Univ Stirling, Div Psychol, Stirling, Scotland; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium	Maas, AIR (corresponding author), Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Laureys, Steven/AAN-2097-2021; Wilson, Lindsay/A-3659-2009; Cooper, D. James/G-7961-2013; Oresic, Matej/K-7673-2016; Posti, Jussi P./Y-2908-2019; Sahuquillo, Juan/B-3577-2008; Lagares, Alfonso/B-2969-2011; Volovici, Victor/AAZ-8901-2020; Badenes, Rafael/K-6628-2019; Golubovic, Jagos/AAD-1270-2019; Maas, Andrew IR/C-5584-2013; Castano-Leon, Ana M/ABF-6322-2020; Ercole, Ari/B-6288-2009; Raj, Rahul/K-7693-2012; Bartels, R.H.M.A./L-4184-2015; Gomez, Pedro/E-2411-2014	Laureys, Steven/0000-0002-3096-3807; Wilson, Lindsay/0000-0003-4113-2328; Cooper, D. James/0000-0002-5872-9051; Oresic, Matej/0000-0002-2856-9165; Posti, Jussi P./0000-0002-5925-5193; Sahuquillo, Juan/0000-0003-0713-5875; Lagares, Alfonso/0000-0003-3996-0554; Volovici, Victor/0000-0002-5798-5360; Badenes, Rafael/0000-0001-7017-0150; Golubovic, Jagos/0000-0001-5524-246X; Maas, Andrew IR/0000-0003-1612-1264; Castano-Leon, Ana M/0000-0002-7918-5049; Ercole, Ari/0000-0001-8350-8093; Donoghue, Emma/0000-0002-2745-9108; Caccioppola, Alessio/0000-0003-1936-3111; Gratz, Johannes/0000-0001-8717-0544; Sanchez-Porras, Renan/0000-0002-9084-8114; Zoerle, Tommaso/0000-0001-8713-8085; Dawes, Helen/0000-0002-2933-5213; Kondziella, Daniel/0000-0001-5562-9808; Huijben, Jilske (Antonia)/0000-0002-2892-5406; Kunzmann, Kevin/0000-0002-1140-7143; Te Ao, Braden/0000-0002-1050-200X; Anke, Audny/0000-0002-2491-2560; George, Pradeep/0000-0001-6771-2828; Wang, Kevin/0000-0002-9343-6473; Newcombe, Virginia/0000-0001-6044-9035; Parizel, Paul M./0000-0002-0221-2854; Rossi, Sandra/0000-0002-9963-8121; Bragge, Peter/0000-0003-0745-5131; Andelic, Nada/0000-0002-3719-4406; Raj, Rahul/0000-0003-4243-9591; Della Corte, Francesco/0000-0003-1736-2318; Blaabjerg, Morten/0000-0001-6007-1861; Esser, Patrick/0000-0002-3227-0115; Radoi, Andreea/0000-0002-0677-3544; Carbonara, Marco/0000-0002-1431-8322; Bartels, R.H.M.A./0000-0002-8638-4660; Gomez, Pedro/0000-0002-4185-5238; Zeiler, Frederick/0000-0003-1737-0510; Kolias, Angelos/0000-0003-3992-0587	European Union 7th Framework Programme; Hannelore Kohl Stiftung; OneMind; Integra LifeSciences Corporation	European Union 7th Framework Programme, the Hannelore Kohl Stiftung, OneMind, and Integra LifeSciences Corporation.	Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; CENTER-TBI, ETH APPR; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Foks KA, 2017, J NEUROTRAUM, V34, P2529, DOI 10.1089/neu.2016.4919; Huijben JA, 2018, J NEUROTRAUM, V35, P323, DOI 10.1089/neu.2017.5194; Huijben JA, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2000-6; Jackson CH, 2011, J STAT SOFTW, V38, P1; Jain S, 2019, J NEUROTRAUM, V36, P1794, DOI 10.1089/neu.2018.6183; Kehoe A, 2015, EMERG MED J, V32, P911, DOI 10.1136/emermed-2015-205265; Kirkman MA, 2013, J NEUROTRAUM, V30, P1385, DOI 10.1089/neu.2013.2881; LAMM AG, 2019, J NEUROTRAUM, V36, P2513, DOI DOI 10.1089/neu.2018.6014; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Legrand SA, 2012, FORENSIC SCI INT, V220, P224, DOI 10.1016/j.forsciint.2012.03.006; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Marshall LF, 1991, NEW CLASSIFICATION H; Martin JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187320; Matsushima K, 2015, J TRAUMA ACUTE CARE, V79, P838, DOI 10.1097/TA.0000000000000719; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Seabury SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0210; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Timmermans C, 2019, J MAGN RESON IMAGING, V49, P955, DOI 10.1002/jmri.26333; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Van Buuren S., 2012, FLEXIBLE IMPUTATION; Volovici V, 2019, J CRIT CARE, V49, P158, DOI 10.1016/j.jcrc.2018.11.002; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; Ware JE, 2002, USERS MANUAL SF 12V2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson L, 2017, J NEUROTRAUM, V34, P59, DOI 10.1089/neu.2015.4287; Yue JK, 2017, J CLIN NEUROSCI, V45, P293, DOI 10.1016/j.jocn.2017.07.022; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	38	73	73	5	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					923	934		10.1016/S1474-4422(19)30232-7			12	Clinical Neurology	Neurosciences & Neurology	IX6HN	WOS:000485784000017	31526754	Green Accepted, Green Published	Y	N	2021-06-18	
J	Gao, XF; Zheng, P; Kasani, S; Wu, S; Yang, F; Lewis, S; Nayeem, S; Engler-Chiurazzi, EB; Wigginton, JG; Simpkins, JW; Wu, NQ				Gao, Xuefei; Zheng, Peng; Kasani, Sujan; Wu, Steven; Yang, Feng; Lewis, Sara; Nayeem, Sara; Engler-Chiurazzi, Elizabeth B.; Wigginton, Jane G.; Simpkins, James W.; Wu, Nianqiang			Paper-Based Surface-Enhanced Raman Scattering Lateral Flow Strip for Detection of Neuron-Specific Enolase in Blood Plasma	ANALYTICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; LABEL-FREE DETECTION; SENSITIVE DETECTION; ENZYME-IMMUNOASSAY; BIOMARKER; IMMUNOSENSOR; NANOPARTICLES; BIOSENSOR; MARKERS; PROTEIN	An inexpensive and disposable paper-based lateral flow strip (PLFS) has been developed as an immunoassay, in which surface-enhanced Raman scattering (SERS) is utilized for sensing signal transduction. The Au nanostar@Raman Reporter@silica sandwich nanoparticles are developed as the SERS probes, which is the key to the high sensitivity of the device. Compared with a colorimetric PLFS, the SERS-PLFS exhibits superior performance in terms of sensitivity and limit of detection (LOD) in a blood plasma-containing sample matrix. In addition, the SERS-PLFS has been successfully used for detection of neuron-specific enolase (NSE), a traumatic brain injury (TBI) protein biomarker, in diluted blood plasma samples, achieving a LOD of 0.86 ng/mL. Moreover, the SERS-PLFS was successfully employed to measure the NSE level in clinical blood plasma samples taken from deidentified TBI patients. This work demonstrates that the SERS-PLFS has great potential in assisting screening of TBI patients in the point-of-care setting.	[Gao, Xuefei; Zheng, Peng; Wu, Steven; Wu, Nianqiang] West Virginia Univ, Dept Mech & Aerosp Engn, Morgantown, WV 26506 USA; [Kasani, Sujan] West Virginia Univ, Lane Dept Comp Sci & Elect Engn, Morgantown, WV 26506 USA; [Yang, Feng] West Virginia Univ, Ind & Management Syst Engn Dept, Morgantown, WV 26506 USA; [Lewis, Sara; Nayeem, Sara; Engler-Chiurazzi, Elizabeth B.; Simpkins, James W.] Ctr Neurosci, Ctr Basic & Translat Stroke Res, Physiol & Pharmacol, Morgantown, WV 26505 USA; [Wigginton, Jane G.] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA	Wu, NQ (corresponding author), West Virginia Univ, Dept Mech & Aerosp Engn, Morgantown, WV 26506 USA.	nick.wu@mail.wvu.edu	Kasani, Sujan/AAG-9345-2019; Kasani, Sujan Phani Kumar/K-2869-2019; Gao, Xuefei/G-4028-2015; Wu, Nianqiang/B-9798-2015	Kasani, Sujan Phani Kumar/0000-0003-1458-9509; Gao, Xuefei/0000-0003-0641-2244; Wu, Nianqiang/0000-0002-8888-2444	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS087515]; UT Southwestern High Impact/High Risk Grant; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001105]; National Heart, Lung and Blood Institute in partnershipUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077887]; U.S. Army Medical Research & Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); American Heart AssociationAmerican Heart Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001105] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077887, U01HL077863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS087515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027956] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (R15NS087515). The resources provided by the Byars-Tarnay Endowment in the WVU Foundation are also appreciated. The characterization was performed at WVU Shared Facility. In addition, J.G.W. was involved in the RESCUE study in this manuscript that was funded in part by the UT Southwestern High Impact/High Risk Grant, the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1TR001105, and the Resuscitation Outcomes Consortium cooperative agreements (5U01 HL077863-University of Washington Data Coordinating Center, HL077887-University of Texas Southwestern Medical Center in Dallas) from the National Heart, Lung and Blood Institute in partnership with the U.S. Army Medical Research & Material Command and the American Heart Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Al-Ogaidi I, 2014, CHEM COMMUN, V50, P1344, DOI 10.1039/c3cc47701k; Centers for Disease Control and Prevention, 2017, TBI GET THE FACTS; Centers for Disease Control and Prevention, 2017, SEV TBI; Cheng SS, 2015, SENSOR ACTUAT B-CHEM, V212, P329, DOI 10.1016/j.snb.2015.02.038; Fu XH, 2014, ANAL METHODS-UK, V6, P2233, DOI 10.1039/c3ay42075b; Fu XL, 2012, ANAL CHIM ACTA, V722, P114, DOI 10.1016/j.aca.2012.02.007; Fu X, 2016, BIOSENS BIOELECTRON, V78, P530, DOI 10.1016/j.bios.2015.11.099; Gao XF, 2016, TALANTA, V146, P648, DOI 10.1016/j.talanta.2015.06.060; Gao XF, 2014, BIOSENS BIOELECTRON, V54, P578, DOI 10.1016/j.bios.2013.10.055; Han J, 2012, BIOSENS BIOELECTRON, V31, P399, DOI 10.1016/j.bios.2011.10.055; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Lee Bruce, 2005, NeuroRx, V2, P372; Li M, 2015, ANALYST, V140, P386, DOI 10.1039/c4an01079e; Li M, 2013, ACS NANO, V7, P4967, DOI 10.1021/nn4018284; Li M, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/11/115501; Li ZH, 2010, ANAL CHEM, V82, P7008, DOI 10.1021/ac101405a; Liang JJ, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/49/495501; Lin YY, 2008, BIOSENS BIOELECTRON, V23, P1659, DOI 10.1016/j.bios.2008.01.037; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Ngom B, 2010, ANAL BIOANAL CHEM, V397, P1113, DOI 10.1007/s00216-010-3661-4; North S., 2013, NRL REV, V13, P164; Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2; Wang X, 2017, ANAL CHEM, V89, P1163, DOI 10.1021/acs.analchem.6b03536; Yu TX, 2012, TALANTA, V93, P433, DOI 10.1016/j.talanta.2012.02.047; Yu XY, 2015, ANAL CHEM, V87, P4237, DOI 10.1021/ac504456w; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhou LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep22234	28	73	75	16	208	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	SEP 19	2017	89	18					10104	10110		10.1021/acs.analchem.7b03015			7	Chemistry, Analytical	Chemistry	FH9RJ	WOS:000411549100068	28817769	Green Accepted			2021-06-18	
J	Chen, CK; Wu, YT; Chang, YC				Chen, Chang-Kai; Wu, Yung-Tsan; Chang, Yu-Chao			Association between chronic periodontitis and the risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study	ALZHEIMERS RESEARCH & THERAPY			English	Article						Alzheimer's disease; Periodontitis; Risk factors; Nationwide population; Cohort study	SUGGESTS INCREASED RISK; COGNITIVE DECLINE; TOOTH LOSS; DEMENTIA; INFLAMMATION; ATHEROSCLEROSIS; THERAPY; LINK	Background: Although recent short-term cross-sectional studies have revealed that chronic periodontitis (CP) may be a risk factor for increased cognitive impairment in patients with Alzheimer's disease (AD), systematic reviews and long-term longitudinal studies have provided less clear evidence regarding the relationship between CP and AD. Therefore, we conducted a retrospective cohort study using the National Health Insurance Research Database (NHIRD) of Taiwan to determine whether patients with CP are at increased risk of developing AD. Methods: We conducted a retrospective matched-cohort study using the NHIRD of Taiwan. We identified 9291 patients newly diagnosed with CP between 1997 and 2004. A total of 18,672 patients without CP were matched to the patient cohort according to sex, age, index year, co-morbidity and urbanisation level. Cox proportional hazards regression analyses were performed to evaluate the subsequent risk of AD. Results: Patients with CP had a higher prevalence of hyperlipidaemia, depression, traumatic brain injury and co-morbidities, as well as higher urbanisation levels, than those in the unexposed cohort (all p < 0.01). At the final follow-up, totals of 115 (1.24%) and 208 (1.11%) individuals in the CP exposed and unexposed groups, respectively, had developed AD. Patients with 10 years of CP exposure exhibited a higher risk of developing AD than unexposed groups (adjusted HR 1.707, 95% CI 1.152-2.528, p = 0.0077). Conclusions: Our findings demonstrate that 10-year CP exposure was associated with a 1.707-fold increase in the risk of developing AD. These findings highlight the need to prevent progression of periodontal disease and promote healthcare service at the national level.	[Chen, Chang-Kai; Chang, Yu-Chao] Chung Shan Med Univ, Sch Dent, 110,Sect 1,Jianguo N Rd, Taichung 40201, Taiwan; [Chen, Chang-Kai] Kaohsiung Armed Forces Gen Hosp, Sect Dent, Zuoying Branch, Kaohsiung, Taiwan; [Wu, Yung-Tsan] Triserv Gen Hosp, Natl Def Med Ctr, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, Yu-Chao] Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan	Chang, YC (corresponding author), Chung Shan Med Univ, Sch Dent, 110,Sect 1,Jianguo N Rd, Taichung 40201, Taiwan.; Chang, YC (corresponding author), Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan.	cyc@csmu.edu.tw					Abbayya K, 2015, N AM J MED SCI, V7, P241, DOI 10.4103/1947-2714.159325; Al-Shammari KF, 2005, J PERIODONTOL, V76, P1910, DOI 10.1902/jop.2005.76.11.1910; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Burke SL, 2016, INT PSYCHOGERIATR, V28, P1409, DOI 10.1017/S1041610216000405; Campos CH, 2017, J ORAL REHABIL, V44, P178, DOI 10.1111/joor.12476; Campos CH, 2017, CLIN ORAL INVEST, V21, P573, DOI 10.1007/s00784-016-1923-z; Chan WSH, 2010, EPMA J, V1, P563, DOI 10.1007/s13167-010-0056-8; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; D'Aiuto F, 2005, Int J Immunopathol Pharmacol, V18, P1; Gaur S, 2015, GERIATR GERONTOL INT, V15, P391, DOI 10.1111/ggi.12425; Gil-Montoya JA, 2015, J PERIODONTOL, V86, P244, DOI 10.1902/jop.2014.140340; Helmer C, 2011, NEUROLOGY, V77, P2043, DOI 10.1212/WNL.0b013e31823b4765; Honig LS, 2005, NEUROLOGY, V64, P494, DOI 10.1212/01.WNL.0000150886.50187.30; Hsu CC, 2011, J ALZHEIMERS DIS, V24, P485, DOI 10.3233/JAD-2011-101524; Huang CY, 2015, CURR ALZHEIMER RES, V12, P287, DOI 10.2174/1567205012666150302155536; Huang CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087095; Ide M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151081; Kamer AR, 2008, ALZHEIMERS DEMENT, V4, P242, DOI 10.1016/j.jalz.2007.08.004; Lakschevitz F, 2011, CURR DIABETES REV, V7, P433, DOI 10.2174/157339911797579205; Lee YT, 2017, J AM GERIATR SOC, V65, P301, DOI 10.1111/jgs.14449; Lin RT, 1998, J NEUROL SCI, V160, P67, DOI 10.1016/S0022-510X(98)00225-1; Liu CY, 2006, J HLTH MANAGEMENT, V4, P1, DOI DOI 10.29805/JHM.200606.0001; Liu TC, 2013, MOVEMENT DISORD, V28, P1307, DOI 10.1002/mds.25359; Llibre R., 2008, LANCET, V372, P464, DOI DOI 10.1016/S0140-6736(08)61002-8; Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm; Martande SS, 2014, AM J ALZHEIMERS DIS, V29, P498, DOI 10.1177/1533317514549650; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Cervantes CM, 2017, NEUROLOGIA, V32, P309, DOI 10.1016/j.nrl.2015.12.006; Paraskevas S, 2008, J CLIN PERIODONTOL, V35, P277, DOI 10.1111/j.1600-051X.2007.01173.x; Passoja A, 2010, J CLIN PERIODONTOL, V37, P881, DOI 10.1111/j.1600-051X.2010.01602.x; Peng DT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003727; Roher AE, 2003, ARTERIOSCL THROM VAS, V23, P2055, DOI 10.1161/01.ATV.0000095973.42032.44; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895-4356(93)90106-B; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Teles R, 2011, ORAL DIS, V17, P450, DOI 10.1111/j.1601-0825.2010.01784.x; Tonsekar PP, 2017, GERODONTOLOGY, V34, P151, DOI 10.1111/ger.12261; Tzeng NS, ARE CHRONIC PERIODON; Uppoor AS, 2013, GERODONTOLOGY, V30, P239, DOI 10.1111/j.1741-2358.2012.00660.x; Vanhanen M, 2006, NEUROLOGY, V67, P843, DOI 10.1212/01.wnl.0000234037.91185.99; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Watts Amber, 2008, Neuropsychiatr Dis Treat, V4, P865; Wen BW, 2014, QJM-INT J MED, V107, P283, DOI 10.1093/qjmed/hct248; WONG CS, 2016, MEDICINE, V95; Yan Q, 2003, J NEUROSCI, V23, P7504	44	73	76	5	38	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1758-9193			ALZHEIMERS RES THER	Alzheimers Res. Ther.	AUG 8	2017	9								56	10.1186/s13195-017-0282-6			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FD1KQ	WOS:000407296600001	28784164	DOAJ Gold, Green Published			2021-06-18	
J	Otero-Ortega, L; Laso-Garcia, F; Gomez-de Frutos, MD; Rodriguez-Frutos, B; Pascual-Guerra, J; Fuentes, B; Diez-Tejedor, E; Gutierrez-Fernandez, M				Otero-Ortega, Laura; Laso-Garcia, Fernando; del Carmen Gomez-de Frutos, Maria; Rodriguez-Frutos, Berta; Pascual-Guerra, Jorge; Fuentes, Blanca; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria			White Matter Repair After Extracellular Vesicles Administration in an Experimental Animal Model of Subcortical Stroke	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; NEUROVASCULAR PLASTICITY; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; STROMAL CELLS; EXOSOMES; RATS; THERAPY; TOOL	Mesenchymal stem cells have previously been shown to mediate brain repair after stroke; they secrete 50-100 nm complexes called extracellular vesicles (EVs), which could be responsible for provoking neurovascular repair and functional recovery. EVs have been observed by electron microscopy and NanoSight, and they contain associated proteins such as CD81 and Alix. This purified, homogeneous population of EVs was administered intravenously after subcortical stroke in rats. To evaluate the EVs effects, we studied the biodistribution, proteomics analysis, functional evaluation, lesion size, fiber tract integrity, axonal sprouting and white matter repair markers. We found that a single administration of EVs improved functional recovery, fiber tract integrity, axonal sprouting and white matter repair markers in an experimental animal model of subcortical stroke. EVs were found in the animals' brain and peripheral organs after euthanasia. White matter integrity was in part restored by EVs administration mediated by molecular repair factors implicated in axonal sprouting, tract connectivity, remyelination and oligodendrogenesis. These findings are associated with improved functional recovery. This novel role for EVs presents a new perspective in the development of biologics for brain repair.	[Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria] Autonomous Univ Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Neurosci & Cerebrovasc Res Lab,Dept Neurol,Neuros, Madrid, Spain; Autonomous Univ Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Stroke Ctr,Neurosci Area, Madrid, Spain	Diez-Tejedor, E; Gutierrez-Fernandez, M (corresponding author), Autonomous Univ Madrid, IdiPAZ Hlth Res Inst, La Paz Univ Hosp, Neurosci & Cerebrovasc Res Lab,Dept Neurol,Neuros, Madrid, Spain.	exuperio.diez@salud.madrid.org; mgutierrezfernandez@salud.madrid.org	Fuentes, Blanca/I-2114-2019; Laso Garcia, Fernando/F-2259-2018	Fuentes, Blanca/0000-0002-0363-862X; Laso Garcia, Fernando/0000-0002-5481-0514; Otero Ortega, Laura/0000-0001-8765-6341; Pascual Guerra, Jorge/0000-0001-6667-3310	INVICTUS (Spanish Neurovascular Network) [RD12/0014]; Miguel Servet [CP15/00069]; Sara Borrell postdoctoral fellowship from Research Institute Carlos III [CD12/00706]; Ministry of Science and Innovation of SpainSpanish Government; European Regional Development FundEuropean Commission;  [PS15/01318]	This study has been partially supported by grants from PS15/01318 and INVICTUS (RD12/0014) (Spanish Neurovascular Network), Miguel Servet (CP15/00069 to Maria Gutierrez-Fernandez) and a Sara Borrell postdoctoral fellowship (CD12/00706, to Laura Otero-Ortega) from Research Institute Carlos III, Ministry of Science and Innovation of Spain and European Regional Development Fund. We greatly appreciate the support of ServingMed.com for editing assistance. Also greatly thanked is Prof. Carmichael for his supervision of the Laura Otero-Ortega's stay at his laboratory regarding experiments of neuronal tracers.	Back SA, 2007, STROKE, V38, P724, DOI 10.1161/01.STR.0000254729.27386.05; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Barratt HE, 2014, J CEREBR BLOOD F MET, V34, P1463, DOI 10.1038/jcbfm.2014.107; Beer L., 2016, APOPTOSIS IN PRESS; Chen T, 2016, SCI REP-UK, V6, DOI 10.1038/srep33862; Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078; Eckert MA, 2013, J CEREBR BLOOD F MET, V33, P1322, DOI 10.1038/jcbfm.2013.91; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Ellwanger JH, 2016, MED HYPOTHESES, V95, P67, DOI 10.1016/j.mehy.2016.09.005; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gutierrez-Fernandez M, 2011, NEUROSCIENCE, V175, P394, DOI 10.1016/j.neuroscience.2010.11.054; Gutierrez-Fernandez M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0406-3; Hu L, 2016, SCI REP IN PRESS; Kalani A, 2016, INT J BIOCHEM CELL B, V79, P360, DOI 10.1016/j.biocel.2016.09.002; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Lee M, 2016, BIOCH BIOPH IN PRESS; Leu S, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-63; Li GH, 2016, NEURAL REGEN RES, V11, P1015, DOI 10.4103/1673-5374.184506; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; Matute C, 2013, STROKE, V44, P1204, DOI 10.1161/STROKEAHA.112.658328; Navarro P, 2014, J PROTEOME RES, V13, P1234, DOI 10.1021/pr4006958; Otero-Ortega L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0111-4; Ramos-Cejudo J, 2015, STROKE, V46, P221, DOI 10.1161/STROKEAHA.114.006692; Rodriguez-Frutos B, 2016, BIOMATERIALS, V100, P41, DOI 10.1016/j.biomaterials.2016.05.028; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sozmen EG, 2012, NEUROTHERAPEUTICS, V9, P349, DOI 10.1007/s13311-012-0106-0; Sozmen EG, 2009, J NEUROSCI METH, V180, P261, DOI 10.1016/j.jneumeth.2009.03.017; Suzuki E, 2016, WORLD J STEM CELLS, V8, P297, DOI 10.4252/wjsc.v8.i9.297; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xu WT, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0429-5; Zhang Y, 2016, NEUROCHEM I IN PRESS; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770	36	73	75	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 16	2017	7								44433	10.1038/srep44433			11	Multidisciplinary Sciences	Science & Technology - Other Topics	EO3CN	WOS:000396572600001	28300134	DOAJ Gold, Green Published			2021-06-18	
J	Wan, S; Cheng, YY; Jin, H; Guo, DW; Hua, Y; Keep, RF; Xi, GH				Wan, Shu; Cheng, Yingying; Jin, Hang; Guo, Dewei; Hua, Ya; Keep, Richard F.; Xi, Guohua			Microglia Activation and Polarization After Intracerebral Hemorrhage in Mice: the Role of Protease-Activated Receptor-1	TRANSLATIONAL STROKE RESEARCH			English	Article						Cerebral hemorrhage; Microglia; Mouse; Protease-activated receptor-1	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MICROGLIA/MACROPHAGE POLARIZATION; ALTERNATIVE ACTIVATION; ADULT MICROGLIA; CELL-DEATH; MACROPHAGES; THROMBIN; INFLAMMATION; MECHANISMS	Polarized microglia play a dual (beneficial/detrimental) role in neurological diseases. However, the status and the factors that modulate microglia polarization in intracerebral hemorrhage (ICH) remain unclear. In the present study, we investigated the role of protease-activated receptor-1 (PAR-1, a thrombin receptor) in ICH-induced microglia polarization in mice. Male wild-type (WT) and PAR-1 knockout (PAR-1 KO) mice received an infusion of 30-mu L autologous blood or saline into the right basal ganglia. Mice were euthanized at different time points and the brains were used for Western blotting and immunohistochemistry. Some mice had magnetic resonance imaging. We found that ICH induced microglia activation and polarization. M1 phenotypic markers were markedly increased and reached a peak as early as 4 h, remained high at 3 days and decreased 7 days after ICH. M2 phenotypic markers were upregulated later than M1 markers reaching a peak at day 1 and declining by day 7 after ICH. PAR-1 was upregulated after ICH and expressed in the neurons and microglia. ICH induced less brain swelling and neuronal death in PAR-1 KO mice, and this was associated with less M1 polarization and reduced proinflammatory cytokine levels in the brain. In conclusion, these results suggest that polarized microglia occur dynamically after ICH and that PAR-1 plays a role in the microglia activation and polarization.	[Wan, Shu; Cheng, Yingying; Jin, Hang; Guo, Dewei; Hua, Ya; Keep, Richard F.; Xi, Guohua] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [Wan, Shu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China; [Cheng, Yingying; Jin, Hang] Jilin Univ, Sch Med, Affiliated Hosp 1, Dept Neurol, Changchun, Peoples R China; [Xi, Guohua] Univ Michigan, Room5018 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA	Xi, GH (corresponding author), Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.; Xi, GH (corresponding author), Univ Michigan, Room5018 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	guohuaxi@umich.edu		Keep, Richard/0000-0001-6441-5334	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-073595, NS-079157, NS-084049, NS-090925, NS-091545, NS-096917]; 973 ProgramNational Basic Research Program of China [2014CB541600]; National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81371336, 81400942, 81400945]; Natural Science Foundation of Zhejiang Province (ZJNSF)Natural Science Foundation of Zhejiang Province [LY13H090005]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090925, R01NS073595, R01NS079157, R01NS096917, R21NS084049, R21NS091545] Funding Source: NIH RePORTER	This study was supported by grants NS-073595, NS-079157, NS-084049, NS-090925, NS-091545 and NS-096917 from the National Institutes of Health (NIH), 973 Program-2014CB541600, and by grants 81371336, 81400942, 81400945 from National Natural Science Foundation of China (NSFC) and grants LY13H090005 from Natural Science Foundation of Zhejiang Province (ZJNSF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NSFC, and ZJNSF.	Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Cheng YY, 2014, TRANSL STROKE RES, V5, P472, DOI 10.1007/s12975-013-0288-8; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Eyo UB, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/456857; Gieseler F, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-86; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kahn ML, 1998, NATURE, V394, P690; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Luo W, 2007, BRAIN RES REV, V56, P331, DOI 10.1016/j.brainresrev.2007.08.002; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; McLaughlin JN, 2007, P NATL ACAD SCI USA, V104, P5662, DOI 10.1073/pnas.0700763104; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Ni W, 2016, STROKE, V47, P505, DOI 10.1161/STROKEAHA.115.010920; Okauchi M, 2009, BRAIN RES, V1249, P229, DOI 10.1016/j.brainres.2008.10.035; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Storer PD, 2005, J NEUROIMMUNOL, V161, P113, DOI 10.1016/j.jneuroim.2004.12.015; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Xue MZ, 2009, STROKE, V40, P2199, DOI 10.1161/STROKEAHA.108.540393; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Yabluchanskiy A, 2010, INT J NEUROSCI, V120, P765, DOI 10.3109/00207454.2010.523129; Zhao H, 2015, TRANSL STROKE RES, V6, P407, DOI 10.1007/s12975-015-0428-4; Zheng MZ, 2015, TRANSL STROKE RES, V6, P215, DOI 10.1007/s12975-015-0388-8; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	46	73	74	1	32	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2016	7	6					478	487		10.1007/s12975-016-0472-8			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EA1VJ	WOS:000386379800004	27206851	Green Accepted			2021-06-18	
J	Siegmund, GP; Guskiewicz, KM; Marshall, SW; DeMarco, AL; Bonin, SJ				Siegmund, Gunter P.; Guskiewicz, Kevin M.; Marshall, Stephen W.; DeMarco, Alyssa L.; Bonin, Stephanie J.			Laboratory Validation of Two Wearable Sensor Systems for Measuring Head Impact Severity in Football Players	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Head impact; Wearable sensors; Validity; Acceleration; Concussion; Football	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; HYBRID III; HELMET; ACCELERATION; CONCUSSION; KINEMATICS; MODEL; RISK; BIOMECHANICS	Wearable sensors can measure head impact frequency and magnitude in football players. Our goal was to quantify the impact detection rate and validity of the direction and peak kinematics of two wearable sensors: a helmet system (HITS) and a mouthguard system (X2). Using a linear impactor, modified Hybrid-III headform and one helmet model, we conducted 16 impacts for each system at 12 helmet sites and 5 speeds (3.6-11.2 m/s) (N = 896 tests). Peak linear and angular accelerations (PLA, PAA), head injury criteria (HIC) and impact directions from each device were compared to reference sensors in the headform. Both sensors detected similar to 96% of impacts. Median angular errors for impact directions were 34A degrees for HITS and 16A degrees for X2. PLA, PAA and HIC were simultaneously valid at 2 sites for HITS (side, oblique) and one site for X2 (side). At least one kinematic parameter was valid at 2 and 7 other sites for HITS and X2 respectively. Median relative errors for PLA were 7% for HITS and -7% for X2. Although sensor validity may differ for other helmets and headforms, our analyses show that data generated by these two sensors need careful interpretation.	[Siegmund, Gunter P.; DeMarco, Alyssa L.] MEA Forens Engn & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada; [Siegmund, Gunter P.] Univ British Columbia, Sch Kinesiol, Vancouver, BC V5Z 1M9, Canada; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC USA; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Bonin, Stephanie J.] MEA Forens Engineers & Scientists, Laguna Hills, CA USA	Siegmund, GP (corresponding author), MEA Forens Engn & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada.	gunter.siegmund@meaforensic.com	Siegmund, Gunter P/B-7003-2013	Siegmund, Gunter/0000-0003-2387-941X; DeMarco, Alyssa/0000-0002-3106-386X	National Football League (NFL); Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49-CE002479]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE002479] Funding Source: NIH RePORTER	This study was funded by the National Football League (NFL). The authors thank Chris Withnall, Michael Wonnacott, Dave Halstead and Elizabeth McCalley for helping refine the protocol and acquire the data; and Christoph Mack, Jason Thibado, Jonathan Beckwith, Richard Greenwald, and Thad Ide for answering questions about their products. Our conclusions do not reflect the views of the NFL. SWM is partly funded by the Centers for Disease Control and Prevention (R49-CE002479). The NFL paid MEA Forensic for time and disbursements related to work performed by GPS, ALD, SJB and other MEA employees for this study. GPS and his spouse own shares in MEA Forensic, and GPS, ALD and SJB are salaried employees of MEA Forensic. KMG is a member of the NFL's Head, Neck and Spine Committee and Chair of the Subcommittee on Equipment and Playing Rules. SWM is associated with the Datalys Center for Sports Injury Research and Prevention. None of the authors have a financial interest in either device. Biokinetics & Associates produce the MLSH and linear impactor, but had no hand in post-processing the data reported here. The NFL also paid Biokinetics & Associates and Southern Impact Research Center for their staff time, disbursements and lab usage. Drs. Barry Myers and David Meaney worked as paid consultants to the NFL and contributed to developing the protocol.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cobb BR, 2015, P I MECH ENG P-J SPO, V229, P39, DOI 10.1177/1754337114548245; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Higgins M, 2007, J ATHL TRAINING, V42, P5; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; KENT JT, 1982, J ROY STAT SOC B MET, V44, P71; Knox T, 2009, SAE INT J PASSENG CA, V1, P652; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Leong P, 1998, J NEUROSCI METH, V80, P191, DOI 10.1016/S0165-0270(97)00201-X; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCulloch C.E., 2008, GEN LINEAR MIXED MOD, P424; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Olvey SE, 2004, NEUROSURGERY, V54, P672, DOI 10.1227/01.NEU.0000108782.68099.29; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Siegmund GP, 2014, ANN BIOMED ENG, V42, P1834, DOI 10.1007/s10439-014-1052-2; Stroup W. W., 2012, GEN LINEAR MIXED MOD, P555; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Withnall C., 2010, DEV ARTICULATING MAN; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	45	73	73	1	31	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2016	44	4					1257	1274		10.1007/s10439-015-1420-6			18	Engineering, Biomedical	Engineering	DI8HJ	WOS:000373741800036	26268586				2021-06-18	
J	Wasserman, EB; Kerr, ZY; Zuckerman, SL; Covassin, T				Wasserman, Erin B.; Kerr, Zachary Y.; Zuckerman, Scott L.; Covassin, Tracey			Epidemiology of Sports-Related Concussions in National Collegiate Athletic Association Athletes From 2009-2010 to 2013-2014: Symptom Prevalence, Symptom Resolution Time, and Return-to-Play Time	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussions; epidemiology; collegiate athletics	STATES HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; FOOTBALL PLAYERS; NCAA CONCUSSION; SEX-DIFFERENCES; RECOVERY-TIME; IMPACT; AGE; METAANALYSIS; SEVERITY	Background: Limited data exist among collegiate student-athletes on the epidemiology of sports-related concussion (SRC) outcomes, such as symptoms, symptom resolution time, and return-to-play time. Purpose: This study used the National Collegiate Athletic Association (NCAA) Injury Surveillance Program (ISP) to describe the epidemiology of SRC outcomes in 25 collegiate sports. Study Design: Descriptive epidemiology study. Methods: SRC data from the NCAA ISP during the 2009-2010 to 2013-2014 academic years were analyzed regarding symptoms, time to resolution of symptoms, and time to return to play. Findings were also stratified by sex in sex-comparable sports (ie, ice hockey, soccer, basketball, lacrosse, baseball/softball) and whether SRCs were reported as recurrent. Results: Of the 1670 concussions reported during the 2009-2010 to 2013-2014 academic years, an average (SD) of 5.29 +/- 2.94 concussion symptoms were reported, with the most common being headache (92.2%) and dizziness (68.9%). Most concussions had symptoms resolve within 1 week (60.1%); however, 6.2% had a symptom resolution time of over 4 weeks. Additionally, 8.9% of concussions required over 4 weeks before return to play. The proportion of SRCs that required at least 1 week before return to play increased from 42.7% in 2009-2010 to 70.2% in 2013-2014 (linear trend, P < .001). Within sex-comparable sports analyses, the average number of symptoms and symptom resolution time did not differ by sex. However, a larger proportion of concussions in male athletes included amnesia and disorientation; a larger proportion of concussions in female athletes included headache, excess drowsiness, and nausea/vomiting. A total of 151 SRCs (9.0%) were reported as recurrent. The average number of symptoms reported with recurrent SRCs (5.99 +/- 3.43) was greater than that of nonrecurrent SRCs (5.22 +/- 2.88; P = .01). A greater proportion of recurrent SRCs also resulted in a long symptom resolution time (14.6% vs 5.4%, respectively; P < .001) and long return-to-play time (21.2% vs 7.7%, respectively; P < .001) compared with nonrecurrent SRCs. Conclusion: Trends in return-to-play time may indicate changing concussion management practices in which team medical staff members withhold players from participation longer to ensure symptom resolution. Concussion symptoms may differ by sex and recurrence. Future research should continue to examine the trends and discrepancies in symptom resolution time and return-to-play time.	[Wasserman, Erin B.] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA; [Wasserman, Erin B.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Wasserman, Erin B.; Kerr, Zachary Y.; Zuckerman, Scott L.; Covassin, Tracey] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN 46202 USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37212 USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 W Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Wasserman, Erin/0000-0001-5957-5878; Kerr, Zachary/0000-0003-1423-1259			Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kerr ZY, 2014, PEDIATRICS, V134, P489, DOI 10.1542/peds.2014-0770; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mayers LB, 2013, J NEUROPSYCH CLIN N, V25, P115, DOI 10.1176/appi.neuropsych.11120374; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKeon JMM, 2013, J ATHL TRAINING, V48, P836, DOI 10.4085/1062-6050-48.6.17; National Collegiate Athletic Association, CONC GUID DIAGN MAN; National Collegiate Athletic Association, STUD ATHL PART 1981; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8	32	73	73	0	37	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN	2016	44	1					226	233		10.1177/0363546515610537			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DA2GU	WOS:000367614100035	26546304				2021-06-18	
J	Kumar, RG; Boles, JA; Wagner, AK				Kumar, Raj G.; Boles, Jennifer A.; Wagner, Amy K.			Chronic Inflammation After Severe Traumatic Brain Injury: Characterization and Associations With Outcome at 6 and 12 Months Postinjury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cytokines; inflammation; interleukins; traumatic brain injury; Rehabilomics	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CEREBROSPINAL-FLUID; MICROGLIAL ACTIVATION; CYTOKINE PROFILE; IMMUNE-RESPONSE; HEAD TRAUMA; INTERLEUKIN-6; BIOMARKERS; SEX; MODULATION	Objective: Examine associations between chronic inflammatory profiles and outcome 6 to 12 months following severe traumatic brain injury (TBI). Setting: University-affiliated level 1 trauma center and community. Participants: Adults with severe TBI (n = 87); healthy controls (n = 7). Design: Prospective cohort study. Main Measures: Glasgow Outcome Scale; serum cytokines (interleukin [IL]-1 beta, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, tumor necrosis factor alpha), 2 weeks to 3 months, 4-to 6-month averages, 6-and 12-month levels. Results: Serum levels of IL-1 beta, IL-6, IL-8, IL-10, and tumor necrosis factor alpha were elevated over 3 months following TBI. Multivariate analysis showed that increased cytokine load score was associated with a 1.21 (95% confidence interval, 1.06-1.38) and 1.18 (95% confidence interval, 1.02-1.37) increase in odds of unfavorable Glasgow Outcome Scale score at 6 and 12 months, respectively. Also, elevated IL-6/IL-10 ratios were associated with increased odds of unfavorable outcomes at 6 months (adjusted odds ratio = 1.76; 95% confidence interval, 1.08-2.88). Conclusions: Chronic inflammation has not been well characterized following TBI. Our subacute cytokine load score classifies individuals at risk for unfavorable outcomes following injury. Higher proinflammatory burden with IL-6, relative to the antiinflammatory marker IL-10, is significantly associated with outcome. Further research should examine whether inflammatory genes and other inflammatory biomarkers affect risk for unfavorable outcomes and TBI complications.	[Kumar, Raj G.; Boles, Jennifer A.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Rehabil Res, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA.; Wagner, AK (corresponding author), Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR 323155]; DODUnited States Department of Defense [W81XWH-071-0701]; NIDRR [H133A120087]; University of Pittsburgh Women's Studies Faculty Research Fund	This work was supported in part by CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR H133A120087, University of Pittsburgh Women's Studies Faculty Research Fund.	Andaluz-Ojeda D, 2012, CYTOKINE, V57, P332, DOI 10.1016/j.cyto.2011.12.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bird MD, 2008, CELL IMMUNOL, V252, P57, DOI 10.1016/j.cellimm.2007.09.007; BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832, DOI 10.1016/0016-5085(93)90667-2; BOELEN A, 1995, J CLIN ENDOCR METAB, V80, P971, DOI 10.1210/jc.80.3.971; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Correia LCL, 2010, CLIN CHIM ACTA, V411, P540, DOI 10.1016/j.cca.2010.01.011; Curran JE, 2005, NAT GENET, V37, P1234, DOI 10.1038/ng1655; Deinzer R, 2004, BRAIN BEHAV IMMUN, V18, P458, DOI 10.1016/j.bbi.2003.11.008; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Diamond M, 2014, IL 1 BETA INFLUENCES; Dupuis J, 2005, ATHEROSCLEROSIS, V182, P307, DOI 10.1016/j.atherosclerosis.2005.02.015; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; JENNETT B, 1975, LANCET, V1, P480; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kemper RHA, 2001, CEPHALALGIA, V21, P549, DOI 10.1046/j.1468-2982.2001.00196.x; Klimas NG, 2012, BRAIN BEHAV IMMUN, V26, P1202, DOI 10.1016/j.bbi.2012.06.006; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maiden L, 2007, CLIN GASTROENTEROL H, V5, P1040, DOI 10.1016/j.cgh.2007.04.031; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maier SF, 2003, BRAIN BEHAV IMMUN, V17, P69, DOI 10.1016/S0889-1591(03)00032-1; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; O'Connor KA, 2003, BRAIN RES, V991, P123, DOI 10.1016/j.brainres.2003.08.006; Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022; Ong CKS, 2007, CLIN MED RES, V5, P17, DOI 10.3121/cmr.2007.698; Pankow JS, 2001, ATHEROSCLEROSIS, V154, P681, DOI 10.1016/S0021-9150(00)00586-4; Patel A, 2013, PSYCHIAT DANUB, V25, pS216; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RINK A, 1995, AM J PATHOL, V147, P1575; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; SAS Institute, 2010, SAS 9 2 LANG REF CON; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schnabel R, 2008, HYPERTENSION, V51, P1651, DOI 10.1161/HYPERTENSIONAHA.107.105668; Schnabel RB, 2009, CIRC-CARDIOVASC GENE, V2, P229, DOI 10.1161/CIRCGENETICS.108.804245; Serafini G, 2013, EUR NEUROPSYCHOPHARM, V23, P1672, DOI 10.1016/j.euroneuro.2013.06.002; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sorrells SF, 2007, BRAIN BEHAV IMMUN, V21, P259, DOI 10.1016/j.bbi.2006.11.006; Suleyman H, 2007, PHARMACOL REP, V59, P247; TEASDALE G, 1974, LANCET, V2, P81; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; Toyama H, 2008, ANN NUCL MED, V22, P417, DOI 10.1007/s12149-008-0136-1; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Vogelzangs N, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.27; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wakelkamp IMMJ, 2003, CLIN ENDOCRINOL, V58, P280, DOI 10.1046/j.1365-2265.2003.01708.x; Wang HC, 2013, CLIN CHIM ACTA, V423, P122, DOI 10.1016/j.cca.2013.04.023; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Weckbach S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/890816; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	79	73	75	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					369	381		10.1097/HTR.0000000000000067			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300009	24901329				2021-06-18	
J	Lu, SM; Kanekura, K; Hara, T; Mahadevan, J; Spears, LD; Oslowski, CM; Martinez, R; Yamazaki-Inoue, M; Toyoda, M; Neilson, A; Blanner, P; Brown, CM; Semenkovich, CF; Marshall, BA; Hershey, T; Umezawa, A; Greer, PA; Urano, F				Lu, Simin; Kanekura, Kohsuke; Hara, Takashi; Mahadevan, Jana; Spears, Larry D.; Oslowski, Christine M.; Martinez, Rita; Yamazaki-Inoue, Mayu; Toyoda, Masashi; Neilson, Amber; Blanner, Patrick; Brown, Cris M.; Semenkovich, Clay F.; Marshall, Bess A.; Hershey, Tamara; Umezawa, Akihiro; Greer, Peter A.; Urano, Fumihiko			A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						Wolfram syndrome; endoplasmic reticulum; diabetes; neurodegeneration; treatment	ENDOPLASMIC-RETICULUM STRESS; UBIQUITOUS CALPAINS PROMOTE; TRAUMATIC BRAIN-INJURY; BETA-CELL DEATH; HYPERINSULINEMIC HYPOGLYCEMIA; METABOLIC DISEASE; DIDMOAD SYNDROME; ER STRESS; APOPTOSIS; MICE	Wolfram syndrome is a genetic disorder characterized by diabetes and neurodegeneration and considered as an endoplasmic reticulum (ER) disease. Despite the underlying importance of ER dysfunction in Wolfram syndrome and the identification of two causative genes, Wolfram syndrome 1 (WFS1) and Wolfram syndrome 2 (WFS2), a molecular mechanism linking the ER to death of neurons and beta cells has not been elucidated. Here we implicate calpain 2 in the mechanism of cell death in Wolfram syndrome. Calpain 2 is negatively regulated by WFS2, and elevated activation of calpain 2 by WFS2-knockdown correlates with cell death. Calpain activation is also induced by high cytosolic calcium mediated by the loss of function of WFS1. Calpain hyperactivation is observed in the WFS1 knockout mouse as well as in neural progenitor cells derived from induced pluripotent stem (iPS) cells of Wolfram syndrome patients. A small-scale small-molecule screen targeting ER calcium homeostasis reveals that dantrolene can prevent cell death in neural progenitor cells derived from Wolfram syndrome iPS cells. Our results demonstrate that calpain and the pathway leading its activation provides potential therapeutic targets for Wolfram syndrome and other ER diseases.	[Lu, Simin; Kanekura, Kohsuke; Hara, Takashi; Mahadevan, Jana; Spears, Larry D.; Brown, Cris M.; Semenkovich, Clay F.; Urano, Fumihiko] Washington Univ, Div Endocrinol Metab & Lipid Res, Sch Med, Dept Med, St Louis, MO 63110 USA; [Lu, Simin] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA 01655 USA; [Oslowski, Christine M.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Martinez, Rita; Neilson, Amber; Blanner, Patrick] Washington Univ, Sch Med, iPSC Core Facil, Dept Genet, St Louis, MO 63110 USA; [Yamazaki-Inoue, Mayu; Toyoda, Masashi; Umezawa, Akihiro] Natl Ctr Child Hlth & Dev, Dept Reprod Biol, Tokyo 1578535, Japan; [Marshall, Bess A.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Hershey, Tamara] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Hershey, Tamara] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Hershey, Tamara] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Greer, Peter A.] Queens Univ, Queens Canc Res Inst, Div Canc Biol & Genet, Dept Pathol & Mol Med, Kingston, ON K7L3N6, Canada; [Urano, Fumihiko] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Urano, F (corresponding author), Washington Univ, Div Endocrinol Metab & Lipid Res, Sch Med, Dept Med, St Louis, MO 63110 USA.	urano@dom.wustl.edu	Urano, Fumihiko/AAF-4492-2020	Semenkovich, Clay/0000-0003-1163-1871; Hershey, Tamara/0000-0001-7549-0698; Spears, Larry/0000-0003-2797-684X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK067493, P60 DK020579, UL1 TR000448]; Juvenile Diabetes Research FoundationJuvenile Diabetes Research Foundation [47-2012-760, 17-2013-512]; American Diabetes AssociationAmerican Diabetes Association [1-12-CT-61]; Team Alejandro; Team Ian; Ellie White Foundation for Rare Genetic Disorders; Scientific Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD070855] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P60DK020579, R01DK067493, P30DK020579] Funding Source: NIH RePORTER	We thank all of the participants in the Washington University Wolfram Registry and Clinic and their families for their time and effort (wolframsyndrome.dom.wustl.edu/). We also thank Mai Kanekura, Mariko Hara, and Karen Sargent for technical support and the Washington University Wolfram Study Group Members and the study staff for advice and support in the greater research program. This work was supported by NIH Grants DK067493, P60 DK020579, and UL1 TR000448; Juvenile Diabetes Research Foundation Grants 47-2012-760 and 17-2013-512; American Diabetes Association Grant 1-12-CT-61, the Team Alejandro, The Team Ian, the Ellie White Foundation for Rare Genetic Disorders, and the Jack and J. T. Snow Scientific Research Foundation (F.U.).	Akiyama M, 2009, DIABETOLOGIA, V52, P653, DOI 10.1007/s00125-009-1270-6; Amr S, 2007, AM J HUM GENET, V81, P673, DOI 10.1086/520961; Arya VB, 2014, HORM METAB RES, V46, P157, DOI 10.1055/s-0034-1367063; Bachar-Wikstrom E, 2013, DIABETES, V62, P1227, DOI 10.2337/db12-1474; Barrett TG, 1997, J MED GENET, V34, P838, DOI 10.1136/jmg.34.10.838; BARRETT TG, 1995, LANCET, V346, P1458, DOI 10.1016/S0140-6736(95)92473-6; Bonnycastle LL, 2013, DIABETES, V62, P3943, DOI 10.2337/db13-0571; Chakroborty S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052056; Chang NC, 2010, EMBO J, V29, P606, DOI 10.1038/emboj.2009.369; Chen YF, 2009, GENE DEV, V23, P1183, DOI 10.1101/gad.1779509; Cui W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059921; Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3; DYKES MHM, 1975, JAMA-J AM MED ASSOC, V231, P862, DOI 10.1001/jama.231.8.862; Fonseca SG, 2005, J BIOL CHEM, V280, P39609, DOI 10.1074/jbc.M507426200; Fonseca SG, 2010, J CLIN INVEST, V120, P744, DOI 10.1172/JCI39678; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hara T, 2014, ENDOCRINOLOGY, V155, P758, DOI 10.1210/en.2013-1519; Hershey T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040604; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Hotamisligil GS, 2010, NAT MED, V16, P396, DOI 10.1038/nm0410-396; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Huang CJ, 2010, J BIOL CHEM, V285, P339, DOI 10.1074/jbc.M109.024190; Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441; Ishihara H, 2004, HUM MOL GENET, V13, P1159, DOI 10.1093/hmg/ddh125; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Luciani DS, 2009, DIABETES, V58, P422, DOI 10.2337/db07-1762; Marshall BA, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-64; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Ozcan L, 2012, ANNU REV MED, V63, P317, DOI 10.1146/annurev-med-043010-144749; Riggs AC, 2005, DIABETOLOGIA, V48, P2313, DOI 10.1007/s00125-005-1947-4; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sandhu MS, 2007, NAT GENET, V39, P951, DOI 10.1038/ng2067; Shah P, 2014, SEMIN PEDIATR SURG, V23, P76, DOI 10.1053/j.sempedsurg.2014.03.005; Shang LS, 2014, DIABETES, V63, P923, DOI 10.2337/db13-0717; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takei D, 2006, FEBS LETT, V580, P5635, DOI 10.1016/j.febslet.2006.09.007; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Urano F, 2014, NAT REV ENDOCRINOL, V10, P129, DOI 10.1038/nrendo.2013.261; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Wei HF, 1996, J NEUROCHEM, V67, P2390; Wiley SE, 2013, EMBO MOL MED, V5, P904, DOI 10.1002/emmm.201201429; Wolfram DJ., 1938, MAYO CLIN PROC, V13, P715; Yusta B, 2006, CELL METAB, V4, P391, DOI 10.1016/j.cmet.2006.10.001; Zatyka M, 2008, HUM MOL GENET, V17, P190, DOI 10.1093/hmg/ddm296	48	73	76	0	8	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 9	2014	111	49					E5292	E5301		10.1073/pnas.1421055111			10	Multidisciplinary Sciences	Science & Technology - Other Topics	AU9NR	WOS:000345921500007	25422446	Green Published, Bronze			2021-06-18	
J	Hinzman, JM; Andaluz, N; Shutter, LA; Okonkwo, DO; Pahl, C; Strong, AJ; Dreier, JP; Hartings, JA				Hinzman, Jason M.; Andaluz, Norberto; Shutter, Lori A.; Okonkwo, David O.; Pahl, Clemens; Strong, Anthony J.; Dreier, Jens P.; Hartings, Jed A.			Inverse neurovascular coupling to cortical spreading depolarizations in severe brain trauma	BRAIN			English	Article						spreading depression; peri-infarct depolarization; pressure reactivity index (PRx); hemedex	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; RAT-BRAIN; RECEPTOR ACTIVATION; DEPRESSION; ISCHEMIA; CORTEX; AUTOREGULATION; OXYGEN	Cortical spreading depolarization causes a breakdown of electrochemical gradients following acute brain injury, and also elicits dynamic changes in regional cerebral blood flow that range from physiological neurovascular coupling (hyperaemia) to pathological inverse coupling (hypoperfusion). In this study, we determined whether pathological inverse neurovascular coupling occurred as a mechanism of secondary brain injury in 24 patients who underwent craniotomy for severe traumatic brain injury. After surgery, spreading depolarizations were monitored with subdural electrode strips and regional cerebral blood flow was measured with a parenchymal thermal diffusion probe. The status of cerebrovascular autoregulation was monitored as a correlation between blood pressure and regional cerebral blood flow. A total of 876 spreading depolarizations were recorded in 17 of 24 patients, but blood flow measurements were obtained for only 196 events because of technical limitations. Transient haemodynamic responses were observed in time-locked association with 82 of 196 (42%) spreading depolarizations in five patients. Spreading depolarizations induced only hyperaemic responses (794% increase) in one patient with intact cerebrovascular autoregulation; and only inverse responses (-24% decrease) in another patient with impaired autoregulation. In contrast, three patients exhibited dynamic changes in neurovascular coupling to depolarizations throughout the course of recordings. Severity of the pathological inverse response progressively increased (-14%, -29%, -79% decrease, P < 0.05) during progressive worsening of cerebrovascular autoregulation in one patient (Pearson coefficient 0.04, 0.14, 0.28, P < 0.05). A second patient showed transformation from physiological hyperaemic coupling (44% increase) to pathological inverse coupling (-30% decrease) (P < 0.05) coinciding with loss of autoregulation (Pearson coefficient 0.19 -> 0.32, P < 0.05). The third patient exhibited a similar transformation in brain tissue oxygenation, a surrogate of blood flow, from physiologic hyperoxic responses (20% increase) to pathological hypoxic responses (-14% decrease, P < 0.05). Pathological inverse coupling was only observed with electrodes placed in or adjacent to evolving lesions. Overall, 31% of the pathological inverse responses occurred during ischaemia (<18 ml/100 g/min) thus exacerbating perfusion deficits. Average perfusion was significantly higher in patients with good 6-month outcomes (46.8 +/- 6.5 ml/100 g/min) than those with poor outcomes (32.2 +/- 3.7 ml/100 g/min, P < 0.05). These results establish inverse neurovascular coupling to spreading depolarization as a novel mechanism of secondary brain injury and suggest that cortical spreading depolarization, the neurovascular response, cerebrovascular autoregulation, and ischaemia are critical processes to monitor and target therapeutically in the management of acute brain injury.	[Hinzman, Jason M.; Andaluz, Norberto; Hartings, Jed A.] Univ Cincinnati, Neurotrauma Ctr, Neurosci Inst, UC Coll Med,Dept Neurosurg, Cincinnati, OH 45267 USA; [Hinzman, Jason M.; Andaluz, Norberto; Hartings, Jed A.] Mayfield Clin, Cincinnati, OH 45267 USA; [Shutter, Lori A.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; [Pahl, Clemens; Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London, England; [Dreier, Jens P.] Charite, Dept Neurol, D-13353 Berlin, Germany	Hinzman, JM (corresponding author), Univ Cincinnati, 231 Albert Sabin Way,ML0517, Cincinnati, OH 45267 USA.	jmhinz2@gmail.com	Shutter, Lori A/G-2957-2013	Hartings, Jed/0000-0001-8583-3471; Dreier, Jens/0000-0001-7459-2828; Shutter, Lori/0000-0002-1390-0628	US Army CDMRP PH/TBI Research Program [W81XWH-08-2-0016]; DFGGerman Research Foundation (DFG)European Commission [323/5-1]; Era-Net Neuron [01EW1212]; BMBFFederal Ministry of Education & Research (BMBF) [CSB 01 EO 0801]; BCCN [01GQ1001C]	This work was funded by the US Army CDMRP PH/TBI Research Program (contract number W81XWH-08-2-0016), DFG 323/5-1, Era-Net Neuron 01EW1212, BMBF CSB 01 EO 0801, BCCN 01GQ1001C, and thermal diffusion probes were donated by Hemedex, Inc.	Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Devor A, 2007, J NEUROSCI, V27, P4452, DOI 10.1523/JNEUROSCI.0134-07.2007; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1097/00006123-200212000-00017; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; FLORENCE G, 1994, AM J PHYSIOL, V266, pR1136; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; Koide M, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/819340; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; LAURITZEN M, 1984, J CEREBR BLOOD F MET, V4, P546, DOI 10.1038/jcbfm.1984.79; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lindquist BE, 2012, NEUROSCIENCE, V223, P365, DOI 10.1016/j.neuroscience.2012.07.053; Luckl J, 2009, J NEUROSCI RES, V87, P1219, DOI 10.1002/jnr.21933; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MAYEVSKY A, 1991, J CEREBR BLOOD F MET, V11, P829, DOI 10.1038/jcbfm.1991.142; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Offenhauser N, 2011, ACTA NEUROCHIR SUPPL, V110, P119, DOI [10.1007/978-3-7091-0353-1_2l, 10.1007/978-3-7091-0353-1_21]; PIPER RD, 1991, AM J PHYSIOL, V261, pH96; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; Somjen GG., 2004, IONS BRAIN NORMAL FU; Strong AJ, 2005, J NEUROPHYSIOL, V94, P5, DOI 10.1152/classicessays.00032.2005; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; STRONG AJ, 1988, J CEREBR BLOOD F MET, V8, P79, DOI 10.1038/jcbfm.1988.10; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Sukhotinsky I, 2008, J CEREBR BLOOD F MET, V28, P1369, DOI 10.1038/jcbfm.2008.35; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Wilson JA, 2013, ACTA NEUROCHIR SUPPL, V115, P67, DOI 10.1007/978-3-7091-1192-5_15; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	58	73	73	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2014	137		11				2960	2972		10.1093/brain/awu241			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AX2GG	WOS:000346760900019	25154387	Bronze			2021-06-18	
J	Bartnik-Olson, BL; Holshouser, B; Wang, H; Grube, M; Tong, K; Wong, V; Ashwal, S				Bartnik-Olson, Brenda L.; Holshouser, Barbara; Wang, Harrison; Grube, Matthew; Tong, Karen; Wong, Valarie; Ashwal, Stephen			Impaired Neurovascular Unit Function Contributes to Persistent Symptoms after Concussion: A Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; concussion; metabolism; MRI; pediatric; white matter integrity	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; CEREBRAL-BLOOD-FLOW; POSTTRAUMATIC HEADACHE; WHITE-MATTER; POSTCONCUSSION SYNDROME; PATHOPHYSIOLOGY; AUTOREGULATION; PERSPECTIVE; REPAIR	Research shows that approximately 14% of school age children with mild traumatic brain injury (TBI) including sports-related concussions (SRCs) remain symptomatic three months after injury. Advanced imaging studies early after injury have shown evidence of axonal damage, reduced N-acetyl aspartate (NAA) and impaired cerebral blood flow (CBF) in individuals with mild TBI. This study was undertaken to determine whether these techniques can provide valuable information in pediatric SRC patients with persistent post-concussive symptoms. Fifteen pediatric subjects ages 8 to 17 years with persistent post-concussive symptoms were evaluated using perfusion-weighted imaging (PWI), three-dimensional (3D) magnetic resonance spectroscopic imaging, and diffusion tensor imaging (DTI) three to 12 months post-SRC. Data were compared with 15 demographically similar (age, gender, and body mass index) controls. In the bilateral thalami, SRC patients showed reduced CBF (p=0.02 and p=0.02) and relative cerebral blood volume (CBV; p=0.05 and p=0.03), compared with controls. NAA/creatine (Cr) and NAA/choline (Cho) ratios were reduced in the corpus callosum (p=0.003; p=0.05) and parietal white matter (p<0.001; p=0.006) of SRC subjects, compared with controls. Significant differences in DTI metrics differentiated patients with cognitive symptoms, compared with those without cognitive symptoms and controls. Advanced imaging methods detect a spectrum of injury including impaired axonal function, neuronal metabolism and perfusion, suggesting involvement of the neurovascular unit in the presence of persistent symptoms in pediatric SRC patients.	[Bartnik-Olson, Brenda L.; Holshouser, Barbara; Wang, Harrison; Grube, Matthew; Tong, Karen] Loma Linda Univ, Dept Radiol, Sch Med, Loma Linda, CA 92354 USA; [Wong, Valarie; Ashwal, Stephen] Loma Linda Univ, Dept Pediat, Sch Med, Loma Linda, CA 92354 USA	Bartnik-Olson, BL (corresponding author), Loma Linda Univ, Dept Radiol, 11234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@llu.edu	Meijer, Anna/K-5118-2016	Bartnik-Olson, Brenda/0000-0002-1137-9437			Arai K, 2011, J CHILD NEUROL, V26, P1193, DOI 10.1177/0883073811408610; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; del Zoppo GJ, 2010, J INTERN MED, V267, P156, DOI 10.1111/j.1365-2796.2009.02199.x; del Zoppo GJ, 2012, ANN NY ACAD SCI, V1268, P127, DOI 10.1111/j.1749-6632.2012.06686.x; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lecrux C, 2011, ACTA PHYSIOL, V203, P47, DOI 10.1111/j.1748-1716.2011.02256.x; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 2012, INT J DEV NEUROSCI, V30, P167, DOI 10.1016/j.ijdevneu.2011.12.008; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Raichle M., 1998, ANN NY ACAD SCI, V19, P373; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Solomon S, 2009, HEADACHE, V49, P1112, DOI 10.1111/j.1526-4610.2009.01462.x; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xing CH, 2012, NEUROL RES, V34, P325, DOI 10.1179/1743132812Y.0000000019; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310	50	73	73	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1497	1506		10.1089/neu.2013.3213			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700004	24735414				2021-06-18	
J	Lagarde, E; Salmi, LR; Holm, LW; Contrand, B; Masson, F; Ribereau-Gayon, R; Laborey, M; Cassidy, JD				Lagarde, Emmanuel; Salmi, Louis-Rachid; Holm, Lena W.; Contrand, Benjamin; Masson, Francoise; Ribereau-Gayon, Regis; Laborey, Magali; Cassidy, J. David			Association of Symptoms Following Mild Traumatic Brain Injury With Posttraumatic Stress Disorder vs Postconcussion Syndrome	JAMA PSYCHIATRY			English	Article							HEAD-INJURY; CONCUSSION SYMPTOMS; PTSD; AFGHANISTAN; PERCEPTION; SEQUELAE; COHORT; IRAQ	IMPORTANCE A proportion of patients experience long-lasting symptoms following mild traumatic brain injury (MTBI). The postconcussion syndrome (PCS), included in the DSM-IV, has been proposed to describe this condition. Because these symptoms are subjective and common to other conditions, there is controversy whether PCS deserves to be identified as a diagnostic syndrome. OBJECTIVE To assess whether persistent symptoms 3 months following head injury are specific to MTBI or whether they are better described as part of posttraumatic stress disorder (PTSD). DESIGN, SETTING, AND PARTICIPANTS We conducted a prospective cohort study of injured patients recruited at the adult emergency department of the University Hospital of Bordeaux from December 4, 2007, to February 25, 2009. MAIN OUTCOMES AND MEASURES At 3-month follow-up, we compared the prevalence and risk factors for PCS and PTSD. Multiple correspondence analyses were used to assess clustering of symptoms and their associations with the type of injury. RESULTS We included 534 patients with head injury and 827 control patients with other nonhead injuries. Three months following the trauma, 21.2% of head-injured and 16.3% of nonhead-injured patients fulfilled the DSM-IV diagnosis of PCS; 8.8% of head-injured patients fulfilled the diagnostic criteria for PTSD compared with 2.2% of control patients. In multivariate analysis, MTBI was a predictor of PTSD (odds ratio, 4.47; 95% CI, 2.38-8.40) but not of PCS (odds ratio, 1.13; 95% CI, 0.82-1.55). Correspondence analysis suggested that symptoms considered part of PCS behave similarly to PTSD symptoms in the hyperarousal dimension. None of these 22 symptoms showed any pattern of clustering, and no clear proximity with head or nonhead injury status could be found. CONCLUSIONS AND RELEVANCE Persistent subjective symptoms frequently reported 3 months after MTBI are not specific enough to be identified as a unique PCS and should be considered part of the hyperarousal dimension of PTSD.	[Lagarde, Emmanuel; Salmi, Louis-Rachid; Contrand, Benjamin; Masson, Francoise; Ribereau-Gayon, Regis; Laborey, Magali] INSERM, ISPED, Ctr INSERM Epidemiol Biostat U897, Equipe Prevent & Prise Charge Traumatismes, F-33000 Bordeaux, France; [Lagarde, Emmanuel; Salmi, Louis-Rachid; Contrand, Benjamin; Laborey, Magali] Univ Bordeaux, ISPED, Ctr INSERM Epidemiol Biostat U897, F-33000 Bordeaux, France; [Salmi, Louis-Rachid] CHU Bordeaux, Pole Sante Publ, Serv Informat Med, F-33000 Bordeaux, France; [Holm, Lena W.] Karolinska Inst, Inst Environm Med, Div Epidemiol, S-10401 Stockholm, Sweden; [Masson, Francoise] CHU Bordeaux, Pole Anesthesie Reanimat, F-33000 Bordeaux, France; [Ribereau-Gayon, Regis] CHU Bordeaux, Pole Med, F-33000 Bordeaux, France; [Cassidy, J. David] Univ Southern Denmark, Fac Hlth, Inst Sports Sci & Clin Biomech, Odense, Denmark; [Cassidy, J. David] Univ Toronto, Univ Hlth Network, Toronto Western Res Inst, Div Hlth Care & Outcomes Res, Toronto, ON M5S 1A1, Canada; [Cassidy, J. David] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON M5S 1A1, Canada; [Cassidy, J. David] Univ Toronto, Inst Hlth Policy Management & Evaluat, Fac Med, Toronto, ON M5S 1A1, Canada	Lagarde, E (corresponding author), Univ Bordeaux, INSERM Res Ctr U897, 146 Rue Leo Saignat,CS61292, F-33076 Bordeaux, France.	emmanuel.lagarde@isped.u-bordeaux2.fr	Salmi, Louis-Rachid/T-1982-2019; contrand, benjamin/T-1994-2019; Regis, RIBEREAU-GAYON/U-5423-2019; Lagarde, Emmanuel/F-7132-2013	Lagarde, Emmanuel/0000-0001-8031-7400	INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; REUNICA Group; Bordeaux University Hospital	This study was funded by INSERM, the REUNICA Group, and Bordeaux University Hospital (PHRC 2007).	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Asmundson GJG, 2004, J TRAUMA STRESS, V17, P467, DOI 10.1007/s10960-004-5795-7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; de Leon MB, 2009, ARCH PHYS MED REHAB, V90, P956, DOI 10.1016/j.apmr.2008.12.016; EVANS RW, 1992, NEUROL CLIN, V10, P815; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Pietrzak RH, 2009, AM J PSYCHIAT, V166, P726, DOI 10.1176/appi.ajp.2009.09010032; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; World Health Organization, 1992, INT STAT CLASS DIS 1; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	28	73	74	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	SEP	2014	71	9					1032	1040		10.1001/jamapsychiatry.2014.666			9	Psychiatry	Psychiatry	AP0SV	WOS:000341775300009	25029015	Bronze			2021-06-18	
J	Murray, N; Salvatore, A; Powell, D; Reed-Jones, R				Murray, Nicholas; Salvatore, Anthony; Powell, Douglas; Reed-Jones, Rebecca			Reliability and Validity Evidence of Multiple Balance Assessments in Athletes With a Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						Clinical Test of Sensory Organization and Balance; Sensory Organization Test; Balance Error Scoring System; Romberg test; Wii Fit; sensitivity; specificity	COLLEGIATE FOOTBALL PLAYERS; SENSORY ORGANIZATION TEST; TEST-RETEST RELIABILITY; STATES HIGH-SCHOOL; MILD HEAD-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; STANDING BALANCE; SPORT; MANAGEMENT	Context: An estimated 300 000 sport-related concussion injuries occur in the United States annually. Approximately 30% of individuals with concussions experience balance disturbances. Common methods of balance assessment include the Clinical Test of Sensory Organization and Balance (CTSIB), the Sensory Organization Test (SOT), the Balance Error Scoring System (BESS), and the Romberg test; however, the National Collegiate Athletic Association recommended the Wii Fit as an alternative measure of balance in athletes with a concussion. A central concern regarding the implementation of the Wii Fit is whether it is reliable and valid for measuring balance disturbance in athletes with concussion. Objective: To examine the reliability and validity evidence for the CTSIB, SOT, BESS, Romberg test, and Wii Fit for detecting balance disturbance in athletes with a concussion. Data Sources: Literature considered for review included publications with reliability and validity data for the assessments of balance (CTSIB, SOT, BESS, Romberg test, and Wii Fit) from PubMed, PsycINFO, and CINAHL. Data Extraction: We identified 63 relevant articles for consideration in the review. Of the 63 articles, 28 were considered appropriate for inclusion and 35 were excluded. Data Synthesis: No current reliability or validity information supports the use of the CTSIB, SOT, Romberg test, or Wii Fit for balance assessment in athletes with a concussion. The BESS demonstrated moderate to high reliability (interclass correlation coefficient = 0.87) and low to moderate validity (sensitivity = 34%, specificity = 87%). However, the Romberg test and Wii Fit have been shown to be reliable tools in the assessment of balance in Parkinson patients. Conclusions: The BESS can evaluate balance problems after a concussion. However, it lacks the ability to detect balance problems after the third day of recovery. Further investigation is needed to establish the use of the CTSIB, SOT, Romberg test, and Wii Fit for assessing balance in athletes with concussions.	[Murray, Nicholas] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA; [Salvatore, Anthony] Univ Texas El Paso, El Paso, TX 79902 USA; [Powell, Douglas] Campbell Univ, Buies Creek, NC 27506 USA; [Reed-Jones, Rebecca] Univ Prince Edward Isl, Charlottetown, PE C1A 4P3, Canada	Murray, N (corresponding author), Georgia So Univ, Dept Hlth & Kinesiol, POB 8076, Statesboro, GA 30460 USA.	nmurray@georgiasouthern.edu	Reed-Jones, Rebecca/L-2021-2019	Reed-Jones, Rebecca/0000-0002-2128-2671			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Holmes JD, 2013, CLIN REHABIL, V27, P361, DOI 10.1177/0269215512458684; Howley E. T., 2012, FITNESS PROFESSIONAL; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Jacobson GP, 2011, EAR HEARING, V32, pE1, DOI 10.1097/AUD.0b013e31822802bb; Kandel ER, 2000, PRINCIPLES NEURAL SC, P810; Khasnis A, 2003, J Postgrad Med, V49, P169; Lanska DJ, 2000, NEUROLOGY, V55, P1201, DOI 10.1212/WNL.55.8.1201; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Looney MA, 2006, MEASUREMENT THEORY P, P297; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Michalski A, 2012, GAIT POSTURE, V36, P449, DOI 10.1016/j.gaitpost.2012.04.005; NCAA Publications, 2010, NCAA SPORTS MED HDB; Reed-Jones RJ, 2012, GAIT POSTURE, V36, P430, DOI 10.1016/j.gaitpost.2012.03.027; Riemann BL, 2000, J ATHL TRAINING, V35, P19; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214; Whitney SL, 1998, AM J OCCUP THER, V52, P666, DOI 10.5014/ajot.52.8.666; Wikstrom EA, 2012, J ATHL TRAINING, V47, P306, DOI 10.4085/1062-6050-47.3.16; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003; Yamada M, 2011, GERIATR NURS, V32, P188, DOI 10.1016/j.gerinurse.2011.02.002	35	73	74	0	30	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2014	49	4					540	549		10.4085/1062-6050-49.3.32			10	Sport Sciences	Sport Sciences	AQ4LO	WOS:000342768700014	24933431	Green Published			2021-06-18	
J	Fluiter, K; Opperhuizen, AL; Morgan, BP; Baas, F; Ramaglia, V				Fluiter, Kees; Opperhuizen, Anne Loes; Morgan, B. Paul; Baas, Frank; Ramaglia, Valeria			Inhibition of the Membrane Attack Complex of the Complement System Reduces Secondary Neuroaxonal Loss and Promotes Neurologic Recovery after Traumatic Brain Injury in Mice	JOURNAL OF IMMUNOLOGY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; AXONAL INJURY; WALLERIAN DEGENERATION; MYELIN PHAGOCYTOSIS; ALTERNATIVE PATHWAY; HEAD-INJURY; DEFICIENCY; ACTIVATION; RECEPTOR; DEMYELINATION	Traumatic brain injury (TBI) is the leading cause of disability and death in young adults. The secondary neuroinflammation and neuronal damage that follows the primary mechanical injury is an important cause of disability in affected people. The membrane attack complex (MAC) of the complement system is detected in the traumatized brain early after TBI; however, its role in the pathology and neurologic outcome of TBI has not yet been investigated. We generated a C6 antisense oligonucleotide that blocks MAC formation by inhibiting C6, and we compared its therapeutic effect to that of Ornithodoros moubata complement inhibitor (OmCI), a known inhibitor of C5 activation that blocks generation of the anaphylatoxin C5a and C5b, an essential component of MAC. Severe closed head injury in mice induced abundant MAC deposition in the brain. Treatment with C6 antisense reduced C6 synthesis (85%) and serum levels (90%), and inhibited MAC deposition in the injured brain (91-96%). Treatment also reduced accumulation of microglia/macrophages (50-88%), neuronal apoptosis, axonal loss and weight loss (54-93%), and enhanced neurologic performance (84-92%) compared with placebo-treated controls after injury. These data provide the first evidence, to our knowledge, that inhibition of MAC formation in otherwise complement-sufficient animals reduces neuropathology and promotes neurologic recovery after TBI. Given the importance of maintaining a functional complement opsonization system to fight infections, a critical complication in TBI patients, inhibition of the MAC should be considered to reduce posttraumatic neurologic damage. This work identifies a novel therapeutic target for TBI and will guide the development of new therapy for patients.	[Fluiter, Kees; Opperhuizen, Anne Loes; Baas, Frank; Ramaglia, Valeria] Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, NL-1105 AZ Amsterdam, Netherlands; [Morgan, B. Paul] Cardiff Univ, Inst Infect & Immun, Sch Med, Cardiff CF14 4YU, S Glam, Wales	Ramaglia, V (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	v.ramaglia@amc.nl	Fluiter, Kees/H-2828-2015; Opperhuizen, Anneloes/AAW-4823-2020; Baas, Frank/F-9574-2010	Fluiter, Kees/0000-0003-0898-7260; Opperhuizen, Anneloes/0000-0002-0995-7517; Baas, Frank/0000-0003-3912-5428; Morgan, Paul/0000-0003-4075-7676	Hersenstichting Nederlands Fellowship [F2010 (1)-05]	This work was supported by Hersenstichting Nederlands Fellowship F2010 (1)-05 (to V.R.).	Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bijsterbosch MK, 1997, NUCLEIC ACIDS RES, V25, P3290, DOI 10.1093/nar/25.16.3290; BRAUER RB, 1994, J IMMUNOL, V153, P3168; Burk AM, 2012, SHOCK, V37, P348, DOI 10.1097/SHK.0b013e3182471795; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fluiter K, 2009, MOL BIOSYST, V5, P838, DOI 10.1039/b903922h; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; GRAHAM MJ, 1993, NUCLEIC ACIDS RES, V21, P3737, DOI 10.1093/nar/21.16.3737; Hepburn NJ, 2007, J BIOL CHEM, V282, P8292, DOI 10.1074/jbc.M609858200; Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kurz MW, 2013, ACTA NEUROL SCAND, V127, P57, DOI 10.1111/ane.12051; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Li R, 2013, FASEB J, V27, P855, DOI 10.1096/fj.12-220509; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Orren A, 2012, CLIN EXP IMMUNOL, V167, P459, DOI 10.1111/j.1365-2249.2011.04525.x; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Plurad DS, 2010, AM SURGEON, V76, P43; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Ramaglia V, 2008, MOL IMMUNOL, V45, P3865, DOI 10.1016/j.molimm.2008.06.018; Ramaglia V, 2007, J NEUROSCI, V27, P7663, DOI 10.1523/JNEUROSCI.5623-06.2007; Ramaglia V, 2009, MOL IMMUNOL, V47, P302, DOI 10.1016/j.molimm.2009.09.019; Ramaglia V, 2009, MOL IMMUNOL, V46, P1892, DOI 10.1016/j.molimm.2009.01.017; Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rostami E, 2013, J NEUROTRAUM, V30, P1954, DOI 10.1089/neu.2012.2583; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Turnberg D, 2004, AM J PATHOL, V165, P825, DOI 10.1016/S0002-9440(10)63345-7; Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543; Woodruff TM, 2011, MOL IMMUNOL, V48, P1631, DOI 10.1016/j.molimm.2011.04.014; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiong ZQ, 2003, J NEUROSCI, V23, P955	47	73	73	0	7	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	MAR 1	2014	192	5					2339	2348		10.4049/jimmunol.1302793			10	Immunology	Immunology	AC7IL	WOS:000332701400038	24489093	Bronze			2021-06-18	
J	Sabaz, M; Simpson, GK; Walker, AJ; Rogers, JM; Gillis, I; Strettles, B				Sabaz, Mark; Simpson, Grahame K.; Walker, Alexandra J.; Rogers, Jeffrey M.; Gillis, Inika; Strettles, Barbara			Prevalence, Comorbidities, and Correlates of Challenging Behavior Among Community-Dwelling Adults With Severe Traumatic Brain Injury: A Multicenter Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						challenging behavior; participation; prevalence; psychiatric disorders; support needs; traumatic brain injury	NEUROBEHAVIORAL REHABILITATION SERVICE; CLOSED HEAD-INJURY; AGGRESSIVE-BEHAVIOR; SCALE; APATHY; PERSONALITY; AGITATION; PROGRAM; PEOPLE; IMPACT	Objective: Investigate the prevalence, comorbidities, and correlates of challenging behaviors among clients of the New South Wales Brain Injury Rehabilitation Program. Setting: All community-based rehabilitation services of the statewide program. Participants: Five hundred seven active clients with severe traumatic brain injury. Design: Prospective multicenter study. Main Measures: Eighty-eight clinicians from the 11 services rated clients on the Overt Behaviour Scale, Disability Rating Scale, Sydney Psychosocial Reintegration Scale-2, Care and Needs Scale, and Health of the Nation Outcome Scale-Acquired Brain Injury. Results: Overall prevalence rate of challenging behaviors was 54%. Inappropriate social behavior (33.3%), aggression (31.9%), and adynamia (23.1%) were the 3 most common individual behaviors, with 35.5% of the sample displaying more than 1 challenging behavior. Significant associations were found between increasing levels of challenging behavior and longer duration of posttraumatic amnesia, increasing functional disability, greater restrictions in participation, increased support needs, and greater degrees of psychiatric disturbance, respectively (P < 0.004). Multivariate binomial logistic regression found that premorbid alcohol abuse, postinjury restrictions in participation, and higher levels of postinjury psychiatric disturbance were independent predictors of challenging behavior. Conclusions: Challenging behaviors are widespread among community-dwelling adults with severe traumatic brain injury. Services need to deliver integrated anger management, social skills, and motivational treatments.	[Sabaz, Mark; Simpson, Grahame K.] Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Sydney, NSW 1871, Australia; [Simpson, Grahame K.] Univ Sydney, Sydney Sch Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Walker, Alexandra J.] Australian Catholic Univ, Westmead Hosp, Westmead Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Rogers, Jeffrey M.] Univ New S Wales, Fac Med, Sch Psychiat, Sydney, NSW, Australia; [Gillis, Inika] Univ New S Wales, Fac Med, Black Dog Inst, Sydney, NSW, Australia; [Strettles, Barbara] Agcy Clin Innovat, Sydney, NSW, Australia	Sabaz, M (corresponding author), Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Locked Bag 7279 Liverpool BC, Sydney, NSW 1871, Australia.	mark.sabaz@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Rogers, Jeffrey M/0000-0002-0320-969X	New South Wales Agency for Clinical Innovation	The New South Wales Agency for Clinical Innovation funded the project. Dr Sabaz, Dr Rogers, and Ms Gillis were employed by the Agency for Clinical Innovation when working on the project. The authors thank Natalie Pride, Dr Adeline Hodgkinson, Suzanne Benson, Naomi Brookes, Matthew Dowton, Marion Fisher, Kate O'Reilly, Vicki Solomon, and Maysaa Daher.	Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 2007, BRAIN INJURY, V21, P891, DOI 10.1080/02699050701543560; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Belanger HG, 2008, ARCH PHYS MED REHAB, V89, P244, DOI 10.1016/j.apmr.2007.08.145; Brain Injury Rehabilitation Directorate, 2010, NSW BRAIN INJ REH PR; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Coetzer R., 2001, PSYCHIAT B, V25, P421, DOI DOI 10.1192/pb.25.11.421; Colantonio A, 2010, BRAIN IMPAIR, V11, P31, DOI 10.1375/brim.11.1.31; Dickens G L, 2001, J Psychiatr Ment Health Nurs, V8, P543, DOI 10.1046/j.1351-0126.2001.00426.x; Emerson Eric, 2001, CHALLENGING BEHAV AN; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Feeney TJ, 2001, J HEAD TRAUMA REHAB, V16, P61, DOI 10.1097/00001199-200102000-00008; Fleminger S, 2005, PSYCHIATR BULL, V29, P53, DOI 10.1192/pb.29.2.53; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greve KW, 2001, BRAIN INJURY, V15, P255; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kelly G., 2004, BRAIN IMPAIR, V5, DOI [10.1375/brim.5.1.42.35398, DOI 10.1375/brim.5.1.42.35398]; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lane-Brown A, 2010, J HEAD TRAUMA REHAB, V25, P459, DOI 10.1097/HTR.0b013e3181d98e1d; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SABHESAN S, 1989, ARCH SEX BEHAV, V18, P349, DOI 10.1007/BF01541953; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Tate RL, 2003, STUD NEUROPSYCHOL DE, P137; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; van Reekum R, 2005, J NEUROPSYCH CLIN N, V17, P7, DOI 10.1176/appi.neuropsych.17.1.7; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; Wood RL, 2001, NEUROBEHAVIOURAL DIS; Wood RL, 2006, J NEUROPSYCH CLIN N, V18, P333, DOI 10.1176/appi.neuropsych.18.3.333; Worthington AD, 2006, BRAIN INJURY, V20, P947, DOI 10.1080/02699050600888314	46	73	73	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2014	29	2					E19	E30		10.1097/HTR.0b013e31828dc590			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9ZH	WOS:000336504600003	23640541				2021-06-18	
J	Dobryakova, E; DeLuca, J; Genova, HM; Wylie, GR				Dobryakova, Ekaterina; DeLuca, John; Genova, Helen M.; Wylie, Glenn R.			Neural Correlates of Cognitive Fatigue: Cortico-Striatal Circuitry and Effort-Reward Imbalance	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive fatigue; Basal ganglia; Reward network; Effort-reward relationship; MRI	VENTROMEDIAL PREFRONTAL CORTEX; MENTAL FATIGUE; BASAL GANGLIA; FRONTAL-CORTEX; MOTIVATION; RESPONSES; DOPAMINE; BEHAVIOR	Recently, there has been renewed interest in the study of cognitive fatigue. It is known that fatigue is one of the most disabling symptoms in numerous neurological populations, including stroke, multiple sclerosis, Parkinson's disease, and traumatic brain injury. Behavioral studies of cognitive fatigue are hampered by lack of correlation of self-report measures with objective performance. Neuroimaging studies provide new insight about cognitive fatigue and its neural correlates. Impairment within the cortico-striatal network, involved in effort-reward calculation, has been suggested to be critically related to fatigue. The current review surveys the recent neuroimaging literature, and suggests promising avenues for future research.	[Dobryakova, Ekaterina; DeLuca, John; Genova, Helen M.; Wylie, Glenn R.] Kessler Fdn Res Ctr, W Orange, NJ USA; [Dobryakova, Ekaterina; DeLuca, John; Genova, Helen M.; Wylie, Glenn R.] Rutgers State Univ, Newark, NJ 07102 USA; [Wylie, Glenn R.] War Related Illness & Injury Study Ctr, Dept Vet Affairs, E Orange, NJ USA	Dobryakova, E (corresponding author), Kessler Fdn Res Ctr, 300 Execut Dr,Suite 70, W Orange, NJ USA.	edobryakova@kesslerfoundation.org			National Institute on Disability and Rehabilitation Research [H133P070007]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG 4232A1/1]; New Jersey Commission on Brain Injury Research [RG 10-3216-BIR-E-0]; Kessler Research Foundation Center	The authors acknowledge grant support from The National Institute on Disability and Rehabilitation Research (H133P070007), National Multiple Sclerosis Society RG 4232A1/1 to H.G. and New Jersey Commission on Brain Injury Research RG 10-3216-BIR-E-0 to G.W., and the Kessler Research Foundation Center. The authors declare no conflict of interest.	Boksem MAS, 2008, BRAIN RES REV, V59, P125, DOI 10.1016/j.brainresrev.2008.07.001; Boksem MAS, 2006, BIOL PSYCHOL, V72, P123, DOI 10.1016/j.biopsycho.2005.08.007; Boksem MAS, 2005, COGNITIVE BRAIN RES, V25, P107, DOI 10.1016/j.cogbrainres.2005.04.011; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Botvinick MM, 2009, PSYCHOL RES-PSYCH FO, V73, P835, DOI 10.1007/s00426-008-0197-8; Capuron L, 2012, ARCH GEN PSYCHIAT, V69, P1044, DOI 10.1001/archgenpsychiatry.2011.2094; CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Claros-Salinas D, 2013, NEUROPSYCHOL REHABIL, V23, P182, DOI 10.1080/09602011.2012.726925; DeLuca J, 2005, ISS CLIN COGN NEUROP, P1; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Haber SN, 2000, J NEUROSCI, V20, P2369; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; Hollerman JR, 1998, J NEUROPHYSIOL, V80, P947; Kluger BM, 2013, NEUROLOGY, V80, P409, DOI 10.1212/WNL.0b013e31827f07be; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Leocani L, 2008, NEUROL SCI, V29, pS241, DOI 10.1007/s10072-008-0950-1; Lorist MM, 2009, BRAIN RES, V1270, P95, DOI 10.1016/j.brainres.2009.03.015; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Moeller SJ, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.110; O'Doherty JP, 2011, ANN NY ACAD SCI, V1239, P118, DOI 10.1111/j.1749-6632.2011.06290.x; Pardini M, 2013, MULT SCLER J, V19, P233, DOI 10.1177/1352458512451509; Pardini M, 2010, BEHAV NEUROSCI, V124, P329, DOI 10.1037/a0019585; Pardini M, 2010, NEUROLOGY, V74, P749, DOI 10.1212/WNL.0b013e3181d25b6b; Roelcke U, 1997, NEUROLOGY, V48, P1566, DOI 10.1212/WNL.48.6.1566; Salamone JD, 2003, J PHARMACOL EXP THER, V305, P1, DOI 10.1124/jpet.102.035063; Strober L. D., 2013, SECONDARY INFLUENCES; Tang WK, 2013, J NEUROL SCI, V324, P131, DOI 10.1016/j.jns.2012.10.022; Tang WK, 2010, J NEUROL, V257, P178, DOI 10.1007/s00415-009-5284-2; Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507; Walton ME, 2003, J NEUROSCI, V23, P6475; Wylie G., 2012, INVESTIGATION COGNIT	33	73	73	0	36	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2013	19	8					849	853		10.1017/S1355617713000684			5	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	209AQ	WOS:000323725800001	23842042				2021-06-18	
J	Bryant, RA; O'Donnell, ML; Creamer, M; McFarlane, AC; Silove, D				Bryant, Richard A.; O'Donnell, Meaghan L.; Creamer, Mark; McFarlane, Alexander C.; Silove, Derrick			A Multisite Analysis of the Fluctuating Course of Posttraumatic Stress Disorder	JAMA PSYCHIATRY			English	Article							DELAYED-ONSET PTSD; MOTOR-VEHICLE ACCIDENTS; TRAUMATIC BRAIN-INJURY; FOLLOW-UP; CONDITIONED FEAR; IMMEDIATE-ONSET; HEART-RATE; EXTINCTION; PREDICTORS; SURVIVORS	IMPORTANCE Delayed-onset posttraumatic stress disorder (PTSD) accounts for approximately 25% of PTSD cases. Current models do not adequately explain the delayed increases in PTSD symptoms after trauma exposure. OBJECTIVE To test the roles of initial psychiatric reactions, mild traumatic brain injury (MTBI), and ongoing stressors on delayed-onset PTSD. DESIGN, SETTING, AND PARTICIPANTS In this prospective cohort study, patients were selected from recent admissions to 4 major trauma hospitals across Australia. A total of 1084 traumatically injured patients were assessed during hospital admission from April 1, 2004, through February 28, 2006, and 785 (72.4%) were followed up at 3, 12, and 24 months after injury. MAIN OUTCOME AND MEASURE Severity of PTSD was determined at each assessment with the Clinician-Administered PTSD Scale. RESULTS Of those who met PTSD criteria at 24 months, 44.1% reported no PTSD at 3 months and 55.9% had subsyndromal or full PTSD. In those who displayed subsyndromal or full PTSD at 3 months, PTSD severity at 24 months was predicted by prior psychiatric disorder, initial PTSD symptom severity, and type of injury. In those who displayed no PTSD at 3 months, PTSD severity at 24 months was predicted by initial PTSD symptom severity, MTBI, length of hospitalization, and the number of stressful events experienced between 3 and 24 months. CONCLUSIONS AND RELEVANCE These data highlight the complex trajectories of PTSD symptoms over time. This study also points to the roles of ongoing stress and MTBI in delayed cases of PTSD and suggests the potential of ongoing stress to compound initial stress reactions and lead to a delayed increase in PTSD symptom severity. This study also provides initial evidence that MTBI increases the risk of delayed PTSD symptoms, particularly in those with no acute symptoms.	[Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Bryant, Richard A.] Univ Sydney, Brain Dynam Ctr, Sydney, NSW, Australia; [Bryant, Richard A.] Westmead Millennium Inst, Sydney, NSW, Australia; [O'Donnell, Meaghan L.] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Natl Trauma Res Inst, Dept Psychiat, Melbourne, Vic, Australia; [Creamer, Mark] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Melbourne, Vic, Australia; [McFarlane, Alexander C.] Ctr Mil & Veteran Hlth, Brisbane, Qld, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	National Health and Medical Research Council ProgramNational Health and Medical Research Council of Australia [568970]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical Research FellowshipNational Health and Medical Research Council of Australia [359284]	This research was supported by grant 568970 from the National Health and Medical Research Council Program (Drs Byrant, Silove, McFarlane, and Creamer), Victorian Trauma Foundation grant V-11 (Drs Creamer and O'Donnell), and National Health and Medical Research Council Australian Clinical Research Fellowship grant 359284 (Drs Creamer and O'Donnell).	American Psychiatric Association, 1994, DIAGNOSTIC AND STATI; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; Andrews B, 2009, J ABNORM PSYCHOL, V118, P767, DOI 10.1037/a0017203; [Anonymous], 2004, AM J PSYCHIAT, V161, P1321; Berninger A, 2010, AM J IND MED, V53, P1177, DOI 10.1002/ajim.20894; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Boscarino JA, 2009, SOC PSYCH PSYCH EPID, V44, P887, DOI 10.1007/s00127-009-0011-y; Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804; Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9; BRESLAU N, 1995, AM J PSYCHIAT, V152, P529; Brewin CR, 2010, PSYCHOL REV, V117, P210, DOI 10.1037/a0018113; BRUGHA T, 1985, PSYCHOL MED, V15, P189, DOI 10.1017/S003329170002105X; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2002, AUST NZ J PSYCHIAT, V36, P205, DOI 10.1046/j.1440-1614.2002.01009.x; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2011, J CLIN PSYCHIAT, V72, P233, DOI 10.4088/JCP.09r05072blu; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2008, J CLIN PSYCHIAT, V69, P1694, DOI 10.4088/JCP.v69n1104; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carty J, 2006, J AFFECT DISORDERS, V90, P257, DOI 10.1016/j.jad.2005.11.011; Clohessy S, 1999, BRIT J CLIN PSYCHOL, V38, P251, DOI 10.1348/014466599162836; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Freedman SA, 1999, BRIT J PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353; Gillies ML, 2003, J TRAUMA STRESS, V16, P523, DOI 10.1023/A:1025774915005; Gray MJ, 2004, J CONSULT CLIN PSYCH, V72, P909, DOI 10.1037/0022-006X.72.5.909; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Griffin MG, 2008, J TRAUMA STRESS, V21, P91, DOI 10.1002/jts.20300; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hermans D, 2005, BEHAV RES THER, V43, P533, DOI 10.1016/j.brat.2004.03.013; Hobfoll SE, 2006, J TRAUMA STRESS, V19, P867, DOI 10.1002/jts.20166; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horesh D, 2011, SOC PSYCH PSYCH EPID, V46, P863, DOI 10.1007/s00127-010-0255-6; Kessler RC, 2008, MOL PSYCHIATR, V13, P374, DOI 10.1038/sj.mp.4002119; King DW, 1996, J CONSULT CLIN PSYCH, V64, P520, DOI 10.1037/0022-006X.64.3.520; LaBar KS, 2005, BEHAV NEUROSCI, V119, P677, DOI 10.1037/0735-7044.119.3.677; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; Milad MR, 2006, BIOL PSYCHOL, V73, P61, DOI 10.1016/j.biopsycho.2006.01.008; Monroe SM, 2008, ANNU REV CLIN PSYCHO, V4, P33, DOI 10.1146/annurev.clinpsy.4.022007.141207; Norrholm SD, 2006, LEARN MEMORY, V13, P681, DOI 10.1101/lm.393906; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Ruzich MJ, 2005, AM J GERIAT PSYCHIAT, V13, P424, DOI 10.1176/appi.ajgp.13.5.424; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 2000, J CLIN PSYCHIAT, V61, P33; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smid GE, 2012, PSYCHOL MED, V42, P1675, DOI 10.1017/S0033291711002765; Smid GE, 2009, J CLIN PSYCHIAT, V70, P1572, DOI 10.4088/JCP.08r04484; SOLOMON Z, 1991, J COMMUNITY PSYCHOL, V19, P231, DOI 10.1002/1520-6629(199107)19:3<231::AID-JCOP2290190304>3.0.CO;2-C; SOLOMON Z, 1989, PSYCHIATRY, V52, P428, DOI 10.1080/00332747.1989.11024467; Stam R, 2007, NEUROSCI BIOBEHAV R, V31, P530, DOI 10.1016/j.neubiorev.2006.11.010; Stam R, 2007, NEUROSCI BIOBEHAV R, V31, P558, DOI 10.1016/j.neubiorev.2007.01.001; Tsai KY, 2007, J PSYCHIATR RES, V41, P90, DOI 10.1016/j.jpsychires.2005.10.004; Wolfe J, 1999, J CONSULT CLIN PSYCH, V67, P520, DOI 10.1037/0022-006X.67.4.520; Yehuda R, 1998, BIOL PSYCHIAT, V44, P1305, DOI 10.1016/S0006-3223(98)00276-5	60	73	73	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	AUG	2013	70	8					839	846		10.1001/jamapsychiatry.2013.1137			8	Psychiatry	Psychiatry	197EW	WOS:000322833600010	23784521	Bronze			2021-06-18	
J	Bouix, S; Pasternak, O; Rathi, Y; Pelavin, PE; Zafonte, R; Shenton, ME				Bouix, Sylvain; Pasternak, Ofer; Rathi, Yogesh; Pelavin, Paula E.; Zafonte, Ross; Shenton, Martha E.			Increased Gray Matter Diffusion Anisotropy in Patients with Persistent Post-Concussive Symptoms following Mild Traumatic Brain Injury	PLOS ONE			English	Article							PRINCIPAL EIGENVECTOR MEASUREMENTS; TENSOR IMAGING FINDINGS; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; HEAD-INJURY; REPRODUCIBILITY; DEGENERATION; DTI	A significant percentage of individuals diagnosed with mild traumatic brain injury (mTBI) experience persistent post-concussive symptoms (PPCS). Little is known about the pathology of these symptoms and there is often no radiological evidence based on conventional clinical imaging. We aimed to utilize methods to evaluate microstructural tissue changes and to determine whether or not a link with PPCS was present. A novel analysis method was developed to identify abnormalities in high-resolution diffusion tensor imaging (DTI) when the location of brain injury is heterogeneous across subjects. A normative atlas with 145 brain regions of interest (ROI) was built from 47 normal controls. Comparing each subject's diffusion measures to the atlas generated subject-specific profiles of injury. Abnormal ROIs were defined by absolute z-score values above a given threshold. The method was applied to 11 PPCS patients following mTBI and 11 matched controls. Z-score information for each individual was summarized with two location-independent measures: "load'' (number of abnormal regions) and "severity'' (largest absolute z-score). Group differences were then computed using Wilcoxon rank sum tests. Results showed statistically significantly higher load (p = 0.018) and severity (p = 0.006) for fractional anisotropy (FA) in patients compared with controls. Subject-specific profiles of injury evinced abnormally high FA regions in gray matter (30 occurrences over 11 patients), and abnormally low FA in white matter (3 occurrences over 11 subjects). Subject-specific profiles provide important information regarding the pathology associated with PPCS. Increased gray matter (GM) anisotropy is a novel in-vivo finding, which is consistent with an animal model of brain trauma that associates increased FA in GM with pathologies such as gliosis. In addition, the individualized analysis shows promise for enhancing the clinical care of PPCS patients as it could play a role in the diagnosis of brain injury not revealed using conventional imaging.	[Bouix, Sylvain; Pasternak, Ofer; Rathi, Yogesh; Pelavin, Paula E.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Dept Psychiat, Brockton Div, Brockton, MA USA	Bouix, S (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.	sylvain@bwh.harvard.edu	Shenton, Martha/V-8780-2019	Bouix, Sylvain/0000-0003-1326-6054	Center for Integration of Medicine and Innovative Technology Soldier in Medicine Award; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH082918, R01 NS078337, NAMIC-U54 EB005149]; INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium; Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB005149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH082918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER	This work was supported in part by the Center for Integration of Medicine and Innovative Technology Soldier in Medicine Award [to S.B.], by the National Institute of Health [R01 MH082918 to S.B., R01 NS078337 to M.E.S., NAMIC-U54 EB005149 to M.E.S.] and by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD to M.E.S., S.B., O.P., Y.R. and R.Z.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; ARNETT JA, 1995, PSYCHOL ASSESSMENT, V7, P220; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benton LA, MULTILINGUAL APHASIA; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blumenfeld-Katzir T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020678; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Delis DC, CALIFORNIA VERBAL LE; Dobson AJ., 2008, INTRO GEN LINEAR MOD; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Hannoun S, 2012, AM J NEURORADIOL, V33, P1363, DOI 10.3174/ajnr.A2983; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Jones DK, 2008, CORTEX, V44, P936, DOI 10.1016/j.cortex.2008.05.002; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kaufman L., 2005, FINDING GROUPS DATA; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Peled S, 2009, J MAGN RESON IMAGING, V30, P243, DOI 10.1002/jmri.21808; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Seber G. A. F., 2004, MULTIVARIATE OBSERVA; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280	41	73	73	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2013	8	6							e66205	10.1371/journal.pone.0066205			9	Multidisciplinary Sciences	Science & Technology - Other Topics	169CU	WOS:000320755400120	23776631	DOAJ Gold, Green Published			2021-06-18	
J	Walker, PA; Bedi, SS; Shah, SK; Jimenez, F; Xue, H; Hamilton, JA; Smith, P; Thomas, CP; Mays, RW; Pati, S; Cox, CS				Walker, Peter A.; Bedi, Supinder S.; Shah, Shinil K.; Jimenez, Fernando; Xue, Hasen; Hamilton, Jason A.; Smith, Philippa; Thomas, Chelsea P.; Mays, Robert W.; Pati, Shibani; Cox, Charles S., Jr.			Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: modulation of the resident microglia population	JOURNAL OF NEUROINFLAMMATION			English	Article						Multipotent adult progenitor cells; Traumatic brain injury; Stem cells; Splenocytes; Blood brain barrier; Microglia	CENTRAL-NERVOUS-SYSTEM; INFLAMMATORY RESPONSE; SPINAL-CORD	Introduction: We have demonstrated previously that the intravenous delivery of multipotent adult progenitor cells (MAPC) after traumatic brain injury affords neuroprotection via interaction with splenocytes, leading to an increase in systemic anti-inflammatory cytokines. We hypothesize that the observed modulation of the systemic inflammatory milieu is related to T regulatory cells and a subsequent increase in the locoregional neuroprotective M2 macrophage population. Methods: C57B6 mice were injected with intravenous MAPC 2 and 24 hours after controlled cortical impact injury. Animals were euthanized 24, 48, 72, and 120 hours after injury. In vivo, the proportion of CD4(+)/CD25(+)/FOXP3(+) T-regulatory cells were measured in the splenocyte population and plasma. In addition, the brain CD86(+) M1 and CD206(+) M2 macrophage populations were quantified. A series of in vitro co-cultures were completed to investigate the need for direct MAPC:splenocyte contact as well as the effect of MAPC therapy on M1 and M2 macrophage subtype apoptosis and proliferation. Results: Significant increases in the splenocyte and plasma T regulatory cell populations were observed with MAPC therapy at 24 and 48 hours, respectively. In addition, MAPC therapy was associated with an increase in the brain M2/M1 macrophage ratio at 24, 48 and 120 hours after cortical injury. In vitro cultures of activated microglia with supernatant derived from MAPC:splenocyte co-cultures also demonstrated an increase in the M2/M1 ratio. The observed changes were secondary to an increase in M1 macrophage apoptosis. Conclusions: The data show that the intravenous delivery of MAPC after cortical injury results in increases in T regulatory cells in splenocytes and plasma with a concordant increase in the locoregional M2/M1 macrophage ratio. Direct contact between the MAPC and splenocytes is required to modulate activated microglia, adding further evidence to the central role of the spleen in MAPC-mediated neuroprotection.	[Walker, Peter A.; Shah, Shinil K.; Xue, Hasen; Pati, Shibani; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Dept Surg, Houston, TX 77030 USA; [Walker, Peter A.; Bedi, Supinder S.; Shah, Shinil K.; Jimenez, Fernando; Xue, Hasen; Smith, Philippa; Thomas, Chelsea P.; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Hamilton, Jason A.; Mays, Robert W.] Athersys Inc, Dept Regenerat Med, Cleveland, OH 44115 USA	Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.s.cox@uth.tmc.edu			Athersys, Inc.; Cord Blood Registry, Inc.; BD Biosciences, Inc.; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM 08 79201]; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; BD Biosciences;  [M01 RR 02558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024148, M01RR002558] Funding Source: NIH RePORTER	There are no known conflicts between the authors and the information presented in this paper. Charles S. Cox Jr. MD has sponsored research agreements with Athersys, Inc. and Cord Blood Registry, Inc. Peter A. Walker MD, Fernando Jimenez MS, Shinil K. Shah DO, and Charles S. Cox, Jr. MD have received grant support from BD Biosciences, Inc. Jason A. Hamilton PhD and Robert W. Mays PhD are employed by Athersys, Inc. Athersys Inc. supplied the bone marrow derived progenitor cells for all experiments.; NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; Athersys, Inc.; BD Biosciences.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kovacsovics-Bankowski M, 2008, CYTOTHERAPY, V10, P730, DOI 10.1080/14653240802320245; Kovacsovics-Bankowski M, 2009, CELL IMMUNOL, V255, P55, DOI 10.1016/j.cellimm.2008.10.004; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005	18	73	73	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 28	2012	9								228	10.1186/1742-2094-9-228			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	087GW	WOS:000314750500002	23020860	DOAJ Gold, Green Published			2021-06-18	
J	Rosenbaum, SB; Lipton, ML				Rosenbaum, Sara B.; Lipton, Michael L.			Embracing chaos: the scope and importance of clinical and pathological heterogeneity in mTBI	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury (mTBI); Heterogeneity; Biomechanics; Diffusion tensor imaging (DTI); Post-concussive symptoms PCS)	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POST-CONCUSSIVE SYMPTOMS; APOLIPOPROTEIN-E POLYMORPHISM; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; DIFFUSE AXONAL INJURY; GLASGOW COMA SCALE; QUALITY-OF-LIFE; POSTCONCUSSION SYNDROME	Mild traumatic brain injury (mTBI) manifests a wide array of clinical features, indicating great heterogeneity of its underlying pathologic features. mTBI diversity is related to pre-injury inter-individual differences and differences in the characteristics of each injury. This review summarizes key features of mTBI patients, their injuries and outcomes to give context to the scope of complexity inherent in this disorder. These differences are underscored by heterogeneity in postmortem pathology and in vivo imaging studies. Recognition, understanding and accounting for disease heterogeneity in mTBI are needed to enhance diagnosis and patient management, as approaches that do not account for inter-individual variation in pathology and patient characteristics relevant to real-life clinical trial participants, may entirely miss therapeutic targets. Refining our approach to TBI diagnosis, in light of inter-individual differences, can facilitate the development of effective prognostic tools and algorithms. New paradigms, which embrace heterogeneity of mTBI, in both preclinical and clinical investigation as well the appreciation of this variability in clinical care, offer much promise for enhancing outcomes and mitigating the burden of mTBI on its victims.	[Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Dept Radiol, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Dept Psychiat, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Dept Behav Sci, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Montefiore Med Ctr, Bronx, NY 10461 USA	Lipton, ML (corresponding author), Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Dept Radiol, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Aiken AH, 2010, SEMIN ROENTGENOL, V45, P63, DOI 10.1053/j.ro.2009.09.007; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Alexander MP, 1995, NEUROLOGY; Allen DN, 2009, APPL NEUROPSYCHOL, V16, P186, DOI 10.1080/09084280903098687; ALTERMAN AI, 1985, J STUD ALCOHOL, V46, P256, DOI 10.15288/jsa.1985.46.256; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baugh C. M., 2012, BRAIN IMAGING BEHAV; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler E. D, 2012, BRAIN IMAGING BEHAV; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Bordignon KC, 2002, ARQ NEURO-PSIQUIAT, V60, P204, DOI 10.1590/S0004-282X2002000200004; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bose D, 2010, ACCIDENT ANAL PREV, V42, P1398, DOI 10.1016/j.aap.2010.03.004; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chou YC, 2009, BRAIN INJURY, V23, P1095, DOI 10.3109/02699050903379396; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; De Guise E, 2009, BRAIN INJURY, V23, P853, DOI 10.1080/02699050903283221; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Demakis GJ, 2010, ARCH CLIN NEUROPSYCH, V25, P191, DOI 10.1093/arclin/acq004; DeRosia John, 2004, Traffic Inj Prev, V5, P50, DOI 10.1080/15389580490269182; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elliott MR, 2006, J TRAUMA, V61, P1244, DOI 10.1097/01.ta.0000195983.48529.0d; Eppinger R., 1999, DEV IMPROVED INJURY; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hault-Dubrulle A, 2011, ACCIDENT ANAL PREV, V43, P75, DOI 10.1016/j.aap.2010.07.013; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hulkower M. B., 2011, AM AC NEUR HON HAW; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; ICHISE M, 1994, J NUCL MED, V35, P217; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Ives JC, 2007, J ATHL TRAINING, V42, P431; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim N., 2011, ISMRM MONTR QUEB CAN; KING AI, 1995, J TRAUMA, V38, P570, DOI 10.1097/00005373-199504000-00017; King AI, 2011, CLIN ANAT, V24, P294, DOI 10.1002/ca.21151; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koura SS, 1998, ACT NEUR S, V71, P244; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lipton M. L., 2012, BRAIN IMAGING BEHAV; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M., 2009, CLIN NEUROPSYCHOLOGI; McCrory P., 2009, S AFRICAN J SPORTS M, V21; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; Newman J, 2000, NEW BIOMECHANICAL 2; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Peterson TD, 1999, ANN EMERG MED, V34, P384, DOI 10.1016/S0196-0644(99)70135-6; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Roudsari BS, 2004, INJURY PREV, V10, P154, DOI 10.1136/ip.2003.003814; Ruff R. M., 1990, J HEAD TRAUMA REHABI; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwartz I, 2008, BRAIN INJURY, V22, P255, DOI 10.1080/02699050801941763; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shenton M. E., 2012, BRAIN IMAGING BEHAV; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stevens MC, 2012, BRAIN IMAGING BEHAV; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teasdale TW, 2003, J NEUROL NEUROSUR PS, V74, P933, DOI 10.1136/jnnp.74.7.933; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	237	73	73	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		255	282		10.1007/s11682-012-9162-7			28	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900008	22549452				2021-06-18	
J	Covassin, T; Elbin, RJ; Sarmiento, K				Covassin, Tracey; Elbin, R. J.; Sarmiento, Kelly			Educating Coaches About Concussion in Sports: Evaluation of the CDC's "Heads Up: Concussion in Youth Sports" Initiative	JOURNAL OF SCHOOL HEALTH			English	Article						concussions; youth coaches; CDC Heads Up	2ND IMPACT; EPIDEMIOLOGY	BACKGROUND: Concussions remain a serious public health concern. It is important that persons involved in youth sports, particularly coaches, be made aware and educated on the signs and symptoms of concussion. This study assessed the perceptions of youth sport coaches who have received the Centers for Disease Control and Prevention's (CDC's) Heads Up: Concussion in Youth Sports materials in preventing, recognizing, and responding to concussions. METHODS: A 22-item survey was developed with questions pertaining to demographics, awareness of sports-related concussion, and the usefulness of the CDC's "Heads Up: Concussion in Youth Sports'' initiative and materials. A total of 340 youth sport coaches completed the survey, for a response rate of 34.0%. RESULTS: All youth sport coaches reported having the "Heads Up'' materials for approximately 6 months before completing the survey. Seventy-seven percent of youth sports coaches reported being better able to identify athletes who may have a concussion, with 50% reported having learned something new about concussion after reviewing the materials. Sixty-three percent of youth sport coaches viewed concussions as being more serious, while 72% of coaches reporting that they are now educating others on concussion. CONCLUSION: The "Heads Up'' materials demonstrated that youth sports coaches' were able to appropriately prevent, recognize, and respond to sports-related concussions after reviewing the materials. Future studies should concentrate on evaluating the impact of concussion policies, laws and media coverage on coaches' awareness and prevention, recognition, and response to concussions using a rigorous design including a control group.	[Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Elbin, R. J.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15261 USA; [Sarmiento, Kelly] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu; rje13@pitt.edu; egz8@cdc.gov					Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; National Center for Injury Prevention and Control, 2007, HEADS CONC HIGH SCH; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538	13	73	73	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4391	1746-1561		J SCHOOL HEALTH	J. Sch. Health	MAY	2012	82	5					233	238		10.1111/j.1746-1561.2012.00692.x			6	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	923NI	WOS:000302625600005	22494094				2021-06-18	
J	Thibaut, A; Bruno, MA; Chatelle, C; Gosseries, O; Vanhaudenhuyse, A; Demertzi, A; Schnakers, C; Thonnard, M; Charland-Verville, V; Bernard, C; Bahri, MA; Phillips, C; Boly, M; Hustinx, R; Laureys, S				Thibaut, Aurore; Bruno, Marie-Aurelie; Chatelle, Camille; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Demertzi, Athena; Schnakers, Caroline; Thonnard, Marie; Charland-Verville, Vanessa; Bernard, Claire; Bahri, Mohammed Ali; Phillips, Christophe; Boly, Melanie; Hustinx, Roland; Laureys, Steven			METABOLIC ACTIVITY IN EXTERNAL AND INTERNAL AWARENESS NETWORKS IN SEVERELY BRAIN-DAMAGED PATIENTS	JOURNAL OF REHABILITATION MEDICINE			English	Article; Proceedings Paper	Workshop on Consciousness and the Vegetative State - Today/2nd Conference on Consciousness and Coma	JUL 06, 2010	Salerno, ITALY			vegetative state; minimally conscious state; positron emission tomography; consciousness; self-awareness; traumatic brain injury	MINIMALLY CONSCIOUS STATE; VEGETATIVE STATE; CEREBRAL METABOLISM; POSTERIOR CINGULATE; DEFAULT NETWORK; DISORDERS; RECOVERY; INJURY; CONNECTIVITY; PERCEPTION	Objective: An extrinsic cerebral network (encompassing lateral frontoparietal cortices) related to external/sensory awareness and an intrinsic midline network related to internal/self-awareness have been identified recently. This study measured. brain metabolism in both networks in patients with severe brain damage. Design: Prospective [18F]-fluorodeoxyglucose-positron emission tomography and Coma Recovery Scale-Revised assessments in a university hospital setting. Subjects: Healthy volunteers and patients in vegetative state/unresponsive wakefulness syndrome (VS/UWS), minimally conscious state (MCS), emergence from MCS (EMCS), and locked-in syndrome (LIS). Results: A total of 70 patients were included in the study: 24 VS/UWS, 28 MCS, 10 EMCS, 8 LIS and 39 age-matched controls. VS/UWS showed metabolic dysfunction in extrinsic and intrinsic networks and thalami. MCS showed dysfunction mostly in intrinsic network and thalami. EMCS showed impairment in posterior cingulate/retrosplenial cortices. LIS showed dysfunction only in infratentorial regions. Coma Recovery Scale-Revised total scores correlated with metabolic activity in both extrinsic and part of the intrinsic network and thalami. Conclusion: Progressive recovery of extrinsic and intrinsic awareness network activity was observed in severely brain-damaged patients, ranging from VS/UWS, MCS, EMCS to LIS. The predominance of intrinsic network impairment in MCS could reflect altered internal/self-awareness in these patients, which is difficult to quantify at the bedside.	[Thibaut, Aurore; Bruno, Marie-Aurelie; Chatelle, Camille; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Demertzi, Athena; Schnakers, Caroline; Thonnard, Marie; Charland-Verville, Vanessa; Bahri, Mohammed Ali; Boly, Melanie; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Thibaut, Aurore; Bruno, Marie-Aurelie; Chatelle, Camille; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Demertzi, Athena; Schnakers, Caroline; Thonnard, Marie; Charland-Verville, Vanessa; Bahri, Mohammed Ali; Boly, Melanie; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Bernard, Claire; Hustinx, Roland] Univ Hosp Liege, Dept Nucl Med, B-4000 Liege, Belgium	Laureys, S (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020; Demertzi, Athena/I-1251-2019; Vanhaudenhuyse, Audrey/AAP-2455-2020; Thibaut, Aurore/U-8101-2019; Phillips, Christophe/M-3025-2017	Laureys, Steven/0000-0002-3096-3807; Demertzi, Athena/0000-0001-8021-3759; Phillips, Christophe/0000-0002-4990-425X; Chatelle, Camille/0000-0002-7526-2107; Boly, Melanie/0000-0001-9584-0907; Gosseries, Olivia/0000-0001-9011-7496			Alpert GF, 2008, J NEUROSCI, V28, P5344, DOI 10.1523/JNEUROSCI.5039-07.2008; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Bornhovd K, 2002, BRAIN, V125, P1326, DOI 10.1093/brain/awf137; Bruno MA, 2011, PROG BRAIN RES, V193, P323, DOI 10.1016/B978-0-444-53839-0.00021-1; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Bruno MA, 2011, CURR OPIN CRIT CARE, V17, P146, DOI 10.1097/MCC.0b013e328343476d; Bruno MA, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-35; Cologan V, 2010, SLEEP MED REV, V14, P97, DOI 10.1016/j.smrv.2009.04.003; Dehaene S, 2001, COGNITION, V79, P1, DOI 10.1016/S0010-0277(00)00123-2; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Goldberg II, 2006, NEURON, V50, P329, DOI 10.1016/j.neuron.2006.03.015; Gosseries O, 2011, NEUROREHABILITATION, V28, P3, DOI 10.3233/NRE-2011-0625; Graham DI, 2005, NEUROPSYCHOL REHABIL, V15, P198, DOI 10.1080/09602010443000452; Juengling FD, 2005, J NEUROL SCI, V228, P179, DOI 10.1016/j.jns.2004.11.052; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Knauff M, 2003, J COGNITIVE NEUROSCI, V15, P559, DOI 10.1162/089892903321662949; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2004, NEUROREHABILITATION, V19, P335; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2000, LANCET, V355, P1825, DOI 10.1016/S0140-6736(05)73084-1; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Machado C, 2010, NEUROLOGY, V74, P1156, DOI 10.1212/WNL.0b013e3181d5df0d; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Majerus S, 2009, PROG BRAIN RES, V177, P49, DOI 10.1016/S0079-6123(09)17705-1; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Phillips CL, 2011, NEUROIMAGE, V56, P797, DOI 10.1016/j.neuroimage.2010.05.083; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rees G, 2007, PHILOS T R SOC B, V362, P877, DOI 10.1098/rstb.2007.2094; Schnakers C, 2008, J NEUROL, V255, P323, DOI 10.1007/s00415-008-0544-0; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sergent C, 2004, J PHYSIOL-PARIS, V98, P374, DOI 10.1016/j.jphysparis.2005.09.006; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Soddu A, 2011, HUM BRAIN MAPP  0411, DOI [10.1002/hbm.21249, DOI 10.1002/HBM.21249.]; Vanhaudenhuyse A, 2008, NEUROLOGY, V71, P1374, DOI 10.1212/01.wnl.0000320110.70134.60; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vogt BA, 2005, PROG BRAIN RES, V150, P205, DOI 10.1016/S0079-6123(05)50015-3; Vogt BA, 2006, NEUROIMAGE, V29, P452, DOI 10.1016/j.neuroimage.2005.07.048; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	55	73	78	0	14	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2012	44	6			SI		487	494		10.2340/16501977-0940			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	956TW	WOS:000305113000003	22366927	DOAJ Gold, Green Published			2021-06-18	
J	Oddo, M; Levine, JM; Mackenzie, L; Frangos, S; Feihl, F; Kasner, SE; Katsnelson, M; Pukenas, B; Macmurtrie, E; Maloney-Wilensky, E; Kofke, WA; LeRoux, PD				Oddo, Mauro; Levine, Joshua M.; Mackenzie, Larami; Frangos, Suzanne; Feihl, Francois; Kasner, Scott E.; Katsnelson, Michael; Pukenas, Bryan; Macmurtrie, Eileen; Maloney-Wilensky, Eileen; Kofke, W. Andrew; LeRoux, Peter D.			Brain Hypoxia Is Associated With Short-term Outcome After Severe Traumatic Brain Injury Independently of Intracranial Hypertension and Low Cerebral Perfusion Pressure	NEUROSURGERY			English	Article						Brain hypoxia; Brain tissue oxygen pressure; Cerebral perfusion pressure; Indepedent predictor; Intracranial Pressure; Outcome; Traumatic brain injury	SEVERE HEAD-INJURY; TISSUE OXYGEN-TENSION; NEUROCRITICAL CARE; HYPERTONIC SALINE; INTENSIVE-CARE; BLOOD-FLOW; METABOLISM; DELIVERY; CLASSIFICATION; MICRODIALYSIS	BACKGROUND: Brain hypoxia (BH) can aggravate outcome after severe traumatic brain injury (TBI). Whether BH or reduced brain oxygen (Pbto(2)) is an independent outcome predictor or a marker of disease severity is not fully elucidated. OBJECTIVE: To analyze the relationship between Pbto(2), intracranial pressure (ICP), and cerebral perfusion pressure (CPP) and to examine whether BH correlates with worse outcome independently of ICP and CPP. METHODS: We studied 103 patients monitored with ICP and Pbto2 for > 24 hours. Durations of BH (Pbto(2) < 15 mm Hg), ICP > 20 mm Hg, and CPP < 60 mm Hg were calculated with linear interpolation, and their associations with outcome within 30 days were analyzed. RESULTS: Duration of BH was longer in patients with unfavorable (Glasgow Outcome Scale score, 1-3) than in those with favorable (Glasgow Outcome Scale, 4-5) outcome (8.3 +/- 15.9 vs 1.7 +/- 3.7 hours; P < .01). In patients with intracranial hypertension, those with BH had fewer favorable outcomes (46%) than those without (81%; P < .01); similarly, patients with low CPP and BH were less likely to have favorable outcome than those with low CPP but normal Pbto2 (39% vs 83%; P < .01). After ICP, CPP, age, Glasgow Coma Scale score, Marshall computed tomography grade, and Acute Physiology and Chronic Health Evaluation II score were controlled for, BH was independently associated with poor prognosis (adjusted odds ratio for favorable outcome, 0.89 per hour of BH; 95% confidence interval, 0.79-0.99; P = .04). CONCLUSION: Brain hypoxia is associated with poor short-term outcome after severe traumatic brain injury independently of elevated ICP, low CPP, and injury severity. Pbto2 may be an important therapeutic target after severe traumatic brain injury.	[LeRoux, Peter D.] Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, Philadelphia, PA 19107 USA; [Levine, Joshua M.; Mackenzie, Larami; Kasner, Scott E.; Katsnelson, Michael] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19107 USA; [Levine, Joshua M.; Kofke, W. Andrew] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19107 USA; [Pukenas, Bryan] Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19107 USA; [Oddo, Mauro] Univ Lausanne, Dept Intens Care Med, Med Ctr, Lausanne, Switzerland; [Feihl, Francois] Univ Lausanne, Div Pathophysiol, Med Ctr, Lausanne, Switzerland	LeRoux, PD (corresponding author), Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, 330 S 9th St, Philadelphia, PA 19107 USA.	peter.leroux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525			Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Limaye AP, 2008, JAMA-J AM MED ASSOC, V300, P413, DOI 10.1001/jama.300.4.413; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Schaller B, 2005, J TRAUMA, V59, P1521, DOI 10.1097/01.ta.0000197402.20180.6b; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E	49	73	77	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	NOV	2011	69	5					1037	1045		10.1227/NEU.0b013e3182287ca7			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	832UV	WOS:000295835300024	21673608				2021-06-18	
J	Signoretti, S; Lazzarino, G; Tavazzi, B; Vagnozzi, R				Signoretti, Stefano; Lazzarino, Giuseppe; Tavazzi, Barbara; Vagnozzi, Roberto			The Pathophysiology of Concussion	PM&R			English	Article							TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; REPETITIVE HEAD-INJURY; N-ACETYLASPARTATE; TEMPORAL WINDOW; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; INTERNATIONAL-CONFERENCE; GLUCOSE-UTILIZATION; LIPID-PEROXIDATION	Concussion is defined as a biomechanically induced brain injury characterized by the absence of gross anatomic lesions. Early and late clinical symptoms, including impairments of memory and attention, headache, and alteration of mental status, are the result of neuronal dysfunction mostly caused by functional rather than structural abnormalities. The mechanical insult initiates a complex cascade of metabolic events leading to perturbation of delicate neuronal homeostatic balances. Starting from neurotoxicity, energetic metabolism disturbance caused by the initial mitochondrial dysfunction seems to be the main biochemical explanation for most postconcussive signs and symptoms. Furthermore, concussed cells enter a peculiar state of vulnerability, and if a second concussion is sustained while they are in this state, they may be irreversibly damaged by the occurrence of swelling. This condition of concussion-induced brain vulnerability is the basic pathophysiology of the second impact syndrome. N-acetylaspartate, a brain-specific compound representative of neuronal metabolic wellness, is proving a valid surrogate marker of the post-traumatic biochemical damage, and its utility in monitoring the recovery of the aforementioned "functional" disturbance as a concussion marker is emerging, because it is easily detectable through proton magnetic resonance spectroscopy. PM R 2011;3:S359-S368	[Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; [Signoretti, Stefano] San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Dept Biol Geol & Environm Sci, Div Biochem & Mol Biol, Catania, Italy; [Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy	Vagnozzi, R (corresponding author), Univ Roma Tor Vergata, Dept Neurosci, Via Montpellier 1, I-00133 Rome, Italy.	vagnozzi@uniroma2.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barkhoudarian G, CLIN SPORTS MED, V30, P33; Baslow MH, 2006, DRUG NEWS PERSPECT, V19, P145, DOI 10.1358/dnp.2006.19.3.985930; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P132; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Cobb Sarah, 2004, J Sch Nurs, V20, P262; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fabbri A, 2010, INJURY, V41, P913, DOI 10.1016/j.injury.2010.03.002; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HARFORD S, 1975, BIOCHEM J, V151, P455, DOI 10.1042/bj1510455; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kelly J., 1997, MMWR-MORBID MORTAL W, V46, P224; Khodorov B, 1996, FEBS LETT, V393, P135, DOI 10.1016/0014-5793(96)00873-3; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; MORGAN WA, 1995, BIOCHEM PHARMACOL, V49, P1179, DOI 10.1016/0006-2952(95)00034-W; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nojiri H, 2006, J BIOL CHEM, V281, P33789, DOI 10.1074/jbc.M602118200; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; PALOZZA P, 1992, FREE RADICAL BIO MED, V13, P127, DOI 10.1016/0891-5849(92)90074-Q; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schinder AF, 1996, J NEUROSCI, V16, P6125; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; SUNAMI, 1989, NEUROSURG REV, V12, P400; SWANN IJ, 1981, INJURY, V12, P274, DOI 10.1016/0020-1383(81)90200-X; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tavazzi B, 2000, FREE RADICAL RES, V33, P1, DOI 10.1080/10715760000300561; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yates D, 2007, BMJ-BRIT MED J, V335, P719, DOI 10.1136/bmj.39331.702951.47; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	89	73	73	0	45	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S359	S368		10.1016/j.pmrj.2011.07.018			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	966YK	WOS:000305873100003	22035678				2021-06-18	
J	Hemphill, MA; Dabiri, BE; Gabriele, S; Kerscher, L; Franck, C; Goss, JA; Alford, PW; Parker, KK				Hemphill, Matthew A.; Dabiri, Borna E.; Gabriele, Sylvain; Kerscher, Lucas; Franck, Christian; Goss, Josue A.; Alford, Patrick W.; Parker, Kevin Kit			A Possible Role for Integrin Signaling in Diffuse Axonal Injury	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; FOCAL ADHESION KINASE; RHO-ASSOCIATED KINASE; MECHANICAL STRETCH; ACTIVATION; CELLS; CALCIUM; NEURONS; MECHANOTRANSDUCTION; RETRACTION	Over the past decade, investigators have attempted to establish the pathophysiological mechanisms by which non-penetrating injuries damage the brain. Several studies have implicated either membrane poration or ion channel dysfunction pursuant to neuronal cell death as the primary mechanism of injury. We hypothesized that traumatic stimulation of integrins may be an important etiological contributor to mild Traumatic Brain Injury. In order to study the effects of forces at the cellular level, we utilized two hierarchical, in vitro systems to mimic traumatic injury to rat cortical neurons: a high velocity stretcher and a magnetic tweezer system. In one system, we controlled focal adhesion formation in neurons cultured on a stretchable substrate loaded with an abrupt, one dimensional strain. With the second system, we used magnetic tweezers to directly simulate the abrupt injury forces endured by a focal adhesion on the neurite. Both systems revealed variations in the rate and nature of neuronal injury as a function of focal adhesion density and direct integrin stimulation without membrane poration. Pharmacological inhibition of calpains did not mitigate the injury yet the inhibition of Rho-kinase immediately after injury reduced axonal injury. These data suggest that integrin-mediated activation of Rho may be a contributor to the diffuse axonal injury reported in mild Traumatic Brain Injury.	[Hemphill, Matthew A.; Dabiri, Borna E.; Gabriele, Sylvain; Kerscher, Lucas; Franck, Christian; Goss, Josue A.; Alford, Patrick W.; Parker, Kevin Kit] Harvard Univ, Dis Biophys Grp, Sch Engn & Appl Sci, Wyss Inst Biol Inspired Engn, Cambridge, MA 02138 USA	Hemphill, MA (corresponding author), Harvard Univ, Dis Biophys Grp, Sch Engn & Appl Sci, Wyss Inst Biol Inspired Engn, Cambridge, MA 02138 USA.	kkparker@seas.harvard.edu	GABRIELE, Sylvain/N-6412-2014; Franck, Christian/C-6077-2012	GABRIELE, Sylvain/0000-0001-8696-8052; Franck, Christian/0000-0002-2347-620X	Defense Advance Research Projects Agency (Office of Naval) [N66001-09-c-2064]; Harvard School of Engineering and Applied Sciences	Financial support from the Defense Advance Research Projects Agency's PREVENT Program (Office of Naval Research SPAWAR N66001-09-c-2064) and the Harvard School of Engineering and Applied Sciences. The authors acknowledge Harvard University's Center for Nanoscale Systems (CNS) for the use of cleanroom facilities. S.G. is Charge de Recherches of the F.R.S.-FNRS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alford PW, 2003, J BIOMECH, V36, P1135, DOI 10.1016/S0021-9290(03)00089-7; Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fass JN, 2004, BIOPHYS J, V87, P2099, DOI 10.1529/biophysj.104.900105; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hashimoto R, 1998, BIOCHEM BIOPH RES CO, V245, P407, DOI 10.1006/bbrc.1998.8446; Hoang B, 1998, J NEUROSCI, V18, P7847; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Kam Z, 2001, TRENDS CELL BIOL, V11, P329, DOI 10.1016/S0962-8924(01)02067-0; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lemons ML, 2006, EXP NEUROL, V202, P324, DOI 10.1016/j.expneurol.2006.06.008; Lin CY, 2008, MOL CELL NEUROSCI, V37, P770, DOI 10.1016/j.mcn.2008.01.001; Lin YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004293; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760; Meyer CJ, 2000, NAT CELL BIOL, V2, P666; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Nakayama K, 2008, NEUROSCI LETT, V444, P127, DOI 10.1016/j.neulet.2008.08.034; Nishimura SL, 1998, BRAIN RES, V791, P271, DOI 10.1016/S0006-8993(98)00118-8; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Robles E, 2006, NAT NEUROSCI, V9, P1274, DOI 10.1038/nn1762; Rodriguez MA, 2000, P NATL ACAD SCI USA, V97, P3550, DOI 10.1073/pnas.050589797; Schmid RS, 2003, CEREB CORTEX, V13, P219, DOI 10.1093/cercor/13.3.219; SCHMIDT CE, 1995, J NEUROSCI, V15, P3400; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shi Y, 2006, J NEUROSCI, V26, P1813, DOI 10.1523/JNEUROSCI.4091-05.2006; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Staubli U, 1998, J NEUROSCI, V18, P3460; Stevens GR, 1996, J NEUROSCI RES, V46, P445, DOI 10.1002/(SICI)1097-4547(19961115)46:4<445::AID-JNR6>3.3.CO;2-D; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Su L, 2008, NEUROMOL MED, V10, P316, DOI 10.1007/s12017-008-8042-1; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; UPTON GJG, 1992, J ROY STAT SOC A STA, V155, P395, DOI 10.2307/2982890; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; Watson PMD, 2007, MOL CELL NEUROSCI, V34, P147, DOI 10.1016/j.mcn.2006.10.007; Webb DJ, 2007, J BIOL CHEM, V282, P6929, DOI 10.1074/jbc.M610981200; Wernig F, 2003, HYPERTENSION, V41, P903, DOI 10.1161/01.HYP.0000062882.42265.88; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Zamir E, 1999, J CELL SCI, V112, P1655	67	73	74	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2011	6	7							e22899	10.1371/journal.pone.0022899			11	Multidisciplinary Sciences	Science & Technology - Other Topics	797BJ	WOS:000293097300082	21799943	DOAJ Gold, Green Published			2021-06-18	
J	Chase, TN				Chase, Thomas N.			Apathy in Neuropsychiatric Disease: Diagnosis, Pathophysiology, and Treatment	NEUROTOXICITY RESEARCH			English	Article						Depression; Alzheimer's disease; Parkinson's disease; Schizophrenia; Depression; Prefrontal cortex; Basal ganglia; Therapeutics	UNIFIED PARKINSONS-DISEASE; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; SUBTHALAMIC NUCLEUS STIMULATION; SUSTAINED CEREBRAL-ISCHEMIA; DOPAMINE TRANSPORTER LEVELS; SYSTEMS BEHAVIOR SCALE; EFFORT-RELATED CHOICE; QUALITY-OF-LIFE; ALZHEIMERS-DISEASE	Apathy is an increasingly recognized concomitant of a broad range of central nervous system disorders. Nevertheless, its nosology, pathogenesis and therapy remain shrouded in confusion and controversy. As yet, there is little consensus regarding methods for detecting apathy, or distinguishing it from depression, or for assessing its severity. Many now regard the apathy syndrome as primarily reflecting a lack of motivation that compromises emotional, cognitive, and overt behavioral function. Even though under-recognized and under-diagnosed, apathy hardly appears uncommon: current epidemiologic studies suggest over 10 million Americans may be affected. Its reported frequency in various neurologic and psychiatric conditions varies widely, from less than 10 to over 80%, reflecting differences in population characteristics and assessment procedures. Often apathy has been associated with such neurodegenerative disorders as Alzheimer's disease, Parkinson's disease, and fronto-temporal dementia. But it also occurs in those with psychiatric disorders such as schizophrenia and major depression. Clinical, neuropathologic, and neuroimaging observations increasingly suggest that apathy reflects dysfunction of frontal-subcortical circuits, especially those linking the ventromedial prefrontal cortex to related regions in the basal ganglia. Therapeutically, numerous small studies suggest that psychostimulants, dopaminergics, and cholinesterase inhibitors may benefit those manifesting this syndrome. However, no adequately powered, randomized controlled trials have reported success and no medication have ever been approved for this disorder. The accelerating pace of current research nevertheless promises to improve our understanding of apathy and to better address the unmet medical needs of those suffering its consequences.	Chase Pharmaceut Corp, Washington, DC USA	Chase, TN (corresponding author), Chase Pharmaceut Corp, Washington, DC USA.	tchase@chasepharmaceuticals.com					Aalten P, 2005, INT J GERIATR PSYCH, V20, P523, DOI 10.1002/gps.1316; Aalten P, 2006, INT PSYCHOGERIATR, V18, P3, DOI 10.1017/S1041610205002772; Aarsland D, 2007, J NEUROL NEUROSUR PS, V78, P36, DOI 10.1136/jnnp.2005.083113; ACQUAS E, 1989, PSYCHOPHARMACOLOGY, V99, P151, DOI 10.1007/BF00442800; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Alves GS, 2009, ARQ NEURO-PSIQUIAT, V67, P173, DOI 10.1590/S0004-282X2009000200001; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Angelelli P, 2004, ACTA PSYCHIAT SCAND, V110, P55, DOI 10.1111/j.1600-0447.2004.00297.x; Apostolova LG, 2007, DEMENT GERIATR COGN, V24, P91, DOI 10.1159/000103914; Barbas NR, 2006, CLIN GERIATR MED, V22, P773, DOI 10.1016/j.cger.2006.06.004; Benoit M, 2004, INT J GERIATR PSYCH, V19, P864, DOI 10.1002/gps.1163; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Borek Leora L, 2007, Expert Rev Neurother, V7, P711, DOI 10.1586/14737175.7.6.711; Borroni B, 2008, ARCH GERONTOL GERIAT, V46, P101, DOI 10.1016/j.archger.2007.03.003; Borroni B, 2009, INT PSYCHOGERIATR, V21, P463, DOI 10.1017/S1041610209008862; Bressan RA, 2005, ACTA PSYCHIAT SCAND, V111, P14, DOI 10.1111/j.1600-0447.2005.00540.x; Brodaty H, 2005, PSYCHOL MED, V35, P1707, DOI 10.1017/S0033291705006173; Bruen PD, 2008, BRAIN, V131, P2455, DOI 10.1093/brain/awn151; Cattelani R, 2008, EUR J PHYS REHAB MED, V44, P245; Chilovi BV, 2009, DEMENT GERIATR COGN, V27, P390, DOI 10.1159/000210045; Clarke DE, 2007, J NEUROPSYCH CLIN N, V19, P57, DOI 10.1176/appi.neuropsych.19.1.57; Corcoran C, 2004, J PSYCHOPHARMACOL, V18, P133, DOI 10.1177/0269881104043284; Craig D, 2005, AM J GERIAT PSYCHIAT, V13, P460, DOI 10.1176/appi.ajgp.13.6.460; Crespi Francesco, 2002, Curr Opin Investig Drugs, V3, P788; Cummings JL, 2008, ALZHEIMERS DEMENT, V4, P49, DOI 10.1016/j.jalz.2007.10.011; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Czernecki V, 2008, MOVEMENT DISORD, V23, P964, DOI 10.1002/mds.21949; Daiello Lori A, 2007, Med Health R I, V90, P191; David R, 2008, CLIN NEUROL NEUROSUR, V110, P19, DOI 10.1016/j.clineuro.2007.08.007; DeFord SM, 2001, PHARMACOL BIOCHEM BE, V69, P611, DOI 10.1016/S0091-3057(01)00559-7; Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305; Derouesne Christian, 2004, Psychol Neuropsychiatr Vieil, V2, P19; DeVito EE, 2007, ACTA NEUROL SCAND, V116, P328, DOI 10.1111/j.1600-0404.2007.00906.x; Drapier D, 2008, NEUROPSYCHOLOGIA, V46, P2796, DOI 10.1016/j.neuropsychologia.2008.05.006; Drijgers RL, 2009, DEMENT GERIATR COGN, V28, P13, DOI 10.1159/000228840; Dujardin K, 2008, MOVEMENT DISORD, V23, P845, DOI 10.1002/mds.21968; Dujardin K, 2007, MOVEMENT DISORD, V22, P778, DOI 10.1002/mds.21316; Faerden A, 2008, EUR PSYCHIAT, V23, P33, DOI 10.1016/j.eurpsy.2007.09.002; Faerden A, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-1; Farrar AM, 2008, NEUROSCIENCE, V152, P321, DOI 10.1016/j.neuroscience.2007.12.034; Farrar AM, 2007, PSYCHOPHARMACOLOGY, V191, P579, DOI 10.1007/s00213-006-0554-5; Fava M, 2006, J CLIN PSYCHIAT, V67, P1754, DOI 10.4088/JCP.v67n1113; Feil D, 2003, INT J GERIATR PSYCH, V18, P479, DOI 10.1002/gps.869; Ferreri F, 2006, CAN MED ASSOC J, V175, P1545, DOI 10.1503/cmaj.060542; Figved N, 2005, ACTA PSYCHIAT SCAND, V112, P463, DOI 10.1111/j.1600-0447.2005.00624.x; Filali M, 2009, GENES BRAIN BEHAV, V8, P143, DOI 10.1111/j.1601-183X.2008.00453.x; FREELS S, 1992, J GERONTOL, V47, pM177; Funkiewiez A, 2004, J NEUROL NEUROSUR PS, V75, P834, DOI 10.1136/jnnp.2002.009803; Galvin JE, 2007, NEUROLOGY, V68, P1895, DOI 10.1212/01.wnl.0000263131.80945.ad; Gauthier S, 2007, INT J CLIN PRACT, V61, P886, DOI 10.1111/j.1742-1241.2007.01387.x; Ghobrial MW, 2002, SOUTHERN MED J, V95, P552; Goetz CG, 2008, MOVEMENT DISORD, V23, pS192; GOULIAEV AH, 1994, BRAIN RES REV, V19, P180, DOI 10.1016/0165-0173(94)90011-6; Haegelen C, 2009, MED HYPOTHESES, V72, P421, DOI 10.1016/j.mehy.2008.07.065; Hamilton JM, 2003, J NEUROL NEUROSUR PS, V74, P120, DOI 10.1136/jnnp.74.1.120; Hasegawa M, 1996, BEHAV BRAIN RES, V78, P93, DOI 10.1016/0166-4328(95)00235-9; Jin JJ, 2002, PHARMACOLOGY, V64, P119, DOI 10.1159/000056160; Joseph R, 1999, PSYCHIATRY, V62, P138, DOI 10.1080/00332747.1999.11024862; Ketter TA, 1999, NEUROLOGY, V53, pS53; Kiang M, 2003, SCHIZOPHR RES, V63, P79, DOI 10.1016/S0920-9964(02)00433-4; Kingma EM, 2008, GEN HOSP PSYCHIAT, V30, P155, DOI 10.1016/j.genhosppsych.2007.11.005; Kirsch-Darrow L, 2006, NEUROLOGY, V67, P33, DOI 10.1212/01.wnl.0000230572.07791.22; Kirsch-Darrow L, 2009, MOVEMENT DISORD, V24, P684, DOI 10.1002/mds.22437; Kulisevsky J, 2008, MOVEMENT DISORD, V23, P1889, DOI 10.1002/mds.22246; Lanctot KL, 2007, DEMENT GERIATR COGN, V24, P65, DOI 10.1159/000103633; Landes AM, 2005, J NEUROPSYCH CLIN N, V17, P342, DOI 10.1176/appi.neuropsych.17.3.342; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; LANEBROWN A, 2009, COCHRANE DB SYST REV, V15; Lauterbach EC, 2004, PSYCHIAT CLIN N AM, V27, P801, DOI 10.1016/j.psc.2004.07.001; Lavretsky H, 2007, AM J GERIAT PSYCHIAT, V15, P386, DOI 10.1097/JGP.0b013e3180325a16; Lechowski L, 2009, INT J GERIATR PSYCH, V24, P341, DOI 10.1002/gps.2125; Leentjens AFG, 2008, MOVEMENT DISORD, V23, P2004, DOI 10.1002/mds.22229; Leentjens AFG, 2009, CLIN THER, V31, P89, DOI 10.1016/j.clinthera.2009.01.012; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Levy R, 2006, J NEUROL, V253, P54, DOI 10.1007/s00415-006-7012-5; Lueken U, 2007, AM J GERIAT PSYCHIAT, V15, P376, DOI 10.1097/JGP.0b013e3180437db3; LUTHMAN J, 1994, ARCH INT PHARMACOD T, V328, P125; MALLA AK, 1993, CAN J PSYCHIAT, V38, P617, DOI 10.1177/070674379303800910; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Marangell LB, 2002, J CLIN PSYCHIAT, V63, P391, DOI 10.4088/JCP.v63n0503; Marin R.S., 1996, SEMIN CLIN NEUROPSYC, V1, P304, DOI [10.1053/SCNP00100304, DOI 10.1053/SCNP00100304]; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; Marin RS, 2005, J HEAD TRAUMA REHAB, V20, pCP1; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; Marin RS, 2003, J GERIATR PSYCH NEUR, V16, P112, DOI 10.1177/0891988703016002009; Marshall GA, 2006, DEMENT GERIATR COGN, V21, P144, DOI 10.1159/000090674; Marshall GA, 2007, ARCH NEUROL-CHICAGO, V64, P1015, DOI 10.1001/archneur.64.7.1015; Massimo L, 2009, DEMENT GERIATR COGN, V27, P96, DOI 10.1159/000194658; Mayo NE, 2009, STROKE, V40, P3299, DOI 10.1161/STROKEAHA.109.554410; McAllister T W, 2000, Semin Clin Neuropsychiatry, V5, P275, DOI 10.1053/scnp.2000.9557; Mendez MF, 2008, J NEUROPSYCH CLIN N, V20, P130, DOI 10.1176/appi.neuropsych.20.2.130; Migneco O, 2001, NEUROIMAGE, V13, P896, DOI 10.1006/nimg.2000.0741; Mizrahi R, 2007, DRUG AGING, V24, P547, DOI 10.2165/00002512-200724070-00003; Moriguchi S, 2007, MOL PHARMACOL, V71, P580, DOI 10.1124/mol.106.027607; OHTOMO E, 1994, IGAKU AYUMI, V170, P777; Okada K, 1997, STROKE, V28, P2437, DOI 10.1161/01.STR.28.12.2437; Padala PR, 2007, ANN PHARMACOTHER, V41, P346, DOI 10.1345/aph.1H302; Padala PR, 2010, AM J GERIAT PSYCHIAT, V18, P371, DOI 10.1097/JGP.0b013e3181cabcf6; Pedersen KF, 2008, PARKINSONISM RELAT D, V14, P183, DOI 10.1016/j.parkreldis.2007.07.015; Pedersen KF, 2009, PARKINSONISM RELAT D, V15, P295, DOI 10.1016/j.parkreldis.2008.07.006; Peters F, 2006, DEMENT GERIATR COGN, V21, P373, DOI 10.1159/000091898; Pluck GC, 2002, J NEUROL NEUROSUR PS, V73, P636, DOI 10.1136/jnnp.73.6.636; Ramirez SM, 2001, PSYCHOL REP, V88, P189, DOI 10.2466/PR0.88.1.189-200; Reijnders JSAM, 2009, PARKINSONISM RELAT D, V15, P379, DOI 10.1016/j.parkreldis.2008.09.003; Remy P, 2005, BRAIN, V128, P1314, DOI 10.1093/brain/awh445; Reyes S, 2009, NEUROLOGY, V72, P905, DOI 10.1212/01.wnl.0000344166.03470.f8; Robert P, 2009, EUR PSYCHIAT, V24, P98, DOI 10.1016/j.eurpsy.2008.09.001; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; Robert PH, 2006, CLIN NEUROL NEUROSUR, V108, P733, DOI 10.1016/j.clineuro.2006.02.003; ROBINSON RG, 1977, BIOL PSYCHIAT, V12, P669; Robinson RG, 2009, J NEUROPSYCH CLIN N, V21, P144, DOI 10.1176/appi.neuropsych.21.2.144; Rodda J, 2009, INT PSYCHOGERIATR, V21, P813, DOI 10.1017/S1041610209990354; Roselli F, 2009, MOVEMENT DISORD, V24, pS171; Rosen HJ, 2005, BRAIN, V128, P2612, DOI 10.1093/brain/awh628; Roth RM, 2004, AM J PSYCHIAT, V161, P157, DOI 10.1176/appi.ajp.161.1.157; Roth Robert M, 2007, Curr Treat Options Neurol, V9, P363, DOI 10.1007/s11940-007-0022-5; Rushworth MFS, 2007, TRENDS COGN SCI, V11, P168, DOI 10.1016/j.tics.2007.01.004; Sakurai T, 1998, NEUROSCI LETT, V246, P69, DOI 10.1016/S0304-3940(98)00244-4; Samus QM, 2005, GERONTOLOGIST, V45, P19, DOI 10.1093/geront/45.suppl_1.19; Santa N, 2008, INT J REHABIL RES, V31, P321, DOI 10.1097/MRR.0b013e3282fc0f0e; Siddique H, 2009, J CLIN PSYCHIAT, V70, P915, DOI 10.4088/JCP.08m04828; Sockeel P, 2006, J NEUROL NEUROSUR PS, V77, P579, DOI 10.1136/jnnp.2005.075929; Spiegel DR, 2009, J NEUROPSYCH CLIN N, V21, P216, DOI 10.1176/appi.neuropsych.21.2.216; Starkstein SE, 2008, J NEUROL NEUROSUR PS, V79, P1088, DOI 10.1136/jnnp.2007.136895; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Starkstein SE, 2006, J NEUROL NEUROSUR PS, V77, P8, DOI 10.1136/jnnp.2005.069575; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.6.872; Starkstein SE, 2007, MOVEMENT DISORD, V22, P2156, DOI 10.1002/mds.21521; Starkstein SE, 2009, MOVEMENT DISORD, V24, P1211, DOI 10.1002/mds.22577; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Svetel M, 2009, PARKINSONISM RELAT D, V15, P772, DOI 10.1016/j.parkreldis.2009.01.010; Swanberg MM, 2007, ALZ DIS ASSOC DIS, V21, P164, DOI 10.1097/WAD.0b013e318047df5d; Tagariello P, 2009, ARCH GERONTOL GERIAT, V49, P246, DOI 10.1016/j.archger.2008.09.002; Takeo S, 2003, BRIT J PHARMACOL, V138, P642, DOI 10.1038/sj.bjp.0705096; Takeo S, 2003, J PHARMACOL EXP THER, V304, P513, DOI 10.1124/jpet.102.043653; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Thompson JC, 2002, J NEUROPSYCH CLIN N, V14, P37, DOI 10.1176/appi.neuropsych.14.1.37; Turro-Garriga O, 2009, REV NEUROLOGIA, V48, P7, DOI 10.33588/rn.4801.2008565; van Duijn E, 2007, J NEUROPSYCH CLIN N, V19, P441, DOI 10.1176/appi.neuropsych.19.4.441; van Reekum R, 2005, J NEUROPSYCH CLIN N, V17, P7, DOI 10.1176/appi.neuropsych.17.1.7; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; von Cramon D Y, 1994, Appl Neuropsychol, V1, P2, DOI 10.1207/s15324826an0101&2_2; WATABE S, 1994, ARZNEIMITTEL-FORSCH, V44-1, P195; Weintraub D, 2004, J AM GERIATR SOC, V52, P784, DOI 10.1111/j.1532-5415.2004.52219.x; Wicks P, 2009, J NEUROL, V256, P234, DOI 10.1007/s00415-009-0078-0; Wongpakaran Nahathai, 2007, Ann Gen Psychiatry, V6, P7, DOI 10.1186/1744-859X-6-7; Yeager CA, 2008, PSYCHOL REP, V102, P718, DOI 10.2466/PR0.102.3.718-722; Yoshii M, 2000, ALZ DIS ASSOC DIS, V14, pS95, DOI 10.1097/00002093-200000001-00014; Zahodne LB, 2009, MOVEMENT DISORD, V24, P677, DOI 10.1002/mds.22441; Zamboni G, 2008, NEUROLOGY, V71, P736, DOI 10.1212/01.wnl.0000324920.96835.95	153	73	76	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428			NEUROTOX RES	Neurotox. Res.	FEB	2011	19	2					266	278		10.1007/s12640-010-9196-9			13	Neurosciences	Neurosciences & Neurology	721QK	WOS:000287369500005	20473601				2021-06-18	
S	Friedman, J		Gadoth, N; Gobel, HH		Friedman, Joseph			Why Is the Nervous System Vulnerable to Oxidative Stress?	OXIDATIVE STRESS AND FREE RADICAL DAMAGE IN NEUROLOGY	Oxidative Stress in Applied Basic Research and Clinical Practice		English	Article; Book Chapter						Neuron; Microglia; Mitochondria; ROS; OS; NO; O-2 consumption; PUFA; Excitoxicity; Ca2+; Iron; NADPH oxidase; Auto-oxidation; Neurotransmitters; Antioxidants; BBB	BRAIN; DISEASE; RAT; NEURODEGENERATION; NEUROTOXICITY; CALCIUM; NEURONS; CELLS; ACID; IRON	The nervous system is especially vulnerable to reactive oxygen species (ROS)-mediated injury for the following reasons. (1) High oxygen consumption of the brain for high energy needs, that is, high O-2 consumption, results in excessive ROS produced. (2) Neuronal membranes are rich in polyunsaturated fatty acids (PUPA), which are particularly vulnerable to free radical attack. (3) The ratio of membrane surface area to cytoplasmic volume is high. (4) Specialized neuronal conduction and synaptic transmission activity depend on efficient membrane function. (5) Extended axonal morphology is prone to peripheral injury. (6) Neuronal anatomic network is vulnerable to disruptions. (7) The excitotoxic glutamate is the major effector that causes oxidative stress (OS). (8) The high Ca2+ traffic across neuronal membranes and interference of ion transport increase intracellular Ca2+, often leading to OS. (9) Auto-oxidation of neurotransmitters can generate O-2 and quinones that reduce glutathione. (10) Iron is formed throughout the brain, and brain damage readily releases iron ions capable of catalyzing free radical reactions. (11) Antioxidant defense mechanisms are modest, in particular, low levels of catalase, glutathione peroxidase, and vitamin E. (12) ROS directly downregulate proteins of tight junctions and indirectly activate matrix metalloproteinases (AMP) that contribute to open the blood brain barrier (BBB). (13) Activated microglia produce ROS and cytokines in a perpetual process. (14) Cytochrome P450 produces ROS. (15) Loss of trophic support can activate NADPH oxidase, which increases ROS. (16) The presence of hemoglobin within the neural tissues secondary to spontaneous, iatrogenic, or traumatic causes is neurotoxic. Heme and iron are released and promote ROS. (17) Neuronal mitochondria generate O-2. (18) The interaction of NO with superoxide can be implicated also in neuronal degeneration. (19) Neuronal cells are nonreplicating and thus are sensitive to ROS. In comparison with other organs, the neuronal network may be especially vulnerable to ROS-mediated injury because of the following anatomic, physiological, and biochemical properties of the brain.		Friedman, J (corresponding author), Weizmann Sci Pk, Ness Ziona, Israel.	dr.josephfriedman@gmail.com					Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307; Ameijeiras A.H., 2004, NEUROCHEM INT, V45, P103; Asaeda M, 2005, NEUROSCI LETT, V373, P222, DOI 10.1016/j.neulet.2004.10.008; Carey J., 2002, BRAIN FACTS PRIMER B; Chen CT, 2008, PROSTAG LEUKOTR ESS, V79, P85, DOI 10.1016/j.plefa.2008.09.003; Chen-Roetling J, 2009, NEUROPHARMACOLOGY, V56, P922, DOI 10.1016/j.neuropharm.2009.01.022; Devi SA, 2009, THESCIENTIFICWORLDJO, V9, P366, DOI 10.1100/tsw.2009.46; Duncan Andrew J., 2005, Molecular Aspects of Medicine, V26, P67, DOI 10.1016/j.mam.2004.09.004; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Fishel ML, 2007, MUTAT RES-FUND MOL M, V614, P24, DOI 10.1016/j.mrfmmm.2006.06.007; Gonzalez A, 2002, CELL SIGNAL, V14, P153, DOI 10.1016/S0898-6568(01)00247-9; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hider RC, 2008, BIOCHEM SOC T, V36, P1304, DOI 10.1042/BST0361304; Howard LA, 2003, BRIT J PHARMACOL, V138, P1376, DOI 10.1038/sj.bjp.0705146; Kim GW, 2003, J NEUROSCI, V23, P8733; Kudin AP, 2005, BIOMED PHARMACOTHER, V59, P163, DOI 10.1016/j.biopha.2005.03.012; Mailly F, 1999, J NEUROCHEM, V73, P1181, DOI 10.1046/j.1471-4159.1999.0731181.x; Miksys S, 2004, DRUG METAB REV, V36, P313, DOI 10.1081/DMR-120034149; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Phillis JW, 2003, NEUROCHEM INT, V43, P461, DOI 10.1016/S0197-0186(03)00035-4; Phumala N, 2003, FREE RADICAL RES, V37, P129, DOI 10.1080/1071576031000060607; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Puntambekar P, 2005, J NEUROCHEM, V95, P1689, DOI 10.1111/j.1471-4159.2005.03518.x; Sanchez-Carbente MR, 2005, CELL DEATH DIFFER, V12, P279, DOI 10.1038/sj.cdd.4401560; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Stankiewicz JM, 2009, CURR OPIN CLIN NUTR, V12, P22, DOI 10.1097/MCO.0b013e32831ba07c; Troadec JD, 2001, J NEUROCHEM, V79, P200, DOI 10.1046/j.1471-4159.2001.00556.x; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vannucci RC, 2001, DEV BRAIN RES, V126, P117, DOI 10.1016/S0165-3806(00)00135-8	29	73	76	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	2197-7224	2197-7232	978-1-60327-513-2	OXID STRESS APPL BAS	Oxid. Stress Appl. Basic Res. Clin. Pract.		2011							19	27		10.1007/978-1-60327-514-9_2	10.1007/978-1-60327-514-9		9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	BSM94	WOS:000284978600002					2021-06-18	
J	Leonardi, AD; Bir, CA; Ritzel, DV; VandeVord, PJ				Leonardi, Alessandra Dal Cengio; Bir, Cynthia A.; Ritzel, Dave V.; VandeVord, Pamela J.			Intracranial Pressure Increases during Exposure to a Shock Wave	JOURNAL OF NEUROTRAUMA			English	Article						blast; improvised explosive device; intracranial pressure; overpressure; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; BLAST INJURY; TRANSMISSION; BRAIN; RAT	Traumatic brain injuries (TBI) caused by improvised explosive devices (IEDs) affect a significant percentage of surviving soldiers wounded in Iraq and Afghanistan. The extent of a blast TBI, especially initially, is difficult to diagnose, as internal injuries are frequently unrecognized and therefore underestimated, yet problems develop over time. Therefore it is paramount to resolve the physical mechanisms by which critical stresses are inflicted on brain tissue from blast wave encounters with the head. This study recorded direct pressure within the brains of male Sprague-Dawley rats during exposure to blast. The goal was to understand pressure wave dynamics through the brain. In addition, we optimized in vivo methods to ensure accurate measurement of intracranial pressure (ICP). Our results demonstrate that proper sealing techniques lead to a significant increase in ICP values, compared to the outside overpressure generated by the blast. Further, the values seem to have a direct relation to a rat's size and age: heavier, older rats had the highest ICP readings. These findings suggest that a global flexure of the skull by the transient shockwave is an important mechanism of pressure transmission inside the brain.	[Leonardi, Alessandra Dal Cengio; Bir, Cynthia A.; VandeVord, Pamela J.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Ritzel, Dave V.] Dyn FX Consulting Ltd, Amherstburg, ON, Canada	VandeVord, PJ (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	pvord@wayne.edu	VandeVord, Pamela/B-4606-2012	Bir, Cynthia/0000-0002-0777-0951	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0207]; Office of Naval ResearchOffice of Naval Research [N00014-08-1-0585]	We would like to acknowledge the Department of Defense (award no. W81XWH-08-2-0207), and the Office of Naval Research (award no. N00014-08-1-0585) for funding this project.	Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; CELANDER H, 1954, ACTA PHYSL SCANDINAV, V33, P6; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLEMEDSON C, 1961, J APPL PHYSIOL, V16, P426; CLEMEDSON C, 1961, ACTA PHYSIOL SCAND, V51, P47, DOI 10.1111/j.1748-1716.1961.tb02112.x; CLEMEDSON CJ, 1956, ACTA PHYSL SCAND, V37, P204, DOI DOI 10.1111/J.1748-1716.1956.TB01356.X); COOPER GJ, 1991, J BIOMECH, V24, P273, DOI 10.1016/0021-9290(91)90346-O; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Guy R J, 2000, J R Nav Med Serv, V86, P27; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; LEONARDI AD, 2009, 2 JOINT S INT NAT NE; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; ROMBA JJ, 1961, 1761 US ARM ORDN HUM, P1; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; YOUNG MW, 1945, WAR MED, V8, P73	20	73	75	1	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					85	94		10.1089/neu.2010.1324			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800008	21091267				2021-06-18	
J	Caplan, LJ; Ivins, B; Poole, JH; Vanderploeg, RD; Jaffee, MS; Schwab, K				Caplan, Leslie J.; Ivins, Brian; Poole, John H.; Vanderploeg, Rodney D.; Jaffee, Michael S.; Schwab, Karen			The Structure of Postconcussive Symptoms in 3 US Military Samples	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; neuropsychology; postconcussive symptoms; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; COMPUTER; INTERVIEW; QUESTIONNAIRE; NUMBER; RISK	Objective: To evaluate alternative models of symptom clusters for the 22-item Neurobehavioral Symptom Inventory. Participants: Three military samples, including 2 nonclinical samples (n = 2420, n = 4244) and 1 sample of individuals with recent head injury (n = 617). Methods: In the first sample, exploratory factor analysis of Neurobehavioral Symptom Inventory responses was performed with tests of significant factors and model fit. In the other 2 samples, confirmatory factor analysis evaluated the fit of 3 models: 2- and 3-factor models based on the initial exploratory factor analysis, and a 9-factor model based on prior research. Main Outcome Measures: The exploratory factor analysis used 2 tests for the number of factors: Parallel Analysis and Minimum Average Partial test. Confirmatory factor analysis models were evaluated using 2 measures of model fit, Root Mean Square Error of Approximation and Comparative Fit Index. Results: Postconcussive symptoms can be described accurately by the 9 factors. However, the model of 3 intercorrelated factors, reflecting cognitive, affective, and somatic/sensory symptoms, fits the data more parsimoniously with little loss in model fit. Conclusion: Although the 9-cluster result from prior research provides a valid description of the relations among items of the inventory, a 3-factor model, consisting of somatic/sensory, affective, and cognitive factors, provides nearly as good a fit to the data, with greater parsimony. We encourage clinicians and researchers to conceptualize the Neurobehavioral Symptom Inventory in terms of 3 coherent clusters of symptoms rather than as 22 individual items.	[Caplan, Leslie J.] NIMH, NIH, Bethesda, MD 20892 USA; [Ivins, Brian; Jaffee, Michael S.; Schwab, Karen] Def & Vet Brain Injury Ctr, Washington, DC USA; [Poole, John H.] Vet Affairs Hlth Care Syst, Palo Alto, CA USA; [Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, James A Haley Vet Affairs Med Ctr, Palo Alto, CA USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Behav Sci & Psychol, Tampa, FL USA	Caplan, LJ (corresponding author), US Dept Educ, Natl Inst Disabil & Rehabil Res, 400 Maryland Ave SW, Washington, DC 20202 USA.	Leslie.Caplan@ed.gov					ALVESW, 1993, J Head Trauma Rehabi, V8, P48; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BROWNE W, 1993, TESTING STRUCTURAL E, P126; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; ERDMAN HP, 1992, J PSYCHIAT RES, V26, P85, DOI 10.1016/0022-3956(92)90019-K; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GUNSTAD J, 2004, J FORENSIC NEUROPSYC, V4, P33, DOI DOI 10.1300/J151V04N01_; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LOCKE SE, 1992, JAMA-J AM MED ASSOC, V268, P1301, DOI 10.1001/jama.268.10.1301; LUCAS RW, 1977, BRIT J PSYCHIAT, V131, P160, DOI 10.1192/bjp.131.2.160; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; MILLSTEIN SG, 1987, EDUC PSYCHOL MEAS, V47, P523, DOI 10.1177/0013164487472028; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; NAVALINE HA, 1994, AIDS RES HUM RETROV, V10, pS281; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; O'Reilly James M, 1994, J Off Stat, V10, P197; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Tiersky LA, 1998, CLIN NEUROPSYCHOL, V12, P503, DOI 10.1076/clin.12.4.503.7237; Velicer WF., 2000, PROBLEMS SOLUTIONS H, P41, DOI [10.1007/978-1-4615-4397-8_3, DOI 10.1007/978-1-4615-4397-8_3]; WILSON RF, 1985, COMPUT HUM BEHAV, V1, P265; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	29	73	73	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					447	458		10.1097/HTR.0b013e3181d5bdbd			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300007					2021-06-18	
J	Wade, SL; Walz, NC; Carey, J; Williams, KM; Cass, J; Herren, L; Mark, E; Yeates, KO				Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; Williams, Kendra M.; Cass, Jennifer; Herren, Luke; Mark, Erin; Yeates, Keith Owen			A Randomized Trial of Teen Online Problem Solving for Improving Executive Function Deficits Following Pediatric Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescent; brain injury; executive functions; family; pediatric; problem solving; telehealth	SOCIAL COMPETENCE; ADOLESCENTS; CHILDREN; INTERVENTION; EFFICACY; BEHAVIOR	Objective: To examine the efficacy of teen online problem solving (TOPS) in improving executive function (EF) deficits following traumatic brain injury (TBI) in adolescence. Methods: Families of adolescents (aged 11-18 years) with moderate to severe TBI were recruited from the trauma registry of 2 tertiary-care children's hospitals and then randomly assigned to receive TOPS (n = 20), a cognitive-behavioral, skill-building intervention, or access to online resources regarding TBI (Internet resource comparison; n = 21). Parent and teen reports of EF were assessed at baseline and a posttreatment follow-up (mean = 7.88 months later). Results: Improvements in self-reported EF skills were moderated by TBI severity, with teens with severe TBI in the TOPS treatment reporting significantly greater improvements than did those with severe TBI in the Internet resource comparison. The treatment groups did not differ on parent ratings of EF at the follow up. Conclusions: Findings suggest that TOPS may be effective in improving EF skills among teens with severe TBI.	[Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; Williams, Kendra M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Cass, Jennifer; Herren, Luke; Mark, Erin; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Cass, Jennifer; Herren, Luke; Mark, Erin; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Disability and Rehabilitation Research [H133G050239]; Ohio Department of Safety [10503]	This work was supported by grant H133G050239 to the first author from the National Institute of Disability and Rehabilitation Research, US Department of Education and Emergency Medical Services grant 10503 from the Ohio Department of Safety. These results were presented in part at the 2009 Meeting of the Ohio Brain Injury Association and the American Psychological Association Conference in San Diego, California, on August 15, 2010.	Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Guy S.C., 2004, BRIEF SR BEHAV RATIN; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI DOI 10.1375/BRIM.7.3.246; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	13	73	73	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					409	415		10.1097/HTR.0b013e3181fb900d			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300002	21076241				2021-06-18	
J	Kasahara, M; Menon, DK; Salmond, CH; Outtrim, JG; Tavares, JVT; Carpenter, TA; Pickard, JD; Sahakian, BJ; Stamatakis, EA				Kasahara, M.; Menon, D. K.; Salmond, C. H.; Outtrim, J. G.; Tavares, J. V. Taylor; Carpenter, T. A.; Pickard, J. D.; Sahakian, B. J.; Stamatakis, E. A.			Altered functional connectivity in the motor network after traumatic brain injury	NEUROLOGY			English	Article							CORTEX; ACTIVATION; MOVEMENT; MILD; DEACTIVATION; INHIBITION; IMPAIRMENT; CEREBELLUM; EXECUTION; AREAS	Background: A large proportion of survivors of traumatic brain injury (TBI) have persistent cognitive impairments, the profile of which does not always correspond to the size and location of injuries. One possible explanation could be that TBI-induced damage extends beyond obvious lesion sites to affect remote brain networks. We explored this hypothesis in the context of a simple and well-characterized network, the motor network. The aim of this cross-sectional study was to establish the residual integrity of the motor network as an important proof of principle of abnormal connectivity in TBI. Methods: fMRI data were obtained from 12 right-handed patients and 9 healthy controls while they performed the finger-thumb opposition task with the right hand. We used both conventional and psychophysiologic interaction (PPI) analyses to examine the integrity of functional connections from brain regions we found to be activated in the paradigm we used. Results: As expected, the analysis showed significant activations of the left primary motor cortex (M1), right cerebellum (Ce), and bilateral supplementary motor area (SMA) in controls. However, only the activation of M1 survived robust statistical thresholding in patients. In controls, the PPI analysis revealed that left M1, SMA, and right Ce positively interacted with the left frontal cortex and negatively interacted with the right supramarginal gyrus. In patients, we observed no negative interaction and reduced interhemispheric interactions from these seed regions. Conclusions: These observations suggest that patients display compromised activation and connectivity patterns during the finger-thumb opposition task, which may imply functional reorganization of motor networks following TBI. Neurology(R) 2010;75:168-176	[Kasahara, M.; Menon, D. K.; Outtrim, J. G.; Stamatakis, E. A.] Univ Cambridge, Div Anaesthesia, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Kasahara, M.; Menon, D. K.; Salmond, C. H.; Outtrim, J. G.; Tavares, J. V. Taylor; Carpenter, T. A.; Pickard, J. D.; Sahakian, B. J.; Stamatakis, E. A.] Univ Cambridge, Wolfson Brain Imaging Ctr, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Salmond, C. H.; Tavares, J. V. Taylor; Sahakian, B. J.] Univ Cambridge, Dept Psychiat, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Pickard, J. D.] Univ Cambridge, Acad Neurosurg Unit, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England	Stamatakis, EA (corresponding author), Univ Cambridge, Div Anaesthesia, Sch Clin Med, Addenbrookes Hosp, Hills Rd, Cambridge CB2 2QQ, England.	eas46@cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Outtrim, Joanne/0000-0001-8118-6430	Addenbrooke's Charitable Trust; GlaxoSmithKlineGlaxoSmithKline; Linde Gas Inc.; NHS National Institute for Health Research, the Department of Health (UK)National Institute for Health Research (NIHR); Health Technology Agency (UK); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Wellcome TrustWellcome TrustEuropean Commission; Royal College of Anaesthetists; Evelyn Trust; Queens' College; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; European UnionEuropean Commission; Royal SocietyRoyal Society of LondonEuropean Commission; McDonnell Foundation; NHS National Institute for Health ResearchNational Institute for Health Research (NIHR); Queens' College Cambridge; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Dr. Kasahara was funded by Addenbrooke's Charitable Trust (Cambridge, UK). Prof. Menon serves on scientific advisory boards for Solvay Pharmaceuticals, Inc. and GlaxoSmithKline; serves as a Specialty Editor for Critical Care and on the editorial boards of Neurocritical Care and PLoS Medicine; has filed a patent re: Technique for imaging mitochondrial function; receives royalties from the publication of Textbook of Neuroanaesthesia and Critical Care (Greenwich Medical Media, 2000); and receives research support from GlaxoSmithKline, Linde Gas Inc. (formerly British Oxygen Corporation), NHS National Institute for Health Research, the Department of Health (UK), the Health Technology Agency (UK), MRC, Wellcome Trust, the Royal College of Anaesthetists (British Oxygen Professorship), the Evelyn Trust, and from Queens' College (Stephen Erskine Fellowship). Dr. Salmond was funded by the Medical Research Council. Ms. Outtrim and Dr. Taylor Tavares report no disclosures. Dr. Carpenter serves on the editorial advisory board of Magnetic Resonance Imaging; serves as a consultant for Osteotronix Ltd.; and receives research support from MRC, the European Union, and from the Royal Society. Prof. Pickard serves on a scientific advisory board for and received funding for travel and speaker honoraria from Codman (Johnson & Johnson); serves as Chief Editor for Advances and Technical Standards in Neurosurgery; receives royalties from the publication of Pseudotumor Cerebri Syndrome (Cambridge University Press, 2007), serves as Honorary Consultant Advisor to the Army; receives research support from GlaxoSmithKline, McDonnell Foundation, MRC, NHS National Institute for Health Research; serves as the executive director of Medicam/Technicam Ltd; and has provided medicolegal expert reports in neurosurgery for a large number of legal firms. Prof. Sahakian has served/serves as a consultant for Cambridge Cognition Ltd, Novartis, Shire plc, GlaxoSmithKline, Eli Lilly & Company, and Boehringer Ingelheim; serves as an Associate Editor for Psychological Medicine; receives research support from MRC and Wellcome Trust and holds stock in CeNeS. Dr. Stamatakis serves on the editorial board of Neuroscience Imaging and is funded by the Stephen Erskine Fellowship from Queens' College Cambridge.	Allison JD, 2000, NEUROLOGY, V54, P135, DOI 10.1212/WNL.54.1.135; BRUTKOWSKI S, 1964, FRONTAL GRANULAR COR, P242; CROW LJ, 2001, HUMAN MOVEMENT, P69; Cunnington R, 2002, NEUROIMAGE, V15, P373, DOI 10.1006/nimg.2001.0976; Daskalakis ZJ, 2004, J PHYSIOL-LONDON, V557, P689, DOI 10.1113/jphysiol.2003.059808; Di Russo F, 2005, J NEUROTRAUM, V22, P297; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hanakawa T, 2003, J NEUROPHYSIOL, V89, P989, DOI 10.1152/jn.00132.2002; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Liepert J, 2001, CLIN NEUROPHYSIOL, V112, P114, DOI 10.1016/S1388-2457(00)00503-4; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Lotze M, 1999, J COGNITIVE NEUROSCI, V11, P491, DOI 10.1162/089892999563553; Manson SC, 2008, EXP BRAIN RES, V187, P25, DOI 10.1007/s00221-008-1276-1; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mochizuki H, 2004, J PHYSIOL-LONDON, V561, P331, DOI 10.1113/jphysiol.2004.072843; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Pelgrims B, 2009, CEREB CORTEX, V19, P2298, DOI 10.1093/cercor/bhn248; Perez MA, 2009, J PHYSIOL-LONDON, V587, P725, DOI 10.1113/jphysiol.2008.166926; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Rizzolatti G, 2001, NEURON, V31, P889, DOI 10.1016/S0896-6273(01)00423-8; Shane MS, 2008, NEUROIMAGE, V42, P450, DOI 10.1016/j.neuroimage.2007.12.067; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; TEASDALE G, 1974, LANCET, V2, P81; Tunik E, 2008, J NEUROSCI, V28, P14422, DOI 10.1523/JNEUROSCI.4734-08.2008; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Wiese H, 2006, NEUROIMAGE, V30, P1292, DOI 10.1016/j.neuroimage.2005.11.012; Ziemann U, 2001, CLIN NEUROPHYSIOL, V112, P107, DOI 10.1016/S1388-2457(00)00502-2	37	73	74	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 13	2010	75	2					168	176		10.1212/WNL.0b013e3181e7ca58			9	Clinical Neurology	Neurosciences & Neurology	628GW	WOS:000280103900013	20625170	Green Published			2021-06-18	
J	Xu, YQ; McArthur, DL; Alger, JR; Etchepare, M; Hovda, DA; Glenn, TC; Huang, SC; Dinov, I; Vespa, PM				Xu, Yueqiao; McArthur, David L.; Alger, Jeffry R.; Etchepare, Maria; Hovda, David A.; Glenn, Thomas C.; Huang, Sungcheng; Dinov, Ivo; Vespa, Paul M.			Early nonischemic oxidative metabolic dysfunction leads to chronic brain atrophy in traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						atrophy; metabolism; MRI; positron emission tomography; traumatic brain injury	IRREVERSIBLE TISSUE-DAMAGE; ISCHEMIC-INJURY; HEAD-INJURY; CHILDREN; MODERATE; CRISIS; MRI; MICRODIALYSIS; VOLUME; SCALE	Chronic brain atrophy after traumatic brain injury (TBI) is a well-known phenomenon, the causes of which are unknown. Early nonischemic reduction in oxidative metabolism is regionally associated with chronic brain atrophy after TBI. A total of 32 patients with moderate-to-severe TBI prospectively underwent positron emission tomography (PET) and volumetric magnetic resonance imaging (MRI) within the first week and at 6 months after injury. Regional lobar assessments comprised oxidative metabolism and glucose metabolism. Acute MRI showed a preponderance of hemorrhagic lesions with few irreversible ischemic lesions. Global and regional chronic brain atrophy occurred in all patients by 6 months, with the temporal and frontal lobes exhibiting the most atrophy compared with the occipital lobe. Global and regional reduction in cerebral metabolic rate of oxygen (CMRO2), cerebral blood flow (CBF), oxygen extraction fraction (OEF), and cerebral metabolic rate of glucose were observed. The extent of metabolic dysfunction was correlated with the total hemorrhage burden on initial MRI (r = 0.62, P = 0.01). The extent of regional brain atrophy correlated best with CMRO2 and CBF. Lobar values of OEF were not in the ischemic range and did not correlate with chronic brain atrophy. Chronic brain atrophy is regionally specific and associated with regional reductions in oxidative brain metabolism in the absence of irreversible ischemia. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 883-894; doi:10.1038/jcbfm.2009.263; published online 23 December 2009	[Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Huang, Sungcheng] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Huang, Sungcheng] Univ Calif Los Angeles, DOE Ctr Mol Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Xu, Yueqiao] Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, Beijing, Peoples R China	Vespa, PM (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, 757 Westwood Blvd,Room RR 6236A, Los Angeles, CA 90095 USA.	PVespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Dinov, Ivo/0000-0003-3825-4375; Glenn, Thomas/0000-0003-4273-3408	California State Neurotrauma Initiative;  [NS049471];  [NS02089]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049471] Funding Source: NIH RePORTER	The research was supported by Grant nos NS049471, NS02089, and the California State Neurotrauma Initiative.	Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; DINOV I, 2009, NEUROINFORMATICS, V3, P22, DOI DOI 10.3389/NEURO.11.022.2009; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Fiehler J, 2002, STROKE, V33, P79, DOI 10.1161/hs0102.100884; GOLDBERG KM, 1992, TECHNOMETRICS, V34, P307, DOI 10.2307/1270037; Hayman LA, 1992, CLIN BRAIN IMAGING N, P130; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.3.CO;2-P; Kidwell CS, 2002, ANN NEUROL, V52, P698, DOI 10.1002/ana.10380; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P179, DOI 10.1038/jcbfm.1992.28; Okauchi M, 2009, STROKE, V40, P1858, DOI 10.1161/STROKEAHA.108.535765; Press W.H., 1986, NUMERICAL RECIPES AR; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shattuck DW, 2002, MED IMAGE ANAL, V6, P129, DOI 10.1016/S1361-8415(02)00054-3; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Verger K, 2001, BRAIN INJURY, V15, P211; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wilcox R. R., 2005, INTRO ROBUST ESTIMAT; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	36	73	73	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2010	30	4					883	894		10.1038/jcbfm.2009.263			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	577BZ	WOS:000276197200023	20029449	Green Published, Bronze			2021-06-18	
J	Pesaresi, M; Maschi, O; Giatti, S; Garcia-Segura, LM; Caruso, D; Melcangi, RC				Pesaresi, Marzia; Maschi, Omar; Giatti, Silvia; Garcia-Segura, Luis Miguel; Caruso, Donatella; Melcangi, Roberto Cosimo			Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats	HORMONES AND BEHAVIOR			English	Article						Peripheral nervous system; Central nervous system; Rat; Diabetes; Liquid chromatography-tandem mass spectrometry; Pregnenolone; Progesterone; Testosterone; Dehydroepiandrosterone; Neurosteroids	MESSENGER-RNA EXPRESSION; TRAUMATIC BRAIN-INJURY; GENDER-DIFFERENCES; HIPPOCAMPAL NEUROGENESIS; ALZHEIMERS-DISEASE; NEUROPROTECTIVE AGENTS; COGNITIVE DYSFUNCTION; NEUROPATHY; ALLOPREGNANOLONE; PROGESTERONE	Neuropathy and encephalopathy represent important complications of diabetes. Recent observations obtained in experimental models have suggested that, in male rats, neuroactive steroids are protective agents and that their levels in peripheral (PNS) and central (CNS) nervous system are strongly affected by the disease. It is interesting to highlight that incidence, progression and severity of diabetic neuropathy and diabetic encephalopathy are different in the two sexes. Consequently, it is important to determine the changes in neuroactive steroid levels in the PNS and the CNS of both males and females. To this aim, we have evaluated the levels of neuroactive steroids such as, pregnenolone, progesterone and its metabolites, testosterone and its metabolites, and dehydroepiandrosterone in different CNS regions (i.e., cerebral cortex, cerebellum and spinal cord) and in the sciatic nerve of control and diabetic (i.e., induced by streptozotocin) male and female rats. Data obtained by liquid chromatography-tandem mass spectrometry indicate that the levels of neuroactive steroids show sex and regional differences in control animals. Streptozotocin-induced diabetes resulted in a strong general decrease in neuroactive steroid levels, in both the PNS and the CNS. In addition, the effects of diabetes on neuroactive steroid levels also show sex and regional differences. These findings may have strong implications for the development of new sex-oriented therapies for the treatment of diabetic neuropathy and diabetic encephalopathy, based on the use of neuroactive steroids. (C) 2009 Elsevier Inc. All rights reserved.	[Pesaresi, Marzia; Giatti, Silvia; Melcangi, Roberto Cosimo] Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Endocrinol Pathophysiol & Appl Biol, I-20133 Milan, Italy; [Maschi, Omar; Caruso, Donatella] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; [Garcia-Segura, Luis Miguel] CSIC, Inst Cajal, E-28002 Madrid, Spain	Melcangi, RC (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Endocrinol Pathophysiol & Appl Biol, Via Balzaretti 9, I-20133 Milan, Italy.	roberto.melcangi@unimi.it	Garcia-Segura, Luis M/U-3711-2017; caruso, donatella/A-3332-2014; Giatti, Silvia/G-9334-2016	Garcia-Segura, Luis M/0000-0002-2450-2916; caruso, donatella/0000-0003-2115-778X; Giatti, Silvia/0000-0001-7741-826X; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967	University of Milan, Italy [20074SPYCM_002]	The financial support of PRIN (20074SPYCM_002) and PUR from University of Milan, Italy, to R. C. Melcangi is gratefully acknowledged. We wish to thank Dr. Marc J. Tetel for his critical reading of the manuscript.	Aaberg ML, 2008, J DIABETES COMPLICAT, V22, P83, DOI 10.1016/j.jdiacomp.2007.06.009; Albers JW, 1996, NEUROLOGY, V46, P85, DOI 10.1212/WNL.46.1.85; Alvarez EO, 2009, BEHAV BRAIN RES, V198, P224, DOI 10.1016/j.bbr.2008.11.001; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; Aragno M, 2002, ENDOCRINOLOGY, V143, P3250, DOI 10.1210/en.2002-220182; Babich VM, 1998, WAVE MOTION, V28, P1, DOI 10.1016/S0165-2125(97)00059-0; Backstrom T, 2005, EUR J PHARMACOL, V512, P15, DOI 10.1016/j.ejphar.2005.01.049; Basit Abdul, 2004, J Coll Physicians Surg Pak, V14, P79; Beauquis J, 2008, EXP NEUROL, V210, P359, DOI 10.1016/j.expneurol.2007.11.009; Beauquis J, 2006, EUR J NEUROSCI, V23, P1539, DOI 10.1111/j.1460-9568.2006.04691.x; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; Biessels GJ, 2008, LANCET NEUROL, V7, P184, DOI 10.1016/S1474-4422(08)70021-8; Biessels GJ, 2002, EUR J PHARMACOL, V441, P1, DOI 10.1016/S0014-2999(02)01486-3; Biessels GJ, 2005, NEUROBIOL AGING, V26, pS36, DOI 10.1016/j.neurobiolaging.2005.08.015; Biessels GJ, 1999, BRAIN, V122, P757, DOI 10.1093/brain/122.4.757; BILLIAR RB, 1975, BRAIN RES, V94, P99, DOI 10.1016/0006-8993(75)90880-X; BITRAN D, 1991, BRAIN RES, V561, P157, DOI 10.1016/0006-8993(91)90761-J; Booya F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-24; Brown RC, 2003, NEUROBIOL AGING, V24, P57, DOI 10.1016/S0197-4580(02)00048-9; Caruso D, 2008, NEUROCHEM INT, V52, P560, DOI 10.1016/j.neuint.2007.06.004; Caruso D, 2008, J MOL NEUROSCI, V34, P249, DOI 10.1007/s12031-007-9029-3; De Nicola AF, 2009, EXP GERONTOL, V44, P34, DOI 10.1016/j.exger.2008.03.005; Durant S, 1998, AUTOIMMUNITY, V28, P249, DOI 10.3109/08916939808995373; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Franzon R, 2005, DIABETES RES CLIN PR, V69, P107, DOI 10.1016/j.diabres.2004.11.010; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; GEE KW, 1988, J PHARMACOL EXP THER, V246, P803; Gispen WH, 2000, TRENDS NEUROSCI, V23, P542, DOI 10.1016/S0166-2236(00)01656-8; Hedstrom H, 2009, PSYCHOPHARMACOLOGY, V203, P85, DOI 10.1007/s00213-008-1372-8; Huang XF, 2000, J BIOL CHEM, V275, P29452, DOI 10.1074/jbc.M000562200; Jacobson AM, 2002, INT REV NEUROBIOL, V51, P455, DOI 10.1016/S0074-7742(02)51013-8; Joseph EK, 2003, NEUROSCIENCE, V120, P907, DOI 10.1016/S0306-4522(03)00400-7; Kamboj SS, 2008, METAB BRAIN DIS, V23, P427, DOI 10.1007/s11011-008-9104-7; Kawashima R, 2007, NEUROCHEM RES, V32, P1002, DOI 10.1007/s11064-006-9260-2; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Kiziltan ME, 2007, J NEUROL SCI, V258, P75, DOI 10.1016/j.jns.2007.02.028; Kiziltan ME, 2008, DIABETES RES CLIN PR, V79, pE17, DOI 10.1016/j.diabres.2007.07.013; Kodl CT, 2008, ENDOCR REV, V29, P494, DOI 10.1210/er.2007-0034; Kohchi C, 1998, BRAIN RES, V801, P233, DOI 10.1016/S0006-8993(98)00585-X; Lauria G, 2005, J PERIPHER NERV SYST, V10, P202, DOI 10.1111/j.1085-9489.2005.0010210.x; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Lundgren P, 2003, BRAIN RES, V982, P45, DOI 10.1016/S0006-8993(03)02939-1; Marcus SM, 2008, COMPR PSYCHIAT, V49, P238, DOI 10.1016/j.comppsych.2007.06.012; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Mastrocola R, 2005, J ENDOCRINOL, V187, P37, DOI 10.1677/joe.1.06269; McCall AL, 2002, INT REV NEUROBIOL, V51, P415, DOI 10.1016/S0074-7742(02)51012-6; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 2006, NEUROSCIENCE, V138, P733, DOI 10.1016/j.neuroscience.2005.10.066; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; Meyer L, 2008, NEUROBIOL DIS, V30, P30, DOI 10.1016/j.nbd.2007.12.001; Naik AK, 2008, NEUROSCIENCE, V154, P1539, DOI 10.1016/j.neuroscience.2008.04.061; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nitta A, 2002, NEUROTOXICOL TERATOL, V24, P695, DOI 10.1016/S0892-0362(02)00220-9; Pathirathna S, 2005, PAIN, V117, P326, DOI 10.1016/j.pain.2005.06.019; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; Roglio I, 2007, CELL MOL LIFE SCI, V64, P1158, DOI 10.1007/s00018-007-7002-5; Salonia A, 2006, DIABETES CARE, V29, P312, DOI 10.2337/diacare.29.02.06.dc05-1067; Saravia F, 2004, J NEUROENDOCRINOL, V16, P704, DOI 10.1111/j.1365-2826.2004.01223.x; Saravia FE, 2006, CELL MOL NEUROBIOL, V26, P943, DOI 10.1007/s10571-006-9096-y; Simonds VA, 2003, J AFFECT DISORDERS, V77, P197, DOI 10.1016/S0165-0327(02)00113-1; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Stranahan AM, 2008, NAT NEUROSCI, V11, P309, DOI 10.1038/nn2055; Sugimoto K, 2000, DIABETES-METAB RES, V16, P408; Tanaka M, 2001, ENDOCR RES, V27, P109, DOI 10.1081/ERC-100107174; van Dam EWCM, 2003, DIABETES CARE, V26, P1812, DOI 10.2337/diacare.26.6.1812; Veiga S, 2006, NEUROSCI LETT, V402, P150, DOI 10.1016/j.neulet.2006.03.058; Vinik AI, 2000, DIABETOLOGIA, V43, P957, DOI 10.1007/s001250051477; Wang MD, 2002, J NEUROSCI, V22, P3366; Watzka M, 1999, J NEUROENDOCRINOL, V11, P901; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Yagihashi S, 1997, J Peripher Nerv Syst, V2, P113; Yorek MA, 2002, AM J PHYSIOL-ENDOC M, V283, pE1067, DOI 10.1152/ajpendo.00173.2002; Zhang WJ, 2008, ACTA NEUROL SCAND, V117, P205, DOI 10.1111/j.1600-0404.2007.00928.x	76	73	73	1	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0018-506X	1095-6867		HORM BEHAV	Horm. Behav.	JAN	2010	57	1			SI		46	55		10.1016/j.yhbeh.2009.04.008			10	Behavioral Sciences; Endocrinology & Metabolism	Behavioral Sciences; Endocrinology & Metabolism	549NC	WOS:000274056700006	19422828				2021-06-18	
J	Rickels, E; von Wild, K; Wenzlaff, P				Rickels, Eckhard; von Wild, Klaus; Wenzlaff, Paul			Head injury in Germany: A population-based prospective study on epidemiology, causes, treatment and outcome of all degrees of head-injury severity in two distinct areas	BRAIN INJURY			English	Article						Head injury; all degrees of severity; causes; epidemiology; outcome	TRAUMATIC BRAIN-INJURY; CLINICAL-TRIALS; MANAGEMENT; MORTALITY; VALIDATION; AGE	Introduction: Little is known about the ratio of mild traumatic brain injury (TBI) to moderate and severe TBI, about the time that elapses until primary care is given, about the number of patients requiring immediate surgery and about the early outcome and the costs. Method: In a prospective study two regions taken as model examples were investigated: the City of Hanover with its surrounding catchment area and Munster with its regions. Results: From 1 March 2000 until 28 February 2001 all patients were recruited who were admitted to a hospital emergency department due to a TBI; 6783 patients (58.4% male, 41.6% female; 29.7% children < 16 years) were included; 5220 (73%) received in-hospital treatment; and 258 were given early rehabilitation. The incidence of TBI is 332 per 100 000 head of population. The GCS (Glasgow Coma Scale) or other forms of neurological examinations were performed in only 56% of all cases. According to the GCS status, 90.2% are classified as mild, 3.9% as moderate and 5.2% as severe. Intubation is given only to 76.1% of patients with severe TBI. Lethality was 1%. The predominant cause of TBI is falls, with 52.5% of all cases, while 26.3% were due to road accidents. The time elapsing between the accident event and initial examination at the hospital is less than 1 hour in 63% of all cases. X-rays were taken in 82% of all cases of TBI, with 19.3% of the patients receiving a CT scan; 58.7% of all TBI patients have additional injuries of the facial skull, 8.8% of the vertebral column, 7.2% of the thorax, 2.6% of the abdomen, 3.4% of the pelvis and 19.6% of one or more extremities. One year after the accident, 50% of all patients still required treatment even after mild TBI. Conclusion: It is necessary to follow the TBI guidelines, e. g. regarding intubation and neurological examination. The indication for cranial x-rays and CT should be reconsidered.	[Rickels, Eckhard] AKH Celle, Neurosurg, DE-29223 Celle, Germany; [von Wild, Klaus] Kvw Neurosci Consulting, Munster, Germany; [Wenzlaff, Paul] Zentrum Qualitatsmanagement, Hannover, Germany	Rickels, E (corresponding author), AKH Celle, Neurosurg, Siemenspl 4, DE-29223 Celle, Germany.	emrickels@t-online.de			'Hannelore-Kohl-Stiftung- Kuratorium ZNS', Bonn, Germany; World Federation of Neurology Research and Education Foundation; Winston-Salem, NC/USA; Forderverein fur neurotraumatologische Rehabilitation e. V.; Munster, Germany	This study was supported by grants from 'Hannelore-Kohl-Stiftung- Kuratorium ZNS', Bonn, Germany; World Federation of Neurology Research and Education Foundation, Winston-Salem, NC/USA, Forderverein fur neurotraumatologische Rehabilitation e. V.; (Cerebprotect), Munster, Germany. The authors want to thank all colleagues in the participating hospitals for their efforts to include and to document the patients.	Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; BADER MK, 2004, WORLDVIEWS EVIDIDENC, V1, P227; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Farin A, 2004, ACT NEUR S, V89, P101; GREINER W, 2000, GESUNDHEITSOKONOMISC; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hillier SL, 1997, BRAIN INJURY, V11, P649; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Keris V, 2007, WORLD J SURG, V31, P1352, DOI 10.1007/s00268-007-9002-x; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Langlois JA., TRAUMATIC BRAIN INJU; Leidl R, 2003, PUBLIC HLTH BUCH GES, P461; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Servadei F, 2002, J Neurosurg Sci, V46, P111; *STAT BUND, 2001, TOD S02 S09 NACH ICD; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; von Wild K., 2000, SCHMIDEK SWEET OPERA, V4, P45; von Wild KRH, 2002, ACT NEUR S, V79, P3; VONWILD KRH, 2005, EUROPEAN J TRAUMA, V4, P344; VONWILD KRH, 1998, PATHOPHYSIOLOGICAL P; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wirth A, 2004, ACT NEUR S, V89, P119; Zhang J, 2001, Chin J Traumatol, V4, P152	38	73	79	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	12					1491	1504		10.3109/02699052.2010.498006			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667NR	WOS:000283200800012	20645706				2021-06-18	
J	Hayhurst, C; Byrne, P; Eldridge, PR; Mallucci, CL				Hayhurst, Caroline; Byrne, Patricia; Eldridge, Paul R.; Mallucci, Conor L.			Application of electromagnetic technology to neuronavigation: a revolution in image-guided neurosurgery Technical note	JOURNAL OF NEUROSURGERY			English	Article						frameless neuronavigation; electromagnetic neuronavigation; magnetic field	IDIOPATHIC INTRACRANIAL HYPERTENSION; FRAMELESS STEREOTAXY; SYSTEM; NEUROENDOSCOPY; NAVIGATION; PLACEMENT; ACCURACY; FIXATION	Object. The authors investigated the practicality of electromagnetic neuronavigation in routine clinical use, and determined the applications for which it is at the advantage compared with other systems. Methods. A magnetic field is generated encompassing the surgical volume. Devices containing miniaturized coils can be located within the field. The authors report on their experience in 150 cases performed with this technology. Results. Electromagnetic neuronavigation was performed in 44 endoscopies, 42 ventriculoperitoneal shunt insertions for slit ventricles, 21 routine shunt insertions, 6 complex shunt insertions, 14 external ventricular drain placements for traumatic brain injury, 5 awake craniotomies, 5 Ommaya reservoir placements, and for 13 other indications. Satisfactory positioning of ventricular catheters was achieved in all cases. No particular changes to the operating theater set-up were required, and no significant interference from ferromagnetic instruments was experienced. Neurophysiological monitoring was not affected, nor did it affect electromagnetic guidance. Conclusions. Neuronavigation enables safe, accurate surgery, and may ultimately reduce complications and improve outcome. Electromagnetic technology allows frameless, pinless, image-guided surgery, and can be used in all procedures for which neuronavigation is appropriate. This technology was found to be particularly advantageous compared with other technologies in cases in which freedom of head movement was helpful. Electromagnetic neuronavigation was therefore well suited to CSF diversion procedures, awake craniotomies, and cases in which rigid head fixation was undesirable, such as in neonates. This technology extends the application of neuronavigation to routine shunt placement and ventricular catheter placement in patients with traumatic brain injury. (DOI: 10.3171/2008.12.JNS08628)	[Hayhurst, Caroline; Byrne, Patricia; Eldridge, Paul R.] Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool L9 7LJ, Merseyside, England; [Mallucci, Conor L.] Royal Liverpool Childrens Hosp, Dept Neurosurg, Liverpool L7 7DG, Merseyside, England	Hayhurst, C (corresponding author), Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Lower Lane Fazakerley, Liverpool L9 7LJ, Merseyside, England.	carolinehayhurst@hotmail.com					Abu-Serieh B, 2007, NEUROSURGERY, V60, P1039, DOI 10.1227/01.NEU.0000255456.12978.31; Azeem SS, 2007, NEUROSURGERY, V60, P243, DOI 10.1227/01.NEU.0000255387.03088.53; Barazi SA, 2006, BRIT J NEUROSURG, V20, P43, DOI 10.1080/02688690600598554; Benardete EA, 2001, NEUROSURGERY, V49, P1409, DOI 10.1097/00006123-200112000-00020; Broggi G, 2000, ACTA NEUROCHIR, V142, P893, DOI 10.1007/s007010070075; Karabatsou K, 2004, ACTA NEUROCHIR, V146, P1193, DOI 10.1007/s00701-004-0392-3; KATO A, 1991, J NEUROSURG, V74, P845, DOI 10.3171/jns.1991.74.5.0845; Kestle JRW, 2003, J NEUROSURG, V98, P284, DOI 10.3171/jns.2003.98.2.0284; Leuthardt EC, 2002, STEREOT FUNCT NEUROS, V79, P256, DOI 10.1159/000070839; Mascott CR, 2005, NEUROSURGERY, V57, P295, DOI 10.1227/01.NEU.0000176411.55324.1E; Mayberg Marc R, 2005, Neurosurg Focus, V19, pE10; Reavey-Cantwell JF, 2006, J NEUROSURG, V104, P392, DOI 10.3171/ped.2006.104.6.392; Rosenow JM, 2007, STEREOT FUNCT NEUROS, V85, P75, DOI 10.1159/000097922; Rousu JS, 1998, ST HEAL T, V50, P103; SAINTEROSE C, 1992, PEDIATR NEUROSURG, V17, P2, DOI 10.1159/000120557; Schicho K, 2005, PHYS MED BIOL, V50, P2089, DOI 10.1088/0031-9155/50/9/011; Schroeder HWS, 2001, J NEUROSURG, V94, P72, DOI 10.3171/jns.2001.94.1.0072; Tirakotai W, 2004, CHILD NERV SYST, V20, P790, DOI 10.1007/s00381-004-0932-4; Vougioukas VI, 2003, CHILD NERV SYST, V19, P783, DOI 10.1007/s00381-003-0836-8; Woodworth GF, 2005, STEREOT FUNCT NEUROS, V83, P12, DOI 10.1159/000084059; Zaaroor M, 2001, NEUROSURGERY, V48, P1100, DOI 10.1097/00006123-200105000-00027	21	73	77	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2009	111	6					1179	1184		10.3171/2008.12.JNS08628			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	529CM	WOS:000272493300011	19326991				2021-06-18	
J	Yuen, TJ; Browne, KD; Iwata, A; Smith, DH				Yuen, Tracy J.; Browne, Kevin D.; Iwata, Akira; Smith, Douglas H.			Sodium Channelopathy Induced by Mild Axonal Trauma Worsens Outcome After a Repeat Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						axon trauma; calcium; diffuse axonal injury; repetitive injury; sodium channels; traumatic brain injury	BRAIN-INJURY; HEAD-INJURY; MULTIPLE-SCLEROSIS; MOUSE MODEL; CONCUSSION; CALCIUM; TETRODOTOXIN; PERFORMANCE; NEURONS; DAMAGE	There is great concern that one mild traumatic brain injury (mTBI) predisposes individuals to an exacerbated response with a subsequent mTBI. Although no mechanism has been identified, mounting evidence suggests traumatic axonal injury (TAI) plays a role in this process. By using a cell culture system, a threshold of mild TAI was found where dynamic stretch of cortical axons at strains lower than 5% induced no overt pathological changes. However, the axons were found to display an increased expression of sodium channels (NaChs) by 24 hr. After a second, identical mild injury, pathologic increases in [Ca2+](i) were observed, leading to axon degeneration. The central role of NaChs in this response was demonstrated by blocking NaChs with tetrodotoxin prior to the second injury, which completely abolished postinjury increases in [Ca2+](i). These data suggest that mild TAI induces a form of sodium channelopathy on axons that greatly exaggerates the pathophysiologic response to subsequent mild injuries. (C) 2009 Wiley-Liss, Inc.	[Yuen, Tracy J.; Browne, Kevin D.; Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Yuen, Tracy J.; Browne, Kevin D.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Iwata, Akira] Nagakute Minami Clin, Aichi, Japan	Smith, DH (corresponding author), Univ Penn, Ctr Brain Injury & Repair, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS38104]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant numbers: NS38104 and NS38104 (to Douglas H. Smith).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Baker MD, 2001, TRENDS PHARMACOL SCI, V22, P27, DOI 10.1016/S0165-6147(00)01585-6; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVRAM V, 1992, J NEUROPHYSIOL, V68, P1167; LUPA MT, 1993, J NEUROSCI, V13, P1326; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pfister BJ, 2006, FEBS LETT, V580, P3525, DOI 10.1016/j.febslet.2006.05.030; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Rhodes TH, 2004, P NATL ACAD SCI USA, V101, P11147, DOI 10.1073/pnas.0402482101; Rosenbluth J, 2009, BRAIN RES, V1253, P191, DOI 10.1016/j.brainres.2008.11.066; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Takahashi A, 1999, PHYSIOL REV, V79, P1089; Tarnawa Istvan, 2007, Recent Pat CNS Drug Discov, V2, P57, DOI 10.2174/157488907779561754; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	34	73	74	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC	2009	87	16					3620	3625		10.1002/jnr.22161			6	Neurosciences	Neurosciences & Neurology	515AN	WOS:000271438600010	19565655	Green Accepted			2021-06-18	
J	Bryant, RA; Creamer, M; O'Donnell, M; Silove, D; Clark, CR; McFarlane, AC				Bryant, Richard A.; Creamer, Mark; O'Donnell, Meaghan; Silove, Derrick; Clark, C. Richard; McFarlane, Alexander C.			Post-traumatic amnesia and the nature of post-traumatic stress disorder after mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Trauma; Memory; Stress; Risk; Intrusions; Anxiety	POSTCONCUSSIVE SYMPTOMS; MEMORIES; MECHANISMS; SEQUELAE; PTSD; IRAQ; TBI	The prevalence and nature of post-traumatic stress disorder (PTSD) following mild traumatic brain injury (MTBI) is controversial because of the apparent paradox of suffering PTSD with impaired memory for the traumatic event. In this study, 1167 survivors of traumatic injury (MTBI: 459, No TBI: 708) were assessed for PTSD symptoms and post-traumatic amnesia during hospitalization, and were subsequently assessed for PTSD 3 months later (N=920). At the follow-up assessment, 90 (9.4%) patients met criteria for PTSD (MTBI: 50, 11.8%; No-TBI: 40, 7.5%); MTBI patients were more likely to develop PTSD than no-TBI patients, after controlling for injury severity (adjusted odds ratio: 1.86; 95% confidence interval, 1.78-2.94). Longer post-traumatic amnesia was associated with less severe intrusive memories at the acute assessment. These findings indicate that PTSD may be more likely following MTBI, however, longer post-traumatic amnesia appears to be protective against selected re-experiencing symptoms. (JINS, 2009, 157 862-867.)	[Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; [Creamer, Mark; O'Donnell, Meaghan] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia; [Clark, C. Richard] Flinders Univ S Australia, Dept Psychol, Adelaide, SA, Australia; [McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	NHMRCNational Health and Medical Research Council of Australia [300403]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical ResearchNational Health and Medical Research Council of Australia [359284]	This study was Supported by an NHMRC Program Grant (300403), a Victorian Trauma Foundation grant (#V-11), and a National Health and Medical Research Council Australian Clinical Research Fellowship (359284).	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; Blake DD, 1998, CLIN ADM PTSD SCALE; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2007, J CONSULT CLIN PSYCH, V75, P812, DOI 10.1037/0022-006X.75.5.812; Castro CA, 2008, J TRAUMA, V64, pS205; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Dunmore E, 2001, BEHAV RES THER, V39, P1063, DOI 10.1016/S0005-7967(00)00088-7; DUNMORE E, 1997, BEHAV COGN PSYCHOTH, V25, P147, DOI DOI 10.1017/S135246580001835X; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lovibond PF, 2002, J EXP PSYCHOL-ANIM B, V28, P3, DOI 10.1037//0097-7403.28.1.3; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; PITMAN RK, 1988, PSYCHIAT ANN, V18, P182, DOI 10.3928/0048-5713-19880301-11; Rauch SL, 1997, ANN NY ACAD SCI, V821, P83, DOI 10.1111/j.1749-6632.1997.tb48271.x; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	36	73	74	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2009	15	6					862	867		10.1017/S1355617709990671			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	523ZV	WOS:000272114500006	19703323	Green Published			2021-06-18	
J	Garay, L; Deniselle, MCG; Meyer, M; Costa, JJL; Lima, A; Roig, P; DeNicola, AF				Garay, Laura; Gonzalez Deniselle, Maria Claudia; Meyer, Maria; Lopez Costa, Juan Jose; Lima, Analia; Roig, Paulina; DeNicola, Alejandro F.			Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis	BRAIN RESEARCH			English	Article						Axon; Axonoprotection; Experimental autoimmune encephalomyelitis; Growth-associated protein; Progesterone	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; GAP-43 EXPRESSION; STEROID-HORMONES; MOUSE MODEL; PREGNANCY; RAT; ESTROGEN	Experimental autoimmune encephalomyelitis (EAE), an induced model of Multiple Sclerosis presents spinal cord demyelination, axonal pathology and neuronal dysfunction. Previous work has shown that progesterone attenuated the clinical severity, demyelination and neuronal dysfunction of EAE mice (Garay et al., J. Steroid Biochem. Mol. Biol., 2008). Here we studied if progesterone also prevented axonal damage, a main cause of neurological disability. To this end, some axonal parameters were compared in EAE mice pretreated with progesterone a week before immunization with MOG(40-54) and in a group of steroid-free EAE mice. On day 16th after EAE induction, we determined in both groups and in control mice: a) axonal density in semithin sections of the spinal cord ventral funiculus; b) appearance of amyloid precursor protein (APP) immunopositive spheroids as an index of damaged axons; c) levels of the growth associated protein GAP43 mRNA and immunopositive cell bodies, as an index of aberrant axonal sprouting. Steroid-naive EAE mice showed decreased axonal density, shrunken axons, abundance of irregular vesicular structures, degenerating APP+ axons, increased expression of GAP43 mRNA and immunoreactive protein in motoneurons. Instead, EAE mice receiving progesterone treatment showed increased axonal counts, high proportion of small diameter axons, reduced APP+ profiles, and decreased GAP43 expression. In conclusion, progesterone enhanced axonal density, decreased axonal damage and prevented GAP43 hyperexpression in the spinal cord of EAE mice. Thus, progesterone also exerts protective effects on the axonal pathology developing in EAE mice. (C) 2009 Elsevier B.V. All rights reserved.	[DeNicola, Alejandro F.] Inst Biol & Med Expt, CONICET, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Garay, Laura; Gonzalez Deniselle, Maria Claudia; DeNicola, Alejandro F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1053 Buenos Aires, DF, Argentina; [Lopez Costa, Juan Jose] Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencias, RA-1053 Buenos Aires, DF, Argentina; [DeNicola, Alejandro F.] Fdn HA Barcelo, Inst Univ Ciencias Salud, Buenos Aires, DF, Argentina	DeNicola, AF (corresponding author), Inst Biol & Med Expt, CONICET, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar			FONCYTFONCyT [PICT 2004 25610, PICT 2007-01044]; National Research Council of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 5542, PIP 112-200801-00542]; University of Buenos AiresUniversity of Buenos Aires [M016]	We thank the following institutions for financial support: FONCYT (PICT 2004 25610 and PICT 2007-01044), the National Research Council of Argentina (CONICET, PIP 5542 and PIP 112-200801-00542), and the University of Buenos Aires (M016). The assistance of Mariana Lopez Ravasio with the preparation of semithin sections is gratefully acknowledged.	Ayers MM, 2004, NEUROCHEM INT, V45, P409, DOI 10.1016/j.neuint.2003.08.018; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blamire AM, 2007, MAGN RESON MED, V58, P880, DOI 10.1002/mrm.21382; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; CURTIS R, 1993, J NEUROCYTOL, V22, P51, DOI 10.1007/BF01183975; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; DELAMONTE SM, 1995, AM J PATHOL, V147, P934; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Diem R, 2007, J NEUROIMMUNOL, V184, P27, DOI 10.1016/j.jneuroim.2006.11.025; Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010; Dutta R, 2007, NEUROLOGY, V68, pS22, DOI 10.1212/01.wnl.0000275229.13012.32; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; Elliott EJ, 1997, BRAIN RES, V755, P221, DOI 10.1016/S0006-8993(97)00100-5; Elloso MM, 2005, J ENDOCRINOL, V185, P243, DOI 10.1677/joe.1.06063; EVRON S, 1984, AM J REPROD IMMUNOL, V5, P109, DOI 10.1111/j.1600-0897.1984.tb00298.x; GARAY L, 2005, MULT SCLER, V11, P43; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Giardino L, 2004, NEUROPATH APPL NEURO, V30, P522, DOI 10.1111/j.1365-2990.2004.00559.x; Herrero-Herranz E, 2008, NEUROBIOL DIS, V30, P162, DOI 10.1016/j.nbd.2008.01.001; HOLINKA CF, 1979, BIOL REPROD, V20, P1201, DOI 10.1095/biolreprod20.5.1201; Hughes MD, 2004, NEUROL CLIN, V22, P757, DOI 10.1016/j.ncl.2004.06.004; KAPFHAMMER JP, 1994, J COMP NEUROL, V340, P194, DOI 10.1002/cne.903400206; KEITH AB, 1978, J NEUROL SCI, V38, P317, DOI 10.1016/0022-510X(78)90138-7; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Linker RA, 2005, J NEUROL SCI, V233, P167, DOI 10.1016/j.jns.2005.03.021; McQualter JL, 2007, J NEUROCHEM, V100, P295, DOI 10.1111/j.1471-4159.2006.04232.x; Melcangi RC, 2005, BRAIN RES REV, V48, P328, DOI 10.1016/j.brainresrev.2004.12.021; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Offner H, 2004, J NEUROSCI RES, V78, P603, DOI 10.1002/jnr.20330; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Olby NJ, 1996, J NEUROCYTOL, V25, P465, DOI 10.1007/BF02284816; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Palaszynski KM, 2004, J NEUROIMMUNOL, V149, P84, DOI 10.1016/j.jneuroim.2003.12.015; Papadopoulos D, 2006, EXP NEUROL, V197, P373, DOI 10.1016/j.expneurol.2005.10.033; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rovaris M, 2005, ARCH NEUROL-CHICAGO, V62, P898, DOI 10.1001/archneur.62.6.898; RUSSELL JH, 2006, NEUROBIOL DIS, V21, P626; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; Werner P, 2000, ADV RES NEURODEGENER, V8, P375; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23; Zawadzka M, 2007, CURR OPIN NEUROL, V20, P294, DOI 10.1097/WCO.0b013e32813aee7f	55	73	77	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 4	2009	1283						177	185		10.1016/j.brainres.2009.04.057			9	Neurosciences	Neurosciences & Neurology	484FQ	WOS:000269029700018	19497309				2021-06-18	
J	Williams, G; Morris, ME; Schache, A; McCrory, PR				Williams, Gavin; Morris, Meg E.; Schache, Anthony; McCrory, Paul R.			Incidence of Gait Abnormalities After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Brain-Injury-Association	APR 09-12, 2008	Lisbon, PORTUGAL	Int Brain Injury Assoc		Biomechanics; Brain injuries; Gait; Rehabilitation	MOBILITY ASSESSMENT-TOOL; BOTULINUM-TOXIN; REHABILITATION; WALKING; ADULTS; ANKLE; FOOT; DISORDERS; INJECTION; VALIDITY	Williams G, Morris ME, Schache A, McCrory PR. Incidence of gait abnormalities after traumatic brain injury. Arch Phys Med Rehabil 2009;90:587-93. Objective: To identify the most common gait abnormalities presenting after traumatic brain injury (TBI) and quantify their incidence rate. Design: Case series. Setting: Biomechanics laboratory. Participants: A convenience sample of 41 people with TBI receiving therapy for gait abnormalities, and a sample of 25 healthy controls. Intervention: Three-dimensional gait analysis. Main Outcome Measures: Spatiotemporal, kinematic, and kinetic data at a self-selected walking speed. Results: People with TBI walked with a significantly slower speed than matched healthy controls. There was a significant difference between groups for cadence, step length, stance time on the affected leg, double support phase, and width of base of support. The most frequently observed biomechanical abnormality was excessive knee flexion at initial foot contact. Other significant gait abnormalities were increased trunk anterior/posterior amplitude of movement, increased anterior pelvic tilt, increased peak pelvic obliquity, reduced peak knee flexion at toe-off, and increased lateral center of mass displacement. Ankle equinovarus at foot-contact occurred infrequently. Conclusions: People with TBI were found to have multijoint gait abnormalities. Many of these abnormalities have not been previously reported in this Population.	[Williams, Gavin] Epworth Med Fdn, Melbourne, Vic, Australia; [Williams, Gavin; McCrory, Paul R.] Univ Melbourne, Sch Physiotherapy, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Schache, Anthony] Univ Melbourne, Sch Mech Engn, Melbourne, Vic, Australia	Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavin.williams@epworth.org.au	McCrory, Paul/Q-8688-2019; Schache, Anthony G/F-4482-2016	Schache, Anthony G/0000-0002-1041-5213; McCrory, Paul/0000-0003-4850-0568; Williams, Gavin/0000-0003-2758-7473; Morris, Meg/0000-0002-0114-4175			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Bracewell RM, 2005, NEUROLOGY, V64, P751, DOI 10.1212/01.WNL.0000151972.37634.33; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chua KSG, 2001, BRAIN INJURY, V15, P733, DOI 10.1080/02699050010009775; De Bujanda E, 2003, J REHABIL MED, V35, P259, DOI 10.1080/16501970310012428; DeLuca PA, 1997, J PEDIATR ORTHOPED, V17, P608, DOI 10.1097/00004694-199709000-00007; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Fuller DA, 2002, FOOT ANKLE INT, V23, P738, DOI 10.1177/107110070202300810; Gradenigo B, 2002, EURA MEDICOPHYS, V38, P215; Griffin D., 1990, TROPICAL BRYOLOGY, V2, P127; Harrington ME, 2007, J BIOMECH, V40, P595, DOI 10.1016/j.jbiomech.2006.02.003; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Horn TS, 2005, ARCH PHYS MED REHAB, V86, P1127, DOI 10.1016/j.apmr.2004.11.013; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kay RM, 2000, CLIN ORTHOP RELAT R, P217; Kerrigan DC, 1996, ARCH PHYS MED REHAB, V77, P645, DOI 10.1016/S0003-9993(96)90002-7; Kerrigan DCC, 1999, J HEAD TRAUMA REHAB, V14, P136, DOI 10.1097/00001199-199904000-00004; Lee LW, 1997, AM J PHYS MED REHAB, V76, P502, DOI 10.1097/00002060-199711000-00013; Liu MQ, 2006, J BIOMECH, V39, P2623, DOI 10.1016/j.jbiomech.2005.08.017; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Medley A, 2006, BRAIN INJURY, V20, P1403, DOI 10.1080/02699050601082057; Molteni F, 1995, EUR J NEUROL, V2, P61; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Perry J, 1999, J HEAD TRAUMA REHAB, V14, P116, DOI 10.1097/00001199-199904000-00003; Pohl M, 2006, CLIN REHABIL, V20, P324, DOI 10.1191/0269215506cr951oa; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Schache AG, 2007, GAIT POSTURE, V25, P440, DOI 10.1016/j.gaitpost.2006.05.018; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711	37	73	74	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2009	90	4					587	593		10.1016/j.apmr.2008.10.013			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	432TD	WOS:000265156200008	19345773				2021-06-18	
J	McGinn, MJ; Kelley, BJ; Akinyi, L; Oli, MW; Liu, MC; Hayes, RL; Wang, KKW; Povilshock, JT				McGinn, Melissa J.; Kelley, Brian J.; Akinyi, Linnet; Oli, Monika W.; Liu, Ming Cheng; Hayes, Ronald L.; Wang, Kevin K. W.; Povilshock, John T.			Biochemical, Structural, and Biomarker Evidence for Calpain-Mediated Cytoskeletal Change After Diffuse Brain Injury Uncomplicated by Contusion	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Biomarker; Calpain; Cytoskeleton; Diffuse axonal injury; Spectrin; Traumatic brain injury	TRAUMATIC AXONAL INJURY; ALPHA-II-SPECTRIN; CONTROLLED CORTICAL IMPACT; BREAKDOWN PRODUCTS; CEREBROSPINAL-FLUID; PROTEIN BREAKDOWN; CORPUS-CALLOSUM; IMMATURE RATS; HEAD-INJURY; ACTIVATION	Calpain-mediated degradation of the cytoskeletal protein alpha-II-spectrin has been implicated in tire pathobiology of experimental and human traumatic brain injury (TBI). Spectrin proteolysis after diffuse/widespread TBI uncomplicated by either Subtle or overt contusion and/or mass lesions, (i.e. mild to moderate TBI), has not been previously evaluated. To determine the spatiotemporal pattern and cellular localization of calpain-mediated spectrin proteolysis after diffuse/widespread TBI and the extent to which parenchymal changes in calpain-mediated spectrin proteolysis are reflected ill the cerebrospinal fluid, adult rats were subjected to a moderate midline fluid percussion injury and allowed to Survive for 3 hours to 7 days postinjury. Light and electron microscopic immunocytochemical and Western blot analyses were performed to identify the calpain-specific 145-kDa breakdown product of a-II-spectrin (SBDP145). After diffuse TBI, enhanced levels of SBDP145 immunoreactivity were observed in the neocortex, subcortical white matter, thalamus, and hippocampus. peaking between 24 and 48 hours postinjury. Immunoreactivity was localized almost exclusively to damaged axons and axonal terminal debris. Heightened levels of SBDP145 were also observed in the cerebrospinal fluid at 24 hours postinjury. These results confirm the widespread Occurrence of calpain-mediated spectrin proteolysis after diffuse TBI without contusion and support the potential utility of SBDPs as biomarkers of a diffusely injured brain.	[Povilshock, John T.] Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Akinyi, Linnet; Oli, Monika W.] Banyan Biomarkers Inc, Diagnost Res & Dev Dept, Alachua, FL USA; [Liu, Ming Cheng; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, McKnight Brain Inst, Ctr Neuroprote & Biomarkers Res,Dept Anesthesiol, Gainesville, FL 32611 USA	Povilshock, JT (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, 1101 E Marshall St,Sanger Hall 12-050,POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu		Wang, Kevin/0000-0002-9343-6473	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01HD055813-25, 5P30NS047463-05, R01 NS049175-01 A1]; Department of DefenseUnited States Department of Defense [DAMD17-03-1-0066, DAMD17-01-1-0765]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, P30NS047463] Funding Source: NIH RePORTER	This work was supported by Grant Nos. 5R01HD055813-25 (JTP), 5P30NS047463-05 (JTP). and R01 NS049175-01 A1 (KKW) from the National Institutes of Health and Grant Nos. DAMD17-03-1-0066 and DAMD17-01-1-0765 (RLH) from the Department of Defense.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cardali S, 2006, J Neurosurg Sci, V50, P25; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu J, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.123tr3; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4	43	73	75	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2009	68	3					241	249		10.1097/NEN.0b013e3181996bfe			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	413QG	WOS:000263807000003	19225412	Green Accepted, Bronze			2021-06-18	
J	Aguirre, CC; Baudry, M				Aguirre, Claudia C.; Baudry, Michel			Progesterone reverses 17 beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						excitotoxicity; hippocampus; hormones; neurodegeneration; rat	NEUROTROPHIC FACTOR EXPRESSION; ESTROGEN-RECEPTOR-ALPHA; TRAUMATIC BRAIN-INJURY; FEMALE RATS; MEDROXYPROGESTERONE ACETATE; NERVOUS-SYSTEM; NEURONS; ALLOPREGNANOLONE; PROGESTINS; MEDIATE	Due to the many similarities in mechanisms of action, targets and effects, progesterone (P4), estrogen and neurotrophins have been implicated in synaptic plasticity as well as in neuroprotection and neurodegeneration. In this study, we examined the interactions between 17 beta-estradiol (E2) and P4 and brain-derived neurotrophic factor (BDNF) on both plasticity and excitotoxicity in rat cultured hippocampal slices. First, we evaluated the neuroprotective effects of E2 and P4 against N-methyl-d-aspartate (NMDA) toxicity in cultured rat hippocampal slices. As previously reported, pretreatment with 10 nm E2 (24 h) was neuroprotective against NMDA toxicity. However, P4 (10 nm) added 20 h after E2 treatment for 4 h reversed its protective effect. In addition, the same E2 treatment resulted in an increase in BDNF protein levels as well as in activation of its receptor, TrkB, while addition of P4 attenuated E2-mediated increase in BDNF and TrkB levels. Furthermore, E2-mediated neuroprotection was eliminated by a BDNF scavenger, TrkB-Fc. Our results indicate that E2 neuroprotective effects are mediated through the BDNF pathway and that, under certain conditions, P4 antagonizes the protective effect of estrogen.	[Baudry, Michel] HNB534 USC, Los Angeles, CA 90089 USA; [Aguirre, Claudia C.] Univ So Calif, Grad Program Neurosci, Los Angeles, CA 90089 USA	Baudry, M (corresponding author), HNB534 USC, Los Angeles, CA 90089 USA.	baudry@usc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P01AG026572, T32 AG000093-25]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG000093-25]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000093, P01AG026572] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant number: 1P01AG026572; Contract training grant number: T32 AG000093-25.; The authors thank Anna Knize for technical assistance. This study was supported by NIA training grant T32 AG000093-25 to C.C.A. and NIH grant 1P01AG026572 to M.B.	Alves SE, 2000, J COMP NEUROL, V427, P185, DOI 10.1002/1096-9861(20001113)427:2<185::AID-CNE2>3.0.CO;2-G; Baulieu EE, 1996, CELL MOL NEUROBIOL, V16, P143, DOI 10.1007/BF02088173; Bi RF, 2000, P NATL ACAD SCI USA, V97, P3602, DOI 10.1073/pnas.060034497; Bimonte-Nelson HA, 2004, NEUROREPORT, V15, P2659, DOI 10.1097/00001756-200412030-00021; Blurton-Jones M, 2004, J COMP NEUROL, V468, P347, DOI 10.1002/cne.10989; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Chung WCJ, 2006, BRAIN RES, V1082, P50, DOI 10.1016/j.brainres.2006.01.109; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Daniel JM, 1997, HORM BEHAV, V32, P217, DOI 10.1006/hbeh.1997.1433; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Izumi Y, 2007, EUR J NEUROSCI, V26, P1881, DOI 10.1111/j.1460-9568.2007.05809.x; Jayaraman A, 2009, J NEUROENDOCRINOL, V21, P77, DOI 10.1111/j.1365-2826.2008.01801.x; Jensen T, 2001, J EXP BIOL, V204, P2087; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; McEwen BS, 1999, ENDOCRINOLOGY, V140, P1044, DOI 10.1210/en.140.3.1044; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; Mostallino MC, 2006, J NEUROCHEM, V99, P321, DOI 10.1111/j.1471-4159.2006.04055.x; Murphy DD, 2000, NEUROENDOCRINOLOGY, V72, P133, DOI 10.1159/000054580; Nakagami Y, 1997, NEUROSCIENCE, V81, P1, DOI 10.1016/S0306-4522(97)00161-9; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Rhodes ME, 2005, EPILEPSY BEHAV, V6, P320, DOI 10.1016/j.yebeh.2005.02.006; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Rosario ER, 2006, BRAIN RES, V1099, P206, DOI 10.1016/j.brainres.2006.03.127; Scharfman HE, 2006, FRONT NEUROENDOCRIN, V27, P415, DOI 10.1016/j.yfrne.2006.09.004; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Sohrabji F, 2006, FRONT NEUROENDOCRIN, V27, P404, DOI 10.1016/j.yfrne.2006.09.003; Spencer JL, 2008, FRONT NEUROENDOCRIN, V29, P219, DOI 10.1016/j.yfrne.2007.08.006; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x	35	73	76	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2009	29	3					447	454		10.1111/j.1460-9568.2008.06591.x			8	Neurosciences	Neurosciences & Neurology	401OQ	WOS:000262951200003	19175406	Green Accepted			2021-06-18	
J	Mbye, LH; Singh, IN; Carrico, KM; Saatman, KE; Hall, ED				Mbye, Lamin Han; Singh, Indrapal N.; Carrico, Kimberly M.; Saatman, Kathryn E.; Hall, Edward D.			Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calpain; alpha-spectrin; motor function; mitochondrial permeability transition pore; NIM811; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; EXPERIMENTAL HEAD-INJURY; INDUCED AXONAL INJURY; CORTICAL DAMAGE; CELL-DEATH; OXIDATIVE DAMAGE; CYTOCHROME-C; MOUSE MODEL; DYSFUNCTION; NEURODEGENERATION	Earlier experiments have shown that cyclosporin A (CsA) and its non-calcineurin inhibitory analog NIM811 attenuate mitochondrial dysfunction after experimental traumatic brain injury (TBI). Presently, we compared the neuroprotective effects of previously determined mitochondrial protective doses of CsA (20 mg/kg intraperitoneally) and NIM811 (10 mg/kg intraperitoneally) when administered at 15 mins postinjury in preventing cytoskeletal (alpha-spectrin) degradation, neuro-degeneration, and neurological dysfunction after severe (1.0 mm) controlled cortical impact (CCI) TBI in mice. In a first set of experiments, we analyzed calpain-mediated alpha-spectrin proteolysis at 24 h postinjury. Both NIM811 and CsA significantly attenuated the increased alpha-spectrin breakdown products observed in vehicle-treated animals (P<0.005). In a second set of experiments, treatment of animals with either NIM811 or CsA at 15 mins and again at 24 h postinjury attenuated motor function impairment at 48 h and 7 days (P<0.005) and neurodegeneration at 7 days postinjury (P<0.0001). Delayed administration of NIM811 out to 12 h was still able to significantly reduce a-spectrin degradation. These results show that the neuroprotective mechanism of CsA involves maintenance of mitochondrial integrity and that calcineurin inhibition plays little or no role because the non-calcineurin inhibitory analog, NIM811, is as effective as CsA.	[Mbye, Lamin Han; Singh, Indrapal N.; Carrico, Kimberly M.; Saatman, Kathryn E.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,Room B483 BBSRB, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 NS046566, 1P30 NS051220]; Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS046566] Funding Source: NIH RePORTER	This research was supported by funding from the NIH (1R01 NS046566, 1P30 NS051220) and the Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pattison James M., 1997, P331; Povlishock JT, 1999, ACT NEUR S, V73, P15; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	43	73	75	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2009	29	1					87	97		10.1038/jcbfm.2008.93			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	389QS	WOS:000262110200011	18714331	Bronze, Green Accepted			2021-06-18	
J	Reid-Arndt, SA; Yee, A; Perry, MC; Hsieh, C				Reid-Arndt, Stephanie A.; Yee, Albert; Perry, Michael C.; Hsieh, Catherine			Cognitive and Psychological Factors Associated with Early Posttreatment Functional Outcomes in Breast Cancer Survivors	JOURNAL OF PSYCHOSOCIAL ONCOLOGY			English	Article						breast cancer; cognitive; quality of life; social support; community integration	QUALITY-OF-LIFE; LONG-TERM SURVIVORS; TRAUMATIC BRAIN-INJURY; CELL LUNG-CANCER; RECEIVING ADJUVANT CHEMOTHERAPY; STANDARD-DOSE CHEMOTHERAPY; FOLLOW-UP; PREMORBID INTELLIGENCE; SOCIAL SUPPORT; NEED-SATISFACTION	Breast cancer survivors experience cognitive difficulties following chemotherapy, yet the effects of these deficits on functional outcomes have not been systematically evaluated. This study assessed the relationships between postchemotherapy cognitive difficulties and functional outcomes. Forty-six women with breast cancer were seen at 1-month postchemotherapy; data were collected on cognitive functioning, psychological variables, and physical symptoms. Wilcoxon signed-rank analyses revealed cognitive deficits in executive functioning and verbal fluency. Subsequent regression analyses demonstrated that poorer executive functioning was associated with decreased productivity, community involvement, and social role functioning. Poorer quality of life was predicted by depression and reluctance to seek social support, but not cognitive functioning. These findings indicate that executive functioning deficits are associated with important functional outcomes among breast cancer survivors 1-month postchemotherapy. Thus, treatment efforts should focus on addressing cognitive, as well as psychological and physical, issues among cancer survivors.	[Reid-Arndt, Stephanie A.] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA; [Yee, Albert] Atascadero State Hosp, Atascadero, CA USA; [Perry, Michael C.] Univ Missouri, Div Hematol & Med Oncol, Columbia, MO 65212 USA; [Hsieh, Catherine] Univ Missouri, Dept Educ Sch & Counseling Psychol, Columbia, MO 65212 USA	Reid-Arndt, SA (corresponding author), Univ Missouri, Dept Hlth Psychol, 1 Hosp Dr,DC116-88, Columbia, MO 65212 USA.	reidarndts@health.missouri.edu			NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R03CA108340] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R03 CA108340, R03 CA108340-02] Funding Source: Medline		Ahles TA, 2001, CANCER INVEST, V19, P812, DOI 10.1081/CNV-100107743; Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Ahles TA, 1998, J CLIN ONCOL, V16, P1954, DOI 10.1200/JCO.1998.16.5.1954; *AM CANC SOC, 2006, FACTS FIG 2006; Anderson-Hanley C, 2003, J INT NEUROPSYCH SOC, V9, P967, DOI 10.1017/S1355617703970019; Antoni MH, 2006, J CONSULT CLIN PSYCH, V74, P1143, DOI 10.1037/0022-006X.74.6.1152; Baker F, 2002, PSYCHO-ONCOLOGY, V11, P273, DOI 10.1002/pon.564; Benton A, 1989, MULTILINGUAL APHASIA; Bettencourt BA, 2001, J PERS SOC PSYCHOL, V81, P1131, DOI 10.1037/0022-3514.81.6.1131; Bradley CJ, 2005, J HEALTH ECON, V24, P137, DOI 10.1016/j.jhealeco.2004.07.003; Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974; Brezden CB, 2000, J CLIN ONCOL, V18, P2695, DOI 10.1200/JCO.2000.18.14.2695; Carver CS, 2006, PSYCHO-ONCOLOGY, V15, P749, DOI 10.1002/pon.1006; Carver CS, 2005, HEALTH PSYCHOL, V24, P508, DOI 10.1037/0278-6133.24.5.508; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Falleti MG, 2005, BRAIN COGNITION, V59, P60, DOI 10.1016/j.bandc.2005.05.001; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Ferguson RJ, 2007, PSYCHO-ONCOL, V16, P772, DOI 10.1002/pon.1133; Figueiredo MI, 2004, PSYCHO-ONCOLOGY, V13, P96, DOI 10.1002/pon.717; Freeman Jason R, 2002, Clin Breast Cancer, V3 Suppl 3, pS91, DOI 10.3816/CBC.2002.s.019; Friedman LC, 2006, PSYCHO-ONCOLOGY, V15, P595, DOI 10.1002/pon.992; Ganz PA, 2002, J NATL CANCER I, V94, P39; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Golden C., 1978, STROOP COLOR WORD TE; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; Hack TF, 2006, PSYCHO-ONCOL, V15, P9, DOI 10.1002/pon.907; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Helgeson VS, 2005, PSYCHO-ONCOLOGY, V14, P307, DOI 10.1002/pon.848; Holland KD, 2003, PSYCHOL HEALTH, V18, P15, DOI 10.1080/0887044031000080656; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KAREKEN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P147, DOI 10.1016/0887-6177(94)E0012-E; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Main DS, 2005, PSYCHO-ONCOLOGY, V14, P992, DOI 10.1002/pon.913; MEYERS CA, 1995, LUNG CANCER, V12, P231, DOI 10.1016/0169-5002(95)00446-8; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; Minisini A, 2004, LANCET ONCOL, V5, P273, DOI 10.1016/S1470-2045(04)01465-2; Mols F, 2005, EUR J CANCER, V41, P2613, DOI 10.1016/j.ejca.2005.05.017; *NAT CANC I, 2005, DEXM RED SOM SYMPT C; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Osoba D, 2006, QUAL LIFE RES, V15, P273, DOI 10.1007/s11136-005-0580-5; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Reid-Arndt SA, 2006, NEUROREHABILITATION, V21, P51; REITAN RM, 1955, J CONSULT PSYCHOL, V16, P383; Rugo HS, 2003, SEMIN ONCOL, V30, P749, DOI 10.1053/j.seminoncol.2003.09.008; Saykin Andrew J, 2003, Semin Clin Neuropsychiatry, V8, P201; Schagen SB, 2002, ANN ONCOL, V13, P1387, DOI 10.1093/annonc/mdf241; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Schou I, 2005, QUAL LIFE RES, V14, P1813, DOI 10.1007/s11136-005-4344-z; SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14; Sheldon KM, 2002, BRIT J SOC PSYCHOL, V41, P25, DOI 10.1348/014466602165036; SILBERFARB PM, 1980, AM J PSYCHIAT, V137, P597; Spreen O., 1991, COMPENDIUM NEUROPSYC; STANTON AL, 1993, HEALTH PSYCHOL, V12, P16, DOI 10.1037/0278-6133.12.1.16; Stewart A, 2006, CLIN NEUROPSYCHOL, V20, P76, DOI 10.1080/138540491005875; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; TALLEY AE, PSYCHOL HLT IN PRESS; Tannock IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; Tchen N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; VanOosterhout AGM, 1996, INT J RADIAT ONCOL, V34, P1037, DOI 10.1016/0360-3016(95)02257-0; Visser MRM, 1998, SUPPORT CARE CANCER, V6, P101, DOI 10.1007/s005200050142; Wechsler D, 1997, WMS 3 ADM SCORING MA; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wefel JS, 2004, CANCER-AM CANCER SOC, V100, P2292, DOI 10.1002/cncr.20272; WEINS AN, 1993, CLIN NEUROPSYCHOL, V7, P70; Wenzel LB, 1999, CANCER, V86, P1768, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1768::AID-CNCR19>3.0.CO;2-O; WIENEKE MH, 1995, PSYCHO-ONCOL, V4, P61, DOI 10.1002/pon.2960040108; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME, V3; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	72	73	73	0	14	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	0734-7332			J PSYCHOSOC ONCOL	J. Psychosoc. Oncol.		2009	27	4					415	434		10.1080/07347330903183117			20	Psychology, Social	Psychology	504CZ	WOS:000270592800003	19813133	Green Accepted			2021-06-18	
J	Gebhard, F; Huber-Lang, M				Gebhard, F.; Huber-Lang, M.			Polytrauma - pathophysiology and management principles	LANGENBECKS ARCHIVES OF SURGERY			English	Article						trauma; damage-control orthopedics; ATLS; SIRS; MODS	EMERGENCY-ROOM MANAGEMENT; SEVERELY INJURED PATIENTS; TRAUMATIC BRAIN-INJURY; MULTIPLE TRAUMA; ABDOMINAL-TRAUMA; CARE; COMPLEMENT; PATIENT; SURGERY; NEUTROPHILS	Background Multiple injury results in a complex pathophysiological and immunological response. Depending on the individual injury pattern, the time elapsed after injury, and the systemic "danger response", the surgical treatment has to be modified. Objectives This overview provides new insights in the pathophysiology of the early danger response after polytrauma and outlines the main resulting consequences for surgical management. Results First, synchronically to the clinical assessment, life-saving procedures need to be performed rapidly, such as control of massive intra-thoracic or abdominal bleeding and decompression of the chest and brain, as standardized by advanced trauma life support guidelines. During the second phase of "day-one-surgery" damage-control interventions such as debridement, decompression and temporary fracture stabilization are needed to avoid an excessive molecular and cellular danger response. Trauma-adjusted surgical techniques are crucial to limit the systemic response known to put remote organs at risk. In the "vulnerable phase" when the patient's defense is rather uncontrolled, only "second look" debridement to minimize a "second hit" is recommended. After stabilization of the patient as indicated by improvement of tissue oxygenation, coagulation, and decreased inflammatory mediators, "reconstructive surgery" can be applied. Conclusion Individually adjusted surgical "damage control" and "immune control" are important interactive concepts in polytrauma management.	[Gebhard, F.; Huber-Lang, M.] Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, D-89075 Ulm, Germany	Gebhard, F (corresponding author), Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, Steinhoevelstr 9, D-89075 Ulm, Germany.	florian.gebhard@uniklinik-ulm.de	Huber-Lang, Markus/AAJ-2209-2020				Albers S, 2006, SHOCK, V26, P14, DOI 10.1097/00024382-200610001-00044; Beck A, 2004, UNFALLCHIRURG, V107, P862, DOI 10.1007/s00113-004-0812-0; Biffl WL, 1999, SURGERY, V126, P198, DOI 10.1016/S0039-6060(99)70155-8; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Burkhardt M, 2005, UNFALLCHIRURG, V108, P812, DOI 10.1007/s00113-005-0997-x; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; DELIRE M, 1988, ANN BIOL CLIN-PARIS, V46, P272; ERTEL W, 1994, ZBL CHIR, V119, P159; Flierl MA, 2007, NATURE, V449, P721, DOI 10.1038/nature06185; Flohe S, 2007, LANGENBECK ARCH SURG, V392, P639, DOI 10.1007/s00423-007-0203-4; Frank J, 1996, ZBL CHIR, V121, P943; Gebhard F., 2000, HEFTE UNFALLCHIRURG, V276; HAAS NP, 1995, CLIN ORTHOP RELAT R, P25; Haas NP, 1997, UNFALLCHIRURG, V100, P2, DOI 10.1007/s001130050087; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; Heinzelmann M, 2004, UNFALLCHIRURG, V107, P871, DOI 10.1007/s00113-004-0846-3; Hessmann MH, 2006, ACTA CHIR BELG, V106, P500; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kienlen J, 1999, J CHIR-PARIS, V136, P240; Kobbe P, 2007, UNFALLCHIRURG, V110, P235, DOI 10.1007/s00113-007-1231-9; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Koller M, 2001, INFLAMMATION, V25, P53, DOI 10.1023/A:1007027712387; Kuhne CA, 2004, UNFALLCHIRURG, V107, P851, DOI 10.1007/s00113-004-0813-z; LAMPL L, 1994, ZBL CHIR, V119, P683; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Liener UC, 2006, UNFALLCHIRURG, V109, P447, DOI 10.1007/s00113-005-1048-3; Lindner T, 2004, UNFALLCHIRURG, V107, P892, DOI 10.1007/s00113-004-0849-0; Maghsudi M, 1998, CHIRURG, V69, P313, DOI 10.1007/s001040050419; Matthes G, 2001, ZBL CHIR, V126, P995, DOI 10.1055/s-2001-19658; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Moore EE, 1998, WORLD J SURG, V22, P1184, DOI 10.1007/s002689900542; Mutschler W, 2002, RADIOLOGE, V42, P506, DOI 10.1007/s00117-002-0768-4; Nast-Kolb D, 2006, CHIRURG, V77, P861, DOI 10.1007/s00104-006-1231-2; Nast-Kolb D, 2005, UNFALLCHIRURG, V108, P804, DOI 10.1007/s00113-005-1004-2; Pape HC, 1999, UNFALLCHIRURG, V102, P861, DOI 10.1007/s001130050495; Pape HC, 2004, UNFALLCHIRURG, V107, P927, DOI 10.1007/s00113-004-0848-1; PAPE HC, 2000, MULTIPLE ORGAN FAILU, P279; Platzer P, 2006, EUR SPINE J, V15, P1801, DOI 10.1007/s00586-006-0084-1; Ruchholtz S, 1997, UNFALLCHIRURG, V100, P859, DOI 10.1007/s001130050205; Sauerland S, 2004, UNFALLCHIRURG, V107, P833, DOI 10.1007/s00113-004-0851-6; Sauerland S, 2002, UNFALLCHIRURG, V105, P1022, DOI 10.1007/s00113-002-0514-4; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seekamp A, 2004, UNFALLCHIRURG, V107, P903, DOI 10.1007/s00113-004-0831-x; Siebert H, 2006, UNFALLCHIRURG, V109, P815, DOI 10.1007/s00113-006-1154-x; Stahel PF, 2005, ORTHOPADE, V34, P852, DOI 10.1007/s00132-005-0844-3; Stahel PF, 2005, ORTHOPADE, V34, P823, DOI 10.1007/s00132-005-0842-5; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Staib L, 2004, CHIRURG, V75, P447, DOI 10.1007/s00104-004-0855-3; Toh CH, 2007, J THROMB HAEMOST, V5, P604, DOI 10.1111/j.1538-7836.2007.02313.x; TRACEY KJ, 2002, NATURE, V421, P384; Voggenreiter G, 2004, UNFALLCHIRURG, V107, P881, DOI 10.1007/s00113-004-0837-4; Walz CR, 2007, LANGENBECK ARCH SURG, V392, P339, DOI 10.1007/s00423-007-0164-7; Weber U, 2005, ORTHOPADE, V34, P821, DOI 10.1007/s00132-005-0841-6; Westhoff J, 2003, INJURY, V34, P674, DOI 10.1016/S0020-1383(03)00147-5; Woltmann A, 2004, UNFALLCHIRURG, V107, P911, DOI 10.1007/s00113-004-0829-4; WURB T, 2005, ANAESTHESIST, V54, P763	61	73	88	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1435-2443	1435-2451		LANGENBECK ARCH SURG	Langenbecks Arch. Surg.	NOV	2008	393	6					825	831		10.1007/s00423-008-0334-2			7	Surgery	Surgery	357AS	WOS:000259819300002	18431593				2021-06-18	
J	Hou, SP; Duale, H; Cameron, AA; Abshire, SM; Lyttle, TS; Rabchevsky, AG				Hou, Shaoping; Duale, Hanad; Cameron, Adrian A.; Abshire, Sarah M.; Lyttle, Travis S.; Rabchevsky, Alexander G.			Plasticity of lumbosacral propriospinal neurons is associated with the development of autonomic dysreflexia after thoracic spinal cord transection	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						dorsal gray commissure; dorsal commissural nucleus; neuronal tracers; c-Fos; hypertension; stereology; colorectal distension	SYMPATHETIC PREGANGLIONIC NEURONS; PHASEOLUS-VULGARIS-LEUKOAGGLUTININ; GLUTAMATE-IMMUNOREACTIVE SYNAPSES; DORSAL COMMISSURAL NUCLEUS; TRAUMATIC BRAIN-INJURY; C-FOS PROTEIN; CYTOARCHITECTONIC ORGANIZATION; COMPRESSION INJURY; CORRELATED NEURONS; PRIMARY AFFERENTS	Complete thoracic (T) spinal cord injury (SCI) above the T6 level typically results in autonomic dysreflexia, an abnormal hypertensive condition commonly triggered by nociceptive stimuli below the level of SCI. Overexpression of nerve growth factor in the lumbosacral spinal cord induces profuse sprouting of nociceptive pelvic visceral afferent fibers that correlates with increased hypertension in response to noxious colorectal distension. After complete T4 SCI, we evaluated the plasticity of propriospinal neurons conveying visceral input rostrally to thoracic sympathetic preganglionic neurons. The anterograde tracer biotinylated dextran amine (BDA) was injected into the lumbosacral dorsal gray commissure (DGC) of injured/nontransected rats immediately after injury (acute) or 2 weeks later (delayed). At 1 or 2 weeks after delayed or acute injections, respectively, a higher density (P < 0.05) of BDA(+) fibers was found in thoracic dorsal gray matter of injured vs. nontransected spinal cords. For corroboration, fast blue (FB) or cholera toxin subunit beta (CTb) was injected into the T9 dorsal horns 2 weeks postinjury/nontransection. After 1 week transport, more retrogradely labeled (P G 0.05) DGC propriospinal neurons (T13-S1) were quantified in injured vs. nontransected cords. We also monitored immediate early gene c-fos expression following colorectal distension and found increased (P < 0.01) c-Fos(+) cell numbers throughout the DGC after injury. Collectively, these results imply that, in conjunction with local primary afferent fiber plasticity, injury-induced sprouting of DGC neurons may be a key constituent in relaying visceral sensory input to sympathetic preganglionic neurons that elicit autonomic dysreflexia after high thoracic SCI.	[Hou, Shaoping; Duale, Hanad; Cameron, Adrian A.; Abshire, Sarah M.; Lyttle, Travis S.; Rabchevsky, Alexander G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Hou, Shaoping; Duale, Hanad; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA	Rabchevsky, AG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS049901] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049901, R01 NS049901-01, P30 NS051220] Funding Source: Medline		ABERCROMBIE M, 1946, J ANAT, V80, P37; AlChaer ED, 1996, J NEUROPHYSIOL, V76, P2675; ANDERSON CR, 1994, J NEUROSCI METH, V53, P137, DOI 10.1016/0165-0270(94)90170-8; BACON SJ, 1988, J AUTONOM NERV SYST, V24, P97, DOI 10.1016/0165-1838(88)90140-3; Brown A, 2004, EXP NEUROL, V188, P115, DOI 10.1016/j.expneurol.2004.03.017; Cameron AA, 2006, J NEUROSCI, V26, P2923, DOI 10.1523/JNEUROSCI.4390-05.2006; Chau D, 2000, J NEUROPHYSIOL, V83, P2699; CHUNG KS, 1983, J COMP NEUROL, V217, P47, DOI 10.1002/cne.902170105; CUELLO AC, 1984, J HISTOCHEM CYTOCHEM, V32, P947, DOI 10.1177/32.9.6086744; DAMPNEY RAL, 1994, PHYSIOL REV, V74, P323; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; Diaz-Ruiz A, 2007, NEUROCHEM RES, V32, P57, DOI 10.1007/s11064-006-9225-5; DIETZ GW, 1980, J BIOL CHEM, V255, P612; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Grider MH, 2006, J NEUROSCI METH, V155, P172, DOI 10.1016/j.jneumeth.2005.12.021; Guillery RW, 2002, J COMP NEUROL, V447, P1, DOI 10.1002/cne.10221; HANCOCK MB, 1979, J COMP NEUROL, V183, P65, DOI 10.1002/cne.901830106; Hirshberg RM, 1996, PAIN, V67, P291, DOI 10.1016/0304-3959(96)03127-2; HOLETS V, 1982, NEUROSCIENCE, V7, P1155, DOI 10.1016/0306-4522(82)91123-X; HOSOYA Y, 1994, EXP BRAIN RES, V98, P21; Karlsson AK, 1999, SPINAL CORD, V37, P383, DOI 10.1038/sj.sc.3100867; KRASSIOUKOV AV, 1995, AM J PHYSIOL-HEART C, V268, pH2077; Krassioukov AV, 2002, J NEUROTRAUM, V19, P1521, DOI 10.1089/089771502762300193; Krassioukov AV, 1996, NEUROSCIENCE, V70, P211, DOI 10.1016/0306-4522(95)00294-S; Kratskin IL, 1997, BRAIN RES BULL, V44, P199, DOI 10.1016/S0361-9230(97)00092-0; Krenz NR, 1998, NEUROSCIENCE, V85, P443, DOI 10.1016/S0306-4522(97)00622-2; Krenz NR, 1998, NEUROSCI LETT, V243, P61, DOI 10.1016/S0304-3940(98)00101-3; Landrum LM, 2002, NEUROSCIENCE, V110, P569, DOI 10.1016/S0306-4522(01)00548-6; LINDAN R, 1980, PARAPLEGIA, V18, P285, DOI 10.1038/sc.1980.51; Llewellyn-Smith IJ, 1998, J AUTONOM NERV SYST, V71, P96, DOI 10.1016/S0165-1838(98)00069-1; LLEWELLYNSMITH IJ, 1992, BRAIN RES, V581, P67, DOI 10.1016/0006-8993(92)90345-A; Lu Y, 2001, J COMP NEUROL, V437, P156, DOI 10.1002/cne.1276; Marsh DR, 2002, J NEUROTRAUM, V19, P1531, DOI 10.1089/089771502762300201; MASSON RL, 1991, J COMP NEUROL, V307, P120, DOI 10.1002/cne.903070111; Matsushita M, 1998, EXP BRAIN RES, V119, P356, DOI 10.1007/s002210050351; Mayorov DN, 2001, J NEUROTRAUM, V18, P727, DOI 10.1089/089771501750357663; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MINSON JB, 1994, BRAIN RES, V646, P44, DOI 10.1016/0006-8993(94)90056-6; MOLANDER C, 1989, J COMP NEUROL, V289, P375, DOI 10.1002/cne.902890303; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NESS TJ, 1987, J NEUROPHYSIOL, V57, P1867; Novikov LN, 2001, J NEUROSCI METH, V112, P145, DOI 10.1016/S0165-0270(01)00461-7; Pan B, 2007, AM J PHYSIOL-REG I, V293, pR178, DOI 10.1152/ajpregu.00044.2007; Pan BH, 2005, J NEUROTRAUM, V22, P1399, DOI 10.1089/neu.2005.22.1399; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; PASCUAL JI, 1993, J UROLOGY, V150, P500, DOI 10.1016/S0022-5347(17)35535-0; Petko M, 2000, J COMP NEUROL, V422, P312, DOI 10.1002/(SICI)1096-9861(20000626)422:2<312::AID-CNE11>3.0.CO;2-A; Preston GA, 1996, MOL CELL BIOL, V16, P211; Rabchevsky AG, 2006, PROG BRAIN RES, V152, P265, DOI 10.1016/S0079-6123(05)52017-X; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Rodriguez MJ, 2005, J NEUROCHEM, V95, P651, DOI 10.1111/j.1471-4159.2005.03394.x; ROMAGNANO MA, 1987, J COMP NEUROL, V266, P319, DOI 10.1002/cne.902660303; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; Seki Y, 2008, J COMP NEUROL, V506, P93, DOI 10.1002/cne.21528; SNOW JC, 1978, PARAPLEGIA, V15, P327, DOI 10.1038/sc.1977.49; Steward O., 2007, NEURON, V38, P187, DOI DOI 10.1016/J.NEURON.2007.04.004; Steward O, 2007, NEURON, V54, P191, DOI 10.1016/j.neuron.2007.04.004; Sun D, 2007, J COMP NEUROL, V505, P92, DOI 10.1002/cne.21478; Tang XR, 2003, BRAIN RES, V976, P185, DOI 10.1016/S0006-8993(03)02601-5; THOR KB, 1994, NEUROREPORT, V5, P1673, DOI 10.1097/00001756-199408150-00033; TODD AJ, 1989, NEUROSCIENCE, V31, P799, DOI 10.1016/0306-4522(89)90442-9; Vizzard MA, 2000, AM J PHYSIOL-REG I, V279, pR295; Wang CC, 1999, J COMP NEUROL, V415, P341, DOI 10.1002/(SICI)1096-9861(19991220)415:3<341::AID-CNE3>3.0.CO;2-7; Weaver LC, 2001, J NEUROTRAUM, V18, P1107, DOI 10.1089/08977150152693782; Weaver LC, 1997, NEUROSCIENCE, V81, P535, DOI 10.1016/S0306-4522(97)00151-6; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048; Xu YJ, 2006, BRAIN RES, V1087, P175, DOI 10.1016/j.brainres.2006.03.003; Yaici ED, 2002, INT J IMPOT RES, V14, P151, DOI 10.1038/sj.ijir.3900809; Yaici ED, 2002, NEUROSCIENCE, V114, P945, DOI 10.1016/S0306-4522(02)00367-6; Ye Y, 2000, J COMP NEUROL, V420, P127	73	73	74	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	AUG 1	2008	509	4					382	399		10.1002/cne.21771			18	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	323XS	WOS:000257482400004	18512692	Green Accepted			2021-06-18	
J	Griesbach, GS; Hovda, DA; Gomez-Pinilla, F; Sutton, RL				Griesbach, G. S.; Hovda, D. A.; Gomez-Pinilla, F.; Sutton, R. L.			Voluntary exercise or amphetamine treatment, but not the combination, increases hippocampal brain-derived neurotrophic factor and synapsin I following cortical contusion injury in rats	NEUROSCIENCE			English	Article						controlled cortical impact; norepinephrine; oxidized proteins; running wheel; traumatic brain injury	VAGUS NERVE-STIMULATION; SENSORIMOTOR CORTEX INJURY; PHYSICAL-ACTIVITY; FACTOR EXPRESSION; GENE-EXPRESSION; MOTOR RECOVERY; GROWTH-FACTOR; COGNITIVE DEFICITS; OXIDATIVE STRESS; MESSENGER-RNA	Prior work has shown that d-amphetamine (AMPH) treatment or voluntary exercise improves cognitive functions after traumatic brain injury (TBI). In addition, voluntary exercise increases levels of brain-derived neurotrophic factor (BDNF). The current study was conducted to determine how AMPH and exercise treatments, either alone or in combination, affect molecular events that may underlie recovery following controlled cortical impact (CCI) injury in rats. We also determined if these treatments reduced injury-induced oxidative stress. Following a CCI or sham injury, rats received AMPH (1 mg/kg/day) or saline treatment via an ALZET (R) pump and were housed with or without access to a running wheel for 7 days. CCI rats ran significantly less than sham controls, but exercise level was not altered by drug treatment. On day 7 the hippocampus ipsilateral to injury was harvested and BDNF, synapsin I and phosphorylated (P) -synapsin I proteins were quantified. Exercise or AMPH alone significantly increased BDNF protein in sham and CCI rats, but this effect was lost with the combined treatment. In sham-injured rats synapsin I increased significantly after AMPH or exercise, but did not increase after combined treatment. Synapsin levels, including the P-synapsin/total synapsin ratio, were reduced from sham controls in the saline-treated CCI groups, with or without exercise. AMPH treatment significantly increased the P-synapsin/total synapsin ratio after CCI, an effect that was attenuated by combining AMPH with exercise. Exercise or AMPH treatment alone significantly decreased hippocampal carbonyl groups on oxidized proteins in the CCI rats, compared with saline-treated sedentary counterparts, but this reduction in a marker of oxidative stress was not found with the combination of exercise and AMPH treatment. These results indicate that, whereas exercise or AMPH treatment alone may induce plasticity and reduce oxidative stress after TEI, combining these treatments may cancel each other's therapeutic effects. Published by Elsevier Ltd on behalf of IBRO.	[Griesbach, G. S.; Hovda, D. A.; Gomez-Pinilla, F.; Sutton, R. L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90095 USA; [Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol Sci, Los Angeles, CA 90095 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS027544-12, R01 NS050465-04, NS50465, R01 NS027544, R01 NS050465, NS27544, R21 NS048535-01A1, R21 NS048535, R01 NS050465-03, R21 NS048535-02, NS048535, R01 NS027544-10A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465, R01NS027544, R21NS048535] Funding Source: NIH RePORTER		Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Akbarian S, 2002, J NEUROSCI, V22, P4153, DOI 10.1523/JNEUROSCI.22-10-04153.2002; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; Butefisch CM, 2002, ANN NEUROL, V51, P59, DOI 10.1002/ana.10056; Chen MJ, 2007, CELL SIGNAL, V19, P114, DOI 10.1016/j.cellsig.2006.05.028; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Clough RW, 2007, NEUROSCIENCE, V147, P286, DOI 10.1016/j.neuroscience.2007.04.043; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3; Dunn AL, 1996, MED SCI SPORT EXER, V28, P204, DOI 10.1097/00005768-199602000-00008; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DunnMeynell AA, 1997, J NEUROTRAUM, V14, P43, DOI 10.1089/neu.1997.14.43; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140; FLORIN SM, 1994, BRAIN RES, V654, P53, DOI 10.1016/0006-8993(94)91570-9; Follesa P, 2007, BRAIN RES, V1179, P28, DOI 10.1016/j.brainres.2007.08.045; Fumagalli F, 2003, MOL PSYCHIATR, V8, P898, DOI 10.1038/sj.mp.4001370; Garcia C, 2003, NEUROSCIENCE, V119, P721, DOI 10.1016/S0306-4522(03)00192-1; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; HOVDA DA, 1996, NEUROTRAUMA, P1459; Juric DM, 2006, BRAIN RES, V1108, P54, DOI 10.1016/j.brainres.2006.06.008; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kozisek ME, 2008, NEUROPHARMACOLOGY, V54, P251, DOI 10.1016/j.neuropharm.2007.08.001; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; LANTERI C, 2007, NEUROPSYCHOPHARMACOL, DOI DOI 10.1038/SJ.NPP.1301548D0I; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Luellen BA, 2007, GENES BRAIN BEHAV, V6, P482, DOI 10.1111/j.1601-183X.2006.00279.x; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Meredith GE, 2002, BRAIN RES, V949, P218, DOI 10.1016/S0006-8993(02)03160-8; Miklic S, 2004, INT J DEV NEUROSCI, V22, P119, DOI 10.1016/j.ijdevenue.2004.03.001; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pae CU, 2007, MED HYPOTHESES, V69, P132, DOI 10.1016/j.mehy.2006.11.009; Pan YX, 2007, HYPERTENSION, V49, P519, DOI 10.1161/01.HYP.0000256955.74461.93; Peng Q, 2008, EXP NEUROL, V210, P154, DOI 10.1016/j.expneurol.2007.10.015; Prasad RM, 1995, RESTOR NEUROL NEUROS, V9, P65, DOI 10.3233/RNN-1995-9201; Ramic M, 2006, BRAIN RES, V1111, P176, DOI 10.1016/j.brainres.2006.06.063; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Russo-Neustadt A, 1999, NEUROPSYCHOPHARMACOL, V21, P679, DOI 10.1016/S0893-133X(99)00059-7; Russo-Neustadt A, 2001, BEHAV BRAIN RES, V120, P87, DOI 10.1016/S0166-4328(00)00364-8; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Russo-Neustadt AA, 2004, NEUROPSYCHOPHARMACOL, V29, P2189, DOI 10.1038/sj.npp.1300514; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salomon L, 2006, P NATL ACAD SCI USA, V103, P7476, DOI 10.1073/pnas.0600839103; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; SUTTON RL, 1994, NEUROLOGICAL REHABIL, P469; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu B, 2006, BIOCHEM BIOPH RES CO, V347, P656, DOI 10.1016/j.bbrc.2006.06.117; ZAFRA F, 1992, J NEUROSCI, V12, P4793	89	73	74	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 23	2008	154	2					530	540		10.1016/j.neuroscience.2008.04.003			11	Neurosciences	Neurosciences & Neurology	319OB	WOS:000257172200013	18479829	Green Accepted			2021-06-18	
J	Ho, CL; Wang, CM; Lee, KK; Ng, I; Ang, BT				Ho, Chi Long; Wang, Chee Meng; Lee, Kah Keow; Ng, Ivan; Ang, Beng Ti			Cerebral oxygenation, vascular reactivity, and neurochemistry following decompressive craniectomy for severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral microdialysis; cerebral oxygenation; decompressive craniectorny; intracranial pressure; vascular reactivity	SEVERE HEAD-INJURY; TISSUE OXYGEN; INTRACRANIAL HYPERTENSION; VASOMOTOR REACTIVITY; INFARCTION; PRESSURE; AUTOREGULATION; PREVENTION; MANAGEMENT; RELEASE	Object. This study addresses the changes in brain oxygenation, cerebrovascular reactivity, and cerebral neurochemistry in patients following decompressive craniectomy for the control of elevated intracranial pressure (ICP) after severe traumatic brain injury (TBI). Methods. Sixteen consecutive patients with isolated TBI and elevated ICP, who were refractory to maximal medical therapy, underwent decompressive craniectomy over a 1-year period. Thirteen patients were male and 3 were female. The mean age of the patients was 38 years and the median Glasgow Coma Scale score on admission was 5. Results. Six months following TBI, 11 patients had a poor outcome (Group 1, Glasgow Outcome Scale [GOS] Score 1-3), whereas the remaining 5 patients had a favorable outcome (Group 2, GOS Score 4 or 5). Decompressive craniectomy resulted in a significant reduction (p < 0.001) in the mean ICP and cerebrovascular pressure reactivity index to autoregulatory values (< 0.3) in both groups of patients. There was a significant improvement in brain tissue oxygenation (PbtO(2)) in Group 2 patients from 3 to 17 mm Hg and an 85% reduction in episodes of cerebral ischemia. In addition, the durations of abnormal PbtO(2) and biochemical indices were significantly reduced in Group 2 patients after decompressive craniectomy, but there was no improvement in the biochemical indices in Group 1 patients despite surgery. Conclusions. Decompressive craniectomy, when used appropriately in protocol-driven intensive care regimens for the treatment of recalcitrant elevated ICP, is associated with a return of abnormal metabolic parameters to normal values in patients with eventually favorable outcomes.	[Ho, Chi Long; Wang, Chee Meng; Lee, Kah Keow; Ng, Ivan; Ang, Beng Ti] Natl Inst Neurosci, Dept Neurosurg, Singapore 308433, Singapore	Ang, BT (corresponding author), Natl Inst Neurosci, Dept Neurosurg, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	beng_ti_ang@nni.com.sg					Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Johnston JB, 1902, J COMP NEUROL, V12, P1, DOI 10.1002/cne.910120102; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; MAX AR, 1996, YB INTENSIVE CARE EM, P707; Mulvey JM, 2004, NEUROCRIT CARE, V1, P391, DOI 10.1385/NCC:1:3:391; Munch E, 2000, NEUROSURGERY, V47, P315; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosner Michael J., 1993, P57; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; UNTERBERG AW, 1997, J TRAUMA, V42, P532; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Zauner A, 1996, ACT NEUR S, V67, P40	35	73	77	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2008	108	5					943	949		10.3171/JNS/2008/108/5/0943			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	293RE	WOS:000255351600007	18447711				2021-06-18	
J	Utagawa, A; Truettner, JS; Dietrich, WD; Bramlett, HM				Utagawa, Akira; Truettner, Jessie S.; Dietrich, W. Dalton; Bramlett, Helen M.			Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						brain trauma; cytokine; leukocytes; inflammation; polytrauma	NEURONAL CELL-DEATH; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; BARRIER PERMEABILITY; ENDOTHELIAL-CELLS; ACUTE-PHASE; INTERLEUKIN-1; DAMAGE; CYTOKINES; DYSFUNCTION	The proinflammatory cytokine interleukin-1 beta (IL-1 beta) is induced rapidly after traumatic brain injury (TBI) and contributes to the inflammatory events that lead to neuronal loss. Although an important source of IL-1 beta is from the injured brain itself, in patients with multiple organ trauma (polytrauma) IL-1 beta is also released into the bloodstream which may potentially influence brain vulnerability. The purpose of this study was to determine the effects of systemic inflammation induced by peripheral administration of IL-1 beta on histopathological and behavioral outcome after moderate fluid percussion (FP) brain injury in rats. At 30 minor 24 h after TBI, saline, 20 mu g/kg or 40 mu g/kg of IL-1 beta was injected (n=4-9/group) intraperitoneally(IP). Sham operated animals (n=9) received either saline or IL-1 beta (20 or 40 mu g/kg) injections. The somatosensory tactile placing test was administered at 1, 2 and 3 days posttrauma. IL-1 beta-treated animals showed significant placing deficits compared to vehicle-treated TBI animals. Three days after injection, contusion areas and volumes were significantly increased (p < 0.05) with both IL-1 beta doses and at both treatment times compared to vehicle-treated animals. IL-1 beta-treated rats showed more contusion injury and hippocampal neuronal damage as well as enhanced perivascular neutrophil accumulation. Cortical IL-1rl mRNA increased as early as I It following TBI, peaking at 24 h and remained elevated 3 days posttrauma. These data show that the posttraurnatic administration of IL-1 beta significantly aggravates behavioral outcome and increases overall contusion volume after TBI. Increased systemic inflammatory processes, including extravasation of activated leukocytes and proinflammatory cytokines could participate in this detrimental outcome. Because peripherally circulating cytokines and other neurotoxic factors may be increased following multi-organ trauma, these findings may be important in targeting therapeutic interventions in this patient population. (C) 2008 Elsevier Inc. All rights reserved.	[Utagawa, Akira; Truettner, Jessie S.; Dietrich, W. Dalton; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Bramlett, HM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,Suite 3-18, Miami, FL 33136 USA.	hbramlett@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291, R01NS056072] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS030291, R01 NS056072, P50 NS030291-15, R01 NS042133-05, NS 42133, NS 30291, R01 NS042133] Funding Source: Medline		Alheim K, 1998, ANN NY ACAD SCI, V840, P51, DOI 10.1111/j.1749-6632.1998.tb09548.x; Ando Tomoaki, 2007, BMC Physiology, V7, P10, DOI 10.1186/1472-6793-7-10; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Conti B, 2004, FRONT BIOSCI-LANDMRK, V9, P1433, DOI 10.2741/1341; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; *DEP VET AFF, 2005, VET HLTH AD DIR, P2; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DINARELLO CA, 1984, SURV IMMUNOL RES, V3, P29; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gavins F, 2007, MICROCIRCULATION, V14, P667, DOI 10.1080/10739680701404903; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Shahbazian LM, 1999, METABOLISM, V48, P1397, DOI 10.1016/S0026-0495(99)90149-X; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Wilson RF, 2001, NEUROL RES, V23, P117, DOI 10.1179/016164101101198415; Wong D, 2007, J NEUROIMMUNOL, V184, P136, DOI 10.1016/j.jneuroim.2006.12.003; ZILLES L, 1985, CORTEX RAT STEREOTAX	46	73	78	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2008	211	1					283	291		10.1016/j.expneurol.2008.02.001			9	Neurosciences	Neurosciences & Neurology	298ZM	WOS:000255725600029	18355811	Green Accepted			2021-06-18	
J	Sun, DA; Deshpande, LS; Sombati, S; Baranova, A; Wilson, MS; Hamm, RJ; DeLorenzo, RJ				Sun, David A.; Deshpande, Laxmikant S.; Sombati, Sompong; Baranova, Anya; Wilson, Margaret S.; Hamm, Robert J.; DeLorenzo, Robert J.			Traumatic brain injury causes a long-lasting calcium (Ca2+)-plateau of elevated intracellular Ca levels and altered Ca2+ homeostatic mechanisms in hippocampal neurons surviving brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						acute dissociation of neuron; calcium dynamics; Fura-2/Fura-FF; Sprague-Dawley rats	STROKE-INDUCED EPILEPSY; TEMPORAL-LOBE EPILEPSY; IN-VITRO MODEL; CELL-DEATH; COGNITIVE DEFICITS; ACQUIRED EPILEPSY; CORTICAL-NEURONS; GENE-EXPRESSION; RAT; EXCHANGE	Traumatic brain injury (TBI) survivors often suffer chronically from significant morbidity associated with cognitive deficits, behavioral difficulties and a post-traumatic syndrome and thus it is important to understand the pathophysiology of these long-term plasticity changes after TBI. Calcium (Ca2+) has been implicated in the pathophysiology of TBI-induced neuronal death and other forms of brain injury including stroke and status epilepticus. However, the potential role of long-term changes in neuronal Ca2+ dynamics after TBI has not been evaluated. In the present study, we measured basal free intracellular Ca2+ concentration ([Ca2+](i)) in acutely isolated CA3 hippocampal neurons from Sprague-Dawley rats at 1, 7 and 30 days after moderate central fluid percussion injury. Basal [Ca2+](i) was significantly elevated when measured 1 and 7 days post-TBI without evidence of neuronal death. Basal [Ca2+](i) returned to normal when measured 30 days post-TBI. In contrast, abnormalities in Ca2+ homeostasis were found for as long as 30 days after TBI. Studies evaluating the mechanisms underlying the altered Ca2+ homeostasis in TBI neurons indicated that necrotic or apoptotic cell death and abnormalities in Ca2+ influx and efflux mechanisms could not account for these changes and suggested that long-term changes in Ca2+ buffering or Ca2+ sequestration/release mechanisms underlie these changes in Ca2+ homeostasis after TBI. Further elucidation of the mechanisms of altered Ca2+ homeostasis in traumatized, surviving neurons in TBI may offer novel therapeutic interventions that may contribute to the treatment and relief of some of the morbidity associated with TBI.	[Deshpande, Laxmikant S.; Sombati, Sompong; DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA; [Sun, David A.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; [Baranova, Anya; DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; [Baranova, Anya; Hamm, Robert J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23298 USA; [Wilson, Margaret S.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA	DeLorenzo, RJ (corresponding author), Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA.	rdeloren@hsc.vcu.edu	Deshpande, Laxmikant S./B-7679-2013	Deshpande, Laxmikant S./0000-0003-1491-1561	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS058213-01, U01NS058213, R01NS052529, U01 NS058213, R01 NS052529-01A2, R01 NS051505-01A2, R01 NS052529-03, R01 NS052529, R01 NS051505-03, R01 NS051505-02, U01 NS058213-03, R01 NS052529-02, U01 NS058213-02, R01NS051505, R01 NS051505] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051505, R01NS052529, U01NS058213] Funding Source: NIH RePORTER		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Annunziato L, 2004, PHARMACOL REV, V56, P633, DOI 10.1124/pr.56.4.5; Blaustein MP, 1999, PHYSIOL REV, V79, P763; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; *CDCP, 2002, TRAUM BRAIN INJ US; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P2139; GLEASON E, 1995, J NEUROSCI, V15, P3612; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haugland R.P., 1996, HDB FLUORESCENT PROB, V6th, P503; Hauser WA, 1990, EPILEPSY FREQUENCY C; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hyrc KB, 2000, CELL CALCIUM, V27, P75, DOI 10.1054/ceca.1999.0092; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Morris TA, 1999, J NEUROSCI, V19, P8234; Morris TA, 2000, MOL BRAIN RES, V79, P138, DOI 10.1016/S0169-328X(00)00112-1; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL; Pal S, 2000, CELL CALCIUM, V28, P181, DOI 10.1054/ceca.2000.0146; Pal S, 1999, BRAIN RES, V851, P20, DOI 10.1016/S0006-8993(99)02035-1; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raza M, 2004, P NATL ACAD SCI USA, V101, P17522, DOI 10.1073/pnas.0408155101; Raza M, 2001, BRAIN RES, V903, P1, DOI 10.1016/S0006-8993(01)02127-8; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sidky AO, 1997, J PHYSIOL-LONDON, V504, P579, DOI 10.1111/j.1469-7793.1997.579bd.x; Sun DA, 2004, CELL CALCIUM, V35, P155, DOI 10.1016/j.ceca.2003.09.003; Sun DA, 2002, EPILEPSIA, V43, P1296, DOI 10.1046/j.1528-1157.2002.09702.x; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	50	73	75	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	APR	2008	27	7					1659	1672		10.1111/j.1460-9568.2008.06156.x			14	Neurosciences	Neurosciences & Neurology	282HX	WOS:000254559600008	18371074	Green Accepted			2021-06-18	
J	Chiaretti, A; Antonelli, A; Mastrangelo, A; Pezzotti, P; Tortorolo, L; Tosi, F; Genovese, O				Chiaretti, Antonio; Antonelli, Alessia; Mastrangelo, Antonio; Pezzotti, Patrizio; Tortorolo, Luca; Tosi, Federica; Genovese, Orazio			Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						interleukin-6; nerve growth factor; neuroinflammation; neuroprotection; traumatic brain injury	CEREBROSPINAL-FLUID; HEAD-INJURY; CHOLINERGIC NEURONS; NEUROTROPHIC FACTOR; TRANSGENIC MICE; SERUM; ASTROCYTES; RECEPTOR; DEATH; OVEREXPRESSION	Secondary brain damage after traumatic brain injury ( TBI) involves neuro-inflammatory mechanisms that are mainly dependent on the intracerebral production of cytokines. Interleukin-6 ( IL-6) may have a role both in the pathogenesis of neuronal damage and in the recovery mechanisms of injured neurons through the modulation of nerve growth factor ( NGF) biosynthesis. However, the relationship between IL-6 and NGF expression and the severity and outcome of TBI remains controversial. We have conducted a prospective observational clinical study to determine whether the concentration of IL-6 and NGF in the cerebrospinal fluid ( CSF) of children with TBI correlates with the severity of the injury and neurologic outcome of patients. CSF samples were collected from 29 children at 2 h ( time T1) and 48 h ( time T2) after severe TBI, and from 31 matched controls. TBI severity was evaluated by Glasgow Coma Scale ( GCS) and neurologic outcome by Glasgow Outcome Score ( GOS). CSF concentrations of IL-6 and NGF were measured by immunoenzymatic assays. Early NGF concentrations ( T1) correlated significantly with head injury severity, whereas no correlation was found between GCS and IL-6. Furthermore, IL-6 and NGF upregulation after injury was associated with better neurologic outcomes. Based on these findings, we posit that NGF expression is a useful marker of brain damage following severe TBI. Moreover, the early upregulation of both IL-6 and NGF, which correlates with a favorable neurologic outcome, may reflect an endogenous attempt at neuroprotection in response to the damaging biochemical and molecular cascades triggered by traumatic insult.	[Chiaretti, Antonio] Policlin Gemelli, Terapia Intens Pediat, I-00168 Rome, Italy; [Chiaretti, Antonio; Antonelli, Alessia; Mastrangelo, Antonio; Tortorolo, Luca; Tosi, Federica; Genovese, Orazio] Catholic Univ, Sch Med, Pediat Intens Care Unit, Rome, Italy; [Pezzotti, Patrizio] Agcy Publ Hlth Lazio Reg, Rome, Italy	Chiaretti, A (corresponding author), Policlin Gemelli, Terapia Intens Pediat, 1 Largo Gemelli, I-00168 Rome, Italy.	achiaretti@yahoo.it		GENOVESE, Orazio/0000-0002-1989-1363			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barde Y. A., 1994, PROG CLIN BIOL RES, V390, P1855; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Johnston MV, 2005, BRAIN PATHOL, V15, P234; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; Juric DM, 2001, INT J DEV NEUROSCI, V19, P675, DOI 10.1016/S0736-5748(01)00044-2; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Luk YO, 2004, DRUG DELIV, V11, P319, DOI 10.1080/10717540490494104; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Robertson Charlene M T, 2002, Pediatr Crit Care Med, V3, P345, DOI 10.1097/00130478-200210000-00003; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217	46	73	75	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2008	25	3					225	234		10.1089/neu.2007.0405			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	282PJ	WOS:000254579400006	18352836				2021-06-18	
J	Graham, DP; Cardon, AL				Graham, David P.; Cardon, Aaron L.			An Update on Substance Use and Treatment following Traumatic Brain Injury	ADDICTION REVIEWS 2008	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article						traumatic brain injury; substance abuse; prevalence; treatment outcome; review	ALCOHOL-USE PATTERNS; ABUSE TREATMENT; HEAD-INJURY; DRUG-USE; REHABILITATION; PREVALENCE; OUTCOMES; PROGRAM; INDIVIDUALS; POPULATION	Traumatic brain injury (TBI) is a leading cause of mortality and morbidity among young adults. Substance abusers constitute a disproportionate percentage of these patients. A history of substance abuse predicts increased disability, poorer prognosis, and delayed recovery. While consensus in the literature indicates that substance-abuse rates decline following injury, conflicting literature shows a significant history of brain injury in addicts. We reviewed the literature on substance abuse after TBI to explore the state of knowledge on TBI as a risk factor for substance abuse. While recent reviews regarding substance abuse in TBI patients concur that substance-abuse rates decline even after mild TBI, an emerging literature suggests mild TBI may cause subtle impairments in cognitive, executive, and decision-making functions that are often poorly recognized in early diagnosis and treatment. When combined with difficulties in psychosocial adjustment and coping skills, these impairments may increase the risk for chronic substance abuse in a subset of TBI patients. Preliminary results from veterans indicate these patterns hold in a combat-related post-traumatic stress disorder population with TBI. This increasingly prevalent combination presents a specific challenge in rehabilitation. While this comorbidity presents a challenge for the successful treatment and rehabilitation of both disorders, there is sparse evidence to recommend any specific treatment strategy for these individuals. Mild TBI and substance abuse are bidirectionally related both for risks and treatment. Further understanding the neuropsychiatric pathology and different effects of different types of injuries will likely improve the implementation of effective treatments for each of these two conditions.	[Graham, David P.] Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res, Houston, TX 77030 USA; [Graham, David P.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA; [Graham, David P.] Menninger Dept Psychiat & Behav Sci, Houston, TX USA; [Graham, David P.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA; [Cardon, Aaron L.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA	Graham, DP (corresponding author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res, 2002 Holcombe, Houston, TX 77030 USA.	david.graham@med.va.gov	Graham, David/J-1158-2014				[Anonymous], 1998, REH PERS TRAUM BRAIN; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; CORRIGAN JD, 2005, REHABILITATION TRAUM, P133; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; Cox WM, 2003, J ADDICT DIS, V22, P93, DOI 10.1300/J069v22n01_07; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; DONOVAN NJ, 1994, AM J PSYCHIAT, V151, P618; Ederoth P, 2004, BRIT J CLIN PHARMACO, V57, P427, DOI 10.1046/j.1365-2125.2003.02032.x; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Heinemann AW, 2004, REHABIL PSYCHOL, V49, P156, DOI 10.1037/0090-5550.49.2.156; HENSOLD TC, 1997, BRAIN INJURY, V20, P369; HESTAD K, 1995, SCAND J PSYCHOL, V36, P246, DOI 10.1111/j.1467-9450.1995.tb00984.x; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; HOOFT PJ, 1994, INT J LEGAL MED, V106, P328, DOI 10.1007/BF01224781; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LANGLEY MJ, 1991, ADV BRAIN INJURY REH; Martin CD, 2006, PSYCHIATRY, V69, P351, DOI 10.1521/psyc.2006.69.4.351; McCullagh S, 2005, TXB TRAUMATIC BRAIN, P321; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Payne HC, 2000, BRAIN INJURY, V14, P479, DOI 10.1080/026990500120583; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Regard M, 2003, COGN BEHAV NEUROL, V16, P47, DOI 10.1097/00146965-200303000-00006; Robaei D, 2004, MED J AUSTRALIA, V181, P329, DOI 10.5694/j.1326-5377.2004.tb06302.x; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suarez JI, 1999, CRIT CARE MED, V27, P262, DOI 10.1097/00003246-199902000-00025; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Turner AP, 2003, ARCH PHYS MED REHAB, V84, P358, DOI 10.1053/apmr.2003.50107; Vungkhanching M, 2007, J HEAD TRAUMA REHAB, V22, P167, DOI 10.1097/01.HTR.0000271117.19652.98; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003	54	73	76	1	20	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923			ANN NY ACAD SCI	Ann.NY Acad.Sci.		2008	1141						148	162		10.1196/annals.1441.029			15	Multidisciplinary Sciences; Neurosciences	Science & Technology - Other Topics; Neurosciences & Neurology	BIM56	WOS:000260859100008	18991956				2021-06-18	
J	Singh, M; Sumien, N; Kyser, C; Simpkins, JW				Singh, Meharvan; Sumien, Nathalie; Kyser, Cheryl; Simpkins, James W.			Estrogens and progesterone as neuroprotectants: what animal models teach us	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						estrogens; progestins; neuroprotection; Alzheimer's disease; animal models; review	HEALTH INITIATIVE MEMORY; CEREBRAL-ARTERY OCCLUSION; FEMALE C57BL/6J MICE; CONJUGATED EQUINE ESTROGENS; RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; SPRAGUE-DAWLEY RATS; POSTMENOPAUSAL WOMEN; ISCHEMIC DAMAGE	Estradiol and progesterone are two steroid hormones that target a variety of organ systems, including the heart, the bone and the brain. With respect to the latter, a large volume of basic science studies support the neuroprotective role of estradiol and/or progesterone. In fact, the results of such studies prompted the assessment of these hormones as protective agents against such disorders as Alzheimer's disease, stroke and traumatic brain injury. Interestingly, results from the Women's Health Initiative (WHI) yielded results that appeared to be inconsistent with the data derived from in vitro and in vivo models. However, we argue that the results from the basic science studies were not inconsistent with the clinical trials, but rather, are consistent with, and may even have predicted, the results from the WHI. To illustrate this point, we review here certain in vivo paradigms that have been used to assess the protective effects of estrogens and progesterone, and describe how the results from these animal models point to the importance of the type of hormone, the age of the subjects and the method of hormone administration, in determining whether or not hormones are neuroprotective.	[Singh, Meharvan; Sumien, Nathalie; Kyser, Cheryl; Simpkins, James W.] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	Singh, M (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	msingh@hsc.unt.edu		Singh, Meharvan/0000-0002-8072-1769	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054651, R01NS054687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026672, P01AG022550, P01AG010485] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 22550, AG 10485, P01 AG022550, AG 26672, P01 AG010485, R21 AG026672] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS054687-01A2, R01 NS054651, R01 NS054651-01A2, R01 NS054687] Funding Source: Medline		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JF, 2001, ANESTH ANALG, V92, P1520, DOI 10.1097/00000539-200106000-00033; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chin M, 2005, AM J PATHOL, V166, P1629, DOI 10.1016/S0002-9440(10)62473-X; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Dabrosin C, 2002, AM J PATHOL, V161, P909, DOI 10.1016/S0002-9440(10)64251-4; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; Gibbs RB, 1998, BRAIN RES, V787, P259, DOI 10.1016/S0006-8993(97)01511-4; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G; GORDON MN, 1986, BIOL REPROD, V35, P1088, DOI 10.1095/biolreprod35.5.1088; Green PS, 2005, ENDOCRINOLOGY, V146, P2774, DOI 10.1210/en.2004-1433; Greenberg LH, 2004, AM J OBSTET GYNECOL, V190, P1788, DOI 10.1016/j.ajog.2004.02.047; Greenberg LH, 2004, AM J OBSTET GYNECOL, V190, P1796; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; HENDERSON VW, 2007, AM ACAD NEUROLOGY; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; IGUCHI T, 1986, ACTA ANAT, V127, P110; Jezierski MK, 2000, MOL BRAIN RES, V85, P77, DOI 10.1016/S0169-328X(00)00244-8; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jung EY, 2004, J VET MED SCI, V66, P1347, DOI 10.1292/jvms.66.1347; Jung ME, 2002, ALCOHOL, V26, P83, DOI 10.1016/S0741-8329(01)00199-9; KAUR P, 2007, J NEUROSCI RES; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Latham KA, 2003, J IMMUNOL, V171, P5820, DOI 10.4049/jimmunol.171.11.5820; Lee Beom Jun, 2004, J Vet Sci, V5, P227; Littleton-Kearney MT, 2005, J CEREBR BLOOD F MET, V25, P421, DOI 10.1038/sj.jcbfm.9600052; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; Luine VN, 1998, HORM BEHAV, V34, P149, DOI 10.1006/hbeh.1998.1473; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Miller L, 1998, J IMMUNOL, V160, P5098; MOBBS CV, 1984, BIOL REPROD, V30, P556, DOI 10.1095/biolreprod30.3.556; MOBBS CV, 1985, BIOL REPROD, V32, P1010, DOI 10.1095/biolreprod32.5.1010; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Nordell VL, 2003, NEUROBIOL AGING, V24, P733, DOI 10.1016/S0197-4580(02)00193-8; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROSENBLUM WI, 1985, THROMB RES, V39, P253, DOI 10.1016/0049-3848(85)90220-8; ROSENBLUM WI, 1985, STROKE, V16, P980, DOI 10.1161/01.STR.16.6.980; Savonenko AV, 2003, NEUROSCIENCE, V119, P821, DOI 10.1016/S0306-4522(03)00213-6; Sawada H, 2000, FASEB J, V14, P1202; Shi J, 2001, STROKE, V32, P987, DOI 10.1161/01.STR.32.4.987; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; SOHRABJI F, 1994, J NEUROSCI, V14, P459; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; SUGO N, 2001, SOC NEUR 31 ANN M; THEODORSSON A, 2005, PEPTIDES; Tse J, 1999, ATHEROSCLEROSIS, V144, P303, DOI 10.1016/S0021-9150(98)00325-6; van den Berg MP, 2004, PHARM RES-DORDR, V21, P799, DOI 10.1023/B:PHAM.0000026431.55383.69; Verdu EF, 2002, AM J PHYSIOL-GASTR L, V283, pG27, DOI 10.1152/ajpgi.00460.2001; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Yang SH, 2001, J CEREBR BLOOD F MET, V21, P174, DOI 10.1097/00004647-200102000-00009	69	73	73	0	5	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	JAN 1	2008	13						1083	1089		10.2741/2746			7	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	299SQ	WOS:000255775700090	17981614	Green Accepted			2021-06-18	
J	Scheid, R; Ott, DV; Roth, H; Schroeter, ML; Von Cramon, DY				Scheid, Rainer; Ott, Derek V.; Roth, Henrik; Schroeter, Matthias L.; Von Cramon, D. Yves			Comparative magnetic resonance imaging at 1.5 and 3 tesla for the evaluation of traumatic microbleeds	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; diagnosis; high-field MR imaging; traumatic microbleeds	DIFFUSE AXONAL INJURY; HEAD-INJURY; MRI; HEMOSIDERIN; HEMORRHAGE; CHILDREN; SCALE; COMA	Traumatic microbleeds (TMBs) can be regarded as a radiological marker of diffuse axonal injury (DAI). We sought to investigate the impact of the field strengths on the depiction of TMBs by T2*-weighted gradient echo magnetic resonance imaging (MRI). By the use of comparative MRI of 14 patients (age range, 22-62 years) on 1.5-and a 3 T (Tesla) systems at a median time interval of 61 months after traumatic brain injury (TBI), we found 239 (range 0.5-48.5, median 7.5) TMBs at 1.5 T, and 470 (range 2-118, median 18.5) TMBs at 3 T, respectively (p = 0.001). However, in all but one patients MRI at 1.5 T also clearly showed TMBs. A significant negative correlation between the number of TMBs and the time interval TBI-MRI was observed, which was weaker for the imaging at 3 T (r(s) = -0.798; p = 0.001; and r(s) = -0.649; p = 0.012, respectively). In conclusion, T2*-weighted gradient-echo MRI at 3 T is superior as compared to MRI at 1.5 T for the detection of TMBs. Nevertheless, in clinical practice, MRI at 1.5 T seems to be sufficient for this purpose. MRI at 3 T may be appropriate if there is a strong clinical suspicion of DAI, despite unremarkable routine MRI, and possibly also if evidence of DAI is sought after a long interval from trauma.	[Scheid, Rainer; Schroeter, Matthias L.; Von Cramon, D. Yves] Univ Leipzig, Day Clin Cognit Neurol, D-04103 Leipzig, Germany; [Scheid, Rainer; Ott, Derek V.; Schroeter, Matthias L.; Von Cramon, D. Yves] Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany; [Roth, Henrik] Univ Leipzig, Dept Radiol, D-7010 Leipzig, Germany	Scheid, R (corresponding author), Univ Leipzig, Day Clin Cognit Neurol, Liebigstr 22a, D-04103 Leipzig, Germany.	scheid@cbs.mpg.de					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Ezaki Y, 2006, ACTA NEUROCHIR, V148, P547, DOI 10.1007/s00701-005-0692-2; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Fiehler J, 2006, INT J STROKE, V1, P122, DOI 10.1111/j.1747-4949.2006.00042.x; Graham DI GT, 2000, HEAD INJURY, P133; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	18	73	76	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1811	1816		10.1089/neu.2007.0382			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000003	18159992				2021-06-18	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Zhang, ZG; Lu, C; Chopp, M				Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Zhang, Zheng Gang; Lu, Chang; Chopp, Michael			Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin	JOURNAL OF NEUROSURGERY			English	Article						carbamylated erythropoietin; erythropoietin; hematocrit; rat; traumatic brain injury	ENHANCES NEUROGENESIS; CEREBRAL-ISCHEMIA; PROTECTS NEURONS; ANGIOGENESIS; ATORVASTATIN; EXPRESSION; DEFICIT; DEATH; CELLS	Object. This study was designed to investigate the neuroprotective properties of recombinant erythropoietin (EPO) and carbamylated erythropoietin (CEPO) administered following traumatic brain injury (TBI) in rats. Methods. Sixty adult male Wistar rats were injured with controlled cortical impact, and then EPO, CEPO, or a placebo (phosphate-buffered saline) was injected intraperitoneally. These injections were performed either 6 or 24 hours after TBI. To label newly regenerating cells, bromodeoxyuridine was injected intraperitoneally for 14 days after TBI. Blood samples were obtained on Days 1, 2, 3, 7, 14, and 35 to measure hematocrit. Spatial learning was tested using the Morris water maze. All rats were killed 35 days after TBI. Brain sections were immunostained as well as processed for the enzyme-linked immunosorbent assay to measure brain-detived neurotrophic factor (BDNF). Results. A statistically significant improvement in spatial learning was seen in rats treated with either EPO or CEPO 6 or 24 hours after TBI (p < 0.05); there was no difference in the effects of EPO and CEPO. Also, these drugs were equally effective in increasing the number of newly proliferating cells within the dentate gyrus at both time points. A statistically significant increase in BDNF expression was seen in animals treated with both EPO derivatives at 6 or 24 hours after TBI. Systemic hematocrit was significantly increased at 48 hours and 1 and 2 weeks after treatment with EPO but not with CEPO. Conclusions. These data demonstrate that at the doses used, EPO and CEPO are equally effective in enhancing spatial learning and promoting neural plasticity after TBI.	Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Syst, Dept Neurosurg Res, Detroit, MI USA; Henry Ford Hlth Syst, Dept Neurol Res, Detroit, MI USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042259] Funding Source: Medline		Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Jumbe NL, 2002, ONCOLOGY-NY, V16, P91; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lipton P, 1999, PHYSIOL REV, V79, P1431; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sasaki R, 2001, NEWS PHYSIOL SCI, V16, P110; TAN CC, 1992, AM J PHYSIOL, V263, P474; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166	29	73	76	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2007	107	2					392	397		10.3171/JNS-07/08/0392			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	196XT	WOS:000248517300021	17695395				2021-06-18	
J	Laskowitz, DT; McKenna, SE; Song, PP; Wang, HC; Durham, L; Yeung, N; Christensen, D; Vitek, MP				Laskowitz, Daniel T.; McKenna, Suzanne E.; Song, Pingping; Wang, Haichen; Durham, Lori; Yeung, Nolan; Christensen, Dale; Vitek, Michael P.			COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; neuroinflammation; neuroprotection; traumatic brain injury	CLOSED-HEAD INJURY; E-DEFICIENT MICE; SYSTEM INFLAMMATORY RESPONSE; APOE GENOTYPE; WATER-MAZE; MICROGLIAL ACTIVATION; OPTICAL FRACTIONATOR; MIMETIC PEPTIDES; TRANSGENIC MICE; SPATIAL MEMORY	Traumatic brain injury (TBI) is a silent epidemic affecting approximately 1.4 million Americans annually, at an estimated annual cost of $60 billion in the United States alone. Despite an increased understanding of the pathophysiology of closed head injury, there remains no pharmacological intervention proven to improve functional outcomes in this setting. Currently, the existing standard of care for TBI consists primarily of supportive measures. Apolipoprotein E ( apoE) is the primary apolipoprotein synthesized in the brain in response to injury, where it modulates several components of the neuroinflammatory cascade associated with TBI. We have previously demonstrated that COG133, an apoE mimetic peptide, improved functional outcomes and attenuated neuronal death when administered as a single intravenous injection at 30 min post-TBI in mice. Using the principles of rational drug design, we developed a more potent analog, COG1410, which expands the therapeutic window for the treatment of TBI by a factor of four, from 30 min to 2 h. Mice that received a single intravenous injection of COG1410 at 120 min post-TBI exhibited significant improvement on a short term test of vestibulomotor function and on a long term test of spatial learning and memory. This was associated with a significant attenuation of microglial activation and neuronal death in the hippocampus, the neuroanatomical substrate for learning and memory. Rationally derived apoE mimetic peptides have been demonstrated to exert neuroprotective and anti-inflammatory effects in vitro and in clinically relevant models of brain injury. This represents a novel therapeutic strategy in the treatment of TBI.	Cognosci Inc, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC USA	Vitek, MP (corresponding author), Cognosci Inc, 2 Davis Dr,POB 12076, Res Triangle Pk, NC 27709 USA.	mikevitek@cognosci.com		Vitek, Michael/0000-0001-8140-8048	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS043954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R43AG020473, R44AG020473] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 020473] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 043954, R21NS4487] Funding Source: Medline		Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; *CDC, 2006, FACTS TRAUM BRAIN IN; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gay EA, 2006, J PHARMACOL EXP THER, V316, P835, DOI 10.1124/jpet.105.095505; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Holscher C, 1999, BEHAV BRAIN RES, V100, P225, DOI 10.1016/S0166-4328(98)00134-X; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; LINTON M, 1991, J CLIN INVEST, V81, P270; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; MARSHALL GR, 1990, P NATL ACAD SCI USA, V87, P487, DOI 10.1073/pnas.87.1.487; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT AC SCI, 1996, GUID CAR US LAB AN; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wolfer DP, 1998, NEWS PHYSIOL SCI, V13, P118	62	73	78	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1093	1107		10.1089/neu.2006.0192			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200002	17610350				2021-06-18	
J	Wilde, EA; Bigler, ED; Hunter, JV; Fearing, MA; Scheibel, RS; Newsome, MR; Johnson, JL; Bachevalier, J; Li, XQ; Levin, HS				Wilde, Elisabeth A.; Bigler, Erin D.; Hunter, Jill V.; Fearing, Michael A.; Scheibel, Randall S.; Newsome, Mary R.; Johnson, Jamie L.; Bachevalier, Jocelyne; Li, Xiaoqi; Levin, Harvey S.			Hippocampus, amygdala, and basal ganglia morphometrics in children after moderate-to-severe traumatic brain injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; HEAD-INJURY; NEURONAL DAMAGE; MEMORY; RAT; VOLUME; MRI; MILD; VULNERABILITY; ISCHEMIA	While closed head injury frequently results in damage to the frontal and temporal lobes, damage to deep cortical structures, such as the hippocampus, amygdala, and basal ganglia, has also been reported. Five deep central structures (hippocampus, amygdala, globus pallidus, putamen, and caudate) were examined in 16 children (eight males, eight females; aged 9-16y), imaged 1 to 10 years after moderate-tosevere traumatic brain injury JBI), and in 16 individuallymatched uninjured children. Analysis revealed significant volume loss in the hippocampus, amydala, and globus pallidus of the TBI group. Investigation of relative volume loss between these structures and against five cortical areas (ventromedial frontal, superomedial frontal, lateral frontal, temporal, and parieto-occipital) revealed the hippocampus to be the most vulnerable structure following TBI (i.e. greatest relative difference between the groups). In a separate analysis excluding children with focal hippocampal abnormalities (e.g. lesions), group differences in hippocampal volume were still evident, suggesting that hippocampal damage may be diffuse rather than focal.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Brigham Young Univ, Provo, UT 84602 USA; Texas Childrens Hosp, Houston, TX 77030 USA; Emory Univ, Atlanta, GA 30322 USA	Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD-35476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; *ASS ADV AUT MED, 1998, ABBR INJ SCAL 1990 R; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brierley B, 2002, BRAIN RES REV, V39, P84, DOI 10.1016/S0165-0173(02)00160-1; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Convit A, 1999, PSYCHIAT RES-NEUROIM, V90, P113, DOI 10.1016/S0925-4927(99)00007-4; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Hattori N, 2003, J NUCL MED, V44, P1709; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; JORGENSEN MB, 1990, J CEREBR BLOOD F MET, V10, P243, DOI 10.1038/jcbfm.1990.41; Kates WR, 1997, PSYCHIAT RES-NEUROIM, V75, P31, DOI 10.1016/S0925-4927(97)00019-X; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; NAKANO S, 1990, NEUROSCIENCE, V38, P115, DOI 10.1016/0306-4522(90)90378-H; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Primus EA, 1997, BRAIN INJURY, V11, P577; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sheline YI, 1998, NEUROREPORT, V9, P2023, DOI 10.1097/00001756-199806220-00021; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TERAYAMA Y, 1991, J CEREBR BLOOD F MET, V11, P852, DOI 10.1038/jcbfm.1991.145; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	45	73	74	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	APR	2007	49	4					294	299		10.1111/j.1469-8749.2007.00294.x			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	156HC	WOS:000245637700012	17376141	Bronze			2021-06-18	
J	Mdzinarishvili, A; Kiewert, C; Kumar, V; Hillert, M; Klein, J				Mdzinarishvili, A.; Kiewert, C.; Kumar, V.; Hillert, M.; Klein, J.			Bilobalide prevents ischemia-induced edema formation in vitro and in vivo	NEUROSCIENCE			English	Article						brain water content; Ginkgo biloba; hippocampal slices; middle cerebral artery occlusion; oxygen-glucose deprivation; water intoxication	CEREBRAL-ARTERY OCCLUSION; GINKGO-BILOBA; BRAIN EDEMA; PHOSPHOLIPID BREAKDOWN; EXTRACT; WATER; INJURY; MODEL; CONSTITUENT; AQUAPORIN-4	EGb761, a standardized extract of Ginkgo biloba, has neuroprotective properties in animal models of ischemia, an activity that is partially attributed to its constituent, bilobalide. EGb761 has also been reported to inhibit edema formation induced by toxins such as triethyltin. The goal of this study was to test the activity of pure bilobalicle to prevent edema formation in models of ischemia. Oxygen-glucose deprivation (OGD) in rat hippocampal slices served as a model of in vitro-ischemia. OGD caused cellular edema formation as indicated by an increase of slice water contents in 30 min. Bilobalide (1-10 mu M) reduced slice water contents in ischemic slices in a concentration-dependent manner. As a model of in vivo-ischemia, we performed middle cerebral artery occlusion (MCAO) in mice. Permanent MCAO caused cell death and swelling of the ischemic hemisphere within 24 h. Pretreatment of the mice with bilobalicle (10 mg/kg i.p.) reduced infarct area by 43% (as judged by 2,3,5-triphenyl-tetrazolium chloride (TTC) staining) and edema formation by 70% (as judged by hemispheric enlargement). In parallel experiments, pretreatment with bilobalide also reduced fore-brain water contents in the ischemic hemisphere by 57%. As an alternative model of brain edema formation, we used water intoxication to increase brain water content; bilobalicle, was, however, inactive in this model. We conclude that bilobalide strongly and specifically attenuates edema formation in models of brain ischemia in vitro and in vivo. Bilobalide may be therapeutically effective in brain edema which occurs secondarily to large hemispheric stroke and traumatic brain injury in humans. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA	Klein, J (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.	jochen.klein@ttuhsc.edu	Klein, Jochen/B-9730-2008	Klein, Jochen/0000-0001-6971-3381			Ahlemeyer B, 2003, CELL MOL LIFE SCI, V60, P1779, DOI 10.1007/s00018-003-3080-1; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Biber A, 2003, PHARMACOPSYCHIATRY, V36, pS32; Chandrasekaran K, 2001, BRAIN RES, V922, P282, DOI 10.1016/S0006-8993(01)03188-2; Chatterjee S.S., 1986, US patent, Patent No. [4571407, 4,571,407]; Chatterjee SS, 2003, PHARMACOPSYCHIATRY, V36, pS68; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; Defeudis FV, 2002, PHARMACOL RES, V46, P565, DOI 10.1016/S1043-6618(02)00233-5; DORMAN DC, 1992, AM J VET RES, V53, P138; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; Gueniau C, 1997, J PHARMACOL EXP THER, V282, P1; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.med.44.1.289; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Klein J, 1997, BRAIN RES, V755, P347, DOI 10.1016/S0006-8993(97)00239-4; Klein J, 2003, PHARMACOPSYCHIATRY, V36, pS78; KRIEGLSTEIN J, 1995, EUR J PHARM SCI, V3, P39, DOI 10.1016/0928-0987(94)00073-9; LEES KR, 2000, BRIT MED J, V56, P400; Lopachin RM, 2001, NEUROSCIENCE, V103, P971, DOI 10.1016/S0306-4522(01)00035-5; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mdzinarishvili A, 2005, NEUROSCI LETT, V383, P49, DOI 10.1016/j.neulet.2005.03.042; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; OLSON JE, 1990, ANN EMERG MED, V19, P1113, DOI 10.1016/S0196-0644(05)81514-8; OTANI M, 1986, ACTA NEUROPATHOL, V69, P54, DOI 10.1007/BF00687039; Pierre S, 1999, NEUROREPORT, V10, P47, DOI 10.1097/00001756-199901180-00009; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; SANCESARIO G, 1986, ACTA NEUROPATHOL, V72, P3, DOI 10.1007/BF00687941; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Siklos L, 1997, NEUROSCIENCE, V79, P1013, DOI 10.1016/S0306-4522(97)00031-6; Steiner T, 2001, NEUROLOGY, V57, pS61, DOI 10.1212/WNL.57.suppl_2.S61; Sydserff SG, 1996, NEURODEGENERATION, V5, P81, DOI 10.1006/neur.1996.0011; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Weichel O, 1999, N-S ARCH PHARMACOL, V360, P609, DOI 10.1007/s002109900131; Westman J, 2000, AMINO ACIDS, V19, P339, DOI 10.1007/s007260070065; Zheng SX, 2000, ACTA PHARMACOL SIN, V21, P151	38	73	84	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 5	2007	144	1					217	222		10.1016/j.neuroscience.2006.08.037			6	Neurosciences	Neurosciences & Neurology	117GD	WOS:000242860100022	17014966				2021-06-18	
J	Riess, P; Molcanyi, M; Bentz, K; Maegele, M; Simanski, C; Carlitscheck, C; Schneider, A; Hescheler, J; Bouillon, B; Schafer, U; Neugebauer, E				Riess, Peter; Molcanyi, Marek; Bentz, Kristine; Maegele, Mark; Simanski, Christian; Carlitscheck, Christoph; Schneider, Annette; Hescheler, Juergen; Bouillon, Bertil; Schaefer, Ute; Neugebauer, Edmund			Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; motor function; Sprautte-Dawley rats; tumorigenesis	NERVE GROWTH-FACTOR; FLUID-PERCUSSION MODEL; MARROW STROMAL CELLS; NEURAL TRANSPLANTATION; SENSORIMOTOR FUNCTION; THERAPEUTIC STRATEGY; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; MOTOR FUNCTION; IN-VIVO	Transplantation of embryonic stem (ES) cells may provide cures for the damaged nervous system. Pre-differentiated ES or neuronal precursor cells have been investigated in various animal models of neurodegenerative diseases including traumatic brain injury (TBI). To our knowledge, no study has yet examined the effects of undifferentiated, murine ES cells on functional recovery and tumorigenity following implantation into injured rat brains. We evaluated the effect of transplantation of undifferentiated, murine embryonic cells on the recovery of motor function following lateral fluid percussion brain injury in Sprague-Dawley rats. At 3 days post-injury, animals received stereotactic injections of either embryonic stem cell suspension or injections of phosphate buffered saline without cells (control) into the injured cortex. Neurological motor function assessments were performed before injury, 72 h, 1, 3, and 6 weeks after transplantation using a Rotatrod and a Composite Neuroscore test. During this time period brain injured animals receiving ES cell transplantation showed a significant improvement in the Rotarod Test and in the Composite Neuroscore Test as compared to phosphate buffered saline (PBS)-treated animals. At 1 week post-transplantation, ES cells were detectable in 100% of transplanted animals. At 7 weeks following transplantation, ES cells were detectable in only one animal. Two of 10 xenotransplanted animals revealed tumor formation over the observation period. These findings provide evidence for therapeutic potency of embryonic stem cell transplantation after TBI in rat, but also raise serious safety concerns about the use of such cells in human.	Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; Univ Cologne, Fac Med, Clin Neurosurg, D-5000 Cologne 41, Germany; Natl Res Ctr Environm & Hlth, Inst Dev Genet, Munich, Germany; Univ Witten Herdecke, Fac Med, Inst Operat Med, Cologne, Germany; Univ Cologne, Fac Med, Dept Neurophysiol, D-5000 Cologne 41, Germany	Riess, P (corresponding author), Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	riessp@kliniken-koeln.de					Arnhold S, 2000, J NEUROSURG, V93, P1026, DOI 10.3171/jns.2000.93.6.1026; BENTZ K, IN PRESS J NEUROSCI; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P79, DOI 10.1016/0149-7634(95)00063-1; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chiba S, 2003, CELL TRANSPLANT, V12, P457, DOI 10.3727/000000003108747019; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Erdo Franciska, 2004, Orvosi Hetilap, V145, P1307; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Kerr DA, 2003, J NEUROSCI, V23, P5131; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOLCANYI M, IN PRESS J NEUROTRAU; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Park KI, 2006, EXP NEUROL, V199, P156, DOI 10.1016/j.expneurol.2006.04.002; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROSCI, V15, P8223; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wilkins A, 2003, J NEUROSCI, V23, P4967, DOI 10.1523/jneurosci.23-12-04967.2003; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	39	73	77	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					216	225		10.1089/neu.2006.0141			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100021	17263685				2021-06-18	
J	Berger, RP				Berger, Rachel Pardes			The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						neuron-specific enolase; outcome; serum biomarkers; S100B; traumatic brain injury	NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; S-100 PROTEIN MEASUREMENTS; POST-CONCUSSION SYMPTOMS; CARDIAC-ARREST; S100B LEVELS; NEUROPSYCHOLOGICAL FUNCTION; NEUROCOGNITIVE PERFORMANCE; COMPUTED-TOMOGRAPHY; BEHAVIOR PROBLEMS	Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in adults and children. Predicting outcome after TBI is difficult, but it is important for acute management, counseling of family members, and provision of rehabilitation services. Serum biomarkers may be useful alone or in combination with clinical variables to predict outcome after TBI. This article reviews the potential uses of serum biomarkers for the clinician, current literature related to the use of serum biomarkers for outcome prediction after adult and pediatric TBI, limitations of the literature, and future direction for this field.	Childrens Hosp Pittsburgh, Dept Pediat, Div Child Advocacy, Pittsburgh, PA 15213 USA	Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Div Child Advocacy, 3705 5th Ave, Pittsburgh, PA 15213 USA.	rberger@pitt.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD43843-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER		Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BEERS S, IN PRESS J NEUROTRAU; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BLAU TH, 1977, PROF PSYCHOL, V8, P464, DOI 10.1037/0735-7028.8.4.464; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carter BG, 2005, INTENS CARE MED, V31, P840, DOI 10.1007/s00134-005-2634-0; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; EVANS RW, 1992, NEUROL CLIN, V10, P815; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; HANS P, 1983, J NEUROSURG, V58, P689, DOI 10.3171/jns.1983.58.5.0689; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kratz A, 2002, AM J CLIN PATHOL, V118, P856, DOI 10.1092/BTWQ5YMYVQ67QK9L; Lima JE, 2004, BRAZ J MED BIOL RES, V37, P19, DOI 10.1590/S0100-879X2004000100003; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Martz LL, 1998, DESCANT, V29, P11; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Portela LVC, 2002, CLIN DIAGN LAB IMMUN, V9, P164, DOI 10.1128/CDLI.9.1.164-166.2002; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; Rabinowicz AL, 1996, EPILEPSIA, V37, P122, DOI 10.1111/j.1528-1157.1996.tb00002.x; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; THOMAS DGT, 1977, LANCET, V1, P113; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANDEPOL M, 1994, J NEURO-ONCOL, V19, P149, DOI 10.1007/BF01306456; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	78	73	76	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2006	21	4					315	333		10.1097/00001199-200607000-00004			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	064SJ	WOS:000239109100004	16915008				2021-06-18	
J	Farr, TD; Liu, L; Colwell, KL; Whishaw, IQ; Metz, GA				Farr, Tracy D.; Liu, Lily; Colwell, Keri L.; Whishaw, Ian Q.; Metz, Gerlinde A.			Bilateral alteration in stepping pattern after unilateral motor cortex injury: A new test strategy for analysis of skilled limb movements in neurological mouse models	JOURNAL OF NEUROSCIENCE METHODS			English	Article						motor system; movement performance; skilled walking; rotorod; ladder rung task; mouse behaviour	TRAUMATIC BRAIN-INJURY; DOPAMINE-DEPLETED RATS; MICE MUS-MUSCULUS; ADULT-RATS; SENSORIMOTOR DYSFUNCTION; BEHAVIORAL-DIFFERENCES; CORTICOSPINAL TRACT; TRANSGENIC MICE; END-POINT; FORELIMB	Mice are becoming increasingly popular to model neurological disease and motor system dysfunction. For evaluation of discrete, chronic motor impairments, skilled limb movements represent a valuable extension of standard mouse test batteries. This study introduces an efficient and sensitive test strategy for comprehensive assessment of skilled fore- and hind-limb stepping in mice. Adult C57BL/6 mice were trained and video-recorded in two walking tasks, the widely used rotorod test and a new ladder rung task. The animals then received a unilateral ischemic lesion in the motor cortex forelimb and hind limb area and were video-recorded on days 12 and 26 post-lesion. Forelimb and hind limb stepping movements were rated using a combination of endpoint measures and qualitative assessment. The results showed that while animals maintained a weight-supported gait, posture and stepping movements were abnormal at both post-operative intervals. The rotorod analysis revealed stepping deficits in both forelimbs that led to adoption of compensatory movement strategies. The ladder rung task revealed stepping errors in ipsi- and contralateral fore- and hind-limbs. The findings demonstrate that this test strategy provides comprehensive assessment of motor impairments in mice and that qualitative movement analysis is a valuable tool for elaborating subtle motor disturbances. (c) 2005 Elsevier B.V. All rights reserved.	Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada; Univ Glasgow, Div Clin Neurosci, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Div Clin Neurosci, 7TMRI Facil, Glasgow G61 1QH, Lanark, Scotland	Farr, TD (corresponding author), Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada.	0309845f@student.gla.ac.uk	Farr, Tracy D/I-2876-2019	Farr, Tracy D/0000-0002-6781-5226; Metz, Gerlinde/0000-0002-5801-7716			Anagnostopoulos AV, 2001, PHYSIOL BEHAV, V73, P675, DOI 10.1016/S0031-9384(01)00525-X; Augustsson H, 2004, PHYSIOL BEHAV, V81, P685, DOI 10.1016/j.physbeh.2004.03.014; Baird AL, 2001, BRAIN RES BULL, V54, P243, DOI 10.1016/S0361-9230(00)00457-3; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bothe GWM, 2004, GENES BRAIN BEHAV, V3, P149, DOI 10.1111/j.1601-183x.2004.00064.x; Brambilla G, 2004, TOXICOLOGY, V196, P1, DOI 10.1016/j.tox.2003.11.003; Branchi I, 2002, GENES BRAIN BEHAV, V1, P135, DOI 10.1034/j.1601-183X.2002.10301.x; Bucan M, 2002, NAT REV GENET, V3, P114, DOI 10.1038/nrg728; Caston J, 2003, BEHAV BRAIN RES, V141, P35, DOI 10.1016/S0166-4328(02)00319-4; Chapillon P, 1998, BEHAV BRAIN RES, V93, P77, DOI 10.1016/S0166-4328(97)00137-X; Chu CJ, 2000, EXP NEUROL, V166, P403, DOI 10.1006/exnr.2000.7509; Cook MN, 2002, BEHAV NEUROSCI, V116, P600, DOI 10.1037//0735-7044.116.4.600; Dijkstra JR, 2000, J NEUROSCI METH, V96, P89, DOI 10.1016/S0165-0270(99)00174-0; DONATELLE JM, 1977, J COMP NEUROL, V175, P207, DOI 10.1002/cne.901750205; Farr TD, 2002, STROKE, V33, P1869, DOI 10.1161/01.STR.0000020714.48349.4E; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Fouad K, 2000, BEHAV BRAIN RES, V115, P107, DOI 10.1016/S0166-4328(00)00244-8; FOX WM, 1965, ANIM BEHAV, V13, P234, DOI 10.1016/0003-3472(65)90041-2; Goldstein LB, 2003, ILAR J, V44, P125, DOI 10.1093/ilar.44.2.125; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; Kim D, 2001, NEUROREHAB NEURAL RE, V15, P141, DOI 10.1177/154596830101500207; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; Lalonde R, 2003, BEHAV PROCESS, V63, P9, DOI 10.1016/S0376-6357(03)00013-5; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; MIKLYAEVA EI, 1994, J NEUROSCI, V14, P7148; Muir GD, 1999, EXP BRAIN RES, V126, P307, DOI 10.1007/s002210050739; OLSSON M, 1995, J NEUROSCI, V15, P3863; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pecaut MJ, 2002, COGN AFFECT BEHAV NE, V2, P329, DOI 10.3758/CABN.2.4.329; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Smith LK, 2005, PHYSIOL BEHAV, V85, P581, DOI 10.1016/j.physbeh.2005.06.013; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Tillerson JL, 2002, EXP NEUROL, V178, P80, DOI 10.1006/exnr.2002.8021; van der Staay FJ, 2001, BEHAV BRAIN RES, V125, P3, DOI 10.1016/S0166-4328(01)00278-9; WAGNER GC, 1987, PSYCHOPHARMACOLOGY, V92, P470; Wahlsten D, 2003, GENES BRAIN BEHAV, V2, P71, DOI 10.1034/j.1601-183X.2003.00012.x; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1992, BEHAV BRAIN RES, V48, P113, DOI 10.1016/S0166-4328(05)80147-0; WHISHAW IQ, 1994, BEHAV BRAIN RES, V60, P15, DOI 10.1016/0166-4328(94)90058-2; Whishaw IQ, 2003, J NEUROSCI METH, V126, P13, DOI 10.1016/S0165-0270(03)00049-9; WHISHAW IQ, 1991, BEHAV BRAIN RES, V42, P77, DOI 10.1016/S0166-4328(05)80042-7; Whishaw IQ, 1996, BEHAV BRAIN RES, V78, P101, DOI 10.1016/0166-4328(95)00236-7; WOLGIN DL, 1983, PHYSIOL BEHAV, V31, P197, DOI 10.1016/0031-9384(83)90118-X; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	47	73	74	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAY 15	2006	153	1					104	113		10.1016/j.jneumeth.2005.10.011			10	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	047MC	WOS:000237882400012	16309746				2021-06-18	
J	Hurlbert, RJ				Hurlbert, R. John			Strategies of medical intervention in the management of acute spinal cord injury	SPINE			English	Article						trauma; medical management; therapy; paraplegia; quadriplegia	HIGH-DOSE METHYLPREDNISOLONE; OLFACTORY ENSHEATHING CELLS; STEM-CELLS; TIRILAZAD MESYLATE; CONTROLLED-TRIAL; RECOVERY; TRANSPLANTATION; BRAIN; DIFFERENTIATION; REGENERATION	Study Design. Literature review. Objective. The purpose of this paper is to review clinical treatment strategies and future developments in the treatment of acute spinal cord injury. Summary of Background Data. The treatment of acute spinal cord injury continues to be supportive. The search for specialized pharmacologic agents to prevent secondary injury and promote repair or regeneration remains heated. Methods. Medline search from 1996 to present limited to clinical research and basic science review articles in the English Language. Results. Steroids continue to be administered in the clinical setting of acute spinal cord injury primarily out of peer pressure and fear of litigation. Basic science experiments suggest that modulation of post-traumatic inflammation may provide the best opportunity to arrest the secondary injury cascade. Protein kinase and metalloproteinase inhibition are promising treatment strategies. Regeneration techniques are concentrating on cell transplantation and manipulating glial receptors and protein production. Clinical investigations are limited to Phase III trials on a very select few of these drugs. Conclusions. While many advances in the basic science of spinal cord injury provide optimism for future treatments, clinical science lags. At present, there are no pharmacologic strategies of proven benefit. Although steroids continue to be given to patients with spinal cord injury in many institutions, evidence of deleterious effects continues to accumulate. Current standard of care management includes support of arterial oxygenation and spinal cord perfusion pressure.	Univ Calgary, Foothills Hosp, Dept Clin Neurosci, Spine Program, Calgary, AB T2N 2T9, Canada; Med Ctr, Calgary, AB T2N 2T9, Canada	Hurlbert, RJ (corresponding author), Univ Calgary, Foothills Hosp, Dept Clin Neurosci, Spine Program, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.	jhurlber@ucalgary.ca					Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arlotta P, 2003, ANN NY ACAD SCI, V991, P229; Blesch A, 2004, YONSEI MED J, V45, P28; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coleman WP, 2000, J SPINAL DISORD, V13, P185, DOI 10.1097/00002517-200006000-00001; Dergham P, 2002, J NEUROSCI, V22, P6570; Diers-Fenger M, 2001, GLIA, V34, P213, DOI 10.1002/glia.1055; DOLAN EJ, 1982, J NEUROSURG, V56, P350, DOI 10.3171/jns.1982.56.3.0350; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fournier AE, 2003, J NEUROSCI, V23, P1416; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Glaser J, 2004, J NEUROSCI RES, V77, P701, DOI 10.1002/jnr.20204; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Hadley M, 2002, NEUROSURGERY, V50, pS58; Hadley MN, 2002, NEUROSURGERY, V50, pS63; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Horner PJ, 2000, J NEUROSCI, V20, P2218; Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992; Hurlbert RJ, 2000, J NEUROSURG, V93, P340; Hurlbert RJ, 2002, CAN J NEUROL SCI, V29, P236, DOI 10.1017/S0317167100002006; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; King BS, 2000, SURG CLIN N AM, V80, P855, DOI 10.1016/S0039-6109(05)70100-6; Knoller N, 2005, J NEUROSURG-SPINE, V3, P173, DOI 10.3171/spi.2005.3.3.0173; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myckatyn TM, 2004, TRANSPL IMMUNOL, V12, P343, DOI 10.1016/j.trim.2003.12.017; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; Otani K., 1994, SEKITSUI SEKIZUI, V7, P633; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; Qian T, 2005, SPINAL CORD, V43, P199, DOI 10.1038/sj.sc.3101681; Raisman G, 2004, CLONING STEM CELLS, V6, P364, DOI 10.1089/clo.2004.6.364; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; SCHWAB JM, 2002, SOC NEUR ABSTR, V204, P7; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; Shapiro S, 2005, J NEUROSURG-SPINE, V2, P3, DOI 10.3171/spi.2005.2.1.0003; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; TATOR CH, 1992, J NEUROTRAUM, V9, P139, DOI 10.1089/neu.1992.9.139; TATOR CH, 1984, CAN J SURG, V27, P289; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; TURNBULL IM, 1971, J NEUROSURG, V35, P141, DOI 10.3171/jns.1971.35.2.0141; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; Vogel G, 2005, SCIENCE, V308, P1534, DOI 10.1126/science.308.5728.1534; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Woolf CJ, 2002, SCIENCE, V297, P1132, DOI 10.1126/science.1076247; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Zach G A, 1976, Paraplegia, V14, P58	69	73	81	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAY 15	2006	31	11		S			S16	S21		10.1097/01.brs.0000218264.37914.2c			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	042HL	WOS:000237518800004	16685230				2021-06-18	
J	Liu, MC; Akle, V; Zheng, W; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW				Liu, MC; Akle, V; Zheng, W; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW			Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis	BIOCHEMICAL JOURNAL			English	Article						calpain; caspase; degradome; high throughput immunoblotting (HTPI); proteomics; traumatic brain injury (TBI)	II-SPECTRIN; PROTEOLYSIS; EXPRESSION; PROTEINS; CASPASE; INHIBITION; CHALLENGE; BREAKDOWN; TOOL	A major theme of TBI (traumatic brain injury) pathology is the over-activation of multiple proteases. We have previously shown that calpain-1 and -2, and caspase-3 simultaneously produced alpha II-spectrin BDPs (breakdown products) following TBI. In the present study, we attempted to identify a comprehensive set of protease substrates (degradome) for calpains and caspase-3. We further hypothesized that the TBI differential proteome is I likely to overlap significantly with the calpain- and caspase-3-degradomes. Using a novel HTPI (high throughput immunoblotting) approach and 1000 monoclonal antibodies (PowerB lot(TM)), we compared rat hippocampal lysates from 4 treatment groups: (i) naive, (ii) TBI (48 h after controlled cortical impact), (iii) in vitro calpain-2 digestion and (iv) in vitro caspase-3 digestion. In total, we identified 54 and 38 proteins that were vulnerable to calpain-2 and caspase-3 proteolysis respectively. In addition, the expression of 48 proteins was down-regulated following TBI, whereas that of only 9 was up-regulated. Among the proteins down-regulated in TBI, 42 of them overlapped with the calpain-2 and/or caspase-3 degradomes, suggesting that they might be proteolytic targets after TBI. We further confirmed several novel TBI-linked proteolytic substrates, including beta II-spectrin, striatin, synaptotagmin-1, synaptojanin-1 and NSF (N-ethylmaleimide-sensitive fusion protein) by traditional immunoblotting. In summary, we demonstrated that HTPI is a novel and powerful method for studying proteolytic pathways in vivo and in vitro.	Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Walter Reed Army Inst Res, Div Neurosci, Dept Neuropharmacol & Mol Biol, Silver Spring, MD USA; Banyan Biomarkers Inc, Alachua, FL 32615 USA	Wang, KKW (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, POB 100256, Gainesville, FL 32610 USA.	kwang1@ufl.edu	akle, veronica/AAD-7577-2019; Dave, Jitendra R/A-8940-2011	Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049175-01 A1, R01 NS049175] Funding Source: Medline		Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Castle JE, 2001, ELEC SOC S, V2001, P1; Cicala C, 2002, P NATL ACAD SCI USA, V99, P9380, DOI 10.1073/pnas.142287999; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; Gifford SM, 2003, ENDOCRINOLOGY, V144, P3639, DOI 10.1210/en.2002-0006; Hajimohammadreza I, 1997, J NEUROCHEM, V69, P1006; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; LEVILLIERS N, 1986, BIOCHIM BIOPHYS ACTA, V882, P113, DOI 10.1016/0304-4165(86)90062-0; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lorenz P, 2003, PROTEOMICS, V3, P991, DOI 10.1002/pmic.200300412; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; MCGINNIN KM, 1998, J BIOL CHEM, V273, P1999; Melnick M, 2001, BMC Dev Biol, V1, P15, DOI 10.1186/1471-213X-1-15; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Pasinetti GM, 2001, RESTOR NEUROL NEUROS, V18, P137; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Santella L, 2000, EXP CELL RES, V259, P117, DOI 10.1006/excr.2000.4969; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yoo GH, 2002, CLIN CANCER RES, V8, P3910	29	73	77	0	2	PORTLAND PRESS LTD	LONDON	5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND	0264-6021	1470-8728		BIOCHEM J	Biochem. J.	MAR 15	2006	394		3				715	725		10.1042/BJ20050905			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	023OV	WOS:000236137000020	16351572	Green Published			2021-06-18	
J	Abrahamson, EE; Ikonomovic, MD; Ciallella, JR; Hope, CE; Paljug, WR; Isanski, BA; Flood, DG; Clark, RSB; DeKosky, ST				Abrahamson, EE; Ikonomovic, MD; Ciallella, JR; Hope, CE; Paljug, WR; Isanski, BA; Flood, DG; Clark, RSB; DeKosky, ST			Caspase inhibition therapy abolishes brain trauma-induced increases in A beta peptide: Implications for clinical outcome	EXPERIMENTAL NEUROLOGY			English	Article						alzheimer; apoptosis; BOC-fink; hippocampus; knockin; neurodegeneration	AMYLOID PRECURSOR PROTEIN; SEVERE HEAD-INJURY; IN-SITU HYBRIDIZATION; RAT CORTICAL-NEURONS; ALZHEIMERS-DISEASE; AXONAL INJURY; CELL-DEATH; NEUROLOGICAL DYSFUNCTION; CYTOPLASMIC DOMAIN; MULTIPLE CASPASES	The detrimental effects of traumatic brain injury (TBI) on brain tissue integrity involve progressive axonal damage, necrotic cell loss, and both acute and delayed apoptotic neuronal death due to activation of caspases. Post-injury accumulation of amyloid precursor protein (APP) and its toxic metabolite amyloid-beta peptide (A beta) has been implicated in apoptosis as well as in increasing the risk for developing Alzheimer's disease (AD) after TBI. Activated caspases proteolyze APP and are associated with increased A beta production after neuronal injury. Conversely, A beta and related APP/A beta fragments stimulate caspase activation, creating a potential vicious cycle of secondary injury after TBI. Blockade of caspase activation after brain injury suppresses apoptosis and improves neurological outcome, but it is not known whether such intervention also prevents increases in A beta levels in vivo. The present study examined the effect of caspase inhibition on post-injury levels of soluble A, APP, activated caspase-3, and caspase-cleaved APP in the hippocampus of nontransgenic mice expressing human A beta, subjected to controlled cortical injury (M). CCI produced brain tissue damage with cell loss and elevated levels of activated caspase-3, A beta (1-42) and A beta (1-40), APP, and caspase-cleaved APP fragments in hippocampal neurons and axons. Post-CCI intervention with intracerebroventricular injection of 100 nM Boc-Asp(OMe)-CH2F (BAF, a pan-caspase inhibitor) significantly reduced caspase-3 activation and improved histological outcome, suppressed increases in A beta and caspase-cleaved APP. but showed no significant effect on overall APP levels in the hippocampus after M. These data demonstrate that after TBI, caspase inhibition can suppress elevations in A beta. The extent to which A beta suppression contributes to improved outcome following inhibition of caspases after TBI is unclear, but such intervention may be a valuable therapeutic strategy for preventing the long-term evolution of A beta-mediated pathology in TBI patients who are at risk for developing AD later in life. (c) 2005 Elsevier Inc. All rights reserved.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; Cephalon Inc, W Chester, PA 19380 USA	DeKosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 3471 5th Ave,Suite 811, Pittsburgh, PA 15213 USA.	DeKoskyST@upmc.edu		DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; AWASTHI A, 2005, EXP NEUROL; Ayala-Grosso C, 2002, BRAIN PATHOL, V12, P430; Barnes NY, 1998, J NEUROSCI, V18, P5869; Bertrand E, 2001, MOL CELL NEUROSCI, V18, P503, DOI 10.1006/mcne.2001.1030; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cheng AG, 1999, BRAIN RES, V850, P234, DOI 10.1016/S0006-8993(99)01983-6; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gottlieb S, 2000, BRIT MED J, V321, P1100; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; IKONOMOVIC MD, 1995, J COMP NEUROL, V359, P239, DOI 10.1002/cne.903590205; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P13122; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu DC, 2000, NAT MED, V6, P397; Lu DC, 2003, J NEUROCHEM, V87, P733, DOI 10.1046/j.1471-4159.2003.02059.x; Marin N, 2000, MECH AGEING DEV, V119, P63, DOI 10.1016/S0047-6374(00)00172-X; MARK RJ, 1995, J NEUROSCI, V15, P6239; Masliah E, 1998, J NEUROPATH EXP NEUR, V57, P1041, DOI 10.1097/00005072-199811000-00007; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MIZE RR, 1994, J NEUROSCI METH, V54, P219, DOI 10.1016/0165-0270(94)90195-3; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nishimura I, 2002, CELL DEATH DIFFER, V9, P199, DOI 10.1038/sj/cdd/4400931; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Savage MJ, 1998, J NEUROSCI, V18, P1743; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smolen AJ, 1990, METHODS NEUROSCIENCE, P208; SOMOGYI P, 1982, NEUROSCIENCE, V7, P1779, DOI 10.1016/0306-4522(82)90035-5; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Su JH, 2002, ACTA NEUROPATHOL, V104, P1, DOI 10.1007/s00401-002-0548-2; Takeda K, 2004, FASEB J, V18, P1755, DOI 10.1096/fj.03-1070fje; Tesco G, 2003, J BIOL CHEM, V278, P46074, DOI 10.1074/jbc.M307809200; Troy CM, 2000, J NEUROSCI, V20, P1386; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Wang CN, 2001, J BIOL CHEM, V276, P5287, DOI 10.1074/jbc.M006406200; Wei N, 2002, JCR-J CLIN RHEUMATOL, V8, P125, DOI 10.1097/00124743-200206000-00001; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; White AR, 2001, NEUROBIOL DIS, V8, P299, DOI 10.1006/nbdi.2001.0386; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006	91	73	74	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2006	197	2					437	450		10.1016/j.expneurol.2005.10.011			14	Neurosciences	Neurosciences & Neurology	009RV	WOS:000235131000020	16300758				2021-06-18	
J	Faden, AI; Movsesyan, VA; Knoblach, SM; Ahmed, F; Cernak, B				Faden, AI; Movsesyan, VA; Knoblach, SM; Ahmed, F; Cernak, B			Neuroprotective effects of novel small peptides in vitro and after brain injury	NEUROPHARMACOLOGY			English	Article						traumatic brain injury; neuroprotection; cyclic dipeptides; cell death; microarray; magnetic resonance imaging	NEURONAL CELL-DEATH; SPINAL-CORD-INJURY; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; NMDA RECEPTORS; RATS; ACTIVATION; EXPRESSION; RECOVERY; TRH	Thyrotropin-releasing hormone (TRH) and TRH analogues have been reported to be neuroprotective in experimental models of spinal cord injury and head injury. We have previously shown that a diketopiperazine structurally related to the TRH metabolite cyclo-his-pro reduces neuronal cell death in vitro and in vivo. Here we report the neuroprotective activity of other cyclic dipeptides in multiple in vitro models of neuronal injury and after controlled cortical impact (CCI) in mice. Using primary neuronal cultures, three novel dipeptides were compared to the previously reported diketopiperazine as well as to vehicle controls; each of the compounds reduced cell death after direct physical trauma or trophic withdrawal. Two of these peptides also protected against glutamate toxicity and P-amyloid-induced injury; the latter also strongly inhibited glutamate-induced increases in intracellular calcium. Treatment with each of the test compounds resulted in highly significant improvement of motor and cognitive recovery after CO, as well as markedly reducing lesion volumes as shown by high field magnetic resonance imaging. DNA microarray studies following fluid percussion induced traumatic brain injury (TBI) in rats showed that treatment with one of these dipeptides after injury significantly down-regulated expression of mRNAs for cell cycle proteins, aquaporins, cathepsins and calpain in ipsilateral cortex and/or hippocampus, while up-regulating expression of brain-derived neurotrophic factor, hypoxia-inducible factor and several heat-shock proteins. Many of these mRNA expression changes were paralleled at the protein level. The fact that these small peptides modulate multiple mechanisms favoring neuronal cell survival, as well as their ability to improve functional outcome and reduce posttraumatic lesion size, suggests that they may have potential utility in clinical head injury. (c) 2005 Elsevier Ltd. All rights reserved.	Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, Washington, DC 20057 USA	Cernak, B (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, 3970 Reservoir Rd,NW,Res Bldg,Room EP04, Washington, DC 20057 USA.	ifc@georgetown.edu		Ibolja, Cernak/0000-0003-3214-698X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41119] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER		Allen JW, 2001, EXP NEUROL, V169, P449, DOI 10.1006/exnr.2001.7672; ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Faden AI, 2004, J ALZHEIMERS DIS, V6, pS93; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1989, ANN NY ACAD SCI, V553, P380; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Gulino R, 2004, BRAIN RES, V1013, P174, DOI 10.1016/j.brainres.2004.03.055; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOSKINEN LOD, 1986, BRIT J PHARMACOL, V87, P509, DOI 10.1111/j.1476-5381.1986.tb10193.x; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Prakash KRC, 2002, BIOORGAN MED CHEM, V10, P3043, DOI 10.1016/S0968-0896(02)00132-3; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Seyfried DM, 2001, BRAIN RES, V901, P94, DOI 10.1016/S0006-8993(01)02289-2; Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1007/BF03206563; Yenari MA, 2002, ADV EXP MED BIOL, V513, P281; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	40	73	75	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	SEP	2005	49	3					410	424		10.1016/j.neuropharm.2005.04.001			15	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	960DN	WOS:000231570500014	15907950				2021-06-18	
J	Truettner, JS; Suzuki, T; Dietrich, WD				Truettner, JS; Suzuki, T; Dietrich, WD			The effect of therapeutic hypothermia on the expression of inflammatory response genes following moderate traumatic brain injury in the rat	MOLECULAR BRAIN RESEARCH			English	Article						hypothermia; trauma; gene array; protection; inflammation	MIGRATION INHIBITORY FACTOR; TUMOR-NECROSIS-FACTOR; TRANSIENT FOREBRAIN ISCHEMIA; NITRIC-OXIDE SYNTHASE; NERVE GROWTH-FACTOR; CLOSED-HEAD INJURY; MESSENGER-RNA; TNF-ALPHA; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA	Traumatic brain injury (TBI) initiates a cascade of cellular and molecular responses including both pro- and anti-inflammatory. Although post-traumatic hypothermia has been shown to improve outcome in various models of brain injury, the underlying mechanisms responsible for these effects have not been clarified. in this study, inflammation cDNA arrays and semi-quantitative RT-PCR were used to detect genes that are differentially regulated after TBI. In addition, the effect of post-traumatic hypothermia on the expression of selective genes was also studied. Rats (n = 6-8 per group) underwent moderate fluid-percussion (F-P) brain injury with and without hypothermic treatment (33 degrees C/3h). RNA from 3-h or 24-h survival was analyzed for the expression of IL1-beta, IL2, IL6, TGF-beta 2, growth-regulated oncogene (GRO), migration inhibitory factor (MIF), and MCP (a transcription factor). The interleukins IL-1 beta, IL-2, and IL-6 and TGF-beta and GRO were strongly upregulated early and transiently from 2- to 30-fold over sham at 3 h, with normalization by 24 h. In contrast, the expressions of MIF and MCP were both reduced by TBI compared to sham. Post-traumatic hypothermia had no significant effect on the acute expression of the majority of genes investigated. However, the expression of TGF-2 at 24 h was significantly reduced by temperature manipulation. The mechanism by which post-traumatic hypothermia is protective may not involve a general genetic response of the inflammatory genes. However, specific genes, including TGF-beta 2, may be altered and effect cell death mechanisms after TBI. Hypothermia differentially regulates certain genes and may target more delayed responses underlying the secondary damage following TBI. (c) 2005 Elsevier B.V. All rights reserved.	Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, POB 016960,R-48, Miami, FL 33136 USA.	ddietrich@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P50-NS30291, NS42133] Funding Source: Medline		Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Aoki M, 2001, MOL BRAIN RES, V95, P117, DOI 10.1016/S0169-328X(01)00255-8; Baugh JA, 2003, J ENDOCRINOL, V179, P15, DOI 10.1677/joe.0.1790015; Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Boris-Moller F, 1998, MOL BRAIN RES, V63, P163, DOI 10.1016/S0169-328X(98)00286-1; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Daun JM, 2000, AM J PHYSIOL-REG I, V279, pR1043; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; GHIMIKAR RS, 1996, J NEUROSCI RES, V46, P727; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gregersen PK, 2003, ARTHRITIS RHEUM-US, V48, P1171, DOI 10.1002/art.10880; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hicks SD, 2000, NEUROSCIENCE, V98, P677, DOI 10.1016/S0306-4522(00)00169-X; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kamme F, 1996, MOL BRAIN RES, V43, P51, DOI 10.1016/S0169-328X(96)00151-9; Kataoka M, 2002, TRANSPLANTATION, V73, P1730, DOI 10.1097/00007890-200206150-00007; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; KINOSHITA K, 2002, NEUROSURGERY, V5, P1105; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Krieglstein K, 1996, NEUROCHEM RES, V21, P843, DOI 10.1007/BF02532308; Kumar K, 1996, MOL BRAIN RES, V42, P337, DOI 10.1016/S0169-328X(96)00181-7; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Loukinova E, 2001, INT J CANCER, V94, P637, DOI 10.1002/ijc.1514; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Mancuso A, 2000, BRAIN RES, V887, P34, DOI 10.1016/S0006-8993(00)02963-2; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; RELTON JK, 1997, NEUROPROTECTION CNS, P225; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tomasevic G, 1998, MOL BRAIN RES, V60, P168, DOI 10.1016/S0169-328X(98)00173-9; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; UNSICKER K, 2002, EUR J BIOCHEM, V267, P6972; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wu XL, 1995, NEUROREPORT, V7, P302, DOI 10.1097/00001756-199512290-00072; Zhou ZHL, 2001, FASEB J, V15, P383, DOI 10.1096/fj.00-0373com; Zhumabayeva B, 2004, ADV BIOCHEM ENG BIOT, V86, P191	91	73	79	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 18	2005	138	2					124	134		10.1016/j.molbrainres.2005.04.006			11	Neurosciences	Neurosciences & Neurology	958VH	WOS:000231475800003	15922484				2021-06-18	
J	Sebelius, FCP; Rosen, BN; Lundborg, GN				Sebelius, FCP; Rosen, BN; Lundborg, GN			Refined myoelectric control in below-elbow amputees using artificial neural networks and data glove	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						hand prosthesis; EMG recordings; ANN; virtual hands; myoelectric control; amputee	PRIMARY MOTOR CORTEX; MASSIVE CORTICAL REORGANIZATION; BRAIN PLASTICITY; SOMATOSENSORY CORTEX; MACAQUE MONKEYS; HAND PROSTHESIS; NERVE INJURY; AMPUTATION; REPRESENTATION; PATTERNS	Purpose: To develop a system for refined motor control of artificial hands based on multiple electromyographic (EMG) recordings, allowing multiple patterns of hand movements. Methods: Five subjects with traumatic below-elbow amputations and 1 subject with a congenital below-elbow failure of formation performed 10 imaginary movements with their phantom hand while surface electrodes recorded the EMG data. In a training phase a data glove with 18 degrees of freedom was used for positional recording of movements in the contralateral healthy hand. These movements were performed at the same time as the imaginary movements in the phantom hand. An artificial neural network (ANN) then could be trained to associate the specific EMG patterns recorded from the amputation stump with the analogous specific hand movements synchronously performed in the healthy hand. The ability of the ANN to predict the 10 imaginary movements off line, when they were reflected in a virtual computer hand, was assessed and calculated. Results: After the ANN was trained the subjects were able to perform and control 10 hand movements in the virtual computer hand. The subjects showed a median performance of 5 types of movement with a high correlation with the movement pattern of the data glove. The subjects seemed to relearn to execute motor commands rapidly that had been learned before the accident, independent of how old the injury was. The subject with congenital below-elbow failure of formation was able to perform and control several hand movements in the computer hand that cannot be performed in a myoelectric prosthesis (eg, opposition of the thumb). Conclusions: With the combined use of an ANN and a data glove, acting in concert in a training phase, amputees rapidly can learn to execute several imaginary movements in a virtual computerized hand, this opens promising possibilities for motor control of future hand prostheses.	Lund Univ, Malmo Univ Hosp, Dept Elect Measurements, Lund, Sweden; Lund Univ, Malmo Univ Hosp, Dept Hand Surg, Lund, Sweden	Sebelius, FCP (corresponding author), Lund Univ, Dept Elect Measurements, Box 188, SE-22100 Lund, Sweden.	Fredrik.Sebelius@elmat.lth.se	Sebelius, Fredrik/AAG-4473-2020				ALMSTROM C, 1981, INT ORTHOP, V5, P15; Atkeson CG, 1997, ARTIF INTELL REV, V11, P11, DOI 10.1023/A:1006559212014; Behnke S, 1998, IEEE T NEURAL NETWOR, V9, P1352, DOI 10.1109/72.728387; Behnke S, 1996, IEEE IJCNN, P1439, DOI 10.1109/ICNN.1996.549111; Billock J. N., 1995, REHABILITATION HAND, P1189; Borsook D, 1998, NEUROREPORT, V9, P1013, DOI 10.1097/00001756-199804200-00011; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; CODE RA, 1992, EXP BRAIN RES, V88, P341, DOI 10.1007/BF02259109; Demet K, 2003, DISABIL REHABIL, V25, P480, DOI 10.1080/0963828031000090434; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; Dubernard JM, 2003, ANN SURG, V238, P128, DOI 10.1097/01.SLA.0000078945.70869.82; Engelhart K, 1999, MED ENG PHYS, V21, P431, DOI 10.1016/S1350-4533(99)00066-1; ERIKSSON L, 2001, ARTIFICIAL NEURAL NE; Ersland L, 1996, NEUROREPORT, V8, P207, DOI 10.1097/00001756-199612200-00042; Gallant PJ, 1998, MED BIOL ENG COMPUT, V36, P485, DOI 10.1007/BF02523219; Giraux P, 2001, NAT NEUROSCI, V4, P691, DOI 10.1038/89472; HERBERTS P, 1973, ACTA ORTHOP SCAND, V44, P389, DOI 10.3109/17453677308989075; Hubbard S., 1995, REHABILITATION HAND, P1241; HUDGINS B, 1993, IEEE T BIO-MED ENG, V40, P82, DOI 10.1109/10.204774; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; KELAHAN AM, 1981, BRAIN RES, V223, P151, DOI 10.1016/0006-8993(81)90815-5; Lanzetta M, 2004, SCAND J PLAST RECONS, V38, P106, DOI 10.1080/02844310310019860; Levy LM, 2002, ANN NEUROL, V52, P755, DOI 10.1002/ana.10372; Light C. M., 2002, Journal of Medical Engineering and Technology, V26, P139, DOI 10.1080/03091900210142459; Light CM, 2000, MED ENG PHYS, V22, P679, DOI 10.1016/S1350-4533(01)00017-0; Lundborg G, 2003, J PERIPHER NERV SYST, V8, P209, DOI 10.1111/j.1085-9489.2003.03027.x; Lundborg G, 2001, HAND CLIN, V17, P481; Lundborg G, 1999, J HAND SURG-AM, V24A, P219, DOI 10.1053/jhsu.1999.0219; Lundborg G, 2000, SCAND J PLAST RECONS, V34, P97, DOI 10.1080/02844310050159927; Lundborg G, 2000, J HAND SURG-BRIT EUR, V25B, P242, DOI 10.1054/jhsb.1999.0339; Manger PR, 1996, P ROY SOC B-BIOL SCI, V263, P933, DOI 10.1098/rspb.1996.0138; Merzenich M M, 1993, J Hand Ther, V6, P89; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Perani D, 2001, NEUROSCI LETT, V303, P62, DOI 10.1016/S0304-3940(01)01649-4; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Qi HX, 2000, J NEUROPHYSIOL, V84, P2133; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; ROSSINI PM, 1994, BRAIN RES, V642, P169, DOI 10.1016/0006-8993(94)90919-9; SANES JN, 1990, EXP BRAIN RES, V79, P479; SEBELIUS F, 2004, IN PRESS J MED ENG T; SEBELIUS F, 2001, INTUITIVE CONTROL AR, P9; Shoham D, 2001, J NEUROSCI, V21, P6820; SILCOX DH, 1993, J BONE JOINT SURG AM, V75A, P1781, DOI 10.2106/00004623-199312000-00007; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Wall JT, 2002, BRAIN RES REV, V39, P181, DOI 10.1016/S0165-0173(02)00192-3; Weiss T, 2000, EXP BRAIN RES, V134, P199, DOI 10.1007/s002210000456; WINTER DA, 1994, J ELECTROMYOGR KINES, V4, P15, DOI 10.1016/1050-6411(94)90023-X; 1991, P INT JOINT C NEUR N, P2709	50	73	73	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023	1531-6564		J HAND SURG-AM	J. Hand Surg.-Am. Vol.	JUL	2005	30A	4					780	789		10.1016/j.jhsa.2005.01.002			10	Orthopedics; Surgery	Orthopedics; Surgery	949RB	WOS:000230804700020	16039372				2021-06-18	
J	Inglese, M; Bomsztyk, E; Gonen, O; Mannon, LJ; Grossman, RI; Rusinek, H				Inglese, M; Bomsztyk, E; Gonen, O; Mannon, LJ; Grossman, RI; Rusinek, H			Dilated perivascular spaces: Hallmarks of mild traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							VIRCHOW-ROBIN SPACES; HEAD-INJURY; MR; PREVALENCE; APPEARANCE; EXPRESSION; SPECTRUM; DAMAGE; FLUID	BACKGROUND AND PURPOSE: Recent animal and human studies have shown an increased frequency of enlarged, high-convexity Virchow-Robin spaces (VRS) in several neurologic diseases, suggesting their role as neuroradiologic markers of inflammatory changes. The aim of this study was to determine the prevalence of high-convexity dilated VRS in mild traumatic brain injury (TBI). METHODS: T2-weighted, T1-weighted, fluid-attenuated inversion recovery, and T2*-weighted gradient-echo brain MR images were acquired in 24 patients with TBI (10 women, 14 men; mean age, 33.6; range, 18.1-50.8 years) and 17 age- and sex-matched healthy control subjects (nine women, eight men; mean age, 32.8; range, 18.4-47.8 years). The mean interval after TBI was 3.6 days (range, 1-9 days) in 15 patients and 3.7 years (range, 0.6-13.4 years) in nine patients. Axial T2-weighted images were used to identify dilated VRS and to measure CSF volume; T1-weighted images were used to measure brain volume. Dilated VRS were identified as punctuate areas with CSF-like signal intensity in the high-convexity white matter. RESULTS: Mean (+/- standard deviation) number of VRS was significantly higher in patients (7.1 +/- 4.6) than in controls (2.4 +/- 2.9, P < .0003). In controls, VRS were associated with age (R = 0.69, P < .001) whereas in patients, they neither correlated with brain and CSF volumes nor with age and the elapsed time from injury. CONCLUSION. Our results suggest that the increased number of dilated VRS is a radiologic marker of mild head injury that is readily detectable on T2-weighted images. Because their number does not vary with time from injury, VRS probably reflect early and permanent brain changes.	NYU, Sch Med, Dept Radiol, New York, NY 10016 USA	Inglese, M (corresponding author), NYU, Sch Med, Dept Radiol, 650 1St Ave, New York, NY 10016 USA.		Inglese, Matilde/AAH-3189-2020	Inglese, Matilde/0000-0002-9610-0297; Gonen, Oded/0000-0002-3148-2028	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00096, M01 RR000096] Funding Source: Medline; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB01015, R01 EB001015] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39135, R01 NS039135] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER		Achiron A, 2002, AM J NEURORADIOL, V23, P376; AWAD IA, 1986, STROKE, V17, P1090, DOI 10.1161/01.STR.17.6.1090; BRAFFMAN BH, 1988, AM J ROENTGENOL, V151, P559, DOI 10.2214/ajr.151.3.559; De Santi S, 2001, NEUROBIOL AGING, V22, P529, DOI 10.1016/S0197-4580(01)00230-5; ESIRI MM, 1990, J NEUROL SCI, V100, P3, DOI 10.1016/0022-510X(90)90004-7; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; HIRABUKI N, 1994, AM J NEURORADIOL, V15, P277; Holbourn AHS, 1943, LANCET, V2, P438; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HUGHES W, 1965, LANCET, V2, P19; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; MIRFAKHRAEE M, 1986, RADIOLOGY, V158, P715, DOI 10.1148/radiology.158.3.3945745; Miszkiel KA, 1996, CLIN RADIOL, V51, P842, DOI 10.1016/S0009-9260(96)80080-8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mueller CA, 2003, J NEUROTRAUM, V20, P1007, DOI 10.1089/089771503770195858; MURATA R, 1989, AM J NEURORADIOL, V10, P1165; ROLLINS NK, 1993, RADIOLOGY, V189, P53, DOI 10.1148/radiology.189.1.7690491; Schick S, 1999, NEURORADIOLOGY, V41, P283, DOI 10.1007/s002340050749; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Soares HD, 1995, J NEUROSCI, V15, P8223; Suzuki R, 2003, ACTA NEUROCHIR SUPPL, V86, P277; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tsui WH, 2001, PROC SPIE, V4322, P1725, DOI 10.1117/12.431059; WAGNER HJ, 1974, ACTA NEUROPATHOL, V27, P299, DOI 10.1007/BF00690695	28	73	76	0	4	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2005	26	4					719	724					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	915BU	WOS:000228273400010	15814911				2021-06-18	
J	Thota, AK; Watson, SC; Knapp, E; Thompson, B; Jung, R				Thota, AK; Watson, SC; Knapp, E; Thompson, B; Jung, R			Neuromechanical control of locomotion in the rat	JOURNAL OF NEUROTRAUMA			English	Article						biomechanics; coordination; electromyograms; gait analysis; joint angles; kinematics; stance	SPINAL-CORD INJURY; GROUND REACTION FORCES; OVERGROUND LOCOMOTION; TREADMILL LOCOMOTION; FUNCTIONAL RECOVERY; QUADRUPEDAL LOCOMOTION; HINDLIMB MUSCLE; PARAPLEGIC RATS; GAIT ANALYSIS; PATTERNS	Rodent models are being extensively used to investigate the effects of traumatic injury and develop and assess the mechanisms of repair and regeneration. We present quantitative assessment of two-dimensional (2D) kinematics of overground walking and for the first time three-dimensional (3D) joint angle kinematics of all four limbs during treadmill walking in intact adult female Long-Evans rats. Gait cycle with subphases and intralimb and interlimb cyclograms are presented. Phase relationships between joint angles on a cycle-by-cycle basis and interlimb footfalls are assessed using a simple technique. Electromyogram (EMG) data from major flexor and extensor muscles for each of the hindlimb joints and elbow extensor muscles of the forelimbs synchronized to the 3D kinematics are also obtained. Overground walking kinematics, provides information on base of support, stride length, and hindfoot rotation. Treadmill walking kinematics indicate primarily monophasic angle trajectories for the hip and shoulder joints, weak double peak patterns for the knee and elbow joints, and a prominent double peak pattern for the ankle joints. Maximum flexion of the knee during swing precedes that of the ankle, which precedes that of the hip. A mild exercise regimen over 8 weeks does not alter the kinematics. EMG activity indicates specific relationships of the neural activity to joint angle kinematics. We find that the ankle flexors as well as the hip and elbow extensors maintain constant burst duration with changing cycle duration. Data and techniques described here are likely to be useful for quantitative assessment of altered gait and neural control mechanisms after neurotrauma.	Arizona State Univ, Biodesign Inst, Ctr Rehabil Neurosci & Rehabil Engn, Tempe, AZ 85287 USA; Arizona State Univ, Harrington Dept Bioengn, Tempe, AZ 85287 USA; Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA	Jung, R (corresponding author), Arizona State Univ, Biodesign Inst, Ctr Rehabil Neurosci & Rehabil Engn, POB 879709, Tempe, AZ 85287 USA.	jung@asu.edu	Jung, Ranu/AAA-5112-2019; Thota, Anil/C-5395-2015; Thota, Anil/J-3305-2019	Jung, Ranu/0000-0003-2042-0638; Thota, Anil/0000-0003-0605-2269; Thota, Anil/0000-0003-0605-2269	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 40335, R01 HD040335] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD040335] Funding Source: NIH RePORTER		Antri M, 2002, EUR J NEUROSCI, V16, P467, DOI 10.1046/j.1460-9568.2002.02088.x; Assaiante C, 2000, J MOTOR BEHAV, V32, P211, DOI 10.1080/00222890009601373; Barbeau H, 1999, BRAIN RES REV, V30, P27, DOI 10.1016/S0165-0173(99)00008-9; BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BASSO DM, 1994, RESTOR NEUROL NEUROS, V7, P95, DOI 10.3233/RNN-1994-7205; Beattie MS, 2002, PROG BRAIN RES, V137, P37; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Bregman BS, 2002, PROG BRAIN RES, V137, P257; Broton JG, 1996, J NEUROTRAUM, V13, P409, DOI 10.1089/neu.1996.13.409; Brustein E, 1998, J NEUROPHYSIOL, V80, P1245; Cavanagh P., 1973, BRIT J SPORT MED, V7, P129; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; CLARKE KA, 1986, PHYSIOL BEHAV, V38, P345, DOI 10.1016/0031-9384(86)90105-8; COHEN AH, 1975, J MORPHOL, V146, P177, DOI 10.1002/jmor.1051460202; COLLINS JJ, 1993, J NONLINEAR SCI, V3, P349, DOI 10.1007/BF02429870; de Leon RD, 1999, J NEUROPHYSIOL, V82, P359; de Leon RD, 2001, PHYS THER, V81, P1904, DOI 10.1093/ptj/81.12.1904; De Luca CJ, 1997, J APPL BIOMECH, V13, P135, DOI 10.1123/jab.13.2.135; DELEON R, 1994, BRAIN RES, V654, P241, DOI 10.1016/0006-8993(94)90485-5; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Edgerton VR, 2002, CURR OPIN NEUROBIOL, V12, P658, DOI 10.1016/S0959-4388(02)00379-3; ENGBERG I, 1969, ACTA PHYSIOL SCAND, V75, P614, DOI 10.1111/j.1748-1716.1969.tb04415.x; Fischer MS, 2002, J EXP BIOL, V205, P1315; Fouad K, 2000, BEHAV BRAIN RES, V115, P107, DOI 10.1016/S0166-4328(00)00244-8; Gillis GB, 2001, J EXP BIOL, V204, P2717; GOSLOW GE, 1973, J MORPHOL, V141, P1, DOI 10.1002/jmor.1051410102; GRUNER JA, 1980, EXP BRAIN RES, V40, P361; HALBERTSMA JM, 1983, ACTA PHYSIOL SCAND, P1; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Hase T, 2002, J NEUROTRAUM, V19, P267, DOI 10.1089/08977150252807009; HELGREN ME, 1993, EXP NEUROL, V123, P17, DOI 10.1006/exnr.1993.1137; HERMAN RM, 1976, NEURAL CONTROL LOCOM; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; HUTCHISON DL, 1989, BRAIN RES, V502, P233, DOI 10.1016/0006-8993(89)90618-5; JACKSON KM, 1979, IEEE T BIO-MED ENG, V26, P122, DOI 10.1109/TBME.1979.326551; JASMIN BJ, 1987, J APPL PHYSIOL, V63, P713; Jiang W, 1996, J NEUROPHYSIOL, V76, P849; Jung R, 2001, IEEE T NEUR SYS REH, V9, P319, DOI 10.1109/7333.948461; JUNG R, 2002, J NEUOTRAUMA, V19, pP359; Kaegi S, 2002, EUR J NEUROSCI, V16, P249, DOI 10.1046/j.1460-9568.2002.02076.x; Kiehn O, 1996, J NEUROPHYSIOL, V75, P1472; Kim DH, 1999, J NEUROSCI, V19, P6213, DOI 10.1523/JNEUROSCI.19-14-06213.1999; KuhtzBuschbeck JP, 1996, EXP NEUROL, V137, P212, DOI 10.1006/exnr.1996.0020; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Leblond H, 2003, J NEUROSCI, V23, P11411; McEwen ML, 2001, J NEUROTRAUM, V18, P1383, DOI 10.1089/08977150152725678; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; Muir GD, 1999, EXP BRAIN RES, V126, P307, DOI 10.1007/s002210050739; Muir GD, 2000, EUR J NEUROSCI, V12, P3079, DOI 10.1046/j.1460-9568.2000.00205.x; Multon S, 2003, J NEUROTRAUM, V20, P699, DOI 10.1089/089771503767869935; Phillipson M., 1905, TRAV LAB PHYSIOL I S, V7, P1; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Raineteau O, 2002, EUR J NEUROSCI, V16, P1761, DOI 10.1046/j.1460-9568.2002.02243.x; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ribotta MGY, 1998, ANN NY ACAD SCI, V860, P521; ROSE SA, 1993, J PEDIATR ORTHOPED, V13, P727, DOI 10.1097/01241398-199311000-00007; ROY RR, 1991, J APPL PHYSIOL, V70, P2522; ROY RR, 1985, BRAIN RES, V337, P175, DOI 10.1016/0006-8993(85)91627-0; Tepavac D, 2001, J APPL BIOMECH, V17, P259, DOI 10.1123/jab.17.3.259; Thota A, 2001, Biomed Sci Instrum, V37, P63; Trank TV, 1996, J NEUROPHYSIOL, V76, P2316; vanMeeteren NLU, 1997, ARCH PHYS MED REHAB, V78, P70, DOI 10.1016/S0003-9993(97)90013-7; WESTERGA J, 1990, DEV BRAIN RES, V57, P163, DOI 10.1016/0165-3806(90)90042-W; WESTERGA J, 1993, EXP BRAIN RES, V92, P479; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610; WINSTEIN CJ, 1989, J MOTOR BEHAV, V21, P373; Winter D.A., 1990, BIOMECHANICS MOTOR C, V2nd; Witte H, 2002, J EXP BIOL, V205, P1339; Wolpaw JR, 2001, ANNU REV NEUROSCI, V24, P807, DOI 10.1146/annurev.neuro.24.1.807	74	73	73	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2005	22	4					442	465		10.1089/neu.2005.22.442			24	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	920YM	WOS:000228731400003	15853462				2021-06-18	
J	Leith, KH; Phillips, L; Sample, PL				Leith, KH; Phillips, L; Sample, PL			Exploning the service needs and experiences of persons with TBI and their families: the South Carolina expertience	BRAIN INJURY			English	Article; Proceedings Paper	Annual Meeting of the South-Carolina-Public-Health-Association	2003	Myrtle Beach, SC	S Carolina Public Hlth Assoc			TRAUMATIC BRAIN-INJURY; QUALITATIVE RESEARCH; DECISION-MAKING; REHABILITATION; PERCEPTIONS; NARRATIVES; ACCESS; SELF	Primary objective: This article presents the results of four focus groups with persons with traumatic brain injury (TBI) and their families living in South Carolina. The objective was to learn what participants perceive their service needs to be and where they experience service gaps in the existing system of TBI services. Methods and procedures: Four focus groups were conducted. In each group, a convenience sample of persons <5 years post-injury and family members responded to 10 semi-structured questions. Main outcomes: Qualitative content analysis revealed overwhelming consensus regarding the need for (1) early, continuous, comprehensive service delivery; (2) information/education; (3) formal/informal advocacy; (4) empowerment of persons with TBI/families; and (5) human connectedness/social belonging. Conclusions: Persons with TBI and families in South Carolina experience the service system as unorganized, uneducated, unresponsive and uncaring. Effective strategies are needed that link services into an ongoing continuum of TBI care, increase TBI-specific education and awareness and foster social re-integration.	Univ S Carolina, Norman J Arnold Sch Publ Hlth, Ctr Hlth Serv & Policy Res, Columbia, SC 29208 USA; Colorado State Univ, Dept Occupat Therapy, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA	Leith, KH (corresponding author), Carolina Plaza,Room 1121, Columbia, SC 29201 USA.	leith@sc.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/VVU419436-01] Funding Source: Medline		Abreu BC, 2002, BRAIN INJURY, V16, P691, DOI 10.1080/02699050210128942; American Speech and Hearing Association, 1995, ASHA S14, V37, P23; *BRAIN INJ ASS AM, 2002, WHAT IS BRAIN INJ; BRYANT B, 2002, HEALTHCARE REV NE NE, V3, P5; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CONEELY AL, 2002, BRIT J OCCUPATIONAL, V65, P356; CORRIGAN JD, IN PRESS J HEAD TRAU; Creswell J.W., 2013, QUAL INQ; Darragh AR, 2001, AM J OCCUP THER, V55, P191, DOI 10.5014/ajot.55.2.191; Dean S, 2000, PSYCHOL REP, V86, P653, DOI 10.2466/pr0.2000.86.2.653; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Forbes S, 1998, QUAL HEALTH RES, V8, P736, DOI 10.1177/104973239800800602; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; FYFEE C, 1996, AUSTR J RURAL HLTH, V4, P232; GUILMETTE TJ, 2003, IN PRESS ARCH CLIN N; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HOOPER SR, 2001, N CAROLINA MED J N, V62, P341; KAYSERJONES J, 1995, MED ANTHROPOL Q, V9, P236, DOI 10.1525/maq.1995.9.2.02a00070; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; MCCULLOUGH LB, 1993, GERONTOLOGIST, V33, P324, DOI 10.1093/geront/33.3.324; MCDANIEL RW, 1994, NURS SCI QUART, V7, P4, DOI 10.1177/089431849400700103; MCMORDIE W R, 1991, Brain Injury, V5, P43, DOI 10.3109/02699059108998510; Miles M.B., 1994, QUALITATIVE DATA ANA; MORGAN DL, 1998, FOCUS GROUP KIT 1 FO; Morse JM., 1995, QUALITATIVE RES METH, V2; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Patton M., 2001, QUALITATIVE RES EVAL, V3; Patton MQ., 1990, QUALITATIVE EVALUATI; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rauch RJ, 2001, NEUROREHABILITATION, V16, P11; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; SAMPLE PL, UNPUB THEY LAUNCHED; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P179, DOI 10.1002/nur.4770180211; Sandelowski M, 1999, RES NURS HEALTH, V22, P79, DOI 10.1002/(SICI)1098-240X(199902)22:1<79::AID-NUR9>3.0.CO;2-3; Selassie A, 2003, S CAROLINA TRAUMATIC; Silverman D., 2001, INTERPRETING QUALITA; Smith B, 1998, Perspectives, V22, P2; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tashakkori Abbas, 1998, MIXED METHODOLOGY CO	40	73	74	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2004	18	12					1191	1208		10.1080/02699050410001719943			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	871BW	WOS:000225105300002	15666564				2021-06-18	
J	Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Powell, J				Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Powell, J			Concussion in professional football: Injuries involving 7 or more days out - Part 5	NEUROSURGERY			English	Article						concussion; concussion guidelines; epidemiology; injury surveillance; postconcussion syndrome; sport injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; HIGH-SCHOOL; NEUROPSYCHOLOGICAL DEFICITS; SPORTS; RECOVERY; SYMPTOMS; PERFORMANCE; PLAYERS; IMPACTS	OBJECTIVE: A 6-year study was conducted to determine the signs, symptoms, and outcome of concussions with 7 or more (7+) days out from play or extended postconcussion recovery in the National Football League (NFL). METHODS: From 1996 to 2001, reporting of concussion was performed by NFL teams using a special standardized reporting form filled out by team physicians. Signs and symptoms were grouped by general symptoms, somatic complaints, cranial nerve effects, cognition problems, memory problems, and unconsciousness. Medical action taken and management were recorded. In all, 887 concussions were reported in practices and games. RESULTS: There were 72 concussions (8.1%) involving 7+ days out from play. The highest frequency occurred in quarterbacks (14.8%), the return unit on special teams (11.8%), and secondary (10.8%). Quarterbacks had the highest odds ratio (OR) of 7+ days out with concussion (OR = 2.10, P = 0.049), whereas running backs had the lowest relative risk (OR = 0.13, P = 0.021). The greatest fraction of 7+ days out occurred in passing plays (36.1%) and kickoffs (22.2%). Many signs and symptoms occurred at a greater frequency on initial examination in players 7+ days out; the average number per player was 4.64 with 7+ days out versus 2.58 with fewer days out (t = 6.02, df = 77.1). The signs and symptoms with the highest incidence for 7+ days out were disorientation to time (chi(2) = 51.2, P = 001), retrograde amnesia (chi(2) = 33.2, P = 0.001), fatigue (chi(2) = 28.1, P = 0.001), and the general category of cognition problems (chi(2) = 21.7, P = 0.001). Loss of consciousness for more than 1 minute was a predictor of 7+ days out (chi(2) = 33.5, P = 0.001), although it only occurred in only 7.9% of cases. Of players with 7+ days out, 72.2% were removed from the game and 12.5% were hospitalized. These frequencies were significantly greater than for players with fewer than 7 days out (chi(2) = 68.03, df = 3, P < 0.0001). Approximately 90% of players were managed by rest, irrespective of days out, but a greater fraction were given drug or medical therapies with prolonged days out. CONCLUSION: The most vulnerable players for 7+ days out with concussion were quarterbacks and the secondary in professional football. Although 8.1% of concussions involved 7+ days out, only 1.6% involved a prolonged postconcussion syndrome. They recovered from symptoms and had a consistent return to play in the NFL.	Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA; ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Wayne State Univ, Ctr Hlth Effect Res, Dept Psychiat & Behav Neurosci, Detroit, MI USA; Michigan State Univ, Dept Kinesiol, Lansing, MI USA; Michigan State Univ, Dept Phys Med & Rehabil, Lansing, MI USA	Viano, DC (corresponding author), Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA.	dviano@comcast.net					BOHNEN N, 1992, NEUROSURGERY, V30, P692; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; *CO MED SOC, 1991, REP SPORTS MED COMM; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MANDEL S, 1989, POSTGRAD MED, V85, P213; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POLIN R, 1996, NEUROLOGY TRAUMA, P166; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001	45	73	74	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2004	55	5					1100	1116		10.1227/01.NEU.0000147063.12873.F5			17	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	871FA	WOS:000225114000030	15509317				2021-06-18	
J	Daugherty, WP; Levasseur, JE; Sun, D; Rockswold, GL; Bullock, MR				Daugherty, WP; Levasseur, JE; Sun, D; Rockswold, GL; Bullock, MR			Effects of hyperbaric oxygen therapy on cerebral oxygenation and mitochondrial function following moderate lateral fluid-percussion injury in rats	JOURNAL OF NEUROSURGERY			English	Article						hyperbaric oxygen; mitochondria; brain injury; fluid-percussion injury; rat	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; METABOLISM; GLUCOSE; TISSUE; ISCHEMIA; LACTATE; MODEL	Object. In the current study, the authors examined the effects of hyperbaric O-2 (HBO) following fluid-percussion brain injury and its implications on brain tissue oxygenation (PO2) and O-2 consumption (VO2) and mitochondrial function (redox potential). Methods. Cerebral tissue PO2 was measured following induction of a lateral fluid-percussion brain injury in rats. Hyperbaric O-2 treatment (100% O-2 at 1.5 ata) significantly increased brain tissue PO2 in both injured and sham-injured animals. For VO2, and redox potential experiments, animals were treated using 30% O-2 or HBO therapy for 1 or 4 hours (that is, 4 hours 30% O-2 or 1 hour HBO and 3 hours 100% O-2). Microrespirometer measurements of VO2, demonstrated significant increases following HBO treatment in both injured and sham-injured animals when compared with animals that underwent 30% O-2 treatment. Mitochondrial redox potential, as measured by Alamar blue fluorescence, demonstrated injury-induced reductions at 1 hour postinjury. These reductions were partially reversed at 4 hours postinjury in animals treated with 30% O-2, and completely reversed at 4 hours postinjury in animals on HBO therapy when compared with animals treated for only 1 hour. Conclusions. Analysis of data in the current study demonstrates that HBO significantly increases brain tissue PO, after injury. Nonetheless, treatment with HBO was insufficient to overcome injury-induced reductions in mitochondrial redox potential at 1 hour postinjury but was able to restore redox potential by 4 hours postinjury. Furthermore, HBO induced an increase in VO2, in both injured and sham-injured animals. Taken together, these data demonstrate that mitochondrial function is depressed by injury and that the recovery of aerobic metabolic function may be enhanced by treatment with HBO.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA	Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Dept Neurosurg, POB 980631,1200 E Marshall St, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alessandri B, 1999, ACT NEUR S, V75, P21; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ARTRU F, 1976, EUR NEUROL, V14, P351, DOI 10.1159/000114759; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9; Clifton G L, 1995, New Horiz, V3, P474; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Di Piero V, 2002, EUR J NEUROL, V9, P419, DOI 10.1046/j.1468-1331.2002.00436.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Elayan IM, 2000, J NEUROPHYSIOL, V83, P2022; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; HOLLIN SA, 1968, J NEUROSURG, V29, P229, DOI 10.3171/jns.1968.29.3.0229; JAIN KK, 1999, TXB HYPERBARIC MED, P10; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MINK RB, 1995, CRIT CARE MED, V23, P1398, DOI 10.1097/00003246-199508000-00014; Mogami H, 1969, No To Shinkei, V21, P261; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Ogilvie R W, 1973, Adv Exp Med Biol, V37A, P299; Omae T, 1998, STROKE, V29, P94, DOI 10.1161/01.STR.29.1.94; Ren H, 2001, Chin J Traumatol, V4, P239; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; Sukoff MH, 2001, J NEUROSURG, V95, P544; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Veltkamp R, 2000, BRAIN RES, V853, P68, DOI 10.1016/S0006-8993(99)02250-7; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WOODHALL B, 1971, J NEUROSURG, V34, P3, DOI 10.3171/jns.1971.34.1.0003; Woolley S M, 1999, Pediatr Rehabil, V3, P81; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	44	73	95	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2004	101	3					499	504		10.3171/jns.2004.101.3.0499			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	851NF	WOS:000223691100020	15352608				2021-06-18	
J	Kashluba, S; Paniak, C; Reynolds, S; Toller-Lobe, G; Nagy, J				Kashluba, S; Paniak, C; Reynolds, S; Toller-Lobe, G; Nagy, J			A longitudinal, controlled study of patient complaints following treated mild traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; longitudinal	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RANDOMIZED-TRIAL; LONG; PEOPLE	This study provided 3-month follow-up data to a previous paper that compared symptom complaints of patients with mild traumatic brain injury (MTBI) with those of non-injured control participants within 1 month of injury. The 110 MTBI patients and 118 control participants were group-matched on age, gender, education level, and socioeconomic status. As a group, MTBI patients no longer endorsed significantly more symptoms (M = 14.09, S.D. = 10.77) than did the control group (M = 12.56, S.D. = 8.46, P = .232). Only 3 of the 43 queried symptoms were endorsed by significantly more (Bonferroni-corrected P < .00116) MTBI patients than controls. Using the same Bonferroni-corrected criteria, 10 of the 43 symptoms were endorsed at a significantly higher severity level by MTBI patients. Overall, the treated MTBI group's symptom complaints diminished from baseline to 3 months post-injury, with relatively few differences remaining between the two groups. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Glenrose Rehabil Hosp, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.	cpaniak@cha.ab.ca					Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK C, 1992, DISS ABSTR INT, V52, P6093; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	34	73	73	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2004	19	6					805	816		10.1016/j.acn.2003.09.005			12	Psychology, Clinical; Psychology	Psychology	847SF	WOS:000223414500008	15288333	Bronze			2021-06-18	
J	Hawley, CA				Hawley, CA			Behaviour and school performance after brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; CHILDREN; ADOLESCENTS; SEQUELAE; FAMILY; TEMPERAMENT; INFANTS; SCALE; MILD	Primary objective : To examine the relationship between behavioural problems and school performance following traumatic brain injury (TBI). Methods and procedures : Subjects: 67 school-age children with TBI (35 mild, 13 moderate, 19 severe) and 14 uninjured matched controls. Parents and children were interviewed at a mean of 2 years post-TBI. Teachers reported on academic performance and educational needs. Children were assessed using the Vineland Adaptive Behaviour Scales (VABS) and the Weschler Intelligence Scale for Children (WISC-III). Main outcomes and results : Two-thirds of children with TBI exhibited significant behavioural problems, significantly more than controls ( p = 0.02). Children with behavioural problems had a mean IQ similar to 15 points lower than those without ( p = 0.001, 95% CI: 7-26.7). At school, 76%(19) of children with behavioural problems also had difficulties with schoolwork. Behavioural problems were associated with social deprivation and parental marital status ( p less than or equal to 0.01). Conclusions : Children with TBI are at risk of developing behavioural problems which may affect school performance. Children with TBI should be screened to identify significant behavioural problems before they return to school.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England	Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; *AUD COMM, 2002, STAT ASS STAT SPEC E; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Bevington J, 1999, BRIT J EDUC PSYCHOL, V69, P19, DOI 10.1348/000709999157545; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Greenberg JM, 1999, ADV SPACE RES-SERIES, V23, P289, DOI 10.1016/S0273-1177(99)00049-6; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; JONES GS, 1994, NUCL MED BIOL, V21, P117, DOI 10.1016/0969-8051(94)90138-4; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; MARTIN RP, 1988, SCHOOL PSYCHOL REV, V17, P125; Max JE, 1998, BRAIN INJURY, V12, P41; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; Parmelee D X, 1989, Psychiatr Med, V7, P11; PFEFFER J, 1983, J CLIN PSYCHOL, V39, P1013, DOI 10.1002/1097-4679(198311)39:6<1013::AID-JCLP2270390634>3.0.CO;2-5; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; SEMRUDCLIKEMAN M, 2001, TRAUMATIC BRAIN INJU; Sharples PM, 1998, INJURY YOUNG, P151; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO; Wechsler D., 1991, MANUAL WECHSLER INTE; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P42, DOI 10.1097/00001199-199512000-00007; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P25, DOI 10.1097/00001199-199512000-00006; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271	41	73	73	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					645	659		10.1080/02699050310001646189			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700002	15204326				2021-06-18	
J	Mhatre, M; Nguyen, A; Kashani, S; Pham, T; Adesina, A; Grammas, P				Mhatre, M; Nguyen, A; Kashani, S; Pham, T; Adesina, A; Grammas, P			Thrombin, a mediator of neurotoxicity and memory impairment	NEUROBIOLOGY OF AGING			English	Article						thrombin; cognition; spatial memory; neurotoxicity; glial fibrillary acidic protein; neurofilament; memory deficits	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; ALZHEIMERS-DISEASE; WORKING-MEMORY; CELL-DEATH; NEURITE OUTGROWTH; EDEMA FORMATION; BETA-PROTEIN; RECEPTOR	Thrombin has been found in neuritic plaques in Alzheimer's disease (AD). Also, traumatic brain injury, where neurons are exposed to high thrombin levels, is associated with an increased incidence of AD. Our objective was to determine the effects of thrombin administered in vivo on cognitive function and neuropathology. Rats were trained using a radial eight-arm maze and then thrombin (25 or 100 nM, 0.25 mu/h, 28 days) or vehicle was delivered via intracerebroventricular infusion. Animals that received 100 nM thrombin demonstrated cognitive impairments including deficits in reference memory and an increase in task latency. Also, significant neuropathology was detected in these animals such as enlargement of cerebral ventricles, an increased number of TUNEL-positive cells, astrogliosis, and an increase in the immumoreactivity for phosphorylated neurofilament, and apolipoprotein-E fragments. Thrombin-induced changes in cognitive function and ventricular enlargement were inhibited by hirudin. These findings demonstrate that thrombin is a mediator of neurotoxicity and cognitive deficits and suggest that inhibition of thrombin may be a treatment strategy for AD- or head trauma-associated cognitive deficits. (C) 2003 Elsevier Inc. All rights reserved.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Oklahoma City, OK 73104 USA	Grammas, P (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 975 NE 10th St, Oklahoma City, OK 73104 USA.	paula-grammas@ouhsc.edu	sharifkashani, shervin/AAP-3773-2020	sharifkashani, shervin/0000-0002-5226-9621	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG015964] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 15964] Funding Source: Medline		AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Armao D, 1997, BRAIN RES, V767, P259, DOI 10.1016/S0006-8993(97)00567-2; Bimonte-Nelson HA, 2003, BEHAV BRAIN RES, V139, P47, DOI 10.1016/S0166-4328(02)00082-7; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHONG YH, 1994, LIFE SCI, V54, P1259; Ciallella JR, 1999, THROMB HAEMOSTASIS, V81, P630; Colon GP, 1996, J NEUROSURG, V85, P335, DOI 10.3171/jns.1996.85.2.0335; Conti AC, 1998, J NEUROSCI, V18, P5663; CRUTCHER KA, 1997, ALZHEIMERS DIS BIOL, P545; Dickson TC, 1999, EXP NEUROL, V156, P100, DOI 10.1006/exnr.1998.7010; Dickson TC, 2001, NEUROSCIENCE, V105, P99, DOI 10.1016/S0306-4522(01)00169-5; Donovan FM, 1997, J NEUROSCI, V17, P5316; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Garcia JH, 1994, INTRACEREBRAL HEMORR, P45; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; Gill JS, 1998, BRAIN RES, V797, P321, DOI 10.1016/S0006-8993(98)00344-8; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gould TJ, 2002, BRAIN RES BULL, V58, P581, DOI 10.1016/S0361-9230(02)00832-8; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; Jiang YJ, 2002, J CEREBR BLOOD F MET, V22, P404, DOI 10.1097/00004647-200204000-00004; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LORET C, 1989, J BIOL CHEM, V264, P19; Marques MA, 1996, NEUROREPORT, V7, P2529, DOI 10.1097/00001756-199611040-00025; Martinez I, 2002, NEUROPSYCHOBIOLOGY, V46, P97, DOI 10.1159/000065419; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; Miyoshi E, 2002, BRAIN RES BULL, V58, P41, DOI 10.1016/S0361-9230(02)00754-2; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Quintana J, 2003, BIOL PSYCHIAT, V53, P12, DOI 10.1016/S0006-3223(02)01435-X; Reimann-Philipp U, 2001, J NEUROSCI RES, V64, P654, DOI 10.1002/jnr.1119; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Sarker KP, 1999, THROMB HAEMOSTASIS, V82, P1071; Smirnova IV, 1996, J NEUROCHEM, V67, P2188; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Turgeon VL, 1999, J NEUROBIOL, V38, P571, DOI 10.1002/(SICI)1097-4695(199903)38:4<571::AID-NEU11>3.3.CO;2-Y; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; VAUGHAN PL, 1994, NEUROREPORT, V5, P2529; Vergnolle N, 1999, BRIT J PHARMACOL, V126, P1262, DOI 10.1038/sj.bjp.0702408; WHITE RP, 1980, STROKE, V11, P363, DOI 10.1161/01.STR.11.4.363; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408	55	73	75	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	JUL	2004	25	6					783	793		10.1016/j.neurobiolaging.2003.07.007			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	834PS	WOS:000222423600014	15165703				2021-06-18	
J	Sundstrom, A; Marklund, P; Nilsson, LG; Cruts, M; Adolfsson, R; Van Broeckhoven, C; Nyberg, L				Sundstrom, A; Marklund, P; Nilsson, LG; Cruts, M; Adolfsson, R; Van Broeckhoven, C; Nyberg, L			APOE influences on neuropsychological function after mild head injury - Within-person comparisons	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E GENOTYPES; PROSPECTIVE COHORT; SYMPTOMS; RECOVERY; SEQUELAE; MEMORY	Objective: To examine the relationship between neuropsychological outcome following mild head injury (MHI) and APOE genotype. Methods: Data from a population-based longitudinal study (n = 3,500) were used to identify 34 adults who experienced MHI during the course of the study. Their pre- and postinjury performances on a battery of nine neuropsychological tests were compared within person, and the postinjury performance was compared with that of age- and gender-matched control subjects. Results: The within-person comparisons showed that participants with at least one APOE epsilon4 allele (n = 11) had a significantly decreased postinjury performance on three of the tests, whereas the postinjury performance for APOE epsilon4-negative participants (n = 23) was unchanged. There was no significant difference in postinjury performance between participants with/without the epsilon4 allele, and neither group was impaired relative to controls. Conclusions: APOE genotype may influence the outcome following an MHI. Pre/postinjury within-person comparisons seem more sensitive than control group comparisons for detecting injury-related effects.	Umea Univ, Dept Psychol, S-90187 Umea, Sweden; Umea Univ, Dept Clin Sci & Psychiat, S-90187 Umea, Sweden; Univ Stockholm, Dept Psychol, S-10691 Stockholm, Sweden; Univ Antwerp VIB, Dept Mol Genet, Antwerp, Belgium	Sundstrom, A (corresponding author), Umea Univ, Dept Psychol, S-90187 Umea, Sweden.	anna.sundstrom@psy.umu.se	Nyberg, Lars/C-2514-2009; Van Broeckhoven, Christine/M-7853-2019; Nyberg, Lars/M-5986-2019; Cruts, Marc/J-6161-2013; Van Broeckhoven, Christine/G-8362-2017	Nyberg, Lars/0000-0002-3367-1746; Van Broeckhoven, Christine/0000-0003-0183-7665; Nyberg, Lars/0000-0002-3367-1746; Cruts, Marc/0000-0002-1338-992X; Van Broeckhoven, Christine/0000-0003-0183-7665; Adolfsson, Rolf/0000-0001-9785-8473			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bartres-Faz D, 1999, NEUROREPORT, V10, P2923, DOI 10.1097/00001756-199909290-00009; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Bretsky P, 2003, NEUROLOGY, V60, P1077, DOI 10.1212/01.WNL.0000055875.26908.24; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; JORDON BD, 1997, JAMA-J AM MED ASSOC, V9, P136; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nilsson LG, 1997, AGING NEUROPSYCHOL C, V4, P1, DOI 10.1080/13825589708256633; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Smith JD, 2002, AGEING RES REV, V1, P345, DOI 10.1016/S1568-1637(02)00005-3; Staehelin HB, 1999, ACTA NEUROL SCAND, V100, P53, DOI 10.1111/j.1600-0404.1999.tb00723.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WENHAM PR, 1991, CLIN CHEM, V37, P241	23	73	73	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUN 8	2004	62	11					1963	1966		10.1212/01.WNL.0000129268.83927.A8			4	Clinical Neurology	Neurosciences & Neurology	827HN	WOS:000221890400011	15184597				2021-06-18	
J	Nicholson, BD				Nicholson, BD			Evaluation and treatment of central pain syndromes	NEUROLOGY			English	Article; Proceedings Paper	Symposium on Neurology of Special Population held at the 30th Annual Meeting of the Southern-Clinical-Neurological-Society	JAN 20, 2003	Ixtapa, MEXICO	SO Clin Neurol Soc			CENTRAL POSTSTROKE PAIN; MOTOR CORTEX STIMULATION; SPINAL-CORD STIMULATION; POST-STROKE PAIN; INTRATHECAL BACLOFEN; NEUROPATHIC PAIN; BOTULINUM TOXIN; SPASTICITY; LAMOTRIGINE; MECHANISMS	Central pain syndromes represent a form of neuropathic pain that is associated with lesions of the brain or the spinal cord after a stroke or other traumatic injury. Although spinal cord injury (SCI) pain and central post-stroke pain (CPSP) are both classified as central pain syndromes, they may have differing etiologies. The pathophysiology of SCI pain and CPSP has yet to be completely elucidated, but both spinal and supraspinal pathways may be involved. Pain resulting from an injury to the CNS may be vague or difficult to classify or characterize, and patients may describe painful sensations that are poorly localized or that change over time. Pharmacologic interventions that have demonstrated efficacy in central pain syndromes include iv lidocaine and opioids as well as the tricyclic antidepressant amitriptyline and the AEDs gabapentin and lamotrigine. Nonpharmacologic interventions have also demonstrated benefit in some patients who are refractory to pharmacologic treatments. Additional studies are needed to further evaluate the efficacy and safety of both pharmacologic and nonpharmacologic treatments for central pain syndromes.	Lehigh Valley Hosp & Hlth Network, Div Pain Med & Hospice, Allentown, PA 18105 USA; Penn State Univ, Sch Med, Dept Anesthesia, Allentown, PA 18105 USA	Nicholson, BD (corresponding author), Lehigh Valley Hosp & Hlth Network, Div Pain Med & Hospice, 1240 S Cedar Crest Blvd,Ste 307, Allentown, PA 18105 USA.						*AM HEART ASS, 2002, HEART DIS STROK STAT; ANDERSEN G, 1995, PAIN, V61, P187, DOI 10.1016/0304-3959(94)00144-4; Attal N, 2002, NEUROLOGY, V58, P554, DOI 10.1212/WNL.58.4.554; Attal N, 2000, NEUROLOGY, V54, P564, DOI 10.1212/WNL.54.3.564; BONICA JJ, 1991, SYMP PAIN R, P13; Bouhassira D, 2000, PROG PAIN RES MANAG, V16, P401; Bowsher D, 1998, NEUROLOGY, V51, P1352, DOI 10.1212/WNL.51.5.1352; BOWSHER D, 1999, P 9 WORLD C PAIN, P435; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; Canavero S, 2002, NEUROLOGY, V58, P831, DOI 10.1212/WNL.58.5.831-a; DOSTROVSKY J, 2000, 9 WORLD C PAIN PROGR, P419; Eide PK, 1998, SPINAL CORD, V36, P601, DOI 10.1038/sj.sc.3100737; Eisenberg E, 2001, NEUROLOGY, V57, P505, DOI 10.1212/WNL.57.3.505; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Finnerup NB, 2002, PAIN, V96, P375, DOI 10.1016/S0304-3959(01)00484-5; FINNERUP NB, 2001, INT ASS STUDY PAIN, P9; Gelber DA, 1999, NEUROREHAB NEURAL RE, V13, P5, DOI 10.1177/154596839901300103; Gelber DA, 2001, STROKE, V32, P1841, DOI 10.1161/01.STR.32.8.1841; GELBER DA, 2000, STROKE CLIN UPDATES, P10; Gracies JM, 1997, MUSCLE NERVE, pS92; Gruenthal M, 1997, SPINAL CORD, V35, P686, DOI 10.1038/sj.sc.3100481; Gwartz BL, 2001, AM J PHYS MED REHAB, V80, P383, DOI 10.1097/00002060-200105000-00014; JENSEN TS, 1995, PAIN, V61, P161, DOI 10.1016/0304-3959(94)00227-6; Katayama Y, 2001, STEREOT FUNCT NEUROS, V77, P183, DOI 10.1159/000064618; LEIJON G, 1989, PAIN, V36, P13, DOI 10.1016/0304-3959(89)90107-3; LEIJON G, 1989, PAIN, V36, P27, DOI 10.1016/0304-3959(89)90108-5; Linderoth B., 1993, Stereotactic and Functional Neurosurgery, V61, P157, DOI 10.1159/000100634; Maruno N, 2000, NEUROREHAB NEURAL RE, V14, P345, DOI 10.1177/154596830001400410; MCHENRY KW, 2002, INT ASS STUDY PAIN, P10; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Meythaler JA, 2001, ARCH PHYS MED REHAB, V82, P1155, DOI 10.1053/apmr.2001.25141; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; *NAT SPIN CORD INJ, 2001, SPIN CORD INJ FACTS; OBrien CF, 1996, DRUG AGING, V9, P332, DOI 10.2165/00002512-199609050-00004; Roux FE, 2001, NEUROSURGERY, V48, P681, DOI 10.1097/00006123-200103000-00050; SIDDALL PJ, 2000, IASP NEWSLETTER; Stiller CO, 1996, NEUROSURGERY, V39, P367, DOI 10.1097/00006123-199608000-00026; Tai Qing, 2002, J Spinal Cord Med, V25, P100; TASKER R, 2001, BONICAS MANAGEMENT P, P432; Vestergaard K, 2001, NEUROLOGY, V56, P184, DOI 10.1212/WNL.56.2.184; Wang HC, 2002, AM J PHYS MED REHAB, V81, P272, DOI 10.1097/00002060-200204000-00005; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0	43	73	78	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 9	2004	62	5		2			S30	S36		10.1212/WNL.62.5_suppl_2.S30			7	Clinical Neurology	Neurosciences & Neurology	802DG	WOS:000220143600006	15007162				2021-06-18	
J	Self, ML; Blake, AM; Whitley, M; Nadalo, L; Dunn, E				Self, ML; Blake, AM; Whitley, M; Nadalo, L; Dunn, E			The benefit of routine thoracic, abdominal, and pelvic computed tomography to evaluate trauma patients with closed head injuries	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	55th Annual Meeting of the Southwestern-Surgical-Congress	APR 27-30, 2003	TUCSON, ARIZONA	Southwestern Surg Congress		computed tomography; blunt trauma; closed head injury; physical examination	DIAGNOSTIC PERITONEAL-LAVAGE; BLUNT TRAUMA; SONOGRAPHY; EXPERIENCE; ULTRASOUND; CT	Background: The evaluation of multitrauma patients for blunt truncal injuries remains open for debate. We sought to evaluate the role of routine computed tomography (CT) of the chest, abdomen, and pelvis as a screening tool for patients already undergoing cranial CT studies. Methods: Charts of blunt trauma patients admitted from June 2000 to June 2001 were reviewed for demographics, Glascow Coma Scale (GCS), physical and radiological findings, and length of stay. Results: Our study found that 38% of patients undergoing cranial CT scanning had a unexpected finding on body scans. Changes were made in 26% of the study group because results found on the adjuvant CTs. Conclusions: Additional body CTs add minimal cost to the care of trauma patients but can significantly change the management. We believe it is beneficial to perform routine body CT examinations when performing cranial imaging for blunt head injury. (C) 2003 Excerpta Medica, Inc. All rights reserved.	Methodist Hosp, Dept Surg, Dallas, TX USA; Methodist Hosp, Dept Radiol, Dallas, TX USA; Gen Surg, Dallas, TX 75265 USA	Dunn, E (corresponding author), Methodist Hosp, Dept Surg, Dallas, TX USA.						CATRE MG, 1995, CAN J SURG, V38, P117; Chiu WC, 1997, J TRAUMA, V42, P617, DOI 10.1097/00005373-199704000-00006; Demetriades D, 1998, ARCH SURG-CHICAGO, V133, P1084, DOI 10.1001/archsurg.133.10.1084; Downing SW, 2001, ANN THORAC SURG, V72, P495, DOI 10.1016/S0003-4975(01)02827-2; Fakhry SM, 2003, J TRAUMA, V54, P1, DOI 10.1097/00005373-200301000-00001; Feliciano D V, 1992, Semin Thorac Cardiovasc Surg, V4, P156; Fernandez L, 1998, J TRAUMA, V45, P841, DOI 10.1097/00005373-199810000-00047; Guillamondegui OD, 2002, J TRAUMA, V53, P1043, DOI 10.1097/00005373-200212000-00002; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; MACKERSIE RC, 1989, ARCH SURG-CHICAGO, V124, P809; McKenney MG, 1996, J TRAUMA, V40, P607, DOI 10.1097/00005373-199604000-00015; Mirvis SE, 1998, J TRAUMA, V45, P922, DOI 10.1097/00005373-199811000-00014; Ochsner MG, 2000, J TRAUMA, V49, P505, DOI 10.1097/00005373-200009000-00019; OLSEN WR, 1971, J TRAUM, V11, P824, DOI 10.1097/00005373-197110000-00002; Rhee PM, 2002, J TRAUMA, V53, P663, DOI 10.1097/00005373-200210000-00007; ROOT HD, 1965, SURGERY, V57, P633; ROZYCKI GS, 1993, J TRAUMA, V34, P516, DOI 10.1097/00005373-199304000-00008; Scaglione M, 2001, EUR RADIOL, V11, P2444, DOI 10.1007/s003300100836; Scalea TM, 1999, J TRAUMA, V46, P466, DOI 10.1097/00005373-199903000-00022; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; TSO P, 1992, J TRAUMA, V33, P39, DOI 10.1097/00005373-199207000-00009; Voggenreiter G, 2000, CRIT CARE MED, V28, P1033, DOI 10.1097/00003246-200004000-00020	22	73	75	0	0	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0002-9610			AM J SURG	Am. J. Surg.	DEC	2003	186	6					609	614		10.1016/j.amjsurg.2003.08.003			6	Surgery	Surgery	753NN	WOS:000187237600006	14672766				2021-06-18	
J	Satchell, MA; Zhang, XP; Kochanek, PM; Dixon, CE; Jenkins, LW; Melick, J; Szabo, C; Clark, RSB				Satchell, MA; Zhang, XP; Kochanek, PM; Dixon, CE; Jenkins, LW; Melick, J; Szabo, C; Clark, RSB			A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD(+) depletion and ribosylation of 14-3-3 gamma	JOURNAL OF NEUROCHEMISTRY			English	Article						14-3-3; DNA damage; head injury; 5-iodo-6-amino-1,2-benzopyrone; nicotinamide adenine dinucleotide; poly(ADP-ribose) synthetase	NITRIC-OXIDE SYNTHASE; LONG-TERM POTENTIATION; NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE; CEREBRAL-ISCHEMIA; RIBOSE POLYMERASE; DNA-DAMAGE; RATS; ACTIVATION; TRANSCRIPTION	Poly(ADP-ribose) polymerase-1 (PARP-1) is a homeostatic enzyme that paradoxically contributes to disturbances in spatial memory acquisition after traumatic brain injury (TBI) in transgenic mice, thought to be related to depletion of its substrate nicotinamide adenine dinucleotide (NAD(+)). In this study, systemic administration of the PARP-1 inhibitor 5-iodo-6-amino-1,2-benzopyrone (INH2BP) after TBI preserved brain NAD(+) levels and dose-dependently reduced poly-ADP-ribosylation 24 h after injury. While moderate-dose INH2BP improved spatial memory acquisition after TBI; strikingly, both injured- and sham-mice receiving high-dose INH2BP were unable to learn in the Morris-water maze. Poly-ADP-ribosylated peptides identified using a proteomics approach yielded several proteins potentially associated with memory, including structural proteins (tubulin alpha and beta, gamma-actin, and alpha-internexin neuronal intermediate filament protein) and 14-3-3gamma. Nuclear poly-ADP-ribosylation of 14-3-3gamma was completely inhibited by the dose of INH2BP that produced profound memory disturbances. Thus, partial inhibition of poly-ADP-ribosylation preserves NAD(+) and improves functional outcome after TBI, whereas more complete inhibition impairs spatial memory acquisition independent of injury, and is associated with ribosylation of 14-3-3gamma.	Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Inotek Pharmaceut Corp, Beverly, MA USA	Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318, R44 NS37985] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620, R44NS037985] Funding Source: NIH RePORTER		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bauer PI, 2000, INT J MOL MED, V5, P533; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BENARI Y, 1995, TRENDS NEUROSCI, V18, P519, DOI 10.1016/0166-2236(95)98371-5; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; DAWSON TM, 1995, NEW HORIZONS, V3, P86; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Fountoulakis M, 1999, J NEURAL TRANSM-SUPP, P323; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; KASLOW HR, 1981, J CELL BIOL, V91, P410, DOI 10.1083/jcb.91.2.410; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kleppisch T, 1999, J NEUROSCI, V19, P48; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Oei SL, 2001, BIOCHEM BIOPH RES CO, V284, P450, DOI 10.1006/bbrc.2001.4985; Peyrl A, 2002, ELECTROPHORESIS, V23, P152, DOI 10.1002/1522-2683(200201)23:1<152::AID-ELPS152>3.0.CO;2-T; Philip N, 2001, J NEUROSCI, V21, P8417; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Rao A, 2000, HIPPOCAMPUS, V10, P527, DOI 10.1002/1098-1063(2000)10:5<527::AID-HIPO3>3.0.CO;2-B; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Rozental R, 2001, DEV NEUROSCI-BASEL, V23, P420, DOI 10.1159/000048729; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tsukahara F, 2000, MOL PHARMACOL, V58, P1257; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Wheal HV, 1998, PROG NEUROBIOL, V55, P611, DOI 10.1016/S0301-0082(98)00026-4; YOSHIHARA K, 1994, MOL CELL BIOCHEM, V135, P143, DOI 10.1007/BF00926517; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	49	73	76	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2003	85	3					697	708		10.1046/j.1471-4159.2003.01707.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	667XJ	WOS:000182259900016	12694396	Bronze			2021-06-18	
J	Kim, J; Gearhart, MM; Zurick, A; Zuccarello, M; James, L; Luchette, FA				Kim, J; Gearhart, MM; Zurick, A; Zuccarello, M; James, L; Luchette, FA			Preliminary report on the safety of heparin for deep venous thrombosis prophylaxis after severe head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						heparin; deep venous thrombosis; head injury; venous thromboembolism; trauma; prophylaxis	LOW-DOSE HEPARIN; MOLECULAR-WEIGHT HEPARIN; TRAUMA PATIENTS; MAJOR TRAUMA; NEUROSURGICAL PATIENTS; VEIN THROMBOSIS; THROMBOEMBOLISM; PREVENTION; RISK; ENOXAPARIN	Background: Prophylaxis for venous thromboembolism (VTE) in head injured patients has avoided heparin products because of concern for exacerbating intracranial bleeding. The purpose of this study was to evaluate the safety of unfractionated heparin (UFH) for VTE prophylaxis after traumatic brain injury. Methods: We retrospectively evaluated the early use of UFH in patients sustaining a severe closed head injury (Abbreviated Injury Scale score > 3) from January 1, 2000, through December 31, 2000. Two groups were formed on the basis of the timing of UFH administration: within 72 hours of admission (Early group), or after the third day of hospitalization (Late group), if at all. Intracranial bleeding related to UFH administration was assessed by computed tomographic scan of the head and/or clinical examination. Results: Sixty-four of 76 patients with intracranial blood on admission head computed tomographic scan fulfilled study criteria. Seventy-three percent (n = 47) were in the Early group and 27% (n = 17) were in the Late group. None of the Early group had an increase in intracranial bleeding or deterioration on neurologic examination as a result of UFH administration. However, there was no statistical difference in VTE events between the two groups. Conclusion: Early use of UFH in the severe head injured patient does not increase bleeding complications.	Loyola Univ, Stritch Sch Med, Dept Surg, Div Trauma Crit Care & Burns, Maywood, IL 60153 USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Pharm Serv, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH USA	Luchette, FA (corresponding author), Loyola Univ, Stritch Sch Med, Dept Surg, Div Trauma Crit Care & Burns, 2160 S 1st Ave, Maywood, IL 60153 USA.		Luchette, Fred/ABF-1710-2020	Luchette, Fred/0000-0002-8857-9111			Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARNETT HG, 1977, J NEUROSURG, V47, P27, DOI 10.3171/jns.1977.47.1.0027; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; Greenfield LJ, 1997, J TRAUMA, V42, P100, DOI 10.1097/00005373-199701000-00017; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; Macdonald RL, 1999, NEUROSURGERY, V45, P245, DOI 10.1097/00006123-199908000-00008; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; Shackford SR, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; Velmahos GC, 1998, J AM COLL SURGEONS, V187, P529, DOI 10.1016/S1072-7515(98)00223-3; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Wen DY, 1998, SURG NEUROL, V50, P521, DOI 10.1016/S0090-3019(98)00083-4	24	73	76	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2002	53	1					38	42		10.1097/00005373-200207000-00008			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	573BR	WOS:000176809900012	12131387				2021-06-18	
J	Ownsworth, TL; McFarland, K; Young, RM				Ownsworth, TL; McFarland, K; Young, RM			The investigation of factors underlying deficits in self-awareness and self-regulation	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; HEAD-INJURY; IMPAIRED AWARENESS; REHABILITATION; ANOSOGNOSIA; UNAWARENESS; DYSFUNCTION; DISORDER; ADULTS	Primary objective: To examine a theoretical model which suggests that a contribution of both psychological and neuropsychological factors underlie deficits in self-awareness and self-regulation. Research design: Multivariate design including correlations and analysis of variance (ANOVA). Methods: Sixty-one subjects with acquired brain injury (ABI) were administered standardized measures of self-awareness and self-regulation. Psychological factors included measures of coping-related denial, personality-related denial and personality change. Neuropsychological factors included an estimate of IQ and two measures of executive functioning that assess capacity for volition and purposive behaviour. Main outcomes and results: The findings indicated that the relative contribution of neuropsychological factors to an outcome of deficits in self-awareness and self-regulation had a more direct effect than psychological factors. In general, measures of executive functioning had a direct relationship, while measures of coping-related and personality-related denial had an indirect relationship with measures of self-awareness and self-regulation. Conclusion: The findings highlighted the importance of measuring both neuropsychological and psychological factors and demonstrated that the relative contribution of these variables varies according to different levels of self-awareness and self-regulation.	Univ Queensland, Sch Psychol, St Lucia, Qld 4067, Australia; Univ Queensland, Dept Psychiat, St Lucia, Qld 4067, Australia	Ownsworth, TL (corresponding author), Brain Injury Assoc Queensland, POB 1519, Milton, Qld 4064, Australia.		Young, Ross/AAF-2082-2021	Young, Ross/0000-0002-6806-6503; Ownsworth, Tamara/0000-0003-1835-7094			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BLUMER D, 1975, PSYCHIATRIC ASPECTS, V1, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cramer P, 1998, J PERS, V66, P919, DOI 10.1111/1467-6494.00037; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1093/neucas/3.1.73; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GISI TM, 1999, DISS ABSTR INT B, V59, P4463; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; KEPPEL G, 1991, DESIGN ANAL; Kiersky JE, 1998, INSIGHT AND PSYCHOSIS, P91; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LANE RD, 1990, AM J PSYCHIAT, V147, P573; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; LOEB PA, 1986, INDEPENDENT LIVING S; MALCOLM CD, 1993, THESIS BOSTON U; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Prigatano G. P., 1993, NEUROPSYCHOL REHABIL, V3, P53; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Prigatano GP, 1986, CLIN NEUROPSYCHOLOGY, P135; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosenthal M., 1983, REHABILITATION HEAD, P197; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Tabachnick BG, 2013, USING MULTIVARIATE S; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; TUPPER DE, 1989, ANN M NAT AC NEUR WA; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO	56	73	73	0	18	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2002	16	4					291	309		10.1080/02699050110103986			19	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700002	11953001				2021-06-18	
J	Smythe, GA; Braga, O; Brew, BJ; Grant, RS; Guillemin, GJ; Kerr, SJ; Walker, DW				Smythe, GA; Braga, O; Brew, BJ; Grant, RS; Guillemin, GJ; Kerr, SJ; Walker, DW			Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry	ANALYTICAL BIOCHEMISTRY			English	Article							KYNURENINE PATHWAY METABOLISM; TRAUMATIC BRAIN INJURY; RAT-BRAIN; TRYPTOPHAN-METABOLITES; NEUROLOGICAL DISEASE; CEREBROSPINAL-FLUID; HUMAN ASTROCYTES; MODULATION; MECHANISM; DEPLETION	Quinolinic, picolinic, and nicotinic acids and nicotinamide are end products of the kynurenine pathway from L-tryptophan and are intermediates in the biosynthesis of nicotinamide adenine dinucleotide. These compounds are involved in complex interrelationships with inflammatory and apoptotic responses associated with neuronal cell damage and death in the central nervous system. To facilitate the study of these compounds, we have utilized gas chromatography-mass spectrometry in electron capture negative ionization mode for their concurrent trace quantification in a single sample. Deuterium-labeled quinolinic, picolinic, and nicotinic acids were used as internal standards and the compounds were converted to their hexafluoroisopropyl esters prior to chromatography. Nicotinamide was readily quantified after conversion to nicotinic acid using gas-phase hydrolysis-a process which did not affect the deuterated internal standards. The on-column limit of quantification was less than 1 fmol for each of the analytes and calibration curves were linear. A packed column liner was used in the gas chromatograph inlet to effectively eliminate sample interference effects in the analysis of trace (femtomolar) levels of quinolinic acid. The method enables rapid and specific concurrent quantification of quinolinic, picolinic, and nicotinic acids in tissue extracts and physiological and culture media. (C) 2002 Elsevier Science.	Univ New S Wales, Fac Med, Ray Williams Biomed Mass Spectrometry Facil, Sydney, NSW 2052, Australia; St Vincents Hosp, Dept Neuroimmunol, Ctr Immunol, Sydney, NSW 2010, Australia; Sydney Adventist Hosp, Dept Microbiol, Wahroonga, NSW 2076, Australia; Natl Prescribing Serv, Surry Hills, NSW 2010, Australia; Monash Univ, Dept Physiol, Melbourne, Vic 3168, Australia	Smythe, GA (corresponding author), Univ New S Wales, Fac Med, Ray Williams Biomed Mass Spectrometry Facil, Sydney, NSW 2052, Australia.		Guillemin, Gilles J/C-3878-2015; McLean, Emma/F-4616-2012; Kerr, Stephen J/J-6126-2012; Brew, Bruce/J-6513-2012	Guillemin, Gilles J/0000-0001-8105-4470; Kerr, Stephen J/0000-0002-1919-4525; 			Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; BENINGER RJ, 1994, NEUROSCIENCE, V61, P603, DOI 10.1016/0306-4522(94)90438-3; Bosco MC, 2000, J IMMUNOL, V164, P3283, DOI 10.4049/jimmunol.164.6.3283; Dobbie M, 2000, AM J TROP MED HYG, V62, P284, DOI 10.4269/ajtmh.2000.62.284; Guillemin GJ, 2000, REDOX REP, V5, P108, DOI 10.1179/135100000101535375; Guillemin GJ, 1999, ADV EXP MED BIOL, V467, P125; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1993, BRAIN, V116, P1425, DOI 10.1093/brain/116.6.1425; HORNING EC, 1955, ORG SYNTH, V3, P740; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; JHAMANDAS K, 1990, BRAIN RES, V529, P185, DOI 10.1016/0006-8993(90)90826-W; JHAMANDAS KH, 1994, CAN J PHYSIOL PHARM, V72, P1473, DOI 10.1139/y94-213; KALISCH BE, 1994, BRAIN RES, V668, P1, DOI 10.1016/0006-8993(94)90504-5; LEHMANN J, 1985, J PHARMACOL EXP THER, V232, P873; MELILLO G, 1994, J BIOL CHEM, V269, P8128; NARITSIN DB, 1995, ANAL CHEM, V67, P863, DOI 10.1021/ac00101a012; Nicholls T, 2001, AM J OBSTET GYNECOL, V184, P203, DOI 10.1067/mob.2001.108862; Nicholls T, 1999, AM J OBSTET GYNECOL, V181, P1452, DOI 10.1016/S0002-9378(99)70391-1; Sanni LA, 1998, AM J PATHOL, V152, P611; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; STONE TW, 1993, PHARMACOL REV, V45, P309; Stone TW, 2001, TOXICON, V39, P61, DOI 10.1016/S0041-0101(00)00156-2; STREFFER C, 1975, ACTA VITAMINOL ENZYM, V29, P262; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; VROOMAN L, 1993, BRAIN RES, V627, P193, DOI 10.1016/0006-8993(93)90320-M; WOLF H, 1974, SCAND J CLIN LAB INV, V33, P1	29	73	74	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0003-2697	1096-0309		ANAL BIOCHEM	Anal. Biochem.	FEB 1	2002	301	1					21	26		10.1006/abio.2001.5490			6	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	518HG	WOS:000173661300004	11811963				2021-06-18	
J	Kontopoulos, V; Foroglou, N; Patsalas, J; Magras, J; Foroglou, G; Yiannakou-Pephtoulidou, M; Sofianos, E; Anastassiou, H; Tsaoussi, G				Kontopoulos, V; Foroglou, N; Patsalas, J; Magras, J; Foroglou, G; Yiannakou-Pephtoulidou, M; Sofianos, E; Anastassiou, H; Tsaoussi, G			Decompressive craniectomy for the management of patients with refractory hypertension: Should it be reconsidered?	ACTA NEUROCHIRURGICA			English	Article						diffuse brain injury; refractory post-traumatic brain oedema; decompressive craniectomy	SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; INTRACRANIAL HYPERTENSION; PRESSURE; EXPERIENCE	Introduction. The management of refractory post-traumatic cerebral oedema remains a frustrating endeavor for the neurosurgeon and the intensivist. Mortality and morbidity rates remain high, despite refinements in medical and pharmacological means of controlling intracranial hypertension. Method and Material. In this retrospective study we have evaluated the efficacy of decompressive craniectomy as a last resort therapy, from the data of nine patients with severe brain injury and delayed cerebral oedema (diffuse injury type III), treated between January 1997 and September 1999. The following parameters were considered: age, Glascow Coma Scale, injury severity, intracranial pressure, CT findings, pupil reaction/posturing. Follow-up period was over at least 2 years and outcome measured on the GOS. Results. Patients have been operated on post-trauma median day 3, mean age 26 +/- 9, GCS 7 +/- 3.7, mean APACHE II 16 +/- 6.4, mean ISS 27.8 +/- 16.1, mean preoperative ICP 37.7 +/- 10.0, mean postoperative ICP 18.1 +/- 16.01. Seven patients have been operated by a frontotemporoparietal approach (six of them bilateral, one unilateral) and two patients have been operated on by a bilateral subtemporal approach. Mortality rates 22%, severe disability 11%, good recovery 66%. Discussion. Patients with STBI, developing delayed intracranial hypertension caused by diffuse cerebral oedema, definitely benefit from craniectomy when current medical treatment has failed. The encouraging results of outcome in this and more recent studies, indicate the need for a multi-institutional randomized prospective study evaluating early indicators of raised ICP, timing, efficacy of treatment, operative technique and complications of decompressive craniectomy.	Aristotle Univ Thessaloniki, Dept Neurosurg, AHEPA Hosp, Hellas, Greece; AHEPA Hosp, Intens Care Unit, Hellas, Greece	Foroglou, N (corresponding author), Aristotle Univ Thessaloniki, Dept Neurosurg, AHEPA Hosp, Univ Campus, Hellas, Greece.		Foroglou, Nicolaos/AAP-4396-2020	Foroglou, Nikolaos/0000-0003-3660-6293; Patsalas, Ioannis/0000-0002-8672-9497	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22591579] Funding Source: KAKEN		*APACHE 2 SCOR SYS, 1993, C GRAND TXB TRAUM AN, P71; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Clifton GL, 2001, J NEUROSURG, V95, P733; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; DeWitt D S, 1995, New Horiz, V3, P376; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1976, INTRACRANIAL PRESSUR, V3, P67; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHAL LF, 1988, J NEUROSURG, V89, P519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Safar P, 2001, NEW ENGL J MED, V345, P66; WHITFIELD PC, 2000, BRIT J NEUROSURG, V14, P292	31	73	75	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		2002	144	8					791	796		10.1007/s00701-002-0948-z			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	588KU	WOS:000177701300011	12181688				2021-06-18	
J	Cuny, E; Richer, E; Castel, JP				Cuny, E; Richer, E; Castel, JP			Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: relief with intrathecal Baclofen therapy	BRAIN INJURY			English	Article							ALLEVIATES AUTONOMIC DYSFUNCTION; DIENCEPHALIC SEIZURES	In the initial phase of severe head injury, dysautonomic abnormalities are frequent. Within the framework of a prospective study, evaluating the efficacy of continuous intrathecal Baclofen therapy (CIBT) on hypertonia during the initial recovery phase of severe head injury, the authors report on the preliminary results of this treatment on paroxysmal dysautonomia about four patients. Continuous intrathecal Baclofen infusion was first delivered, for a test period, continuously for 6 days. If a relapse of dysautonomia occurred at the end of the test period, an implantation of a continuous intrathecal infusion pump delivering Baclofen was performed. Results were assessed with four continuous variables; duration (days), dose of Baclofen per day (mug/d), number of dysautonomic paroxysmal episodes per day, and initial recovery evaluated by a scale of the first initial stages of head injury coma recovery. For three patients: (1) the number of dysautonomic paroxysmal episodes per day and the doses of Baclofen during the follow-up period were correlated (p=0.02, p<0.001, p=0.008, respectively, distribution-free test of Spearman), (2) during the test period and the relapse after the test period, the number of paroxysmal episodes and the Baclofen dose are correlated to p<0.05, p=0.03, p=0.04, respectively (distribution-free test of Spearman). The second statistical test was used to prove that Baclofen doses and number of paroxysmal dysautonomic episodes are correlated independently of the duration of follow-up. The fourth patient improved with CIBT without any recurrence at the end of the treatment test period. For the four patients, recovery score increased during the overall follow-up. In the authors' experience CIBT is very efficient to control paroxysmal dysautonomia during the initial recovery phase in severe head injury, and seems to facilitate recovery.	CHU Bordeaux, Hop Pellegrin, Clin Univ Neurochirurg, F-33076 Bordeaux, France; Ctr Reeduc, Cenac, France	Cuny, E (corresponding author), CHU Bordeaux, Hop Pellegrin, Clin Univ Neurochirurg, Pl Amelie Raba Leon, F-33076 Bordeaux, France.						Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 1999, J NEUROL NEUROSUR PS, V66, P114, DOI 10.1136/jnnp.66.1.114; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; COHADON F, 1993, NEUROCHIRURGIE, V39, P281; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204	8	73	76	0	0	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2001	15	10					917	925		10.1080/02699050110065277			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483HF	WOS:000171627000008	11595088				2021-06-18	
J	Lewen, A; Sugawara, T; Gasche, Y; Fujimura, M; Chan, PH				Lewen, A; Sugawara, T; Gasche, Y; Fujimura, M; Chan, PH			Oxidative cellular damage and the reduction of APE/Ref-1 expression after experimental traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						traumatic brain injury; mice; cellular injury; oxidative stress; DNA repair; DNA oxidation; DNA fragmentation; outcome	FOCAL CEREBRAL-ISCHEMIA; SUPEROXIDE-DISMUTASE PREVENTS; HYDROXYL RADICAL GENERATION; DNA STRAND SCISSION; APURINIC/APYRIMIDINIC ENDONUCLEASE; EARLY DECREASE; EDEMA FORMATION; RAT-BRAIN; REPAIR; FRAGMENTATION	The DNA repair enzyme, apurinic/apyrimidinic endonuclease (or redox effector factor-1, APE/Ref-1), is involved in base excision repair of apurinic/apyrimidinic sites after oxidative DNA damage. We investigated the expression of APE/Ref-1 and its relationship to oxidative stress after severe traumatic brain injury produced by controlled cortical impact in normal mice, and in mice over- or underexpressing copper-zinc superoxide dismutase (SOD1TG and SOD1KO, respectively). Oxygen free radical-mediated cellular injury was visualized with 8-hydroxyguanine immunoreactivity as a marker for DNA oxidation, and in situ hydroethidine oxidation as a marker for superoxide production. After trauma there was a reduced expression of APE/Ref-1 in the ipsilateral cortex and hippocampus that correlated with the gene dosage levels of cytosolic superoxide dismutase. The decrease in APE/Ref-1 expression preceded DNA fragmentation. There was also a close correlation between APE/Ref-1 protein levels 4 h after trauma and the volume of the lesion 1 week after injury. Our data have demonstrated that reduction of APE/Ref-1 protein levels correlates closely with the level of oxidative stress after traumatic brain injury. We suggest that APE/Ref-1 immunoreactivity is a sensitive marker for oxidative cellular injury. (C) 2001 Academic Press.	Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Neurosci Program, Stanford, CA 94305 USA	Lewen, A (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS082386, P01NS014543, R01NS036147, P50NS014543, R01NS038653, R01NS025372] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 82386, NS 38653, NS 14543, NS 25372, NS 36147] Funding Source: Medline		ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Carey DC, 1999, BIOCHEMISTRY-US, V38, P16553, DOI 10.1021/bi9907429; Chen J, 1997, J NEUROCHEM, V69, P232; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; Cui JK, 2000, FASEB J, V14, P955; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; Edwards M, 1998, NEUROREPORT, V9, P4015, DOI 10.1097/00001756-199812210-00005; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; Fujimura M, 1999, STROKE, V30, P2408, DOI 10.1161/01.STR.30.11.2408; Fujimura M, 2000, J NEUROSCI, V20, P2817; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMANA K, 1985, BIOCHEM INT, V10, P301; Hayashi T, 1999, BRAIN RES, V832, P159, DOI 10.1016/S0006-8993(99)01409-2; Huang DY, 2000, FASEB J, V14, P407; Kawamata T, 1997, ACT NEUR S, V70, P191; Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016; Kondo T, 1997, J NEUROSCI, V17, P4180; Lan J, 2000, J NEUROCHEM, V74, P302, DOI 10.1046/j.1471-4159.2000.0740302.x; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lin LH, 2000, J NEUROCHEM, V74, P1098; Maeda M, 1998, NEUROSCI LETT, V240, P69, DOI 10.1016/S0304-3940(97)00901-4; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Morita-Fujimura Y, 1999, NEUROSCIENCE, V93, P1465, DOI 10.1016/S0306-4522(99)00231-6; Murakami K, 1998, J NEUROSCI, V18, P205; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Namura S, 1998, J NEUROSCI, V18, P3659; Nunomura A, 1999, J NEUROSCI, V19, P1959; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; Povlishock J T, 1992, Hum Cell, V5, P345; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SATCHELL M, 1999, SOC NEUR ABSTR, V29; SEN S, 1993, FREE RADICAL RES COM, V19, P255, DOI 10.3109/10715769309056513; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5	50	73	79	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2001	8	3					380	390		10.1006/nbdi.2001.0396			11	Neurosciences	Neurosciences & Neurology	445LM	WOS:000169459000002	11447995				2021-06-18	
J	Harris, JKJ; Godfrey, HPD; Partridge, FM; Knight, RG				Harris, JKJ; Godfrey, HPD; Partridge, FM; Knight, RG			Caregiver depression following traumatic brain injury (TBI): a consequence of adverse effects on family members?	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RELATIVES VIEW; BURDEN	Many studies have demonstrated that the behaviour of individuals with traumatic brain injury (TBI) predicts the emotional adjustment of their caregivers. The primary objective of the present study was to obtain an understanding of potential moderating and mediating variables between carer depression and analogous stressors. Seven sets of predictor variables (demographic variables, concurrent stressful life events, behavioural problems, social role problems, extent of adverse effects on family members, appraisal, and support) and the criterion variable of depression in caregivers were examined. Fifty- eight carers participated in the study at 6 months, 1 year, 2 years, or 3 years following injury. The number of adverse effects on family members (other than the informant) was the only stressor significantly related to carer depression. However, carer appraisal of adverse family effects was found to mediate the relationship between stressor and depression, and carer perception of support effectiveness was found to moderate the effect of adverse family effects on depression. Forty- six per cent of the variance in caregiver depression was accounted for by carers appraisal of adverse family effects and the interaction of adverse family effects and support effectiveness. These findings highlight the importance of supporting families as a whole in the rehabilitation of persons with TBI.	Univ Otago, Dept Psychol, Dunedin, New Zealand	Godfrey, HPD (corresponding author), Univ Otago, Dept Psychol, POB 56, Dunedin, New Zealand.	hgodfrey@psy.otago.ac.nz					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS WP, 1986, LETT APPL MICROBIOL, V2, P1, DOI 10.1111/j.1472-765X.1986.tb01502.x; CLEARY PD, J HLTH SOCIAL BEHAV, V23, P159; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Frosch S, 1997, BRAIN INJURY, V11, P891; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; OAKLEYBROWNE MA, 1989, AUST NZ J PSYCHIAT, V23, P327, DOI 10.3109/00048678909068290; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PLATT S, 1983, SOCIAL BEHAV ASSESSM; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Smith L.M., 1995, FAMILY SUPPORT PROGR; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	24	73	75	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2001	15	3					223	238					16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100003	11260771				2021-06-18	
J	Passler, MA; Riggs, RV				Passler, MA; Riggs, RV			Positive outcomes in traumatic brain injury-vegetative state: Patients treated with bromocriptine	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; vegetative state; minimally conscious state; bromocriptine; rehabilitation	RECOVERY; REHABILITATION; COMA; METHYLPHENIDATE; AROUSAL	Objective: To assess the effects of multidisciplinary rehabilitation interventions and use of bromocriptine on outcome in patients with traumatic brain injury-vegetative state (TBI-VS). Design: Retrospective review of clinical cases. Setting: Free-standing rehabilitation hospital; Acute and extended rehabilitation hospital. Participants: Five consecutive TBI-VS patients, as well as 33 TBI-VS patients and 37 traumatic brain injury-minimally conscious state (TBI-MCS) patients reported in the literature. Interventions: Bromocriptine administration, systematic neuropsychologic testing, sensory stimulation, and traditional comprehensive rehabilitation with physical therapy, occupational therapy, and speech therapy. Main Outcome Measures: Disability Rating Scale (DRS) at 1, 3, 6, and 12 months postinjury and FIM(TM) instrument scores at 1 month and 12 months postinjury, Coma Recovery Scale, and Barry Rehabilitation Inpatient Screening of Cognition. Results: The 5 TBI-VS patients emerged from a VS into a MCS and regained functional status. Their recovery of physical and cognitive functioning, as rated by the DRS, was greater than previously reported in the literature for patients in a VS or MCS at 3, 6, and 12 months postinjury. Conclusion: Bromocriptine administration, systematic neuropsychologic testing, sensory stimulation, a comprehensive rehabilitation program, or a combination of these treatments may enhance functional recovery in this TBI-VS patient group. Further systematic study to quantify the contribution of these variables and to reproduce this data in a larger patient population should be pet-formed.	Healthsouth Rehabil Hosp, Dothan, AL USA	Passler, MA (corresponding author), 335 S St Andrews St, Dothan, AL 36301 USA.						ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; *ASP CONS C, 1996, WORKGR VEG MIN CONSC; Barrett AM, 1999, ARCH PHYS MED REHAB, V80, P600, DOI 10.1016/S0003-9993(99)90205-8; BARRETT K, 1991, J NEUROL NEUROSUR PS, V54, P718, DOI 10.1136/jnnp.54.8.718; BARRY P, 1989, ARCH PHYS MED REHAB, V70, P902; BARTKOWSKI HM, 1986, J HEAD TRAUMA REHAB, V1, P1; BRADDOM RL, 1996, PHYSICAL MED REHABIL, P1027; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BRICOLO A, 1976, HDB CLIN NEUROLOGY, P699; CARDENAS DD, 1992, PSYCHOPHARMACOLOGIC, P273; CELESIA, 1993, ANN NEUROL, V33, P386; DIRICCO C, 1974, J NEUROSURG SCI, V18, P169; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; MCDOWELL FH, 1991, ARZNEIMITTEL-FORSCH, V41-1, P355; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; ODell MW, 1996, J HEAD TRAUMA REHAB, V11, P61, DOI 10.1097/00001199-199606000-00009; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; ODELL MW, 1996, MED REHABILITATION T, P103; PASSLER MA, 1987, REHABIL PSYCHOL, V32, P215; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Stanczak DE, 1998, NEUROPSYCHOL REV, V8, P191, DOI 10.1023/A:1021670203013; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Worzniak M, 1997, J FAM PRACTICE, V44, P495; ZASLER N D, 1992, Brain Injury, V6, P1, DOI 10.3109/02699059209008117; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7	42	73	77	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2001	82	3					311	315		10.1053/apmr.2001.20831			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	407RG	WOS:000167284100004	11245751				2021-06-18	
J	Kabat, MH; Kane, RL; Jefferson, AL; DiPino, RK				Kabat, MH; Kane, RL; Jefferson, AL; DiPino, RK			Construct validity of selected Automated Neuropsychological Assessment Metrics (ANAM) battery measures	CLINICAL NEUROPSYCHOLOGIST			English	Article							BRAIN INJURY; MONITORING RECOVERY; PERFORMANCE; CONSISTENCY; CONCUSSION	The Automated Neuropsychological Assessment Metrics (ANAM) is a computerized library of tests designed to assess neurocognitive functioning across administrations (Kane & Reeves, 1997). This study was designed to examine neuropsychological constructs measured by selected ANAM measures and to compare them with traditional measures putatively assessing similar domains. The sample consisted of 191 outpatients with suspected neurocognitive dysfunction. Correlations and regressions indicated significant relationships between traditional and computerized tests measuring similar constructs. PCA results yielded a three-factor solution: Factor I (Processing Speed / Efficiency), Factor II (Retention / Memory), and Factor III (Working Memory).	Dept Vet Affairs Med Ctr, Mental Hlth Clin Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Loyola Coll, Baltimore, MD 21210 USA	Kane, RL (corresponding author), Dept Vet Affairs Med Ctr, Mental Hlth Clin Ctr, 10 N Greene St, Baltimore, MD 21201 USA.						Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Gorsuch R. L., 1983, FACTOR ANAL; HARRIS WD, 1996, 9602 ERPL ENG PSYCH; Heaton R.K., 1991, COMPREHENSIVE NORMS; JORDAN J, 1996, EFFECT ACTIVE NOISE; Kane R., 1997, NEUROPSYCHOLOGY HDB; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KANE RL, 1999, J INT NEUROPSYCH SOC, V5, P129; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; LEWANDOWSKI AG, 1995, ARCH CLIN NEUROPSYCH, V10, P357; Mirsky A. F., 1989, INTEGRATING THEORY P, P75; Reeves D, 1996, NCRFSR9601; REEVES DL, 1998, NCRFTR9801; SPSS Inc., 1998, SPSS 8 0 WIND; STARBUCK VN, 1995, NEUROPSY NEUROPSY BE, V8, P189; TINSLEY HEA, 1987, J COUNS PSYCHOL, V34, P14	20	73	74	0	10	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2001	15	4					498	507		10.1076/clin.15.4.498.1882			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QR	WOS:000174656100008	11935451				2021-06-18	
J	DeLuca, J; Schultheis, MT; Madigan, NK; Christodoulou, C; Averill, A				DeLuca, J; Schultheis, MT; Madigan, NK; Christodoulou, C; Averill, A			Acquisition versus retrieval deficits in traumatic brain injury: Implications for memory rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						memory; recall; brain injuries; rehabilitation	CLOSED-HEAD-INJURY; VERBAL-LEARNING TEST; MULTIPLE-SCLEROSIS; PATTERNS; RECOVERY; STORAGE; RECALL; SCALE	Objective: To examine whether impaired memory in persons with traumatic brain injury (TBI) is caused by impaired initial acquisition or compromised retrieval from long-term storage. Design: Prospective matched controlled trial. Setting: Postacute rehabilitation institute. Participants: Patients with moderate to severe TBI (n = 28) and 21 matched, healthy controls (HCs). Main Outcome Measures: Patients with TBI and HC subjects were equated on initial acquisition on a verbal list-learning task. Recall and recognition performance was then evaluated at 30- and 90-minutes after learning. Results: All HC subjects and 20 subjects with TBI (TBI-MET) were able to meet the learning criterion, but the TBI-MET group took significantly more trials than HC subjects to do so. However, after equating groups on acquisition, the TBI-MET group did not differ from controls on recall and recognition at both the 30- and 90-minute delays. Eight TBI subjects showed severe learning deficits (TBI-NOT MET) because they never learned the task, and showed significantly impaired recall and recognition performance. The 2 TBI groups did not differ on measures of severity of injury, but the TBI-NOT MET group performed significantly below the TBI-MET group on executive functioning. Rate of forgetting did not differ across the 3 groups. Conclusions: Results suggest that memory impairment after TBI is caused primarily by deficiencies in initial acquisition of verbal information rather than in compromised retrieval. The findings have significant implications for the rehabilitation and treatment of individuals with TBI.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neursci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, W Orange, NJ 07052 USA; Massachusetts Mental Hlth Ctr, Dept Psychiat, Boston, MA 02115 USA	DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neursci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.			Schultheis, Maria/0000-0002-6558-548X			BAUER RM, 1993, CLIN NEUROPSYCHOLOGY, P523; Baum KM, 1996, CLIN NEUROPSYCHOL, V10, P340; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BEGG I, 1988, MEM COGNITION, V16, P232, DOI 10.3758/BF03197756; BELLEZZA FS, 1989, J EXP PSYCHOL LEARN, V15, P990, DOI 10.1037/0278-7393.15.5.990; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS N, 1984, CLOSED HEAD INJURY P, P44; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DEMERY JA, 1999, P INT NEUR SOC ANN C; Diamond BJ, 1997, BRAIN, V120, P1015, DOI 10.1093/brain/120.6.1015; GASS CS, 1995, ARCH CLIN NEUROPSYCH, V10, P475, DOI 10.1016/0887-6177(95)98192-G; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; GORDON WA, 1989, J HEAD TRAUMA REHAB, V4, P76; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hart R. P., 1994, NEUROPSYCHOLOGY, V8, P325, DOI [10.1037/0894-4105.8.3.325, DOI 10.1037/0894-4105.8.3.325]; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Heaton R., 1993, WISCONSIN CARD SORTI; JANOWSKY JS, 1993, J CLIN EXP NEUROPSYC, V15, P159, DOI 10.1080/01688639308402554; KEARCOLWELL JJ, 1980, J CLIN PSYCHOL, V36, P782, DOI 10.1002/1097-4679(198007)36:3<782::AID-JCLP2270360334>3.0.CO;2-K; Lange G, 2000, ARCH PHYS MED REHAB, V81, P89, DOI 10.1016/S0003-9993(00)90227-2; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PANIAK CE, 1989, J CLIN EXP NEUROPSYC, V11, P631, DOI 10.1080/01688638908400921; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 1981, WESCHLER ADULT INTEL; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; WITOL A, 1990, REHABILITATION ADULT, P167	39	73	74	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2000	81	10					1327	1333		10.1053/apmr.2000.9390			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	360WA	WOS:000089689300002	11030497				2021-06-18	
J	Fineman, I; Giza, CC; Nahed, BV; Lee, SM; Hovda, DA				Fineman, I; Giza, CC; Nahed, BV; Lee, SM; Hovda, DA			Inhibition of neocortical plasticity during development by a moderate concussive brain injury	JOURNAL OF NEUROTRAUMA			English	Article						concussive brain injury; cortex; development; enriched environment; Morris water maze; plasticity	PEDIATRIC HEAD-INJURY; ENVIRONMENTAL ENRICHMENT; DEVELOPING RAT; AMINO-ACIDS; CORTEX; MEMORY; ADULT; EXPERIENCE; ASPARTATE; RECEPTORS	To determine if a moderate traumatic brain injury (TBI) sustained early in life alters the capacity for developmental plasticity, 17-20-day-old rat pups received a lateral fluid percussion and then reared in an enriched environment for 17 days. Compared to sham-injured controls, this moderate TBI prevented the increase in cortical thickness (1.48 vs. 1.68 mm, p < 0.01) as well as the corresponding enhancement in cognitive performance in the Morris Water Maze (39 vs. 25 trials to criterion, p < 0.05), These injured animals exhibited no significant neuronal degeneration and no evidence of neurologic or motor deficits, These findings strongly support the conclusion that a diffuse brain injury is capable of inhibiting both anatomical and cognitive manifestations of experience-dependent developmental plasticity.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Fineman, I (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Brain Injury Res Ctr, 18-228 NPI,Box 957039, Los Angeles, CA 90095 USA.		Nahed, Brian/E-4239-2014	Nahed, Brian/0000-0001-8537-106X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037363, P50NS030308, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS27544, NS37363] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DIAMOND MC, 1972, J NEUROBIOL, V3, P47, DOI 10.1002/neu.480030105; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GORMAN LK, 1995, J NEUROTRAUM, V12, P120; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; GREENOUGH WT, 1972, PSYCHON SCI, V27, P279; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEBB DO, 1976, J ABNORM CHILD PSYCH, V4, P309, DOI 10.1007/BF00922529; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; JURASKA JM, 1984, DEV PSYCHOBIOL, V17, P209, DOI 10.1002/dev.420170302; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOLB B, 1987, BEHAV BRAIN RES, V26, P119, DOI 10.1016/0166-4328(87)90161-6; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MOSS ML, 1972, ACTA ANAT, V81, P161; NAHED BV, 1998, J NEUROTRAUM, V15, P887; NIETOSAMPEDRO M, 1985, SYNAPTIC PLASTICITY, P407; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rosenzweig MR, 1996, ANNU REV PSYCHOL, V47, P1, DOI 10.1146/annurev.psych.47.1.1; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SIREVAAG AM, 1988, BRAIN RES, V441, P386, DOI 10.1016/0006-8993(88)91420-5; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; VENABLE N, 1988, BEHAV BRAIN RES, V31, P89, DOI 10.1016/0166-4328(88)90162-3; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	38	73	73	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2000	17	9					739	749		10.1089/neu.2000.17.739			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	356LM	WOS:000089444800002	11011814				2021-06-18	
J	Quaresima, V; Sacco, S; Totaro, R; Ferrari, M				Quaresima, V; Sacco, S; Totaro, R; Ferrari, M			Noninvasive measurement of cerebral hemoglobin oxygen saturation using two near infrared spectroscopy approaches	JOURNAL OF BIOMEDICAL OPTICS			English	Article						cerebral oximetry; near infrared spectroscopy; spatially resolved spectroscopy; oxygenation; tissue oxygen saturation; noninvasive measurements	SPATIALLY-RESOLVED SPECTROSCOPY; CLOSED-HEAD INJURY; CARDIOPULMONARY BYPASS; CAROTID ENDARTERECTOMY; BULB OXIMETRY; BRAIN; INVOS-3100; PHANTOM; SPECTROPHOTOMETERS; MONITORS	Spatially resolved spectroscopy (SRS) is a new near infrared spectroscopy (NIRS) method that, using the multi-distance approach, measures local cerebral cortex hemoglobin oxygen saturation [J. Matcher, P. Kirkpatrick, K. Nahid, M. Cope, and D. T. Delpy, Proc. SPIE 2389, 486-495 (1995)], Using a conventional continuous wave NIRS photometer, cerebral venous oxygen saturation (SvO(2)) can be calculated from oxyhemoglobin and total hemoglobin rise induced by partial occlusion of jugular vein [C. E. Elwell, S. J. Matcher, L. Tyszczuk, J. H. Meek, and D. T. Delpy, Adv. Exp. Med. Biol. 411, 453-460 (1997)]. The aim of this study was to compare direct measurements of forehead tissue oxygenation index (TOI) with the calculated SvO(2) during venous occlusion in 16 adult volunteers using a clinical two-channel SRS oximeter (NIRO-300). Measured TOI and calculated SvO(2) values of either right or left forehead did not significantly differ. A good agreement between the two NIRS methods was also demonstrated. On 16 other subjects, no significant differences were found between the right and left forehead TOI values measured simultaneously, and between the TOI values measured by channel 1 or 2 on the same side. The results confirm that cerebral cortex hemoglobin oxygen saturation, measured directly by the SRS method, reflects predominantly the saturation of the intracranial venous compartment of circulation. (C) 2000 Society of Photo-Optical instrumentation Engineers. [S1083-3668(00)00802-9].	Univ Aquila, Dept Biomed Technol, I-67100 Laquila, Italy; Univ Aquila, Dept Neurol, I-67100 Laquila, Italy	Quaresima, V (corresponding author), Univ Aquila, Dept Biomed Technol, Via Vetoio, I-67100 Laquila, Italy.	vale@univaq.it	Quaresima, Valentina/AAQ-7387-2021; Sacco, Simona/I-5253-2012; Ferrari, Marco/AAF-3486-2019	Sacco, Simona/0000-0003-0651-1939; FERRARI, Marco/0000-0002-3041-2917; quaresima, valentina/0000-0001-9884-0304			Al-Rawi PG, 1999, J BIOMED OPT, V4, P208, DOI 10.1117/1.429911; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Buunk G, 1998, ANAESTHESIA, V53, P13, DOI 10.1111/j.1365-2044.1998.00263.x; Carlin RE, 1998, J CLIN ANESTH, V10, P109, DOI 10.1016/S0952-8180(97)00252-3; CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; CHANCE B, 1997, PHILOS T R SOC LON B, V352, P647; Colier W N, 1995, Acta Anaesthesiol Scand Suppl, V107, P101; Duncan A, 1996, PEDIATR RES, V39, P889, DOI 10.1203/00006450-199605000-00025; Elwell CE, 1997, ADV EXP MED BIOL, V411, P453; Fantini S, 1999, PHYS MED BIOL, V44, P1543, DOI 10.1088/0031-9155/44/6/308; FERRARI M, 1992, J PHOTOCH PHOTOBIO B, V16, P141, DOI 10.1016/1011-1344(92)80005-G; FERRARI M, 1989, AM J PHYSIOL, V256, pH1493; FIRBANK M, 1994, PHYS MED BIOL, V39, P1509, DOI 10.1088/0031-9155/39/9/015; FIRBANK M, 1993, PHYS MED BIOL, V38, P847, DOI 10.1088/0031-9155/38/6/015; Gomersall CD, 1998, ANAESTH INTENS CARE, V26, P548, DOI 10.1177/0310057X9802600512; Grubhofer G, 1999, ACTA ANAESTH SCAND, V43, P470, DOI 10.1034/j.1399-6576.1999.430417.x; Henson LC, 1998, ANESTHESIOLOGY, V88, P58, DOI 10.1097/00000542-199801000-00011; Kurth CD, 1995, PHYS MED BIOL, V40, P2079, DOI 10.1088/0031-9155/40/12/006; KURTH CD, 1993, J CLIN MONITOR, V9, P163, DOI 10.1007/BF01617023; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; Litscher G, 1998, BIOMED TECH, V43, P133, DOI 10.1515/bmte.1998.43.5.133; Madsen PL, 1999, PROG NEUROBIOL, V58, P541, DOI 10.1016/S0301-0082(98)00093-8; MATCHER SJ, 1995, P SOC PHOTO-OPT INS, V2359, P486; McKeating EG, 1997, ANAESTHESIA, V52, P136, DOI 10.1111/j.1365-2044.1997.18-az015.x; Misra M, 1998, NEUROL RES, V20, P137; Nielsen HB, 1999, AM J PHYSIOL-HEART C, V277, pH1045; Samra SK, 1996, STROKE, V27, P49, DOI 10.1161/01.STR.27.1.49; Sapire KJ, 1997, CRIT CARE MED, V25, P1655, DOI 10.1097/00003246-199710000-00014; Suzuki S, 1999, P SOC PHOTO-OPT INS, V3597, P582, DOI 10.1117/12.356862; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; Totaro R, 1999, CEREBROVASC DIS, V9, P142, DOI 10.1159/000015943; Totaro R, 1998, CLIN SCI, V95, P497, DOI 10.1042/CS19980122; YOXALL CW, 1995, PEDIATR RES, V38, P319, DOI 10.1203/00006450-199509000-00008	33	73	73	0	10	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668	1560-2281		J BIOMED OPT	J. Biomed. Opt.	APR	2000	5	2					201	205		10.1117/1.429987			5	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	325AU	WOS:000087654800011	10938784				2021-06-18	
J	Baskaya, MK; Dogan, A; Rao, AM; Dempsey, RJ				Baskaya, MK; Dogan, A; Rao, AM; Dempsey, RJ			Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain edema; blood-brain barrier; citicoline; traumatic brain injury	EXPERIMENTAL FOCAL ISCHEMIA; FREE FATTY-ACIDS; CDP-CHOLINE; GERBIL; RATS	Object. Cytidine 5'-diphosphocholine (CDPC), or citicoline, is a naturally occurring endogenous compound that has been reported to provide neuroprotective effects after experimental cerebral ischemia. However, in no study has such protection been shown after traumatic brain injury (TBI). In this study the authors examined the effect of CDPC on secondary injury factors, brain edema and blood-brain barrier (BBB) breakdown, after TBI. Methods. After anesthesia had been induced in Sprague-Dawley rats by using 1.5% halothane, an experimental TBI was created using a controlled cortical impact (CCI) device with a velocity of 3 m/second, resulting in a 2-mm deformation. Four sham-operated control animals used for brain edema and BBB breakdown studies underwent the same surgical procedure, but received no injury. Brain edema was evaluated using the wet-dry method 24 hours postinjury, and BBB breakdown was evaluated by measuring Evans blue dye (EBD) extravasation with fluorescein 6 hours after TBI. The animals received intraperitoneal injections of CDPC (50, 100, or 400 mg/kg two times after TBI [eight-10 animals in each group]) or saline (eight animals) after TBI. Traumatic brain injury induced an increase in the percentage of water content and in EBD extravasation in the injured cortex and the ipsilateral hippocampus. No significant benefit from CDPC treatment was observed at a dose of 50 mg/kg. Cytidine 5'-diphosphocholine at a dose of 100 mg/kg attenuated EBD extravasation in both regions, although it reduced brain edema only in the injured cortex. In both regions, 400 mg/kg of CDPC significantly decreased brain edema and BBB breakdown. Conclusions. This is the first report in which dose-dependent neuroprotective effects of CDPC have been demonstrated in the injured cortex as well as in the hippocampus, a brain region known to be vulnerable to injury, after experimental TBI. The results of this study suggest that CDPC is an effective neuroprotective agent on secondary injuries that appear following TBI.	Louisiana State Univ, Med Ctr, Dept Neurosurg, Shreveport, LA 71130 USA; Univ Wisconsin, Madison, WI USA; Vet Adm Hosp, Madison, WI USA	Baskaya, MK (corresponding author), Louisiana State Univ, Med Ctr, Dept Neurosurg, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.		Dogan, Aclan/AAF-8305-2019				BAETHMAN A, 1978, NEUROSURG REV, V1, P85; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DORMAN RV, 1983, J NEUROCHEM, V40, P276, DOI 10.1111/j.1471-4159.1983.tb12682.x; KAKIHANA M, 1988, STROKE, V19, P217, DOI 10.1161/01.STR.19.2.217; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.3.CO;2-2; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; SECADES JJ, 1995, METHODS FIND EXP SB, V17, P2; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59	19	73	85	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2000	92	3					448	452		10.3171/jns.2000.92.3.0448			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	285DX	WOS:000085375400011	10701532				2021-06-18	
J	Fleming, J; Strong, J				Fleming, J; Strong, J			A longitudinal study of self-awareness: Functional deficits underestimated by persons with brain injury	OCCUPATIONAL THERAPY JOURNAL OF RESEARCH			English	Article						insight; head injury; rehabilitation; cognition	SEVERE HEAD-INJURY; ADULTS; TRAUMA	A longitudinal study of 55 adults with severe traumatic brain injury (TBI) investigated the areas of function for which they lacked self-awareness of their level of competency. Data were collected at 3 and 12 months post-injury using the Patient Competency Rating Scale. Self-awareness was measured by comparing patient self-ratings with the ratings of an infor mant. The results were consistent with previous studies, indicating that self-awareness was most impaired for activities with a large cognitive and socioemotional component, and least impaired for basic activities of daily living, memory activities, and overt emotional responses. For most areas of function that were overestimated at 3 months post-injury, self-awareness subsequently improved during the first year after injury.	Princess Alexandra Hosp, Occupat Therapy Dept, Woolloongabba, Qld, Australia; Univ Queensland, Dept Occupat Therapy, Brisbane, Qld, Australia	Fleming, J (corresponding author), Princess Alexandra Hosp, Occupat Therapy Dept, Ipswich Rd, Woolloongabba, Qld, Australia.		Strong, Jenny/F-1211-2010; Fleming, Jennifer M/B-4436-2011	Strong, Jenny/0000-0002-9367-8755; 			FAHY TJ, 1967, LANCET, V2, P475; FLEMING J, 1997, BRIT J OCCUPATIONAL, V60, P295, DOI DOI 10.1177/030802269706000703; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACOBS MP, 1993, NEUROPSYCHOL REHABIL, V3, P341, DOI 10.1080/09602019308401446; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCWILLIAMS S, 1991, BRIT J OCCUPATIONAL, V54, P246; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; NORUSIS MJ, 1990, SPSS PCPLUS STAT 4 0; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PONSFORD J, 1996, TRAUMATIC BRAIN INJU; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1986, CLIN NEUROPSYCHOLOGY, P135; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; PRIGATANO GP, 1998, NEUROPSYCHOLOGICAL R; ROUECHE JR, 1984, COGNITIVE REHABILITA, V2, P4; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; ZEIGLER EA, 1987, J REHABIL, V53, P50	24	73	73	0	14	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0276-1599			OCCUP THER J RES	Occup. Ther. J. Res.	WIN	1999	19	1					3	17		10.1177/153944929901900101			15	Rehabilitation	Rehabilitation	174VC	WOS:000079055800001					2021-06-18	
J	Hanlon, RE; Demery, JA; Martinovich, Z; Kelly, JP				Hanlon, RE; Demery, JA; Martinovich, Z; Kelly, JP			Effects of acute injury characteristics on neuropsychological status and vocational outcome following mild traumatic brain injury	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; DIFFUSE AXONAL INJURY; CONCUSSION; SYMPTOMS; PATHOPHYSIOLOGY; EPIDEMIOLOGY; MANAGEMENT; SEQUELAE; DEFICITS; ASSAULT	Despite recent attempts to define acute injury characteristics of mild traumatic brain injury (MTBI), neuropsychological outcome is often unpredictable. One hundred MTBI casts were prospectively collected, which were consecutive referrals to a concussion clinic, and thr rules of various acute neurologic variables were examined in relation to neuropsychological status and vocational outcome. Significant differents were found between subgroups of patients classified by (1) mechanism of injury (i.e. acceleration/deceleration trauma in which the head strikes an object (HSO) venus acceleration/deceleration trauma in which the head does not strike an object (HNSO) venus trauma in which an object strikes the head (OSH), and (2) type of injury (i.e. motor vehicle collision, fall, assault, motor vehicle-pedestrian collision, falling object, sports/recreation). There was no difference, with respect to neuropsychological status or vocational outcome, between patients who had positive findings on computerized tomography (CT) versus those who were CT negative. Additionally, there was no difference between patients who had suffered brief loss of consciousness (LOC) and those without LOG. These findings suggest that selective acute injury characteristics may be used to classify subtypes of MTBI patients.	Northwestern Univ, Sch Med, Dept Psychiat, Chicago, IL 60611 USA; Univ Florida, Gainesville, FL 32611 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA	Hanlon, RE (corresponding author), Northwestern Univ, Sch Med, Dept Psychiat, 675 N St Clair,Ste 20-250, Chicago, IL 60611 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Eslinger Paul J., 1996, P415; EVANS RW, 1992, NEUROL CLIN, V10, P815; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1993, BIOMECHANICS IMPACT, P595; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; HODGSON VR, 1993, BIOMECHANICS IMPACT, P539; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KIKUCHI A, 1993, BIOMECHANICS IMPACT, P361; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1993, BIOMECHANICS IMPACT, P265; ONO K, 1993, BIOMECHANICS IMPACT, P509; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; Teasdale TW, 1997, BRIT MED J, V315, P569; TIRET L, 1990, INT J EPIDEMIOL, V8, P133; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; VASQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	43	73	73	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1999	13	11					873	887					15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253FZ	WOS:000083547000004	10579659				2021-06-18	
J	Kirkpatrick, AW; Chun, R; Brown, R; Simons, RK				Kirkpatrick, AW; Chun, R; Brown, R; Simons, RK			Hypothermia and the trauma patient	CANADIAN JOURNAL OF SURGERY			English	Article							RETROHEPATIC VENOUS INJURY; DAMAGE CONTROL SURGERY; CIRCULATORY ARREST; ACCIDENTAL HYPOTHERMIA; MILD HYPOTHERMIA; ABBREVIATED LAPAROTOMY; MASSIVE TRANSFUSION; HEMORRHAGIC-SHOCK; ABDOMINAL-TRAUMA; DEEP HYPOTHERMIA	Hypothermia has profound effects on every system in the body, causing an overall slowing of enzymatic reactions and reduced metabolic requirements. Hypothermic, acutely injured patients with multisystem trauma have adverse outcomes when compared with normothermic control patients. Trauma patients are inherently predisposed to hypothermia from a variety of intrinsic and iatrogenic causes, Coagulation and cardiac sequelae are the most pertinent physiological concerns. Hypothermia and coagulopathy often mandate a simplified approach to complex surgical problems. A modification of traditional classification systems of hypothermia, applicable to trauma patients is suggested. There are few controlled investigations, but clinical opinion strongly supports the active prevention of hypothermia in the acutely traumatized patient. Preventive measures are simple and inexpensive, but the active reversal of hypothermia is much more complicated, often invasive and controversial. The ideal method of rewarming is unclear but must be individualized to the patient and is institution specific. An algorithm reflecting newer approaches to traumatic injury and technical advances in equipment and techniques is suggested. Conversely, hypothermia has selected clinical benefits when appropriately used in cases of trauma. Severe hypothermia has allowed remarkable survivals in the course of accidental circulatory arrest. The selective application of mild hypothermia in severe traumatic brain injury is an area with promise, Deliberate circulatory arrest with hypothermic cerebral protection has also been used for seemingly unrepairable injuries and is the focus of ongoing research.	Vancouver Hosp & Hlth Sci Ctr, Sect Trauma Serv, Vancouver, BC V5Z 1L7, Canada; Univ Toronto, Anesthesia Training Program, Toronto, ON, Canada	Kirkpatrick, AW (corresponding author), Vancouver Hosp & Hlth Sci Ctr, Sect Trauma Serv, 3rd Floor,855 W 10th Ave, Vancouver, BC V5Z 1L7, Canada.	andykirk@istar.ca					ADAMS F, 1939, GENIUINE WORKS HIPPO, P145; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP P; ANTRETTER H, 1994, ANN THORAC SURG, V58, P1786, DOI 10.1016/0003-4975(94)91698-5; ANTRETTER H, 1994, NEW ENGL J MED, V330, P219, DOI 10.1056/NEJM199401203300318; BAUMGARTNER F, 1995, J TRAUMA, V39, P671, DOI 10.1097/00005373-199510000-00009; Bellamy R, 1996, CRIT CARE MED, V24, pS24; BERNABEI AF, 1992, J TRAUMA, V33, P835, DOI 10.1097/00005373-199212000-00007; BEST R, 1985, AM J EMERG MED, V3, P48, DOI 10.1016/0735-6757(85)90013-0; BICKEL KD, 1998, CURRENT SURG THERAPY, P1018; Block EFJ, 1999, CRIT CARE MED, V27, pA172, DOI 10.1097/00003246-199901001-00516; BRITT LD, 1991, SURG CLIN N AM, V71, P345; Burch JM, 1997, SURG CLIN N AM, V77, P779, DOI 10.1016/S0039-6109(05)70583-1; BURCH JM, 1992, ANN SURG, V215, P476, DOI 10.1097/00000658-199205000-00010; Capone A, 1996, J TRAUMA, V40, P388, DOI 10.1097/00005373-199603000-00011; CARRILLO C, 1993, J TRAUMA, V34, P233, DOI 10.1097/00005373-199302000-00009; CHIPPAUX C, 1954, Int Rec Med Gen Pract Clin, V167, P328; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLLINS JA, 1974, SURGERY, V75, P274; Cullinane D C, 1997, Tenn Med, V90, P323; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Farmer J. Christopher, 1997, P1451; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; FISCHER RP, 1996, TRAUMA, P951; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Gentilello L M, 1995, J Intensive Care Med, V10, P5; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; Giesbrecht GG, 1998, RESUSCITATION, V38, P59; Grahn D, 1998, J APPL PHYSIOL, V85, P1643; Grant P, 1998, SCOT MED J, V43, P36, DOI 10.1177/003693309804300202; GREGORY JS, 1991, J TRAUMA, V31, P1247, DOI 10.1097/00005373-199109000-00008; GROSSO MA, 1991, J TRAUMA, V31, P395, DOI 10.1097/00005373-199103000-00016; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; Hamilton SM, 1996, CAN J SURG, V39, P11; HARNETT RM, 1983, AVIAT SPACE ENVIR MD, V54, P487; HARTMAN AR, 1991, J TRAUMA, V31, P1310, DOI 10.1097/00005373-199109000-00017; HAYWARD JS, 1975, AVIAT SPACE ENVIR MD, V46, P1236; HELM M, 1997, ACTA ANAESTHESIOL S, V111, pS44; HERNANDEZ E, 1993, NEPHRON, V63, P214; Hirshberg A, 1997, SURG CLIN N AM, V77, P813, DOI 10.1016/S0039-6109(05)70586-7; Josephs JD, 1998, CRIT CARE MED, V26, P1944, DOI 10.1097/00003246-199812000-00009; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Lazar DK, 1997, NEW ENGL J MED, V337, P1545, DOI 10.1056/NEJM199711203372111; LEDINGHAM IM, 1980, BRIT MED J, V280, P1102, DOI 10.1136/bmj.280.6222.1102; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; MARELLI D, 1995, J TRAUMA, V38, P609, DOI 10.1097/00005373-199504000-00024; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; Martin RR, 1997, SURG CLIN N AM, V77, P929, DOI 10.1016/S0039-6109(05)70595-8; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Mattox KL, 1997, SURG CLIN N AM, V77, P753, DOI 10.1016/S0039-6109(05)70581-8; MENDEZ C, 1998, CURRENT SURG THERAPY, P928; Moore EE, 1996, AM J SURG, V172, P405, DOI 10.1016/S0002-9610(96)00216-4; ORKIN F, 1996, COMPLICATIONS ANESTH, P131; PATT A, 1988, SURG CLIN N AM, V68, P775; PRUECKER S, 1999, CRIT CARE MED, V27, pS105; Robertson CL, 1999, CRIT CARE MED, V27, pA52, DOI 10.1097/00003246-199901001-00090; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724; ROSOMOFF HL, 1955, AM J PHYSIOL, V183, P19; SAFAR P, 1999, CRIT CAR S 199 TECHN, P473; SCHALLER MD, 1990, JAMA-J AM MED ASSOC, V264, P1842, DOI 10.1001/jama.264.14.1842; SCHUBERT A, 1995, J NEUROSURG ANESTH, V7, P139, DOI 10.1097/00008506-199504000-00021; SEDLAK SK, 1995, INT J TRAUMA NURS, V1, P199; Seigler RS, 1998, CRIT CARE MED, V26, P2016, DOI 10.1097/00003246-199812000-00033; Sessler DI, 1994, ANESTHESIA, P1363; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SORI AJ, 1987, AM SURGEON, V53, P706; Stedman TL, 1982, STEDMANS MED DICT; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; STONE HH, 1983, ANN SURG, V197, P532, DOI 10.1097/00000658-198305000-00005; STONER HB, 1969, BRIT J EXP PATHOL, V50, P125; TERASAKI H, 1999, CRIT CAR S 1999 TECH, P481; TERNDRUP TE, 1992, ANN EMERG MED, V21, P1483, DOI 10.1016/S0196-0644(05)80067-8; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; TISHERMAN SA, 1999, CRITICAL CARE S 1999, P485; TISHERMAN T, 1992, CRIT CARE MED, V4, pS41; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; Walpoth BH, 1997, NEW ENGL J MED, V337, P1500, DOI 10.1056/NEJM199711203372103; Walpoth BH, 1998, NEW ENGL J MED, V338, P1161; Weinberg AD, 1998, RESUSCITATION, V36, P101, DOI 10.1016/S0300-9572(98)00004-5; WILSON RF, 1987, AM SURGEON, V53, P410; ZELL SC, 1985, ANN EMERG MED, V14, P339, DOI 10.1016/S0196-0644(85)80101-3	83	73	76	0	2	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0008-428X	1488-2310		CAN J SURG	Can. J. Surg.	OCT	1999	42	5					333	343					11	Surgery	Surgery	243ZM	WOS:000083027400008	10526517				2021-06-18	
J	Taylor, PN; Burridge, JH; Dunkerley, AL; Lamb, A; Wood, DE; Norton, JA; Swain, ID				Taylor, PN; Burridge, JH; Dunkerley, AL; Lamb, A; Wood, DE; Norton, JA; Swain, ID			Patients' perceptions of the Odstock Dropped Foot Stimulator (ODFS)	CLINICAL REHABILITATION			English	Article							WALKING	Objective: To determine the perceived benefit, pattern and problems of use of the Odstock Dropped Foot Stimulator (ODFS) and the users' opinion of the service provided. Design: Questionnaire sent in a single mailshot to current and past users of the ODFS. Returns were sent anonymously. Setting: Outpatient-based clinical service. Subjects: One hundred and sixty-eight current and 123 past users with diagnoses of stroke (CVA), multiple sclerosis (MS), incomplete spinal cord injury (SCI), traumatic brain injury (TBI) and cerebral palsy (CP). Intervention: Functional electrical stimulation (FES) to correct dropped foot in subjects with an upper motor neuron lesion, using the ODFS. Main outcome measures: Purpose-designed questionnaire. Results: Return rate 64% current users (mean duration of use 19.5 months) and 43% past users (mean duration of use 10.7 months). Principal reason cited for using equipment was a reduction in the effort of walking. Principal reasons identified for discontinuing were an improvement in mobility, electrode positioning difficulties and deteriorating mobility. There were some problems with reliability of equipment. Level of service provided was thought to be good. Conclusion: The ODFS was perceived by the users to be of considerable benefit. A comprehensive clinical follow-up service is essential to achieve the maximum continuing benefit from FES-based orthoses.	Salisbury Dist Hosp, Dept Med Phys & Biomed Engn, Salisbury SP2 8BJ, Wilts, England	Taylor, PN (corresponding author), Salisbury Dist Hosp, Dept Med Phys & Biomed Engn, Salisbury SP2 8BJ, Wilts, England.		Norton, Jonathan/AAN-3076-2021	Norton, Jonathan/0000-0002-6816-3047; Burridge, Jane/0000-0003-3497-6725			ALRECK PL, 1995, SURVEY RES HDB, P115; Burridge J, 1997, ARTIF ORGANS, V21, P254, DOI 10.1111/j.1525-1594.1997.tb04662.x; Burridge J, 1997, PHYSIOTHERAPY, V83, P82; Burridge JH, 1997, CLIN REHABIL, V11, P201, DOI 10.1177/026921559701100303; Burridge JH, 1998, REV CLIN GERONTOL, V8, P155; Karsznia A, 1990, ADV EXTERNAL CONTROL, V10, P251; Liberson W., 1961, ARCH PHYS MED REHAB, V42, P202; MERLETTI R, 1978, ADV EXTERNAL CONTROL, V6, P277; Nene A., 1993, CLIN REHABIL, V7, P319; STEFANOVSKA A, 1989, IEEE T BIO-MED ENG, V36, P738, DOI 10.1109/10.32106; TAYLOR P, 1998, P 6 VIENN INT WORKSH, P189; WADE DT, 1987, SCAND J REHABIL MED, V19, P25	12	73	78	0	10	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	OCT	1999	13	5					439	446		10.1191/026921599677086409			8	Rehabilitation	Rehabilitation	235UR	WOS:000082561400009	10498351				2021-06-18	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			The influence of traumatic brain injury on acute stress disorder and post-traumatic stress disorder following motor vehicle accidents	BRAIN INJURY			English	Article							HEAD-INJURY; EVENTS	This study compared the acute stress disorder and post-traumatic stress disorder (PTSD) symptom profiles in motor vehicle accident survivors who sustained a mild traumatic brain injury (MTBI) or no TBI. Consecutive adult patients who sustained a MTBI (n = 79) and no TBI (n = 92) were assessed for acute stress disorder within 1 month of their trauma and reassessed for PTSD (MTBI: n = 63; non-TBI; n = 72) 6-months post-trauma. Comparable rates of acute stress disorder and PTSD were reported in MTBI and non-TBI patients. Intrusive memories and fear and helplessness in response to the trauma were reported less frequently by MTBI than non-TBI patients at the acute phase. Six-months post-trauma fewer MTBI patients than non-TBI reported fear and helplessness in response to the trauma. These findings suggest that, whereas impaired consciousness at the time of a trauma may reduce the frequency of traumatic memories in the initial month post-trauma, MTBI does not result in a different profile of longer-term PTSD.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Oxford, Oxford, England	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; BOHNEN J, 1992, J NERV MENT DIS, V180, P183; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BRYANT RA, 1998, IN PRESS J NERVOUS M; Ehlers A, 1995, Behav Cogn Psychother, V23, P217, DOI 10.1017/S135246580001585X; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Price K. P., 1994, DEF LAW J, V43, P113; RATTOCK J, 1993, J CLIN EXPT NEUROPSY, V6, P243; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302; Van Der Kolk Bessel A., 1996, P214	31	73	75	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1999	13	1					15	22		10.1080/026990599121836			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	158TA	WOS:000078131200002	9972438				2021-06-18	
J	Eachempati, SR; Vaslef, SN; Sebastian, MW; Reed, RL				Eachempati, SR; Vaslef, SN; Sebastian, MW; Reed, RL			Blunt vascular injuries of the head and neck: Is heparinization necessary?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							CAROTID-ARTERY DISSECTION; EARLY DIAGNOSIS; TRAUMA; ARTERIOGRAPHY; ANGIOGRAPHY; THERAPY	Background: Blunt vascular injuries to the head and neck (BHVI) represent some of the most devastating and morbid injuries seen by a trauma surgeon. This series reviewed the experience of a single institution to determine if diagnostic and therapeutic guidelines can be established for these uncommon injuries. In particular, the utility of anticoagulation in the treatment of these injuries is examined. Methods: The institutional trauma registry of a single state-designated Level I trauma center was examined for patients with BHVI, Patients were identified and their charts reviewed individually with regard to multiple data points including the type of injury, its presentation, the treatment of the injury, and the functional outcome of the patient. Results: Twenty-nine BHVI in 23 patients were reviewed from 1989 to 1997, No mortalities were noted. Among the injuries noted were 14 internal carotid artery dissections and 8 carotid artery tears. Thirteen patients had accompanying closed head injuries. Ten patients were diagnosed after an abnormal neurologic examination, and eight others were diagnosed after having carotid canal fractures. Heparin was started within 48 hours of injury in 4 patients (17%) and was used in a total of 12 patients (52%), No patient worsened neurologically after diagnosis independent of the use of heparin, Thirteen patients (57%) had no or minimal deficits upon discharge. Conclusion: BHVI represent a serious cause of morbidity in the patient with multiple injuries. Patients with closed head injuries and carotid canal fractures appear most at risk, A multicenter, randomized trial involving antiplatelet therapy, full systemic anticoagulation, or observation with a long-term functional assessment is indicated to determine the optimal management of these injuries.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Cornell Univ, Med Ctr, Dept Surg, New York, NY 10021 USA; Loyola Univ, Med Ctr, Dept Surg, Chicago, IL 60611 USA	Eachempati, SR (corresponding author), New York Hosp, Dept Surg, 525 E 68th St, New York, NY 10021 USA.	seachempati@cornell.surgery.med.edu	Reed, Robert/AAJ-2575-2020				Bilbao R, 1997, AM J OPHTHALMOL, V123, P562, DOI 10.1016/S0002-9394(14)70191-6; Bok APL, 1996, J TRAUMA, V40, P968, DOI 10.1097/00005373-199606000-00017; Carter DA, 1998, J TRAUMA, V44, P230, DOI 10.1097/00005373-199801000-00039; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Colella JJ, 1996, AM SURGEON, V62, P212; DAlise MD, 1996, J TRAUMA, V40, P452, DOI 10.1097/00005373-199603000-00023; DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013; DUKE BJ, 1997, 57 ANN M AM ASS SURG; Englund R, 1988, Ann Vasc Surg, V2, P362, DOI 10.1016/S0890-5096(06)60817-0; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FAKHRY SM, 1988, J VASC SURG, V8, P501; FRY WR, 1994, AM J SURG, V168, P693, DOI 10.1016/S0002-9610(05)80147-3; GaskillShipley MF, 1996, NEUROIMAG CLIN N AM, V6, P607; GOUAZE A, 1969, NEURO-CHIR, V15, P234; Laitt RD, 1996, CLIN RADIOL, V51, P117, DOI 10.1016/S0009-9260(96)80268-6; LANNUZEL A, 1994, NEUROPEDIATRICS, V25, P106, DOI 10.1055/s-2008-1071595; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; Lewis AI, 1996, J NEUROSURG, V84, P400, DOI 10.3171/jns.1996.84.3.0400; PALMER SH, 1995, INJURY, V26, P555, DOI 10.1016/0020-1383(95)00114-O; PANETTA TF, 1992, J TRAUMA, V33, P627, DOI 10.1097/00005373-199210000-00019; Parikh AA, 1997, J AM COLL SURGEONS, V185, P80, DOI 10.1016/S1072-7515(01)00886-9; PERRY MO, 1980, ANN SURG, V192, P74, DOI 10.1097/00000658-198007000-00013; PRETRE R, 1995, J TRAUMA, V39, P1012, DOI 10.1097/00005373-199511000-00036; PRETRE R, 1994, SURGERY, V115, P375; RICHARDSON JD, 1988, SURGERY, V104, P673; ROGERS FB, 1998, 28 ANN M W TRAUM ASS; ROMNER B, 1994, ACTA NEUROCHIR, V126, P815; Urwin RW, 1996, NEUROIMAG CLIN N AM, V6, P957; WELLING RE, 1987, J TRAUMA, V27, P1221; YAMADA S, 1967, J TRAUM, V7, P333, DOI 10.1097/00005373-196705000-00001	30	73	74	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1998	45	6					997	1004		10.1097/00005373-199812000-00004			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	151DF	WOS:000077704900004	9867039				2021-06-18	
J	Giacino, JT; Cicerone, KD				Giacino, JT; Cicerone, KD			Varieties of deficit unawareness after brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anosognosia; brain injury; deficit awareness; feedback; rehabilitation outcome	IMPLICIT KNOWLEDGE; ANOSOGNOSIA; CONFABULATION; HYPOTHESIS; AWARENESS; STROKE	The failure to recognize the existence of disease is known as anosognosia, This article provides a brief discussion of the evolution of this concept and reviews some qualitative differences in the manner in which the disavowal of neurogenic impairment is expressed. Theoretical explanations for the unawareness of deficit after neurologic illness include motivational-symbolic, cognitive subsystem, and supraordinate system theories. Observations from a clinically derived, structured awareness interview are presented, suggesting three factors that may underlie patients' apparent lack of awareness of deficits after traumatic brain injury. These include diminished awareness of deficits secondary to impaired cognition, especially memory and reasoning deficits; psychological reactance and denial of deficits; and a relatively 'pure" inability to recognize areas of impaired functioning as a direct consequence of brain injury. The causes of unawareness are likely to be complex and multiply determined in any given patient, although it may be possible to identify primary, secondary, and even tertiary contributions according to specific behavioral and phenomenological characteristics. The ability of patients to modify their perceptions and acknowledgment of deficits after objective feedback may have particular diagnostic value and clinical utility in this regard.	JFK Johnson Rehabil Inst, Edison, NJ USA; Seton Hall Univ, Sch Grad Med Educ, Edison, NJ USA	Giacino, JT (corresponding author), 2048 Oak Tree Rd, Edison, NJ 08820 USA.		Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			ANTON G, 1899, ARCH PSYCHIAT NERVEN, V32, P86, DOI DOI 10.1007/BF02126945; Babinski J., 1914, REV NEUROL-FRANCE, V27, P845; BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109; Berti A, 1996, J Int Neuropsychol Soc, V2, P426; Bisiach E, 1991, AWARENESS DEFICIT BR; Celesia GG, 1997, NEUROLOGY, V49, P88, DOI 10.1212/WNL.49.1.88; CRITCHLE.M, 1974, MT SINAI J MED, V41, P82; Critchley M, 1966, PARIETAL LOBES; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1093/neucas/3.1.73; FEINBERG TE, 1995, BRAIN, V118, P789, DOI 10.1093/brain/118.3.789; Gerstmann J, 1942, ARCH NEURO PSYCHIATR, V48, P890, DOI 10.1001/archneurpsyc.1942.02290120042003; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GOLD M, 1994, NEUROLOGY, V44, P1804, DOI 10.1212/WNL.44.10.1804; HALLIGAN PW, 1995, CORTEX, V31, P173, DOI 10.1016/S0010-9452(13)80115-3; Heilman K. M., 1991, AWARENESS DEFICIT BR; Heilman K.M.V.E., 1993, CLIN NEUROPSYCHOLOGY; Heilman KM, 1997, J NEUROPSYCH CLIN N, V9, P439, DOI 10.1176/jnp.9.3.439; KAPLAN RF, 1990, NEUROLOGY, V40, P1299, DOI 10.1212/WNL.40.8.1299; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; Lu LH, 1997, NEUROLOGY, V49, P1316, DOI 10.1212/WNL.49.5.1316; Mazzoni M, 1997, NEUROCASE, V3, P223; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MOSS AD, 1997, J NEUROL NEUROSUR PS, V62, P210; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Prigatano GP, 1995, BNI Q, V11, P10; RAMACHANDRAN VS, 1995, CONSCIOUS COGN, V4, P22, DOI 10.1006/ccog.1995.1002; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; SHUREN JE, 1995, NEUROLOGY, V45, P376, DOI 10.1212/WNL.45.2.376; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; TEGNER R, 1991, J NEUROL NEUROSUR PS, V54, P882, DOI 10.1136/jnnp.54.10.882; von Monakow C., 1885, ARCH PSYCHIAT NERVEN, V16, P151, DOI DOI 10.1007/BF02227304; WARRINGTON EK, 1962, J NEUROL NEUROSUR PS, V25, P208, DOI 10.1136/jnnp.25.3.208; WATSON RT, 1994, ARCH NEUROL-CHICAGO, V51, P1014, DOI 10.1001/archneur.1994.00540220060015; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; Weinstein EA, 1996, B MENNINGER CLIN, V60, P331; WEINSTEIN EA, 1963, ARCH GEN PSYCHIAT, V18, P348; WEINSTEIN EA, 1969, HDB CLIN NEUROLOGY, P4	39	73	73	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					1	15		10.1097/00001199-199810000-00003			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600003	9753531				2021-06-18	
J	Zafonte, RD; Watanabe, T; Mann, NR				Zafonte, RD; Watanabe, T; Mann, NR			Amantadine: a potential treatment for the minimally conscious state	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; ATTENTION; AROUSAL	Pharmacologic strategies have been advocated to enhance the: neurorehabilitation of persons with severe traumatic brain injury. Dopaminergic pathways have been felt to play a significant role in arousal. Employing single case design methodology we present the case of a survivor of severe traumatic brain injury who appeared to have a dose dependent response to the pro-dopaminergic medication amantadine. Further research is necessary to clarify the role of pharmacotherapy in the improvement of functional outcome.	Wayne State Univ, Rehabil Inst Michigan, Detroit, MI USA	Zafonte, RD (corresponding author), 261 Mack Blvd, Detroit, MI 48201 USA.						HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KELLEY J, 1996, P ASP NEUR I; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; NICKELS J, 1994, BRAIN INJURY, V8, P809; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940	10	73	79	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					617	621					5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200008	9653525				2021-06-18	
J	Busch, CR; Alpern, HP				Busch, CR; Alpern, HP			Depression after mild traumatic brain injury: A review of current research	NEUROPSYCHOLOGY REVIEW			English	Article						mild traumatic brain injury; depression; postconcussion syndrome; head injury	CLOSED-HEAD-INJURY; POSTCONCUSSION SYMPTOMS; PSYCHIATRIC-DISORDERS; CEREBRAL CONCUSSION; SEQUELAE; ANTIDEPRESSANTS; DEMOGRAPHICS; PERFORMANCE; MANAGEMENT; DISABILITY	Research pertaining to the occurrence of depression and/or depression symptomatology after a Mild Traumatic Brain Injury (MTBI) was reviewed. We found that methodological differences such as the criteria used to assess MTBI and depression, time that elapsed since brain injury, and control group variations confounded comparisons across studies. Nevertheless, the studies are consistent with at least a 35% prevalence of, and left frontal damage with depression after MTBI, an overlap of symptoms of depression and Postconcussion Syndrome (PCS), and indicate that depression can continue for many years following the injury. Our conclusion is that MTBI is the triggering event for a set of pathophysiological changes and a concomitant depressive episode in a vulnerable subset of the population. Due to a paucity of research, it cannot be definitively concluded that the underlying substrates of depression seen after MTBI and clinical depression are the same. Implications for future investigations are discussed.	Univ Colorado, Dept Psychol, Behav Neurosci Program, Boulder, CO 80309 USA	Alpern, HP (corresponding author), Univ Colorado, Dept Psychol, Behav Neurosci Program, Campus Box 345, Boulder, CO 80309 USA.						ALEXANDER MP, 1992, J HED TRAUMA REHABIL, V1, P50; ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; BERROL S, 1992, PHYSICAL MED REHABIL, V6, P1; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BOND M, 1984, CLOSED HEAD INJURY P, P44; BUSCH CR, 1995, UNPUB BASAL SALIVARY; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; COYNE JC, 1994, PSYCHOL BULL, V116, P29, DOI 10.1037/0033-2909.116.1.29; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; DOWNHILL JE, 1994, J NERV MENT DIS, V182, P425, DOI 10.1097/00005053-199408000-00001; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GASPARRINI WG, 1978, J NEUROL NEUROSUR PS, V41, P470, DOI 10.1136/jnnp.41.5.470; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, GC SNIV MEM LECT WAS; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GLAZER HI, 1981, DEPRESSION BEHAV DIR; GOTLIB IH, 1984, J PERS SOC PSYCHOL, V47, P427, DOI 10.1037/0022-3514.47.2.427; Gotlib IH., 1992, PSYCHOL ASPECTS DEPR; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HARRINGTON KT, 1993, J HEAD TRAUMA REHAB, V8, P86; HELLER W, 1993, J AFFECT DISORDERS, V29, P129, DOI 10.1016/0165-0327(93)90028-I; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1981, MANAGEMENTS HEAD INJ; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1982, J CONSULT CLIN PSYCH, V50, P590, DOI 10.1037/0022-006X.50.4.590; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISTER RG, 1985, NEUROSCI BIOBEHAV R, V9, P87, DOI 10.1016/0149-7634(85)90034-X; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; MERSKEY H, 1996, NEUROLOGY TRAUMA; Mialet JP, 1996, PSYCHOL MED, V26, P1009, DOI 10.1017/S0033291700035339; Miller L., 1993, PSYCHOTHERAPY BRAIN; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; MOBAYED M, 1990, J AFFECT DISORDERS, V19, P237, DOI 10.1016/0165-0327(90)90100-M; NOCKLEBY DM, 1984, J NEUROL NEUROSUR PS, V47, P260; NOLENHOEKSMA S, 1990, SEX DIFFERENCES DEPR; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; OHARA C, 1988, COGNITIVE REHABILITA, V6, P26; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; POST RM, 1984, NEUROBIOLOGY MOOD DI; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; POVLSHOCK JT, 1983, J NEUROSURG, V62, P96; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON R G, 1989, Journal of Geriatric Psychiatry, V22, P1; ROBINSON RG, 1986, HOSP PRACT, V21, P83; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; SEKINO H, 1981, Neurologia Medico-Chirurgica, V21, P677; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; STAUSS I, 1934, ARCH NEUROLOGICAL PS, V31, P893; STEIN SC, 1996, NEUROTRAMA; STRICH SJ, 1961, LANCET, V2, P443; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; SYZMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357; TUCKER GJ, 1994, J NEUROPSYCH CLIN N, V6, P58; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; VANWOERKOM TCAM, 1977, LANCET, V1, P812; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; World Health Organization (WHO), 1978, MENT DIS GLOSS GUID	97	73	75	0	10	PLENUM PUBL CORP	NEW YORK	CONSULTANTS BUREAU, 233 SPRING ST, NEW YORK, NY 10013 USA	1040-7308			NEUROPSYCHOL REV	Neuropsychol. Rev.	JUN	1998	8	2					95	108		10.1023/A:1025661200911			14	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	ZX490	WOS:000074521400003	9658412				2021-06-18	
J	Heard, SO; Fink, MP; Gamelli, RL; Solomkin, JS; Joshi, M; Trask, AL; Fabian, TC; Hudson, LD; Gerold, KB; Logan, ED				Heard, SO; Fink, MP; Gamelli, RL; Solomkin, JS; Joshi, M; Trask, AL; Fabian, TC; Hudson, LD; Gerold, KB; Logan, ED		Filgrastim Study Grp	Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage	CRITICAL CARE MEDICINE			English	Article						nosocomial pneumonia; granulocyte colony-stimulating factor; infection; bacteremia; brain injury; cerebral hemorrhage	FACTOR G-CSF; RESPIRATORY-DISTRESS-SYNDROME; BLOOD-STREAM INFECTIONS; ACUTE LUNG INJURY; HEAD-INJURY; VENTILATED PATIENTS; IMMUNE FUNCTION; SECULAR TRENDS; PNEUMONIA; ENDOTOXIN	Objective: To determine whether the use of prophylactic recombinant human granulocyte colony-stimulating factor (filgrastim) reduces the frequency of nosocomial infections in patients with either acute traumatic brain injury or cerebral hemorrhage. Design: Randomized, placebo-controlled, double-blind, multicenter phase II study. Setting: Intensive cave units of seven medical centers. Patients: Patients with either acute traumatic brain injury or cerebral hemorrhage who were intubated within 6 hrs of admission and who were expected to be ventilated for >72 hrs. Interventions: Patients were randomized to receive daily subcutaneous injections of placebo (n = 21) or one of two doses of filgrastim (75 mu g [n = 20] or 300 mu g [n = 20]) for 10 days or until the absolute neutrophil count was >75,000 cells/mm(3) or until extubation. Measurements and Main Results: End points included increase in absolute neutrophil count, safety of filgrastim, and frequency of nosocomial infections (pneumonia, bacteremia, and urinary tract infection). Filgrastim caused a dose-dependent increase in absolute neutrophil count. There were no differences in the frequency of pneumonia or urinary tract infection; however, there was a dose dependent decrease in the frequency of bacteremias (p < .05). Adverse events were similar among the three groups. There was one case of acute respiratory distress syndrome in the placebo group. Conclusion: In this patient population, use of filgrastim was safe and the agent appeared to reduce the risk of primary bacteremias but had no beneficial effects on mortality, length of stay, or other nosocomial infections.	Univ Massachusetts, Med Ctr, Dept Anesthesiol, Worcester, MA 01655 USA; Univ Massachusetts, Med Ctr, Dept Surg, Worcester, MA 01655 USA	Heard, SO (corresponding author), Univ Massachusetts, Med Ctr, Dept Anesthesiol, 55 Lake Ave N, Worcester, MA 01655 USA.			Solomkin, Joseph/0000-0001-6382-4902			*AMG INC, 1995, FILGR INV BROCH; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BEGLEY CG, 1986, BLOOD, V68, P162; BONTEN MJM, 1994, CRIT CARE MED, V22, P1683; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Colton T., 1974, STAT MED; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DEMUYNCK H, 1995, ANN HEMATOL, V70, P143, DOI 10.1007/s002770050047; DIXON WJ, 1990, BMDP STAT SOFTWARE M, V1, P1385; DIXON WJ, 1990, BMDP STAT SOFTWARE M, V2; DONOWITZ LG, 1982, CRIT CARE MED, V10, P355, DOI 10.1097/00003246-198206000-00001; FINK MP, 1990, CHEST, V97, P132, DOI 10.1378/chest.97.1.132; FINK MP, 1993, J TRAUMA, V34, P571, DOI 10.1097/00005373-199304000-00015; Freeman BD, 1996, J APPL PHYSIOL, V80, P2066; GLASPY JA, 1988, ANN INTERN MED, V109, P789, DOI 10.7326/0003-4819-109-10-789; GORGEN I, 1992, J IMMUNOL, V149, P918; HEBERT JC, 1990, ARCH SURG-CHICAGO, V125, P1075; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; KANAZAWA M, 1992, AM REV RESPIR DIS, V145, P1030, DOI 10.1164/ajrccm/145.5.1030; KING J, 1995, AM J RESP CRIT CARE, V151, P302, DOI 10.1164/ajrccm.151.2.7531097; KOIZUMI T, 1993, AM REV RESPIR DIS, V148, P132, DOI 10.1164/ajrccm/148.1.132; LEIBOVICI L, 1995, JAMA-J AM MED ASSOC, V274, P807, DOI 10.1001/jama.274.10.807; LUNDBLAD R, 1995, SHOCK, V4, P68, DOI 10.1097/00024382-199507000-00011; MACGREGOR RR, 1972, ARCH INTERN MED, V130, P84, DOI 10.1001/archinte.130.1.84; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; MOONEY DP, 1988, ARCH SURG-CHICAGO, V123, P1353; OREILLY M, 1992, J TRAUMA, V33, P679, DOI 10.1097/00005373-199211000-00014; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; SCARFFE JH, 1990, CANCER SURV, V9, P115; SCHILERO GJ, 1995, CHEST, V107, P276, DOI 10.1378/chest.107.1.276; SILVER GM, 1989, SURGERY, V106, P452; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; STARK RP, 1984, NEW ENGL J MED, V311, P560, DOI 10.1056/NEJM198408303110903; WANG JM, 1988, BLOOD, V72, P1456; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WHITE K, 1995, LANCET, V345, P1022, DOI 10.1016/S0140-6736(95)90759-9; WOLACH B, 1993, BRAIN INJURY, V7, P401, DOI 10.3109/02699059309029683	42	73	78	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	1998	26	4					748	754		10.1097/00003246-199804000-00027			7	Critical Care Medicine	General & Internal Medicine	ZH472	WOS:000073113900024	9559614				2021-06-18	
J	Bowen, A; Neumann, V; Conner, M; Tennant, A; Chamberlain, MA				Bowen, A; Neumann, V; Conner, M; Tennant, A; Chamberlain, MA			Mood disorders following traumatic brain injury: identifying the extent of the problem and the people at risk	BRAIN INJURY			English	Article							HEAD-INJURY; DEPRESSION; POPULATION; RELATIVES; SCALE; COMA	The extent of mood disorders following traumatic brain injury (TBI), and the possible risk factors, are investigated. New data are presented from a prospective study of consecutive hospital admissions. Six months post-TBI, 99 adults completed a standardized assessment of emotional state, the Wimbledon Self-Report Scale. Cognitive performance and the impact of the injury on everyday functioning were also assessed. The rate of clinically significant mood disorders (caseness) was 38%. of the demographic or injury characteristics, only pre-injury occupational status predicted post-injury caseness. Those unoccupied pre-injury were more likely to report mood disturbances post-injury. In contrast, post-injury occupational status was not related to caseness either for the whole group or the subgroup of those previously occupied, despite the adverse effects on occupational functioning for a significant proportion of subjects. Associations were found between emotional state and cognitive and everyday functioning 6 months post-injury. Psychosocial disabilities appeared more strongly associated to mood disorders than did physical disabilities. A significant level of unmet need has been highlighted, and possible risk factors identified, which may inform the purchase and provision of TBI rehabilitation services. Follow-up data on these subjects are available and will be reported separately.	Univ Leeds, Rheumatol & Rehabil Res Unit, Leeds, W Yorkshire, England; Univ Manchester, Stroke Assoc, Therapy Res Unit, Manchester, Lancs, England; Univ Leeds, Dept Psychol, Leeds LS2 9JT, W Yorkshire, England	Bowen, A (corresponding author), Hope Hosp, CSB, Dept Geriatr Med, Stroke Assoc,Therapy Res Unit, Salford M6 8HD, Lancs, England.		Bowen, Audrey/K-5544-2012; Conner, Mark/N-9063-2013	Conner, Mark/0000-0002-6229-8143; Bowen, Audrey/0000-0003-4075-1215			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benton AL, 1978, MULTILINGUAL APHASIA; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; BURTON LA, 1994, J NEUROLOGICAL REHAB, V8, P63, DOI DOI 10.1177/136140969400800202; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; Derogatis LR, 1983, SCL 90 ADM SCORING P; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; HATHAWAY S, 1951, MMPI MANUAL REVISED; HUGHES D, 1995, TRAUMATIC BRAIN INJU, P66; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin HS, 1984, NEUROPSYCHOLOGY MEMO, P247; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Patrick D L, 1982, J R Coll Gen Pract, V32, P429; REITAN, 1983, NEUROPSYCHOLOGICAL A, P557; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; TEASDALE G, 1974, LANCET, V2, P81; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wechsler D., 1987, WECHSLER MEMORY SCAL; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	73	74	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	1998	12	3					177	190		10.1080/026990598122656			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZA456	WOS:000072365100001	9547948				2021-06-18	
J	Zafonte, RD; Mann, NR; Millis, SR; Black, KL; Wood, DL; Hammond, F				Zafonte, RD; Mann, NR; Millis, SR; Black, KL; Wood, DL; Hammond, F			Posttraumatic amnesia: Its relation to functional outcome	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							GLASGOW COMA SCALE; SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; PREDICTION; DISABILITY; PRESSURE; RECOVERY	Objective: To investigate the relation between duration of posttraumatic amnesia (PTA) and functional outcome in a traumatically brain injured population. Patients: Two hundred seventy-six patients with traumatic brain injury (TBI) who were admitted to a Level I university trauma center and required inpatient rehabilitation. Measures: Duration of PTA was assessed by serial administrations of the Galveston Orientation Amnesia Test (GOAT). Functional Independence Measure (FIM) total scores, FIM cognitive and motor subscores, and Disability Rating Scale (DRS) scores were obtained at admission and discharge from inpatient rehabilitation. Results: Duration of PTA was a significant predictor of all admission and discharge DRS and FIM scores. Duration of PTA and age at the time of injury, in combination, contributed significantly to the prediction of the DRS score and FIM total, cognitive, and motor scores at discharge. Conclusion: Duration of PTA appears to be a useful variable in predicting specific functional outcome in the TBI population receiving inpatient rehabilitation services. The use of age as a factor in addition to duration of PTA enhances the prediction of functional outcome. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.		Zafonte, RD (corresponding author), WAYNE STATE UNIV,INST REHABIL,261 MACK BLVD,DETROIT,MI 48201, USA.						CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ D, 1996, BRAIN INJ ASS P 1996, P216; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NORUSIS MJ, 1995, SPSS WINDOWS RELEASE; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; THATCHER R, 1983, J NEUROSURG, V59, P294; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	23	73	76	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1997	78	10					1103	1106		10.1016/S0003-9993(97)90135-0			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YA044	WOS:A1997YA04400009	9339160				2021-06-18	
J	Ohry, A; Rattok, J; Solomon, Z				Ohry, A; Rattok, J; Solomon, Z			Post-traumatic stress disorder in brain injury patients	BRAIN INJURY			English	Article							EVENT SCALE; COMBAT; VALIDATION; SOLDIERS; IMPACT; PTSD; WAR	In the absence of the recognition of the emotional sequelae following traumatic brain injury (TBI), many patients are deprived of adequate treatment. The purpose of the current study is to evaluate the prevalence of post-traumatic stress disorder (PTSD) and explore the clinical picture among TBI patients. Twenty-four outpatients with diagnosed head injuries following various traumas filled out standardized questionnaires, assessing post-traumatic residuals. Thirty-three per cent of these patients met criteria for PTSD diagnosis. The clinical picture of PTSD following TBI is somewhat distinguished from those following other traumatic events. Issues concerning the specific nature of the syndrome following TBI, and the difficulties in differentiating between PTSD and postconcussive syndrome, are discussed.	TEL AVIV UNIV,BOB SHAPELL SCH SOCIAL WORK,IL-69978 TEL AVIV,ISRAEL; LONG ISL JEWISH MED CTR,NEW YORK,NY							American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BRACKSTONE MJ, 1995, INT J REHABILITATION, V1, P37; COLLINS A, 1985, SEX ROLES, V12, P1219, DOI 10.1007/BF00287831; Epstein Richard S., 1994, P285; HARTMAN CR, 1993, INT HDB TRAUMATIC ST, P507; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Kraus Jess F., 1994, P3; McAllister Thomas W., 1994, P357; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; RATTOK J, 1993, J CLIN EXPT NEUROPSY, V16, P243; Rattok Jack, 1994, P703; Robinson Robert G., 1994, P219; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHWARZWALD J, 1987, J CONSULT CLIN PSYCH, V55, P251, DOI 10.1037/0022-006X.55.2.251; SELTZER DJ, 1994, NEUROPSYCHIATRY TRAU, P251; Silver Jonathan M., 1994, P313; Smith E. M., 1993, INT HDB TRAUMATIC ST, P405; SOLOMON Z, 1993, ISRAEL J PSYCHIAT, V30, P110; SOLOMON Z, 1987, AM J PSYCHIAT, V144, P448; SOLOMON Z, 1994, AM J PSYCHIAT, V151, P554; SOLOMON Z, 1986, AM J PSYCHIAT, V143, P613; Solomon Z., 1993, COMBAT STRESS REACTI; Solomon Z., 1995, COPING WAR INDUCED S; Taylor Craig A., 1994, P81	25	73	73	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1996	10	9					687	695		10.1080/026990596124106			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VB635	WOS:A1996VB63500006	8853871				2021-06-18	
J	Dietrich, WD; Alonso, O; Busto, R; Prado, R; Dewanjee, S; Dewanjee, MK; Ginsberg, MD				Dietrich, WD; Alonso, O; Busto, R; Prado, R; Dewanjee, S; Dewanjee, MK; Ginsberg, MD			Widespread hemodynamic depression and focal platelet accumulation after fluid percussion brain injury: A double-label autoradiographic study in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; platelets; cerebral blood flow; vasoactive substances	CEREBRAL BLOOD-FLOW; CAROTID-ARTERY THROMBOSIS; HEAD-INJURIES; COMMON; METABOLISM; ISCHEMIA; BARRIER	Cerebrovascular damage leading to subsequent reductions in local cerebral blood flow (ICBF) may represent an important secondary injury mechanism following traumatic brain injury (TBI). We determined whether patterns of (111)indium-labeled platelet accumulation were spatially related to alterations in ICBF determined autoradiographically 30 min after TBI. Sprague-Dawley rats (n = 8), anesthetized with halothane and maintained on a 70:30 (vol/vol) mixture of nitrous oxide/oxygen and 0.5% halothane, underwent parasagittal fluid percussion brain injury (1.7-2.2 atm). (111)Indium-tropolone-labeled platelets were injected 30 min prior to TBI while [C-14]-iodoantipyrine was infused 30 min after trauma. Sham-operated animals (n = 7) underwent similar surgical procedures but were not injured, In autoradiographic images of the indium-labeled platelets, focal sites of platelet accumulation within the traumatized hemisphere were restricted to the pial surface (five of eight rats), the external capsule underlying the lateral parietal cortex (five of eight rats), and within cerebrospinal fluid (CSF) compartments (six of eight rats). In contrast, mild-to-moderate reductions in lCBF, not restricted to sites of platelet accumulation, were seen throughout the traumatized hemisphere. Flow reductions were most severe in coronal sections underlying the impact site, For example, within the lateral parietal cortex and hippocampus, 1CBF was significantly reduced [p < 0.01; analysis of variance (ANOVA)] from 1.71 +/- 0.34 (mean +/- SD) and 0.78 +/- 0.12 ml/g/min, respectively, versus 0.72 +/- 0.17 and 0.41 +/- 0.06 ml/g/min within the traumatized hemisphere. Significant flow reductions were also seen in remote cortical and subcortical areas, including the right frontal cortex and striatum. These results indicate that focal platelet accumulation and widespread hemodynamic depression are both early consequences of TBI, Therapeutic strategies directed at these early microvascular consequences of TBI may be neuroprotective by attenuating secondary ischemic processes.	UNIV MIAMI, SCH MED, DEPT RADIOL, MIAMI, FL 33101 USA	Dietrich, WD (corresponding author), UNIV MIAMI, SCH MED, DEPT NEUROL D45, NEUROTRAUMA CLIN RES CTR, POB 016960, MIAMI, FL 33101 USA.						ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWANJEE MK, 1983, MAYO CLIN PROC, V58, P307; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1991, J CEREBR BLOOD F MET, V11, P957, DOI 10.1038/jcbfm.1991.161; DIETRICH WD, 1993, STROKE, V24, P1534, DOI 10.1161/01.STR.24.10.1534; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1977, STROKE, V8, P480, DOI 10.1161/01.STR.8.4.480; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JONSSON BA, 1992, J NUCL MED, V33, P1825; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1983, INTRACRANIAL PRESSUR, P491; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Reivich M, 1974, Res Publ Assoc Res Nerv Ment Dis, V53, P125; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Roy C S, 1890, J Physiol, V11, P85; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; THOMPSON JA, 1984, STROKE, V15, P1021, DOI 10.1161/01.STR.15.6.1021; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZILLES L, 1985, CORTEX RAT STEREOTAX	48	73	74	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	1996	16	3					481	489		10.1097/00004647-199605000-00015			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	UF710	WOS:A1996UF71000015	8621753	Bronze			2021-06-18	
J	Germann, G; Steinau, HU				Germann, G; Steinau, HU			The clinical reliability of vein grafts in free-flap transfer	JOURNAL OF RECONSTRUCTIVE MICROSURGERY			English	Article							MICROSURGERY; ANASTOMOSIS; INJURIES; HEAD	The use of interposition vein grafts has been associated in the literature with a high complication and flap failure rate. Ninety-three vein grafts in 55 patients over a 46-month period were analyzed to evaluate the clinical reliability of vein grafts in a predominantly trauma patient population (37/55). Fifty-two arterio-arterial grafts and 41 veno-venous grafts were performed. A-V loops prior to flap transfer were created in 26 patients. The revision rate was 14.8 percent, with a salvage rate of 75 percent. Flap survival was 96.2 percent, compared to 96.7 percent for a large series of flaps without vein grafts. it can be concluded from the study, that the use of vein grafts is not associated with a higher flap failure rate, when technical pitfalls can be avoided, and close monitoring by an experienced staff is guaranteed.		Germann, G (corresponding author), BG TRAUMA HOSP,BURN CTR,DEPT PLAST & HAND SURG,LUDWIG GUTTMANN STR 13,D-67071 LUDWIGSHAFEN,GERMANY.						ACLAND RD, 1994, PLAST RECONSTR SURG, V93, P479; DILLEY RJ, 1986, PLAST RECONSTR SURG, V77, P451, DOI 10.1097/00006534-198603000-00021; DUMINY FJ, 1989, J SURG RES, V46, P189, DOI 10.1016/0022-4804(89)90054-1; ETHRIDGE CP, 1988, BRIT J PLAST SURG, V41, P52, DOI 10.1016/0007-1226(88)90145-2; FUJIKAWA S, 1975, BRIT J PLAST SURG, V28, P244, DOI 10.1016/0007-1226(75)90024-7; GREENBERG BM, 1988, J HAND SURG-AM, V13A, P753, DOI 10.1016/S0363-5023(88)80142-4; GROTTING JC, 1991, CLIN PLAST SURG, V18, P485; HALLOCK G G, 1988, Journal of Reconstructive Microsurgery, V4, P155, DOI 10.1055/s-2007-1006914; HIDALGO DA, 1990, PLAST RECONSTR SURG, V86, P492, DOI 10.1097/00006534-199009000-00019; HIGGS PE, 1993, PLAST RECONSTR SURG, V91, P726, DOI 10.1097/00006534-199304000-00028; HIRASE Y, 1989, BRIT J PLAST SURG, V42, P216, DOI 10.1016/0007-1226(89)90207-5; HORNG SY, 1993, PLAST RECONSTR SURG, V92, P752, DOI 10.1097/00006534-199309001-00031; JONES NF, 1985, J HAND SURG-AM, V10A, P675, DOI 10.1016/S0363-5023(85)80206-9; KHOURI R, 1992, CLIN PLAST SURG, V4, P773; MEHLHOFF TL, 1991, J HAND SURG-AM, V16A, P274, DOI 10.1016/S0363-5023(10)80110-8; MILLER MJ, 1993, J RECONSTR MICROSURG, V9, P245, DOI 10.1055/s-2007-1006652; MITCHELL FL, 1990, J TRAUMA, V30, P336, DOI 10.1097/00005373-199003000-00014; MONEIM MS, 1985, J BONE JOINT SURG AM, V67A, P880, DOI 10.2106/00004623-198567060-00009; MUTIMER KL, 1987, PLAST RECONSTR SURG, V79, P535, DOI 10.1097/00006534-198704000-00003; NAHAI F, 1986, PLAST RECONSTR SURG, V77, P312, DOI 10.1097/00006534-198602000-00028; OLIVA A, 1990, PLAST SURG FORUM, V13, P28; RYAN AD, 1988, PLAST RECONSTR SURG, V81, P414, DOI 10.1097/00006534-198803000-00018; SCHUSTERMAN MA, 1994, PLAST RECONSTR SURG, V93, P472, DOI 10.1097/00006534-199493030-00004; SIDOROV VB, 1992, J RECONSTR MICROSURG, V8, P277, DOI 10.1055/s-2007-1006708; STEVANOVIC MV, 1991, PLAST RECONSTR SURG, V87, P1099, DOI 10.1097/00006534-199106000-00012; TAKATO T, 1991, BRIT J PLAST SURG, V44, P593, DOI 10.1016/0007-1226(91)90096-3; YAFFE B, 1983, PLAST RECONSTR SURG, V72, P526, DOI 10.1097/00006534-198310000-00021; ZEEMAN BJV, 1988, BRIT J PLAST SURG, V41, P509, DOI 10.1016/0007-1226(88)90009-4; ZHANG F, 1994, J RECONSTR MICROSURG, V10, P223, DOI 10.1055/s-2007-1006588; ZHANG F, 1994, J RECONSTR MICROSURG, V10, P229, DOI 10.1055/s-2007-1006589	30	73	74	0	2	THIEME MEDICAL PUBL INC	NEW YORK	381 PARK AVE SOUTH, NEW YORK, NY 10016	0743-684X			J RECONSTR MICROSURG	J. Reconstr. Microsurg.	JAN	1996	12	1					11	17		10.1055/s-2007-1006446			7	Surgery	Surgery	TR261	WOS:A1996TR26100004	8618220				2021-06-18	
J	FEENEY, TJ; YLVISAKER, M				FEENEY, TJ; YLVISAKER, M			CHOICE AND ROUTINE - ANTECEDENT BEHAVIORAL INTERVENTIONS FOR ADOLESCENTS WITH SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							FRONTAL-LOBE DAMAGE; CLOSED-HEAD-INJURY; CHILDREN; DISABILITIES; CHILDHOOD; MOMENTUM; CONSEQUENCES; SEQUELAE; STUDENTS; LESION	Objective: To investigate the effectiveness of an antecedent intervention in reducing aggressive behavior. Design: Three single-subject A-B-C-A (changing treatment) designs. Setting: High school and prevocational settings. Patients: Three adolescent males whose behavior had deteriorated badly over several years after severe traumatic brain injury. Intervention: Integrative intervention that addressed the subjects' cognitive impairment (including their need for well-established routines and advance organizers), their oppositional behavior (associated with their need to be involved in making decisions about their routines), and their history of failure (associated with their need to experience success before attacking difficult tasks). Main Outcome Measures: Frequency counts of aggressive behavior; standardized ratings of severity of aggressive behavior; quantity of assigned work completed. Results: Each subject demonstrated reduction of aggressive behavior to acceptable levels with a concomitant increase in quantity of assigned work completed. Anecdotal follow-up reports indicate that each subject is employed with minimal or no support. Conclusions: The combination of behavioral and cognitive antecedent intervention procedures produced a sufficient reduction in aggressive behavior to enable the subjects to succeed in their educational and subsequent vocational programs. The design was insufficient to identify the relative contribution of each component of the intervention.	COLL ST ROSE, ALBANY, NY USA	FEENEY, TJ (corresponding author), ALBANY SCHENECTADY SCHOHARIE SARATOGA BOARD COOPE, TBI REENTRY PROJECT, ALBANY, NY USA.						ACKERLY SS, 1964, FRONTAL GRANULAR COR; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; AMAN MG, 1988, ABERRANT BEHAVIOR CH; BANNERMAN DJ, 1990, J APPL BEHAV ANAL, V23, P79, DOI 10.1901/jaba.1990.23-79; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; BERKMAN KA, 1988, J ASSOC PERS SEVERE, V13, P76; BROWN F, 1991, J ASSOC PERS SEVERE, V16, P75; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHILDS KE, 1994, J APPL BEHAV ANAL, V27, P7, DOI 10.1901/jaba.1994.27-7; DESHLER DD, 1988, ALTERNATIVE ED DELIV; DOSS S, 1989, J ASSOC PERS SEVERE, V14, P101; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; DYER K, 1990, J APPL BEHAV ANAL, V23, P515, DOI 10.1901/jaba.1990.23-515; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Flannery K. B., 1994, J BEHAV EDUC, V4, P157, DOI [DOI 10.1007/BF01544110, 10.1007/BF01544110]; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; GOLDSTEIN FC, 1989, INTEGRATING THEORY P; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Harchik A E, 1993, Ann Clin Psychiatry, V5, P151, DOI 10.3109/10401239309148979; HARCHIK AE, 1990, J ASSOC PERS SEVERE, V15, P40; HARING TG, 1990, J APPL BEHAV ANAL, V23, P235, DOI 10.1901/jaba.1990.23-235; HART, 1988, J HEAD TRAUMA REHAB, V3, P53; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; HOMER R, 1990, J ASSOC PERS SEVERE, V15, P125; Horner R. H, 1988, GENERALIZATION MAINT; HORNER RH, 1991, J APPL BEHAV ANAL, V24, P719, DOI 10.1901/jaba.1991.24-719; HORNER RH, 1985, EDUC TRAIN MENT RET, V20, P39; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; LEVIN HS, 1991, FRANTAL LOBE FUNCTIO; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MACE FC, 1990, J EXP ANAL BEHAV, V54, P163, DOI 10.1901/jeab.1990.54-163; MACE FC, 1988, J APPL BEHAV ANAL, V21, P123, DOI 10.1901/jaba.1988.21-123; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; NEVIN JA, 1992, J EXP ANAL BEHAV, V57, P301, DOI 10.1901/jeab.1992.57-301; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; ROSENTHAL M, 1990, REHABILITATION ADULT; SCHWARTZ MF, 1993, J HEAD TRAUMA REHAB, V8, P59, DOI DOI 10.1097/00001199-199303000-00007; SHEVIN M, 1984, J ASSOC PERS SEVERE, V9, P159; Singh NN, 1994, ABERRANT BEHAVIOR CH; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STOKES TF, 1977, J APPL BEHAV ANAL, V10, P349, DOI 10.1901/jaba.1977.10-349; Stuss D.T., 1986, FRONTAL LOBES; SZEKERES S, 1993, SEMIN SPEECH LANG, V13, P293; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WETZEL RJ, 1984, RESIDENTIAL TEACHING; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RLL, 1990, NEUROBEHAVIORAL SEQU; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005; YLVISAKER M, 1993, STAFF DEV CLIN INTER; YLVISAKER M, 1987, COMMUNITY REENTRY HE; Ylvisaker Mark, 1993, Seminars in Speech and Language, V14, P74, DOI 10.1055/s-2008-1064160; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	63	73	73	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1995	10	3					67	86					20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RC717	WOS:A1995RC71700007					2021-06-18	
J	FUKUDA, K; TANNO, H; OKIMURA, Y; NAKAMURA, M; YAMAURA, A				FUKUDA, K; TANNO, H; OKIMURA, Y; NAKAMURA, M; YAMAURA, A			THE BLOOD-BRAIN-BARRIER DISRUPTION TO CIRCULATING PROTEINS IN THE EARLY PERIOD AFTER FLUID PERCUSSION BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article						BLOOD-BRAIN BARRIER; EXPERIMENTAL BRAIN INJURY; ALBUMIN; HORSERADISH PEROXIDASE	VASCULAR-PERMEABILITY; SUBARACHNOID HEMORRHAGE; FREE-RADICALS; SPINAL-CORD; EDEMA; DAMAGE; EXTRAVASATION; MEDIATORS; ANTIBODY; RELEASE	Breakdown of the blood-brain barrier (BBB) immediately after traumatic brain injury is not clearly understood. In the present study we focused on the integrity of the BBB to circulating proteins within the first hour after injury. For this purpose, vascular permeability to endogenous albumin and to the exogenous protein tracer horseradish peroxidase (HRP) was examined after a lateral fluid percussion brain injury in rats. Albumin was immunolocalized in brain sections at 3 and 60 min after impact. This distribution was compared with the histochemical localization of HRP given before impact at the same time points. In a separate experiment HRP was given prior to sacrifice to determine the time course for the barrier disruption. Permeability to this protein was assessed at 13, 30, and 60 min after impact. Prominent extravasation of albumin occurred within 3 min of injury and was present in multiple foci within the injured hemisphere. At 60 min the extravasated albumin was present in the same sites, where it was widely distributed. Throughout the related brain parenchyma, little difference was found between the extravascular distribution of albumin and HRP. In the delayed administration paradigm breakdown of the BBB was noted in the impact site, hemorrhagic site in the deep cortical layer, hippocampus, thalamus, and midbrain at 13 min after injury. This injured barrier was restored in most regions by 30 min. However, the impact site and hemorrhagic site remained permeable up to 60 min postinjury. In addition, newly developed barrier disruption to HRP occurred in the parasagittal cortex at 30 and 60 min. In conclusion, widespread breakdown of the BBB to circulating proteins occurred within a few minutes after traumatic brain injury. The time course for this barrier disruption is characterized by three different patterns: (1) transient, (2) prolonged, and (3) delayed opening. This variation in the development of barrier disruption may be related to the secondary barrier failure as well as the primary opening after injury.		FUKUDA, K (corresponding author), CHIBA UNIV,SCH MED,DEPT NEUROSURG,CHUO KU,1-8-1 INOHANA,CHIBA 260,JAPAN.						AARABI B, 1979, J NEUROSURG, V51, P779, DOI 10.3171/jns.1979.51.6.0779; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BODSCH W, 1983, J NEUROCHEM, V41, P239, DOI 10.1111/j.1471-4159.1983.tb11833.x; BODSCH W, 1982, BRAIN RES, V249, P111, DOI 10.1016/0006-8993(82)90175-5; Chan P H, 1990, Adv Neurol, V52, P177; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CHAN PH, 1985, BRAIN EDEMA, P317; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROCKARD A, 1982, HEAD INJURY BASIC CL, P159; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; Fukuda Kazumasa, 1994, Brain and Nerve (Tokyo), V46, P1030; GERMANO A, 1992, NEUROSURGERY, V30, P882, DOI 10.1227/00006123-199206000-00011; Houthoff H J, 1980, Adv Neurol, V28, P75; HOUTHOFF HJ, 1982, ACTA NEUROPATHOL, V56, P99, DOI 10.1007/BF00690580; IKEDA Y, 1990, NEUROSURGERY, V27, P1; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JOHANSSON BB, 1992, PROG BRAIN RES, V91, P171; Katayama Y, 1990, Adv Neurol, V52, P105; Kempski O, 1990, Adv Neurol, V52, P219; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; LEVIN E, 1976, DYNAMICS BRAIN EDEMA, P23; LOBERG EM, 1991, ACTA NEUROPATHOL, V81, P479, DOI 10.1007/BF00310126; Nakamura T, 1987, Neurol Med Chir (Tokyo), V27, P396, DOI 10.2176/nmc.27.396; NOBLE LJ, 1983, EXP NEUROL, V79, P188, DOI 10.1016/0014-4886(83)90390-4; OKIMURA Y, 1994, 1994 INT C REC ADV N, V2, P543; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RAPOPORT SI, 1986, ANN NY ACAD SCI, V481, P250; SOKRAB TEO, 1988, ACTA NEUROPATHOL, V75, P557, DOI 10.1007/BF00686200; SOKRAB TEO, 1988, ACTA NEUROL SCAND, V77, P387, DOI 10.1111/j.1600-0404.1988.tb05924.x; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Tornheim P A, 1990, Adv Neurol, V52, P377; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; TORNHEIM PA, 1985, CENTRAL NERVOUS SYST, P431; Unterberg A, 1990, Adv Neurol, V52, P211; Villacara A, 1990, Adv Neurol, V52, P195; VORBRODT AW, 1985, ACTA NEUROPATHOL, V66, P265, DOI 10.1007/BF00690958; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Westergaard E, 1980, Adv Neurol, V28, P55	45	73	74	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1995	12	3					315	324		10.1089/neu.1995.12.315			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RM331	WOS:A1995RM33100009	7473806				2021-06-18	
J	BIAGAS, KV; UHL, MW; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM				BIAGAS, KV; UHL, MW; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM			ASSESSMENT OF POSTTRAUMATIC POLYMORPHONUCLEAR LEUKOCYTE ACCUMULATION IN RAT-BRAIN USING TISSUE MYELOPEROXIDASE ASSAY AND VINBLASTINE TREATMENT	JOURNAL OF NEUROTRAUMA			English	Article							BLOOD-FLOW; INJURY; INFILTRATION; INFLAMMATION; MACROPHAGES; RELEASE	Polymorphonuclear leukocytes (PMN) are implicated in the pathogenesis of traumatic brain injury. We tested the following hypotheses: (1) leukocyte accumulation is present in brain tissue 24 h posttrauma, (2) leukocyte accumulation represents PMN, and (3) prior systemic PMN depletion attenuates brain tissue PMN accumulation. Trauma was induced in exposed right parietal cortex by weightdrop in anesthetized Wistar rats (n = 24). Of the traumatized rats, 12 were PMN-depleted with vinblastine sulfate i.v. Controls were 12 normal rats and 5 sham-operated rats (craniotomy). Sections of traumatized and contralateral hemispheres were analyzed for myeloperoxidase (MPO) activity. Brain MPO activity was increased fivefold at 24 h posttrauma, but only in the traumatized hemisphere (0.448 +/- 0.133 U/g vs 0.090 +/- 0.022 U/g in trauma vs normal, respectively, p < 0.05, mean +/- SEM). PMN depletion attenuated this increase in MPO activity and decreased circulating PMN counts (0.07 +/- 0.032 x 10(9)/L vs 0.894 +/- 0.294 x 10(9)/L PMN-depleted-trauma vs trauma rats, respectively, p < 0.05). Leukocyte accumulation in the brain posttrauma was confirmed by MPO assay. Inhibition of MPO activity in the PMN-depleted group and the specificity of vinblastine treatment for depletion of circulating PMN suggest that leukocyte accumulation in the brain at 24 h posttrauma is largely due to PMN.	UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA				Kochanek, Patrick/0000-0002-2627-913X			Barman T.E., 1985, ENZYME HDB, VI, P234; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; BOYA J, 1986, ACTA ANAT, V127, P142; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CLARK RA, 1979, J CLIN INVEST, V63, P177, DOI 10.1172/JCI109287; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DUVAL DL, 1990, LIFE SCI, V47, pPL145; FARACI FM, 1991, STROKE, V22, P790, DOI 10.1161/01.STR.22.6.790; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GRUNDL P D, 1991, Society for Neuroscience Abstracts, V17, P721; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; KATZ IR, 1990, J NEUROIMMUNOL, V29, P33, DOI 10.1016/0165-5728(90)90145-D; KAUR C, 1987, J ANAT, V154, P215; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; RINALDO JE, 1988, AM REV RESPIR DIS, V137, P345, DOI 10.1164/ajrccm/137.2.345; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; UHL MW, IN PRESS ADV EXPT ME; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	25	73	74	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					363	371		10.1089/neu.1992.9.363			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300006	1337917				2021-06-18	
J	KRIEL, RL; KRACH, LE; PANSER, LA				KRIEL, RL; KRACH, LE; PANSER, LA			CLOSED HEAD-INJURY - COMPARISON OF CHILDREN YOUNGER AND OLDER THAN 6 YEARS OF AGE	PEDIATRIC NEUROLOGY			English	Article										KRIEL, RL (corresponding author), GILLETTE CHILDRENS HOSP,DEPT PEDIAT NEUROL,200 E UNIV AVE,ST PAUL,MN 55101, USA.							0	73	73	0	3	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	SEP-OCT	1989	5	5					296	300		10.1016/0887-8994(89)90021-0			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	AW661	WOS:A1989AW66100005	2803387				2021-06-18	
J	Vink, R; Faden, AI; McIntosh, TK				Vink, Robert; Faden, Alan I.; McIntosh, Tracy K.			Changes in Cellular Bioenergetic State Following Graded Traumatic Brain Injury in Rats: Determination by Phosphorus 31 Magnetic Resonance Spectroscopy	JOURNAL OF NEUROTRAUMA			English	Article							HUMAN MITOCHONDRIAL MYOPATHIES; P-31 NMR; IN-VIVO; CREATINE-KINASE; ENERGY-STATE; HEAD-INJURY; FREE MG-2+; METABOLISM; MAGNESIUM; PH	Phosphorus 31 magnetic resonance spectroscopy (P-31 MRS) was used to study noninvasively the intracellular free Mg2+ concentration and cellular bioenergetic state of rat brain in vivo before and after fluid percussion-induced traumatic brain injury of graded severity. Brain injury was induced at four levels: low (1.0 +/- 0.5 atm); moderate (2.1 +/- 0.4 atm); high (3.9 +/- 0.9 atm); and severe (5.9 +/- 0.7 atm). Prior to injury, mean intracellular values for all groups (n = 24; mean +/- SE) were as follows: pH = 7.11 +/- 0.03; free [Mg2+] = 0.99 +/- 0.07 mM; cytosolic [ADP] = 25.2 +/- 0.8 nmol/g wet weight; cytosolic [AMP] = 0.29 +/- 0.02 nmol/g wet weight; cytosolic phosphorylation potential = 118.5 +/- 3.1 x 10(3) M-1; free energy of ATP hydrolysis = 62.11 +/- 0.04 kJ/mole; and energy charge = 0.99 +/- 0.01. Following every level of injury, there were decreases in intracellular free Mg2+ concentration, and alterations in the intracellular pH. These posttraumatic changes in Mg2+ and pH induced shifts in the equilibrium constants of the creatine kinase, adenylate kinase, and ATPase reactions, resulting in alterations in [ADP], [AMP], cytosolic phosphorylation potential, and free energy of hydrolysis, but not in the energy charge. The alterations in cytosolic phosphorylation potential following trauma were linearly correlated with the changes in intracellular free Mg2+ concentration. None of the individual bioenergetic parameters could be correlated with the severity of injury over the entire injury range; however, an association between cytosolic phosphorylation potential and reversibility of injury was apparent. These results suggest that reductions in cellular bioenergetic state following traumatic brain injury occur through a posttraumatic decrease in the cells' capacity for oxidative phosphorylation, which itself may be directly related to the intracellular free Mg2+ concentration.	[Vink, Robert; Faden, Alan I.; McIntosh, Tracy K.] Univ Calif San Francisco, Dept Neurol, Ctr Neural Injury, San Francisco, CA USA; [Vink, Robert; Faden, Alan I.; McIntosh, Tracy K.] Vet Adm Med Ctr, San Francisco, CA 94121 USA	Vink, R (corresponding author), James Cook Univ, Dept Chem & Biochem, Townsville, Qld 4811, Australia.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [902269]; Veterans Administration Merit ReviewUS Department of Veterans Affairs [79]; Queen Elizabeth II Fellowship [79]	This work was supported, in part, by Centers for Disease Control Grant # 902269 to AIF, and by a Veterans Administration Merit Review to TKM. R. Vink is a recipient of a Queen Elizabeth II Fellowship. We thank Dr. Peter J. Rogers of Griffith University, Australia, for helpful discussions.	Aikawa J., 1981, MAGNESIUM ITS BIOL S; ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257; ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; AVISON MJ, 1986, ANNU REV BIOPHYS BIO, V15, P377; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; BINET A, 1975, ARCH BIOCHEM BIOPHYS, V170, P576, DOI 10.1016/0003-9861(75)90153-8; Boyer P. D., 1959, ENZYMES, V6, P515; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; CUNNINGHAM CC, 1986, BIOCHIM BIOPHYS ACTA, V885, P12, DOI 10.1016/0167-4889(86)90033-9; DAGANI F, 1987, J NEUROCHEM, V49, P1229, DOI 10.1111/j.1471-4159.1987.tb10015.x; DAWSON MJ, 1980, J PHYSIOL-LONDON, V299, P465, DOI 10.1113/jphysiol.1980.sp013137; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; EVELHOCH JL, 1985, MAGNET RESON MED, V2, P410, DOI 10.1002/mrm.1910020409; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GADIAN DG, 1982, NUCL MAGNETIC RESONA; GUNTHER T, 1984, BIOCHEM BIOPH RES CO, V119, P124, DOI 10.1016/0006-291X(84)91627-9; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Mclntosh T.K., 1989, NEUROSCIENC IN PRESS; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; OGAWA S, 1986, ARCH BIOCHEM BIOPHYS, V248, P43, DOI 10.1016/0003-9861(86)90399-1; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Siesjo B.K., 1981, J CEREB BLOOD FLOW M, V1, P1; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VELOSO D, 1973, J BIOL CHEM, V248, P4811; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1984, BIOCHEMISTRY-US, V23, P3667, DOI 10.1021/bi00311a015; Yamakami I., 1987, ABSTR SOC NEUROSCI, P1501	45	73	76	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					315	U90		10.1089/neu.1988.5.315			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300005	3249310				2021-06-18	
J	WARD, A				WARD, A			ATROPINE IN THE TREATMENT OF CLOSED HEAD INJURY	JOURNAL OF NEUROSURGERY			English	Article																BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; DAVIS JE, 1946, J PHARMACOL EXP THER, V88, P246; de No RL, 1938, AM J PHYSIOL, V121, P331; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; GREIG ME, 1949, SCIENCE, V110, P237, DOI 10.1126/science.110.2853.237; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HENDERSON W. R., 1936, QUART JOUR EXP PHYSIOL, V26, P83; Kremer M, 1942, Q J EXP PHYSIOL CMS, V31, P337, DOI 10.1113/expphysiol.1942.sp000867; PARFITT DN, 1947, J NEUROL NEUROSUR PS, V10, P85, DOI 10.1136/jnnp.10.2.85; PILCHER C, 1941, SURG GYNECOL OBSTET, V72, P755; SCHEINKER IM, 1948, J NEUROPATH EXP NEUR, V7, P321, DOI 10.1097/00005072-194807000-00007; Scheinker IM, 1948, NEUROSURGICAL PATHOL; SCHEINKER JM, 1949, ARCH NEUROL CHIC, V61, P248; SEGERBERG LH, 1949, JAMA-J AM MED ASSOC, V141, P371, DOI 10.1001/jama.1949.02910060009003; TOWER DB, 1948, J CLIN INVEST, V27, P558; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WELBOURN R B, 1948, Lancet, V2, P211; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	19	73	73	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1950	7	5					398	402		10.3171/jns.1950.7.5.0398			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UN062	WOS:A1950UN06200004	14774757				2021-06-18	
J	Otero-Ortega, L; de Frutos, MCG; Laso-Garcia, F; Rodriguez-Frutos, B; Medina-Gutierrez, E; Lopez, JA; Vazquez, J; Diez-Tejedor, E; Gutierrez-Fernandez, M				Otero-Ortega, Laura; Gomez de Frutos, Mari Carmen; Laso-Garcia, Fernando; Rodriguez-Frutos, Berta; Medina-Gutierrez, Esperanza; Antonio Lopez, Juan; Vazquez, Jesus; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria			Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Brain repair; exosome; intracerebral hemorrhage; subcortical stroke; white matter injury	MESENCHYMAL STROMAL CELLS; SUBCORTICAL ISCHEMIC-STROKE; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; NEUROVASCULAR PLASTICITY; FUNCTIONAL RECOVERY; THERAPY; DAMAGE; RATS	Exosomes are gaining importance because they show great promise in therapeutic applications for several diseases. Particularly in stroke, exosomes derived from mesenchymal stem cell (MSC) therapy work as paracrine effectors responsible for promoting neurovascular remodeling and functional recovery. Adult male rats were subjected to intracerebral hemorrhage (ICH) by intrastriatal injection of collagenase type IV; 24 h after surgery, MSC-derived exosomes were administered through the tail vein. The rats were euthanized at 7 or 28 days after treatment. Functional evaluation, lesion size, fiber tract integrity, axonal sprouting and white matter repair markers, biodistribution of exosomes and secretome proteomics were analyzed. DiI-labeled exosomes were found in the brains of the ICH-treated group and in the liver, lung and spleen. Animals receiving treatment with exosomes showed significantly better results in terms of functional recovery, lesion size, fiber tract integrity, axonal sprouting and white matter repair markers compared with the control group 28 days after stroke. Proteomics analysis of the exosomes identified more than 2000 proteins that could be implicated in brain repair function. In conclusion, white matter integrity was partly restored by exosome administration mediated by molecular repair factors. Exosomes as a treatment could be a heterogeneous process by nature and presents many factors that can influence brain plasticity in an adaptable and versatile manner.	[Otero-Ortega, Laura; Gomez de Frutos, Mari Carmen; Laso-Garcia, Fernando; Rodriguez-Frutos, Berta; Medina-Gutierrez, Esperanza; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria] Autonomous Univ Madrid, La Paz Univ Hosp, IdiPAZ Hlth Res Inst, Dept Neurol,Neurosci Area, Madrid, Spain; [Otero-Ortega, Laura; Gomez de Frutos, Mari Carmen; Laso-Garcia, Fernando; Rodriguez-Frutos, Berta; Medina-Gutierrez, Esperanza; Diez-Tejedor, Exuperio; Gutierrez-Fernandez, Maria] Autonomous Univ Madrid, La Paz Univ Hosp, IdiPAZ Hlth Res Inst, Neurosci & Cerebrovasc Res Lab,Stroke Ctr,Neurosc, Madrid, Spain; [Antonio Lopez, Juan; Vazquez, Jesus] CNIC, Natl Ctr Cardiovasc Res, Cardiovasc Prote Lab, Madrid, Spain; [Antonio Lopez, Juan; Vazquez, Jesus] CNIC, Natl Ctr Cardiovasc Res, Prote Unit, Madrid, Spain	Diez-Tejedor, E; Gutierrez-Fernandez, M (corresponding author), Univ Autonoma Madrid, Dept Neurol & Stroke, Neurosci & Cerebrovasc Res Lab, La Paz Univ Hosp,IdiPAZ Hlth Res Inst, Paseo Castellana 261, Madrid 28046, Spain.	exuperio.diez@salud.madrid.org; mgutierrezfernandez@salud.madrid.org	Lopez, Juan Antonio/G-7750-2015; Vazquez, Jesus/B-7697-2015; Laso Garcia, Fernando/F-2259-2018	Lopez, Juan Antonio/0000-0002-9097-6060; Vazquez, Jesus/0000-0003-1461-5092; Laso Garcia, Fernando/0000-0002-5481-0514; Otero Ortega, Laura/0000-0001-8765-6341	Spanish Neurovascular Network [PS15/01318, INVICTUS (RD12/0014)]; Research Institute Carlos III [CD12/00706]; Spanish Ministry of Science and InnovationSpanish Government; European Regional Development FundEuropean Commission; Roche Farma project	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study has been partially supported by grants from PS15/01318 and INVICTUS (RD12/0014) (Spanish Neurovascular Network), Miguel Servet (CP15/00069 to Maria Gutierrez-Fernandez) and a Sara Borrell postdoctoral fellowship (CD12/00706, to Laura Otero-Ortega) from the Research Institute Carlos III, the Spanish Ministry of Science and Innovation and the European Regional Development Fund. This study was also co-funded within the Roche Farma project. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Back SA, 2007, STROKE, V38, P724, DOI 10.1161/01.STR.0000254729.27386.05; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Barratt HE, 2014, J CEREBR BLOOD F MET, V34, P1463, DOI 10.1038/jcbfm.2014.107; Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015; Gutierrez-Fernandez M, 2011, NEUROSCIENCE, V175, P394, DOI 10.1016/j.neuroscience.2010.11.054; Kanazawa H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019195; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Kumar D, 2015, ONCOTARGET, V6, P3280, DOI 10.18632/oncotarget.2462; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173; Manaenko A, 2011, ACTA NEUROCHIR SUPPL, V111, P9, DOI 10.1007/978-3-7091-0693-8_2; Matute C, 2013, STROKE, V44, P1204, DOI 10.1161/STROKEAHA.112.658328; Navarro P, 2014, J PROTEOME RES, V13, P1234, DOI 10.1021/pr4006958; Otero L, 2010, HISTOL HISTOPATHOL, V25, P453, DOI 10.14670/HH-25.453; Otero L, 2012, CYTOTHERAPY, V14, P34, DOI 10.3109/14653249.2011.608349; Otero L, 2011, CYTOTHERAPY, V13, P562, DOI 10.3109/14653249.2010.544720; Otero-Ortega L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0111-4; Paschon V, 2016, MOL NEUROBIOL, V53, P2016, DOI 10.1007/s12035-015-9142-1; Ramos-Cejudo J, 2015, STROKE, V46, P221, DOI 10.1161/STROKEAHA.114.006692; Rodriguez-Frutos B, 2016, BIOMATERIALS, V100, P41, DOI 10.1016/j.biomaterials.2016.05.028; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sozmen EG, 2009, J NEUROSCI METH, V180, P261, DOI 10.1016/j.jneumeth.2009.03.017; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZG, 2016, J CLIN INVEST, V126, P1190, DOI 10.1172/JCI81133	35	72	75	2	59	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2018	38	5					767	779		10.1177/0271678X17708917			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GF6ND	WOS:000432083300003	28524762	Green Published, Bronze			2021-06-18	
J	Gattringer, T; Pinter, D; Enzinger, C; Seifert-Held, T; Kneihsl, M; Fandler, S; Pichler, A; Barro, C; Grobke, S; Voortman, M; Pirpamer, L; Hofer, E; Ropele, S; Schmidt, R; Kuhle, J; Fazekas, F; Khalil, M				Gattringer, Thomas; Pinter, Daniela; Enzinger, Christian; Seifert-Held, Thomas; Kneihsl, Markus; Fandler, Simon; Pichler, Alexander; Barro, Christian; Grobke, Svenya; Voortman, Margarete; Pirpamer, Lukas; Hofer, Edith; Ropele, Stefan; Schmidt, Reinhold; Kuhle, Jens; Fazekas, Franz; Khalil, Michael			Serum neurofilament light is sensitive to active cerebral small vessel disease	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; WHITE-MATTER LESIONS; MULTIPLE-SCLEROSIS; NEURODEGENERATION; BIOMARKERS; PROTEIN; STROKE; BLOOD; CHAIN	Objective: To explore whether serum neurofilament light chain protein (NfL) levels are increased in patients with MRI-confirmed recent small subcortical infarcts (RSSI) compared to healthy controls and to determine the subsequent course and determinants of NfL levels in a longitudinal manner. Methods: In a prospectively collected group of symptomatic patients with an RSSI (n = 79, mean age 61 6 11 years, 67% male), we analyzed brain MRI and serum NfL using a Single Molecule Array (Simoa) assay at baseline and at 3 and 15 months after stroke. Community-dwelling healthy age-and sex-matched individuals with comparable severity of MRI white matter hyperintensities (WMH) (n = 53) served as controls. Results: Patients with an RSSI had higher NfL baseline levels compared to controls (73.45 vs 34.59 pg/mL, p < 0.0001), and they were increasingly higher with the time from stroke symptom onset to blood sampling (median 4 days, range 1-11 days, r(s) < 0.51, p < 0.0001). NfL levels remained increased at the 3-month follow-up but returned to normal at 15 months after stroke. NfL levels were associated with RSSI size and baselineWMH severity and were especially high in patients with new, clinically silent cerebral small vessel disease (CSVD)-related lesions at followup. Conclusions: Serum NfL is increased in patients with an RSSI and the occurrence of new CSVDrelated MRI lesions, even when clinically silent. This suggests NfL as a blood biomarker for active CSVD.	[Gattringer, Thomas; Pinter, Daniela; Enzinger, Christian; Seifert-Held, Thomas; Kneihsl, Markus; Fandler, Simon; Pichler, Alexander; Voortman, Margarete; Pirpamer, Lukas; Hofer, Edith; Ropele, Stefan; Schmidt, Reinhold; Fazekas, Franz; Khalil, Michael] Med Univ Graz, Dept Neurol, Graz, Austria; [Enzinger, Christian] Med Univ Graz, Div Neuroradiol Vasc & Intervent Radiol, Graz, Austria; [Hofer, Edith] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria; [Barro, Christian; Grobke, Svenya; Kuhle, Jens] Univ Basel, Univ Basel Hosp, Neurol Clin & Policlin, Dept Med, Basel, Switzerland; [Barro, Christian; Grobke, Svenya; Kuhle, Jens] Univ Basel, Univ Basel Hosp, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland; [Barro, Christian; Grobke, Svenya; Kuhle, Jens] Univ Basel, Univ Basel Hosp, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland	Gattringer, T (corresponding author), Med Univ Graz, Dept Neurol, Graz, Austria.	thomas.gattringer@medunigraz.at	Barro, Christian/AAO-3567-2021; Fandler-Hofler, Simon/AAL-9956-2020; Schmidt, Reinhold/E-1137-2014	Barro, Christian/0000-0002-7795-7383; Fandler-Hofler, Simon/0000-0001-9043-0378; Pinter, Daniela/0000-0003-3138-5225; Gattringer, Thomas/0000-0002-6065-6576; Khalil, Michael/0000-0002-5350-3328	Austrian Science FundAustrian Science Fund (FWF) [T690-B23]	Daniela Pinter receives funding from the Austrian Science Fund: T690-B23.	Benjamin P, 2016, J CEREBR BLOOD F MET, V36, P228, DOI 10.1038/jcbfm.2015.113; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Conklin J, 2014, ANN NEUROL, V76, P899, DOI 10.1002/ana.24285; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; FAZEKAS F, 1987, AM J ROENTGENOL, V149, P351, DOI 10.2214/ajr.149.2.351; Fazekas F, 2013, NEUROLOGY, V81, P1914, DOI 10.1212/01.wnl.0000436611.28210.ec; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gunnarsson M, 2011, ANN NEUROL, V69, P83, DOI 10.1002/ana.22247; Jonsson M, 2010, EUR J NEUROL, V17, P377, DOI 10.1111/j.1468-1331.2009.02808.x; Kim KW, 2008, BIOL PSYCHIAT, V64, P273, DOI 10.1016/j.biopsych.2008.03.024; Kolominsky-Rabas PL, 2001, STROKE, V32, P2735, DOI 10.1161/hs1201.100209; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kuhle J, 2015, NEUROLOGY, V84, P1639, DOI 10.1212/WNL.0000000000001491; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kuhle J, 2013, MULT SCLER J, V19, P1597, DOI 10.1177/1352458513482374; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; Norgren N, 2002, HYBRIDOMA HYBRIDOM, V21, P53, DOI 10.1089/15368590252917647; Pirpamer L, 2016, NEUROBIOL AGING, V43, P149, DOI 10.1016/j.neurobiolaging.2016.04.002; Schmidt R, 2005, ANN NEUROL, V58, P610, DOI 10.1002/ana.20630; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Steinacker P, 2017, NEUROLOGY, V88, P961, DOI 10.1212/WNL.0000000000003688; Teunissen CE, 2009, NEUROLOGY, V73, P1914, DOI 10.1212/WNL.0b013e3181c47cc2; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; Traenka C, 2015, CEREBROVASC DIS, V40, P222, DOI 10.1159/000440774; Vilar-Bergua A, 2016, J CEREBR BLOOD F MET, V36, P55, DOI 10.1038/jcbfm.2015.68; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Weydt P, 2016, ANN NEUROL, V79, P152, DOI 10.1002/ana.24552; Yan J, 2009, J NEUROIMMUNOL, V206, P112, DOI 10.1016/j.jneuroim.2008.11.001	29	72	72	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 14	2017	89	20					2108	2114		10.1212/WNL.0000000000004645			7	Clinical Neurology	Neurosciences & Neurology	FP5RA	WOS:000417676500014	29046363	Green Published			2021-06-18	
J	Olson, DM; Stutzman, S; Saju, C; Wilson, M; Zhao, WD; Aiyagari, V				Olson, DaiWai M.; Stutzman, Sonja; Saju, Ciji; Wilson, Margaret; Zhao, Weidan; Aiyagari, Venkatesh			Interrater Reliability of Pupillary Assessments	NEUROCRITICAL CARE			English	Article						Pupillometry; Interrater reliability; Neurological illness; Traumatic brain injury; Pupil assessment	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; DILATED PUPILS; INFRARED PUPILLOMETRY; ANISOCORIA; PREDICTION; REACTIVITY; HERNIATION; AGREEMENT; TRAUMA	Background Subjective scoring of pupil reactivity is a fundamental element of the neurological examination for which the pupillometer provides an objective measure. Methods This single-blinded observational study examined interrater reliability of pupil exam findings between two practitioners and between practitioners and a pupillometer. Results From 2329 paired assessments, the interrater reliability between practitioners was only moderate for pupil size (k = 0.54), shape (k = 0.62), and reactivity (k = 0.40). Only 33.3 % of pupils scored as non-reactive by practitioners were scored as non-reactive by pupillometry. Conclusions Despite the strong emphasis placed on the traditional pupil examination, especially for patients with a neurological illness, there is limited interrater reliability for subjective scoring of pupillary assessments. Thus, the use of automated pupillometers should be examined as a potential method to increase the reliability of measuring of pupil reactivity.	[Olson, DaiWai M.; Stutzman, Sonja; Saju, Ciji; Wilson, Margaret; Zhao, Weidan; Aiyagari, Venkatesh] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Aiyagari, Venkatesh] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	Olson, DM (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	daiwai.olson@utsouthwestern.edu	Olson, DaiWai/I-5932-2019	Olson, DaiWai/0000-0002-9280-078X; Aiyagari, Venkatesh/0000-0001-8139-3819			AANN, 2010, AANN COR CURR NEUR N, P21; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Blumenfeld H, 2002, NEUROANATOMY CLIN CA; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Campbell W. W., 2005, DEJONGS NEUROLOGIC E; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chen YJ, 2013, INVEST OPHTH VIS SCI, V54, P2951, DOI 10.1167/iovs.12-10916; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Chesnut RM, 1994, NEUROSURGERY, V34, P845; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Du R, 2005, NEUROSURGERY, V57, P198, DOI 10.1227/01.NEU.0000163425.79170.CB; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; GOEBERT HW, 1970, SURG CLIN N AM, V50, P427; Greenberg MS, 2006, HDB NEUROSURGERY; Gwet KL, 2010, INTERRATER RALIABILI; Kramer CL, 2014, NEUROCRIT CARE, V21, P309, DOI 10.1007/s12028-014-9988-5; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; Rebolleda G, 2013, ARCH SOC ESP OFTALMO, V88, P125, DOI [10.1016/j.oftal.2013.02.014, DOI 10.1016/J.0FTAL.2013.02.014]; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Schallenberg M, 2010, J REFRACT SURG, V26, P134, DOI 10.3928/1081597X-20100121-09; Song Z, 2012, CLIN NEUROL NEUROSUR, V114, P634, DOI 10.1016/j.clineuro.2011.12.029; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Viera AJ, 2005, FAM MED, V37, P360; Wilson S F, 1988, J Neurosci Nurs, V20, P189; Witting MD, 2003, ANN EMERG MED, V41, P832, DOI 10.1067/mem.2003.193; Zafar SF, 2014, J CRIT CARE, V29, P599, DOI 10.1016/j.jcrc.2014.01.012	34	72	72	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2016	24	2					251	257		10.1007/s12028-015-0182-1			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	DJ3JN	WOS:000374101200014	26381281				2021-06-18	
J	Cheng, T; Wang, WZ; Li, Q; Han, XN; Xing, J; Qi, CF; Lan, X; Wan, JR; Potts, A; Guan, FX; Wang, J				Cheng, Tian; Wang, Wenzhu; Li, Qian; Han, Xiaoning; Xing, Jing; Qi, Cunfang; Lan, Xi; Wan, Jieru; Potts, Alexa; Guan, Fangxia; Wang, Jian			Cerebroprotection of flavanol (-)-epicatechin after traumatic brain injury via Nrf2-dependent and -independent pathways	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						(-)-Epicatechin; NF-E2-related factor; Traumatic brain injury	OXIDATIVE STRESS; INTRACEREBRAL HEMORRHAGE; LIQUID-CHROMATOGRAPHY; SIGNALING PATHWAY; COCOA FLAVANOLS; RAT MODEL; NRF2; METABOLITES; EXPRESSION; IMPACT	Traumatic brain injury (TBI), which leads to disability, dysfunction, and even death, is a prominent health problem worldwide with no effective treatment. A brain-permeable flavonoid named (-)-epicatechin (EC) modulates redox/oxidative stress and has been shown to be beneficial for vascular and cognitive function in humans and for ischemic and hemorrhagic stroke in rodents. Here we examined whether EC is able to protect the brain against TBI-induced brain injury in mice and if so, whether it exerts neuro-protection by modulating the NF-E2-related factor (Nrf2) pathway. We used the controlled cortical impact model to mimic TBI. EC was administered orally at 3 h after TBI and then every 24 h for either 3 or 7 days. We evaluated lesion volume, brain edema, white matter injury, neurologic deficits, cognitive performance and emotion-like behaviors, neutrophil infiltration, reactive oxygen species (ROS), and a variety of injury-related protein markers. Nrf2 knockout mice were used to determine the role of the Nrf2 signaling pathway after EC treatment. In wild-type mice, EC significantly reduced lesion volume, edema, and cell death and improved neurologic function on days 3 and 28; cognitive performance and depression-like behaviors were also improved with EC administration. In addition, EC reduced white matter injury, heme oxygenase-1 expression, and ferric iron deposition after TBI. These changes were accompanied by attenuation of neutrophil infiltration and oxidative insults, reduced activity of matrix metalloproteinase 9, decreased Keap 1 expression, increased Nrf2 nuclear accumulation, and increased expression of superoxide dismutase 1 and quinone 1. However, EC did not significantly reduce lesion volume or improve neurologic deficits in Nrf2 knockout mice after TBI. Our results show that EC protects the TBI brain by activating the Nrf2 pathway, inhibiting heme oxygenase-1 protein expression, and reducing iron deposition. The latter two effects could represent an Nrf2-independent mechanism in this model of TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Cheng, Tian; Guan, Fangxia; Wang, Jian] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450000, Henan, Peoples R China; [Cheng, Tian; Wang, Wenzhu; Li, Qian; Han, Xiaoning; Xing, Jing; Qi, Cunfang; Lan, Xi; Wan, Jieru; Potts, Alexa; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA; [Guan, Fangxia] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450000, Henan, Peoples R China	Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA.; Guan, FX (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.	13613813972@126.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Li, Qian/0000-0003-0359-5604	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81071008]; Excellent Youth Foundation of Henan Scientific Committee [114100510005]; Technology Foundation for Selected Overseas Chinese Scholars; American Heart AssociationAmerican Heart Association [13GRNT15730001]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]; China Scholarship Council Joint Ph.D. Training awardChina Scholarship Council; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER	This study was supported by the National Natural Science Foundation of China (81071008), the Excellent Youth Foundation of Henan Scientific Committee (114100510005), the Technology Foundation for Selected Overseas Chinese Scholars, American Heart Association Grant 13GRNT15730001, and National Institutes of Health Grants R01NS078026 and R01AT007317. T.C. is the recipient of the China Scholarship Council Joint Ph.D. Training award.	Abd El Mohsen MM, 2002, FREE RADICAL BIO MED, V33, P1693, DOI 10.1016/S0891-5849(02)01137-1; Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Baba S, 2001, J NUTR, V131, P2885; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chang Q, 2005, J CLIN PHARMACOL, V45, P106, DOI 10.1177/0091270004270500; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Chen LS, 1997, DRUG METAB DISPOS, V25, P1045; Cheng T, 2015, CELL MOL NEUROBIOL, V35, P641, DOI 10.1007/s10571-015-0159-9; Cox CJ, 2015, NEUROBIOL AGING, V36, P178, DOI 10.1016/j.neurobiolaging.2014.07.032; Cuevas E, 2009, EUR J PHARMACOL, V616, P122, DOI 10.1016/j.ejphar.2009.06.013; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Fraga CG, 2011, FREE RADICAL BIO MED, V51, P813, DOI 10.1016/j.freeradbiomed.2011.06.002; Han XN, 2016, J CEREBR BLOOD F MET, V36, P1059, DOI 10.1177/0271678X15606462; Harada H, 2008, FREE RADICAL RES, V42, P297, DOI 10.1080/10715760801975735; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hsieh HL, 2014, MOL NEUROBIOL, V50, P520, DOI 10.1007/s12035-013-8628-y; Hsieh HL, 2010, ANTIOXID REDOX SIGN, V13, P1829, DOI 10.1089/ars.2009.2957; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Mak JCW, 2012, CLIN EXP PHARMACOL P, V39, P265, DOI 10.1111/j.1440-1681.2012.05673.x; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Nehlig A, 2013, BRIT J CLIN PHARMACO, V75, P716, DOI 10.1111/j.1365-2125.2012.04378.x; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Ramkumar KM, 2013, CURR MED CHEM, V20, P1127; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rodriguez-Mateos A, 2015, MOL NUTR FOOD RES, V59, P1504, DOI 10.1002/mnfr.201500091; Roura E, 2005, J AGR FOOD CHEM, V53, P6190, DOI 10.1021/jf050377u; Ruijters EJB, 2013, EUR J PHARMACOL, V715, P147, DOI 10.1016/j.ejphar.2013.05.029; Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103; Shah ZA, 2010, J CEREBR BLOOD F MET, V30, P1951, DOI 10.1038/jcbfm.2010.53; Sokolov AN, 2013, NEUROSCI BIOBEHAV R, V37, P2445, DOI 10.1016/j.neubiorev.2013.06.013; Sugawara T, 2009, STROKE, V40, P1530, DOI 10.1161/STROKEAHA.108.531699; van Praag H, 2007, J NEUROSCI, V27, P5869, DOI 10.1523/JNEUROSCI.0914-07.2007; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wang J, 2012, J NEUROSCI, V32, P5144, DOI 10.1523/JNEUROSCI.6437-11.2012; Wang W., 2015, MOL NEUROBI IN PRESS; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Wu L, 2012, J AGR FOOD CHEM, V60, P9377, DOI 10.1021/jf301787f; Wu T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-22; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zan L, 2014, NEUROSCIENCE, V262, P118, DOI 10.1016/j.neuroscience.2013.12.060; Zhao JB, 2014, TRANSL STROKE RES, V5, P586, DOI 10.1007/s12975-014-0353-y; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423	59	72	77	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAR	2016	92						15	28		10.1016/j.freeradbiomed.2015.12.027			14	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	DE5BJ	WOS:000370645400002	26724590	Green Accepted			2021-06-18	
J	Di Battista, AP; Rhind, SG; Hutchison, MG; Hassan, S; Shiu, MY; Inaba, K; Topolovec-Vranic, J; Neto, AC; Rizoli, SB; Baker, AJ				Di Battista, Alex P.; Rhind, Shawn G.; Hutchison, Michael G.; Hassan, Syed; Shiu, Maria Y.; Inaba, Kenji; Topolovec-Vranic, Jane; Neto, Antonio Capone; Rizoli, Sandro B.; Baker, Andrew J.			Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Catecholamines; Traumatic brain injury; Systemic inflammation; Sympathetic nervous system activation; Epinephrine; Norepinephrine; IL-10; IL-1 beta	SYSTEMIC INTERLEUKIN-10 RELEASE; SYMPATHETIC-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; SEVERE HEAD-INJURY; LEUKOCYTE MOBILIZATION; CEREBROSPINAL-FLUID; SERUM; CATECHOLAMINES; ACTIVATION	Background: Traumatic brain injury (TBI) elicits intense sympathetic nervous system (SNS) activation with profuse catecholamine secretion. The resultant hyperadrenergic state is linked to immunomodulation both within the brain and systemically. Dysregulated inflammation post-TBI exacerbates secondary brain injury and contributes to unfavorable patient outcomes including death. The aim of this study was to characterize the early dynamic profile of circulating inflammatory cytokines/chemokines in patients admitted for moderate-to-severe TBI, to examine interrelationships between these mediators and catecholamines, as well as clinical indices of injury severity and neurological outcome. Methods: Blood was sampled from 166 isolated TBI patients (aged 45 +/- 20.3 years; 74.7 % male) on admission, 6-, 12-, and 24-h post-injury and from healthy controls (N = 21). Plasma cytokine [interleukin (IL)-1 beta, -2, -4, -5, -10, -12p70, -13, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma] and chemokine [IL-8, eotaxin, eotaxin-3, IFN-gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, -4, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1 beta, thymus activation regulated chemokine (TARC)] concentrations were analyzed using high-sensitivity electrochemiluminescence multiplex immunoassays. Plasma catecholamines [epinephrine (Epi), norepinephrine (NE)] were measured by immunoassay. Neurological outcome at 6 months was assessed using the extended Glasgow outcome scale (GOSE) dichotomized as good (>4) or poor (<= 4) outcomes. Results: Patients showed altered levels of IL-10 and all chemokines assayed relative to controls. Significant differences in a number of markers were evident between moderate and severe TBI cohorts. Elevated IL-8, IL-10, and TNF-alpha, as well as alterations in 8 of 9 chemokines, were associated with poor outcome at 6 months. Notably, a positive association was found between Epi and IL-1 beta, IL-10, Eotaxin, IL-8, and MCP-1. NE was positively associated with IL-1 beta, IL-10, TNF-alpha, eotaxin, IL-8, IP-10, and MCP-1. Conclusions: Our results provide further evidence that exaggerated SNS activation acutely after isolated TBI in humans may contribute to harmful peripheral inflammatory cytokine/chemokine dysregulation. These findings are consistent with a potentially beneficial role for therapies aimed at modulating the inflammatory response and hyperadrenergic state acutely post-injury.	[Di Battista, Alex P.; Rhind, Shawn G.; Hassan, Syed; Shiu, Maria Y.] Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada; [Di Battista, Alex P.; Hassan, Syed; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Rhind, Shawn G.; Hutchison, Michael G.; Shiu, Maria Y.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Hutchison, Michael G.; Topolovec-Vranic, Jane; Rizoli, Sandro B.; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Inaba, Kenji] Univ So Calif, Div Trauma & Crit Care, Los Angeles, CA USA; [Inaba, Kenji] LA Cty USC Med Ctr, Los Angeles, CA USA; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Anesthesia, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON, Canada; [Neto, Antonio Capone] IHI, Cambridge, MA USA	Di Battista, AP (corresponding author), Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada.; Di Battista, AP (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.	dibattista.alex@gmail.com	INABA, KENJI/AAC-8532-2020; Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Di Battista, Alex/0000-0002-3325-6833; Rhind, Shawn/0000-0003-2300-0620	Physicians' Services Incorporated Foundation; Defence Research and Development Canada Technology Investment Fund Programme; Canadian Armed Forces (CAF) Surgeon General's Health Research Program	The authors gratefully acknowledge the assistance of Sandy Trpcic, Yangmei Li, Marlene Santos, Ingrid Smith, and Martin Chapman. This research was funded by the Physicians' Services Incorporated Foundation and Defence Research and Development Canada Technology Investment Fund Programme. This study was approved by the Canadian Armed Forces (CAF) Surgeon General's Health Research Program. In accordance with the Department of National Defence (DND) policy, the paper was reviewed and approved for submission without modification by the DRDC Publications Office.	Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Chen TJ, 2016, CLIN CHIM ACTA, V454, P6, DOI 10.1016/j.cca.2015.12.033; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Da Luz LT, 2015, CAN J SURG, V18, pS7; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000; Giles JA, 2015, EUR J IMMUNOL, V45, P525, DOI 10.1002/eji.201444748; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Grund B, 2010, CURR OPIN HIV AIDS, V5, P473, DOI 10.1097/COH.0b013e32833ed742; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Kavelaars A, 1997, J NEUROIMMUNOL, V77, P211, DOI 10.1016/S0165-5728(97)00076-3; Kenney MJ, 2002, AM J PHYSIOL-HEART C, V283, pH501, DOI 10.1152/ajpheart.00181.2002; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Ley EJ, 2012, J TRAUMA ACUTE CARE, V73, P33, DOI 10.1097/TA.0b013e31825a769b; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Osuchowski MF, 2006, J IMMUNOL, V177, P1967, DOI 10.4049/jimmunol.177.3.1967; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; Rhodes J, 2009, J TRAUMA, V66, P1591, DOI 10.1097/TA.0b013e31819a0344; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rough J, 2009, SURGERY, V145, P235, DOI 10.1016/j.surg.2008.09.013; Saindon CS, 2001, AUTON NEUROSCI-BASIC, V87, P243, DOI 10.1016/S1566-0702(00)00280-0; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Sohrevardi SM, 2013, TURK NEUROSURG, V23, P151, DOI 10.5137/1019-5149.JTN.5858-12.2; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Takahashi H, 2004, BURNS, V30, P317, DOI 10.1016/j.burns.2003.12.005; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; vanderPoll T, 1997, INFECT IMMUN, V65, P2378, DOI 10.1128/IAI.65.6.2378-2381.1997; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Woiciechowsky C, 1999, NEUROBIOL DIS, V6, P200, DOI 10.1006/nbdi.1999.0242; Woiciechowsky C, 2005, ACTA NEUROCHIR S, V95, P373; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1988, AM J PHYSIOL, V254, pE287; Xu L, 2015, MED SCI MONITOR, V21, P468, DOI 10.12659/MSM.893544	67	72	72	0	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 16	2016	13								40	10.1186/s12974-016-0500-3			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DD9JU	WOS:000370242300001	26883121	DOAJ Gold, Green Published			2021-06-18	
J	Welch, RD; Ayaz, SI; Lewis, LM; Unden, J; Chen, JY; Mika, VH; Saville, B; Tyndall, JA; Nash, M; Buki, A; Barzo, P; Hack, D; Tortella, FC; Schmid, K; Hayes, RL; Vossough, A; Sweriduk, ST; Bazarian, JJ				Welch, Robert D.; Ayaz, Syed I.; Lewis, Lawrence M.; Unden, Johan; Chen, James Y.; Mika, Valerie H.; Saville, Ben; Tyndall, Joseph A.; Nash, Marshall; Buki, Andras; Barzo, Pal; Hack, Dallas; Tortella, Frank C.; Schmid, Kara; Hayes, Ronald L.; Vossough, Arastoo; Sweriduk, Stephen T.; Bazarian, Jeffrey J.			Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article							NEW-ORLEANS CRITERIA; INTRACRANIAL LESIONS; RULE; BIOMARKERS; MANAGEMENT; S100-BETA; DIAGNOSIS; ACCURACY; GFAP	Head computed tomography (CT) imaging is still a commonly obtained diagnostic test for patients with minor head injury despite availability of clinical decision rules to guide imaging use and recommendations to reduce radiation exposure resulting from unnecessary imaging. This prospective multicenter observational study of 251 patients with suspected mild to moderate traumatic brain injury (TBI) evaluated three serum biomarkers' (glial fibrillary acidic protein [GFAP], ubiquitin C-terminal hydrolase-L1 [UCH-L1] and S100B measured within 6h of injury) ability to differentiate CT negative and CT positive findings. Of the 251 patients, 60.2% were male and 225 (89.6%) had a presenting Glasgow Coma Scale score of 15. A positive head CT (intracranial injury) was found in 36 (14.3%). UCH-L1 was 100% sensitive and 39% specific at a cutoff value >40pg/mL. To retain 100% sensitivity, GFAP was 0% specific (cutoff value 0pg/mL) and S100B had a specificity of only 2% (cutoff value 30pg/mL). All three biomarkers had similar values for areas under the receiver operator characteristic curve: 0.79 (95% confidence interval; 0.70-0.88) for GFAP, 0.80 (0.71-0.89) for UCH-L1, and 0.75 (0.65-0.85) for S100B. Neither GFAP nor UCH-L1 curve values differed significantly from S100B (p=0.21 and p=0.77, respectively). In our patient cohort, UCH-L1 outperformed GFAP and S100B when the goal was to reduce CT use without sacrificing sensitivity. UCH-L1 values <40pg/mL could potentially have aided in eliminating 83 of the 215 negative CT scans. These results require replication in other studies before the test is used in actual clinical practice.	[Welch, Robert D.; Ayaz, Syed I.; Mika, Valerie H.] Wayne State Univ, Dept Emergency Med, Detroit, MI 48230 USA; [Lewis, Lawrence M.] Washington Univ, Dept Emergency Med, St Louis, MO USA; [Unden, Johan] Clin Sci Malmo, Dept Anesthesiol & Intens Care, Malmo, Sweden; [Chen, James Y.] Univ Calif San Diego Hlth Syst, Dept Radiol, San Diego, CA USA; [Saville, Ben] Berry Consultants, Austin, TX USA; [Tyndall, Joseph A.] Univ Florida, Dept Emergency Med, Gainesville, FL USA; [Nash, Marshall] Neurostudies Net, Decatur, GA USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Barzo, Pal] Univ Szeged, Dept Neurosurg, Szeged, Hungary; [Hack, Dallas] US Army, Med Res & Mat Command, Ft Detrick, MD USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Appl Neurobiol, Silver Spring, MD USA; [Schmid, Kara] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Vossough, Arastoo] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Sweriduk, Stephen T.] Shields Hlth Care Grp, Dept Radiol, Brockton, MA USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA	Welch, RD (corresponding author), Wayne State Univ, Dept Emergency Med, Detroit, MI 48230 USA.	rwelch@med.wayne.edu	Mika, Valerie H./AAO-2816-2020		U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-1-0517, W81XWH-10-C-0251]	This work is supported by the U.S. Army Medical Research and Material Command under Contract N. W81XWH-06-1-0517 and Contract N. W81XWH-10-C-0251. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.	Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Florkowski Christopher M, 2008, Clin Biochem Rev, V29 Suppl 1, pS83; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Korevaar Daniel A, 2014, Evid Based Med, V19, P47, DOI 10.1136/eb-2013-101637; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Sauerbrei W, 2014, STAT MED, V33, P5413, DOI 10.1002/sim.6265; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	33	72	73	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2016	33	2					203	214		10.1089/neu.2015.4149			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DA7PH	WOS:000367995800006	26467555	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Brotfain, E; Gruenbaum, SE; Boyko, M; Kutz, R; Zlotnik, A; Klein, M				Brotfain, Evgeni; Gruenbaum, Shaun E.; Boyko, Matthew; Kutz, Ruslan; Zlotnik, Alexander; Klein, Moti			Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury	CURRENT NEUROPHARMACOLOGY			English	Article						Estrogen; neuroprotection; progesterone; spinal cord injury; traumatic brain injury	CORTICAL PERICONTUSIONAL ZONE; BLOOD GLUTAMATE LEVELS; PROGRAMMED CELL-DEATH; PLASMA GLUTAMATE; MENSTRUAL-CYCLE; CLINICAL-TRIAL; HORMONE-LEVELS; UP-REGULATION; RECOVERY; RECEPTOR	In recent years there has been a growing body of clinical and laboratory evidence demonstrating the neuroprotective effects of estrogen and progesterone after traumatic brain injury (TBI) and spinal cord injury (SCI). In humans, women have been shown to have a lower incidence of morbidity and mortality after TBI compared with age-matched men. Similarly, numerous laboratory studies have demonstrated that estrogen and progesterone administration is associated with a mortality reduction, improvement in neurological outcomes, and a reduction in neuronal apoptosis after TBI and SCI. Here, we review the evidence that supports hormone-related neuroprotection and discuss possible underlying mechanisms. Estrogen and progesterone-mediated neuroprotection are thought to be related to their effects on hormone receptors, signaling systems, direct antioxidant effects, effects on astrocytes and microglia, modulation of the inflammatory response, effects on cerebral blood flow and metabolism, and effects on mediating glutamate excitotoxicity. Future laboratory research is needed to better determine the mechanisms underlying the hormones' neuroprotective effects, which will allow for more clinical studies. Furthermore, large randomized clinical control trials are needed to better assess their role in human neurodegenerative conditions.	[Brotfain, Evgeni; Boyko, Matthew; Kutz, Ruslan; Zlotnik, Alexander; Klein, Moti] Ben Gurion Univ Negev, Soroka Med Ctr, Dept Anesthesia & Crit Care, Beer Sheva, Israel; [Gruenbaum, Shaun E.] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA	Brotfain, E (corresponding author), Ben Gurion Univ Negev, Soroka Med Ctr, Dept Anesthesia & Crit Care, Beer Sheva, Israel.	bem1975@gmail.com	klein, moti/AAR-6552-2021; Boyko, Matthew/AAC-7341-2021	Boyko, Matthew/0000-0003-3116-1643			ABRAHAM GE, 1972, J CLIN ENDOCR METAB, V34, P312, DOI 10.1210/jcem-34-2-312; Allitt BJ, 2016, J NEUROTRAUM, V33, P375, DOI 10.1089/neu.2015.3946; Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176; Andreadou E, 2008, IN VIVO, V22, P137; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; BARILE G, 1979, EUR J OBSTET GYN R B, V9, P243, DOI 10.1016/0028-2243(79)90062-5; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Behl C, 2000, J NEUROCYTOL, V29, P351, DOI 10.1023/A:1007109222673; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Beyer C., 1999, ESTROGEN DEV MAMMALI; Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Bunting H, 2010, OPHTHAL RES, V43, P197, DOI 10.1159/000272024; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chen J, 2001, J Tongji Med Univ, V21, P62; Chen J., 2001, J TONGJI MED U, V21, P74; Cimarosti H, 2006, NEUROCHEM RES, V31, P483, DOI 10.1007/s11064-006-9043-9; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dluzen DE, 2005, TRENDS PHARMACOL SCI, V26, P485, DOI 10.1016/j.tips.2005.08.001; Dubal DB, 1999, J NEUROSCI, V19, P6385; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Espey MG, 2002, NEUROLOGY, V58, P1439, DOI 10.1212/WNL.58.9.1439; Fernholm R, 2009, GROWTH HORM IGF RES, V19, P206, DOI 10.1016/j.ghir.2008.09.001; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Geddes RI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087252; GOEBELSMANN U, 1969, J CLIN ENDOCR METAB, V29, P1222, DOI 10.1210/jcem-29-9-1222; Green P S, 2000, Novartis Found Symp, V230, P202, DOI 10.1002/0470870818.ch15; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Griffin GD, 2011, J NEUROENDOCRINOL, V23, P465, DOI 10.1111/j.1365-2826.2011.02143.x; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hu R, 2012, CRIT CARE MED, V40, P3230, DOI 10.1097/CCM.0b013e3182657560; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Kim H, 2015, J NEUROTRAUM, V32, P1210, DOI 10.1089/neu.2014.3771; Li LZ, 2011, NEUROCHEM INT, V58, P126, DOI 10.1016/j.neuint.2010.11.006; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; McClean J, 2008, EXP NEUROL, V210, P41, DOI 10.1016/j.expneurol.2007.09.027; Meltser I, 2008, J CLIN INVEST, V118, P1563, DOI 10.1172/JCI32796; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Naderi V, 2015, IRAN J BASIC MED SCI, V18, P138; Neese SL, 2010, BRAIN RES, V1362, P93, DOI 10.1016/j.brainres.2010.09.055; Nudi ET, 2015, J NEUROTRAUM, V32, P1117, DOI 10.1089/neu.2014.3618; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Peterson TC, 2015, J NEUROTRAUM, V32, P765, DOI 10.1089/neu.2014.3530; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Punnonen R, 1976, Acta Obstet Gynecol Scand Suppl, V51, P63; ROGER M, 1975, NOUV PRESSE MED, V4, P2173; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Shakeri M, 2013, CLIN NEUROL NEUROSUR, V115, P2019, DOI 10.1016/j.clineuro.2013.06.013; SHERMAN BM, 1976, J CLIN ENDOCR METAB, V42, P629, DOI 10.1210/jcem-42-4-629; SHERMAN BM, 1975, J CLIN INVEST, V55, P699, DOI 10.1172/JCI107979; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Simpkins JW, 2012, NEUROENDOCRINOLOGY, V96, P119, DOI 10.1159/000338409; Singh M, 2006, ENDOCRINE, V29, P271, DOI 10.1385/ENDO:29:2:271; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Stover JF, 2005, ACTA NEUROCHIR, V147, P847, DOI 10.1007/s00701-005-0562-y; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tsesis S, 2013, GYNECOL ENDOCRINOL, V29, P912, DOI 10.3109/09513590.2013.813467; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wise PM, 2002, RECENT PROG HORM RES, V57, P235, DOI 10.1210/rp.57.1.235; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Yang LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009851; Zauner A, 1996, ACT NEUR S, V67, P40; Zeng YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140624; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2012, INTENS CARE MED, V38, P137, DOI 10.1007/s00134-011-2401-3; Zlotnik A, 2011, BIOL REPROD, V84, P581, DOI 10.1095/biolreprod.110.088120; Zlotnik A, 2011, J NEUROSURG ANESTH, V23, P45, DOI 10.1097/ANA.0b013e3181f82a8f	102	72	76	0	12	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.		2016	14	6					641	653		10.2174/1570159X14666160309123554			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	EE2YH	WOS:000389451600008	26955967	Green Published			2021-06-18	
J	Puvenna, V; Engeler, M; Banjara, M; Brennan, C; Schreiber, P; Dadas, A; Bahrami, A; Solanki, J; Bandyopadhyay, A; Morris, JK; Bernick, C; Ghosh, C; Rapp, E; Bazarian, JJ; Janigro, D				Puvenna, Vikram; Engeler, Madeline; Banjara, Manoj; Brennan, Chanda; Schreiber, Peter; Dadas, Aaron; Bahrami, Ashkon; Solanki, Jesal; Bandyopadhyay, Anasua; Morris, Jacqueline K.; Bernick, Charles; Ghosh, Chaitali; Rapp, Edward; Bazarian, Jeffrey J.; Janigro, Damir			Is phosphorylated tau unique to chronic traumatic encephalopathy? Phosphorylated tau in epileptic brain and chronic traumatic encephalopathy	BRAIN RESEARCH			English	Article						American football; Cognitive decline; Traumatic brain injury; Blood-brain barrier; Serum markers	INJURY	Repetitive traumatic brain injury (rTBI) is one of the major risk factors for the abnormal deposition of phosphorylated tau (PT) in the brain and chronic traumatic encephalopathy (CTE). CTE and temporal lobe epilepsy (TLE) affect the limbic system, but no comparative studies on PT distribution in TLE and CTE are available. It is also unclear whether PT pathology results from repeated head hits (rTBI). These gaps prevent a thorough understanding of the pathogenesis and clinical significance of PT, limiting our ability to develop preventative and therapeutic interventions. We quantified PT in TLE and CTE to unveil whether a history of rTBI is a prerequisite for PT accumulation in the brain. Six postmortem CTE (mean 73.3 years) and age matched control samples were compared to 19 surgically resected TLE brain specimens (4 months-58 years; mean 27.6 years). No history of TBI was present in TLE or control; all CTE patients had a history of rTBI. TLE and GTE brain displayed increased levels of PT as revealed by immunohistochemistry. No age-dependent changes were noted, as PT was present as early as 4 months after birth. In TLE and GTE, cortical neurons, perivascular regions around penetrating pial vessels and meninges were immunopositive for PT; white matter tracts also displayed robust expression of extracellular PT organized in bundles parallel to venules. Microscopically, there were extensive tau-immunoreactive neuronal, astrocytic and degenerating neurites throughout the brain. In GTE perivascular tangles were most prominent. Overall, significant differences in staining intensities were found between GTE and control (P<0.01) but not between GTE and TLE (P=0.08). pS199 tau analysis showed that GTE had the most high molecular weight tangle-associated tau, whereas epileptic brain contained low molecular weight tau. Tau deposition may not be specific to rTBI since TLE recapitulated most of the pathological features of GTE. (C) 2015 Elsevier B.V. All rights reserved.	[Rapp, Edward; Janigro, Damir] Flocel Inc, Cleveland, OH 44103 USA; [Puvenna, Vikram; Engeler, Madeline; Banjara, Manoj; Brennan, Chanda; Schreiber, Peter; Dadas, Aaron; Bahrami, Ashkon; Solanki, Jesal; Bandyopadhyay, Anasua; Ghosh, Chaitali; Janigro, Damir] Cerebrovasc Res, Cleveland, OH USA; [Puvenna, Vikram; Banjara, Manoj; Brennan, Chanda; Ghosh, Chaitali] Cleveland Clin, Lerner Coll Med, Dept Biomed Engn & Mol Med, Cleveland, OH 44106 USA; [Schreiber, Peter] Univ Pittsburgh, Pittsburgh, PA USA; [Dadas, Aaron; Solanki, Jesal] Ohio State Univ, Columbus, OH 43210 USA; [Engeler, Madeline] Brandeis Univ, Waltham, MA USA; [Bandyopadhyay, Anasua] Emory Univ, Atlanta, GA 30322 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA; [Bahrami, Ashkon] Baldwin Wallace Univ, Dept Biol, Berea, OH USA; [Bernick, Charles] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA	Janigro, D (corresponding author), Flocel Inc, Cleveland, OH 44103 USA.	djanigro@flocel.com		Ghosh, Chaitali/0000-0003-4078-0278	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH3TR000491, R21HD057256]; American Heart AssociationAmerican Heart Association [13SDG13950015]; Brain Behavior Research FoundationNARSAD; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UH3TR000491, UH2TR000491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R42MH093302, R41MH093302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043284, R21NS077236, R01NS078307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH3TR000491 and R21HD057256] to DJ and a Scientist Development Grant from the American Heart Association [13SDG13950015] and a Brain Behavior Research Foundation Grant to CG.	Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Devos SL, 2013, J NEUROSCI, V33, P12887, DOI 10.1523/JNEUROSCI.2107-13.2013; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Janigro D, 2012, EPILEPSIA, V53, P26, DOI 10.1111/j.1528-1167.2012.03472.x; Mandelkow E.-M., 2012, COLD SPRING HARB PER, V2; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Porzig R, 2007, BIOCHEM BIOPH RES CO, V358, P644, DOI 10.1016/j.bbrc.2007.04.187; Sahara N, 2014, J ALZHEIMERS DIS, V40, pS91, DOI 10.3233/JAD-132429; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; Sen A, 2007, EPILEPSIA, V48, P1447, DOI 10.1111/j.1528-1167.2007.01107.x; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209	21	72	72	1	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 1	2016	1630						225	240		10.1016/j.brainres.2015.11.007			16	Neurosciences	Neurosciences & Neurology	CZ4YU	WOS:000367109900021	26556772	Green Accepted			2021-06-18	
J	Bryan, CJ; Griffith, JE; Pace, BT; Hinkson, K; Bryan, AO; Clemans, TA; Imel, ZE				Bryan, Craig J.; Griffith, James E.; Pace, Brian T.; Hinkson, Kent; Bryan, AnnaBelle O.; Clemans, Tracy A.; Imel, Zac E.			Combat Exposure and Risk for Suicidal Thoughts and Behaviors Among Military Personnel and Veterans: A Systematic Review and Meta-Analysis	SUICIDE AND LIFE-THREATENING BEHAVIOR			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SERVICEMEMBERS ARMY STARRS; TRAUMATIC BRAIN-INJURY; ACQUIRED CAPABILITY; NATIONAL-GUARD; IDEATION; SOLDIERS; HEALTH; RESILIENCE; SYMPTOMS	Due to seemingly mixed empirical results, questions persist about the possible role of deployments and combat exposure. We conducted a narrative review and meta-analysis of 22 published studies to integrate findings regarding the relationship of deployment-related predictors (i.e., deployment, deployment to a combat zone, combat experience, and exposure to specific combat events) with suicide-related outcomes (i.e., suicide ideation, attempt, and death). Across all predictors and outcomes, the combined effect was small and positive, r=.08 [0.04, 0.13], and marked by significant heterogeneity, I-2=99.9%, Q(21)=4880.16, p<.0001, corresponding to a 25% increased risk for suicide-related outcomes among those who have deployed. Studies examining the relationship between exposure to killing and atrocities (k=5) showed the largest combined effect, r=.12 [0.08, 0.17], and less heterogeneity, I-2=84.4%, Q(4)=34.96, p<.0001, corresponding to a 43% increased risk for suicide-related outcomes among those exposed to killing or atrocity. Implications for theory, research, and clinical practice are discussed.	[Bryan, Craig J.; Pace, Brian T.; Imel, Zac E.] Univ Utah, Salt Lake City, UT 84112 USA; [Bryan, Craig J.; Griffith, James E.; Bryan, AnnaBelle O.; Clemans, Tracy A.] Natl Ctr Vet Studies, Salt Lake City, UT USA; [Hinkson, Kent] Utah Valley Univ, Provo, UT USA	Bryan, CJ (corresponding author), Univ Utah, Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu	Imel, Zac E./AAH-9491-2019	Imel, Zac E./0000-0001-9645-7184; Bryan, Craig/0000-0002-9714-0733			American Psychiatric Association, 2003, PRACT GUID ASS TREAT; Anestis M., 2009, J MENTAL HEALTH COUN, V31, P60, DOI [10.17744/mehc.31.1.u394h1470248844n, DOI 10.17744/MEHC.31.1.U394H1470248844N, DOI 10.17744/MEHC.31.1.U394H1470]; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryan A. O., 2015, TRAUMATOLOGY, V21, P40, DOI DOI 10.1037/TRM0000017; Bryan Annabelle O, 2014, TRAUMATOLOGY, V20, P154; Bryan C. J., INT J COGNI IN PRESS; Bryan CJ, 2006, J CLIN PSYCHOL, V62, P185, DOI 10.1002/jclp.20222; Bryan C, 2011, J CLIN PSYCHOL, V67, P856, DOI 10.1002/jclp.20808; Bryan CJ, 2015, J NERV MENT DIS, V203, P48, DOI 10.1097/NMD.0000000000000236; Bryan CJ, 2013, JAMA-J AM MED ASSOC, V310, P2564, DOI 10.1001/jama.2013.282698; Bryan CJ, 2013, COGNITIVE THER RES, V37, P996, DOI 10.1007/s10608-013-9536-1; Bryan CJ, 2013, J AFFECT DISORDERS, V150, P1226, DOI 10.1016/j.jad.2013.05.087; Bryan CJ, 2013, J AFFECT DISORDERS, V148, P37, DOI 10.1016/j.jad.2012.11.044; Bryan CJ, 2013, DEPRESS ANXIETY, V30, P55, DOI 10.1002/da.22002; Bryan CJ, 2013, J CLIN PSYCHOL, V69, P64, DOI 10.1002/jclp.21932; Bryan CJ, 2012, J PSYCHIATR RES, V46, P843, DOI 10.1016/j.jpsychires.2012.03.012; Bryan CJ, 2011, SUICIDE LIFE-THREAT, V41, P126, DOI 10.1111/j.1943-278X.2011.00023.x; Bryan CJ, 2010, J CLIN PSYCHOL, V66, P1044, DOI 10.1002/jclp.20703; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Crosby AE., 2011, SELF DIRECTED VIOLEN; Del Re A. C., 2010, MAC METAANALYSIS COR; Department of Defense, 2013, DODSER DEP DEF SUIC; Department of the Army, 2011, ARM HLTH PROM RISK R; Fanning JR, 2013, J PSYCHIATR RES, V47, P1766, DOI 10.1016/j.jpsychires.2013.07.015; FONTANA A, 1992, J NERV MENT DIS, V180, P748, DOI 10.1097/00005053-199212000-00002; Gibbons RD, 2012, AM J PUBLIC HEALTH, V102, pS17, DOI 10.2105/AJPH.2011.300491; Griffith J, 2013, ARMED FORCES SOC, V39, P628, DOI 10.1177/0095327X12471333; Griffith J, 2012, SUICIDE LIFE-THREAT, V42, P453, DOI 10.1111/j.1943-278X.2012.00104.x; Griffith J, 2012, SUICIDE LIFE-THREAT, V42, P104, DOI 10.1111/j.1943-278X.2011.00075.x; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; HENDIN H, 1991, AM J PSYCHIAT, V148, P586; Hoge CW, 2013, JAMA-J AM MED ASSOC, V310, P2565, DOI 10.1001/jama.2013.282701; Hoge CW, 2012, JAMA-J AM MED ASSOC, V308, P671, DOI 10.1001/jama.2012.9955; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Hunter J.E., 2004, METHODS METAANALYSIS; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Larson MJ, 2013, JAMA-J AM MED ASSOC, V310, P2565, DOI 10.1001/jama.2013.282695; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Maguen S, 2012, DEPRESS ANXIETY, V29, P918, DOI 10.1002/da.21954; Nevin RL, 2013, JAMA-J AM MED ASSOC, V310, P2563, DOI 10.1001/jama.2013.282692; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Nye EC, 2007, MIL MED, V172, P1144; Peterson AL, 2010, J TRAUMA STRESS, V23, P674, DOI 10.1002/jts.20585; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; R Core Development Team, 2011, R LANG ENV STAT COMP; Ramchand R, 2011, WAR PREVENTING SUICI; Rudd M. D., AM J PSYCHI IN PRESS; Rudd M.D., 2006, COGNITION SUICIDE TH, P355, DOI DOI 10.1037/11377-016; Rudd MD, 2012, MIL PSYCHOL, V24, P592, DOI 10.1080/08995605.2012.736325; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schoenbaum M, 2014, JAMA PSYCHIAT, V71, P493, DOI 10.1001/jamapsychiatry.2013.4417; Selby EA, 2010, CLIN PSYCHOL REV, V30, P298, DOI 10.1016/j.cpr.2009.12.004; Thoresen S, 2008, J NERV MENT DIS, V196, P814, DOI 10.1097/NMD.0b013e31818b6a92; Viechtbauer W., 2014, METAFOR METAANALYSIS; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wampold BE, 1997, PSYCHOL BULL, V122, P203, DOI 10.1037/0033-2909.122.3.203; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900	58	72	73	0	20	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0363-0234	1943-278X		SUICIDE LIFE-THREAT	Suicide Life-Threat. Behav.	OCT	2015	45	5					633	649		10.1111/sltb.12163			17	Psychiatry; Psychology, Multidisciplinary	Psychiatry; Psychology	CT3FR	WOS:000362693100010	29889337				2021-06-18	
J	Hijazi, N; Abu Fanne, R; Abramovitch, R; Yarovoi, S; Higazi, M; Abdeen, S; Basheer, M; Maraga, E; Cines, DB; Higazi, AAR				Hijazi, Nuha; Abu Fanne, Rami; Abramovitch, Rinat; Yarovoi, Serge; Higazi, Muhamed; Abdeen, Suhair; Basheer, Maamon; Maraga, Emad; Cines, Douglas B.; Higazi, Abd Al-Roof			Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice	BLOOD			English	Article							CLOSED-HEAD INJURY; RECOMMENDED RESEARCH PRIORITIES; LYS HUMAN-PLASMINOGEN; TRANEXAMIC ACID; NERVOUS-SYSTEM; KNOWLEDGE GAPS; NATIVE GLU; TISSUE; RECEPTOR; BINDING	Persistent intracerebral hemorrhage (ICH) is amajor cause of death and disability after traumatic brain injury (TBI) for which no medical treatment is available. Delayed bleeding is often ascribed to consumptive coagulopathy initiated by exposed brain tissue factor. We examined an alternative hypothesis, namely, that marked release of tissue-type plasminogen activator (tPA) followed by delayed synthesis and release of urokinase plasminogen activator (uPA) from injured brain leads to posttraumatic bleeding by causing premature clot lysis. Using a murine model of severe TBI, we found that ICH is reduced in tPA(-/-) and uPA(-/-) mice but increased in PAI-1(-/-) mice compared with wild-type (WT) mice. tPA(-/-), but not uPA(-/-), mice developed a systemic coagulopathy post-TBI. Tranexamic acid inhibited ICH expansion in uPA(-/-) mice but not in tPA(-/-) mice. Catalytically inactive tPA-S 481 A inhibited plasminogen activation by tPA and uPA, attenuated ICH, lowered plasma D-dimers, lessened thrombocytopenia, and improved neurologic outcome in WT, tPA(-/-), anduPA(-/-) mice. ICH expansion was also inhibited by tPA-S 481 A in WT mice anticoagulated with warfarin. These data demonstrate that protracted endogenous fibrinolysis induced by TBI is primarily responsible for persistent ICH and post-TBI coagulopathy in this model and offer a novel approach to interrupt bleeding.	[Hijazi, Nuha; Abu Fanne, Rami; Higazi, Muhamed; Abdeen, Suhair; Basheer, Maamon; Maraga, Emad; Higazi, Abd Al-Roof] Hebrew Univ Jerusalem, Dept Clin Biochem, Hadassah Med Ctr, Jerusalem, Israel; [Abramovitch, Rinat] Hebrew Univ Jerusalem, MRI MRS Lab, Human Biol Res Ctr, Dept Med Biophys,Hadassah Med Ctr, Jerusalem, Israel; [Yarovoi, Serge; Cines, Douglas B.; Higazi, Abd Al-Roof] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA	Higazi, AAR (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, 513A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	higazi@mail.med.upenn.edu		Cines, Douglas/0000-0001-5986-504X	National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS080014]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [PO1 HL076406, HL82545]; Israeli Science FoundationIsrael Science Foundation [930/04]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL123912, P01HL076406, T32HL007971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS080014] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke grant R21 NS080014 and National Heart, Lung, and Blood Institute grants PO1 HL076406 and HL82545; and the Israeli Science Foundation grant 930/04.	Abu Fanne R, 2011, AM J PHYSIOL-REG I, V301, pR668, DOI 10.1152/ajpregu.00058.2011; Akkawi S, 2006, AM J PHYSIOL-HEART C, V291, pH1351, DOI 10.1152/ajpheart.01042.2005; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Armstead WM, 2008, BRAIN RES, V1231, P121, DOI 10.1016/j.brainres.2008.06.115; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chitlur M, 2011, HAEMOPHILIA, V17, P532, DOI 10.1111/j.1365-2516.2010.02451.x; Day SM, 2003, CIRCULATION, V107, P2601, DOI 10.1161/01.CIR.0000066910.02844.D0; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Fan ZQ, 1998, BLOOD, V91, P1987, DOI 10.1182/blood.V91.6.1987.1987_1987_1998; Fanne Rami Abu, 2011, J Neurosurg, V114, P85, DOI 10.3171/2010.4.JNS10263; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; HIGAZI AAR, 1995, J BIOL CHEM, V270, P9472, DOI 10.1074/jbc.270.16.9472; Higazi AAR, 1996, J BIOL CHEM, V271, P17650, DOI 10.1074/jbc.271.30.17650; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Hultman K, 2014, J THROMB HAEMOST, V12, P701, DOI 10.1111/jth.12553; Klak M, 2010, SCAND J INFECT DIS, V42, P351, DOI 10.3109/00365540903510690; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; Maiya R, 2009, P NATL ACAD SCI USA, V106, P1983, DOI 10.1073/pnas.0812491106; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MARKUS G, 1978, J BIOL CHEM, V253, P733; MARKUS G, 1979, J BIOL CHEM, V254, P1211; Morowski M, 2013, BLOOD, V121, P4938, DOI 10.1182/blood-2012-10-461459; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nassar T, 2004, BLOOD, V103, P897, DOI 10.1182/blood-2003-05-1685; Nassar T, 2011, AM J PHYSIOL-LUNG C, V301, pL307, DOI 10.1152/ajplung.00429.2010; Nicole O, 2001, NAT MED, V7, P59; Norris EH, 2007, P NATL ACAD SCI USA, V104, P13473, DOI 10.1073/pnas.0705848104; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pawlak R, 2003, NAT NEUROSCI, V6, P168, DOI 10.1038/nn998; Pusateri AE, 2013, SHOCK, V39, P121, DOI 10.1097/SHK.0b013e318280409a; Reade MC, 2013, SHOCK, V40, P160, DOI 10.1097/SHK.0b013e31829ab240; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Silva MMCG, 2012, J THROMB HAEMOST, V10, P2354, DOI 10.1111/j.1538-7836.2012.04925.x; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Yepes M, 2004, EXP BIOL MED, V229, P1097; Yepes M, 2004, TRENDS CARDIOVAS MED, V14, P173, DOI 10.1016/j.tcm.2004.03.004	50	72	73	0	9	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	APR 16	2015	125	16					2558	2567		10.1182/blood-2014-08-588442			10	Hematology	Hematology	CI4VK	WOS:000354751700017	25673638	Green Published, Bronze			2021-06-18	
J	Oishi, K; Faria, AV; Hsu, J; Tippett, D; Mori, S; Hillis, AE				Oishi, Kenichi; Faria, Andreia V.; Hsu, John; Tippett, Donna; Mori, Susumu; Hillis, Argye E.			Critical Role of the Right Uncinate Fasciculus in Emotional Empathy	ANNALS OF NEUROLOGY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; KLUVER-BUCY-SYNDROME; WHITE-MATTER DAMAGE; ORBITOFRONTAL CORTEX; SOCIAL-BEHAVIOR; BRAIN; DEMENTIA; PAIN; DISEASE; NETWORKS	ObjectiveCommon neurological diseases or injuries that can affect the right hemisphere, including stroke, traumatic brain injury, and frontotemporal dementia, disrupt emotional empathythe ability to share in and make inferences about how other people feel. This impairment negatively impacts social interactions and relationships. Accumulating evidence indicates that emotional empathy depends on coordinated functions of orbitofrontal cortex, anterior insula, anterior cingulate, temporal pole, and amygdala, but few studies have investigated effects of lesions to white matter tracts that connect these structures. We tested the hypothesis that percentage damage to specific white matter tracts connecting these gray matter structures predicts error rate in an emotional empathy task after acute right hemisphere ischemic stroke. MethodsWe used multivariate linear regression with percentage damage to 8 white matter tracts, age, and education as independent variables and error rate on emotional empathy as the dependent variable to test a predictive model of emotional empathy in 30 patients with acute ischemic right hemisphere stroke. ResultsPercentage damage to 8 white matter tracts along with age and education predicted the error rate in emotional empathy, but only percentage damage to the uncinate fasciculus was independently associated with error rate. Participants with right uncinate fasciculus lesions were significantly more impaired than right hemisphere stroke patients without uncinate fasciculus lesions in the emotional empathy task. InterpretationThe right uncinate fasciculus plays an important role in the emotional empathy network. Patients with lesions in this network should be evaluated for empathy, so that deficits can be addressed. ANN NEUROL 2015;77:68-74	[Oishi, Kenichi; Faria, Andreia V.; Hsu, John; Mori, Susumu] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Tippett, Donna; Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Tippett, Donna; Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Tippett, Donna] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Hillis, Argye E.] Johns Hopkins Univ, Dept Cognit Sci, Krieger Sch Arts & Sci, Baltimore, MD 21218 USA	Hillis, AE (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, Phipps 446,600 North Wolfe St, Baltimore, MD 21287 USA.	argye@JHMI.edu	Oishi, Kenichi/H-1371-2013	Oishi, Kenichi/0000-0002-1200-8611	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS47691, R01NS084957]; NIH National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD065955]; Yousem Family Research Fund; American Heart AssociationAmerican Heart Association [12SDG12080169]; NIH National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015909]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD065955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015909, R03EB014357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS084957, R01NS047691] Funding Source: NIH RePORTER	This work was supported by the NIH National Institute of Neurological Disorders and Stroke (RO1NS47691, A.E.H.; R01NS084957, S.M.), NIH National Institute of Child Health and Human Development award (R01HD065955, K.O.), Yousem Family Research Fund (K.O.), American Heart Association (12SDG12080169, A.V.F.), and NIH National Institute of Biomedical Imaging and Bioengineering (P41EB015909, S.M.).	Bernhardt BC, 2012, ANNU REV NEUROSCI, V35, P1, DOI 10.1146/annurev-neuro-062111-150536; Borroni B, 2008, REJUV RES, V11, P585, DOI 10.1089/rej.2007.0623; Brunnlieb C, 2013, BRAIN RES, V1499, P29, DOI 10.1016/j.brainres.2013.01.009; Bzdok D, 2012, BRAIN STRUCT FUNCT, V217, P783, DOI 10.1007/s00429-012-0380-y; Chakrabarti B, 2006, SOC NEUROSCI-UK, V1, P364, DOI 10.1080/17470910601041317; Critchley HD, 2009, INT J PSYCHOPHYSIOL, V73, P88, DOI 10.1016/j.ijpsycho.2009.01.012; Decety J, 2011, NEUROPSYCHOLOGIA, V49, P2994, DOI 10.1016/j.neuropsychologia.2011.06.024; Gu XS, 2012, BRAIN, V135, P2726, DOI 10.1093/brain/aws199; Gu XS, 2010, J NEUROSCI, V30, P3739, DOI 10.1523/JNEUROSCI.4844-09.2010; Hetu S, 2012, BRAIN STIMUL, V5, P95, DOI 10.1016/j.brs.2012.03.005; Hillis AE, 2014, BRAIN, V137, P981, DOI 10.1093/brain/awt317; Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010; Jabbi M, 2007, NEUROIMAGE, V34, P1744, DOI 10.1016/j.neuroimage.2006.10.032; Kim EJ, 2012, CEREB CORTEX, V22, P251, DOI 10.1093/cercor/bhr004; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; LANSKA DJ, 1994, J CHILD NEUROL, V9, P67, DOI 10.1177/088307389400900117; Leigh R, 2013, BRAIN, V136, P2539, DOI 10.1093/brain/awt177; Matsuo K, 2008, NEURORADIOLOGY, V50, P605, DOI 10.1007/s00234-008-0379-5; Max JE, 2012, J AM ACAD CHILD PSY, V51, P1208, DOI 10.1016/j.jaac.2012.08.026; MESULAM MM, 1982, J COMP NEUROL, V212, P1, DOI 10.1002/cne.902120102; Narvid J, 2009, NEUROCASE, V15, P190, DOI 10.1080/13554790802632967; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Perry RJ, 2001, NEUROCASE, V7, P145, DOI 10.1093/neucas/7.2.145; Rankin KP, 2006, BRAIN, V129, P2945, DOI 10.1093/brain/awl254; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Ross ED, 2008, BRAIN LANG, V104, P51, DOI 10.1016/j.bandl.2007.04.007; Saito Y, 2009, PEDIATR INT, V51, P736, DOI 10.1111/j.1442-200X.2009.02896.x; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Viskontas IV, 2007, ANN NY ACAD SCI, V1121, P528, DOI 10.1196/annals.1401.025; Zahn R, 2007, P NATL ACAD SCI USA, V104, P6430, DOI 10.1073/pnas.0607061104; Zahn R, 2009, BRAIN, V132, P604, DOI 10.1093/brain/awn343; Zhang Y, 2009, BRAIN, V132, P2579, DOI 10.1093/brain/awp071	36	72	73	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2015	77	1					68	74		10.1002/ana.24300			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AZ7UN	WOS:000348423200008	25377694	Green Accepted, Other Gold			2021-06-18	
J	Yuan, Y; Zha, H; Rangarajan, P; Ling, EA; Wu, CY				Yuan, Yun; Zha, Hao; Rangarajan, Parakalan; Ling, Eng-Ang; Wu, Chunyun			Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia	BMC NEUROSCIENCE			English	Article						Activated microglia; Cerebral ischemia; Edaravone; Scutellarin; Anti-inflammation	FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; FREE-RADICAL SCAVENGER; INFLAMMATORY CELLS; HYDROGEN-PEROXIDE; AMEBOID MICROGLIA; ARTERY OCCLUSION; FACTOR-ALPHA; SPINAL-CORD	Background: In response to cerebral ischemia, activated microglia release excessive inflammatory mediators which contribute to neuronal damage. Therefore, inhibition of microglial over-activation could be a therapeutic strategy to alleviate various microglia-mediated neuroinflammation. This study was aimed to elucidate the anti-inflammatory effects of Scutellarin and Edaravone given either singly, or in combination in activated microglia in rats subjected to middle cerebral artery occlusion (MCAO), and in lipopolysaccharide (LPS)-induced BV-2 microglia. Expression of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and inducible nitric oxide synthase (iNOS) was assessed by immunofluorescence staining and Western blot. Reactive oxygen species (ROS) and nitric oxide (NO) levels were determined by flow cytometry and fluorescence microscopy, respectively. Results: In vivo, both Edaravone and Scutellarin markedly reduced the infarct cerebral tissue area with the latter drug being more effective with the dosage used; furthermore, when used in combination the reduction was more substantial. Remarkably, a greater diminution in distribution of activated microglia was observed with the combined drug treatment which also attenuated the immunoexpression of TNF-alpha, IL-1 beta and iNOS to a greater extent as compared to the drugs given separately. In vitro, both drugs suppressed upregulated expression of inflammatory cytokines, iNOS, NO and ROS in LPS-induced BV-2 cells. Furthermore, Edaravone and Scutellarin in combination cumulatively diminished the expression levels of the inflammatory mediators being most pronounced for TNF-alpha as evidenced by Western blot. Conclusion: The results suggest that Edaravone and Scutellarin effectively suppressed the inflammatory responses in activated microglia, with Scutellarin being more efficacious within the dosage range used. Moreover, when both drugs were used in combination, the infarct tissue area was reduced more extensively; also, microglia-mediated inflammatory mediators notably TNF-alpha expression was decreased cumulatively.	[Yuan, Yun; Zha, Hao; Wu, Chunyun] Kunming Med Univ, Dept Anat & Histol Embryol, Fac Basic Med Sci, Kunming 650500, Peoples R China; [Yuan, Yun; Rangarajan, Parakalan; Ling, Eng-Ang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore	Ling, EA (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Blk MD10,4 Med Dr, Singapore 117597, Singapore.	antlea@nus.edu.sg; wuchunyunkm@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31260254]; Applied Basic Research Program of Yunnan Province [2011FB243]; National University of SingaporeNational University of Singapore [R-180-000-140-592]	This project is supported by National Natural Science Foundation of China [Project number 31260254, CY Wu], Applied Basic Research Program of Yunnan Province [Project number 2011FB243, CY Wu] and National University of Singapore [Project number R-180-000-140-592 E-A Ling].	ABE K, 1988, STROKE, V19, P480, DOI 10.1161/01.STR.19.4.480; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bohacek I, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-191; Cao Q, 2010, J NEUROSCI RES, V88, P2701, DOI 10.1002/jnr.22429; Cao Q, 2008, GLIA, V56, P1224, DOI 10.1002/glia.20692; Ceulemans AG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-60; Chen XY, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/432623; Czeh M, 2011, DEV NEUROSCI-BASEL, V33, P199, DOI 10.1159/000328989; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dohi K, 2006, J NEUROTRAUM, V23, P1591, DOI 10.1089/neu.2006.23.1591; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Guillot-Sestier MV, 2013, CNS NEUROL DISORD-DR, V12, P593; Hong H, 2004, LIFE SCI, V74, P2959, DOI 10.1016/j.lfs.2003.09.074; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kaur C, 2009, PROG NEUROBIOL, V87, P264, DOI 10.1016/j.pneurobio.2009.01.003; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; Lalancette-Hebert M, 2009, BRAIN, V132, P940, DOI 10.1093/brain/awn345; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Ling E A, 2001, Prog Brain Res, V132, P61; Liu H, 2005, PHARMACOL RES, V51, P205, DOI 10.1016/j.phrs.2004.09.001; Luo P, 2008, YAKUGAKU ZASSHI, V128, P1293, DOI 10.1248/yakushi.128.1293; Ma JY, 2008, J ASIAN NAT PROD RES, V10, P1147, DOI 10.1080/10286020802361255; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Qian L, 2010, J NEURAL TRANSM, V117, P971, DOI 10.1007/s00702-010-0428-1; Sivakumar V, 2010, GLIA, V58, P507, DOI 10.1002/glia.20940; Tang H, 2014, PHARMACOL BIOCHEM BE, V118, P51, DOI 10.1016/j.pbb.2014.01.003; Uno M, 2005, FREE RADICAL BIO MED, V39, P1109, DOI 10.1016/j.freeradbiomed.2005.06.001; Vidal PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.466; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang S, 2011, NEUROSCIENCE, V185, P150, DOI 10.1016/j.neuroscience.2011.04.005; Wu CY, 2013, MOL CELL BIOCHEM, V382, P47, DOI 10.1007/s11010-013-1717-4; Wu YP, 1997, EXP BRAIN RES, V115, P129, DOI 10.1007/PL00005672; Yao LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078439; Zgavc T, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-105; Zhang HF, 2009, PLANTA MED, V75, P121, DOI 10.1055/s-0028-1088368; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06; Zhang P, 2012, NEUROSCIENCE, V201, P297, DOI 10.1016/j.neuroscience.2011.11.005; Ziegler G, 2007, BIOCHEM BIOPH RES CO, V359, P574, DOI 10.1016/j.bbrc.2007.05.157; Ziegler G, 2011, J CEREBR BLOOD F MET, V31, P757, DOI 10.1038/jcbfm.2010.161	48	72	82	2	23	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	NOV 22	2014	15								125	10.1186/s12868-014-0125-3			21	Neurosciences	Neurosciences & Neurology	AU9SK	WOS:000345934800001	25416145	DOAJ Gold, Green Published			2021-06-18	
J	McKinlay, A; Corrigan, J; Horwood, LJ; Fergusson, DM				McKinlay, Audrey; Corrigan, J.; Horwood, L. J.; Fergusson, D. M.			Substance Abuse and Criminal Activities Following Traumatic Brain Injury in Childhood, Adolescence, and Early Adulthood	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescence; birth cohort; childhood; criminal activities; longitudinal; substance abuse; traumatic brain injury; young adult	NEUROPSYCHOLOGICAL FUNCTION; PSYCHOSOCIAL OUTCOMES; MENTAL-DISORDERS; HEAD-INJURY; CHILDREN; PREVALENCE; RISK; ASSOCIATION; SYMPTOMS	Objective: Use a longitudinal birth cohort to evaluate the association of traumatic brain injury at ages 0 to 5, 6 to 15, and 16 to 21 years with drug and alcohol abuse and engagement in criminal activities. Main Measures: Follow-up over 21 to 25 years using self-report of drug and alcohol use, arrests, and violent and property offenses. Outcomes were assessed for 2 levels of severity (inpatient, hospitalized; outpatient, seen by general practitioner or at emergency department). Participants: Members of the Christchurch Health and Development Study, a longitudinal birth cohort. Setting: Christchurch, New Zealand. Results: Adjusted for child and family factors, compared with noninjured individuals, inpatients injured at 0 to 5 years or 16 to 21 years were more likely to have symptoms consistent with drug dependence. All inpatient groups had increased risk of arrest, with the age groups of 0 to 5 and 6 to 15 years more likely to be involved in violent offenses and the age group of 0 to 5 years more likely to engage in property offenses. Outpatient group had an increased risk of violent offenses for first injury 0 to 5 years, arrests and property offenses for injury 6 to 15 years, and increased risk of arrests and violent offenses for injury 16 to 21 years of age. However, when alcohol dependence and drug dependence were added as an additional covariate, traumatic brain injury was no longer associated with criminal behavior for the age group of 0 to 5 years. Conclusions: Traumatic brain injury is associated with increased criminal behavior and may represent a risk factor for offending. However, early substance use is a mediating factor for those injured early in life.	[McKinlay, Audrey] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [McKinlay, Audrey] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Corrigan, J.] Ohio State Univ, Med Ctr, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Horwood, L. J.; Fergusson, D. M.] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand	McKinlay, A (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia.	audrey.mckinlay@unimelb.edu.au		Horwood, L./0000-0003-4881-1956; McKinlay, Audrey/0000-0001-9846-8514	Health Research Council/Accident Compensation Corporation of New Zealand	Dr McKinlay was supported by a postdoctoral fellowship from the Health Research Council/Accident Compensation Corporation of New Zealand.	Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; ELLIOTT DS, 1989, NATO ADV SCI I D-BEH, V50, P155; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Fergusson DM, 1998, J EMOT BEHAV DISORD, V6, P2, DOI 10.1177/106342669800600101; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Glaze L.E., 2009, PARENTS PRISON THEIR; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Luukkainen S, 2012, PSYCHIAT RES, V200, P767, DOI 10.1016/j.psychres.2012.04.018; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McKinlay A, 2003, BRAIN INJ S1, V17, P39; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; MOFFITT TE, 1988, AUST NZ J CRIMINOL, V21, P227, DOI 10.1177/000486588802100405; Shiroma EJ, 2012, J CORRECT HEALTH CAR, V16, P273, DOI DOI 10.1177/1078345810378253; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Slade EP, 2008, DRUG ALCOHOL DEPEN, V95, P1, DOI 10.1016/j.drugalcdep.2007.11.019; Tiihonen J, 1997, AM J PSYCHIAT, V154, P840; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI 10.15288/jsa.1989.50.30; Wilde EA, 2012, NEUROREHABILITATION, V31, P245, DOI 10.3233/NRE-2012-0794; Williams H, 2010, TLS-TIMES LIT SUPPL, P20; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Wilson JJ, 2001, CHILD PSYCHIAT HUM D, V31, P297, DOI 10.1023/A:1010234422719; Winqvist S, 2006, J ADOLESCENT HEALTH, V39; World Health Organization, 1993, COMP INT DIAGN INT C, V1.1	36	72	72	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					498	506		10.1097/HTR.0000000000000001			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800010	24263173				2021-06-18	
J	Mitsis, EM; Riggio, S; Kostakoglu, L; Dickstein, DL; Machac, J; Delman, B; Goldstein, M; Jennings, D; D'Antonio, E; Martin, J; Naidich, TP; Aloysi, A; Fernandez, C; Seibyl, J; DeKosky, ST; Elder, GA; Marek, K; Gordon, W; Hof, PR; Sano, M; Gandy, S				Mitsis, E. M.; Riggio, S.; Kostakoglu, L.; Dickstein, D. L.; Machac, J.; Delman, B.; Goldstein, M.; Jennings, D.; D'Antonio, E.; Martin, J.; Naidich, T. P.; Aloysi, A.; Fernandez, C.; Seibyl, J.; DeKosky, S. T.; Elder, G. A.; Marek, K.; Gordon, W.; Hof, P. R.; Sano, M.; Gandy, S.			Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury	TRANSLATIONAL PSYCHIATRY			English	Article							BRAIN-INJURY; ALZHEIMERS-DISEASE; RISK-FACTOR; ASSOCIATION; LIFE	Single, severe traumatic brain injury (TBI) which elevates CNS amyloid, increases the risk of Alzheimer's disease (AD); while repetitive concussive and subconcussive events as observed in athletes and military personnel, may increase the risk of chronic traumatic encephalopathy (CTE). We describe two clinical cases, one with a history of multiple concussions during a career in the National Football League (NFL) and the second with frontotemporal dementia and a single, severe TBI. Both patients presented with cognitive decline and underwent [F-18]-Florbetapir positron emission tomography (PET) imaging for amyloid plaques; the retired NFL player also underwent [F-18]-T807 PET imaging, a new ligand binding to tau, the main constituent of neurofibrillary tangles (NFT). Case 1, the former NFL player, was 71 years old when he presented with memory impairment and a clinical profile highly similar to AD. [F-18]-Florbetapir PET imaging was negative, essentially excluding AD as a diagnosis. CTE was suspected clinically, and [F-18]-T807 PET imaging revealed striatal and nigral [F-18]-T807 retention consistent with the presence of tauopathy. Case 2 was a 56-year-old man with personality changes and cognitive decline who had sustained a fall complicated by a subdural hematoma. At 1 year post injury, [F-18]-Florbetapir PET imaging was negative for an AD pattern of amyloid accumulation in this subject. Focal [F-18]-Florbetapir retention was noted at the site of impact. In case 1, amyloid imaging provided improved diagnostic accuracy where standard clinical and laboratory criteria were inadequate. In that same case, tau imaging with [F-18]-T807 revealed a subcortical tauopathy that we interpret as a novel form of CTE with a distribution of tauopathy that mimics, to some extent, that of progressive supranuclear palsy (PSP), despite a clinical presentation of amnesia without any movement disorder complaints or signs. A key distinguishing feature is that our patient presented with hippocampal involvement, which is more frequently seen in CTE than in PSP. In case 2, focal [F-18]-Florbetapir retention at the site of injury in an otherwise negative scan suggests focal amyloid aggregation. In each of these complex cases, a combination of [F-18]-fluorodeoxyglucose, [F-18]-Florbetapir and/or [F-18]-T807 PET molecular imaging improved the accuracy of diagnosis and prevented inappropriate interventions.	[Mitsis, E. M.; Riggio, S.; Martin, J.; Aloysi, A.; Fernandez, C.; Elder, G. A.; Sano, M.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Mitsis, E. M.; Dickstein, D. L.; Fernandez, C.; Hof, P. R.; Sano, M.; Gandy, S.] Icahn Sch Med Mt Sinai, Mt Sinais Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Mitsis, E. M.; Riggio, S.; Fernandez, C.; Elder, G. A.; Sano, M.; Gandy, S.] James J Peters VA Med Ctr, Bronx, NY USA; [Riggio, S.; Goldstein, M.; Elder, G. A.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Riggio, S.; Gordon, W.; Gandy, S.] Icahn Sch Med Mt Sinai, NFL Neurol Program, New York, NY 10029 USA; [Kostakoglu, L.; Machac, J.] Icahn Sch Med Mt Sinai, Dept Nucl Med, New York, NY 10029 USA; [Dickstein, D. L.; Hof, P. R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Delman, B.; Naidich, T. P.] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA; [Jennings, D.; Seibyl, J.; Marek, K.] Yale Univ, Inst Neurodegenerat Disorders, New Haven, CT USA; [D'Antonio, E.; Gordon, W.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [DeKosky, S. T.] Univ Virginia, Dept Neurol, Charlottesville, VA USA	Gandy, S (corresponding author), James J Peters VA Med Ctr, Mt Sinais Alzheimers Dis Res Ctr, One Gustave L Levy Pl,Box 1187, New York, NY 10029 USA.	samuel.gandy@mssm.edu	Dickstein, Dara/AAH-6603-2020	Delman, Bradley/0000-0002-9792-8942; Fernandez, Corey/0000-0003-3901-5552; DeKosky, Steven/0000-0003-3743-2758; Marek, Kenneth/0000-0002-4197-5627	Veterans Affairs AdministrationUS Department of Veterans Affairs; Icahn School of Medicine Clinical Research Center.; Cure Alzheimer's Fund; Department of Veteran AffairsUS Department of Veterans Affairs; Gideon and Sarah Gartner Foundation; Louis B. Mayer Foundation; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Baxter Pharmaceuticals; Polyphenolics; Amicus Pharmaceuticals; Icahn School of Medicine Alzheimer's Disease Research Center [P50 AG005138]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000684] Funding Source: NIH RePORTER	We gratefully acknowledge Ash Rafique for technical support. EMM received grants from the Veterans Affairs Administration and the Icahn School of Medicine Clinical Research Center. SG thanks the Cure Alzheimer's Fund, the Department of Veteran Affairs, the Gideon and Sarah Gartner Foundation and the Louis B. Mayer Foundation. SG has received grants from NIA, NINDS, Baxter Pharmaceuticals, Polyphenolics and Amicus Pharmaceuticals. He has served as a member of the Data and Safety Monitoring Board for the Pfizer-Janssen Alzheimer's Immunotherapy Alliance, as a member of the Scientific Advisory Board of DiaGenic and as a consultant to Amicus Pharmaceuticals and to Cerora. This research was supported in part by the Icahn School of Medicine Alzheimer's Disease Research Center grant P50 AG005138.	Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Goodwin Linda, 2006, J Insur Med, V38, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Landau SM, 2012, ANN NEUROL, V72, P578, DOI 10.1002/ana.23650; Ling H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-24; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mitsis EM, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-10; Nordberg A, 2013, EUR J NUCL MED MOL I, V40, P104, DOI 10.1007/s00259-012-2237-2; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008	28	72	75	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	SEP	2014	4								e441	10.1038/tp.2014.91			8	Psychiatry	Psychiatry	AT3HS	WOS:000344827000011	25226550	DOAJ Gold, Green Published			2021-06-18	
J	Sekhon, MS; Griesdale, DE; Robba, C; McGlashan, N; Needham, E; Walland, K; Shook, AC; Smielewski, P; Czosnyka, M; Gupta, AK; Menon, DK				Sekhon, Mypinder S.; Griesdale, Donald E.; Robba, Chiara; McGlashan, Nick; Needham, Edward; Walland, Katherine; Shook, Alyssa C.; Smielewski, Peter; Czosnyka, Marek; Gupta, Arun K.; Menon, David K.			Optic nerve sheath diameter on computed tomography is correlated with simultaneously measured intracranial pressure in patients with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Optic nerve sheath diameter; Computed tomography; Traumatic brain injury; Intracranial pressure	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; NEUROCRITICAL CARE; HYPERTENSION; ULTRASONOGRAPHY; SCAN; AUTOREGULATION; EPIDEMIOLOGY; ULTRASOUND; SONOGRAPHY	Assess the relationship between optic nerve sheath diameter (ONSD) measured on bedside portable computed tomography (CT) scans and simultaneously measured intracranial pressure (ICP) in patients with severe traumatic brain injury. Retrospective cohort study of 57 patients admitted between 2009 and 2013. Linear and logistic regression were used to model the correlation and discrimination between ONSD and ICP or intracranial hypertension, respectively. The cohort had a mean age of 40 years (SD 16) and a median admission Glasgow coma score of 7 (IQR 4-10). The between-rater agreement by intraclass coefficient was 0.89 (95 % CI 0.83-0.93, P < 0.001). The mean ONSD was 6.7 mm (SD 0.75) and the mean ICP during CT was 21.3 mmHg (SD 8.4). Using linear regression, there was a strong correlation between ICP and ONSD (r = 0.74, P < 0.001). ONSD had an area under the curve to discriminate elevated ICP (a parts per thousand yen20 mmHg vs. < 20 mmHg) of 0.83 (95 % CI 0.73-0.94). Using a cutoff of 6.0 mm, ONSD had a sensitivity of 97 %, specificity of 42 %, positive predictive value of 67 %, and a negative predictive value of 92 %. Comparing linear regression models, ONSD was a much stronger predictor of ICP (R (2) of 0.56) compared to other CT features (R (2) of 0.21). Simultaneous measurement of ONSD on CT and ICP were strongly correlated and ONSD was discriminative for intracranial hypertension. ONSD was much more predictive of ICP than other CT features. There was excellent agreement between raters in measuring ONSD.	[Sekhon, Mypinder S.; Griesdale, Donald E.] Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Sekhon, Mypinder S.; Robba, Chiara; McGlashan, Nick; Needham, Edward; Walland, Katherine; Smielewski, Peter; Czosnyka, Marek; Gupta, Arun K.; Menon, David K.] Univ Cambridge, Cambridge Univ Hosp Trust, Addenbrookes Hosp, Neurocrit Care Unit, Cambridge CB2 0QQ, England; [Griesdale, Donald E.] Univ British Columbia, Vancouver Gen Hosp, Dept Anaesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada; [Shook, Alyssa C.] St Pauls Hosp, Ctr Heart, Vancouver, BC V6Z 1Y6, Canada	Sekhon, MS (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, Room 2438,Jim Pattison Pavil,2nd Floor,855 West 1, Vancouver, BC V5Z 1M9, Canada.	mypindersekhon@gmail.com	Needham, EJ/AAM-7049-2020; Robba, Chiara/AAS-7421-2020	Needham, EJ/0000-0001-7042-7462; Griesdale, Donald/0000-0001-5985-8624; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986, G0001354] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish		Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; FOUNDATION TB, 2007, J NEUROTRAUMA S1, V24, pS7, DOI DOI 10.1089/NEU.2007.9995; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kalantari H, 2013, AM J EMERG MED, V31, P1595, DOI 10.1016/j.ajem.2013.07.028; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008; Launey Y, 2014, J NEUROTRAUM, V31, P984, DOI 10.1089/neu.2012.2829; Legrand A, 2013, CRIT CARE, V17, DOI 10.1186/cc12589; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Moretti R, 2011, ACTA ANAESTH SCAND, V55, P644, DOI 10.1111/j.1399-6576.2011.02432.x; Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Radolovich DK, 2011, NEUROCRIT CARE, V15, P379, DOI 10.1007/s12028-011-9553-4; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rumboldt Z, 2009, AM J NEURORADIOL, V30, P1630, DOI 10.3174/ajnr.A1603; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	37	72	76	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2014	40	9					1267	1274		10.1007/s00134-014-3392-7			8	Critical Care Medicine	General & Internal Medicine	AO5IK	WOS:000341377400007	25034476				2021-06-18	
J	Angelakis, E; Liouta, E; Andreadis, N; Korfias, S; Ktonas, P; Stranjalis, G; Sakas, DE				Angelakis, Efthymios; Liouta, Evangelia; Andreadis, Nikos; Korfias, Stephanos; Ktonas, Periklis; Stranjalis, George; Sakas, Damianos E.			Transcranial Direct Current Stimulation Effects in Disorders of Consciousness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Deep brain stimulation; Persistent vegetative state; Rehabilitation; tDCS	PERSISTENT VEGETATIVE STATE; MOTOR CORTEX; INTRATHECAL BACLOFEN; BRAIN POLARIZATION; EVOKED POTENTIALS; PREFRONTAL CORTEX; DC STIMULATION; MODULATION; TDCS; WAKEFULNESS	Objective: To assess the efficacy of transcranial direct current stimulation (tDCS) on improving consciousness in patients with persistent unresponsive wakefulness syndrome (UWS) (previously termed persistent vegetative state [PVS]) or in a minimally conscious state (MCS). Design: Prospective, case series trial with follow-up at 12 months. Setting: General and research hospital. Participants: Inpatients in a PVS/UWS or MCS (N=10; 7 men, 3 women; age range, 19-62y; etiology: traumatic brain injury, n=5; anoxia, n=4; postoperative infarct, n=1; duration of PVS/UWS or MCS range, 6mo-10y). No participant withdrew because of adverse effects. Intervention: All patients received sham tDCS for 20 minutes per day, 5 days per week, for 1 week, and real tDCS for 20 minutes per day, 5 days per week, for 2 weeks. An anodal electrode was placed over the left primary sensorimotor cortex or the left dorsolateral prefrontal cortex, with cathodal stimulation over the right eyebrow. One patient in an MCS received a second round of 10 tDCS sessions 3 months after initial participation. Main Outcome Measure: JFK Coma Recovery Scale-Revised. Results: All patients in an MCS showed clinical improvement immediately after treatment. The patient who received a second round of tDCS 3 months after initial participation showed further improvement and emergence into consciousness after stimulation, with no change between treatments. One patient who was in an MCS for <1 year before treatment (postoperative infarct) showed further improvement and emergence into consciousness at 12-month follow-up. No patient showed improvement before stimulation. No patient in a PVS/UWS showed immediate improvement after stimulation, but 1 patient who was in a PVS/UWS for 6 years before treatment showed improvement and change of status to an MCS at 12-month follow-up. Conclusions: tDCS seems promising for the rehabilitation of patients with severe disorders of consciousness. Severity and duration of pathology may be related to the degree of tDCS' beneficial effects. (C) 2014 by the American Congress of Rehabilitation Medicine	[Angelakis, Efthymios; Liouta, Evangelia; Andreadis, Nikos; Korfias, Stephanos; Ktonas, Periklis; Stranjalis, George; Sakas, Damianos E.] Hellen Ctr Neurosurg Res Prof Petros Kokkalis, GR-10675 Athens, Greece; [Angelakis, Efthymios; Liouta, Evangelia; Korfias, Stephanos; Stranjalis, George; Sakas, Damianos E.] Natl & Kapodistrian Univ Athens, Sch Med, Dept Neurosurg, Evangelismos Hosp, Athens 11528, Greece	Angelakis, E (corresponding author), Hellen Ctr Neurosurg Res Prof Petros Kokkalis, 3 Ploutarchou Str, GR-10675 Athens, Greece.	eaggelak@med.uoa.gr			European CommissionEuropean CommissionEuropean Commission Joint Research Centre [222079]; Hellenic Center for Neurosurgical Research "Prof. Petros Kokkalis"	Supported in part by the HIVE project (http://hive-eu.org), a Future and Emerging Technologies program within the 7th Framework Programme for Research of the European Commission (grant no. 222079) and the Hellenic Center for Neurosurgical Research "Prof. Petros Kokkalis."	Accornero N, 2007, EXP BRAIN RES, V178, P261, DOI 10.1007/s00221-006-0733-y; Anaclet C, 2009, J NEUROSCI, V29, P14423, DOI 10.1523/JNEUROSCI.2604-09.2009; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; Antal A, 2008, CLIN J PAIN, V24, P56, DOI 10.1097/AJP.0b013e318157233b; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Baudewig J, 2001, MAGN RESON MED, V45, P196, DOI 10.1002/1522-2594(200102)45:2<196::AID-MRM1026>3.0.CO;2-1; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Boggio PS, 2008, INT J NEUROPSYCHOPH, V11, P249, DOI 10.1017/S1461145707007833; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Childs NL, 1996, BRIT MED J, V313, P944; Clark VP, 2011, NEUROSCI LETT, V500, P67, DOI 10.1016/j.neulet.2011.05.244; CREUTZFELDT O, 1962, EXP NEUROL, V5, P436, DOI 10.1016/0014-4886(62)90056-0; Dell'Osso B, 2012, EUR PSYCHIAT, V27, P513, DOI 10.1016/j.eurpsy.2011.02.008; Floel A, 2008, J COGNITIVE NEUROSCI, V20, P1415, DOI 10.1162/jocn.2008.20098; Frank E, 2010, BRAIN STIMUL, V3, P58, DOI 10.1016/j.brs.2009.04.002; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Furubayashi T, 2008, EXP BRAIN RES, V185, P279, DOI 10.1007/s00221-007-1149-z; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-73; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; JENNETT B, 1972, LANCET, V1, P734; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Kwon YH, 2008, NEUROSCI LETT, V435, P56, DOI 10.1016/j.neulet.2008.02.012; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lang N, 2007, INVEST OPHTH VIS SCI, V48, P5782, DOI 10.1167/iovs.07-0706; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leon-Carrion J, 2012, BRAIN RES, V1476, P22, DOI 10.1016/j.brainres.2012.03.055; Lin JS, 2011, CELL MOL LIFE SCI, V68, P2499, DOI 10.1007/s00018-011-0631-8; Marshall L, 2004, J NEUROSCI, V24, P9985, DOI 10.1523/JNEUROSCI.2725-04.2004; Monti A, 2008, J NEUROL NEUROSUR PS, V79, P451, DOI 10.1136/jnnp.2007.135277; Nakamura-Palacios EM, 2012, INT J NEUROPSYCHOPH, V15, P601, DOI 10.1017/S1461145711001040; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Palm U, 2008, BRAIN STIMUL, V1, P241; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166; Quartarone A, 2004, NEUROREPORT, V15, P1287, DOI 10.1097/01.wnr.0000127637.22805.7c; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Stempien L, 2000, AM J PHYS MED REHAB, V79, P536, DOI 10.1097/00002060-200011000-00010; Terney D, 2008, J PAIN SYMPTOM MANAG, V36, P79, DOI 10.1016/j.jpainsymman.2007.08.014; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Vines BW, 2006, NEUROREPORT, V17, P671, DOI 10.1097/00001756-200604240-00023; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353; Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018	54	72	85	1	30	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2014	95	2					283	289		10.1016/j.apmr.2013.09.002			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AA2LW	WOS:000330927100011	24035769				2021-06-18	
J	McClure, DJ; Zuckerman, SL; Kutscher, SJ; Gregory, AJ; Solomon, GS				McClure, D. Jake; Zuckerman, Scott L.; Kutscher, Scott J.; Gregory, Andrew J.; Solomon, Gary S.			Baseline Neurocognitive Testing in Sports-Related Concussions The Importance of a Prior Night's Sleep	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	39th Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUL, 2013	Chicago, IL			concussion; ImPACT; athletes; sleep; mild traumatic brain injury	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; SEX-DIFFERENCES; UNITED-STATES; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; ADOLESCENT SLEEP; PERFORMANCE	Background: The management of sports-related concussions (SRCs) utilizes serial neurocognitive assessments and self-reported symptom inventories to assess recovery and safety for return to play (RTP). Because postconcussive RTP goals include symptom resolution and a return to neurocognitive baseline levels, clinical decisions rest in part on understanding modifiers of this baseline. Several studies have reported age and sex to influence baseline neurocognitive performance, but few have assessed the potential effect of sleep. We chose to investigate the effect of reported sleep duration on baseline Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) performance and the number of patient-reported symptoms. Hypothesis: We hypothesized that athletes receiving less sleep before baseline testing would perform worse on neurocognitive metrics and report more symptoms. Study Design: Cross-sectional study; Level of evidence, 3. Methods: We retrospectively reviewed 3686 nonconcussed athletes (2371 male, 1315 female; 3305 high school, 381 college) with baseline symptom and ImPACT neurocognitive scores. Patients were stratified into 3 groups based on self-reported sleep duration the night before testing: (1) short, <7 hours; (2) intermediate, 7-9 hours; and (3) long, >9 hours. A multivariate analysis of covariance (MANCOVA) with an a level of .05 was used to assess the influence of sleep duration on baseline ImPACT performance. A univariate ANCOVA was performed to investigate the influence of sleep on total self-reported symptoms. Results: When controlling for age and sex as covariates, the MANCOVA revealed significant group differences on ImPACT reaction time, verbal memory, and visual memory scores but not visual-motor (processing) speed scores. An ANCOVA also revealed significant group differences in total reported symptoms. For baseline symptoms and ImPACT scores, subsequent pairwise comparisons revealed these associations to be most significant when comparing the short and intermediate sleep groups. Conclusion: Our results indicate that athletes sleeping fewer than 7 hours before baseline testing perform worse on 3 of 4 ImPACT scores and report more symptoms. Because SRC management and RTP decisions hinge on the comparison with a reliable baseline evaluation, clinicians should consider sleep duration before baseline neurocognitive testing as a potential factor in the assessment of athletes' recovery.	[McClure, D. Jake; Zuckerman, Scott L.; Kutscher, Scott J.; Gregory, Andrew J.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	McClure, DJ (corresponding author), POB 32861, Charlotte, NC 28232 USA.	jake.mcclure@carolinashealthcare.org	Solomon, Gary/K-9011-2019; Meijer, Anna/K-5118-2016				Astill RG, 2012, PSYCHOL BULL, V138, P1109, DOI 10.1037/a0028204; Belenky G, 2003, J SLEEP RES, V12, P1, DOI 10.1046/j.1365-2869.2003.00337.x; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carskadon MA, 2004, ANN NY ACAD SCI, V1021, P276, DOI 10.1196/annals.1308.032; Carskadon MA, 2002, SLEEP, V25, P606, DOI 10.1093/sleep/25.6.606; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dinges DF, 1997, SLEEP, V20, P267; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Faul M, TRAUMATIC BRAIN INJU; Ferri R, 2010, SLEEP MED, V11, P378, DOI 10.1016/j.sleep.2010.01.006; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fredriksen K, 2004, CHILD DEV, V75, P84, DOI 10.1111/j.1467-8624.2004.00655.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kleitman N., 1963, SLEEP WAKEFULNESS; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kribbs N.B., 1994, SLEEP ONSET MECH, P113, DOI 10.1037/10166-007; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell M., IMPACT VERSION 2 0 C; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lund HG, 2010, J ADOLESCENT HEALTH, V46, P124, DOI 10.1016/j.jadohealth.2009.06.016; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Matricciani L, 2011, SLEEP, V34, P651, DOI 10.1093/sleep/34.5.651; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; MURRAY EJ, 1965, SLEEP DREAMS AROUSAL; Oginska H, 2006, CHRONOBIOL INT, V23, P1317, DOI 10.1080/07420520601089349; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Roberts RE, 2001, J YOUTH ADOLESCENCE, V30, P1, DOI 10.1023/A:1005230820074; Saint Martin M, 2012, SLEEP MED, V13, P1146, DOI 10.1016/j.sleep.2012.06.021; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Sosin DM, 1996, BRAIN INJURY, V10, P47; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Dongen HPA, 2004, SLEEP, V27, P423; Weiss EM, 2005, FORTSCHR NEUROL PSYC, V73, P587, DOI 10.1055/s-2004-830296; Wolfson AR, 2003, SLEEP MED REV, V7, P491, DOI 10.1016/S1087-0792(03)90003-7; Wolfson AR, 1998, CHILD DEV, V69, P875, DOI 10.1111/j.1467-8624.1998.tb06149.x; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	53	72	72	1	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2014	42	2					472	478		10.1177/0363546513510389			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AH6CS	WOS:000336218900034	24256713				2021-06-18	
J	Sawmiller, D; Li, S; Shahaduzzaman, M; Smith, AJ; Obregon, D; Giunta, B; Borlongan, CV; Sanberg, PR; Tan, J				Sawmiller, Darrell; Li, Song; Shahaduzzaman, Md; Smith, Adam J.; Obregon, Demian; Giunta, Brian; Borlongan, Cesar V.; Sanberg, Paul R.; Tan, Jun			Luteolin Reduces Alzheimer's Disease Pathologies Induced by Traumatic Brain Injury	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; tauopathy; neuroinflammation; luteolin; amyloidogenesis; GSK; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; AXONAL INJURY; BETA-APP; RISK; ACCUMULATION; DIAGNOSIS; PLAQUES; EGCG	Traumatic brain injury (TBI) occurs in response to an acute insult to the head and is recognized as a major risk factor for Alzheimer's disease (AD). Indeed, recent studies have suggested a pathological overlap between TBI and AD, with both conditions exhibiting amyloid-beta (A beta) deposits, tauopathy, and neuroinflammation. Additional studies involving animal models of AD indicate that some AD-related genotypic determinants may be critical factors enhancing temporal and phenotypic symptoms of TBI. Thus in the present study, we examined sub-acute effects of moderate TBI delivered by a gas-driven shock tube device in A beta depositing Tg2576 mice. Three days later, significant increases in b-amyloid deposition, glycogen synthase-3 (GSK-3) activation, phospho-tau, and pro-inflammatory cytokines were observed. Importantly, peripheral treatment with the naturally occurring flavonoid, luteolin, significantly abolished these accelerated pathologies. This study lays the groundwork for a safe and natural compound that could prevent or treat TBI with minimal or no deleterious side effects in combat personnel and others at risk or who have experienced TBI.	[Sawmiller, Darrell; Obregon, Demian; Tan, Jun] James A Haley Vet Adm Hosp, Tampa, FL 33612 USA; [Sawmiller, Darrell; Li, Song; Obregon, Demian; Giunta, Brian; Tan, Jun] Univ S Florida, Dept Psychiat, Morsani Coll Med, Tampa, FL 33613 USA; [Li, Song] Dalian Univ Technol, Sch Phys & Optoelect Technol, Dept Biophys, Dalian 116024, Peoples R China; [Shahaduzzaman, Md; Smith, Adam J.; Borlongan, Cesar V.; Sanberg, Paul R.] Univ S Florida, Dept Neurosurg & Brain Repair, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Tampa, FL 33613 USA	Sawmiller, D (corresponding author), James A Haley Vet Adm Hosp, Tampa, FL 33612 USA.	dsawmill@health.usf.edu; songli@mail.usf.edu; mshahad@health.usf.edu; asmith1@health.usf.edu; dobregon@health.usf.edu; bgiunta@health.usf.edu; cborlong@health.usf.edu; psanberg@health.usf.edu; jtan@health.usf.edu	Sawmiller, Darrell/AAQ-9722-2021; Li, Song/C-6701-2014; Borlongan, Cesar/I-5696-2012	Li, Song/0000-0003-2713-9136; Borlongan, Cesar/0000-0002-2966-9782; Sawmiller, Darrell/0000-0003-3599-6859	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Medical Research Service - DoD TATRCUS Department of Veterans Affairs [W81XWH-11-1-0634]; Veterans AffairsUS Department of Veterans Affairs [I01BX001143] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by funds from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Medical Research Service through a Veterans Affairs Merit grant to J.T. C.V.B. and P.R.S. are funded by DoD TATRC W81XWH-11-1-0634. Luteolin (Pureolin (TM)) was a gift from Pharma Science Nutrients, Inc. (Tampa Bay, FL, USA). We would like to thank Doug Shytle for his helpful discussion. Contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984; Chauhan NB, 2005, NEUROPHARMACOLOGY, V48, P93, DOI 10.1016/j.neuropharm.2004.09.014; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Giunta B, 2010, NEUROSCI LETT, V471, P134, DOI 10.1016/j.neulet.2010.01.026; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham DI, 1996, ACT NEUR S, V66, P96; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 1998, J NEURAL TRANSM-SUPP, P77; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Lee K. K., 2006, SMJ Singapore Medical Journal, V47, P31; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; Rezai-Zadeh K, 2009, J CELL MOL MED, V13, P574, DOI 10.1111/j.1582-4934.2008.00344.x; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith A, 2010, INT J PHARMACEUT, V389, P207, DOI 10.1016/j.ijpharm.2010.01.012; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Zhou FT, 2012, BIOL TRACE ELEM RES, V149, P273, DOI 10.1007/s12011-012-9411-z	33	72	72	0	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JAN	2014	15	1					895	904		10.3390/ijms15010895			10	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	AG9YM	WOS:000335776100052	24413756	DOAJ Gold, Green Published			2021-06-18	
J	Cooney, SJ; Bermudez-Sabogal, SL; Byrnes, KR				Cooney, Sean J.; Bermudez-Sabogal, Sara L.; Byrnes, Kimberly R.			Cellular and temporal expression of NADPH oxidase (NOX) isotypes after brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Animal studies; Models of injury; Oxidative stress; Traumatic brain injury	OXIDATIVE DAMAGE; NITRIC-OXIDE; ACTIVATED MICROGLIA; GENE-EXPRESSION; NEURONAL DEATH; PEROXYNITRITE; INHIBITION; STRESS; RAT; INFLAMMATION	Background: Brain injury results in an increase in the activity of the reactive oxygen species generating NADPH oxidase (NOX) enzymes. Preliminary studies have shown that NOX2, NOX3, and NOX4 are the most prominently expressed NOX isotypes in the brain. However, the cellular and temporal expression profile of these isotypes in the injured and non-injured brain is currently unclear. Methods: Double immunofluorescence for NOX isotypes and brain cell types was performed at acute (24 hours), sub-acute (7 days), and chronic (28 days) time points after controlled cortical impact-induced brain injury or sham-injury in rats. Results: NOX2, NOX3, and NOX4 isotypes were found to be expressed in neurons, astrocytes, and microglia, and this expression was dependent on both cellular source and post-injury time. NOX4 was found in all cell types assessed, while NOX3 was positively identified in neurons only, and NOX2 was identified in microglia and neurons. NOX2 was the most responsive to injury, increasing primarily in microglia in response to injury. Quantitation of this isotype showed a significant increase in NOX2 expression at 24 hours, with reduced expression at 7 days and 28 days post-injury, although expression remained above sham levels at later time points. Cellular confirmation using purified primary or cell line culture demonstrated similar patterns in microglia, astrocytes, and neurons. Further, inhibition of NOX, and more specifically NOX2, reduced pro-inflammatory activity in microglia, demonstrating that NOX is not only up-regulated after stimulation, but may also play a significant role in post-injury neuroinflammation. Conclusions: This study illustrates the expression profiles of NOX isotypes in the brain after injury, and demonstrates that NOX2, and to a lesser extent, NOX4, may be responsible for the majority of oxidative stress observed acutely after traumatic brain injury. These data may provide insight into the design of future therapeutic approaches.	[Cooney, Sean J.; Bermudez-Sabogal, Sara L.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	kimberly.byrnes@usuhs.edu		Byrnes, Kimberly/0000-0002-7501-7734	Uniformed Services University Intramural Program; NINDS/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS073667-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073667] Funding Source: NIH RePORTER	This work was funded by the Uniformed Services University Intramural Program and the NINDS/NIH (Grant number 1R01NS073667-01A1). The authors would like to thank Ms. Guzal Khayrullina and Ms. Ramona von Leden for technical and editorial assistance.	Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI [10.1089/neu.2008.0870, 10.1089/neu.2008-0870]; Chen Y, 2007, NAT PROTOC, V2, P1044, DOI 10.1038/nprot.2007.149; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Csanyi G, 2011, FREE RADICAL BIO MED, V51, P1116, DOI 10.1016/j.freeradbiomed.2011.04.025; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Dugan LL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005518; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171; Guemez-Gamboa A, 2011, J NEUROPATH EXP NEUR, V70, P1020, DOI 10.1097/NEN.0b013e3182358e4e; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hattori H, 2010, P NATL ACAD SCI USA, V107, P3546, DOI 10.1073/pnas.0914351107; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Jaquet V, 2009, ANTIOXID REDOX SIGN, V11, P2535, DOI [10.1089/ars.2009.2585, 10.1089/ARS.2009.2585]; Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Ju KD, 2011, INFLAMM RES, V60, P791, DOI 10.1007/s00011-011-0335-4; Kallenborn-Gerhardt W, 2012, J NEUROSCI, V32, P10136, DOI 10.1523/JNEUROSCI.6227-11.2012; Khanna A, 2013, J NEUROIMMUNOL, V254, P69, DOI 10.1016/j.jneuroim.2012.09.006; Kim D, 2010, P NATL ACAD SCI USA, V107, P14851, DOI 10.1073/pnas.1009926107; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Leto TL, 2009, ANTIOXID REDOX SIGN, V11, P2607, DOI [10.1089/ars.2009.2637, 10.1089/ARS.2009.2637]; Li B, 2008, BRAIN RES, V1226, P199, DOI 10.1016/j.brainres.2008.06.024; Li JR, 2005, P NATL ACAD SCI USA, V102, P9936, DOI 10.1073/pnas.0502552102; Li S, 2011, NEUROSCIENCE, V184, P107, DOI 10.1016/j.neuroscience.2011.04.007; Lin CC, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-35; McCann SK, 2008, J NEUROSCI RES, V86, P2524, DOI 10.1002/jnr.21700; Nakano Y, 2007, BIOCHEM J, V403, P97, DOI 10.1042/BJ20060819; Pajoohesh-Ganji A, 2012, BRAIN RES, V1475, P96, DOI 10.1016/j.brainres.2012.07.058; Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016; Reddy PVB, 2012, NEUROCHEM INT, V61, P807, DOI 10.1016/j.neuint.2011.06.011; Reyes RC, 2012, J NEUROSCI, V32, P12973, DOI 10.1523/JNEUROSCI.1597-12.2012; Savchenko VL, 2013, NEUROTOX RES, V23, P201, DOI 10.1007/s12640-012-9327-6; Simonyi A, 2010, MOL NEUROBIOL, V41, P73, DOI 10.1007/s12035-010-8107-7; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Vallet P, 2005, NEUROSCIENCE, V132, P233, DOI 10.1016/j.neuroscience.2004.12.038; Vendrov AE, 2010, J BIOL CHEM, V285, P26545, DOI 10.1074/jbc.M110.143917; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	55	72	72	2	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	DEC 17	2013	10								155	10.1186/1742-2094-10-155			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	282XV	WOS:000329209000001	24344836	DOAJ Gold, Green Published			2021-06-18	
J	Johansson, PI; Sorensen, AM; Larsen, CF; Windelov, NA; Stensballe, J; Perner, A; Rasmussen, LS; Ostrowski, SR				Johansson, Paer I.; Sorensen, Anne Marie; Larsen, Claus F.; Windelov, Nis A.; Stensballe, Jakob; Perner, Anders; Rasmussen, Lars S.; Ostrowski, Sisse R.			Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets	TRANSFUSION			English	Article							BLOOD-PRODUCT RATIO; RAPID THROMBELASTOGRAPHY; ENDOTHELIAL GLYCOCALYX; MASSIVE TRANSFUSION; ACUTE COAGULOPATHY; CELL RATIOS; ADMISSION; SURVIVAL; COAGULATION; SHOCK	BackgroundHemorrhage accounts for most preventable trauma deaths, but still the optimal strategy for hemostatic resuscitation remains debated. Study Design and MethodsThis was a prospective study of adult trauma patients admitted to a Level I trauma center. Demography, Injury Severity Score (ISS), transfusion therapy, and mortality were registered. Hemostatic resuscitation was based on a massive transfusion protocol encompassing transfusion packages and thromboelastography (TEG)-guided therapy. ResultsA total of 182 patients were included (75% males, median age 43 years, ISS of 17, 92% with blunt trauma). Overall 28-day mortality was 12% with causes of death being exsanguinations (14%), traumatic brain injury (72%, two-thirds expiring within 24hr), and other (14%). One-fourth, 16 and 15% of the patients, received red blood cells (RBCs), plasma, or platelets (PLTs) within 2 hours from admission and 68, 71, and 75%, respectively, of patients transfused within 24 hours received the respective blood products within the first 2 hours. In patients transfused within 24 hours, the median number of blood products at 2 hours was 5 units of RBCs, 5 units of plasma, and 2 units of PLT concentrates. Nonsurvivors had lower clot strength by kaolin-activated TEG and TEG functional fibrinogen and lower kaolin-tissue factor-activated TEG -angle and lysis after 30 minutes compared to survivors. None of the TEG variables were independent predictors of massive transfusion or mortality. ConclusionThree-fourths of the patients transfused with plasma or PLTs within 24 hours received these in the first 2 hours. Hemorrhage caused 14% of the deaths. We introduced transfusion packages and early TEG-directed hemostatic resuscitation at our hospital 10 years ago and this may have contributed to reducing hemorrhagic trauma deaths.	Rigshosp, Copenhagen Univ Hosp, Capital Reg Blood Bank, Transfus Med Sect, DK-2100 Copenhagen, Denmark; Rigshosp, Copenhagen Univ Hosp, Dept Anesthesia, DK-2100 Copenhagen, Denmark; Rigshosp, Copenhagen Univ Hosp, TraumaCtr 3193, Ctr Head & Orthoped, DK-2100 Copenhagen, Denmark; Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, DK-2100 Copenhagen, Denmark; Univ Texas Med Sch Houston, Dept Surg, Div Acute Care Surg, Ctr Translat Injury Res,CeTIR, Houston, TX USA	Johansson, PI (corresponding author), Univ Copenhagen, Rigshosp, Capital Reg Blood Bank, Transfus Med Sect, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	per.johansson@rh.regionh.dk	Johansson, Par I/P-9283-2015; Ostrowski, Sisse R/E-7423-2011	Johansson, Par I/0000-0001-9778-5964; Ostrowski, Sisse R/0000-0001-5288-3851; Perner, Anders/0000-0002-4668-0123; Rasmussen, Lars/0000-0002-7480-3004	Haemonetics Corp. (Braintree, MA); University of Copenhagen; Tryg Foundation; B. Braun Medical; Fresenius Kabi	The study was supported by an unrestricted research grant from Haemonetics Corp. (Braintree, MA). NAW received a fellowship grant from the University of Copenhagen and LSR received funding from the Tryg Foundation. AP received grant support from B. Braun Medical and Fresenius Kabi.	Amer Soc Anesthesiologists Task Fo, 2006, ANESTHESIOLOGY, V105, P198; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P358, DOI 10.1097/TA.0b013e31825889ba; Cotton BA, 2012, J TRAUMA ACUTE CARE, V73, P365, DOI 10.1097/TA.0b013e31825c1234; Cotton BA, 2011, J TRAUMA, V71, P407, DOI 10.1097/TA.0b013e31821e1bf0; Cotton BA, 2009, J TRAUMA, V66, P41, DOI 10.1097/TA.0b013e31819313bb; Dirks J, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-65; Duchesne JC, 2010, J TRAUMA, V69, P46, DOI 10.1097/TA.0b013e3181df91fa; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Frith D, 2012, CURR OPIN CRIT CARE, V18, P631, DOI 10.1097/MCC.0b013e3283599ab9; Gando S, 2011, ANN SURG, V254, P10, DOI 10.1097/SLA.0b013e31821221b1; Gando S, 2010, CRIT CARE MED, V38, pS35, DOI 10.1097/CCM.0b013e3181c9e31d; Gruen RL, 2006, ANN SURG, V244, P371, DOI 10.1097/01.sla.0000234655.83517.56; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Ho AMH, 2012, BRIT J SURG, V99, P132, DOI 10.1002/bjs.7732; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Holcomb JB, 2011, ANN SURG, V254, P201, DOI 10.1097/SLA.0b013e318226483d; Jeger V, 2009, J TRAUMA, V66, P1253, DOI 10.1097/TA.0b013e31819d3caf; Johansson PI, 2008, EUR J VASC ENDOVASC, V36, P397, DOI 10.1016/j.ejvs.2008.04.015; Johansson PI, 2010, MED HYPOTHESES, V75, P564, DOI 10.1016/j.mehy.2010.07.031; Johansson PI, 2009, VOX SANG, V96, P111, DOI 10.1111/j.1423-0410.2008.01130.x; Johansson PI, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-45; Johansson PI, 2008, TRANSFUSION, V48, P2377, DOI 10.1111/j.1537-2995.2008.01846.x; Johansson PI, 2007, TRANSFUSION, V47, p176S, DOI 10.1111/j.1537-2995.2007.01381.x; Johansson PI, 2007, TRANSFUSION, V47, P593, DOI 10.1111/j.1537-2995.2007.01160.x; Johansson Par I, 2012, J Emerg Trauma Shock, V5, P120, DOI 10.4103/0974-2700.96479; Johansson PI, 2011, CRIT CARE, V15, DOI 10.1186/cc10553; Johansson PI, 2012, CURR OPIN ANESTHESIO, V25, P235, DOI 10.1097/ACO.0b013e32834fab76; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2010, TRANSFUS APHER SCI, V43, P401, DOI 10.1016/j.transci.2010.09.002; Kashuk JL, 2012, TRANSFUSION, V52, P23, DOI 10.1111/j.1537-2995.2011.03264.x; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Nystrup KB, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-52; Plotkin AJ, 2008, J TRAUMA, V64, pS64, DOI 10.1097/TA.0b013e318160772d; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Schols SEM, 2008, THROMB HAEMOSTASIS, V99, P64, DOI 10.1160/TH07-07-0438; Shiraki R, 2004, THROMB RES, V113, P379, DOI 10.1016/j.thromres.2004.03.023; Snyder CW, 2009, J TRAUMA, V66, P358, DOI 10.1097/TA.0b013e318196c3ac; Tapia NM, 2013, J TRAUMA ACUTE CARE, V74, P378, DOI 10.1097/TA.0b013e31827e20e0; Tien HC, 2007, J TRAUMA, V62, P142, DOI 10.1097/01.ta.0000251558.38388.47; World Health Organization, 2011, WORLD HLTH STAT CAUS; World Health Organization (WHO), 2008, GLOB BURD DIS 2004 U	48	72	77	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	DEC	2013	53	12					3088	3099		10.1111/trf.12214			12	Hematology	Hematology	265CD	WOS:000327926400010	23614333				2021-06-18	
J	Tate, CM; Wang, KKW; Eonta, S; Zhang, Y; Carr, W; Tortella, FC; Hayes, RL; Kamimori, GH				Tate, Charmaine M.; Wang, Kevin K. W.; Eonta, Stephanie; Zhang, Yang; Carr, Walter; Tortella, Frank C.; Hayes, Ronald L.; Kamimori, Gary H.			Serum Brain Biomarker Level, Neurocognitive Performance, and Self-Reported Symptom Changes in Soldiers Repeatedly Exposed to Low-Level Blast: A Breacher Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; biomarker; military injury; neurocognitive; symptoms	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; SPECTRIN BREAKDOWN PRODUCTS; INTRACRANIAL LESIONS; INJURY; MILD; S100B; OVERPRESSURE; GFAP	Breachers are a unique military and law enforcement population because they are routinely exposed to low-level blast (LLB) during training and operations. This repeated exposure has been associated with symptoms similar to that of sports concussion. This study examined effects of repeated exposure to LLB during an explosive entry course. Twenty-one members of the New Zealand Defence Force volunteered for this study. Serum samples, neurocognitive performance, and self-reported symptoms were periodically measured before, during, and after a 2-week course. Serum concentrations of three biomarkers, ubiquitin C-terminal hydrolase-L1, II-spectrin breakdown product, and glial fibrillary acidic protein, were determined with sandwich enzyme-linked immunosorbent assays, and rank scores were derived using the area under the curve (relative to baseline) for each subject. Neurocognitive performance was measured with a computer-based test battery, and symptoms were assessed by paper-based inventory. There was a significant relationship (p<0.05) between composite biomarker and neurocognitive performance and between neurocognitive performance and symptoms. The individuals with the five highest (Top 5) and lowest (Bottom 5) composite biomarker scores were identified and compared using Wilcoxon's rank-sum test. The Top 5 had significantly longer reaction times and lower percent correct on neurocognitive performance and an increase in symptom reporting. The difference between individuals expressing the highest biomarker load during breacher training (Top 5) and those with the lowest biomarker load (Bottom 5) is reflected in neurocognitive performance deficits and self-reported symptoms. This suggests a measureable degree of brain perturbation linked to LLB exposure. Follow-up studies are underway to expand upon these results.	[Tate, Charmaine M.] New Zealand Def Force, Auckland, New Zealand; [Wang, Kevin K. W.; Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA; [Eonta, Stephanie; Carr, Walter] Naval Med Res Ctr, Silver Spring, MD USA; [Zhang, Yang; Kamimori, Gary H.] Walter Reed Army Inst Res, Dept Behav Biol, Silver Spring, MD USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Brain Trauma Neuroprotect Neurorestorat Branch, Silver Spring, MD USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarker Res, Gainesville, FL 32610 USA	Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarker Res, 100 South Newell Dr POB 100256, Gainesville, FL 32610 USA.	kwang@ufl.edu		Wang, Kevin/0000-0002-9343-6473	NZDF; Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-09-2-0055 of]; RAD III of the U.S. Army Medical Research and Materiel Command	This work was funded by the NZDF, a grant from the Congressionally Directed Medical Research Program (award no.: W81XWH-09-2-0055 of), and RAD III of the U.S. Army Medical Research and Materiel Command. The authors thank Christina R. LaValle for her statistical support, the contributing New Zealand military unit medical staff, and the staff of the Walter Reed Army Institute of Research and Naval Medical Research Center for their assistance in the completion of this study and the preparation of the manuscript for this article. The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the NZDF, the U.S. Army, the U.S. Navy, or of the U.S. DoD.	American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; Arnaoutakis GJ, 2011, J THORAC CARDIOV SUR, V142, P902, DOI 10.1016/j.jtcvs.2011.06.027; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Britt TW, 2000, J APPL SOC PSYCHOL, V30, P1599, DOI 10.1111/j.1559-1816.2000.tb02457.x; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; FEINSTEIN DL, 1992, J NEUROSCI RES, V32, P1, DOI 10.1002/jnr.490320102; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs JE, 1996, AM J ROENTGENOL, V166, P579, DOI 10.2214/ajr.166.3.8623631; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS3, DOI 10.1016/j.acn.2006.10.001; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MOKUNO K, 1989, J NEUROSCI RES, V23, P396, DOI 10.1002/jnr.490230405; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Shiang K-D., 2004, SAS CONFERENCE PROCE; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanielian T., 2008, INVISIBLE WOUNDS OF; The Breacher Injury Consortium, 2011, ADVANCED TECH NOLOGY; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Welch W. M., 2005, US TODAY; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x	43	72	74	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2013	30	19					1620	1630		10.1089/neu.2012.2683			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	227WQ	WOS:000325146800002	23687938				2021-06-18	
J	Ichai, C; Payen, JF; Orban, JC; Quintard, H; Roth, H; Legrand, R; Francony, G; Leverve, XM				Ichai, Carole; Payen, Jean-Francois; Orban, Jean-Christophe; Quintard, Herve; Roth, Hubert; Legrand, Robin; Francony, Gilles; Leverve, Xavier M.			Half-molar sodium lactate infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a randomized controlled trial	INTENSIVE CARE MEDICINE			English	Article						Intracranial pressure; Intracranial hypertension; Lactate solution; Osmotherapy; Traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; HYPERTONIC SALINE; COGNITIVE DEFICITS; METABOLISM; RAT; COTRANSPORTERS; MICRODIALYSIS; HYPOGLYCEMIA; PRESSURE	Preventive treatments of traumatic intracranial hypertension are not yet established. We aimed to compare the efficiency of half-molar sodium lactate (SL) versus saline serum solutions in preventing episodes of raised intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI). This was a double-blind, randomized controlled trial including 60 patients with severe TBI requiring ICP monitoring. Patients were randomly allocated to receive a 48-h continuous infusion at 0.5 ml/kg/h of either SL (SL group) or isotonic saline solution (control group) within the first 12 h post-trauma. Serial measurements of ICP, as well as fluid, sodium, and chloride balance were performed over the 48-h study period. The primary outcome was the number of raised ICP (a parts per thousand yen20 mmHg) requiring a specific treatment. Raised ICP episodes were reduced in the SL group as compared to the control group within the 48-h study period: 23 versus 53 episodes, respectively (p < 0.05). The proportion of patients presenting raised ICP episodes was smaller in the SL group than in the saline group: 11 (36 %) versus 20 patients (66 %) (p < 0.05). Cumulative 48-h fluid and chloride balances were reduced in the SL group compared to the control group (both p < 0.01). A 48-h infusion of SL decreased the occurrence of raised ICP episodes in patients with severe TBI, while reducing fluid and chloride balances. These findings suggest that SL solution could be considered as an alternative treatment to prevent raised ICP following severe TBI.	[Ichai, Carole; Orban, Jean-Christophe; Quintard, Herve] Univ Nice Sophia Antipolis, St Roch Hosp, Medicosurg Intens Care Unit, F-06000 Nice, France; [Payen, Jean-Francois; Legrand, Robin; Francony, Gilles] Albert Michallon Hosp, Dept Anesthesiol & Intens Care, F-38043 Grenoble, France; [Payen, Jean-Francois; Francony, Gilles] Univ Grenoble 1, Grenoble Inst Neurosci, INSERM, U836, F-38042 Grenoble, France; [Roth, Hubert; Leverve, Xavier M.] Univ Grenoble 1, Albert Michallon Hosp, INSERM, U1055,Lab Biol Fondamentale & Appl, F-38042 Grenoble, France	Ichai, C (corresponding author), Univ Nice Sophia Antipolis, St Roch Hosp, Medicosurg Intens Care Unit, F-06000 Nice, France.	ichai@unice.fr	Payen, Jean-Francois/L-6667-2014	ROTH, Hubert/0000-0002-1980-3220			Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jourdain P, 2011, J NEUROSCI, V31, P11846, DOI 10.1523/JNEUROSCI.0286-11.2011; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; King P, 1998, CLIN SCI, V94, P157, DOI 10.1042/cs0940157; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Leverve XM, 2008, INTENS CARE MED, V34, P1796, DOI 10.1007/s00134-008-1165-x; MARAN A, 1994, LANCET, V343, P16, DOI 10.1016/S0140-6736(94)90876-1; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Mustafa I, 2002, SHOCK, V18, P306, DOI 10.1097/00024382-200210000-00003; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; PANNIER JL, 1974, STROKE, V5, P324, DOI 10.1161/01.STR.5.3.324; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; STEWART PA, 1978, RESP PHYSIOL, V33, P9, DOI 10.1016/0034-5687(78)90079-8; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Yoon S, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00365	40	72	73	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	AUG	2013	39	8					1413	1422		10.1007/s00134-013-2978-9			10	Critical Care Medicine	General & Internal Medicine	182UC	WOS:000321769100009	23749153				2021-06-18	
J	Liao, YL; Liu, P; Guo, FY; Zhang, ZY; Zhang, ZR				Liao, Yiliu; Liu, Peng; Guo, Fangyuan; Zhang, Zhi-Yuan; Zhang, Zhiren			Oxidative Burst of Circulating Neutrophils Following Traumatic Brain Injury in Human	PLOS ONE			English	Article							SYSTEMIC INFLAMMATORY RESPONSE; SPINAL-CORD-INJURY; SEVERE HEAD-INJURY; MULTIPLE ORGAN FAILURE; C-REACTIVE PROTEIN; LEUKOCYTE MOBILIZATION; ANTIOXIDANT THERAPIES; BLOOD NEUTROPHILS; BLUNT TRAUMA; RATS	Besides secondary injury at the lesional site, Traumatic brain injury (TBI) can cause a systemic inflammatory response, which may cause damage to initially unaffected organs and potentially further exacerbate the original injury. Here we investigated plasma levels of important inflammatory mediators, oxidative activity of circulating leukocytes, particularly focusing on neutrophils, from TBI subjects and control subjects with general trauma from 6 hours to 2 weeks following injury, comparing with values from uninjured subjects. We observed increased plasma level of inflammatory cytokines/molecules TNF-alpha, IL-6 and CRP, dramatically increased circulating leukocyte counts and elevated expression of TNF-alpha and iNOS in circulating leukocytes from TBI patients, which suggests a systemic inflammatory response following TBI. Our data further showed increased free radical production in leukocyte homogenates and elevated expression of key oxidative enzymes iNOS, COX-2 and NADPH oxidase (gp91(phox)) in circulating leukocytes, indicating an intense induction of oxidative burst following TBI, which is significantly greater than that in control subjects with general trauma. Furthermore, flow cytometry assay proved neutrophils as the largest population in circulation after TBI and showed significantly up-regulated oxidative activity and suppressed phagocytosis rate for circulating neutrophils following brain trauma. It suggests that the highly activated neutrophils might play an important role in the secondary damage, even outside the injured brain. Taken together, the potent systemic inflammatory response induced by TBI, especially the intensively increase oxidative activity of circulating leukocytes, mainly neutrophils, may lead to a systemic damage, dysfunction/damage of bystander tissues/organs and even further exacerbate secondary local damage. Controlling these pathophysiological processes may be a promising therapeutic strategy and will protect unaffected organs and the injured brain from the secondary damage.	[Liao, Yiliu; Liu, Peng; Guo, Fangyuan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Traumat Surg, Wuhan 430074, Peoples R China; [Zhang, Zhi-Yuan] Univ Tubingen, Dept Neuropathol, Tubingen, Germany; [Zhang, Zhiren] Third Mil Med Univ PLA, Inst Immunol, Chongqing, Peoples R China	Zhang, ZY (corresponding author), Univ Tubingen, Dept Neuropathol, Tubingen, Germany.	zhiyuan.zhang@medizin.uni-tuebingen.de; zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835	Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC); CQ CSTCNatural Science Foundation Project of CQ CSTC [2010BB5025]; State Science and Technology Major Projects of New Drugs [2012ZX09103301-035]	The present study was partially supported by two project fundings as following: Natural Science Foundation of China (http://www.nsfc.gov.cn/e_nsfc/desktop/zn/0101.htm), Project of CQ CSTC (No. 2010BB5025); and State Science and Technology Major Projects of New Drugs (http://www.nmp.gov.cn/) (No. 2012ZX09103301-035). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Baskaran H, 2000, J SURG RES, V93, P88, DOI 10.1006/jsre.2000.5955; Basu S, 2009, FREE RADICAL RES, V43, P85, DOI 10.1080/10715760802610851; Bhatia R, 2006, J TRAUMA, V60, P590, DOI 10.1097/01.ta.0000205614.51885.ff; Bhatia RK, 2005, INJURY, V36, P956, DOI 10.1016/j.injury.2005.03.009; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BOTHA AJ, 1995, J TRAUMA, V39, P411; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Castelli GP, 2004, CRIT CARE, V8, pR234, DOI 10.1186/cc2877; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cocks RA, 1998, J TRAUMA, V45, P1, DOI 10.1097/00005373-199807000-00001; D'Aiuto F, 2010, J DENT RES, V89, P1241, DOI 10.1177/0022034510375830; Furlan JC, 2006, SPINE, V31, P2674, DOI 10.1097/01.brs.0000244569.91204.01; Gaforio JJ, 2002, CYTOMETRY, V48, P93, DOI 10.1002/cyto.10107; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Kanyilmaz S, 2013, ARCH PHYS MED REHAB, V94, P369, DOI 10.1016/j.apmr.2012.09.015; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; LaPar DJ, 2012, J AM COLL SURGEONS, V214, P478, DOI 10.1016/j.jamcollsurg.2011.12.015; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mimoz O, 1998, INTENS CARE MED, V24, P185, DOI 10.1007/s001340050543; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Motoyama T, 2003, CRIT CARE MED, V31, P1048, DOI 10.1097/01.CCM.0000055371.27268.36; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Nowotarski PJ, 2000, J BONE JOINT SURG AM, V82A, P781, DOI 10.2106/00004623-200006000-00004; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; Peluso I, 2013, J IMMUNOL METHODS, V390, P113, DOI 10.1016/j.jim.2013.02.005; Peluso I, 2012, J IMMUNOL METHODS, V379, P61, DOI 10.1016/j.jim.2012.02.015; Pillay J, 2007, INJURY, V38, P1365, DOI 10.1016/j.injury.2007.09.016; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Sunil VR, 2002, RESP RES, V3, DOI 10.1186/rr171; TEASDALE G, 1974, LANCET, V2, P81; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Xie LK, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-53	49	72	74	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2013	8	7							e68963	10.1371/journal.pone.0068963			12	Multidisciplinary Sciences	Science & Technology - Other Topics	188BY	WOS:000322167900033	23894384	DOAJ Gold, Green Published			2021-06-18	
J	Harvey, HH				Harvey, Hosea H.			Reducing Traumatic Brain Injuries in Youth Sports: Youth Sports Traumatic Brain Injury State Laws, January 2009-December 2012	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							HIGH-SCHOOL; FOOTBALL PLAYERS; UNITED-STATES; CONCUSSION; IMPACT	Objectives. I sought to describe current state-wide youth sports traumatic brain injury (TBI) laws and their relationship to prevailing scientific understandings of youth sports TBIs, and to facilitate further research by creating an open-source data set of current laws. Methods. I used Westlaw and LexisNexis databases to create a 50-state data set of youth sports TBI laws enacted between January 2009 and December 2012. I collected and coded the text and citations of each law and developed a protocol and codebook to facilitate future research. Results. Forty-four states and Washington, DC, passed youth sports TBI laws between 2009 and 2012. No state's youth sports TBI law focuses on primary prevention. Instead, such laws focus on (1) increasing coaches' and parents' ability to identify and respond to TBIs and (2) reducing the immediate risk of multiple TBIs. Conclusions. Existing youth sports TBI laws were not designed to reduce initial TBIs. Evaluation is required to assess their effectiveness in reducing the risk and consequences of multiple TBIs. Continued research and evaluation of existing laws will be needed to develop a more comprehensive youth TBI-reduction solution.	Temple Univ, Beasley Sch Law, Philadelphia, PA 19122 USA	Harvey, HH (corresponding author), Temple Univ, Beasley Sch Law, 1719 N Broad St, Philadelphia, PA 19122 USA.				Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Center for Health Law, Policy, and Practice at Temple University	The author thanks the Robert Wood Johnson Foundation and the Center for Health Law, Policy, and Practice at Temple University for research support.	[Anonymous], ATTENTION COLLEGE SP; [Anonymous], HIGH SCHOOLS WITH AT; [Anonymous], 2011, NATIONAL FOOTBALL LE; [Anonymous], RCW 28A 600; [Anonymous], GUIDELINES FOR THE M; Bey T, 2009, WEST J EMERG MED, V10, P6; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Centers for Disease Control and Prevention, 2000, TRAUMATIC BRAIN INJU; Danov R., 2006, PEDIATRIC TRAUMATIC; Farrey T., POP WARNER TO LIMIT; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Ibrahim JK, 2011, AM J PREV MED, V40, P659, DOI 10.1016/j.amepre.2011.02.024; Jackson S., JACKSON S PRESIDENT; Jewell CJ, 2008, MILBANK Q, V86, P177, DOI 10.1111/j.1468-0009.2008.00519.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LawAtlas, THE POLICY SURVEILLA; Lazarus Arthur, 2011, Physician Exec, V37, P6; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; National Center for Injury Prevention and Control, 2003, REPORT TO CONGRESS O; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Schwarz A., 2010, NEW YORK TIMES; Sniezek JE, 1995, GUIDELINES FOR SURVE; Tator CH, 2008, CATASTROPHIC INJURIE; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	29	72	77	2	17	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	JUL	2013	103	7					1249	1254		10.2105/AJPH.2012.301107			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AA3FP	WOS:000330978600030	23678903	Green Published			2021-06-18	
J	Mathersul, D; McDonald, S; Rushby, JA				Mathersul, Danielle; McDonald, Skye; Rushby, Jacqueline A.			Understanding advanced theory of mind and empathy in high-functioning adults with autism spectrum disorder	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Autism; Asperger's; Theory of mind; Sarcasm; Empathy; Ecological validity	TRAUMATIC BRAIN-INJURY; NORMALLY DEVELOPING-CHILDREN; STRANGE STORIES TEST; CEREBRAL-BLOOD-FLOW; ASPERGER-SYNDROME; SOCIAL COGNITION; INDIVIDUAL-DIFFERENCES; EMOTION RECOGNITION; MAGNETIC-RESONANCE; REVISED VERSION	It has been argued that higher functioning individuals with autism spectrum disorders (ASDs) have specific deficits in advanced but not simple theory of mind (ToM), yet the questionable ecological validity of some tasks reduces the strength of this assumption. The present study employed The Awareness of Social Inference Test (TASIT), which uses video vignettes to assess comprehension of subtle conversational inferences (sarcasm, lies/deception). Given the proposed relationships between advanced ToM and cognitive and affective empathy, these associations were also investigated. As expected, the high-functioning adults with ASDs demonstrated specific deficits in comprehending the beliefs, intentions, and meaning of nonliteral expressions. They also had significantly lower cognitive and affective empathy. Cognitive empathy was related to ToM and group membership whereas affective empathy was only related to group membership.	[Mathersul, Danielle; McDonald, Skye; Rushby, Jacqueline A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Mathersul, D (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	d.mathersul@unsw.edu.au	Rushby, Jacqueline/D-1820-2010; McDonald, Skye/G-4118-2014	Rushby, Jacqueline/0000-0002-5018-638X; McDonald, Skye/0000-0003-0723-6094; Mathersul, Danielle/0000-0003-2372-8654	Australian Postgraduate Award (APA)Australian Government; Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [APP1013796]; Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia	D. M. is supported by an Australian Postgraduate Award (APA). J.A.R. is supported by an Australian National Health and Medical Research Council (NHMRC) Postdoctoral Fellowship (Clinical Training; APP1013796). This research was funded by the Australian National Health and Medical Research Council (NHMRC). We would like to thank the individuals who gave their time to participate in this study and the clinicians who assisted with participant recruitment.	Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Ashwin C, 2007, NEUROPSYCHOLOGIA, V45, P2, DOI 10.1016/j.neuropsychologia.2006.04.014; Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; BARONCOHEN S, 1988, J AUTISM DEV DISORD, V18, P379, DOI 10.1007/BF02212194; BARONCOHEN S, 1992, J CHILD PSYCHOL PSYC, V33, P1141, DOI 10.1111/j.1469-7610.1992.tb00934.x; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BARONCOHEN S, 1989, J CHILD PSYCHOL PSYC, V30, P285, DOI 10.1111/j.1469-7610.1989.tb00241.x; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; BARONCOHEN S, 1991, BRIT J DEV PSYCHOL, V9, P301, DOI 10.1111/j.2044-835X.1991.tb00879.x; Bishop SL, 1999, AUTISM DIAGNOSTIC OB; Blair RJR, 2008, Q J EXP PSYCHOL, V61, P157, DOI 10.1080/17470210701508855; Brent E, 2004, AUTISM, V8, P283, DOI 10.1177/1362361304045217; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; Carlson SM, 1998, CHILD DEV, V69, P672, DOI 10.2307/1132197; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; Castelli F, 2002, BRAIN, V125, P1839, DOI 10.1093/brain/awf189; Chung YS, 2011, SCHIZOPHRENIA BULL, V37, P1048, DOI 10.1093/schbul/sbq012; Couture SM, 2010, PSYCHOL MED, V40, P569, DOI 10.1017/S003329170999078X; Craig JS, 2004, SCHIZOPHR RES, V69, P29, DOI 10.1016/S0920-9964(03)00154-3; Critchley HD, 2000, BRAIN, V123, P2203, DOI 10.1093/brain/123.11.2203; Davis M.H, 1980, J PERS SOC PSYCHOL, V10, P85; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; Decety J, 2010, DEV NEUROSCI-BASEL, V32, P257, DOI 10.1159/000317771; Di Martino A, 2009, BIOL PSYCHIAT, V65, P63, DOI 10.1016/j.biopsych.2008.09.022; Dichter GS, 2007, NEUROIMAGE, V35, P1219, DOI 10.1016/j.neuroimage.2006.12.038; Dziobek I, 2008, J AUTISM DEV DISORD, V38, P464, DOI 10.1007/s10803-007-0486-x; Frith U, 1989, AUTISM EXPLAINING EN; Hall GBC, 2003, AM J PSYCHIAT, V160, P1439, DOI 10.1176/appi.ajp.160.8.1439; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Heberlein AS, 2004, J COGNITIVE NEUROSCI, V16, P1143, DOI 10.1162/0898929041920423; Hubert B, 2007, J AUTISM DEV DISORD, V37, P1386, DOI 10.1007/s10803-006-0275-y; Jarrold C, 2000, DEV PSYCHOL, V36, P126, DOI 10.1037/0012-1649.36.1.126; Johnston L., 2007, AUSTR J PSYCHOL, V1, P1, DOI 10.1080/00049530701449521; Jolliffe T, 1999, J AUTISM DEV DISORD, V29, P395, DOI 10.1023/A:1023082928366; Kaland N, 2005, EUR CHILD ADOLES PSY, V14, P73, DOI 10.1007/s00787-005-0434-2; Kern RS, 2009, PSYCHOL MED, V39, P645, DOI 10.1017/S0033291708003966; Kipps CM, 2009, BRAIN, V132, P592, DOI 10.1093/brain/awn314; Kohls G, 2009, DEVELOPMENTAL SCI, V12, P614, DOI 10.1111/j.1467-7687.2009.00816.x; Langleben DD, 2002, NEUROIMAGE, V15, P727, DOI 10.1006/nimg.2001.1003; Lawrence EJ, 2004, PSYCHOL MED, V34, P911, DOI 10.1017/S0033291703001624; Li AS, 2011, J AUTISM DEV DISORD, V41, P185, DOI 10.1007/s10803-010-1045-4; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Loveland KA, 2008, PERCEPT MOTOR SKILL, V107, P557, DOI 10.2466/PMS.107.2.557-575; Mathersul D, 2013, INT J PSYCHOPHYSIOL, V87, P88, DOI 10.1016/j.ijpsycho.2012.11.005; Mathersul D, 2013, PHYSIOL BEHAV, V109, P14, DOI 10.1016/j.physbeh.2012.10.008; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; McDonald S., 2002, AWARENESS SOCIAL INF; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Muncer SJ, 2006, PERS INDIV DIFFER, V40, P1111, DOI 10.1016/j.paid.2005.09.020; Ohnishi T, 2000, BRAIN, V123, P1838, DOI 10.1093/brain/123.9.1838; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Perner J, 2002, CHILD DEV, V73, P752, DOI 10.1111/1467-8624.00436; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Philip RCM, 2012, NEUROSCI BIOBEHAV R, V36, P901, DOI 10.1016/j.neubiorev.2011.10.008; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Pierce K, 2001, BRAIN, V124, P2059, DOI 10.1093/brain/124.10.2059; Pilowsky T, 2000, SCHIZOPHR RES, V42, P145, DOI 10.1016/S0920-9964(99)00101-2; Rankin KP, 2009, NEUROIMAGE, V47, P2005, DOI 10.1016/j.neuroimage.2009.05.077; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Reinecke DR, 1997, J AUTISM DEV DISORD, V27, P127, DOI 10.1023/A:1025835706522; Ritvo RA, 2008, J AUTISM DEV DISORD, V38, P213, DOI 10.1007/s10803-007-0380-6; Ritvo RA, 2011, J AUTISM DEV DISORD, V41, P1076, DOI 10.1007/s10803-010-1133-5; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Rogers K, 2007, J AUTISM DEV DISORD, V37, P709, DOI 10.1007/s10803-006-0197-8; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2002, NEUROCASE, V8, P245; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Silani G, 2008, SOC NEUROSCI-UK, V3, P97, DOI 10.1080/17470910701577020; Sparks A, 2010, SCHIZOPHR RES, V122, P172, DOI 10.1016/j.schres.2010.06.011; Spek AA, 2010, J AUTISM DEV DISORD, V40, P280, DOI 10.1007/s10803-009-0860-y; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Spence SA, 2001, NEUROREPORT, V12, P2849, DOI 10.1097/00001756-200109170-00019; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Talwar V, 2008, CHILD DEV, V79, P866, DOI 10.1111/j.1467-8624.2008.01164.x; Uchiyama H, 2006, BRAIN RES, V1124, P100, DOI 10.1016/j.brainres.2006.09.088; Wang AT, 2007, ARCH GEN PSYCHIAT, V64, P698, DOI 10.1001/archpsyc.64.6.698; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Yirmiya N, 1998, PSYCHOL BULL, V124, P283, DOI 10.1037/0033-2909.124.3.283	93	72	73	3	97	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL 1	2013	35	6					655	668		10.1080/13803395.2013.809700			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	238BH	WOS:000325914900009	23799244				2021-06-18	
J	Goyal, A; Failla, MD; Niyonkuru, C; Amin, K; Fabio, A; Berger, RP; Wagner, AK				Goyal, Akash; Failla, Michelle D.; Niyonkuru, Christian; Amin, Krutika; Fabio, Anthony; Berger, Rachel P.; Wagner, Amy K.			S100b as a Prognostic Biomarker in Outcome Prediction for Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; S100b; outcome; serum; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; SERUM S-100B PROTEIN; BIOLOGICAL-FLUIDS; HEAD-INJURY; DAMAGE; BLOOD; MARKERS; MODELS; AGE	As an astrocytic protein specific to the central nervous system, S100b is a potentially useful marker in outcome prediction after traumatic brain injury (TBI). Some studies have questioned the validity of S100b, citing the extracerebral origins of the protein as reducing the specificity of the marker. This study evaluated S100b as a prognostic biomarker in adult subjects with severe TBI (sTBI) by comparing outcomes with S100b temporal profiles generated from both cerebrospinal fluid (CSF) (n = 138 subjects) and serum (n = 80 subjects) samples across a 6-day time course. Long-bone fracture, Injury Severity Score (ISS), and isolated head injury status were variables used to assess extracerebral sources of S100b in serum. After TBI, CSF and serum S100b levels were increased over healthy controls across the first 6 days post-TBI (p <= 0.005 and p <= 0.031). Though CSF and serum levels were highly correlated during early time points post-TBI, this association diminished over time. Bivariate analysis showed that subjects who had temporal CSF profiles with higher S100b concentrations had higher acute mortality (p < 0.001) and worse Glasgow Outcome Scale (GOS; p = 0.002) and Disability Rating Scale (DRS) scores (p = 0.039) 6 months post-injury. Possibly as a result of extracerebral sources of S100b in serum, as represented by high ISS scores (p = 0.032), temporal serum profiles were associated with acute mortality (p = 0.015). High CSF S100b levels were observed in women (p = 0.022) and older subjects (p = 0.004). Multivariate logistic regression confirmed CSF S100b profiles in predicting GOS and DRS and showed mean and peak serum S100b as acute mortality predictors after sTBI.	[Goyal, Akash; Failla, Michelle D.; Niyonkuru, Christian; Amin, Krutika; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Berger, Rachel P.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Fabio, Anthony] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA; [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Fabio, Anthony/0000-0002-6808-4939	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR323155]; Department of DefenseUnited States Department of Defense [W81XWH-07-1-0701]	This work was supported by the Centers for Disease Control (grant no.: R49/CCR323155) and the Department of Defense (grant no.: W81XWH-07-1-0701). The authors acknowledge the University of Pittsburgh Medical Center UPMC Trauma Registry team and the Brain Trauma Research Center for their role in data collection.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Crownover J, 2012, CURR TRANSL IN PRESS; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2001, CLIN CHEM, V47, P1132; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; JENNETT B, 1975, LANCET, V1, P480; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P247, DOI 10.1007/978-3-211-98811-4_46; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Michetti F, 2002, CLIN CHEM, V48, P2097; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Missler U, 1999, CLIN CHEM, V45, P138; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Niyankuru C., 2013, J NEUROTRAU IN PRESS; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	64	72	75	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					946	957		10.1089/neu.2012.2579			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300005	23190274	Green Published			2021-06-18	
J	Xu, JS; Li, Y; Lin, HQ; Sinha, R; Potenza, MN				Xu, Jiansong; Li, Yang; Lin, Haiqun; Sinha, Rajita; Potenza, Marc N.			Body mass index correlates negatively with white matter integrity in the fornix and corpus callosum: A diffusion tensor imaging study	HUMAN BRAIN MAPPING			English	Article						DTI; obese; overweight; neuroimaging; BMI; brain structure	TRAUMATIC BRAIN-INJURY; MIDDLE-AGED ADULTS; MAGNETIC-RESONANCE; WALLERIAN DEGENERATION; COGNITIVE IMPAIRMENT; MEASURED HEIGHT; HUMAN OBESITY; VISCERAL FAT; VOLUME; WEIGHT	Overweight or obese body habitus is associated with cognitive deficits, impaired brain function, gray matter atrophy, and white matter (WM) hyperintensities. However, few diffusion tensor imaging (DTI) studies have assessed WM integrity in relation to overweight or obese status. This study assessed relationships between body mass index (BMI) and values of DTI parameters among 51 normal weight (lean), overweight, and obese participants who were otherwise healthy. BMI correlated negatively with fractional anisotropy and axial eigenvalues (1) in the body of corpus callosum (CC), positively with mean diffusivity and radial eigenvalues () in the fornix and splenium of CC, and positively with 1 in the right corona radiata (CR) and superior longitudinal fasciculus (SLF). These data indicate that BMI correlates negatively with WM integrity in the fornix and CC. Furthermore, the different patterns of BMI-related differences in DTI parameters at the fornix, body, and splenium of the CC, and the right CR and SLF suggest that different biological processes may underlie BMI-related impairments of WM integrity in different brain regions. Hum Brain Mapp, 2013. (c) 2011 Wiley Periodicals, Inc.	[Xu, Jiansong; Sinha, Rajita; Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Li, Yang; Lin, Haiqun] Yale Univ, Sch Publ Hlth, Div Biostat, New Haven, CT USA; [Potenza, Marc N.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA; [Potenza, Marc N.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA	Xu, JS (corresponding author), 2 Church St,Suite 215, New Haven, CT USA.	Jiansong.xu@yale.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Veteran's AdministrationUS Department of Veterans Affairs; Mohegan Sun Casino; National Center for Responsible Gaming, and its affiliated Institute for Research on Gambling Disorders; Forest Laboratories; Psyadon pharmaceuticals; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01 DA027750R01 DA020908R01 DA019039RL1 AA017539P50 DA09241P20 DA027844]; VA VISN1 MIRECC; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [RL1AA017539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA019039, P20DA027844, R01DA020908, P50DA009241, K01DA027750, R03DA022364] Funding Source: NIH RePORTER	Dr. Potenza has consulted for and advised Boehringer Ingelheim; He has financial interests in Somaxon; He has received research support from the National Institutes of Health, Veteran's Administration, Mohegan Sun Casino, the National Center for Responsible Gaming, and its affiliated Institute for Research on Gambling Disorders, and Forest Laboratories and Psyadon pharmaceuticals; He has participated in surveys, mailings, or telephone consultations related to drug addiction, impulse control disorders or other health topics; He has consulted for law offices on issues related to addictions or impulse control disorders; He has provided clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; He has performed grant reviews for the National Institutes of Health and other agencies; He has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts.; Contract grant sponsor: NIDA; Contract grant number: K01 DA027750R01 DA020908R01 DA019039RL1 AA017539P50 DA09241P20 DA027844; Contract grant sponsor: VA VISN1 MIRECC.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anan F, 2009, EUR J CLIN INVEST, V39, P368, DOI 10.1111/j.1365-2362.2009.02103.x; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Bruce-Keller AJ, 2009, BBA-MOL BASIS DIS, V1792, P395, DOI 10.1016/j.bbadis.2008.10.004; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; Cazettes F, 2011, BRAIN RES, V1373, P101, DOI 10.1016/j.brainres.2010.12.008; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Cournot M, 2006, NEUROLOGY, V67, P1208, DOI 10.1212/01.wnl.0000238082.13860.50; Debette S, 2010, ANN NEUROL, V68, P136, DOI 10.1002/ana.22062; Di Paola M, 2010, J ALZHEIMERS DIS, V20, P67, DOI 10.3233/JAD-2010-1370; Fergenbaum JH, 2009, OBESITY, V17, P1957, DOI 10.1038/oby.2009.161; First M.B., 1996, STRUCTURED CLIN INTE; First MB., 1997, STRUCTURED CLIN INTE; Fitzpatrick AL, 2009, ARCH NEUROL-CHICAGO, V66, P336, DOI 10.1001/archneurol.2008.582; Fujiwara S, 2008, NEURORADIOLOGY, V50, P131, DOI 10.1007/s00234-007-0317-y; Gazdzinski S, 2008, ANN NEUROL, V63, P652, DOI 10.1002/ana.21377; Gazdzinski S, 2010, ALCOHOL CLIN EXP RES, V34, P2089, DOI 10.1111/j.1530-0277.2010.01305.x; Gorber SC, 2007, OBES REV, V8, P307, DOI 10.1111/j.1467-789X.2007.00347.x; Griebeler ML, 2011, J WOMENS HEALTH, V20, P599, DOI 10.1089/jwh.2009.1850; Gunstad J, 2008, INT J NEUROSCI, V118, P1582, DOI 10.1080/00207450701392282; Gunstad J, 2010, NEUROEPIDEMIOLOGY, V34, P222, DOI 10.1159/000297742; Gustafson D, 2004, NEUROLOGY, V63, P1876, DOI 10.1212/01.WNL.0000141850.47773.5F; Gustafson DR, 2004, INT PSYCHOGERIATR, V16, P327, DOI 10.1017/s1041610204000353; Haltia LT, 2007, J CLIN ENDOCR METAB, V92, P3278, DOI 10.1210/jc.2006-2495; Hill A, 1998, J PUBLIC HEALTH MED, V20, P206, DOI 10.1093/oxfordjournals.pubmed.a024744; Ho AJ, 2010, NEUROBIOL AGING, V31, P1326, DOI 10.1016/j.neurobiolaging.2010.04.006; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Jagust W, 2005, ARCH NEUROL-CHICAGO, V62, P1545, DOI 10.1001/archneur.62.10.1545; Jbabdi S, 2010, NEUROIMAGE, V49, P247, DOI 10.1016/j.neuroimage.2009.08.039; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Marks B, BR J SPORTS IN PRESS; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Mori S, 2009, CURR OPIN NEUROL, V22, P362, DOI 10.1097/WCO.0b013e32832d954b; Mueller K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018544; Neil JJ, 2008, J MAGN RESON IMAGING, V27, P1, DOI 10.1002/jmri.21087; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Pannacciulli N, 2006, NEUROIMAGE, V31, P1419, DOI 10.1016/j.neuroimage.2006.01.047; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; SENA A, 1985, J NEUROL SCI, V68, P233, DOI 10.1016/0022-510X(85)90104-2; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, BRIT J RADIOL, V77, pS167, DOI 10.1259/bjr/33553595; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith S, 2007, NEUROIMAGE, V34, P127, DOI 10.1016/j.neuroimage.2006.09.019; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sriram K, 2002, NEUROSCIENCE, V115, P1335, DOI 10.1016/S0306-4522(02)00306-8; Stanek KM, 2011, OBESITY, V19, P500, DOI 10.1038/oby.2010.312; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Taki Y, 2008, OBESITY, V16, P119, DOI 10.1038/oby.2007.4; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Volkow ND, 2011, TRENDS COGN SCI, V15, P37, DOI 10.1016/j.tics.2010.11.001; Walther K, 2010, HUM BRAIN MAPP, V31, P1052, DOI 10.1002/hbm.20916; Ward MA, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-23; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zarei M, 2006, J ANAT, V209, P311, DOI 10.1111/j.1469-7580.2006.00615.x; Zhang Y, 2010, NEUROBIOL AGING, V31, P1991, DOI 10.1016/j.neurobiolaging.2008.10.009	61	72	73	0	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2013	34	5					1044	1052		10.1002/hbm.21491			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	122DT	WOS:000317297500005	22139809	Green Published, Green Accepted			2021-06-18	
J	Schuss, P; Vatter, H; Oszvald, A; Marquardt, G; Imohl, L; Seifert, V; Guresir, E				Schuss, Patrick; Vatter, Hartmut; Oszvald, Agi; Marquardt, Gerhard; Imoehl, Lioba; Seifert, Volker; Gueresir, Erdem			Bone Flap Resorption: Risk Factors for the Development of a Long-Term Complication following Cranioplasty after Decompressive Craniectomy	JOURNAL OF NEUROTRAUMA			English	Article						BFR; cranioplasty; complications; DC	MIDDLE CEREBRAL-ARTERY; SUBARACHNOID HEMORRHAGE; DURA-MATER; INFARCTION; CHILDREN; IMMATURE; GRAFTS; DESIGN; INJURY	Aseptic bone flap resorption (BFR) is a known long-term complication after cranioplasty (CP). We analyzed our institutional data in order to identify risk factors for BFR. From October 1999 to April 2012, 254 patients underwent CP after decompressive craniectomy (DC) at our institution, and had a long-term follow-up period of >1 year after CP (range 12146 months). Overall, BFR occurred in 10 of 254 patients as a long-term complication after CP (4%). BFR developed more often in patients aged <= 18 years (p = 0.008), in patients who previously underwent DC for traumatic brain injury (p = 0.04), and in patients with multiple fractures within the reinserted bone flap (p = 0.002). Furthermore, BFR developed significantly more often in patients who underwent cranioplasty <= 2 months after DC (p = 0.008), as well as in patients with wound healing disturbance or abscess as an early complication after the CP procedure (p = 0.01). The multivariate analysis of the present data identified the presence of multiple fractures within the bone flap (p = 0.002, OR 10.3, 95% CI 2.4-43.8), wound infection after CP (p = 0.003, OR 12.3, 95% CI 2.3-65.3), and cranioplasty performed <= 2 months after DC (p = 0.01, OR 6.3, 95% CI 1.5-26.3) as independent risk factors for the development of BFR after CP in a large series with long-term follow-up. This might influence future surgical decision making, especially in patients fulfilling high risk criteria for developing BFR.	[Schuss, Patrick; Vatter, Hartmut; Oszvald, Agi; Marquardt, Gerhard; Imoehl, Lioba; Seifert, Volker; Gueresir, Erdem] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany	Schuss, P (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	patrick.schuss@med.uni-frankfurt.de	guresir, erdem/AAL-4484-2020; Schuss, Patrick/ABC-6469-2020	guresir, erdem/0000-0002-6624-6885; Schuss, Patrick/0000-0002-5806-2576; Guresir, Erdem/0000-0001-8319-0847			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Elsalanty ME, 2009, CRANIOMAX TRAUM REC, V2, P125, DOI 10.1055/s-0029-1215875; Eppley BL, 2002, PLAST RECONSTR SURG, V109, P864, DOI 10.1097/00006534-200203000-00005; EPPLEY BL, 1990, PLAST RECONSTR SURG, V86, P1085, DOI 10.1097/00006534-199012000-00006; Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6; Frassanito P, 2012, ACTA NEUROCHIR, V154, P927, DOI 10.1007/s00701-011-1253-5; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Greenwald JA, 2000, PLAST RECONSTR SURG, V105, P1382, DOI 10.1097/00006534-200004040-00018; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2012, NEUROSURGERY, V70, P881, DOI 10.1227/NEU.0b013e318237a6a6; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Heino TJ, 2002, J CELL BIOCHEM, V85, P185, DOI 10.1002/jcb.10109; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Marion DW, 2006, NEUROSURGERY, V58, P655; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Roberson J B, 1997, J Craniomaxillofac Trauma, V3, P8; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; Stevenson S, 1997, J BONE JOINT SURG AM, V79A, P1; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Vaananen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4	28	72	73	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					91	95		10.1089/neu.2012.2542			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000004	22970998				2021-06-18	
J	Koerte, IK; Kaufmann, D; Hartl, E; Bouix, S; Pasternak, O; Kubicki, M; Rauscher, A; Li, DKB; Dadachanji, SB; Taunton, JA; Forwell, LA; Johnson, AM; Echlin, PS; Shenton, ME				Koerte, Inga K.; Kaufmann, David; Hartl, Elisabeth; Bouix, Sylvain; Pasternak, Ofer; Kubicki, Marek; Rauscher, Alexander; Li, David K. B.; Dadachanji, Shiroy B.; Taunton, Jack A.; Forwell, Lorie A.; Johnson, Andrew M.; Echlin, Paul S.; Shenton, Martha E.			A prospective study of physician-observed concussion during a varsity university hockey season: white matter integrity in ice hockey players. Part 3 of 4	NEUROSURGICAL FOCUS			English	Article						ice hockey; mild traumatic brain injury; axial diffusivity; diffusion tensor imaging; sports-related concussion; radial diffusivity; fractional anisotropy; Canada	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; RECURRENT CONCUSSION; SPORTS CONCUSSION; LONG-TERM; CORPUS-CALLOSUM; NCAA CONCUSSION; RUGBY UNION; HEAD-INJURY	Object. The aim of this study was to investigate the effect of repetitive head impacts on white matter integrity that were sustained during 1 Canadian Interuniversity Sports (CIS) ice hockey season, using advanced diffusion tensor imaging (DTI). Methods. Twenty-five male ice hockey players between 20 and 26 years of age (mean age 22.24 +/- 1.59 years) participated in this study. Participants underwent pre- and postseason 3-T MRI, including DTI. Group analyses were performed using paired-group tract-based spatial statistics to test for differences between preseason and postseason changes. Results. Tract-based spatial statistics revealed an increase in trace, radial diffusivity (RD), and axial diffusivity (AD) over the course of 1 season. Compared with preseason data, postseason images showed higher trace, AD, and RD values in the right precentral region, the right corona radiata, and the anterior and posterior limb of the internal capsule. These regions involve parts of the corticospinal tract, the corpus callosum, and the superior longitudinal fasciculus. No significant differences were observed between preseason and postseason for fractional anisotropy. Conclusions. Diffusion tensor imaging revealed changes in white matter diffusivity in male ice hockey players over the course of 1 season. The origin of these findings needs to be elucidated. (http://thejns.org/doi/abs/10.3171/2012.10.FOCUS12303)	[Echlin, Paul S.] Elliott Sports Med Clin, Burlington, ON L7N 2G3, Canada; [Koerte, Inga K.; Kaufmann, David; Hartl, Elisabeth; Bouix, Sylvain; Pasternak, Ofer; Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; [Koerte, Inga K.; Kaufmann, David] Univ Munich, Inst Clin Radiol, Munich, Germany; [Rauscher, Alexander; Li, David K. B.] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada; [Dadachanji, Shiroy B.; Taunton, Jack A.] Univ British Columbia, Dept Med, Div Sports Med, Vancouver, BC, Canada; [Forwell, Lorie A.] Univ Western Ontario, Fowler Kennedy Sport Med Clin, London, ON, Canada; [Forwell, Lorie A.; Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Shenton, Martha E.] VA Boston Healthcare Syst, Dept Psychiat, Neurosci Lab, Clin Neurosci Div, Brockton, MA USA	Echlin, PS (corresponding author), Elliott Sports Med Clin, 1100 Walkers Line,Suite 2, Burlington, ON L7N 2G3, Canada.	psechlin@gmail.com	Johnson, Andrew M/B-2048-2012; Shenton, Martha/V-8780-2019	Johnson, Andrew M./0000-0002-7269-3016; Rauscher, Alexander/0000-0002-1961-8252; Bouix, Sylvain/0000-0003-1326-6054	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR013218] Funding Source: Medline; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB015902] Funding Source: Medline		Acosta-Cabronero J, 2010, BRAIN, V133, P529, DOI 10.1093/brain/awp257; Agel J, 2007, J ATHL TRAINING, V42, P249; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King DA, 2009, BRIT J SPORT MED, V43, P595, DOI 10.1136/bjsm.2009.061481; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Malcolm JG, 2009, LECT NOTES COMPUT SC, V5636, P126, DOI 10.1007/978-3-642-02498-6_11; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rathi Y, 2011, MAGN RESON IMAGING, V29, P507, DOI 10.1016/j.mri.2010.10.005; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zazryn T, 2007, SPORTS MED, V37, P467	63	72	72	0	22	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E3	10.3171/2012.10.FOCUS12303			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500004	23199426	Green Accepted, Bronze			2021-06-18	
J	Rincon, F; Ghosh, S; Dey, S; Maltenfort, M; Vibbert, M; Urtecho, J; McBride, W; Moussouttas, M; Bell, R; Ratliff, JK; Jallo, J				Rincon, Fred; Ghosh, Sayantani; Dey, Saugat; Maltenfort, Mitchell; Vibbert, Matthew; Urtecho, Jacqueline; McBride, William; Moussouttas, Michael; Bell, Rodney; Ratliff, John K.; Jallo, Jack			Impact of Acute Lung Injury and Acute Respiratory Distress Syndrome After Traumatic Brain Injury in the United States	NEUROSURGERY			English	Article						Administrative database; Epidemiology; Hypoxia; International Classification of Diseases; Nationwide Inpatient Sample; Outcome; Respiratory failure	PULMONARY-ARTERY; WEDGE PRESSURE; HEAD-INJURY; MORTALITY; EPIDEMIOLOGY; OUTCOMES; SEPSIS; ARDS; DEFINITIONS; SEVERITY	BACKGROUND: Traumatic brain injury (TBI) is a major cause of disability, morbidity, and mortality. The effect of the acute respiratory distress syndrome and acute lung injury (ARDS/ALI) on in-hospital mortality after TBI remains controversial. OBJECTIVE: To determine the epidemiology of ARDS/ALI, the prevalence of risk factors, and impact on in-hospital mortality after TBI in the United States. METHODS: Retrospective cohort study of admissions of adult patients >18 years with a diagnosis of TBI and ARDS/ALI from 1988 to 2008 identified through the Nationwide Inpatient Sample. RESULTS: During the 20-year study period, the prevalence of ARDS/ALI increased from 2% (95% confidence interval [CI], 2.1%-2.4%) in 1988 to 22% (95% CI, 21%-22%) in 2008 (P < .001). ARDS/ALI was more common in younger age; males; white race; later year of admission; in conjunction with comorbidities such as congestive heart failure, hypertension, chronic obstructive pulmonary disease, chronic renal and liver failure, sepsis, multiorgan dysfunction; and nonrural, medium/large hospitals, located in the Midwest, South, and West continental US location. Mortality after TBI decreased from 13% (95% CI, 12%-14%) in 1988 to 9% (95% CI, 9%-10%) in 2008 (P < .001). ARDS/ALI-related mortality after TBI decreased from 33% (95% CI, 33%-34%) in 1988 to 28% (95% CI, 28%-29%) in 2008 (P < .001). Predictors of in-hospital mortality after TBI were older age, male sex, white race, cancer, chronic kidney disease, hypertension, chronic liver disease, congestive heart failure, ARDS/ALI, and organ dysfunctions. CONCLUSION: Our analysis demonstrates that ARDS/ALI is common after TBI. Despite an overall reduction of in-hospital mortality, ARDS/ALI carries a higher risk of in-hospital death after TBI.	[Rincon, Fred; Vibbert, Matthew; Urtecho, Jacqueline; McBride, William; Moussouttas, Michael; Bell, Rodney] Thomas Jefferson Univ, Dept Neurol, Div Crit Care, Philadelphia, PA 19107 USA; [Rincon, Fred; Ghosh, Sayantani; Dey, Saugat; Vibbert, Matthew; Urtecho, Jacqueline; Bell, Rodney; Jallo, Jack] Thomas Jefferson Univ, Dept Neurosurg, Div Neurotrauma, Philadelphia, PA 19107 USA; [Maltenfort, Mitchell] Rothman Inst, Dept Biostat, Philadelphia, PA USA; [McBride, William; Moussouttas, Michael; Bell, Rodney] Thomas Jefferson Univ, Div Cerebrovasc Dis, Philadelphia, PA 19107 USA; [Ratliff, John K.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA	Rincon, F (corresponding author), Thomas Jefferson Univ, Dept Neurol Surg, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.	fred.rincon@jefferson.edu	Dey, Saugat/ABI-5969-2020	Dey, Saugat/0000-0003-4128-3337; Jallo, Jack/0000-0002-5512-1729; Rincon, Fred/0000-0002-8510-118X			Adams DL, 2002, J NATL MED ASSOC, V94, P430; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035; [Anonymous], NATL IMPATIENT SAMPL; ASHBAUGH DG, 1967, LANCET, V2, P319; Bateman BT, 2010, ANESTHESIOLOGY, V112, P917, DOI 10.1097/ALN.0b013e3181cea3d0; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cedeno Arturo, 2002, P R Health Sci J, V21, P305; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Erickson SE, 2009, CRIT CARE MED, V37, P1, DOI 10.1097/CCM.0b013e31819292ea; Ferguson ND, 2005, CRIT CARE MED, V33, P2228, DOI 10.1097/01.CCM.0000181529.08630.49; Ferguson ND, 2002, INTENS CARE MED, V28, P1073, DOI 10.1007/s00134-002-1354-y; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Forfia PR, 2005, J AM COLL CARDIOL, V45, P1667, DOI 10.1016/j.jacc.2005.01.046; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Howard AE, 2004, AM J CRIT CARE, V13, P59, DOI 10.4037/ajcc2004.13.1.59; Hudson LD, 1999, CHEST, V116, p74S, DOI 10.1378/chest.116.suppl_1.74S-a; Johnston CJ, 2003, CHEST, V124, P653, DOI 10.1378/chest.124.2.653; LEWANDOWSKI K, 1995, AM J RESP CRIT CARE, V151, P1121; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Luhr OR, 2000, INTENS CARE MED, V26, P508, DOI 10.1007/s001340051197; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001; Phua J, 2008, CRIT CARE MED, V36, P2912, DOI 10.1097/CCM.0b013e31817d20bd; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rana R, 2006, CRIT CARE MED, V34, P1941, DOI 10.1097/01.CCM.0000220492.15645.47; Reynolds HN, 1998, CRIT CARE, V2, P29, DOI DOI 10.1186/CC121; Richard C, 2011, CURR OPIN CRIT CARE, V17, P296, DOI 10.1097/MCC.0b013e3283466b85; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976; Ryb GE, 2010, J NATL MED ASSOC, V102, P865, DOI 10.1016/S0027-9684(15)30700-8; Salim A, 2008, INJURY, V39, P30, DOI 10.1016/j.injury.2007.06.015; Silverboard H, 2005, J TRAUMA, V59, P717, DOI 10.1097/01.ta.0000174919.35240.21; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; THOMSEN GE, 1995, AM J RESP CRIT CARE, V152, P965, DOI 10.1164/ajrccm.152.3.7663811; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196; Villar J, 1999, INTENS CARE MED, V25, P930, DOI 10.1007/s001340050984; VILLAR J, 1989, AM REV RESPIR DIS, V140, P814, DOI 10.1164/ajrccm/140.3.814; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	49	72	75	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2012	71	4					795	803		10.1227/NEU.0b013e3182672ae5			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	010TO	WOS:000309117200027	22855028				2021-06-18	
J	Prevost, TP; Jin, G; de Moya, MA; Alam, HB; Suresh, S; Socrate, S				Prevost, Thibault P.; Jin, Guang; de Moya, Marc A.; Alam, Hasan B.; Suresh, Subra; Socrate, Simona			Dynamic mechanical response of brain tissue in indentation in vivo, in situ and in vitro	ACTA BIOMATERIALIA			English	Article						Brain indentation; Porcine; Viscoelasticity; Constitutive properties; Brain injury	MAGNETIC-RESONANCE ELASTOGRAPHY; VISCOELASTIC PROPERTIES; DURA-MATER; BEHAVIOR; SHEAR; BIOMECHANICS; INJURY; DEFORMATION; COMPRESSION; ELASTICITY	Characterizing the dynamic mechanical properties of brain tissue is deemed important for developing a comprehensive knowledge of the mechanisms underlying brain injury. The results gathered to date on the tissue properties have been mostly obtained in vitro. Learning how these results might differ quantitatively from those encountered in vivo is a critical step towards the development of biofidelic brain models. The present study provides novel and unique experimental results on, and insights into, brain biorheology in vivo, in situ and in vitro, at large deformations, in the quasi-static and dynamic regimes. The nonlinear dynamic response of the cerebral cortex was measured in indentation on the exposed frontal and parietal lobes of anesthetized porcine subjects. Load-unload cycles were applied to the tissue surface at sinusoidal frequencies of 10, 1, 0.1 and 0.01 Hz. Ramp-relaxation tests were also conducted to assess the tissue viscoelastic behavior at longer times. After euthanasia, the indentation test sequences were repeated in situ on the exposed cortex maintained in its native configuration within the cranium. Mixed gray and white matter samples were subsequently excised from the superior cortex to be subjected to identical indentation test segments in vitro within 6-7 h post mortem. The main response features (e.g. nonlinearities, rate dependencies, hysteresis and conditioning) were measured and contrasted in vivo, in situ and in vitro. The indentation response was found to be significantly stiffer in situ than in vivo. The consistent, quantitative set of mechanical measurements thereby collected provides a preliminary experimental database, which may be used to support the development of constitutive models for the study of mechanically mediated pathways leading to traumatic brain injury. (C) 2011 Acts Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Socrate, Simona] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Prevost, Thibault P.; Suresh, Subra] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Jin, Guang; de Moya, Marc A.; Alam, Hasan B.] Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA	Socrate, S (corresponding author), MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.	ssocrate@mit.edu	Suresh, Subra/B-8289-2008	Suresh, Subra/0000-0002-6223-6831	US Army Research Office; Joint Improvised Explosive Devices Defeat Organization [W911NF-07-1-0035]; US Army Medical Research Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; MIT Institute for Soldier Nanotechnologies [W911NF-07-D-0004]; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); Singapore-MIT Alliance (SMA); Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology (SMART)	This work was supported by the US Army Research Office and Joint Improvised Explosive Devices Defeat Organization, under Contract No. W911NF-07-1-0035; the US Army Medical Research Material Command GRANTT00521959 (to HBA); the MIT Institute for Soldier Nanotechnologies, under contract number W911NF-07-D-0004; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); the Computational Systems Biology Programme of the Singapore-MIT Alliance (SMA); and the Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology (SMART). The authors are grateful to Dr. Asha Balakrishnan for designing the testing frame used in the in vivo experiments.	Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Balakrishnan A, 2008, EXP MECH, V48, P549, DOI 10.1007/s11340-007-9087-z; BALAKRISHNAN A, 2007, THESIS MIT; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bernick KB, 2011, ACTA BIOMATER, V7, P1210, DOI 10.1016/j.actbio.2010.10.018; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Garo A, 2007, BIORHEOLOGY, V44, P51; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gefen A, 2001, CLIN BIOMECH, V16, P921, DOI 10.1016/S0268-0033(01)00074-2; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Hamhaber U, 2007, ACTA BIOMATER, V3, P127, DOI 10.1016/j.actbio.2006.08.007; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hrapko M, 2008, BIORHEOLOGY, V45, P663, DOI 10.3233/BIR-2008-0512; Kerdok AE, 2006, J BIOMECH, V39, P2221, DOI 10.1016/j.jbiomech.2005.07.005; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LAIFOOK SJ, 1976, J APPL PHYSIOL, V40, P508; Li LP, 2006, CLIN BIOMECH, V21, P420, DOI 10.1016/j.clinbiomech.2005.12.010; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; MCCRORY P, 2005, BRIT J SPORT MED, V39, P158; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miga MI, 2000, J BIOMECH ENG-T ASME, V122, P354, DOI 10.1115/1.1288207; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Runza M, 1999, ANESTH ANALG, V88, P1317, DOI 10.1097/00000539-199906000-00022; SCHETTINI A, 1988, AM J PHYSIOL, V255, P799; Schiavone P, 2009, MED IMAGE ANAL, V13, P673, DOI 10.1016/j.media.2009.04.001; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A., 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Vannah WM, 1996, J REHABIL RES DEV, V33, P239; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Xu L, 2007, ACTA RADIOL, V48, P327, DOI 10.1080/02841850701199967; Zheng YP, 1999, J REHABIL RES DEV, V36, P71	54	72	73	2	51	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061			ACTA BIOMATER	Acta Biomater.	DEC	2011	7	12					4090	4101		10.1016/j.actbio.2011.06.032			12	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	853OV	WOS:000297436500001	21742064				2021-06-18	
J	Kamnaksh, A; Kovesdi, E; Kwon, SK; Wingo, D; Ahmed, F; Grunberg, NE; Long, J; Agoston, DV				Kamnaksh, Alaa; Kovesdi, Erzsebet; Kwon, Sook-Kyung; Wingo, Daniel; Ahmed, Farid; Grunberg, Neil E.; Long, Joseph; Agoston, Denes V.			Factors Affecting Blast Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; inflammation; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; CEREBRAL-ISCHEMIA; INFLAMMATION; NEUROPROTECTION; MECHANISMS; EXPRESSION; CYTOKINES; EXPOSURE; IMMUNE	The overlapping pathologies and functional outcomes of blast-induced TBI (bTBI) and stress-related neurobehavioral disorders like post-traumatic stress disorder (PTSD) are significant military health issues. Soldiers are exposed to multiple stressors with or without suffering bTBI, making diagnosis and treatment as well as experimental modeling of bTBI a challenge. In this study we compared anxiety levels of Naive rats to ones that were exposed to each of the following conditions daily for 4 consecutive days: C I: transportation alone; C II: transportation and anesthesia; C III: transportation, anesthesia, and blast sounds; Injured: all three variables plus mild blast overpressure. Following behavioral testing we analyzed sera and select brain regions for protein markers and cellular changes. C I, C II, and C III animals exhibited increased anxiety, but serum corticosterone levels were only significantly elevated in C III and Injured rats. C III and Injured animals also had elevated interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) levels in the amygdala (AD) and ventral hippocampus (VHC). Glial fibrillary acidic protein (GFAP) levels were only significantly elevated in the VHC, prefrontal cortex (PFC), and AD of Injured animals; they showed an apparent increase in ionized calcium-binding adapter molecule (Iba1) and GFAP immunoreactivity, as well as increased numbers of TUNEL-positive cells in the VHC. Our findings demonstrate that experimental conditions, particularly the exposure to blast acoustics, can increase anxiety and trigger specific behavioral and molecular changes without injury. These findings should be taken into consideration when designing bTBI studies, to better understand the role of stressors in the development of post-traumatic symptoms, and to establish a differential diagnosis for PTSD and bTBI.	[Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; [Kamnaksh, Alaa; Kwon, Sook-Kyung; Ahmed, Farid; Grunberg, Neil E.; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Long, Joseph] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurotrauma, Blast Induced Neurotrauma Branch, Silver Spring, MD USA	Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense [G1703F]	We thank the Neurotrauma Team (WRAIR) for their technical help during the exposures. This work was supported by Center for Neuroscience and Regenerative Medicine (CNRM) grant no. G1703F.	Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BLALOCK JE, 1989, PHYSIOL REV, V69, P1, DOI 10.1152/physrev.1989.69.1.1; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Breslau N, 2001, BIOL PSYCHIAT, V50, P699, DOI 10.1016/S0006-3223(01)01167-2; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Dancer A, 1998, SCAND AUDIOL, V27, P123; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Garcia-Bueno B, 2008, NEUROSCI BIOBEHAV R, V32, P1136, DOI 10.1016/j.neubiorev.2008.04.001; Guy RJ, 2004, J ROY SOC MED, V97, P255, DOI 10.1258/jrsm.97.5.255-a; Gyorgy A.B., 2010, J NEUROSCI METHODS; Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0; Holscher C, 2003, REV NEUROSCIENCE, V14, P253; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Keane TM, 2006, ANNU REV CLIN PSYCHO, V2, P161, DOI 10.1146/annurev.clinpsy.2.022305.095305; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kurz A, 1997, ANN NY ACAD SCI, V813, P778, DOI 10.1111/j.1749-6632.1997.tb51780.x; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Risling M., 2010, NEUROIMAGE; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sorrells SF, 2009, NEURON, V64, P33, DOI 10.1016/j.neuron.2009.09.032; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047; Zhang HP, 2010, ANESTH ANALG, V111, P506, DOI 10.1213/ANE.0b013e3181e45519	46	72	73	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2145	2153		10.1089/neu.2011.1983			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500015	21861635				2021-06-18	
J	Zanelli, S; Buck, M; Fairchild, K				Zanelli, S.; Buck, M.; Fairchild, K.			Physiologic and pharmacologic considerations for hypothermia therapy in neonates	JOURNAL OF PERINATOLOGY			English	Article						hypothermia; hypoxic-ischemic encephalopathy; neonate; pharmacologic effect; physiology effect; rewarming	WHOLE-BODY HYPOTHERMIA; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; MILD SYSTEMIC HYPOTHERMIA; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; CARDIOPULMONARY BYPASS; MODERATE HYPOTHERMIA; CYTOKINE PRODUCTION; PLATELET-AGGREGATION; ASPHYXIATED INFANTS	With mounting evidence that hypothermia is neuroprotective in newborns with hypoxic-ischemic encephalopathy (HIE), an increasing number of centers are offering this therapy. Hypothermia is associated with a wide range of physiologic changes affecting every organ system, and awareness of these effects is essential for optimum patient management. Lowering the core temperature also alters pharmacokinetic and pharmacodynamic properties of medications commonly used in asphyxiated neonates, necessitating close attention to drug efficacy and side effects. Rewarming introduces additional risks and challenges as the hypothermia-associated physiologic and pharmacologic changes are reversed. In this review we provide an organ system-based assessment of physiologic changes associated with hypothermia. We also summarize evidence from randomized controlled trials showing lack of serious adverse effects of moderate hypothermia therapy in term and near-term newborns with moderate-to-severe HIE. Finally, we review the effects of hypothermia on drug metabolism and clearance based on studies in animal models and human adults, and limited data from neonates. Journal of Perinatology (2011) 31, 377-386; doi:10.1038/jp.2010.146; published online 23 December 2010	[Zanelli, S.; Buck, M.; Fairchild, K.] Univ Virginia, Dept Pediat, Charlottesville, VA 22903 USA; [Buck, M.] Univ Virginia, Dept Pharm, Charlottesville, VA 22903 USA	Zanelli, S (corresponding author), Univ Virginia, Dept Pediat, Box 800386, Charlottesville, VA 22903 USA.	sz5d@virginia.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD051609] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD051609] Funding Source: NIH RePORTER		AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51; Alderson P, 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001048.PUB2, 10.1002/14651858.CD001048.pub2]; Alston Theodore A, 2004, Int Anesthesiol Clin, V42, P73, DOI 10.1097/00004311-200404240-00008; Ancora G, 2009, BRAIN DEV-JPN, V31, P442, DOI 10.1016/j.braindev.2008.06.003; Arpino PA, 2008, PHARMACOTHERAPY, V28, P102, DOI 10.1592/phco.28.1.102; Azzopardi D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-17; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bacher A, 2005, INTENS CARE MED, V31, P24, DOI 10.1007/s00134-004-2369-3; Battin M, 2004, PEDIATRICS, V114, P1369, DOI 10.1542/peds.2004-1695; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; BENUMOF JL, 1977, J APPL PHYSIOL, V42, P56; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bhagat H, 2006, J CLIN NEUROSCI, V13, P953, DOI 10.1016/j.jocn.2005.09.018; Bisson Jamie, 2006, Nurs Crit Care, V11, P232, DOI 10.1111/j.1478-5153.2006.00177.x; BODIS J, 1984, Acta Paediatrica Hungarica, V25, P343; Boldt J, 1996, ANN THORAC SURG, V62, P130, DOI 10.1016/0003-4975(96)00239-1; Burnsed J, 2011, J CLIN NEUROPHYSIOL, V28, P10, DOI 10.1097/WNP.0b013e318205134b; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Chakkarapani E, 2009, ACTA PAEDIATR, V98, P1844, DOI 10.1111/j.1651-2227.2009.01470.x; CLARDY CW, 1985, PEDIATR INFECT DIS J, V4, P379, DOI 10.1097/00006454-198507000-00009; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; CURRY DL, 1970, ENDOCRINOLOGY, V87, P750, DOI 10.1210/endo-87-4-750; Doherty DR, 2009, CIRCULATION, V119, P1492, DOI 10.1161/CIRCULATIONAHA.108.791384; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Fairchild K, 2010, J PERINATOL, V30, P324, DOI 10.1038/jp.2009.168; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; Filippi L, 2009, EPILEPSIA, V50, P2355, DOI 10.1111/j.1528-1167.2009.02302.x; Frank SM, 2003, CLIN SCI, V104, P503, DOI 10.1042/CS20020256; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; GAMBASSI G, 1994, CARDIOVASC RES, V28, P391, DOI 10.1093/cvr/28.3.391; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; Gerrits LC, 2005, PEDIATR RES, V57, P342, DOI 10.1203/01.PDR.0000150801.61188.5F; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; GREELEY WJ, 1989, CIRCULATION, V80, P209; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; Groenendaal F, 2009, PEDIATRICS, V123, P170, DOI 10.1542/peds.2008-1955; Groenendaal F, 2009, EARLY HUM DEV, V85, P73, DOI 10.1016/j.earlhumdev.2008.11.006; Guignard JP, 1997, ACTA PAEDIATR, V86, P1040, DOI 10.1111/j.1651-2227.1997.tb14802.x; Hall MW, 2002, AM J HEMATOL, V69, P45, DOI 10.1002/ajh.10018; Hallberg B, 2010, ACTA PAEDIATR, V99, P531, DOI 10.1111/j.1651-2227.2009.01653.x; Hallberg B, 2009, ACTA PAEDIATR, V98, P942, DOI 10.1111/j.1651-2227.2009.01303.x; Heinius G, 2002, J SURG RES, V108, P7, DOI 10.1006/jsre.2002.6470; HELMAN A, 1984, ENDOCRINOLOGY, V115, P1722, DOI 10.1210/endo-115-5-1722; Holzer M, 2002, NEW ENGL J MED, V346, P549; Horan M, 2007, EARLY HUM DEV, V83, P217, DOI 10.1016/j.earlhumdev.2006.05.016; Horan M, 2007, EARLY HUM DEV, V83, P69, DOI 10.1016/j.earlhumdev.2006.05.004; Horan MR, 2004, J PEDIATR-US, V144, P301, DOI 10.1016/j.jpeds.2003.11.034; Horn A, 2009, PEDIATRICS, V123, pE1090, DOI 10.1542/peds.2007-3766; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Iyer P, 1996, CRIT CARE MED, V24, P507, DOI 10.1097/00003246-199603000-00023; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; KADAR D, 1982, CAN ANAESTH SOC J, V29, P16, DOI 10.1007/BF03007942; Karlsson M, 2008, PEDIATR RES, V64, P74, DOI 10.1203/PDR.0b013e318174efdd; Kawamura S, 2000, ACTA NEUROCHIR, V142, P1117, DOI 10.1007/s007010070039; Keller E, 2000, Neurosurg Focus, V8, pe4; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; KOCHS E, 1995, J NEUROSURG ANESTH, V7, P222, DOI 10.1097/00008506-199507000-00022; KOREN G, 1985, CRIT CARE MED, V13, P844, DOI 10.1097/00003246-198510000-00014; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Kuwagata Y, 1999, J TRAUMA, V47, P666, DOI 10.1097/00005373-199910000-00010; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Laptook AR, 2002, CLIN PERINATOL, V29, P623, DOI 10.1016/S0095-5108(02)00057-X; Liu X, 2009, PEDIATRICS, V124, P310, DOI 10.1542/peds.2008-2942; MACNAB AJ, 1990, CRIT CARE MED, V18, P1066, DOI 10.1097/00003246-199010000-00003; Mattu A, 2002, AM J EMERG MED, V20, P314, DOI 10.1053/ajem.2002.32633; McGowan JE, 2006, CLIN PERINATOL, V33, P183, DOI 10.1016/j.clp.2005.11.007; Meek JH, 1999, ARCH DIS CHILD-FETAL, V81, pF110, DOI 10.1136/fn.81.2.F110; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; Ohri SK, 1997, ANN THORAC SURG, V64, P163, DOI 10.1016/S0003-4975(97)00290-7; OKADA M, 1984, J ELECTROCARDIOL, V17, P123, DOI 10.1016/S0022-0736(84)81085-7; Parikh NA, 2009, J PERINATOL, V29, P143, DOI 10.1038/jp.2008.184; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; POULOS ND, 1991, J TRAUMA, V31, P996, DOI 10.1097/00005373-199107000-00020; Powell RW, 1999, J PEDIATR SURG, V34, P193, DOI 10.1016/S0022-3468(99)90255-5; PUIG MM, 1987, BRIT J ANAESTH, V59, P1459, DOI 10.1093/bja/59.11.1459; Roelfsema V, 2005, EXP PHYSIOL, V90, P545, DOI 10.1113/expphysiol.2005.030320; Roelfsema V, 2005, J SOC GYNECOL INVEST, V12, P232, DOI 10.1016/j.jsgi.2005.01.025; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Roka A, 2007, ACTA PAEDIATR, V96, P1118, DOI 10.1111/j.1651-2227.2007.00361.x; Royl G, 2008, NEUROIMAGE, V40, P1523, DOI 10.1016/j.neuroimage.2008.01.041; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; Rutherford M, 2010, LANCET NEUROL, V9, P39, DOI 10.1016/S1474-4422(09)70295-9; Sakoh M, 2003, AM J PHYSIOL-HEART C, V285, pH17, DOI 10.1152/ajpheart.01112.2002; Salman H, 2000, ACTA PHYSIOL SCAND, V168, P431; Sarkar S, 2009, J PERINATOL, V29, P558, DOI 10.1038/jp.2009.37; Satas S, 2000, BIOL NEONATE, V77, P50; Saur J, 2008, IN VIVO, V22, P143; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Speziale G, 2000, J CARDIOVASC SURG, V41, P819; STAYER SA, 1994, ANESTH ANALG, V79, P834; Thoren A, 2001, ANESTH ANALG, V92, P5, DOI 10.1097/00000539-200101000-00003; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; Thoresen M, 2003, PAS, P137; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; Thoresen M, 2008, CLIN PERINATOL, V35, P749, DOI 10.1016/j.clp.2008.07.018; Toet MC, 2006, PEDIATRICS, V117, P333, DOI 10.1542/peds.2005-0987; Tooley JR, 2003, ANN NEUROL, V53, P65, DOI 10.1002/ana.10402; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VANBEL F, 1993, PEDIATRICS, V92, P365; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Xavier RG, 2007, THROMB HAEMOSTASIS, V98, P1266, DOI 10.1160/TH07-03-0189; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	116	72	74	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	JUN	2011	31	6					377	386		10.1038/jp.2010.146			10	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	769NX	WOS:000291024300001	21183927	Green Accepted, Bronze			2021-06-18	
J	Ruff, RM				Ruff, Ronald M.			Mild traumatic brain injury and neural recovery: Rethinking the debate	NEUROREHABILITATION			English	Article							EMOTIONAL RISK-FACTORS; HEAD-INJURY; MISERABLE MINORITY; CONCUSSION; CLAIMANTS; SYMPTOMS; STRESS; MEMORY	A debate exists concerning whether a mild traumatic brain injury (MTBI) can cause permanent brain-based residuals. This debate is examined by reviewing meta-analytic studies that found no significant effect sizes between large samples of patients with and without MTBI at three months post-accident. In contrast, research studies with MTBI patients have captured cognitive deficits corroborated by positive neuroimaging, which supports the viewpoint that brain-based postconcussive disorders likely exist in a small minority of individuals. Ongoing hurdles that likely contribute to this debate are identified. This includes the lack of agreed upon definitions; substantial differences exist between the ICD-10 definition for Postconcussion Syndrome and the DSM-IV-TR definition for Postconcussional Disorder. Confining the debate to brain-based versus psychologically-based viewpoints results in a false dichotomy. Instead, a more refined sub-classification of the postconcussive complex is proposed that captures different constellations across the physical, emotional, and cognitive symptoms complex. Moreover, this diagnostic framework attempts to expand discipline-based approaches with a patient-based understanding.	San Francisco Clin Neurosci, San Francisco, CA 94109 USA	Ruff, RM (corresponding author), San Francisco Clin Neurosci, 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.	ronruff@mindspring.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDC INJ PREV, 2003, REP US C MILD TRAUM; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1981, NEUROPATHOLOGY, V7, P23; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2008, MILD TRAUMATIC BRAIN; Nagin D., 2005, GROUP BASED MODELING; *NAT CTR HLTH STAT, 2003, 2000 NAT HOSP AMB ME; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Popper K, 1968, LOGIC SCI DISCOVERY; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R. M., 1999, MILD HEAD INJURY CAU, P99; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stuss DT, 2002, PRINCIPLES FRONTAL L; VARNEY NR, 1999, MILD HEAD INJURY CAU; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 INT STAT CLAS; YATES OK, 2010, J INT NEUROPSYCHOGIC, V16, P953	56	72	73	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2011	28	3					167	180		10.3233/NRE-2011-0646			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	783MF	WOS:000292086600001	21558623				2021-06-18	
J	Udy, A; Boots, R; Senthuran, S; Stuart, J; Deans, R; Lassig-Smith, M; Lipman, J				Udy, Andrew; Boots, Robert; Senthuran, Siva; Stuart, Janine; Deans, Renae; Lassig-Smith, Melissa; Lipman, Jeffrey			Augmented Creatinine Clearance in Traumatic Brain Injury	ANESTHESIA AND ANALGESIA			English	Article							GLOMERULAR-FILTRATION RATE; RENAL-FUNCTION; NOREPINEPHRINE; RESERVE	BACKGROUND: Hypertonic saline and/or norepinephrine infusion are routinely used to achieve a desired cerebral perfusion pressure (CPP) in the management of traumatic brain injury (TBI). We hypothesized that creatinine clearances (CrCls) would be significantly augmented in this setting. METHODS: This was an observational cohort study in TBI patients older than 16 years with normal serum creatinine concentrations, requiring maintenance of CPP. Eight-hour urinary CrCl collections were performed while on and off active management. Demographic data, use of vasoactive medications, fluid balance, feeding regimen, and hemodynamic variables were recorded throughout the study period. Augmented CrCl was defined as > 150 mL/min/1.73 m(2) in women and > 160 mL/min/1.73 m(2) in men. RESULTS: Twenty patients were enrolled, and augmented clearances were demonstrated in 17 (85%). The mean maximum CrCl was 179 mL/min/1.73 m(2) while receiving CPP therapy (95% confidence interval [CI], 159-198), returning to a mean of 111 mL/min/1.73 m(2) (95% CI, 91-131; P < 0.001) when measured after discharge from the intensive care unit. The mean CrCl in the intensive care unit while not receiving CPP therapy was 150 mL/min/1.73 m(2) (95% CI, 134-167; P = 0.03). The mean time to reach peak CrCl while receiving active treatment was 4.7 days (95% CI, 3.0-6.4). In a multivariate analysis, norepinephrine use, saline loading, mean arterial blood pressure, and central venous pressure were associated with augmented CrCl on the day of measurement. CONCLUSIONS: Augmented CrCls are common in TBI patients receiving active management of CPP and persist even after discontinuation of such therapy. Further work is needed to clarify the impact of such clearances on renally excreted drugs in this setting.	[Udy, Andrew; Boots, Robert; Senthuran, Siva; Stuart, Janine; Deans, Renae; Lassig-Smith, Melissa; Lipman, Jeffrey] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Herston, Qld 4029, Australia; [Udy, Andrew; Boots, Robert; Senthuran, Siva; Lipman, Jeffrey] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Herston, Qld, Australia	Boots, R (corresponding author), Royal Brisbane & Womens Hosp, Dept Intens Care Med, Herston Rd, Herston, Qld 4029, Australia.		Lipman, Jeffrey/G-2211-2010; Udy, Andrew A/G-2538-2010; Udy, Andrew/S-1314-2016; Boots, Robert/K-1159-2013	Lipman, Jeffrey/0000-0002-5965-9876; Udy, Andrew A/0000-0002-6284-2022; Udy, Andrew/0000-0002-6284-2022; Boots, Robert/0000-0002-2436-7654	Royal Brisbane and Women's Hospital Research Foundation; Queensland Health; AstraZenecaAstraZeneca; Janssen-CilagJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc; Wyeth Australia AstraZeneca	Supported by a special purpose grant awarded to Dr Siva Senthuran from the Royal Brisbane and Women's Hospital Research Foundation Dr Andrew Udy was supported by a Clinical Research Skills Development grant from Queensland Health The funding source had no role in protocol development, patient recruitment, study analysis, interpretation, or the decision to submit for publication Professor Lipman is a consultant to AstraZeneca and Janssen-Cilag, and has received an honoraria from AstraZeneca, Janssen-Cilag, and Wyeth Australia AstraZeneca provides an annual donation to the Burns, Trauma and Critical Care Research Center, University of Queensland	Albanese J, 2004, CHEST, V126, P534, DOI 10.1378/chest.126.2.534; ANDERSON WP, 1981, J PHYSIOL-LONDON, V321, P21, DOI 10.1113/jphysiol.1981.sp013969; BAUMANN TJ, 1987, CLIN PHARMACY, V6, P393; Benmalek F, 1999, INTENS CARE MED, V25, P399, DOI 10.1007/s001340050865; BOSCH JP, 1983, AM J MED, V75, P943, DOI 10.1016/0002-9343(83)90873-2; BROWN R, 1980, CRIT CARE MED, V8, P68, DOI 10.1097/00003246-198002000-00004; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CASTELLINO P, 1988, AM J PHYSIOL, V255, pF444; Conil JM, 2007, BRIT J CLIN PHARMACO, V63, P583, DOI 10.1111/j.1365-2125.2006.02807.x; Garcia MD, 2007, INTENS CARE MED, V33, P279, DOI 10.1007/s00134-006-0470-5; Di Giantomasso D, 2002, INTENS CARE MED, V28, P1804, DOI 10.1007/s00134-002-1444-x; DIGLANTOMASSO D, 2003, INTENS CARE MED, V29, P1774; Fuster-Lluch O, 2008, ANAESTH INTENS CARE, V36, P674, DOI 10.1177/0310057X0803600507; Hoste EAJ, 2005, NEPHROL DIAL TRANSPL, V20, P747, DOI 10.1093/ndt/gfh707; KIM KE, 1969, BRIT MED J, V4, P11, DOI 10.1136/bmj.4.5674.11; Kohl BA, 2006, CURR OPIN CRIT CARE, V12, P325, DOI 10.1097/01.ccx.0000235210.85073.fc; Lipman J, 2003, ANESTH ANALG, V97, P1149, DOI 10.1213/01.ANE.0000077077.54084.B0; LOIRAT P, 1978, NEW ENGL J MED, V299, P915, DOI 10.1056/NEJM197810262991703; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; SHIPLEY RE, 1951, AM J PHYSIOL, V167, P676; Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415; Sunder-Plassmann G, 2004, AM J KIDNEY DIS, V43, P396, DOI 10.1053/j.ajkd.2003.11.017; THOMAS DM, 1994, KIDNEY INT, V45, P411, DOI 10.1038/ki.1994.53; Toschlog EA, 2003, J TRAUMA, V55, P255, DOI 10.1097/01.TA.0000079367.23481.8D; Udy A, 2009, ANAESTH INTENS CARE, V37, P11, DOI 10.1177/0310057X0903700123; Udy AA, 2010, CLIN PHARMACOKINET, V49, P1, DOI 10.2165/11318140-000000000-00000; VALDES ME, 1979, J SURG RES, V26, P473, DOI 10.1016/0022-4804(79)90036-2; Vincent F, 2005, CHEST, V127, P2282, DOI 10.1378/chest.127.6.2282; Wan L, 2007, ANESTH ANALG, V105, P141, DOI 10.1213/01.ane.0000266438.90360.62	29	72	74	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2010	111	6					1505	1510		10.1213/ANE.0b013e3181f7107d			6	Anesthesiology	Anesthesiology	690AU	WOS:000284973300027	21048095				2021-06-18	
J	Kim, J; Whyte, J; Patel, S; Avants, B; Europa, E; Wang, JJ; Slattery, J; Gee, JC; Coslett, HB; Detre, JA				Kim, Junghoon; Whyte, John; Patel, Sunil; Avants, Brian; Europa, Eduardo; Wang, Jiongjiong; Slattery, John; Gee, James C.; Coslett, H. Branch; Detre, John A.			Resting Cerebral Blood Flow Alterations in Chronic Traumatic Brain Injury: An Arterial Spin Labeling Perfusion fMRI Study	JOURNAL OF NEUROTRAUMA			English	Article						arterial spin labeling; cerebral blood flow; lesion; magnetic resonance imaging; traumatic brain injury	CLOSED-HEAD-INJURY; DEFAULT-MODE NETWORK; ALZHEIMERS-DISEASE; WORKING-MEMORY; COGNITIVE REHABILITATION; UNITED-STATES; SPECT; CORTEX; PET; CONNECTIVITY	Non-invasive measurement of resting state cerebral blood flow (CBF) may reflect alterations of brain structure and function after traumatic brain injury (TBI). However, previous imaging studies of resting state brain in chronic TBI have been limited by several factors, including measurement in relative rather than absolute units, use of crude spatial registration methods, exclusion of subjects with substantial focal lesions, and exposure to ionizing radiation, which limits repeated assessments. This study aimed to overcome those obstacles by measuring absolute CBF with an arterial spin labeling perfusion fMRI technique, and using an image preprocessing protocol that is optimized for brains with mixed diffuse and focal injuries characteristic of moderate and severe TBI. Resting state CBF was quantified in 27 individuals with moderate to severe TBI in the chronic stage, and 22 demographically matched healthy controls. In addition to global CBF reductions in the TBI subjects, more prominent regional hypoperfusion was found in the posterior cingulate cortices, the thalami, and multiple locations in the frontal cortices. Diffuse injury, as assessed by tensor-based morphometry, was mainly associated with reduced CBF in the posterior cingulate cortices and the thalami, where the greatest volume losses were detected. Hypoperfusion in superior and middle frontal cortices, in contrast, was associated with focal lesions. These results suggest that structural lesions, both focal and diffuse, are the main contributors to the absolute CBF alterations seen in chronic TBI, and that CBF may serve as a tool to assess functioning neuronal volume. We also speculate that resting reductions in posterior cingulate perfusion may reflect alterations in the default-mode network, and may contribute to the attentional deficits common in TBI.	[Kim, Junghoon; Whyte, John; Patel, Sunil; Europa, Eduardo; Slattery, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Coslett, H. Branch; Detre, John A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Avants, Brian; Gee, James C.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Avants, Brian; Wang, Jiongjiong; Gee, James C.; Coslett, H. Branch; Detre, John A.] Univ Penn, Ctr Funct Neuroimaging, Philadelphia, PA 19104 USA	Kim, J (corresponding author), Albert Einstein Healthcare Network, Moss Rehabil Res Inst, 60 Township Line Rd, Elkins Pk, PA 19027 USA.	kimj@einstein.edu	Kim, Junghoon John/I-6702-2019; Kim, Junghoon/A-6669-2012; Wang, Danny JJ/O-2482-2018	Kim, Junghoon John/0000-0001-5729-8993; Wang, Danny JJ/0000-0002-0840-7062; Whyte, John/0000-0002-4381-1474; avants, brian/0000-0002-4212-3362	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD39621, R24HD050836, P30NS045839, RR002305, NS045839]; Albert Einstein Society; Pennsylvania Department of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621, R24HD050836] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER	The authors wish to thank Kathy Z. Tang, B. A., John Pluta, B. S., Gang Song, M. S., and Allen Osman, Ph.D. for their help with subject recruitment, data analysis, and manuscript review. The assistance of MRI technicians Doris Cain, Patricia O'Donnell, and Norman Butler is also gratefully acknowledged. This study was supported by grant R24HD39621, R24HD050836 (www.ncrrn.org), P30NS045839, RR002305, and NS045839 from the NIH. This project was also funded in part by the Albert Einstein Society and the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations, or conclusions included in this article.	Ances BM, 2000, J CEREBR BLOOD F MET, V20, P921, DOI 10.1097/00004647-200006000-00004; ANDERSON KE, 2005, TXB TRAUMATIC BRAIN, P107; Avants B, 2004, NEUROIMAGE, V23, pS139, DOI 10.1016/j.neuroimage.2004.07.010; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Borghammer P, 2009, NEUROIMAGE, V47, P1514, DOI 10.1016/j.neuroimage.2009.05.040; Borghammer P, 2009, NEUROIMAGE, V45, P249, DOI 10.1016/j.neuroimage.2008.07.042; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Casanova R, 2007, NEUROIMAGE, V34, P137, DOI 10.1016/j.neuroimage.2006.09.011; Detre JA, 2002, CLIN NEUROPHYSIOL, V113, P621, DOI 10.1016/S1388-2457(02)00038-X; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Grunder G, 2009, NEUROIMAGE, V45, P258, DOI 10.1016/j.neuroimage.2008.10.042; Hattori N, 2003, ACTA NEUROCHIR SUPPL, V86, P49; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; ICHISE M, 1994, J NUCL MED, V35, P217; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kim E, 2009, BRAIN, V132, P369, DOI 10.1093/brain/awn311; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim J, 2006, NEUROIMAGE, V31, P376, DOI 10.1016/j.neuroimage.2005.11.035; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kogure D, 2000, J NUCL MED, V41, P1155; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Mai J.K., 2004, ATLAS HUMAN BRAIN; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; NGAI AC, 1988, AM J PHYSIOL, V254, pH133; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PRAYER L, 1993, ACTA RADIOL, V34, P593; Rao HY, 2007, HUM BRAIN MAPP, V28, P593, DOI 10.1002/hbm.20288; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Rombouts SARB, 2005, HUM BRAIN MAPP, V26, P231, DOI 10.1002/hbm.20160; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; SASAKI K, 1979, EXP BRAIN RES, V37, P193, DOI 10.1007/BF01474266; Schmahmann JD, 1997, J NEUROSCI, V17, P438; Schwartz MF, 2005, ARCH PHYS MED REHAB, V86, P1807, DOI 10.1016/j.apmr.2005.03.009; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Troiani V, 2008, NEUROIMAGE, V40, P932, DOI 10.1016/j.neuroimage.2007.12.002; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Wang JJ, 2005, RADIOLOGY, V235, P218, DOI 10.1148/radiol.2351031663; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolf RL, 2007, NEUROTHERAPEUTICS, V4, P346, DOI 10.1016/j.nurt.2007.04.005; Wong SBC, 2006, PROG BRAIN RES, V157, P173, DOI 10.1016/S0079-6123(06)57011-6	55	72	73	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1399	1411		10.1089/neu.2009.1215			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900005	20528163	Green Published			2021-06-18	
J	Sribnick, EA; Samantaray, S; Das, A; Smith, J; Matzelle, DD; Ray, SK; Banik, NL				Sribnick, Eric A.; Samantaray, Supriti; Das, Arabinda; Smith, Joshua; Matzelle, D. Denise; Ray, Swapan K.; Banik, Naren L.			Postinjury Estrogen Treatment of Chronic Spinal Cord Injury Improves Locomotor Function in Rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						axonal damage; cell death; chronic spinal cord injury; estrogen; locomotor function	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; KAPPA-B ACTIVATION; CALPAIN INHIBITOR; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; RECEPTOR-ALPHA; CELL-DEATH; NEUROPROTECTIVE AGENT	Spinal cord injury (SCI) causes loss of neurological function and, depending on serverity, may cause paralysis. The only recommended pharmacotherapy for the treatment of SCI is high-dose methylprednisolone, and its use is controversial. We have previously shown that estrogen treatment attenuated cell death, axonal and myelin damage, calpain and caspase activities, and inflammation in acute SCI. The aim of this study was to examine whether posttreatment of SCI with estrogen would improve locomotor function by protecting cells and axons and reducing inflammation during the chronic phase following injury. Moderately severe injury (40 g . cm force) was induced in male Sprague-Dawley rats following laminectomy at T10. Three groups of animals were used: sham (laminectomy only), vehicle (dimethyl sulfoxide; DMSO)-treated injury group, and estrogen-treated injury group. Animals were treated with 4 mg/kg estrogen at 15 min and 24 hr postnjury, followed by 2 mg/kg estrogen daily for the next 5 days. After treatment, animals were sacrificed at the end of 6 weeks following injury, and 1-cm segments of spinal cord (lesion, rostral to lesion, and caudal to lesion) were removed for biochemical analyses. Estrogen treatment reduced COX-2 activity, blocked nuclear factor-kappa B translocation, prevented glial reactivity, attenuated neuron death, inhibited activation and activity of calpain and caspase-3, decreased axonal damage, reduced myelin loss in the lesion and penumbra, and improved locomotor function compared with vehicle-treated animals. These findings suggest that estrogen may be useful as a promising therapeutic agent for prevention of damage and improvement of locomotor function in chronic SCI. (C) 2010 Wiley-Liss, Inc.	[Sribnick, Eric A.; Samantaray, Supriti; Das, Arabinda; Smith, Joshua; Matzelle, D. Denise; Banik, Naren L.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA	Banik, NL (corresponding author), Med Univ S Carolina, Div Neurol, Dept Neurosci, 96 Jonathan Lucas St,309CSB, Charleston, SC 29425 USA.	baniknl@musc.edu	Sribnick, Eric/AAH-6693-2020	Smith, Joshua/0000-0003-2172-9207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-31622, NS-45967]; State of South Carolina Spinal Cord Injury Research Fund [SCIRF-1205]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031622, R01NS045967] Funding Source: NIH RePORTER	Contract grant sponsor: NIH; Contract grant number: NS-31622; Contract grant number: NS-45967; Contract grant sponsor: State of South Carolina Spinal Cord Injury Research Fund; Contract grant number: SCIRF-1205.	Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 2000, NEUROSCIENCE, V99, P179, DOI 10.1016/S0306-4522(00)00165-2; Aronica SM, 2004, BREAST CANCER RES TR, V84, P235, DOI 10.1023/B:BREA.0000019961.59306.f6; BANIK NL, 1983, NEUROCHEM RES, V8, P1389, DOI 10.1007/BF00964996; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Das A, 2005, J NEUROSCI RES, V81, P551, DOI 10.1002/jnr.20581; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Gao MX, 2000, NEUROIMMUNOMODULAT, V8, P78, DOI 10.1159/000026456; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Guyton MK, 2005, J NEUROSCI RES, V81, P53, DOI 10.1002/jnr.20470; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; Mills CD, 2000, NEUROREPORT, V11, P3067, DOI 10.1097/00001756-200009280-00007; Miyamoto N, 1999, J IMMUNOL, V163, P374; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; RAY SK, 2002, ENCY MOL MED, P435; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Samantaray S, 2007, NEUROSCIENCE, V146, P741, DOI 10.1016/j.neuroscience.2007.01.056; Samantaray S, 2009, J NEUROCHEM, V108, P105; Schaecher K, 2004, NEUROCHEM RES, V29, P1443, DOI 10.1023/B:NERE.0000026410.56000.dd; Schneider A, 1999, NAT MED, V5, P554; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Smith JA, 2009, J NEUROCHEM, V108, P137; Sribnick E.A., 2009, BRAIN SPINAL CORD TR, pp581; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2007, NEUROCHEM RES, V32, P2210, DOI 10.1007/s11064-007-9433-7; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Sur P, 2003, BRAIN RES, V971, P178, DOI 10.1016/S0006-8993(03)02349-7; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wingrave JM, 2004, EXP NEUROL, V187, P529, DOI 10.1016/j.expneurol.2004.02.001; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xie LP, 2002, EUR J IMMUNOL, V32, P2837, DOI 10.1002/1521-4141(2002010)32:10<2837::AID-IMMU2837>3.0.CO;2-V; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086	65	72	77	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2010	88	8					1738	1750		10.1002/jnr.22337			13	Neurosciences	Neurosciences & Neurology	590RQ	WOS:000277245500012	20091771	Green Accepted			2021-06-18	
J	Douglas, JM				Douglas, Jacinta M.			Relation of Executive Functioning to Pragmatic Outcome Following Severe Traumatic Brain Injury	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						traumatic brain injury; pragmatics; executive function	CLOSED-HEAD-INJURY; DISABILITY RATING-SCALE; COMMUNICATIVE ABILITY; COGNITIVE-ABILITIES; KINEMATIC ANALYSIS; LANGUAGE-SKILLS; SELF-AWARENESS; FRONTAL LOBES; DISCOURSE; DEFICITS	Purpose: This study was designed to explore the behavioral nature of pragmatic impairment following severe traumatic brain injury (TBI) and to evaluate the contribution of executive skills to the experience of pragmatic difficulties after TBI. Method: Participants were grouped into 43 TBI dyads (TBI adults and close relatives) and 43 control dyads. All TBI participants had sustained severe injury (mean posttraumatic amnesia duration = 45.19 days, SD = 39.15) due to a moving vehicle-related trauma. A minimum of 2 years had elapsed since injury (M = 5.36 years, SD = 3.61). The La Trobe Communication Questionnaire (LCQ; Douglas, O'Flaherty, & Snow, 2000) was administered to all participants. Measures of executive function included the following: the FAS verbal fluency task (Spreen & Benton, 1969), the Speed and Capacity of Language Processing test (Baddeley, Emslie, & Nimmo-Smith, 1992), and the Rey Auditory Verbal Learning Task (Rey, 1964). Results: Perceptions of TBI participants and their relatives were significantly correlated (r = .63, p <.001) and significantly different from those of controls, F(1, 84) = 37.2, p <.001. Pragmatic difficulties represented violations in 3 domains of Grice's (1975) Cooperative Principle (Quantity, Relation, and Manner), and executive function measures predicted 37% (32% adjusted) of the variability in LCQ scores. Conclusions: The study demonstrates evidence of a significant association between executive impairment and the pragmatic communication difficulties experienced by individuals with TBI.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Baddeley A, 1998, J INT NEUROPSYCH SOC, V4, P523, DOI 10.1017/S135561779800513X; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bittner RM, 2006, BRAIN INJURY, V20, P971, DOI 10.1080/02699050600909763; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BODY R, 2006, BRAIN IMPAIR, V7, P212, DOI DOI 10.1375/BRIM.7.3.212; BODY R, 1999, BRAIN DAM B, P81; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Carstairs JR, 2006, AUST PSYCHOL, V41, P48, DOI 10.1080/00050060500391878; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, P95, DOI DOI 10.1007/978-1-4613-2211-5_; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cummings Louise, 2007, Seminars in Speech and Language, V28, P96, DOI 10.1055/s-2007-970568; Cummings Louise, 2005, PRAGMATICS MULTIDISC; Damico JS, 1985, COMMUNICATION SKILLS, P165; Douglas J., 2004, EVIDENCE BASED PRACT, P59; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [DOI 10.1007/BF02214959, 10.1007/BF02214959]; Goozee JV, 2000, BRAIN INJURY, V14, P153, DOI 10.1080/026990500120817; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Grafman J, 1999, LANCET, V354, P1921, DOI 10.1016/S0140-6736(99)90438-5; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Heaton R., 1993, WISCONSIN CARD SORTI; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ivnik R. J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; Joanette Y, 1999, BRAIN LANG, V68, P529, DOI 10.1006/brln.1999.2126; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MUSCOVITCH M, 2002, PRINCIPLES FRONTAL L, P188; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Perkins MR, 2005, CLIN LINGUIST PHONET, V19, P367, DOI 10.1080/02699200400027155; Perkins MR, 1998, J PRAGMATICS, V29, P291, DOI 10.1016/S0378-2166(97)00055-6; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Rolls ET, 1999, NEUROCASE, V5, P301, DOI 10.1080/13554799908411984; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 2000, BRAIN INJURY, V14, P397; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O, 1969, NEUROSENSORY CTR COM; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2005, CURR DIR PSYCHOL SCI, V14, P84, DOI 10.1111/j.0963-7214.2005.00340.x; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Szatkowska I, 2000, ACTA NEUROBIOL EXP, V60, P503; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Turkstra L., 1995, BRAIN INJURY, V10, P319; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wang YT, 2005, FOLIA PHONIATR LOGO, V57, P59, DOI 10.1159/000083569; Wechsler D., 1945, WECHSLER MEMORY SCAL; Wheeler M A, 1995, J Int Neuropsychol Soc, V1, P525; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson D, 2005, LINGUA, V115, P1129, DOI 10.1016/j.lingua.2004.02.005; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	108	72	75	0	20	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	APR 1	2010	53	2					365	382		10.1044/1092-4388(2009/08-0205)			18	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	585EI	WOS:000276806800010	20360462				2021-06-18	
J	Brenner, LA; Terrio, H; Homaifar, BY; Gutierrez, PM; Staves, PJ; Harwood, JEF; Reeves, D; Adler, LE; Ivins, BJ; Helmick, K; Warden, D				Brenner, Lisa A.; Terrio, Heidi; Homaifar, Beeta Y.; Gutierrez, Peter M.; Staves, Pamela J.; Harwood, Jeri E. F.; Reeves, Dennis; Adler, Lawrence E.; Ivins, Brian J.; Helmick, Katherine; Warden, Deborah			Neuropsychological Test Performance in Soldiers With Blast-Related Mild TBI	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; TBI; Iraq; posttraumatic stress disorder; PTSD	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHIATRIC INTERVIEW MINI; HEAD-INJURY; IRAQ; CONCUSSION; AFGHANISTAN; ATTENTION; OUTCOMES; MEMORY	This exploratory study was conducted to increase understanding of neuropsychological test performance in those with blast-related mild traumatic brain injury (mTBI). The two variables of interest for their impact oil test performance were presence of mTBI symptoms and history of posttraumatic stress disorder (PTSD). Forty-five soldiers postblast mTBI, 27 with enduring mTBI symptoms and 18 without, completed a series of neuropsychological tests. Seventeen of the 45 met criteria for PTSD. The Paced Auditory Serial Addition Test (Frencham, Fox, & Mayberry. 2005; Spreen & Strauss, 1998) was the primary Outcome Measure. Two-sided. 2-sample t tests were used to compare scores between groups of interest. Presence of mTBI symptoms did not impact test performance. In addition, no significant differences between soldiers with and without PTSD were identified. Standard neuropsychological assessment may not increase understanding about impairment associated with mTBI symptoms. Further research in this area is indicated.	[Brenner, Lisa A.; Homaifar, Beeta Y.; Gutierrez, Peter M.; Staves, Pamela J.; Adler, Lawrence E.] VA VISN 19 MIRECC, Denver, CO 80220 USA; [Brenner, Lisa A.; Homaifar, Beeta Y.; Gutierrez, Peter M.; Harwood, Jeri E. F.; Adler, Lawrence E.] Univ Colorado Denver, Sch Med, Denver, CO USA; [Terrio, Heidi] Evans Army Community Hosp, Dept Deployment Hlth & Headquarters, Ft Carson, CO USA; [Terrio, Heidi; Ivins, Brian J.; Helmick, Katherine; Warden, Deborah] Def & Vet Brain Injury Ctr, Washington, DC USA; [Reeves, Dennis] Behav Neurosci Syst, Springfield, MO USA	Brenner, LA (corresponding author), VA VISN 19 MIRECC, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Gutierrez, Peter/K-8905-2019; Brenner, Lisa A./AAG-2442-2019	Gutierrez, Peter/0000-0001-8981-8404; 			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blakesley RE, 2009, NEUROPSYCHOLOGY, V23, P255, DOI 10.1037/a0012850; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BRADSHAW D, 2007, TRAUMATIC BRAIN INJU; Bremner JD, 1995, PSYCHIAT RES, V59, P97; Brenner L. A., J HEAD TRAU IN PRESS; BRENNER LA, 2009, MILITARY MED; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Computerised Wisconsin card sort task, 2003, COMP WISC CARD SORT; CONDER R, 1992, MANUAL COMPUTERIZED; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Elsmore TF, 2007, ARCH CLIN NEUROPSYCH, V22, pS135, DOI 10.1016/j.acn.2006.10.009; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Golden C., 1978, STROOP COLOR WORD TE; Gurvits TV, 2000, ARCH GEN PSYCHIAT, V57, P181, DOI 10.1001/archpsyc.57.2.181; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heaton RK, 2004, REVISED COMPREHENSIV; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Lebowitz B. K., 2006, J INT NEUROPSYCHO S1, V12, P217; LETZ R, 2000, NES 3 USERS MANUAL; McNally RJ, 2006, TRENDS COGN SCI, V10, P271, DOI 10.1016/j.tics.2006.04.007; McNally RJ, 1998, CLIN PSYCHOL REV, V18, P971, DOI 10.1016/S0272-7358(98)00036-1; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Reeves D., 2002, ANAM 2001 USERS MANU; Reeves D, 2007, ANN REV CYBERTHERAPY, V5, P173; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sheehan D., 2005, MINI INT NEUROPSYCHI; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smith A., 1968, LEARNING DISORDERS, P83; Spitzer RL, 1990, STRUCTURED CLIN INTE; Spreen O., 1998, COMPENDIUM NEUROPSYC; *SRP, 2007, WARR ADM RETR CAS AS; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125	56	72	72	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2010	24	2					160	167		10.1037/a0017966			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	567XV	WOS:000275483100004	20230110				2021-06-18	
J	Kirkwood, MW; Kirk, JW				Kirkwood, Michael W.; Kirk, John W.			The base rate of suboptimal effort in a pediatric mild TBI sample: Performance on the Medical Symptom Validity Test	CLINICAL NEUROPSYCHOLOGIST			English	Article						Medical Symptom Validity Test; Effort testing; Children; Post-concussion; Mild traumatic brain injury	WORD MEMORY TEST; RESPONSE BIAS; BRAIN-INJURY; HEAD-INJURY; CHILDREN; NEUROPSYCHOLOGY; ADOLESCENTS; CAPACITY; ADULTS; TOMM	Performance on the Medical Symptom Validity Test (MSVT) was examined in 193 consecutively referred patients aged 8 through 17 years who had sustained a mild traumatic brain injury. A total of 33 participants failed to meet actuarial criteria for valid effort on the MSVT. After accounting for possible false positives and false negatives, the base rate of suboptimal effort in this clinical sample was 17%. Only one MSVT failure was thought to be influenced by litigation. The present results suggest that a sizable minority of children is capable of putting forth suboptimal effort during neuropsychological exam, even when external incentives are not readily apparent. The MSVT appears to have good potential value as an objective measure for detecting symptom invalidity in school-age youth.	[Kirkwood, Michael W.; Kirk, John W.] Department of Phys Medicine Rehabilitat, Univers of Colorado Denver and Childrens Hospital, Aurora, CO USA							Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P., 2004, MANUAL GREENS MED SY; Green P., 2007, ASSESSMENT FEIGNED C; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; McCrea M, 2008, MILD TRAUMATIC BRAIN; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; OLDERSHAW L, 1997, CLIN ASSESSMENT MALI, P153; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Talwar V, 2008, CHILD DEV, V79, P866, DOI 10.1111/j.1467-8624.2008.01164.x; Tombaugh TN, 1996, TEST MEMORY MALINGER; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	35	72	72	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	5					860	872	PII 919486568	10.1080/13854040903527287			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	616PM	WOS:000279221300008	20182954				2021-06-18	
J	Scafidi, S; Racz, J; Hazelton, J; McKenna, MC; Fiskum, G				Scafidi, Susanna; Racz, Jennifer; Hazelton, Julie; McKenna, Mary C.; Fiskum, Gary			Neuroprotection by Acetyl-L-Carnitine after Traumatic Injury to the Immature Rat Brain	DEVELOPMENTAL NEUROSCIENCE			English	Article						Controlled cortical impact; Sensorimotor function; Memory; Hippocampus; Acetyl-L-carnitine; Neuroprotection; Novel object recognition	TRANSIENT FOREBRAIN ISCHEMIA; CORTICAL IMPACT INJURY; OXIDATIVE STRESS; PYRUVATE-DEHYDROGENASE; RECOGNITION MEMORY; ENERGY-METABOLISM; OBJECT RECOGNITION; CEREBRAL-ISCHEMIA; PROTEIN OXIDATION; NEURONAL DAMAGE	Traumatic brain injury (TBI) is the leading cause of mortality and morbidity in children and is characterized by reduced aerobic cerebral energy metabolism early after injury, possibly due to impaired activity of the pyruvate dehydrogenase complex. Exogenous acetyl-L-carnitine (ALCAR) is metabolized in the brain to acetyl coenzyme A and subsequently enters the tricarboxylic acid cycle. ALCAR administration is neuroprotective in animal models of cerebral ischemia and spinal cord injury, but has not been tested for TBI. This study tested the hypothesis that treatment with ALCAR during the first 24 h following TBI in immature rats improves neurologic outcome and reduces cortical lesion volume. Postnatal day 21-22 male rats were isoflurane anesthetized and used in a controlled cortical impact model of TBI to the left parietal cortex. At 1, 4, 12 and 23 h after injury, rats received ALCAR (100 mg/kg, intraperitoneally) or drug vehicle (normal saline). On days 3-7 after surgery, behavior was assessed using beam walking and novel object recognition tests. On day 7, rats were transcardially perfused and brains were harvested for histological assessment of cortical lesion volume, using stereology. Injured animals displayed a significant increase in foot slips compared to sham-operated rats (6 +/- 1 SEM vs. 2 +/- 0.2 on day 3 after trauma; n = 7; p < 0.05). The ALCAR-treated rats were not different from shams and had fewer foot slips compared to vehicle-treated animals (2 +/- 0.4; n = 7; p < 0.05). The frequency of investigating a novel object for saline-treated TBI animals was reduced compared to shams (45 +/- 5% vs. 65 +/- 10%; n = 7; p < 0.05), whereas the frequency of investigation for TBI rats treated with ALCAR was not significantly different from that of shams but significantly higher than that of saline-treated TBI rats (68 +/- 7; p < 0.05). The left parietal cortical lesion volume, expressed as a percentage of the volume of tissue in the right hemisphere, was significantly smaller in ALCAR-treated than in vehicle-treated TBI rats (14 +/- 5% vs. 28 +/- 6%; p < 0.05). We conclude that treatment with ALCAR during the first 24 h after TBI improves behavioral outcomes and reduces brain lesion volume in immature rats within the first 7 days after injury. Copyright (C) 2011 S. Karger AG, Basel	[Racz, Jennifer; Hazelton, Julie; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Scafidi, Susanna; McKenna, Mary C.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Racz, Jennifer; Hazelton, Julie; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W Baltimore St, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu		Scafidi, Susanna/0000-0002-1229-8778	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01HD16596]; University of Maryland Departmet of Pediatrics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER	The study was supported by NIH grant No. P01HD16596 and by a grant from the University of Maryland Departmet of Pediatrics.	Al-Majed AA, 2006, CLIN EXP PHARMACOL P, V33, P725, DOI 10.1111/j.1440-1681.2006.04425.x; Allen GV, 2001, NEUROSCIENCE, V102, P603, DOI 10.1016/S0306-4522(00)00519-4; Ames BN, 2004, ANN NY ACAD SCI, V1033, P108, DOI 10.1196/annals.1320.010; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; AURELI T, 1994, BRAIN RES, V643, P92, DOI 10.1016/0006-8993(94)90013-2; Barhwal K, 2009, NEUROSCIENCE, V161, P501, DOI 10.1016/j.neuroscience.2009.02.086; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Calabrese V, 2005, J NEUROSCI RES, V79, P509, DOI 10.1002/jnr.20386; Calabrese V, 2008, NEUROCHEM RES, V33, P2444, DOI 10.1007/s11064-008-9775-9; Carter R J, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0812s15; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ennaceur A, 2010, BEHAV BRAIN RES, V215, P244, DOI 10.1016/j.bbr.2009.12.036; Ferraresi R, 2006, FEBS LETT, V580, P6612, DOI 10.1016/j.febslet.2006.11.016; FISKUM G, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P487; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Faria MHG, 2007, ACTA CIR BRAS, V22, P125, DOI 10.1590/S0102-86502007000200009; Hagberg H, 2009, J CHILD NEUROL, V24, P1141, DOI 10.1177/0883073809338212; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Ishii T, 2000, JPN J PHARMACOL, V83, P119, DOI 10.1254/jjp.83.119; Jalal FY, 2010, ANN NY ACAD SCI, V1199, P95, DOI 10.1111/j.1749-6632.2009.05351.x; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Koppaka SS, 2008, ADV EXP MED BIOL, V614, P361; Liu JK, 2004, ANN NY ACAD SCI, V1033, P117, DOI 10.1196/annals.1320.011; LIU YB, 1993, FREE RADICAL BIO MED, V15, P667, DOI 10.1016/0891-5849(93)90171-P; Lolic MM, 1997, ANN EMERG MED, V29, P758, DOI 10.1016/S0196-0644(97)70197-5; Loots DT, 2004, LIFE SCI, V75, P1243, DOI 10.1016/j.lfs.2004.03.007; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PARNETTI L, 1992, EUR J CLIN PHARMACOL, V42, P89, DOI 10.1007/BF00314926; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; PETTEGREW JW, 1990, J NEUROPATH EXP NEUR, V49, P237, DOI 10.1097/00005072-199005000-00005; Poon HF, 2006, ANTIOXID REDOX SIGN, V8, P381, DOI 10.1089/ars.2006.8.381; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; Shen W, 2008, J CELL BIOCHEM, V104, P1232, DOI 10.1002/jcb.21701; SHUAIB A, 1995, NEUROCHEM RES, V20, P1021, DOI 10.1007/BF00995555; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Virmani MA, 2001, ANN NY ACAD SCI, V939, P162; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; WINTER BK, 1995, BRIT J CANCER, V72, P1173, DOI 10.1038/bjc.1995.482; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yasui F, 2002, NEUROSCI LETT, V334, P177, DOI 10.1016/S0304-3940(02)01127-8; Youle M, 2007, HIV MED, V8, P241, DOI 10.1111/j.1468-1293.2007.00467.x; Zanelli SA, 2005, ANN NY ACAD SCI, V1053, P153, DOI 10.1196/annals.1344.013	66	72	74	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					480	487		10.1159/000323178			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900016	21228558	Green Published, Bronze			2021-06-18	
J	Pandey, DK; Yadav, SK; Mahesh, R; Rajkumar, R				Pandey, Dilip Kumar; Yadav, Sushil Kumar; Mahesh, Radhakrishnan; Rajkumar, Ramamoorthy			Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: A model of comorbid depression and anxiety?	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Comorbid; Depression; Anxiety; Behavioural test battery; Escitalopram	SEROTONIN REUPTAKE INHIBITOR; OLFACTORY BULBECTOMIZED RAT; MARBLE-BURYING BEHAVIOR; ELEVATED PLUS-MAZE; MAJOR DEPRESSION; ANIMAL-MODELS; AMYGDALOID-LESIONS; SOCIAL-INTERACTION; SEXUAL-BEHAVIOR; HEAD-INJURY	Depression and anxiety tend to be the most prevalent conditions among the multitude of neurobehavioural disorders which cause distress in the survivors of traumatic brain injury (TBI) The objective of the present investigation was to examine depression-like and anxiety-like behaviour of rats following diffuse TBI Impact accelerated TBI was induced in anaesthetised rats by a modified weight drop method. TBI and sham-operated rats received either a chronic (14 days) regimen of escitalopram (5-20 mg/kg) or vehicle, following which they were subjected to a behavioural test battery. The results evince the depression-like behaviour of TBI rats in modified open field exploration. hyperemotionality. socio-sexual interaction and elevated plus-maze exploration paradigms. In addition. an anxiety-like behaviour was evident in social interaction and marble-burying tests Chronic escitalopram (10 and 20 mg/kg) treatment significantly attenuated the TBI associated behavioural deficits. In conclusion, the aforesaid behavioural anomalies observed in TBI rats are analogous to comorbid anxiety and depression in humans. These findings substantiate the TBI rats as a candidate model of comorbid anxiety and depression. (C) 2009 Elsevier B V All rights reserved.	[Pandey, Dilip Kumar; Mahesh, Radhakrishnan; Rajkumar, Ramamoorthy] Birla Inst Technol & Sci, Pharm Grp, FD III, Pilani 333031, Rajasthan, India; [Yadav, Sushil Kumar] Birla Inst Technol & Sci, Cent Anim Facil, Pilani 333031, Rajasthan, India	Rajkumar, R (corresponding author), Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Ctr Life Sci, Level 4,28 Med Dr, Singapore 117456, Singapore.	rajkumar.sai@gmail.com	Rajkumar, Ramamoorthy/M-8135-2014	Rajkumar, Ramamoorthy/0000-0002-8047-7524	Council of Scientific and Industrial ResearchCouncil of Scientific & Industrial Research (CSIR) - India	The authors thank Glenmark Pharmaceuticals Limited, India for providing escitalopram as a generous gift sample in short notice. Pandey DK wishes to thank the Council of Scientific and Industrial Research for partly funding this work.	American Psychiatric Association, 2000, TEXT REV, P780; Andrews G, 2000, B WORLD HEALTH ORGAN, V78, P446; Aquilani R, 2003, ARCH PHYS MED REHAB, V84, P1258, DOI 10.1016/S0003-9993(03)00148-5; Bareggi SR, 2007, EXPERT OPIN DRUG MET, V3, P741, DOI 10.1517/17425225.3.5.741; BRITTON A, 1988, BRAIN INJURY, V12, P703; BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; DENENBERG VH, 1969, ANN NY ACAD SCI, V159, P852, DOI 10.1111/j.1749-6632.1969.tb12983.x; EDWARDS DA, 1990, PHYSIOL BEHAV, V48, P447, DOI 10.1016/0031-9384(90)90342-2; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; File S E, 1990, Drug Des Deliv, V5, P195; FILE SE, 1978, BRIT J PHARMACOL, V62, P19, DOI 10.1111/j.1476-5381.1978.tb07001.x; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; GOMITA Y, 1984, PHYSIOL BEHAV, V32, P1011, DOI 10.1016/0031-9384(84)90294-4; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Ho YJ, 2002, BEHAV BRAIN RES, V136, P1, DOI 10.1016/S0166-4328(02)00089-X; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; HOWLAND RH, 2002, J PSYCHIAT, V329, P891; ICHIMARU Y, 1995, JPN J PHARMACOL, V68, P65, DOI 10.1254/jjp.68.65; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JOSEPH AB, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199504000-00010; KARLOVSKY ME, 2007, ACQUIRED BRAIN INJUR, P64; Kelly JP, 1997, PHARMACOL THERAPEUT, V74, P299, DOI 10.1016/S0163-7258(97)00004-1; Kennedy Sidney H, 2008, Dialogues Clin Neurosci, V10, P271; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KING FA, 1958, SCIENCE, V128, P655, DOI 10.1126/science.128.3325.655; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; LIGHTOWLER S, 1994, PHARMACOL BIOCHEM BE, V49, P281, DOI 10.1016/0091-3057(94)90422-7; LIJIMA M, 2007, PROG NEUROPSYCHOPHAR, V31, P622; Malin Paulajo, 2004, Expert Rev Neurother, V4, P769, DOI 10.1586/14737175.4.5.769; Markel A L, 1989, Neurosci Behav Physiol, V19, P279, DOI 10.1007/BF01236015; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MEYERSON BJ, 1981, ACTA PHARMACOL TOX, V48, P168; Michelson A M, 1988, Free Radic Res Commun, V4, P209, DOI 10.3109/10715768809055145; Mohamed Somaia, 2006, Am J Geriatr Pharmacother, V4, P201, DOI 10.1016/j.amjopharm.2006.08.001; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; O'Neil MF, 2003, HUM PSYCHOPHARM CLIN, V18, P239, DOI 10.1002/hup.496; OCONNOR WT, 1988, PROG NEURO-PSYCHOPH, V12, P41, DOI 10.1016/0278-5846(88)90060-7; Olie JP, 2007, DEPRESS ANXIETY, V24, P318, DOI 10.1002/da.20207; Pandey DK, 2008, J PHARM PHARMACOL, V60, P1643, DOI 10.1211/jpp/60.12.0010; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pinheiro SN, 2008, J PSYCHOPHARMACOL, V22, P132, DOI 10.1177/0269881107079866; Primeaux SD, 1999, PHYSIOL BEHAV, V67, P41, DOI 10.1016/S0031-9384(99)00027-X; RAITT JR, 1961, BRIT J PHARM CHEMOTH, V17, P473, DOI 10.1111/j.1476-5381.1961.tb01134.x; Rajkumar R, 2009, EUR J PHARMACOL, V608, P32, DOI 10.1016/j.ejphar.2009.02.041; Ramamoorthy R, 2008, BEHAV PHARMACOL, V19, P29, DOI 10.1097/FBP.0b013e3282f3cfd4; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; Rodgers RJ, 1997, BEHAV PHARMACOL, V8, P477, DOI 10.1097/00008877-199711000-00003; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Sanchez C, 2003, PSYCHOPHARMACOLOGY, V167, P353, DOI 10.1007/s00213-002-1364-z; SHIBATA S, 1982, PHYSIOL BEHAV, V28, P289, DOI 10.1016/0031-9384(82)90077-4; SHIBATA S, 1984, PHARMACOL BIOCHEM BE, V21, P225, DOI 10.1016/0091-3057(84)90219-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stamouli S, 2008, EUR PSYCHIAT, V23, pS207, DOI 10.1016/j.eurpsy.2008.01.342; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Stein DJ, 2006, EUR NEUROPSYCHOPHARM, V16, P33, DOI 10.1016/j.euroneuro.2005.05.004; Stein MB, 2008, LANCET, V371, P1115, DOI 10.1016/S0140-6736(08)60488-2; Sziray N, 2007, BRAIN RES BULL, V71, P376, DOI 10.1016/j.brainresbull.2006.10.006; TREIT D, 1981, PHARMACOL BIOCHEM BE, V15, P619, DOI 10.1016/0091-3057(81)90219-7; Uday G, 2007, EUR J PHARMACOL, V563, P155, DOI 10.1016/j.ejphar.2007.02.016; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wade A, 2002, INT CLIN PSYCHOPHARM, V17, P95, DOI 10.1097/00004850-200205000-00001; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wang DY, 2007, BEHAV BRAIN RES, V178, P262, DOI 10.1016/j.bbr.2007.01.003; Waugh J, 2003, CNS DRUGS, V17, P343, DOI 10.2165/00023210-200317050-00004; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	94	72	74	1	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 28	2009	205	2					436	442		10.1016/j.bbr.2009.07.027			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	512MI	WOS:000271253100017	19660499				2021-06-18	
J	Brady, KM; Shaffner, DH; Lee, JK; Easley, RB; Smielewski, P; Czosnyka, M; Jallo, GI; Guerguerian, AM				Brady, Ken M.; Shaffner, Donald H.; Lee, Jennifer K.; Easley, R. Blaine; Smielewski, Peter; Czosnyka, Marek; Jallo, George I.; Guerguerian, Anne-Marie			Continuous Monitoring of Cerebrovascular Pressure Reactivity After Traumatic Brain Injury in Children	PEDIATRICS			English	Article						traumatic brain injury; cerebrovascular pressure reactivity; autoregulation	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; BLOOD-FLOW; WAVE-FORM; AUTOREGULATION; AGE; METABOLISM	OBJECTIVE: We hypothesized that pressure reactivity index (PRx) values indicating preserved cerebrovascular pressure autoregulation would be associated with survival in children with traumatic brain injury (TBI). This hypothesis was tested in a prospective, blinded, observational, pilot study. METHODS: Twenty-one children admitted between May 2006 and September 2008 with severe TBI necessitating invasive intracranial pressure monitoring were enrolled in this study. The PRx was continuously monitored as a moving, linear correlation coefficient between low-frequency waves of intracranial and arterial blood pressures. Positive values of PRx approaching 1 indicate impaired cerebrovascular pressure reactivity, whereas negative PRx values or values close to 0 indicate preserved cerebrovascular pressure reactivity. Survival was the primary outcome and was compared with the average PRx value obtained during the intracranial pressure-monitoring period. RESULTS: PRx was associated with survival in this cohort; survivors (N = 15) had a mean PRx +/- SD of 0.08 +/- 0.19, and nonsurvivors (N = 6) had a mean PRx of 0.69 +/- 0.21 (P = .0009). In this sample, continuous PRx monitoring suggested impaired cerebrovascular pressure reactivity at low levels of cerebral perfusion pressure (CPP) and intact cerebrovascular pressure reactivity at higher levels of CPP. CONCLUSIONS: Intact cerebrovascular pressure reactivity quantified with the PRx is associated with survival after severe head trauma in children. The PRx is CPP dependent in children. The PRx may be useful for defining age-specific and possibly patient-specific optimal targets for CPP after TBI. Pediatrics 2009; 124: e1205-e1212	[Brady, Ken M.] Johns Hopkins Univ, Div Pediat Anesthesiol & Crit Care Med, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Jallo, George I.] Johns Hopkins Univ, Dept Neurosurg, Sch Med, Baltimore, MD 21287 USA; [Smielewski, Peter; Czosnyka, Marek] Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge, England; [Guerguerian, Anne-Marie] Hosp Sick Children, Dept Crit Care, Toronto, ON M5G 1X8, Canada; [Guerguerian, Anne-Marie] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada	Brady, KM (corresponding author), Johns Hopkins Univ, Div Pediat Anesthesiol & Crit Care Med, Sch Med, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Blalock 904, Baltimore, MD 21287 USA.	kbrady5@jhmi.edu		Smielewski, Peter/0000-0001-5096-3938; SHAFFNER, DONALD/0000-0001-5530-0746	National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: Medline		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; GUILLAUME J, 1951, REV NEUROL, V84, P131; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Martin JA, 2008, PEDIATRICS, V121, P788, DOI 10.1542/peds.2007-3753; MEINERT CL, 1996, CLIN TRIALS DICT TER; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Monro A, 1823, OBSERVATIONS STRUCTU; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	30	72	72	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2009	124	6					E1205	E1212		10.1542/peds.2009-0550			8	Pediatrics	Pediatrics	524SE	WOS:000272162400049	19948619				2021-06-18	
J	Shein, NA; Grigoriadis, N; Alexandrovich, AG; Simeonidou, C; Lourbopoulos, A; Polyzoidou, E; Trembovler, V; Mascagni, P; Dinarello, CA; Shohami, E				Shein, Na'ama A.; Grigoriadis, Nikolaos; Alexandrovich, Alexander G.; Simeonidou, Constantina; Lourbopoulos, Athanasios; Polyzoidou, Eleni; Trembovler, Victoria; Mascagni, Paolo; Dinarello, Charles A.; Shohami, Esther			Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury	FASEB JOURNAL			English	Article						epigenetic; closed head injury; regeneration	FOCAL CEREBRAL-ISCHEMIA; CLOSED-HEAD INJURY; SUBEROYLANILIDE HYDROXAMIC ACID; AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; BINDING-PROTEIN CBP; HUNTINGTONS-DISEASE; ANTILEUKEMIC ACTIVITY; NERVOUS-SYSTEM; VALPROIC ACID	Despite efforts aimed at developing novel therapeutics for traumatic brain injury (TBI), no specific pharmacological agent is currently clinically available. Here, we show that the pan-histone deacetylase (HDAC) inhibitor ITF2357, a compound shown to be safe and effective in humans, improves functional recovery and attenuates tissue damage when administered as late as 24 h postinjury. Using a well-characterized, clinically relevant mouse model of closed head injury (CHI), we demonstrate that a single dose of ITF2357 administered 24 h postinjury improves neurobehavioral recovery from d 6 up to 14 d postinjury (improved neurological score vs. vehicle; P <= 0.05), and that this functional benefit is accompanied by decreased neuronal degeneration, reduced lesion volume (22% reduction vs. vehicle; P <= 0.01), and is preceded by increased acetylated histone H3 levels and attenuation of injury-induced decreases in cytoprotective heat-shock protein 70 kDa and phosphorylated Akt. Moreover, reduced glial accumulation and activation were observed 3 d postinjury, and total p53 levels at the area of injury and caspase-3 immunoreactivity within microglia/macrophages at the trauma area were elevated, suggesting enhanced clearance of these cells via apoptosis following treatment. Hence, our findings underscore the relevance of HDAC inhibitors for ameliorating trauma-induced functional deficits and warrant consideration of applying ITF2357 for this indication.-Shein, N. A., Grigoriadis, N., Alexandrovich, A. G., Simeonidou, C., Lourbopoulos, A., Polyzoidou, E., Trembovler, V., Mascagni, P., Dinarello, C. A., Shohami, E. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23, 4266-4275 (2009). www.fasebj.org	[Shein, Na'ama A.; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Grigoriadis, Nikolaos; Lourbopoulos, Athanasios; Polyzoidou, Eleni] AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Dept Physiol, GR-54006 Thessaloniki, Greece; [Mascagni, Paolo] Res Ctr, Balsamo, Italy; [Dinarello, Charles A.] Univ Colorado Denver, Dept Med, Aurora, CO USA	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Dinarello, Charles/C-8524-2013		U. S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI-15614]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI015614, R37AI015614] Funding Source: NIH RePORTER	E. S. is the incumbent of the Dr. Leon and Mina Deutch Chair in psychopharmacology at the Hebrew University. This work was supported by U. S. National Institutes of Health grant AI-15614 (to C. A. D.). P. M. is an employee of Italfarmaco, S. p. A., Italy. The authors thank Prof. A. Rubinstein (Hebrew University) for his assistance in obtaining antibodies used in this series of experiments.	Albert MS, 2007, NEW ENGL J MED, V357, P502, DOI 10.1056/NEJMcibr073273; Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Atweh GF, 1999, BLOOD, V93, P1790; Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brown IR, 2007, ANN NY ACAD SCI, V1113, P147, DOI 10.1196/annals.1391.032; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Carlisi D, 2008, INT J ONCOL, V32, P177; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gerstner T, 2008, EXPERT OPIN PHARMACO, V9, P285, DOI [10.1517/14656566.9.2.285, 10.1517/14656566.9.2.285 ]; Glauben R, 2008, GUT, V57, P613, DOI 10.1136/gut.2007.134650; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Golay J, 2007, LEUKEMIA, V21, P1892, DOI 10.1038/sj.leu.2404860; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Hahnen E, 2008, EXPERT OPIN INV DRUG, V17, P169, DOI 10.1517/13543784.17.2.169; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin KL, 2001, J MOL NEUROSCI, V16, P49, DOI 10.1385/JMN:16:1:49; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Khan O, 2008, NAT CLIN PRACT ONCOL, V5, P714, DOI 10.1038/ncponc1238; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006-00005.Dinarello; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Moussaieff A, 2008, J CEREBR BLOOD F MET, V28, P1341, DOI 10.1038/jcbfm.2008.28; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; Perrine SP, 2005, ANN NY ACAD SCI, V1054, P257, DOI 10.1196/annals.1345.033; Petri S, 2006, NEUROBIOL DIS, V22, P40, DOI 10.1016/j.nbd.2005.09.013; Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339; Rouaux C, 2004, BIOCHEM PHARMACOL, V68, P1157, DOI 10.1016/j.bcp.2004.05.035; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Thomas EA, 2008, P NATL ACAD SCI USA, V105, P15564, DOI 10.1073/pnas.0804249105; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Vojinovic J, 2008, ARTHRITIS RHEUM-US, V58, pS943; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Ying MY, 2006, J BIOL CHEM, V281, P12580, DOI 10.1074/jbc.M511677200; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085	51	72	73	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4266	4275		10.1096/fj.09-134700			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	WOS:000272193700021	19723705	Green Published			2021-06-18	
J	Smith, RM; Conn, AKT				Smith, R. Malcolm; Conn, Alasdair K. T.			Prehospital care - Scoop and run or stay and play?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Prehospital Care; "Scoop and run"; "Stay and play"	TRAUMATIC BRAIN-INJURY; LIFE-SUPPORT; HEAD-INJURY; INTUBATION	Improved training and expertise has enabled emergency medical personnel to provide advanced levels of care at the scene of trauma. While this could be expected to improve the outcome from major injury, current data does not support this. Indeed, prehospital interventions beyond the BLS level have not been shown to be effective and in many cases have proven to be detrimental to patient outcome. It is better to "scoop and run" than "stay and play". Current data relates to the urban environment where transport times to trauma centres are short and where it appears better to simply rapidly transport the patient to hospital than attempt major interventions at the scene. There may be more need for advanced techniques in the rural environment or where transport times are prolonged and certainly a need for more studies into subsets of patients who may benefit from interventions in the field.	[Smith, R. Malcolm] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Trauma Serv, Boston, MA 02114 USA	Smith, RM (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Trauma Serv, 55 Fruit St,WACC 5-525, Boston, MA 02114 USA.	rmsmith@partners.org					Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Cornwell EE, 2000, ARCH SURG-CHICAGO, V135, P315, DOI 10.1001/archsurg.135.3.315; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Isenberg DL, 2005, PREHOSPITAL DISASTER, V20, P265, DOI 10.1017/S1049023X0000265X; Liberman M, 2003, ANN SURG, V237, P153, DOI 10.1097/00000658-200302000-00001; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Novak L, 1999, J TRAUMA, V47, P834, DOI 10.1097/00005373-199911000-00003; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154	9	72	74	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	NOV	2009	40						S23	S26		10.1016/j.injury.2009.10.033			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	534YI	WOS:000272933100004	19895949				2021-06-18	
J	Tejima, E; Guo, SZ; Murata, Y; Arai, K; Lok, J; van Leyen, K; Rosell, A; Wang, XY; Lo, EH				Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Rosell, Anna; Wang, Xiaoying; Lo, Eng H.			Neuroprotective Effects of Overexpressing Tissue Inhibitor of Metalloproteinase TIMP-1	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; neuroprotection; neurovascular unit; stroke; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; BLOOD-BRAIN-BARRIER; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; ALZHEIMERS-DISEASE; CELL-DEATH; PLASMINOGEN-ACTIVATOR; MMP-9/TIMP-1 RATIO; REPERFUSION INJURY; ENDOTHELIAL-CELLS	Accumulating data suggest that matrix metalloproteinases (MMPs) may be important mediators in the pathophysiology of acute brain injury after trauma or stroke. Here, we test the hypothesis that the endogenous tissue inhibitor of metalloproteinase (TIMP-1) is neuroprotective in vitro and in vivo. For in vitro studies, primary cortical neuronal cultures were subjected to hypoxia and reoxygenation. Treatment with recombinant TIMP-1 protein significantly decreased neuronal death. In vivo studies in models of brain trauma and stroke supported these cell culture results. After controlled cortical impact, 24-h MMP-9 levels were significantly reduced in transgenic mice overexpressing TIMP-1 compared to wild-type mice. And at 7 days post-trauma, brain lesion volumes were also significantly decreased by TIMP-1 overexpression as well. In a model of transient 2-h focal cerebral ischemia, MMP-9 levels were lower in TIMP-1 transgenic mice compared with wild-types. Correspondingly, blood-brain barrier leakage was ameliorated by TIMP-1 overexpression, and 24-h infarction volumes were also reduced. Taken together, these cell culture and in vivo data provide initial proof-of-principle that TIMP-1 is neuroprotective against traumatic and ischemic brain injury in mice.	[Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Rosell, Anna; Wang, Xiaoying; Lo, Eng H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, Charlestown, MA 02129 USA; [Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Rosell, Anna; Wang, Xiaoying; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Sch Med, Program Neurosci, Charlestown, MA USA; [Lok, Josephine] Harvard Univ, Sch Med, Boston, MA USA; [Lok, Josephine] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA	Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, MGH E 149-2401, Charlestown, MA 02129 USA.	Lo@helix.mgh.harvard.edu	van Leyen, Klaus/C-9126-2013	van Leyen, Klaus/0000-0003-1032-3754; Rosell Novel, Anna/0000-0003-1082-3599	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); American Stroke Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS057339] Funding Source: NIH RePORTER	This research was supported in part by grants from NINDS and a Bugher award from the American Stroke Association.	Adair JC, 2004, STROKE, V35, pE159, DOI 10.1161/01.STR.0000127420.10990.76; Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; Baker AH, 2007, P NATL ACAD SCI USA, V104, P3597, DOI 10.1073/pnas.0611112104; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Chirco R, 2006, CANCER METAST REV, V25, P99, DOI 10.1007/s10555-006-7893-x; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guedez L, 2001, AM J PATHOL, V158, P1207, DOI 10.1016/S0002-9440(10)64070-9; Jiang XF, 2001, NEUROSCI LETT, V305, P41, DOI 10.1016/S0304-3940(01)01800-6; Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kruger A, 1998, ONCOGENE, V16, P2419, DOI 10.1038/sj.onc.1201774; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4; Magnoni S, 2007, GENE THER, V14, P621, DOI 10.1038/sj.gt.3302894; Montaner J, 2006, DRUG NEWS PERSPECT, V19, P523, DOI 10.1358/dnp.2006.19.9.1050422; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Reeves TM, 2003, J NEUROSCI, V23, P10182; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 2001, STROKE, V32, P1162, DOI 10.1161/01.STR.32.5.1162; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Sellner J, 2006, NEUROBIOL DIS, V21, P647, DOI 10.1016/j.nbd.2005.09.007; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Stetler-Stevenson WG, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127re6; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Tejima E, 2007, J CEREBR BLOOD F MET, V27, P460, DOI 10.1038/sj.jcbfm.9600354; Thirumangalakudi L, 2006, J ALZHEIMERS DIS, V10, P111; Tsuji K, 2005, STROKE, V36, P1954, DOI 10.1161/01.STR.0000177517.01203.eb; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang L, 2006, J NEUROSCI, V26, P5996, DOI 10.1523/JNEUROSCI.5380-05.2006; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Waubant E, 2003, NEUROLOGY, V60, P52, DOI 10.1212/WNL.60.1.52; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	49	72	77	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1935	1941		10.1089/neu.2009.0959			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600009	19469687	Green Published			2021-06-18	
J	Ho, J; Kleiven, S				Ho, Johnson; Kleiven, Svein			Can sulci protect the brain from traumatic injury?	JOURNAL OF BIOMECHANICS			English	Article						Human head model; Finite element analysis; Cerebral convolution; Traumatic brain injury	DIFFUSE AXONAL INJURY; WHITE-MATTER; HEAD IMPACT; MODEL; SEGMENTATION; EPIDEMIOLOGY; SIMULATIONS; PRIMATE; MATER	The influence of sulci in dynamic finite element simulations of the human head has been investigated. First, a detailed 3D FE model was constructed based on an MRI scan of a human head. A second model with a smoothed brain surface was created based on the same MRI scan as the first FE model. These models were validated against experimental data to confirm their human-like dynamic responses during impact. The validated FE models were subjected to several acceleration impulses and the maximum principle strain and strain rate in the brain were analyzed. The results suggested that the inclusion of sulci should be considered for future FE head models as it alters the strain and strain distribution in an FE model. (C) 2009 Elsevier Ltd. All rights reserved.	[Ho, Johnson; Kleiven, Svein] Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, Stockholm, Sweden	Ho, J (corresponding author), Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, Stockholm, Sweden.	johnsonh@kth.se; sveink@kth.se		Ho, Johnson/0000-0001-9785-2071	School of Technology and Health; Royal Institute of Technology, Stockholm, Sweden	This study was supported by the School of Technology and Health, Royal Institute of Technology, Stockholm, Sweden. Also, the authors are thankful for the comments and ideas given by Professor Hans von Hoist, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.	Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; Arbogast K., 1997, P 41 STAPP CAR CRASH; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; CLOOTS RJH, 2008, J BIOMECH, V43, P804; FRANCESCHINI G, 2006, THESIS U TRENTO ITAL; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gray H ., 2000, ANATOMY HUMAN BODY; HARDY WH, 2001, STAPP CAR CRASH J, P375; HO J, 2008, 20087 TRITASTH SCH T; HO J, 2009, INT J CRAS IN PRESS; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kwan RKS, 1999, IEEE T MED IMAGING, V18, P1085, DOI 10.1109/42.816072; Livermore Software Technology corporation, 2007, LS DYN KEYW US MAN V; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; Netter F. H., 1953, COMPILATION PAINTING; Nishimoto T, 2000, JSAE REV, V21, P117, DOI 10.1016/S0389-4304(99)00079-X; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P885, DOI 10.1109/42.811268; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Wells WM, 1996, IEEE T MED IMAGING, V15, P429, DOI 10.1109/42.511747; Wilcox Ruth K, 2003, J Orthop Sci, V8, P432, DOI 10.1007/s10776-003-0644-9; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zaidi H, 2006, NEUROIMAGE, V32, P1591, DOI 10.1016/j.neuroimage.2006.05.031; Zhang L, 2001, Stapp Car Crash J, V45, P369	37	72	75	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	SEP 18	2009	42	13					2074	2080		10.1016/j.jbiomech.2009.06.051			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	502RO	WOS:000270478000010	19679308				2021-06-18	
J	Sherlock, M; O'Sullivan, E; Agha, A; Behan, LA; Owens, D; Finucane, F; Rawluk, D; Tormey, W; Thompson, CJ				Sherlock, M.; O'Sullivan, E.; Agha, A.; Behan, L. A.; Owens, D.; Finucane, F.; Rawluk, D.; Tormey, W.; Thompson, C. J.			Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients	POSTGRADUATE MEDICAL JOURNAL			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; THERAPY; FLUID	Background: Hyponatraemia is a well-recognised complication of neurosurgical conditions, but the incidence and implications have not been well documented. Objective: To define the incidence, pathophysiology and clinical implications of significant hyponatraemia in several neurosurgical conditions. Methods: All patients admitted to the Irish National Neurosciences Centre at Beaumont Hospital, Dublin with traumatic brain injury, subarachnoid haemorrhage, intracranial neoplasm, pituitary disorders and spinal disorders who developed significant hyponatraemia (plasma sodium,130 mmol/l) from January 2002 to September 2003 were identified from computerised laboratory records. Data were collected by retrospective case note analysis. Results: Hyponatraemia was more common in patients with pituitary disorders (5/81, 6.25%; p = 0.004), traumatic brain injury (44/457, 9.6%; p<0.001), intracranial neoplasm (56/355, 15.8%; p<0.001) and subarachnoid haemorrhage (62/316, 19.6%; p<0.001) than in those with spinal disorders (4/489, 0.81%). The pathophysiology of hyponatraemia was: syndrome of inappropriate antidiuretic hormone secretion (SIADH) in 116 cases (62%) (31 (16.6%) drug-associated), hypovolaemic hyponatraemia in 50 cases (26.7%) ( which included patients with insufficient data to assign to the cerebral salt-wasting group (CSWS)), CSWS in nine cases (4.8%), intravenous fluids in seven cases (3.7%) and mixed SIADH/CSWS in five cases (2.7%). Hyponatraemic patients with cerebral irritation had significantly lower plasma sodium concentrations (mean (SD) 124.8 (0.34) mmol/l) than asymptomatic patients (126.6 (0.29) mmol/l) (p<0.0001). Hyponatraemic patients had a significantly longer hospital stay (median 19 days (interquartile range (IQR) 12-28)) than normonatraemic patients (median 12 days (IQR 10.5-15)) (p<0.001). Conclusions: Hyponatraemia is common in intracerebral disorders and is associated with a longer hospital stay. Cerebral irritation is associated with more severe hyponatraemia. SIADH is the most common cause of hyponatraemia and is often drug-associated.	[Sherlock, M.; O'Sullivan, E.; Agha, A.; Behan, L. A.; Owens, D.; Finucane, F.; Thompson, C. J.] Beaumont Hosp, Dept Acad Endocrinol, Dublin 9, Ireland; [Rawluk, D.] Beaumont Hosp, Dept Neurosurg, Dublin 9, Ireland; [Tormey, W.] Beaumont Hosp, Dept Chem Pathol, Dublin 9, Ireland	Thompson, CJ (corresponding author), Beaumont Hosp, Dept Acad Endocrinol, Dublin 9, Ireland.	christhompson@beaumont.ie	Finucane, Francis M/G-6031-2012	Finucane, Francis M/0000-0002-5374-7090			Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ANDERSON RJ, 1986, KIDNEY INT, V29, P1237, DOI 10.1038/ki.1986.134; Arinzon ZH, 2002, ANN PHARMACOTHER, V36, P1175; Betjes Michiel G.H., 2002, Eur J Intern Med, V13, P9, DOI 10.1016/S0953-6205(01)00192-3; Boughey JC, 2004, AM SURGEON, V70, P500; BOUTROS NN, 1995, J CLIN PSYCHIAT, V56, P377; DOCZI T, 1981, NEUROSURGERY, V9, P394, DOI 10.1227/00006123-198110000-00008; Egge A, 2001, NEUROSURGERY, V49, P593, DOI 10.1097/00006123-200109000-00012; HASAN D, 1990, ANN NEUROL, V27, P106, DOI 10.1002/ana.410270118; Janicic N, 2003, ENDOCRIN METAB CLIN, V32, P459, DOI 10.1016/S0889-8529(03)00004-5; LEE ST, 1990, J NEUROSURG, V73, P541, DOI 10.3171/jns.1990.73.4.0541; Morimatsu H, 2003, ANESTHESIOLOGY, V98, P1077, DOI 10.1097/00000542-200305000-00009; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; NELSON RJ, 1991, J CEREBR BLOOD F MET, V11, P661, DOI 10.1038/jcbfm.1991.118; Olson BR, 1997, J NEUROSURG, V87, P499, DOI 10.3171/jns.1997.87.4.0499; Oropello JM, 1996, CRIT CARE CLIN, V12, P709, DOI 10.1016/S0749-0704(05)70274-8; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; Rabinstein AA, 2003, NEUROLOGIST, V9, P290, DOI 10.1097/01.nrl.0000095258.07720.89; Sherlock M, 2006, CLIN ENDOCRINOL, V64, P250, DOI 10.1111/j.1365-2265.2006.02432.x; Smith DM, 2000, CLIN ENDOCRINOL, V52, P667, DOI 10.1046/j.1365-2265.2000.01027.x; Story DA, 2007, ANESTH ANALG, V104, P893, DOI 10.1213/01.ane.0000258015.87381.61; TAKAKU A, 1979, SURG NEUROL, V11, P349; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340	24	72	82	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0032-5473	1469-0756		POSTGRAD MED J	Postgrad. Med. J.	APR	2009	85	1002					171	175		10.1136/pgmj.2008.072819			5	Medicine, General & Internal	General & Internal Medicine	441GE	WOS:000265756500002	19417163				2021-06-18	
J	Chen, G; Shi, JX; Jin, W; Wang, L; Xie, WY; Sun, J; Hang, CH				Chen, Gang; Shi, Jixin; Jin, Wei; Wang, Lin; Xie, Weiying; Sun, Jie; Hang, Chunhua			Progesterone administration modulates TLRs/NF-kappa B signaling pathway in rat brain after cortical contusion	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article						progesterone; traumatic brain injury; toll-like receptors; nuclear factor-kappaB	TOLL-LIKE RECEPTORS; INFLAMMATORY RESPONSE; GENE-EXPRESSION; INNATE IMMUNITY; GROWTH-FACTOR; CELL-DEATH; INJURY; ALLOPREGNANOLONE; RECOVERY; CORTEX	This study investigated whether progesterone administration modulates toll-like receptors (TLRs) and the nuclear factor-kappa B (NF-kappa B) signaling pathway in the injured rat brain following traumatic brain injury (TBI). Right parietal cortical contusion was made by a weight-dropping method. Male rats were given 0 or 16 mg/kg injections of progesterone at postinjury hr 1 and 6 and on days 1, 2, 3, 4, and 5. Brain samples were extracted at 5 days after trauma. We measured mRNA expression of TLR2 and TLR4 by reverse-transcriptase polymerase chain reaction (RT-PCR), NF-kappa B binding activity by electrophoretic mobility shift assay (EMSA), concentrations of interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA), intercellular adhesion molecule-1 (ICAM-1) expression by immunohistochemistry, and brain damage by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL). The results showed that TBI induces strong upregulation of TLR2, TLR4, NF-kappa B, pro-inflammatory cytokines, and ICAM-1 in the pericontusional area. Administration of progesterone following TBI down-regulates the cortical levels of these agents related to the TLRs/NF-kappa B signaling pathway. After progesterone administration, apoptotic TUNEL-positive cells in the injured brain were significantly decreased. In summary, post-TBI progesterone administration attenuates the TLRs/NF-kappa B signaling pathway in injured rat brain, and this may be a mechanism whereby progesterone improves the outcome following TBI.	[Chen, Gang; Shi, Jixin; Jin, Wei; Wang, Lin; Hang, Chunhua] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China; [Xie, Weiying; Sun, Jie] Nanjing Univ, Dept Anesthesiol, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	nju_neurosurgery@163.com		Chen, Gang/0000-0002-0758-1907			ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Bergeron R, 1996, J NEUROSCI, V16, P1193; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Cristofaro P, 2003, EXPERT OPIN THER TAR, V7, P603, DOI 10.1517/14728222.7.5.603; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; MANNEL DN, 1990, IMMUNOL LETT, V26, P89, DOI 10.1016/0165-2478(90)90181-O; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sun J, 2004, ANN CLIN LAB SCI, V34, P181; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wang L, 2005, ANN CLIN LAB SCI, V35, P79; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Xie WY, 2006, ANN CLIN LAB SCI, V36, P39; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	40	72	79	0	3	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	WIN	2008	38	1					65	74					10	Medical Laboratory Technology	Medical Laboratory Technology	267ER	WOS:000253492800011	18316784				2021-06-18	
J	Tisdall, MM; Tachtsidis, I; Leung, TS; Elwell, CE; Smith, M				Tisdall, Martin M.; Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin			Increase in cerebral aerobic metabolism by normobaric hyperoxia after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral microdialysis; cytochrome c oxidase; near-infrared spectroscopy; normobaric hyperoxia; traumatic brain injury	NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; CYTOCHROME-C-OXIDASE; INTRACEREBRAL MICRODIALYSIS; OXIDATIVE-METABOLISM; BLOOD-FLOW; OXYGEN; MODEL; RAT; TOMOGRAPHY	Object. Traumatic brain injury (TBI) is associated with depressed aerobic metabolism and mitochondrial dysfunction. Normobaric hyperoxia (NBH) has been suggested as a treatment for TBI, but studies in humans have produced equivocal results. In this study the authors used brain tissue O-2 tension measurement, cerebral microdialysis, and near-infrared spectroscopy to study the effects of NBH after TBI. They investigated the effects on cellular and mitochondrial redox states measured by the brain tissue lactate/pyruvate ratio (LPR) and the change in oxidized cytochrome c oxidase (CCO) concentration, respectively. Methods. The authors studied 8 adults with TBI within the first 48 hours postinjury. Inspired oxygen percentage at normobaric pressure was increased from baseline to 60% for 60 minutes and then to 100% for 60 minutes before being returned to baseline for 30 minutes. Results. The results are presented as the median with the interquartile range in parentheses. During the 100% inspired oxygen percentage phase, brain tissue O-2 tension increased by 7.2 kPa (range 4.5-9.6 kPa) (p < 0.0001), microdialysate lactate concentration decreased by 0.26 mmol/L (range 0.0-0.45 mmol/L) (p = 0.01), microdialysate LPR decreased by 1.6 (range 1.0-2.3) (p = 0.02), and change in oxidized CCO concentration increased by 0.21 mu mol/L (0.13-0.38 mu mol/L) (p = 0.0003). There were no significant changes in intracranial pressure or arterial or microdialysate glucose concentration. The change in oxidized CCO concentration correlated with changes in brain tissue O-2 tension (r(s) = 0.57, p = 0.005) and in LPR (r(s)= -0.53, p = 0.006). Conclusions. The authors have demonstrated oxidation in cerebral cellular and mitochondrial redox states during NBH in adults with TBI. These findings are consistent with increased aerobic metabolism and suggest that NBH has the potential to improve outcome after TBI. Further studies are warranted.	[Tisdall, Martin M.; Smith, Martin] Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, London WC1N 3BG, England; [Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.] UCL, Dept Med Phys & Bioengn, London, England	Smith, M (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, Box 30,Queen Sq, London WC1N 3BG, England.	martin.smith@uclh.nhs.uk	Tachtsidis, Ilias/N-2747-2018; Smith, Martin/B-2616-2009	Tachtsidis, Ilias/0000-0002-8125-0313; Tisdall, Martin/0000-0001-8880-8386; Elwell, Clare/0000-0002-7281-7234	Welcome Research Fellow [075608]; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [GR/N14248/01]; Department of Health's National Institute for Health Research Centres funding schemeNational Institute for Health Research (NIHR); Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/D060982/1, EP/G005036/1] Funding Source: researchfish	Terrance S. Leung, Ph.D., is supported by Hamamatsu Photonics. Martin M. Tisdall, M.B.B.S., is a Welcome Research Fellow (Grant No. 075608). Ilias Tachtsidis, Ph.D., is supported by the Engineering and Physical Sciences Research Council (Grant No. GR/N14248/01). This study was also supported in part by a donation in memory of Karolyn Margaret Jones. This work was undertaken at University College London Hospitals and partially funded by the Department of Health's National Institute for Health Research Centres funding scheme.	Alves OL, 2004, CURR PHARM DESIGN, V10, P2163, DOI 10.2174/1381612043384187; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P273, DOI 10.1016/S0005-2728(05)80109-4; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Cooper CE, 1999, J CEREBR BLOOD F MET, V19, P27, DOI 10.1097/00004647-199901000-00003; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; ELWELL CE, 1994, J APPL PHYSIOL, V77, P2753; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fehlings MG, 2007, J NEUROSURG, V106, P525, DOI 10.3171/jns.2007.106.4.525; Hlatky R, 2004, NEUROSURGERY, V55, P1318, DOI 10.1227/01.NEU.0000143029.42638.2C; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Kakihana Y, 2002, EUR J CARDIO-THORAC, V21, P434, DOI 10.1016/S1010-7940(01)01139-3; Kirkpatrick PJ, 1998, J NEUROSURG, V89, P389, DOI 10.3171/jns.1998.89.3.0389; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MATCHER SJ, 1995, ANAL BIOCHEM, V227, P54, DOI 10.1006/abio.1995.1252; MATCHER SJ, 1994, PHYS MED BIOL, V39, P177, DOI 10.1088/0031-9155/39/1/011; McGown AD, 2003, SLEEP, V26, P710; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okada E, 2003, APPL OPTICS, V42, P2915, DOI 10.1364/AO.42.002915; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Sakamoto T, 2001, PEDIATR RES, V49, P770, DOI 10.1203/00006450-200106000-00010; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Springett R, 2000, AM J PHYSIOL-HEART C, V279, pH2202; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; Tachtsidis I, 2007, PHYSIOL MEAS, V28, P199, DOI 10.1088/0967-3334/28/2/008; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tisdall MM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718541; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	47	72	72	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2008	109	3					424	432		10.3171/JNS/2008/109/9/0424			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	344CX	WOS:000258904400011	18759572				2021-06-18	
J	Murray, CK				Murray, Clinton K.			Epidemiology of infections associated with combat-related injuries in Iraq and Afghanistan	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Iraq; Afghanistan; infection; combat	TRAUMATIC BRAIN-INJURY; ACINETOBACTER-BAUMANNII; UNITED-STATES; ENDURING FREEDOM; WAR WOUNDS; MILITARY; CASUALTIES; EXPERIENCE; SUSCEPTIBILITY; COMPLICATIONS	Enhanced medical training of front line medical personnel, personal protective equipment, and the presence of far forward surgical assets have improved the survival of casualties in the current wars in Iraq and Afghanistan. As such, casualties are at higher risk of infectious complications of their injuries including sepsis, which was a noted killer of casualties in previous wars. During the current conflicts, military personnel who develop combat-related injuries are at substantial risk of developing infections with multidrug resistant bacteria. Herein, we describe the bacteriology of combat-related injuries in Operation Iraqi Freedom and Operation Enduring Freedom that develop infections with particular attention to injuries of the extremities, central nervous system, abdomen and thorax, head and neck, and burns. In addition, the likely sources of combat-related injuries with multidrug resistant bacteria infections are explored.	Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA	Murray, CK (corresponding author), Brooke Army Med Ctr, Infect Dis Serv, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	chnton.murray@amedd.army.mil					Al-Assaf DA, 2007, J CRANIOFAC SURG, V18, P606, DOI 10.1097/01.scs.0000248661.91522.c5; Albrecht MA, 2006, J AM COLL SURGEONS, V203, P546, DOI 10.1016/j.jamcollsurg.2006.06.013; ARNOLD K, 1978, MIL MED, V143, P161; Aronson NE, 2006, CLIN INFECT DIS, V43, P1045, DOI 10.1086/507539; Beitler AL, 2006, MIL MED, V171, P189, DOI 10.7205/MILMED.171.3.189; Bird SM, 2007, INT J EPIDEMIOL, V36, P841, DOI 10.1093/ije/dym103; Centers for Disease Control and Prevention (CDC), 2004, MMWR MORB MORTAL WKL, V53, P1063; Chambers LW, 2006, J TRAUMA, V60, P1155, DOI 10.1097/01.ta.0000220340.91356.7e; Cho JM, 2005, MIL MED, V170, P268, DOI 10.7205/MILMED.170.4.268; Davis KA, 2005, EMERG INFECT DIS, V11, P1218, DOI 10.3201/1108.050103; Ecker JA, 2006, J CLIN MICROBIOL, V44, P2921, DOI 10.1128/JCM.00619-06; Ellis MW, 2004, CLIN INFECT DIS, V39, P971, DOI 10.1086/423965; Fitzpatrick S., 2004, J CARIBBEAN ARCHAEOL, V5, P1; Fleming A, 1915, LANCET, V2, P638; Gagne PJ, 2007, J VASC SURG, V45, P1204; Gao Z, 2007, P NATL ACAD SCI USA, V104, P2927, DOI 10.1073/pnas.0607077104; Garzoni C, 2005, EMERG INFECT DIS, V11, P1591, DOI 10.3201/eid1110.050715; Gleeson T, 2005, J ANTIMICROB CHEMOTH, V56, P602, DOI 10.1093/jac/dki274; Griffith ME, 2007, INFECT CONT HOSP EP, V28, P720, DOI 10.1086/518966; Griffith ME, 2006, INFECT CONT HOSP EP, V27, P659, DOI 10.1086/506596; HARDAWAY RM, 1978, J TRAUMA, V18, P635, DOI 10.1097/00005373-197809000-00004; Hawley JS, 2007, ANTIMICROB AGENTS CH, V51, P376, DOI 10.1128/AAC.00858-06; HEGGERS JP, 1969, MIL MED, V134, P602; Hujer KM, 2006, ANTIMICROB AGENTS CH, V50, P4114, DOI 10.1128/AAC.00778-06; Ingari John V, 2007, Tech Hand Up Extrem Surg, V11, P130, DOI 10.1097/bth.0b013e3180312738; JACOB E, 1989, MIL MED, V154, P311; Jerassy Z, 2006, J HOSP INFECT, V62, P230, DOI 10.1016/j.jhin.2005.07.007; Johnson Brent A, 2005, J Foot Ankle Surg, V44, P177, DOI 10.1053/j.jfas.2005.02.007; Johnson EN, 2007, CLIN INFECT DIS, V45, P409, DOI 10.1086/520029; Kanafani ZA, 2003, INFECT CONT HOSP EP, V24, P864, DOI 10.1086/502151; Kauvar DS, 2006, BURNS, V32, P853, DOI 10.1016/j.burns.2006.03.008; KLEIN RS, 1975, ANN SURG, V182, P15, DOI 10.1097/00000658-197507000-00003; Kortepeter MG, 2005, CLIN INFECT DIS, V41, P1604; KOVARIC JJ, 1968, MIL MED, V133, P622; Leininger BE, 2006, J TRAUMA, V61, P1207, DOI 10.1097/01.ta.0000241150.15342.da; Lin DL, 2004, J ORTHOP TRAUMA, V18, P300; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; Murray CK, 2006, CLIN INFECT DIS, V43, P383, DOI 10.1086/505601; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Murray CK, 2005, MIL MED, V170, P501, DOI 10.7205/MILMED.170.6.501; Murray CK, 2006, MIL MED, V171, P821; Murray CK, 2006, MIL MED, V171, P826, DOI 10.7205/MILMED.171.9.826; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oncul O, 2002, J HOSP INFECT, V51, P47, DOI 10.1053/jhin.2002.1205; Owens BD, 2007, J ORTHOP TRAUMA, V21, P254, DOI 10.1097/BOT.0b013e31802f78fb; Peck MA, 2007, J VASC SURG, V45, P1197, DOI 10.1016/j.jvs.2007.02.003; Peoples GE, 2005, MIL MED, V170, P462, DOI 10.7205/MILMED.170.6.462; Petersen K, 2007, ANN SURG, V245, P803, DOI 10.1097/01.sla.0000251707.32332.c1; PETTIT RT, 1919, JAMA-J AM MED ASSOC, P73; RESSNER RA, IN PRESS J AM COLL S; Rotimi VO, 1998, DIAGN MICR INFEC DIS, V30, P53, DOI 10.1016/S0732-8893(97)00180-6; Scott P, 2007, CLIN INFECT DIS, V44, P1577, DOI 10.1086/518170; Sise MJ, 2006, J TRAUMA, V60, P1162; Steele SR, 2007, DIS COLON RECTUM, V50, P870, DOI 10.1007/s10350-007-0235-4; Stoddard JL, 1918, J AMER MED ASSOC, V71, P1400, DOI 10.1001/jama.1918.26020430022009g; THORESBY FP, 1967, BRIT J SURG, V54, P359, DOI 10.1002/bjs.1800540509; Tien HC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-95; TONG MJ, 1972, J AMER MED ASSOC, V219, P1044, DOI 10.1001/jama.219.8.1044; Turton JF, 2006, J CLIN MICROBIOL, V44, P2630, DOI 10.1128/JCM.00547-06; Wolf SE, 2006, ANN SURG, V243, P786, DOI 10.1097/01.sla.0000219645.88867.b7; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	61	72	77	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2008	64	3		S			S232	S238		10.1097/TA.0b013e318163c3f5			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	276SY	WOS:000254164300004	18316967				2021-06-18	
J	Diamond, PM; Harzke, AJ; Magaletta, PR; Cummins, AG; Frankowski, R				Diamond, Pamela M.; Harzke, Amy J.; Magaletta, Philip R.; Cummins, A. Gaye; Frankowski, Ralph			Screening for traumatic brain injury in an offender sample: A first look at the reliability and validity of the Traumatic Brain Injury Questionnaire	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; offenders; corrections; prisons; assessment	ASSESSMENT INVENTORY PAI; HEAD-INJURY; PSYCHOMETRIC PROPERTIES; SUBSTANCE-ABUSE; AGGRESSION; OUTCOMES; BPAQ	Objective: To assess the reliability and validity of the Traumatic Brain Injury Questionnaire (TBIQ) for assessing history of traumatic brain injury (TBI) in an offender population. Setting/Participants: Offenders (118 women and 107 men) from 6 federal prison facilities in 3 geographic regions. Measures: TBIQ and multiple measures of cognitive and behavioral functioning. Results: Preliminary results indicated good test-retest reliability for lifetime history of head injury, good internal consistency for symptom severity and frequency scales, and good criterion validity for frequency of head injury and frequency and severity of symptoms. Conclusion: The TBIQ holds promise as an instrument for the assessment of TBI history in offender populations.	Univ Texas Houston, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA; Fed Bur Prisons, Psychol Serv Branch, Washington, DC USA	Diamond, PM (corresponding author), Univ Texas Houston, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA.				NCIPC CDC HHS [U49 CE000365-01S1] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE000365] Funding Source: NIH RePORTER		[Anonymous], 2002, HLTH STAT SOON TO BE, V1; BABE S, 2001, PERSONALITY DISORDER; Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; Bryant FB, 2001, J RES PERS, V35, P138, DOI 10.1006/jrpe.2000.2302; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Coolidge F. L., 1998, INT J REHABILITATION, V4, P193; COOLIDGE FL, 1992, J PERS ASSESS, V59, P223, DOI 10.1207/s15327752jpa5902_1; COOLIDGE FL, 1995, PSYCHOL REP, V77, P24, DOI 10.2466/pr0.1995.77.1.24; COOLIDGE FL, 1993, COOLIDGE AXIS 2 INVE; COOLIDGE FL, 1996, INDIAN J PSYCHOL ISS, V4, P1; DAOUST SW, 2006, PSYCHOL SERV, V3, P88; Diamond PM, 2006, ASSESSMENT, V13, P227, DOI 10.1177/1073191106287666; Diamond PM, 2005, CRIM JUSTICE BEHAV, V32, P546, DOI 10.1177/0093854805278416; Eaton W. W., 2004, USE PSYCHOL TESTING, V3; *FED BUR PRIS PSYC, 2006, MENT HLTH PREV PROJ; Fossati A, 2001, J CLIN PSYCHOL, V57, P815, DOI 10.1002/jclp.1051; HARRISON PM, 2005, PRISONERS 2003; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; KOKKEVI A, 1995, COMPR PSYCHIAT, V36, P329, DOI 10.1016/S0010-440X(95)90113-2; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leukefeld C. G., 2002, TREATMENT DRUG OFFEN; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCALLISTER TW, 2005, TXB TRAUMATIC BRAIN; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Morey L, 1996, INTERPRETIVE GUIDE P; Morey L. C., 1991, PERSONALITY ASSESSME; Morey LC, 2002, INT J OFFENDER THER, V46, P333, DOI 10.1177/03024X02046003007; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089; Wang EW, 1997, BEHAV SCI LAW, V15, P469, DOI 10.1002/(SICI)1099-0798(199723/09)15:4<469::AID-BSL279>3.0.CO;2-A	40	72	72	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2007	22	6					330	338		10.1097/01.HTR.0000300228.05867.5c			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	234RN	WOS:000251181500003	18025965				2021-06-18	
J	Rauh, MJ; Macera, CA; Ji, M; Wiksten, DL				Rauh, Mitchell J.; Macera, Caroline A.; Ji, Ming; Wiksten, Denise L.			Subsequent injury patterns in girls' high school sports	JOURNAL OF ATHLETIC TRAINING			English	Article						epidemiology; surveillance; sports injuries; reinjuries; female athletes	RISK-FACTORS; CONCUSSION; PREVENTION; EPIDEMIOLOGY; BASKETBALL; MANAGEMENT; ATHLETICS; SOCCER; RATES	Context: Girls' participation in high school sports has increased 79.5% since 1975-1976. The incidence of injury among boys in high school sports has been well documented, but information regarding the incidence, severity, and type of injury among girls in high school sports is limited. Objective: To examine the effects of subsequent injuries among high school girls in 5 sports. Design: Observational cohort. Setting: Existing data from the 1995-1997 National Athletic Trainers' Association High School Injury Surveillance database. Patients or Other Participants: Girl athletes (n = 25 187 player-seasons) participating in 5 varsity high school sports: basketball, field hockey, soccer, softball, and volleyball. Main Outcome Measure(s): Injury status, body location, injury type, time lost from injury, and number of players at risk for injury as recorded by athletic trainers and submitted to the Sports Injury Monitoring System. Results: Overall, 23.3% of the athletes had 2 or more injuries within a sport; basketball and soccer athletes were most vulnerable. Overall, the probability of an athlete sustaining 3 or more injuries was 38.6%, and the risk was highest for field hockey players (61.9%). The risk of subsequent injury at a new body location was almost 2 times higher than reinjury at the same body location (risk ratio = 1.7, 95% confidence interval = 1.6, 1.8) and was similar for all sports except volleyball. Only in softball was the proportion of reinjuries causing 8 or more days lost from participation greater than the proportion of new injuries causing similar time loss. Softball and volleyball had the highest proportion of reinjuries at the shoulder, especially rotator cuff strains. The proportion of knee reinjuries was significantly higher than new injuries for all sports except soccer. The proportion of anterior cruciate ligament injuries was significantly higher for volleyball players only. Overall, the proportion of reinjuries was significantly higher for stress fractures and musculoskeletal condition injuries. Conclusions: Patterns of subsequent injury risk appear to vary among these 5 sports. Almost one quarter of the athletes incurred 2 or more injuries over a 3-year period, so the effects of subsequent injuries deserve more consideration.	[Rauh, Mitchell J.] Rocky Mt Univ Hlth Prof, Grad Program Orthopaed & Sports Phys Therapy, Provo, UT 84601 USA; [Rauh, Mitchell J.; Macera, Caroline A.; Ji, Ming; Wiksten, Denise L.] San Diego State Univ, San Diego, CA 92182 USA	Rauh, MJ (corresponding author), Rocky Mt Univ Hlth Prof, Grad Program Orthopaed & Sports Phys Therapy, 1662 West 820 North, Provo, UT 84601 USA.	mrauh@rmuohp.edu					Beachy G, 1997, AM J SPORT MED, V25, P675, DOI 10.1177/036354659702500515; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; CAINE DJ, 1996, EPIDEMIOLOGY SPORTS, P387; Chalmers DJ, 2002, INJ PREV S4, V8, P22; CHANDY T A, 1985, Physician and Sportsmedicine, V13, P106; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; EKSTRAND J, 1983, AM J SPORT MED, V11, P116, DOI 10.1177/036354658301100302; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; GARRICK JG, 1978, JAMA-J AM MED ASSOC, V239, P2245, DOI 10.1001/jama.239.21.2245; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Kucera KL, 2005, BRIT J SPORT MED, V39, P462, DOI 10.1136/bjsm.2004.013672; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lowe E B Jr, 1987, R I Med J, V70, P265; LYSENS RJ, 1989, AM J SPORT MED, V17, P612, DOI 10.1177/036354658901700504; LYSENS RJ, 1991, SPORTS MED, V12, P281, DOI 10.2165/00007256-199112050-00001; McGuine T, 2006, CLIN J SPORT MED, V16, P488, DOI 10.1097/01.jsm.0000248848.62368.43; MCKEAG D, 1993, PRIMARY CARE SPORTS; MCLAIN LG, 1989, PEDIATRICS, V84, P446; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murtaugh K, 2001, MED SCI SPORT EXER, V33, P201; *NAT FED STAT HIGH, PART HIGH SCHOOL INC; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Rauh MJ, 2006, AM J EPIDEMIOL, V163, P151, DOI 10.1093/aje/kwj022; Rauh MJ, 2000, CLIN J SPORT MED, V10, P110, DOI 10.1097/00042752-200004000-00005; RENSTROM PAF, 1993, INSTR COURSE LECT, V42, P225; REQUA RK, 1991, SPORTS YOUTH SURV ST; RICE SG, 1985, WESTERN J MED, V142, P352; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shively R A, 1981, Phys Sportsmed, V9, P46, DOI 10.1080/00913847.1981.11711135; vanMechelen W, 1996, MED SCI SPORT EXER, V28, P1171, DOI 10.1097/00005768-199609000-00014; WATSON MD, 1987, AM J SPORT MED, V15, P251, DOI 10.1177/036354658701500310; Weaver NL, 2002, PATIENT EDUC COUNS, V46, P199, DOI 10.1016/S0738-3991(01)00213-0	38	72	73	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2007	42	4					486	494					9	Sport Sciences	Sport Sciences	251AQ	WOS:000252343100008	18176621				2021-06-18	
J	Zhou, ML; Shi, JX; Hang, CH; Cheng, HL; Qi, XP; Mao, L; Chen, KF; Yin, HX				Zhou, Men-Liang; Shi, Ji-Xin; Hang, Chun-Hua; Cheng, Hui-Lin; Qi, Xiao-Ping; Mao, Lei; Chen, Ke-Fei; Yin, Hong-Xia			Potential contribution of nuclear factor-kappa B to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral vasospasm; inflammation; NF-kappa B; subarachnoid hemorrhage	SMOOTH-MUSCLE-CELLS; TRAUMATIC BRAIN-INJURY; PYRROLIDINE DITHIOCARBAMATE; OXIDATIVE STRESS; BASILAR ARTERY; TNF-ALPHA; ISCHEMIA; ACTIVATION; RATS; INFLAMMATION	Nuclear factor-kappa B (NF-kappa B) plays a key role in inflammation, which is involved in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH). In the present study, we assessed the potential role of NF-kappa B in regulation of cerebral vasospasm. Nuclear factor-kappa B DNA-binding activity was measured in cultured vascular smooth muscle cells (VSMCs) treated with hemolysate and pyrrolidine dithiocarbamate (PDTC, 80 mu mol/L), an inhibitor of NF-kappa B. Forty-two rabbits were divided into three groups: control, SAH, and PDTC groups (n= 14 for each group). The caliber of the basilar artery was evaluated. Nuclear factor-kappa B DNA-binding activity and the gene expression levels of cytokines and adhesion molecules in the basilar artery were measured. Immunohistochernical study was performed to assess the expression and localization of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule (ICAM)-1, and myeloperoxidase (MPO). It was observed that NF-kappa B DNA-binding activity was significantly increased by treatment with hemolysate in cultured VSCMs, but this increase was suppressed by pretreatment with PDTC. Severe vasospasm was observed in the SAH group, which was attenuated in the PDTC group. Subarachnoid hemorrhage could induce increases of NF-KB DNA-binding activity and the gene expression levels of TNF-alpha, interleukin (IL)-1 beta, ICAM-1, and vascular cell adhesion molecule (VCAM)-1 which were reduced in the PDTC group. Immunohistochemical study demonstrated that the expression levels of TNF-alpha, ICAM-1, and MPO were all increased in the SAH group, but these increases were attenuated in the PDTC group. Our results suggest that NF-KB is activated in the arterial wall after SAH, which potentially leads to vasospasm development through induction of inflammatory response.	Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China	Shi, JX (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	shiix52@hotmail.com	Yin, Hong/AAC-5784-2020	Zhou, Meng-liang/0000-0002-1165-5489			Aihara Y, 2001, STROKE, V32, P212, DOI 10.1161/01.STR.32.1.212; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; El Eter E, 2005, CAN J PHYSIOL PHARM, V83, P483, DOI 10.1139/Y05-034; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HANDA Y, 1995, ACTA NEUROCHIR, V132, P92, DOI 10.1007/BF01404854; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Iseki A, 2000, BIOCHEM BIOPH RES CO, V276, P88, DOI 10.1006/bbrc.2000.3452; KAHN SE, 1981, ANN CLIN LAB SCI, V11, P126; Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009; Kawanabe Y, 2002, J CARDIOVASC PHARM, V40, P438, DOI 10.1097/00005344-200209000-00013; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Lau D, 2006, PHARMACOL THERAPEUT, V111, P16, DOI 10.1016/j.pharmthera.2005.06.023; Li CF, 1999, AM J PHYSIOL-HEART C, V276, pH543; Liu SF, 1999, MOL PHARMACOL, V55, P658; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; Moellering D, 1999, FREE RADICAL BIO MED, V26, P1138, DOI 10.1016/S0891-5849(98)00300-1; Monaco C, 2004, CARDIOVASC RES, V61, P671, DOI 10.1016/j.cardiores.2003.11.038; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nurmi A, 2004, J NEUROCHEM, V91, P755, DOI 10.1111/j.1471-4159.2004.02756.x; Nurmi A, 2004, STROKE, V35, P987, DOI 10.1161/01.STR.0000120732.45951.26; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Shi XZ, 2003, GASTROENTEROLOGY, V124, P1369, DOI 10.1016/S0016-5085(03)00263-4; Song YS, 2005, J CEREBR BLOOD F MET, V25, P1301, DOI 10.1038/sj.jcbfm.9600123; STEELE JA, 1991, CIRC RES, V68, P416, DOI 10.1161/01.RES.68.2.416; Stephenson D, 2000, J CEREBR BLOOD F MET, V20, P592, DOI 10.1097/00004647-200003000-00017; Treggiari-Venzi MM, 2001, NEUROSURGERY, V48, P249, DOI 10.1097/00006123-200102000-00001; VARSOS VG, 1983, J NEUROSURG, V58, P11, DOI 10.3171/jns.1983.58.1.0011; Zeiffer U, 2004, CIRC RES, V94, P776, DOI 10.1161/01.RES.0000121105.72718.5C; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004; Zhou ML, 2007, J NEUROSCI METH, V159, P318, DOI 10.1016/j.jneumeth.2006.07.026; Zingarelli B, 2005, CRIT CARE MED, V33, pS414, DOI 10.1097/01.CCM.0000186079.88909.94; Zubkov AY, 1999, J NEUROSURG, V90, P1091, DOI 10.3171/jns.1999.90.6.1091	39	72	80	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2007	27	9					1583	1592		10.1038/sj.jcbfm.9600456			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	202ZY	WOS:000248946100006	17293842	Bronze			2021-06-18	
J	Miller, JR; Adamson, GJ; Pink, MM; Sweet, JC				Miller, Jennifer R.; Adamson, Gregory J.; Pink, Marilyn M.; Sweet, John C.			Comparison of preseason, midseason, and postseason neurocognitive scores in uninjured collegiate football players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	30th Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUN, 2004	Quebec City, CANADA	Amer Orthopaed Soc Sports Med		concussion; athletic injury; neurocognitive tests; head injury	STANDARDIZED ASSESSMENT; COGNITIVE IMPAIRMENT; CONCUSSION; HEAD; RECOVERY; SOCCER; PERFORMANCE; INJURIES	Background: College football players sustain an average of 3 subconcussive blows to the head per game. Concussions correlate with decreases in standardized neurocognitive test scores. It is not known whether repetitive, subconcussive microtrauma associated with participation in a full season of collision sport affects neurocognitive test scores. Hypothesis: No difference exists between preseason, midseason, and postseason Standardized Assessment of Concussion (SAC) and Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) scores when collegiate football players sustain subconcussive microtrauma from forceful, repetitive contact activity. Study Design: Case series; Level of evidence, 4. Methods: Fifty-eight members of a Division III collegiate football team who had no known concussion during the season voluntarily completed the SAC and ImPACT instruments preseason, midseason, and postseason. A repeated measures analysis of variance was used to compare the scores at the 3 time intervals (P <.05). Results: No statistically significant decreases were found in overall SAC or ImPACT scores or in any of the domains or composites of the tests (P <.05) when preseason, midseason, and postseason scores were evaluated. Conclusions: ImPACT and SAC neurocognitive test scores are not significantly altered by a season of repetitive contact in collegiate football athletes who have not sustained a concussion. Clinical Relevance: A diminution in SAC or ImPACT scores in concert with clinical symptoms and findings should be interpreted as evidence of a postconcussive event.	Congress Med Associates, Pasadena, CA 91105 USA; Idaho Sports Med Inst, Boise, ID USA; Occidental Coll, Los Angeles, CA 90041 USA	Adamson, GJ (corresponding author), Congress Med Associates, 39 Congress St, Pasadena, CA 91105 USA.	susan@congressmedical.com	Adamson, Gregory/L-2794-2019				Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, PSYCHOL REP, V89, P457, DOI 10.2466/pr0.2001.89.2.457; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2006, ORTHOP TECH REV, V8, P24; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006	33	72	72	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2007	35	8					1284	1288		10.1177/0363546507300261			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	196AB	WOS:000248452500007	17405886				2021-06-18	
J	Yaka, R; Biegon, A; Grigoriadis, N; Simeonidou, C; Grigoriadis, S; Alexandrovich, AG; Matzner, H; Schumann, J; Trembovler, V; Tsenter, J; Shohami, E				Yaka, Rami; Biegon, Anat; Grigoriadis, Nikolaos; Simeonidou, Constantina; Grigoriadis, Savvas; Alexandrovich, Alexander G.; Matzner, Henri; Schumann, Johanna; Trembovler, Victoria; Tsenter, Jeanna; Shohami, Esther			D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury	FASEB JOURNAL			English	Article						traumatic brain injury; NMDA receptors; synaptic plasticity; BDNF	TRAUMATIC BRAIN-INJURY; FLUID-PERCUSSION INJURY; PERIPHERAL BENZODIAZEPINE-RECEPTORS; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; NEUROTROPHIC FACTOR; INTRACEREBRAL MICRODIALYSIS; HIPPOCAMPAL-NEURONS; NMDA RECEPTORS; RAT-BRAIN	Traumatic brain injury triggers a massive glutamate efflux, activation of NMDA receptor channels, and cell death. Recently, we reported that NMDA receptors in mice are down-regulated from hours to days following closed head injury (CHI), and treatment with NMDA improved recovery of motor and cognitive functions up to 14 d post-injury. Here we show that a single injection of a low dose of D-cycloserine (DCS), a partial NMDA receptor agonist, in CHI mice 24 h post-injury, resulted in a faster and greater recovery of motor and memory functions as assessed by neurological severity score and object recognition tests, respectively. Moreover, DCS treatment of CHI mice led to a significant improvement of hippocampal long-term potentiation (LTP) in the CA1 region that was completely blunted in CHI control mice. However, DCS did not improve CHI-induced impairment in synaptic glutamate release measured by paired pulse facilitation (PPF) ratio in hippocampal CA1 region. Finally, CHI-induced reduction of brain-derived neurotrophic factor (BDNF) was fully restored following DCS treatment. Since DCS is in clinical use for other indications, the present study offers a novel approach to treat human brain injury.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Brookhaven Natl Lab, Upton, NY 11973 USA; Aristotle Univ Thessaloniki, Fac Med, Dept Physiol, Thessaloniki, Greece; Hadassah Univ Hosp, Dept Neurosurg, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Rehabil, IL-91120 Jerusalem, Israel	Yaka, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	yaka@md.huji.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 050285-01 A2] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2000, J NEUROSCI RES, V62, P177, DOI 10.1002/1097-4547(20001015)62:2&lt;177::AID-JNR3&gt;3.0.CO;2-D; Andersen JM, 2002, BEHAV BRAIN RES, V129, P211, DOI 10.1016/S0166-4328(01)00318-7; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Cao R, 2006, NEUROSCI LETT, V401, P136, DOI 10.1016/j.neulet.2006.03.005; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Duncan EJ, 2004, SCHIZOPHR RES, V71, P239, DOI 10.1016/j.schres.2004.03.013; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FRIEDMAN C, 2001, BIOINFORMATICS, V1, P1; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Heresco-Levy U, 2002, INT J NEUROPSYCHOPH, V5, P301, DOI 10.1017/S1461145702003061; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LAAKE K, 2002, COCHRANE DB SYST REV; Lelong V, 2001, NEUROPHARMACOLOGY, V41, P517, DOI 10.1016/S0028-3908(01)00085-5; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Owens J, 2000, NUCL MED BIOL, V27, P557, DOI 10.1016/S0969-8051(00)00102-5; PAXINOS G, 2000, MOUSE BRAIN STEREOTA; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; WALLACE MC, 1992, J NEUROSURG, V76, P127, DOI 10.3171/jns.1992.76.1.0127; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZAFRA F, 1992, J NEUROSCI, V12, P4793	53	72	74	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2033	2041		10.1096/fj.06-7856com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	WOS:000247500300013	17351125				2021-06-18	
J	Baguley, IJ; Heriseanu, RE; Gurka, JA; Nordenbo, A; Cameron, ID				Baguley, Ian J.; Heriseanu, Roxana E.; Gurka, Joseph A.; Nordenbo, Annette; Cameron, Ian D.			Gabapentin in the management of dysautonomia following severe traumatic brain injury: a case series	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							INTRATHECAL BACLOFEN; AUTONOMIC DYSFUNCTION; NEUROPATHIC PAIN; MECHANISMS; SPASTICITY; ISCHEMIA; NEURONS	The pharmacological management of dysautonomia, otherwise known as autonomic storms, following acute neurological insults, is problematic and remains poorly researched. This paper presents six subjects with dysautonomia following extremely severe traumatic brain injury where gabapentin controlled paroxysmal autonomic changes and posturing in the early post-acute phase following limited success with conventional medication regimens. In two subjects, other medications were reduced or ceased without a recurrence of symptoms. It is proposed that medications that can block or minimise abnormal afferent stimuli may represent a better option for dysautonomia management than drugs which increase inhibition of efferent pathways. Potential mechanisms for these effects are discussed.	Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia; Hvidovre Univ Hosp, Brain Injury Unit, DK-2650 Hvidovre, Denmark; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; ALLERTON CA, 1989, BRIT J PHARMACOL, V96, P29, DOI 10.1111/j.1476-5381.1989.tb11780.x; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2005, BRAIN INJURY, V19, P545, DOI 10.1080/02699050400025075; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Cheng JK, 2006, J PHARMACOL SCI, V100, P471, DOI 10.1254/jphs.CR0050020; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; Cohen SP, 2004, AM J PHYS MED REHAB, V83, P142, DOI 10.1097/01.PHM.0000107499.24698.CA; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Dooley DJ, 2000, NEUROSCI LETT, V280, P107, DOI 10.1016/S0304-3940(00)00769-2; Guillaume D, 2005, ARCH PHYS MED REHAB, V86, P2165, DOI 10.1016/j.apmr.2005.05.018; Ivanhoe C B, 2001, Phys Med Rehabil Clin N Am, V12, P923; KROIN JS, 1993, J NEUROSURG, V79, P544, DOI 10.3171/jns.1993.79.4.0544; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; Rose MA, 2002, ANAESTHESIA, V57, P451, DOI 10.1046/j.0003-2409.2001.02399.x; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Scott JS, 1997, AM J PHYS MED REHAB, V76, P200, DOI 10.1097/00002060-199705000-00007; Smith PA, 2004, DRUG NEWS PERSPECT, V17, P5, DOI 10.1358/dnp.2004.17.1.829021; Sutton KG, 2002, BRIT J PHARMACOL, V135, P257, DOI 10.1038/sj.bjp.0704439; Tremont-Lukats IW, 2000, DRUGS, V60, P1029, DOI 10.2165/00003495-200060050-00005; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013	28	72	81	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2007	78	5					539	541		10.1136/jnnp.2006.096388			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	156YO	WOS:000245686000028	17435191	Green Published			2021-06-18	
J	Dick, R; Romani, WA; Agel, J; Case, JG; Marshall, SW				Dick, Randall; Romani, William A.; Agel, Julie; Case, Jim G.; Marshall, Stephen W.			Descriptive epidemiology of collegiate men's lacrosse injuries: National Collegiate Athletic Association Injury surveillance system, 1988-1989 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; lower extremity injuries; ankle sprains; concussions; shoulder injuries		Objective: To review 16 years of National Collegiate Athletic Association (NCAA) injury surveillance data for men's lacrosse and identify potential areas for injury prevention initiatives. Background: During the sample period, the number of sponsoring institutions and the number of participants in men's college lacrosse grew significantly. Overall, an average of 18% of NCAA institutions participated in the annual NCAA Injury Surveillance System data collection for this sport. Main Results: Over the sample period, athletes were almost 4 times more likely to sustain injuries in games than in practices (12.58 versus 3.24 injuries per 1000 athlete-exposures [A-Es], rate ratio = 3.9, 95% confidence interval = 3.7, 4.1). Approximately half of all game (48.1%) and practice (58.7%) injuries were to the lower extremity, followed by the upper extremity (26.2% in games, 16.9% in practices), and the head and neck (111.7% in games, 6.2% in practices). In games and practices, the most common injuries were ankle ligament sprains (11.3% and 16.4%, respectively). The disparity among preseason, regular-season, and postseason injuries may be due to athlete acclimatization to the rigors of the sport throughout the season. Changes in helmet design may account for the rise in the concussion rate since the 1995-1996 season. Recommendations: We recommend research into the mechanism of head injuries and the implications of design changes to protective helmets, as well as further investigation of the best designs for shoulder and chest protection.	Univ Maryland, Sch Med, Dept Phys Therapy, Baltimore, MD 21201 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Cornell Univ, Ithaca, NY 14853 USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA	Romani, WA (corresponding author), Univ Maryland, Sch Med, Dept Phys Therapy, 100 Penn St, Baltimore, MD 21201 USA.	wromani@som.umaryland.edu		Marshall, Stephen/0000-0002-2664-9233			Caswell SV, 2002, J ATHL TRAINING, V37, P164; Dick R, 2007, J ATHL TRAINING, V42, P173; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA	4	72	72	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					255	261					7	Sport Sciences	Sport Sciences	180RC	WOS:000247382300012	17710174				2021-06-18	
J	Zhou, ZW; Daugherty, WP; Sun, D; Levasseur, JE; Altememi, N; Hamm, RJ; Rockswold, GL; Bullock, MR				Zhou, Zhengwen; Daugherty, Wilson P.; Sun, Dong; Levasseur, Joseph E.; Altememi, Nabil; Hamm, Robert J.; Rockswold, Gaylan L.; Bullock, M. Ross			Protection of mitochondrial function and improvement in cognitive recovery in rats treated with hyperbaric oxygen following lateral fluid-percussion injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; fraction of inspired oxygen; hyperbaric oxygen treatment; cognitive function; adenosine triphosphate; hippocampal cell count; rat	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; SELECTIVE VULNERABILITY; INTRACRANIAL-PRESSURE; ARTERIAL HYPEROXIA; ENERGY-METABOLISM; DAMAGE; HIPPOCAMPUS; CONTUSION	Object. Hyperbaric oxygen (HBO2) has been shown to improve Outcome after severe traumatic brain injury, but its underlying mechanisms are unknown. Following lateral fluid-percussion injury (FPI), the authors tested the effects of HBO2 treatment as well as enhanced normobaric oxygenation on mitochondrial function, as measured by both cognitive recovery and cellular adenosine triphosphate (ATP) levels. Methods. Adult male Sprague-Dawley rats were Subjected to moderate lateral FPI or sham injury and were allocated to one of four treatment groups: 1) FPI treated with 4 hours of normobaric 30% O-2; 2) FPI treated with 4 hours of normobaric 100% O-2; 3) FPI treated with 1 hour of HBO2 Plus 3 hours of normobaric 100% O-2; and 4) sham-injured treated with normobaric 30% O-2. Cognitive outcome was assessed using the Morris water maze (MWM) on Days 11 to 15 after injury. Animals were then killed 21 days postinjury to assess hippocampal neuronal loss. Adenosine triphosphate was extracted from the neocortex and measured using hi.-h-performance liquid chromatography. The results showed that injured animals treated with HBO2 or normobaric 100% O-2 alone had significantly higher levels of cerebral ATP as compared with animals treated using normobaric 30% O-2 (p <= 0.05). The injured animals treated with HBO2 had significant improvements in cognitive recovery, as characterized by a shorter latency in MWM performance (p <= 0.05), and decreased neuronal loss in the CA2/3 and hilar regions as compared with those treated with 30% or 100% O-2 (p <= 0.05). Conclusions. Both hyperbaric and normobaric hyperoxia increased cerebral ATP levels after lateral FPI. In addition, HBO2 treatment improved cognitive recovery and reduced hippocampal neuronal cell loss after brain injury in the rat.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, 1200 E Broad St,W Hosp 8 S, Richmond, VA 23298 USA.	Mbullock@mcvh-vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		ABDELFATTAH AS, 1987, J LIQ CHROMATOGR, V10, P2653, DOI 10.1080/01483918708066819; Alves OL, 2004, CURR PHARM DESIGN, V10, P2163, DOI 10.2174/1381612043384187; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BOCHICCHIO M, 1990, INTENS CARE MED, V16, P444, DOI 10.1007/BF01711223; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Buczek M, 2002, METAB BRAIN DIS, V17, P153, DOI 10.1023/A:1019973921217; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Elayan IM, 2000, J NEUROPHYSIOL, V83, P2022; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; JAIN KK, 2004, TXB HYPERBARIC MED, P264; KAWAMURA S, 1990, SURG NEUROL, V34, P101, DOI 10.1016/0090-3019(90)90104-W; Kessler L, 2003, DIABETES CARE, V26, P2378, DOI 10.2337/diacare.26.8.2378; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P435; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mader J T, 1990, Infect Dis Clin North Am, V4, P433; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Muehlberger PM, 2004, AVIAT SPACE ENVIR MD, V75, P496; Nishio S, 1997, ACT NEUR S, V70, P84; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Zamboni WA, 2003, CLIN PLAST SURG, V30, P67, DOI 10.1016/S0094-1298(02)00068-8	50	72	83	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2007	106	4					687	694		10.3171/jns.2007.106.4.687			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	155OJ	WOS:000245586900027	17432723				2021-06-18	
J	Ponath, G; Schettler, C; Kaestner, F; Voigt, B; Wentker, D; Arolt, V; Rothermundt, M				Ponath, Gerald; Schettler, Christiane; Kaestner, Florian; Voigt, Bjoern; Wentker, Dennis; Arolt, Volker; Rothermundt, Matthias			Autocrine S100B effects on astrocytes are mediated via RAGE	JOURNAL OF NEUROIMMUNOLOGY			English	Article						glia; S100B proteins; proinflammatory cytokines; autocrine pathway; RAGE	GLYCATION END-PRODUCTS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CELL-SURFACE RECEPTOR; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; SCHIZOPHRENIC-PATIENTS; NEURITE OUTGROWTH; GLIAL ACTIVATION; GENE-EXPRESSION	To find out if the astrocytic protein S100B involves its autocrine effects via RAGE we investigated the capacity of astrocytes to upregulate IL-6 and TNF-alpha expression by stimulation with S100B. The subcellular localization of RAGE expression at the cell surface membrane of cultured astrocytes was demonstrated by immunofluorescence microscopy, flow cytometry and Western blotting. S100B was able to stimulate IL-6 and TNF-alpha secretion in cultured astrocytes in a concentration- and time-dependent manner as shown by ELISA. S100B induced IL-6 and TNF-alpha secretion was blocked by the use of RAGE siRNA specific for knocking down RAGE expression. (c) 2006 Elsevier B.V. All rights reserved.	Univ Munster, Dept Psychiat, Mol Psychiat Div, D-48149 Munster, Germany	Rothermundt, M (corresponding author), Univ Munster, Dept Psychiat, Mol Psychiat Div, Albert Schweitzer Str 11, D-48149 Munster, Germany.	rothermu@uni-muenster.de					Adami C, 2004, BBA-MOL CELL RES, V1742, P169, DOI 10.1016/j.bbamcr.2004.09.008; Basta G, 2002, CIRCULATION, V105, P816, DOI 10.1161/hc0702.104183; BRETT J, 1993, AM J PATHOL, V143, P1699; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Guo L, 2001, NEUROBIOL AGING, V22, P975, DOI 10.1016/S0197-4580(01)00295-0; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kess D, 2003, J IMMUNOL, V171, P5697, DOI 10.4049/jimmunol.171.11.5697; Lam AGM, 2001, NEUROBIOL AGING, V22, P765, DOI 10.1016/S0197-4580(01)00233-0; Lara DR, 2001, J PSYCHIATR RES, V35, P11, DOI 10.1016/S0022-3956(01)00003-6; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Li YK, 2000, J NEUROCHEM, V74, P143; Liu L, 2005, J NEUROCHEM, V92, P546, DOI 10.1111/j.1471-4159.2004.02909.x; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Muller N, 2000, World J Biol Psychiatry, V1, P173, DOI 10.3109/15622970009150588; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; Park IH, 2004, MOL IMMUNOL, V40, P1203, DOI 10.1016/j.molimm.2003.11.027; Penkowa M, 1999, GLIA, V25, P343; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Rothermundt M, 2001, MOL PSYCHIATR, V6, P445, DOI 10.1038/sj.mp.4000889; Rothermundt M, 2004, NEUROPSYCHOPHARMACOL, V29, P1004, DOI 10.1038/sj.npp.1300403; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rothermundt M, 2004, MOL PSYCHIATR, V9, P897, DOI 10.1038/sj.mp.4001548; Rothermundt M, 2001, BRAIN BEHAV IMMUN, V15, P319, DOI 10.1006/brbi.2001.0648; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Valencia JV, 2004, DIABETES, V53, P743, DOI 10.2337/diabetes.53.3.743; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	51	72	74	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAR	2007	184	1-2					214	222		10.1016/j.jneuroim.2006.12.011			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	157NR	WOS:000245727400022	17254641				2021-06-18	
J	Tweedie, D; Milman, A; Holloway, HW; Li, YZ; Harvey, BK; Shen, H; Pistell, PJ; Lahiri, DK; Hoffer, BJ; Wang, Y; Pick, CG; Greig, NH				Tweedie, David; Milman, Anat; Holloway, Harold W.; Li, Yazhou; Harvey, Brandon K.; Shen, Hui; Pistell, Paul J.; Lahiri, Debomoy K.; Hoffer, Barry J.; Wang, Yun; Pick, Chaim G.; Greig, Nigel H.			Apoptotic and behavioral sequelae of mild brain trauma in mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; mild (mTBI); apoptosis; amyloid-beta precursor protein; apoptosis inducing factor (AIF); cytochrome-c; Bax	AMYLOID PRECURSOR PROTEINS; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; CELL-DEATH; RAT-BRAIN; CASPASE ACTIVATION; INBRED STRAINS; HEAD-INJURY; BETA; IMPAIRMENT	Mild traumatic brain injury (mTBI) is a not uncommon event in adolescents and young adults. Although it does not result in clear morphological brain defects, it is associated with long-term cognitive, emotional, and behavioral problems. Herein, we characterized the biochemical and behavioral changes associated with experimental mTBI in mice that may act as either targets or surrogate markers for interventional therapy. Specifically, mTBI was induced by 30-g and 50-g weight drop, and at 8 and 72 hr thereafter markers of cellular apoptosis-caspase-3, Bax, apoptosis-inducing factor (AIF), and cytochrome-c (Cyt-c)-were quantified by Western blot analysis in hippocampus ipsilateral to the impact. Levels of amyloid-P precursor protein (APP) were also measured, and specific behavioral tests-passive avoidance, open field, and forced swimming (Porsolt) paradigms-were undertaken to assess learning, emotionality, and emotional memory. In the absence of hemorrhage or infarcts, as assessed by triphenyltetrazolium chloride staining, procaspase-3 and Bax levels were markedly altered following mTBI at both times. No cleaved caspase-3 was detected, and levels of AIF and Cyt-c, but not APP, were significantly changed at 72 hr. Mice subjected to mTBI were indistinguishable from controls by neurological examination at 1 and 24 hr, and by passive avoidance/open field at 72 hr, but could be differentiated in the forced swimming paradigm. In general, this model mimics the diffuse effects of mTBI on brain function associated with the human condition and highlights specific apoptotic proteins and a behavioral paradigm as potential markers for prospective interventional strategies. (c) 2007 Wiley-Liss,Inc.	NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA; Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; NIDA, Neural Protect & Regenerat Sect, Mol Neuropsychiat Branch, Intramural Res Program, Baltimore, MD 21224 USA; NIA, Lab Expt Gerontol, Intramural Res Program, Baltimore, MD 21224 USA; Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46204 USA; NIDA, Cellular Neurobiol Branch, Intramural Res Program, Baltimore, MD 21224 USA	Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA.	greign@grc.nia.nih.gov	Harvey, Brandon K/A-5559-2010; Pick, Chaim/D-4789-2009	/0000-0002-4036-1383; Milman, Anat/0000-0002-8551-4101	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG023055] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG023055, Z01AG000311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [Z01DA000461] Funding Source: NIH RePORTER		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; BARTUS RT, 1986, PROG BRAIN RES, V70, P345; Bolivar VJ, 2000, BEHAV GENET, V30, P285, DOI 10.1023/A:1026545316455; Bouwknecht JA, 2004, EUR J PHARMACOL, V494, P35, DOI 10.1016/j.ejphar.2004.04.036; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; Cho SG, 2002, J BIOCHEM MOL BIOL, V35, P24, DOI 10.5483/BMBRep.2002.35.1.024; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; LaFerla FM, 2005, TRENDS MOL MED, V11, P170, DOI 10.1016/j.molmed.2005.02.009; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Pierce JES, 1996, J NEUROSCI, V16, P1083; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Sosin DM, 1996, BRAIN INJURY, V10, P47; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; TAGHZOUTI K, 1985, BRAIN RES, V344, P9, DOI 10.1016/0006-8993(85)91184-9; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WALLACE WC, 1995, J NEUROSCI, V15, P4896; Wang Y, 2003, J NEUROSCI, V23, P7958; Wang Y, 1997, J NEUROSCI, V17, P4341; WINOCUR G, 1985, BEHAV BRAIN RES, V16, P135, DOI 10.1016/0166-4328(85)90088-9; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	56	72	73	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAR	2007	85	4					805	815		10.1002/jnr.21160			11	Neurosciences	Neurosciences & Neurology	149PK	WOS:000245158800013	17243171				2021-06-18	
J	Andersson, EE; Emanuelson, I; Bjorklund, R; Stalhammar, DA				Andersson, E. Elgmark; Emanuelson, I.; Bjorklund, R.; Stalhammar, D. A.			Mild traumatic brain injuries: the impact of early intervention on late sequelae. A randomized controlled trial	ACTA NEUROCHIRURGICA			English	Article						mild traumatic brain injuries; post-concussion symptoms; randomised controlled trial; rehabilitation	SF-36 HEALTH SURVEY; 18-TO 64-YEAR-OLD SWEDES; ROUTINE FOLLOW-UP; HEAD-INJURY; LIFE SATISFACTION; WESTERN SWEDEN; ADULTS; REHABILITATION; RELIABILITY; POPULATION	Background. Positive results from early clinical intervention of mild traumatic brain injury (MTBI) patients by rehabilitation specialists have been reported. Various treatments have been used, but few controlled studies are published. We hypothesised that early rehabilitation of selected MTBI patients would reduce long term sequelae. Method. A randomised controlled trial with one year follow-up. Among 1719 consecutive patients with MTBI, 395 individuals, 16-60 years of age, met the MTBI definition. Exclusion criteria were: previous clinically significant brain disorders and/or a history of substance abuse. The control group (n = 131) received regular care. The intervention group (n = 264) was examined by a rehabilitation specialist. 78 patients were mainly referred to an occupational therapist. The problems were identified in daily activities and in terms of post-concussion symptoms (PCS), an individualised, tailored treatment was given. Primary endpoint was change in rate of PCS and in life satisfaction at one-year follow-up between the groups. Findings. No statistical differences were found between the intervention and control groups. Patients who experienced few PCS two to eight weeks after the injury and declined rehabilitation recovered and returned to their pre-injury status. Patients who suffered several PCS and accepted rehabilitation did not recover after one year. Interpretation. In this particular MTBI sample, early active rehabilitation did not change the outcome to a statistically-significant degree. Further studies should focus on patients with several complaints during the first 1-3 months and test various types of interventions.	Jonkoping Univ, Dept Rehabil, Sch Hlth Sci, SE-55111 Jonkoping, Sweden; Univ Gothenburg, Inst Clin Neurosci, Dept Rehabil Med, Gothenburg, Sweden; Univ Gothenburg, Reg Rehabil Unit, Dept Hlth & Women & Children, Gothenburg, Sweden; Sodra Alvsborgs Hosp, Rehabil Ctr, Boras, Sweden; Univ Gothenburg, Inst Clin Neurosci, Sahlgrenska Univ Hosp, Dept Neurosurg, Gothenburg, Sweden	Andersson, EE (corresponding author), Jonkoping Univ, Dept Rehabil, Sch Hlth Sci, Box 1026, SE-55111 Jonkoping, Sweden.	elisabeth.elgmark@telia.com					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Branholm I-B, 1992, THESIS U UMEA UMEA; BRANHOLM IB, 1994, DISABIL REHABIL, V16, P205; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; EGLMARK EA, 2006, J REHABIL MED, V38, P26; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Good P., 2000, PERMUTATION TESTS PR; GREEN BS, 1997, MILD TRAUMATIC BRAIN, P2; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hoffmann B, 2002, ACT NEUR S, V79, P33; HOLM S, 1979, SCAND J STAT, V6, P65; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1038, DOI 10.1001/jama.231.10.1038; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MATSUTSUYU JS, 1969, AM J OCCUP THER, V23, P323; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ, P3; Melin R, 2003, J REHABIL MED, V35, P84, DOI 10.1080/16501970306119; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; ODEN A, 1975, ANN STAT, V3, P518, DOI 10.1214/aos/1176343082; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; POCOCK SJ, 1979, BIOMETRICS, V35, P183, DOI 10.2307/2529944; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Pocock SJ, 1983, CLIN TRIALS PRACTICA; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Salazar AM, 2002, J NEUROL NEUROSUR PS, V73, P239, DOI 10.1136/jnnp.73.3.239; SILVERBAGECARLS, 1986, EPIDEMIOLOGY INJURIE, P1; SIMOVICI S, 1976, WORK LEISURE SOCIOGE, P84; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; *WHO SWED COUNC, 1996, ICD 10 STAT CLASS DI; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	53	72	73	1	9	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	FEB	2007	149	2					151	160		10.1007/s00701-006-1082-0			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	132UV	WOS:000243968800009	17252176				2021-06-18	
J	Scheibel, RS; Newsome, MR; Steinberg, JL; Pearson, DA; Rauch, RA; Mao, H; Troyanskaya, M; Sharma, RG; Levin, HS				Scheibel, Randall S.; Newsome, Mary R.; Steinberg, Joel L.; Pearson, Deborah A.; Rauch, Ronald A.; Mao, Hui; Troyanskaya, Maya; Sharma, Rajkumar G.; Levin, Harvey S.			Altered brain activation during cognitive control in patients with moderate to severe traumatic brain injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						functional magnetic resonance imaging; traumatic brain injury; cognition	ANTERIOR CINGULATE CORTEX; CLOSED-HEAD INJURY; EVENT-RELATED FMRI; WORKING-MEMORY; PREFRONTAL CORTEX; PRACTICAL SCALE; STROOP TASK; INTERFERENCE; INFORMATION; IMPAIRMENT	Background. Persistent deficits in cognitive control have been documented following traumatic brain injury (TBI) but are inconsistently related to the presence and location of focal lesions. Objective. Functional magnetic resonance imaging (fMRI) was used to examine brain activation during a cognitive control task in patients with moderate to severe TBI or orthopedic injury (OI). Methods. Fourteen TBI patients and 10 OI patients underwent fMRI at 3 months postinjury using a stimulus-response compatibility task in which response accuracy and reaction time were measured. Performance between the groups was equated by individually adjusting the amount of training. Groups did not differ in age, gender, or education. Results. Brain activation during stimulus-response incompatibility was greater in TBI patients than in OI patients within the cingulate, medial frontal, middle frontal, and superior frontal gyri. However, the positive regression of activation with response accuracy during stimulus-response incompatibility indicated a stronger relationship for OI patients than the TBI group within the anterior cingulate gyrus, medial frontal, and parietal regions, as well as deep brain structures (eg, brainstem). The number of focal lesions within either the whole brain or within prefrontal areas was not related to brain activation, but there was a relationship between activation and TBI severity. Conclusions. These findings suggest that neural networks mediating cognitive control are altered after moderate to severe TBI, possibly as a result of diffuse axonal injury, and that the typical relationship of brain activation to performance is disrupted.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Houston, TX USA; Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA	Scheibel, RS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	scheibel@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-42772, NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER		Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brown JW, 2005, SCIENCE, V307, P1118, DOI 10.1126/science.1105783; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Easdon C, 2004, BRAIN COGNITION, V54, P136; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liu X, 2004, NEUROIMAGE, V22, P1097, DOI 10.1016/j.neuroimage.2004.02.033; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Rakitin BC, 2005, J EXP PSYCHOL HUMAN, V31, P685, DOI 10.1037/0096-1523.31.4.685; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; SIMON JR, 1969, J APPL PSYCHOL, V53, P433, DOI 10.1037/h0028034; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Turner R, 2002, NEUROIMAGE, V16, P1062, DOI 10.1006/nimg.2002.1082; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	39	72	73	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN-FEB	2007	21	1					36	45		10.1177/1545968306294730			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	119GX	WOS:000243001900004	17172552				2021-06-18	
J	Zhao, CP; Zhang, C; Zhou, SN; Xie, YM; Wang, YH; Huang, H; Shang, YC; Li, WY; Zhou, C; Yu, MJ; Feng, SW				Zhao, C-P; Zhang, C.; Zhou, S-N; Xie, Y-M; Wang, Y-H; Huang, H.; Shang, Y-C; Li, W-Y; Zhou, C.; Yu, M-J; Feng, S-W			Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice	CYTOTHERAPY			English	Article						amyotrophic lateral sclerosis; mesenchymal stromal cells; SOD1-G93A mice therapy; transplantation	AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; BONE-MARROW-CELLS; MOTOR-NEURON DEGENERATION; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; CEREBRAL-ISCHEMIA; GROWTH-FACTOR; SPINAL-CORD	Background Amyotrophic lateral sclerosis (ALS) is a progressive, lethal, neurodegenerative disease, currently without any effective therapy. Multiple advantages make mesenchymal stromal cells (MSC) a good candidate for cellular therapy in many intractable diseases such as stroke and brain injury. Until now, no irrefutable evidence exists regarding the outcome of MSC transplantation in the mouse model of ALS. The present study was designed to investigate the therapeutic potential of human MSC (hMSC) in the mouse model of ALS (SOD1-G93A mice). Methods hMSC were isolated from iliac crest aspirates from healthy donors and kept in cell cultures. hMSC of the fifth passage were delivered intravenously into irradiated pre-symptomatic SOD1-G93A mice. Therapeutic effects were analyzed by survival analysis, rotarod test, motor neuron count in spinal cord and electrophysiology. The engraftment and in vivo differentiation of hMSC were examined in the brain and spinal cord of hMSC-transplanted mice. Results After intravenous injection into irradiated pre-symptomatic SOD1-G93A mice, hMSC survived more than 20 weeks in recipient mice, migrated into the parenchyma of brain and spinal cord and showed neuroglia differentiation. Moreover, hMSC-transplanted mice showed significantly delayed disease onset (14 days), increased lifespan (18 days) and delayed disease progression compared with untreated mice. Discussion Our data document the positive effects of hMSC transplantation in the mouse model of ALS. It may signify the potential use of hMSC in treatment of ALS.	Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510080, Peoples R China; Sun Yat Sen Univ, Stemm Cells & Tissue Engn Res Ctr, Guangzhou 510080, Peoples R China; Shandong Univ, Qi Lu Hosp, Dept Neurol, Jinan, Peoples R China; Univ N Carolina, Dept Neurol, Chapel Hill, NC USA; Affiliated Hosp, Dept Neurosurg, Yang Zhou, Peoples R China	Zhang, C (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510080, Peoples R China.	Zhangch6@mail.sysu.edu.cn	Shang, Yanchang/B-2910-2008	Shang, Yanchang/0000-0002-4200-6000			Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Alberch J, 2002, BRAIN RES BULL, V57, P817, DOI 10.1016/S0361-9230(01)00775-4; Allers C, 2004, TRANSPLANTATION, V78, P503, DOI 10.1097/01.TP.0000128334.93343.B3; Azzouz M, 1997, MUSCLE NERVE, V20, P45, DOI 10.1002/(SICI)1097-4598(199701)20:1<45::AID-MUS6>3.0.CO;2-H; Beaulieu JM, 2000, J NEUROSCI, V20, P5321, DOI 10.1523/JNEUROSCI.20-14-05321.2000; Bentzon JF, 2005, BIOCHEM BIOPH RES CO, V330, P633, DOI 10.1016/j.bbrc.2005.03.072; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Corti S, 2004, BRAIN, V127, P2518, DOI 10.1093/brain/awh273; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Gaber MW, 2004, BRAIN RES PROTOC, V13, P1, DOI 10.1016/j.brainresprot.2003.11.005; Gao Q, 2005, NEUROSCIENCE, V136, P123, DOI 10.1016/j.neuroscience.2005.06.091; Garbuzova-Davis S, 2002, EXP NEUROL, V174, P169, DOI 10.1006/exnr.2002.7860; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Gomes FCA, 2001, BRAZ J MED BIOL RES, V34, P611, DOI 10.1590/S0100-879X2001000500008; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Henkel JS, 2006, MOL CELL NEUROSCI, V31, P427, DOI 10.1016/j.mcn.2005.10.016; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Honma T, 2006, EXP NEUROL, V199, P56, DOI 10.1016/j.expneurol.2005.05.004; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; Levine JB, 1999, GLIA, V28, P215; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LI Y, 2003, CANCER RES, V63, P5650; Li YQ, 2004, RADIAT RES, V161, P143, DOI 10.1667/RR3117; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mazzini L, 2006, NEUROL RES, V28, P523, DOI 10.1179/016164106X116791; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mohajeri MH, 1998, EXP NEUROL, V150, P329, DOI 10.1006/exnr.1998.6758; Niebroj-Dobosz I, 1999, ACTA NEUROL SCAND, V100, P238; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Pena LA, 2000, CANCER RES, V60, P321; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Rothstein JD, 1996, NEUROLOGY, V47, pS19, DOI 10.1212/WNL.47.4_Suppl_2.19S; Shefner JM, 2002, MUSCLE NERVE, V25, P39, DOI 10.1002/mus.10000; Shibata N, 2001, NEUROPATHOLOGY, V21, P82, DOI 10.1046/j.1440-1789.2001.00361.x; Shinohara C, 1997, CANCER RES, V57, P2694; Silani V, 2004, CURR NEUROVASC RES, V1, P283, DOI 10.2174/1567202043362243; Silani V, 2004, LANCET, V364, P200, DOI 10.1016/S0140-6736(04)16634-8; Sisodia R, 2006, J RADIOL PROT, V26, P227, DOI 10.1088/0952-4746/26/2/007; Solomon JN, 2006, GLIA, V53, P744, DOI 10.1002/glia.20331; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Villoslada P, 2004, PROG BRAIN RES, V146, P403; Wang Lei, 2002, Hematology, V7, P113; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Yuan H, 2003, BRAIN RES, V969, P59, DOI 10.1016/S0006-8993(03)02278-9; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhong C, 2003, NEUROSCI LETT, V342, P93, DOI 10.1016/S0304-3940(03)00255-6	57	72	74	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy		2007	9	5					414	426		10.1080/14653240701376413			13	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	206HH	WOS:000249174000002	17786603				2021-06-18	
J	Copenhaver, BR; Rabin, LA; Saykin, AJ; Roth, RM; Wishart, HA; Flashman, LA; Santulli, RB; McHugh, TL; Mamourian, AC				Copenhaver, Brittany R.; Rabin, Laura A.; Saykin, Andrew J.; Roth, Robert M.; Wishart, Heather A.; Flashman, Laura A.; Santulli, Robert B.; McHugh, Tara L.; Mamourian, Alexander C.			The fornix and mammillary bodies in older adults with Alzheimer's disease, mild cognitive impairment, and cognitive complaints: A volumetric MRI study	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Alzheimer's disease; mild cognitive impairment; cognitive complaints; fornix; mammillary bodies; volumetric MRI	VOXEL-BASED MORPHOMETRY; TRAUMATIC BRAIN INJURY; MEMORY; ATROPHY; BODY; VALIDATION; DEMENTIA; AMNESIA; SYSTEM; SCHIZOPHRENIA	The fomix and mammillary bodies are important limbic structures that have not been systematically investigated in the earliest stages of preclinical dementia. The present study examined volumetric changes in the fornix and mammillary bodies and improved previously established tracing guidelines to increase reliability and provide more comprehensive measurements. Volumetric measurements were made in euthymic older adults, including 16 patients with mild Alzheimer's disease (AD), 20 patients with amnestic mild cognitive impairment (MCI), 20 individuals with cognitive complaints (CC) but normal neuropsychological test performance, and 20 demographically matched healthy controls (HC). Structural magnetic resonance imaging included a T1-weighted 1.5-mm coronal volume, acquired on a GE 1.5T LX scanner. After adjustment for total intracranial volume (ICV), significant volume reductions were observed in the fornix and mammillary bodies in patients with AD as compared with HC, CC, and MCI participants. No volume differences were seen between the HC, CC, and MCI groups. Study findings are consistent with previous research showing volume decreases of the fornix and mammillary bodies in AD, and provide new data on the relative preservation of these structures in preclinical disease stages. Results suggest that atrophy of the fomix and mammillary bodies becomes apparent at the point of conversion from MCI to AD. Longitudinal assessments are needed to delineate the time course and extent of the observed volumetric changes. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Dartmouth Coll Sch Med, Dept Psychiat, DHMC, Brain Imaging Lab, Lebanon, NH 03756 USA; Dartmouth Coll, Dept Psychol, Hanover, NH 03755 USA; CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA; Dartmouth Coll Sch Med, Dept Radiol, DHMC, Lebanon, NH 03756 USA	Saykin, AJ (corresponding author), Dartmouth Coll Sch Med, Dept Psychiat, DHMC, Brain Imaging Lab, Lebanon, NH 03756 USA.	Andrew.J.Saykin@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG19771] Funding Source: Medline		Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; Anstey KJ, 2003, AGING MENT HEALTH, V7, P238, DOI 10.1080/1360786031000120732; Baron JC, 2001, NEUROIMAGE, V14, P298, DOI 10.1006/nimg.2001.0848; Bilir E, 1998, NEURORADIOLOGY, V40, P138, DOI 10.1007/s002340050554; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Callen DJA, 2001, NEUROLOGY, V57, P1669, DOI 10.1212/WNL.57.9.1669; CHARNESS ME, 1987, ANN NEUROL, V22, P595, DOI 10.1002/ana.410220506; Chetelat G, 2005, NEUROIMAGE, V27, P934, DOI 10.1016/j.neuroimage.2005.05.015; DeCarli C, 2001, CLIN GERIATR MED, V17, P255, DOI 10.1016/S0749-0690(05)70068-9; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DELIS DC, 2000, CALIFORNIA VERBAL LE; Duvernoy H.M., 1999, HUMAN BRAIN SURFACE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gaffan D, 2001, BEHAV BRAIN RES, V127, P5, DOI 10.1016/S0166-4328(01)00360-6; Gaffan D., 1992, NEUROPSYCHOLOGY MEMO, P336; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; Heaton R., 1993, WISCONSIN CARD SORTI; Hensel A, 2005, J NEUROL SCI, V238, P71, DOI 10.1016/j.jns.2005.06.011; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Jurica PJ., 2001, DEMENTIA RATING SCAL; Kapur N, 1998, NEUROCASE, V4, P509, DOI 10.1093/neucas/4.6.509; Kapur N., 1994, NEUROPSYCHOLOGICAL E, P159; Kuzniecky R, 1999, NEUROLOGY, V53, P496, DOI 10.1212/WNL.53.3.496; Lee BCP, 2003, J NEUROIMAGING, V13, P199, DOI 10.1177/1051228403013003001; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Parker A, 1997, J COGNITIVE NEUROSCI, V9, P512, DOI 10.1162/jocn.1997.9.4.512; Pennanen C, 2005, J NEUROL NEUROSUR PS, V76, P11, DOI 10.1136/jnnp.2004.035600; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; RABIN LA, 2004, P INT NEUROPSYCHOLOG, V32, P3; SAYKIN AJ, 1991, J NEUROPSYCH CLIN N, V3, P286; SAYKIN AJ, 2003, J NEUROPSYCHIATRY CL, V15, P263; Shear PK, 1996, ALCOHOL CLIN EXP RES, V20, P1489, DOI 10.1111/j.1530-0277.1996.tb01153.x; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SQUIRE LR, 1979, BIOL PSYCHIAT, V14, P791; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; van der Flier WM, 2004, J NEUROL, V251, P671, DOI 10.1007/s00415-004-0390-7; WANG PJ, IN PRESS NEUROBIOLOG; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whitworth AB, 2005, PSYCHIAT RES-NEUROIM, V140, P225, DOI 10.1016/j.pscychresns.2005.07.006; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x; Wolf H, 2003, ACTA NEUROL SCAND, V107, P52, DOI 10.1034/j.1600-0404.107.s179.10.x; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zahajszky J, 2001, SCHIZOPHR RES, V47, P87, DOI 10.1016/S0920-9964(00)00051-7	52	72	74	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927			PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	OCT 30	2006	147	2-3					93	103		10.1016/j.pscychresns.2006.01.015			11	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	095RX	WOS:000241326800001	16920336				2021-06-18	
J	Bermpohl, D; You, ZR; Korsmeyer, SJ; Moskowitz, MA; Whalen, MJ				Bermpohl, Daniela; You, Zerong; Korsmeyer, Stanley J.; Moskowitz, Michael A.; Whalen, Michael J.			Traumatic brain injury in mice deficient in Bid: effects on histopathology and functional outcome	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; Bid; brain injury; necrosis; trauma	CELL-DEATH; NEURONAL APOPTOSIS; SIGNALING COMPLEX; ACTIVATION; CASPASE-3; MITOCHONDRIA; RECEPTORS; CLEAVAGE; PATHWAY	Bid is a proapoptotic member of the Bcl-2 family that mediates cell death by caspase-dependent and -independent pathways. We tested mice genetically deficient in Bid in a controlled cortical impact (CCI) model to examine the hypothesis that Bid contributes to cell death and functional outcome after traumatic brain injury. After CCI, truncated Bid (15 kDa) was robustly detected in cortical brain homogenates of wild-type mice. Bid-/- mice had decreased numbers of cortical cells with acute plasmalemma injury at 6 h (wild type (WT), 1721 +/- 124; Bid-/-, 1173 +/- 129 cells/ x 200 field; P < 0.01), decreased numbers of cells expressing cleaved caspase-3 in the dentate gyrus at 48 h (WT, 113 +/- 15; Bid-/-, 65 +/- 9 cells/ x 200 field; P < 0.05), and reduced lesion volume at 12 days (Bid-/-, 5.9 +/- 0.4 mm(3); WT, 8.4 +/- 0.4 mm(3); P < 0.001), but did not differ from WT mice at later times after injury regarding lesion size (30 days) or brain tissue atrophy (40 days). Compared with naive mice, injured mice in both groups performed significantly worse on motor and Morris water maze (MWM) tests; however, mice deficient in Bid did not differ from WT in postinjury motor and MWM performance. The data show that Bid deficiency decreases early posttraumatic brain cell death and tissue damage, but does not reduce functional outcome deficits after CCI in mice.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat,Neurosci Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA 02129 USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat,Neurosci Ctr, 149 13th St RM 6403, Charlestown, MA 02129 USA.	mwhalen@partners.org	Moskowitz, Michael A/D-9916-2011		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37141, KO8NS41969, R01NS47447] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, K08NS041969, R01NS037141] Funding Source: NIH RePORTER		Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bermpohl D, 2003, J NEUROTRAUM, V20, P1053; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Krajewska M, 2002, NEOPLASIA, V4, P129, DOI 10.1038/sj.neo.7900222; Krajewska M, 2004, EXP NEUROL, V189, P261, DOI 10.1016/j.expneurol.2004.05.020; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Wei MC, 2000, GENE DEV, V14, P2060; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Yin XM, 1999, NATURE, V400, P886; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	32	72	75	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2006	26	5					625	633		10.1038/sj.jcbfm.9600258			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	038RA	WOS:000237239500004	16395279	Bronze			2021-06-18	
J	Dockree, PM; Bellgrove, MA; O'Keeffe, FM; Moloney, P; Aimola, L; Carton, S; Robertson, IH				Dockree, PM; Bellgrove, MA; O'Keeffe, FM; Moloney, P; Aimola, L; Carton, S; Robertson, IH			Sustained attention in traumatic brain injury (tbi) and healthy controls: enhanced sensitivity with dual-task load	EXPERIMENTAL BRAIN RESEARCH			English	Article						dual-task; sustained attention; traumatic brain injury; prefrontal cortex	INTRINSIC ALERTNESS; FUNCTIONAL-ANATOMY; FRONTAL LOBES; PERFORMANCE; DEFICITS; NETWORK; DAMAGE	Poor sustained attention or alertness is a common consequence of traumatic brain injury (TBI) and has a considerable impact on the recovery and adjustment of TBI patients. Here, we describe the development of a sensitive laboratory task in healthy subjects (Experiment 1) and its enhanced sensitivity to sustained attention errors in TBI patients (Experiment 2). The task involves withholding a key press to an infrequent no-go target embedded within a predictable sequence of numbers (primary goal) and detecting grey-coloured targets within the sequence (secondary goal). In Experiment 1, we report that neurologically healthy subjects are more likely to experience a lapse of attention and neglect the primary task goal, despite ceiling performance on the secondary task. Further, attentional lapses on the task correlated with everyday attentional failures and variability of response time. In Experiment 2, the task discriminates between TBI patients and controls with a large effect size. The dual-task yields more errors in both groups than a simple task involving only the primary goal that is commonly used to detect sustained attention deficits in neurologically impaired groups. TBI patients' errors also correlated with everyday cognitive failures and variability of response time. This was not the case in the simple version of the task. We conclude that the dual-task demand associated with this task enhances its sensitivity as a measure of sustained attention in TBI patients and neurologically healthy controls that relates to everyday slips of attention.	Univ Dublin Trinity Coll, Inst Neurosci, Dept Psychol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Psychiat, Dublin 2, Ireland; Natl Rehabil Hosp, Dun Laoghaire, Co Dublin, Ireland	Dockree, PM (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Dept Psychol, Dublin 2, Ireland.	dockreep@tcd.ie	Bellgrove, Mark/AAB-3114-2019	Bellgrove, Mark/0000-0003-0186-8349; Robertson, Ian H/0000-0001-8637-561X			Bellgrove MA, 2004, NEUROREPORT, V15, P1065, DOI 10.1097/00001756-200404290-00027; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Kondo H, 2004, NEUROIMAGE, V21, P2, DOI 10.1016/j.neuroimage.2003.09.046; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lindgren KA, 1999, BIOL PSYCHIAT, V45, P943, DOI 10.1016/S0006-3223(98)00350-3; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; Manly T., 2000, CLIN NEUROPSYCHOLOGI, V3, P167; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Portas CM, 1998, J NEUROSCI, V18, P8979; Posner MI, 2000, PSYCHOL BULL, V126, P873, DOI 10.1037/0033-2909.126.6.873; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOLOGI; Robertson IH, 2004, COGNITIVE NEUROSCIENCES III, THIRD EDITION, P631; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P563, DOI 10.1016/j.neuropsychologia.2003.11.004; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	72	73	0	9	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JAN	2006	168	1-2					218	229		10.1007/s00221-005-0079-x			12	Neurosciences	Neurosciences & Neurology	991OG	WOS:000233822700021	16044297				2021-06-18	
J	Yilmazlar, S; Arslan, E; Kocaeli, H; Dogan, S; Aksoy, K; Korfali, E; Doygun, M				Yilmazlar, S; Arslan, E; Kocaeli, H; Dogan, S; Aksoy, K; Korfali, E; Doygun, M			Cerebrospinal fluid leakage complicating skull base fractures: analysis of 81 cases	NEUROSURGICAL REVIEW			English	Article						cerebrospinal fluid leakage; skull base fracture; complication	TEMPORAL BONE-FRACTURES; SEVERE HEAD-INJURY; PROPHYLACTIC ANTIBIOTICS; MANAGEMENT; RHINORRHEA; FISTULAS; METAANALYSIS; DIAGNOSIS; ANTERIOR	The aim of this study was to evaluate the results of conservative and surgical management options for traumatic cerebrospinal fluid (CSF) leakage complicating skull base fractures. The subjects were 81 patients who were treated between 1996 and 2003 for CSF leaks that had persisted for 24 h or longer after head injury. For each case the medical records were reviewed, and the data collected were as follows: demographic features, clinical and radiological findings, management options, complications and outcome scores. Analysis was done with patients grouped according to Glasgow coma scale (GCS) score at admission (<= 8 vs >8), and findings for three treatment methods (conservative, CSF drainage, surgery) were evaluated. In 32 cases (39.5%), the CSF leakage resolved spontaneously, and the mean hospital stay for these patients was 14 +/- 11 days. Twenty-four patients (29.6%) were treated by CSF drainage, and seven of these individuals ultimately required surgery to close the leak. Hospital stay was 17 +/- 7 days. Twenty-five patients (30.9%) underwent surgery as the initial treatment step, and the mean hospital stay for these individuals was 15 +/- 9 days. The large majority (74.2%) of patients with admission GCS scores <= 8 had poor outcomes. Compared with this group, a greater proportion of the CSF leaks in the patients with admission GCS scores >8 resolved spontaneously. The factors that had a critical influence on outcome in this series were level of consciousness on admission and presence of additional intracranial pathology associated with CSF leakage within cases of traumatic CSF fistulae due to skull base fractures. Treatment decisions should be dictated by the severity of neurological decline during the emergency period and the presence/absence of associated intracranial lesions. The timing for surgery and CSF drainage procedures must be decided with great care and with a clear strategy. The authors offer a treatment algorithm.	Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey	Yilmazlar, S (corresponding author), Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey.	selsus@uludag.edu.tr	, selcuk/AAH-5070-2021	, selcuk/0000-0003-3633-7919			AARABI B, 1992, Ear Nose and Throat Journal, V71, P300; BECKHARDT RN, 1991, OTOLARYNG HEAD NECK, V104, P425, DOI 10.1177/019459989110400402; Brodie HA, 1997, ARCH OTOLARYNGOL, V123, P749; Brodie HA, 1997, AM J OTOL, V18, P188; CALCATERRA TC, 1985, OTOLARYNG CLIN N AM, V18, P99; CLEMENZA JW, 1995, J ORAL MAXIL SURG, V53, P1004, DOI 10.1016/0278-2391(95)90114-0; CONSTANTINO PD, 1998, HEAD NECK SURG OTOLA, P1848; COOPER PW, 1982, J OTOLARYNGOL, V11, P319; Dagi T F, 1983, Am J Emerg Med, V1, P295, DOI 10.1016/0735-6757(83)90109-2; DALY D T, 1992, Ear Nose and Throat Journal, V71, P311; DEMETRIADES D, 1992, INJURY, V23, P377, DOI 10.1016/0020-1383(92)90011-G; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; HUBBARD JL, 1985, NEUROSURGERY, V16, P314, DOI 10.1227/00006123-198503000-00006; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; Lanza DC, 1996, LARYNGOSCOPE, V106, P1119, DOI 10.1097/00005537-199609000-00015; LAUN A, 1982, ACTA NEUROCHIR, V60, P215, DOI 10.1007/BF01406308; Lee D, 1998, LARYNGOSCOPE, V108, P816, DOI 10.1097/00005537-199806000-00008; LEECH PJ, 1973, LANCET, V1, P1013; Loew F, 1984, Adv Tech Stand Neurosurg, V11, P169; MARENTETTE LJ, 1991, OTOLARYNG CLIN N AM, V24, P151; Marion D W, 1991, Neurosurg Clin N Am, V2, P411; MCGUIRT WF, 1995, LARYNGOSCOPE, V105, P359, DOI 10.1288/00005537-199504000-00003; PARK JI, 1983, LARYNGOSCOPE, V93, P1294; Villalobos T, 1998, CLIN INFECT DIS, V27, P364, DOI 10.1086/514666; ZLAB M K, 1992, Ear Nose and Throat Journal, V71, P314	25	72	77	3	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JAN	2006	29	1					64	71		10.1007/s10143-005-0396-3			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	986QU	WOS:000233465600014	15937689				2021-06-18	
J	Sarajuuri, JM; Kaipio, ML; Koskinen, SK; Niemela, MR; Servo, AR; Vilkki, JS				Sarajuuri, JM; Kaipio, ML; Koskinen, SK; Niemela, MR; Servo, AR; Vilkki, JS			Outcome of a comprehensive neurorehabilitation program for patients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	European Platform for Vocational Rehabilitation	FEB 23-24, 2001	Birmingham, ENGLAND			brain injuries; neuropsychology; outcome assessment (health care); rehabilitation	TERM-FOLLOW-UP; NEUROPSYCHOLOGICAL REHABILITATION; COGNITIVE REHABILITATION; COMMUNITY INTEGRATION; SUPPORTED EMPLOYMENT; HEAD-INJURY; RETURN; WORK; PREDICTION; COST	Objective: To evaluate the outcome of a comprehensive neurorehabilitation program compared with that of conventional clinical care and rehabilitation for patients with traumatic brain injury (TBI). Design: Nonrandomized, controlled trial with a 2-year follow-up. Setting: Nationwide rehabilitation center and level I trauma center, both in Finland. Participants: We studied 19 consecutive adults with a significant TBI who underwent a comprehensive neurorehabilitation program and 20 control patients who received conventional rehabilitation referred by physicians in the general health care system. The outcome of the control patients was not known before the selection. The groups were similar in age, sex, education, injury severity (assessed on the Glasgow Coma Scale, radiologic and neuropsychologic findings, neurosurgical interventions), time from the injury, and preinjury employment status. Interventions: A postacute, intensive, interdisciplinary, 6-week rehabilitation program for TBI patients who are considered to have adequate potential to achieve productivity by this means; focus on neuropsychologic rehabilitation and psychotherapy with vocational interventions and follow-up support. Main Outcome Measure: Status of productivity, judged as productive (defined as working, studying, or participating in volunteer activities) or nonproductive, evaluated on questionnaires filled in by patients and their significant others at the time of follow-up evaluation. Results: At follow-up, 89% of the treated patients were productive compared with 55% of the controls. The rehabilitation program was significantly predictive of the productive status at follow-up (odds ratio=6.96; 95% confidence interval, 1.26-38.44; P=.017). Other factors did not explain the better productivity of the treatment group. Two neuropsychologist-evaluators, who were blind to the rehabilitation history of patients and to each other's evaluations, were perfectly consistent in their classification of patients' productivity statuses. Conclusions: The findings support the proposition that comprehensive neuropsychologically oriented rehabilitation programs can improve psychosocial functioning in terms of productivity in postacute patients with moderate to severe TBI. Additional larger controlled studies are needed to establish the efficacy of TBI rehabilitation interventions.	Kapyla Rehabil Ctr, Dept Clin Neuropsychol, Finnish Assoc People Mobil Disabil, FIN-00251 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Radiol, Helsinki, Finland; Univ Helsinki, Dept Psychol, SF-00100 Helsinki, Finland	Sarajuuri, JM (corresponding author), Kapyla Rehabil Ctr, Dept Clin Neuropsychol, Finnish Assoc People Mobil Disabil, Nordenskioldinkatu 18 B,POB 103, FIN-00251 Helsinki, Finland.	jaana.sarajuuri@invalidiliitto.fi	Sarajuuri, Jaana/AAD-8665-2019; Niemela, Mika R/F-2539-2015	Sarajuuri, Jaana/0000-0002-6432-0295; Niemela, Mika R/0000-0003-1526-0684; Koskinen, Sanna/0000-0002-3453-5084			Armitage P, 2002, STAT METHODS MED RES; Ashley MJ, 1997, BRAIN INJURY, V11, P677; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAMES P, 1989, MODELS BRAIN INJURY, P31; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Jones M L, 1992, J Insur Med, V24, P186; Kaipio M.-L., 2000, INT HDB NEUROPSYCHOL, P247; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP, 2000, JAMA-J AM MED ASSOC, V284, P1783, DOI 10.1001/jama.284.14.1783; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; STEIN DG, 1995, BRAIN REPAIR; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	42	72	73	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2005	86	12					2296	2302		10.1016/j.apmr.2005.06.018			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	995VE	WOS:000234131700010	16344026				2021-06-18	
J	Viant, MR; Lyeth, BG; Miller, MG; Berman, RF				Viant, MR; Lyeth, BG; Miller, MG; Berman, RF			An NMR metabolomic investigation of early metabolic disturbances following traumatic brain injury in a mammalian model	NMR IN BIOMEDICINE			English	Article						traumatic brain injury; lateral fluid percussion; rat; hippocarnpus; cortex; ascorbate; metabolomics; metabonomics	LATERAL FLUID-PERCUSSION; MAGNETIC-RESONANCE SPECTROSCOPY; CEREBROSPINAL-FLUID; PATTERN-RECOGNITION; N-ACETYLASPARTATE; OXIDATIVE STRESS; AMINO-ACIDS; HEAD-INJURY; RAT; DISORDERS	The effects of traumatic brain injury (TBI) on brain chemistry and metabolism were examined in three Groups of rats using high-resolution H-1 NMR metabolomics of brain tissue extracts and plasma. Brain injury in the TBI group (n = 6) was produced by lateral fluid percussion and regional changes in brain metabolites were analyzed at 1 h after injury in hippocampus, cortex and plasma and compared with changes in both a sham-surgery control group (n = 6) and an untreated control group (it = 6). Evidence was found of oxidative stress (e.g. decreases in ascorbate of 16.4% (P < 0.01) and 29.7% (p < 0.05) in cortex and hippocarnpus, respectively) in TBI rats versus the untreated control group, as well as excitotoxic damage (e.g. decreases in glutamate of 14.7% (p < 0.05) and 12.3% (p < 0.01) in the cortex and hippocampus, respectively), membrane disruption (e.g. decreases in the total level of phosphocholine and glycerophosphocholine of 23.0% (p < 0.01) and 19.0% (p < 0.01) in the cortex and hippocarnpus, respectively) and neuronal injury (e.g. decreases in N-acetylaspartate of 15.3% (p < 0.01) and 9.7% (p > 0.05) in the cortex and hippocampus, respectively). Significant changes in the overall pattern of NMR-observable metabolites using principal components analysis were also observed in TBI animals. Although TBI clearly had an effect on the metabolic profile found in brain tissue, no clear effects could be discerned in plasma samples. This was at least partly due to large variability in dominant Glucose and lactate peaks in plasma. However, disruption of the blood-brain barrier and the subsequent movement of metabolites from brain into blood may have been relatively small and below the detection limits of out-analytical procedures. Overall. these data indicate that TBI results in several significant changes in brain metabolism early after trauma and that a metabolomic approach based on H-1 NMR spectroscopy can provide a metabolic profile comprising several metabolite classes and allow for relative quantification of such changes within specific brain regions. The results also provide Support for further development and application of metabolomic technologies for studying TBI and for the utilization of multivariate models for classifying the extent of trauma within an individual. Copyright (c) 2005 John Wiley & Sons, Ltd.	Univ Calif Davis, Coll Agr & Environm Sci, Dept Environm Toxicol, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Neurol Surg, Davis, CA 95616 USA	Viant, MR (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	m.viant@bham.ac.uk	Viant, Mark R/B-6339-2009	Viant, Mark R/0000-0001-5898-4119; Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39090, NS29995, NS45136] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS039090, R01NS045136] Funding Source: NIH RePORTER		Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dunne VG, 2005, NMR BIOMED, V18, P24, DOI 10.1002/nbm.918; Eriksson L., 2001, MULTI MEGAVARIATE DA; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan WMT, 1996, PROG NUCL MAG RES SP, V28, P161, DOI 10.1016/0079-6565(95)01017-3; Forshed J, 2003, ANAL CHIM ACTA, V487, P189, DOI 10.1016/S0003-2670(03)00570-1; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Griffin JL, 2001, ANAL BIOCHEM, V293, P16, DOI 10.1006/abio.2001.5096; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Huang W, 2000, J PHARMACOL EXP THER, V295, P392; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KUMAGAE Y, 1991, J NEUROCHEM, V56, P1169, DOI 10.1111/j.1471-4159.1991.tb11407.x; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Takahashi M, 1997, J EXP BIOL, V200, P401; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Viant MR, 2003, BIOCHEM BIOPH RES CO, V310, P943, DOI 10.1016/j.bbrc.2003.09.092; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	32	72	78	0	19	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0952-3480			NMR BIOMED	NMR Biomed.	DEC	2005	18	8					507	516		10.1002/nbm.980			10	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	997XE	WOS:000234281400004	16177961				2021-06-18	
J	Besson, VC; Chen, XR; Plotkine, M; Marchand-Verrecchia, C				Besson, VC; Chen, XR; Plotkine, M; Marchand-Verrecchia, C			Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						cerebral oedema; fenofibrate; inflammation; neuroprotection; peroxisome proliferator-activated receptor alpha; traumatic brain injury	PPAR-ALPHA; KAPPA-B; INFLAMMATION; GAMMA; RATS; METABOLISM; EXPRESSION; RILUZOLE; LIGANDS; PATHWAY	Peroxisome proliferator-activated receptor alpha (PPAR alpha) has been demonstrated to reduce inflammation in various inflammatory diseases. As traumatic brain injury (TBI) caused a neuroinflammatory response, we examined the effect of fenofibrate, a PPAR alpha agonist, on the post-traumatic consequences caused by lateral fluid percussion of brain in rats. The effects of fenofibrate (50 and 100 mg/kg) were evaluated on the consequences of TBI in the early phase (6 and 24 h) and the late phase (7 days) after TBI. Neurological deficit, brain lesion, cerebral oedema and ICAM-1 expression were evaluated. Treatment with fenofibrate (given p.o. at 1 and 6h after TBI) decreases the neurological deficit induced by TBI at 24 h. Furthermore, fenofibrate reduces brain oedema and ICAM-1 expression at 24 h post-TBI. Rats given fenofibrate at 1, 6, 24, 48 and 72 It after TBI show neurological recovery associated with a reduction of the brain lesion at 7 days post-TBI. The present data represents the first demonstration that fenofibrate, a PPAR alpha agonist, exerts neuroprotective effects in TBI. The activation of receptor PPAR alpha could be beneficial by counteracting the deleterious inflammatory response following TBI. This suggests that PPAR alpha activation could be a new and promising therapeutic strategy for the treatment of brain trauma. (C) 2005 Elsevier Ireland Ltd. All rights reserved.	Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, F-75006 Paris, France	Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, 4 Ave Observ, F-75006 Paris, France.	catherine.marchand@univ-paris5.fr	BESSON, VALERIE/AAZ-9989-2020; besson, valerie C/L-7388-2017; MARCHAND-LEROUX, Catherine/L-7453-2017	BESSON, VALERIE/0000-0002-1491-2380; besson, valerie C/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brunmair B, 2004, J PHARMACOL EXP THER, V311, P109, DOI 10.1124/jpet.104.068312; Cuzzocrea S, 2004, SHOCK, V22, P340, DOI 10.1097/01.shk.0000136704.26372.2d; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Deplanque D, 2003, J NEUROSCI, V23, P6264; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Diep QN, 2004, J MOL CELL CARDIOL, V36, P295, DOI 10.1016/j.yjmcc.2003.11.004; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Genovese T, 2005, EXP NEUROL, V194, P267, DOI 10.1016/j.expneurol.2005.03.003; Gervois P, 2004, J BIOL CHEM, V279, P16154, DOI 10.1074/jbc.M400346200; Inoue H, 2003, NEUROSCI LETT, V352, P203, DOI 10.1016/j.neulet.2003.09.001; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Ogata T, 2004, J AM COLL CARDIOL, V43, P1481, DOI 10.1016/j.jacc.2003.11.043; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sedova L, 2004, INT J OBESITY, V28, P719, DOI 10.1038/sj.ijo.0802613; Soria A, 2002, J LIPID RES, V43, P74; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384	31	72	74	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 4	2005	388	1					7	12		10.1016/j.neulet.2005.06.019			6	Neurosciences	Neurosciences & Neurology	962OW	WOS:000231743100002	16087294				2021-06-18	
J	Alderfer, BS; Arciniegas, DB; Silver, JM				Alderfer, BS; Arciniegas, DB; Silver, JM			Treatment of depression following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						antidepressants; depression; drug interactions; electroconvulsive therapy; monoamine axidase inhibitors; seizures; serotonin uptake inhibitors; tricyclic antidepressive agents; traumatic brain injury	MAJOR DEPRESSION; HEAD-INJURY; PSYCHIATRIC-DISORDERS; FLUOXETINE; MILD; MOOD; REHABILITATION; INDIVIDUALS; SYMPTOMS; ECT	Depression is a common consequence of traumatic brain injury (TBI), and is a source of substantial distress and disability for persons with TBI and their families. This article offers a practical approach to the evaluation and treatment of this condition. Diagnostic and etiologic considerations relevant to this issue are reviewed first. Next, somatic therapies for posttraumatic depression, including antidepressant medications and electroconvulsive therapy, are discussed. Use of these therapies is also considered in the context of the common medical and neurological comorbidities among persons with TBI. Finally, psychosocial interventions relevant to the care of persons with posttraumatic depression are presented.	HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA; Univ Colorado, Sch Med, Dept Psychiat, Neuropsychiat Serv, Denver, CO 80202 USA; Vet Integrated Serv Network 19 Mental Illness Res, Rocky Mt Network, Denver, CO USA; Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO 80202 USA; NYU, Sch Med, Dept Psychiat, New York, NY USA	Alderfer, BS (corresponding author), HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA.		Arciniegas, David/A-3792-2009				Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Arciniegas David B, 2004, Phys Med Rehabil Clin N Am, V15, P177, DOI 10.1016/S1047-9651(03)00104-9; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/088971804780957108; BESSETTE RF, 1992, PSYCHOSOMATICS, V33, P224, DOI 10.1016/S0033-3182(92)72001-5; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Breen R, 1997, COMMUNITY MENT HLT J, V33, P359, DOI 10.1023/A:1025007510330; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Crow S, 1996, CONVULSIVE THER, V12, P113; DAVIDSON J, 1989, J CLIN PSYCHIAT, V50, P256; DESMET Y, 1982, J NEUROL NEUROSUR PS, V45, P1161, DOI 10.1136/jnnp.45.12.1161; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DUBOIS B, 1990, ANN NEUROL, V28, P117, DOI 10.1002/ana.410280202; DUBOVSKY S, 1992, AM PSYCHIAT PRESS TX; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fujishiro J, 2002, EUR J PHARMACOL, V454, P183, DOI 10.1016/S0014-2999(02)02557-8; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; GRIMSLEY SR, 1991, CLIN PHARMACOL THER, V50, P10, DOI 10.1038/clpt.1991.98; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; JALIL P, 1992, J NEUROL NEUROSUR PS, V55, P412, DOI 10.1136/jnnp.55.5.412-a; JOHNSTON CM, 1991, J CAN DIET ASSOC, V52, P11; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Jurado M A, 1993, Neurologia, V8, P91; Kalpakjian CZ, 2002, BRAIN INJURY, V16, P501, DOI 10.1080/02699050110119123; Kanetani Kouichi, 2003, Journal of Nippon Medical School, V70, P313; Kant R, 1999, J NEUROPSYCH CLIN N, V11, P32, DOI 10.1176/jnp.11.1.32; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Khouzam HR, 1998, GEN HOSP PSYCHIAT, V20, P62, DOI 10.1016/S0163-8343(97)00097-2; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Liotti M, 2001, J CLIN EXP NEUROPSYC, V23, P121, DOI 10.1076/jcen.23.1.121.1223; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; LIPSEY JR, 1983, BRIT J PSYCHIAT, V143, P266, DOI 10.1192/bjp.143.3.266; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MOBAYED M, 1990, J AFFECT DISORDERS, V19, P237, DOI 10.1016/0165-0327(90)90100-M; Newburn G, 1999, BRAIN INJURY, V13, P637; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; OJEMANN LM, 1987, NEUROLOGY, V37, P1525, DOI 10.1212/WNL.37.9.1525; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Patterson DE, 1997, BRAIN INJURY, V11, P287, DOI 10.1080/026990597123593; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PINDER RM, 1977, DRUGS, V13, P321, DOI 10.2165/00003495-197713050-00001; POST RM, 1992, AM J PSYCHIAT, V149, P999; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RICKELS K, 1990, J CLIN PSYCHIAT, V51, P9; Robinson RG, 2000, AM J PSYCHIAT, V157, P351, DOI 10.1176/appi.ajp.157.3.351; RUEDRICH SL, 1983, AM J PSYCHIAT, V140, P928; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Schmitt JAJ, 2001, J PSYCHOPHARMACOL, V15, P173, DOI 10.1177/026988110101500304; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Seminowicz DA, 2004, NEUROIMAGE, V22, P409, DOI 10.1016/j.neuroimage.2004.01.015; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SILVER JM, 2005, TXB TRAMATIC BRAIN I; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SOVNER R, 1991, J CLIN PSYCHOPHARM, V11, P389, DOI 10.1097/00004714-199112000-00018; Spinella M, 2002, BRAIN INJURY, V16, P359, DOI 10.1080/02699050110103319; Stahl S.M., 2000, ESSENTIAL PSYCHOPHAR; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Teng CJ, 2001, BRAIN INJURY, V15, P463, DOI 10.1080/02699050010005931; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Viguier D, 2001, BRAIN INJURY, V15, P263; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273; ZWIL AS, 1992, CONVULSIVE THER, V8, P103	99	72	79	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2005	20	6					544	562		10.1097/00001199-200511000-00006			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	986YF	WOS:000233484900006	16304490				2021-06-18	
J	Kizony, R; Raz, L; Katz, N; Weingarden, H; Weiss, PLT				Kizony, R; Raz, L; Katz, N; Weingarden, H; Weiss, PLT			Video-capture virtual reality system for patients with paraplegic spinal cord injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						balance; Functional Reach Test; paraplegia; rehabilitation; spinal cord injury; therapy; training; traumatic injury; video-capture virtual reality; wheelchair	BRAIN-INJURY; FUNCTIONAL REACH; BALANCE CONTROL; REHABILITATION; EXERCISE; ENVIRONMENTS; RELIABILITY; STROKE	This article presents results from a feasibility study of a video-capture virtual reality (VR) system used with patients who have paraplegic spinal cord injury (SCI) and who need balance training. The advantages of the VR system include providing the user with natural control of movements, the ability to use as many parts of the body as are deemed suitable within the context of therapeutic goals, and flexibility in the way the system can be adapted to suit specific therapeutic objectives. Thirteen participants with SCI experienced three virtual environments (VEs). Their responses to a Short Feedback Questionnaire showed high levels of presence. We compared performance in the environments with a group of 12 nondisabled participants. Response times for the patient group were significantly higher and percentage of success was significantly lower than that for the nondisabled group. In addition, significant moderate correlations were found between performance within a VE and static balance ability as measured by the Functional Reach Test. This study is a first step toward future studies aimed at determining the potential of using this VR system during the rehabilitation of patients with SCI.	Univ Haifa, Dept Occupat Therapy, IL-31999 Haifa, Israel; Hebrew Univ & Hadassah, Sch Occupat Therapy, Jerusalem, Israel; Chaim Sheba Med Ctr, Dept Neurol Rehabil, IL-52621 Tel Hashomer, Israel	Kizony, R (corresponding author), Univ Haifa, Dept Occupat Therapy, IL-31999 Haifa, Israel.	rkizony@univ.haifa.ac.il					AXELSON PW, 1996, P 12 INT SEAT S 1996, P81; BROMLEY I, 1998, TETRAPLEGIA PARAPLEG, P63; CARDENAS DD, 2000, PHYS MED REHABILITAT, P1305; Cunningham D, 1999, ST HEAL T, V62, P90; Cunningham D, 1999, Cyberpsychol Behav, V2, P19, DOI 10.1089/cpb.1999.2.19; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Duran FS, 2001, ARCH PHYS MED REHAB, V82, P1349, DOI 10.1053/apmr.2001.26066; Granger CV, 1993, GUIDE UNIFORM DATA S; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; HOLLAR LD, 1995, OCCUPATIONAL THERAPY, P795; HOLLAR LD, 2002, OCCUPATIONAL THERAPY, P795; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Janssen-Potten YJ, 2002, ARCH PHYS MED REHAB, V83, P642, DOI 10.1053/apmr.2002.32437; Janssen-Potten YJ, 2001, ARCH PHYS MED REHAB, V82, P1393, DOI 10.1053/apmr.2001.25989; Kim N G, 1999, IEEE Trans Rehabil Eng, V7, P482, DOI 10.1109/86.808952; Kizony R, 2003, J VISUAL COMP ANIMAT, V14, P261, DOI 10.1002/vis.323; Ku JH, 2002, CYBERPSYCHOL BEHAV, V5, P151, DOI 10.1089/109493102753770543; Lott A, 2003, CYBERPSYCHOL BEHAV, V6, P477, DOI 10.1089/109493103769710505; Lynch SM, 1998, PHYS THER, V78, P128, DOI 10.1093/ptj/78.2.128; Mantovani F, 2003, EMERG COMMUNICAT, V5, P167; Middleton JW, 1999, ARCH PHYS MED REHAB, V80, P1558, DOI 10.1016/S0003-9993(99)90330-1; Midha M, 1999, ARCH PHYS MED REHAB, V80, P258, DOI 10.1016/S0003-9993(99)90135-1; Potten YJM, 1999, ERGONOMICS, V42, P1200, DOI 10.1080/001401399185081; Riva G, 1999, Cyberpsychol Behav, V2, P577, DOI 10.1089/cpb.1999.2.577; Riva G, 2000, REHABIL PSYCHOL, V45, P81, DOI 10.1037/0090-5550.45.1.81; Rizzo A, 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI 10.1162/1054746053967094; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 2002, HUM FAC ER, P1027; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Rose FD, 1999, DISABIL REHABIL, V21, P548; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Seelen HAM, 1998, ERGONOMICS, V41, P302, DOI 10.1080/001401398187053; Song CG, 2004, IEEE T INF TECHNOL B, V8, P200, DOI 10.1109/TITB.2004.828887; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Sveistrup H., 2004, J NEUROENG REHABIL, V1, P10, DOI [DOI 10.1186/1743-0003-1-10, 10.1186/1743-0003-1-10]; Weiss P L, 1998, Work, V11, P277, DOI 10.3233/WOR-1998-11305; Weiss P. L., 2006, TXB NEURAL REPAIR NE, P182; Weiss PL, 2004, J REHABIL RES DEV, V41, pVII; Weiss PL, 2004, J NEUROENG REHABIL, V1, P1, DOI DOI 10.1186/1743-0003-1-12; Witmer BG, 1998, PRESENCE-TELEOP VIRT, V7, P225, DOI 10.1162/105474698565686; Wu CY, 2001, STROKE, V32, P70, DOI 10.1161/01.STR.32.1.70; Youngstrom MJ, 2002, AM J OCCUP THER, V56, P609; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X	44	72	77	2	13	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	SEP-OCT	2005	42	5					595	607		10.1682/JRRD.2005.01.0023			13	Rehabilitation	Rehabilitation	036KD	WOS:000237069100005	16586185				2021-06-18	
J	Davis, DP; Stern, J; Ochs, M; Sise, MJ; Hoyt, DB				Davis, DP; Stern, J; Ochs, M; Sise, MJ; Hoyt, DB			A follow-up analysis of factors associated with head-injury mortality after paramedic rapid sequence intubation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 29-JUN 01, 2003	BOSTON, MA	Soc Acad Emergency Med			RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-FLOW; MECHANICAL VENTILATION; LUNG INJURY; HYPERVENTILATION; ASPIRATION; MANAGEMENT; PNEUMONIA; HYPOXIA	Background: The San Diego Paramedic Rapid Sequence Intubation (RSI) Trial documented an increase in mortality after paramedic RSI, with hyperventilation identified as a contributing factor in a small subgroup analysis. Here we explore factors affecting outcome in the entire cohort of patients undergoing paramedic RSI to confirm previous findings. This also represents a synthesis of findings from previous analyses Methods. Adult trauma patients with severe head injury (Glasgow Coma Scale score, 3-8) who could not be intubated without RSI were prospectively enrolled in the trial. This analysis excluded patients without traumatic brain injury (head/neck abbreviated injury score < 2 or failure to meet Major Trauma Outcome Stud), criteria) or death in the field or within 30 minutes of arrival. Each remaining trial patient was matched to two nonintubated historical controls from the county trauma registry based on age, sex, mechanism, abbreviated injury scores for each body system, and Injury Severity Score. Logistic regression, cohort analysis, mean least squares regression, and discordant group analysis were used to explore the impact of various factors on outcome. Results. Of the 426 trial patients, 352 met inclusion criteria for this analysis and were hand-matched to 704 controls. Trial patients and controls were identical with regard to all matching variables. Mortality was increased in RSI patients versus matched controls (31.8 versus 23.7%; odds ratio, 1.5; 95% confidence interval, 1.1-2.0; p < 0.01). Hyperventilation was associated with an increase in mortality, whereas transport by aeromedical crews after paramedic RSI was associated with improved outcomes. The reported incidence of aspiration pneumonia was higher for the RSI patients. Conclusion: Paramedic RSI was associated with an increase in mortality compared with matched historical controls. The association between hyperventilation and mortality was confirmed. In addition, patients transported by helicopter after paramedic RSI had improved outcomes. Paramedic RSI did not seem to prevent aspiration pneumonia.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA; Scripps Mercy Hosp, San Diego Cty Emergency Med Serv, San Diego, CA USA; NYU, Sch Med, New York, NY USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Adnet F, 1996, LANCET, V348, P123, DOI 10.1016/S0140-6736(05)64630-2; Bao Yinghui, 2000, Chin J Traumatol, V3, P210; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; JOHNSTON I H, 1970, Lancet, V2, P433; Lockey DJ, 1999, ANAESTHESIA, V54, P1097, DOI 10.1046/j.1365-2044.1999.00754.x; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Orr RA, 1997, INT ANESTHESIOL CLIN, V35, P31, DOI 10.1097/00004311-199703530-00005; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Rello J, 1999, AM J RESP CRIT CARE, V159, P1742, DOI 10.1164/ajrccm.159.6.9808030; ROSSANDA M, 1968, SCAND J CLIN LAB I S, V102, P13; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wayne M A, 1999, Prehosp Emerg Care, V3, P290, DOI 10.1080/10903129908958956; WHITWAM JG, 1966, BRIT J ANAESTH, V38, P846, DOI 10.1093/bja/38.11.846; Woratyla S P, 1995, Conn Med, V59, P643	30	72	72	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2005	59	2					484	488		10.1097/00005373-200508000-00037			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	014BX	WOS:000235454800048	16294099				2021-06-18	
J	Fehlings, MG; Baptiste, DC				Fehlings, MG; Baptiste, DC			Current status of clinical trials for acute spinal cord injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						clinical trials; acute spinal cord injury; neurotrauma; neuroprotection; pharmacological; apoptosis	THYROTROPIN-RELEASING-HORMONE; METHYLPREDNISOLONE SODIUM SUCCINATE; NEUROPROTECTIVE AGENT; DOSE-RESPONSE; RECOVERY; NIMODIPINE; GACYCLIDINE; MACROPHAGES; MULTICENTER; NALOXONE	Acute spinal cord injury (ASCI) occurs as a result of physical disruption of spinal cord axons through the epicenter of injury leading to deficits in motor, sensory, and autonomic function. This is a debilitating neurological disorder common in young adults that often requires life-long therapy and rehabilitative care, placing a significant burden on our healthcare system. While no cure exists, research has identified various pharmacological compounds that specifically antagonize primary and secondary mechanisms contributing to the etiology of ASCI. Several compounds including methylprednisotone (MPSS), GM-1 ganglioside, thyrotropin releasing hormone (TRH), nimodipine, and gacyclidine have been tested in prospective randomized clinical trials of ASCI. MPSS and GM-1 ganglioside have shown evidence of modest benefits. Clearly trials of improved neuroprotective agents are required. Promising potential therapies for ASCI include riluzole, minocycline, erythropoietin, and the fusogen polyethylene glycol, as well as mild hypothermia.	Univ Toronto, Toronto Western Hosp, Toronto Western Res Inst, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Toronto Western Res Inst, Div Neurosurg, 4th Floor,W Wing,Room 449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364			Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; BOSE B, 1986, NEUROSCI LETT, V63, P165, DOI 10.1016/0304-3940(86)90055-8; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; Dergham P, 2002, J NEUROSCI, V22, P6570; Drian MJ, 1999, J NEUROSCI RES, V57, P927, DOI 10.1002/(SICI)1097-4547(19990915)57:6<927::AID-JNR18>3.0.CO;2-C; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; DUCKER TB, 1994, SPINE, V19, P2281, DOI 10.1097/00007632-199410150-00006; FADEN AI, 1989, ANN NY ACAD SCI, V553, P380; FADEN AI, 1984, J NEUROSURG, V60, P796, DOI 10.3171/jns.1984.60.4.0796; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; Fehlings MG, 2001, SPINE, V26, pS56, DOI 10.1097/00007632-200112151-00012; Feldblum S, 2000, J NEUROTRAUM, V17, P1079, DOI 10.1089/neu.2000.17.1079; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; FEUERSTEIN G, 1984, Neuroscience Research, V2, P121, DOI 10.1016/0168-0102(84)90010-5; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; Ford R W, 1985, Cent Nerv Syst Trauma, V2, P9; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; Gaviria M, 2000, BRAIN RES, V874, P200, DOI 10.1016/S0006-8993(00)02581-6; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Geisler FH, 2001, SPINE, V26, pS58, DOI 10.1097/00007632-200112151-00013; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Geisler FH, 2001, SPINE, V26, pS68, DOI 10.1097/00007632-200112151-00014; GUHA A, 1987, J NEUROSURG, V66, P423, DOI 10.3171/jns.1987.66.3.0423; Hadley MN, 2002, NEUROSURGERY, V50, pS63; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; Hall ED, 1989, J NEUROTRAUM, V6, P227, DOI 10.1089/neu.1989.6.227; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hirbec H, 2002, J NEUROSCI RES, V68, P305, DOI 10.1002/jnr.10203; Hirbec H, 2001, CNS DRUG REV, V7, P172; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KALIA M, 1982, NEUROSCI LETT, V34, P1, DOI 10.1016/0304-3940(82)90083-0; Karpiak S E, 1984, Adv Exp Med Biol, V174, P489; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; KAZDA S, 1982, ARZNEIMITTEL-FORSCH, V32-1, P331; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; LAINETTI RD, 1993, BRAZ J MED BIOL RES, V26, P841; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; LAZAREWICZ JW, 1990, STROKE, V21, P108; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; LazarovSpiegler O, 1996, FASEB J, V10, P1296; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; Lepeintre JF, 2004, NEUROCHIRURGIE, V50, P83; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mitha A P, 2001, Curr Opin Investig Drugs, V2, P814; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; NAFTCHI NE, 1982, PEPTIDES, V3, P235, DOI 10.1016/0196-9781(82)90084-5; Otani K., 1994, SEKITSUI SEKIZUI, V7, P633; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Petitjean ME, 1998, ANN FR ANESTH, V17, P114, DOI 10.1016/S0750-7658(98)80058-0; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Ross IB, 1991, J NEUROTRAUM, V8, P229, DOI 10.1089/neu.1991.8.229; ROSS IB, 1993, SURG NEUROL, V40, P461, DOI 10.1016/0090-3019(93)90048-6; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; STEEN PA, 1983, J CEREBR BLOOD F MET, V3, P38, DOI 10.1038/jcbfm.1983.4; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sung JK, 2003, BRAIN RES, V959, P29, DOI 10.1016/S0006-8993(02)03717-4; TADIE M, 1999, SOCN EUR ABSTR, P1090; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; WINKLER T, 1994, ACTA NEUROCHIR, P511	74	72	74	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JUL	2005	36			2			113	122		10.1016/j.injury.2005.06.022			10	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	951DA	WOS:000230908000014					2021-06-18	
J	Hang, CH; Shi, JX; Li, JS; Li, WQ; Wu, W				Hang, CH; Shi, JX; Li, JS; Li, WQ; Wu, W			Expressions of intestinal NF-kappa B, TNF-alpha, and IL-6 following traumatic brain injury in rats	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; NF-kappa B; TNF-alpha; IL-6; inflammation; intestine	MULTIPLE ORGAN DYSFUNCTION; IN-VIVO; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CECAL LIGATION; ACTIVATION; PERMEABILITY; CYTOKINE; ENDOTOXEMIA	Background. NF-kappaB regulates a large number of genes involved in the inflammatory response to critical illness, but it is not well known if and how NF-kappaB is activated in the gut following traumatic brain injury (TBI) and what is the role of cytokine-mediated inflammation in the pathogenesis of acute gut mucosal injury. Materials and methods. Male Wistar rats were randomly divided into control and TBI groups, each of which was subgrouped at hours 3, 12, 24, and 72 and on day 7. Parietal brain contusion was produced by a free-falling weight on the exposed dura of the right parietal lobe. NF-kappaB binding activity in jejunal tissue was measured using EMSA and the concentrations of TNF-alpha and IL-6 were detected using ELISA. Results. NF-kappaB binding activity in the jejunum was significantly increased at 3 h following TBI, was maximal at 72 h, and remained elevated by 7 days post-injury. TNF-alpha and IL-6 concentrations were also significantly increased by 3 h postinjury, but peaked at 24 h and remained elevated on Day 7 postinjury. Conclusions. TBI induced a rapid and persistent up-regulation of NF-kappaB and proinflammatory cytokines in the gut, which may play an important role in the pathogenesis of acute gut mucosal injury mediated by inflammation. (C) 2004 Elsevier Inc. All rights reserved.	Nanjing Univ, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Jinling Hosp, Sch Clin Med, Res Inst Gen Surg, Nanjing 210002, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	hang1965@public1.ptt.js.cn					BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BLACKWELL TS, 1994, AM J RESP CELL MOL, V11, P464, DOI 10.1165/ajrcmb.11.4.7917314; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769; Gong JP, 2002, WORLD J GASTROENTERO, V8, P923, DOI 10.3748/wjg.v8.i5.923; Gong JP, 2002, WORLD J GASTROENTERO, V8, P346; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; HUANG L, 1994, IMMUNOLOGY, V83, P65; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liu SF, 1997, J IMMUNOL, V159, P3976; Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008; MESTER M, 1993, J SURG RES, V54, P584, DOI 10.1006/jsre.1993.1089; MEYER TA, 1995, SURGERY, V118, P336, DOI 10.1016/S0039-6060(05)80342-3; Neurath MF, 1997, IMMUNOBIOLOGY, V198, P91, DOI 10.1016/S0171-2985(97)80030-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Parikh AA, 1997, J SURG RES, V69, P139, DOI 10.1006/jsre.1997.5061; Pritts TA, 2000, ARCH SURG-CHICAGO, V135, P860, DOI 10.1001/archsurg.135.7.860; Pritts TA, 1998, ARCH SURG-CHICAGO, V133, P1311, DOI 10.1001/archsurg.133.12.1311; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Shenkar R, 1996, AM J PHYSIOL-LUNG C, V270, pL729; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Spies M, 2002, AM J PHYSIOL-GASTR L, V283, pG703, DOI 10.1152/ajpgi.00149.2001; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Tu B, 2003, WORLD J GASTROENTERO, V9, P179, DOI 10.3748/wjg.v9.i1.179; Wang JP, 1998, J MATER PROCESS TECH, V74, P1, DOI 10.1016/S0924-0136(97)00241-0; Wu RQ, 2002, WORLD J GASTROENTERO, V8, P131, DOI 10.3748/wjg.v8.i1.131; Wu RQ, 2001, WORLD J GASTROENTERO, V7, P128; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yin MJ, 1998, NATURE, V396, P77; Zhou W, 2003, WORLD J GASTROENTERO, V9, P1567, DOI 10.3748/wjg.v9.i7.1567	39	72	86	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	FEB	2005	123	2					188	193		10.1016/j.jss.2004.08.002			6	Surgery	Surgery	902ER	WOS:000227337500004	15680377				2021-06-18	
J	Marshall, SW; Loomis, DP; Waller, AE; Chalmers, DJ; Bird, YN; Quarrie, KL; Feehan, M				Marshall, SW; Loomis, DP; Waller, AE; Chalmers, DJ; Bird, YN; Quarrie, KL; Feehan, M			Evaluation of protective equipment for prevention of injuries in rugby union	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						protective devices; mouth protectors; contact sports; athletic injuries; brain concussion	LONGITUDINAL DATA-ANALYSIS; PERFORMANCE PROJECT; OROFACIAL INJURIES; EGO ORIENTATION; SPORTS INJURIES; CONTACT SPORTS; ANKLE INJURIES; MOUTHGUARDS; FOOTBALL; PREVALENCE	Background Rugby union has a high rate of injury. The increased use of protective equipment may help mitigate these injuries. This study investigated the injury prevention effectiveness of the protective equipment used in rugby union. Methods A cohort of 304 rugby players in Dunedin, New Zealand was followed weekly during the 1993 club season to assess protective equipment use, participation in rugby, and injury outcomes. Generalized Poisson regression was used to model the rate of injury while adjusting for covariates such as level of competition, playing position, and injury history. Results The use of mouthguards appeared to lower the risk of orofacial injury [rate ratio (RR) = 0.56, 95% confidence interval (CI): 0.07-4.63], and padded headgear tended to prevent damage to the scalp and ears (RR = 0.59, 95% CI: 0.19-1.86). Support sleeves tended to reduce the risk of sprains and strains (RR = 0.58, 95% CI: 0.26-1.27). The risk of concussion was not lessened by the use of padded headgear (RR = 1.13, 95% CI: 0.40-3.16) or mouthguards (RR = 1.62, 95% CI: 0.51-5.11). There was no evidence of protective effects for any other equipment item (taping, shinguards, and grease). Conclusions The protective equipment used in rugby union has limited effectiveness in preventing injuries. The results are supportive, however, of a role for mouthguards and padded headgear in preventing orofacial and scalp injuries, respectively, and for support sleeves in preventing sprains and strains.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Orthoped, Chapel Hill, NC 27599 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA; Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand; Observant LLV, Wellesley, MA USA	Marshall, SW (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, CB 7435,McGarvan Greenberg Hall, Chapel Hill, NC 27599 USA.	SMarshall@unc.edu	Loomis, Dana/AAE-3988-2019	Loomis, Dana/0000-0003-3297-5200; Marshall, Stephen/0000-0002-2664-9233	ODCDC CDC HHS [R49 CCR 402444] Funding Source: Medline		ALBRIGHT JP, 1995, SPORTS MED, V20, P281, DOI 10.2165/00007256-199520050-00001; BIR CA, 1995, CLIN J SPORT MED, V5, P95, DOI 10.1097/00042752-199504000-00005; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Blignaut J B, 1987, Br J Sports Med, V21, P5; Callaghan MJ, 1997, BRIT J SPORT MED, V31, P102, DOI 10.1136/bjsm.31.2.102; Carter J.E.L., 1980, HEATH CARTER SOMATOT, V3rd; Chalmers DJ, 1998, SPORTS MED, V25, P339, DOI 10.2165/00007256-199825050-00006; Chapman P, 1985, AUST J SCI MED SPORT, V17, P23; Chapman P J, 1990, Br J Sports Med, V24, P156; CHAPMAN PJ, 1993, BRIT J SPORT MED, V27, P197, DOI 10.1136/bjsm.27.3.197; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; CHAPMAN PJ, 1991, AUST J SCI MED SPORT, V23, P113; CHI LK, 1995, RES Q EXERCISE SPORT, V66, P91, DOI 10.1080/02701367.1995.10762216; de Wet F A, 1981, J Dent Assoc S Afr, V36, P249; DEWET FA, 1981, INT DENT J, V31, P313; Dixon G, 1993, NZ J SPORTS MED, V21, P18; DUDA JL, 1995, INT J SPORT PSYCHOL, V26, P40; EDGAR M, 1995, LANCET, V345, P1452, DOI 10.1016/S0140-6736(95)91031-X; Firer P, 1990, Br J Sports Med, V24, P47; GARRICK JG, 1973, MED SCI SPORT EXER, V5, P200; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P401; HARCOURT JK, 1989, AUST DENT J, V34, P485; HAREL Y, 1994, AM J PUBLIC HEALTH, V84, P599, DOI 10.2105/AJPH.84.4.599; HEINTZ WD, 1975, PHYSICIAN SPORTSMED, V3, P61; Hume PA, 1998, SPORTS MED, V25, P285, DOI 10.2165/00007256-199825050-00001; Jennings D C, 1990, Br J Sports Med, V24, P159; KAMMANN R, 1983, AUST J PSYCHOL, V35, P259, DOI 10.1080/00049538308255070; KERR IL, 1986, SPORTS MED, V3, P415, DOI 10.2165/00007256-198603060-00003; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; Marshall SW, 2001, MED SCI SPORT EXER, V33, P2131, DOI 10.1097/00005768-200112000-00024; Martens R., 1990, COMPETITIVE ANXIETY; McCullagh P., 1989, GEN LINEAR MODELS; MEEUWISSE WH, 1991, SPORTS MED, V12, P8, DOI 10.2165/00007256-199112010-00002; Morton J G, 1979, N Z Dent J, V75, P151; *NHMRC, 1994, FOOTB INJ HEAD NECK; NICHOLAS JA, 1988, JAMA-J AM MED ASSOC, V260, P939, DOI 10.1001/jama.260.7.939; NORTON R, 1995, NZ J SPORTS MED, V22, P37; Quarrie KL, 1995, BRIT J SPORT MED, V29, P263, DOI 10.1136/bjsm.29.4.263; Robbins S, 1998, SPORTS MED, V25, P63, DOI 10.2165/00007256-199825010-00005; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; ROBINS JM, 1992, EPIDEMIOLOGY, V3, P319, DOI 10.1097/00001648-199207000-00007; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P69; SEALS RR, 1985, J AM DENT ASSOC, V110, P904, DOI 10.14219/jada.archive.1985.0005; SITLER M, 1994, AM J SPORT MED, V22, P454, DOI 10.1177/036354659402200404; Spielberger CD, 1985, ANGER HOSTILITY CARD, P5; STOKES AN, 1991, NZ J SPORTS MED, V19, P66; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	52	72	73	0	47	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2005	34	1					113	118					6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	899FF	WOS:000227129600022	15561749	Bronze			2021-06-18	
J	Mayes, SD; Calhoun, SL				Mayes, SD; Calhoun, SL			Similarities and differences in Wechsler intelligence scale for children-third edition (WISC-III) profiles: Support for subtest analysis in clinical referrals	CLINICAL NEUROPSYCHOLOGIST			English	Article						WISC-III profiles; ADHD; autism; brain injury; anxiety; depression; oppositional-defiant disorder; LD	TRAUMATIC HEAD-INJURY; LEARNING-DISABILITIES; ACADEMIC-ACHIEVEMENT; STRATEGY INSTRUCTION; ATTENTION DISORDERS; DISABLED STUDENTS; ASPERGER-SYNDROME; DEFICIT; ADHD; METHYLPHENIDATE	Our study supports the reliability and validity of profile analysis in children with neurobiological disorders. Three mutually exclusive WISC-III profiles were identified that characterized the majority of children with autism (low coding or Freedom from Distractibility Index with low Comprehension), attention deficit hyperactivity disorder and learning disability (low Coding or FDI without low comprehension), and brain injury (low Performance without low Coding or FDI). The profiles suggest attention, writing, and performance speed deficits in autism, ADHD, and LD; global visual-motor problems in brain injury; and specific difficulty with language comprehension and social reasoning in autism. Children with anxiety, depression, and behavior disorders did not exhibit distinct profiles. Our profile analysis is based on the simple rank ordering of standard scores. The profiles are clinically useful because they may alert clinicians to certain diagnostic possibilities, they reveal characteristic strengths and weaknesses that have implications for educational intervention, and they are consistent with preliminary WISC-IV data.	Penn State Coll Med, Dept Psychiat, Hershey, PA 17033 USA	Mayes, SD (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Psychiat, H073,POB 850, Hershey, PA 17033 USA.	smayes@psu.edu					ACKERMAN PT, 1995, DEV NEUROPSYCHOL, V11, P351, DOI 10.1080/87565649509540625; ALLEN MH, 1991, J AUTISM DEV DISORD, V21, P483, DOI 10.1007/BF02206872; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anastasi A., 1998, PSYCHOL TESTING; ASARNOW RF, 1987, J CHILD PSYCHOL PSYC, V28, P273, DOI 10.1111/j.1469-7610.1987.tb00210.x; ATTWOOD T, 1998, ASPERGER SYNDROME GU; Attwood T., 2000, AUTISM, V4, P85, DOI DOI 10.1177/1362361300004001006; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; BARKLEY RA, 1994, ADHD CLASSROOM STRAT; Bauminger N, 2002, J AUTISM DEV DISORD, V32, P283, DOI 10.1023/A:1016378718278; BIRMAHER B, 1988, J AM ACAD CHILD PSY, V27, P248, DOI 10.1097/00004583-198803000-00020; Bray MA, 1998, SCHOOL PSYCHOL INT, V19, P209, DOI 10.1177/0143034398193002; DAINER KB, 1981, J ABNORM CHILD PSYCH, V9, P79, DOI 10.1007/BF00917859; DANOFF B, 1993, J READING BEHAV, V25, P295, DOI 10.1080/10862969009547819; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Ehlers S, 1997, J CHILD PSYCHOL PSYC, V38, P207, DOI 10.1111/j.1469-7610.1997.tb01855.x; Fessler M. A., 1991, BEHAVIORAL DISORDERS, V16, P97; Fiorello CA, 2001, LEARN INDIVID DIFFER, V13, P115, DOI 10.1016/S1041-6080(02)00075-4; Fletcher JM, 1999, PEDIATR CLIN N AM, V46, P885, DOI 10.1016/S0031-3955(05)70161-9; FLETCHER JM, 1992, J CLIN EXP NEUROPSYC, V14, P593, DOI 10.1080/01688639208402847; FRANKENBERGER W, 1991, J LEARN DISABIL, V24, P495, DOI 10.1177/002221949102400809; FRIEDRICH WN, 1991, J PEDIATR PSYCHOL, V16, P423, DOI 10.1093/jpepsy/16.4.423; Glassberg LA, 1999, BEHAV DISORDERS, V25, P9; GLUTTING JJ, 1994, SCHOOL PSYCHOL REV, V23, P619; GORDON M, 1991, GSI PUBLICATIONS; GRAHAM S, 1990, J EDUC PSYCHOL, V82, P781, DOI 10.1037/0022-0663.82.4.781; Graham S., 2001, LEARN DISABIL RES PR, V16, P74, DOI [DOI 10.1111/0938-8982.00009, 10.1111/0938- 8982.00009]; Gray C. A., 1993, FOCUS AUTISTIC BEHAV, V8, P1, DOI DOI 10.1177/108835769300800101; Gresham FM, 1996, J LEARN DISABIL, V29, P570, DOI 10.1177/002221949602900601; Hale JB, 2001, SCHOOL PSYCHOL QUART, V16, P31, DOI 10.1521/scpq.16.1.31.19158; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; HAPPE FGE, 1994, J CHILD PSYCHOL PSYC, V35, P1461, DOI 10.1111/j.1469-7610.1994.tb01287.x; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Hoskyn M, 2000, SCHOOL PSYCHOL REV, V29, P102; Jacobs R, 2001, J DEV PHYS DISABIL, V13, P389, DOI 10.1023/A:1012289513829; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Jordan R, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P212; Kaufman A, 1994, INTELLIGENT TESTING; KAVALE KA, 1994, LEARNING DISABILITIE, V9, P70; Kay JB, 1999, J CLIN EXP NEUROPSYC, V21, P186, DOI 10.1076/jcen.21.2.186.927; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KRAMER JH, 1993, PSYCHOL ASSESSMENT, V5, P193; Kunce L, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P244; LANE SE, 1994, J PSYCHOEDUC ASSESS, V12, P142, DOI 10.1177/073428299401200204; LINCOLN AJ, 1988, J AUTISM DEV DISORD, V18, P505, DOI 10.1007/BF02211870; Lindgren S. D., 1987, ADV BEHAV ASSESSMENT, P57; LUFI D, 1990, PSYCHOL SCHOOLS, V27, P28, DOI 10.1002/1520-6807(199001)27:1<28::AID-PITS2310270105>3.0.CO;2-L; MacArthur CA, 1996, J LEARN DISABIL, V29, P344, DOI 10.1177/002221949602900403; MacArthur CA, 2000, TOP LANG DISORD, V20, P85, DOI 10.1097/00011363-200020040-00008; Manjiviona J, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P55; Mayes S., 1998, J ATTEN DISORD, V2, P217, DOI DOI 10.1177/108705479800200402; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; Mayes SD, 1998, PSYCHOL SCHOOLS, V35, P309; Mayes SD, 2000, J LEARN DISABIL-US, V33, P417, DOI 10.1177/002221940003300502; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; MCCARNEY SB, 1989, ATTENTION DEFICIT DI; MCDERMOTT PA, 1990, J PSYCHOEDUC ASSESS, V8, P290, DOI 10.1177/073428299000800307; McNaughton D., 1997, LEARNING DISABILITIE, V12, P16; Mealer C, 1996, J ATTEN DISORD, V1, P133, DOI DOI 10.1177/108705479600100302; Mesibov Gary B., 1992, HIGH FUNCTIONING IND, P143; Naglieri JA, 2003, J PSYCHOEDUC ASSESS, V21, P32, DOI 10.1177/073428290302100103; National Research Council, 2001, ED CHILDR AUT; NEWBY R, 1993, J PSYCHOEDUCATIONAL, V11, P87; Nyden A, 2001, DEV MED CHILD NEUROL, V43, P165, DOI 10.1017/S0012162201000329; Oh HJ, 1999, J PSYCHOEDUC ASSESS, V17, P362, DOI 10.1177/073428299901700406; PARKER HC, 1988, ADD HYPERACTIVITY WO; Pfeiffer SI, 2000, SCHOOL PSYCHOL QUART, V15, P376, DOI 10.1037/h0088795; PRIFITERA A, 1993, J PSYCHOEDUC ASSESS, P43; PRIOR M, 2003, LEARNING BEHAV PROBL; QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289; ROBINS PM, 1992, J ABNORM CHILD PSYCH, V20, P65, DOI 10.1007/BF00927117; Saklofske D. H., 1995, CANADIAN J SCH PSYCH, V10, P167, DOI [10.1177/082957359501000210, DOI 10.1177/082957359501000210]; Sattler JM, 2002, ASSESSMENT CHILDREN; SAWYER RJ, 1992, J EDUC PSYCHOL, V84, P340, DOI 10.1037/0022-0663.84.3.340; SCHUERHOLZ LJ, 1995, J LEARN DISABIL, V28, P18, DOI 10.1177/002221949502800104; SCHWEAN VL, 1993, J PSYCHOEDUC ASSESS, P56; Shaked M, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P104; Siegel DJ, 1996, J AUTISM DEV DISORD, V26, P389, DOI 10.1007/BF02172825; Snow JB, 2000, PSYCHOL REP, V87, P759, DOI 10.2466/PR0.87.7.759-765; Stanton HC, 2000, SCHOOL PSYCHOL QUART, V15, P434, DOI 10.1037/h0088799; STRAYHORN JM, 1988, J AM ACAD CHILD PSY, V27, P244, DOI 10.1097/00004583-198803000-00019; SWANSON HL, 1983, J ABNORM CHILD PSYCH, V11, P415, DOI 10.1007/BF00914249; SWANSON L, 1981, J CHILD PSYCHOL PSYC, V22, P393, DOI 10.1111/j.1469-7610.1981.tb00563.x; Tannock R., 2000, ATTENTION DEFICIT DI; TARNOWSKI KJ, 1986, J ABNORM PSYCHOL, V95, P341, DOI 10.1037/0021-843X.95.4.341; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vaughn S, 2000, EXCEPT CHILDREN, V67, P99; Ward TJ, 1999, SCHOOL PSYCHOL REV, V28, P629; Wechsler D., 1992, MANUAL WECHSLER INDI; Wechsler D, 2003, WISC 4 TECHNICAL INT; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS K, 1995, FOCUS AUTISTIC BEHAV, V10, P9, DOI DOI 10.1177/108835769501000202; 1999, FED REG         0312	94	72	75	0	61	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2004	18	4					559	572		10.1080/13854040490888530			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	895BH	WOS:000226835400006	15841957				2021-06-18	
J	Hart, T; Sherer, M; Whyte, J; Polansky, M; Novack, TA				Hart, T; Sherer, M; Whyte, J; Polansky, M; Novack, TA			Awareness of behavioral, cognitive, and physical deficits in acute traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						awareness; brain injuries; rehabilitation	IMPAIRED SELF-AWARENESS; HEAD-INJURY; PRACTICAL SCALE; LIMITATIONS; REHABILITATION; DYSFUNCTION; DISABILITY; RELATIVES; ADULTS; COMA	Objective: To compare awareness of deficit in 3 domains of function (physical, cognitive, behavioral/emotional) in acute traumatic brain injury (TBI), controlling for severity of impairment in the different domains. Design: Inception cohort. Setting: Three inpatient rehabilitation programs. Participants: People with acute TBI (N=161), tested as soon as feasible after posttraumatic amnesia. Interventions: Not applicable. Main Outcome Measures: Awareness Questionnaire (AQ) completed by the person with TBI and the treating neuropsychologist; and self- and clinician-rating scores calculated in the 3 domains. Results: For participants who were rated by clinicians as more impaired in at least 1 domain (ie, scored lower on the AQ), self-ratings differed significantly from one another in all 3 domains, with behavioral self-ratings highest, physical self-ratings lowest, and cognitive self-ratings intermediate. In subgroups of participants rated at the same level by clinicians in all 3 domains, physical self-ratings were also lowest, that is, more consonant with clinician ratings. Participants tended to rate themselves as relatively unchanged in cognitive and behavioral domains regardless of the level of clinician ratings on these factors. Conclusions: Patterns of discrepant awareness of deficit in different functional areas seen in postacute TBI also appear to be present acutely and are not entirely related to differential severity of deficit. We discuss several possible reasons for discrepant awareness of deficit, including differences in internal and external feedback, cultural and psychologic factors, and different levels of ambiguity inherent in causal explanations for different types of problems.	Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; Methodist Rehabil Ctr, Jackson, MS USA; MCP Hahnemann Sch Publ Hlth, Philadelphia, PA USA; Univ Alabama, Birmingham, AL USA	Hart, T (corresponding author), Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu		Whyte, John/0000-0002-4381-1474			Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Newman AC, 2000, BRAIN INJURY, V14, P333; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; OLIVER JH, 1996, BRAIN INJURY, V10, P841; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142	35	72	72	0	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2004	85	9					1450	1456		10.1016/j.apmr.2004.01.030			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	852DW	WOS:000223736400010	15375815				2021-06-18	
J	Oquendo, MA; Friedman, JH; Grunebaum, MF; Burke, A; Silver, JM; Mann, JJ				Oquendo, MA; Friedman, JH; Grunebaum, MF; Burke, A; Silver, JM; Mann, JJ			Suicidal behavior and mild traumatic brain injury in major depression	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						suicidal behavior; traumatic brain injury; major depression; aggression; cluster B personality disorder	PSYCHIATRIC-DISORDERS; AXIS-I; SCALE; IDEATION; RISK; PSYCHOPATHOLOGY; INDIVIDUALS; INVENTORY; CHILDREN; ILLNESS	Traumatic brain injury (TBI) is associated with psychiatric illness, suicidal ideation, suicide attempts, and completed suicide. We investigated the relationship between mild TBI and other risk factors for suicidal behavior in major depressive episode. We hypothesized that mild TBI would be associated with suicidal behavior at least partly because of shared risk factors that contribute to the diathesis for suicidal acts. Depressed patients (N = 325) presenting for treatment were evaluated for psychopathology, traumatic history, and suicidal behavior. Data were analyzed using Student t-test, chi-square statistic, or Fisher exact test. A backward stepwise logistic regression model (N = 255) examined the relationship between attempter status and variables that differed in the TBI and non-TBI patients. Forty-four percent of all subjects reported mild TBI. Subjects with TBI were more likely to be male, have a history of substance abuse, have cluster B personality disorder, and be more aggressive and hostile compared with subjects without TBI. They were also more likely to be suicide attempters, although their suicidal behavior was not different from that of suicide attempters without TBI. Attempt status was mostly predicted by aggression and hostility, but not the presence of TBI. Of note, for males, a history of TBI increased the likelihood of being a suicide attempter, whereas the risk was elevated for females regardless of TBI history. Our data suggest that suicidal behavior and TBI share antecedent risk factors: hostility and aggression. Future studies may yield confirmation using a prospective design.	Columbia Univ, New York State Psychiat Inst, Dept Neurosci, New York, NY 10032 USA; Lenox Hill Hosp, New York, NY 10021 USA; NYU, Sch Med, New York, NY USA	Oquendo, MA (corresponding author), Columbia Univ, New York State Psychiat Inst, Dept Neurosci, 1051 Riverside Dr,Unit 41, New York, NY 10032 USA.		Oquendo, Maria/AAC-6237-2019		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH062185, R01MH048514] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH62185, MH48514-09] Funding Source: Medline		*AM PSYCH ASS TASK, 1987, DIAGN STAT MAN MENT; Anderson K., 1998, SEMIN CLIN NEUROPSYC, V3, P232; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1975, AM J PSYCHIAT, V132, P285; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Beck AT, 1961, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Deb S, 1999, AM J PSYCHIAT, V156, P374; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; First M.B., 1996, STRUCTURED CLIN INTE; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Keilp JG, 2001, AM J PSYCHIAT, V158, P735, DOI 10.1176/appi.ajp.158.5.735; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; LORANGER AW, 1987, J PERSONALITY DISORD, V1, P1, DOI DOI 10.1521/PEDI.1987.1.1.1; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, BRAIN INJURY, V12, P41; Oquendo MA, 2003, STANDARDIZED EVALUAT, P103; PERSINGER MA, 1994, PSYCHOL REP, V75, P1059, DOI 10.2466/pr0.1994.75.3.1059; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436	35	72	72	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	2004	192	6					430	434		10.1097/01.nmd.0000126706.53615.7b			5	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	828BB	WOS:000221946400006	15167407				2021-06-18	
J	Phillips, TM				Phillips, TM			Rapid analysis of inflammatory cytokines in cerebrospinal fluid using chip-based immunoaffinity electrophoresis	ELECTROPHORESIS			English	Article						chip-based immunoaffinity capillary electrophoresis; head trauma; inflammatory cytokines; miniaturization	INDUCED FLUORESCENCE DETECTION; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; CAPILLARY-ELECTROPHORESIS; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; BIOLOGICAL-FLUIDS; COLUMN CLEANUP; INTERLEUKIN-6; PROTEINS	A chip-based capillary electrophoresis system has been designed for rapidly measuring the concentrations of inflammatory cytokines in the cerebrospinal fluid of patients with head trauma. Isolation of the reactive cytokines was achieved by immunoaffinity capture using a panel of six immobilized antibodies, directly attached to the injection port of the chip. The captured cytokines were labeled in situ with a red light-emitting laser dye and electroeluted into the separation channel. Separation of the isolated cytokines was achieved by electrophoresis in under 2 min with quantification of the resolved peaks being achieved by on-line laser-induced fluorescence and integration of each peak area. Comparison of the results to commercially available high-sensitivity immunoassays demonstrates that the chip-based assay provides a fast, accurate procedure for studying the concentrations of these analytes in complex biological materials. The degree of accuracy and precision achieved by the chip-based CE is comparable to conventional immunoassays, the system being able to analyze between 10-12 samples per hour. With the ever-expanding array of antibodies that are commercially available, this chip-based system can be applied to a wide variety of different analyses.	NIH, ORS, DBEPS, UAIR, Bethesda, MD 20892 USA	Phillips, TM (corresponding author), NIH, ORS, DBEPS, UAIR, 13-3E42 9000 Rockville Pike, Bethesda, MD 20892 USA.	phillipt@mail.nih.gov			OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01OD011059] Funding Source: NIH RePORTER		Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Baldwin RP, 2000, ELECTROPHORESIS, V21, P4017, DOI 10.1002/1522-2683(200012)21:18<4017::AID-ELPS4017>3.0.CO;2-5; Bilitewski U, 2003, ANAL BIOANAL CHEM, V377, P556, DOI 10.1007/s00216-003-2179-4; Cahill LM, 1999, J CHROMATOGR A, V859, P23, DOI 10.1016/S0021-9673(99)00846-8; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Entwisle AC, 2000, J AOAC INT, V83, P1377; Gam LH, 2003, J CHROMATOGR B, V792, P187, DOI 10.1016/S1570-0232(03)00264-2; Guzman NA, 1997, J CHROMATOGR B, V697, P37, DOI 10.1016/S0378-4347(97)00275-2; Ham AJL, 1999, CHEM RES TOXICOL, V12, P1240, DOI 10.1021/tx990150r; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hennion MC, 2003, J CHROMATOGR A, V1000, P29, DOI 10.1016/S0021-9673(03)00529-6; Hu S, 2002, ELECTROPHORESIS, V23, P3136, DOI 10.1002/1522-2683(200209)23:18<3136::AID-ELPS3136>3.0.CO;2-S; Huwe JK, 2001, J CHROMATOGR B, V757, P285, DOI 10.1016/S0378-4347(01)00159-1; LEE KJ, 1991, J CHROMATOGR, V559, P317, DOI 10.1016/0021-9673(91)80081-Q; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; McWhorter S, 2000, ELECTROPHORESIS, V21, P1267, DOI 10.1002/(SICI)1522-2683(20000401)21:7<1267::AID-ELPS1267>3.0.CO;2-C; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; Phillips TM, 2003, BIOMED CHROMATOGR, V17, P182, DOI 10.1002/bmc.240; Phillips TM, 1998, ANAL CHIM ACTA, V372, P209, DOI 10.1016/S0003-2670(98)00342-0; Phillips TM, 1998, ELECTROPHORESIS, V19, P2991, DOI 10.1002/elps.1150191632; PHILLIPS TM, 1992, AFFINITY IMMUNOAFFIN, P287; Regnier FE, 1999, TRENDS BIOTECHNOL, V17, P101, DOI 10.1016/S0167-7799(98)01294-3; Sen JW, 2003, ANAL CHEM, V75, P1196, DOI 10.1021/ac026174b; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stroka J, 2000, J AOAC INT, V83, P320; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Taylor J, 2001, ELECTROPHORESIS, V22, P3699, DOI 10.1002/1522-2683(200109)22:17<3699::AID-ELPS3699>3.0.CO;2-A; Thormann W, 2002, THER DRUG MONIT, V24, P222, DOI 10.1097/00007691-200204000-00004; Verpoorte E, 2002, ELECTROPHORESIS, V23, P677, DOI 10.1002/1522-2683(200203)23:5<677::AID-ELPS677>3.0.CO;2-8; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Xiong GH, 2003, ANALYST, V128, P581, DOI 10.1039/b301035j	34	72	72	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	JUN	2004	25	10-11					1652	1659		10.1002/elps.200305873			8	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	830RK	WOS:000222140400031	15188254				2021-06-18	
J	van den Broek, M; Beghi, E				van den Broek, M; Beghi, E		RESt-1 Grp	Accidents in patients with epilepsy: Types, circumstances, and complications: A European cohort study	EPILEPSIA			English	Article						epilepsy; accidents; injuries	MOTOR-VEHICLE CRASHES; RISK-FACTORS; INJURY; BURNS; FREQUENCY; FRACTURES; MORBIDITY; SEIZURES; CHILDREN	Purpose: To investigate the risk of accidents in a cohort of patients with epilepsy and in matched nonepilepsy controls. by type, circumstances, and complications. Methods: A total of 95 1 children and adults with idiopathic, cryptogenic, or remote symptomatic epilepsy and 904 matched controls seen in secondary and tertiary centers in eight European Countries (England. Estonia, Germany, Italy, the Netherlands, Portugal. Russia. and Slovenia) were followed Lip prospectively for 17,484 and 17.206 person-months and asked to report any accident requiring medical attention. its site, and complications. Risk assessment was done by using actuarial methods, relative risks (RRs). and 95% confidence intervals (CIs). Results: During the study period, 199 (21%) patients and 123 (14%) controls reported all accident (p < 0.0001); 24% were seizure related. The Cumulative probability of accidents at 12 and 24 months was 17 and 27% in the cases and 12 and 17% in the controls. The risk was highest for concussions (RR, 2.6; 95% Cl, 1.2-5.8), abrasions (RR, 2.1; 95% Cl, 1.1-4.0), and Wounds (RR, 1.9; Cl, 1.2-3.1). Domestic accidents prevailed in both groups, followed by street and work accidents, and were more common among cases. Compared with controls, patients with epilepsy reported more hospitalization, complications, and medical action. Disease characteristics associated with an increased risk of accidents included generalized epilepsy (conclusions), active epilepsy, and at least monthly seizures (abrasions). Most risks decreased, becoming nonsignificant after excluding, seizure-related events. Conclusions: Patients with epilepsy are at higher risk of accidents and their complications. However, the risk was substantially lower after exclusion of seizure-related events.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	Beghi, E (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	beghi@marionegri.it	Gambardella, Antonio/F-5295-2012; Beghi, Ettore/AAA-7426-2020; Cosottini, Mirco/K-7991-2016; Cavestro, Cinzia/S-1115-2019; Zarrelli, Michele/K-2210-2016	Gambardella, Antonio/0000-0001-7384-3074; Beghi, Ettore/0000-0003-2542-0469; Cosottini, Mirco/0000-0001-9400-6574; Cavestro, Cinzia/0000-0003-1172-1009; Zarrelli, Michele/0000-0001-7768-1762; AGUGLIA, Umberto/0000-0002-4574-2951; SPECCHIO, NICOLA/0000-0002-8120-0287; Belousova, Elena Dmitrievna/0000-0003-3594-6974			ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Beaussart M, 1997, Med Law, V16, P295; Beghi E, 2002, EPILEPSIA, V43, P1076, DOI 10.1046/j.1528-1157.2002.18701.x; Beghi E, 1997, NEUROEPIDEMIOLOGY, V16, P207, DOI 10.1159/000109689; BEGHI E, 2002, MED RISKS EPILEPSY, P7; Begley CE, 2002, EPILEPSIA, V43, P3, DOI 10.1046/j.1528-1157.43.s.4.2.x; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; COX DR, 1972, J R STAT SOC B, V34, P187; Drazkowski JF, 2003, MAYO CLIN PROC, V78, P819, DOI 10.4065/78.7.819; Gislason T, 1997, J INTERN MED, V241, P213; HAMPTON KK, 1988, BRIT MED J, V296, P1659, DOI 10.1136/bmj.296.6637.1659; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Josty IC, 2000, EPILEPSIA, V41, P453, DOI 10.1111/j.1528-1157.2000.tb00188.x; Kirsch R, 2001, J CHILD NEUROL, V16, P100, DOI 10.2310/7010.2001.6916; Krauss GL, 1999, NEUROLOGY, V52, P1324, DOI 10.1212/WNL.52.7.1324; Lassouw G, 1997, SEIZURE, V6, P95, DOI 10.1016/S1059-1311(97)80061-1; Lings S, 2001, NEUROLOGY, V57, P435, DOI 10.1212/WNL.57.3.435; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x; Neufeld MY, 2000, SEIZURE-EUR J EPILEP, V9, P595, DOI 10.1053/seiz.2000.0469; Neufeld MY, 1999, EPILEPSY RES, V34, P123, DOI 10.1016/S0920-1211(98)00105-3; Persson HBI, 2002, EPILEPSIA, V43, P768, DOI 10.1046/j.1528-1157.2002.15801.x; RUSSELLJONES DL, 1989, J NEUROL NEUROSUR PS, V52, P659, DOI 10.1136/jnnp.52.5.659; SPITZ MC, 1994, EPILEPSIA, V35, P764, DOI 10.1111/j.1528-1157.1994.tb02508.x; Taylor J, 1996, J NEUROL NEUROSUR PS, V60, P621, DOI 10.1136/jnnp.60.6.621; van den Broek M, 2004, EPILEPSIA, V45, P71, DOI 10.1111/j.0013-9580.2004.33803.x; Vestergaard P, 1999, ACTA NEUROL SCAND, V99, P269, DOI 10.1111/j.1600-0404.1999.tb00675.x; Wirrell EC, 1996, ARCH NEUROL-CHICAGO, V53, P929, DOI 10.1001/archneur.1996.00550090141020; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	30	72	72	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUN	2004	45	6					667	672		10.1111/j.0013-9580.2004.33903.x			6	Clinical Neurology	Neurosciences & Neurology	828SI	WOS:000221992900013	15144432				2021-06-18	
J	Hawley, CA; Ward, AB; Magnay, AR; Mychalkiw, W				Hawley, CA; Ward, AB; Magnay, AR; Mychalkiw, W			Return to school after brain injury	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; CHILDREN; ADOLESCENTS; MEMORY; TEMPERAMENT; PERFORMANCE; CHILDHOOD; INFANTS; SCALE	Aims: To examine return to school and classroom performance following traumatic brain injury (TBI). Methods: This cross-sectional study set in the community comprised a group of 67 school-age children with TBI ( 35 mild, 13 moderate, 19 severe) and 14 uninjured matched controls. Parents and children were interviewed and children assessed at a mean of 2 years post injury. Teachers reported on academic performance and educational needs. The main measures used were classroom performance, the Children's Memory Scale (CMS), the Wechsler Intelligence Scale for Children - third edition UK (WISC-III) and the Weschler Objective Reading Dimensions ( WORD). Results: One third of teachers were unaware of the TBI. On return to school, special arrangements were made for 18 children (27%). Special educational needs were identified for 16 (24%), but only six children (9%) received specialist help. Two thirds of children with TBI had difficulties with school work, half had attention/concentration problems and 26 (39%) had memory problems. Compared to other pupils in the class, one third of children with TBI were performing below average. On the CMS, one third of the severe group were impaired/borderline for immediate and delayed recall of verbal material, and over one quarter were impaired/borderline for general memory. Children in the severe group had a mean full-scale IQ significantly lower than controls. Half the TBI group had a reading age greater than or equal to1 year below their chronological age, one third were reading greater than or equal to2 years below their chronological age. Conclusions: Schools rely on parents to inform them about a TBI, and rarely receive information on possible long-term sequelae. At hospital discharge, health professionals should provide schools with information about TBI and possible long-term impairments, so that children returning to school receive appropriate support.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England; City Gen Hosp, Dept Psychol, Stoke On Trent ST4 6QG, Staffs, England	Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Bevington J, 1999, BRIT J EDUC PSYCHOL, V69, P19, DOI 10.1348/000709999157545; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; COHEN B, 1997, CHILDRENS MEMORY SCA; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; JOHNSON DA, 1998, ED NEEDS HEAD INJURY; JONES A, 1994, BR J SPEC ED, V21, P113; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kennard MA, 1936, AM J PHYSIOL, V115, P138; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; MARTIN RP, 1988, SCHOOL PSYCHOL REV, V17, P125; *NAT I CLIN EXC, 2002, HEAD INJ INF CHILDR; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Parmelee D X, 1989, Psychiatr Med, V7, P11; PFEFFER J, 1983, J CLIN PSYCHOL, V39, P1013, DOI 10.1002/1097-4679(198311)39:6<1013::AID-JCLP2270390634>3.0.CO;2-5; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; Sharples PM, 1998, INJURY YOUNG, P151; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO; WECHSLER D, 1993, WESCHLER OBJECTIVE R; Wechsler D., 1991, MANUAL WECHSLER INTE	37	72	73	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	FEB 1	2004	89	2					136	141		10.1136/adc.2002.025577			6	Pediatrics	Pediatrics	765UP	WOS:000188302500018	14736628	Bronze, Green Published			2021-06-18	
J	Hoane, MR; Becerra, GD; Shank, JE; Tatko, L; Pak, ES; Smith, M; Murashov, AK				Hoane, MR; Becerra, GD; Shank, JE; Tatko, L; Pak, ES; Smith, M; Murashov, AK			Transplantation of neuronal and glial precursors dramatically improves sensorimotor function but not cognitive function in the traumatically injured brain	JOURNAL OF NEUROTRAUMA			English	Article						behavior; brain injury; embryonic stem cells; neural stem cells; rat; recovery of function; transplantation	FACILITATE RECOVERY; MAGNESIUM THERAPY; NMDA ANTAGONISTS; CORTEX LESIONS; RAT; DEFICITS; SURVIVAL; ATROPHY; MODEL	Embryonic stem (ES) cells have been investigated in various animal models of neurodegenerative disease; however, few studies have examined the ability of ES cells to improve functional outcome following traumatic brain injury (TBI). The purpose of the present study was to examine the ability of pre-differentiated murine ES cells (neuronal and glial precursors) to improve functional outcome. Rats were prepared with a unilateral controlled cortical impact injury or sham and then transplanted 7 days later with 100K ES cells (WW6G) (similar to30% neurons) or media. Two days following transplantation rats were tested on a battery of behavioral tests. It was found that transplantation of ES cells improved behavioral outcome by reducing the initial magnitude of the deficit on the bilateral tactile removal and locomotor placing tests. ES cells also induced almost complete recovery on the vibrissae (-->) forelimb placing test, whereas, media-transplanted rats failed to show recovery. Acquisition of a reference memory task in the Morris water maze was not improved by transplantation of ES cells. Histological analysis revealed a large number of surviving ES cells in the lesion cavity and showed migration of ES cells into subcortical structures. It was found that transplantation of ES cells prevented the occurrence of multiple small necrotic cavities that were seen in the cortex adjacent to the lesion cavity in media transplanted rats. Additionally, ES cells transplants also significantly reduced lesion size. Results of this study suggest that ES cells that have been pre-differentiated into neuronal precursors prior to transplantation have therapeutic potential.	E Carolina Univ, Dept Psychol, Brain Injury Lab, Brody Sch Med, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Neurosci Program, Greenville, NC USA; E Carolina Univ, Brody Sch Med, Dept Physiol, Greenville, NC USA	Hoane, MR (corresponding author), E Carolina Univ, Dept Psychol, Brain Injury Lab, Brody Sch Med, Greenville, NC 27858 USA.	hoanem@mail.ecu.edu	Murashov, Alexander/ABB-2151-2020; Murashov, Alexander K/F-2241-2011	Murashov, Alexander/0000-0002-8912-5891; Murashov, Alexander K/0000-0002-8912-5891; Hoane, Michael/0000-0001-7779-2657			BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BARTH TM, 1990, STROKE, V21, P153; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kerr DA, 2003, J NEUROSCI, V23, P5131; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Murashov AK, 2001, MOL BRAIN RES, V93, P199, DOI 10.1016/S0169-328X(01)00212-1; OHANE MR, 2002, J NEUROTRAUM, V19, P1328; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wilkins A, 2003, J NEUROSCI, V23, P4967, DOI 10.1523/jneurosci.23-12-04967.2003	32	72	77	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					163	174		10.1089/089771504322778622			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200004	15000757				2021-06-18	
J	Bonini, P; Cicconi, S; Cardinale, A; Vitale, C; Serafino, AL; Ciotti, MT; Marlier, LNJL				Bonini, P; Cicconi, S; Cardinale, A; Vitale, C; Serafino, AL; Ciotti, MT; Marlier, LNJL			Oxidative stress induces p53-mediated apoptosis in glia: p53 transcription-independent way to die	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						astrocyte; C6 glioma; ischemia; MDM2; cytochrome; mitochondria; caspase	CELL-DEATH; CASPASE ACTIVATION; PROTEIN; MITOCHONDRIA; BAX; NEURONS; EXPRESSION; INHIBITOR; MODEL; MDM2	Oxidative stress has been implicated in the pathogenesis of stroke, traumatic brain injuries, and neurodegenerative diseases affecting both neuronal and glial cells in the central nervous system (CNS). The tumor suppressor protein p53 plays a pivotal function in neuronal apoptosis triggered by oxidative stress. We investigated the role of p53 and related molecular mechanisms that support oxidative stress-induced apoptosis in glia. For this purpose, we exposed C6 glioma cells and primary cultures of rat cortical astrocytes to an H2O2-induced oxidative stress protocol followed by a recovery period. We evaluated the effects of pifithrin-alpha (PF-alpha), which has been reported to protect neurons from ischemic insult by specifically inhibiting p53 DNA-binding activity. Strikingly, PF-alpha was unable to prevent oxidative stress-induced astrocyte apoptosis. We demonstrate that p53 is able to mediate an apoptotic response by direct signaling at mitochondria, despite its transcriptional activity. The z-VAD-fmk-sensitive apoptotic response requires a caspase-dependent MDM-2 degradation, leading to p53 mitochondrial targeting accompanied by cytochrome c release and nucleosomal fragmentation. (C) 2003 Wiley-Liss, Inc.	CNR, Inst Neurobiol & Mol Med, Sect Mol Med, Signal Transduct Apoptot Mech Lab, I-00137 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; San Raffaele Roma Hosp, Dept Med Sci, Rome, Italy; CNR, Inst Neurobiol & Mol Med, Sect Neurosci, I-00137 Rome, Italy	Marlier, LNJL (corresponding author), CNR, Inst Neurobiol & Mol Med, Sect Mol Med, Signal Transduct Apoptot Mech Lab, Viale Marx 15-43, I-00137 Rome, Italy.	l.marlier@in.rm.cnr.it	Marlier, Lionel NJL/G-9488-2013; Serafino, Annalucia/AAC-1719-2019	Serafino, Annalucia/0000-0002-1142-4752; MARLIER, LIONEL/0000-0002-6840-3127			Avshalumov MV, 2002, J NEUROPHYSIOL, V87, P2896, DOI 10.1152/jn.2002.87.6.2896; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brady HJM, 1998, INT J BIOCHEM CELL B, V30, P647, DOI 10.1016/S1357-2725(98)00006-5; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chen RW, 1999, J NEUROSCI, V19, P9654; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chung YH, 2002, NEUROL RES, V24, P324, DOI 10.1179/016164102101199828; Culmsee C, 2001, MOL BRAIN RES, V87, P257, DOI 10.1016/S0169-328X(01)00008-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; de la Monte SM, 1998, LAB INVEST, V78, P401; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jordan J, 1997, J NEUROSCI, V17, P1397; Joseph JA, 1997, J NEUROCHEM, V69, P1252; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Karbowski M, 1999, FREE RADICAL BIO MED, V26, P396, DOI 10.1016/S0891-5849(98)00209-3; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.3.CO;2-J; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakkaraju A, 2001, J BIOL CHEM, V276, P32000, DOI 10.1074/jbc.M100138200; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; MERCANTI D, 1987, EXP CELL RES, V168, P182, DOI 10.1016/0014-4827(87)90427-7; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Robertson J, 2001, J CELL BIOL, V155, P217, DOI 10.1083/jcb.200107058; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Teranishi M, 2000, EXP MOL PATHOL, V68, P104, DOI 10.1006/exmp.1999.2288; VOLONTE C, 1994, CYTOMETRY, V17, P274, DOI 10.1002/cyto.990170311; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiang H, 1998, J NEUROSCI, V18, P1363; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	59	72	75	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 1	2004	75	1					83	95		10.1002/jnr.10822			13	Neurosciences	Neurosciences & Neurology	761YB	WOS:000187942100009	14689451				2021-06-18	
J	Cook, DJ; Cusimano, MD; Tator, CH; Chipman, ML				Cook, DJ; Cusimano, MD; Tator, CH; Chipman, ML			Evaluation of the ThinkFirst Canada, Smart Hockey, brain and spinal cord injury prevention video	INJURY PREVENTION			English	Article							ICE HOCKEY; PLAYERS; IMPACT; HEAD; CONCUSSIONS; CHECKING; SPORTS; NECK	Objective: The ThinkFirst Canada Smart Hockey program is an educational injury prevention video that teaches the mechanisms, consequences, and prevention of brain and spinal cord injury in ice hockey. This study evaluates knowledge transfer and behavioural outcomes in 11-12 year old hockey players who viewed the video. Design: Randomized controlled design. Setting: Greater Toronto Minor Hockey League, Toronto Ontario. Subjects: Minor, competitive 11-12 year old male ice hockey players and hockey team coaches. Interventions: The Smart Hockey video was shown to experimental teams at mid-season. An interview was conducted with coaches to understand reasons to accept or refuse the injury prevention video. Main outcome measures: A test of concussion knowledge was administered before, immediately after, and three months after exposure to the video. The incidence of aggressive penalties was measured before and after viewing the video. Results: The number of causes and mechanisms of concussion named by players increased from 1.13 to 2.47 and from 0.67 to 1.22 respectively. This effect was maintained at three months. There was no significant change in control teams. There was no significant change in total penalties after video exposure; however, specific body checking related penalties were significantly reduced in the experimental group. Conclusion: This study showed some improvements in knowledge and behaviours after a single viewing of a video; however, these findings require confirmation with a larger sample to understand the sociobehavioural aspects of sport that determine the effectiveness and acceptance of injury prevention interventions.	St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, Toronto, ON M5B 1A6, Canada; Toronto Western Hosp, ThinkFirst Fdn Canada, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	Cusimano, MD (corresponding author), St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, 38 Shuter St,Suite 2-018, Toronto, ON M5B 1A6, Canada.	injuryprevention@smh.toronto.on.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Anderson AJ, 2000, PEDIATRICS, V105, P657; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V83, P23; BORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Glaser B.G., 1992, BASICS GROUNDED THEO; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HAYES D, 1975, PHYSICIAN SPORTS JAN; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCFAULL S, 2001, CHIRRP NEWS, V19; PASHBY TJ, 1992, CAN J OPHTHALMOL, V27, P226; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1991, CAN J SURG, V34, P63; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; VOLPE R, 2002, COMPENDIUM EVIDENCE, P223; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	24	72	72	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	DEC	2003	9	4					361	365		10.1136/ip.9.4.361			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	771EA	WOS:000188771600018	14693901	Bronze, Green Published			2021-06-18	
J	Jorge, R; Robinson, RG				Jorge, R; Robinson, RG			Mood disorders following traumatic brain injury	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							CORTICAL IMPACT INJURY; RAT FRONTAL-CORTEX; CLOSED-HEAD-INJURY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; AGGRESSIVE-BEHAVIOR; MEMORY DEFICITS; AXIS-I; MANIA; MECHANISMS	Mood disorders are a frequent complication of traumatic brain injury that exerts a deleterious effect on the recovery process and psychosocial outcome of brain injured patients. Prior psychiatric history and impaired social support have been consistently reported as risk factors for developing mood disorders after traumatic brain injury (TBI). In addition, biological factors such as the involvement of the prefrontal cortex and probably other limbic and paralimbic structures may play a significant role in the complex pathophysiology of these disorders. Preliminary studies have suggested that selective serotonin reuptake inhibitors such as sertraline, mood stabilizers such as sodium valproate, as well as stimulants and ECT may be useful in treating these disorders. Mood disorders occurring after TBI are clearly an area of neuropsychiatry in which further research in etiology as well as treatment is needed.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA	Jorge, R (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, 200 Hawkins Dr 2887 JPP, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021				Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; BAKCHINE S, 1989, NEUROLOGY, V39, P777, DOI 10.1212/WNL.39.6.777; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BRACKEN P, 1987, BRIT J PSYCHIAT, V150, P690, DOI 10.1192/bjp.150.5.690; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; Cummings JL, 1998, AM J GERIAT PSYCHIAT, V6, pS64, DOI 10.1097/00019442-199821001-00009; CUMMINGS JL, 1984, AM J PSYCHIAT, V141, P1084; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Ella R, 2002, J CLIN PSYCHIAT, V63, P249, DOI 10.4088/JCP.v63n0312d; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Freo U, 2002, J NEURAL TRANSM, V109, P857, DOI 10.1007/s007020200070; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hong Jun, 2002, Chin J Traumatol, V5, P36; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; JOSHI P, 1985, J DEV BEHAV PEDIATR, V6, P352; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kulisevsky J, 2002, NEUROLOGY, V59, P1421, DOI 10.1212/WNL.59.9.1421; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MARKIANOS M, 1992, ACTA NEUROL SCAND, V86, P190, DOI 10.1111/j.1600-0404.1992.tb05064.x; MCHUGH PR, 1992, J ROY SOC MED, V85, P483; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Monji A, 1999, PSYCHOSOMATICS, V40, P448, DOI 10.1016/S0033-3182(99)71215-6; Morgan JR, 2002, NEUROMOL MED, V2, P101, DOI 10.1385/NMM:2:2:101; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NIZAMIE SH, 1988, ACTA PSYCHIAT SCAND, V77, P637, DOI 10.1111/j.1600-0447.1988.tb05181.x; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schneck Christopher D., 2002, Curr Treat Options Neurol, V4, P477, DOI 10.1007/s11940-002-0015-3; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SILVER JM, 1991, J NEUROPSYCHIAT, V3, P22; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STARKSTEIN SE, 1988, J NERV MENT DIS, V176, P87, DOI 10.1097/00005053-198802000-00004; STEWART JT, 1988, J CLIN PSYCHIAT, V49, P74; STOLL AL, 1994, J CLIN PSYCHOPHARM, V14, P311; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; THIENHAUS OJ, 1984, AM J PSYCHIAT, V141, P1459; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	91	72	73	0	17	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0954-0261			INT REV PSYCHIATR	Int. Rev. Psych.	NOV	2003	15	4					317	327		10.1080/09540260310001606700			11	Psychiatry	Psychiatry	739UD	WOS:000186364100004	15276953				2021-06-18	
J	Rodriguez-Baeza, A; La Torre, FRD; Poca, A; Marti, M; Garnacho, A				Rodriguez-Baeza, A; La Torre, FRD; Poca, A; Marti, M; Garnacho, A			Morphological features in human cortical brain microvessels after head injury: A three-dimensional and immunocytochemical study	ANATOMICAL RECORD PART A-DISCOVERIES IN MOLECULAR CELLULAR AND EVOLUTIONARY BIOLOGY			English	Article						human cerebral cortex; head injury; cortical microvessels; morphological changes; cell damage; apoptosis	SCANNING ELECTRON-MICROSCOPE; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; CORROSION CASTS; BLOOD-FLOW; CEREBRAL MICROVESSELS; DNA FRAGMENTATION; NERVOUS-SYSTEM; CELL-DEATH; APOPTOSIS; RATS	We studied the morphology of cortical microvessels in the brains of 10 patients who had died after receiving a traumatic head injury (THI). Scanning electron microscopy (SEM) of vascular corrosion casts, confocal microscopy of histological sections after immunocytochemistry, and detection of apoptosis by terminal dUTP nick end labeling (TUNEL) were used. Microvascular casts showed an angioarchitectonic distribution that was defined as normal according to results obtained in a previous, nontraumatic series of subjects. However, when we compared them with previous works, the cast surface of some of the microvessels showed three types of morphological alterations: longitudinal folds, sunken surfaces with craters, and a significant flattening with reduction of lumen. The vessels that were primarily affected were the arterioles and capillaries of the middle and deep cortical vascular zones. Immunostaining with the monoclonal antibody MAS-336 against endothelial cells also showed the presence of longitudinal folds with a thinning of the vascular lumen, cytoplasmic round bodies, and a thickening of the endothelial cell membrane. The TUNEL technique revealed a positive staining of some endothelial cells. The structural alterations we observed indicate that microvessels undergo endothelial cell damage after THI. We suggest that this kind of lesion and the secondary functional injury to the blood-brain barrier (BBB) could play an important role in the development of the secondary lesions that these patients show in the subacute phase. (C) 2003 Wiley-Liss, Inc.	Univ Autonoma Barcelona, Dept Morphol Sci, Anat & Embryol Unit, Fac Med, Bellaterra 08193, Barcelona, Spain; Vall Hebron Hosp, Neurotraumatol Unit, Dept Neurosurg, Barcelona, Spain; Univ Autonoma Barcelona, Electron Microscopy Serv, E-08193 Barcelona, Spain; Vall hebron Traumatol Hosp, Intens Care Unit, Barcelona, Spain	Rodriguez-Baeza, A (corresponding author), Univ Autonoma Barcelona, Dept Morphol Sci, Anat & Embryol Unit, Fac Med, Bellaterra 08193, Barcelona, Spain.	alfonso.rodriguez@uab.es	Garnacho, Angel/A-9309-2013; Rodriguez-Baeza, Alfonso/L-8284-2014; Poca, Maria A./B-8475-2008	Rodriguez-Baeza, Alfonso/0000-0002-9181-5613; Poca, Maria A./0000-0002-3831-0536			Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Bhutto IA, 1997, OPHTHALMIC RES, V29, P12, DOI 10.1159/000267986; Bouma G J, 1995, New Horiz, V3, P384; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; CASTENHOLZ A, 1982, MIKROSKOPIE, V39, P95; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHRISTOFFERSON RH, 1988, SCANNING, V10, P43, DOI 10.1002/sca.4950100202; CLOWER BR, 1994, ANAT REC, V240, P104, DOI 10.1002/ar.1092400110; CLOWER BR, 1981, STROKE, V12, P501, DOI 10.1161/01.STR.12.4.501; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; DUVERNOY HM, 1981, BRAIN RES BULL, V7, P519, DOI 10.1016/0361-9230(81)90007-1; FEIN JM, 1974, J NEUROSURG, V41, P49, DOI 10.3171/jns.1974.41.1.0049; Gajkowska B, 1997, ACTA NEUROBIOL EXP, V57, P203; GARCIA JH, 1994, AM J PATHOL, V145, P728; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HIRANO A, 1994, MICROSC RES TECHNIQ, V27, P543, DOI 10.1002/jemt.1070270609; Huppertz B, 1999, ANAT EMBRYOL, V200, P1, DOI 10.1007/s004290050254; Hutchins JB, 1998, ANAT REC, V253, P79, DOI 10.1002/(SICI)1097-0185(199806)253:3<79::AID-AR4>3.0.CO;2-9; JOO F, 1989, Neurological Research, V11, P67; KAPP JP, 1982, SURG NEUROL, V18, P40, DOI 10.1016/0090-3019(82)90011-8; KONERDING MA, 1991, SCANNING MICROSCOPY, V5, P851; Konerding MA, 1995, SCANNING MICROSCOPY, V9, P1233; Lafuente JV, 1998, REV NEUROLOGIA, V26, P224, DOI 10.33588/rn.26150.981062; LAMETSCHWANDTNER A, 1984, SCAN ELECTRON MICROS, P663; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MENDELOW AD, 1983, BRIT J SURG, V70, P641, DOI 10.1002/bjs.1800701102; MIRONOV V, 1994, BRAIN RES, V660, P73, DOI 10.1016/0006-8993(94)90840-0; Murayama N, 1997, CERAMICS, V32, P445; MURILLO F, 1996, TRAUMATISMO CRANEOEN, P10; OHTANI O, 1992, SCANNING ELECT MICRO; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Reina-De La Torre F, 1998, ANAT RECORD, V251, P87, DOI 10.1002/(SICI)1097-0185(199805)251:1<87::AID-AR14>3.0.CO;2-7; RICKELS E, 1992, NEUROCHIRURGIA, V35, P99; Rodriguez-Baeza A, 1998, ANAT RECORD, V252, P176, DOI 10.1002/(SICI)1097-0185(199810)252:2<176::AID-AR3>3.0.CO;2-1; Sbarbati A, 1996, ACTA NEUROPATHOL, V92, P56, DOI 10.1007/s004010050489; SCHMIDT EE, 1988, AM J ANAT, V181, P253, DOI 10.1002/aja.1001810304; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAN PB, 1999, SCI MED, V6, P18; Vaz R, 1998, ACTA NEUROCHIR, V140, P76, DOI 10.1007/s007010050061; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; WISNIEWSKI HM, 1995, ACTA NEUROPATHOL, V90, P432; YOSHIDA Y, 1984, J CEREBR BLOOD F MET, V4, P290, DOI 10.1038/jcbfm.1984.40; Zhang J, 1998, ANAT REC, V253, P58, DOI 10.1002/(SICI)1097-0185(199804)253:2<58::AID-AR9>3.0.CO;2-A	49	72	73	0	3	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1552-4884	1552-4892		ANAT REC PART A	Anat. Rec. Part A	JUL	2003	273A	1					583	593		10.1002/ar.a.10069			11	Anatomy & Morphology	Anatomy & Morphology	697ZU	WOS:000183973800002	12808643	Bronze			2021-06-18	
J	Coimbra, R; Hoyt, DB; Potenza, BM; Fortlage, D; Hollingsworth-Fridlund, P				Coimbra, R; Hoyt, DB; Potenza, BM; Fortlage, D; Hollingsworth-Fridlund, P			Does sexual dimorphism influence outcome of traumatic brain injury patients? The answer is no!	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	61st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 26-28, 2002	ORLANDO, FL	Amer Assoc Surg Trauma		blunt trauma; sexual dimorphism; gender differences; traumatic brain injury; shock; complications; mortality	GENDER-DIFFERENCES; RISK-FACTORS; HEAD-INJURY; ESTROGEN; COMPLICATIONS; MORTALITY	Background. The protective effect of female gender on posttraumatic mortality or acute complications after traumatic brain injury (TBI) has been postulated. This effect might be seen if TBIs were analyzed by severity. To assess potential gender effects, we performed a retrospective case-controlled study matching female patients to male counterparts for overall injury severity; hemodynamic status at admission; and head, chest, and abdomen Abbreviated Injury Scale score. Methods: All female patients sustaining TBI admitted over 6.5 years were reviewed. An overall comparison between women (n = 914) and their male matched counterparts (n = 916) was performed. Patients were then stratified according to the severity of head injury on the basis of admission Glasgow Coma Scale (GCS) score into three groups: group 1, GCS score of 13 to 15 (788 female patients, 769 male patients); group 2, GCS score of 9 to 12 (40 female patients, 42 male patients); and group 3, GCS score < 9 (63 female patients, 87 male patients). Cohorts were compared for mortality or the development of acute respiratory distress syndrome, pneumonia, and systemic sepsis using standard definitions. A subset analysis was performed excluding patients with age above 50 years (789 women, 811 men) to exclude the effects of menopause on the results. Results: There was no statistically significant difference in outcome overall or in subset analysis of mild (group 1), moderate (group 2), or severe (group 3) TBI. The exclusion of patients older than 50 years showed no protective effect of female gender on outcome. Conclusion: Gender does not play a role in posttraumatic mortality or in the incidence of acute complications after any degree of TBI.	Univ Calif San Diego, Dept Surg, Div Trauma, Med Ctr, San Diego, CA 92103 USA	Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma, Med Ctr, 200 W Arbor Dr, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			AHMED SA, 1989, J IMMUNOL, V142, P2647; Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001; Angele MK, 1997, ARCH SURG-CHICAGO, V132, P1207; ANGELE MK, 1998, SURG FORUM, V49, P43; ANGELE MK, 2000, EUR J TRAUMA, V6, P267; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Clerici E, 1991, J Clin Lab Immunol, V34, P71; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FARACE E, 2002, NEUROSURG FOCUS, V8; Gannon CJ, 2002, J AM COLL SURGEONS, V195, P11, DOI 10.1016/S1072-7515(02)01187-0; Garner JS, 1996, APIC INFECT CONTROL, pA1; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; KRAUS JF, 2000, NEUROSURG FOCUS, V8; Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Napolitano LM, 2001, J TRAUMA, V50, P274, DOI 10.1097/00005373-200102000-00013; O'Keefe GE, 2001, J AM COLL SURGEONS, V192, P153, DOI 10.1016/S1072-7515(00)00785-7; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Rappold JF, 2002, J TRAUMA, V53, P436, DOI 10.1097/00005373-200209000-00007; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wichmann MW, 1997, AM J PHYSIOL-CELL PH, V273, pC1335; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	27	72	74	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2003	54	4					689	700		10.1097/01.TA.0000058314.31655.5F			12	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	675AT	WOS:000182671400014	12707530				2021-06-18	
J	Watson, DJ; Longhi, L; Lee, EB; Fulp, CT; Fujimoto, S; Royo, NC; Passini, MA; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Wolfe, JH				Watson, DJ; Longhi, L; Lee, EB; Fulp, CT; Fujimoto, S; Royo, NC; Passini, MA; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Wolfe, JH			Genetically modified NT2N human neuronal cells mediate long-term gene expression as CNS grafts in vivo and improve functional cognitive outcome following experimental traumatic brain injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						lentiviral vectors; nerve growth factor (NGF); neural progenitor cells; transplantation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SEPTAL CHOLINERGIC NEURONS; EMBRYONAL CARCINOMA-CELLS; RETINOIC ACID; HNT NEURONS; NTERA-2 CELLS; HEAD-INJURY; LINE; TRANSPLANTATION; DIFFERENTIATION	Human Ntera-2 (NT2) cells can be differentiated in vitro into well-characterized Populations of NT2N neurons that engraft and mature when transplanted into the adult CNS of rodents and humans. Them ha e shown promise as treatments for neurologic disease, trauma, and ischemic stroke. Although these features suggest that NT2N neurons would be an excellent platform for ex vivo gene therapy in the CNS, stable gene expression has been surprisingly difficult to achieve in these cells. In this report we demonstrate stable, efficient. and nontoxic gene transfer into undifferentiated NT2 cells using a pseudotyped lentiviral vector encoding the human elongation factor 1-alpha promoter and the reporter gene eGFP, Expression of eGFP was maintained when the NT2 cells were differentiated into NT2N neurons after treatment with retinoic acid, When transplanted into the striatum of adult nude mice, transduced NT2N neurons survived, engrafted, and continued to express the reporter gene for long-term time points in vivo. Furthermore. transplantation of NT2N neurons genetically modified to express nerve growth factor significantly attenuated cognitive dysfunction following traumatic brain injure in mice. These results demonstrate that defined populations of genetically modified human NT2N neurons are a practical and effective platform for stable ex vivo gene delivery into the CNS.	Childrens Hosp Philadelphia, Dept Neurol & Neurosci Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Ctr Comparat Med Genet, Philadelphia, PA 19104 USA; Osped Maggiore, Policlin IRCCS, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Milan, Italy; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Wolfe, JH (corresponding author), Childrens Hosp Philadelphia, Dept Neurol & Neurosci Res, 502 Abramson Res Ctr,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	jhwolfe@vet.upenn.edu	Longhi, Luca/AAF-9903-2021	Longhi, Luca/0000-0001-9894-8788	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK042707, T32DK007748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH017168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, F32NS011024, P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009215] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00255, AG09215] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK07748, DK42707] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH17168] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS11024, NS08803, NS40978, NS38690, NS07810] Funding Source: Medline		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baker KA, 2000, EXP NEUROL, V162, P350, DOI 10.1006/exnr.1999.7337; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Blesch A, 1998, PROG BRAIN RES, V117, P473; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cook DG, 1996, J COMP NEUROL, V374, P481; COOK DG, 1994, METHOD CELL BIOL, V43, P289; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao ZY, 1998, BIOCHEM BIOPH RES CO, V247, P407, DOI 10.1006/bbrc.1998.8826; Garbuzova-Davis S, 2002, EXP NEUROL, V174, P169, DOI 10.1006/exnr.2002.7860; GREENE LA, 1998, CULTURING NERVE CELL; Guillemain I, 2000, J COMP NEUROL, V422, P380, DOI 10.1002/1096-9861(20000703)422:3<380::AID-CNE5>3.0.CO;2-C; Halene S, 2000, HUM GENE THER, V11, P1259, DOI 10.1089/10430340050032366; Hartley RS, 1999, J COMP NEUROL, V407, P1, DOI 10.1002/(SICI)1096-9861(19990428)407:1<1::AID-CNE1>3.0.CO;2-Z; Hartley RS, 1999, J COMP NEUROL, V415, P404, DOI 10.1002/(SICI)1096-9861(19991220)415:3<404::AID-CNE6>3.0.CO;2-R; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hsu WL, 2001, J VIROL, V75, P3819, DOI 10.1128/JVI.75.8.3819-3831.2001; Hurlbert MS, 1999, CELL TRANSPLANT, V8, P143, DOI 10.1177/096368979900800106; Hynes M, 2000, NEURON, V28, P11, DOI 10.1016/S0896-6273(00)00079-9; Iwakuma T, 1999, VIROLOGY, V261, P120, DOI 10.1006/viro.1999.9850; KESARI S, 1995, LAB INVEST, V73, P636; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; LEE VMY, 1986, J NEUROSCI, V6, P514; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Llanes C, 1995, J NEUROSCI RES, V42, P791, DOI 10.1002/jnr.490420608; Meier JL, 2001, J VIROL, V75, P1581, DOI 10.1128/JVI.75.4.1581-1593.2001; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Mukhtar M, 2000, HUM GENE THER, V11, P347, DOI 10.1089/10430340050016076; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neelands TR, 1999, J NEUROSCI, V19, P7057, DOI 10.1523/JNEUROSCI.19-16-07057.1999; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; Passini MA, 2001, J VIROL, V75, P12382, DOI 10.1128/JVI.75.24.12382-12392.2001; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Watson Deborah J, 2003, Methods Mol Med, V76, P383; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu P, 1996, GENE THER, V3, P246; ZELLER M, 1995, INT J DEV NEUROSCI, V13, P437, DOI 10.1016/0736-5748(95)00025-C; Zigova T, 2000, EXP NEUROL, V163, P31, DOI 10.1006/exnr.2000.7344	61	72	74	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	APR	2003	62	4					368	380		10.1093/jnen/62.4.368			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	664YH	WOS:000182092100005	12722829	Green Published			2021-06-18	
J	Lang, EW; Czosnyka, M; Mehdorn, HM				Lang, EW; Czosnyka, M; Mehdorn, HM			Tissue oxygen reactivity and cerebral autoregulation after severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						arterial blood pressure; cerebral blood flow velocity; static cerebral pressure autoregulation; transcranial Doppler ultrasound; severe head injury; cerebrovascular circulation; cerebral perfusion pressure; tissue oxygen reactivity; cerebral oxygenation	BLOOD-FLOW VELOCITY; PERFUSION-PRESSURE; TRANSCRANIAL DOPPLER; PHASE RELATIONSHIP; HEAD-INJURY; SATURATION; PO2	Objective. To study the relationship between arterial blood pressure, intracranial pressure, directly measured brain tissue oxygenation (Ptio(2)), and middle cerebral artery blood flow velocity in severely head-injured patients. Design: Prospective study. Setting: Neurosurgical intensive care unit. Patients. A total of 14 patients with severe head injury. Interventions. Pharmacologic blood pressure manipulations using norepinephrine. Measurements and Main Results., We assessed the magnitude Of Ptio(2) related to changes in cerebral perfusion pressure in 12 of the patients. We calculated in all the static rate of regulation, which is an index to describe the change of cerebrovascular resistance, using cerebral artery blood flow velocity in relation to changing cerebral perfusion pressure. Finally, we calculated the rate of change in Ptio(2), which quantifies the percentage of change in Ptio(2) divided by the percentage of change in cerebral perfusion pressure. It is a new marker for cerebral tissue oxygen regulation based on direct measurement of Ptio(2). There was a plateau phase for the cerebral perfusion pressure-Ptio(2) relation that was similar to the autoregulatory plateau seen in the relationship between cerebral perfusion pressure and cerebral artery blood flow velocity. The rate of change in Ptio(2) demonstrated a significant correlation with the static rate of regulation (R = -.61, p <.05). A decrease in intracranial pressure when arterial blood pressure increased from 70 to 90 mm Hg was strongly correlated with static rate of regulation (R =.79, p <.001). Conclusions. Cerebral tissue Po-2 demonstrates a plateau phase similar to what is known about cerebral blood flow velocity, which suggests a close link between cerebral blood flow and oxygenation. Static cerebral autoregulation is significantly correlated with cerebral tissue oxygen reactivity.	Univ Kiel, Dept Neurosurg, Kiel, Germany; Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England	Lang, EW (corresponding author), Westmead Hosp, Dept Neurosurg, Level 5, Westmead, NSW 2145, Australia.	keeflang@optusnet.com.au	Mehdorn, Maximilian/D-2495-2010				AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BULLOCK R, 1996, GUIDELINES MANAGEMEN; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Fandino J, 1999, ACTA NEUROCHIR, V141, P825, DOI 10.1007/s007010050383; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kiening KL, 1998, ACT NEUR S, V71, P172; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; MARMAROU A, 1993, ACTA NEUROCHIR, P18; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Schneider GH, 1998, ACT NEUR S, V71, P62; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Stocchetti N, 1998, ACT NEUR S, V71, P162; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	34	72	72	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2003	31	1					267	271		10.1097/00003246-200301000-00042			5	Critical Care Medicine	General & Internal Medicine	640XU	WOS:000180714800042	12545027				2021-06-18	
J	Ciallella, JR; Ikonomovic, MD; Paljug, WR; Wilbur, YI; Dixon, CE; Kochanek, PM; Marion, DW; DeKosky, ST				Ciallella, JR; Ikonomovic, MD; Paljug, WR; Wilbur, YI; Dixon, CE; Kochanek, PM; Marion, DW; DeKosky, ST			Changes in expression of amyloid precursor protein and interleukin-1 beta after experimental traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; amyloid; cytokines; controlled cortical impact; head injury	HUMAN-ENDOTHELIAL-CELLS; ALZHEIMERS-DISEASE; MESSENGER-RNA; HEAD-INJURY; GROWTH-FACTOR; TRANSGENIC MICE; BETA; GENE; APP; IMMUNOREACTIVITY	There is increasing evidence linking neurodegenerative mechanisms in Alzheimer's disease (AD) and traumatic brain injury (TBI), including increased production of amyloid precursor protein (APP), and amyloid-beta (Abeta) peptide. In vitro data indicate that expression of APP may be regulated in part by the inflammatory cytokine IL-1beta To further investigate the mechanisms involved, we measured APP and IL-1beta protein levels and examined immunohistochemical localization of APP in brain tissue from rats subjected to controlled cortical impact (CCI) injury. Animals were examined at time intervals ranging from 3 h to 4 weeks after TBI. The 24-h time point revealed a dramatic increase in APP immunoreactivity, detected with both N- and C-terminal antibodies, in the hippocampus and cortex ipsilateral to injury. This finding was sustained up to 3 days post-injury. At these early time points, APP increase was particularly robust in:the White matter axonal tracts. By 14 days after injury, APP immunoreactivity was not significantly different from sham controls in,cortex but remained slightly elevated in hippocampus. Western blot data corroborated early increases in hippocampal and cortical APP in injured versus control animals. Despite profound APP changes, no Abeta deposits were observed at any time after injury. Hippocampal and cortical IL-1beta increases were even more robust, with IL-1beta levels peaking by 6 h post-injury and returning to baseline by 24-72 h. Our results demonstrate that both APP and IL-1beta,6 are rapidly elevated after injury. Because of the rapidity in the IL-1beta peak increase, it may serve a role in regulation of APP expression after TBI.	Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA	DeKosky, ST (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol, 3471 5th Ave,Ste 811, Pittsburgh, PA 15213 USA.	dekoskyst@msx.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07391, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P01NS030318, P20NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ALOISI F, 1992, J IMMUNOL, V149, P2358; ALTSTIEL LD, 1991, PROG NEURO-PSYCHOPH, V15, P481, DOI 10.1016/0278-5846(91)90023-T; BEESON JG, 1994, J COMP NEUROL, V342, P69, DOI 10.1002/cne.903420108; Benzing WC, 1999, NEUROBIOL AGING, V20, P581, DOI 10.1016/S0197-4580(99)00065-2; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CIALLELLA JR, 1994, J NEUROSCI RES, V37, P769, DOI 10.1002/jnr.490370611; Ciallella JR, 1999, THROMB HAEMOSTASIS, V81, P630; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HOFMAN FM, 1989, NEUROIMMUNE NETWORKS, P65; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; IKONOMOVIC MD, 1995, J COMP NEUROL, V359, P239, DOI 10.1002/cne.903590205; IVERFELDT K, 1993, P NATL ACAD SCI USA, V90, P4146, DOI 10.1073/pnas.90.9.4146; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; OHYAGI Y, 1993, MOL BRAIN RES, V18, P127, DOI 10.1016/0169-328X(93)90181-N; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; Pierce JES, 1996, J NEUROSCI, V16, P1083; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; WALLACE WC, 1995, J NEUROSCI, V15, P4896; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; YANG FM, 1993, BIOCHEM BIOPH RES CO, V191, P1014, DOI 10.1006/bbrc.1993.1318; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	66	72	74	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1555	1567		10.1089/089771502762300229			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700004	12542857				2021-06-18	
J	Bate, AJ; Mathias, JL; Crawford, JR				Bate, AJ; Mathias, JL; Crawford, JR			Performance on the test of everyday attention and standard tests of attention following severe traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD-INJURY; DEFICITS; RECOVERY; TASK; VALIDITY; SYSTEMS	The Test of Everyday Attention (TEA) was designed to address some of the limitations of established measures of attention. However, very few studies have examined its clinical utility. A group of 35 patients who had sustained a severe TBI were compared with 35 age- and education-matched controls on the TEA, Stroop, SDMT, WMS-R Digit Span, Ruff 2s and 7s Selective Attention Test, and PASAT. Of the TEA subtests, only the Map and Telephone Search subtests of the TEA produced significant differences between the two groups, suggesting a deficit in visual selective attention following TBI. Principal components analysis revealed a four-component/factor structure of attention, largely consistent with previous studies. A logistic regression found that the TEA Map Search and Modified Colour-Word subtest of the Stroop were best able to discriminate between the TBI and control groups. When the TBI group was divided into Early (<1 year post injury) and Late (>2 years post injury) groups, there was an additional deficit on the Lottery (sustained attention) subtest in the Early TBI group, indicating that there is some recovery in attentional function beyond 1 year post injury.	Community Rehabil Program, Julia Farr Serv, Adelaide, SA 5070, Australia; Univ Adelaide, Dept Psychol, Adelaide, SA 5001, Australia; Univ Aberdeen, Kings Coll, Dept Psychol, Aberdeen, Scotland	Bate, AJ (corresponding author), Community Rehabil Program, Julia Farr Serv, 8 Briar Rd, Adelaide, SA 5070, Australia.		Crawford, John R/A-4165-2008; Mathias, J L/L-6295-2013	Crawford, John R/0000-0003-3403-3428; Mathias, Jane/0000-0001-8957-8594			Barth JT, 1989, MILD HEAD INJURY; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P715, DOI 10.1016/S0887-6177(99)80187-5; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; Crawford JR, 1997, BRIT J CLIN PSYCHOL, V36, P609, DOI 10.1111/j.2044-8260.1997.tb01265.x; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; Golden C., 1978, STROOP COLOUR WORD T; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HARTMAN A, 1992, CLIN REHABIL, V6, P133; Ishihara S., 1972, TESTS COLOUR BLINDNE; KERNS KA, 1998, ECOLOGICAL VALIDITY, P147; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; LOWE DG, 1982, CAN J PSYCHOL, V36, P684, DOI 10.1037/h0080661; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Nelson HE, 1982, NATL ADULT READING T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; Rimel RW, 1990, REHABILITATION ADULT, P8; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson I. H., 1994, TEST EVERYDAY ATTENT; ROBERTSON IH, 1995, INS ASSBI C CAIRNS A; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; Sbordone R. J., 1998, ECOLOGICAL VALIDITY, P15; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schmitter-Edgecombe M, 1998, J INT NEUROPSYCH SOC, V4, P144, DOI 10.1017/S1355617798001441; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; SMITH A, 1973, SYBMOL DIGIT MODALIT; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1987, SURG NEUROL, V27, P419, DOI 10.1016/0090-3019(87)90247-3; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEINBERG J, 1972, J CLIN PSYCHOL, V28, P361, DOI 10.1002/1097-4679(197207)28:3+<361::AID-JCLP2270280315>3.0.CO;2-5; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	56	72	75	0	11	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2001	15	3					405	422		10.1076/clin.15.3.405.10279			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	482NA	WOS:000171581200014	11778779				2021-06-18	
J	Kondratyev, A; Sahibzada, N; Gale, K				Kondratyev, A; Sahibzada, N; Gale, K			Electroconvulsive shock exposure prevents neuronal apoptosis after kainic acid-evoked status epilepticus	MOLECULAR BRAIN RESEARCH			English	Article						epilepsy; seizure; electroconvulsive shock; neuroprotection; apoptosis; gene induction	FIBROBLAST GROWTH-FACTOR; TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; KAINATE-INDUCED APOPTOSIS; DEEP PREPIRIFORM CORTEX; INDUCED SEIZURES; MESSENGER-RNA; BCL-X; DNA FRAGMENTATION; UP-REGULATION	In the aftermath of prolonged continuous seizure activity (status epilepticus. SE), neuronal cell death occurs in the brain regions through which the seizure propagates. The vulnerability to adrenalectomy-induced apoptotic neuronal death was recently reported to be reduced by prior exposure to repeated daily noninjurious electroconvulsive shock (ECS). The present studies identified apoptosis and apoptosis-associated gene products in the neurodegenerative response to experimentally controlled periods (1 or 2 h) of SE in the rat, and determined whether exposure to ECS can interrupt these apoptotic responses mechanisms. Internucleosomal DNA fragmentation and the presence of apoptotic-like neurons (as assessed by in situ double labeling technique) was detected in hippocampus and rhinal cortex at 24 h after SE. Under these conditions, levels of both mRNA and protein encoded by the 'death promoting' bcl-X-s gene were increased in the same brain areas. Pretreatment of animals for 7 days with low intensity (minimal) ECS conferred resistance to SE-evoked neurodegeneration, as assessed histopathologically by silver staining. Associated with this neuroprotective action was a reduction in the incidence of apoptosis-like neuronal morphology and DNA fragmentation, and a prevention of the increase in Bcl-X-s protein and mRNA in hippocampus and rhinal cortex. These data suggest that pre-exposure to controlled, brief noninjurious seizures decreases vulnerability to programmed neuronal cell death, that this neuroprotective action occurs upstream from Bcl-X-s, and that increases in bcl-X-s gene expression may serve as a sensitive indicator of neurodegeneration following SE. (C) 2001 Elsevier Science B.V. All rights reserved.	Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Kondratyev, A (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, Res Bldg,Room W217,3970 Reservoir Rd NW, Washington, DC 20007 USA.	kondrata@georgetown.edu		Sahibzada, Niaz/0000-0002-4169-370X	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 08005] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20576, NS 36035] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020576, S11NS036035] Funding Source: NIH RePORTER		Bellows DS, 2000, J VIROL, V74, P5024, DOI 10.1128/JVI.74.11.5024-5031.2000; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; de Olmos JS, 1981, NEUROANATOMICAL TRAC, P117; Ferrer I, 1998, EXP BRAIN RES, V121, P167, DOI 10.1007/s002210050448; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; FOLLESA P, 1994, EXP NEUROL, V127, P37, DOI 10.1006/exnr.1994.1077; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Giardina SF, 1998, J NEUROCHEM, V71, P1325; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Guegan C, 1998, EXP NEUROL, V154, P371, DOI 10.1006/exnr.1998.6913; Katoh S, 1997, NEUROSCI LETT, V232, P71, DOI 10.1016/S0304-3940(97)00582-X; KELLY ME, 1994, BRAIN RES, V634, P245, DOI 10.1016/0006-8993(94)91927-5; Kitamura Y, 1998, NEUROSCI LETT, V255, P57, DOI 10.1016/S0304-3940(98)00714-9; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; LIU Z, 1993, BRAIN RES, V626, P335, DOI 10.1016/0006-8993(93)90598-H; MAGGIO R, 1993, EXP NEUROL, V119, P11, DOI 10.1006/exnr.1993.1002; Masco D, 1999, NEUROSCIENCE, V91, P1315, DOI 10.1016/S0306-4522(98)00636-8; MASCO D, 1995, P SOC NEUROSCI, V21; MONTPIED P, 1993, BIOCHEM BIOPH RES CO, V195, P623, DOI 10.1006/bbrc.1993.2091; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POLLARD H, 1994, NEUROREPORT, V5, P1053, DOI 10.1097/00001756-199405000-00009; Pretel S, 1997, ACTA HISTOCHEM, V99, P71, DOI 10.1016/S0065-1281(97)80010-4; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; Sankar R, 1998, J NEUROSCI, V18, P8382; SASAHIRA M, 1995, NEUROSCI LETT, V185, P95, DOI 10.1016/0304-3940(94)11233-9; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIMOSAKA S, 1994, NEUROSCIENCE, V61, P817, DOI 10.1016/0306-4522(94)90404-9; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang LX, 1998, MOL BRAIN RES, V55, P198, DOI 10.1016/S0169-328X(97)00316-1	45	72	72	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JUL 13	2001	91	1-2					1	13		10.1016/S0169-328X(01)00099-7			13	Neurosciences	Neurosciences & Neurology	455ZA	WOS:000170056600001	11457487				2021-06-18	
J	Weber, JT; Rzigalinski, BA; Ellis, EF				Weber, JT; Rzigalinski, BA; Ellis, EF			Traumatic injury of cortical neurons causes changes in intracellular calcium stores and capacitative calcium influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; OPERATED HTRP3 CHANNELS; STRETCH-INDUCED INJURY; CENTRAL-NERVOUS-SYSTEM; BRAIN INJURY; DELAYED DEPOLARIZATION; ENDOPLASMIC-RETICULUM; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; ARACHIDONIC-ACID	Using an in vitro traumatic injury model, we examined the effects of mechanical (stretch) injury on intracellular Ca2+ store-mediated signaling in cultured cortical neurons using fura-2. We previously found that elevation of [Ca2+](i) by the endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, was abolished 15 min post-injury. In the current studies, pre-injury inhibition of phospholipase C with neomycin sulfate maintained Ca2+-replete stores 15 min post-injury, suggesting that the initial injury-induced store depletion may be due to increased inositol trisphosphate production. Thapsigargin-stimulated elevation of [Ca2+], returned with time after injury and was potentiated at 3 h. Stimulation with thapsigargin in Ca2+-free media revealed that the size of the Ca2+ stores was normal at 3 h post-injury, However, Ca2+ influx triggered by depletion of intracellular Ca2+ stores (capacitative Ca2+ influx) was enhanced 3 h after injury. Enhancement was blocked by inhibitors of cytosolic phospholipase A, and cytochrome P450 epoxygenase. Since intracellular Ca2+ store-mediated signaling plays an important role in neuronal function, the observed changes may contribute to dysfunction produced by traumatic brain injury. Additionally, our results suggest that capacitative Ca2+ influx may be mediated by both conformational coupling and a diffusible messenger synthesized by the combined action of cytosolic PLA, and P450.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Box 980613, Richmond, VA 23298 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL57869] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL057869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		AbdulGhani MA, 1996, J NEUROPHYSIOL, V76, P2691; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BRORSON JR, 1991, J NEUROSCI, V11, P4024; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Budd SL, 1996, J NEUROCHEM, V67, P2282; Choi S, 1996, J NEUROSCI, V16, P36; DELAHUNTY TM, 1992, BRAIN RES, V594, P507; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Doutheil J, 1997, BRAIN RES, V775, P43, DOI 10.1016/S0006-8993(97)00899-8; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Fomina AF, 1999, J NEUROSCI, V19, P3711; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kiselyov K, 1998, NATURE, V396, P478; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kohn EC, 1996, CANCER RES, V56, P569; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Ma L, 1998, J NEUROPHYSIOL, V79, P1183; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sakaki Y, 1997, J NEUROBIOL, V32, P62, DOI 10.1002/(SICI)1097-4695(199701)32:1<62::AID-NEU6>3.0.CO;2-C; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; Scholz WK, 1998, J NEUROCHEM, V71, P580; SCHREIBER D, 1995, P 1995 INT RES C BIO; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; TRUMP BF, 1995, FASEB J, V9, P219; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; White RJ, 1996, J NEUROSCI, V16, P5688; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	70	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1800	1807		10.1074/jbc.M009209200			8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	394MN	WOS:000166528000022	11050103	Other Gold			2021-06-18	
J	Aibiki, M; Maekawa, S; Yokono, S				Aibiki, M; Maekawa, S; Yokono, S			Moderate hypothermia improves imbalances of thromboxane A(2) and prostaglandin I-2 production after traumatic brain injury in humans	CRITICAL CARE MEDICINE			English	Article						arterial-jugular bulb difference; moderate hypothermia; normothermia; prostaglandins; traumatic brain injury	CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; RAT; INTERLEUKIN-1; PROSTACYCLIN; EICOSANOIDS; ASTROCYTES; RELEASE; EDEMA	Objective: To examine the levels of thromboxane B-2 (TXB2) and 6-keto prostaglandin F-1 alpha (6-keto PGF(1 alpha)) production in arterial and internal jugular bulb sera in patients with traumatic brain injury (TBI). TBI is associated with arachidonate release and may be associated with an imbalance of vasoconstricting and vasodilating cyclooxygenase metabolites. Design: A prospective, randomized study. Setting: The intensive care unit of a medical university hospital. Interventions: Twenty-six ventilated TBI patents (Glasgow Coma Scale score on admission, less than or equal to8 points) were divided randomly into two groups: a hypothermic group (n = 15), in which the patients were cooled to 32 to 33 degreesC after being giving vecuronium, midazolam, and buprenorphine; and a normothermic group (n = 11), in which the patients' body temperature was controlled at 36 to 37 degreesC by surface cooling using the same treatment as the hypothermic group. Body temperature control including normothermia was started 3 to 4 hrs after injury. The duration of hypothermia usually lasted for 3 to 4 days, after which the patients were rewarmed at a Fate of approximately 1 degreesC per day. Measurements and Main Results: Blood sampling for TXB2 and 6-keto PGF(1 alpha) was started shortly after admission in both groups. Arterial TXB2 levels on admission in both groups were elevated remarkably, but not 6-keto PGF(1 alpha), thereby causing an imbalance of the prostanoids after injury. In the normothermic group, TXB2 decreased transiently, but this prostanoid increased again 3 days after the injury. In the hypothermic group, such prostanoid differences disappeared shortly after therapy, and the condition was sustained for 10 days. Hypothermia attenuated differences in TXB2 levels between arterial and Internal jugular bulb sera, which may reflect reduced cerebral prostanoid production. The Glasgow Outcome Scale score 6 months after the insult in the hypothermic group was significantly higher than that in the normothermic group (p = .04). Conclusion: The current results from a limited number of patients suggest that moderate hypothermia may reduce prostanoid production after TBI, thereby attenuating an imbalance of thromboxane A(2) and prostaglandin I-2. However, it must be clarified whether the changes in the prostanoid after moderate hypothermia are a secondary effect of other mediator changes or whether they simply represent an epiphenomenon that is mechanistically unrelated to damage in TBI.	Kagawa Med Univ Hosp, Intens Care Unit, Kita Ku, Kagawa 7610793, Japan; Ehime Univ, Sch Med, Dept Emergency Med, Matsuyama, Ehime, Japan	Aibiki, M (corresponding author), Kagawa Med Univ Hosp, Intens Care Unit, Kita Ku, 1750-1 Ikenode, Kagawa 7610793, Japan.						Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; ASAGA T, 1997, ICU CCU JAP J INTENS, V21, P967; BOULLIN DJ, 1979, BRIT J CLIN PHARMACO, V7, P139, DOI 10.1111/j.1365-2125.1979.tb00914.x; COOK JA, 1993, PATHOPHYSIOLOGY SHOC, P518; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DEVRIES HE, 1995, J NEUROIMMUNOL, V59, P1, DOI 10.1016/0165-5728(95)00009-Q; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRICE SC, 1987, STROKE, V18, P787, DOI 10.1161/01.STR.18.4.787; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KENT KC, 1993, CIRC RES, V72, P958, DOI 10.1161/01.RES.72.5.958; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Leffler CW, 1997, NEWS PHYSIOL SCI, V12, P72; MAEKAWA S, 1997, IMMUNE CONSEQUENCES, P135; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MURPHY S, 1985, NEUROSCI LETT, V61, P61, DOI 10.1016/0304-3940(85)90401-X; PICKARD JD, 1994, ACTA NEUROCHIR, V129, P152, DOI 10.1007/BF01406495; SAEEDABDELHALIM M, 1980, J NEUROCHEM, V34, P1331, DOI 10.1111/j.1471-4159.1980.tb09980.x; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stella N, 1997, J NEUROSCI, V17, P2939; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2	29	72	74	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2000	28	12					3902	3906		10.1097/00003246-200012000-00029			5	Critical Care Medicine	General & Internal Medicine	388NB	WOS:000166186200020	11153633				2021-06-18	
J	Rothstein, TL				Rothstein, TL			The role of evoked potentials in anoxic-ischemic coma and severe brain trauma	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						anoxic-ischemic coma; cardiac arrest; traumatic brain injury; somatosensory evoked potentials; cortical evoked potentials; central conduction time; brainstem auditory evoked potentials; persistent vegetative state; outcome prediction	SEVERE HEAD-INJURY; HOSPITAL CARDIAC-ARREST; PERSISTENT VEGETATIVE STATE; PREDICTIVE VALUE; CARDIOPULMONARY-RESUSCITATION; PROGNOSTIC VALUE; CEREBRAL TRAUMA; RECOVERY; DEATH; MANAGEMENT	The early recognition of comatose patients with a hopeless prognosis-regardless of how aggressively they rue managed-is of utmost importance. Median somatosensory evoked potentials supplement and enhance neurologic examination findings in anoxic-ischemic coma and severe brain trauma, and are useful as an early guide to outcome. The key finding is that bilateral absence of cortical evoked potentials, generated by thalamocortical tracts, reliably predicts unfavorable outcome in comatose patients after cardiac arrest, and correlates strongly with death or persistent vegetative state in severe brain trauma. The author studied 50 comatose patients with preserved brainstem function after cardiac arrest. All 23 patients with bilateral absence of cortical evoked potentials died without awakening. Neuropathologic study in seven patients disclosed widespread ischemic changes or frank cortical laminar necrosis. The remaining 27 patients with normal or delayed central conduction times had an uncertain prognosis because some died without awakening or entered a persistent vegetative state. The majority of patients with normal central conduction times had a good outcome, whereas a delay in central conduction times increased the likelihood of neurologic deficit or death. This report includes a systematic review of the literature concerning adults in anoxic-ischemic coma and severe brain trauma, in which somatosensory evoked potentials were used as an early guide to predict clinical outcome. Greater use of somatosensory evoked potentials in anoxic-ischemic coma and severe brain trauma would identify those patients unlikely to recover and would avoid costly medical care that is to no avail.	NW Neurosci Inst, Seattle, WA 98133 USA	Rothstein, TL (corresponding author), NW Neurosci Inst, 10330 Meridan Ave N,Suite 300, Seattle, WA 98133 USA.						AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BARELLI A, 1991, CRIT CARE MED, V19, P1374, DOI 10.1097/00003246-199111000-00013; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; Berek K, 1997, EUR NEUROL, V37, P135, DOI 10.1159/000117426; Bernat JL, 1998, HASTINGS CENT REP, V28, P14, DOI 10.2307/3527567; BINIEK R, 1989, INTENS CARE MED, V15, P212, DOI 10.1007/BF01058577; BRENDLER SJ, 1970, BRAIN, V93, P381, DOI 10.1093/brain/93.2.381; BRIERLEY JB, 1971, LANCET, V2, P560; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P43; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Cheliou-Heraut F., 1992, Neurophysiologie Clinique, V22, P269, DOI 10.1016/S0987-7053(05)80259-X; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COBB LA, 1976, MED CLIN N AM, V60, P283, DOI 10.1016/S0025-7125(16)31909-5; DANZE F, 1989, Neurosurgical Review, V12, P477, DOI 10.1007/BF01790694; DELECLUSE F, 1987, ANN NEUROL, V22, P142; DEMEIRLEIR LJ, 1987, PEDIATR NEUROL, V3, P78, DOI 10.1016/0887-8994(87)90031-2; DEWEERD AW, 1985, ACTA NEUROL SCAND, V72, P489; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; Edgren E, 1988, Acta Anaesthesiol Belg, V39, P121; EDGREN E, 1989, RESUSCITATION, V17, pS131, DOI 10.1016/0300-9572(89)90097-X; FACCO E, 1990, ELECTROEN CLIN NEURO, P330; FACCO E, 1994, MINERVA ANESTESIOL, V60, P595; GANJI S, 1988, CLIN ELECTROENCEPHAL, V19, P55, DOI 10.1177/155005948801900206; GENARELLI TA, 1982, HEAD INJURY BASIC CL, P129; GOLBY A, 1995, NEUROLOGY, V45, P1629, DOI 10.1212/WNL.45.8.1629; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit J M, 1992, Eur J Med, V1, P233; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HEYMANS C, 1950, PHYSIOL REV, V30, P375; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jennett B, 1981, MANAGEMENT HEAD INJU; JORGENSEN EO, 1978, RESUSCITATION, V6, P217, DOI 10.1016/0300-9572(78)90001-1; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; KANO T, 1992, RESUSCITATION, V23, P235, DOI 10.1016/0300-9572(92)90007-Y; KAPLAN PW, 2000, IN PRESS J CLIN NEUR; Kraus J F, 1978, Adv Neurol, V19, P261; Krieger DW, 1998, LANCET, V352, P1796, DOI 10.1016/S0140-6736(98)00081-6; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; Longstreth Jr WT, 1994, NEUROLOGY GEN MED, P166; LONGSTRETH WT, 1983, ANN INTERN MED, V98, P588, DOI 10.7326/0003-4819-98-5-588; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; LOWN B, 1979, AM J CARDIOL, V43, P313, DOI 10.1016/S0002-9149(79)80021-1; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; Mahapatra A K, 1990, J Indian Med Assoc, V88, P217; Marcus EM, 1984, EVOKED POTENTIAL, VII, P609; MULLIE A, 1989, RESUSCITATION, V17, pS23, DOI 10.1016/0300-9572(89)90088-9; MULLIE A, 1988, LANCET, V1, P137; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; NUWER MR, 1994, ELECTROENCEPHALOGR C, V9, P6; PLUM F, 1982, DIAGNOSIS STUPOR COM, P846; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Ragazzoni A, 1999, CLIN NEUROPHYSIOL, V110, pS245; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; Sherman AL, 2000, NEUROLOGY, V54, P889, DOI 10.1212/WNL.54.4.889; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; SNYDER BD, 1981, NEUROLOGY, V31, P1092, DOI 10.1212/WNL.31.9.1092; *SOC CRIT CAR MED, 1988, CRIT CARE MED, V16, P807; SOHMER H, 1986, ELECTROEN CLIN NEURO, V64, P334, DOI 10.1016/0013-4694(86)90157-4; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; YING Z, 1992, J NEUROL NEUROSUR PS, V55, P470, DOI 10.1136/jnnp.55.6.470; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	82	72	74	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0736-0258	1537-1603		J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	SEP	2000	17	5					486	497		10.1097/00004691-200009000-00007			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	371MQ	WOS:000165183100007	11085552				2021-06-18	
J	Dempsey, RJ; Baskaya, MK; Dogan, A				Dempsey, RJ; Baskaya, MK; Dogan, A			Attenuation of brain edema, blood-brain barrier breakdown, and injury volume by ifenprodil, a polyamine-site N-methyl-D-aspartate receptor antagonist, after experimental traumatic brain injury in rats	NEUROSURGERY			English	Article						blood-brain barrier; brain edema; ifenprodil; NMDA receptors; polyamines; traumatic brain injury	EXCITATORY AMINO-ACIDS; FOCAL CEREBRAL-ISCHEMIA; NMDA RECEPTOR; NITRIC-OXIDE; ORNITHINE DECARBOXYLASE; GLUTAMATE NEUROTOXICITY; TRANSIENT ISCHEMIA; GLUCOSE USE; RELEASE; NEURONS	OBJECTIVE: Traumatic brain injury (TBI) has been shown to induce a significant change in polyamine metabolism. Polyamines and polyamine-dependent calcium influx play an important role in mediating the effects of excitotoxic amino acids at the N-methyl-D-aspartate (NMDA) receptor site. We studied the effects of ifenprodil, known as a noncompetitive inhibitor of polyamine sites at the NMDA receptor, on brain edema formation, blood-brain barrier breakdown, and volume of injury after TBI. METHODS: Experimental TBI was induced in Sprague-Dawley rats by a controlled cortical impact device, functioning at a velocity of 3 m/s to produce a 2-mm deformation. Ifenprodil or saline (10 mg/kg) was injected intraperitoneally immediately after the cortical impact injury and then every 90 minutes until 6 hours after TBI. Blood-brain barrier breakdown was evaluated quantitatively 6 hours after injury by fluorometric assay of Evans blue extravasation. Brain water content, an indicator of brain edema, was measured with the wet-dry method 24 hours after TBI. Injury volume was quantitated from the brain slices stained with 2% cresyl violet solution 7 days after TBI. RESULTS: Blood-brain barrier breakdown was significantly lower in the traumatic cortex of the ifenprodil-treated group than in the saline-treated group (84.4 +/- 26.8 mu g/g versus 161.8 +/- 27 mu g/g, respectively, P < 0.05). Brain edema was significantly reduced in the cortex of the ifenprodil-treated group relative to that in the saline-treated group (80.9 +/- 0.5% versus 82.4 +/- 0.6% respectively, P < 0.05). Ifenprodil treatment reduced injury volume significantly (14.9 +/- 8.1 mm(3) versus 24.4 +/- 6.7 mm(3), P < 0.05). CONCLUSION: The polyamine-site NMDA receptor antagonist ifenprodil affords significant neuroprotection in a controlled cortical impact brain injury model and may hold promise for the discovery and treatment of the mechanism of delayed neurological deficits after TBI.	Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Med Ctr, Shreveport, LA 71130 USA; Univ Wisconsin, Dept Neurol Surg, Madison, WI USA	Baskaya, MK (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Med Ctr, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.		Dogan, Aclan/AAF-8305-2019				ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Badolo L, 1998, EUR J PHARMACOL, V342, pR1, DOI 10.1016/S0014-2999(97)01601-4; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1997, NEUROSURGERY, V40, P364; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CALDWELL M, 1994, EUR J PHARMACOL, V260, P191, DOI 10.1016/0014-2999(94)90337-9; CARRON C, 1971, ARZNEI-FORSCHUNG, V21, P1992; CARTER C, 1989, EUR J PHARMACOL, V164, P611, DOI 10.1016/0014-2999(89)90275-6; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; CHOI DW, 1987, J NEUROSCI, V7, P369; CUDENNEC A, 1994, BRAIN RES, V664, P41, DOI 10.1016/0006-8993(94)91951-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; DUVAL D, 1992, NEUROSCI LETT, V137, P193, DOI 10.1016/0304-3940(92)90402-S; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE G, 1986, NEUROSCIENCE, V18, P437, DOI 10.1016/0306-4522(86)90164-8; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KERWIN JF, 1994, MED RES REV, V14, P23, DOI 10.1002/med.2610140103; KURUMAJI A, 1989, BRAIN RES, V496, P268, DOI 10.1016/0006-8993(89)91074-3; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Morley P, 1998, J CEREBR BLOOD F MET, V18, P396, DOI 10.1097/00004647-199804000-00008; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; SCHOEMAKER H, 1990, EUR J PHARMACOL, V176, P249, DOI 10.1016/0014-2999(90)90539-I; SHALABY IA, 1992, J PHARMACOL EXP THER, V260, P925; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SPROSEN TS, 1990, EUR J PHARMACOL, V179, P477, DOI 10.1016/0014-2999(90)90193-A; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L; YOUNG AR, 1981, J CEREBR BLOOD F MET, V1, P117, DOI 10.1038/jcbfm.1981.12	45	72	81	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	2000	47	2					399	404		10.1097/00006123-200008000-00024			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	339WZ	WOS:000088502000066	10942013				2021-06-18	
J	Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, I; Gurka, J				Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, I; Gurka, J			Coping style and post-traumatic stress disorder following severe traumatic brain injury	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; SEVERE HEAD-INJURY; PSEUDOMEMORIES; PTSD	There is increasing evidence that a proportion of severe traumatically brain injured (TBI) patients do suffer post-traumatic stress disorder (PTSD). The aim of this study was to investigate the predictors of PTSD following severe TBI in a sample of 96 patients who sustained a severe TBI, of whom 27% satisfied diagnostic criteria for PTSD. The Post-traumatic Stress Disorder interview, the Coping Style Questionnaire, and the Functional Assessment Measure was administered to these patients 6 months after hospital discharge. Avoidant coping style, behavioural coping style, and a history of prior unemployment were the significant predictors of PTSD severity. These findings indicate that reduction of PTSD and management of severe TBI may be facilitated by teaching patients more adaptive coping strategies.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013; Bryant, Richard/AAA-6479-2019	Baguley, Ian J/0000-0001-5650-3705; Bryant, Richard/0000-0002-9607-819X			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, IN PRESS AM J PSYCHI; DAVIDSON JRT, 1993, POSTTRAUMATIC STRESS, P147; DAVIES RJ, 1991, CLIN EXP ALLERGY, V21, P1, DOI 10.1111/j.1365-2222.1991.tb01750.x; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Jennett B, 1981, MANAGEMENT HEAD INJU; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Price K. P., 1994, DEF LAW J, V43, P113; Robins LN, 1985, DIAGNOSTIC INTERVIEW; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302; VANDERKOLK BA, 1906, TRAUMATIC STRESS EFF, P214; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	27	72	72	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					175	180		10.1080/026990500120826			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000006	10695572				2021-06-18	
J	Herskovits, EH; Megalooikonomou, V; Davatzikos, C; Chen, A; Bryan, RN; Gerring, JP				Herskovits, EH; Megalooikonomou, V; Davatzikos, C; Chen, A; Bryan, RN; Gerring, JP			Is the spatial distribution of brain lesions associated with closed-head injury predictive of subsequent development of attention-deficit/hyperactivity disorder? Analysis with brain-image database?	RADIOLOGY			English	Article						attention-deficit/hyperactivity disorder; brain, injuries; brain, MR; children, central nervous system; images, analysis; images, display	BEHAVIOR; SCALE; ADHD	PURPOSE: To determine whether there is an association between the spatial distribution of lesions detected at magnetic resonance (MR) imaging of the brain in children after closed-head injury and the development of secondary attention-deficit/hyperactivity disorder (ADHD). MATERIALS AND METHODS: Data obtained from 76 children without prior history of ADHD were analyzed. MR images were obtained 3 months after closed-head injury. After manual delineation of lesions, images were registered to the Talairach coordinate system. For each subject, registered images and secondary ADHD status were integrated into a brain-image database, which contains depiction (visualization) and statistical analysis software. Using this database, we assessed visually the spatial distributions of lesions and performed statistical analysis of image and clinical variables. RESULTS: Of the 76 children, 15 developed secondary ADHD. Depiction of the data suggested that children who developed secondary ADHD had more lesions in the right putamen than children who did not develop secondary ADHD; this impression was confirmed statistically. After Bonferroni correction, we could not demonstrate significant differences between secondary ADHD status and lesion burdens for the right caudate nucleus or the right globus pallidus. CONCLUSION: Closed-head injury-induced lesions in the right putamen in children are associated with subsequent development of secondary ADHD. Depiction software is useful in guiding statistical analysis of image data.	Johns Hopkins Med Inst, Div Neuroradiol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Sch Publ Hlth, Dept Biostat, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Bayview Med Ctr, Dept Psychiat, Baltimore, MD 21287 USA; NIH, Dept Diagnost Radiol, Bethesda, MD 20892 USA	Herskovits, EH (corresponding author), Johns Hopkins Med Inst, Div Neuroradiol, 600 N Wolfe St, Baltimore, MD 21287 USA.		Bryan, R. Nick/P-1661-2014	Davatzikos, Christos/0000-0002-1025-8561	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013743] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG13743-03] Funding Source: Medline		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Andres AM, 1997, BIOMETRICAL J, V39, P935; Brodmann K., 1909, VERGLEICHENDE LOKALI; Castellanos FX, 1997, CHILD ADOL PSYCH CL, V6, P383, DOI 10.1016/S1056-4993(18)30310-9; CHAMBERLIN DD, 1976, IBM J RES DEV, V20, P560, DOI 10.1147/rd.206.0560; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Davatzikos C, 1997, COMPUT VIS IMAGE UND, V66, P207, DOI 10.1006/cviu.1997.0605; Fisher L, 1993, BIOSTATISTICS METHOD; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Letovsky SI, 1998, AM J NEURORADIOL, V19, P1869; Nowinski WL, 1997, ELECT CLIN BRAIN ATL; RICHTERS JE, 1995, J AM ACAD CHILD PSY, V34, P987, DOI 10.1097/00004583-199508000-00008; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; WILSON J T L, 1990, Brain Injury, V4, P349	19	72	73	0	3	RADIOLOGICAL SOC NORTH AMER	EASTON	20TH AND NORTHAMPTON STS, EASTON, PA 18042 USA	0033-8419			RADIOLOGY	Radiology	NOV	1999	213	2					389	394		10.1148/radiology.213.2.r99nv45389			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	249AE	WOS:000083308900013	10551217				2021-06-18	
J	Langan, EM; Miller, RS; Casey, WJ; Carsten, CG; Graham, RM; Taylor, SM				Langan, EM; Miller, RS; Casey, WJ; Carsten, CG; Graham, RM; Taylor, SM			Prophylactic inferior vena cava filters in trauma patients at high risk: Follow-up examination and risk/benefit assessment	JOURNAL OF VASCULAR SURGERY			English	Article; Proceedings Paper	23rd Annual Meeting of the Southern-Association-for-Vascular-Surgery	JAN 27-30, 1999	NAPLES, FLORIDA	So Assoc Vasc Surg			PULMONARY-EMBOLISM; VENOUS THROMBOEMBOLISM; PLACEMENT; PREVENTION	Purpose: The efficacy of prophylactic inferior vena cava filters in selected trauma patients at high risk has come into question in relation to risk/benefit assessment. To evaluate the usefulness of prophylactic inferior vena cava filters, we reviewed our experience and overall complication rate. Methods: From February 1991 to April 1998, the trauma registry identified 7333 admissions. One hundred eighty-seven prophylactic inferior vena cava filters were inserted. After the exclusion of 27 trauma-related deaths (none caused by thromboembolism), 160 patients were eligible for the study. The eligible patients were contacted and asked to complete a survey and return for a follow-up examination to include physical examination, Doppler scan study, vena cava duplex scanning, and fluoroscopic examination. The patients' hospital charts were reviewed in detail. The indications for prophylactic inferior vena cava filter insertion included prolonged immobilization with multiple injuries, closed head injury, pelvic fracture, spine fracture, multiple long bone fracture, and attending discretion. Results: Of the 160 eligible patients, 127 were men, the mean age was 40.3 years, and the mean injury severity score was 26.1. The mean day of insertion was hospital day 6. Seventy-five patients (47%) returned for evaluation, with a mean follow-up period of 19.4 months after implantation (range, 7 to 60 months). On survey, patients had leg swelling (n = 27), lower extremity numbness (n = 14), shortness of breath (n = 9), chest pain (n = 7), and skin changes (n = 4). All the survey symptoms appeared to be attributable to patient injuries and not related to prophylactic inferior vena cava filter Physical examination results revealed edema (n = 12) and skin changes (n = 2). Tell Doppler scan studies had results that were suggestive of venous insufficiency, nine of which had histories of deep vein thrombosis. With duplex scanning, 93% (70 of 75) of the vena cavas were visualized, and all were patent. Only 52% (39 of 75) of the prophylactic inferior vena cava filters were visualized with duplex scanning. ALL the prophylactic inferior vena cava filters were visualized with fluoroscopy, with no evidence of filter migration. Of the total 187 patients, 24 (12.8%) had deep vein thrombosis develop after prophylactic inferior vena cava filter insertion, including 10 of 75 (13.3%) in the follow-up, group, and one patient had a nonfatal pulmonary embolism despite filter placement. Filter insertion complications occurred in 1.6% (three of 187) of patients and included one groin hematoma, one arteriovenous fistula, and one misplacement in the common iliac vein. Conclusion: This study's results show that prophylactic inferior vena cava filters can be placed safely with low morbidity and no attributable long-term disabilities. In this patient population with a high risk of pulmonary embolism, prophylactic inferior vena cava filters offered a 99.5% protection rate, with only one of 187 patients having a nonfatal pulmonary embolism.	Greenville Hosp Syst, Dept Surg Educ, Greenville, SC 29605 USA; Greenville Hosp Syst, Dept Res, Greenville, SC 29605 USA	Langan, EM (corresponding author), Greenville Hosp Syst, Dept Surg Educ, 701 Grove Rd, Greenville, SC 29605 USA.						BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Brasel KJ, 1997, J TRAUMA, V42, P456, DOI 10.1097/00005373-199703000-00013; COON WW, 1976, SURG GYNECOL OBSTET, V143, P385; ENDERSON BL, 1991, J TRAUMA, V31, P1230; Erstad BL, 1998, PHARMACOTHERAPY, V18, P1011; FITTS WT, 1964, SURGERY, V56, P663; Gosin JS, 1997, ANN VASC SURG, V11, P100, DOI 10.1007/s100169900017; GREENFIELD LJ, 1995, J AM COLL SURGEONS, V180, P725; GREENFIELD LJ, 1998, PERSPECTIVES VASCULA, P41; KHANSARINIA S, 1995, J VASC SURG, V22, P231, DOI 10.1016/S0741-5214(95)70135-4; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; LEACH TA, 1994, AM SURGEON, V60, P292; McCartney JS, 1935, SURG GYNECOL OBSTET, V61, P369; MONTREY JS, 1985, J TRAUMA, V25, P534, DOI 10.1097/00005373-198506000-00011; Patton JH, 1996, J TRAUMA, V41, P231, DOI 10.1097/00005373-199608000-00006; Quirke TE, 1997, J TRAUMA, V43, P333, DOI 10.1097/00005373-199708000-00020; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; Rosenthal D, 1994, Cardiovasc Surg, V2, P52; RUIZ AJ, 1991, AM J SURG, V162, P159, DOI 10.1016/0002-9610(91)90180-L; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SUE LP, 1995, J TRAUMA, V39, P693, DOI 10.1097/00005373-199510000-00014; Webb L X, 1992, J Orthop Trauma, V6, P139, DOI 10.1097/00005131-199206000-00002; WINCHELL RJ, 1994, J TRAUMA, V37, P600, DOI 10.1097/00005373-199410000-00013	24	72	72	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	SEP	1999	30	3					484	488		10.1016/S0741-5214(99)70075-3			5	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	234YP	WOS:000082512200020	10477641				2021-06-18	
J	Trudel, TM; Tryon, WW; Purdum, CM				Trudel, TM; Tryon, WW; Purdum, CM			Awareness of disability and long-term outcome after traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							BLUNT HEAD-INJURY; FOLLOW-UP; SOCIAL-ADJUSTMENT; RELATIVES VIEW; REHABILITATION; PERSONALITY; IMPAIRMENT; DEFICITS; RECOVERY; ADULTS	The degree of long-term (7.41 years postinjury) impairment of disability awareness was quantified in 63 adults with closed-head injuries as the difference between self-ratings and staff ratings on the Scales of Independent Behavior. Impaired awareness was significantly associated with lower vocational and residential status, maladaptive behavior, greater distractibility, and increased perseveration. Impaired awareness is directly proportional to duration of posttraumatic amnesia and general memory. Impaired awareness of disability appears to be a consequence of a general cognitive impairment rather than a specific deficit.	Lakeview NeuroRehabil Ctr, Effingham Falls, NH 03814 USA	Trudel, TM (corresponding author), Lakeview NeuroRehabil Ctr, 101 Highwatch Rd, Effingham Falls, NH 03814 USA.						ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bond M R, 1979, Acta Neurochir Suppl (Wien), V28, P124; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BRUININKS R, 1988, AM J MENT RETARD, V93, P265; Bruininks R.H., 1984, SCALES INDEPENDENT B; Bruininks RH, 1985, DEV STANDARDIZATION; CAVALLO MM, 1993, BRAIN INJURY, V6, P327; Chittum WR, 1996, BRAIN INJURY, V10, P763; DREWE E A, 1974, Cortex, V10, P159; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Farmer J E, 1988, Brain Inj, V2, P323, DOI 10.3109/02699058809150903; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FRALISH KB, 1992, INNOVATIONS HEAD INJ, P100; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman K., 1991, AWARENESS DEFICIT BR, P53; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; KREUZER JS, 1990, VOCATIONAL REHABILIT, P35; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK M, 1995, NEUROLOGICAL ASSESSM; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MIDDLETON HA, 1990, AM J MENT RETARD, V94, P669; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PARKER K, 1983, J CONSULT CLIN PSYCH, V51, P302, DOI 10.1037/0022-006X.51.2.302; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1987, NEUROPSYCHOL REHABIL, P355; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sattler JM, 1988, ASSESSMENT CHILDREN; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wechsler D., 1987, MANUAL WECHSLER MEMO; Wechsler D., 1981, WAIS R MANUAL WECHSL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN P, 1990, VOCATIONAL REHABILIT; Willer B, 1994, BRAIN INJURY REHABIL, P355	63	72	72	0	7	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	WIN	1998	43	4					267	281		10.1037/0090-5550.43.4.267			15	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	158FL	WOS:000078105300001					2021-06-18	
J	Zhang, C; Raghupathi, R; Saatman, KE; Smith, DH; Stutzmann, JM; Wahl, F; McIntosh, TK				Zhang, C; Raghupathi, R; Saatman, KE; Smith, DH; Stutzmann, JM; Wahl, F; McIntosh, TK			Riluzole attenuates cortical lesion size, but not hippocampal neuronal loss, following traumatic brain injury in the rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						excitotoxicity; fluid-percussion; glutamate antagonist; lesion volume; neuroprotection	FOCAL CEREBRAL-ISCHEMIA; AMINO-ACID NEUROTRANSMISSION; SODIUM-CHANNEL BLOCKER; GLUTAMATE RELEASE; 2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE; POSSIBLE ANTAGONIST; DAMAGE; HYPOTHERMIA; EXCITOTOXICITY; NEUROTOXICITY	The neuroprotective effects of Riluzole, a compound with several mechanisms of action including the inhibition of sodium channel activity and glutamate release, were evaluated in a rat model of parasagittal fluid-percussion (FP) brain injury. Male Sprague-Dawley rats (350-400 g, n = 17) were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and subjected to parasagittal FP brain injury of moderate severity (2.3-2.5 atm), Fifteen min following injury, animals randomly received an i,v, bolus of either Riluzole (8 mg/kg, n = 8) or vehicle (n = 9), followed by subcutaneous injections (identical dose) at 6 hr and 24 hr, Two weeks after injury and drug treatment, animals were sacrificed and a series of brain sections, stained with Hematoxylin and Eosin (H&E) or cresyl violet, were evaluated for quantitative cortical lesion volume and cell counts of hippocampal CA3 neurons, respectively, using a computerized image analysis system. Administration of Riluzole significantly reduced FP-induced tissue loss in the temporal/occipital cortices ipsilateral to the site of impact by 46%, compared to vehicle-treated, brain-injured animals (P = 0.01), In contrast, the selective neuronal loss observed in the CA3 region of the ipsilateral hippocampus was unaffected by Riluzole treatment. The present study demonstrates that Riluzole can attenuate cortical lesion size following brain trauma. These neuroprotective effects may be related to the synergy of the different mechanisms of action of Riluzole. (C) 1998 Wiley-Liss, Inc.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Rhone Poulenc Rorer, Pharmaceut Discovery, Neurodegenerat Dis Dept, Vitry Sur Seine, France	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENAZZOUZ A, 1995, EUR J PHARMACOL, V284, P299, DOI 10.1016/0014-2999(95)00362-O; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BOIREAU A, 1994, NEUROREPORT, V5, P2157, DOI 10.1097/00001756-199410270-00042; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; FADEN AI, 1989, SCIENCE, V244, P789; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HOVDA DA, 1992, J NEUROTRAUMA, V9, P547; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; Mary V, 1995, NEUROSCI LETT, V201, P92, DOI 10.1016/0304-3940(95)12137-S; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; Miller RG, 1996, NEUROLOGY, V47, pS86, DOI 10.1212/WNL.47.4_Suppl_2.86S; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PELUFFO H, 1997, NEUROSCI LETT, V228, P1; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; STUTZMANN JM, 1991, EUR J PHARMACOL, V193, P223, DOI 10.1016/0014-2999(91)90040-W; STUTZMANN JM, 1995, NEURODEGENERATIVE DI, P205; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	65	72	74	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAY 1	1998	52	3					342	349		10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8			8	Neurosciences	Neurosciences & Neurology	ZM121	WOS:000073506800010	9590442				2021-06-18	
J	Gourin, CG; Shackford, SR				Gourin, CG; Shackford, SR			Production of tumor necrosis factor-alpha and interleukin-1 beta by human cerebral microvascular endothelium after percussive trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SECONDARY BRAIN INJURY; PLATELET-ACTIVATING-FACTOR; SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; NEUTROPHIL FUNCTION; ICAM-1 EXPRESSION; RAT-BRAIN; CELLS; ADHESION; LIPOPOLYSACCHARIDE	Intracerebral cytokine production is thought to be partially responsible for the brain edema and increased leukocyte adhesion seen after head injury by both a direct effect on vascular permeability and by causing leukocyte activation, Cerebrospinal fluid concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and IL-6 are elevated after traumatic brain injury, The cerebral endothelium has not been investigated as a de novo source of cytokines after injury, We have found that conditioned media from cultured human cerebral microvascular endothelium (HCME) subjected to percussion trauma increases neutrophil chemotaxis, To test the hypothesis that percussive trauma increases the production of TNF-alpha and IL-1 beta by HCME, serial supernatant samples from passage 2 HCME were collected for 24 hours and analyzed for TNF-alpha and IL-beta concentration by enzyme-linked immunosorbent assay after trauma, HCME subjected to percussion injury secreted significantly more TNF-alpha at 8 and 24 hours end significantly more IL-1 beta at 4 and 24 hours compared with uninjured controls (p < 0.05, Student's t test), These data suggest that HCME production of inflammatory cytokines occurs after traumatic brain injury independent of systemic influences. In situ cytokine production by HCME after percussion trauma may mediate the increased cerebral leukocyte accumulation and cerebrovascular dysfunction observed after focal brain injury.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05401					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20-NS30324-03] Funding Source: Medline		BIFFL WL, 1994, ARCH SURG-CHICAGO, V129, P1131; BOTHA AJ, 1995, J TRAUMA, V39, P411; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHUNG IY, 1990, J IMMUNOL, V144, P2999; CINAT M, 1995, J TRAUMA, V39, P112, DOI 10.1097/00005373-199507000-00015; CLARK WM, 1994, STROKE, V25, P115; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FAN L, 1993, SOC NEUR ABSTR, V76, P9; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P161; FRIESE RS, 1994, SHOCK, V1, P388, DOI 10.1097/00024382-199405000-00013; Gourin CG, 1996, J TRAUMA, V41, P129, DOI 10.1097/00005373-199607000-00021; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735; HESS DC, 1994, NEUROSCI LETT, V168, P201, DOI 10.1016/0304-3940(94)90450-2; HIRAFUJI M, 1991, BRIT J PHARMACOL, V103, P1333, DOI 10.1111/j.1476-5381.1991.tb09789.x; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; HUGHES CCW, 1988, IMMUNOLOGY, V64, P677; ISHII E, 1991, LEUKEMIA RES, V15, P143, DOI 10.1016/0145-2126(91)90095-B; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; PRICE TH, 1987, J IMMUNOL, V139, P4174; READ RA, 1994, J TRAUMA, V37, P13, DOI 10.1097/00005373-199407000-00004; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schmoker Joseph D., 1993, Surgical Forum, V44, P568; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHARIF SF, 1993, NEUROL RES, V15, P109; SHEPARD SR, 1990, ACT NEUR S, V51, P58; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIMPSON R, 1993, ANN SURG, V218, P444, DOI 10.1097/00000658-199310000-00005; SOMERSALO K, 1990, ANAL BIOCHEM, V185, P238, DOI 10.1016/0003-2697(90)90286-I; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WATANABE M, 1991, BRIT J PHARMACOL, V102, P239, DOI 10.1111/j.1476-5381.1991.tb12160.x; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOODROOFE MN, 1995, NEUROLOGY, V45, pS6, DOI 10.1212/WNL.45.6_Suppl_6.S6; YEE J, 1994, ARCH SURG-CHICAGO, V129, P1249; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	47	72	82	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1997	42	6					1101	1107		10.1097/00005373-199706000-00020			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	XH700	WOS:A1997XH70000027	9210549				2021-06-18	
J	Kelly, DF; Lee, SM; Pinanong, PA; Hovda, DA				Kelly, DF; Lee, SM; Pinanong, PA; Hovda, DA			Paradoxical effects of acute ethanolism in experimental brain injury	JOURNAL OF NEUROSURGERY			English	Article						ethanol; excitotoxicity; traumatic brain injury; N-methyl-D-aspartate receptor; rat	CORTICAL IMPACT MODEL; BLOOD-ALCOHOL LEVELS; HEAD-INJURY; RAT; TRAUMA; CALCIUM; EXCITOTOXICITY; INTOXICATION; MICRODIALYSIS; ABNORMALITIES	Acute ethanol intoxication is a frequent complicating factor in human head injury, yet its impact on neurological outcome remains poorly defined. This study was undertaken to assess the effect of varying levels of preinjury ethanol on early postinjury mortality, recovery of motor function, and degree of neural degeneration after cortical contusion injury in the rat. Adult rats were pretrained on a beam-walking task, then randomized to one of five groups: low-dose ethanol and injury (1 g/kg, 16 animals); moderate-dose ethanol and injury (2.5 g/kg, 11 animals); high-dose ethanol and injury (3 g/kg, 17 animals); no ethanol and injury (nine animals); or ethanol and sham injury (seven animals). Forty minutes after intraperitoneal injection of ethanol or saline, the rats received a pneumatic piston-induced contusion injury of the left primary motor cortex. Their beam-walking ability was assessed daily for the next 7 days. At 4 weeks postinjury, the brains were sectioned and the dimensions of the cortical lesions were determined. Preinjury ethanol administration was associated with an acute postinjury mortality rate of 29.5% (p <0.05); the highest mortality rate (47.1%) occurred in the high-dose ethanol group, whereas no deaths occurred in the animals in the no ethanol or sham-injured groups (p <0.01). However, injured animals receiving low- and moderate-dose ethanol had significantly less severe beam-walking impairment initially, and a more rapid return to normal beam-walking ability, compared to the no and high-dose ethanol groups (p <0.05). Additionally, the mean lesion volumes were significantly smaller in the low- and moderate-dose ethanol treatment groups compared to the no and high-dose ethanol groups (23.2+/-8 mm(3) and 29+/-6.7 mm(3) vs. 52+/-8.8 mm(3) and 53.7+/-10.9 mm(3), respectively, p <0.01). In this cortical contusion model, the presence of ethanol before injury appears to exert a potent neuroprotective effect when administered in low or moderate doses. This action is postulated to result from ethanol-induced inhibition of N-methyl-D-aspartate receptor-mediated excitotoxicity. The loss of neuroprotection and increased mortality rates observed with high-dose ethanol may be related to ethanol-induced hemodynamic and respiratory depression.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MOL & MED PHARMACOL,LOS ANGELES,CA 90095	Kelly, DF (corresponding author), UNIV CALIF LOS ANGELES,DIV NEUROSURG,BRAIN INJURY RES CTR,INST BRAIN RES,ROOM 18-218A NPI,LOS ANGELES,CA 90095, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27544, NS 30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER		ABEL EL, 1979, PHYSIOL PSYCHOL, V7, P391; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BENGMARK S, 1980, THROMB HAEMOSTASIS, V43, P203; BLOOM F, 1982, BRIT J PHARMACOL, V75, P251, DOI 10.1111/j.1476-5381.1982.tb08780.x; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; DECRESCITO V, 1994, SURG FORUM, V25, P438; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELMER O, 1984, HAEMOSTASIS, V14, P223; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FERRARO TN, 1990, ALCOHOL, V7, P129, DOI 10.1016/0741-8329(90)90073-L; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; HOFSTEDE DJ, 1995, J NEUROTRAUM, V12, P974; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; INGLIS FM, 1990, ACT NEUR S, V51, P277; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KELLY DF, 1995, CRIT CARE MED, V23, pA245; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kraus JF, 1993, HEAD INJURY, P1; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LEE SM, 1995, J CEREB BLOOD FLO S1, V15, pS722; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; McQueen J D, 1975, Surg Neurol, V4, P375; MODELL JG, 1990, NEW ENGL J MED, V323, P455, DOI 10.1056/NEJM199008163230706; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; OTT JF, 1985, ALCOHOL CLIN EXP RES, V9, P59, DOI 10.1111/j.1530-0277.1985.tb05051.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROINE RP, 1991, ALCOHOL CLIN EXP RES, V15, P734, DOI 10.1111/j.1530-0277.1991.tb00589.x; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Smith D H, 1995, New Horiz, V3, P562; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; *US DEP TRANSP, 1994, TRAFFIC SAFETY FACTS; VOGEL WH, 1986, BIOCHEM PHARMACOL, V35, P3983, DOI 10.1016/0006-2952(86)90015-8; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	59	72	75	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1997	86	5					876	882		10.3171/jns.1997.86.5.0876			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WV756	WOS:A1997WV75600020	9126906				2021-06-18	
J	Adelson, PD; Robichaud, P; Hamilton, RL; Kochanek, PM				Adelson, PD; Robichaud, P; Hamilton, RL; Kochanek, PM			A model of diffuse traumatic brain injury in the immature rat	JOURNAL OF NEUROSURGERY			English	Article						head injury; immature model; brain swelling; pathophysiology; rat	FLUID-PERCUSSION MODEL; HEAD-INJURY; AXONAL INJURY; CHILDREN; RESPONSES; COMA; CAT	Diffuse cerebral swelling after severe traumatic brain injury (TBI) develops more commonly in children than adults; however, models of diffuse brain injury in immature animals are lacking. The authors developed a new model of diffuse severe TBI in immature rats by modifying a recently described closed head injury model for adult rats. A total of 105 Sprague-Dawley immature rats (17 days old; average weight 38.5 +/- 5.46 g) were subjected to he:td impact using variable weights (0 g (sham), 75 g, 100 g, or 125 g) delivered from a height of 2 m onto a metal disk cemented to the intact cranium. Mortality, physiological and neurological parameters (from early reflex recovery to escape), and early histopathological changes were assessed. During the acute period after severe injury (SI) (100 g delivered from a height of 2 m; 50 rats), apnea was frequently observed and the mortality rate was 38%. Neurological recovery was complete in the sham-injured animals (11 rats) by 4.1 +/- 0.23 minutes (mean +/- standard error of the mean), but was delayed in both moderately injured (MI) (75 g/2 m; Il rats) (14.97 +/- 3.99 minutes) and ST (20.57 +/- 1.31 minutes (p < 0.05)) rats. In the first 24 hours, the sham-injured animals were more active than the injured ones as reflected by a greater net weight gain: 2.9 +/- 1.0 g, 1.2 +/- 1.6 g, and -0.6 +/- 2.1 g in sham-injured, MI, and SI animals, respectively. Immediately after injury, transient hypertension (lasting < 15 seconds) was followed by hypotension (lasting < 3 minutes) and loss of temperature regulation. Both injuries also induced apnea (0.75 +/- 0.7 minutes and 1.27 +/- 0.53 minutes in MI and SI groups, respectively), which either resolved or deteriorated to death. Intubation and assisted ventilation in animals with SI for 9.57 +/- 3.27 minutes in the peritrauma period eliminated mortality (p < 0.05, intubated vs. nonintubated). Histologically, after SI, there was diffuse edema throughout the corpus callosum below the region of injury and in the thalami. Other injuries included neuronal death in the deep nuclei, bilateral disruption of CA3, diffuse subarachnoid hemorrhage, and, in some, ventriculomegaly. Following a diffuse TBI in immature rats, SI produced a mortality rate, neurological deficit, and histological changes similar to those previously reported for an injury resulting from a 450-g weight dropped from 2 m in adult rats. A graded insult was achieved by maintaining the height of the weight drop but varying the weights. Weight loss, acute physiological instability, and acute neurological deficits were also indicative of an SI. Mortality was eliminated when ventilatory support was used during the peritrauma period. This model should be useful in studying the response of the immature rat to diffuse severe TBI.	CHILDRENS HOSP PITTSBURGH,DEPT NEUROPATHOL,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA	Adelson, PD (corresponding author), CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT NEUROSURG,3705 5TH AVE,PITTSBURGH,PA 15213, USA.		Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; 			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADELSON PD, 1995, J NEUROTRAUM, V412, P9970; ADELSON PD, 1995, J NEUROTRAUM, V12, P984; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRAHAM DI, 1988, J CLIN PATHOL, V42, P18; GRUBB RL, 1970, J NEUROSURG, V32, P320, DOI 10.3171/jns.1970.32.3.0320; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HARWOODNASH DC, 1971, RADIOLOGY, V101, P151, DOI 10.1148/101.1.151; HENDRICK EB, 1965, CLIN NEUROSURG, V11, P46; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LEONIDAS JC, 1982, PEDIATRICS, V69, P139; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SMITH ML, 1995, J NEUROTRAUM, V12, P143; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	38	72	73	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					877	884		10.3171/jns.1996.85.5.0877			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900019	8893727				2021-06-18	
J	Biddle, KR; McCabe, A; Bliss, LS				Biddle, KR; McCabe, A; Bliss, LS			Narrative skills following traumatic brain injury in children and adults	JOURNAL OF COMMUNICATION DISORDERS			English	Article							CLOSED HEAD-INJURY; DISCOURSE; CHILDHOOD; LANGUAGE; ADOLESCENTS; DAMAGE	Personal narratives serve an important function in virtually all societies (Peterson & McCabe, 1991). Through narratives individuals make sense of their experiences and represent themselves to others (Bruner, 1990). The ability to produce narratives has been linked to academic success (Feagans, 1982). Persons who have sustained a traumatic brain injury (TBI) are at risk for impaired narrative ability (Dennis, 1991). However, a paucity of information exists on the discourse abilities of persons with TBI. This is partly due to a lack of reliable tools with which to assess narrative discourse. The present study utilized dependency analysis (Deese, 1984) to document and describe the narrative discourse impairments of children and adults with TBI. Ten children (mean age 12;0) and 10 adults (mean age 35;2) were compared with matched controls. Dependency analysis reliably differentiated the discourse of the individuals with TBI from their controls. Individuals with TBI were significantly more dysfluent than their matched controls. Furthermore, their performance on the narrative task revealed a striking listener burden. (C) 1996 Elsevier Science Inc.	UNIV LOWELL,DEPT PSYCHOL,LOWELL,MA 01854; TUFTS UNIV,ELIOT PEARSON DEPT CHILD STUDY,MEDFORD,MA 02155; HARVARD UNIV,GRAD SCH EDUC,CAMBRIDGE,MA 02138; WAYNE STATE UNIV,DEPT COMMUN SCI & DISORDERS,DETROIT,MI 48202					NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HDO 7415] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007415] Funding Source: NIH RePORTER		ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Benton A. L., 1987, NEUROBEHAVIORAL RECO, P111; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; Bruner J., 1990, ACTS MEANING; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DEESE J, 1984, THOUGHT INTO SPEECH; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; ERLICH JS, 1988, J COMMUN DISORD, V21, P1; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; Feagans L, 1982, LANGUAGE CHILDREN RE; FINGER S, 1991, DEV NEUROPSYCHOL, V7, P261, DOI 10.1080/87565649109540494; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; Glosser G., 1990, BRAIN LANG, V40, P67; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Labov William., 1972, LANGUAGE INNER CITY; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; McCabe A., 1991, DEV NARRATIVE STRUCT; MCCABE A, 1990, 5 INT C STUD CHILD L; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Peterson C., 1991, DEV NARRATIVE STRUCT, P29; Peterson C., 1983, DEV PSYCHOLINGUISTIC; PREECE A, 1987, J CHILD LANG, V14, P353, DOI 10.1017/S0305000900012976; TEASDALE G, 1974, LANCET, V2, P81; WYCKOFF LH, 1984, THESIS U FLORIDA; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48	43	72	73	0	7	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0021-9924			J COMMUN DISORD	J. Commun. Disord.	NOV-DEC	1996	29	6					447	469		10.1016/0021-9924(95)00038-0			23	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	VW284	WOS:A1996VW28400002	8956102				2021-06-18	
J	Klein, M; Houx, PJ; Jolles, J				Klein, M; Houx, PJ; Jolles, J			Long-term persisting cognitive sequelae of traumatic brain injury and the effect of age	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							MILD HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; FOLLOW-UP; SYMPTOMS; HEALTH	This study examined the notion that mild to moderate traumatic brain injury (TBI) may have persistent effects that become evident upon neurocognitive testing in a phase in which the effects of physiological aging become manifest. Neurocognitive performance was tested in 25 middle-aged and 20 old subjects who had sustained mild to moderate TBI, on average, several decades earlier. The TBI subjects regarded themselves as normal and healthy. The performance of the TBI subjects was inferior to that of matched healthy controls on all aspects of primary and secondary memory and on the majority of tests used to measure speed of performance. There was no interaction between the effects of TBI and those of age, and the performance of middle-aged TBI subjects was similar to that of old controls, The results are taken to indicate that TBI sustained earlier in life may cause permanent sequelae in specific domains of cognitive functioning and that it might attenuate the age-related decline in cognitive functioning. Most striking, however, was that these deficits were not perceived as a limiting factor in everyday life, which suggests that coping strategies may be important.	UNIV LIMBURG,DEPT PSYCHIAT & NEUROPSYCHOL,NL-6200 MD MAASTRICHT,NETHERLANDS	Klein, M (corresponding author), UNIV LIMBURG,MAASTRICHT BRIN & BEHAV INST,UNS 50,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.		Klein, Martin/C-4192-2012	Klein, Martin/0000-0003-4160-5746; Klein, Martin/0000-0001-5553-7911			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOTWINNICK J, 1981, HDB CLIN NEUROPSYCHO, P135; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Craik FIM, 1982, AGING COGNITIVE PROC, P191, DOI DOI 10.1007/978-1-4684-4178-9_11; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EVANS RW, 1992, NEUROL CLIN, V10, P815; GREEN J, 1992, CLIN ELECTROENCEPHAL, V23, P79, DOI 10.1177/155005949202300207; Gupta A, 1991, J PERS CLIN STUD, V7, P55; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; HOUX PJ, 1991, BRAIN COGNITION, V15, P246, DOI 10.1016/0278-2626(91)90029-8; HOUX PJ, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P353; HOUX PJ, 1993, EXP AGING RES, V19, P209, DOI 10.1080/03610739308253934; Houx PJ, 1994, VULNERABLE BRAIN ENV, P25; JOLLES J, 1993, NEUROSCI RES COMMUN, V13, pS47; LEESTMA JE, 1991, FORENSIC NEUROPSYCHO, P45; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LUTEIJN F, 1982, GRONTINGER INTELLIGE; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Posner M.I., 1975, INFORM PROCESSING CO, P55; REEDER KP, 1994, ARCH CLIN NEUROPSYCH, V9, P491, DOI 10.1016/0887-6177(94)90040-X; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Salthouse T. A., 1985, HDB AGING HDB PSYCHO, P400; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; Schreurs PJG., 1988, UTRECHTSE COPING LIJ; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; Sternberg R. J, 1982, HDB HUMAN INTELLIGEN; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SYMONDS C, 1962, LANCET, V1, P1; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANDERMEULEN WRE, 1980, SLEEP 80; Verhage F., 1964, THESIS U GRONINGEN; ZUNG WWK, 1973, ARCH GEN PSYCHIAT, V29, P328; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V9, P334	48	72	72	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	AUG	1996	184	8					459	467		10.1097/00005053-199608000-00002			9	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	VD331	WOS:A1996VD33100002	8752074				2021-06-18	
J	Hetherington, CR; Stuss, DT; Finlayson, MAJ				Hetherington, CR; Stuss, DT; Finlayson, MAJ			Reaction time and variability 5 and 10 years after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; LONG; CONSISTENCY; PERFORMANCE	Improvement in performance can occur up to 10 years after traumatic brain injury (TBI). Few previous studies have examined the long-term effects of TBI on information processing. This study used reaction time (RT) tasks of increasing complexity with 10-year post-injury, 5-year post-injury, and control groups to assess any such effects. There were no significant group differences in mean RT; however, in the groups of persons with head injury only, response latency was related to age and to task demands. Older members of the groups of persons with head injury were slower than controls. The variability in performance was significantly higher in the 5-year post-injury group than in both the 10-year group and the control group. There were no significant differences among the groups in their ability to inhibit the processing of redundant information. There were no correlations between any dependent measure and severity of injury. Speed of processing is more sensitive to task complexity in individuals with head injury, but only when age at injury is considered. Most importantly, for rehabilitation purposes, recovery of consistency in performance can be expected more than 5 years after a TBI.	UNIV TORONTO, DEPT PSYCHOL, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, DEPT MED NEUROL, TORONTO, ON M5S 1A1, CANADA; CHEDOKE MCMASTER HOSP, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT PSYCHIAT, HAMILTON, ON L8S 4L8, CANADA	Hetherington, CR (corresponding author), HOSP SICK CHILDREN, DEPT PATHOL, 555 UNIV AVE, TORONTO, ON M5G 1X8, CANADA.						ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; Allport A., 1989, FDN COGNITIVE SCI, P631; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DYE OA, 1979, ACTA NEUROL SCAND, V59, P10; Dyer-Smith M. B., 1995, CONT ERGONOMICS, P56; ESON ME, 1978, J NEUROL NEUROSUR PS, V41, P1036, DOI 10.1136/jnnp.41.11.1036; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HALE S, 1988, PSYCHOL AGING, V3, P407, DOI 10.1037/0882-7974.3.4.407; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1976, LANCET, V1, P1031; Kolb B, 1985, FUNDAMENTALS HUMAN N; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1988, SCAND J REHABIL MED, P33; Luria A. R., 1966, HIGHER CORTICAL FUNC; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MIRSKY AF, 1995, J PSYCHIATR RES, V29, P23, DOI 10.1016/0022-3956(94)00041-O; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; SEGALOWITZ NS, 1993, APPL PSYCHOLINGUIST, V14, P369, DOI 10.1017/S0142716400010845; SEGALOWITZ S, 1992, J CLIN EXPT NEUROPSY, V14, P73; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; STREISSGUTH AP, 1994, ALCOHOL CLIN EXP RES, V18, P202, DOI 10.1111/j.1530-0277.1994.tb00904.x; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; STUSS DT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P157; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003; WOOD RL, 1988, J LEARN DISABIL, V21, P327, DOI 10.1177/002221948802100603	39	72	72	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1996	10	7					473	486		10.1080/026990596124197			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UU819	WOS:A1996UU81900001	8806008				2021-06-18	
J	Azouvi, P; Jokic, C; VanDerLinden, M; Marlier, N; Bussel, B				Azouvi, P; Jokic, C; VanDerLinden, M; Marlier, N; Bussel, B			Working memory and supervisory control after severe closed-head injury. A study of dual task performance and random generation	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	17th European Conference of the International-Neuropsychological-Society	JUN, 1994	ANGERS, FRANCE	Int Neuropsychol Soc			RANDOM NUMBER GENERATION; REACTION-TIME; BRAIN-DAMAGE; DEFICITS; ATTENTION; SCALE; RECOVERY	Survivors of severe closed-head injury (CHI) frequently suffer from slowed information processing. Whether supervisory strategies are additionally impaired remains a point of debate. The first part of this study employed a self-paced dual task; the second part, a random generation task, performed at a paced rate, under single and dual task conditions. A measure of information processing speed was used as a covariate in statistical analysis. In the first experiment, in addition to slow processing, patients performed slightly poorer than controls on each task. In the second experiment, patients' performance (one randomness index in single task condition, and processing of dual task) was impaired even after statistical control of slow processing. These results suggest that there is at least some degree of impairment in supervisory strategies in addition to, but independent of, slowed processing. The clinical significance of this finding is discussed.	DEPT NEUROL REHABIL,GARCHES,FRANCE; UNIV LIEGE,DEPT NEUROPSYCHOL,B-4000 LIEGE,BELGIUM	Azouvi, P (corresponding author), UNIV PARIS 05,HOP RAYMOND POINCARE,SERV REEDUCAT NEUROL,F-92380 GARCHES,FRANCE.						ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ATTNEAVE F, 1959, APPLICATIONS INFORMA; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; BROWN RG, 1991, BRAIN, V114, P215; CALICIS F, 1991, UNPUB ADAPTATION LAN; Cicerone K., 1987, ARCH PHYSICAL MED RE, V68, P11; Crossman ERFW, 1953, Q J EXP PSYCHOL, V5, P41; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HORNE RL, 1982, ARCH GEN PSYCHIAT, V39, P680; Kendall M. G., 1973, TIME SERIES; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Norman D. A., 1980, 99 CHIP U CAL; NORMAN DA, 1975, COGNITIVE PSYCHOL, V7, P44, DOI 10.1016/0010-0285(75)90004-3; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; ROSENBERG S, 1990, PSYCHOL MED, V20, P953, DOI 10.1017/S0033291700036643; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, NEUROPSYCHOLOGY COGN, P199; SPATT J, 1993, BRAIN COGNITION, V23, P231, DOI 10.1006/brcg.1993.1057; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TULVING E, 1962, PSYCHOL REV, V69, P344, DOI 10.1037/h0043150; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; VANDERLINDEN M, 1994, WORK MEM C CAMBR UK; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VELTMAN JC, IN PRESS NEUROPSYCHO; VILKKI J, 1994, 17 ANN EUR C INT NEU; VONCRAMON DY, 1994, NEUROPSYCHOLOGICAL R, V14, P399; WAGENAAR WA, 1972, PSYCHOL BULL, V77, P65, DOI 10.1037/h0032060	50	72	73	0	8	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1996	18	3					317	337		10.1080/01688639608408990			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	VF466	WOS:A1996VF46600001	8877617				2021-06-18	
J	WHITLOCK, JA; HAMILTON, BB				WHITLOCK, JA; HAMILTON, BB			FUNCTIONAL OUTCOME AFTER REHABILITATION FOR SEVERE TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article								Objective: (1) Define functional status at rehabilitation discharge and follow-up for patients admitted with Functional Independence Measure (FIM) of 18 after traumatic brain injury; (2) describe patterns of function measured at discharge, rehabilitation lengths of stay and costs, and disposition. Design: Retrospective, descriptive study using data from the Uniform Data System for Medical Rehabilitation (UDSMR) dataset. Setting: Acute rehabilitation hospitals and, for follow-up data, variety of settings, from community to long-term care. Patients: 328 patients with rehabilitation admission FIM of 18 (principal impairment group ''Brain Dysfunction, Traumatic'') drawn from 5,430 TBI patients entered into the data set during 1989-1991. Excluded were 22 persons readmitted to rehab, 5 deaths, 1 case without recorded disposition, and 49 cases without 1CD-9 code consistent with brain trauma. Main Outcome Measures: FIM scores at rehab discharge and follow-up; disposition; length of stay; cost. Results: (1) Mean FIM score at discharge for the group overall (n = 328) was 53 (median = 42 with interquartile range of 18 to 87); (2) 7.6% had functional scores consistent with independence in motor areas measured by FIM; (3) 2.7% had functional scores consistent with independence in cognitive areas measured by FIM; (4)26.1% showed no change in FIM score between admission and discharge; (5) 53% were discharged to community settings, 25% to long-term care, 11% to acute facilities, and 11% to other rehab facilities; (6) average length of stay in acute rehab was 110 days (SD = 70.9, median = 99 days, interquartile range = 57 to 153 days); (7) average rehabilitation charges (n = 322) were $110,891; (8) for those with follow-up data (n = 59), average FIM score was 79 (median, 90); 24% were in school and 5% worked in sheltered workshops. Conclusions: (1) Even the most severely disabled persons admitted to acute rehabilitation after traumatic brain injury can show a large degree of measurable functional improvement; (2) while about 25% of patients showed no measured FIM change, some showed dramatic degrees of functional recovery; (3) most common discharge setting was home (and community). (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	SUNY BUFFALO,BUFFALO,NY	WHITLOCK, JA (corresponding author), NE REHABIL HOSP,70 BUTLER ST,SALEM,NH 03079, USA.			Whitlock, James/0000-0002-6150-1111			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BRICOLO A, 1988, J NEUROSURG, V52, P625; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; FIEDLER R, 1993, PROGR MED REHABILITA, V7, P1; FOULKES MA, 1991, J NEUROSURG, V75, pS11; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GROSWASSER Z, 1990, J NEUROSURG, V72, P75; HAFFEY WJ, 1989, TRAUMATIC BRAIN INJU, P203; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HAMILTON BB, 1994, PHYS THER, V74, P499; HEIDEN JS, 1979, SEMINARS NEUROLOGICA, P181; HEINEMANN AW, 1992, REHABILITATION EFFIC; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNETT B, 1975, LANCET, V1, P480; KARAFFA MC, 1992, INT CLASSIFICATION D; Kraus JF, 1993, HEAD INJURY, P1; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MACK A, 1989, TBI STAR PM R, P13; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Rasch G., 1980, PROBABILISTIC MODELS; SANDEL ME, 1990, COMA EMERGING PATIEN, P409; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; TEASDALE G, 1974, LANCET, V2, P81; Timmons M, 1987, J HEAD TRAUMA REHAB, V2, P64; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; VOLLMER DG, 1993, HEAD INJURY, P553; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; 1990, PARADOX RELATIONAL D; 1995, STATA VERSION 3 1 CO; 1993, QUATTRO PRO VERSION	40	72	74	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1995	76	12					1103	1112		10.1016/S0003-9993(95)80117-0			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TJ667	WOS:A1995TJ66700003	8540785				2021-06-18	
J	KATAYAMA, Y; MAEDA, T; KOSHINAGA, M; KAWAMATA, T; TSUBOKAWA, T				KATAYAMA, Y; MAEDA, T; KOSHINAGA, M; KAWAMATA, T; TSUBOKAWA, T			ROLE OF EXCITATORY AMINO ACID-MEDIATED IONIC FLUXES IN TRAUMATIC BRAIN INJURY	BRAIN PATHOLOGY			English	Article							CORTICAL SPREADING DEPRESSION; EXTRACELLULAR POTASSIUM CONCENTRATION; DIFFUSE CEREBRAL-ISCHEMIA; EXPERIMENTAL HEAD-INJURY; RAT-BRAIN; GLUTAMATE NEUROTOXICITY; GLUCOSE-UTILIZATION; BLOOD-FLOW; METABOLIC-ACTIVITY; REGIONAL CHANGES	One major event taking place at the moment of traumatic brain injury in neuronal cells is the occurrence of massive ionic fluxes across the plasma membrane, which can be referred to as traumatic depolarization (TD). Unlike spreading depression, TD can occur over wide brain areas simultaneously. Furthermore, recovery from TD often takes far longer than recovery from ionic perturbation elicited by the passage of a single wave of spreading depression. Neuronal cell damage caused by ischemic brain injury is also initiated by massive ionic fluxes, termed anoxic depolarization. The occurrence of similar ionic events in these two forms of brain injury may account for the genesis of diffuse ischemia-like damage without actual episodes of hypoxia or ischemia in traumatic brain injury. We review the data indicating that excitatory amino acids (EAA) may play a vital role in producing TD, and that such EAA-mediated ionic perturbation is responsible for a number of posttraumatic events including subcellular metabolic dysfunction and cellular responses such as microglial activation and astrocytic transformation. TD may represent one of the most important mechanisms of diffuse neuronal cell dysfunction and damage associated with traumatic brain injury.		KATAYAMA, Y (corresponding author), NIHON UNIV,SCH MED,DEPT NEUROL SURG,TOKYO 173,JAPAN.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		AQUINO DA, 1988, J NEUROCHEM, V51, P1085, DOI 10.1111/j.1471-4159.1988.tb03072.x; AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J CEREB BLOOD FLOW M, V9, pS46; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CSIBA L, 1985, BRAIN RES, V336, P167, DOI 10.1016/0006-8993(85)90430-5; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; Duchen L. W, 1984, GREENFIELDS NEUROPAT, P1; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GANONG AH, 1986, J PHARMACOL EXP THER, V236, P293; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GORELOVA NA, 1987, ELECTROEN CLIN NEURO, V66, P440, DOI 10.1016/0013-4694(87)90213-6; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HANSEN AJ, 1980, ACTA PHYSIOL SCAND, V108, P355, DOI 10.1111/j.1748-1716.1980.tb06544.x; HANSEN AJ, 1977, ACTA PHYSIOL SCAND, V99, P412, DOI 10.1111/j.1748-1716.1977.tb10394.x; HANSEN AJ, 1985, PHYIOL REV, V165, P101; HANSEN AJ, 1988, RECENT ADV EXCITATOR; HARRIS RJ, 1987, J CEREBR BLOOD F MET, V7, P599, DOI 10.1038/jcbfm.1987.111; HAYES RL, 1991, J NEUROTRAUMA S1, V9, pS157; HERNANDEZCACERE.J, 1987, BRAIN RES, V437, P360; HOVDA DA, 1991, J NEUROTRAUMA S1, V9, pS47; HOWSE DC, 1975, J NEUROCHEM, V24, P935, DOI 10.1111/j.1471-4159.1975.tb03658.x; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KATAYAMA Y, 1991, BRAIN RES, V567, P57, DOI 10.1016/0006-8993(91)91435-4; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, ACT NEUR S, V51, P183; KATAYAMA Y, 1992, BRAIN RES, V584, P329, DOI 10.1016/0006-8993(92)90916-W; KATAYAMA Y, 1994, BRAIN RES, V635, P331, DOI 10.1016/0006-8993(94)91457-5; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KATAYAMA Y, 1992, BRAIN RES, V568, P294; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; KATAYAMA Y, 1993, INTRACRANIAL PRESSUR, V8, P484; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; Koshinaga Morimichi, 1995, Journal of Neurotrauma, V12, P401; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KRAIG RP, 1991, J NEUROSCI, V11, P2187; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAEDA T, 1995, IN PRESS J NEUROTRAU, V12; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; MARRANNES R, 1988, MECHANISMS CEREBRAL, P303; MAYER ML, 1987, TRENDS NEUROSCI, V10, P59, DOI 10.1016/0166-2236(87)90023-3; MOGHADDAM B, 1987, CAN J PHYSL PHARM, V54, P1105; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; Nelson S, 1966, HEAD INJURY, P444; NICHOLSON C, 1979, BRAIN RES, V169, P580, DOI 10.1016/0006-8993(79)90408-6; Nicholson C., 1981, APPLICATION ION SELE, P217; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OLNEY JW, 1986, NEUROSCI LETT, V65, P65, DOI 10.1016/0304-3940(86)90121-7; PASCHEN W, 1987, J NEUROCHEM, V48, P154, DOI 10.1111/j.1471-4159.1987.tb13140.x; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; PHILLIPS JM, 1979, BRAIN RES, V173, P567, DOI 10.1016/0006-8993(79)90254-3; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REICHENBACH A, 1989, GLIA, V2, P71, DOI 10.1002/glia.440020202; ROSENTHAL M, 1973, J NEUROPHYSIOL, V36, P739; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SIESJO BK, 1985, CEREBROVASC DIS, P187; SOMJEN GG, 1984, BRAIN RES, V311, P186, DOI 10.1016/0006-8993(84)91416-1; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tsubokawa T, 1983, No Shinkei Geka, V11, P563; VANHARREVELD A, 1978, J NEUROBIOL, V9, P419, DOI 10.1002/neu.480090602; VANHARREVELD A, 1956, AM J PHYSIOL, V187, P180; WEISEND M P, 1989, Society for Neuroscience Abstracts, V15, P69; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	86	72	74	0	3	INT SOC NEUROPATHOLOGY	ZURICH	ISN JOURNAL PO BOX, CH-8033 ZURICH, SWITZERLAND	1015-6305			BRAIN PATHOL	Brain Pathol.	OCT	1995	5	4					427	435		10.1111/j.1750-3639.1995.tb00621.x			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	TK374	WOS:A1995TK37400009	8974625				2021-06-18	
J	VANREEKUM, R; BAYLEY, M; GARNER, S; BURKE, IM; FAWCETT, S; HART, A; THOMPSON, W				VANREEKUM, R; BAYLEY, M; GARNER, S; BURKE, IM; FAWCETT, S; HART, A; THOMPSON, W			N OF 1 STUDY - AMANTADINE FOR THE AMOTIVATIONAL-SYNDROME IN A PATIENT WITH TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RANDOMIZED TRIALS; RELATIVES; DEMENTIA	Severe amotivation, apathy, and abulia, significantly retard rehabilitation following traumatic brain injury. Preliminary, uncontrolled research has suggested possible benefit with amantadine for this behavioural syndrome. This N of 1, double-blind, placebo-controlled study employed amantadine 100 mg three times daily in one such patient. Therapists and nurses completed inventories scoring efforts towards initiation of therapeutic activities during each session, progress in therapy, and participation in therapy. Four treatment periods (two active medication, two placebo), of 2 weeks duration, were completed. Across four therapists, and for both treatment pairs, the average effect score increased from 0.86 on placebo to 1.74 on amantadine (possible range 0-6, 3 = 'average'). There were no side-effects. The study suggests possible benefit with amantadine for patients with amotivational syndrome after traumatic brain injury; a randomized clinical trial appears warranted and required.		VANREEKUM, R (corresponding author), CHEDOKE MCMASTER HOSP,MCMASTER UNIV,PATTERSON BLDG,BOX 2000,HAMILTON,ON L8N 3Z5,CANADA.			Bayley, Mark/0000-0001-7860-9463			ALBERT ML, 1974, J NEUROL NEUROSUR PS, V37, P121, DOI 10.1136/jnnp.37.2.121; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; ERKULWATER S, 1989, SOUTHERN MED J, V82, P550, DOI 10.1097/00007611-198905000-00004; GUALTIERI T, CLIN NEUROPHARMACOL, V12, P258; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	12	72	74	0	2	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					49	53		10.3109/02699059509004571			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200007	7874096				2021-06-18	
J	KAO, GD; GOLDWEIN, JW; SCHULTZ, DJ; RADCLIFFE, J; SUTTON, L; LANGE, B				KAO, GD; GOLDWEIN, JW; SCHULTZ, DJ; RADCLIFFE, J; SUTTON, L; LANGE, B			THE IMPACT OF PERIOPERATIVE FACTORS ON SUBSEQUENT INTELLIGENCE QUOTIENT DEFICITS IN CHILDREN TREATED FOR MEDULLOBLASTOMA POSTERIOR-FOSSA PRIMITIVE NEUROECTODERMAL TUMORS	CANCER			English	Article						MEDULLOBLASTOMA; RADIATION THERAPY; INTELLIGENCE QUOTIENT; NEUROCOGNITIVE DEFICITS; PERIOPERATIVE FACTORS	WHOLE-BRAIN RADIOTHERAPY; CLOSED HEAD-INJURY; BACTERIAL-MENINGITIS; HALSTEAD-REITAN; CHILDHOOD; SEQUELAE; INFECTION; PRESCHOOL; SURVIVAL; AGE	Background. Despite success in treating children with medulloblastoma/posterior fossa primitive neuroectodermal tumor (PF PNET), some children survive with significant neurocognitive sequelae. This study was performed to understand better the significance of perioperative factors on subsequent full scale intelligence quotient (FSIQ) deterioration in these children. Methods. Twenty-eight children who underwent prospective and serial neurocognitive testing were studied. All children underwent surgery followed by radiotherapy with or without chemotherapy between 1983 and 1987 for medulloblastoma/PF PNET and were disease free when this study was conducted. IQ testing was performed before surgery and after the completion of radiation therapy. The clinical courses of the patients were correlated with changes in the corresponding intelligence quotients of each child. Factors correlating with neurocognitive declines were examined by chi-square or Fisher exact test analysis. Differences in mean IQs were examined by the t test. Factors found to be significant were analyzed by exact logistic regression analysis. Results. The presence of adverse factors such as neurologic deficits, meningitis, or shunt infections, or the need for repeat surgery was correlated significantly with IQ deficits after treatment. Of the subset of children with one or more of these factors, 13 of 16 (81%) sustained decreases in FSIQ; 7 of 16 (43.8%) had decreases of 20 points of more. In contrast, only 3 of 12 (25%) of the children without the factors sustained FSIQ decreases, and no child sustained a decrease of more than 13 points. The mean FSIQ change after treatment in the group with factors was -15.7 (95% confidence interval [CI]: -24.0, -8.4), and the median was -18. The mean FSIQ change in the group without factors was 4.8 (95% CI: -0.5, 10.1), and the median was 5. The difference in mean FSIQ change between the two groups was significant (P < 0.0001). On univariate analysis, both the presence of adverse factors and an age less than six years correlated with neurocognitive deficit. On regression analysis, only the presence of adverse factors was significant (odds ratio 11.53; 95% CI, 1.65-116.58; P = 0.009), whereas age was not (P = 0.27). Conclusions. Perioperative events or complications may account for some of the neurocognitive deterioration seen in these children after treatment, especially in the very young. The occurrence of these factors is associated with a significantly greater risk of IQ deterioration. Studies of the neurocognitive effects of treatment for children with medulloblastoma/PF PNET should include an analysis of these postoperative factors.	CHILDRENS HOSP PHILADELPHIA,CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA 19104; MILLERSVILLE UNIV PENNSYLVANIA,DEPT MATH,MILLERSVILLE,PA 17551; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104	KAO, GD (corresponding author), HOSP UNIV PENN,DEPT RADIAT ONCOL,2 DONNER,PHILADELPHIA,PA 19104, USA.						ALBRIGHT AL, 1989, PEDIATR NEUROSCI, V15, P276; ALLEN JC, 1982, J NEUROSURG, V57, P446, DOI 10.3171/jns.1982.57.4.0446; ALLEN JC, 1993, NEW ENGL J MED, V328, P1780, DOI 10.1056/NEJM199306173282410; BANICH MT, 1990, NEUROPSYCHOLOGIA, V28, P35, DOI 10.1016/0028-3932(90)90084-2; Bayley N., 1969, BAYLEY SCALES INFANT; BERRY MP, 1981, J NEUROSURG, V55, P43, DOI 10.3171/jns.1981.55.1.0043; Bonner K, 1988, J Neurosci Nurs, V20, P84; BROOKSHIRE B, 1990, NEUROSURGERY, V27, P887, DOI 10.1227/00006123-199012000-00005; BUONAGURO A, 1989, CHILD NERV SYST, V5, P153, DOI 10.1007/BF00272117; CONBOY TJ, 1987, J PEDIATR-US, V111, P343, DOI 10.1016/S0022-3476(87)80451-1; ELLENBERG L, 1987, NEUROSURGERY, V21, P638, DOI 10.1227/00006123-198711000-00006; FADUL C, 1988, NEUROLOGY, V38, P1374, DOI 10.1212/WNL.38.9.1374; FEIGIN RD, 1976, PEDIATR CLIN N AM, V23, P541; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; HIRSCH JF, 1979, ACTA NEUROCHIR, V48, P1, DOI 10.1007/BF01406016; HOPESTONE HF, 1970, J NEUROSURG, V32, P83, DOI 10.3171/jns.1970.32.1.0083; HOPPEHIRSCH E, 1990, CHILD NERV SYST, V6, P60, DOI 10.1007/BF00307922; HORWITZ NH, 1982, POSTOPERATIVE COMPLI, P32; HUGHES EN, 1988, CANCER, V61, P1992, DOI 10.1002/1097-0142(19880515)61:10<1992::AID-CNCR2820611011>3.0.CO;2-J; JONES RFC, 1967, J NEUROSURG, V26, P313, DOI 10.3171/jns.1967.26.3.0313; KANE RL, 1987, J CONSULT CLIN PSYCH, V55, P783; LANDBERG TG, 1980, CANCER, V45, P670, DOI 10.1002/1097-0142(19800215)45:4<670::AID-CNCR2820450409>3.0.CO;2-K; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P190; MULHERN RK, 1985, MED PEDIATR ONCOL, V13, P318, DOI 10.1002/mpo.2950130604; PACKER RJ, 1986, ANN NEUROL, V20, P396; PACKER RJ, 1989, J NEUROSURG, V70, P707, DOI 10.3171/jns.1989.70.5.0707; PRIGATANO GP, 1983, CHILD BRAIN, V10, P112; RABBITT P, 1993, Q J EXP PSYCHOL-A, V46, P385, DOI 10.1080/14640749308401055; RADCLIFFE J, 1992, ANN NEUROL, V32, P551, DOI 10.1002/ana.410320411; RENIER D, 1984, J NEUROSURG, V61, P1072, DOI 10.3171/jns.1984.61.6.1072; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; RICHARDSON RR, 1989, STEREOT FUNCT NEUROS, V53, P105, DOI 10.1159/000099525; SAMEROFF AJ, 1993, CHILD DEV, V64, P80, DOI 10.2307/1131438; SELL SHW, 1972, PEDIATRICS, V49, P212; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; STAMBROOK M, 1987, INT J NEUROSCI, V35, P73, DOI 10.3109/00207458708987112; Terman L.M., 1960, STANFORD BINET INTEL; THOMPSON NM, 1991, J CLIN EXP NEUROPSYC, V13, P245, DOI 10.1080/01688639108401041; Wechsler, 1949, WECHSLER INTELLIGENC; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; WILLIAMS JM, 1986, CANCER TREAT REV, V13, P113; Wisoff J H, 1984, Neurosurgery, V15, P707	48	72	72	0	6	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0008-543X			CANCER	Cancer	AUG 1	1994	74	3					965	971		10.1002/1097-0142(19940801)74:3<965::AID-CNCR2820740328>3.0.CO;2-Z			7	Oncology	Oncology	NZ352	WOS:A1994NZ35200027	8039126				2021-06-18	
J	ALLEN, K; LINN, RT; GUTIERREZ, H; WILLER, BS				ALLEN, K; LINN, RT; GUTIERREZ, H; WILLER, BS			FAMILY BURDEN FOLLOWING TRAUMATIC BRAIN INJURY	REHABILITATION PSYCHOLOGY			English	Article							GENDER DIFFERENCES; COPING STRATEGIES; HEAD-INJURY; CAREGIVERS; RELATIVES; DEMENTIA; STRESS; SYMPTOMS; IMPACT; WIVES	This study investigated burden experienced by 60 spouses and 71 parents who served as primary caregivers to individuals with traumatic brain injury. Burden levels, as assessed by the Questionnaire on Resources and Stress (QRS-SF), were compared for spouses and parents. Overall, both parents and spouses of individuals with traumatic brain injury exhibited high levels of burden. Relative to spouses, parents reported significantly greater burden related to lifespan care. Spouses reported significantly less personal reward than did parents. The presence of social aggression and cognitive disability in the individual with brain injury was found to have a greater association with subjective burden of caregivers than was the presence of physical disability or injury severity. Comparisons were made between QRS-SF scores for relatives of individuals with brain injury and QRS-SF scores reported in previous investigations focused on caregivers to individuals with other disabling conditions. It was found that the responsibility assumed by spouses and parents of individuals with brain injury was as great as that experienced by families of people with severe chronic physical disabilities.		ALLEN, K (corresponding author), SUNY BUFFALO, CTR STUDY BIOBEHAV & SOCIAL ASPECTS HLTH, 316 PK HALL, BUFFALO, NY 14260 USA.						BARUSCH AS, 1989, GERONTOLOGIST, V29, P667, DOI 10.1093/geront/29.5.667; BOUMA R, 1990, J CLIN PSYCHOL, V46, P722, DOI 10.1002/1097-4679(199011)46:6<722::AID-JCLP2270460605>3.0.CO;2-6; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHENOWETH B, 1986, GERONTOLOGIST, V26, P267, DOI 10.1093/geront/26.3.267; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Cohen J., 1983, APPL MULTIPLE REGRES; DAY AM, 1988, REHABIL PSYCHOL, V33, P113; DEIMLING GT, 1986, J GERONTOL, V41, P778, DOI 10.1093/geronj/41.6.778; Hays W. L., 1988, STATISTICS; HOLROYD J, 1976, AM J MENT DEF, V80, P431; HOLROYD J, 1986, J CLIN PSYCHOL, V42, P552, DOI 10.1002/1097-4679(198607)42:4<552::AID-JCLP2270420403>3.0.CO;2-8; Holroyd J., 1987, MANUAL QUESTIONNAIRE; HOLROYD J, 1985, QUESTIONNAIRE RESOUR; Holroyd J., 1974, J COMMUNITY PSYCHOL, V2, P92, DOI [10.1002/1520-6629(197401)2:13.0.CO;2-A., DOI 10.1002/1520-6629(197401)2:13.0.CO;2-A]; *HOUGHT MIFFL CO, 1985, AM HER DICT; INANAMI M, 1980, JAPANESE J SPECIAL E, V18, P33; Kuder GF, 1937, PSYCHOMETRIKA, V2, P151, DOI 10.1007/BF02288391; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1988, J HEAD TRAUMA REHAB, V2, P6; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCDOWELL J, 1988, DISABILITY SCORE HLT; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MORRIS RG, 1991, BRIT J PSYCHIAT, V158, P69, DOI 10.1192/S0007125000292027; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; PRATT CC, 1985, FAM RELAT, V34, P27, DOI 10.2307/583754; RABINS PV, 1982, JAMA-J AM MED ASSOC, V248, P333, DOI 10.1001/jama.248.3.333; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SCHARLACH AE, 1989, RES AGING, V11, P225, DOI 10.1177/0164027589112005; *STAT CAN, 1989, HLTH ACT LIM SURV DA; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wood R. L., 1987, BRAIN INJURY REHABIL	36	72	72	0	3	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	SPR	1994	39	1					29	48		10.1037/h0080313			20	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	NQ432	WOS:A1994NQ43200003					2021-06-18	
J	GOLDENBERG, G; ODER, W; SPATT, J; PODREKA, I				GOLDENBERG, G; ODER, W; SPATT, J; PODREKA, I			CEREBRAL CORRELATES OF DISTURBED EXECUTIVE FUNCTION AND MEMORY IN SURVIVORS OF SEVERE CLOSED HEAD-INJURY - A SPECT STUDY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							BRAIN-LESIONS; DISEASE; TOMOGRAPHY; TASKS; MILD	Thirty six patients in the chronic stage after severe closed head injury were examined with tests of executive function, memory, intelligence, and functional capacities in daily living. Correlations were sought between test results and Tc-99m-HMPAO uptake of frontal, temporal, and thalamic regions assessed by SPECT. Neither the number of significant correlation coefficients between memory tests and regional uptake nor that between temporal uptake and tests exceeded chance. For the remaining tests, correlations to thalamic regions were stronger than those to the frontal regions, and those to right brain regions stronger than those to homologous left brain regions. Relationships of thalamic isotope uptake to neuropsychological performance may reflect the impact of diffuse brain damage and particularly of diffuse axonal injury on mental capacities.	UNIV VIENNA,NEUROL KLIN,A-1010 VIENNA,AUSTRIA							ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; Baddeley A. D., 1986, WORKING MEMORY; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P746; BROOKS N, 1990, TRAUMATIC BRAIN INJU, P77; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DIEM K, 1968, WISSENSCHAFTLICHE TA; Gainotti G, 1972, Cortex, V8, P41; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GOLDENBERG G, 1990, J NEUROL, V237, P191, DOI 10.1007/BF00314593; GOLDENBERG G, 1989, NEUROPSYCHOLOGIA, V27, P1315, DOI 10.1016/0028-3932(89)90127-9; GOLDENBERG G, 1989, BEHAV NEUROL, V2, P79; HECAEN H, 1978, CEREBRAL CORRELATES, P119; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; HEISS WD, 1990, J CEREBR BLOOD F MET, V10, P687, DOI 10.1038/jcbfm.1990.122; HOLM S, 1979, SCAND J STAT, V6, P65; JENKINS A, 1986, LANCET, V2, P445; LASSEN NA, 1987, J CEREB BLOOD FLOW S, V7, P535; Lehrl S, 1977, MEHRFACHWAHL WORTSCH; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; METTER EJ, 1981, ANN NEUROL, V10, P173, DOI 10.1002/ana.410100208; OSTROVE JM, 1990, BRAIN COGNITION, V12, P144, DOI 10.1016/0278-2626(90)90010-L; PODREKA I, 1987, J NUCL MED, V28, P1657; Prigatano G. P, 1988, BRAIN INJURY RECOVER, P335; RAVEN JC, 1965, COLOURED PROGR MATRI; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHOULSON I, 1981, NEUROLOGY, V31, P1333, DOI 10.1212/WNL.31.10.1333; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; UZZELL BP, 1986, CLIN NEUROPSYCHOLOGY, P3; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; Wilson JTL, 1989, NEUROPSYCHOLOGY, V3, P255, DOI 10.1037//0894-4105.3.4.255; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	41	72	72	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1992	55	5					362	368		10.1136/jnnp.55.5.362			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	HV661	WOS:A1992HV66100007	1602308	Bronze, Green Published			2021-06-18	
J	BIGLER, ED; ROSA, L; SCHULTZ, F; HALL, S; HARRIS, J				BIGLER, ED; ROSA, L; SCHULTZ, F; HALL, S; HARRIS, J			REY-AUDITORY VERBAL-LEARNING AND REY-OSTERRIETH COMPLEX FIGURE DESIGN PERFORMANCE IN ALZHEIMERS-DISEASE AND CLOSED HEAD-INJURY	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article									UNIV TEXAS,AUSTIN,TX 78712	BIGLER, ED (corresponding author), AUSTIN NEUROL CLIN,BLDG F MED SCI CTR,711 W 38TH ST,AUSTIN,TX 78705, USA.						BIGLER ED, 1985, J NERV MENT DIS, V173, P347, DOI 10.1097/00005053-198506000-00004; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Denman S. B., 1984, MANUAL DENMAN NEUROP; Jennett B, 1981, MANAGEMENT HEAD INJU; LEZAK MD, 1985, NEUROPSYCHOLOGICAL A; MARTIN A, 1987, J CLIN EXP NEUROPSYC, V9, P191, DOI 10.1080/01688638708405361; MUNGAS D, 1983, J CONSULT CLIN PSYCH, V51, P848, DOI 10.1037/0022-006X.51.6.848; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; QUERY WT, 1983, J CLIN PSYCHOL, V39, P136, DOI 10.1002/1097-4679(198301)39:1<136::AID-JCLP2270390125>3.0.CO;2-Q; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSENBERG SJ, 1984, J CLIN PSYCHOL, V40, P785, DOI 10.1002/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4	12	72	73	0	8	CLINICAL PSYCHOLOGY PUBL CO	BRANDON	4 CONANT SQUARE, BRANDON, VT 05733	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	MAR	1989	45	2					277	280		10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M			4	Psychology, Clinical	Psychology	U2824	WOS:A1989U282400014	2723084				2021-06-18	
J	LEZAK, MD; OBRIEN, KP				LEZAK, MD; OBRIEN, KP			LONGITUDINAL-STUDY OF EMOTIONAL, SOCIAL, AND PHYSICAL CHANGES AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF LEARNING DISABILITIES			English	Article									OREGON HLTH SCI UNIV,DEPT NEUROL L226,PORTLAND,OR 97201; BARROW NEUROL INST,PORTLAND,OR; ADULT DAY HOSP NEUROL REHABIL,PORTLAND,OR							ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P239; Bond M R, 1975, Ciba Found Symp, P141; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1984, CLOSED HEAD INJURY P, P123; CRAWFORD C, 1983, NEW ZEAL MED J, V96, P972; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Goldstein K., 1942, AFTEREFFECTS BRAIN I; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; HEILMAN KM, 1983, NEUROPSYCHOLOGY HUMA; LEIGH D, 1979, PSYCHIAT DIG, V40, P21; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P172; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LISHMAN WA, 1978, ORGANIC PSYCHIATRY; Luria A. R., 1966, HIGHER CORTICAL FUNC; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; OBRIEN KP, 1982, 4TH EUR M INT NEUR S; OBRIEN KP, 1986, THESIS U VICTORIA VI; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, IN PRESS CLIN MANAGE; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VIGOUROUX RP, 1971, P INT S HEAD INJURIE, P335	30	72	73	0	3	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	OCT	1988	21	8					456	463		10.1177/002221948802100802			8	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	Q4889	WOS:A1988Q488900010	2972786				2021-06-18	
J	Xu, X; Yin, DP; Ren, HL; Gao, WW; Li, F; Sun, DD; Wu, YG; Zhou, S; Lyu, L; Yang, MC; Xiong, JH; Han, LL; Jiang, RC; Zhang, JM				Xu, Xin; Yin, Dongpei; Ren, Honglei; Gao, Weiwei; Li, Fei; Sun, Dongdong; Wu, Yingang; Zhou, Shuai; Lyu, Li; Yang, Mengchen; Xiong, Jianhua; Han, Lulu; Jiang, Rongcai; Zhang, Jianning			Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic updates brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Neuroinflammation; NLRP3 inflammasome; Interleukin-1 beta; Microglia; MCC950	CEREBROSPINAL-FLUID; ACTIVATION; MICE; NEUROPROTECTION; DISRUPTION; DEFICITS; CORTEX	The nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated inflammatory response has emerged as a prominent contributor to the pathophysiological processes of traumatic brain injury (TBI). Recently, a potent, selective, small-molecule NLRP3 inflammasome inhibitor, MCC950, was described. Here, we investigated the effect of MCC950 on inflammatory brain injury and long-term neurological outcomes in a mouse model of TBI. Male C57/BL6 mice were subjected to TBI using the controlled cortical impact injury (CCI) system. Western blotting, flow cytometry, and immunofluorescence assays were utilized to analyze post-traumatic NLRP3 inflammasome expression and determine its cellular source. We found that NLRP3 inflammasome expression was significantly increased in the peri-contusional cortex and that microglia were the primary source of this expression. The effects of MCC950 on mice with TBI were then determined using post-assessments including analyses of neurological deficits, brain water content, traumatic lesion volume, neuroinflammation, blood-brain barrier (BBB) integrity, and cell death. MCC950 treatment resulted in a better neurological outcome after TBI by alleviating brain edema, reducing lesion volume, and improving long-term motor and cognitive functions. The therapeutic window for MCC950 against TBI was as long as 6 h. Furthermore, the neuroprotective effect of MCC950 was associated with reduced microglial activation, leukocyte recruitment, and pro-inflammatory cytokine production. In addition, MCC950 preserved BBB integrity, alleviated TBI-induced loss of tight junction proteins, and attenuated cell death. Notably, the efficacy of MCC950 was abolished in microglia-depleted mice. These results indicate that microglia-derived NLRP3 inflammasome may be primarily involved in the inflammatory response to TBI, and specific NLRP3 inflammasome inhibition using MCC950 may be a promising therapeutic approach for patients with TBI.	[Xu, Xin; Yin, Dongpei; Gao, Weiwei; Li, Fei; Sun, Dongdong; Wu, Yingang; Zhou, Shuai; Yang, Mengchen; Xiong, Jianhua; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Xu, Xin; Yin, Dongpei; Ren, Honglei; Gao, Weiwei; Li, Fei; Sun, Dongdong; Wu, Yingang; Zhou, Shuai; Yang, Mengchen; Xiong, Jianhua; Han, Lulu; Jiang, Rongcai; Zhang, Jianning] Minist Educ & Tianjin City, Key Lab Postneuroinjury Neurorepair & Regenerat C, Tianjin Neurol Inst, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Gao, Weiwei] Tianjin Huanhu Hosp, Dept Neurol, 6 Jizhao Rd, Tianjin 300350, Peoples R China; [Li, Fei] Tianjin Baodi Hosp, Dept Neurosurg, 8 Guangchuan Rd, Tianjin 301800, Peoples R China; [Lyu, Li] Tianjin Childrens Hosp, Dept Cardiovasc, 238 Longyan Rd, Tianjin 300074, Peoples R China	Jiang, RC; Zhang, JM (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jiang116216@163.com; jianningzhang@hotmail.com		Xu, Xin/0000-0003-3395-9923; Dongpei, Yin/0000-0003-2572-3689	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81671380, 81502173, 81501055]; Natural Science Foundation of Tianjin CityNatural Science Foundation of Tianjin [17JCZDJC35900]; Tianjin Research Program of Application Foundation and Advanced Technology [16JCYBJC27200]; Tianjin Research Program [16PTSYJC00180]	The authors are grateful to Jing-fei Dong, Qiang Liu, Li Liu, Weiyun Cui, Fanglian Chen, and Lei Zhou from the Tianjin Neurological Institute for their excellent technical support. This work was supported by grants from the National Natural Science Foundation of China (grant 81330029, 81671380, 81502173, and 81501055), the Natural Science Foundation of Tianjin City (grant 17JCZDJC35900), the Tianjin Research Program of Application Foundation and Advanced Technology (grant 16JCYBJC27200), and the Tianjin Research Program (grant 16PTSYJC00180).	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; da Fonseca ACC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00362; Chen WQ, 2017, NAT MICROBIOL, V2, P1435, DOI 10.1038/s41564-017-0015-4; Cheng YJ, 2017, METAB BRAIN DIS, V32, P1133, DOI 10.1007/s11011-017-0003-7; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Gao L, 2017, INFLAMM RES, V66, P17, DOI 10.1007/s00011-016-0981-7; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gustin A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130624; Harrison JL, 2015, BRAIN BEHAV IMMUN, V47, P131, DOI 10.1016/j.bbi.2015.01.001; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee J, 2014, J TRAUMA ACUTE CARE, V77, P709, DOI 10.1097/TA.0000000000000445; Li MS, 2017, FASEB J, V31, P3278, DOI 10.1096/fj.201601377RR; Li MS, 2017, J CEREBR BLOOD F MET, V37, P2383, DOI 10.1177/0271678X16666551; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YL, 2017, ACTA PHARMACOL SIN, V38, P1445, DOI 10.1038/aps.2017.103; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Netea MG, 2015, ANNU REV IMMUNOL, V33, P49, DOI 10.1146/annurev-immunol-032414-112306; Pan Y, 2014, BRAIN BEHAV IMMUN, V41, P90, DOI 10.1016/j.bbi.2014.04.007; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Ren HL, 2018, STROKE, V49, P184, DOI 10.1161/STROKEAHA.117.018904; Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; van Hout GPJ, 2017, EUR HEART J, V38, P828, DOI 10.1093/eurheartj/ehw247; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wang XQ, 2014, NAT IMMUNOL, V15, P1126, DOI 10.1038/ni.3015; Wang ZX, 2016, MOL NEUROBIOL, V53, P1905, DOI 10.1007/s12035-015-9143-0; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Yang L, 2017, METAB BRAIN DIS, V32, P1395, DOI 10.1007/s11011-017-9991-6; Yang XX, 2018, FASEB J, V32, P3336, DOI 10.1096/fj.201700833RR; Zhou KR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9238290; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	48	71	76	7	36	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2018	117						15	27		10.1016/j.nbd.2018.05.016			13	Neurosciences	Neurosciences & Neurology	GO8ZO	WOS:000440392100002	29859317				2021-06-18	
J	Ferreira, GC; McKenna, MC				Ferreira, Gustavo C.; McKenna, Mary C.			L-Carnitine and Acetyl-l-carnitine Roles and Neuroprotection in Developing Brain	NEUROCHEMICAL RESEARCH			English	Article						L-Carnitine; Acetyl-L-carnitine; Neuroprotection; Neonatal hypoxia-ischemia; Pediatric traumatic brain injury; Metabolism; Inborn errors of metabolism; Carnitine shuttle	PERFORMANCE LIQUID-CHROMATOGRAPHY; COA DEHYDROGENASE-DEFICIENCY; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; MAGNETIC-RESONANCE-SPECTROSCOPY; ACETYLCHOLINE-RECEPTOR AGONIST; CENTRAL-NERVOUS-SYSTEM; C-13 NMR-SPECTROSCOPY; FATTY-ACID OXIDATION; FREELY MOVING RATS; ALPHA-LIPOIC ACID	L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by beta-oxidation. Treatment with l-carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism. In recent years there has been considerable interest in the therapeutic potential of l-carnitine and its acetylated derivative acetyl-l-carnitine (ALCAR) for neuroprotection in a number of disorders including hypoxia-ischemia, traumatic brain injury, Alzheimer's disease and in conditions leading to central or peripheral nervous system injury. There is compelling evidence from preclinical studies that l-carnitine and ALCAR can improve energy status, decrease oxidative stress and prevent subsequent cell death in models of adult, neonatal and pediatric brain injury. ALCAR can provide an acetyl moiety that can be oxidized for energy, used as a precursor for acetylcholine, or incorporated into glutamate, glutamine and GABA, or into lipids for myelination and cell growth. Administration of ALCAR after brain injury in rat pups improved long-term functional outcomes, including memory. Additional studies are needed to better explore the potential of l-carnitine and ALCAR for protection of developing brain as there is an urgent need for therapies that can improve outcome after neonatal and pediatric brain injury.	[Ferreira, Gustavo C.] Univ Fed Rio de Janeiro, Inst Med Biochem Leopoldo de Meis, Rio De Janeiro, Brazil; [Ferreira, Gustavo C.; McKenna, Mary C.] Univ Maryland, Sch Med, Dept Pediat, 655 W Baltimore St,BRB 13-019, Baltimore, MD 21201 USA; [McKenna, Mary C.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	McKenna, MC (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 655 W Baltimore St,BRB 13-019, Baltimore, MD 21201 USA.; McKenna, MC (corresponding author), Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA.	mmckenna@umaryland.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01 HD016596, P01 HD085928]; "Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro"Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Coordination for the Improvement of Higher Education Personnel (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD085928, P01HD016596] Funding Source: NIH RePORTER	The authors would like to gratefully acknowledge and thank Bruna Klippel Ferreira for her excellent effort in preparing Figs. 2 and 3, and Dr. Jaylyn Waddell and Dr. Susanna Scafidi for their very helpful suggestions. Research described from Dr. McKenna's laboratory was supported in part by NIH Grants 5P01 HD016596 and P01 HD085928. Dr. Ferreira's research is supported by the "Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro", Coordination for the Improvement of Higher Education Personnel (CAPES) and National Council for Scientific and Technological Development (CNPq).	Al-Majed AA, 2006, CLIN EXP PHARMACOL P, V33, P725, DOI 10.1111/j.1440-1681.2006.04425.x; Al-sharefi Ahmed, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-210727; Alves E, 2009, NEUROSCIENCE, V158, P514, DOI 10.1016/j.neuroscience.2008.10.041; ANGELINI C, 1987, CLIN BIOCHEM, V20, P1, DOI 10.1016/S0009-9120(87)80090-5; Aureli T, 1998, BRAIN RES, V796, P75, DOI 10.1016/S0006-8993(98)00319-9; Aureli T, 1999, EUR J BIOCHEM, V263, P287, DOI 10.1046/j.1432-1327.1999.00524.x; AURELI T, 1994, BRAIN RES, V643, P92, DOI 10.1016/0006-8993(94)90013-2; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Badve Monica S, 2015, N Z Med J, V128, P61; Barhwal K, 2008, J NEUROSCI RES, V86, P2705, DOI 10.1002/jnr.21722; BARNES CA, 1990, NEUROBIOL AGING, V11, P499, DOI 10.1016/0197-4580(90)90110-L; Bigford GE, 2014, ADV NUTR, V5, P394, DOI 10.3945/an.113.005264; Binienda ZK, 2006, NEUROSCI LETT, V410, P62, DOI 10.1016/j.neulet.2006.09.070; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Brekke EMF, 2014, J CEREBR BLOOD F MET, V34, P724, DOI 10.1038/jcbfm.2014.8; Cahova M, 2015, APPL PHYSIOL NUTR ME, V40, P280, DOI [10.1139/apnm-2014-0163, 10.1139/apnm-2014-016]; Calabrese V, 2006, J NUTR BIOCHEM, V17, P73, DOI 10.1016/j.jnutbio.2005.03.027; Calabrese V, 2005, J NEUROSCI RES, V79, P509, DOI 10.1002/jnr.20386; Calabrese V, 2003, NEUROCHEM RES, V28, P1321, DOI 10.1023/A:1024984013069; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Celestino-Soper PBS, 2012, P NATL ACAD SCI USA, V109, P7974, DOI 10.1073/pnas.1120210109; CERDAN S, 1990, J BIOL CHEM, V265, P12916; CHALMERS RA, 1984, PEDIATR RES, V18, P1325, DOI 10.1203/00006450-198412000-00021; Chavez-Valdez R, 2014, NEUROSCIENCE, V260, P106, DOI 10.1016/j.neuroscience.2013.12.023; Chiechio S, 2006, CURR NEUROPHARMACOL, V4, P233, DOI 10.2174/157015906778019509; Clark RH, 2014, PEDIATRICS, V134, pE37, DOI 10.1542/peds.2014-0329; Cruz F, 1998, J NEUROCHEM, V70, P2613; Czeredys M, 2008, BIOCHEM BIOPH RES CO, V376, P267, DOI 10.1016/j.bbrc.2008.08.122; Czeredys M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082105; DAVIES SEC, 1991, CLIN CHIM ACTA, V204, P263, DOI 10.1016/0009-8981(91)90237-7; de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8; Demarest TG, 2016, J BIOENERG BIOMEMBR, V48, P591, DOI 10.1007/s10863-016-9678-4; Demarest TG, 2016, J NEUROCHEM, V137, P714, DOI 10.1111/jnc.13590; DESIMONE R, 1991, INT J DEV NEUROSCI, V9, P39, DOI 10.1016/0736-5748(91)90071-S; Ebert D, 2003, J NEUROSCI, V23, P5928; El-Hattab AW, 2015, MOL GENET METAB, V116, P107, DOI 10.1016/j.ymgme.2015.09.004; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferreira GC, 2007, INT J DEV NEUROSCI, V25, P391, DOI 10.1016/j.ijdevneu.2007.05.009; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.143; Furukawa S, 2014, INT J DEV NEUROSCI, V37, P52, DOI 10.1016/j.ijdevneu.2014.06.011; Furukawa S, 2014, J PERINAT MED, V42, P379, DOI 10.1515/jpm-2013-0175; Furukawa S, 2014, BRAIN RES, V1562, P52, DOI 10.1016/j.brainres.2014.03.028; Gibson GE, 2015, J NEUROCHEM, V134, P86, DOI 10.1111/jnc.13096; Gold PE, 2003, NEUROBIOL LEARN MEM, V80, P194, DOI 10.1016/j.nlm.2003.07.003; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; HASSEL B, 1995, J NEUROCHEM, V64, P2773; Higgins RD, 2011, J PEDIATR-US, V159, P851, DOI 10.1016/j.jpeds.2011.08.004; Hoffmann GF, 1996, NEUROPEDIATRICS, V27, P115, DOI 10.1055/s-2007-973761; Hori T, 2010, TOHOKU J EXP MED, V221, P191, DOI 10.1620/tjem.221.191; Hota KB, 2012, HIPPOCAMPUS, V22, P723, DOI 10.1002/hipo.20934; IMPERATO A, 1989, NEUROSCI LETT, V107, P251, DOI 10.1016/0304-3940(89)90826-4; Inazu M, 2006, J NEUROCHEM, V97, P424, DOI 10.1111/j.1471-4159.2006.03757.x; Inazu Masato, 2008, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V28, P113; Invernizzi F, 2001, J INHERIT METAB DIS, V24, P601, DOI 10.1023/A:1012476029536; Ishii T, 2000, JPN J PHARMACOL, V83, P119, DOI 10.1254/jjp.83.119; JANIRI L, 1991, J NEURAL TRANSM-GEN, V86, P135, DOI 10.1007/BF01250574; Januszewicz E, 2010, NEUROCHEM RES, V35, P743, DOI 10.1007/s11064-010-0131-5; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Juul SE, 2014, CLIN PERINATOL, V41, P119, DOI 10.1016/j.clp.2013.09.004; Karakoc E, 2006, CLIN NEUROL NEUROSUR, V108, P794, DOI 10.1016/j.clineuro.2005.10.012; KAWAMURA N, 1988, ARCH BIOCHEM BIOPHYS, V264, P546, DOI 10.1016/0003-9861(88)90320-7; KIDOUCHI K, 1987, CLIN CHIM ACTA, V164, P261, DOI 10.1016/0009-8981(87)90300-7; Kim H, 2012, NEUROL SCI, V33, P1393, DOI 10.1007/s10072-012-0939-7; Kobayashi S, 2010, GERIATR GERONTOL INT, V10, pS99, DOI 10.1111/j.1447-0594.2010.00595.x; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2010, DEV NEUROSCI-BASEL, V32, P335, DOI 10.1159/000323016; Kocsis K, 2015, J NEURAL TRANSM, V122, P867, DOI 10.1007/s00702-014-1343-7; Kolker S, 2011, J INHERIT METAB DIS, V34, P677, DOI 10.1007/s10545-011-9289-5; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; Kuratsune H, 1997, BIOCHEM BIOPH RES CO, V231, P488, DOI 10.1006/bbrc.1996.5919; Lamhonwah AM, 2008, BRAIN DEV-JPN, V30, P31, DOI 10.1016/j.braindev.2007.05.005; Limketkai BN, 2008, J GEN INTERN MED, V23, P210, DOI 10.1007/s11606-007-0473-0; LIU YB, 1993, FREE RADICAL BIO MED, V15, P667, DOI 10.1016/0891-5849(93)90171-P; LLOYDSTILL JD, 1993, ACTA PAEDIATR, V82, P145, DOI 10.1111/j.1651-2227.1993.tb12626.x; Longo N, 2006, AM J MED GENET C, V142C, P77, DOI 10.1002/ajmg.c.30087; Longo N, 2016, ANN NUTR METAB, V68, P5, DOI 10.1159/000448321; Madiraju Padma, 2009, Epigenetics, V4, P399; Marcovina SM, 2013, TRANSL RES, V161, P73, DOI 10.1016/j.trsl.2012.10.006; MARKOWSKA AL, 1990, NEUROBIOL AGING, V11, P491, DOI 10.1016/0197-4580(90)90109-D; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MATSUISHI T, 1991, BIOCHEM MED METAB B, V45, P244, DOI 10.1016/0885-4505(91)90027-I; MATSUMOTO K, 1993, CLIN CHIM ACTA, V216, P135, DOI 10.1016/0009-8981(93)90146-U; McKenna MC, 2016, ADV NEUROBIOL, V13, P59, DOI 10.1007/978-3-319-45096-4_4; McKenna MC, 2015, NEUROCHEM RES, V40, P2527, DOI 10.1007/s11064-015-1600-7; McKenna MC, 2015, J NEUROCHEM, V134, P3, DOI 10.1111/jnc.13150; Mescka CP, 2013, INT J DEV NEUROSCI, V31, P21, DOI 10.1016/j.ijdevneu.2012.10.109; Miecz D, 2008, J NEUROCHEM, V104, P113, DOI 10.1111/j.1471-4159.2007.05024.x; MINKLER PE, 1993, J CHROMATOGR-BIOMED, V613, P203, DOI 10.1016/0378-4347(93)80135-Q; Mitsushima D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3760; Morken TS, 2014, STROKE, V45, P2777, DOI 10.1161/STROKEAHA.114.005341; Muoio DM, 2012, CELL METAB, V15, P764, DOI 10.1016/j.cmet.2012.04.005; Nalecz KA, 1996, ACTA NEUROBIOL EXP, V56, P597; Nalecz Katarzyna A., 2004, Molecular Aspects of Medicine, V25, P551; Nasca C, 2013, P NATL ACAD SCI USA, V110, P4804, DOI 10.1073/pnas.1216100110; NOVAK M, 1988, J PEDIATR GASTR NUTR, V7, P220, DOI 10.1097/00005176-198803000-00011; NOVAK M, 1981, PEDIATRICS, V67, P95; Okun JG, 2002, BBA-MOL CELL BIOL L, V1584, P91, DOI 10.1016/S1388-1981(02)00296-2; Ori C, 2002, BRAIN RES, V951, P330, DOI 10.1016/S0006-8993(02)03290-0; Osredkar D, 2010, NEUROBIOL DIS, V38, P259, DOI 10.1016/j.nbd.2010.01.015; PANDE SV, 1971, J BIOL CHEM, V246, P402; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Phillis J. W., 2005, Critical Reviews in Neurobiology, V17, P161; Picconi B, 2006, NEUROPHARMACOLOGY, V50, P917, DOI 10.1016/j.neuropharm.2006.01.002; PIOVESAN P, 1995, INT J DEV NEUROSCI, V13, P13, DOI 10.1016/0736-5748(94)00070-J; POORTHUIS BJHM, 1993, CLIN CHIM ACTA, V216, P53, DOI 10.1016/0009-8981(93)90138-T; RASHED MS, 1995, PEDIATR RES, V38, P324, DOI 10.1203/00006450-199509000-00009; Rashidi-Nezhad A, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-75; Rau TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040881; Reuter SE, 2012, CLIN PHARMACOKINET, V51, P553, DOI 10.2165/11633940-000000000-00000; Ribas GS, 2014, GENE, V533, P469, DOI 10.1016/j.gene.2013.10.017; Ricciolini R, 1998, J NEUROCHEM, V71, P2510; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; ROE CR, 1983, ARCH DIS CHILD, V58, P916, DOI 10.1136/adc.58.11.916; ROE CR, 1985, PEDIATR RES, V19, P459, DOI 10.1203/00006450-198505000-00011; ROE CR, 1984, J CLIN INVEST, V73, P1785, DOI 10.1172/JCI111387; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Sakai E, 2013, NEUROPEDIATRICS, V44, P218, DOI 10.1055/s-0032-1333439; Sarter M, 2003, NEUROBIOL LEARN MEM, V80, P245, DOI 10.1016/S1074-7427(03)00070-4; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; SCHMIDTSOMMERFELD E, 1989, J PEDIATR-US, V115, P577, DOI 10.1016/S0022-3476(89)80284-7; Schols L, 2005, J NEURAL TRANSM, V112, P789, DOI 10.1007/s00702-004-0216-x; Schuck PF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126606; Schuck PF, 2010, LIFE SCI, V87, P139, DOI 10.1016/j.lfs.2010.05.019; Shea TB, 2007, NEUROMOL MED, V9, P264, DOI 10.1007/s12017-007-8005-y; Shinohara M, 2011, BRAIN DEV-JPN, V33, P512, DOI 10.1016/j.braindev.2010.09.002; SHUG AL, 1975, AM J PHYSIOL, V228, P689; Sitta A, 2011, CELL MOL NEUROBIOL, V31, P429, DOI 10.1007/s10571-010-9636-3; Smeland OB, 2012, NEUROCHEM INT, V61, P100, DOI 10.1016/j.neuint.2012.04.008; Smith AL, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2585230; Spiekerkoetter U, 2010, J INHERIT METAB DIS, V33, P539, DOI 10.1007/s10545-010-9121-7; Stanley C A, 1995, Adv Pediatr, V42, P209; Stanley C.A., 2014, ONLINE METABOLIC MOL; Stanley CA, 2004, ANN NY ACAD SCI, V1033, P42, DOI 10.1196/annals.1320.004; STUMPF DA, 1980, PEDIATR RES, V14, P1127, DOI 10.1203/00006450-198010000-00008; Suchy J, 2009, NUTR RES, V29, P70, DOI 10.1016/j.nutres.2008.11.004; Szabo K, 2017, DRUG METAB PHARMACOK, V32, P165, DOI 10.1016/j.dmpk.2016.08.005; Tang SY, 2016, DEV NEUROSCI-BASEL, V38, P384, DOI 10.1159/000455041; Thomas RH, 2010, J NEUROCHEM, V113, P515, DOI 10.1111/j.1471-4159.2010.06614.x; Ueno Y, 2015, J CEREBR BLOOD F MET, V35, P382, DOI 10.1038/jcbfm.2014.210; Vaz FM, 2002, BIOCHEM J, V361, P417, DOI 10.1042/0264-6021:3610417; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; Neto EV, 2012, BRAZ J MED BIOL RES, V45, P546, DOI 10.1590/S0100-879X2012007500056; Virmani A, 2011, CURR NEUROPHARMACOL, V9, P195, DOI 10.2174/157015911795017182; Virmani MA, 2001, ANN NY ACAD SCI, V939, P162; Wainwright MS, 2006, STROKE, V37, P524, DOI 10.1161/01.STR.0000198892.15269.f7; Wainwright MS, 2003, PEDIATR RES, V54, P688, DOI 10.1203/01.PDR.0000085036.07561.9C; Walters JL, 2017, NEUROTOXICOL TERATOL, V60, P2, DOI 10.1016/j.ntt.2016.11.005; Waniewski RA, 1998, J NEUROSCI, V18, P5225; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; WHITE HL, 1990, NEUROCHEM RES, V15, P597, DOI 10.1007/BF00973749; Wilson ADH, 2007, J PLAST RECONSTR AES, V60, P114, DOI 10.1016/j.bjps.2006.04.017; WOLFF JA, 1986, LANCET, V1, P289; Xu S, 2015, MAGN RESON MED, V74, P1530, DOI 10.1002/mrm.25537; Yang J, 2008, IEEE ENG MED BIO, P363, DOI 10.1109/IEMBS.2008.4649165; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yu ZP, 1997, N-S ARCH PHARMACOL, V355, P545, DOI 10.1007/PL00004981; Zaitone SA, 2012, PHARMACOL BIOCHEM BE, V100, P347, DOI 10.1016/j.pbb.2011.09.002; Zanelli SA, 2005, ANN NY ACAD SCI, V1053, P153, DOI 10.1196/annals.1344.013; Zhang R, 2012, INT J MOL SCI, V13, P2078, DOI 10.3390/ijms13022078; Zhang X, 2013, J MOL PHARM ORG PROC, DOI [10.4172/2329-9029.1000102, DOI 10.4172/2329-9029.1000102]; Zhang X, 2016, ANESTHESIOLOGY, V125, P133, DOI 10.1097/ALN.0000000000001154; Zou X, 2008, NEUROSCIENCE, V151, P1053, DOI 10.1016/j.neuroscience.2007.12.013	169	71	75	1	30	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUN	2017	42	6			SI		1661	1675		10.1007/s11064-017-2288-7			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EW4GA	WOS:000402458800010	28508995	Green Accepted			2021-06-18	
J	Szwajgier, D; Borowiec, K; Pustelniak, K				Szwajgier, Dominik; Borowiec, Kamila; Pustelniak, Katarzyna			The Neuroprotective Effects of Phenolic Acids: Molecular Mechanism of Action	NUTRIENTS			English	Article						cinnamic acids; benzoic acids; polyphenols; neuroprotection; neuroinflammation; central nervous system; neuron; glial cell; neurological disorder	CORD ISCHEMIA/REPERFUSION INJURY; MAJOR FOOD SOURCES; P-COUMARIC ACID; FERULIC ACID; CAFFEIC ACID; ROSMARINIC ACID; PHENETHYL ESTER; GALLIC ACID; CHLOROGENIC ACID; ELLAGIC ACID	The neuroprotective role of phenolic acids from food has previously been reported by many authors. In this review, the role of phenolic acids in ameliorating depression, ischemia/reperfusion injury, neuroinflammation, apoptosis, glutamate-induced toxicity, epilepsy, imbalance after traumatic brain injury, hyperinsulinemia-induced memory impairment, hearing and vision disturbances, Parkinson's disease, Huntington's disease, anti-amyotrophic lateral sclerosis, Chagas disease and other less distributed diseases is discussed. This review covers the in vitro, ex vivo and in vivo studies concerning the prevention and treatment of neurological disorders (on the biochemical and gene expression levels) by phenolic acids.	[Szwajgier, Dominik; Borowiec, Kamila; Pustelniak, Katarzyna] Univ Life Sci Lublin, Human Nutr & Sci Food Commod, Dept Biotechnol, PL-20704 Lublin, Poland	Borowiec, K (corresponding author), Univ Life Sci Lublin, Human Nutr & Sci Food Commod, Dept Biotechnol, PL-20704 Lublin, Poland.	dszwajgier@hotmail.com; kam.borowiec@gmail.com; kasia.pustus@wp.pl		Borowiec, Kamila/0000-0001-6795-8713; Szwajgier, Dominik/0000-0002-2285-0669	Ministry of Science and Higher Education of the Republic of PolandMinistry of Science and Higher Education, Poland [2339/B/P01/2010/38]; University of Life Sciences in Lublin; Polish Government	This scientific work was supported by the Ministry of Science and Higher Education of the Republic of Poland (Scientific Grant No. 2339/B/P01/2010/38) and the University of Life Sciences in Lublin, which is financed by the Polish Government.	Abou-Abbass H, 2016, ELECTROPHORESIS, V37, P1562, DOI 10.1002/elps.201500583; Akyol S, 2015, J INTERCULT ETHNOPHA, V4, P192, DOI 10.5455/jice.20150620024326; Alfredsson CF, 2015, BIOMED PHARMACOTHER, V76, P39, DOI 10.1016/j.biopha.2015.10.008; Alfredsson CF, 2014, BIOMED PHARMACOTHER, V68, P129, DOI 10.1016/j.biopha.2013.08.010; Alkis HE, 2015, INT J RADIAT RES, V13, P297, DOI 10.7508/ijrr.2015.04.002; Aseervatham GSB, 2016, BIOMED PHARMACOTHER, V82, P54, DOI 10.1016/j.biopha.2016.04.066; Ashafaq M., 2016, MOL NEUROBIOL; Ashafaq M, 2016, NEUROSCI LETT, V617, P94, DOI 10.1016/j.neulet.2016.02.001; Aswar M, 2016, INFLAMMOPHARMACOLOGY, V24, P181, DOI 10.1007/s10787-016-0272-5; [白俊鹏 Bai Junpeng], 2015, [中草药, Chinese Traditional and Herbal Drugs], V46, P163; Bak J, 2016, KOREAN J PHYSIOL PHA, V20, P279, DOI 10.4196/kjpp.2016.20.3.279; Balkhi HM, 2016, CNS NEUROL DISORD-DR, V15, P54, DOI 10.2174/1871527315666151110125435; Bhatt R, 2015, DRUG DELIV, V22, P931, DOI 10.3109/10717544.2014.880860; Blanchard HC, 2015, PROSTAG LEUKOTR ESS, V96, P25, DOI 10.1016/j.plefa.2015.01.002; Bourne LC, 1998, BIOCHEM BIOPH RES CO, V253, P222, DOI 10.1006/bbrc.1998.9681; Cao YD, 2016, INT J MOL MED, V38, P567, DOI 10.3892/ijmm.2016.2623; Cetin D, 2016, CYTOTECHNOLOGY, V68, P1361, DOI 10.1007/s10616-015-9896-3; Chang M X, 1993, Zhongguo Zhong Yao Za Zhi, V18, P300; Chang WC, 2015, FOOD RES INT, V77, P24, DOI 10.1016/j.foodres.2015.04.010; Chen JL, 2015, METAB BRAIN DIS, V30, P129, DOI 10.1007/s11011-014-9635-z; Chen SY, 2016, TROP J PHARM RES, V15, P241, DOI 10.4314/tjpr.v15i2.4; Coelho VR, 2016, N-S ARCH PHARMACOL, V389, P1195, DOI 10.1007/s00210-016-1281-z; Coelho VR, 2015, LIFE SCI, V122, P65, DOI 10.1016/j.lfs.2014.11.009; Crozier A, 2009, NAT PROD REP, V26, P1001, DOI 10.1039/b802662a; Andrade JMD, 2016, CHEM-BIOL INTERACT, V254, P135, DOI 10.1016/j.cbi.2016.06.005; Del Bo C, 2010, J AGR FOOD CHEM, V58, P2491, DOI 10.1021/jf903472x; Dong GC, 2015, MAT SCI ENG C-MATER, V49, P691, DOI 10.1016/j.msec.2015.01.030; Fang SQ, 2016, BIOMED PHARMACOTHER, V79, P254, DOI 10.1016/j.biopha.2016.02.018; Farbood Y., 2015, BASIC CLIN NEUROSCI, V6, P15; Fazili NA, 2015, BIOCHIMIE, V108, P178, DOI 10.1016/j.biochi.2014.11.011; Ferruzzi MG, 2009, J ALZHEIMERS DIS, V18, P113, DOI 10.3233/JAD-2009-1135; Fetoni AR, 2015, FREE RADICAL BIO MED, V85, P269, DOI 10.1016/j.freeradbiomed.2015.04.021; Ge LJ, 2015, ASIAN PAC J TROP MED, V8, P299, DOI 10.1016/S1995-7645(14)60334-5; Ginis Z, 2016, TOXICOL IND HEALTH, V32, P337, DOI 10.1177/0748233713500817; Grigoletto J, 2016, EPILEPSY BEHAV, V62, P27, DOI 10.1016/j.yebeh.2016.06.037; Grosso G, 2016, MATURITAS, V84, P11, DOI 10.1016/j.maturitas.2015.10.014; Grosso G, 2016, MOL NUTR FOOD RES, V60, P223, DOI 10.1002/mnfr.201500620; Grosso G, 2014, NUTRITION, V30, P1398, DOI 10.1016/j.nut.2014.04.012; dos Santos NAG, 2014, NEUROTOXICOLOGY, V45, P131, DOI 10.1016/j.neuro.2014.09.007; Gul Z, 2016, NEUROCHEM RES, V41, P2075, DOI 10.1007/s11064-016-1919-8; Guo YJ, 2015, LIFE SCI, V127, P12, DOI 10.1016/j.lfs.2015.01.036; Guven M, 2015, INFLAMMATION, V38, P2124, DOI 10.1007/s10753-015-0195-0; Guven M, 2015, INFLAMMATION, V38, P1986, DOI 10.1007/s10753-015-0179-0; Guven M, 2015, IRAN J BASIC MED SCI, V18, P356; Guven M, 2015, TURK J MED SCI, V45, P233, DOI 10.3906/sag-1402-71; Hajimoradi M, 2015, AVICENNA J PHYTOMEDI, V5, P288; He F, 2015, J CLIN NEUROSCI, V22, P83, DOI 10.1016/j.jocn.2014.05.038; HERRMANN K, 1989, CRIT REV FOOD SCI, V28, P315, DOI 10.1080/10408398909527504; Hsu SS, 2016, CHEM-BIOL INTERACT, V252, P61, DOI 10.1016/j.cbi.2016.04.010; Huang H, 2016, ACTA PHARMACOL SIN, V37, P1543, DOI 10.1038/aps.2016.88; Hwang ES, 2016, BIOCHEM BIOPH RES CO, V475, P44, DOI 10.1016/j.bbrc.2016.04.153; Ibero-Baraibar I, 2016, J NUTR, V146, p897S, DOI 10.3945/jn.115.222828; Ju DT, 2015, CHINESE J PHYSIOL, V58, P412, DOI 10.4077/CJP.2015.BAD340; Ju DT, 2015, AM J CHINESE MED, V43, P653, DOI 10.1142/S0192415X15500408; Khamse S, 2015, PHARM BIOL, V53, P1818, DOI 10.3109/13880209.2015.1010738; Khan M., 2015, CAFFEIC ACID BIOL PR; Khatri D., 2016, INT J NUTR PHARM NEU, V6, P90, DOI DOI 10.4103/2231-0738.179969; Koh PO, 2015, NEUROSCI LETT, V588, P18, DOI 10.1016/j.neulet.2014.12.047; Kondo S, 2015, J FUNCT FOODS, V14, P758, DOI 10.1016/j.jff.2015.03.001; Lee AY, 2016, BIOMOL THER, V24, P338, DOI 10.4062/biomolther.2015.135; Lee CC, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/678487; Lenzi J, 2015, METAB BRAIN DIS, V30, P1453, DOI 10.1007/s11011-015-9725-6; Li GW, 2015, METAB BRAIN DIS, V30, P1505, DOI 10.1007/s11011-015-9704-y; Lin WC, 2015, IRAN J BASIC MED SCI, V18, P478; Liu HP, 2016, INT J CLIN EXP MED, V9, P12514; Liu QS, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600587; Liu XQ, 2016, NUTRITION, V32, P296, DOI 10.1016/j.nut.2015.09.009; Liu YM, 2017, PHYSIOL BEHAV, V169, P184, DOI 10.1016/j.physbeh.2016.12.003; Lowthian JA, 2016, CONTEMP CLIN TRIALS, V46, P60, DOI 10.1016/j.cct.2015.11.014; Luan H, 2013, J NEUROINFLAMM, V17, P10; Mallik SB, 2016, NEUROSCI LETT, V632, P218, DOI 10.1016/j.neulet.2016.08.044; Mansouri MT, 2016, PHARM BIOL, V54, P1947, DOI 10.3109/13880209.2015.1137601; Margalef M, 2015, J NUTR BIOCHEM, V26, P987, DOI 10.1016/j.jnutbio.2015.04.006; Massocatto C. L., 2016, DIS ESOPHAGUS; Mattila P, 2006, J AGR FOOD CHEM, V54, P7193, DOI 10.1021/jf0615247; Mikami Y, 2015, LIFE SCI, V139, P69, DOI 10.1016/j.lfs.2015.08.005; Moghadas M, 2016, CELL J, V17, P659; Nagarajan S, 2015, PHARM BIOL, V53, P1591, DOI 10.3109/13880209.2014.993041; Naghizadeh B, 2015, DRUG RES, V65, P515, DOI 10.1055/s-0034-1377012; Neider D, 2016, NEUROPSYCH DIS TREAT, V12, P1711, DOI 10.2147/NDT.S107178; [宁巧庆 Ning Qiaoqing], 2016, [中草药, Chinese Traditional and Herbal Drugs], V47, P2497; Ojha S, 2015, DRUG DES DEV THER, V9, P5499, DOI 10.2147/DDDT.S90616; Oyagbemi Ademola Adetokunbo, 2016, Journal of Dietary Supplements, V13, P402, DOI 10.3109/19390211.2015.1103827; Pemminati S, 2015, INDIAN J PSYCHIAT, V57, pS125; Hung PV, 2016, CRIT REV FOOD SCI, V56, P25, DOI 10.1080/10408398.2012.708909; Fernandes FDP, 2014, BEHAV PHARMACOL, V25, P637, DOI 10.1097/FBP.0000000000000076; Qu L, 2016, AM J HEMATOL, V91, pE95; Rahbardar MG, 2017, BIOMED PHARMACOTHER, V86, P441, DOI 10.1016/j.biopha.2016.12.049; Ramanauskiene K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1564257; RITSCHEL WA, 1989, METHOD FIND EXP CLIN, V11, P345; Roehrich ME, 2015, IMMUNOPHARM IMMUNOT, V37, P434, DOI 10.3109/08923973.2015.1081606; Rosinczuk J., 2015, BIOMED RES INT; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Scapagnini G, 2004, ANTIOXID REDOX SIGN, V6, P811, DOI 10.1089/ars.2004.6.811; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; Semaming Y, 2015, APPL PHYSIOL NUTR ME, V40, P1078, DOI 10.1139/apnm-2015-0158; Sen HM, 2015, INFLAMMATION, V38, P1624, DOI 10.1007/s10753-015-0138-9; Shailasree S, 2015, MOL NEUROBIOL, V51, P119, DOI 10.1007/s12035-014-8700-2; Shan Y, 2016, J ALZHEIMERS DIS, V49, P829, DOI 10.3233/JAD-150486; Shang AJ, 2017, NUTR NEUROSCI, V20, P172, DOI 10.1080/1028415X.2015.1103460; Shen Y, 2016, CELL MOL BIOL, V62, P109; Song M, 2016, CELL MOL BIOL, V62, P50, DOI 10.14715/cmb/2016.62.6.9; Szwajgier D., 2017, CURR ALZHEI IN PRESS; Taram F, 2016, BRAIN RES, V1648, P69, DOI 10.1016/j.brainres.2016.07.028; Tarozzi A, 2007, NEUROSCI LETT, V424, P36, DOI 10.1016/j.neulet.2007.07.017; Thrash-Williams B, 2016, LIFE SCI, V154, P24, DOI 10.1016/j.lfs.2016.02.072; Tokmak M, 2015, INFLAMMATION, V38, P1969, DOI 10.1007/s10753-015-0177-2; Tresserra-Rimbau A, 2013, NUTR METAB CARDIOVAS, V23, P953, DOI 10.1016/j.numecd.2012.10.008; Tsai CF, 2015, INT J MOL SCI, V16, P5572, DOI 10.3390/ijms16035572; Tsai CP, 2015, J EPIDEMIOL, V25, P172, DOI 10.2188/jea.JE20140070; Tuzmen MN, 2015, TOXICOL MECH METHOD, V25, P120, DOI 10.3109/15376516.2014.997947; van de Kerkhof NWA, 2015, NEUROPSYCHOBIOLOGY, V71, P212, DOI 10.1159/000431095; Vauzour D, 2007, J AGR FOOD CHEM, V55, P2854, DOI 10.1021/jf063304z; Wang DJ, 2015, MOL NUTR FOOD RES, V59, P1025, DOI 10.1002/mnfr.201400544; Wang DL, 2016, ACTA CIR BRAS, V31, P143, DOI 10.1590/S0102-865020160020000010; Wang HY, 2015, NEUROCHEM RES, V40, P1655, DOI 10.1007/s11064-015-1646-6; Wang LY, 2016, MOL MED REP, V14, P3403, DOI 10.3892/mmr.2016.5586; Wu J. M., 2016, MOLECULES, P21; Wu Jian-liang, 2015, Chinese Pharmacological Bulletin, V31, P97, DOI 10.3969/j.issn.1001-1978.2015.01.021; Wu K, 2014, J ETHNOPHARMACOL, V151, P1133, DOI 10.1016/j.jep.2013.12.027; Xu YX, 2015, NEUROCHEM INT, V91, P72, DOI 10.1016/j.neuint.2015.10.014; Xu Y, 2016, ONCOTARGET, V7, P20455, DOI 10.18632/oncotarget.7973; Yan JJ, 2001, BRIT J PHARMACOL, V133, P89, DOI 10.1038/sj.bjp.0704047; Yao Y, 2015, J ETHNOPHARMACOL, V162, P97, DOI 10.1016/j.jep.2014.12.047; Yi XY, 2017, J STROKE CEREBROVASC, V26, P352, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.030; [尹雪 Yin Xue], 2015, [中草药, Chinese Traditional and Herbal Drugs], V46, P866; Zamora-Ros R, 2016, EUR J NUTR, V55, P1359, DOI 10.1007/s00394-015-0950-x; Zare K, 2015, METAB BRAIN DIS, V30, P205, DOI 10.1007/s11011-014-9604-6; Zhang LM, 2015, EXP THER MED, V9, P972, DOI 10.3892/etm.2014.2157; Zhang YJ, 2011, J ETHNOPHARMACOL, V136, P129, DOI 10.1016/j.jep.2011.04.023; Zhang ZJ, 2015, FREE RADICAL BIO MED, V84, P331, DOI 10.1016/j.freeradbiomed.2015.02.030; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858	132	71	72	0	32	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2072-6643			NUTRIENTS	Nutrients	MAY	2017	9	5							477	10.3390/nu9050477			21	Nutrition & Dietetics	Nutrition & Dietetics	EV8SU	WOS:000402054500055	28489058	DOAJ Gold, Green Published	Y	N	2021-06-18	
J	Bar-Kochba, E; Scimone, MT; Estrada, JB; Franck, C				Bar-Kochba, Eyal; Scimone, Mark T.; Estrada, Jonathan B.; Franck, Christian			Strain and rate-dependent neuronal injury in a 3D in vitro compression model of traumatic brain injury	SCIENTIFIC REPORTS			English	Article							MECHANICAL STRETCH; AMYLOID-BETA; CULTURE; MICROTUBULES; DEFORMATION; ACTIVATION; VIABILITY; CASPASE-3; BREAKING; AXONS	In the United States over 1.7 million cases of traumatic brain injury are reported yearly, but predictive correlation of cellular injury to impact tissue strain is still lacking, particularly for neuronal injury resulting from compression. Given the prevalence of compressive deformations in most blunt head trauma, this information is critically important for the development of future mitigation and diagnosis strategies. Using a 3D in vitro neuronal compression model, we investigated the role of impact strain and strain rate on neuronal lifetime, viability, and pathomorphology. We find that strain magnitude and rate have profound, yet distinctively different effects on the injury pathology. While strain magnitude affects the time of neuronal death, strain rate influences the pathomorphology and extent of population injury. Cellular injury is not initiated through localized deformation of the cytoskeleton but rather driven by excess strain on the entire cell. Furthermore we find that, mechanoporation, one of the key pathological trigger mechanisms in stretch and shear neuronal injuries, was not observed under compression.	[Bar-Kochba, Eyal; Scimone, Mark T.; Estrada, Jonathan B.; Franck, Christian] Brown Univ, Sch Engn, Providence, RI 02912 USA	Franck, C (corresponding author), Brown Univ, Sch Engn, Providence, RI 02912 USA.	franck@brown.edu	Estrada, Jonathan/ABC-3088-2020	Estrada, Jonathan/0000-0003-1083-4597; Scimone, Mark/0000-0003-0123-3765	RI Science and Technology Council; Haythornthwaite Research Initiation Grant; Office of Naval ResearchOffice of Naval Research; National Science FoundationNational Science Foundation (NSF); Graduate Assistance in Areas of National Need (GAANN) fellowship from the Brown University Institute for Molecular and Nanoscale Innovation	The authors acknowledge Molly Boutin and Alana Levine for helpful discussions, and Jennet Toyjanova for her input on early protocol development. Gratefully acknowledge financial support from the RI Science and Technology Council, a Haythornthwaite Research Initiation Grant, and the Office of Naval Research (Dr. Timothy Bentley). E.B.-K. acknowledges support from a National Science Foundation Graduate Research Fellowship. J.B.E. acknowledges support from a Graduate Assistance in Areas of National Need (GAANN) fellowship from the Brown University Institute for Molecular and Nanoscale Innovation.	Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Ahmed WW, 2014, SCI REP-UK, V4, DOI 10.1038/srep04481; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bar-Kochba E, 2015, EXP MECH, V55, P261, DOI 10.1007/s11340-014-9874-2; Berthiaume F., 2014, METHODS BIOENGINEERI; Botev ZI, 2010, ANN STAT, V38, P2916, DOI 10.1214/10-AOS799; Bratosin D, 2005, CYTOM PART A, V66A, P78, DOI 10.1002/cyto.a.20152; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Dingle YTL, 2015, TISSUE ENG PART C-ME, V21, P1274, DOI [10.1089/ten.tec.2015.0135, 10.1089/ten.TEC.2015.0135]; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Estrada JB, 2015, J APPL MECH-T ASME, V82, DOI 10.1115/1.4030821; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fratzl P., 2008, COLLAGEN STRUCTURE M; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Garland P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047552; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Henry SJ, 2014, INTEGR BIOL-UK, V6, P348, DOI 10.1039/c3ib40225h; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Morse JD, 2014, ANN BIOMED ENG, V42, P2501, DOI 10.1007/s10439-014-1091-8; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prevedel R, 2014, NAT METHODS, V11, P727, DOI [10.1038/NMETH.2964, 10.1038/nmeth.2964]; Rajagopalan J, 2010, BIOPHYS J, V99, P3208, DOI 10.1016/j.bpj.2010.09.029; Rousseeuw PJ, 1999, TECHNOMETRICS, V41, P212, DOI 10.2307/1270566; ROUSSEEUW PJ, 1984, J AM STAT ASSOC, V79, P871, DOI 10.2307/2288718; Saif T., 2010, MRS P, V1274; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Siechen S, 2009, P NATL ACAD SCI USA, V106, P12611, DOI 10.1073/pnas.0901867106; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Toyjanova J, 2015, J BIOL CHEM, V290, P3752, DOI 10.1074/jbc.M114.619643; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	58	71	71	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 2	2016	6								30550	10.1038/srep30550			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DS2SB	WOS:000380632800002	27480807	DOAJ Gold, Green Published			2021-06-18	
J	Krajcova, A; Waldauf, P; Andel, M; Duska, F				Krajcova, Adela; Waldauf, Petr; Andel, Michal; Duska, Frantisek			Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports	CRITICAL CARE			English	Article							RAT-LIVER MITOCHONDRIA; FATTY-ACID OXIDATION; GENERAL ANESTHETIC 2,6-DIISOPROPYLPHENOL; FATAL MYOCARDIAL FAILURE; CRITICALLY-ILL ADULTS; INTENSIVE-CARE-UNIT; METABOLIC-ACIDOSIS; LACTIC-ACIDOSIS; MECHANICAL VENTILATION; OVERLOAD SYNDROME	Introduction: Propofol infusion syndrome (PRIS) is a rare, but potentially lethal adverse effect of a commonly used drug. We aimed to review and correlate experimental and clinical data about this syndrome. Methods: We searched for all case reports published between 1990 and 2014 and for all experimental studies on PRIS pathophysiology. We analysed the relationship between signs of PRIS and the rate and duration of propofol infusion causing PRIS. By multivariate logistic regression we looked at the risk factors for mortality. Results: Knowledge about PRIS keeps evolving. Compared to earlier case reports in the literature, recently published cases describe older patients developing PRIS at lower doses of propofol, in whom arrhythmia, hypertriglyceridaemia and fever are less frequently seen, with survival more likely. We found that propofol infusion rate and duration, the presence of traumatic brain injury and fever are factors independently associated with mortality in reported cases of PRIS (area under receiver operator curve = 0.85). Similar patterns of exposure to propofol (in terms of time and concentration) are reported in clinical cases and experimental models of PRIS. Cardiac failure and metabolic acidosis occur early in a dose-dependent manner, while arrhythmia, other electrocardiographic changes and rhabdomyolysis appear more frequently after prolonged propofol infusions, irrespective of dose. Conclusion: PRIS can develop with propofol infusion <4 mg/kg per hour and its diagnosis may be challenging as some of its typical features (hypertriglyceridaemia, fever, hepatomegaly, heart failure) are often (>95 %) missing and others (arrhythmia, electrocardiographic changes) occur late.	[Krajcova, Adela; Andel, Michal; Duska, Frantisek] Charles Univ Prague, Lab Metab & Bioenerget, Fac Med 3, Prague, Czech Republic; [Krajcova, Adela; Andel, Michal] Charles Univ Prague, Ctr Res Diabet Metab & Nutr, Fac Med 3, Prague, Czech Republic; [Waldauf, Petr; Duska, Frantisek] Charles Univ Prague, Dept Anaesthesiol & Intens Care, Fac Med 3, Prague, Czech Republic; [Duska, Frantisek] Nottingham Univ Hosp NHS Trust, Adult Intens Care Unit, Nottingham, England	Krajcova, A (corresponding author), Charles Univ Prague, Lab Metab & Bioenerget, Fac Med 3, Prague, Czech Republic.	adela.krajcova@seznam.cz	Andel, Michal/E-4305-2012; Krajcova, Adela/AAM-6645-2020; Waldauf, Petr/K-6785-2017	Waldauf, Petr/0000-0003-4668-5837; Krajcova, Adela/0000-0002-9859-960X	grant SVV;  [GAUK 270915];  [PRVOUK P31]	We thank Dr. Dale Gardiner and Dr. Tom Munford for valuable comments. Supported by grant GAUK 270915 Mitochondrial pathogenesis of propofol infusion syndrome in an in vitro model of human skeletal muscle and by grants PRVOUK P31 and SVV 2015.	Adolph M., 2009, GER MED SCI, V7, pDoc22; Ahlen K, 2006, EUR J ANAESTH, V23, P990, DOI 10.1017/S0265021506001281; BARCLAY K, 1992, BRIT MED J, V305, P953, DOI 10.1136/bmj.305.6859.953; Baumeister FAM, 2004, NEUROPEDIATRICS, V35, P250, DOI 10.1055/s-2004-820992; BODD E, 1992, TIDSSKR NOR LAEGEFOR, V112, P1636; BRANCA D, 1991, ARCH BIOCHEM BIOPHYS, V290, P517, DOI 10.1016/0003-9861(91)90575-4; BRANCA D, 1991, BIOCHEM PHARMACOL, V42, P87, DOI 10.1016/0006-2952(91)90684-W; BRANCA D, 1995, COMP BIOCHEM PHYS C, V110, P41, DOI 10.1016/0742-8413(94)00078-O; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Burow BK, 2004, ANESTHESIOLOGY, V101, P239, DOI 10.1097/00000542-200407000-00035; Chukwuemeka A, 2006, ANAESTH INTENS CARE, V34, P651, DOI 10.1177/0310057X0603400503; Commissioner COT, MEDWATCH FDA SAF INF; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cree MG, 2008, AM J PHYSIOL-ENDOC M, V294, pE1, DOI 10.1152/ajpendo.00562.2007; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Fong JJ, 2008, CRIT CARE MED, V36, P2281, DOI 10.1097/CCM.0b013e318180c1eb; Fraser GL, 2013, CRIT CARE MED, V41, pS30, DOI 10.1097/CCM.0b013e3182a16898; Gura KM, 2010, NUTR CLIN PRACT, V25, P399, DOI 10.1177/0884533610373770; Haase R, 2005, J NEUROSURG ANESTH, V17, P122, DOI 10.1097/01.ana.0000161267.63160.13; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; HEYMAN MB, 1981, AM J DIS CHILD, V135, P628, DOI 10.1001/archpedi.1981.02130310034012; Holzki J, 2004, PEDIATR ANESTH, V14, P265, DOI 10.1046/j.1460-9592.2003.01179.x; Jiang W, 2012, ACTA PHARMACOL SIN, V33, P27, DOI 10.1038/aps.2011.155; Jouven X, 2001, CIRCULATION, V104, P756, DOI 10.1161/hc3201.094151; Kill C, 2003, PAEDIATR ANAESTH, V13, P823, DOI 10.1046/j.1460-9592.2003.01114.x; KIRKPATRICK M, 1992, BRIT MED J, V305, P1223, DOI 10.1136/bmj.305.6863.1223-a; Koch M, 2004, INTENS CARE MED, V30, P522, DOI 10.1007/s00134-003-2130-3; Lee SK, 2012, CELL SIGNAL, V24, P2329, DOI 10.1016/j.cellsig.2012.07.022; Lin MC, 2012, TOXICOL APPL PHARM, V265, P253, DOI 10.1016/j.taap.2012.08.013; Linko R, 2014, J BURN CARE RES, V35, pE364, DOI 10.1097/BCR.0000000000000053; Lonardo NW, 2014, AM J RESP CRIT CARE, V189, P1383, DOI 10.1164/rccm.201312-2291OC; Marinella MA, 1996, CHEST, V109, P292, DOI 10.1378/chest.109.1.292; Mehta N, 1999, LANCET, V354, P866, DOI 10.1016/S0140-6736(05)75936-5; Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052; Notisfra Bivirkningsnaenet, 1990, UGESKRIFT LAEGER, V152, P1176; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Richter S, 2012, Herzschrittmacherther Elektrophysiol, V23, P56, DOI 10.1007/s00399-011-0156-8; Rigoulet M, 1996, EUR J BIOCHEM, V241, P280; Rinaido P, ACYLCARNITINE PROFIL; Roberts RJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8145; Romero C, 2008, REV MED CHILE, V136, P88, DOI /S0034-98872008000100011; ROTTENBERG H, 1983, P NATL ACAD SCI-BIOL, V80, P3313, DOI 10.1073/pnas.80.11.3313; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Schroeppel TJ, 2014, INJURY, V45, P245, DOI 10.1016/j.injury.2013.05.004; STANLEY CA, 2006, INBORN METABOLIC DIS, P175; Stelow EB, 2000, CLIN CHEM, V46, P577; STRICKLAND RA, 1995, CRIT CARE MED, V23, P405, DOI 10.1097/00003246-199502000-00029; Terrone G, 2014, NEUROLOGY, V82, pE1, DOI 10.1212/01.wnl.0000438217.31437.72; Tiwari R., US ANESTHESIA DRUGS; Tong Xian-xiang, 2010, Sichuan Da Xue Xue Bao Yi Xue Ban, V41, P1021; U.S. Food and Drug Administration MedWatch, 2001, 2001 SAF AL DRUGS BI; U.S. Food snd Drug Administration, 2007, DET VIEW SAF LAB CHA; Vanlander AV, 2015, ANESTHESIOLOGY, V122, P343, DOI 10.1097/ALN.0000000000000484; Westhout FD, 2007, J NEUROSURG, V106, P139, DOI 10.3171/ped.2007.106.2.139; Withington DE, 2004, PEDIATR ANESTH, V14, P505, DOI 10.1111/j.1460-9592.2004.01299.x; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; Wolf AR, 2004, PEDIATR ANESTH, V14, P435, DOI 10.1111/j.1460-9592.2004.01332.x; Ypsilantis P, 2007, ANESTH ANALG, V105, P155, DOI 10.1213/01.ane.0000265544.44948.0b	60	71	72	1	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	NOV 12	2015	19								398	10.1186/s13054-015-1112-5			9	Critical Care Medicine	General & Internal Medicine	CV8RZ	WOS:000364556700001	26558513	DOAJ Gold, Green Published			2021-06-18	
J	Stein, MB; Kessler, RC; Heeringa, SG; Jain, S; Campbell-Sills, L; Colpe, LJ; Fullerton, CS; Nock, MK; Sampson, NA; Schoenbaum, M; Sun, XY; Thomas, ML; Ursano, RJ				Stein, Murray B.; Kessler, Ronald C.; Heeringa, Steven G.; Jain, Sonia; Campbell-Sills, Laura; Colpe, Lisa J.; Fullerton, Carol S.; Nock, Matthew K.; Sampson, Nancy A.; Schoenbaum, Michael; Sun, Xiaoying; Thomas, Michael L.; Ursano, Robert J.		Army STARRS Collaborators	Prospective Longitudinal Evaluation of the Effect of Deployment-Acquired Traumatic Brain Injury on Posttraumatic Stress and Related Disorders: Results From the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							MILITARY PERSONNEL; CLINICAL PRESENTATION; MENTAL-HEALTH; SUICIDE RISK; SYMPTOMS; PTSD; DEPRESSION; ASSOCIATION; IRAQ; TBI	Objective: Traumatic brain injury (TBI) is increasingly recognized as a risk factor for deleterious mental health and functional outcomes. The purpose of this study was to examine the strength and specificity of the association between deployment-acquired TBI and subsequent posttraumatic stress and related disorders among U.S. Army personnel. Method: A prospective, longitudinal survey of soldiers in three Brigade CombatTeams was conducted 1-2 months prior to an average 10-month deployment to Afghanistan (T0), upon redeployment to the United States (T1), approximately 3 months later (T2), and approximately 9 months later (T3). Outcomes of interest were 30-day prevalence. postdeployment of posttraumatic stress disorder (PTSD), major depressive episode, generalized anxiety disorder, and suicidality, as well as presence and severity of postdeployment PTSD symptoms. Results: Complete information was available for 4,645 soldiers. Approximately one in five soldiers reported exposure to mild (18.0%) or more-than-mild (1.2%) TBI(s) during the index deployment. Even after adjusting for other risk factors (e g., predeployment mental health status, severity of deployment stress, prior TBI history), deployment-acquired TBI was associated with elevated adjusted odds of PTSD and generalized anxiety disorder at T2 and T3 and of major depressive episode at T2. Suicidality risk at T2 appeared similarly elevated, but this association did not reach statistical significance. Conclusions: The findings highlight the importance of surveillance efforts to identify soldiers who have sustained TBIs and are therefore at risk for an array of postdeployment adverse mental health outcomes, including but not limited to PTSD. The mechanism(s) accounting for these associations need to be elucidated to inform development of effective preventive and early intervention programs.	[Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; VA San Diego Healthcare Syst, San Diego, CA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Univ Michigan, Inst Social Res, Ann Arbor, MI USA; NIMH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Psychiat, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; Harvard Univ, Dept Psychol, Cambridge, MA USA	Stein, MB (corresponding author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.	mstein@ucsd.edu	Nock, Matthew/AAE-8330-2019; Ursano, Robert/ABE-6533-2020	Ursano, Robert/0000-0002-1861-9173	Department of the Army [U01MH087981]; U S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH087981] Funding Source: NIH RePORTER	Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 with the U S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH).	Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Bryant RA, 2015, BRIT J PSYCHIAT, V206, P417, DOI 10.1192/bjp.bp.114.145516; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Goodkind M, 2015, JAMA PSYCHIAT, V72, P305, DOI 10.1001/jamapsychiatry.2014.2206; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; Heeringa SG., 2010, APPL SURVEY DATA ANA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, JAMA-J AM MED ASSOC, V312, P1685, DOI 10.1001/jama.2014.6670; Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2013, INT J METH PSYCH RES, V22, P303, DOI 10.1002/mpr.1398; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Miller MW, 2014, MOL PSYCHIATR, V19, P1156, DOI 10.1038/mp.2014.111; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Ramsawh HJ, 2014, J AFFECT DISORDERS, V161, P116, DOI 10.1016/j.jad.2014.03.016; Roitman P, 2013, J TRAUMA STRESS, V26, P727, DOI 10.1002/jts.21862; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanev KS, 2014, BRAIN INJURY, V28, P261, DOI 10.3109/02699052.2013.873821; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	40	71	71	0	21	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	NOV	2015	172	11					1101	1111		10.1176/appi.ajp.2015.14121572			11	Psychiatry	Psychiatry	CV0CJ	WOS:000363914700013	26337036	Green Accepted, Bronze			2021-06-18	
J	Goldshmit, Y; Kanner, S; Zacs, M; Frisca, F; Pinto, AR; Currie, PD; Pinkas-Kramarski, R				Goldshmit, Yona; Kanner, Sivan; Zacs, Maria; Frisca, Frisca; Pinto, Alexander R.; Currie, Peter D.; Pinkas-Kramarski, Ronit			Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Rapamycin; Spinal cord injury; Akt; Inflammation; Astrogliosis; Neuronal survival	UP-REGULATION; CEREBRAL-ISCHEMIA; PROTEIN-KINASE; AUTOPHAGY; INHIBITION; PATHWAY; TARGET; REGENERATION; IMPROVEMENT; ACTIVATION	Spinal cord injury (SCI) frequently leads to a permanent functional impairment as a result of the initial injury followed by secondary injury mechanism, which is characterised by increased inflammation, glial scarring and neuronal cell death. Finding drugs that may reduce inflammatory cell invasion and activation to reduce glial scarring and increase neuronal survival is of major importance for improving the outcome after SCI. In the present study, we examined the effect of rapamycin, an mTORC1 inhibitor and an inducer of autophagy, on recovery from spinal cord injury. Autophagy, a process that facilitates the degradation of cytoplasmic proteins, is also important for maintenance of neuronal homeostasis and plays a major role in neurodegeneration after neurotrauma. We examined rapamycin effects on the inflammatory response, glial scar formation, neuronal survival and regeneration in vivo using spinal cord hemisection model in mice, and in vitro using primary cortical neurons and human astrocytes. We show that a single injection of rapamycin, inhibited p62/SQSTM1, a marker of autophagy, inhibited mTORC1 downstream effector p70S6K, reduced macrophage/neutrophil infiltration into the lesion site, microglia activation and secretion of TNF alpha. Rapamycin inhibited astrocyte proliferation and reduced the number of GFAP expressing cells at the lesion site. Finally, it increased neuronal survival and axonogenesis towards the lesion site. Our study shows that rapamycin treatment increased significantly p-Akt levels at the lesion site following SCI. Similarly, rapamycin treatment of neurons and astrocytes induced p-Akt elevation under stress conditions. Together, these findings indicate that rapamycin is a promising candidate for treatment of acute SCI condition and may be a useful therapeutic agent. (C) 2015 Elsevier Inc. All rights reserved.	[Goldshmit, Yona; Kanner, Sivan; Zacs, Maria; Pinkas-Kramarski, Ronit] Tel Aviv Univ, Dept Neurobiol, IL-69978 Ramat Aviv, Israel; [Goldshmit, Yona; Frisca, Frisca; Pinto, Alexander R.; Currie, Peter D.] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3800, Australia; [Frisca, Frisca] Univ Melbourne, Dept Ophthalmol, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia	Goldshmit, Y (corresponding author), Tel Aviv Univ, Dept Neurobiol, IL-69978 Ramat Aviv, Israel.	yona.goldshmit@monash.edu; lironit@post.tau.ac.il	Pinto, Alexander/AAF-5556-2021	Pinto, Alexander/0000-0001-6421-4970; Pinkas-Kramarski, Ronit/0000-0002-1000-369X; Currie, Peter/0000-0001-8874-8862	Ministry of Aliyah and Immigrant Absorption [00050001000]; Ministry of Defence for Medical Research [00340051000]	This work was supported by the Ministry of Aliyah and Immigrant Absorption no. 00050001000, and by the Ministry of Defence for Medical Research no. 00340051000, Israel (to YG).	Angliker Nico, 2013, Bioarchitecture, V3, P113, DOI 10.4161/bioa.26497; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; Cicora F, 2010, TRANSPL P, V42, P365, DOI 10.1016/j.transproceed.2009.11.013; Codeluppi S, 2009, J NEUROSCI, V29, P1093, DOI 10.1523/JNEUROSCI.4103-08.2009; Das F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109608; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636; Gregory EN, 2013, J NEUROSCI RES, V91, P300, DOI 10.1002/jnr.23144; Herzog N, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056008; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Pinto AR, 2013, J IMMUNOL METHODS, V393, P74, DOI 10.1016/j.jim.2013.03.012; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Song Y, 2015, J BIOCHEM MOL TOXIC, V29, P29, DOI 10.1002/jbt.21603; Tachibana T, 2005, J THORAC CARDIOV SUR, V129, P123, DOI 10.1016/j.jtcvs.2004.04.047; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Xie LK, 2014, J IMMUNOL, V192, P6009, DOI 10.4049/jimmunol.1303492	35	71	75	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	SEP	2015	68						82	91		10.1016/j.mcn.2015.04.006			10	Neurosciences	Neurosciences & Neurology	CU2MO	WOS:000363357800008	25936601				2021-06-18	
J	Leddy, JJ; Baker, JG; Merchant, A; Picano, J; Gaile, D; Matuszak, J; Willer, B				Leddy, John J.; Baker, John G.; Merchant, Asim; Picano, John; Gaile, Daniel; Matuszak, Jason; Willer, Barry			Brain or Strain? Symptoms Alone Do Not Distinguish Physiologic Concussion From Cervical/Vestibular Injury	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; cervical; symptoms; vestibular; strain	SPORT-RELATED CONCUSSION; POSTTRAUMATIC HEADACHE; CERVICOGENIC HEADACHE; WHIPLASH; MANAGEMENT; THRESHOLD; DIZZINESS; STATEMENT; DIAGNOSIS; REST	Objective: To compare symptoms in patients with physiologic postconcussion disorder (PCD) versus cervicogenic/vestibular PCD. We hypothesized that most symptoms would not be equivalent. In particular, we hypothesized that cognitive symptoms would be more often associated with physiologic PCD. Design: Retrospective review of symptom reports from patients who completed a 22-item symptom questionnaire. Setting: University-based concussion clinic. Patients: Convenience sample of 128 patients who had symptoms after head injury for more than 3 weeks and who had provocative treadmill exercise testing. Independent Variables: Subjects were classified as either physiologic PCD (abnormal treadmill performance and a normal cervical/vestibular physical examination) or cervicogenic/vestibular PCD (CGV, normal treadmill performance, and an abnormal cervical/vestibular physical examination). Main Outcome Measures: Self-reported symptoms. Univariate and multivariate methods, including t tests, tests of equivalence, a logistic regression model, k-nearest neighbor analysis, multidimensional scaling, and principle components analysis were used to see whether symptoms could distinguish PCD from CGV. Results: None of the statistical methods used to analyze self-reported symptoms was able to adequately distinguish patients with PCD from patients with CGV. Conclusions: Symptoms after head injury, including cognitive symptoms, have traditionally been ascribed to brain injury, but they do not reliably discriminate between physiologic PCD and cervicogenic/vestibular PCD. Clinicians should consider specific testing of exercise tolerance and perform a physical examination of the cervical spine and the vestibular/ocular systems to determine the etiology of postconcussion symptoms.	[Leddy, John J.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14214 USA; [Leddy, John J.; Merchant, Asim] SUNY Buffalo, Univ Sports Med, Dept Orthopaed, Buffalo, NY 14214 USA; [Baker, John G.] SUNY Buffalo, Dept Nucl Med & Orthopaed, Buffalo, NY 14214 USA; [Merchant, Asim; Matuszak, Jason] SUNY Buffalo, Dept Family Med, Buffalo, NY 14214 USA; [Picano, John] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; [Gaile, Daniel] SUNY Buffalo, Dept Biostat, Buffalo, NY 14214 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA	Leddy, JJ (corresponding author), SUNY Buffalo, Univ Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu			Robert Rich Family Foundation; Buffalo Sabres Foundation; Program for Understanding Childhood Concussion and Stroke; Ralph C. Wilson Foundation; National Football League Charities	The authors thank the following organizations for financial support of the project described in this article: The Robert Rich Family Foundation, The Buffalo Sabres Foundation, Program for Understanding Childhood Concussion and Stroke, The Ralph C. Wilson Foundation, and the National Football League Charities.	Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Cooper MT, 2003, CLIN SPORT MED, V22, P427, DOI 10.1016/S0278-5919(02)00110-2; Drottning M, 2002, CEPHALALGIA, V22, P165, DOI 10.1046/j.1468-2982.2002.00315.x; Endo K, 2006, EUR SPINE J, V15, P886, DOI 10.1007/s00586-005-0970-y; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Findling O, 2011, GAIT POSTURE, V34, P473, DOI 10.1016/j.gaitpost.2011.06.021; Giza CC, 2001, J ATHL TRAINING, V36, P228; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Leslie O, 2013, CLIN J SPORT MED, V23, P331, DOI 10.1097/JSM.0b013e318295bbb1; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Spitzer W, 1995, SPINE, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Treleaven J, 2011, MANUAL THER, V16, P252, DOI 10.1016/j.math.2010.11.002; Wellek S., 2010, TESTING STAT HYPOTHE; Whiteside JW, 2006, AM FAM PHYSICIAN, V74, P1357; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Zumsteg D, 2006, CAN J NEUROL SCI, V33, P379, DOI 10.1017/S0317167100005333	37	71	72	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2015	25	3					237	242		10.1097/JSM.0000000000000128			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	CH3EX	WOS:000353911700007	25051194				2021-06-18	
J	Ling, H; Hardy, J; Zetterberg, H				Ling, Helen; Hardy, John; Zetterberg, Henrik			Neurological consequences of traumatic brain injuries in sports	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Chronic traumatic encephalopathy; Dementia pugilistica; Tau; Concussion; Traumatic brain injury; TDP-43	COLLEGIATE FOOTBALL PLAYERS; AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; ALZHEIMERS-DISEASE; PROFESSIONAL FOOTBALL; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; CEREBROSPINAL-FLUID	Traumatic brain injury (TBI) is common in boxing and other contact sports. The long term irreversible and progressive aftermath of TBI in boxers depicted as punch drunk syndrome was described almost a century ago and is now widely referred as chronic traumatic encephalopathy (CTE). The short term sequelae of acute brain injury including subdural haematoma and catastrophic brain injury may lead to death, whereas mild TBI, or concussion, causes functional disturbance and axonal injury rather than gross structural brain damage. Following concussion, symptoms such as dizziness, nausea, reduced attention, amnesia and headache tend to develop acutely but usually resolve within a week or two. Severe concussion can also lead to loss of consciousness. Despite the transient nature of the clinical symptoms, functional neuroimaging, electrophysiological, neuropsychological and neurochemical assessments indicate that the disturbance of concussion takes over a month to return to baseline and neuropathological evaluation shows that concussion-induced axonopathy may persist for years. The developing brains in children and adolescents are more susceptible to concussion than adult brain. The mechanism by which acute TBI may lead to the neurodegenerative process of CTE associated with tau hyperphosphorylation and the development of neurofibrillary tangles (NFTs) remains speculative. Focal tau-positive NFTs and neurites in close proximity to focal axonal injury and foci of microhaemorrhage and the predilection of CTE-tau pathology for perivascular and subcortical regions suggest that acute TBI-related axonal injury, loss of microvascular integrity, breach of the blood brain barrier, resulting inflammatory cascade and microglia and astrocyte activation are likely to be the basis of the mechanistic link of TBI and CTE. This article provides an overview of the acute and long-term neurological consequences of TBI in sports. Clinical, neuropathological and the possible pathophysiological mechanisms are discussed. This article is part of a Special Issue entitled 'Traumatic Brain Injury'. (C) 2015 The Authors. Published by Elsevier Inc.	[Ling, Helen; Hardy, John; Zetterberg, Henrik] UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, London WC1N 1PJ, England; [Ling, Helen; Hardy, John; Zetterberg, Henrik] UCL Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London WC1N 1PJ, England; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Clin Neurochem Lab,Inst Neurosci & Physiol, SE-43180 Molndal, Sweden	Ling, H (corresponding author), UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, 1 Wakefield St, London WC1N 1PJ, England.	h.ling@ucl.ac.uk; j.hardy@ucl.ac.uk; henrik.zetterberg@clinchem.gu.se	Meijer, Anna/K-5118-2016; Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423	Corticobasal Degeneration Solutions Research Grant; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Alzheimer's AssociationAlzheimer's Association; Swedish State Support for Clinical Research; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Leonard Wolfson Experimental Neurology Centre	Helen Ling is employed by UCL Institute of Neurology and is funded by the Corticobasal Degeneration Solutions Research Grant. Henrik Zetterberg is a Wallenberg Academy Fellow and receives research support from the Swedish Research Council, Alzheimer's Association, Swedish State Support for Clinical Research and the Knut and Alice Wallenberg Foundation. We gratefully acknowledge the support of the Leonard Wolfson Experimental Neurology Centre.	Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Baird LC, 2010, NEUROSURGERY, V67, P1444, DOI 10.1227/NEU.0b013e3181e5e2cd; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Critchley M, 1949, PUNCH DRUNK SYNDROME; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOSTER JB, 1976, LANCET, V1, P981; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Ling H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-24; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Logan SM, 2001, J ATHL TRAINING, V36, P433; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Miele VJ, 2004, MED SCI SPORT EXER, V36, P1852, DOI 10.1249/01.MSS.0000145470.16938.7A; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Morales R, 2009, CNS NEUROL DISORD-DR, V8, P363, DOI 10.2174/187152709789541998; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mueller F, 2009, CATASTROPHIC FOOTBAL; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Ohhashi G, 2002, BRIT J SPORT MED, V36, P346, DOI 10.1136/bjsm.36.5.346; Okawa Y, 2003, FEBS LETT, V535, P183, DOI 10.1016/S0014-5793(02)03883-8; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Osnato M, 1927, ARCH NEURO PSYCHIATR, V18, P181, DOI 10.1001/archneurpsyc.1927.02210020025002; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramage SN, 2005, NEUROPATH APPL NEURO, V31, P439, DOI 10.1111/j.1365-2990.2005.00670.x; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; STRICEVIC MV, 1983, AM J SPORT MED, V11, P320, DOI 10.1177/036354658301100507; Svinth J.R., 2011, J COMBAT SPORT, P1; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	104	71	73	3	90	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		114	122		10.1016/j.mcn.2015.03.012			9	Neurosciences	Neurosciences & Neurology	CK7FT	WOS:000356398900007	25770439	Other Gold, Green Published			2021-06-18	
J	Wunderle, K; Hoeger, KM; Wasserman, E; Bazarian, JJ				Wunderle, Kathryn; Hoeger, Kathleen M.; Wasserman, Erin; Bazarian, Jeffrey J.			Menstrual Phase as Predictor of Outcome After Mild Traumatic Brain Injury in Women	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; brain injuries; follicular phase; luteal phase; menstrual cycle; postconcussion syndrome; progesterone; quality of life	CONCUSSION SYMPTOMS QUESTIONNAIRE; GENDER-DIFFERENCE; SEX-DIFFERENCES; HEAD-INJURY; CYCLE; PROGESTERONE; FEMALES; HORMONE; IMPACT; TRIAL	Objective: To determine whether menstrual cycle phase in women at the time of mild traumatic brain injury (mTBI) predicts 1-month outcomes. Setting: Six emergency departments; 5 in Upstate New York, and 1 in Pennsylvania. Participants: One hundred forty-four female participants (age, 16-60) who presented to participating emergency departments within 4 hours of mTBI. Design: Nested cohort study with neurologic and quality-of-life outcome assessment, 1 month after enrollment. Female subjects aged 16 to 60 enrolled in the parent cohort study, with 1-month neurological determination data available, were classified into menstrual cycle groups by serum progesterone concentration and self-reported contraceptive use. Main Measures: Rivermead Post Concussion Questionnaire and EuroQoL/EQ5D. Results: Women injured during the luteal phase of their menstrual cycle, when progesterone concentration is high, had significantly lower EuroQoL General Health Ratings and Index Scores than women injured during the follicular phase of their cycle or women taking oral contraceptives. Multivariate analysis confirmed a significant independent effect of menstrual cycle phase on EuroQoL Index Score and the Rivermead Post Concussion Questionnaire Somatic Subscore. Conclusion: Menstrual cycle phase and progesterone concentration at the time of mTBI affect 1-month quality-of-life and neurologic outcomes. This association has important implications for treatment and prognosis after mTBI.	[Wunderle, Kathryn] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA; [Hoeger, Kathleen M.] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA; [Wasserman, Erin] Univ Rochester, Sch Med & Dent, Div Epidemiol, Dept Publ Hlth Sci, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY 14642 USA	Bazarian, JJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Emergency Med, 601 Elmwood Ave,Box 655, Rochester, NY 14642 USA.	Jeff_bazarian@urmc.rochester.edu		Wasserman, Erin/0000-0001-5957-5878	Banyan Biomarkers; Roche Diagnostics; New York State Department of Health; Academic Health Center Consortium; Emergency Research Network of the Empire State (ERNIES); Pilot Research Collaborative Program of the Foundation for Healthy Living; University of Rochester's Clinical and Translational Science Award; Upstate New York Translational Research Network (UNYTRN); Upstate New York Consortium for Healthcare Research and Quality (UNYCHRQ); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024160, KL2RR024136] Funding Source: NIH RePORTER	Jeffrey J. Bazarian has received consulting fees from Banyan Biomarkers and Roche Diagnostics. Jeffrey J. Bazarian was supported by funds from the New York State Department of Health, the Academic Health Center Consortium, and the Emergency Research Network of the Empire State (ERNIES). ERNIES is supported by the Pilot Research Collaborative Program of the Foundation for Healthy Living, the University of Rochester's Clinical and Translational Science Award, the Upstate New York Translational Research Network (UNYTRN) and the Upstate New York Consortium for Healthcare Research and Quality (UNYCHRQ).	Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Belanger Lesley, 2013, J Can Chiropr Assoc, V57, P76; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; CDC, 2003, NATL CENT INJ PREV C; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Mihalik JP, 2009, J SCI MED SPORT, V12, P383, DOI 10.1016/j.jsams.2008.05.003; MOLLERNIELSEN J, 1989, MED SCI SPORT EXER, V21, P126; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Ross C, 2003, J PSYCHOSOM OBST GYN, V24, P15, DOI 10.3109/01674820309042797; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wunder DM, 2008, FERTIL STERIL, V89, P927, DOI 10.1016/j.fertnstert.2007.04.054; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	28	71	71	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					E1	E8		10.1097/HTR.0000000000000006			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700001	24220566	Green Accepted			2021-06-18	
J	Tang, YH; Cai, BB; Yuan, FL; He, XS; Lin, XJ; Wang, JX; Wang, YT; Yang, GY				Tang, Yaohui; Cai, Beibei; Yuan, Falei; He, Xiaosong; Lin, Xiaojie; Wang, Jixian; Wang, Yongting; Yang, Guo-Yuan			Melatonin Pretreatment Improves the Survival and Function of Transplanted Mesenchymal Stem Cells After Focal Cerebral Ischemia	CELL TRANSPLANTATION			English	Article						Melatonin; Mesenchymal stem cells (MSCs); Ischemia; Survival; Angiogenesis	MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; INFARCTED MYOCARDIUM; RAT-BRAIN; STROKE; ANGIOGENESIS; MODEL; REPERFUSION; RECOVERY; THERAPY	Mesenchymal stem cell (MSC) transplantation has been shown to be beneficial in treating cerebral ischemia. However, such benefit is limited by the low survival of transplanted MSCs in an ischemic microenvironment. Previous studies showed that melatonin pretreatment can increase MSC survival in the ischemic kidney. However, whether it will improve MSC survival in cerebral ischemia is unknown. Our study examined the effect of melatonin pretreatment on MSCs under ischemia-related conditions in vitro and after transplantation into ischemic rat brain. Results showed that melatonin pretreatment greatly increased survival of MSCs in vitro and reduced their apoptosis after transplantation into ischemic brain. Melatonin-treated MSCs (MT-MSCs) further reduced brain infarction and improved neurobehavioral outcomes. Angiogenesis, neurogenesis, and the expression of vascular endothelial growth factor (VEGF) were greatly increased in the MT-MSC-treated rats. Melatonin treatment increased the level of p-ERK1/2 in MSCs, which can be blocked by the melatonin receptor antagonist luzindole. ERK phosphorylation inhibitor U0126 completely reversed the protective effects of melatonin, suggesting that melatonin improves MSC survival and function through activating the ERK1/2 signaling pathway. Thus, stem cells pretreated by melatonin may represent a feasible approach for improving the beneficial effects of stem cell therapy for cerebral ischemia.	[Tang, Yaohui; Cai, Beibei; Yuan, Falei; He, Xiaosong; Lin, Xiaojie; Wang, Yongting; Yang, Guo-Yuan] Med X Res Inst, Neurosci & Neuroengn Res Ctr, Shanghai, Peoples R China; [Tang, Yaohui; Cai, Beibei; Yuan, Falei; He, Xiaosong; Lin, Xiaojie; Wang, Yongting; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China; [Wang, Jixian; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, Shanghai 200030, Peoples R China	Yang, GY (corresponding author), Shanghai Jiao Tong Univ, Neurosci & Neuroengn Res Ctr, Med X Res Inst, 1954 Hua Shan Rd, Shanghai 200030, Peoples R China.	yongting.wang@gmail.com; gyyang0626@gmail.com	Tang, Yaohui/AAE-9746-2019; Wang, Yongting/C-2916-2014	Tang, Yaohui/0000-0002-9603-2650; 	Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070939, 81100868]; National Basic Research Program of China (973 Program)National Basic Research Program of China [2011CB504405]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [10JC1408100]; KC Wong Foundation	This study was supported by research Natural Science Foundation of China (81070939 and 81100868), National Basic Research Program of China (973 Program 2011CB504405), the Science and Technology Commission of Shanghai Municipality (10JC1408100), and KC Wong Foundation (G.Y.Y.). We thank Dr Richard E Keep from the University of Michigan and Tiffany Dai from the University of California Berkeley for their valuable discussion and kind editorial assistance. The authors declare no conflicts of interest.	Arendt J, 2000, NEW ENGL J MED, V343, P1114, DOI 10.1056/NEJM200010123431510; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; BOSSI P, 1995, CANCER RES, V55, P5049; Cervantes M, 2008, J PINEAL RES, V45, P1, DOI 10.1111/j.1600-079X.2007.00551.x; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Cheung RTF, 2003, J PINEAL RES, V34, P153, DOI 10.1034/j.1600-079X.2003.00034.x; Edalatmanesh MA, 2011, NEUROL RES, V33, P913, DOI 10.1179/1743132811Y.0000000036; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Folkerth RD, 2000, J NEURO-ONCOL, V50, P165, DOI 10.1023/A:1006499824379; Fraser SE, 1996, METHOD CELL BIOL, V51, P147, DOI 10.1016/S0091-679X(08)60627-5; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harris AL, 1996, BREAST CANCER RES TR, V38, P97, DOI 10.1007/BF01803788; Henrich D, 2009, TISSUE ENG PART C-ME, V15, P551, DOI [10.1089/ten.tec.2008.0385, 10.1089/ten.TEC.2008.0385]; Jin KL, 2011, BRAIN RES, V1374, P56, DOI 10.1016/j.brainres.2010.12.037; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Maharaj DS, 2007, BIOSCIENCE REP, V27, P299, DOI 10.1007/s10540-007-9052-1; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; Mias C, 2008, STEM CELLS, V26, P1749, DOI 10.1634/stemcells.2007-1000; Moriya T, 2007, J PINEAL RES, V42, P411, DOI 10.1111/j.1600-079X.2007.00435.x; Muller-Ehmsen J, 2002, J MOL CELL CARDIOL, V34, P107, DOI 10.1006/jmcc.2001.1491; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Penn MS, 2012, CIRC RES, V110, P304, DOI 10.1161/CIRCRESAHA.111.253427; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x; Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1; Reiter RJ, 2010, ANN MED, V42, P276, DOI 10.3109/07853890903485748; Roh JK, 2008, CURR STEM CELL RES T, V3, P185, DOI 10.2174/157488808785740352; Tambara K, 2003, CIRCULATION, V108, P259, DOI 10.1161/01.cir.0000087430.17543.b8; Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020; Wechsler LR, 2009, STROKE, V40, pS149, DOI 10.1161/STROKEAHA.108.533208; Wei L, 2012, NEUROBIOL DIS, V46, P635, DOI 10.1016/j.nbd.2012.03.002; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099; Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Yang Guo-Yuan, 2003, Angiogenesis, V6, P151, DOI 10.1023/B:AGEN.0000011803.56605.78; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658; Zhang L, 2011, STROKE, V42, P1437, DOI 10.1161/STROKEAHA.110.593129; Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600-079X.2010.00803.x; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	46	71	75	2	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2014	23	10					1279	1291		10.3727/096368913X667510			13	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	AR1YW	WOS:000343381500010	23635511				2021-06-18	
J	Yang, SH; Gangidine, M; Pritts, TA; Goodman, MD; Lentsch, AB				Yang, Sung H.; Gangidine, Matt; Pritts, Timothy A.; Goodman, Michael D.; Lentsch, Alex B.			INTERLEUKIN 6 MEDIATES NEUROINFLAMMATION AND MOTOR COORDINATION DEFICITS AFTER MILD TRAUMATIC BRAIN INJURY AND BRIEF HYPOXIA IN MICE	SHOCK			English	Article						Traumatic brain injury; neuroinflammation; motor coordination; hypoxia; trauma; inflammation	IMPACT; HYPOXEMIA	Traumatic brain injury (TBI) is a leading cause of mortality and disability. Acute postinjury insults after TBI, such as hypoxia, contribute to secondary brain injury and worse clinical outcomes. The functional and neuroinflammatory effects of brief episodes of hypoxia experienced following TBI have not been evaluated. Our previous studies have identified interleukin 6 (IL-6) as a potential mediator of mild TBIYinduced pathology. In the present study, we sought to determine the effects of brief hypoxia on mild TBI and whether IL-6 played a role in the neuroinflammatory and functional deficits after injury. A murine model of mild TBI was induced by a weight drop (500 g from 1.5 cm). After injury, mice were exposed to immediate hypoxia (FIO2 = 15.1%) or normoxia (FIO2 = 21%) for 30 min. Serum and brain samples were analyzed for inflammatory cytokines 24 h after TBI. Neuron-specific enolase was measured as a serum biomarker of brain injury. Evaluation of motor coordination was performed for 5 days after TBI using a rotarod device. In some animals, anti-IL-6 was administered following TBI and hypoxia to neutralize systemic IL-6. Mice undergoing TBI had significant increases in brain injury. Exposure to brief hypoxia after TBI resulted in a more than 5-fold increase in serum neuron-specific enolase. This increase was associated with increases in serum and brain cytokine expression, suggesting that brief hypoxia exacerbates systemic and brain inflammation. Neutralization of IL-6 suppressed postinjury neuroinflammation and neuronal injury. In addition, TBI and hypoxia induced significant motor coordination deficits that were completely abrogated by IL-6 blockade. Exposure to hypoxia after TBI induces neuroinflammation and brain injury. These changes can be mitigated by neutralization of systemic IL-6. Interleukin 6 blockade also corrected the TBI-induced deficit in motor coordination. These data suggest that systemic IL-6 modulates the degree of neuroinflammation and contributes to reduced motor coordination after mild TBI.	[Yang, Sung H.; Gangidine, Matt; Pritts, Timothy A.; Goodman, Michael D.; Lentsch, Alex B.] Univ Cincinnati, Inst Mil Med, Dept Surg, Cincinnati, OH 45267 USA	Lentsch, AB (corresponding author), Univ Cincinnati, Inst Mil Med, Dept Surg, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA.	alex.lentsch@uc.edu		Pritts, Timothy/0000-0003-2495-3255	US Air ForceUnited States Department of Defense [FA8650-10-2-6B01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM08478]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478, K08GM088589] Funding Source: NIH RePORTER	This work was supported by US Air Force grant FA8650-10-2-6B01 and NIH training grant T32 GM08478.	Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Coronado Victor G, 2010, TRAUMATIC BRAIN INJU; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; DILLARD TA, 1995, CHEST, V107, P352, DOI 10.1378/chest.107.2.352; Dine CJ, 2008, CHEST, V133, P1002, DOI 10.1378/chest.07-1354; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Grissom CK, 2006, J TRAUMA, V61, P461, DOI 10.1097/01.ta.0000221699.71596.9d; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaSpina M, 2008, J SURG RES, V148, P121, DOI 10.1016/j.jss.2007.12.786; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075	25	71	72	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	DEC	2013	40	6					471	475		10.1097/SHK.0000000000000037			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	297IL	WOS:000330249000005	24088994	Green Accepted			2021-06-18	
J	Sours, C; Zhuo, JC; Janowich, J; Aarabi, B; Shanmuganathan, K; Gullapalli, RP				Sours, Chandler; Zhuo, Jiachen; Janowich, Jacqueline; Aarabi, Bizhan; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Default mode network interference in mild traumatic brain injury - A pilot resting state study	BRAIN RESEARCH			English	Article						Resting state fMRI; Mild traumatic brain injury; Working memory; Default mode network	NEUROPSYCHOLOGICAL ASSESSMENT METRICS; DIFFUSE AXONAL INJURY; WORKING-MEMORY LOAD; FUNCTIONAL CONNECTIVITY; HEAD-INJURY; COGNITIVE DEFICITS; EXECUTIVE CONTROL; TASK; PERFORMANCE; ATTENTION	In this study we investigated the functional connectivity in 23 Mild TBI (mTBI) patients with and without memory complaints using resting state fMRI in the sub-acute stage of injury as well as a group of control participants. Results indicate that mTBI patients with memory complaints performed significantly worse than patients without memory complaints on tests assessing memory from the Automated Neuropsychological Assessment Metrics (ANAM). Altered functional connectivity was observed between the three groups between the default mode network (DMN) and the nodes of the task positive network (TPN). Altered functional connectivity was also observed between both the TPN and DMN and nodes associated with the Salience Network (SN). Following mTBI there is a reduction in anti-correlated networks for both those with and without memory complaints for the DMN, but only a reduction in the anti-correlated network in mTBI patients with memory complaints for the TPN. Furthermore, an increased functional connectivity between the TPN and SN appears to be associated with reduced performance on memory assessments. Overall the results suggest that a disruption in the segregation of the DMN and the TPN at rest may be mediated through both a direct pathway of increased PC between various nodes of the TPN and DMN, and through an indirect pathway that links the TPN and DMN through nodes of the SN. This disruption between networks may cause a detrimental impact on memory functioning following mTBI, supporting the Default Mode Interference Hypothesis in the context of mTBI related memory deficits. (C) 2013 Elsevier B.V. All rights reserved.	[Sours, Chandler; Zhuo, Jiachen; Janowich, Jacqueline; Gullapalli, Rao P.] Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [Sours, Chandler; Zhuo, Jiachen; Janowich, Jacqueline; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Aarabi, Bizhan] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Sours, Chandler; Gullapalli, Rao P.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 South Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu		Janowich, Jacqueline/0000-0003-3443-589X	DODUnited States Department of Defense [W81XWH-08-1-0725]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081984] Funding Source: NIH RePORTER	The authors would like to thank Joshua Betz for his help with patient recruitment and George Makris and Steve Roys for their help with acquiring and processing the data. This study was supported by DOD award W81XWH-08-1-0725.	Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bluhm RL, 2011, HUM BRAIN MAPP, V32, P1029, DOI 10.1002/hbm.21090; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Centers for Disease Control and Prevention, 2003, NAT CTR INJ PREV CON; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hampson M, 2010, MAGN RESON IMAGING, V28, P1051, DOI 10.1016/j.mri.2010.03.021; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M., 2000, COMPREHENSIVE NEUROP; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reichle ME, 2010, TRENDS COGN SCI, V14, P180, DOI 10.1016/j.tics.2010.01.008; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wu JT, 2011, NEUROSCI LETT, V504, P62, DOI 10.1016/j.neulet.2011.08.059; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	53	71	74	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 6	2013	1537						201	215		10.1016/j.brainres.2013.08.034			15	Neurosciences	Neurosciences & Neurology	264XV	WOS:000327915200022	23994210	Green Accepted			2021-06-18	
J	Tanaka, Y; Matsuwaki, T; Yamanouchi, K; Nishihara, M				Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.			INCREASED LYSOSOMAL BIOGENESIS IN ACTIVATED MICROGLIA AND EXACERBATED NEURONAL DAMAGE AFTER TRAUMATIC BRAIN INJURY IN PROGRANULIN-DEFICIENT MICE	NEUROSCIENCE			English	Article						progranulin; traumatic brain injury; microglia; lysosome	FRONTOTEMPORAL LOBAR DEGENERATION; HOST-DEFENSE; GRANULIN; PROTEIN; GENE; PRECURSOR; INFLAMMATION; MODEL; NEURODEGENERATION; NEUROPROTECTION	Progranulin (PGRN) is known to play a role in the pathogenesis of neurodegenerative diseases. Recently, it has been demonstrated that patients with the homozygous mutation in the GRN gene present with neuronal ceroid lipofuscinosis, and there is growing evidence that PGRN is related to lysosomal function. In the present study, we investigated the possible role of PGRN in the lysosomes of activated microglia in the cerebral cortex after traumatic brain injury (TBI). We showed that the mouse GRN gene has two possible coordinated lysosomal expression and regulation (CLEAR) sequences that bind to transcription factor EB (TFEB), a master regulator of lysosomal genes. PGRN was colocalized with Lamp1, a lysosomal marker, and Lamp1-positive areas in GRN-deficient (KO) mice were significantly expanded compared with wild-type (WT) mice after TBI. Expression of all the lysosome-related genes examined in KO mice was significantly higher than that in WT mice. The number of activated microglia with TFEB localized to the nucleus was also significantly increased in KO as compared with WT mice. Since the TFEB translocation is regulated by the mammalian target of rapamycin complex 1 (mTORC1) activity in the lysosome, we compared ribosomal S6 kinase 1 (S6K1) phosphorylation that reflects mTORC1 activity. S6K1 phosphorylation in KO mice was significantly lower than that in WT mice. In addition, the number of nissl-positive and fluoro-jade B-positive cells around the injury was significantly decreased and increased, respectively, in KO as compared with WT mice. These results suggest that PGRN localized in the lysosome is involved in the activation of mTORC1, and its deficiency leads to increased TFEB nuclear translocation with a resultant increase in lysosomal biogenesis in activated microglia and exacerbated neuronal damage in the cerebral cortex after TBI. (c) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, Tokyo 1138657, Japan	Nishihara, M (corresponding author), Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amnishi@mail.ecc.u-tokyo.ac.jp	Yamanouchi, Keitaro/R-5003-2019		JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23228004, 24-7548]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [12J07548, 23228004] Funding Source: KAKEN	This work was supported in part by JSPS KAKENHI Grant Number 23228004 to MN, and 24-7548 to YT	Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Asakura R, 2011, NEUROREPORT, V22, P881, DOI 10.1097/WNR.0b013e32834bf4ca; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Barrachina M, 2006, NEUROPATH APPL NEURO, V32, P505, DOI 10.1111/j.1365-2990.2006.00756.x; Bateman A, 2009, BIOESSAYS, V31, P1245, DOI 10.1002/bies.200900086; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Carecchio M, 2009, J NEUROL SCI, V287, P291, DOI 10.1016/j.jns.2009.07.011; Ceccariglia S, 2011, NEUROSCIENCE, V174, P160, DOI 10.1016/j.neuroscience.2010.11.024; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Chen HJ, 2012, REV NEUROSCIENCE, V23, P279, DOI 10.1515/revneuro-2012-0001; Chiba S, 2007, J REPROD DEVELOP, V53, P297, DOI 10.1262/jrd.18108; Conus S, 2008, BIOCHEM PHARMACOL, V76, P1374, DOI 10.1016/j.bcp.2008.07.041; Cortini F, 2008, EUR J NEUROL, V15, P1111, DOI 10.1111/j.1468-1331.2008.02266.x; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Ghoshal N, 2012, NEUROBIOL DIS, V45, P395, DOI 10.1016/j.nbd.2011.08.029; Hadano S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009805; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jalanko A, 2009, BBA-MOL CELL RES, V1793, P697, DOI 10.1016/j.bbamcr.2008.11.004; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Khurana V, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001026; Kim S, 2007, J NEUROCHEM, V103, P2640, DOI 10.1111/j.1471-4159.2007.04995.x; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Leibinger M, 2012, NEUROBIOL DIS, V46, P314, DOI 10.1016/j.nbd.2012.01.004; Malik M, 2011, NEUROCHEM RES, V36, P754, DOI 10.1007/s11064-010-0395-9; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCormack R, 2013, J INNATE IMMUN, V5, P185, DOI 10.1159/000345249; Murray PD, 1998, J NEUROSCI, V18, P7306; Nedachi T, 2011, NEUROSCIENCE, V185, P106, DOI 10.1016/j.neuroscience.2011.04.037; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; OBRIEN JS, 1991, FASEB J, V5, P301; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306; Park B, 2011, IMMUNITY, V34, P505, DOI 10.1016/j.immuni.2011.01.018; Pena-Llopis S, 2011, CELL CYCLE, V10, P3987, DOI 10.4161/cc.10.23.18251; Petkau TL, 2010, J COMP NEUROL, V518, P3931, DOI 10.1002/cne.22430; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Selvaraj S, 2012, J CLIN INVEST, V122, P1354, DOI 10.1172/JCI61332; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Sleegers K, 2008, NEUROLOGY, V71, P253, DOI 10.1212/01.wnl.0000289191.54852.75; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Song L, 2011, J LIPID RES, V52, P1542, DOI 10.1194/jlr.M015412; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tao J, 2012, BRAIN RES, V1436, P130, DOI 10.1016/j.brainres.2011.11.063; Thurner L, 2013, J AUTOIMMUN, V42, P29, DOI 10.1016/j.jaut.2012.10.003; Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003; Wang IF, 2012, P NATL ACAD SCI USA, V109, P15024, DOI 10.1073/pnas.1206362109; Wils H, 2012, J PATHOL, V228, P67, DOI 10.1002/path.4043; Xu J, 2011, IET SIGNAL PROCESS, V5, P16, DOI 10.1049/iet-spr.2009.0284; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	61	71	72	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 10	2013	250						8	19		10.1016/j.neuroscience.2013.06.049			12	Neurosciences	Neurosciences & Neurology	223YC	WOS:000324847400002	23830905				2021-06-18	
J	Bramoweth, AD; Germain, A				Bramoweth, Adam D.; Germain, Anne			Deployment-Related Insomnia in Military Personnel and Veterans	CURRENT PSYCHIATRY REPORTS			English	Article						Insomnia; Comorbid insomnia; Military personnel; Veterans; PTSD; Depression; Anxiety; Traumatic brain injury; Suicide; Psychotherapy; Pharmacotherapy; Sleep disorders; Psychiatry	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; BRIEF BEHAVIORAL TREATMENT; ADVERSE CHILDHOOD EXPERIENCES; SLEEP DISTURBANCES; COMBAT VETERANS; CHRONIC NIGHTMARES; SERVICE MEMBERS; DEPRESSION; IRAQ	Insomnia is a prevalent disorder that greatly impacts military personnel, especially those deployed in support of combat efforts. Deployment-related stressors like combat exposure, mild traumatic brain injury (mTBI) irregular sleep-wake schedules, and adjustment to the return home all contribute to insomnia. However, insomnia can also exacerbate the deployment experience and is a risk factor for traumatic stress reactions such as PTSD, depression, and suicide. Military personnel with mTBI are significantly impacted by insomnia; the majority experience sleep disruption and this can impede recovery and rehabilitation. As more service members return home from deployment, treatment is vital to reduce the impact of insomnia. Preliminary outcome data, showing positive results for reduction of sleep disruption, has been found with treatments such as combined cognitive behavioral treatment of insomnia (CBTI) and imagery rehearsal therapy (IRT), preference-based interventions, as well as efforts to broadly disseminate CBTI. The recent literature on the impact and treatment of deployment-related insomnia is reviewed.	[Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15206 USA; [Bramoweth, Adam D.; Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; [Germain, Anne] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA	Germain, A (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St,Sterling Plaza 239, Pittsburgh, PA 15213 USA.	adam.bramoweth@va.gov; germax@upmc.edu	Bramoweth, Adam/ABB-6789-2020	Bramoweth, Adam/0000-0002-3535-0292	VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC), VA Pittsburgh Healthcare System; Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT073961 W81XWH-08-1-0637, PR054093-W81XWH-07-PTSD-IIRA]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH080696]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R34MH080696] Funding Source: NIH RePORTER	Dr. Bramoweth's work is supported by resources and funding from the VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC, Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh Healthcare System. Dr. Germain's work is supported by the Congressionally Directed Medical Research Program (PT073961 W81XWH-08-1-0637; PR054093-W81XWH-07-PTSD-IIRA) and the National Institute of Mental Health (MH080696). The contents do not represent the views of the Department of Veterans Affairs, Department of Defense, or the United States Government.	Agargun MY, 1997, J CLIN PSYCHIAT, V58, P249; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bernert RA, 2005, SLEEP, V28, P1135, DOI 10.1093/sleep/28.9.1135; Bootzin RR., 1972, P AM PSYCHOL ASS, V7, P395, DOI DOI 10.1037/E465522008-198; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Bryan CJ, 2010, MIL MED, V175, P713, DOI 10.7205/MILMED-D-09-00248; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Buysse DJ, 2011, ARCH INTERN MED, V171, P887, DOI 10.1001/archinternmed.2010.535; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; COZZA SJ, 2004, IRAQ WAR CLIN GUIDE; Edinger JD, 2001, SLEEP MED, V2, P493, DOI 10.1016/S1389-9457(01)00078-8; Epstein DR, 2013, REHABIL NURS, V38, P120, DOI 10.1002/rnj.67; Epstein DR, 2012, J REHABIL RES DEV, V49, P867, DOI 10.1682/JRRD.2011.06.0114; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Germain A, 2006, J CLIN SLEEP MED, V2, P403; Germain A, 2007, BEHAV RES THER, V45, P627, DOI 10.1016/j.brat.2006.04.009; Germain A, 2013, AM J PSYCHIAT, V170, P372, DOI 10.1176/appi.ajp.2012.12040432; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Harvey AG, 2001, CLIN PSYCHOL REV, V21, P1037, DOI 10.1016/S0272-7358(00)00083-0; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hughes J, 2013, BEHAV SLEEP MED, V11, P258, DOI 10.1080/15402002.2012.683903; Insana SP, 2012, BIOL PSYCHOL, V89, P570, DOI 10.1016/j.biopsycho.2012.01.001; Karlin BE, 2013, J CONSULT CLIN PSYCH; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; KRAKOW B, 1995, BEHAV RES THER, V33, P837, DOI 10.1016/0005-7967(95)00009-M; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Lande RG, 2013, COMPLEMENT THER MED, V21, P8, DOI 10.1016/j.ctim.2012.11.007; Lavie P, 2001, NEW ENGL J MED, V345, P1825, DOI 10.1056/NEJMra012893; LeardMann CA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-437; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Manber R, 2012, J CLIN SLEEP MED, V8, P209, DOI 10.5664/jcsm.1786; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P1659; Nappi CM, 2010, BEHAV THER, V41, P237, DOI 10.1016/j.beth.2009.03.003; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Reissig CJ, 2009, DRUG ALCOHOL DEPEN, V99, P1, DOI 10.1016/j.drugalcdep.2008.08.001; Roane BM, 2008, SLEEP, V31, P1351; Roehrs T, 2008, SLEEP MED REV, V12, P153, DOI 10.1016/j.smrv.2007.07.004; Roth T, 2011, BIOL PSYCHIAT, V69, P592, DOI 10.1016/j.biopsych.2010.10.023; Sareen J, 2013, PSYCHOL MED, V43, P73, DOI 10.1017/S003329171200102X; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; SPIELMAN AJ, 1987, SLEEP, V10, P45; Spielman AJ, 1991, CASE STUDIES INSOMNI, P1, DOI DOI 10.1007/978-1-4757-9586-8_1; Tanielian T, 2008, RAND CORPORATION MON; Taylor DJ, 2005, SLEEP, V28, P1457, DOI 10.1093/sleep/28.11.1457; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Toblin Robin L., 2012, Morbidity and Mortality Weekly Report, V61, P895; Troxel WM, 2012, BEHAV SLEEP MED, V10, P266, DOI 10.1080/15402002.2011.607200; Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57; van Liempt S, 2013, DEPRESS ANXIETY, V30, P469, DOI 10.1002/da.22054; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Weathers F.W., 1993, PTSD CHECKLIST RELIA; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845	65	71	73	0	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1523-3812			CURR PSYCHIAT REP	Curr. Psychiatry Rep.	OCT	2013	15	10							401	10.1007/s11920-013-0401-4			8	Psychiatry	Psychiatry	224JI	WOS:000324880100003	24005883	Green Accepted			2021-06-18	
J	McCrory, P; Meeuwisse, WH; Aubry, M; Cantu, RC; Dvorak, J; Echemendia, RJ; Engebretsen, L; Johnston, KM; Kutcher, JS; Raftery, M; Sills, A; Benson, BW; Davis, GA; Ellenbogen, R; Guskiewicz, KM; Herring, SA; Iverson, GL; Jordan, BD; Kissick, J; McCrea, M; McIntosh, AS; Maddocks, DL; Makdissi, M; Purcell, L; Putukian, M; Schneider, K; Tator, CH; Turner, M				McCrory, Paul; Meeuwisse, Willem H.; Aubry, Mark; Cantu, Robert C.; Dvorak, Jiri; Echemendia, Ruben J.; Engebretsen, Lars; Johnston, Karen M.; Kutcher, Jeffrey S.; Raftery, Martin; Sills, Allen; Benson, Brian W.; Davis, Gavin A.; Ellenbogen, Richard; Guskiewicz, Kevin M.; Herring, Stanley A.; Iverson, Grant L.; Jordan, Barry D.; Kissick, James; McCrea, Michael; McIntosh, Andrew S.; Maddocks, David L.; Makdissi, Michael; Purcell, Laura; Putukian, Margot; Schneider, Kathryn; Tator, Charles H.; Turner, Michael			Consensus Statement on Concussion in Sport-The 4th International Conference on Concussion in Sport Held in Zurich, November 2012	PM&R			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; POSTURAL CONTROL; HEAD-INJURIES; LONG-TERM; POSTCONCUSSION SYNDROME; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION		[McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Meeuwisse, Willem H.; Schneider, Kathryn] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Aubry, Mark] Int Ice Hockey Federat, Zurich, Switzerland; [Aubry, Mark; Kissick, James] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Cantu, Robert C.] Boston Univ, Med Ctr, Ctr Study Traumat Encephalopathy, Boston, MA USA; [Dvorak, Jiri] Univ Zurich, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin Zulich, Zurich, Switzerland; [Dvorak, Jiri] FIFA Med Assessment & Res Ctr, Zurich, Switzerland; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Engebretsen, Lars] Oslo Univ Hosp, Dept Orthopaed Surg, Oslo, Norway; [Engebretsen, Lars] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Engebretsen, Lars] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Engebretsen, Lars] Int Olymp Comm, Lausanne, Switzerland; [Johnston, Karen M.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Johnston, Karen M.] Athlet Edge Sports Med, Concuss Management Program, Toronto, ON, Canada; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Raftery, Martin] Int Rugby Board, Dublin, Ireland; [Sills, Allen] Vanderbilt Univ, Med Ctr, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Benson, Brian W.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Dept Family Med, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Davis, Gavin A.] Austin Hosp, Dept Neurosurg, Melbourne, Vic 3084, Australia; [Davis, Gavin A.] Cabrini Hosp, Melbourne, Vic, Australia; [Davis, Gavin A.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Sports Med & Neurol Surg, Seattle, WA 98195 USA; [Herring, Stanley A.] Seattle Sports Concuss Program, Seattle, WA USA; [Herring, Stanley A.] Seattle Seahawks, Seattle, WA USA; [Herring, Stanley A.] Seattle Mariners, Seattle, WA USA; [Iverson, Grant L.] Neuropsychol Outcome Assessment Lab, Vancouver, BC, Canada; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Jordan, Barry D.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Jordan, Barry D.] Burke Rehabil Hosp, White Plains, NY USA; [Jordan, Barry D.] New York State Athlet Commiss, New York, NY USA; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI USA; [McIntosh, Andrew S.] Monash Univ, Monash Injury Res Inst, Australian Ctr Res Injury Sports & Its Prevent, Sydney, NSW, Australia; [McIntosh, Andrew S.] Univ New S Wales, Fac Sci, Sydney, NSW, Australia; [McIntosh, Andrew S.] McIntosh Consultancy & Res Pty Ltd, Sydney, NSW, Australia; [Maddocks, David L.] Perry Maddocks Trollope Lawyers, Melbourne, Vic, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Melbourne Physiotherapy Dept, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Purcell, Laura] McMaster Univ, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Newark, NJ 07103 USA; [Tator, Charles H.] Toronto Western Hosp, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Tator, Charles H.] Krembil Neurosci Ctr, Toronto, ON, Canada; [Tator, Charles H.] ThinkFirst Canada, Toronto, ON, Canada; [Turner, Michael] British Horseracing Author, London, England	McCrory, P (corresponding author), Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.			McCrory, Paul/0000-0003-4850-0568; Schneider, Kathryn/0000-0002-5951-5899; Guskiewicz, Kevin/0000-0002-8682-2130; Iverson, Grant/0000-0001-7348-9570			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Broshek DK, 2005, CLIN SPORTS MED, V24, px; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 2002, NEUROSURGERY, V51, P80; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney JS, 2008, BRIT J SPORT MED, V42, P5; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Eckner JT, 2012, PSYCHOL ASSESSMENT, V24, P249, DOI 10.1037/a0025042; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P4; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2004, CLIN SPORTS MED, V23, pix; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI [10.1001/jama.290.19.2556, DOI 10.1001/JAMA.290.19.2556]; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2000, STANDARDIZED ASSESSM, P22; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2011, CLIN SPORTS MED, V30, pxi; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2003, J SCI MED SPORT, V6, P355, DOI 10.1016/S1440-2440(03)80030-0; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Shaw NH, 2004, CMAJ, V170, P8; Shaw NH, 2004, CMAJ, V170, P6; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	163	71	71	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	APR	2013	5	4					255	279		10.1016/j.pmrj.2013.02.012			25	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	137VI	WOS:000318465900002	23466418	Green Accepted			2021-06-18	
J	Cloots, RJH; van Dommelen, JAW; Kleiven, S; Geers, MGD				Cloots, R. J. H.; van Dommelen, J. A. W.; Kleiven, S.; Geers, M. G. D.			Multi-scale mechanics of traumatic brain injury: predicting axonal strains from head loads	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; TBI; Diffuse axonal injury; DAI; Injury criteria; Head model; Finite element method; Multi-scale	PREFRONTAL CORTEX; PYRAMIDAL NEURONS; SOMAL SIZE; MODEL; TISSUE; STEM; NEUROPHYSIOLOGY; CRITERION; BEHAVIOR; STRETCH	The length scales involved in the development of diffuse axonal injury typically range from the head level (i.e., mechanical loading) to the cellular level. The parts of the brain that are vulnerable to this type of injury are mainly the brainstem and the corpus callosum, which are regions with highly anisotropically oriented axons. Within these parts, discrete axonal injuries occur mainly where the axons have to deviate from their main course due to the presence of an inclusion. The aim of this study is to predict axonal strains as a result of a mechanical load at the macroscopic head level. For this, a multi-scale finite element approach is adopted, in which a macro-level head model and a micro-level critical volume element are coupled. The results show that the axonal strains cannot be trivially correlated to the tissue strain without taking into account the axonal orientations, which indicates that the heterogeneities at the cellular level play an important role in brain injury and reliable predictions thereof. In addition to the multi-scale approach, it is shown that a novel anisotropic equivalent strain measure can be used to assess these micro-scale effects from head-level simulations only.	[Cloots, R. J. H.; van Dommelen, J. A. W.; Geers, M. G. D.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands; [Kleiven, S.] Royal Inst Technol, Div Neuron Engn, Sch Technol & Hlth, S-14152 Huddinge, Sweden	van Dommelen, JAW (corresponding author), Eindhoven Univ Technol, Mat Technol Inst, POB 513, NL-5600 MB Eindhoven, Netherlands.	j.a.w.v.dommelen@tue.nl	Geers, Marc G.D./E-4385-2014	Geers, Marc G.D./0000-0002-0009-6351	Dutch Technology Foundation STW, applied science division of NWOTechnologiestichting STWNetherlands Organization for Scientific Research (NWO); Ministry of Economic Affairs; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This work has been supported by the Dutch Technology Foundation STW, applied science division of NWO and the Technology Program of the Ministry of Economic Affairs, and the Swedish Research Council.	Abaqus, 2010, AB 6 10 MAN; Alberts B, 1994, MOL BIOL CELL; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; ARBOGAST KB, 1995, P 39 STAPP CAR CRASH, P153; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cloots RJH, 2012, J MECH BEHAV BIOMED, V5, P41, DOI 10.1016/j.jmbbm.2011.09.012; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Highley JR, 2003, BRIT J PSYCHIAT, V183, P414, DOI 10.1192/bjp.183.5.414; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hutsler JJ, 2003, BRAIN LANG, V86, P226, DOI 10.1016/S0093-934X(02)00531-X; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kouznetsova V, 2001, COMPUT MECH, V27, P37, DOI 10.1007/s004660000212; Marieb E. N., 1998, HUMAN ANATOMY PHYSL; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; Miller R.T., 1998, STAPP CAR CRASH J, P155; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; NHTSA, 1972, OCC CRASH PROT HEAD; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; NOLTE J, 2002, HUMAN BRAIN INTRO IT; Pierri JN, 2001, ARCH GEN PSYCHIAT, V58, P466, DOI 10.1001/archpsyc.58.5.466; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P307, DOI 10.1093/cercor/5.4.307; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; Roberts VL, 1976, HDB HUMAN TOLERANCE; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takhounts EG, 2003, STAPP CAR CRASH J, V47, P51; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	52	71	76	1	31	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JAN	2013	12	1					137	150		10.1007/s10237-012-0387-6			14	Biophysics; Engineering, Biomedical	Biophysics; Engineering	070BF	WOS:000313480100012	22434184	Other Gold			2021-06-18	
J	Piedra, MP; Thompson, EM; Selden, NR; Ragel, BT; Guillaume, DJ				Piedra, Mark P.; Thompson, Eric M.; Selden, Nathan R.; Ragel, Brian T.; Guillaume, Daniel J.			Optimal timing of autologous cranioplasty after decompressive craniectomy in children Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						cranioplasty; intracranial pressure; children decompressive craniectomy; trauma	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; DELAYED CRANIOPLASTY; MULTICENTER; EFFICACY; SURGERY; DEFECTS; REPAIR; FROZEN	Object. The object of this study was to determine if early cranioplasty after decompressive craniectomy for elevated intracranial pressure in children reduces complications. Methods. Sixty-one consecutive cases involving pediatric patients who underwent autologous cranioplasty after decompressive craniectomy for raised intracranial pressure at a single academic children's hospital over 15 years were studied retrospectively. Results. Sixty-one patients were divided into early (< 6 weeks; 28 patients) and late (>= 6 weeks; 33 patients) cranioplasty cohorts. The cohorts were similar except for slightly lower age in the early (8.03 years) than the late (10.8 years) cranioplasty cohort (p < 0.05). Bone resorption after cranioplasty was significantly more common in the late (42%) than the early (14%) cranioplasty cohort (p < 0.05; OR 5.4). No other complication differed in incidence between the cohorts. Conclusions. After decompressive craniectomy for raised intracranial pressure in children, early (< 6 weeks) cranioplasty reduces the occurrence of reoperation for bone resorption, without altering the incidence of other complications. (http://thejns.org/doi/abs/10.3171/2012.6.PEDS1268)	[Piedra, Mark P.; Thompson, Eric M.; Selden, Nathan R.; Ragel, Brian T.; Guillaume, Daniel J.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA	Selden, NR (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol Surg, 3303 SW Bond Ave, Portland, OR 97239 USA.	seldenn@ohsu.edu		Selden, Nathan/0000-0001-6108-9721			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Arnaud E, 2000, CHILD NERV SYST, V16, P659, DOI 10.1007/s003810000321; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chao MT, 2009, PLAST RECONSTR SURG, V123, P976, DOI 10.1097/PRS.0b013e31819ba46f; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; HOCKLEY AD, 1991, PEDIATR NEUROSURG, V16, P271, DOI 10.1159/000120540; Hutchinson Peter, 2007, Neurosurg Focus, V22, pE14; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; POCHON JP, 1991, EUR J PEDIATR SURG, V1, P199, DOI 10.1055/s-2008-1042487; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schuss P, 2012, J NEUROTRAUMA, V29, P2010; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Smith DM, 2011, PLAST RECONSTR SURG, V128, P1053, DOI 10.1097/PRS.0b013e31822b65e4; Sultan SM, 2011, PLAST RECONSTR SURG, V127, P1855, DOI 10.1097/PRS.0b013e31820e89a5; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	30	71	75	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2012	10	4					268	272		10.3171/2012.6.PEDS1268			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	015YX	WOS:000309485300004	22861195				2021-06-18	
J	Vespa, P; McArthur, DL; Stein, N; Huang, SC; Shao, W; Filippou, M; Etchepare, M; Glenn, T; Hovda, DA				Vespa, Paul; McArthur, David L.; Stein, Nathan; Huang, Sung-Cheng; Shao, Weber; Filippou, Maria; Etchepare, Maria; Glenn, Thomas; Hovda, David A.			Tight glycemic control increases metabolic distress in traumatic brain injury: A randomized controlled within-subjects trial	CRITICAL CARE MEDICINE			English	Article						cerebral metabolism; glucose; insulin; microdialysis; positron emission tomography; traumatic brain injury	INTENSIVE INSULIN THERAPY; LACTATE/PYRUVATE RATIO; MICRODIALYSIS; GLUCOSE; TISSUE; SEIZURES; ATROPHY; CRISIS; VALUES; PET	Objective: To determine the effects of tight glycemic control on brain metabolism after traumatic brain injury using brain positron emission tomography and microdialysis. Design: Single-center, randomized controlled within-subject crossover observational trial. Setting: Academic intensive care unit. Methods: We performed a prospective, unblinded randomized controlled within-subject crossover trial of tight (80-110 mg/dL) vs. loose (120-150 mg/dL) glycemic control in patients with severe traumatic brain injury to determine the effects of glycemic control on brain glucose metabolism, as measured by [F-18] deoxy-D-glucose brain positron emission tomography. Brain microdialysis was done simultaneously. Measurements and Main Results: Thirteen severely injured traumatic brain injury patients underwent the study between 3 and 8 days (mean 4.8 days) after traumatic brain injury. In ten of these subjects, global brain and gray matter tissues demonstrated higher glucose metabolic rates while glucose was under tight control as compared with loose control (3.2 +/- 0.6 vs. 2.4 + 0.4, p = .02 [whole brain] and 3.8 +/- 1.4 vs. 2.9 +/- 0.8, p = .05 [gray matter]). However, the responses were heterogeneous with pericontusional tissue demonstrating the least state-dependent change. Cerebral microdialysis demonstrated more frequent critical reductions in glucose (p = .02) and elevations of lactate/pyruvate ratio (p = .03) during tight glycemic control. Conclusion: Tight glycemic control results in increased global glucose uptake and an increased cerebral metabolic crisis after traumatic brain injury. The mechanisms leading to the enhancement of metabolic crisis are unclear, but delivery of more glucose through mild hyperglycemia may be necessary after traumatic brain injury. (Crit Care Med 2012; 40:1923-1929)	[Vespa, Paul] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; [Vespa, Paul; McArthur, David L.; Stein, Nathan; Filippou, Maria; Etchepare, Maria; Glenn, Thomas; Hovda, David A.] Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA USA; [Huang, Sung-Cheng; Shao, Weber] Univ Calif Los Angeles, Sch Med, Dept Nucl Med, Los Angeles, CA USA	Vespa, P (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.	pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408; Filippou-Frye, Maria/0000-0001-5516-0384	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049471, P01 NS 058489-01A2]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049471, P01NS058489] Funding Source: NIH RePORTER	Supported, in part, by NINDS NS049471, P01 NS 058489-01A2, and the UCLA Brain Injury Research Center.	Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; ISHIZU K, 1994, J NUCL MED, V35, P1104; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	25	71	74	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1923	1929		10.1097/CCM.0b013e31824e0fcc			7	Critical Care Medicine	General & Internal Medicine	946EZ	WOS:000304335600031	22610193				2021-06-18	
J	Kabadi, SV; Stoica, BA; Byrnes, KR; Hanscom, M; Loane, DJ; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Hanscom, Marie; Loane, David J.; Faden, Alan I.			Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cell cycle; cyclin-dependent kinases; microglial activation; neurodegeneration	CONTROLLED CORTICAL IMPACT; CELL-CYCLE ACTIVATION; ALZHEIMERS-DISEASE; SPATIAL MEMORY; INJURY; ROSCOVITINE; DAMAGE; NEURONS; DEATH; MICROGLIA	Traumatic brain injury (TBI) induces secondary injury mechanisms, including cell-cycle activation (CCA), which lead to neuronal cell death, microglial activation, and neurologic dysfunction. Here, we show progressive neurodegeneration associated with microglial activation after TBI induced by controlled cortical impact (CCI), and also show that delayed treatment with the selective cyclin-dependent kinase inhibitor roscovitine attenuates posttraumatic neurodegeneration and neuroinflammation. CCI resulted in increased cyclin A and D1 expressions and fodrin cleavage in the injured cortex at 6 hours after injury and significant neurodegeneration by 24 hours after injury. Progressive neuronal loss occurred in the injured hippocampus through 21 days after injury and correlated with a decline in cognitive function. Microglial activation associated with a reactive microglial phenotype peaked at 7 days after injury with sustained increases at 21 days. Central administration of roscovitine at 3 hours after CCI reduced subsequent cyclin A and D1 expressions and fodrin cleavage, improved functional recovery, decreased lesion volume, and attenuated hippocampal and cortical neuronal cell loss and cortical microglial activation. Furthermore, delayed systemic administration of roscovitine improved motor recovery and attenuated microglial activation after CCI. These findings suggest that CCA contributes to progressive neurodegeneration and related neurologic dysfunction after TBI, likely in part related to its induction of microglial activation. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 137-149; doi:10.1038/jcbfm.2011.117; published online 10 August 2011	[Kabadi, Shruti V.; Stoica, Bogdan A.; Hanscom, Marie; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Dept Anesthesiol, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Loane, David J.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, STAR Organized Res Ctr, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Hanscom, Marie/0000-0001-8308-135X; Loane, David/0000-0003-0393-3503; Byrnes, Kimberly/0000-0002-7501-7734	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health, R01 NS052568.	Arendt T, 2003, PROG NEUROBIOL, V71, P83, DOI 10.1016/j.pneurobio.2003.09.007; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gilbert PE, 2009, PROG NEURO-PSYCHOPH, V33, P774, DOI 10.1016/j.pnpbp.2009.03.037; Goldstein LB, 2003, ILAR J, V44, P125, DOI 10.1093/ilar.44.2.125; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lee I, 2005, BEHAV NEUROSCI, V119, P145, DOI 10.1037/0735-7044.119.1.145; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LUNDBERG A, 1998, MOL CELL BIOL, V23, P1044; MARTIN JM, 1996, NEUROANATOMY TEXT AT; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Menn B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012117; Mori T, 1998, ACT NEUR S, V71, P120; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nauta W. J. H., 1986, FUNDAMENTAL NEUROANA; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nutley BP, 2005, MOL CANCER THER, V4, P125; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Zhan XH, 2008, BRAIN RES, V1234, P183, DOI 10.1016/j.brainres.2008.07.094	47	71	73	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2012	32	1					137	149		10.1038/jcbfm.2011.117			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	875DG	WOS:000299010000016	21829212	Green Published, Bronze			2021-06-18	
J	Szmydynger-Chodobska, J; Strazielle, N; Gandy, JR; Keefe, TH; Zink, BJ; Ghersi-Egea, JF; Chodobski, A				Szmydynger-Chodobska, Joanna; Strazielle, Nathalie; Gandy, Jessica R.; Keefe, Timothy H.; Zink, Brian J.; Ghersi-Egea, Jean-Francois; Chodobski, Adam			Posttraumatic invasion of monocytes across the blood-cerebrospinal fluid barrier	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-cerebrospinal fluid barrier; choroid plexus; CC chemokines; monocytes; traumatic brain injury	CHEMOATTRACTANT PROTEIN-1 MCP-1; CHOROID-PLEXUS; INTESTINAL EPITHELIA; BRAIN-INJURY; RAT-BRAIN; EXPRESSION; RECEPTOR; MEDIATORS; CYTOKINE; RECRUITMENT	The invasion of inflammatory cells occurring after ischemic or traumatic brain injury (TBI) has a detrimental effect on neuronal survival and functional recovery after injury. We have recently demonstrated that not only the blood-brain barrier, but also the blood-cerebrospinal fluid (CSF) barrier (BCSFB), has a role in posttraumatic recruitment of neutrophils. Here, we show that TBI results in a rapid increase in synthesis and release into the CSF of a major chemoattractant for monocytes, CCL2, by the choroid plexus epithelium, a site of the BCSFB. Using an in vitro model of the BCSFB, we also show that CCL2 is released across the apical and basolateral membranes of the choroidal epithelium, a pattern of chemokine secretion that promotes leukocyte migration across epithelial barriers. Immunohistochemical and electron microscopic analyses of choroidal tissue provide evidence for the movement of monocytes, sometimes in tandem with neutrophils, along the paracellular pathways between adjacent epithelial cells. These data further support the pathophysiological role of BCSFB in promoting the recruitment of inflammatory cells to the injured brain. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 93-104; doi:10.1038/jcbfm.2011.111; published online 10 August 2011	[Szmydynger-Chodobska, Joanna] Brown Univ, Alpert Med Sch, Dept Emergency Med, Coro Ctr W, Providence, RI 02903 USA; [Strazielle, Nathalie] Brain I Lyon Neurosci Res Ctr, Lyon, France; [Ghersi-Egea, Jean-Francois] Univ Lyon 1, Neurooncol & Neuroinflammat Team, Lyon Neurosci Res Ctr, INSERM U1028,CNRS UMR5292, Lyon, France	Szmydynger-Chodobska, J (corresponding author), Brown Univ, Alpert Med Sch, Dept Emergency Med, Coro Ctr W, Room 112,1 Hoppin St, Providence, RI 02903 USA.	joanna_szmydynger-chodobska@brown.edu		Ghersi-Egea, Jean-Francois/0000-0002-0181-4909	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS49479]; European UnionEuropean Commission [HEALTH-F2-2009-241778]; Department of Emergency Medicine at the Alpert Medical School of Brown University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049479] Funding Source: NIH RePORTER	This work was supported by Grant NS49479 from the NIH (to AC), HEALTH-F2-2009-241778 from the European Union (to NS), and by funds from the Department of Emergency Medicine at the Alpert Medical School of Brown University (to JSC and AC).	Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Batisson M, 2006, J INFECT DIS, V194, P341, DOI 10.1086/505428; Beech JS, 2001, J CEREBR BLOOD F MET, V21, P683, DOI 10.1097/00004647-200106000-00006; Bonini JA, 1997, DNA CELL BIOL, V16, P1249, DOI 10.1089/dna.1997.16.1249; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; COLOTTA F, 1992, J IMMUNOL, V148, P760; DEPASQUALE M, 1989, AM J PHYSIOL, V256, pF1059; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; ERICSSON A, 1995, J COMP NEUROL, V361, P681, DOI 10.1002/cne.903610410; Gouwy M, 2004, J LEUKOCYTE BIOL, V76, P185, DOI 10.1189/jlb.1003479; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; McCormick BA, 1998, J IMMUNOL, V160, P455; Mitchell K, 2009, NEUROSCIENCE, V158, P885, DOI 10.1016/j.neuroscience.2008.10.047; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Newby AC, 2008, ARTERIOSCL THROM VAS, V28, P2108, DOI 10.1161/ATVBAHA.108.173898; PAINE R, 1993, J IMMUNOL, V150, P4561; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; PRODJOSUDJADI W, 1995, KIDNEY INT, V48, P1477, DOI 10.1038/ki.1995.437; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; Strazielle N, 1999, J NEUROSCI, V19, P6275; Strazielle N, 2000, J NEUROPATH EXP NEUR, V59, P561, DOI 10.1093/jnen/59.7.561; Strazielle Nathalie, 2003, Methods Mol Med, V89, P291; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Takahashi M, 2009, J IMMUNOL, V183, P3463, DOI 10.4049/jimmunol.0802812; Thibeault I, 2001, J COMP NEUROL, V434, P461, DOI 10.1002/cne.1187; Toft-Hansen H, 2006, J IMMUNOL, V177, P7242, DOI 10.4049/jimmunol.177.10.7242; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5	36	71	71	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2012	32	1					93	104		10.1038/jcbfm.2011.111			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	875DG	WOS:000299010000012	21829211	Bronze, Green Published			2021-06-18	
J	Truettner, JS; Alonso, OF; Bramlett, HM; Dietrich, WD				Truettner, Jessie S.; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton			Therapeutic hypothermia alters microRNA responses to traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; epigenetics; gene regulation; hypothermia; microscopy	CELL-DEATH MECHANISMS; POSTTRAUMATIC HYPOTHERMIA; EXPRESSION; REGULATORS; MODEL; RNAS; DIFFERENTIATION; ELEGANS	Therapeutic hypothermia promotes protection after traumatic brain injury (TBI). The mechanisms underlying hypothermic protection are multifactorial and may include the modulation of microRNA (miRNA) expression after trauma. We utilized microarrays to examine the effects of posttraumatic hypothermia on the expression of 388 rat miRNAs. Animals were subjected to sham or moderate fluid percussion brain injury, followed by 4 hours of hypothermia (33 degrees C) or normothermia (37 degrees C) and euthanized at 7 or 24 hours. At 7 hours, 47 miRNAs were significantly different (P< 0.05) between TBI and sham (15 higher in TBI and 31 lower). After 24 hours, 15 miRNAs differed by P<0.05 (7 higher and 9 lower). The expression of miRNAs was altered by posttraumatic hypothermia. At 7 hours, seven were higher in hypothermia than normothermia and five were lower. Some miRNAs (e.g., miR874 and miR-451) showed the most difference with hypothermia, with changes verified by quantitative reverse transcriptase-PCR. Regionally specific miRNAs also showed responses to TBI and hypothermia treatments by in situ hybridization. In addition, in vitro neuronal stretch injury studies showed similar temperature-sensitive responses to specific miRNAs. These novel data indicate that the reported beneficial effects of early hypothermia on traumatic outcome may include temperature-sensitive miRNAs involved in basic cell-processing events. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1897-1907; doi:10.1038/jcbfm.2011.33; published online 20 April 2011	[Truettner, Jessie S.; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs, Med Ctr, Miami, FL USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042133, NS 030291]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER	This work supported by NIH/NINDS NS042133, NIH/NINDS NS 030291, and The Miami Project to Cure Paralysis.	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Harris A, 2010, AM J TRANSPLANT, V10, P713, DOI 10.1111/j.1600-6143.2010.03032.x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012; KEANE RW, 1992, TRANSPLANTATION, V54, P520, DOI 10.1097/00007890-199209000-00025; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lee YS, 2006, CURR OPIN INVEST DR, V7, P560; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Liu YT, 2010, PHYSIOL GENOMICS, V42A, P39, DOI 10.1152/physiolgenomics.00054.2010; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Pena JTG, 2009, NAT METHODS, V6, P139, DOI [10.1038/nmeth.1294, 10.1038/NMETH.1294]; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Qurashi A, 2010, CURR PSYCHIAT REP, V12, P154, DOI 10.1007/s11920-010-0102-1; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Zhou XF, 2008, BBA-GENE REGUL MECH, V1779, P780, DOI 10.1016/j.bbagrm.2008.04.005; ZILLES L, 1985, CORTEX RAT STEREOTAX	40	71	77	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2011	31	9					1897	1907		10.1038/jcbfm.2011.33			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	815KK	WOS:000294524300008	21505482	Green Published, Bronze			2021-06-18	
J	Do, AH; Wang, PT; King, CE; Abiri, A; Nenadic, Z				Do, An H.; Wang, Po T.; King, Christine E.; Abiri, Ahmad; Nenadic, Zoran			Brain-Computer Interface Controlled Functional Electrical Stimulation System for Ankle Movement	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							INFORMATION DISCRIMINANT-ANALYSIS; FEATURE-EXTRACTION; EEG; MOTOR; COMMUNICATION; TETRAPLEGIA; STROKE; INJURY; BCI; RECOVERY	Background: Many neurological conditions, such as stroke, spinal cord injury, and traumatic brain injury, can cause chronic gait function impairment due to foot-drop. Current physiotherapy techniques provide only a limited degree of motor function recovery in these individuals, and therefore novel therapies are needed. Brain-computer interface (BCI) is a relatively novel technology with a potential to restore, substitute, or augment lost motor behaviors in patients with neurological injuries. Here, we describe the first successful integration of a noninvasive electroencephalogram (EEG)-based BCI with a noninvasive functional electrical stimulation (FES) system that enables the direct brain control of foot dorsiflexion in able-bodied individuals. Methods: A noninvasive EEG-based BCI system was integrated with a noninvasive FES system for foot dorsiflexion. Subjects underwent computer-cued epochs of repetitive foot dorsiflexion and idling while their EEG signals were recorded and stored for offline analysis. The analysis generated a prediction model that allowed EEG data to be analyzed and classified in real time during online BCI operation. The real-time online performance of the integrated BCI-FES system was tested in a group of five able-bodied subjects who used repetitive foot dorsiflexion to elicit BCI-FES mediated dorsiflexion of the contralateral foot. Results: Five able-bodied subjects performed 10 alternations of idling and repetitive foot dorsifiexion to trigger BCI-FES mediated dorsifiexion of the contralateral foot. The epochs of BCI-FES mediated foot dorsifiexion were highly correlated with the epochs of voluntary foot dorsifiexion (correlation coefficient ranged between 0.59 and 0.77) with latencies ranging from 1.4 sec to 3.1 sec. In addition, all subjects achieved a 100% BCI-FES response (no omissions), and one subject had a single false alarm. Conclusions: This study suggests that the integration of a noninvasive BCI with a lower-extremity FES system is feasible. With additional modifications, the proposed BCI-FES system may offer a novel and effective therapy in the neuro-rehabilitation of individuals with lower extremity paralysis due to neurological injuries.	[Do, An H.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; [Do, An H.] Long Beach Vet Affairs Med Ctr, Dept Neurol, Long Beach, CA 90822 USA; [Wang, Po T.; King, Christine E.; Nenadic, Zoran] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA; [Abiri, Ahmad; Nenadic, Zoran] Univ Calif Irvine, Dept Elect Engn & Comp Sci, Irvine, CA 92697 USA	Do, AH (corresponding author), Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA.	and@uci.edu; znenadic@uci.edu	Nenadic, Zoran/A-9816-2008; Wang, Po T./H-4878-2014; Nenadic, Zoran/P-8772-2019	Wang, Po T./0000-0002-6611-3863; Nenadic, Zoran/0000-0001-5569-3797	Roman Reed Spinal Cord Injury Research Fund of California [RR10-281]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR031985]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031985] Funding Source: NIH RePORTER	This work was partially supported by the Roman Reed Spinal Cord Injury Research Fund of California (RR10-281).; The scientific review of the project described was supported by Grant Number UL1 RR031985 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Reengineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov.	Birbaumer N, 1999, NATURE, V398, P297, DOI 10.1038/18581; Birbaumer N, 2006, PSYCHOPHYSIOLOGY, V43, P517, DOI 10.1111/j.1469-8986.2006.00456.x; Daly JJ, 2009, J NEUROL PHYS THER, V33, P203, DOI 10.1097/NPT.0b013e3181c1fc0b; Das K., 2007, C P IEEE ENG MED BIO, P6519; Das K, 2008, PATTERN RECOGN, V41, P1548, DOI 10.1016/j.patcog.2007.10.001; Das K, 2009, PATTERN RECOGN, V42, P857, DOI 10.1016/j.patcog.2008.08.036; Dombovy M, 2011, NEUROREHABILITATION, V17, P443; Green JB, 1999, STROKE, V30, P2659, DOI 10.1161/01.STR.30.12.2659; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Huber P., 1981, ROBUST STAT; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Kanoh S, 2009, IFMBE PROC, V23, P2264; Kay S. M., 1998, FUNDAMENTALS STAT SI; Knutson JS, 2007, ARCH PHYS MED REHAB, V88, P513, DOI 10.1016/j.apmr.2007.01.003; Kohavi R, 1995, IJCAI, V14, P1137; Krawetz P, 1996, ARCH PHYS MED REHAB, V77, P635, DOI 10.1016/S0003-9993(96)90000-3; Leeb R, 2007, COMPUT INTEL NEUROSC, V2007, DOI [10.1155/2007/79642., DOI 10.1155/2007/79642]; LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623; MAYNARD FM, 1979, J NEUROSURG, V50, P611, DOI 10.3171/jns.1979.50.5.0611; Muller-Putz GR, 2007, BRAIN RES, V1137, P84, DOI 10.1016/j.brainres.2006.12.052; Muller-Putz GR, 2005, NEUROSCI LETT, V382, P169, DOI 10.1016/j.neulet.2005.03.021; NENADIC Z, 2010, SOC NEUR ABSTR, V40, P2946; Nenadic Z, 2007, IEEE T PATTERN ANAL, V29, P1394, DOI 10.1109/TPAMI.2007.1156; Neuper C, 1996, NEUROSCI LETT, V216, P17; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; PFURTSCHELLER G, 1979, ELECTROEN CLIN NEURO, V46, P138, DOI 10.1016/0013-4694(79)90063-4; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; Scherer R, 2008, IEEE T BIO-MED ENG, V55, P675, DOI 10.1109/TBME.2007.903709; Solis-Escalante T, 2008, J NEUROSCI METH, V175, P148, DOI 10.1016/j.jneumeth.2008.07.019; Townsend G, 2004, IEEE T NEUR SYS REH, V12, P258, DOI 10.1109/TNSRE.2004.827220; Townsend G, 2010, CLIN NEUROPHYSIOL, V121, P1109, DOI 10.1016/j.clinph.2010.01.030; Wang PT, 2011, MED ENG PHYS, V33, P546, DOI 10.1016/j.medengphy.2010.12.008; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P306, DOI 10.1016/0003-9993(94)90034-5; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; Wolpaw JR, 2004, P NATL ACAD SCI USA, V101, P17849, DOI 10.1073/pnas.0403504101; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3	36	71	79	0	33	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	AUG 26	2011	8								49	10.1186/1743-0003-8-49			14	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	832RD	WOS:000295823000001	21867567	DOAJ Gold, Green Published			2021-06-18	
J	Emery, C; Kang, J; Shrier, I; Goulet, C; Hagel, B; Benson, B; Nettel-Aguirre, A; McAllister, J; Meeuwisse, W				Emery, Carolyn; Kang, Jian; Shrier, Ian; Goulet, Claude; Hagel, Brent; Benson, Brian; Nettel-Aguirre, Alberto; McAllister, Jenelle; Meeuwisse, Willem			Risk of injury associated with bodychecking experience among youth hockey players	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							OF-THE-LITERATURE; ICE HOCKEY; BODY CHECKING; SPORT INJURY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; HIGH-SCHOOLS; CONCUSSION; RATES; PARTICIPATION	Background: In a previous prospective study, the risk of concussion and all injury was more than threefold higher among Pee Wee ice hockey players (ages 11-12 years) in a league that allows bodychecking than among those in a league that does not. We examined whether two years of bodychecking experience in Pee Wee influenced the risk of concussion and other injury among players in a Bantam league (ages 13-14) compared with Bantam players introduced to bodychecking for the first time at age 13. Methods: We conducted a prospective cohort study in volving hockey players aged 13-14 years in the top 30% of divisions of play in their leagues. Sixty-eight teams from the province of Alberta (n = 995), whose players had two years of bodychecking experience in Pee Wee, and 62 teams from the province of Quebec (n = 976), whose players had no bodychecking experience in Pee Wee, participated. We estimated incidence rate ratios (IRRs) for injury and for concussion. Results: There were 272 injuries (51 concussions) among the Bantam hockey players who had bodychecking experience in Pee Wee and 244 injuries (49 concussions) among those without such experience. The adjusted IRRs for game-related injuries and concussion overall be tween players with bodychecking experience in Pee Wee and those without it were as follows: injury overall 0.85 (95% confidence interval [CI] 0.63 to 1.16); concussion overall 0.84 (95% CI 0.48 to 1.48); and injury resulting in more than seven days of time loss (i.e., time between injury and re turn to play) 0.67 (95% CI 0.46 to 0.99). The unadjusted IRR for concussion resulting in more than 10 days of time loss was 0.60 (95% CI 0.26 to 1.41). Interpretation: The risk of injury resulting in more than seven days of time loss from play was reduced by 33% among Bantam hockey players in a league where bodychecking was allowed two years earlier in Pee Wee compared with Bantam players introduced to bodychecking for the first time at age 13. In light of the increased risk of concussion and other injury among Pee Wee players in a league where bodychecking is permitted, policy regarding the age at which hockey players are introduced to bodychecking re quires further consideration.	[Emery, Carolyn; Kang, Jian; Benson, Brian; McAllister, Jenelle; Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Jackson Ctr Hlth & Wellness Res, Calgary, AB, Canada; [Goulet, Claude] Univ Laval, Dept Phys Educ, Fac Educ, Quebec City, PQ, Canada; [Shrier, Ian] McGill Univ, Jewish Gen Hosp, Ctr Clin Epidemiol & Community Studies, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Emery, Carolyn; Hagel, Brent; Nettel-Aguirre, Alberto] Univ Calgary, Fac Med, Dept Pediat, Calgary, AB, Canada; [Emery, Carolyn; Hagel, Brent; Nettel-Aguirre, Alberto; Meeuwisse, Willem] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB, Canada	Emery, C (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Jackson Ctr Hlth & Wellness Res, Calgary, AB, Canada.	caemery@ucalgary.ca	Shrier, Ian/AAI-6502-2020; Hagel, Brent/AAK-3319-2020; Emery, Carolyn/AAI-2761-2020	Shrier, Ian/0000-0001-9914-3498; Nettel-Aguirre, Alberto/0000-0001-6604-0652	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Max Bell Foundation; Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research; Alberta Children's Hospital Foundation; Fonds de la recherche en sante du QuebecFonds de la Recherche en Sante du Quebec; Canadian National Railway Company	This study was funded by the Canadian Institutes of Health Research (CIHR) and the Max Bell Foundation. Carolyn Emery is supported by a Population Health Investigator Award from the Alberta Heritage Foundation, a CIHR New Investigator Award and an Alberta Children's Hospital Foundation Professorship in Pediatric Rehabilitation. Ian Shrier is supported by the Senior Clinician Scientist Program of the Fonds de la recherche en sante du Quebec. Brent Hagel holds the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness, funded through the support of an anonymous donor and the Canadian National Railway Company; he is also supported by a Population Health Investigator Award from the Alberta Heritage Foundation for Medical Research and a CIHR New Investigator Award. The role of the sponsors and funding bodies was to provide financial support for this research and the translation of the findings to all community partners.	Benson B., 2005, CLIN J SPORT MED, V15, P395; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Emery CA, 2009, PAED CHILD HEALT-CAN, V14, P439, DOI 10.1093/pch/14.7.439; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Emery CA, 2009, CLIN J SPORT MED, V19, P207, DOI 10.1097/JSM.0b013e31819d658e; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; *HOCK CAN, BACKGR CHECK; *HOCK CAN, 2008, ANN REP 2008 HOCK CA; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; *US HOCK INC, 2008, ANN REP 2007 08 US H; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06	27	71	71	0	16	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA	0820-3946			CAN MED ASSOC J	Can. Med. Assoc. J.	AUG 9	2011	183	11					1249	1256		10.1503/cmaj.101540			8	Medicine, General & Internal	General & Internal Medicine	800SR	WOS:000293387700051	21690221	Bronze, Green Published			2021-06-18	
J	Alder, J; Fujioka, W; Lifshitz, J; Crockett, DP; Thakker-Varia, S				Alder, Janet; Fujioka, Wendy; Lifshitz, Jonathan; Crockett, David P.; Thakker-Varia, Smita			Lateral Fluid Percussion: Model of Traumatic Brain Injury in Mice	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Neuroscience; Issue 54; Lateral fluid percussion; hippocampus; traumatic brain injury; Morris Water Maze; mouse model of moderate injury	COGNITIVE IMPAIRMENT; RATS; MODULATION; NECROSIS; MOTOR	Traumatic brain injury (TBI) research has attained renewed momentum due to the increasing awareness of head injuries, which result in morbidity and mortality. Based on the nature of primary injury following TBI, complex and heterogeneous secondary consequences result, which are followed by regenerative processes (1,2). Primary injury can be induced by a direct contusion to the brain from skull fracture or from shearing and stretching of tissue causing displacement of brain due to movement (3,4). The resulting hematomas and lacerations cause a vascular response (3,5), and the morphological and functional damage of the white matter leads to diffuse axonal injury (6-8). Additional secondary changes commonly seen in the brain are edema and increased intracranial pressure (9). Following TBI there are microscopic alterations in biochemical and physiological pathways involving the release of excitotoxic neurotransmitters, immune mediators and oxygen radicals (10-12), which ultimately result in long-term neurological disabilities (13,14). Thus choosing appropriate animal models of TBI that present similar cellular and molecular events in human and rodent TBI is critical for studying the mechanisms underlying injury and repair. Various experimental models of TBI have been developed to reproduce aspects of TBI observed in humans, among them three specific models are widely adapted for rodents: fluid percussion, cortical impact and weight drop/impact acceleration (1). The fluid percussion device produces an injury through a craniectomy by applying a brief fluid pressure pulse on to the intact dura. The pulse is created by a pendulum striking the piston of a reservoir of fluid. The percussion produces brief displacement and deformation of neural tissue (1,15). Conversely, cortical impact injury delivers mechanical energy to the intact dura via a rigid impactor under pneumatic pressure (16,17). The weight drop/impact model is characterized by the fall of a rod with a specific mass on the closed skull (18). Among the TBI models, LFP is the most established and commonly used model to evaluate mixed focal and diffuse brain injury (19). It is reproducible and is standardized to allow for the manipulation of injury parameters. LFP recapitulates injuries observed in humans, thus rendering it clinically relevant, and allows for exploration of novel therapeutics for clinical translation (20). We describe the detailed protocol to perform LFP procedure in mice. The injury inflicted is mild to moderate, with brain regions such as cortex, hippocampus and corpus callosum being most vulnerable. Hippocampal and motor learning tasks are explored following LFP.	[Alder, Janet; Fujioka, Wendy; Crockett, David P.; Thakker-Varia, Smita] Univ Med & Dent, New Jersey Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, New Brunswick, NJ USA; [Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Dept Phys Med & Rehabil, Dept Neurobiol & Anat, Lexington, KY 40506 USA	Thakker-Varia, S (corresponding author), Univ Med & Dent, New Jersey Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, New Brunswick, NJ USA.	varia@umdnj.edu		Alder, Janet/0000-0002-5694-4946	New Jersey Commission on Brain Injury Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072611] Funding Source: NIH RePORTER	This work is funded by the New Jersey Commission on Brain Injury Research.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Brechot N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003950; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HOVDA DA, 1990, ACT NEUR S, V51, P331; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Whiting M.D., 2006, COGNITIVE IMPAIRMENT	30	71	71	0	2	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	AUG	2011		54							e3063	10.3791/3063			7	Multidisciplinary Sciences	Science & Technology - Other Topics	V36MD	WOS:000209215100043	21876530	Bronze, Green Published			2021-06-18	
J	Dimoska-Di Marco, A; McDonald, S; Kelly, M; Tate, R; Johnstone, S				Dimoska-Di Marco, Aneta; McDonald, Skye; Kelly, Michelle; Tate, Robyn; Johnstone, Stuart			A meta-analysis of response inhibition and Stroop interference control deficits in adults with traumatic brain injury (TBI)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Response inhibition; Interference control; Stroop task; Traumatic brain injury; Meta-analysis	CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; INFORMATION-PROCESSING DEFICITS; STOP-SIGNAL PROBABILITY; DIFFUSE AXONAL INJURY; WORKING-MEMORY LOAD; COLOR-WORD TEST; SUSTAINED ATTENTION; COGNITIVE CONTROL; ERROR-AWARENESS	The prominent clinical feature of behavioral impulsivity following traumatic brain injury (TBI) suggests impairment of frontal inhibitory control processes. This meta-analysis consolidates the recent surge in studies across two forms of oeffortfulo inhibition, employing well-defined paradigms of response inhibition (N = 20; i.e., go/no-go, sustained attention to response, stop-signal, Conners' continuous performance tasks) and response interference control (N = 21, i.e., Stroop color word tasks). Across 41 effect sizes involving 989 adults with mild to severe TBI and 969 controls, the overall effect of TBI on reduced inhibitory control was small to moderate (d = 0.3) and significant. The effect was larger in studies measuring response inhibition performance (d = 0.5), while Stroop interference control yielded a nonsignificant overall effect size (d = 0.05). Further analysis of the latter finding revealed a large effect size when Stroop task studies used the outcome measure ototal time on tasko (d = 1.4), but not oRT per trialo or onumber of stimulio (d = -0.8 and -0.9). Response speed in these tasks was impaired to a large degree (d = 0.96). Together these findings support a response inhibition deficit following TBI but suggest factors other than interference control, such as poor processing speed, fatigue, and underarousal, may underlie poor performance in Stroop tasks.	[Dimoska-Di Marco, Aneta; McDonald, Skye; Kelly, Michelle] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn] Univ Sydney, Fac Med, No Clin Sch, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Johnstone, Stuart] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Mathews Bldg, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	Kelly, Michelle/J-9739-2019; McDonald, Skye/G-4118-2014	Kelly, Michelle/0000-0003-0375-816X; McDonald, Skye/0000-0003-0723-6094; Johnstone, Stuart/0000-0001-5380-9952			Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ARMILIO ML, 2003, THESIS U TORONTO TOR; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Bedard AC, 2002, DEV NEUROPSYCHOL, V21, P93, DOI 10.1207/S15326942DN2101_5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Borenstein M., 2008, COMPREHENSIVE METAAN; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cabeza R, 1997, J NEUROSCI, V17, P391; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; Conners C. K., 1995, CONNERS CONTINUOUS P; de Zubicaray GI, 2000, NEUROPSYCHOLOGIA, V38, P1280, DOI 10.1016/S0028-3932(00)00033-6; DeHaan A, 2007, NEUROPSYCHOLOGIA, V45, P406, DOI 10.1016/j.neuropsychologia.2006.06.008; Dimoska A, 2008, BIOL PSYCHOL, V77, P324, DOI 10.1016/j.biopsycho.2007.11.005; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gagnon J, 2006, BRAIN INJURY, V20, P67, DOI 10.1080/02699050500309668; HALES MK, 1999, THESIS U UTAH UTAH; HALPERIN JM, 1994, ADV CH NEUR, V2, P1, DOI DOI 10.1007/978-1-4612-2608-6_; Hedges L.V., 1985, STAT METHODS META AN; Hunter JE, 1990, METHODS METAANALYSIS; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Johnstone SJ, 2005, J PSYCHOPHYSIOL, V19, P11, DOI 10.1027/0269-8803.19.1.11; Johnstone SJ, 2009, INT J PSYCHOPHYSIOL, V72, P145, DOI 10.1016/j.ijpsycho.2008.11.007; Kelly AMC, 2006, NEUROIMAGE, V31, P866, DOI 10.1016/j.neuroimage.2006.01.008; Kenemans JL, 1999, PHARMACOL BIOCHEM BE, V63, P589, DOI 10.1016/S0091-3057(99)00022-2; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lansbergen MM, 2007, NEUROPSYCHOLOGY, V21, P251, DOI 10.1037/0894-4105.21.2.251; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; Li CSR, 2006, NEUROIMAGE, V32, P1918, DOI 10.1016/j.neuroimage.2006.05.017; LOGAN GD, 1994, ABILITY INHIBIT THOU; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McDonald S., 2005, BRAIN IMPAIR, V6, P56, DOI DOI 10.1375/BRIM.6.1.56.65481; Milich R., 1994, DISRUPTIVE BEHAV DIS, P109, DOI 10.1007/978-1-4899-1501-6_5; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; Nigg JT, 2000, PSYCHOL BULL, V126, P220, DOI 10.1037/0033-2909.126.2.220; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Park D.C., 2000, COGNITIVE AGING PRIM, P3, DOI DOI 10.1186/S12883-015-0454-6; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 2000, NEUROPSYCHOLOGICAL A, P355; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Ramautar JR, 2004, BRAIN COGNITION, V56, P234, DOI 10.1016/j.bandc.2004.07.002; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rosenberg MS, 2005, EVOLUTION, V59, P464, DOI 10.1554/04-602; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Summers MJ, 2006, BRAIN INJURY, V20, P51, DOI 10.1080/02699050500309742; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; van den Wildenberg WPM, 2004, J EXP CHILD PSYCHOL, V87, P201, DOI 10.1016/j.jecp.2003.11.003; van Mourik R, 2005, J CHILD PSYCHOL PSYC, V46, P150, DOI 10.1111/j.1469-7610.2004.00345.x; Verbruggen F, 2005, ACTA PSYCHOL, V120, P307, DOI 10.1016/j.actpsy.2005.05.003; Wager TD, 2005, NEUROIMAGE, V27, P323, DOI 10.1016/j.neuroimage.2005.01.054; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	101	71	72	1	36	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	4					471	485	PII 932313901	10.1080/13803395.2010.533158			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	746SC	WOS:000289266300008	21229434				2021-06-18	
J	Yeo, RA; Gasparovic, C; Merideth, F; Ruhl, D; Doezema, D; Mayer, AR				Yeo, Ronald A.; Gasparovic, Charles; Merideth, Flannery; Ruhl, David; Doezema, David; Mayer, Andrew R.			A Longitudinal Proton Magnetic Resonance Spectroscopy Study of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						creatine; mild traumatic brain injury; glutamate-glutamine signal; recovery; spectroscopy	HEAD-INJURY; WORKING-MEMORY; AXONAL INJURY; CREATINE; INTELLIGENCE; TBI; DYSFUNCTION; METABOLISM; ACTIVATION; MECHANISMS	Despite the prevalence and impact of mild traumatic brain injury (mTBI), common clinical assessment methods for mTBI have insufficient sensitivity and specificity. Moreover, few researchers have attempted to document underlying changes in physiology as a function of recovery from mTBI. Proton magnetic resonance spectroscopy (H-1-MRS) was used to assess neurometabolite concentrations in a supraventricular tissue slab in 30 individuals with semi-acute mTBI, and 30 sex-, age-, and education-matched controls. No significant group differences were evident on traditional measures of attention, memory, working memory, processing speed, and executive skills, though the mTBI group reported significantly more somatic, cognitive, and emotional symptoms. At a mean of 13 days post-injury, white matter concentrations of creatine (Cre) and phosphocreatine (PCre) and the combined glutamate-glutamine signal (Glx) were elevated in the mTBI group, while gray matter concentrations of Glx were reduced. Partial normalization of these three neurometabolites and N-acetyl aspartate occurred in the early days post-injury, during the semi-acute period of recovery. In addition, 17 mTBI patients (57%) returned for a follow-up evaluation (mean = 120 days post-injury). A significant group x time interaction indicated recovery in the mTBI group for gray matter Glx, and trends toward recovery in white matter Cre and Glx. An estimate of premorbid intelligence predicted the magnitude of neurometabolite normalization over the follow-up interval for the mTBI group, indicating that biological factors underlying intelligence may also be associated with more rapid recovery.	[Yeo, Ronald A.; Gasparovic, Charles; Merideth, Flannery; Ruhl, David; Mayer, Andrew R.] Mind Res Network, Albuquerque, NM 87106 USA; [Gasparovic, Charles; Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Doezema, David] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Yeo, Ronald A.; Gasparovic, Charles] Univ New Mexico, Sch Med, Dept Psychol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21-NS064464-01A1, 3 R21 NS064464-01S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grants R24-HD050836, R21-NS064464-01A1, and 3 R21 NS064464-01S1 to A.M.).	Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bakiri Y, 2009, NEUROSCIENCE, V158, P266, DOI 10.1016/j.neuroscience.2008.01.015; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Dawson KS, 2007, BRAIN INJURY, V21, P943, DOI 10.1080/02699050701553171; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Furlow FB, 1997, P ROY SOC B-BIOL SCI, V264, P823, DOI 10.1098/rspb.1997.0115; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Gussew A, 2010, NEUROIMAGE, V49, P1895, DOI 10.1016/j.neuroimage.2009.09.007; Hattingen E, 2008, NEURORADIOLOGY, V50, P759, DOI 10.1007/s00234-008-0409-3; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Holli Kirsi K, 2010, BMC Med Imaging, V10, P8, DOI 10.1186/1471-2342-10-8; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2003, MAGNET RESON MED, V50, P190, DOI 10.1002/mrm.10481; Izhikevich EM, 2008, P NATL ACAD SCI USA, V105, P3593, DOI 10.1073/pnas.0712231105; Jung RE, 1999, P ROY SOC B-BIOL SCI, V266, P1375, DOI 10.1098/rspb.1999.0790; Jung RE, 2009, INTELLIGENCE, V37, P192, DOI 10.1016/j.intell.2008.10.009; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Mangia S, 2007, J CEREBR BLOOD F MET, V27, P1055, DOI 10.1038/sj.jcbfm.9600401; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; MAYER AR, HUM BRAIN M IN PRESS; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Michael N, 2003, EUR J NEUROSCI, V17, P2462, DOI 10.1046/j.1460-9568.2003.02683.x; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mullins PG, 2005, NEUROIMAGE, V26, P642, DOI 10.1016/j.neuroimage.2005.02.001; MUNOZ MS, 2008, STROKE, V39, P2467; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Plomin R, 2004, J PERS SOC PSYCHOL, V86, P112, DOI 10.1037/0022-3514.86.1.112; Prokosch MD, 2005, INTELLIGENCE, V33, P203, DOI 10.1016/j.intell.2004.07.007; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Sakellaris G, 2008, ACTA PAEDIATR, V97, P31, DOI 10.1111/j.1651-2227.2007.00529.x; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; YEO RA, CURR ALZHEI IN PRESS	59	71	73	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					1	11		10.1089/neu.2010.1578			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800001	21054143	Green Published			2021-06-18	
J	Cretchley, J; Gallois, C; Chenery, H; Smith, A				Cretchley, Julia; Gallois, Cindy; Chenery, Helen; Smith, Andrew			Conversations Between Carers and People With Schizophrenia: A Qualitative Analysis Using Leximancer	QUALITATIVE HEALTH RESEARCH			English	Article						caregiving; communication; concept mapping; families, mental health and illness; schizophrenia; technology, use in research	TRAUMATIC BRAIN-INJURY; FAMILY BURDEN; LANGUAGE; COMMUNICATION; HEALTH; ILLNESS; ACCOMMODATION; PERFORMANCE; DISORDERS; DISCOURSE	We examined conversations between people with schizophrenia (PwS) and family or professional carers with whom they interacted frequently. We allocated PwS to one of two communication profiles: Low-activity communicators talked much less than their conversational partners, whereas high-activity communicators talked much more. We used Leximancer text analytics software to analyze the conversations. We found that carers used different strategies to accommodate to the PwS's behavior, depending on the PwS's communication profile and their relationship. These findings indicate that optimal communication strategies depend on the PwS's conversational tendencies and the relationship context. They also suggest new opportunities for qualitative assessment via intelligent text analytics technologies.	[Cretchley, Julia] Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia; [Gallois, Cindy] Univ Queensland, Fac Social & Behav Sci, St Lucia, Qld 4072, Australia; [Chenery, Helen] Univ Queensland, Fac Hlth Sci, St Lucia, Qld 4072, Australia; [Smith, Andrew] Univ Queensland, Social Sci Res Inst, St Lucia, Qld 4072, Australia	Cretchley, J (corresponding author), Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.	j.cretchley@uq.edu.au	Chenery, Helen J/F-5194-2010; Gallois, Cindy/F-9546-2014	Gallois, Cindy/0000-0002-7938-7839			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andreasen N, 1978, SCALE ASSESSMENT THO; Andreasen N.C., 1985, CONTROVERSIES SCHIZO, P199; ANDREASEN NC, 1979, ARCH GEN PSYCHIAT, V36, P1325; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; ANDREASEN NC, 1986, SCHIZOPHRENIA BULL, V12, P348, DOI 10.1093/schbul/12.3.348; Arkar H, 1997, SOC PSYCH PSYCH EPID, V32, P171; Atkinson M., 1984, STRUCTURES SOCIAL AC, pix; Berglund N, 2003, SOC PSYCH PSYCH EPID, V38, P116, DOI 10.1007/s00127-003-0615-6; BRUGHA TS, 1988, PSYCHOL MED, V18, P443, DOI 10.1017/S0033291700007984; Carr VJ, 2004, SOC PSYCH PSYCH EPID, V39, P78, DOI 10.1007/s00127-004-0703-2; CHAIKA E, 1974, BRAIN LANG, V1, P257, DOI 10.1016/0093-934X(74)90040-6; Cornwall PL, 1996, SOC PSYCH PSYCH EPID, V31, P345, DOI 10.1007/BF00783423; CRAWFORD JR, 1990, BRIT J CLIN PSYCHOL, V29, P239, DOI 10.1111/j.2044-8260.1990.tb00878.x; CREER C, 1974, SCHIZOPHRENIA HOME; Cretchley J, 2010, J CROSS CULT PSYCHOL, V41, P318, DOI 10.1177/0022022110366105; DAVIES S, 1994, SOC PSYCH PSYCH EPID, V29, P241, DOI 10.1007/BF00802045; De la Varre C, 2005, EXPLORING FRONTIERS; Freeman D. S., 1978, FAMILY THERAPY, V5, P277; Gallois C, 2005, LEA COMMUN SER, P231; Gallois C., 2003, 53 ANN C INT COMM AS; Gallois C., 1995, INTERCULTURAL COMMUN, P115; GALLOIS C, 1996, INT J PSYCHOLINGUIST, V12, P193; GIBBONS JS, 1984, BRIT J PSYCHIAT, V144, P70, DOI 10.1192/bjp.144.1.70; Giles H., 1991, STUDIES EMOTION SOCI, P1; GRECH MR, 2002, P HUM FACT ERG SOC 4; Gudykunst W.B, 2005, THEORIZING INTERCULT, P121; Hamilton H., 1991, STUDIES EMOTION SOCI, P158; Harwood J., 1993, LANG SCI, V15, P15, DOI [10.1016/0388-0001(93)90003-B, DOI 10.1016/0388-0001(93)90003-B]; Hewett DG, 2009, SOC SCI MED, V69, P1732, DOI 10.1016/j.socscimed.2009.09.048; Jones E, 1999, J LANG SOC PSYCHOL, V18, P123, DOI 10.1177/0261927X99018002001; KAVANAGH DJ, 1992, BRIT J PSYCHIAT, V160, P601, DOI 10.1192/bjp.160.5.601; KAVANAGH S, 1995, SOC PSYCH PSYCH EPID, V30, P206; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kuipers E, 1998, OUTCOME AND INNOVATION IN PSYCHOLOGICAL TREATMENT OF SCHIZOPHRENIA, P201; KUIPERS L, 1993, SOC PSYCH PSYCH EPID, V28, P207; LECOURS AR, 1976, BRAIN LANG, V3, P516, DOI 10.1016/0093-934X(76)90046-8; Martin N. J., 2007, RISK MANAGE, V9, P188, DOI DOI 10.1057/PALGRAVE.RM.8250030; McAuliffe D, 2009, ADV MENT HEALTH, V8, P57, DOI 10.5172/jamh.8.1.57; McDonell MG, 2003, FAM PROCESS, V42, P91, DOI 10.1111/j.1545-5300.2003.00091.x; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; McKenna B, 2007, J LANG POLIT, V6, P377, DOI 10.1075/jlp.6.3.06mck; Meilijson SR, 2004, J SPEECH LANG HEAR R, V47, P695, DOI 10.1044/1092-4388(2004/053); Rochester Sherry R., 1979, CRAZY TALK STUDY DIS; Rooney D., MANAGEMENT IN PRESS, V24, P44; Rooney D, 2010, MANAGE COMMUN Q, V24, P44, DOI 10.1177/0893318909351434; Ryan E., 2005, INTERGROUP COMMUNICA; Saavedra J, 2009, QUAL HEALTH RES, V19, P1548, DOI 10.1177/1049732309351110; SCHEGLOFF E, 1973, SEMIOTICA, V8, P289, DOI DOI 10.1515/SEMI.1973.8.4.289; SCHWARTZ S, 1982, BEHAV BRAIN SCI, V5, P579, DOI 10.1017/S0140525X00013650; SMITH AE, 2003, HLT NAACL 2003 HUM L; Smith AE, 2006, BEHAV RES METHODS, V38, P262, DOI 10.3758/BF03192778; Street RL., 2001, NEW HDB LANGUAGE SOC, P541; TARRIER N, 1995, INT J MENT HEALTH, V24, P38, DOI 10.1080/00207411.1995.11449318; THOMAS P, 1990, BRIT J PSYCHIAT, V156, P204, DOI 10.1192/bjp.156.2.204; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; VELTRO F, 1994, SOC PSYCH PSYCH EPID, V29, P66; Watson B, 1998, HEALTH COMMUN, V10, P343, DOI 10.1207/s15327027hc1004_3; Watson B, 2004, LANGUAGE MATTERS COM, P63; Watson B., 2008, 11 INT C LANG SOC PS; Watson B.M., 1999, INT J APPL LINGUISTI, V9, P167, DOI [10.1111/j.1473-4192.1999.tb00170.x, DOI 10.1111/J.1473-4192.1999.TB00170.X]; Watson B, 2007, PALGRAVE ADV, P108; Watson M, 2005, LECT NOTES ARTIF INT, V3683, P1232; Williams A., 2001, INTERGENERATIONAL CO, P85; Wrobel J., 1990, LANGUAGE SCHIZOPHREN	66	71	71	0	29	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323			QUAL HEALTH RES	Qual. Health Res.	DEC	2010	20	12					1611	1628		10.1177/1049732310378297			18	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	683IO	WOS:000284469700002	20675536				2021-06-18	
J	Lange, RT; Iverson, GL; Rose, A				Lange, Rael T.; Iverson, Grant L.; Rose, Alice			Post-concussion Symptom Reporting and the "Good-Old-Days" Bias Following Mild Traumatic Brain Injury(dagger)	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Post-concussion symptoms; Good-old-days bias	POSTCONCUSSION-LIKE SYMPTOMS; PERSONAL-INJURY CLAIMANTS; COMPLAINT BASE RATES; HEAD-INJURY; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; CHRONIC PAIN; ETIOLOGY; INDIVIDUALS; EXPECTATION	The purpose of this study was to examine the influence of the "good-old-days" bias on symptom reporting following mild traumatic brain injury (MTBI). The MTBI sample consisted of 86 patients (51.2% men) referred to a hospital-based concussion clinic in Vancouver, Canada. The majority of patients (83.7%) were evaluated within 3 months following their injury (M = 1.8 months, SD = 1.7, range = 0.2-8.0 months). Patients provided retrospective preinjury symptom ratings on the British Columbia Post-Concussion Symptom Inventory (BC-PSI). Ratings were compared with 177 healthy controls recruited from the community and a local university. MTBI retrospective ratings were significantly lower than the control group on the BC-PSI total score (p < .01, d = 0.27, small effect size) and 6 of the 13 individual items (all p < .05, d = 0.23-0.36, small to small-medium effect sizes). Patients who were currently in litigation reported more post-injury symptoms (p = .009, d = 0.63, medium-large effect size). However, litigation status was not associated with self-reported preinjury retrospective symptom ratings. Consistent with the "good-old-days" bias, patients with MTBI appear to misperceive their preinjury functioning as better than the average person.	[Lange, Rael T.] Univ British Columbia, British Columbia Mental Hlth & Addict Serv, PHSA Res & Networks, Vancouver, BC V5Z 4C2, Canada; [Rose, Alice] GF Strong Rehab Ctr, Vancouver, BC, Canada	Lange, RT (corresponding author), Univ British Columbia, British Columbia Mental Hlth & Addict Serv, PHSA Res & Networks, Suite 201,601 W Broadway St, Vancouver, BC V5Z 4C2, Canada.	rael.lange@gmail.com		Iverson, Grant/0000-0001-7348-9570			Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2009, J HEAD TRAUMA REHAB, V24, P76, DOI 10.1097/HTR.0b013e31819c2190; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Epley N, 2000, J PERS SOC PSYCHOL, V79, P861, DOI 10.1037//0022-3514.79.6.861; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Furnham A, 2004, BRIT J PSYCHOL, V95, P149, DOI 10.1348/000712604773952395; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2002, PSYCHOL ASSESSMENT, V14, P202, DOI 10.1037//1040-3590.14.2.202; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kinard EM, 2001, CHILD ABUSE NEGLECT, V25, P33; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stone CA, 2002, J LEARN DISABIL-US, V35, P370, DOI 10.1177/00222194020350040801; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS	49	71	71	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2010	25	5					442	450		10.1093/arclin/acq031			9	Psychology, Clinical; Psychology	Psychology	627BN	WOS:000280013100009	20447932	Bronze, Green Published			2021-06-18	
J	Leal-Noval, SR; Cayuela, A; Arellano-Orden, V; Marin-Caballos, A; Padilla, V; Ferrandiz-Millon, C; Corcia, Y; Garcia-Alfaro, C; Amaya-Villar, R; Murillo-Cabezas, F				Leal-Noval, Santiago R.; Cayuela, Aurelio; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Padilla, Vicente; Ferrandiz-Millon, Carmen; Corcia, Yael; Garcia-Alfaro, Claudio; Amaya-Villar, Rosario; Murillo-Cabezas, Francisco			Invasive and noninvasive assessment of cerebral oxygenation in patients with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Brain hypoxia; Brain tissue oxygen pressure; Cerebral oxygenation; Neurotrauma; NIRS; rSO(2); PbrO(2); Severe traumatic brain injury and transfusion	NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; PERFUSION-PRESSURE; TISSUE PO-2; SATURATION; TENSION; AUTOREGULATION; DESATURATION; HYPOXIA	The aim of this study is to investigate the relationship between invasive brain tissue oxygen pressure (PbrO(2)) and noninvasive regional transcranial oxygen saturation (rSO(2)) in 22 stable patients with severe traumatic brain injury (TBI) during a 16 h period. This was a prospective, observational study carried out in the Neurocritical Care Unit of a level 1 trauma center in a teaching hospital. A total of 41,809 paired records for neuromonitoring variables were analyzed and compared. A direct and independent correlation between rSO(2) and PbrO(2) was confirmed through adjusted [beta coefficient and (95% confidence interval, CI) = 0.36 (0.35-0.37)] and logistic [PbrO(2) a parts per thousand yen15 mmHg, as a dependent variable; adjusted odds ratio (AOR) and (95% CI) = 1.11 (1.10-1.12)] regression analyses. A receiver-operating characteristic (ROC) curve demonstrated that rSO(2) had low accuracy for detecting moderate (PbrO(2) a parts per thousand currency sign15 mmHg) intracerebral hypoxia [area under curve (AUC) = 0.62], with the likelihood ratio for a positive test (LR+) = 1.2 for an optimal cutoff of rSO(2) a parts per thousand currency sign70%. In contrast, the ROC analysis showed that rSO(2) was moderately accurate for detecting severe (PbrO(2) a parts per thousand currency sign12 mmHg) intracerebral hypoxemia (AUC = 0.82; LR+ = 5.3) for an optimal cutoff of rSO(2) a parts per thousand currency sign60%. In patients with severe TBI, PbrO(2) and rSO(2) were directly and significantly related. Severe intracerebral hypoxia was better detected by rSO(2) than was moderate intracerebral hypoxia. However, the diagnostic accuracy of rSO(2) was limited, and this measure should not be considered a substitute for routine PbrO(2) monitoring.	[Leal-Noval, Santiago R.] Hosp Univ Virgen del Rocio, Serv Cuidados Crit & Urgencias, Inst Biomed Sevilla IBIS, Seville 41013, Spain; [Leal-Noval, Santiago R.; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Padilla, Vicente; Ferrandiz-Millon, Carmen; Corcia, Yael; Garcia-Alfaro, Claudio; Amaya-Villar, Rosario; Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio, Neuro Crit Care Div, Seville 41013, Spain; [Cayuela, Aurelio] Hosp Univ Virgen del Rocio, Div Stat, Seville 41013, Spain	Leal-Noval, SR (corresponding author), Hosp Univ Virgen del Rocio, Serv Cuidados Crit & Urgencias, Inst Biomed Sevilla IBIS, Avda Manuel Siurot S-N, Seville 41013, Spain.	srleal@telefonica.net	Noval, Santiago/K-4515-2019; Cayuela, Aurelio/AAZ-1294-2020; Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROCRITICOS/C-1805-2016; Cayuela, Aurelio/C-6698-2012	Cayuela, Aurelio/0000-0002-4936-9402	Spanish Government funds (Fondo de Investigacion Sanitaria-FIS-Proyecto de Investigacion) [PI 081069]; Consejeria de Salud de la Junta de AndaluciaJunta de Andalucia	Supported by Spanish Government funds (Fondo de Investigacion Sanitaria-FIS-Proyecto de Investigacion: PI 081069) and by Consejeria de Salud de la Junta de Andalucia. Proyecto de Investigacion 0157/2006.	Akobeng AK, 2007, ACTA PAEDIATR, V96, P487, DOI 10.1111/j.1651-2227.2006.00179.x; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brawanski A, 2002, J CEREBR BLOOD F MET, V22, P605, DOI 10.1097/00004647-200205000-00012; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Marcin JP, 2007, CRIT CARE MED, V35, P2212, DOI 10.1097/01.CCM.0000281522.70992.EF; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Marin-Caballos AJ, 2008, MED INTENSIVA, V32, P81, DOI 10.1016/S0210-5691(08)70912-4; Matsumoto S, 2009, NEUROLOGY, V72, P1512, DOI 10.1212/WNL.0b013e3181a2e846; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Nagdyman N, 2008, PEDIATR ANESTH, V18, P160, DOI 10.1111/j.1460-9592.2007.02365.x; Naidech AM, 2008, NEUROCRIT CARE, V9, P326, DOI 10.1007/s12028-008-9077-8; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rothoerl RD, 2002, ACT NEUR S, V81, P311; Shah N, 2000, J NEUROSURG ANESTH, V12, P201, DOI 10.1097/00008506-200007000-00001; Skhirtladze K, 2009, CRIT CARE MED, V37, P471, DOI 10.1097/CCM.0b013e3181953d4c; Smith M, 2009, ANESTH ANALG, V108, P1055, DOI 10.1213/ane.0b013e31819a0301; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stoneham MD, 2008, ANESTH ANALG, V107, P1670, DOI 10.1213/ane.0b013e318184d6c3; Tobias JD, 2006, EXPERT REV MED DEVIC, V3, P235, DOI 10.1586/17434440.3.2.235; Tobias Joseph D, 2008, J Intensive Care Med, V23, P384, DOI 10.1177/0885066608324380; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Watzman HM, 2000, ANESTHESIOLOGY, V93, P947, DOI 10.1097/00000542-200010000-00012; Yao FSF, 2004, J CARDIOTHOR VASC AN, V18, P552, DOI 10.1053/j.jvca.2004.07.007; Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009	40	71	78	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2010	36	8					1309	1317		10.1007/s00134-010-1920-7			9	Critical Care Medicine	General & Internal Medicine	622RP	WOS:000279683400004	20502869				2021-06-18	
J	Honeybul, S; Ho, KM; Lind, CRP; Gillett, GR				Honeybul, Stephen; Ho, Kwok M.; Lind, Christopher R. P.; Gillett, Grant R.			Observed versus Predicted Outcome for Decompressive Craniectomy: A Population-Based Study	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; outcome; neurotrauma	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; COMPLICATIONS; VALIDATION; MANAGEMENT; DISABILITY; SECONDARY; SURGERY; MODEL	A number of studies have shown that decompressive craniectomy can reduce intracranial pressure and may improve outcome for patients with severe head injury. This cohort study assessed the long-term outcome of neurotrauma patients who had a decompressive craniectomy for severe head injury in Western Australia between 2004 and 2008. The web-based outcome prediction model developed by the CRASH trial collaborators was applied to the cohort. Predicted outcome and observed outcome were compared. Characteristics of outcome between those who had had a unilateral and those who had had a bilateral decompressive procedure were compared. All complications were recorded. Among a total of 1,786 adult neurotrauma patients admitted during the study period, 147 patients (8.2%) had a decompressive craniectomy. A significant proportion of patients who required unilateral (37.3%) and bilateral (46.5%) craniectomy were able to return to work or study at 18 months after the injury. The patients who required bilateral craniectomy more likely to be associated with an unfavorable outcome (Glasgow Outcome Scale score >= 3) than those who had unilateral craniectomy (odds ratio 4.42; 95% confidence interval 1.16, 16.81; p = 0.029), after adjusting for the timing of surgery, mechanism of injury, and the predicted risk of unfavorable outcome. The functional outcome after either unilateral or bilateral decompressive craniectomy was significantly better than that predicted by the CRASH head injury prediction model when the predicted risk was less than 80%. This study has demonstrated that in Western Australia decompressive craniectomy is a relatively common surgical procedure for the management of neurotrauma. A significant proportion of patients had a better-than-predicted long-term functional outcome.	[Honeybul, Stephen; Lind, Christopher R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Honeybul, Stephen; Lind, Christopher R. P.] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Lind, Christopher R. P.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia; [Gillett, Grant R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand; [Gillett, Grant R.] Dunedin Publ Hosp, Dunedin, New Zealand	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Lind, Christopher/K-3629-2012	Ho, Kwok M./0000-0002-6705-6004; Lind, Christopher/0000-0001-9991-1725			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2007, J CLIN EPIDEMIOL, V60, P746, DOI 10.1016/j.jclinepi.2006.10.017; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Munch E, 2000, NEUROSURGERY, V47, P315; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	30	71	73	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1225	1232		10.1089/neu.2010.1316			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100007	20412014				2021-06-18	
J	Lew, HL; Pogoda, TK; Hsu, PT; Cohen, S; Amick, MM; Baker, E; Meterko, M; Vanderploeg, RD				Lew, Henry L.; Pogoda, Terri K.; Hsu, Pei-Te; Cohen, Sara; Amick, Melissa M.; Baker, Errol; Meterko, Mark; Vanderploeg, Rodney D.			Impact of the "Polytrauma Clinical Triad" on Sleep Disturbance in a Department of Veterans Affairs Outpatient Rehabilitation Setting	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Traumatic Brain Injury; Post Traumatic Stress Disorder; Pain; Sleep	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; IRAQ-WAR; MANAGEMENT; COMPLAINTS; SYMPTOMS; PREVALENCE; HEADACHES; INSOMNIA	Objective: There is a high prevalence of Operation Enduring Freedom/Operation Iraqi Freedom veterans returning with the "polytrauma clinical triad" of pain, posttraumatic stress disorder, and traumatic brain injury. This study examined the effect of the polytrauma clinical triad on sleep disturbance, defined as difficulty falling or staying asleep, a common problem in Operation Enduring Freedom/Operation Iraqi Freedom veterans. Design: A chart review was conducted for 200 Operation Enduring Freedom/Operation Iraqi Freedom veterans evaluated at a polytrauma outpatient clinic. Data that were abstracted included a sleep disturbance severity index, diagnoses of posttraumatic stress disorder and traumatic brain injury, and reported problems of pain. Results: Sleep disturbance was highly prevalent (93.5%) in this sample, in which the majority of traumatic brain injury diagnoses were mild. In the multiple regression analysis, posttraumatic stress disorder, pain, the interaction of traumatic brain injury and posttraumatic stress disorder, and the interaction of posttraumatic stress disorder and pain significantly accounted for sleep disturbance. As a separate independent variable, traumatic brain injury was not associated with sleep disturbance. Conclusions: Our preliminary results showed that posttraumatic stress disorder and pain significantly contributed to sleep disturbance. When traumatic brain injury or pain coexisted with posttraumatic stress disorder, sleep problems worsened. In this clinical population, where the majority of traumatic brain injury diagnoses tend to be in the mild category, traumatic brain injury alone did not predict sleep disturbance. Through increased awareness of pain, posttraumatic stress disorder, and traumatic brain injury, clinicians can work collaboratively to maximize rehabilitation outcomes.	[Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Dept PM&R, Sch Med, Richmond, VA USA; [Lew, Henry L.; Hsu, Pei-Te; Cohen, Sara] Harvard Univ, Sch Med, Dept PM&R, Boston, MA USA; [Pogoda, Terri K.; Cohen, Sara; Amick, Melissa M.] VA Boston Healthcare Syst, Polytrauma & Traumat Brain Injury Ctr, Boston, MA USA; [Pogoda, Terri K.; Baker, Errol; Meterko, Mark] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.; Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Hsu, Pei-Te] Kaohsiung Vet Gen Hosp, Dept Rehabil, Kaohsiung, Taiwan; [Vanderploeg, Rodney D.] James A Haley Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Vanderploeg, Rodney D.] Vet Brain Injury Ctr, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL USA	Lew, HL (corresponding author), DVBIC, Richmond, VA USA.		Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Atkinson MP, 2009, MANAGE SCI, V55, P1454, DOI 10.1287/mnsc.1090.1042; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Maher MJ, 2006, CNS DRUGS, V20, P567, DOI 10.2165/00023210-200620070-00003; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; ROSS RJ, 1989, AM J PSYCHIAT, V146, P697; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Singareddy Ravi Kumar, 2002, Ann Clin Psychiatry, V14, P183, DOI 10.3109/10401230209147455; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; *US GAO, 2008, GAO08276; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	37	71	71	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	2010	89	6					437	445		10.1097/PHM.0b013e3181ddd301			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	605GY	WOS:000278337100001	20489391				2021-06-18	
J	Rhind, SG; Crnko, NT; Baker, AJ; Morrison, LJ; Shek, PN; Scarpelini, S; Rizoli, SB				Rhind, Shawn G.; Crnko, Naomi T.; Baker, Andrew J.; Morrison, Laurie J.; Shek, Pang N.; Scarpelini, Sandro; Rizoli, Sandro B.			Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients	JOURNAL OF NEUROINFLAMMATION			English	Article							TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; L-SELECTIN EXPRESSION; ADHESION MOLECULE CONCENTRATIONS; REDUCES NEUTROPHIL MARGINATION; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; TISSUE FACTOR; FACTOR-ALPHA; INTERLEUKIN-10 RELEASE	Background: Traumatic brain injury (TBI) initiates interrelated inflammatory and coagulation cascades characterized by wide-spread cellular activation, induction of leukocyte and endothelial cell adhesion molecules and release of soluble pro/antiinflammatory cytokines and thrombotic mediators. Resuscitative care is focused on optimizing cerebral perfusion and reducing secondary injury processes. Hypertonic saline is an effective osmotherapeutic agent for the treatment of intracranial hypertension and has immunomodulatory properties that may confer neuroprotection. This study examined the impact of hypertonic fluids on inflammatory/coagulation cascades in isolated head injury. Methods: Using a prospective, randomized controlled trial we investigated the impact of prehospital resuscitation of severe TBI (GCS < 8) patients using 7.5% hypertonic saline in combination with 6% dextran-70 (HSD) vs 0.9% normal saline (NS), on selected cellular and soluble inflammatory/coagulation markers. Serial blood samples were drawn from 65 patients (30 HSD, 35 NS) at the time of hospital admission and at 12, 24, and 48-h post-resuscitation. Flow cytometry was used to analyze leukocyte cell-surface adhesion (CD62L, CD11b) and degranulation (CD63, CD66b) molecules. Circulating concentrations of soluble (s)L- and sE-selectins (sL-, sE- selectins), vascular and intercellular adhesion molecules (sVCAM-1, sICAM-1), pro/antiinflammatory cytokines [tumor necrosis factor (TNF)-alpha and interleukin (IL-10)], tissue factor (sTF), thrombomodulin (sTM) and D-dimers (D-D) were assessed by enzyme immunoassay. Twenty-five healthy subjects were studied as a control group. Results: TBI provoked marked alterations in a majority of the inflammatory/coagulation markers assessed in all patients. Relative to control, NS patients showed up to a 2-fold higher surface expression of CD62L, CD11b and CD66b on polymorphonuclear neutrophils (PMNs) and monocytes that persisted for 48-h. HSD blunted the expression of these cell-surface activation/adhesion molecules at all time-points to levels approaching control values. Admission concentrations of endothelial-derived sVCAM-1 and sE-selectin were generally reduced in HSD patients. Circulating sL-selectin levels were significantly elevated at 12 and 48, but not 24 h post-resuscitation with HSD. TNF-alpha and IL-10 levels were elevated above control throughout the study period in all patients, but were reduced in HSD patients. Plasma sTF and D-D levels were also significantly lower in HSD patients, whereas sTM levels remained at control levels. Conclusions: These findings support an important modulatory role of HSD resuscitation in attenuating the upregulation of leukocyte/endothelial cell proinflammatory/prothrombotic mediators, which may help ameliorate secondary brain injury after TBI.	[Rhind, Shawn G.; Shek, Pang N.] Def Res & Dev Canada, Toronto, ON, Canada; [Rhind, Shawn G.] York Univ, Grad Program Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada; [Crnko, Naomi T.; Shek, Pang N.] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr,Brain Injury Lab, Cara Phelan Ctr Trauma Res,Li Ka Shing Knowledge, Toronto, ON M5S 1A1, Canada; [Scarpelini, Sandro; Rizoli, Sandro B.] Sunnybrook Hlth Sci Ctr, Dept Surg & Crit Care Med, Toronto, ON M4N 3M5, Canada	Rhind, SG (corresponding author), Def Res & Dev Canada, Toronto, ON, Canada.	shawn.rhind@drdc-rddc.gc.ca	Scarpelini, Sandro/H-7063-2012; morrison, laurie J/A-6325-2012	Scarpelini, Sandro/0000-0001-5727-3913; morrison, laurie J/0000-0001-8369-9774; Rhind, Shawn/0000-0003-2300-0620	Defence Research & Development Canada	The authors are indebted to Sheila Petrongolo, Bartolomeu Nascimento and Maria Shiu for their skillful technical assistance; the paramedic providers employed by Ornge (formerly Ontario Air Ambulance) and Toronto Emergency Medical Services (members CUPE 416) who randomized these patients under conditions of adversity in the prehospital setting; Merita Simitciu and Tyrone Perreira (Rescu) for their study coordination and oversight. This study was funded by Defence Research & Development Canada.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Alam HB, 2000, J SURG RES, V94, P145, DOI 10.1006/jsre.2000.6011; Angle N, 1998, J TRAUMA, V45, P7, DOI 10.1097/00005373-199807000-00002; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Barone M, 1997, ACT NEUR S, V70, P265; Bednar MM, 1997, NEUROL RES, V19, P588; Bernardes-Silva M, 2001, J CEREBR BLOOD F MET, V21, P1115, DOI 10.1097/00004647-200109000-00009; Bing Mei, 2007, Chin J Traumatol, V10, P263; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Boomer L, 2009, SURG INFECT, V10, P379, DOI 10.1089/sur.2008.097; Brummel-Ziedins K, 2006, J TRAUMA, V61, P1350, DOI 10.1097/01.ta.0000235525.64176.01; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P149; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Cernak I., 2009, J CEREB BLOOD FLOW M; COWLEY HC, 1994, CRIT CARE MED, V22, P651, DOI 10.1097/00003246-199404000-00022; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cuschieri J, 2002, J IMMUNOL, V168, P1389, DOI 10.4049/jimmunol.168.3.1389; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dietrich JB, 2002, J NEUROIMMUNOL, V128, P58, DOI 10.1016/S0165-5728(02)00114-5; Dubick MA, 2006, SHOCK, V25, P321, DOI 10.1097/01.shk.0000209525.50990.28; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Esmon CT, 2004, MATURITAS, V47, P305, DOI 10.1016/j.maturitas.2003.10.015; Ferri LE, 2009, SURGERY, V145, P384, DOI 10.1016/j.surg.2008.12.011; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fisher Mark, 2008, Rev Neurol Dis, V5 Suppl 1, pS4; Gando S, 2006, SEMIN THROMB HEMOST, V32, P48, DOI 10.1055/s-2006-933340; GEARING AJH, 1992, ANN NY ACAD SCI, V667, P324, DOI 10.1111/j.1749-6632.1992.tb51633.x; Giddings JC, 2005, BIOCHEM SOC T, V33, P406, DOI 10.1042/BST0330406; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gushchin V, 2002, J TRAUMA, V52, P867, DOI 10.1097/00005373-200205000-00008; HAGIWARA S, 2009, SHOCK; Hammell CL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1683; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Hatanaka E, 2007, SHOCK, V27, P32, DOI 10.1097/01.shk.0000238061.69579.a5; HESS DC, 1994, NEUROSCI LETT, V168, P201, DOI 10.1016/0304-3940(94)90450-2; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; HESS JR, 1992, J TRAUMA, V32, P40, DOI 10.1097/00005373-199201000-00009; Hirsh MI, 2008, CRIT CARE MED, V36, P3220, DOI 10.1097/CCM.0b013e31818f238e; HUANG GS, 2009, J TRAUMA; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Ke QH, 2006, DIGEST DIS SCI, V51, P2257, DOI 10.1007/s10620-006-9135-6; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Koutsi A, 2008, INT J BIOCHEM CELL B, V40, P1669, DOI 10.1016/j.biocel.2007.06.024; Lacy P, 2008, FRONT BIOSCI-LANDMRK, V13, P5559; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Langer HF, 2009, J CELL MOL MED, V13, P1211, DOI 10.1111/j.1582-4934.2009.00811.x; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Levi M, 2006, SEMIN THROMB HEMOST, V32, P33, DOI 10.1055/s-2006-933338; Lim HB, 2007, ANAESTHESIA, V62, P474, DOI 10.1111/j.1365-2044.2007.04998.x; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maekawa K, 1998, J TRAUMA, V44, P460, DOI 10.1097/00005373-199803000-00007; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maskin B, 2001, MEDICINA-BUENOS AIRE, V61, P573; McKeating EG, 1998, BRIT J ANAESTH, V80, P77; McKeating EG, 1998, ACT NEUR S, V71, P200; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morrison LJ, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-105; Mousa SA, 2008, MOL BIOTECHNOL, V38, P33, DOI 10.1007/s12033-007-0072-7; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Oreopoulos GD, 2001, SURGERY, V130, P157, DOI 10.1067/msy.2001.115829; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; Powers KA, 2003, SURGERY, V134, P312, DOI 10.1067/msy.2003.246; Powers KA, 2005, SURGERY, V137, P66, DOI 10.1016/j.surg.2004.05.051; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; RuchaudSparagano MH, 1997, BRIT J HAEMATOL, V98, P612, DOI 10.1046/j.1365-2141.1997.2523070.x; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Santucci CA, 2008, WEST J EMERG MED, V9, P81; SCARPELINI S, 2008, J ORGAN DYSFUNCTION, V4, P99; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Seekamp A, 2001, SHOCK, V15, P254, DOI 10.1097/00024382-200115040-00002; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Sibson NR, 2004, MAGN RESON MED, V51, P248, DOI 10.1002/mrm.10723; Siemiatkowski A, 2001, ARCH IMMUNOL THER EX, V49, P317; Soriano SG, 2008, EUR J ANAESTH, V25, P154, DOI 10.1017/S0265021507003390; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Summy-Long JY, 2009, AM J PHYSIOL-REG I, V297, pR1532, DOI 10.1152/ajpregu.00340.2009; Szotowski B, 2005, CIRC RES, V96, P1233, DOI 10.1161/01.RES.0000171805.24799.fa; Tan TS, 2002, ANAESTHESIA, V57, P644, DOI 10.1046/j.1365-2044.2002.02603.x; Thiel M, 2001, J LEUKOCYTE BIOL, V70, P261; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; West MA, 1998, J TRAUMA, V45, P12; Wilder DM, 2002, THROMB RES, V107, P255, DOI 10.1016/S0049-3848(02)00335-3; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wu Xue-Hai, 2003, Chin J Traumatol, V6, P114; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	109	71	72	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 18	2010	7								5	10.1186/1742-2094-7-5			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	559MX	WOS:000274830600001	20082712	DOAJ Gold, Green Published			2021-06-18	
J	Andelic, N; Sigurdardottir, S; Schanke, AK; Sandvik, L; Sveen, U; Roe, C				Andelic, Nada; Sigurdardottir, Solrun; Schanke, Anne-Kristine; Sandvik, Leiv; Sveen, Unni; Roe, Cecilie			Disability, physical health and mental health 1 year after traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; disability; SF-36; ICF; FIM; CIQ	QUALITY-OF-LIFE; SF-36; OUTCOMES; MODERATE; ADULTS; QUESTIONNAIRE; SATISFACTION; INDIVIDUALS; SCALES; MODEL	Purpose. The purpose of this study was to assess disability and the physical and mental health status 1 year after traumatic brain injury (TBI), using the International Classification of Functioning, Disability and Health (ICF) as a conceptual model for understanding TBI disability. Methods. A prospective study of 85 patients with moderate-to-severe TBI (aged 16-55 years) due to injury occurring from May 2005 to May 2007 and hospitalised at the Trauma Referral Centre in Eastern Norway were included. The severity of structural brain damage and overall trauma were used as indices of body structure impairments. Activity limitations were measured by the Functional Independence Measure, and participation restrictions were assessed via the Community Integration Questionnaire. Physical and mental health dimensions as reported on the Medical Outcome Survey Short-Form were chosen as outcome measures. Results. Roughly one quarter of the patients reported disability requiring personal assistance. One third had major problems with social integration, and 42% were not working. Nearly half of the patients reported poor physical health, and 37% reported poor mental health. Regression models, including demographics, impairments, activity limitations and participation restrictions, accounted for 50% of the variance in physical health and 35% of the variance in mental health. More severe impairments, fewer activity limitations and fewer participation restrictions equated to better overall health. Conclusions. The results demonstrated that a significant proportion of TBI survivors face substantial disability and impaired overall health 1 year after injury. To optimise health and well-being outcomes, clinicians need to ensure that health needs of patients with less severe TBI are identified and treated during the post-acute period.	[Andelic, Nada; Sveen, Unni; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, Nesoddtangen, Norway; [Sandvik, Leiv] Oslo Univ Hosp, Clin Res Ctr, Ulleval, Norway; [Sandvik, Leiv] Univ Oslo, Fac Dent, N-0316 Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, N-0316 Oslo, Norway	Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	nada.andelic@ulleval.no		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority	The authors want to thank all of the subjects for their participation. Special thanks are given to Tone Jerstad (neuroradiologist, Oslo University Hospital, Ulleval) for the CT assessment, Morten Hestnes (Trauma Register, Oslo University Hospital, Ulleval) for the extraction of trauma scores and Nini Hammergren for assistance with patient registrations. This study was supported by grants from the Norwegian Health South-East Authority.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Farivar SS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-54; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hann M, 2008, QUAL LIFE RES, V17, P413, DOI 10.1007/s11136-008-9310-0; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lasa L, 2000, J AFFECT DISORDERS, V57, P261, DOI 10.1016/S0165-0327(99)00088-9; Loge JH, 1998, SCAND J SOC MED, V26, P250; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Novack TA, 2000, BRAIN INJURY, V14, P987; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; TEASDALE G, 1974, LANCET, V2, P81; Uniform Data System for Medical Rehabilitation, 1996, GUID UN DAT SET MED; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 2001, INT CLASS FUNCT DIS	41	71	74	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2010	32	13					1122	1131		10.3109/09638280903410722			10	Rehabilitation	Rehabilitation	608OE	WOS:000278592800007	20113311				2021-06-18	
J	Heile, AMB; Wallrapp, C; Klinge, PM; Samii, A; Kassem, M; Silverberg, G; Brinker, T				Heile, Anna M. B.; Wallrapp, Christine; Klinge, Petra M.; Samii, Amir; Kassem, Moustapha; Silverberg, Gerald; Brinker, Thomas			Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Brain injury; Human mesenchymal stem cells; Cell encapsulation; Cell transplantation	GLUCAGON-LIKE PEPTIDE-1; MARROW STROMAL CELLS; HIPPOCAMPAL-NEURONS; PARKINSONS-DISEASE; EXPRESSION; RECEPTOR; THERAPY; STROKE; RAT; NEUROPROTECTION	Purpose: "Naked" human mesenchymal stem cells (MSC)are neuro-protective in experimental brain injury (TBI). In a controlled cortical impact (CCI) rat model, we investigated whether encapsulated MSC (eMSC) act similarly, and whether efficacy is augmented using cells transfected to produce the neuro-protective substance glucagon-like peptide-1 (GLP-1). Methods: Thirty two Sprague-Dawley rats were randomized to five groups: controls (no CCI), CCI-only, CCI + eMSC, CCI + GLP-1 eMSC, and CCI + empty capsules. On day 14, cisternal cerebro-spinal fluid (CSF) was sampled for measurement of GLP-1 concentration. Brains were immuno-histochemically assessed using specific antibody staining for NeuN, MAP-2 and GFAR In another nine healthy rats, in vitro Results: GLP-1 production rates were measured from cells explanted after 2, 7 and 14 days. GLP-1 production rate in transfected cells, before implantation, was 7.03 fmol/capsule/h. Cells were still secreting GLP-1 at a rate of 3.68 +/- 0.49, 2.85 +/- 0.45 and 3.53 +/- 0.55 after 2, 7 and 14 days, respectively. In both of the stem cell treated CCI groups, hippocampal cell loss was reduced, along with an attenuation of cortical neuronal and glial abnormalities, as measured by MAP-2 and GFAP expression. The effects were more pronounced in animals treated with GLP-1 secreting eMSC. This group displayed an increased CSF level of GLP-1 (17.3 +/- 3.4 pM). Conclusions: Hippocampal neuronal cell loss, and cortical glial and neuronal cyto-skeletal abnormalities, after CCI are reduced following transplantation of encapsulated eMSC. These effects were augmented by GLP-1 transfected eMSC. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Heile, Anna M. B.; Klinge, Petra M.; Samii, Amir; Brinker, Thomas] Int Neurosci Inst GmbH, D-30625 Hannover, Germany; [Wallrapp, Christine] CellMed AG, D-63755 Alzenau, Germany; [Kassem, Moustapha] Odense Univ Hosp, Dept Endocrinol & Metab, DK-5000 Odense, Denmark; [Silverberg, Gerald] Brown Univ, Warren Alpert Med Sch, Dept Clin Neurosci, Providence, RI 02912 USA	Brinker, T (corresponding author), Int Neurosci Inst GmbH, Rudolf Pichlmayr Str 4, D-30625 Hannover, Germany.	thbrinker@gmail.com	Kassem, Moustapha/O-3819-2019; Kassem, Moustapha/J-7688-2013	Kassem, Moustapha/0000-0003-1557-0869; Kassem, Moustapha/0000-0003-1557-0869	German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF); Neurobionics Foundation, Hannover, Germany; Saunders Family Fund at the Neurosurgical Foundation; Warren Alpert Medical School, Brown University, R.I., U.S.A.	This study was supported by the German Federal Ministry of Education and Research; the Neurobionics Foundation, Hannover, Germany; and the Saunders Family Fund at the Neurosurgical Foundation, the Warren Alpert Medical School, Brown University, R.I., U.S.A.	Beak SA, 1998, J CLIN INVEST, V101, P1334, DOI 10.1172/JCI610; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Brandt C, 2004, EPILEPSY RES, V62, P135, DOI 10.1016/j.eplepsyres.2004.08.008; CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chowen JA, 1999, NEUROPEPTIDES, V33, P212, DOI 10.1054/npep.1999.0757; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Drucker DJ, 2002, GUT, V50, P428, DOI 10.1136/gut.50.3.428; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gilman CP, 2003, J NEUROCHEM, V87, P1137, DOI 10.1046/j.1471-4159.2003.02073.x; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; Holst JJ, 2006, DIABETOLOGIA, V49, P253, DOI 10.1007/s00125-005-0107-1; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lindvall O, 2008, EXP NEUROL, V209, P82, DOI 10.1016/j.expneurol.2007.08.019; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Murua A, 2008, J CONTROL RELEASE, V132, P76, DOI 10.1016/j.jconrel.2008.08.010; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Sarnowska A, 2009, EXP NEUROL, V215, P317, DOI 10.1016/j.expneurol.2008.10.023; Savitz SI, 2009, STROKE, V40, pS141, DOI 10.1161/STROKEAHA.108.535864; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Tseng J L, 2000, Prog Brain Res, V127, P189	29	71	72	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 9	2009	463	3					176	181		10.1016/j.neulet.2009.07.071			6	Neurosciences	Neurosciences & Neurology	496JT	WOS:000269968200003	19638295				2021-06-18	
J	Gao, X; Enikolopov, G; Chen, JH				Gao, Xiang; Enikolopov, Grigori; Chen, Jinhui			Moderate traumatic brain injury promotes proliferation of quiescent neural progenitors in the adult hippocampus	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neural stem/progenitor; Proliferation; Transgenic mice	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; STEM-CELLS; NEURONAL DIFFERENTIATION; INTERMEDIATE PROGENITORS; COGNITIVE DEFICITS; MOUSE HIPPOCAMPUS; GRANULE CELLS; NEUROGENESIS	Recent evidence shows that traumatic brain injury (TBI) regulates proliferation of neural stem/progenitor cells in the dentate gyrus (DG) of adult hippocampus. There are distinct classes of neural stem/progenitor cells in the adult DG, including quiescent neural progenitors (QNPs), which carry stem cell properties, and their progeny, amplifying neural progenitors (ANPs). The response of each class of progenitors to TBI is not clear. We here used a transgenic reporter Nestin-GFP mouse line, in which QNP and ANP cells are easily visualized and quantified, to determine the targets of the TBI in the DG. We examined changes in proliferation of QNPs and ANPs in the acute phase following TBI and found that QNPs were induced by TBI insult to enter the cell cycle whereas proliferation of ANPs was not significantly affected. These results indicate that different subtypes of neural stem/progenitor cells respond differently to TBI insult. Stem cell activation by the TBI may reflect the induction of innate repair and plasticity mechanisms by the injured brain. (C) 2009 Elsevier Inc. All rights reserved.	[Gao, Xiang; Chen, Jinhui] Indiana Univ, Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Sch Med, Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA; [Chen, Jinhui] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40236 USA; [Enikolopov, Grigori] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Chen, JH (corresponding author), 950 W Walnut St, Indianapolis, IN 46202 USA.	chen204@iupui.edu	Enikolopov, Grigori/P-5731-2019; Chen, Jinhui/A-7138-2009	Enikolopov, Grigori/0000-0001-8178-8917; Chen, Jinhui/0000-0002-6864-7121	Indiana University School of Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075733, R21NS072631] Funding Source: NIH RePORTER	This work was supported by a startup funding to J. Chen from Indiana University School of Medicine.	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chua HC, 2001, ANN ACAD MED SINGAP, V30, P134; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Encinas JM, 2008, EXP NEUROL, V210, P274, DOI 10.1016/j.expneurol.2007.10.021; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Encinas JM, 2008, METHOD CELL BIOL, V85, P243, DOI 10.1016/S0091-679X(08)85011-X; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Filippov V, 2003, MOL CELL NEUROSCI, V23, P373, DOI 10.1016/S1044-7431(03)00060-5; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAO X, J NEUROTRAU IN PRESS; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V215, P178, DOI 10.1016/j.expneurol.2008.10.009; Gupta Y K, 2006, Indian J Physiol Pharmacol, V50, P7; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Prigatano GP, 2005, ACT NEUR S, V93, P39; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; YAVUZ BB, 2006, INT PSYCHOGERIATR, P1; Yoon KJ, 2008, NEURON, V58, P519, DOI 10.1016/j.neuron.2008.03.018; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang TY, 2007, PSYCHOPHARMACOLOGY, V191, P171, DOI 10.1007/s00213-006-0548-3; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	63	71	77	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2009	219	2					516	523		10.1016/j.expneurol.2009.07.007			8	Neurosciences	Neurosciences & Neurology	498QN	WOS:000270157300017	19615997	Green Accepted			2021-06-18	
J	Kerwin, AJ; Schinco, MA; Tepas, JJ; Renfro, WH; Vitarbo, EA; Muehlberger, M				Kerwin, Andrew J.; Schinco, Miren A.; Tepas, Joseph J., III; Renfro, William H.; Vitarbo, Elizabeth A.; Muehlberger, Michael			The Use of 23.4% Hypertonic Saline for the Management of Elevated Intracranial Pressure in Patients With Severe Traumatic Brain Injury: A Pilot Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 27-29, 2007	Las Vegas, NV	Amer Assoc Surg Trauma		Hypertonic saline; Severe traumatic brain injury; Intracranial pressure; Mannitol	CEREBRAL OXYGEN DELIVERY; HEAD-INJURY; FLUID RESUSCITATION; HYPERTENSION; MANNITOL; EPIDEMIOLOGY; REDUCTION; HEMORRHAGE; DEXTRAN; UREA	Background: Oncotic agents are a therapeutic mainstay for the management of intracranial hypertension. Both mannitol and varied concentrations of hypertonic saline (HTS) have been shown to be effective at reducing elevated intracranial pressure (ICP). We compared the safety and efficacy of 23.4% HTS to mannitol for acute management of elevated ICP after traumatic brain injury (TBI). Methods: After approval from our institutional review board, the records of patients admitted with severe TBI who received mannitol or HTS were reviewed. Demographic and physiologic data were recorded. ICP, cerebral perfusion pressure, reduction of ICP after dose administration, serum sodium, osmolality, and magnitude of dose response during the subsequent 60 minutes were analyzed. Efficacy was determined by comparison of proportion of patients with any response and mean change in ICP after dosing with either agent. Safety was determined by recording any new postinfusion electrolyte or neurologic anomalies. Data were compared using chi(2) test, accepting p < 0.05 as significant. Results: Twenty-two patients with severe TBI received 210 doses of either mannitol or HTS. All patients suffered severe blunt injury (mean Injury Severity Score 28 +/- 11). HTS patients had a significantly higher ICP at the initiation of therapy than that of mannitol group (30.7 +/- 7.94 mm Hg vs. 28.3 +/- 8.07 mm Hg, respectively). There was no difference in initial cerebral perfusion pressure. Mean ICP reduction in the hour after administration of 102 doses of mannitol and 108 doses of HTS was greater for patients receiving HTS (9.3 +/- 7.37 mm Hg vs. 6.4 +/- 6.57 mm Hg, respectively; p = 0.0028, chi(2)). More patients responded to HTS (92.6% HTS vs. 74% mannitol; p = 0.0002, chi(2)). There was no significant difference between groups in the duration of ICP reduction after dose administration (4.1 hours vs. 3.8 hours, respectively). No adverse events after administration of either agent were identified. Conclusion: Based on this retrospective analysis, 23.4% HTS is more efficacious than mannitol in reducing ICP. If these results are confirmed in a prospective, randomized study, 23.4% HTS may become the agent of choice for the management of elevated ICP after TBI.	[Kerwin, Andrew J.; Schinco, Miren A.; Tepas, Joseph J., III; Muehlberger, Michael] Univ Florida, Hlth Sci Ctr, Dept Surg, Jacksonville, FL 32209 USA; [Vitarbo, Elizabeth A.] Univ Florida, Hlth Sci Ctr, Dept Neurosurg, Jacksonville, FL 32209 USA; [Renfro, William H.] Univ Florida, Shands Jacksonville Med Ctr, Dept Pharm, Jacksonville, FL 32209 USA	Kerwin, AJ (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Surg, 655 W 8th St, Jacksonville, FL 32209 USA.	andy.kerwin@jax.ufl.edu					BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; *BRAIN TRAUM FDN I, 2000, MAN PROGN SEV TRAUM; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Ciesla DJ, 2001, SURGERY, V129, P567, DOI 10.1067/msy.2001.113286; Coimbra R, 2005, J TRAUMA, V59, P257, DOI 10.1097/01.ta.0000174678.12523.9f; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; DeWitt DS, 1996, CRIT CARE MED, V24, P109, DOI 10.1097/00003246-199601000-00019; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Fremont-Smith F, 1927, ARCH NEURO PSYCHIATR, V18, P550, DOI 10.1001/archneurpsyc.1927.02210040057002; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hughes J, 1938, ARCH NEURO PSYCHIATR, V39, P1277, DOI 10.1001/archneurpsyc.1938.02270060167009; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; JAVID M, 1961, J NEUROSURG, V18, P51, DOI 10.3171/jns.1961.18.1.0051; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kolsen-Petersen JA, 2004, ACTA ANAESTH SCAND, V48, P667, DOI 10.1111/j.1399-6576.2004.00396.x; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rangel-Castillo L, 2006, CRIT CARE CLIN, V22, P713, DOI 10.1016/j.ccc.2006.06.003; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHENKIN HA, 1962, J NEUROSURG, V19, P897, DOI 10.3171/jns.1962.19.10.0897; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TOKYAY R, 1992, J TRAUMA, V32, P704, DOI 10.1097/00005373-199206000-00006; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Weed LH, 1919, AM J PHYSIOL, V48, P531; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zausinger S, 2004, NEUROSURGERY, V55, P679, DOI 10.1227/01.NEU.0000134558.28977.EE	42	71	76	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2009	67	2					277	282		10.1097/TA.0b013e3181acc726			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	482OL	WOS:000268898500013	19667879				2021-06-18	
J	Hu, X; Xu, P; Scalzo, F; Vespa, P; Bergsneider, M				Hu, Xiao; Xu, Peng; Scalzo, Fabien; Vespa, Paul; Bergsneider, Marvin			Morphological Clustering and Analysis of Continuous Intracranial Pressure	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						Hydrocephalus; injury; intracranial pressure (ICP); traumatic brain pulse morphology	FLUID PULSE-WAVE; APPROXIMATE ENTROPY; SYSTEMS-ANALYSIS; FORM ANALYSIS; SIGNALS; HYPERTENSION; VARIABILITY; REACTIVITY; ALGORITHM	The continuous measurement of intracranial pressure (ICP) is an important and established clinical tool that is used in the management of many neurosurgical disorders such as traumatic brain injury. Only mean ICP information is used currently in the prevailing clinical practice, ignoring the useful information in ICP pulse waveform that can be continuously acquired and is potentially useful for forecasting intracranial and cerebrovascular pathophysiological changes. The present study introduces and validates an algorithm of performing automated analysis of continuous ICP pulse waveform. This algorithm is capable of enhancing ICP signal quality, recognizing nonartifactual ICP pulses, and optimally designating the three well-established subcomponents in an ICP pulse. Validation of the proposed algorithm is done by comparing nonartifactual pulse recognition and peak designation results from a human observer with those from automated analysis based on a large signal database built from 700 h of recordings from 66 neurosurgical patients. An accuracy of 97.84% is achieved in recognizing nonartifactual ICP pulses. An accuracy of 90.17%, 87.56%, and 86.53% was obtained for designating each of the three established ICP subpeaks. These results show that the proposed algorithm can be reliably applied to process continuous ICP recordings from real clinical environment to extract useful morphological features of ICP pulses.	[Hu, Xiao; Xu, Peng; Scalzo, Fabien; Bergsneider, Marvin] Univ Calif Los Angeles, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90024 USA; [Vespa, Paul] Univ Calif Los Angeles, Neurocrit Care Program, Dept Neurosurg, Los Angeles, CA 90095 USA	Hu, X (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90024 USA.	xiaohu@ucla.edu; pengxu@mednet.ucla.edu; fscalzo@mednet.ucla.edu; pvespa@mednet.ucla.edu; mbergsneider@mednet.ucla.edu	Scalzo, Fabien/AAM-6328-2020	Scalzo, Fabien/0000-0001-9755-8104	National institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21-NS055998, R21-NS055045, R21-NS059797, R01-NS054881]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054881, R21NS059797, R21NS055998, R21NS055045] Funding Source: NIH RePORTER	This work was supported in part by the National institute of Neurological Disorders and Stroke (NINDS) under Grant R21-NS055998, Grant R21-NS055045. Grant R21-NS059797, and Grant R01-NS054881.	Aboy M, 2005, IEEE T BIO-MED ENG, V52, P1662, DOI 10.1109/TBME.2005.855725; ADOLPH RJ, 1967, AM J PHYSIOL, V212, P840; Afonso VX, 1999, IEEE T BIO-MED ENG, V46, P192, DOI 10.1109/10.740882; BRANCH C, 1991, BIOMED SCI INSTRUM, V17, P45; CARDOSO ER, 1988, J NEUROSURG, V69, P712, DOI 10.3171/jns.1988.69.5.0712; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; Chopp M, 1980, Biomed Sci Instrum, V16, P149; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Eide PK, 2006, MED ENG PHYS, V28, P579, DOI 10.1016/j.medengphy.2005.09.008; Ellis T, 2007, IEEE T BIO-MED ENG, V54, P1552, DOI 10.1109/TBME.2007.892918; HAMER J, 1977, J NEUROSURG, V46, P36, DOI 10.3171/jns.1977.46.1.0036; Hornero R, 2005, IEEE T BIO-MED ENG, V52, P1671, DOI 10.1109/TBME.2005.855722; HU X, ACTA NEUR S IN PRESS; Hu X, 2008, PHYSIOL MEAS, V29, P459, DOI 10.1088/0967-3334/29/4/004; Hu X, 2008, MED ENG PHYS, V30, P631, DOI 10.1016/j.medengphy.2007.07.002; Hu X, 2007, IEEE T BIO-MED ENG, V54, P1407, DOI 10.1109/TBME.2007.900802; Hu X, 2007, IEEE T BIO-MED ENG, V54, P597, DOI 10.1109/TBME.2006.890130; Kaufman L., 2005, WILEY SERIES PROBABI; Kirkness C J, 2000, J Neurosci Nurs, V32, P271; Morgalla MH, 1999, J NEUROL SCI, V168, P90, DOI 10.1016/S0022-510X(99)00137-9; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Rabiner LR, 1993, FUNDAMENTALS SPEECH; SYMON L, 1975, J NEUROSURG, V42, P258, DOI 10.3171/jns.1975.42.3.0258; TAKIZAWA H, 1987, NEUROSURGERY, V20, P355, DOI 10.1227/00006123-198703000-00001; WILKINSON HA, 1979, J NEUROSURG, V50, P758, DOI 10.3171/jns.1979.50.6.0758	29	71	71	0	8	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855 USA	0018-9294			IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	MAR	2009	56	3					696	705		10.1109/TBME.2008.2008636			10	Engineering, Biomedical	Engineering	437KQ	WOS:000265486800016	19272879	Green Accepted			2021-06-18	
J	Qiu, WS; Guo, CC; Shen, H; Chen, K; Wen, L; Huang, HJ; Ding, M; Sun, L; Jiang, QZ; Wang, WM				Qiu, Wusi; Guo, Chenchen; Shen, Hong; Chen, Keyong; Wen, Liang; Huang, Hongjie; Ding, Min; Sun, Li; Jiang, Qizhou; Wang, Weiming			Effects of unilateral decompressive craniectomy on patients with unilateral acute post-traumatic brain swelling after severe traumatic brain injury	CRITICAL CARE			English	Article							REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL OXYGENATION; HEAD-INJURY; EXPERIENCE; PRESSURE; HYPOTHERMIA; MANAGEMENT	Introduction Acute post-traumatic brain swelling (BS) is one of the pathological forms that need emergent treatment following traumatic brain injury. There is controversy about the effects of craniotomy on acute post-traumatic BS. The aim of the present clinical study was to assess the efficacy of unilateral decompressive craniectomy (DC) or unilateral routine temporoparietal craniectomy on patients with unilateral acute post-traumatic BS. Methods Seventy-four patients of unilateral acute posttraumatic BS with midline shifting more than 5 mm were divided randomly into two groups: unilateral DC group (n = 37) and unilateral routine temporoparietal craniectomy group (control group, n = 37). The vital signs, the intracranial pressure (ICP), the Glasgow outcome scale (GOS), the mortality rate and the complications were prospectively analysed. Results The mean ICP values of patients in the unilateral DC group at hour 24, hour 48, hour 72 and hour 96 after injury were much lower than those of the control group (15.19 +/- 2.18 mmHg, 16.53 +/- 1.53 mmHg, 15.98 +/- 2.24 mmHg and 13.518 +/- 2.33 mmHg versus 19.95 +/- 2.24 mmHg, 18.32 +/- 1.77 mmHg, 21.05 +/- 2.23 mmHg and 17.68 +/- 1.40 mmHg, respectively). The mortality rates at 1 month after treatment were 27% in the unilateral DC group and 57% in the control group (p = 0.010). Good neurological outcome (GOS Score of 4 to 5) rates 1 year after injury for the groups were 56.8% and 32.4%, respectively (p = 0.035). The incidences of delayed intracranial hematoma and subdural effusion were 21.6% and 10.8% versus 5.4% and 0, respectively (p = 0.041 and 0.040). Conclusions Our data suggest that unilateral DC has superiority in lowering ICP, reducing the mortality rate and improving neurological outcomes over unilateral routine temporoparietal craniectomy. However, it increases the incidence of delayed intracranial hematomas and subdural effusion, some of which need secondary surgical intervention. These results provide information important for further large and multicenter clinical trials on the effects of DC in patients with acute post-traumatic BS.	[Qiu, Wusi; Guo, Chenchen; Shen, Hong; Wen, Liang] Zhejiang Univ, Coll Med, Brain Med Res Inst, Hangzhou 310009, Zhejiang, Peoples R China; [Qiu, Wusi; Guo, Chenchen; Chen, Keyong; Huang, Hongjie; Ding, Min; Sun, Li; Jiang, Qizhou; Wang, Weiming] Hangzhou Normal Univ, Coll Med, Hangzhou Hosp 2, Dept Neurosurg, Hangzhou 310015, Zhejiang, Peoples R China; [Qiu, Wusi; Shen, Hong] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China	Shen, H (corresponding author), Zhejiang Univ, Coll Med, Brain Med Res Inst, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	sh_2nd@163.com			Scientific Research Fund of Zhejiang Health Department; Scientific Research Fund of Hangzhou Health Department; Scientific Research Fund of Science and Technology Department of Zhejiang, China	The present study was supported by the Scientific Research Fund of Zhejiang Health Department, the Scientific Research Fund of Hangzhou Health Department and the Scientific Research Fund of Science and Technology Department of Zhejiang, China. The authors gratefully acknowledge the Brain Medicine Research Institute, College of Medicine, Zhejiang University.	Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Agrawal A., 2007, SMJ Singapore Medical Journal, V48, P492; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Armonda RA, 2006, NEUROCRIT CARE, V4, P241, DOI 10.1385/NCC:4:3:241; Bassin SL, 2008, CRIT CARE, V12, DOI 10.1186/cc7020; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Citerio G, 2007, INTENS CARE MED, V33, P45, DOI 10.1007/s00134-006-0381-5; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Figaji AA, 2007, CHILD NERV SYST, V23, P1331, DOI 10.1007/s00381-007-0388-4; Fiorot JA, 2008, ARQ NEURO-PSIQUIAT, V66, P204, DOI 10.1590/S0004-282X2008000200012; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kofke W Andrew, 2007, Anesthesiol Clin, V25, P579; Krishnan P, 2006, NEUROL INDIA, V54, P291; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Liu Wei-guo, 2004, Chin J Traumatol, V7, P175; Missori P, 2008, SURG NEUROL, V70, P437, DOI 10.1016/j.surneu.2007.03.029; Mitchell P, 2007, J NEUROL SCI, V261, P89, DOI 10.1016/j.jns.2007.04.040; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Salvatore C, 2008, J NEUROSURG, V108, P74, DOI 10.3171/JNS/2008/108/01/0074; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Yao Y, 2007, ACTA NEUROCHIR, V149, P1219, DOI 10.1007/s00701-007-1415-7; Zhao Z, 2007, NEUROCRIT CARE, V7, P263, DOI 10.1007/s12028-007-0074-0	33	71	73	2	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	6							R185	10.1186/cc8178			7	Critical Care Medicine	General & Internal Medicine	556DF	WOS:000274567900014	19930556	DOAJ Gold, Green Published			2021-06-18	
J	Ring, H; Treger, I; Gruendlinger, L; Hausdorff, JM				Ring, Haim; Treger, Iuly; Gruendlinger, Leor; Hausdorff, Jeffrey M.			Neuroprosthesis for Footdrop Compared with an Ankle-Foot Orthosis: Effects on Postural Control during Walking	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article; Proceedings Paper	EvoWorkshops 2007	APR 11-13, 2007	Valencia, SPAIN	Univ Politecn Valencia, Inst Tecnol Informat, Minist Educ & Ciencia, Napier Univ, Ctr Emergent Comp		Neuroprosthesis; functional electrical stimulation; ankle-foot orthosis; postural control; gait	FUNCTIONAL ELECTRICAL-STIMULATION; PERONEAL NERVE STIMULATOR; DROPPED FOOT; EXECUTIVE FUNCTION; GAIT VARIABILITY; STROKE; HEMIPLEGIA; COORDINATION; HEMIPARESIS; PERFORMANCE	Objectives: We sought to compare the effects of a radio frequency-controlled neuroprosthesis on gait stability and symmetry to the effects obtained with a standard ankle-foot orthosis (AFO). Methods: A total of 15 patients (mean age: 52.2 +/- 3.6 years) with prior chronic hemiparesis resulting from stroke or traumatic brain injury (5.9 +/- 1.5 year) whose walking was impaired by footdrop and regularly used an AFO participated in the study. There was a 4-week adaptation period during which participants increased their daily use of the neuroprosthesis, while using the AFO for the rest of the day. Gait was then assessed in a 6-minute walk while wearing force-sensitive insoles, by using the neuroprosthesis and the AFO in a randomized order. An additional gait assessment was conducted after using the neuroprosthesis for a further 4 weeks. Gait speed and stride time (inverse of cadence) were determined, as were gait asymmetry index and swing time variability. Results: After the 4-week adaptation period, there were no differences between walking with the neuroprosthesis and walking with the AFO (P >.05). After 8 weeks, there was no significant difference in gait speed, whereas stride time improved from 1.48 +/- 0.21 seconds with the AFO to 1.41 +/- 0.16 seconds with the neuroprosthesis (P < .02). Swing time variability decreased from 5.3 +/- 1.6% with the AFO to 4.3 +/- 1.4% with the neuroprosthesis (P = .01). A gait asymmetry index improved by 15% from 0.20 +/- 0.09 with the AFO to 0.17 +/- 0.08 with the neuroprothesis (P < .05). Conclusions: Compared with AFO, the studied neuroprosthesis appears to enhance balance control during walking and, thus, more effectively manage footdrop.	[Gruendlinger, Leor; Hausdorff, Jeffrey M.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Movement Disorders Unit, IL-69978 Tel Aviv, Israel; [Ring, Haim; Treger, Iuly] Loewenstein Hosp & Rehabil Ctr, Neurol Rehabil Dept, Ranana, Israel; [Ring, Haim; Treger, Iuly] Tel Aviv Univ, Sackler Fac Med, Dept Rehabil Med, IL-69978 Tel Aviv, Israel; [Hausdorff, Jeffrey M.] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Hausdorff, Jeffrey M.] Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA	Hausdorff, JM (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Movement Disorders Unit, Weizmann 6, IL-69978 Tel Aviv, Israel.	jhausdorff@alum.mit.edu	Treger, Iuly/H-6791-2015				Alfieri V, 2001, NEUROMODULATION, V4, P85, DOI 10.1046/j.1525-1403.2001.00085.x; BUNNELL KL, 1994, J ORTHOP SPORT PHYS, V20, P287; Burridge J, 1997, PHYSIOTHERAPY, V83, P82; Donker SF, 2002, ACTA PSYCHOL, V110, P265, DOI 10.1016/S0001-6918(02)00037-9; Eng JJ, 2002, STROKE, V33, P756, DOI 10.1161/hs0302.104195; Fatone S, 2007, J REHABIL RES DEV, V44, P11, DOI 10.1682/JRRD.2006.08.0090; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Geboers JFM, 2002, J REHABIL MED, V34, P80, DOI 10.1080/165019702753557872; Granat MH, 1996, ARCH PHYS MED REHAB, V77, P19, DOI 10.1016/S0003-9993(96)90214-2; Harris-Love ML, 2001, NEUROREHAB NEURAL RE, V15, P105, DOI 10.1177/154596830101500204; Hausdorff JM, 2008, AM J PHYS MED REHAB, V87, P4, DOI 10.1097/PHM.0b013e31815e6680; Hausnerova B, 2005, INT POLYM PROC, V20, P19, DOI 10.3139/217.1853; HILL KD, 1994, ARCH PHYS MED REHAB, V75, P577; Kottink AIR, 2004, ARTIF ORGANS, V28, P577, DOI 10.1111/j.1525-1594.2004.07310.x; Kottink AI, 2007, ARCH PHYS MED REHAB, V88, P971, DOI 10.1016/j.apmr.2007.05.002; LIBERSON W T, 1961, Arch Phys Med Rehabil, V42, P101; Lyons GM, 2002, IEEE T NEUR SYS REH, V10, P260, DOI 10.1109/TNSRE.2002.806832; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Peckham PH, 2005, ANNU REV BIOMED ENG, V7, P327, DOI 10.1146/annurev.bioeng.6.040803.140103; Pohl PS, 2002, J REHABIL RES DEV, V39, P439; SACKLEY C M, 1990, Physiotherapy Theory and Practice, V6, P179, DOI 10.3109/09593989009048293; Sheffler LR, 2006, NEUROREHAB NEURAL RE, V20, P355, DOI 10.1177/1545968306287925; Sheridan PL, 2003, J AM GERIATR SOC, V51, P1633, DOI 10.1046/j.1532-5415.2003.51516.x; Shimada Y, 2006, NEUROMODULATION, V9, P320, DOI 10.1111/j.1525-1403.2006.00074.x; Springer S, 2006, MOVEMENT DISORD, V21, P950, DOI 10.1002/mds.20848; Stein RB, 2006, NEUROREHAB NEURAL RE, V20, P371, DOI 10.1177/1545968306289292; Taylor PN, 1999, ARCH PHYS MED REHAB, V80, P1577, DOI 10.1016/S0003-9993(99)90333-7; Taylor PN, 1999, CLIN REHABIL, V13, P439, DOI 10.1191/026921599677086409; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Wang RY, 2005, CLIN REHABIL, V19, P37, DOI 10.1191/0269215505cr797oa; WOLLY SM, 2001, TOP STROKE REHABIL, V7, P1; WRIGHT A, 2002, 1 ANN C FESNET SEPT; Yogev G, 2007, EXP BRAIN RES, V177, P336, DOI 10.1007/s00221-006-0676-3	33	71	79	0	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JAN	2009	18	1					41	47		10.1016/j.jstrokecerebrovasdis.2008.08.006			7	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	410EJ	WOS:000263560000008	19110144				2021-06-18	
J	Angeleri, R; Bosco, FM; Zettin, M; Sacco, K; Colle, L; Bara, BG				Angeleri, R.; Bosco, F. M.; Zettin, M.; Sacco, K.; Colle, L.; Bara, B. G.			Communicative impairment in traumatic brain injury: A complete pragmatic assessment	BRAIN AND LANGUAGE			English	Article						Communication; Cognitive Pragmatics; Irony; Deceit; Verbal; Non-verbal; Paralinguistic; Inferential process	CLOSED-HEAD-INJURY; EXTRALINGUISTIC COMMUNICATION; SOCIAL-PERCEPTION; LINGUISTIC HUMOR; COMPREHENSION; LANGUAGE; RECOGNITION; ADOLESCENTS; EXPRESSION; ABILITY	The aim of (lie present study was to examine the Communicative abilities of traumatic brain injury patients (TBI). We wish to provide a complete assessment of their Communicative ability/disability using a new experimental protocol, the Assessment Battery of Communication, (ABaCo) comprising five scales-linguistic, extralinguistic, paralinguistic, context and conversational-which investigate all the main pragmatic elements involved in a communicative exchange. The ABaCo was administered to 21 TBI subjects and to a control group. The results showed that performance by TBI patients was worse than that of controls on all scales; moreover they showed a trend of increasing difficulty in understanding and producing different pragmatic phenomena, i.e., standard communication acts, deceits and ironies, whether such phenomena are expressed through the linguistic or extralinguistic modality. (C) 2008 Elsevier Inc. All rights reserved.	[Angeleri, R.; Bosco, F. M.; Sacco, K.; Colle, L.; Bara, B. G.] Univ Turin, Ctr Cognit Sci, I-10123 Turin, Italy; [Angeleri, R.; Bosco, F. M.; Sacco, K.; Colle, L.; Bara, B. G.] Univ Turin, Dept Psychol, I-10123 Turin, Italy; [Bosco, F. M.; Sacco, K.; Colle, L.; Bara, B. G.] Neurosci Inst Turin, Turin, Italy; [Zettin, M.] Ctr Puzzle, Turin, Italy; [Sacco, K.] Univ Turin, CCS fMRI, Neuroradiol Koelliker Hosp, I-10124 Turin, Italy; [Sacco, K.] Univ Turin, Dept Psychol, I-10124 Turin, Italy	Bosco, FM (corresponding author), Univ Turin, Ctr Cognit Sci, Via 14, I-10123 Turin, Italy.	bosco@psych.unito.it	bosco, francesca marina/B-6746-2013; Sacco, Katiuscia/J-2133-2012	bosco, francesca marina/0000-0001-6101-8587; Sacco, Katiuscia/0000-0002-9660-5236			AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1016/0364-0213(93)90011-V; AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; AIRENTI G, 1984, COMPUTATIONAL MODELS; Altman D, 1991, PRACTICAL STAT MED R; Austin John L, 1962, DO THINGS WORDS, Vsecond; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; BARA BG, 1999, P 11 EUR C COGN SCI; BARA BG, 2008, COGNITIVE PRAGMATICS; BARA BG, 1998, SPECIAL ISSUE ANAL P, P317; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2004, PROCEEDINGS OF THE TWENTY-SIXTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P144; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown Penelope, 1987, POLITENESS SOME UNIV, DOI [10.1017/CBO9780511813085, DOI 10.2307/3587263]; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho C. A., 1992, CLIN APHASIOLOGY, V21, P183; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; De Marco I, 2007, J PRAGMATICS, V39, P134, DOI 10.1016/j.pragma.2006.08.009; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J AUTISM DEV DISORD, V31, P47, DOI 10.1023/A:1005661613288; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Docking K, 1999, BRAIN INJURY, V13, P953; EKMAN P, 1979, ANNU REV PSYCHOL, V30, P527, DOI 10.1146/annurev.ps.30.020179.002523; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRASER B, 1981, INT J SOCIOL LANG, P93; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Huber W, 1996, AACHENER APHASIE TES; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JOANNETTE Y, 1990, DISCOURSE ABILITY BR; Kasher A, 1999, BRAIN LANG, V68, P566, DOI 10.1006/brln.1999.2129; Kasher A., 1991, CHOMSKYAN TURN, P122; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; KRAUSS RM, 1991, J PERS SOC PSYCHOL, V61, P743, DOI 10.1037/0022-3514.61.5.743; Krauss RM, 1998, CURR DIR PSYCHOL SCI, V7, P54, DOI 10.1111/1467-8721.ep13175642; Lakatos I., 1970, CRITICISM GROWTH KNO, P91, DOI [DOI 10.1017/CBO9781139171434, 10.1017/CBO9781139171434.009]; LAKOFF R, 1973, PAP 9 REG M CHIC LIN; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Luria A. R., 1976, BASIC PROBLEMS NEURO; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Morgan J., 1975, SYNTAX SEMANTICS, V3; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Penn C, 1999, BRAIN LANG, V68, P535, DOI 10.1006/brln.1999.2127; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; REITER R, 1980, ARTIF INTELL, V13, P81, DOI 10.1016/0004-3702(80)90014-4; Russell B., 1914, OUR KNOWLEDGE EXTERN; SACCO K, ASSESSMENT BAT UNPUB; Sacks H. E. A., 1978, STUDIES ORG CONVERSA, P7; Searle J. R., 1979, EXPRESSION MEANING S; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; WINNER E, 1977, BRAIN, V100, P717, DOI 10.1093/brain/100.4.717; Wozniak RJ, 1999, BRAIN INJURY, V13, P191, DOI 10.1080/026990599121700; Ylvisaker M., 1987, COMMUNITY REENTRY HE, P137	75	71	73	1	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	DEC	2008	107	3					229	245		10.1016/j.bandl.2008.01.002			17	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	379SW	WOS:000261417500006	18267340				2021-06-18	
J	Green, RE; Colella, B; Christensen, B; Johns, K; Frasca, D; Bayley, M; Monette, G				Green, Robin E.; Colella, Brenda; Christensen, Bruce; Johns, Kadeen; Frasca, Diana; Bayley, Mark; Monette, Georges			Examining Moderators of Cognitive Recovery Trajectories After Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Prognosis; Rehabilitation	CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL RECOVERY; FOLLOW-UP; SPEED; PERFORMANCE; ATTENTION; RESERVE; MEMORY; ADULTS; DAMAGE	Objectives: To examine the influence of cognitive reserve-related moderator variables on recovery trajectories during the first year after traumatic brain injury (TBI). Using mixed effects models, we measured (1) the level of cognitive function at 2 and 12 months postinjury and (2) the trajectories of cognitive recovery during the first 12 months postinjury. Design: Repeated-measures design with neuropsychological testing at 2. 5, and 12 months postinjury. Setting: Large, urban inpatient neurorehabilitation program. Participants: Patients (N=75) with moderate-to-severe TBI. Interventions: Not applicable. Main Outcome Measures: Primary outcomes: neuropsychological composite scores including simple speed of processing, complex speed of processing, memory, untimed executive functions, and attention span. Primary predictors: age, estimated premorbid intelligence quotient (IQ), and years of education. Results: Only age significantly moderated trajectories. Decreasing age significantly enhanced recovery of speed of processing, both simple (2-12mo postinjury, P<.001) and complex (2-12mo postinjury, P<.05; 5-12mo postinjury, P<.005). Decreasing age and increasing estimated premorbid IQ were associated with higher performance at 2 and 12mo postinjury for simple speed of processing (premorbid IQ, 2 and 12mo), complex speed of processing (age, 2 and 12mo), untimed executive functions (premorbid IQ, 2 and 12mo), and memory (premorbid IQ, 2 and 12mo). Conclusions: Recovery of speed of processing (both simple and complex) was favorably moderated by younger age. Older age is associated with more neuronal loss and less integrity of white matter, and speed of processing is associated with white matter networks. The recuperative effects of younger age may therefore be attributable to greater reserve capacity (as indexed by white matter integrity). Lower age and higher estimated premorbid IQ were associated with higher functioning on a variety of cognitive outcomes. This may reflect the buffering effects of reserve capacity or premorbid differences in age and IQ-related cognitive functioning. Implications for rehabilitation and recovery mechanisms are discussed.	[Green, Robin E.; Colella, Brenda; Frasca, Diana; Bayley, Mark] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Green, Robin E.; Frasca, Diana; Bayley, Mark] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Monette, Georges] York Univ, Dept Math & Stat, Toronto, ON M3J 2R7, Canada; [Christensen, Bruce] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada	Green, RE (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	green.rohin@torontorehab.on.ca		Bayley, Mark/0000-0001-7860-9463; Green, Robin/0000-0001-9451-3963	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-67072, MOP-86704]	Supported by the Canadian Institutes of Health Research (grant nos. MOP-67072, MOP-86704).	Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HOLM S, 1979, SCAND J STAT, V6, P65; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1979, GLAVESTON ORIENTATIO; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Luria A.R., 1975, HDB CLIN NEUROLOGY, P368; Luria A. R., 1963, RESTORATION FUNCTION; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Shallice, 1997, HAYLING BRIXTON TEST; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Singer J.D., 2003, APPL LONGITUDINAL DA; Smith A., 1982, SYMBOL DIGIT MODALIT; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Stern Y, 2005, CEREB CORTEX, V15, P394, DOI 10.1093/cercor/bhh142; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tombaugh TN, 1996, TEST MEMORY MALINGER; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler D, 1999, WECHSLER ADULT INTEL; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zahn TP, 1999, INT J PSYCHOPHYSIOL, V33, P113, DOI 10.1016/S0167-8760(99)00030-6; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	54	71	71	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12					S16	S24		10.1016/j.apmr.2008.09.551			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	388DB	WOS:000261999400003	19081437				2021-06-18	
J	Bowman, SM; Bird, TM; Aitken, ME; Tilford, JM				Bowman, Stephen M.; Bird, Tommy M.; Aitken, Mary E.; Tilford, John M.			Trends in Hospitalizations Associated With Pediatric Traumatic Brain Injuries	PEDIATRICS			English	Article						traumatic brain injury; hospitalizations; incidence; trends	UNITED-STATES; CARE	OBJECTIVES. The goals were to describe trends in pediatric traumatic brain injury hospitalizations in the United States and to provide national benchmarks for state and regional comparisons. METHODS. Analysis of existing data (1991-2005) from the Nationwide Inpatient Sample, the largest longitudinal, all-payer, inpatient care database in the United States, was performed. Children 0 to 19 years of age were included. Annual rates of traumatic brain injury-related hospitalizations, stratified according to age, gender, severity of traumatic brain injury, and outcome, were determined. RESULTS. From 1991 to 2005, the estimated annual incidence rate of pediatric hospitalizations associated with traumatic brain injury decreased 39%, from 119.4 to 72.7 hospitalizations per 100 000. The rates decreased for all age groups and for both boys and girls, although the rate for boys remained consistently higher at each time point. Fatal hospitalization rates decreased from 3.5 deaths per 100 000 in 1991-1993 to 2.8 deaths per 100 000 in 2003-2005. The rate of mild traumatic brain injury hospitalizations accounted for most of the overall decrease, whereas nonfatal hospitalization rates for moderate and severe traumatic brain injuries remained relatively unchanged. CONCLUSIONS. Although pediatric hospitalization rates for mild traumatic brain injuries have decreased over the past 15 years, rates for moderate and severe traumatic brain injuries are relatively unchanged. Our study provides national estimates of pediatric traumatic brain injury hospitalizations that can be used as benchmarks to increase injury prevention effectiveness through targeting of effective strategies. Pediatrics 2008; 122: 988-993	[Bowman, Stephen M.; Bird, Tommy M.; Aitken, Mary E.; Tilford, John M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA	Bowman, SM (corresponding author), Arkansas Childrens Hosp, Dept Pediat, CARE Peds Slot 512-26,800 Marshall St, Little Rock, AR 72202 USA.	bowmanstephenm@uams.edu	Bowman, Stephen/AAF-2154-2019	Aitken, Mary/0000-0002-8318-9755	Arkansas Biosciences Institute; Arkansas Children's Hospital, Arkansas State University, the University of Arkansas Division of Agriculture, the University of Arkansas, Fayetteville; University of Arkansas for Medical Sciences. The Arkansas Biosciences Institute	Support for Dr Bowman was provided in part by the Arkansas Biosciences Institute, a partnership of scientists from Arkansas Children's Hospital, Arkansas State University, the University of Arkansas Division of Agriculture, the University of Arkansas, Fayetteville, and the University of Arkansas for Medical Sciences. The Arkansas Biosciences Institute is the major research component of the Tobacco Settlement Proceeds Act of 2000.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; American College of Surgeons, 2006, RES OPT CAR INJ PAT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARRETT M, 2006, HCUP METHODS SERIES; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Centers for Disease Control and Prevention, YOUTH RISK BEH SURV; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Moore E. E., 2004, TRAUMA; *NAT CTR HLTH STAT, FRAM PRES NAT INJ DA; *NAT HIGHW TRAFF S, 2006, PUBL DOT HS NAT HIGH; *NAT HIGHW TRAFF S, 2007, PUBL DOT HS NAT HIGH; *NAT HIGHW TRAFF S, 2005, TRAFF SAF FACTS MOT; National Center for Injury Prevention and Control, WEB BAS INJ STAT QUE; Rivara FP, 1999, AM J PREV MED, V16, P1, DOI 10.1016/S0749-3797(98)00111-1; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006	22	71	74	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	NOV	2008	122	5					988	993		10.1542/peds.2007-3511			6	Pediatrics	Pediatrics	367HG	WOS:000260542500010	18977977				2021-06-18	
J	Merkley, TL; Bigler, ED; Wilde, EA; McCauley, SR; Hunter, JV; Levin, HS				Merkley, Tricia L.; Bigler, Erin D.; Wilde, Elisabeth A.; McCauley, Stephen R.; Hunter, Jill V.; Levin, Harvey S.			Diffuse Changes in Cortical Thickness in Pediatric Moderate-to-Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						MRI; neural injury; other tools of modern imaging; pediatric brain injury; traumatic brain injury	SURFACE-BASED ANALYSIS; WORKING-MEMORY; ANTERIOR; ATROPHY; MRI	Generalized whole brain volume loss has been well documented in moderate-to-severe traumatic brain injury (TBI), as has diffuse cerebral atrophy based on magnetic resonance imaging (MRI) volumetric methods where white matter may be more selectively affected than gray matter. However, specific regional differences in gray matter thickness of the cortical mantle have not been previously examined. As such, cortical thickness was assessed using FreeSurfer (R) software to identify regions of significant gray matter cortical thinning in MRI scans of 16 young TBI subjects (age range, 9-16 years) compared to 16 demographically matched controls. Significant cortical thinning was observed globally in the TBI group compared to the cohort of typically developing children. Reduced cortical thickness was related to reported deficits in working memory. TBI-induced cortical thickness reductions are probably due to a combination of focal and diffuse effects and have implications for the neurobehavioral sequelae of TBI.	[Merkley, Tricia L.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; [Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	Ira Fulton Foundation [NS-21889, NIH R01 HD048946]; Home and Social Science, Brigham Young University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grants NS-21889 and NIH R01 HD048946, by the Ira Fulton Foundation, and a grant from the College of Family, Home and Social Science, Brigham Young University. The technical assistance of Tracy J. Abildskov and the editorial assistance of Jo Ann Petrie are gratefully acknowledged.	ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; JENNETT B, 1975, LANCET, V1, P480; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Postle BR, 2006, NEUROIMAGE, V30, P950, DOI 10.1016/j.neuroimage.2005.10.018; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	17	71	71	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1343	1345		10.1089/neu.2008.0615			3	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900006	19061377	Green Published, Green Accepted			2021-06-18	
J	Hatton, J; Rosbolt, B; Empey, P; Kryscio, R; Young, B				Hatton, Jimmi; Rosbolt, Bonnie; Empey, Philip; Kryscio, Richard; Young, Byron			Dosing and safety of cyclosporine in patients with severe brain injury	JOURNAL OF NEUROSURGERY			English	Article						cyclosporine; neuroprotection; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; GROWTH-FACTOR-I; CLINICAL-TRIALS; HEAD-INJURY; PHARMACOLOGICAL-TREATMENT; NEUROPROTECTIVE AGENTS; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; DOSE-RESPONSE; MOUSE MODEL	Object. Cyclosporine neuroprotection has been reported in brain injury models but safety and dosing guidelines have not been determined in humans with severe traumatic brain injury (TBI). The purpose of this investigation was to establish the safety of cyclosporine using 4 clinically relevant closing schemes. Methods. The authors performed a prospective, blinded, placebo-control led, randomized, dose-escalation trial of cyclosporine administration initiated within 8 hours of TBI (Glasgow Coma Scale score range 4-9; motor score range 2-5). Four dosing cohorts (8 patients treated with cyclosporine and 2 receiving placebo treatment per cohort) received cyclosporine (1.25-5 mg/kg/day) or placebo in 2 divided doses (Cohorts I-III) or Continuous infusion (Cohort IV) over 72 hours, Adverse events and outcome were monitored for 6 months. Results. Forty patients were enrolled over 3 years (cyclosporine cohorts, 24 male and 8 female patients placebo group, 8 male patients). Systemic trough concentrations were below 250 ng/ml during intermittent doses. Higher blood concentrations were observed in Cohorts III and IV. There was no significant difference in immunological effects, adverse events, infection, renal dysfunction, or seizures. Mortality rate was not affected by cyclosporine administration, independent of dose, compared with placebo (6 of 32 patients receiving cyclosporine and 2 of 8 receiving placebo died, p > 0.05). At 6 months, a dose-related improvement in favorable Outcome was observed in cyclosporine-treated patients (p < 0.05). Conclusions. In patients with acute TBI who received cyclosporine at doses Lip to 5 mg/kg/day, administered intravenously, with treatment initiated within 8 hours of injury, the rate of mortality or other adverse events was not significantly different from that of the placebo group.	[Hatton, Jimmi] Univ Kentucky, Dept Pharm Practice & Sci, Lexington, KY 40536 USA; [Hatton, Jimmi; Young, Byron] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Empey, Philip] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA; [Hatton, Jimmi; Rosbolt, Bonnie; Young, Byron] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY 40536 USA; [Kryscio, Richard] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY 40536 USA	Hatton, J (corresponding author), Univ Kentucky, Dept Pharm Practice & Sci, 725 Rose St, Lexington, KY 40536 USA.	jhatt1@uky.edu	Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR002602, M01RR02602] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41239-02, 1R01NS 41239-01, R01 NS041239, R01 NS041239-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041239] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Avramut M, 2003, CURR TOP MED CHEM, V3, P1376, DOI 10.2174/1568026033451871; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Borlongan CV, 2002, BRAIN RES, V956, P211, DOI 10.1016/S0006-8993(02)03474-1; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Farin A, 2004, ACT NEUR S, V89, P101; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hatton J, 1997, J NEUROSURG, V86, P779, DOI 10.3171/jns.1997.86.5.0779; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; Hatton J, 2006, J NEUROSURG, V105, P843, DOI 10.3171/jns.2006.105.6.843; Kagawa Y, 2003, BIOL PHARM BULL, V26, P1115; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; Kristal BS, 2004, J BIOENERG BIOMEMBR, V36, P309, DOI 10.1023/B:JOBB.0000041759.35731.70; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2004, ACT NEUR S, V89, P113; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marciano PG, 2001, RESTOR NEUROL NEUROS, V18, P105; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; MARR A, 2001, CENTRAL NERVOUS SYST; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; Uchino H, 2003, ACTA NEUROCHIR SUPPL, V86, P105; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Van den Heuvel C, 2004, J NEUROTRAUM, V21, P1562, DOI 10.1089/0897715042441783; Zieminska E, 2000, Acta Pol Pharm, V57 Suppl, P129	68	71	72	0	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					699	707		10.3171/JNS/2008/109/10/0699			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100016	18826358	Green Accepted			2021-06-18	
J	Nixon, K; Kim, DH; Potts, EN; He, J; Crews, FT				Nixon, K.; Kim, D. H.; Potts, E. N.; He, J.; Crews, F. T.			Distinct cell proliferation events during abstinence after alcohol dependence: Microglia proliferation precedes neurogenesis	NEUROBIOLOGY OF DISEASE			English	Article						alcoholism; regeneration; ethanol; hippocampus; cortex; progenitor; stem cell; adult neurogenesis; microglia; neurodegeneration	ADULT-RAT HIPPOCAMPUS; BINGE ETHANOL EXPOSURE; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; INDUCED NEURODEGENERATION; BENZODIAZEPINE-RECEPTORS; COGNITIVE DEFICITS; NEURONAL LOSS; DAMAGE	Excessive alcohol intake characteristic of Alcohol Use Disorders (AUDs) produces neurodegeneration that may recover with abstinence. The mechanism of regeneration is unclear, however neurogenesis from neural stem/progenitor cells is a feasible mechanism of structural plasticity. Therefore, a timecourse of cell proliferation was examined in a rat model of an AUD and showed a striking burst in cell proliferation at 2 days of abstinence preceding the previously reported neurogenic proliferation at 7 days. New cells at 2 days, assessed by bromo-deoxy-uridine incorporation and endogenous markers, were observed throughout hippocampus and cortex. Although the majority of these new cells did not become neurons, neurogenesis was not altered at this specific time point. These new cells expressed a microglia-specific marker, Iba-1, and survived at least 2 months. This first report of microglia proliferation in a model of an AUD suggests that microgliosis could contribute to volume recovery in non-neurogenic regions during abstinence. (C) 2008 Elsevier Inc. All rights reserved.	[Kim, D. H.; Potts, E. N.; He, J.; Crews, F. T.] Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; [Nixon, K.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA	Crews, FT (corresponding author), Univ N Carolina, Bowles Ctr Alcohol Studies, Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	kim-nixon@uky.edu; FrCrews@med.unc.edu	Nixon, Kimberly/Y-9270-2019; Crews, Fulton/T-1181-2019; Nixon, Kimberly/A-1217-2015; Crews, Fulton/None	Nixon, Kimberly/0000-0002-3466-9912; Crews, Fulton/0000-0003-2393-4976	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P60 AA011605-11, R37 AA006069-18, R37 AA006069, R01 AA016959-02, P60 AA011605, R01 AA016959] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA006069, R01AA016959, P60AA011605] Funding Source: NIH RePORTER		ADACHI J, 1991, J STUD ALCOHOL, V52, P448, DOI 10.15288/jsa.1991.52.448; Agartz I, 1999, ARCH GEN PSYCHIAT, V56, P356, DOI 10.1001/archpsyc.56.4.356; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Bartels C, 2007, ALCOHOL ALCOHOLISM, V42, P92, DOI 10.1093/alcalc/agl104; Beresford TP, 2006, ALCOHOL CLIN EXP RES, V30, P1866, DOI 10.1111/j.1530-0277.2006.00223.x; BRANDT J, 1983, ARCH GEN PSYCHIAT, V40, P435; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Collins MA, 1996, ALCOHOL CLIN EXP RES, V20, P284, DOI 10.1111/j.1530-0277.1996.tb01641.x; Collins MA, 1998, FASEB J, V12, P221; Crews FT, 2000, ALCOHOL CLIN EXP RES, V24, P1712, DOI 10.1111/j.1530-0277.2000.tb01973.x; Crews FT, 2004, ALCOHOL CLIN EXP RES, V28, P350, DOI 10.1097/01.ALC.0000113416.65546.01; Crews FT, 2006, ALCOHOL CLIN EXP RES, V30, P720, DOI 10.1111/j.1530-0277.2006.00084.x; Crews FT, 2006, NEUROSCIENCE, V137, P437, DOI 10.1016/j.neuroscience.2005.08.090; Crews FT, 2004, ALCOHOL, V33, P63, DOI 10.1016/j.alcohol.2004.04.005; Crews F, 2006, ALCOHOL CLIN EXP RES, V30, P1938, DOI 10.1111/j.1530-0277.2006.00239.x; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Eisch AJ, 2002, PROG BRAIN RES, V138, P315, DOI 10.1016/S0079-6123(02)38085-3; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ernst C, 2006, J NEUROSCI RES, V83, P349, DOI 10.1002/jnr.20724; FAGAN AM, 1994, NEUROSCIENCE, V58, P705, DOI 10.1016/0306-4522(94)90449-9; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI 10.1016/j.drugalcdep.2004.02.004; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hall W, 1997, LANCET, V349, P1897, DOI 10.1016/S0140-6736(97)04572-8; Harding AJ, 1997, HIPPOCAMPUS, V7, P78, DOI 10.1002/(SICI)1098-1063(1997)7:1<78::AID-HIPO8>3.0.CO;2-3; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Knapp D J, 1993, Alcohol Alcohol Suppl, V2, P489; Knapp DJ, 1999, ALCOHOL CLIN EXP RES, V23, P633, DOI 10.1097/00000374-199904000-00010; Kril JJ, 1997, NEUROSCIENCE, V79, P983, DOI 10.1016/S0306-4522(97)00083-3; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Laakso MP, 2000, BEHAV BRAIN RES, V109, P177, DOI 10.1016/S0166-4328(99)00172-2; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lukoyanov NV, 2000, ALCOHOL, V20, P139, DOI 10.1016/S0741-8329(99)00069-5; MAJCHROWICZ E, 1975, PSYCHOPHARMACOLOGIA, V43, P245, DOI 10.1007/BF00429258; Marella M, 2004, J NEUROSCI, V24, P620, DOI 10.1523/JNEUROSCI.4303-03.2004; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; MINION GE, 1989, J TOXICOL-CLIN TOXIC, V27, P375, DOI 10.3109/15563658909000358; Nixon K, 2006, HIPPOCAMPUS, V16, P287, DOI 10.1002/hipo.20162; Nixon K, 2004, J NEUROSCI, V24, P9714, DOI 10.1523/JNEUROSCI.3063-04.2004; Nixon K, 2002, J NEUROCHEM, V83, P1087, DOI 10.1046/j.1471-4159.2002.01214.x; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Parent JM, 1997, J NEUROSCI, V17, P3727; PARSONS OA, 1993, NATIONAL I ALCOHOL A, V22, P173; Penland S, 2001, ALCOHOL, V24, P45, DOI 10.1016/S0741-8329(01)00142-2; Popken GJ, 1997, J COMP NEUROL, V386, P8; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Riikonen J, 2002, ALCOHOL ALCOHOLISM, V37, P421, DOI 10.1093/alcalc/37.5.421; Stephens DN, 2005, BIOL PSYCHIAT, V58, P392, DOI 10.1016/j.biopsych.2005.04.025; STREIT WJ, 1994, ALCOHOL GLIAL CELLS, V27, P55; Sullivan EV, 2000, ALCOHOL CLIN EXP RES, V24, P611, DOI 10.1097/00000374-200005000-00005; Sullivan EV, 2005, PSYCHOPHARMACOLOGY, V180, P583, DOI 10.1007/s00213-005-2267-6; Sullivan EV, 2000, NEUROPSYCHOLOGY, V14, P178, DOI 10.1037//0894-4105.14.2.178; SYAPIN PJ, 1988, EUR J PHARMACOL, V147, P101, DOI 10.1016/0014-2999(88)90638-3; URSO T, 1981, LIFE SCI, V28, P1053, DOI 10.1016/0024-3205(81)90752-9; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; WALKER DW, 1980, SCIENCE, V209, P711, DOI 10.1126/science.7394532; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Weissman BA, 2004, ANN NY ACAD SCI, V1025, P584, DOI 10.1196/annals.1316.072; WILLIAMS AE, 1994, NEUROPATH APPL NEURO, V20, P47, DOI 10.1111/j.1365-2990.1994.tb00956.x; Zou JY, 1996, ALCOHOL CLIN EXP RES, V20, P1406, DOI 10.1111/j.1530-0277.1996.tb01141.x	74	71	73	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	AUG	2008	31	2					218	229		10.1016/j.nbd.2008.04.009			12	Neurosciences	Neurosciences & Neurology	332XF	WOS:000258115700006	18585922	Green Accepted			2021-06-18	
J	Palzur, E; Zaaroor, M; Vlodausky, E; Milman, F; Soustiel, JF				Palzur, Eilam; Zaaroor, Menashe; Vlodausky, Eugene; Milman, Felix; Soustiel, Jean F.			Neuroprotective effect of hyperbaric oxygen therapy in brain injury is mediated by preservation of mitochondrial membrane properties	BRAIN RESEARCH			English	Article						brain injury; mitochondrial transition pore; hyperbaric hyperoxia; apoptosis	TRAUMATIC BRAIN; BCL-2 FAMILY; CEREBRAL CONTUSION; HEAD-INJURY; CELL-DEATH; RAT MODEL; APOPTOSIS; GLUTATHIONE; EXPRESSION; PROTECTION	Recent experimental data have shown that hyperbaric oxygen therapy (HBOT) was associated increased Bcl-2 expression at the injury site that correlated with reduced apoptosis. We hypothesized that HBOT mediated enhancement of Bcl-2 expression and increased intracellular oxygen bio-availability may both contribute to preserve mitochondrial integrity and reduce the activation of the mitochondrial pathway of apoptosis. For this purpose, a cortical lesion was created in the parietal cortex of Sprague-Dawley rats by dynamic cortical deformation (DCD) and outcome measures in non-treated animals were compared with that of HBOT treated rats. Morphological analysis showed a profound reduction in neuronal counts in the perilesional area and a marked rarefaction of the density of the axonal-dentritic network. In treated animals, however, there was a significant attenuation of the impact of DCD over perilesional neurons, characterized by significantly higher cell counts and denser axonal network. In mitochondria isolated from injured brain tissue, there was a profound loss of mitochondrial transmembrane potential (Delta psi(M)) that proved to be substantially reversed by HBOT. This finding correlated with a significant reduction of caspases 3 and 9 activation in HBOT treated animals but not of caspase 8, indicating a selective effect over the intrinsic pathway of apoptosis. All together, our results indicate that the neuroprotective effect of HBOT may represent the consequence of preserved mitochondrial integrity and subsequent inhibition of the mPTP and reduction of the mitochondrial pathway of apoptosis. (C) 2008 Elsevier B.V. All rights reserved.	[Palzur, Eilam; Zaaroor, Menashe; Vlodausky, Eugene; Milman, Felix; Soustiel, Jean F.] Technion Israel Inst Technol, Fac Med, Acute Brain Injury Res Lab, IL-31096 Haifa, Israel	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Fac Med, Acute Brain Injury Res Lab, Ephron St,POB 9649, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Benedetti S, 2004, CLIN BIOCHEM, V37, P312, DOI 10.1016/j.clinbiochem.2003.12.001; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Gurer A, 2006, TRANSPL P, V38, P3337, DOI 10.1016/j.transproceed.2006.10.184; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P435; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Papadopoulos MC, 1998, EUR J NEUROSCI, V10, P1252, DOI 10.1046/j.1460-9568.1998.00134.x; Qin ZY, 2007, STROKE, V38, P1362, DOI 10.1161/01.STR.0000259660.62865.eb; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wada K, 2000, ACT NEUR S, V76, P285; Wada K, 1996, BRAIN RES, V740, P15; Xu LJ, 1999, ANESTHESIOLOGY, V91, P1036, DOI 10.1097/00000542-199910000-00024; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	28	71	87	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 24	2008	1221						126	133		10.1016/j.brainres.2008.04.078			8	Neurosciences	Neurosciences & Neurology	334XF	WOS:000258254300015	18561900				2021-06-18	
J	Makley, MJ; English, JB; Drubach, DA; Kreuz, AJ; Celnik, PA; Tarwater, PM				Makley, M. J.; English, J. B.; Drubach, D. A.; Kreuz, A. J.; Celnik, P. A.; Tarwater, P. M.			Prevalence of sleep disturbance in closed head injury patients in a rehabilitation unit	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						brain injury; trauma; sleep disturbance; memory; amnesia; circadian disorder	TRAUMATIC BRAIN-INJURY; EXCESSIVE DAYTIME SLEEPINESS; GLASGOW COMA SCALE; POSTTRAUMATIC NARCOLEPSY; MEMORY CONSOLIDATION	Traumatic brain injury (TBI) is a leading cause of disability in young people in the United States. Disorders of arousal and attention are common in closed head injury (CHI). Daytime drowsiness impairs participation in rehabilitation, whereas nighttime wakefulness leads to falls and behavioral disturbances. Sleep disturbances in TBI reported in the literature have included excessive daytime somnolence, sleep phase cycle disturbance, narcolepsy, and sleep apnea. Although well known to the clinician treating these patients, the extent and prevalence of disrupted sleep in patients in an acute inpatient rehabilitation unit has not been described. Objective. To determine the prevalence of sleep wake cycle disturbance (SWCD) in patients with CHI in a TBI rehabilitation unit. Design. Prospective observational. Setting. Inpatient specialized brain injury rehabilitation unit. Patients. Thirty-one consecutive admissions to a brain injury rehabilitation unit with the diagnosis of CHI. Results. Twenty-one patients (68%) had aberrations of nighttime sleep. There was no significant difference in Glasgow Coma Score on admission to trauma nor was there any significant difference in age between the affected and unaffected groups. Patients with SWCD had longer stays in both the trauma center (P < .003) and the rehabilitation center (P < .03). Conclusions. There is a high prevalence of SWCD in CHI patients admitted to a brain injury rehabilitation unit. Patients with SWCD have longer stays in both acute and rehabilitation settings and may be a marker for more severe injury.	[Makley, M. J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [English, J. B.] MS Ctr Atlanta, Atlanta, GA USA; [Drubach, D. A.] Mayo Clin, Rochester, MN USA; [Kreuz, A. J.] Villa Julie Coll, Baltimore, MD USA; [Celnik, P. A.] Johns Hopkins Sch Med, Baltimore, MD USA; [Tarwater, P. M.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA	Makley, MJ (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.	mmakley@kernan.umm.edu					ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; CULEBRAS A, 1992, NEUROLOGY, V42, P19; Drubach DA, 1994, J NEUROL REHABIL, V8, P92; Economo CV, 1930, J NERV MENT DIS, V71, P249, DOI 10.1097/00005053-193003000-00001; Ellenbogen JM, 2006, CURR OPIN NEUROBIOL, V16, P716, DOI 10.1016/j.conb.2006.10.006; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Ji DY, 2007, NAT NEUROSCI, V10, P100, DOI 10.1038/nn1825; Katsuki H, 2004, NEUROBIOL DIS, V15, P61, DOI 10.1016/j.nbd.2003.09.003; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	20	71	73	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL-AUG	2008	22	4					341	347		10.1177/1545968308315598			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	319DV	WOS:000257145200003	18663247				2021-06-18	
J	Meachen, SJ; Hanks, RA; Millis, SR; Rapport, LJ				Meachen, Sarah-Jane; Hanks, Robin A.; Millis, Scott R.; Rapport, Lisa J.			The reliability and validity of inventory-18 in persons with the brief symptom traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; reliability and validity	DEPRESSION; DISORDERS; INDIVIDUALS; VALIDATION; DISABILITY; COMMUNITY; SEQUELAE; RETURN	Objective: To investigate the psychometric properties of the Brief Symptom Inventory-18 (BSI-18) among persons with traumatic brain injury (TBI). Design: Inception cohort design with cross-sectional follow-up of 6 months to 15 years. Setting: Rehabilitation hospital. Participants: Adults (N=257) with moderate to severe TBI (81 inpatients and 176 follow-up participants, analyzed separately). Interventions: Not applicable. Main Outcome Measures: The BSI-18 is a brief screen of psychologic distress with a Global Severity Index (GSI), and 3 clinical subscales: somatization. anxiety, and depression. Results: Internal consistency of the GSI was high in both follow-up participants (alpha = .91) and inpatients (alpha = .84), whereas estimates for the somatization, anxiety, and depression subscales were more variable (alpha range, .61-.84). As Would be expected for a measure of affective state, retest reliability estimates were only moderate. The BSI-18 GSI correlated with multiple measures of psychosocial adjustment. After accounting for demographics, injury severity, inpatient functional status, years Since injury, and various psychosocial factors. the BSI-18 showed incremental validity in predicting concurrent functional, psychosocial, and psychologic status. Conclusions: The BSI-18 GSI had excellent reliability and validity among inpatients and follow-up participants. Modest reliability estimates may place an upper bound on the validity of the BSI-18 clinical subscales in inpatient TBI populations.	[Meachen, Sarah-Jane; Hanks, Robin A.; Millis, Scott R.] Rehabil Inst Michigan, Detroit, MI USA; [Meachen, Sarah-Jane; Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI 48202 USA	Meachen, SJ (corresponding author), 261 Mack Blvd, Detroit, MI 48201 USA.	smeachett@wayne.edu			National Institute on Disability and Rehabilitation Research [H133A020515]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A020515).	Allison P.D., 2001, MISSING DATA; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Asner-Self Kimberly K, 2006, Cultur Divers Ethnic Minor Psychol, V12, P367, DOI 10.1037/1099-9809.12.2.367; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Christensen B., 1994, ADV MED PSYCHOTHER, V7, P23; CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037/0021-9010.78.1.98; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Deb S, 1999, AM J PSYCHIAT, V156, P374; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Derogatis LR, 1977, SCL 90 MANUAL 1 SCOR; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Leathem JM, 2000, J HEAD TRAUMA REHAB, V15, P1246, DOI 10.1097/00001199-200012000-00005; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Prelow HM, 2005, J COMMUNITY PSYCHOL, V33, P139, DOI 10.1002/jcop.20041; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Slaughter J, 1999, BRAIN INJURY, V13, P125, DOI 10.1080/026990599121782; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zabora J, 2001, PSYCHOSOMATICS, V42, P241, DOI 10.1176/appi.psy.42.3.241	42	71	72	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					958	965		10.1016/j.apmr.2007.12.028			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900023	18452746				2021-06-18	
J	Onyszchuk, G; Al-Hafez, B; He, YY; Bilgen, M; Berman, NEJ; Brooks, WM				Onyszchuk, Gregory; Al-Hafez, Baraa; He, Yong-Yue; Bilgen, Mehmet; Berman, Nancy E. J.; Brooks, William M.			A mouse model of sensorimotor controlled cortical impact: Characterization using longitudinal magnetic resonance imaging, behavioral assessments and histology	JOURNAL OF NEUROSCIENCE METHODS			English	Article						traumatic brain injury; controlled cortical impact; magnetic resonance imaging; mouse model; sensorimotor cortex; lesion evolution; injury characterization; behavioral tests	TRAUMATIC BRAIN-INJURY; CONTUSION VOLUME; SPINAL-CORD; DEFICITS	The present study establishes a new mouse model for traumatic brain injury (TBI), using an electromechanically driven linear motor impactor device to deliver a lateral controlled cortical impact (CCI) injury to the sensorimotor cortex. Lesion cavity size was measured, and inter-animal consistency demonstrated, at 14 days post injury. Qualitative information regarding damage progression over time was obtained by scanning with high field magnetic resonance imaging (MRI) at five time points following injury. Functional impairment and recovery were measured with the Rotarod, gridwalk and cylinder tests, and lesion cavity volume was measured post mortem with thionin-stained tissue sections. The study establishes the reliability of a linear-motor based device for producing repeatable damage in a CCI model, demonstrates the power of longitudinal MRI in studying damage evolution, and confirms that a simple battery of functional tests record sensorimotor impairment and recovery. (c) 2006 Elsevier B.V. All rights reserved.	Univ Kansas, Ctr Med, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Psychol, Kansas City, KS 66160 USA	Brooks, WM (corresponding author), Univ Kansas, Ctr Med, Hoglund Brain Imaging Ctr, 3901 Rainbow Blvd,MS 1052, Kansas City, KS 66160 USA.	wbrooks@kumc.edu		brooks, william/0000-0001-6227-7636	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21 AG026482] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD002528, P30 HD02528] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039123] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM066777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482] Funding Source: NIH RePORTER		Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bilgen M, 2004, MAGN RESON MED, V52, P937, DOI 10.1002/mrm.20228; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; KCOHANEK PM, 1995, J NEUROTRAUM, V12, P1015; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T, 2000, CONT NEUROS, P131; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	20	71	73	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2007	160	2					187	196		10.1016/j.jneumeth.2006.09.007			10	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	146NG	WOS:000244940600001	17049995	Green Accepted			2021-06-18	
J	Arango-Lasprilla, JC; Rosenthal, M; Deluca, J; Komaroff, E; Sherer, M; Cifu, D; Hanks, R				Arango-Lasprilla, Juan Carlos; Rosenthal, Mitchell; Deluca, John; Komaroff, Eugene; Sherer, Mark; Cifu, David; Hanks, Robin			Traumatic brain injury and functional outcomes: Does minority status matter?	BRAIN INJURY			English	Article						functional outcomes; TBI; minority status	SCALE; HEALTH; IMPACT; RACE	Objectives: ( 1) to determine differences between minorities vs. non- minorities on demographic, injury and rehabilitation characteristics and functional outcomes at admission, discharge and 1- year post- injury and ( 2) to examine differences in functional outcome at 1- year post- injury among ( African- Americans, Hispanics and Whites). Design: Retrospective study. Setting: Longitudinal data were extracted from the TBI Model Systems database. Participants: 4929 individuals with moderate- to- severe TBI ( 3354 Whites vs. 1575 Minorities: 1207 African- Americans and 368 Hispanics) hospitalized between 1989 - 2004. Main outcome measures: Functional outcomes at 1- year post- injury ( Disability Rating Scale, Functional Independence Measure, Glasgow Outcome Scale- Extended and Community Integration Questionnaire). Results: At discharge and 1- year post- injury, minorities had poorer functional outcomes compared with Caucasians on all measures. After controlling for sociodemographic, injury and functional characteristics at admission, Hispanics and AfricanAmericans still showed worse functional outcomes at 1- year post- injury compared with Whites on the DRS, FIM and CIQ. There were no significant differences between African Americans and Hispanics. Conclusions: Minorities had significantly reduced long- term functional outcome after rehabilitation relative to Whites. It is imperative that rehabilitation professionals' consider factors related to poorer long- term functional outcome and work to improve the quality of life of minorities with TBI.	Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Jackson, MS 39216 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ W Hosp, Dept Phys Med & Rehabil, 3rd Floor,Room 3-102,1200 E Broad St, Richmond, VA 23298 USA.	jcarangolasp@vcu.edu		Cifu, David/0000-0003-1600-9387	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007522] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD007522-05, HD07522-05] Funding Source: Medline		Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2000, BRAIN INJURY, V14, P713; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hosmer D, 1989, APPL LOGISTIC REGRES; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *TRAUM BRAIN INJ N, 2005, TRAUM BRAIN INJ MOD; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	24	71	71	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	7					701	708		10.1080/02699050701481597			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400006	17653944				2021-06-18	
J	Jones, C; Harvey, AG; Brewin, CR				Jones, Charlie; Harvey, Allison G.; Brewin, Chris R.			The organisation and content of trauma memories in survivors of road traffic accidents	BEHAVIOUR RESEARCH AND THERAPY			English	Article						PTSD; ASD; narrative memory; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; BRAIN-INJURY; HEAD-INJURY; DISSOCIATION; NARRATIVES; SYMPTOMS	We investigated the trauma narratives of 131 road traffic accident survivors prospectively, at I week, 6 weeks, and 3 months post-trauma. At I and 6 weeks, narratives of survivors with acute stress disorder (ASD) or post-traumatic stress disorder (PTSD) were less coherent and included more dissociation content. By 3 months, their narratives also contained more repetition, more non-consecutive chunks, and more sensory words. Traumatic brain injury was associated with a separate characteristic, confusion, at all three time points. Three aspects of narrative organisation at I week-repetition, non-consecutive chunks, and coherence-predicted PTSD severity at 3 months after controlling for initial symptoms. The results suggest both a strong concurrent and predictive relationship between narrative disorganisation and ASD/PTSD but that as people recover from ASD, their narratives do not necessarily become less disorganised. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; Univ Oxford, Dept Expt Psychol, Oxford OX1 2JD, England; Univ Calif Berkeley, Subdept Clin Hlth Psychol, Berkeley, CA 94720 USA	Harvey, AG (corresponding author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall 1650, Berkeley, CA 94720 USA.	aharvey@berkeley.edu	Brewin, Chris R/C-4566-2008	Brewin, Chris R/0000-0002-7462-4460			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 2003, POSTTRAUMATIC STRESS; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; FOA EB, 1995, J TRAUMA STRESS, V8, P675, DOI 10.1002/jts.2490080409; Foa EB., 1998, TREATING TRAUMA RAPE; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Halligan SL, 2003, J CONSULT CLIN PSYCH, V71, P419, DOI 10.1037/0022-006X.71.3.419; Harvey AG, 1999, BRIT J CLIN PSYCHOL, V38, P401, DOI 10.1348/014466599162999; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Harvey AG, 2000, J NERV MENT DIS, V188, P602, DOI 10.1097/00005053-200009000-00007; Hellawell SJ, 2004, BEHAV RES THER, V42, P1, DOI 10.1016/S0005-7967(03)00088-3; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; McNally R. J., 2003, REMEMBERING TRAUMA; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; Pennebaker JW, 2001, LINGUISTIC INQUIRY W; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; RYNEARSON EK, 1993, AM J PSYCHIAT, V150, P258; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Symonds CP, 1943, LANCET, V1, P7; Zoellner LA, 2002, J TRAUMA STRESS, V15, P49, DOI 10.1023/A:1014383228149	28	71	72	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967			BEHAV RES THER	Behav. Res. Ther.	JAN	2007	45	1					151	162		10.1016/j.brat.2006.02.004			12	Psychology, Clinical	Psychology	115KO	WOS:000242733400013	16563341				2021-06-18	
J	Widestrand, A; Faijerson, J; Wilhelmsson, U; Smith, PLP; Li, LZ; Sihlbom, C; Eriksson, PS; Pekny, M				Widestrand, Asa; Faijerson, Jonas; Wilhelmsson, Ulrika; Smith, Peter L. P.; Li, Lizhen; Sihlbom, Carina; Eriksson, Peter S.; Pekny, Milos			Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP(-/-) Vim(-/-) mice	STEM CELLS			English	Article						glial fibrillary acidic protein; vimentin; intermediate filaments; astrocytes; reactive gliosis	FIBRILLARY ACIDIC PROTEIN; STEM-CELLS; INTERMEDIATE-FILAMENTS; DENTATE GYRUS; ADULT-RAT; REACTIVE ASTROCYTES; TRANSGENIC MICE; GLIAL SCAR; CNS; VIMENTIN	After neurotrauma, ischemia, or neurodegenerative disease, astrocytes upregulate their expression of the intermediate filament proteins glial fibrillary acidic protein ( GFAP), vimentin ( Vim), and nestin. This response, reactive gliosis, is attenuated in GFAP(-/-) Vim(-/-) mice, resulting in the promotion of synaptic regeneration after neurotrauma and improved integration of retinal grafts. Here we assessed whether GFAP(-/-) Vim(-/-) astrocytes affect the differentiation of neural progenitor cells. In coculture with GFAP(-/-) Vim(-/-) astrocytes, neural progenitor cells increased neurogenesis by 65% and astrogenesis by 124%. At 35 days after transplantation of neural progenitor cells into the hippocampus, adult GFAP(-/-) Vim(-/-) mice had more transplant-derived neurons and astrocytes than wild-type controls, as well as increased branching of neurite-like processes on transplanted cells. Wnt3 immunoreactivity was readily detected in hippocampal astrocytes in wild-type but not in GFAP(-/-) Vim(-/-) mice. These findings suggest that GFAP(-/-) Vim(-/-) astrocytes allow more neural progenitor cell-derived neurons and astrocytes to survive weeks after transplantation. Thus, reactive gliosis may adversely affect the integration of transplanted neural progenitor cells in the brain.	Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Dept Clin Neurosci & R, SE-41390 Gothenburg, Sweden	Pekny, M (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Dept Clin Neurosci & R, Medicinaregatan 9A, SE-41390 Gothenburg, Sweden.	milos.pekny@medkem.gu.se		Smith, Peter/0000-0001-7258-1711			Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Cai J, 2007, DEVELOPMENT, V134, P1887, DOI 10.1242/dev.02847; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Hinterkeuser S, 2000, EUR J NEUROSCI, V12, P2087, DOI 10.1046/j.1460-9568.2000.00104.x; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu B, 2002, BRAIN RES, V943, P292, DOI 10.1016/S0006-8993(02)02906-2; Lundberg C, 1996, NEUROREPORT, V7, P847, DOI 10.1097/00001756-199603220-00002; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126	41	71	72	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells		2007	25	10					2619	2627		10.1634/stemcells.2007-0122			9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	217DZ	WOS:000249929900025	17628017	Bronze			2021-06-18	
J	Leaver, SG; Cui, Q; Bernard, O; Harvey, AR				Leaver, Simone G.; Cui, Qi; Bernard, Ora; Harvey, Alan R.			Cooperative effects of bcl-2 and AAV-mediated expression of CNTF on retinal ganglion cell survival and axonal regeneration in adult transgenic mice	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						anti-apoptosis; gene therapy; neurotrauma; optic nerve injury	CILIARY NEUROTROPHIC FACTOR; AXOTOMY-INDUCED APOPTOSIS; OPTIC-NERVE REGENERATION; LONG-TERM SURVIVAL; SPINAL-CORD-INJURY; IN-VIVO; GENE-TRANSFER; NEURONAL SURVIVAL; VIRAL VECTORS; CNS NEURONS	We used a gene therapy approach in transgenic mice to assess the cooperative effects of combining anti-apoptotic and growth-promoting stimuli on adult retinal ganglion cell (RGC) survival and axonal regeneration following intraorbital optic nerve injury. Bi-cistronic adeno-associated viral vectors encoding a secretable form of ciliary neurotrophic factor and green fluorescent protein (AAV-CNTF-GFP) were injected into eyes of mice that had been engineered to over-express the anti-apoptotic protein bcl-2. For comparison this vector was also injected into wildtype (wt) mice, and both mouse strains were injected with control AAV encoding GFP. Five weeks after optic nerve injury we confirmed that bcl-2 over-expression by itself promoted the survival of axotomized RGCs, but in contrast to previous reports we also saw regeneration of some mature RGC axons beyond the optic nerve crush. AAV-mediated expression of CNTF in adult retinas significantly increased the survival and axonal regeneration of RGCs following axotomy in wt and bcl-2 transgenic mice; however, the effects were greatest in the transgenic strain. Compared with AAV-GFP-injected bcl-2 mice, RGC viability was increased by about 50% (mean, 36 738 RGCs per retina), and over 1000 axons per optic nerve regenerated 1-1.5 mm beyond the crush. These findings exemplify the importance of using a multifactorial therapeutic approach that enhances both neuroprotection and regeneration after central nervous system injury.	Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia; Univ Western Australia, Sch Anim Biol, Nedlands, WA 6009, Australia; St Vincent Inst Med Res, Melbourne, Vic, Australia	Harvey, AR (corresponding author), Univ Western Australia, Sch Anat & Human Biol, 35 Stirling Hwy, Nedlands, WA 6009, Australia.	arharvey@anhb.uwa.edu.au	Harvey, Alan/A-4911-2008	, Alan/0000-0002-2590-831X			Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Bahr M, 2000, TRENDS NEUROSCI, V23, P483, DOI 10.1016/S0166-2236(00)01637-4; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bernard R, 1997, DEV NEUROSCI-BASEL, V19, P79, DOI 10.1159/000111188; Bonfanti L, 1996, J NEUROSCI, V16, P4186; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Cenni MC, 1996, EUR J NEUROSCI, V8, P1735, DOI 10.1111/j.1460-9568.1996.tb01317.x; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Chierzi S, 1999, J NEUROSCI, V19, P8367; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 2004, J NEUROTRAUM, V21, P617, DOI 10.1089/089771504774129946; Dietz GPH, 2001, NEUROREPORT, V12, P3353, DOI 10.1097/00001756-200110290-00041; Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Heiduschka P, 2000, NEUROPHARMACOLOGY, V39, P889, DOI 10.1016/S0028-3908(99)00245-2; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Hermens WTJMC, 1999, HUM GENE THER, V10, P1885, DOI 10.1089/10430349950017563; Inoue T, 2002, J NEUROSCI, V22, P4468, DOI 10.1523/JNEUROSCI.22-11-04468.2002; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Jiao JW, 2005, EMBO J, V24, P1068, DOI 10.1038/sj.emboj.7600589; Ju WK, 2000, NEUROREPORT, V11, P3893, DOI 10.1097/00001756-200011270-00057; Kretz A, 2004, MOL CELL NEUROSCI, V26, P63, DOI 10.1016/j.mcn.2004.01.007; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252; Lodovichi C, 2001, EUR J NEUROSCI, V13, P833, DOI 10.1046/j.1460-9568.2001.01440.x; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MacLennan AJ, 2000, NEUROSCIENCE, V99, P761, DOI 10.1016/S0306-4522(00)90236-7; Malik JMI, 2005, MOL THER, V11, P373, DOI 10.1016/j.ymthe.2004.11.014; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Simon PD, 1999, HUM GENE THER, V10, P1715, DOI 10.1089/10430349950017716; Straten G, 2002, NEUROBIOL DIS, V11, P123, DOI 10.1006/nbdi.2002.0543; THANOS S, 1993, J NEUROSCI, V13, P455; van Adel BA, 2005, J NEUROBIOL, V63, P215, DOI 10.1002/neu.20117; Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002; Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004; Yin YQ, 2003, J NEUROSCI, V23, P2284; You SW, 2000, INVEST OPHTH VIS SCI, V41, P3165; ZENG BY, 1995, J ANAT, V186, P495; Zhi Y, 2005, BRAIN RES, V1047, P224, DOI 10.1016/j.brainres.2005.04.037	54	71	73	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2006	24	12					3323	3332		10.1111/j.1460-9568.2006.05230.x			10	Neurosciences	Neurosciences & Neurology	116DR	WOS:000242783200001	17229081				2021-06-18	
J	Gardner, MJ; Voos, JE; Wanich, T; Helfet, DL; Lorich, DG				Gardner, Michael J.; Voos, James E.; Wanich, Tony; Helfet, David L.; Lorich, Dean G.			Vascular implications of minimally invasive plating of proximal humerus fractures	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						proximal humerus fracture; vascularity; minimally invasive; locked plating	STABILIZATION SYSTEM; SURGICAL EXPERIENCE; INTERNAL-FIXATION; TIBIA FRACTURES; LOCKING PLATE; HEAD	Objectives: Open reduction and internal fixation of proximal humerus fractures through the anterolateral acromial approach, which uses the anterior deltoid raphe and axillary nerve protection, has recently been advocated as a minimally invasive technique. Several recent reports have indicated variable and unpredictable vascular injuries to the humeral-head blood supply after a proximal humerus fracture, and thus a direct approach that minimizes further vascular compromise may be preferable. The purpose of this study was to define the relationship of this surgical interval to the lateral plating zone of the proximal humerus and to the penetrating vascular supply of the humeral bead. Design: Cadaveric vascular injection study. Setting: Cadaveric dissection laboratory. Patients: Six cadaveric specimens. Intervention: The anterolateral acromial approach was performed on six cadaveric upper-extremity specimens. A locking proximal humerus plate was applied to the lateral proximal humerus, and the axillary artery was cannulated proximal to the circumflex humeral arteries. Dyed latex polymer was injected and allowed to harden, and dissection was performed to visualize the vasculature of the proximal humerus. Plates were then removed and the specimens were further inspected to examine the blood supply. Main Outcome Measurements: The relationship of the anterolateral acromial approach to the lateral plating zone of the proximal humerus and the vascular supply of the humeral head. Results: In all specimens, the filling of the anterior and posterior vessels that supplied the humeral head were undisturbed after use of the anterolateral acromial approach and locked plating. The blood vessels to the head-penetrating vascular branches were not in the surgical field. A bare spot on the lateral proximal humerus existed in the region of the greater tuberosity, which was 30 mm wide and between two penetrating humeral-head epiphyseal vessels. The nearest penetrating vessels were close to the plate, 4 mm anterior and 7 mm posterior. The anterior humeral circumflex vessel and its ascending branch, which provides critical blood supply to the humeral head, coursed directly in the region of the deltopectoral approach. Conclusions: Minimally invasive techniques have many potential benefits for fracture healing, but new surgical approaches often must be used to take full advantage of these newer methods. Splitting the anterior deltoid raphe from the acromion distally allowed direct access to the lateral plating zone of the proximal humerus. The bare spot in this region may be a safe area for plate application, if the plate is placed appropriately with thorough knowledge of the vascular anatomy. These findings may be of particular importance if the vascular supply to the humeral head has already been partially compromised by preceding trauma. This direct approach to the lateral bare spot on the proximal humerus may minimize iatrogenic vascular injury when treating these fractures.	Hosp Special Surg, Dept Orthopaed Surg, New York, NY 10021 USA	Gardner, MJ (corresponding author), Hosp Special Surg, Dept Orthopaed Surg, 535 E 70th St, New York, NY 10021 USA.	gardnerm@hss.edu					ABBOTT LC, 1949, J BONE JOINT SURG AM, V31-A, P235, DOI 10.2106/00004623-194931020-00002; Bathis H, 2001, ZBL CHIR, V126, P211, DOI 10.1055/s-2001-12498; Bjorkenheim JM, 2004, ACTA ORTHOP SCAND, V75, P741, DOI 10.1080/00016470410004120; BROOKS CH, 1993, J BONE JOINT SURG BR, V75, P132; Burkhead W Z Jr, 1992, J Shoulder Elbow Surg, V1, P31, DOI 10.1016/S1058-2746(09)80014-1; Cole PA, 2004, J ORTHOP TRAUMA, V18, P528, DOI 10.1097/00005131-200409000-00008; COUDANE H, 2000, J SHOULDER ELB SURG, P548; Determe D, 1996, SURG RADIOL ANAT, V18, P195, DOI 10.1007/BF02346127; Duparc F, 1997, SURG RADIOL ANAT, V19, P127, DOI 10.1007/s00276-997-0127-2; Duparc F, 2001, SURG RADIOL ANAT, V23, P185, DOI 10.1007/s00276-001-0185-9; Duval M J, 1993, Orthop Rev, V22, P1023; Fankhauser F, 2005, CLIN ORTHOP RELAT R, P176, DOI 10.1097/01.blo.0000137554.91189.a9; Gallo RA, 2005, J ORTHOP TRAUMA, V19, P734, DOI 10.1097/01.bot.0000174708.88108.da; Gardner Michael J, 2004, Bull Hosp Jt Dis, V62, P18; Gardner MJ, 2005, CLIN ORTHOP RELAT R, P123, DOI 10.1097/01.blo.0000152872.95806.09; Gardner MJ, 2005, INJURY, V36, P1197, DOI 10.1016/j.injury.2005.06.038; Gautier E, 2000, J BONE JOINT SURG BR, V82B, P679, DOI 10.1302/0301-620X.82B5.10426; GERBER C, 1990, J BONE JOINT SURG AM, V72A, P1486, DOI 10.2106/00004623-199072100-00009; Haidukewych GJ, 2004, J AM ACAD ORTHOP SUR, V12, P205, DOI 10.5435/00124635-200407000-00001; Hertel R, 2004, J SHOULDER ELB SURG, V13, P427, DOI 10.1016/j.jse.2004.01.034; Hockings M, 2003, INJURY, V34, P443, DOI 10.1016/S0020-1383(02)00189-4; JAKOB RP, 1991, J BONE JOINT SURG BR, V73, P295; Koukakis A, 2006, CLIN ORTHOP RELAT R, P115, DOI 10.1097/01.blo.0000194678.87258.6e; Kregor PJ, 2004, J ORTHOP TRAUMA, V18, P509, DOI 10.1097/00005131-200409000-00006; KRISTIANSEN B, 1986, ACTA ORTHOP SCAND, V57, P320, DOI 10.3109/17453678608994401; LAFLAMME GY, 2005, ORTH TRAUM ASS ANN M; LAING PG, 1956, J BONE JOINT SURG AM, V38, P1105, DOI 10.2106/00004623-195638050-00013; Lin J, 1999, CLIN ORTHOP RELAT R, P247; Meyer C, 2005, SURG RADIOL ANAT, V27, P232, DOI 10.1007/s00276-005-0318-7; Panagopoulos AM, 2004, INT ORTHOP, V28, P333, DOI 10.1007/s00264-004-0581-y; Plecko Michael, 2005, Oper Orthop Traumatol, V17, P25; Ricci WM, 2004, J ORTHOP TRAUMA, V18, P521, DOI 10.1097/00005131-200409000-00007; SAUDAN M, 2003, ORTH TRAUM ASS ANN M; Schutz M, 2005, ARCH ORTHOP TRAUM SU, V125, P102, DOI 10.1007/s00402-004-0779-x; SPECK M, 1996, SWISS SURG, P51; Stannard JP, 2004, J ORTHOP TRAUMA, V18, P552, DOI 10.1097/00005131-200409000-00012; STURZENEGGER M, 1982, ARCH ORTHOP TRAUM SU, V100, P249, DOI 10.1007/BF00381665; SZYSZKOWITZ R, 1993, CLIN ORTHOP RELAT R, P13; Szyszkowitz R, 1999, UNFALLCHIRURG, V102, P422, DOI 10.1007/s001130050430; Traxler H, 2001, CLIN ANAT, V14, P418, DOI 10.1002/ca.1077; Wijgman AJ, 2002, J BONE JOINT SURG AM, V84A, P1919, DOI 10.2106/00004623-200211000-00002	41	71	82	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	OCT	2006	20	9					602	607		10.1097/01.bot.0000246412.10176.14			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	104NR	WOS:000241965600003	17088661				2021-06-18	
J	Leinhase, I; Holers, VM; Thurman, JM; Harhausen, D; Schmidt, OI; Pietzcker, M; Taha, ME; Rittirsch, D; Huber-Lang, M; Smith, WR; Ward, PA; Stahel, PF				Leinhase, Iris; Holers, V. Michael; Thurman, Joshua M.; Harhausen, Denise; Schmidt, Oliver I.; Pietzcker, Malte; Taha, Mohy E.; Rittirsch, Daniel; Huber-Lang, Markus; Smith, Wade R.; Ward, Peter A.; Stahel, Philip F.			Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation	BMC NEUROSCIENCE			English	Article							CLOSED-HEAD INJURY; MEMBRANE ATTACK COMPLEX; TRAUMATIC BRAIN; GENE-EXPRESSION; C5A RECEPTOR; BARRIER DYSFUNCTION; TRANSGENIC MICE; RAT-BRAIN; ADULT-RAT; APOPTOSIS	Background: Neuroprotective strategies for prevention of the neuropathological sequelae of traumatic brain injury (TBI) have largely failed in translation to clinical treatment. Thus, there is a substantial need for further understanding the molecular mechanisms and pathways which lead to secondary neuronal cell death in the injured brain. The intracerebral activation of the complement cascade was shown to mediate inflammation and tissue destruction after TBI. However, the exact pathways of complement activation involved in the induction of posttraumatic neurodegeneration have not yet been assessed. In the present study, we investigated the role of the alternative complement activation pathway in contributing to neuronal cell death, based on a standardized TBI model in mice with targeted deletion of the factor B gene (f beta-/-), a "key" component required for activation of the alternative complement pathway. Results: After experimental TBI in wild-type (f beta+/+) mice, there was a massive time-dependent systemic complement activation, as determined by enhanced C5a serum levels for up to 7 days. In contrast, the extent of systemic complement activation was significantly attenuated in f beta-/- mice (P < 0.05, f beta-/- vs. f beta+/+; t = 4 h, 24 h, and 7 days after TBI). TUNEL histochemistry experiments revealed that posttraumatic neuronal cell death was clearly reduced for up to 7 days in the injured brain hemispheres of f beta-/- mice, compared to f beta+/+ littermates. Furthermore, a strong upregulation of the anti-apoptotic mediator Bcl-2 and downregulation of the pro-apoptotic Fas receptor was detected in brain homogenates of head-injured f beta-/- vs. f beta+/+ mice by Western blot analysis. Conclusion: The alternative pathway of complement activation appears to play a more crucial role in the pathophysiology of TBI than previously appreciated. This notion is based on the findings of (a) the significant attenuation of overall complement activation in head- injured fB-/- mice, as determined by a reduction of serum C5a concentrations to constitutive levels in normal mice, and (b) by a dramatic reduction of TUNEL-positive neurons in conjunction with an upregulation of Bcl-2 and downregulation of the Fas receptor in head- injured f beta-/- mice, compared to f beta+/+ littermates. Pharmacological targeting of the alternative complement pathway during the "time-window of opportunity" after TBI may represent a promising new strategy to be pursued in future studies.	Charite, Sch Med, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Ulm, Sch Med, Dept Traumatol, D-89075 Ulm, Germany; Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, Denver, CO 80204 USA	Smith, WR (corresponding author), Charite, Sch Med, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin, D-12200 Berlin, Germany.	iris.leinhase@charite.de; Michael.Holers@UCHSC.edu; Joshua.Thurman@UCHSC.edu; deniseharhausen@gmx.de; oliver.schmidt@charite.de; m.pietzcker@gmx.de; mohy_kom@yahoo.com; drittirs@med.umich.edu; mshuberlang2000@aol.com; wade.smith@dhha.org	Huber-Lang, Markus/AAJ-2209-2020	Rittirsch, Daniel/0000-0002-1185-2431	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI031105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK064790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37GM029507, R01GM029507, R01GM061656] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI31105, R01 AI031105] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK64790, K08 DK064790] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 61656, R01 GM029507, R01 GM061656, R37 GM029507, GM 029507] Funding Source: Medline		Alexander JJ, 2005, J IMMUNOL, V175, P8312, DOI 10.4049/jimmunol.175.12.8312; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; COLE DS, 2006, EPUB MOL IMMUNOL; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GARNUM SR, 1999, MOL MED, V5, P569; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; HUBERLANG M, 2006, EPUB NAT MED; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Matsumoto M, 1997, P NATL ACAD SCI USA, V94, P8720, DOI 10.1073/pnas.94.16.8720; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Mohamad N, 2005, BIOCELL, V29, P149; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Nataf S, 2000, J IMMUNOL, V165, P5867, DOI 10.4049/jimmunol.165.10.5867; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Ohlsson M, 2003, J NEUROTRAUM, V20, P895, DOI 10.1089/089771503322385827; OHLSSON M, 2005, EPUB NEUROSCI LETT; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; RINK A, 1995, AM J PATHOL, V147, P1575; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shacka JJ, 2005, CNS NEUROL DISORD-DR, V4, P25, DOI 10.2174/1568007053005127; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; SOLOMKIN JS, 1981, SURGERY, V90, P319; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1997, J IMMUNOL, V159, P861; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Thurman JM, 2005, KIDNEY INT, V67, P524, DOI 10.1111/j.1523-1755.2005.67109.x; Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Xiong ZQ, 2003, J NEUROSCI, V23, P955; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	67	71	71	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JUL 14	2006	7								55	10.1186/1471-2202-7-55			12	Neurosciences	Neurosciences & Neurology	074GN	WOS:000239800800001	16842619	DOAJ Gold, Green Published			2021-06-18	
J	McGrath, JC; Linley, PA				McGrath, Joanna Collicutt; Linley, P. Alex			Post-traumatic growth in acquired brain injury: A preliminary small scale study	BRAIN INJURY			English	Article						trauma; adversity; post-traumatic; growth; thriving; stroke; brain injury; benefit	STRESS-DISORDER; BREAST-CANCER; DEPRESSION; ANXIETY; TRAUMA; STROKE; SENSE	Primary objective: To examine the nature, degree and time course of positive psychological change in people with severe acquired brain injury. Research design: This preliminary exploratory study employed a cross-sectional design, comparing two matched samples, one early post-brain injury (M = 7 months) and one late post-brain injury (M = 10 years). Methods and procedures: The Posttraumatic Growth Inventory (PTGI), Sense of Coherence Scale-13 (SOC-13) and Hospital Anxiety and Depression Scale ( HADS) were administered. Main outcomes and results: The samples differed significantly with respect to reported post-traumatic growth, with the late sample reporting higher levels. HADS anxiety was significantly associated with post-traumatic growth. Both samples achieved high scores on the SOC-13. Conclusions: The participants showed evidence of substantial positive psychological change, demonstrating that it is not precluded by severe brain injury. The results suggest that this develops slowly over time and requires a degree of emotional engagement.	Oxford Ctr Enablement, Oxford, England; Univ Leicester, Leicester LE1 7RH, Leics, England	McGrath, JC (corresponding author), Univ Oxford, Wycliffe Hall,54 Banbury Rd, Oxford OX2 6PW, England.	jcollicutt@aol.co.uk	McGrath, John C/G-6485-2012	McGrath, John C/0000-0002-5276-0381			ADAMS N, 1996, AUSTR NZ J FAMILY TH, V17, P75; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; BROOKS DN, 1984, CLOSED HEAD INJURY P; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Calhoun LG, 1998, LEA SER PER CLIN PSY, P215; Clare L, 2004, BRIT J CLIN PSYCHOL, V43, P155, DOI 10.1348/014466504323088033; Collin C, 1988, Int Disabil Stud, V10, P61; Cordova MJ, 2001, HEALTH PSYCHOL, V20, P176, DOI 10.1037//0278-6133.20.3.176; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; HOUSE A, 1992, OX MED PUBL, P51; JOHNSON G, 1995, ACTA PSYCHIAT SCAND, V91, P252, DOI 10.1111/j.1600-0447.1995.tb09778.x; King LA, 2000, J RES PERS, V34, P509, DOI 10.1006/jrpe.2000.2285; Kneebone II, 2000, BRIT J CLIN PSYCHOL, V39, P53, DOI 10.1348/014466500163103; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; Linley PA, 2003, J TRAUMA STRESS, V16, P601, DOI 10.1023/B:JOTS.0000004086.64509.09; Lyon Brenda L, 2002, Top Stroke Rehabil, V9, P1; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; McGrath J, 2004, CLIN REHABIL, V18, P767, DOI 10.1191/0269215504cr802oa; McGrath J, 2000, BEHAV NEUROL, V12, P201, DOI 10.1155/2000/612185; MCGRATH J, 2004, OXFORD GUIDE BEHAV E, P331; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; ODDY M, 1995, TRAUMATIC BRAIN INJU, P167; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Polatinsky S, 2000, J TRAUMA STRESS, V13, P709, DOI 10.1023/A:1007870419116; PRIGATANO G, 1999, PRINCIPLES NEUROPSYC, P89; Sampson MJ, 2003, INT J GERIATR PSYCH, V18, P23, DOI 10.1002/gps.763; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SNAPE MC, 1997, PSYCHOL HEALTH MED, V2, P237, DOI DOI 10.1080/13548509708400581; Snekkevik H, 2003, CLIN REHABIL, V17, P443, DOI 10.1191/0269215503cr630oa; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; TYERMAN A, 1984, INT J REHABILITATION, P11; Weiss T, 2002, J PSYCHOSOC ONCOL, V20, P65, DOI 10.1300/J077v20n02_04; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	71	73	1	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					767	773		10.1080/02699050600664566			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200011	16809209				2021-06-18	
J	Eriksson, G; Tham, K; Borg, J				Eriksson, G; Tham, K; Borg, J			Occupational gaps in everyday life 1-4 years after acquired brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						activities of daily living; rehabilitation; occupational therapy; brain injuries; cerebrovascular accident	REHABILITATION; STROKE	Objective: To explore adaptation, by examining the occupational gaps occurring between what individuals want to do and what they actually do in terms of their everyday activities before and after brain injury. In addition, the relationships between occupational gaps and impairment/activity limitations and the time lapse since the brain injury were explored. Design: A cross-sectional study. Subjects: A total of 187 persons, affected by traumatic brain injury or subarachnoid haemorrhage 1 - 4 years previously. Methods: A postal questionnaire encompassing questions concerning gaps in the performance of activities in everyday life before and after the brain injury and perceived impairment/activity limitations. Results: The numbers of occupational gaps increased after the injury, with the number of gaps having increased from 46% to 71%. The number of occupational gaps was significantly related to executive impairment/activity limitations, and motor impairment/activity limitations and other somatic impairments, such as headache, also had an impact. The time lapse since the brain injury had no significant effect on the number of occupational gaps. Conclusion: The results suggests that there is a need for adaptation in everyday activities, even several years after a brain injury, which indicates that follow-up and access to individualized rehabilitation interventions in the long-term are required.	Karolinska Inst, Div Occupat Therapy, Neurotec Dept, SE-14183 Huddinge, Sweden; Uppsala Univ, Dept Neurosci Rehabil Med, Uppsala, Sweden; Univ Uppsala Hosp, Akad Sjukhuset, Dept Occupat Therapy, Uppsala, Sweden	Eriksson, G (corresponding author), Karolinska Inst, Div Occupat Therapy, Neurotec Dept, SE-14183 Huddinge, Sweden.	gunilla.eriksson@ki.se	; Tham, Kerstin/T-3964-2018	Borg, Jorgen/0000-0002-2372-7478; Tham, Kerstin/0000-0001-7025-5226			*AM OCC THER ASS, 1995, AM J OCCUP THER, V10, P1015; BAUM CM, 1993, THESIS WASHINGTON U; BECKER G, 1993, GERONTOLOGIST, V33, P148, DOI 10.1093/geront/33.2.148; BRANHOLM IB, 1994, DISABIL REHABIL, V16, P205; Carter BS, 2000, NEUROSURGERY, V46, P1326, DOI 10.1097/00006123-200006000-00008; Carter J, 1997, CLIN REHABIL, V11, P131, DOI 10.1177/026921559701100206; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Eriksson Gunilla, 2005, Scand J Occup Ther, V12, P40, DOI 10.1080/11038120510027630; Fisher AG, 1998, AM J OCCUP THER, V52, P509, DOI 10.5014/ajot.52.7.509; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; Hachisuka K, 1997, CLIN REHABIL, V11, P28, DOI 10.1177/026921559701100105; Jonsson ALT, 1999, AM J OCCUP THER, V53, P353; Karlsson G, 1993, PSYCHOL QUALITATIVE; KATZ N, 2005, COGNITION OCCUPATION, P3; Kielhofner G, 2002, MODEL HUMAN OCCUPATI; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McColl MA, 2002, AM J OCCUP THER, V56, P350, DOI 10.5014/ajot.56.3.350; Melin R, 2003, J REHABIL MED, V35, P84, DOI 10.1080/16501970306119; Palmer S, 2003, REHABIL PSYCHOL, V48, P255, DOI 10.1037/0090-5550.48.4.255; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; SCHULTZ S, 1992, AM J OCCUP THER, V46, P917, DOI 10.5014/ajot.46.10.917; Spencer JC, 1996, AM J OCCUP THER, V50, P526, DOI 10.5014/ajot.50.7.526; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Townsend E, 2002, ENABLING OCCUPATION; Von Koch L, 1998, DISABIL REHABIL, V20, P367, DOI 10.3109/09638289809166095; World Health Organization, 2001, INT CLASS FUNCT DIS; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640	28	71	72	0	8	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2006	38	3					159	165		10.1080/16501970500415322			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	039QS	WOS:000237321900003	16702082	DOAJ Gold			2021-06-18	
J	Statler, KD; Alexander, H; Vayni, V; Holubkov, R; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM				Statler, KD; Alexander, H; Vayni, V; Holubkov, R; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM			Isoflurane exerts neuroprotective actions at or near the time of severe traumatic brain injury	BRAIN RESEARCH			English	Article						anaesthesia; traumatic brain injury; fentanyl; rat; narcotic; hippocampus; head injury; contusion; controlled cortical impact	CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; ENDOGENOUS OPIOIDS; FENTANYL; ANESTHESIA; RATS; AUTOREGULATION; ISCHEMIA; DEFICITS; MICE	Isoflurane improves outcome vs. fentanyl anesthesia, in experimental traumatic brain injury (TBI). We assessed the temporal profile of isoflurane neuroprotection and tested whether isoflurane confers benefit at the time of TBI. Adult, male rats were randomized to isoflurane (1%) or fentanyl (10 mcg/kg iv bolus then 50 mcg/kg/h) for 30 min pre-TBI. Anesthesia was discontinued, rats recovered to tail pinch, and TBI was delivered by controlled cortical impact. Immediately post-TBI, rats were randomized to 1 h of isoflurane, fentanyl, or no additional anesthesia, creating 6 anesthetic groups (isoflurane:isoflurane, isoflurane:fentanyl, isoflurane: none, fentanyl:isoflurane, fentanyl:fentanyl, fentanyl:none). Beam balance, beam walking, and Morris water maze (MWM) performances were assessed over post-trauma d1-20. Contusion volume and hippocampal survival were assessed on d21. Rats receiving isoflurane pre- and post-TBI exhibited better beam walking and MWM performances than rats treated with fentanyl pre- and any treatment post-TBI. All rats pretreated with isoflurane had better CA3 neuronal survival than rats receiving fentanyl pre- and post-TBI. In rats pretreated with fentanyl, post-traumatic isoflurane failed to affect function but improved CA3 neuronal survival vs. rats given fentanyl pre- and post-TBI. Posttraumatic isoflurane did not alter histopathological outcomes in rats pretreated with isoflurane. Rats receiving fentanyl pre- and post-TBI had the worst CA1 neuronal survival of all groups. our data support isoflurane neuroprotection, even when used at the lowest feasible level before TBI (i.e., when discontinued with recovery to tail pinch immediately before injury). Investigators using isoflurane must consider its beneficial effects in the design and interpretation of experimental TBI research. (c) 2006 Elsevier B.V. All rights reserved.	Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Statler, KD (corresponding author), Univ Utah, Sch Med, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	kim.statler@hsc.utah.edu; alexanderHL@anes.upmc.edu; vagnva@anes.upmc.edu; rholubkov@hrc.utah.edu; dixonec@upmc.edu; clarkrs@ccm.upmc.edu; ljenkins@pitt.edu; kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318] Funding Source: NIH RePORTER		BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Nikolaishvili L S, 2004, Neurosci Behav Physiol, V34, P467, DOI 10.1023/B:NEAB.0000022631.46176.6b; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1993, J CEREB BLOOD FLOW M, pS685; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Statler KD, 2003, BRAIN RES, V994, P37, DOI 10.1016/j.brainres.2003.09.042; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002	31	71	72	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 3	2006	1076						216	224		10.1016/j.brainres.2005.12.106			9	Neurosciences	Neurosciences & Neurology	031GL	WOS:000236692500025	16473332				2021-06-18	
J	Bor-Seng-Shu, E; Hirsch, R; Teixeira, MJ; De Andrade, AF; Marino, R				Bor-Seng-Shu, E; Hirsch, R; Teixeira, MJ; De Andrade, AF; Marino, R			Cerebral hemodynamic changes gauged by transcranial Doppler ultrasonooraphy in patients with posttraumatic brain swelling treated by surgical decompression	JOURNAL OF NEUROSURGERY			English	Article						brain swelling; head injury; intracranial hypertension; decompressive craniectomy; transcranial Doppler ultrasonography; cerebral hemodynamics	VENOUS OXYGEN-SATURATION; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; HEAD-INJURY; BLOOD-FLOW; CEREBROVASCULAR AUTOREGULATION; VASOMOTOR REACTIVITY; HYPEREMIA PRIOR; CRANIECTOMY; MANAGEMENT	Object. The use of decompressive craniectomy has experienced a revival in the previous decade, although its actual benefit on patients' neurological outcome remains the Subject of debate. A better understanding of the intracranial pressure dynamics, as well as of the metabolic and hemodynamic brain processes, may be useful in assessing the effect of this surgery oil the pathophysiology of the swollen brain. The aim of this study was to use transcranial Doppler (TCD) ultrasonography to examine the hemodynamic changes in the brain after decompressive craniectomy in patients with head ill injury, in addition to examining the relationship between such hemodynamic changes and the patient's neurological outcome. Methods. Nineteen patients presenting with traumatic brain swelling and cerebral herniation syndrome who had undergone decompressive craniectomy with dural expansion were Studied prospectively. The TCD ultrasonography measurements were performed bilaterally in both the middle cerebral artery (MCA) and in the distal portion of the cervical internal carotid artery (ICA) immediately prior to and after Surgical decompression. After surgery, the wean blood flow velocity (BFV) rose to 175 +/- 209% of preoperative Values in the MCA of the operated side, while rising to 132 +/- 183% in the contralateral side; the difference between the mean BFV increase in in the MCA of both the decompressed and the opposite side reached statistical significance (p < 0.05). The mean BFV of the extracranial ICA increased to 91 +/- 119% in the surgical side and 45 +/- 60% in the opposite side. Conversely, the MCA pulsatility index (PI) values decreased, oil average, to 33 +/- 36% of the preoperative value in the operated side and to 30 +/- 34% on the opposite side; the MCA PI value reductions were significantly greater in the decompressed side when compared with the contralateral side (p < 0.05). The PI of the extracranial ICA reduced, on average, to 37 +/- 23% of the initial values in the operated side and to 24 +/- 34%, contralaterally. No correlation was verified between the neurological outcome and cerebral hemodynamic changes seen on TCD ultrasonography. Conclusions. Decompressive craniectomy results in a significant elevation of cerebral BFV ill most patients with traumatic brain swelling and transtentorial herniation syndrome. The increase in cerebral BFV may also occur in the side opposite the decompressed hemisphere; the cerebral BFV increase is significantly greater in the operated hemisphere than contralaterally. Concomitantly, PI values decrease significantly postoperatively, mainly in the decompressed cerebral hemisphere, indicating reduction in cerebrovascular resistance.	Univ Sao Paulo, Sch Med, Div Neurosurg, Hosp Clin, Sao Paulo, Brazil	Bor-Seng-Shu, E (corresponding author), Rua Loefgreen 1272, BR-04040001 Sao Paulo, Brazil.	edsonshu@hotmail.com	BOR-SENG-SHU, EDSON/AAC-9762-2019; Teixeira, Manoel J/E-3110-2012; BOR-SENG-SHU, EDSON/H-7784-2013	BOR-SENG-SHU, EDSON/0000-0002-6713-8974; BOR-SENG-SHU, EDSON/0000-0002-6713-8974			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Babikian VL, 2000, J NEUROIMAGING, V10, P101, DOI 10.1111/jon2000102101; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Cruz J, 2002, ARQ NEURO-PSIQUIAT, V60, P670, DOI 10.1590/S0004-282X2002000400031; Csokay A, 2002, SURG NEUROL, V57, P126, DOI 10.1016/S0090-3019(01)00686-3; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Da Silva J A, 1976, Arq Neuropsiquiatr, V34, P232; de Andrade AF, 2001, WORLD J SURG, V25, P1186; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Doerfler A, 2002, J NEUROSURG, V96, P933, DOI 10.3171/jns.2002.96.5.0933; Engelhorn T, 2003, NEUROSCI LETT, V344, P127, DOI 10.1016/S0304-3940(03)00441-5; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASSLER W, 1988, J NEUROSURG, V68, P745; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; Kunze E, 1998, ACT NEUR S, V71, P16; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lee E, 1997, OPT EXPRESS, V1, P221, DOI 10.1364/OE.1.000221; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Martin N A, 1994, Neurosurg Clin N Am, V5, P607; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Meier U, 2003, ACTA NEUROCHIR SUPPL, V86, P367; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; Newell D W, 1994, Neurosurg Clin N Am, V5, P619; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RINALDI A, 1990, ACT NEUR S, V51, P394; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Schneider GH, 2002, ACT NEUR S, V81, P77; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, BRIT J NEUROSURG, V16, P429, DOI 10.1080/0268869021000030221; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; Wagner S, 2001, J NEUROSURG, V94, P693, DOI 10.3171/jns.2001.94.5.0693; Whitfield PC, 2001, NEUROSURGERY, V49, P225, DOI 10.1097/00006123-200107000-00042; Wirtz C R, 1997, Neurosurg Focus, V2, pE3; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	55	71	75	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2006	104	1					93	100		10.3171/jns.2006.104.1.93			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	001OX	WOS:000234547300015	16509152				2021-06-18	
J	Kelestimur, F; Tanriverdi, F; Atmaca, H; Unluhizarci, K; Selcuklu, A; Casanueva, F				Kelestimur, F; Tanriverdi, F; Atmaca, H; Unluhizarci, K; Selcuklu, A; Casanueva, F			Boxing as a sport activity associated with isolated GH deficiency	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						boxer; GH deficiency; traumatic brain injury; GHRH+GHRP-6 test; pituitary	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HYPOPITUITARISM; NEUROENDOCRINE DYSFUNCTION; PROFESSIONAL BOXERS; GROWTH-HORMONE; HEAD TRAUMA; ADULTS; DIAGNOSIS	Traumatic brain injury (TBI) has long been known as a cause of hypopituitarism, and it is characterized by a high prevalence of neuroendocrine abnormalities. Boxing, one of the most common combative sports, may also result in TBI. As far as we know, pituitary functions including GH status have not been investigated in boxers. Therefore, in this preliminary study, we have assessed the pituitary functions in boxers. Eleven actively competing or retired male boxers with a mean age of 38.0 +/- 3.6 yr and 7 age-, sex- and BMI-matched healthy non-boxing controls were included in the study. Biochemical and basal hormonal parameters including IGF-1 levels were measured. To assess GH secretory status in boxers and healthy controls, GHRH (1 mug/kg) +GHRP-6 (1 mug/kg) test was performed. After GHRH+GHRP-6 test, mean peak GH level in boxers and in controls were 10.9 +/- 1.7 and 41.4 +/- 6.7 mug/l, respectively (p<0.05). Peak GH levels in 5 (45%) boxers were found to be lower than 10 mug/l and considered as severe GH deficient. In the control group, mean IGF-I levels (367 +/- 18.8 ng/ml) were significantly higher than that obtained in boxers (237 +/- 23.3 ng/dl) (p<0.01). All the other pituitary hormones were normal including ADH as no signs and symptoms of diabetes insipidus. There was a significant negative correlation between peak GH levels and boxing duration, and between peak GH levels and number of bouts. In conclusion, we think that boxing is a cause of TBI, and GH deficiency is very common among boxers. Further studies including large number of boxers, both professional and amateur, are needed to clarify pituitary dysfunction in boxers. (C) 2004, Editrice Kurtis.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; Karaelmas Univ, Sch Med, Dept Endocrinol, Zonguldak, Turkey; Univ Santiago de Compostela, Dept Med, Sch Med, Santiago De Compostela, Spain; Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur2001@yahoo.co.uk					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BATES AS, 1995, CLIN ENDOCRINOL, V42, P425, DOI 10.1111/j.1365-2265.1995.tb02652.x; Benvenga S, 2004, AM J MED, V116, P767, DOI 10.1016/j.amjmed.2003.12.038; DANIEL PM, 1961, MOD TRENDS ENDOCRINO, V2, P55; Hillier SL, 1997, BRAIN INJURY, V11, P649; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelestimur Fahrettin, 2003, Pituitary, V6, P181, DOI 10.1023/B:PITU.0000023425.20854.8e; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Molitch ME, 2002, J CLIN ENDOCR METAB, V87, P473, DOI 10.1210/jc.87.2.473; Ohhashi G, 2002, BRIT J SPORT MED, V36, P346, DOI 10.1136/bjsm.36.5.346; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Powell JW, 2001, J ATHL TRAINING, V36, P307; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	20	71	73	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1720-8386			J ENDOCRINOL INVEST	J. Endocrinol. Invest.	DEC	2004	27	11					RC28	RC32		10.1007/BF03345299			5	Endocrinology & Metabolism	Endocrinology & Metabolism	898LR	WOS:000227078800001	15754728				2021-06-18	
J	Pellman, E; Viano, DC; Casson, IR; Tucker, AM; Waeckerle, JF; Powell, JW; Feuer, H				Pellman, E; Viano, DC; Casson, IR; Tucker, AM; Waeckerle, JF; Powell, JW; Feuer, H			Concussion in professional football: Repeat injuries - Part 4	NEUROSURGERY			English	Article						concussion; epidemiology; injury surveillance; repeat or multiple concussions; second-impact syndrome; traumatic brain injury	2ND IMPACT; COLLEGIATE; PLAYERS	OBJECTIVE: A 6-year study was conducted to determine the signs, symptoms, and management of repeat concussion in National Football League players. METHODS: From 1996 to 2001, concussions were reported by 30 National Football League teams using a standardized reporting form filled out by team physicians with input from athletic trainers. Signs and symptoms were grouped by general symptoms, somatic complaints, cranial nerve effects, cognition problems, memory problems, and unconsciousness. Medical actions taken and management were recorded. RESULTS: Data were captured for 887 concussions in practices and games involving 650 players. A total of 160 players experienced repeat injury, with 51 having three or more concussions during the study period. The median time between injuries was 374.5 days, with only six concussions occurring within 2 weeks of the initial injury. Repeat concussions were more prevalent in the secondary (16.9%), the kick unit on special teams (16.3%), and wide receivers (12.5%). The ball return carrier on special teams (odds ratio [OR] = 2.08, P = not significant) and quarterbacks (OR = 1.92, P < 0.1) had elevated odds for repeat injury, followed by the tight end (OR = 1.24, P = not significant) and linebackers (OR = 1.22, P = not significant). There were similar signs and symptoms with single and repeat concussion, except for a higher prevalence of somatic complaints in players on their repeat concussions compared with their first concussion (27.5% versus 18.8%, P< 0.05). More than 90% of players were managed by rest, and 57.5% of those with second injuries returned to play within a day. Players with three or more concussions had signs, symptoms, and treatment similar to those with only a single injury. CONCLUSION: The most vulnerable players for repeat concussion in professional football are the ball return carrier on special teams and quarterbacks. Single and repeat concussions are managed conservatively with rest, and most players return quickly to play.	ProHLTH Care Associates LLP, Lake Success, NY USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; Probiomech LLC, Bloomfield Hills, MI 48304 USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Univ Maryland, Sch Med, Lutherville Timonium, MD USA; Acute Care & Emergency Specialists MD PC, Leawood, KS USA; Michigan State Univ, Dept Kinesiol, Lansing, MI USA; Michigan State Univ, Dept Phys Med & Rehabil, Lansing, MI USA; Indianapolis Neurosurg Grp, Indianapolis, IN USA	Viano, DC (corresponding author), Probiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net		Kaye, Andrew Henry/0000-0001-5049-8861			BAILES J, 2003, NEUROL REV      0627; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P172; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; *CO MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; KWARTZ J, 1990, INJURY, V21, P351, DOI 10.1016/0020-1383(90)90116-C; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POLIN R, 1996, NEUROLOGY TRAUMA, P166; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F, P77; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; UNTERHARNSCHEID.FJ, 1975, HDB CLIN NEUROLOGY, V23, P527; Warden Deborah L., 2003, Neurology, V60, pA362	45	71	71	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2004	55	4					860	873		10.1227/01.NEU.0000137657.00146.7D			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100029	15458594				2021-06-18	
J	Creeley, CE; Wozniak, DF; Bayly, PV; Olney, JW; Lewis, LM				Creeley, CE; Wozniak, DF; Bayly, PV; Olney, JW; Lewis, LM			Multiple episodes of mild traumatic brain injury result in impaired cognitive performance in mice	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 29-JUN 01, 2003	BOSTON, MA	Soc Acad Emergency Med		traumatic brain injury; concussion; memory; cognition; mice	COLLEGIATE FOOTBALL PLAYERS; ALZHEIMERS-DISEASE; HEAD-INJURY; SOCCER INJURIES; RISK; MODEL; CONCUSSION; PROTEIN; SPORTS; TIME	Objectives: Results from recent studies on animal models of concussion suggest that multiple, rather than single, episodes of mild traumatic brain injury result in impaired cognitive performance in mice. The objective of the present study was to administer multiple impacts to the heads of mice while directly measuring the force of the impacts to determine how these parameters are related to transient loss of consciousness, cognitive deficits, and potential neuropathologic effects. Methods: Seven-week-old male C57BL/6 mice were randomly assigned to experimental conditions involving three impacts (weight-drop method) to the head to induce mild traumatic brain injury or to sham control procedures. Some impacted (n = 10) and sham control (n = 10) mice were evaluated behaviorally and tested for spatial learning using the Morris water maze (MWM), whereas other impacted (n = 10) and sham control (n = 5) mice were used for histopathologic analysis. Results: The mean (+/-SD) force of impact was 19 (+/-3.5) N. Impacted mice took longer to regain consciousness compared with sham control mice (p < 0.0005). Behavioral test results showed that the groups did not differ on activity or sensorimotor tests or during cued trials in the MWM. Impacted mice exhibited impaired spatial learning performance during place trials in the MWM (p < 0.05). Silver staining revealed a contra-coup type of injury involving ventral brain structures in contact with or in close proximity to the skull. Conclusions: This multiple-impact model, delivered within a specifiable force range, results in transient, reversible loss of consciousness, a contra-coup brain injury, and cognitive impairment.	Washington Univ, Sch Med, Div Emergency Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mech Engn, St Louis, MO 63110 USA	Lewis, LM (corresponding author), Washington Univ, Sch Med, Div Emergency Med, Box 8072,600 S Euclid Ave, St Louis, MO 63110 USA.	lewisl@msnotes.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG11355, P50AG05681] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005681, P01AG011355] Funding Source: NIH RePORTER		ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fratiglioni L, 1993, Acta Neurol Scand Suppl, V145, P1; GRONWALL D, 1975, LANCET, V2, P995; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ross J, 2000, HAEMOPHILIA, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wozniak DF, 1996, BRAIN RES, V707, P165, DOI 10.1016/0006-8993(95)01230-3	31	71	72	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2004	11	8					809	819		10.1197/j.aem.2004.03.006			11	Emergency Medicine	Emergency Medicine	843NP	WOS:000223090900001	15289185	Bronze			2021-06-18	
J	Conti, A; Sanchez-Ruiz, Y; Bachi, A; Beretta, L; Grandi, E; Beltramo, M; Alessio, M				Conti, A; Sanchez-Ruiz, Y; Bachi, A; Beretta, L; Grandi, E; Beltramo, M; Alessio, M			Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; fibrinogen; proteomics; traumatic brain injury; two-dimensional gel electrophoresis	FIBRINOLYTIC-ACTIVITY; GEL-ELECTROPHORESIS; HEAD-INJURY; CSF; LUMBAR; INTERLEUKIN-6; FIBRINOGEN; PROTEINS; DISEASE; DAMAGE	Traumatic brain injury (TBI), like other central nervous system pathologies, causes changes in the composition of cerebrospinal fluid (CSF). Consequently analysis of the CSF components is important to better understand the pathological processes involved in such diseases. The aim of this work was to identify specific markers of severe TBI. Proteomic analysis including two-dimensional gel electrophoresis combined with mass spectrometry analysis was used to compare the CSF protein profile of severe TBI patients and controls. Proteins (alpha 1 antitrypsin, haptoglobin 1 alpha1, alpha2, and beta) belonging to the acute phase response showed an increased expression in severe TBI patients. Two other proteins, identified as proteolytic degradation products of the carboxyl-terminal portion of the fibrinogen beta, were present only in TBI patients. The presence of these markers could correlate with a post-traumatic local increase in fibrinolysis as well as to an inflammatory event following CNS tissue injury.	Ist Sci San Raffaele, DIBIT, Proteom Lab, Proteom Unit, I-20132 Milan, Italy; Ist Sci San Raffaele, Mass Spectrometry Unit, I-20132 Milan, Italy; Ist Sci San Raffaele, Intens Care Neurosurg Dept, I-20132 Milan, Italy; Schering Plough Res Inst, Milan, Italy	Alessio, M (corresponding author), Ist Sci San Raffaele, DIBIT, Proteom Lab, Proteom Unit, Via Olgettina 58, I-20132 Milan, Italy.	m.alessio@hsr.it	bachi, angela/B-3527-2015; Alessio, Massimo/L-4518-2019; Conti, Antonio/AAN-7161-2020; Alessio, Massimo/K-7028-2014	bachi, angela/0000-0003-4842-6556; Conti, Antonio/0000-0001-9150-5271; Alessio, Massimo/0000-0002-4133-3472			Balasingam V, 1996, J NEUROSCI, V16, P2945; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Beaulieu JM, 2002, BRAIN RES, V946, P153, DOI 10.1016/S0006-8993(02)02830-5; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BRUETON MJ, 1974, J CLIN PATHOL, V27, P402, DOI 10.1136/jcp.27.5.402; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gajjar A, 1999, J CLIN ONCOL, V17, P1825, DOI 10.1200/JCO.1999.17.6.1825; Gerber J, 1998, NEUROLOGY, V51, P1710, DOI 10.1212/WNL.51.6.1710; Hochstrasser DF, 2002, PROTEOMICS, V2, P807, DOI 10.1002/1615-9861(200207)2:7<807::AID-PROT807>3.0.CO;2-4; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HUNTER R, 1974, J NEUROL NEUROSUR PS, V37, P249, DOI 10.1136/jnnp.37.3.249; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; JENNETT B, 1975, LANCET, V1, P480; KALSHEKER N, 1989, NUCLEIC ACIDS RES, V17, P10518, DOI 10.1093/nar/17.24.10518; Kasuya H, 1998, ACTA NEUROCHIR, V140, P579, DOI 10.1007/s007010050143; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; Korschenhausen DA, 1996, SCHIZOPHR RES, V19, P103, DOI 10.1016/0920-9964(95)00073-9; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Lemke R, 1999, GLIA, V27, P75, DOI 10.1002/(SICI)1098-1136(199907)27:1<75::AID-GLIA8>3.3.CO;2-A; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; NOWACKI P, 1990, Neuropatologia Polska, V28, P257; Okamoto S, 1991, Rinsho Byori, V39, P651; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Raby CA, 1998, J NEUROCHEM, V71, P2505; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; RINK A, 1995, AM J PATHOL, V147, P1575; RUBALCAVA MA, 1995, NEUROSURGERY, V37, P668, DOI 10.1227/00006123-199510000-00009; Shaw PJ, 2002, BRAIN, V125, P693, DOI 10.1093/brain/awf138; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sommer JB, 2002, EUR NEUROL, V47, P224, DOI 10.1159/000057904; Spraggon G, 1997, NATURE, V389, P455; Suzuki M, 1997, ACTA NEUROCHIR, V139, P1152, DOI 10.1007/BF01410975; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; TEASDALE G, 1974, LANCET, V2, P81; TOVI D, 1972, ACTA NEUROL SCAND, V48, P403, DOI 10.1111/j.1600-0404.1972.tb07562.x; Vejda S, 2002, MOL CELL PROTEOMICS, V1, P387, DOI 10.1074/mcp.M200004-MCP200; VERMEULEN M, 1985, J NEUROSURG, V63, P573, DOI 10.3171/jns.1985.63.4.0573; Wassell J, 2000, Clin Lab, V46, P547; WEISNER B, 1978, J NEUROL SCI, V37, P205, DOI 10.1016/0022-510X(78)90204-6; WIEDERKEHR F, 1987, J NEUROCHEM, V49, P363, DOI 10.1111/j.1471-4159.1987.tb02874.x; WILDENAUER DB, 1991, ELECTROPHORESIS, V12, P487, DOI 10.1002/elps.1150120706; Wood P. L., 1998, NEUROINFLAMMATION ME, P1; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	55	71	76	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					854	863		10.1089/0897715041526212			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800003	15307898				2021-06-18	
J	Zhang, WP; Hu, H; Zhang, L; Ding, W; Yao, HT; Chen, KD; Sheng, WW; Chen, Z; Wei, EQ				Zhang, WP; Hu, H; Zhang, L; Ding, W; Yao, HT; Chen, KD; Sheng, WW; Chen, Z; Wei, EQ			Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors	NEUROSCIENCE LETTERS			English	Article						cysteinyl leukotriene receptor 1; traumatic brain injury; astrocytoma; ganglioglioma; metastatic adenocarcinoma; microvascular endothelium	FOCAL CEREBRAL-ISCHEMIA; TGF-BETA; INFLAMMATION; INCREASE; RHINITIS	Cysteinyl leukotrienes (CysLTs) are potent proinflammatory mediators. CysLT receptor 1 (CysLT(1)) is one of the two CysLT receptors that has been cloned. Although the expression of CysLT(1) in the brain has been demonstrated by Northern blot and RT-PCR analyses, the location of CysLT(1) in the brain remains unknown. The objective of this study was to examine the distribution of CysLT(1) by immunohistochemical analysis in human brains with traumatic injury or tumors. CysLT(1) was expressed intensely in the microvascular endothelial cells in both normal and abnormal conditions. At 8 days after traumatic injury, microvascular regeneration was found and all of the endothelial cells highly expressed CysLT(1). In gray and white matters of the normal regions of the brain, CysLT(1) was expressed weekly or not at all, However, the CysLT(1) expression increased in the neuron- and glial-appearing cells in gray and white matters after traumatic brain injury. CysLT(1) was also detected in astrocytoma, ganglioglioma and metastatic adenocarcinoma, and the expression in the neuron- and glial-appearing cells around brain tumors increased robustly. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Hangzhou 310027, Peoples R China	Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, 353,Yan An Rd, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; Busse WW, 1998, AM J RESP CRIT CARE, V157, pS210, DOI 10.1164/ajrccm.157.6.mar-1; Chibana K, 2003, J IMMUNOL, V170, P4290, DOI 10.4049/jimmunol.170.8.4290; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Debinski W, 1998, INT J CANCER, V76, P547, DOI 10.1002/(SICI)1097-0215(19980518)76:4<547::AID-IJC17>3.0.CO;2-4; Fujita M, 1999, EUR J PHARMACOL, V369, P349, DOI 10.1016/S0014-2999(99)00037-0; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Inamura Takanori, 1992, Neurological Research, V14, P405; Kjellman C, 2000, INT J CANCER, V89, P251, DOI 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Sarau HM, 1999, MOL PHARMACOL, V56, P657; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shinonaga M, 1990, Adv Neurol, V52, P475; Storms WW, 2003, ANN ALLERG ASTHMA IM, V91, P131, DOI 10.1016/S1081-1206(10)62167-9; Yang MS, 2002, GLIA, V38, P273, DOI 10.1002/glia.10057; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	21	71	74	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 17	2004	363	3					247	251		10.1016/j.neulet.2004.03.088			5	Neurosciences	Neurosciences & Neurology	830OY	WOS:000222133400012	15182953				2021-06-18	
J	Johnston, AJ; Steiner, LA; Chatfield, DA; Coles, JP; Hutchinson, PJ; Al-Rawi, PG; Menon, DK; Gupta, AK				Johnston, AJ; Steiner, LA; Chatfield, DA; Coles, JP; Hutchinson, PJ; Al-Rawi, PG; Menon, DK; Gupta, AK			Effect of cerebral perfusion pressure augmentation with dopamine and norepinephrine on global and focal brain oxygenation after traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						norepinephrine; dopamine; brain tissue oxygen; cerebral microdialysis; head injury; cerebral oxygenation	BLOOD-FLOW; CORTICAL PERFUSION; METABOLISM; BARRIER; EDEMA	Objective. To compare the effects of a cerebral perfusion pressure (CPP) intervention achieved with dopamine and norepinephrine after severe head injury. Design. Prospective, controlled, trial. Setting. Neurosciences critical care unit. Patients. Eleven patients with a head injury, requiring dopamine or norepinephrine infusions to support CPP. Intervention. Cerebral tissue gas measurements were recorded using a multimodal sensor, and regional chemistry was assessed using microdialysis. Patients received in, randomised order, either dopamine or norepinephrine to achieve and maintain a CPP of 65 mmHg, and then, following a 30-min period of stable haemodynamics, a CPP of 85 mmHg. Data were then acquired using the second agent. Haemodynamic measurements and measurements of cerebral physiology were made during each period. Measurements and results. The CPP augmentation with norepinephrine, but not with dopamine, resulted in a significant reduction in arterial-venous oxygen difference (37+/-11 vs 33+/-12 ml/l) and a significant increase in brain tissue oxygen (2.6+/-1.1 vs 3.0+/-1.1 kPa). The CPP intervention did not significantly affect intracranial pressure. There were no significant differences between norepinephrine and dopamine on cerebral oxygenation or metabolism either at baseline or following a CPP intervention; however, the response to a CPP intervention with dopamine seemed to be more variable than the response achieved with norepinephrine. Conclusions. If CPP is to be raised to a level higher than 65-70 mmHg, then it is important to recognise that the response to the intervention may be unpredictable and that the vasoactive agent used may be of importance.	Univ Cambridge, Addenbrookes Hosp, Dept Anaesthet, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Johnston, AJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Anaesthet, Box 93, Cambridge CB2 2QQ, England.	ajj29@cam.ac.uk	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019		Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		ALTURA BM, 1980, BRIT J PHARMACOL, V69, P543, DOI 10.1111/j.1476-5381.1980.tb07900.x; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; EDVINSSON L, 1978, J PHYSIOL-LONDON, V274, P149, DOI 10.1113/jphysiol.1978.sp012140; Edvinsson L, 2002, CEREBRAL BLOOD FLOW; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; MCCALDEN TA, 1977, AM J PHYSIOL, V233, pH458; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Myburgh JA, 1998, ACT NEUR S, V71, P19; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stocchetti N, 1998, ACT NEUR S, V71, P162; TUOR UI, 1986, AM J PHYSIOL, V251, pH824; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	26	71	73	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2004	30	5					791	797		10.1007/s00134-003-2155-7			7	Critical Care Medicine	General & Internal Medicine	817BW	WOS:000221154000010	15048550				2021-06-18	
J	Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Ewing-Cobbs, L; Dennis, M; Barnes, MA; Max, J; Schachar, R; Chapman, SB; Hunter, JV				Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Ewing-Cobbs, L; Dennis, M; Barnes, MA; Max, J; Schachar, R; Chapman, SB; Hunter, JV			Changes in working memory after traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; PREFRONTAL CORTEX; WHITE-MATTER; CHILDHOOD; DAMAGE; SUBVOCALIZATION; INFORMATION; MATURATION; SEVERITY; BEHAVIOR	The impact of traumatic brain injury (TBI) on working memory (WM) was studied in 144 children (79 with mild, 23 with moderate, and 42 with severe injuries) who underwent magnetic resonance imaging (MRI) at 3 months and were tested at baseline and at 3, 6, 12, and 24 months postinjury. An n-back WM task for letter identity was administered with memory load ranging from 1- to 3-back and a 0-back condition. A TBI Severity X Quadratic Time interaction showed that net percentage correct (correct detections of targets minus false alarms) was significantly lower in severe than in mild TBI groups. The Left Frontal Lesions X Age interaction approached significance. Mechanisms mediating late decline in WM and the effects of left frontal lesions are discussed.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Hosp Sick Children, Res Inst, Dept Psychol Brain & Behav Program, Toronto, ON, Canada; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp, San Diego, CA USA; Ctr Hlth, San Diego, CA USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Dept Neurosurg, 6560 Fannin St,Suite 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5K-08MH01800-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; BADDELEY A, 1981, Q J EXP PSYCHOL-A, V33, P439, DOI 10.1080/14640748108400802; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; deJonge P, 1996, PERS INDIV DIFFER, V21, P1007, DOI 10.1016/S0191-8869(96)00161-4; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gathercole SE, 1997, J EXP CHILD PSYCHOL, V67, P290, DOI 10.1006/jecp.1997.2391; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEVY BA, 1977, J VERB LEARN VERB BE, V16, P623, DOI 10.1016/S0022-5371(77)80024-8; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Littell R. C. G. A., 1996, SAS SYSTEM MIXED MOD; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Mehta MA, 2000, J NEUROSCI, V20; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MORRIS N, 1990, BRIT J PSYCHOL, V81, P111, DOI 10.1111/j.2044-8295.1990.tb02349.x; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SLOWIACZEK ML, 1980, J VERB LEARN VERB BE, V19, P573, DOI 10.1016/S0022-5371(80)90628-3; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; TEASDALE G, 1974, LANCET, V2, P81; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181	51	71	72	0	21	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	2004	18	2					240	247		10.1037/0894-4105.18.2.240			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	810SX	WOS:000220725100005	15099146				2021-06-18	
J	Steiner, LA; Johnston, AJ; Czosnyka, M; Chatfield, DA; Salvador, R; Coles, JP; Gupta, AK; Pickard, JD; Menon, DK				Steiner, LA; Johnston, AJ; Czosnyka, M; Chatfield, DA; Salvador, R; Coles, JP; Gupta, AK; Pickard, JD; Menon, DK			Direct comparison of cerebrovascular effects of norepinephrine and dopamine in head-injured patients	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; cerebral perfusion; cerebral blood flow; norepinephrine; dopamine; transcranial Doppler	CEREBRAL-BLOOD-FLOW; CORTICAL IMPACT INJURY; TRANSCRANIAL DOPPLER; PERFUSION; HYPERTENSION; AUTOREGULATION; EPINEPHRINE; CIRCULATION; RATS	Objective: To directly compare the cerebrovascular effects of norepinephrine and dopamine in patients with acute traumatic brain injury. Design. Prospective randomized crossover trial. Setting. Neurosciences critical care unit of a university hospital. Patients: Ten acutely head-injured patients requiring vasoactive drugs to maintain a cerebral perfusion pressure of 65 mm Hg. Interventions: Patients were randomized to start the protocol with either norepinephrine or dopamine. Using an infusion of the allocated drug, cerebral perfusion pressure was adjusted to 65 mm Hg. After 20 mins of data collection, cerebral perfusion pressure was increased to 75 mm Hg by increasing the infusion rate of the vasoactive agent. After 20 mins of data collection, cerebral perfusion pressure was increased to 85 mm Hg and again data were collected for 20 mins. Subsequently, the infusion rate of the vasoactive drug was reduced until a cerebral perfusion pressure of 65 mm Hg was reached and the drug was exchanged against the other agent. The protocol was then repeated. Measurements and Main Results. Mean arterial pressure and intracranial pressure were monitored and cerebral blood flow was estimated with transcranial Doppler. Norepinephrine led to predictable and significant increases in flow velocity for each step increase in cerebral perfusion pressure (57.5 +/- 19.9 cm(.)sec(-1), 61.3 +/- 22.3 cm(.)sec(-1), and 68.4 +/- 24.8 cm-sec(-1) at 65, 75, and 85 mm Hg, respectively; p < .05 for all three comparisons), but changes with dopamine were variable and inconsistent. There were no differences between absolute values of flow velocity or intracranial pressure between the two drugs at any cerebral perfusion pressure level. Conclusions. Norepinephrine may be more predictable and efficient to augment cerebral perfusion in patients with traumatic brain injury.	Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Anesthesia, Cambridge CB2 2QQ, England	Steiner, LA (corresponding author), Univ Basel, Dept Anaesthesia, Kantonsspital, CH-4031 Basel, Switzerland.	lsteiner@uhbs.ch	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019	Salvador, Raymond/0000-0001-5557-1562	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		COLEMAN MR, 2002, J NEUROSURG ANESTHES, V14, P91; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; EDVINSSON L, 1978, ACTA PHYSIOL SCAND, V104, P349, DOI 10.1111/j.1748-1716.1978.tb06286.x; Fukushima U, 1999, J VET MED SCI, V61, P1293, DOI 10.1292/jvms.61.1293; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; MacGregor DA, 2000, ANESTHESIOLOGY, V92, P338, DOI 10.1097/00000542-200002000-00013; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Myburgh JA, 1998, ACT NEUR S, V71, P19; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Prielipp RC, 2001, ANESTH ANALG, V93, P45; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; TUOR UI, 1986, NEUROSCI LETT, V63, P253, DOI 10.1016/0304-3940(86)90365-4; TUOR UI, 1986, AM J PHYSIOL, V251, pH824; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; ZABLOTNY W, 1994, INTRACRANIAL PRESSUR, V9, P439	27	71	74	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	2004	32	4					1049	1054		10.1097/01.CCM.0000120054.32845.A6			6	Critical Care Medicine	General & Internal Medicine	812XR	WOS:000220872700022	15071400				2021-06-18	
J	Carmichael, ST				Carmichael, ST			Gene expression changes after focal stroke, traumatic brain and spinal cord injuries	CURRENT OPINION IN NEUROLOGY			English	Article						aging; angiogenesis; axonal sprouting; inflammation; neural repair; stem cell	MESSENGER-RNA EXPRESSION; DNA MICROARRAY ANALYSIS; CEREBRAL-ISCHEMIA; SERIAL ANALYSIS; CELL-DEATH; KAPPA-B; ANGIOGENESIS; GROWTH; RECEPTOR; NEUROGENESIS	Purpose of review Large-scale gene expression profiling has recently been performed on stroke and spinal cord injuries. These studies provide insights into coordinated patterns of gene expression within the injury and the interrelationships of neurodegenerative and neural repair processes after injury. Recent findings The molecular signals for post-stroke angiogenesis begin within hours of initial cerebral ischemia, with sequential increases in message for initially destabilizing combinations of vascular growth factors and growth factor receptors, followed by growth factor combinations that promote endothelial cell division and stabilization. The overlap in molecular signaling between post-stroke angiogenesis, neurogenesis and axonal sprouting suggests a continuum of vascular and neural reorganization in the tissue adjacent to stroke. Inflammation after injury extends through early and late changes in the cytokine message. SOCS-3, a negative regulator of cytokine signaling, is increased after injury and may be neuroprotective. Components of an adult neuronal growth program have been identified in the peripheral nervous system during axonal regeneration, with overlap to axonal sprouting after stroke. The gene expression profile of the aged brain suggests an altered central nervous system environment that may exacerbate initial injury and impair neural reorganization after stroke and spinal cord injury. Summary When rigorously tested and independently validated, data from large-scale gene expression analyses provide new insights into the aggregate genetic control of stroke and spinal cord injury, and the interrelationship of important cellular events within the damaged region. These data also highlight novel genes in these processes, and suggest new directions in the investigation of tissue reorganization and repair after central nervous system injury.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	Carmichael, ST (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	scarmichael@mednet.ucla.edu		Carmichael, S Thomas/0000-0002-1169-9203			Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bates S, 2001, MOL BRAIN RES, V93, P70, DOI 10.1016/S0169-328X(01)00186-3; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Blalock EM, 2003, J NEUROSCI, V23, P3807; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Bomze HM, 2001, NAT NEUROSCI, V4, P38; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; Bulsara KR, 2002, SPINE, V27, P1946, DOI 10.1097/00007632-200209010-00030; BULSARA KR, 2002, SOC NEUROSCI; Cafferty WBJ, 2001, J NEUROSCI, V21, P7161, DOI 10.1523/JNEUROSCI.21-18-07161.2001; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmichael ST, 2001, NEUROBIOL DIS, V8, P910, DOI 10.1006/nbdi.2001.0425; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chong ZZ, 2002, J HEMATOTH STEM CELL, V11, P863, DOI 10.1089/152581602321080529; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Chung RS, 2003, J NEUROSCI, V23, P3336; Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; Felmeden DC, 2003, EUR HEART J, V24, P586, DOI 10.1016/S0195-668X(02)00635-8; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Hindges R, 2002, NEURON, V35, P475, DOI 10.1016/S0896-6273(02)00799-7; Hoffman JR, 1999, BRAIN RES BULL, V48, P421, DOI 10.1016/S0361-9230(99)00022-2; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Katsman D, 2003, J CEREBR BLOOD F MET, V23, P997, DOI 10.1097/01.WCB.0000084252.20114.BE; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Keyvani K, 2002, J CEREBR BLOOD F MET, V22, P153, DOI 10.1097/00004647-200202000-00003; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Lee CK, 2000, NAT GENET, V25, P294; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Lin TN, 2001, J CEREBR BLOOD F MET, V21, P690, DOI 10.1097/00004647-200106000-00007; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; Lipton P, 1999, PHYSIOL REV, V79, P1431; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lu AG, 2003, J CEREBR BLOOD F MET, V23, P786, DOI 10.1097/01.WCB.0000062340.80057.06; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Patino WD, 2002, CIRC RES, V91, P565, DOI 10.1161/01.RES.0000036018.76903.18; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rao VLR, 2002, J NEUROCHEM, V83, P1072, DOI 10.1046/j.1471-4159.2002.01208.x; Renner O, 2003, MOL BRAIN RES, V113, P44, DOI 10.1016/S0169-328X(03)00085-8; Schmidt-Kastner R, 2002, MOL BRAIN RES, V108, P81, DOI 10.1016/S0169-328X(02)00516-8; Schmidt-Kastner R, 2000, MOL BRAIN RES, V79, P88, DOI 10.1016/S0169-328X(00)00104-2; Schneider A, 1999, NAT MED, V5, P554; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shusta EV, 2002, J CEREBR BLOOD F MET, V22, P245, DOI 10.1097/00004647-200203000-00001; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Studer L, 2000, J NEUROSCI, V20, P7377; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; TODA H, 2002, SOC NEUROSCI, P16; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; Turnley AM, 2002, NAT NEUROSCI, V5, P1155, DOI 10.1038/nn954; Uryu K, 2001, NEUROSCIENCE, V105, P307, DOI 10.1016/S0306-4522(01)00203-2; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Willson CA, 2003, CELL TRANSPLANT, V12, P279, DOI 10.3727/000000003108746830; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x; Yang YH, 2002, NAT REV GENET, V3, P579; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	75	71	75	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2003	16	6					699	704		10.1097/00019052-200312000-00009			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	805MU	WOS:000220371200009	14624079				2021-06-18	
J	Cantu, RC				Cantu, RC			Recurrent athletic head injury: risks and when to retire	CLINICS IN SPORTS MEDICINE			English	Article							2ND IMPACT SYNDROME; COLLEGE FOOTBALL; CONCUSSION; PERFORMANCE; SPORTS	This article focuses on the issues related to recurrent athletic head injuries; specifically, when cumulative exponential injury or the second impact syndrome may be anticipated. Case histories and research studies are used to illustrate the salient points. A signs-and-symptoms checklist for use in concussion evaluation and management is included. Finally, the topic of when to retire after repeated athletic head injuries is discussed and illustrated with a case study.	Emerson Hosp, Neurosurg Serv, Concord, MA 01742 USA; Emerson Hosp, Serv Sports Med, Concord, MA 01742 USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Cantu, RC (corresponding author), Emerson Hosp, Neurosurg Serv, 133 Ormac, Concord, MA 01742 USA.	rcantu@emersonhosp.org					ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Badie H, 1992, J NEUROTRAUM, V9, P56; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; ERLANGER D, 2002, UNPUB JAMA; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GIZA C, 2002, NEUROLOGIC ATHLETIC, P80; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1977, PERCEPT MOTOR SKILL, V4, P367; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F	24	71	71	0	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2003	22	3					593	+		10.1016/S0278-5919(02)00095-9			12	Sport Sciences	Sport Sciences	692LT	WOS:000183663100013	12852688				2021-06-18	
J	Shinoda, S; Skradski, SL; Araki, T; Schindler, CK; Meller, R; Lan, JQ; Taki, W; Simon, RP; Henshall, DC				Shinoda, S; Skradski, SL; Araki, T; Schindler, CK; Meller, R; Lan, JQ; Taki, W; Simon, RP; Henshall, DC			Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						14-3-3; epilepsy; Fas; MAP kinase; neurodegeneration; rat; TNF	KAINATE-INDUCED SEIZURES; TRAUMATIC BRAIN INJURY; EVOKED LIMBIC SEIZURES; SPINAL-CORD INJURY; ADULT-RAT BRAIN; CELL-DEATH; CEREBRAL-ISCHEMIA; TNF-ALPHA; PROTEIN PHOSPHATASE-5; DNA FRAGMENTATION	The consequences of activation of tumour necrosis factor receptor 1 (TNFR1) during neuronal injury remain controversial. The apoptosis signal-regulating kinase 1 (ASK1), a mitogen-activated protein kinase kinase kinase, can mediate cell death downstream of TNFR1. Presently, we examined the formation of the TNFR1 signalling cascade and response of ASK1 during seizure-induced neuronal death. Brief (40 min) seizures were induced in rats by intra-amygdala microinjection of kainic acid, which elicited unilateral hippocampal CA3 neuronal death. Seizures caused a rapid decline in the expression of the silencer of:death domains protein within injured CA3. Coimmunoprecipitation analysis revealed a commensurate assembly of a TNFR1 scaffold complex containing TNFR-associated death domain protein, receptor interacting protein and TNFR-activating factor 2. In addition, recruitment of TNFR-activating factor 2 was likely promoted by Bc110-mediated sequestering of cellular inhibitor of apoptosis protein 2. Apoptosis signal-regulating kinase 1 was sequestered in a complex that contained the molecular chaperone 14-3-3beta and protein phosphatase 5. Seizures triggered its dissociation, and the phosphorylation of the ASK1 substrates, mitogen-activated protein kinase kinase 3/6 and 4. Subsequently, protein phosphatase 5 translocated into the nuclei of degenerating CA3 neurons, while ASK1 colocalized with the adaptor proteins Daxx and TNFR-activating factor2 at the outer membrane of injured CA3 neurons. Neutralizing antibodies to TNFalpha reduced the numbers of DNA damaged cells within the injured hippocampus. These data suggest ASK1 may be involved in the mechanism of seizure-induced neuronal death downstream of a TNFR1 death-signalling complex.	Robert S Dow Neurobiol Labs, Legacy Res, Portland, OR USA; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan	Henshall, DC (corresponding author), Robert S Dow Neurobiol Labs, Legacy Res, Portland, OR USA.		Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041935, R01NS039016] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41935, NS39016] Funding Source: Medline		Akbar MT, 2001, MOL BRAIN RES, V93, P148, DOI 10.1016/S0169-328X(01)00199-1; Albensi BC, 2000, SYNAPSE, V35, P151; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bahl R, 2001, MOL BRAIN RES, V90, P101, DOI 10.1016/S0169-328X(01)00089-4; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bengzon J, 2002, PROG BRAIN RES, V135, P111; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Borthwick EB, 2001, FEBS LETT, V491, P279, DOI 10.1016/S0014-5793(01)02177-9; Brisman JL, 2002, BRAIN RES, V933, P50, DOI 10.1016/S0006-8993(02)02304-1; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; deBock F, 1996, NEUROREPORT, V7, P1125, DOI 10.1097/00001756-199604260-00004; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 2002, ACTA NEUROPATHOL, V103, P391, DOI 10.1007/s00401-001-0481-9; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, BRAIN RES, V858, P290, DOI 10.1016/S0006-8993(99)02452-X; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Henshall DC, 2001, J NEUROCHEM, V77, P886, DOI 10.1046/j.1471-4159.2001.00291.x; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Hofmann TG, 2001, INT J CANCER, V93, P185, DOI 10.1002/ijc.1316; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim GM, 2001, J NEUROSCI, V21, P6617; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Meistrell ME, 1997, SHOCK, V8, P341; Mielke K, 1999, NEUROSCIENCE, V91, P471, DOI 10.1016/S0306-4522(98)00667-8; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Paxinos P., 1997, RAT BRAIN STEREOTAXI; Qiu JH, 2002, J NEUROSCI, V22, P3504; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Tan ZQ, 2001, NEUROREPORT, V12, P1979, DOI 10.1097/00001756-200107030-00040; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114; Yui D, 2001, ONCOGENE, V20, P4317, DOI 10.1038/sj.onc.1204576; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang QG, 2002, NEUROSCI LETT, V329, P232, DOI 10.1016/S0304-3940(02)00650-X	67	71	74	1	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2003	17	10					2065	2076		10.1046/j.1460-9568.2003.02655.x			12	Neurosciences	Neurosciences & Neurology	689FT	WOS:000183481500009	12786973				2021-06-18	
J	Larrabee, GJ				Larrabee, GJ			Detection of symptom exaggeration with the MMPI-2 in litigants with malingered neurocognitive dysfunction	CLINICAL NEUROPSYCHOLOGIST			English	Article							FAKE BAD SCALE; VALIDITY SCALES; BASE RATES; INJURY; MEMORY; SUBTLE	MMPI-2 scores of 26 persons identified as meeting criteria for definite malingered neurocognitive dysfunction (MND), were contrasted with the MMPI-2 scores of 29 persons who had suffered moderate or severe closed head injury. The Lees-Haley Fake Bad Scale (FBS) was the most sensitive MMPI-2 scale in discriminating the malingerers from the head-injured persons, with additional significant differences obtained on standard MMPI-2 clinical scales including Scales 1 (Hs), 2 (D), 3 (Hy), 7 (Pt), and 8 (Sc). Correlational analyses on a larger sample combining additional subjects with evidence of possible or probable MND, with the original sample and the head injured subjects, demonstrated the concurrent validity of the FBS, which correlated with the Portland Digit Recognition Test (PDRT), and with Scales 1 (Hs), 2 (D), 3 (Hy), and 7 (Pt) of the MMPI-2.		Larrabee, GJ (corresponding author), 630 S Orange Ave,S-202, Sarasota, FL 34236 USA.	glarrabee@aol.com					Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 1998, PSYCHOL ASSESSMENT, V10, P221, DOI 10.1037/1040-3590.10.3.221; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BERRY DTR, 1991, CLIN PSYCHOL REV, V11, P585, DOI 10.1016/0272-7358(91)90005-F; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Butcher J.N., 1992, ESSENTIALS MMPI 2 MM; BUTCHER JN, 1989, MANUAL ADM SCORING M, V2; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gass CS, 2001, ASSESSMENT, V8, P425, DOI 10.1177/107319110100800407; GOUGH H, 1957, CALIFORNIA PSYCHOL I; Gough H.G, 1950, J CONSULT PSYCHOL, V14, P408; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; Gouvier WD, 1999, STUD NEUROPSYCHOL DE, P27; Graham JR., 2000, MMPI 2 ASSESSING PER; Greene, 2000, MMPI 2 INTERPRETIVE; GREENE RL, 1997, CLIN ASSESSMENT MALI, P169; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HARTMAN DE, 1995, NEUROPSYCHOLOGICAL T; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; KELLER LS, 1992, ASSESSMENT CHRONIC P; Lanyon R.I, 1993, PSYCHOL ASSESSMENT, V5, P324; Lanyon RI, 2001, J PERS ASSESS, V76, P169, DOI 10.1207/S15327752JPA7601_10; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P139, DOI 10.1076/1385-4046(200002)14:1;1-8;FT139; LARRABEE GJ, 2002, UNPUB DETECTION MALI; LARRABEE GJ, IN PRESS ARCH CLIN N; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MILLER JS, 1995, CHEM ENG NEWS, V73, P30, DOI 10.1021/cen-v073n040.p030; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Pampel F. C., 2000, LOGISTIC REGRESSION; Paulhus D.L., 1991, MEASURES PERSONALITY, P17, DOI [DOI 10.1016/B978-0-12-590241-0.50006-X, 10.1016/B978-0-12-590241-0.50006-X, DOI 10.1016/b978-0-12-590241-0.50006-x]; PUTNAM SH, 1998, ANN M AM PSYCH ASS S; Rogers R., 1995, ASSESSMENT, V2, P81; ROSS SR, IN PRESS J CLIN EXPT; Salekin R. T., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; TRAHAN DE, 1988, PROFESSIONAL MANUAL; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594	56	71	71	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2003	17	1					54	68		10.1076/clin.17.1.54.15627			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	707XM	WOS:000184535300005	12854011				2021-06-18	
J	Feeney, TJ; Ylvisaker, M				Feeney, TJ; Ylvisaker, M			Context-sensitive behavioral supports for young children with TBI - Short-term effects and long-term outcome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior disorders; cognitive-bebavioral intervention; ecological validity; functional assessment; multicomponent intervention; pediatric rehabilitation; positive behavior support; school-based treatment; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE INJURY; CLOSED-HEAD INJURY; ADOLESCENTS; FAMILY; PREDICTORS; SEVERITY; RECOVERY; REHABILITATION; DISABILITY	Objective: To investigate the effects of a multicomponent cognitive-behavioral intervention on the challenging behavior of two young children with growing behavioral concerns after traumatic brain injury. Design. Single-subject reversal designs were used to document the effects of the intervention on the specific dependent variables. In addition, qualitative data were collected to determine the children's long-term outcome and staff evaluations of the intervention. Participants: Both children were normally developing before injury at age 5 years. Both experienced increasing behavior problems as expectations in school escalated. Main Outcome Measures: Quantitative data included frequency and intensity of,aggression and amount of work completed. Qualitative data included children's general engagement in school work and peer interaction and staff evaluations of the intervention. Intervention: The intervention-included components of positive behavior supports, cognitive supports, and an executive function routine. Results: The targeted challenging behaviors were reduced to near zero with decreased intensity. Long-term outcome was positive. Conclusions: These results illustrate the potential for successfully treating behavior disorders in young children With traumatic brain injury using a support-oriented intervention that combines behavioral and cognitive components.	Wildwood Inst, Schenectady, NY 12305 USA; Coll St Rose, Sch Educ, Albany, NY USA	Feeney, TJ (corresponding author), Wildwood Inst, 219 Liberty, Schenectady, NY 12305 USA.		Berger, Emily/N-7268-2017	Berger, Emily/0000-0001-5550-807X			Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Barlow D.H., 1984, SINGLE CASE EXPT DES; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; BIJOU SW, 1968, J APPL BEHAV ANAL, V1, P175, DOI 10.1901/jaba.1968.1-175; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bogdan R., 1984, INTRO QUALITATIVE RE; BRAGA LW, UNPUB REHABIL PSYCHO; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; Bronson MB, 2000, SELF-REGULATION IN EARLY CHILDHOOD, P1; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Carr E.G., 1994, COMMUNICATION BASED; Carr EG, 2002, J POSIT BEHAV INTERV, V4, P4, DOI 10.1177/109830070200400102; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; COSTEFF H, 1985, SCAND J REHABIL MED, P10; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; DURAND M, 1992, MOTIVATION ASSESSMEN; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; FEENEY T, 1997, STUDENTS ACQUIRED BR, P229; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Glesne C., 1992, BECOMING QUALITATIVE; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Harchik A E, 1993, Ann Clin Psychiatry, V5, P151, DOI 10.3109/10401239309148979; HEBB DO, 1947, AM PSYCHOL, V2, P737; KEPPEL G, 1991, DESIGN ANAL INVESTIG; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kolb B., 1995, BRAIN PLASTICITY BEH; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; MACE FC, 1990, J EXP ANAL BEHAV, V54, P163, DOI 10.1901/jeab.1990.54-163; Mace FC, 1997, J APPL BEHAV ANAL, V30, P1, DOI 10.1901/jaba.1997.30-1; MARLOWE WB, 1990, J CLIN EXP NEUROPSYC, V12, P105; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; REICHLE J, 1993, COMMUNICATIVE ALTERN; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; SCHWARTZ L, 2002, IN PRESS J PEDIAT PS; Singh N. N., 1994, ABERRANT BEHAV CHECK; Sternberg RJ., 1993, TRANSFER TRIAL INTEL; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 2002, IN PRESS NEUROPSYCHO, V16; TAYLOR HG, IN PRES J INT NEUROP; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P221; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, IN PRESS BRAIN DISOR; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271; Ylvisaker Mark, 2002, Pediatr Rehabil, V5, P51, DOI 10.1080/1363849021000041891; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	82	71	71	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2003	18	1					33	51		10.1097/00001199-200301000-00006			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	641RR	WOS:000180760200006	12802236				2021-06-18	
J	Hofstetter, HH; Sewell, DL; Liu, F; Sandor, M; Forsthuber, T; Lehmann, PV; Fabry, Z				Hofstetter, HH; Sewell, DL; Liu, F; Sandor, M; Forsthuber, T; Lehmann, PV; Fabry, Z			Autoreactive T cells promote post-traumatic healing in the central nervous system	JOURNAL OF NEUROIMMUNOLOGY			English	Article						experimental allergic encephalomyelitis; myelin oligodendrocyte antigen; Cytokines; Th1/Th2; central nervous system; post-traumatic healing	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY BRAIN-LESIONS; PERTUSSIS TOXIN; BASIC-PROTEIN; IN-VITRO; BORDETELLA-PERTUSSIS; MULTIPLE-SCLEROSIS; ENDOTHELIAL-CELLS	In general, autoimmune responses are considered harmful to the host. In the best-defined model of autoimmune disease, murine experimental allergic encephalomyelitis (EAE), for example, brain-protein-specific autoimmune responses of both major classes, type-1 and type-2, have been implicated in causing brain pathology. We induced type-1 and type-2 autoimmunity to myelin oligodendrocyte protein (MOG) in C57.BL/6 mice. Instead of using pertussis toxin (PTX) to open the blood-brain barrier (131313), which is the classic procedure, we set an aseptic cerebral injury (ACI) to see what the consequences of pre-primed, autoreactive type-1 and type-2 memory T cells gaining access to the brain in the course of sterile tissue injury would be. Neither of these autoimmune response types induced pathology; on the contrary, both accelerated re-vascularization and post-traumatic healing. The data suggest that induction of either type-1 or type-2 autoimmune responses is not inherently noxious to the host, but can have beneficial effects on tissue repair. Autoimmune pathology may develop only if molecules of microbial origin such as pertussis toxin additionally induce the "infectious nonself/danger" reaction in the antigen-presenting cells (APC) of the target organ itself. (C) 2002 Elsevier Science B.V. All rights reserved.	Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA	Lehmann, PV (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, 10900 Euclid Ave,BRB 929, Cleveland, OH 44106 USA.			/0000-0003-0692-7125	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI/DK 44484, AI-42635] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK-48799] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37570-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI042635, R21AI044484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R29DK048799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570, R56NS037570] Funding Source: NIH RePORTER		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abdul-Majid KB, 2000, J NEUROIMMUNOL, V111, P23, DOI 10.1016/S0165-5728(00)00360-X; Anderson AC, 2000, J EXP MED, V191, P761, DOI 10.1084/jem.191.5.761; Arimoto H, 2000, J NEUROIMMUNOL, V104, P15, DOI 10.1016/S0165-5728(99)00242-8; Bauer J, 1998, AM J PATHOL, V153, P715, DOI 10.1016/S0002-9440(10)65615-5; Becker KJ, 1997, P NATL ACAD SCI USA, V94, P10873, DOI 10.1073/pnas.94.20.10873; Blankenhorn EP, 2000, J IMMUNOL, V164, P3420, DOI 10.4049/jimmunol.164.6.3420; Brabb T, 1997, J IMMUNOL, V159, P497; Brocke S, 1998, NATURE, V392, P630, DOI 10.1038/33465; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; BROSNAN CF, 1981, J IMMUNOL, V126, P614; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1979, LAB INVEST, V40, P74; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; DEROSBO NK, 1995, EUR J IMMUNOL, V25, P985, DOI 10.1002/eji.1830250419; EFRON JE, 1990, J SURG RES, V48, P460, DOI 10.1016/0022-4804(90)90013-R; Ehrlich P, 1900, P R SOC            B, V66, P424, DOI DOI 10.1098/RSPL.1899.0121; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Ferber IA, 1996, J IMMUNOL, V156, P5; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Fukushi J, 1998, BIOCHEM BIOPH RES CO, V250, P444, DOI 10.1006/bbrc.1998.9334; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GRENIERBROSSETTE N, 1991, IMMUNOPHARMACOLOGY, V21, P109, DOI 10.1016/0162-3109(91)90014-P; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Heeger PS, 2000, J IMMUNOL, V164, P5771, DOI 10.4049/jimmunol.164.11.5771; HINRICHS DJ, 1987, J EXP MED, V166, P1906, DOI 10.1084/jem.166.6.1906; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Karulin AY, 2000, J IMMUNOL, V164, P1862, DOI 10.4049/jimmunol.164.4.1862; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; KHORUTS A, 1995, J IMMUNOL, V155, P5011; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; Kumar R, 1998, INT J ONCOL, V12, P749; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; LEE JM, 1955, P SOC EXP BIOL MED, V89, P263; Lehmann PV, 1998, IMMUNOL REV, V164, P53, DOI 10.1111/j.1600-065X.1998.tb01207.x; Limmer A, 1998, EUR J IMMUNOL, V28, P2395, DOI 10.1002/(SICI)1521-4141(199808)28:08<2395::AID-IMMU2395>3.0.CO;2-D; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mendel I, 1996, EUR J IMMUNOL, V26, P2470, DOI 10.1002/eji.1830261030; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OURY TD, 1993, J BIOL CHEM, V268, P15394; Pakala SV, 1997, J EXP MED, V186, P299, DOI 10.1084/jem.186.2.299; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; Ryan M, 1998, INT IMMUNOL, V10, P651, DOI 10.1093/intimm/10.5.651; STEINMAN L, 1995, CELL, V80, P7, DOI 10.1016/0092-8674(95)90443-3; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x; SUDWEEKS JD, 1993, P NATL ACAD SCI USA, V90, P3700, DOI 10.1073/pnas.90.8.3700; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Targoni OS, 1998, J EXP MED, V187, P2055, DOI 10.1084/jem.187.12.2055; Torre D, 1996, FEMS IMMUNOL MED MIC, V13, P95; Willenborg DO, 1996, J IMMUNOL, V157, P3223; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yip HC, 1999, J IMMUNOL, V162, P3942	58	71	75	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	JAN	2003	134	1-2					25	34	PII S0165-5728(02)00358-2	10.1016/S0165-5728(02)00358-2			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	637JV	WOS:000180508700003	12507769				2021-06-18	
J	Slade, A; Tennant, A; Chamberlain, MA				Slade, A; Tennant, A; Chamberlain, MA			A randomised controlled trial to determine the effect of intensity of therapy upon length of stay in a neurological rehabilitation setting	JOURNAL OF REHABILITATION MEDICINE			English	Article						cerebrovascular accident; brain injuries; length of stay; intensity; rehabilitation; treatment outcomes; delivery of health care; rehabilitation centres; physical therapy	STROKE PATIENTS; BRAIN-INJURY; DISCHARGE; NHS	A randomised single-blind controlled trial was designed to determine whether intensity of therapy (physiotherapy and occupational therapy) shortened length of stay for patients in a rehabilitation unit. Patients were under 65, primarily with stroke, but also with other conditions such as traumatic brain injury, and multiple sclerosis. The experimental group were timetabled to receive 67% more therapy in any given week, than the control group. After controlling for confounders and case mix (as expressed by type of therapy required) patients in the experimental group showed a significant 14-day reduction in length of stay (<0.01). Concurrently average length of stay was increased for both groups by 16 days due to delays in discharge.	Univ Leeds, Rheumatol & Rehabil Res Unit, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9NZ, W Yorkshire, England	Slade, A (corresponding author), Univ Leeds, Rheumatol & Rehabil Res Unit, Acad Unit Musculoskeletal & Rehabil Med, 36 Clarendon Rd, Leeds LS2 9NZ, W Yorkshire, England.		Slade, Anita/M-3246-2017	Slade, Anita/0000-0003-2827-7741			Andrews K, 1991, CLIN REHABIL, V5, P5, DOI DOI 10.1177/026921559100500102; ANDRICH D, RUMM WINDOWS PROGRAM; ANDRICH D, 1991, APPL LATENT TRAIT LA, P59; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; De Weerdt W, 2002, LANCET, V359, P182, DOI 10.1016/S0140-6736(02)07461-5; DENNIS M, 1994, BMJ-BRIT MED J, V309, P1273, DOI 10.1136/bmj.309.6964.1273; Feachem RGA, 2002, BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; GLADMAN JRF, 1993, J NEUROL NEUROSUR PS, V56, P960, DOI 10.1136/jnnp.56.9.960; Green J, 2002, LANCET, V359, P199, DOI 10.1016/S0140-6736(02)07443-3; Hair J.F, 1998, MULTIVARIATE DATA AN; Hakim EA, 1998, CLIN REHABIL, V12, P151, DOI 10.1191/026921598676265330; Hands B, 2001, J Appl Meas, V2, P101; HENNEKENS H, 1987, EPIDEMIOLOGY MED, P287; HUTCHESON G, 1999, MULTIVARIATE SOCIAL, P55; KALRA L, 1994, STROKE, V25, P821, DOI 10.1161/01.STR.25.4.821; KINNEAR P, 1997, SPSS WINDOWS MADE SI, P105; KOKMEN E, 1987, MAYO CLIN PROC, V62, P281, DOI 10.1016/S0025-6196(12)61905-3; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Munjal RK, 2000, CLIN REHABIL, V14, P203, DOI 10.1191/026921500674191340; NORUSIS MJ, 1997, SPSS 7 5 GUIDE DATA, P445; Rasch G., 1980, PROBABILISTIC MODELS; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; SMITH EV, 2000, J APPL MEASUREMENT, V3, P303; STOKES LT, 1999, CLIN REHABIL, V13, P3; Treasure T, 1998, BRIT MED J, V317, P362; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	34	71	77	0	9	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV 1	2002	34	6					260	266		10.1080/165019702760390347			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	606PL	WOS:000178742300003	12440799	DOAJ Gold			2021-06-18	
J	Vickers, JC; Craig, JE; Stankovich, J; McCormack, GH; West, AK; Dickinson, JL; McCartney, PJ; Coote, MA; Healey, DL; Mackey, DA				Vickers, JC; Craig, JE; Stankovich, J; McCormack, GH; West, AK; Dickinson, JL; McCartney, PJ; Coote, MA; Healey, DL; Mackey, DA			The apolipoprotein epsilon 4 gene is associated with elevated risk of normal tension glaucoma	MOLECULAR VISION			English	Article							RETINAL GANGLION-CELLS; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; OPTIC-NERVE; MACULAR DEGENERATION; NEURONAL DEGENERATION; MULTIPLE-SCLEROSIS; FAMILY HISTORY; ALLELE; PATHOLOGY	PURPOSE: Inheritance of a particular apolipoprotein E gene polymorphism, the epsilon4 allele, has been associated with elevated risk for Alzheimer's disease and a poor outcome following head injury. The neuronal injury associated with Alzheimer's disease and brain injury may have a number of similarities with the nerve cell changes associated with glaucoma. Thus, we have investigated the association of inheritance of apolipoprotein E allelic isoforms (epsilon2, epsilon3, and epsilon4) with relative risk for different forms of glaucoma. METHODS: Apolipoprotein E genotype was examined in a Tasmanian population sample comprised of glaucoma sufferers with elevated or normal intraocular pressure and compared to a control sample of elderly Tasmanians without glaucoma. RESULTS: Approximately twice as many normal tension (38.0%) and high tension (34.2%) glaucoma cases possessed an epsilon4 allele compared to control cases (18.9%). The odds of epsilon4 carriers having normal tension glaucoma were significantly greater than for epsilon3 homozygotes (odds ratio 2.45, 95% confidence interval {1.02-5.91}) even after adjusting for age and gender (odd ratio 2.87 {1.02-8.05}). The increased odds of high tension glaucoma among epsilon4 allele carriers were not significant (adjusted odds ratio 1.53 {0.64-3.68}). CONCLUSIONS: The data indicate that, in the Tasmanian population, inheritance of the epsilon4 allele is associated with elevated risk for glaucomatous changes that are not related to increased intraocular pressure.	Univ Tasmania, Sch Med, Hobart, Tas 7001, Australia; Flinders Med Ctr, Dept Ophthalmol, Bedford Pk, SA, Australia; Menzies Res Inst, Hobart, Tas, Australia; Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia	Vickers, JC (corresponding author), Univ Tasmania, Sch Med, GPO Box 252-29, Hobart, Tas 7001, Australia.		Dickinson, Joanne/J-7728-2014; Vickers, James C/J-7464-2014; Mackey, David A/H-5340-2014	Vickers, James C/0000-0001-5671-4879; Mackey, David A/0000-0001-7914-4709; Stankovich, Jim/0000-0001-9344-7749; Craig, Jamie/0000-0001-9955-9696; Dickinson, Joanne/0000-0003-4621-1703			Agresti A., 1990, CATEGORICAL DATA ANA; Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628; Aung T, 2002, HUM GENET, V110, P52, DOI 10.1007/s00439-001-0645-7; Bayer AU, 2002, AM J OPHTHALMOL, V133, P135, DOI 10.1016/S0002-9394(01)01196-5; Chapman J, 1999, ARCH NEUROL-CHICAGO, V56, P1484, DOI 10.1001/archneur.56.12.1484; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Craig JE, 2001, OPHTHALMOLOGY, V108, P1607, DOI 10.1016/S0161-6420(01)00654-6; CURCIO CA, 1993, ANN NEUROL, V33, P248, DOI 10.1002/ana.410330305; DAVIES DC, 1995, BRIT J OPHTHALMOL, V79, P596, DOI 10.1136/bjo.79.6.596; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Evangelou N, 1999, J NEUROL NEUROSUR PS, V67, P203, DOI 10.1136/jnnp.67.2.203; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901; Kuhrt H, 1997, J BRAIN RES, V38, P223; LEUBA G, 1995, NEUROPATH APPL NEURO, V21, P410, DOI 10.1111/j.1365-2990.1995.tb01078.x; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; McNaught AI, 2000, ARCH OPHTHALMOL-CHIC, V118, P900; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; QUIGLEY HA, 1995, AUST NZ J OPHTHALMOL, V23, P85, DOI 10.1111/j.1442-9071.1995.tb00135.x; REBECK GW, 1993, NEURON, V11, P575; Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901; Sack J, 1996, OPHTHALMIC GENET, V17, P209, DOI 10.3109/13816819609057895; SADUN AA, 1990, OPHTHALMOLOGY, V97, P9; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Schmidt S, 2000, MOL VIS, V6, P287; Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TRICK GL, 1989, ANN NEUROL, V26, P226, DOI 10.1002/ana.410260208; TSAI CS, 1991, ARCH OPHTHALMOL-CHIC, V109, P199, DOI 10.1001/archopht.1991.01080020045040; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; VICKERS JC, 1995, BRAIN RES, V680, P23, DOI 10.1016/0006-8993(95)00211-8; Vickers JC, 1997, AUST NZ J OPHTHALMOL, V25, P105, DOI 10.1111/j.1442-9071.1997.tb01290.x; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	40	71	73	0	5	MOLECULAR VISION	ATLANTA	C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA	1090-0535			MOL VIS	Mol. Vis.	OCT 14	2002	8	40					389	393					5	Biochemistry & Molecular Biology; Ophthalmology	Biochemistry & Molecular Biology; Ophthalmology	604EC	WOS:000178602300001	12379839	DOAJ Gold			2021-06-18	
J	Rousselet, E; Callebert, J; Parain, K; Joubert, C; Hunot, S; Hartmann, A; Jacque, C; Perez-Diaz, F; Cohen-Salmon, C; Launay, JM; Hirsch, EC				Rousselet, E; Callebert, J; Parain, K; Joubert, C; Hunot, S; Hartmann, A; Jacque, C; Perez-Diaz, F; Cohen-Salmon, C; Launay, JM; Hirsch, EC			Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP	EXPERIMENTAL NEUROLOGY			English	Article						Parkinson's disease; MPTP; TNF-alpha; inflammation; behavior; neuroprotection	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; VENTRICULAR CEREBROSPINAL-FLUID; GROWTH-FACTOR-ALPHA; CLOSED-HEAD INJURY; BRAIN INJURY; IN-VITRO; DOPAMINERGIC-NEURONS; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; PROLONGED ACTIVATION	The loss of dopaminergic neurons in Parkinson's disease is associated with a glial reaction and the overproduction of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha). TNF-alpha acts via two different receptors, TNFR1 and TNFR2, and is believed to have both a neuroprotective and a deleterious role for neurons. In order to analyze the putative role of TNF-a in parkinsonism, we compared the effect of the parkinsonian drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice lacking TNFR1, TNFR2, or both receptors and in wild-type littermates. We show that MPTP does not affect spontaneous activity or anxiety in any of the groups and that it reduces motor activity on a rotarod in double knock out mice but not in mice lacking only one receptor. Postmortem analysis revealed no differences in the number of nigral dopaminergic neurons whatever the group. In contrast, striatal dopamine level was slightly decreased in double knock-out mice and more reduced by MPTP in this group than in the other groups of mice. In addition, dopamine turnover was significantly more increased in double knock out mice after MPTP injection. These data suggest that TNF-a does not participate in the death of dopaminergic neurons in parkinsonism but that it slightly alters dopamine metabolism or the survival of dopaminergic terminals by a mechanism involving both receptors. (C) 2002 Elsevier Science (USA).	Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France; Hop La Pitie Salpetriere, CNRS, UMR 7593, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U495, F-75013 Paris, France; Hop La Pitie Salpetriere, IFR Neurosci, F-75013 Paris, France; Hop Lariboisiere, Serv Biochim, CR C Bernard, IFR6,AP HP, F-75010 Paris, France	Rousselet, E (corresponding author), Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France.		Hirsch, Etienne/AAC-7655-2019; callebert, jacques/L-4569-2017	Hirsch, Etienne/0000-0003-4823-276X; Hunot, Stephane/0000-0002-8266-5211			Akaneya Y, 1995, BRAIN RES, V704, P175, DOI 10.1016/0006-8993(95)01110-2; Aloe L, 1997, NEUROSCI LETT, V238, P65, DOI 10.1016/S0304-3940(97)00850-1; Appel E, 1997, NEUROREPORT, V8, P3309, DOI 10.1097/00001756-199710200-00023; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; BOLIN LM, 2001, SOC NEUR ABSTR; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bruce-Keller AJ, 1999, J NEUROIMMUNOL, V93, P53, DOI 10.1016/S0165-5728(98)00190-8; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cho I, 1999, NAT TOXINS, V7, P187, DOI 10.1002/1522-7189(200009/10)7:5<187::AID-NT58>3.0.CO;2-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Damier P, 1999, BRAIN, V122, P1421, DOI 10.1093/brain/122.8.1421; Declercq W, 1998, J IMMUNOL, V161, P390; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FORNO LS, 1992, PROG BRAIN RES, V94, P429; GAMACHE P, 1993, J CHROMATOGR-BIOMED, V614, P213, DOI 10.1016/0378-4347(93)80311-Q; Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO;2-G; Guo GJ, 2001, AM J PHYSIOL-RENAL, V280, pF777; HALE KK, 1995, CYTOKINE, V7, P26, DOI 10.1006/cyto.1995.1004; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; Hamre K, 1999, BRAIN RES, V828, P91, DOI 10.1016/S0006-8993(99)01273-1; Hirsch E C, 1999, Adv Neurol, V80, P9; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HOSKINS JA, 1989, NEUROPHARMACOLOGY, V28, P1389, DOI 10.1016/0028-3908(89)90015-4; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Jarskog LF, 1997, INT J DEV NEUROSCI, V15, P711, DOI 10.1016/S0736-5748(97)00029-4; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Krajcsi P, 1998, SEMIN CELL DEV BIOL, V9, P351, DOI 10.1006/scdb.1998.0244; Kurkowska-Jastrzebska I, 1999, ACTA NEUROBIOL EXP, V59, P1; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462; Lucas R, 1998, EUR J IMMUNOL, V28, P3577, DOI 10.1002/(SICI)1521-4141(199811)28:11<3577::AID-IMMU3577>3.0.CO;2-#; MACKAY F, 1994, J IMMUNOL, V153, P5274; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; McGuire SO, 2001, EXP NEUROL, V169, P219, DOI 10.1006/exnr.2001.7688; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; Mogi M, 1998, NEUROSCI LETT, V250, P25, DOI 10.1016/S0304-3940(98)00427-3; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 1999, NEUROSCI LETT, V268, P101, DOI 10.1016/S0304-3940(99)00388-2; MOGI M, 1995, NEUROSCI LETT, V193, P129, DOI 10.1016/0304-3940(95)11686-Q; MOGI M, 1995, J NEURAL TRANSM-PARK, V9, P87, DOI 10.1007/BF02252965; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nuovo GJ, 1996, MOL MED, V2, P358, DOI 10.1007/BF03401633; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Rozas G, 1997, BRAIN RES, V749, P188, DOI 10.1016/S0006-8993(96)01162-6; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; Shinpo K, 1999, BRAIN RES, V819, P170, DOI 10.1016/S0006-8993(98)01354-7; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SRIRAM K, 2001, SOC NEUR ABSTR; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TCHELINGERIAN JL, 1995, J NEUROCHEM, V65, P2377; Tomimoto H, 1996, ACTA NEUROPATHOL, V92, P281, DOI 10.1007/s004010050519; VONCOELLN R, 1995, DEV BRAIN RES, V89, P150, DOI 10.1016/0165-3806(95)00123-U; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wilde GJC, 2000, EUR J NEUROSCI, V12, P3863, DOI 10.1046/j.1460-9568.2000.00273.x; WILT SG, 1995, ANN NEUROL, V37, P381, DOI 10.1002/ana.410370315; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Yamada Y, 1998, AM J PATHOL, V152, P1577	82	71	76	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2002	177	1					183	192		10.1006/exnr.2002.7960			10	Neurosciences	Neurosciences & Neurology	598EY	WOS:000178263600017	12429221				2021-06-18	
J	Schwab, JM; Beschorner, R; Meyermann, R; Gozalan, F; Schluesener, HJ				Schwab, JM; Beschorner, R; Meyermann, R; Gozalan, F; Schluesener, HJ			Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury	JOURNAL OF NEUROSURGERY			English	Article						prostaglandin; oxidative stress; inflammation; tissue viability	ALZHEIMERS-DISEASE; INDUCIBLE CYCLOOXYGENASE; GENE DISRUPTION; HEAD-INJURY; EXPRESSION; INFLAMMATION; PROTEINS; NEURONS; COX-1; INDOMETHACIN	Object. Secondary damage after central nervous system (CNS) injury is driven in part by oxidative stress and CNS inflammation and is substantially mediated by cyclooxygenases (COXs). To date, the rapidly inducible COX-2 isoform has been primarily linked to inflammatory processes, whereas expression of COX-1 is confined to physiological functions. The authors report the differential localization of COX-1 in human traumatic brain injury (TBI). Methods. Differential cellular COX-1 protein expression profiles were analyzed following TBI in 31 patients and compared with neuropathologically unaltered control brains by using immunohistochemistry. In these patients with TBI, a significant increase of COX-1 protein expression by vessel endothelial and smooth-muscle cells and CD68(+) microglia/macrophages was observed to be strictly confined to the lesion. Accumulation of COX-1(+) microglia/macrophages in the lesion was already evident 6 hours postinjury, reaching maximal levels after several weeks and remaining elevated at submaximal levels for several months after injury. Furthermore, COX-1(+) cell clusters were located in the Virchow-Robin space during the leukocyte infiltration period from Days 4 to 8 after TBI. Double-labeling experiments confirmed coexpression of COX-1 by CD68(-) microglia/macrophages. The numbers of COX-1(+) vessel endothelial and smooth-muscle cells increased from Day 1, remaining at submaximal levels for months after injury. Conclusions. The prolonged accumulation of COX-1(-) microglia/macrophages that were restricted to perilesional areas affected by the acute inflammatory response points to a role of COX-1 in secondary injury. The authors have identified localized, accumulated COX-1 expression as a potential pharmacological target following TBI. Their results challenge the current paradigms of a selective COX-2 role in the postinjury inflammatory, response.	Univ Tubingen, Brain Res Inst, Sch Med, D-72076 Tubingen, Germany	Schwab, JM (corresponding author), Univ Tubingen, Brain Res Inst, Sch Med, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; Schwab, Jan/0000-0001-6784-4919			Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Becher B, 1996, GLIA, V18, P1; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Deininger MH, 1999, J NEUROIMMUNOL, V95, P202, DOI 10.1016/S0165-5728(98)00257-4; Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dubois RN, 1998, FASEB J, V12, P1063; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Graham E M, 1997, J Matern Fetal Med, V6, P1; HALL ED, 1996, NEUROTRAUMA, P1405; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hsu CY, 1996, NEUROTRAUMA, P1433; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Kaplan MD, 1997, J BIOL CHEM, V272, P18534, DOI 10.1074/jbc.272.30.18534; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim GP, 2000, J NEUROSCI, V20, P5709; MALLAT M, 1994, J LEUKOCYTE BIOL, V56, P416; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Roller A, 1999, BIOCHEM BIOPH RES CO, V259, P600, DOI 10.1006/bbrc.1999.0825; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; SANDERS K, 1987, AM J PHYSIOL, V234, pE209; Schwab JM, 2000, ACTA NEUROPATHOL, V99, P609, DOI 10.1007/s004010051170; Shillabeer G, 1998, METABOLISM, V47, P461, DOI 10.1016/S0026-0495(98)90060-9; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2; Wyss-Coray T, 2000, NAT MED, V6, P973, DOI 10.1038/79661; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003	55	71	72	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2002	96	5					892	899		10.3171/jns.2002.96.5.0892			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	547VT	WOS:000175353700011	12005397				2021-06-18	
J	Liu, WF; Wang, GP; Yakovlev, AG				Liu, WF; Wang, GP; Yakovlev, AG			Identification and functional analysis of the rat caspase-3 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; EMBRYONIC CORTICAL-NEURONS; CEREBELLAR GRANULE CELLS; TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS; ACTIVATION; EXPRESSION; INHIBITION; TRANSCRIPTION	Caspase-3 is the major effector in apoptosis triggered by various stimuli. Previous studies demonstrated a significant increase in transcriptional activity of the caspase-3 gene during neuronal apoptosis. Recent findings suggest that differential expression of the caspase-3 gene may underlie the regulation of apoptotic susceptibility during brain development and after acute injury to the mature brain. We identified and cloned the rat caspase-3 gene promoter, determined its structure, and examined its regulation during a course of apoptosis in PC 12 cells. Results demonstrate that this promoter lacks a TATA-box and contains a cluster of Sp1 elements and multiple transcription start sites. The first identified transcription start site is located 87-bp upstream from the first splicing site. A role of Sp1 elements in the regulation of caspase-3 promoter activity is demonstrated by the inhibition of Sp1 binding using mithramycin A. Results of deletion analysis show that an Ets-1-like element located between nucleotides -1646 and -1632 relative to the most extended transcription start site is necessary to achieve sustained transcriptional activity. Homology analysis revealed that the 5'-flanking region of the human caspase-3 gene exhibits significant similarity to a regulatory region of the rat gene.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA	Yakovlev, AG (corresponding author), Georgetown Univ, Dept Neurosci, Res Bldg,WP14,3970 Reservoir Rd NW, Washington, DC 20007 USA.	yakovlev@giccs.georgetown.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38941] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038941] Funding Source: NIH RePORTER		Allen JW, 1999, FASEB J, V13, P1875; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Chatterjee S, 2001, ANN NEUROL, V49, P345, DOI 10.1002/ana.71; Chen J, 1998, J NEUROSCI, V18, P4914; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; de Nigris F, 2001, CANCER RES, V61, P2267; Earle E, 2000, HUM MOL GENET, V9, P187, DOI 10.1093/hmg/9.2.187; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Esch F, 1998, J NEUROSCI, V18, P4083; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Haviv R, 1997, J NEUROSCI RES, V50, P69, DOI 10.1002/(SICI)1097-4547(19971001)50:1<69::AID-JNR8>3.0.CO;2-J; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; Kermer P, 1998, J NEUROSCI, V18, P4656; Kobayashi D, 2000, INT J HYPERTHER, V16, P471, DOI 10.1080/02656730050199322; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Namura S, 1998, J NEUROSCI, V18, P3659; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; OWENS GP, 1992, CANCER METAST REV, V11, P149, DOI 10.1007/BF00048061; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; Sanij E, 2001, BIOCHEM BIOPH RES CO, V287, P1003, DOI 10.1006/bbrc.2001.5680; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WEIS L, 1992, FASEB J, V6, P3300; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; YAKOVLEV AG, 1995, J BIOL CHEM, V270, P6421, DOI 10.1074/jbc.270.12.6421; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300	45	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8273	8278		10.1074/jbc.M110768200			6	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	528WR	WOS:000174268000084	11773055	Other Gold			2021-06-18	
J	Matsushita, Y; Bramlett, HM; Alonso, O; Dietrich, WD				Matsushita, Y; Bramlett, HM; Alonso, O; Dietrich, WD			Posttraumatic hypothermia is neuroprotective in a model of traumatic brain injury complicated by a secondary hypoxic insult	CRITICAL CARE MEDICINE			English	Article						hypothermia; traumatic brain injury; hypoxia; histopathology; rat	CONTROLLED CORTICAL IMPACT; MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; HEAD-INJURY; DAMAGE; MILD; RATS; VULNERABILITY; HYPERTHERMIA; EXPRESSION	Objective: Human traumatic brain injury frequently results in secondary complications, including hypoxia. In previous studies, we have reported that posttraumatic hypothermia is neuroprotective and that secondary hypoxia exacerbates histopathologic outcome after fluid-percussion brain injury. The purpose of this study was to assess the therapeutic effects of mild (33 degreesC) hypothermia after fluid-percussion injury combined with secondary hypoxia. In addition, the importance of the rewarming period on histopathologic outcome was investigated. Design: Prospective experimental study in rats. Setting. Experimental laboratory in a university teaching hospital. Intervention: Intubated, anesthetized rats underwent normothermic parasagittal fluid-percussion brain injury (1.8-2.1 atmospheres) followed by either 30 mins of normoxia (n = 6) or hypoxic (n = 6) gas levels and by 4 hrs of normothermia (37 degreesC). In hypothermic rats, brain temperature was reduced immediately after the 30-min hypoxic insult and maintained for 4 hrs. After hypothermia, brain temperature was either rapidly (n = 6) or slowly (n = 5) increased to normothermic levels. Rats were killed 3 days after traumatic brain injury, and contusion volumes were quantitatively assessed. Measurements and Main Results: As previously shown, posttraumatic hypoxia significantly increased contusion volume compared with traumatic brain injury-normoxic animals (p < .02). Importantly, although posttraumatic hypothermia followed by rapid rewarming (15 mins) failed to decrease contusion volume, those animals undergoing a slow rewarming period (120 mins) demonstrated significantly (p < .03) reduced contusion volumes, compared with hypoxic normothermic rats. Conclusions: These data emphasize the beneficial effects of posttraumatic hypothermia in a traumatic brain injury model complicated by secondary hypoxia and stress the importance of the rewarming period in this therapeutic intervention.	Univ Miami, Sch Med, Dept Neurol, Miami Project Cure Paralysis,Neurotrauma Res Ctr, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis,Neurotrauma Res Ctr, POB 016960 R-48, Miami, FL 33101 USA.	ddietrich@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chesnut R M, 1995, New Horiz, V3, P366; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Dietrich WD, 1996, NEUROTRAUMA, P1491; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; *NIH, 1985, PUBL NIH; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PHILLIS JW, 1993, REGULATION CEREBRAL, P249; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; STATLER KD, IN PRESS NEUROTRAUMA; SUEHIRO E, IN PRESS J NEUROTRAU; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510; ZILLES L, 1985, CORTEX RAT STEREOTAX	50	71	73	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2001	29	11					2060	2066		10.1097/00003246-200111000-00004			7	Critical Care Medicine	General & Internal Medicine	490WL	WOS:000172076700004	11700395				2021-06-18	
J	Bazarian, JJ; Atabaki, S				Bazarian, JJ; Atabaki, S			Predicting postconcussion syndrome after minor traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	SAEM Annual Meeting	MAY, 2000	SAN FRANCISCO, CA	SAEM		traumatic brain injury; brain concussion; postconcussion syndrome; logistic regression; recursive partitioning; decision rule	HEAD-INJURY; SYMPTOMS; SEQUELAE; RULES	Background: Up to 50% of patients with minor traumatic brain injury (mTBI) develop postconcussion syndrome (PCS). A decision rule to stratify risk for PCS is needed. Objective: To identify mTBI patients at low and high risk of PCS by comparing the predictive values of variables generated by logistic regression (LR) and recursive partitioning (RP). Methods: This was a prospective, observational study of 69 mTBI patients aged > 16 years presenting to the emergency department of a university teaching hospital. Minor TBI was defined as loss of consciousness < 10 minutes or amnesia, Glasgow Coma Scale score (GCS) of 15, no skull fracture on physical examination, nonfocal neurologic exam, and no brain injury on computed tomography if one was done. Clinical/demographic data and the results of a brief neurobehavioral test battery were collected for all patients. The presence of PCS was determined by a validated telephone questionnaire at one month after initial presentation. All variables were subjected to both LR and RP. Results: Fifty-eight percent had PCS at one month after initial presentation. Low risk: PCS occurred in 9% of men scoring > 24 on the Hopkins Verbal Learning A (HVLA) (by LR) and in 9% of those injured in sports scoring > 22 on HVLA (RP). High risk: PCS occurred in 89% of women scoring <9 on the Digit Span test (LR) and in 92% of those injured via falls or motor vehicle collision scoring < 11.5 on HVLB2 (RP). Conclusions: Despite the high incidence of PCS, we were able to identify a low-risk subgroup with an average PCS risk of < 10% and a high-risk subgroup with a PCS risk of similar to 90%. Combining results from LR and RP expanded the number of patients able to be classified as high/low risk. Prospective validation is necessary.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; George Washington Univ, Sch Med, Washington, DC USA; Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu					*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P704; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; COOK EF, 1984, J CHRON DIS, V37, P721, DOI 10.1016/0021-9681(84)90041-9; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; Hadzikadic M, 1996, ARTIF INTELL MED, V8, P493, DOI 10.1016/S0933-3657(96)00356-9; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; MCCONNOCHIE KM, 1993, MED DECIS MAKING, V13, P30, DOI 10.1177/0272989X9301300105; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Olshen RA, 1984, CLASSIFICATION REGRE; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAUBERTAS RF, 1994, MED DECIS MAKING, V14, P169, DOI 10.1177/0272989X9401400209; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Tsien CL, 1998, ST HEAL T, V52, P493; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	28	71	71	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2001	8	8					788	795		10.1111/j.1553-2712.2001.tb00208.x			8	Emergency Medicine	Emergency Medicine	459VR	WOS:000170272600003	11483453				2021-06-18	
J	Boake, C; Millis, SR; High, WM; Delmonico, RL; Kreutzer, JS; Rosenthal, M; Sherer, M; Ivanhoe, CB				Boake, C; Millis, SR; High, WM; Delmonico, RL; Kreutzer, JS; Rosenthal, M; Sherer, M; Ivanhoe, CB			Using early neuropsychologic testing to predict long-term productivity outcome from traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; craniocerebral trauma; neuropsychologic tests; prognosis; rehabilitation	COMA-DATA-BANK; HEAD-INJURY; AMNESIA; RETURN; WORK	Objective: To evaluate whether early neuropsychologic testing is useful in predicting long-term productivity outcome after traumatic brain injury (TBI). Design: Validation cohort prediction study. Setting: Four inpatient brain injury rehabilitation programs participating in the Traumatic Brain Injury Model Systems project. Participants: A total or 293 adults with nonpenetrating TBI. Main Outcome Measures: Fifteen neuropsychologic tests were administered to patients who emerged from posttraumatic amnesia before rehabilitation discharge. Test scores were classified in the normal range or impaired range, using objective criteria. Outcome was defined as productive if the patient was competitively employed or enrolled full time in regular education. Results: Productivity at follow-up was predicted by completion of at least 1 neuropsychologic test before discharge, by an injury-test interval of less than 2 months, and by normal range scores on 10 of the 15 neuropsychologic tests, Normal range scores on these tests increased the probability of a productive outcome by 40% to 130%. Conclusions: Neuropsychologic testing can help predict long-term productivity even when performed before discharge from inpatient rehabilitation and at variable injury-test intervals. Early testing should be interpreted in relation to injury-test interval. Because tests of multiple neuropsychologic domains predicted outcome, comprehensive evaluations might be more useful in predicting outcome. (C) 2001 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	TIRR, Houston, TX 77030 USA; Univ Texas, Dept Phys Med, Baylor Coll Med, Sch Med, Houston, TX USA; Univ Texas, Dept Rehabil Alliance, Baylor Coll Med, Sch Med, Houston, TX USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Kaiser Fdn, Rehabil Ctr, Vallejo, CA USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Mississippi Methodist Rehabil Ctr, Jackson, MS USA	Boake, C (corresponding author), TIRR, 1333 Moursund, Houston, TX 77030 USA.						Benton A., 1976, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Caplan B, 1996, J HEAD TRAUMA REHAB, V11, P1; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CRIPE LI, 1989, REHABIL PSYCHOL, V34, P93; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1993, PSYCHOLOGICAL ASSESS; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Millis S R, 1994, Int J Neurosci, V79, P165; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Smith A., 1973, SYMBOL DIGIT MODALIT; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; *TRAUM BRAIN INJ M, 1998, TRAUM BRAIN INJ MOD; Walsh K., 1987, NEUROPSYCHOLOGY CLIN; Wechsler D., 1987, WECHSLER MEMORY SCAL; WECHSLER D, 1981, WEEHSLER ADULT INTEL; 1999, J HEAD TRAUMA REHABI, V14, P189	30	71	72	0	14	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2001	82	6					761	768		10.1053/apmr.2001.23753			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	439KK	WOS:000169115900008	11387580				2021-06-18	
J	Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J				Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J			Outcome from mild head injury in young children: A prospective study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; BEHAVIORAL SEQUELAE; ADOLESCENTS; TOMOGRAPHY	There is a lack of agreement regarding the long-term consequences of mild head injury (HI) at any age, with such effects rarely studied in early childhood. Given the rapid development occurring within the brain during this period, any disruption may have the potential to cause transient or permanent damage to brain structure and function. The present study sought to investigate the behavioral implications of such potential disruptions using a prospective, longitudinal design. Children aged 3-7 years at the time of injury, and suffering from mild HI, were evaluated acutely and at 6 and 30 months post-injury. Pre-injury data were collected with respect to communication, social skills, daily living skills and behavioral function. Results were compared to those from a non-injured control sample matched for age, gender, socioeconomic status, and pre-injury function. Findings showed few group differences. Children with mild HI performed similarly to controls on measures of intellectual ability, receptive language, and both everyday and spatial memory capacity. Group differences were identified for verbal fluency and story recall, with HI children failing to recover over time.	Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Anderson, V (corresponding author), Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia.	v.anderson@psych.unimelb.edu.au					ALVES W, 1992, STATE ARTS REV, V6, P21; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 1995, NEUROPSYCHOLOGICAL A; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; BIJUR PE, 1990, PEDIATRICS, V86, P337; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; CARROWWOOLFOLK E, 1985, EXAMINERS MANUAL TES; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dunn L., 1981, PEABODY PICTURE VOCA; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; EVANS RW, 1992, NEUROL CLIN, V10, P815; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GARDNER M, 1979, MANUAL EXPRESSIVE 1; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HAYES R, 1994, BRAIN, V109, P251; HAYES RL, 1992, PHYS MED REHAB STATE, V6, P9; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Klonoff P., 1996, CLIN NEUROPSYCHOL, V12, P31; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LACHAR D, 1992, PERSONALITY INVENT S; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; McCarthy D., 1972, MANUAL MCCARTHY SCAL; Miller L, 1996, J COGNITIVE REHABILI, V15, P8; MOYES CD, 1980, CHILD CARE HLTH DEV, V6, P1, DOI 10.1111/j.1365-2214.1980.tb00791.x; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PENTLAND L, 2000, CHILD NEUROPSYCHOLOG; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1991, MANUAL WECHSLER SCAL; WECHSLER D, 1987, MANUAL PRESCHOOL PRI; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; YEATES K, 1999, PEDIAT NEUROPSYCHOLO, P192	53	71	71	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					705	717		10.1076/jcen.23.6.705.1015			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200001	11910538				2021-06-18	
J	Bryant, RA				Bryant, RA			Posttraumatic stress disorder and mild brain injury: controversies, causes and consequences	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; COGNITIVE-BEHAVIORAL THERAPY; MOTOR-VEHICLE ACCIDENTS; ROAD TRAFFIC ACCIDENTS; CONTROLLED TRIAL; ANXIETY; HYPOCHONDRIASIS; SYMPTOMS; MODEL; PTSD	Posttraumatic stress disorder (PTSD) is an anxiety condition that often arises following a traumatic experience. It has commonly been argued that impaired consciousness associated with mild brain injury (MBI) precludes encoding of the traumatic experience, and this prevents PTSD development. This review considers the available evidence on PTSD following MBI and indicates the distinctive nature of PTSD after MBI. The review then discusses the possible mechanisms that may mediate PTSD in this population. The interaction of PTSD and postconcussive symptoms is discussed within a cognitive model that emphasizes the role of catastrophic interpretations of postconcussive symptoms. Finally, the implications of PTSD after MBI for assessment and treatment are reviewed.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant R.A., 2000, ACUTE STRESS DISORDE; Bryant RA, 1995, INT J PSYCHOPHYSIOL, V20, P209, DOI 10.1016/0167-8760(95)00036-4; BRYANT RA, 1995, J ABNORM PSYCHOL, V104, P537, DOI 10.1037/0021-843X.104.3.537; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2000, AGGRESS VIOLENT BEH, V5, P79, DOI 10.1016/S1359-1789(98)00021-4; BRYANT RA, IN PRESS CLIN PSYCHO; CARR DB, 1984, J CLIN PSYCHIAT, V45, P323; Clark DM, 1998, BRIT J PSYCHIAT, V173, P218, DOI 10.1192/bjp.173.3.218; CLARK DM, 1988, PANIC PSYCHOL PERSPE, P71; DEITZ J, 1992, J AM ACAD PSYCHOAN, V20, P277, DOI 10.1521/jaap.1.1992.20.2.277; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EIFERT GH, 1992, BEHAV RES THER, V30, P329, DOI 10.1016/0005-7967(92)90045-I; Eifert GH, 2000, BEHAV RES THER, V38, P1039, DOI 10.1016/S0005-7967(99)00132-1; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY JP, 1986, INT J CLIN NEUROPSYC, V8, P65; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1996, COGNITIVE THER RES, V20, P613, DOI 10.1007/BF02227964; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P500, DOI 10.1037/0022-006X.66.3.500; Harvey AG, 1999, J NERV MENT DIS, V187, P443, DOI 10.1097/00005053-199907000-00009; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HARVEY AG, IN PRESS J TRAUMATIC; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; KRYSTAL JH, 1989, BEHAV THER, V20, P177, DOI 10.1016/S0005-7894(89)80068-1; Ledoux J E, 1989, J Cogn Neurosci, V1, P238, DOI 10.1162/jocn.1989.1.3.238; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Marcus DK, 1999, J PSYCHOSOM RES, V47, P79, DOI 10.1016/S0022-3999(99)00008-2; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCNALLY RJ, 1990, PSYCHOL BULL, V108, P403, DOI 10.1037/0033-2909.108.3.403; Middelboe T., 1992, European Psychiatry, V7, P183; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Pitman RK, 1997, ANN NY ACAD SCI, V821, P1, DOI 10.1111/j.1749-6632.1997.tb48264.x; Price K. P., 1994, DEF LAW J, V43, P113; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Reiss S., 1985, THEORETICAL ISSUES B, P107; RUTHERFORD WH, 1989, NEUROBEHAVIORAL RECO, P217; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1992, NEUROLAW LETT   0503; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Schmidt NB, 1999, J ABNORM PSYCHOL, V108, P532, DOI 10.1037/0021-843X.108.3.532; SIVEC HJ, 1995, CLIN PSYCHOL REV, V15, P297, DOI 10.1016/0272-7358(95)00012-E; Smith K, 2000, BEHAV RES THER, V38, P709, DOI 10.1016/S0005-7967(99)00096-0; SOLOMON SD, 1990, COMPR PSYCHIAT, V31, P227, DOI 10.1016/0010-440X(90)90006-E; Speckens A. E. M., 1997, BEHAV COGN PSYCHOTH, V25, P291; Tarrier N, 1999, J CONSULT CLIN PSYCH, V67, P13, DOI 10.1037/0022-006X.67.1.13; Van Der Kolk Bessel A., 1996, P214; Warda G, 1998, BEHAV RES THER, V36, P1171, DOI 10.1016/S0005-7967(98)00082-5; Warwick HMC, 1996, BRIT J PSYCHIAT, V169, P189, DOI 10.1192/bjp.169.2.189; YERAGANI V, 1989, ACTA PSYCHIAT SCAND, V79, P421	79	71	72	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					718	728		10.1076/jcen.23.6.718.1024			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200002	11910539				2021-06-18	
J	Daviss, WB; Racusin, R; Fleischer, A; Mooney, D; Ford, JD; McHugo, GJ				Daviss, WB; Racusin, R; Fleischer, A; Mooney, D; Ford, JD; McHugo, GJ			Acute stress disorder symptomatology during hospitalization for pediatric injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						acute stress disorder; injury	TRAUMATIC BRAIN INJURY; CHILDREN; SYMPTOMS; VICTIMIZATION; CONSEQUENCES; SEQUELAE; ATTACK	Objective: To examine and identity predictors of acute stress disorder (ASD) and ASD symptomatology (ASDS) in children hospitalized for injuries. Method: Fifty-four youths were assessed while hospitalized for injuries. Dependent variables were parent and nurse ratings of children's ASDS. Independent variables included children's prior trauma exposure and behavior problems, injury severity and permanence, brain injury, injury or death to family/friend(s), parental distress, and child reports of the injury/hospitalization experience as meeting criterion A for ASD. Results: A total of 92.6% of children felt the current experience met criterion A, compared with 64.8% of parents. According to parent questionnaires, 4 subjects (7.4%) met DSM-IV criteria for ASD while another 12 (22.2%) had clinically significant but subsyndromal ASDS. Children's ASDS, as reported by parents, correlated highly with parental distress and ratings of children's prior psychopathology, and modestly with injury severity and family/friend(s) injured or killed. Nurses' ratings of children's ASDS correlated strictly with injury- and accident-related variables, and not with parent ratings of children's ASDS. Conclusions: Children perceive injuries and hospitalizations as stressful. ASDS is widely though divergently reported by parents and nurses in children hospitalized for injury. Parental distress, children's prior psychopathology, and injury-related factors may be useful predictors of children's postinjury ASDS.	Dartmouth Med Sch, Psychiat Res Ctr, Lebanon, NH USA; Natl Ctr PTSD, White River Junction, VT USA	Daviss, WB (corresponding author), Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.						Achenbach T. M., 1991, MANUAL CHILD BEHAV C; ACHENBACH TM, 1991, PROGRAM MANUAL 1991; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BoneyMcCoy S, 1996, J CONSULT CLIN PSYCH, V64, P1406, DOI 10.1037/0022-006X.64.6.1406; BONEYMCCOY S, 1995, J CONSULT CLIN PSYCH, V63, P726, DOI 10.1037/0022-006X.63.5.726; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P610, DOI 10.1097/00004583-199705000-00011; Classen C, 1998, AM J PSYCHIAT, V155, P620, DOI 10.1176/ajp.155.5.620; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; EARLS F, 1988, J AM ACAD CHILD PSY, V27, P90, DOI 10.1097/00004583-198801000-00014; ENGEL NA, 1994, PSYCHOL REP, V75, P1251, DOI 10.2466/pr0.1994.75.3.1251; Ford JD, 1997, P INT SOC TRAUM STRE; Foy DW, 1996, J SCHOOL PSYCHOL, V34, P133, DOI 10.1016/0022-4405(96)00003-9; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; MARTINI DR, 1990, J AM ACAD CHILD PSY, V29, P70, DOI 10.1097/00004583-199001000-00012; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; MCKELVEY RS, 1999, SCI P 46 ANN M AM AC; NADER K, 1990, AM J PSYCHIAT, V147, P1526; Peterson L G, 1986, Adv Psychosom Med, V16, P84; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Rossman BBR, 1997, J AM ACAD CHILD PSY, V36, P1089; SANCHEZ R, 1998, SCI P 45 ANN M AM AC; SAXE G, 1997, P INT SOC TRAUM STRE; *SPSS, 1994, SPSS 6 1 BAS SYST 1; Suhr M A, 1986, Adv Psychosom Med, V16, P31	29	71	72	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAY	2000	39	5					569	575		10.1097/00004583-200005000-00010			7	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	308DC	WOS:000086694400010	10802974				2021-06-18	
J	McCrory, PR; Berkovic, SF				McCrory, PR; Berkovic, SF			Video analysis of acute motor and convulsive manifestations in sport-related concussion	NEUROLOGY			English	Article						concussion; traumatic brain injury; head injury; video analysis	MEMORY; AMNESIA; INJURY	Objectives: To describe the motor and convulsive manifestations in acute sports-related head injury. Methods: A total of 234 cases of concussive injuries during the 1995 through 1997 football seasons were obtained from the Australian Football League Medical Officers Association injury survey. Of these, 102 cases were recorded adequately on television videotape and were analyzed by two independent observers using a standardized recording form detailing injury mechanics and clinical features of the episodes. Motor and convulsive features were correlated with mechanical variables and with duration of loss of consciousness using linear modeling techniques. Results: Tonic posturing occurred in 25 subjects, clonic movements in 6, righting movement in 40, and gait unsteadiness in 42. In one subject the tonic and clonic features were sufficiently prolonged to be deemed a concussive convulsion. The only risk factor for tonic posturing using logistic regression was the presence of loss of consciousness (p = 0.0001). There was a trend toward facial impact being an independent predictor of tonic posturing but this did not reach significance. No other independent variable predicted the development of clonic movements, righting movements, or gait unsteadiness. Conclusions: Subtle motor manifestations such as tonic posturing and clonic movements commonly occur in concussion; the main predictive factor for tonic posturing is the presence of loss of consciousness. The authors speculate that these clinical features are due to brainstem dysfunction secondary to biomechanical forces inducing a transient functional decerebration.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Neurol, Heidelberg, Germany	McCrory, PR (corresponding author), 31 Grosvenor Parade, Balwyn, Vic 3108, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			Barth JT., 1989, MILD HEAD INJURY, P257; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GOLDBERG E, 1982, CORTEX, V18, P459, DOI 10.1016/S0010-9452(82)80042-7; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; JACKSON J, 1895, LANCET, V1, P274; Jackson J., 1871, BMJ-BRIT MED J, Vii, p[242, 528]; JACKSON J, 1871, BMJ-BRIT MED J, V2, P528; JACKSON JH, 1863, MED TIMES GAZ, V2, P65; JANE JA, 1985, TRAUMA CENTRAL NERVO, P27; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 1999, NEUROLOGY, V52, P1888, DOI 10.1212/WNL.52.9.1888; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; WESTPHAL CFO, 1871, BERLINER FKLIN WOCHE, V1, P39; WESTPHAL CFO, 1872, BRIT MED J, V1, P399; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863	30	71	72	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 11	2000	54	7					1488	1491		10.1212/WNL.54.7.1488			4	Clinical Neurology	Neurosciences & Neurology	304AT	WOS:000086460900019	10751264				2021-06-18	
J	Matz, PG; Fujimura, M; Chan, PH				Matz, PG; Fujimura, M; Chan, PH			Subarachnoid hemolysate produces DNA fragmentation in a pattern similar to apoptosis in mouse brain	BRAIN RESEARCH			English	Article						apoptosis; hemoglobin; oxidative injury; stroke; subarachnoid hemorrhage	LIPID-PEROXIDATION; HEMOGLOBIN; INDUCTION; RAT; HEMORRHAGE; ISCHEMIA; DAMAGE; STRESS; INJURY; GLIA	Stroke and traumatic brain/spinal cord injuries are often associated with hemorrhage. Despite the relative frequency of hemorrhage in the central nervous system (CNS), little is known about what role blood and hemoglobin (Hb) play in mediating cellular injury. Since Hb and hemolysate have been associated with generation of oxidative stress and cell injury, we examined whether apoptosis was present after cortical exposure to subarachnoid hemolysate. Subarachnoid hemorrhage (SAH) was induced in CD-1 mice (n = 25) by injection of 50 mu l of autologous hemolysate over the right parietal cortex. Saline-injected mice (n. = 13) were used as controls. Subjects were sacrificed at 24 h. Transcardiac perfusion fixation was performed on a subgroup of hemolysate- (n. = 15) and saline-injected (n = 9) animals. Sections were stained for DNA fragmentation using the terminal deoxyuridine nick end-labeling (TUNEL) method and also immunostained for the hemeoxygenase-1 (HO-1) protein to assess blood distribution In the remaining animals (n = 6 SAH, n = 4 saline), DNA was extracted and precipitated from 40 mg of tissue and subjected to electrophoresis on a 1.5% agarose gel. DNA fragmentation was evident on TUNEL staining in 10/15 subjects injected with hemolysate as compared to 0/9 subjects injected with saline (p < 0.01, Fisher exact test). TUNEL-positive cells were most abundant closest to the site of cortical SAH, as evidenced by HO-1 immunoreactivity. TUNEL-positive cells were also seen remotely in the hippocampus and basal forebrain. The presence of apoptosis was suggested by DNA laddering on electrophoresis in the hemolysate-injected subjects (4/6 animals). No laddering was evident in saline-injected subjects (rt = 4). These results provide evidence that the presence of subarachnoid blood products is associated with DNA fragmentation and apoptotic cell death. (C) 2000 Elsevier Science B.V. All rights reserved.	Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; Palo Alto Vet Affairs Hlth Care Syst, Surg Serv, Palo Alto, CA 94304 USA; Stanford Univ, Dept Neurol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Sch Med, Stanford, CA 94305 USA	Matz, PG (corresponding author), Vet Adm Med Ctr, Surg Serv 112N, 3801 Miranda Ave, Palo Alto, CA 94304 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS025372, P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543, NS36144, NS25372] Funding Source: Medline		BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; DELGADO TJ, 1985, STROKE, V16, P595, DOI 10.1161/01.STR.16.4.595; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; Kondo T, 1997, J NEUROSCI, V17, P4180; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MAINES MD, 1988, FASEB J, V2, P2557; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1996, J NEUROSURG, V85, P892, DOI 10.3171/jns.1996.85.5.0892; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; ROSEN AD, 1979, EXP NEUROL, V66, P277, DOI 10.1016/0014-4886(79)90080-3; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004	24	71	75	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 10	2000	858	2					312	319		10.1016/S0006-8993(99)02454-3			8	Neurosciences	Neurosciences & Neurology	292VB	WOS:000085814800009	10708682				2021-06-18	
J	Lewis, DW; Qureshi, F				Lewis, DW; Qureshi, F			Acute headache in children and adolescents presenting to the emergency department	HEADACHE			English	Article						acute headache; children; adolescents; occipital		Objectives.-Our goals were (1) to investigate the causes of acute headache in childhood from the emergency department perspective and (2) to search for clinical clues that might distinguish headache associated with serious underlying disease. Background.-The clinical presentation of headache in children and adolescents can be separated into 5 temporal patterns: acute, acute-recurrent, chronic progressive, chronic nonprogressive, and mixed. Few data exist regarding acute headache in children. Methods.-Consecutive children who presented to our emergency department with the abrupt onset of severe headache were prospectively evaluated. The headache character, location, severity, and associated symptoms, as well as underlying causes, were recorded using a standardized survey. Results.-One hundred fifty children, aged from 2 to 18 years, 87 boys and 63 girls, were enrolled over a 10-month period. Upper respiratory tract infection with fever (viral upper respiratory tract infection 39%, sinusitis 9%, streptococcal pharyngitis 9%) was the most frequently identified cause of acute headache (57%). Other causes included migraine (18%), viral meningitis (9%), posterior fossa tumors (2.6%), ventriculoperitoneal shunt malfunction (2%), epileptic seizure (postictal headache) (1.3%), concussion (postconcussive headache) (1.3%), intracranial hemorrhage (1.3%), and undetermined (7%). Two clinical features were found to have statistically significant associations with serious underlying disease: occipital location of headache anti an inability of the patient to describe the quality of the head pain. All children with surgically remediable conditions had clear and objective neurological signs. Conclusions.-In children and adolescents, the abrupt onset of severe headache is most frequently caused by upper respiratory tract infection with fever, sinusitis, or migraine. Special attention is warranted if the acute headache is occipital in location and if the affected patient is unable to describe the quality of the pain. Serious underlying processes such as brain tumor or intracranial hemorrhage are uncommon and, when present, are accompanied by multiple neurological signs (ataxia, hemiparesis, papilledema).	Childrens Hosp Kings Daughters, Eastern Virginia Med Sch, Dept Pediat, Norfolk, VA USA	Lewis, DW (corresponding author), Child & Adolescent Neurol, 850 Southampton Ave, Norfolk, VA 23510 USA.						Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; GILLES FH, 1991, J NEURO-ONCOL, V10, P31; KANDT RS, 1987, J CHILD NEUROL, V2, P22, DOI 10.1177/088307388700200104; ROTHNER AD, 1986, CONSULTANT, V26, P113	4	71	73	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAR	2000	40	3					200	203		10.1046/j.1526-4610.2000.00029.x			4	Clinical Neurology	Neurosciences & Neurology	296BB	WOS:000086002200003	10759922				2021-06-18	
J	Ghirnikar, RS; Lee, YL; Eng, LF				Ghirnikar, RS; Lee, YL; Eng, LF			Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						spinal cord injury; chemokine receptors; antagonist; vMIPII, apoptosis	CHEMOATTRACTANT PROTEIN-1 MCP-1; TRAUMATIC BRAIN INJURY; MESSENGER-RNA; RECEPTOR ANTAGONIST; APOPTOSIS; RECRUITMENT; INHIBITION; DEATH; MICE; DEGENERATION	Spinal cord injury is accompanied by an initial inflammatory reaction followed by secondary injury that is caused, in part, by apoptosis. Recruitment of leukocytes from the blood compartment to the site of inflammation in the injured spinal cord has been attributed to locally generated chemotactic agents (cytokines and chemokines). In addition to upregulation in the message levels of a number of chemokines, we have found up-regulation in the message levels of several chemokine receptors following spinal cord contusion injury. To reduce the inflammatory response after spinal cord injury, we have blocked the interaction of chemokine receptors with their ligands using the vMIPII chemokine antagonist. Using a rat model of spinal cord contusion injury, we show that continuous infusion of the antagonist for up to 7 days;results in a decrease in infiltrating hematogenous cells at the site of injury. Histological evaluation ofthe tissue showed fewer activated macrophages at the site of injury. Concomitantly, reduced neuronal loss and gliosis were observed in the antagonist infused spinal cord. In addition, increased expression of Bcl-2 gene, an endogenous inhibitor of apoptosis, was seen in the antagonist infused spinal cord at 7 days post injury. Morphologically, staining with the bisbenzamide dye Hoechst 33342 showed significantly more apoptotic bodies in the vehicle compared to antagonist infused spinal cord. Our data suggest that chemokine antagonist infusion post-injury results in limiting the inflammatory response following spinal cord contusion injury, thereby attenuating neuronal loss, possibly due to decreased apoptosis. These findings support the contention that disrupting chemokine interactions with their receptors may be an effective approach in reducing the secondary damage after spinal cord injury. Published 2000 Wiley-Liss, Inc.(dagger).	VAPA Hlth Care Syst, Dept Pathol, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Stanford, CA USA	Eng, LF (corresponding author), VAPA Hlth Care Syst, Dept Pathol, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	lfeng@leland.stanford.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 94304] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-11632] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R33CA094304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS011632] Funding Source: NIH RePORTER		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; ANDERSON DK, 1992, J NEUROTRAUM, V9, P143, DOI 10.1089/neu.1992.9.143; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BROADWELL RD, 1994, MICROSC RES TECHNIQ, V27, P471, DOI 10.1002/jemt.1070270603; BROADWELL RD, 1992, PROG BRAIN RES, V91, P95; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; CROWE MJ, 1997, IN PRESS NAT MED, P240; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; Eng LF, 1987, PROG BRAIN RES <D>, V71, P439; Eng LF, 1999, J NEUROCHEM, V73, pS194; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Ghirnikar RS, 1998, NEUROSCI LETT, V247, P21, DOI 10.1016/S0304-3940(98)00268-7; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lee YL, 1997, J NEUROCHEM, V69, pS144; LEE YL, 1999, IN PRESS NEUROCHEM I; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; McTigue DM, 1998, J NEUROSCI, V18, P5354; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; SHIH K, 1997, 7 INT S NEUR REG P74; Soares HD, 1995, J NEUROSCI, V15, P8223; Sozzani S, 1996, Prog Drug Res, V47, P53; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410; Takahashi K, 1999, J COMP NEUROL, V404, P159, DOI 10.1002/(SICI)1096-9861(19990208)404:2<159::AID-CNE2>3.0.CO;2-E; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zagorski J, 1997, J IMMUNOL, V159, P1059; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	45	71	80	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 1	2000	59	1					63	73		10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.0.CO;2-W			11	Neurosciences	Neurosciences & Neurology	270ZY	WOS:000084568000008	10658186				2021-06-18	
J	Max, JE; Roberts, MA; Koele, SL; Lindgren, SD; Robin, DA; Arndt, S; Smith, WL; Sato, Y				Max, JE; Roberts, MA; Koele, SL; Lindgren, SD; Robin, DA; Arndt, S; Smith, WL; Sato, Y			Cognitive outcome in children and adolescents following severe traumatic brain injury: Influence of psychosocial, psychiatric, and injury-related variables	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; orthopedic injury; children; IQ; memory	PEDIATRIC HEAD-INJURY; BEHAVIOR PROBLEMS; FAMILY; SEQUELAE; COHORT; PERFORMANCE; CHILDHOOD; DISORDERS; VALIDITY; RECOVERY	Previous studies of childhood traumatic brain injury (TBI) have emphasized injury-related variables rather than psychiatric or psychosocial factors as correlates of cognitive outcomes. We addressed this concern by recruiting a consecutive series (N = 24) of children age 5 through 14 years who suffered a severe TBI, a matched group who sustained a mild TBI, and a second matched group who sustained an orthopedic injury. Standardized intellectual, memory, psychiatric, family functioning, family psychiatric history, neurological, and neuroimaging assessments were conducted at an average of 2 years following injury. Severe TBI, when compared to mild TBI and orthopedic injury, was associated with significant decrements in intellectual and memory function. A principal components analysis of independent variables that showed significant (p < .05) bivariate correlations with the outcome measures yielded a nc neuropsychiatric factor encompassing severity of TBI indices and postinjury psychiatric disorders and a psychosocial disadvantage factor. Both factors were independently and significantly related to intellectual and memory function outcome. Postinjury psychiatric disorders added significantly to severity indices and family functioning and family psychiatric history added significantly to socioeconomic status in explaining several specific cognitive outcomes. These results may help to define subgroups of children who will require more intensive services following their injuries.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA	Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Arndt, Stephan/A-6976-2013; Robin, Donald/F-2109-2010	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH031593, P50MH043271, R37MH031593, R01MH040856, P30MH043271] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH40856, MHCRC43271, MH31593] Funding Source: Medline		Achenbach T.M., 1991, MANUAL TEACHERS REPO; ADAMS W, 1990, WIDE RANGE ASSESSMEN; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EPSTEIN NB, 1981, HDB FAMILY THERAPY, P444; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAUFMAN AS, 1991, J PSYCHOEDUC ASSESS, V9, P4, DOI 10.1177/073428299100900101; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAX JE, 1997, J AM ACAD CHILD ADOL, V36, P96; MAX JE, 1998, J AM ACAD CHILD ADOL; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Shaffer D, 1975, Ciba Found Symp, P191; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D., 1974, MANUAL WECHSLER INTE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	43	71	71	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	1999	5	1					58	68		10.1017/S1355617799511089			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	162BR	WOS:000078325800008	9989025				2021-06-18	
J	LaPlaca, MC; Thibault, LE				LaPlaca, MC; Thibault, LE			An in vitro traumatic injury model to examine the response of neurons to a hydrodynamically-induced deformation	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						cellular calcium; in vitro modeling; mechanical loading; shear stress; strain rate	FLUID SHEAR-STRESS; ENDOTHELIAL-CELL; BRAIN INJURY; INVITRO; DEPENDENCE; DAMAGE; SYSTEM; DEATH	A novel in vitro system was developed to examine the effects of traumatic mechanical loading on individual cells. The cell shearing injury device (CSID) is a parallel disk viscometer that applies fluid shear stress with variable onset rate. The CSID was used in conjunction with microscopy and biochemical techniques to obtain a quantitative expression of the deformation and functional response of neurons to injury. Analytical and numerical approximations of the shear stress at the bottom disk were compared to determine the contribution of secondary flows. A significant portion of the shear stress was directed in the r-direction during start-up, and therefore the full Navier-Stokes equation was necessary to accurately describe the transient shear stress. When shear stress was applied at a high rate (800 dyne cm(-2) sec(-1)) to cultured neurons, a range of cell membrane strains (0.01 to 0.53) was obtained, suggesting inhomogeneity in cellular response. Functionally, cytosolic calcium and extracellular lactate dehydrogenase levels increased in response to high strain rate (>1 sec(-1)) loading, compared with quasistatic (<1 sec(-1)) loading. In addition, a subpopulation of the culture subjected to rapid deformation subsequently died, These strain rates are relevant to those shown to occur in traumatic injury, and, as such, the CSID is an appropriate model for studying the biomechanics and pathophysiology of neuronal injury.	UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA; ALLEGHENY UNIV HLTH SCI, DEPT NEUROSURG, DIV BIOENGN, PHILADELPHIA, PA 19102 USA					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R491CCR304684] Funding Source: Medline		BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; EVANS E, 1984, BLOOD, V64, P1028; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GANOT G, 1981, BIOCHIM BIOPHYS ACTA, V649, P487, DOI 10.1016/0005-2736(81)90440-5; GENNARELLI TA, 1984, CENTRAL NERVOUS SYST; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GUILAK F, 1994, J MICROSC-OXFORD, V173, P245, DOI 10.1111/j.1365-2818.1994.tb03447.x; HYMAN WA, 1972, J BIOMECH, V5, P45, DOI 10.1016/0021-9290(72)90018-8; LANDSMAN AS, 1995, J AM PODIAT MED ASSN, V85, P519, DOI 10.7547/87507315-85-10-519; LEAL G, 1992, LAMINAR FLOW CONVECT; Levich V. G., 1962, PHYSICOCHEMICAL HYDR; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; NOMURA H, 1988, BIORHEOLOGY, V25, P461; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; RAND RP, 1964, BIOPHYS J, V4, P115, DOI 10.1016/S0006-3495(64)86773-4; SAATMAN KE, 1994, J NEUROTRAUMA, V11, P125; SATO M, 1990, J BIOMECH ENG-T ASME, V112, P263, DOI 10.1115/1.2891183; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIMON SI, 1990, BIOPHYS J, V58, P319, DOI 10.1016/S0006-3495(90)82379-1; THIBAULT LE, 1993, ACCIDENTAL INJURY BI, P512; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; WATSON PA, 1991, FASEB J, V5, P2013; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397; ZIMMERMANN U, 1980, J MEMBRANE BIOL, V54, P103, DOI 10.1007/BF01940564	33	71	75	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JUL-AUG	1997	25	4					665	677		10.1007/BF02684844			13	Engineering, Biomedical	Engineering	XK197	WOS:A1997XK19700007	9236979				2021-06-18	
J	Hartl, R; Medary, MB; Ruge, M; Arfors, KE; Ghahremani, F; Ghajar, J				Hartl, R; Medary, MB; Ruge, M; Arfors, KE; Ghahremani, F; Ghajar, J			Hypertonic/hyperoncotic saline attenuates microcirculatory disturbances after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	14th Bodensee Symposium on Microcirculation: Small Volume Resuscitation in Head Injury	JUN 14-16, 1996	BODENSEE, GERMANY			leukocytes; head injury; hypertonic saline; small-volume resuscitation	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; ISCHEMIC CELL-DAMAGE; INTRACRANIAL-PRESSURE; HEMORRHAGIC-SHOCK; HYPERTONIC SALINE; FLUID RESUSCITATION; WATER-CONTENT; REPERFUSION; ABNORMALITIES	Background: Traumatic brain injury (TBI) induces an acute inflammatory response characterized by early recruitment of inflammatory cells (white blood cells). Rapid resuscitation of TBI with hypertonic saline/dextran (HS/DEX) yields promising results in clinical and experimental studies. The purpose of this paper was to test the hypothesis that HS/DEX exerts its effects in part through a modulation of the acute inflammatory response to TBI. Methods: Rabbits equipped with chronic cranial windows underwent fluid-percussion injury and were followed up for 6 hours. Intravital fluorescence videomicroscopy technique was used to visualize white blood cell trafficking and to measure pia vessel diameters and venular shear rates. Three groups were studied: sham (group I, n = 5), trauma (group II, n = 7), and trauma and 4 mL/kg 7.2% NaCl/10% dextran 60 IV over 5 minutes at 10 minutes after TBI (group III, n = 7). Results: TBI in groups TI and III led to significant increases of intracranial pressure. Arteriolar diameters after trauma increased by 17 +/- 8% at 6 hours in group LT. Infusion of HS/DEX completely prevented this secondary diameter increase. At 6 hours, the increase of ''sticking'' white blood cells in group III was reduced by approximately 90% compared with group II. Conclusion: Whether the anti-inflammatory effect of HS/DEX plays a role in reducing delayed brain damage (> 6 hours after TBI) or other systemic complications of TBI arises as an important question and should be investigated further.	CORNELL UNIV,COLL MED,NEW YORK,NY; ALLEGHENY GEN HOSP,PITTSBURGH,PA 15212	Hartl, R (corresponding author), AITKEN NEUROSCI INST,523 E 72ND ST,NEW YORK,NY 10021, USA.		Ghahremani, Fatemeh/M-1719-2018	Ghahremani, Fatemeh/0000-0002-7244-6066			BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BATTISTELLA F, 1992, CIRC SHOCK, V37, P16; BAUER M, 1993, CIRC SHOCK, V40, P187; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CIOFFI WG, 1993, ARCH SURG-CHICAGO, V128, P1260; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662; HALL ED, 1993, RES P ARNMD, V71, P81; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; HARTL R, 1995, SHOCK, V3, P274; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; HORNER HC, 1992, SOC NEUR ABSTR, V8, P173; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; KREIMEIER U, 1993, CURR OPIN ANESTHESIO, V6, P400; KUBES P, 1992, CELL MOL MECH INFLAM, P125; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; LIPOWSKY HH, 1978, MICROVASC RES, V15, P93, DOI 10.1016/0026-2862(78)90009-2; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; NAKAYAMA SI, 1985, J SURG RES, V38, P180, DOI 10.1016/0022-4804(85)90025-3; NOLTE D, 1992, AM J PHYSIOL, V263, pH1411; NUYTINCK HKS, 1988, ARCH SURG-CHICAGO, V123, P1519; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PROUGH D S, 1991, Anesthesia and Analgesia, V73, P738; ROSENGREN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1623; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1992, EUR SURG RES, V24, P1, DOI 10.1159/000129183; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VOLLMAR B, 1994, AM J PHYSIOL, V266, pH1927; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WELBOURN CRB, 1991, BRIT J SURG, V78, P651, DOI 10.1002/bjs.1800780607; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WISNER DH, 1992, J TRAUMA, V32, P351, DOI 10.1097/00005373-199203000-00013; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	48	71	73	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1997	42	5		S			S41	S47		10.1097/00005373-199705001-00008			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	XE879	WOS:A1997XE87900009	9191695				2021-06-18	
J	Schagen, S; Schmand, B; deSterke, S; Lindeboom, J				Schagen, S; Schmand, B; deSterke, S; Lindeboom, J			Amsterdam short-term memory test: A new procedure for the detection of feigned memory deficits	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; IMPAIRMENT; AMNESIA; MOTIVATION; VALIDITY	The validity of two malingering tests, the newly developed Amsterdam Short-Term Memory (ASTM) test and the Distraction test (Baker, Hanley, Jackson, Kimmance, & Slade, 1993) was examined in a group of patients with closed-head injury (CHI), a normal control group, and a control group with instruction to feign memory deficits. Both control groups consisted of first-degree relatives of the patients. The ASTM test is a forced-choice verbal memory test, based on the technique of symptom validity testing. Stimulus material was chosen from category norms, and chance level is not transparent. The CHI and normal control groups scored near ceiling on the ASTM test, whereas the feigned deficit group scored significantly worse. The ASTM test classified all subjects correctly. Contrary to expectation, the Distraction test appeared to be invalid. The score profiles of the CHI and feigning groups on conventional memory and concentration tests were indistinguishable from each other. Thus, the ASTM test may be very useful for the detection of malingering and other kinds of less than optimal performance. The test may readily be constructed in any language for which category norms are available.	UNIV AMSTERDAM,AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,AMSTERDAM,NETHERLANDS	Schagen, S (corresponding author), SLOTERVAARTZIEKENHUIS,DEPT PSYCHOL,LOUWESWEG 6,NL-1066 EC AMSTERDAM,NETHERLANDS.						BAKER GA, 1993, J CLIN EXP NEUROPSYC, V15, P668, DOI 10.1080/01688639308402588; BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; BENTON AL, 1963, REVISED VISUAL RETEN; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Bouma A., 1996, NEUROPSYCHOLOGISCHE; CLIFFE MJ, 1992, BRIT J CLIN PSYCHOL, V31, P207, DOI 10.1111/j.2044-8260.1992.tb00985.x; DESTERKE SH, 1993, THESIS U AMSTERDAM; GUILMETTE TJ, 1994, PERCEPT MOTOR SKILL, V78, P1179, DOI 10.2466/pms.1994.78.3c.1179; Hammes JGW., 1978, STROOP KLEUR WOORD T; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HORTON KD, 1992, J EXP PSYCHOL GEN, V121, P326, DOI 10.1037/0096-3445.121.3.326; HUDSON PTW, 1982, 82FU05 CATH U NIJM D; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luteijn F., 1983, GRONINGER INTELLIGEN; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; Morse P, 1992, CLIN SYNDROMES ADULT, P85; Nelson H., 1982, NATIONAL ADULT READI; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; RAWLING P J, 1992, Brain Injury, V6, P381, DOI 10.3109/02699059209034953; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Schmand B., 1992, NEDERLANDSE LEESTEST; SCHMAND B, AMSTERDAM SHORT TERM; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Stinissen J, 1970, HANDLEIDING BIJ NEDE; Stroop JR, 1935, J EXP PSYCHOL, V12, P242; TEADALE G, 1974, LANCET, V2, P81; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Van den Burg W, 1985, 15 WOORDENTEST PROVI; vanBalen HGG, 1987, RIVERMEAD BEHAV MEMO; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	40	71	71	1	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1997	19	1					43	51		10.1080/01688639708403835			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	WN019	WOS:A1997WN01900005	9071640				2021-06-18	
J	McCrory, PR; Bladin, PF; Berkovic, SF				McCrory, PR; Bladin, PF; Berkovic, SF			Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: Phenomenology, aetiology, and outcome	BRITISH MEDICAL JOURNAL			English	Article							SYNCOPE	Objectives: To study the ictal phenomenology, aetiology, and outcome of convulsions occurring within seconds of impact in violent collision sport. Design: Retrospective identification of convulsions associated with concussive brain injury from case records fi-om medical officers of football clubs over a 15 year period. Subjects: Elite Australian rules and rugby league footballers. Main outcome measures: Neuroimaging studies, electroencephalography, neuropsychological test data, and statistics on performance in matches to determine presence of structural or functional brain injury Clinical follow up and electroencephalography for evidence of epilepsy. Results: Twenty two cases of concussive convulsions were identified with four events documented on television videotape. Convulsions began within 2 seconds of impact and comprised an initial period of tonic stiffening followed by myoclonic jerks of all limbs lasting up to 150 seconds. Some asymmetry in the convulsive manifestations was common, and recovery of consciousness was rapid. No structural or permanent brain injury was present on clinical assessment neuropsychological testing, or neuroimaging studies. All players returned to elite competition within two weeks of the incident Epilepsy did not develop in any player over a mean (range) follow up of 3.5 (1-13) years. Conclusions: These concussive or impact convulsions are probably a non-epileptic phenomenon, somewhat akin to convulsive syncope. The mechanism may be a transient traumatic functional decerebration. In concussive convulsions the outcome is universally good, antiepileptic treatment is not indicated, and prolonged absence from sport is unwarranted.	UNIV MELBOURNE,DEPT MED NEUROL,AUSTIN,AUSTRALIA; REPATRIAT MED CTR,HEIDELBERG,VIC 3084,AUSTRALIA			McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			AMINOFF MJ, 1988, ANN INTERN MED, V108, P791, DOI 10.7326/0003-4819-108-6-791; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; DUVOISIN RC, 1962, ARCH NEUROL-CHICAGO, V7, P219, DOI 10.1001/archneur.1962.04210030057008; GASTAUT H, 1957, LANCET, V2, P1018; GASTAUT H, 1974, HDB CLIN NEUROLOGY, V5, P815; GASTAUT H, 1972, EPILEPTIC SEIZURES C, P197; GOWERS WR, 1881, EPILEPSY CHRONIC CON, P26; GOWERS WR, 1907, BORDERLAND EPILEPSY, P1; HOWARD P, 1951, BRIT MED J, V2, P382, DOI 10.1136/bmj.2.4728.382; JENNETT B, 1975, EPILEPSY NON MISSILE; LEMPERT T, 1994, ANN NEUROL, V36, P233, DOI 10.1002/ana.410360217; LIN JTY, 1982, ANN NEUROL, V11, P525, DOI 10.1002/ana.410110513; MADDOCKS D, 1991, J CLIN EXP NEUROPSYC, V3, P439; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, IN PRESS BRAIN INJ; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Seward H. G., 1992, AUST J SCI MED SPORT, V24, P51; STEPHENSON JBP, 1990, FITS FAINTS, P41; WALKER AE, 1969, LATE EFFECTS HEAD IN	21	71	72	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					171	174		10.1136/bmj.314.7075.171			4	Medicine, General & Internal	General & Internal Medicine	WD911	WOS:A1997WD91100021	9022428	Green Published			2021-06-18	
J	Farooque, M; Hillered, L; Holtz, A; Olsson, Y				Farooque, M; Hillered, L; Holtz, A; Olsson, Y			Changes of extracellular levels of amino acids after graded compression trauma to the spinal cord: An experimental study in the rat using microdialysis	JOURNAL OF NEUROTRAUMA			English	Article						excitatory amino acids; glutamate; lactate; microdialysis; rat; spinal cord; trauma	CENTRAL-NERVOUS-SYSTEM; CONCUSSIVE BRAIN INJURY; LIPID-PEROXIDATION; GLUTAMATE; EDEMA; BLOOD; RECOVERY; INFUSION; ALBUMIN; PROTEIN	We evaluated in rats, the time course of changes in extracellular levels of amino acids, lactate and pyruvate, which ensued spinal cord compression of mild, moderate, and severe degrees. The neurochemical findings measured by HPLC were compared with known outcome measures of this model. A laminectomy of vertebrae Th-7 and Th-8 was made and a microdialysis probe was inserted in one dorsal horn. Fluid samples were collected at intervals of 10 min. Dialysate lactate and lactate/pyruvate ratios increased in proportion to the severity of injury, suggesting a progressive derangement of energy metabolism. Mild trauma, with no neurologic deficits, did not induce any remarkable change of amino acids, but taurine values were temporarily slightly elevated. Moderate trauma, leading to transient paraparesis, resulted in a transient rise of glutamate and taurine. Severe trauma resulting in paraplegia of the hind limbs induced profound changes of extracellular amino acids. Glutamate and aspartate rose 5-6 times above basal level. There were marked elevations of taurine, glycine, arginine, alanine, asparagine, histidine, serine, threonine, and tyrosine after this degree of trauma. Glutamate, aspartate, and taurine returned to the basal level within 50 min, whereas most of the other amino acids remained elevated throughout the experiment. Thus, we found profound disturbances of extracellular amino acids and energy metabolites. The elevations of glutamate and aspartate correlated with previously recorded data on neurological outcome. The composition of the early extracellular edema showed marked temporal changes related to the severity of impact. Future studies regarding treatment of traumatic edema should focus on its chemical composition as well as its volume since such edema is not uniform in composition.	UNIV UPPSALA HOSP, DEPT NEUROSURG, S-75185 UPPSALA, SWEDEN; UNIV UPPSALA HOSP, DEPT CLIN CHEM, S-75185 UPPSALA, SWEDEN	Farooque, M (corresponding author), UNIV UPPSALA HOSP, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN.						ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Baethmann A, 1980, Adv Neurol, V28, P171; BEGGS JL, 1975, EXP NEUROL, V49, P86, DOI 10.1016/0014-4886(75)90196-X; BUISSON A, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P417; DELGADO JMR, 1972, ARCH INT PHARMACOD T, V198, P9; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FAROOQUE M, 1992, ACTA NEUROPATHOL, V84, P613; FAROOQUE M, 1994, ACTA NEUROL SCAND, V89, P36; FAROOQUE M, 1995, J NEUROTRAUM, V12, P41, DOI 10.1089/neu.1995.12.41; GRAHAM LT, 1967, J NEUROCHEM, V14, P465, DOI 10.1111/j.1471-4159.1967.tb09545.x; GREENAMYRE JT, 1984, J NEUROSCI, V4, P2133; GRIFFITHS IR, 1974, J NEUROL SCI, V22, P291, DOI 10.1016/0022-510X(74)90002-1; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HALL ED, 1993, RES P ARNMD, V71, P81; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HALLSTROM A, 1989, J PHARMACOL METHOD, V22, P113; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1992, CLIN NEUROPHARMACOL, V15, P695; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; IIZUKA H, 1987, J NEUROSURG, V66, P595, DOI 10.3171/jns.1987.66.4.0595; JANSEN KLR, 1990, NEUROSCI LETT, V108, P53, DOI 10.1016/0304-3940(90)90705-E; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempski O, 1990, Adv Neurol, V52, P219; Li GL, 1996, ACTA NEUROPATHOL, V91, P155, DOI 10.1007/s004010050407; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LI GL, 1995, RESTOR NEUROL NEUROS, V8, P189, DOI 10.3233/RNN-1995-8404; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; MC GEER P L, 1989, BASIC NEUROCHEMISTRY, P311; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; Olney J W, 1986, Adv Exp Med Biol, V203, P631; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; REHNCRONA S, 1989, J CEREBR BLOOD F MET, V9, P65, DOI 10.1038/jcbfm.1989.9; SANDLER AN, 1967, J NEUROSURG, V5, P638; SCHOUSBOE A, 1992, CAN J PHYSIOL PHARM, V70, pS356, DOI 10.1139/y92-283; SHIMADA N, 1989, J CEREBR BLOOD F MET, V9, P603, DOI 10.1038/jcbfm.1989.86; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P1; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; UNGERSTEDT U, 1974, B SCHWEIZ AKAD MED, V30, P44; Ungerstedt U, 1991, MICRODIALYSIS NEUROS, P3; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; WELLS MR, 1978, EXP NEUROL, V61, P214, DOI 10.1016/0014-4886(78)90192-9; WESTERGREN I, 1992, BRAIN RES, V573, P324, DOI 10.1016/0006-8993(92)90781-4; WESTERGREN I, 1994, J NEUROCHEM, V62, P159; WESTERGREN I, 1993, ACTA NEUROPATHOL, V85, P285; ZHANG Y, 1993, SURG NEUROL, V39, P297, DOI 10.1016/0090-3019(93)90009-P	55	71	71	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					537	548		10.1089/neu.1996.13.537			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600006	8913970				2021-06-18	
J	HUNKIN, NM; PARKIN, AJ; BRADLEY, VA; BURROWS, EH; ALDRICH, FK; JANSARI, A; BURDONCOOPER, C				HUNKIN, NM; PARKIN, AJ; BRADLEY, VA; BURROWS, EH; ALDRICH, FK; JANSARI, A; BURDONCOOPER, C			FOCAL RETROGRADE-AMNESIA FOLLOWING CLOSED-HEAD INJURY - A CASE-STUDY AND THEORETICAL ACCOUNT	NEUROPSYCHOLOGIA			English	Article						MEMORY; AMNESIA; RETROGRADE	AUTOBIOGRAPHICAL MEMORY; ENCEPHALITIS; ANTEROGRADE; IMPAIRMENT	In this paper we present data from a closed head injury patient who presents a striking example of what Kapur (Cortex 29, 217-234, 1993) has termed ''focal retrograde amnesia''. The patient, D.H., is unable to recollect any autobiographical incidents from the pre-morbid period, although he is able to provide personal and public information from this period. The data are discussed in relation to other reported instances of focal retrograde amnesia and a preliminary theoretical account is offered.	HURSTWOOD PK NEUROL CTR,HAYWARDS HEATH RH17 7SJ,W SUSSEX,ENGLAND; KING EDWARD VII HOSP,MIDHURST GU29 0BL,W SUSSEX,ENGLAND	HUNKIN, NM (corresponding author), UNIV SUSSEX,EXPTL PSYCHOL LAB,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ANDREWS E, 1982, CORTEX, V18, P441, DOI 10.1016/S0010-9452(82)80041-5; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; ESLINGER PJ, 1993, BRAIN COGNITION, V21, P140, DOI 10.1006/brcg.1993.1011; EVANS J, 1993, J NEUROL NEUROSUR PS, V56, P1227, DOI 10.1136/jnnp.56.11.1227; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; HODGES JR, 1993, BRAIN, V116, P921, DOI 10.1093/brain/116.4.921; HUNKIN NM, 1994, NEUROPSYCHOLOGIA, V32, P819, DOI 10.1016/0028-3932(94)90020-5; KAPUR N, 1994, NEUROPSYCHOLOGIA, V32, P23, DOI 10.1016/0028-3932(94)90066-3; KAPUR N, 1989, CORTEX, V25, P387, DOI 10.1016/S0010-9452(89)80053-X; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Nelson H. E., 1991, NATIONAL ADULT READI; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; PARKIN AJ, 1991, PSYCHOL MED, V21, P11, DOI 10.1017/S0033291700014598; PARKIN AJ, 1990, Q J EXP PSYCHOL-A, V42, P585, DOI 10.1080/14640749008401238; PARKIN AJ, 1991, BRIT J CLIN PSYCHOL, V30, P349, DOI 10.1111/j.2044-8260.1991.tb00955.x; PARKIN AJ, 1993, NEUROPSYCHOLOGY AMNE; PERNER J, 1992, HUM DEV, V35, P146, DOI 10.1159/000277146; ROBINSON JA, 1976, COGNITIVE PSYCHOL, V8, P578, DOI 10.1016/0010-0285(76)90020-7; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SQUIRE LR, 1987, MEMORY BRAIN; STRACCIARI A, 1994, CORTEX, V30, P459, DOI 10.1016/S0010-9452(13)80341-3; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; YONEDA Y, 1992, EUR NEUROL, V32, P340, DOI 10.1159/000116857; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	33	71	71	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	APR	1995	33	4					509	523		10.1016/0028-3932(94)00136-D			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	QV067	WOS:A1995QV06700008	7617158				2021-06-18	
J	HICKS, RR; SMITH, DH; GENNARELLI, TA; MCINTOSH, T				HICKS, RR; SMITH, DH; GENNARELLI, TA; MCINTOSH, T			KYNURENATE IS NEUROPROTECTIVE FOLLOWING EXPERIMENTAL BRAIN INJURY IN THE RAT	BRAIN RESEARCH			English	Article						KYNURENATE; HEAD INJURY PATHOLOGY; EXCITOTOXICITY; NEUROPROTECTION; NMDA ANTAGONIST; HIPPOCAMPUS	D-ASPARTATE RECEPTORS; GLUTAMATE NEUROTOXICITY; NMDA RECEPTOR; NEURONAL DAMAGE; ISCHEMIA; ACID; MECHANISMS; ANTAGONIST; GLYCINE; VULNERABILITY	Pharmacologic inhibition of excitatory amino acid neurotransmission improves physiologic, metabolic, and neurobehavioral outcome following experimental brain trauma. However, no studies to date have demonstrated pharmacologically-induced attenuation of histopathological changes associated with experimental brain injury models. The present study examined the effects of kynurenate, an NMDA and non-NMDA receptor antagonist, on neuronal survival in the hippocampus after lateral fluid-percussion brain injury in the rat. Animals (n = 10/treatment) randomly received an intravenous injection of either kynurenate (300 mg/kg) or buffer (equal volume) 15 min following fluid-percussion brain injury of moderate severity. Two weeks after injury, animals were sacrificed and neuronal cell loss in the hippocampus was examined with Nissl staining. Selective loss of neurons in the CA3 region of the hippocampus, which has previously been characterized in this model of brain injury, was found to be significantly attenuated following kynurenate treatment (P < 0.05). These data suggest that pharmacologic compounds which are known to have beneficial effects on neurobehavioral and physiological outcome following brain injury may also significantly attenuate post-traumatic neuronal cell loss. Our results also support other recent data chat pharmacological intervention with an excitatory amino acid receptor antagonist may be of therapeutic value in the treatment of brain injury.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104	HICKS, RR (corresponding author), UNIV KENTUCKY,DIV PHYS THERAPY,ANNEX 1,LEXINGTON,KY 40536, USA.		smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R55NS026818] Funding Source: NIH RePORTER		AUER RN, 1986, STROKE, V17, P699, DOI 10.1161/01.STR.17.4.699; BAKKER MHM, 1991, NEUROSCIENCE, V42, P387; BENEVISTE H, 1984, J NEUROCHEM, V43, P1369; BERTOLINO M, 1989, NEUROPHARMACOLOGY, V28, P453, DOI 10.1016/0028-3908(89)90078-6; BIRCH PJ, 1988, EUR J PHARMACOL, V151, P313, DOI 10.1016/0014-2999(88)90814-X; BUCHAN A, 1990, J NEUROSCI, V10, P311; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; FADEN AI, 1989, SCIENCE, V244, P780; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HAYES RL, 1991, J NEUROTRAUM, V9, P173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HEUTTNER JE, 1989, SCIENCE, V243, P1611; HICKS RR, 1992, J NEUROTRAUM, V9, P388; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; JOHNSON KM, 1987, PSYCHOPHARMACOLOGY 3, P1581; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMP JA, 1993, TRENDS PHARMACOL SCI, V14, P20, DOI 10.1016/0165-6147(93)90108-V; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS RGM, 1988, TRENDS NEUROSCI, V11, P125, DOI 10.1016/0166-2236(88)90136-1; MOSSINGER JL, 1991, EXP NEUROL, V113, P10; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1986, NEUROSCI LETT, V65, P65, DOI 10.1016/0304-3940(86)90121-7; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SCHMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527, DOI 10.1016/0306-4522(90)90048-9; SEISJO BK, 1988, ANN NY ACAD SCI, V522, P638; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIMON RP, 1986, NEUROPATH APPL NEURO, V12, P567, DOI 10.1111/j.1365-2990.1986.tb00160.x; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1992, PSYCHOL REV, V99, P5821; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110; WRTHALL JR, 1992, EUR J PHARMACOL, V218, P273	52	71	72	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 29	1994	655	1-2					91	96		10.1016/0006-8993(94)91601-2			6	Neurosciences	Neurosciences & Neurology	PD247	WOS:A1994PD24700013	7812795				2021-06-18	
J	LEVY, ML; REZAI, A; MASRI, LS; LITOFSKY, SN; GIANNOTTA, SL; APUZZO, MLJ; WEISS, MH; MILLER, JD; YOUNG, HF				LEVY, ML; REZAI, A; MASRI, LS; LITOFSKY, SN; GIANNOTTA, SL; APUZZO, MLJ; WEISS, MH; MILLER, JD; YOUNG, HF			THE SIGNIFICANCE OF SUBARACHNOID HEMORRHAGE AFTER PENETRATING CRANIOCEREBRAL INJURY - CORRELATIONS WITH ANGIOGRAPHY AND OUTCOME IN A CIVILIAN POPULATION	NEUROSURGERY			English	Article						HEAD INJURY; PENETRATING CRANIOCEREBRAL INJURY; TRAUMATIC ANEURYSM; TRAUMATIC SUBARACHNOID HEMORRHAGE	TRAUMATIC INTRACRANIAL ANEURYSMS; MISSILE HEAD WOUNDS; GUNSHOT WOUNDS; MANAGEMENT; VASOSPASM; BRAIN; SCAN	CERTAIN CLINICAL FACTORS are considered to nave an effect on patient outcome after penetrating missile injury. These include bilateral hemispheric injury, ventricular hemorrhage, intracerebral hemorrhage, mass effect, and missile or bony fragmentation. The relationship of subarachnoid hemorrhage (SAH) after penetrating craniocerebral injury and outcome is unknown. In addition, controversy exists regarding the role of angiography and the incidence of traumatic intracranial aneurysm in this population. Finally, can we assume that the incidence of traumatic intracranial aneurysm is equal in military and civilian populations, given the absence of penetrating shrapnel injury in civilian populations? Now that computed tomography has supplanted angiography as the primary diagnostic modality, increasing vigilance on the part of the physician and examination of angiography in high-risk patients should allow for enhanced outcome. We evaluated 100 patients with a diagnosis of cerebral gunshot wound over a 12-month period. All patients were evaluated neurologically at the time of admission and had imaging studies. Thirty-one patients with radiological evidence of SAH on computed tomography underwent angiography. Angiograms were limited to the side of the injury in patients with single-lobe or unilateral multilobe injuries and were bilateral in patients with bilateral hemispheric involvement. One intracranial aneurysm (3.2%) was documented and treated surgically. In those patients who died within 48 hours of admission, 68% had SAH as compared with only 17% of those surviving. Outcome was based upon neurological evaluation at the time of discharge and at the time of clinical follow-up at 3 and 6 months. Of those patients admitted with SAH, one remained vegetative, four were severely disabled, five were moderately disabled, and three had good recovery. Eighteen patients died (68%). We report on a statistically significant correlation between SAH and poor outcome after penetrating injury (P < 0.001). We found no correlation between the presence of intracerebral hemorrhage and outcome. The incidence of traumatic intracranial aneurysm in our civilian series did not differ from that in large military populations, despite the absence of shrapnel injury.	UNIV SO CALIF,SCH MED,DEPT NEUROL SURG,1200 N STATE ST,SUITE 5046,LOS ANGELES,CA 90033							AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BARNETT JC, 1955, J NEUROSURG, V12, P34, DOI 10.3171/jns.1955.12.1.0034; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BLACK PM, 1986, NEUROSURGERY, V18, P12, DOI 10.1227/00006123-198601000-00003; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; COOPER PR, 1979, NEUROSURGERY, V4, P373, DOI 10.1227/00006123-197905000-00001; CUSHING H, 1918, BRIT MED J, V1, P221; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FALSETTI HL, 1966, DIS CHEST, V49, P420, DOI 10.1378/chest.49.4.420; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FONHANWEHR RI, 1986, INTRACRANIAL ANEURYS, P96; FOX JL, 1983, INTRACRANIAL ANEURYS, V1, P423; FRASER RAR, 1975, STROKE, V6, P153, DOI 10.1161/01.STR.6.2.153; GIANNOTTA SL, 1982, CLIN NEUR, V29, P288; GIANNOTTA SL, 1985, NEUROSURGERY, P1678; GREITZ T, 1961, ANGIOGRAPHY, P95; GROLIMUND P, 1988, LANCET, V2, P1173; GUIBERT, 1895, ANN OCUL, V113, P314; HADDAD FS, 1978, CAN J SURG, V21, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HUBER P, 1963, Fortschr Geb Rontgenstr Nuklearmed, V98, P292; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; LIN PJ, 1966, ACTA RADIOL, V5, P341; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MCCULLOUGH D, 1971, J TRAUM, V11, P422, DOI 10.1097/00005373-197105000-00007; Meirowsky A., 1965, NEUROLOGICAL SURGERY, P103; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PASQUALIN A, 1984, NEUROSURGERY, V15, P344, DOI 10.1227/00006123-198409000-00009; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; SCHWARTZ HG, 1948, ANN SURG, V127, P58, DOI 10.1097/00000658-194801000-00006; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; VILATO RJ, 1962, NEURO-CHIR, V8, P217; WANNAMAKER GT, 1954, J NEUROSURG, V11, P151, DOI 10.3171/jns.1954.11.2.0151; WILKINS RH, 1980, CEREBRAL ARTERIAL SP, P472; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	46	71	74	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1993	32	4					532	540		10.1227/00006123-199304000-00007			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KV759	WOS:A1993KV75900007	8474643				2021-06-18	
J	TANNO, H; NOCKELS, RP; PITTS, LH; NOBLE, LJ				TANNO, H; NOCKELS, RP; PITTS, LH; NOBLE, LJ			BREAKDOWN OF THE BLOOD-BRAIN-BARRIER AFTER FLUID PERCUSSION BRAIN INJURY IN THE RAT .2. EFFECT OF HYPOXIA ON PERMEABILITY TO PLASMA-PROTEINS	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL-ISCHEMIA; HEAD-INJURY; METABOLISM; EDEMA	Clinical studies have demonstrated that hypoxia after severe brain injury is common and significantly worsens neurologic outcome. We have, therefore, developed a rat model of posttraumatic hypoxic injury in order to identify the pathophysiologic responses after head injury that are worsened by this secondary insult. We examined the effect of hypoxia after brain injury on permeability of the blood-brain barrier to plasma proteins. Animals were divided into two experimental groups: group I (impact alone) and group IH (impact plus hypoxia). Rats were subjected to a lateral fluid percussive brain injury (4.8-5.2 atm). Animals in group IH were exposed to hypoxic conditions (10% O2) for 45 min immediately after injury. In each group, vascular permeability to endogenous immunoglobulins (IgG) and to horseradish peroxidase (HRP) was examined at the light microscopic level. IgG was immunolocalized in brain sections at 1-24 h after injury. In other studies, HRP was given i.v. either before impact or 10 min before killing. Permeability to this protein was assessed at 1-72 h after injury. The distribution of extravasated proteins was similar between the experimental groups at 1 h postinjury. Pronounced abnormal permeability to IgG and HRP (given before impact) occurred in discrete regions throughout both the ipsilateral and contralateral hemispheres. By 6 h after injury, a differential response of the blood-brain barrier was noted between groups I and IH. Widespread leakage of proteins was observed in the injured hemisphere in group IH. This finding was in sharp contrast to group I, in which extravasated proteins remained more localized in the injured hemisphere. The time course for reestablishment of the blood-brain barrier to HRP (given before killing) was determined. The impact site remained permeable to HRP up to at least 72 h postinjury within groups I and IH. In group I, the blood-brain barrier was reestablished in the parasagittal cortex and deep cortical layer by 6 h postinjury. In contrast, the blood-brain barrier in group IH was not restored in similar brain regions until 24 h postinjury. These studies demonstrate that (1) hypoxia after brain injury exacerbates the regional breakdown of the blood-brain barrier to circulating proteins, (2) this influence of hypoxia on permeability is not apparent immediately after injury but rather is expressed at 6 h after injury, and (3) hypoxia after traumatic brain injury delays recovery of the blood-brain barrier. These findings suggest that secondary posttraumatic hypoxia contributes to the vascular pathogenesis of brain injury.	SAN FRANCISCO GEN HOSP, DEPT NEUROSURG, 4M-39, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROSURG, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CNS INJURY & EDEMA RES CTR, SAN FRANCISCO, CA 94143 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; DOBBIN J, 1989, J CEREBR BLOOD F MET, V9, P71, DOI 10.1038/jcbfm.1989.10; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; ITO U, 1975, ACTA NEUROPATHOL, V34, P1; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATSURADA K, 1973, SURGERY, V73, P191; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; TODD NV, 1986, ACTA NEUROL SCAND, V74, P269; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	19	71	71	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					335	347		10.1089/neu.1992.9.335			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300003	1291693				2021-06-18	
J	TAHA, JM; SABA, MI; BROWN, JA				TAHA, JM; SABA, MI; BROWN, JA			MISSILE INJURIES TO THE BRAIN TREATED BY SIMPLE WOUND CLOSURE - RESULTS OF A PROTOCOL DURING THE LEBANESE CONFLICT	NEUROSURGERY			English	Article						BRAIN ABSCESS; HEAD INJURY; INTRACRANIAL HEMORRHAGE	CRANIOCEREBRAL GUNSHOT WOUNDS; INTRACRANIAL BONE FRAGMENTS; INTRACEREBRAL HEMORRHAGE; CIVILIAN PRACTICE; MANAGEMENT; EXPERIENCE; PROGNOSIS; VIETNAM; HEAD	This is a prospective study of the treatment of penetrating missile injuries to the brain without intracranial surgery carried out at the American University of Beirut Medical Center between 1981 and 1988. Of 600 patients treated for missile injuries to the head, 32 satisfied the study criteria. There were 27 shrapnel and 5 bullet injuries. The mean patient age was 23 years (range, 3-51 years). Twenty patients had intracranial indriven bone fragments. Six patients had exposed brain tissue. The mean follow-up was 3.5 years (range, 1-7.5 years). The superficial entry wound was debrided and closed without drainage in the Emergency Room within a mean of 3 hours (range, 0.5-6 hours), and the patient received methicillin for 14 days. All patients survived and had no or improved neurological deficits. No leakage of the cerebrospinal fluid, infection, or seizures occurred in 31 patients. One patient with indriven bone fragments had leakage of the cerebrospinal fluid and developed seizures and a brain abscess 20 days after the injury. The management of penetrating missile injuries to the brain without intracranial surgery in a select patient population is a reasonable option. This treatment becomes important for a surgeon facing large numbers of casualties, or when operative personnel or resources are limited or unavailable.	AMER UNIV BEIRUT, MED CTR, DIV NEUROL SURG, BEIRUT, LEBANON; MED COLL OHIO, DEPT NEUROL SURG, TOLEDO, OH 43699 USA	TAHA, JM (corresponding author), UNIV CINCINNATI, MED CTR, DEPT NEUROL SURG, 231 BETHESDA AVE 515, CINCINNATI, OH 45267 USA.						AARABI B, 1989, NEUROSURGERY, V25, P923, DOI 10.1227/00006123-198912000-00011; Ascroft PB, 1943, LANCET, V2, P211; ASCROFT PB, 1947, BR J SURG S, V1, P183; BARNETT JC, 1955, J NEUROSURG, V12, P34, DOI 10.3171/jns.1955.12.1.0034; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BYRNES DP, 1974, BRIT J SURG, V61, P169, DOI 10.1002/bjs.1800610302; CAIRNS H, 1947, BR J SURG WAR SURG S, V1, P198; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CAREY ME, 1970, MIL MED, V135, P1161; CAREY ME, 1974, J NEUROSURG, V41, P542, DOI 10.3171/jns.1974.41.5.0542; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; CLIFTON GL, 1983, CLIN NEUROSCIENCES, P1269; COOPER P, 1985, NEUROSURGERY, P1510; COOPER P, 1982, HEAD INJURY, P257; COURVILLE C B, 1956, Bull Los Angel Neuro Soc, V21, P49; CROCKARD HA, 1975, J TRAUMA, V15, P339, DOI 10.1097/00005373-197504000-00011; Cushing H, 1918, BRIT J SURG, V5, P558; Cushing H, 1918, Br Med J, V1, P221; DUCKER T, 1985, NEUROSURGERY, P1510; ECKER AD, 1946, J NEUROSURG, V3, P1, DOI 10.3171/jns.1946.3.1.0001; FISCHER G, 1957, P STAFF M MAYO CLIN, V32, P14; FREYTAG E, 1963, ARCH PATHOL, V76, P215; FURLOW LT, 1947, J NEUROSURG, V4, P380, DOI 10.3171/jns.1947.4.4.0380; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; GOLDSMITH W, 1966, HEAD INJURY C P, P350; GREENWOOD J, 1950, J NEUROSURG, V7, P169, DOI 10.3171/jns.1950.7.2.0169; GURDJIAN ES, 1973, HEAD INJURY ANTIQUIT, P111; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HARSH GR, 1965, NEUROLOGICAL SURGERY, P135; HAYES GJ, 1967, CLIN NEUROSURG, V14, P380; HEEVER CMV, 1989, J NEUROSURG, V71, P186; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; LILLARD PL, 1978, SURG NEUROL, V9, P79; MALTBY GL, 1946, J NEUROSURG, V3, P239, DOI 10.3171/jns.1946.3.3.0239; MARTIN J, 1946, J NEUROSURG, V3, P58, DOI 10.3171/jns.1946.3.1.0058; MASDEU JC, 1984, NEUROLOGY, V34, P381, DOI 10.1212/WNL.34.3.381; MATHEWS WE, 1972, J TRAUM, V12, P939, DOI 10.1097/00005373-197211000-00004; MATSON DD, 1946, J NEUROSURG, V3, P46, DOI 10.3171/jns.1946.3.1.0046; MATSON DD, 1948, TREATMENT ACUTE CRAN, P34; Meirowsky A., 1965, NEUROLOGICAL SURGERY, P103; MEIROWSKY AM, 1954, JAMA-J AM MED ASSOC, V154, P666, DOI 10.1001/jama.1954.02940420028008; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MEIROWSKY AM, 1968, MIL MED, V133, P887; MEIROWSKY AM, 1953, J NEUROSURG, V10, P373, DOI 10.3171/jns.1953.10.4.0373; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; OMMAYA AK, 1966, HEAD INJURY, P260; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; SCHEIBERT CD, 1965, NEUROLOGICAL SURGERY, P216; SCHWARTZ HG, 1945, ANN SURG, V121, P129; SCHWARTZ HG, 1948, ANN SURG, V127, P58, DOI 10.1097/00000658-194801000-00006; SHOUNG HM, 1985, ACTA NEUROCHIR, V74, P27, DOI 10.1007/BF01413272; TEASDALE G, 1974, LANCET, V2, P81; TEDESCHI G, 1975, J NEUROSURG, V43, P590, DOI 10.3171/jns.1975.43.5.0590; WALKER E, 1961, FOLLOW UP STUDY HEAD, P119; WALLACE PB, 1960, ANN SURG, V151, P174, DOI 10.1097/00000658-196002000-00004; WANNAMAKER GT, 1958, J NEUROSURG, V15, P512, DOI 10.3171/jns.1958.15.5.0512; WANNAMAKER GT, 1954, J NEUROSURG, V11, P151, DOI 10.3171/jns.1954.11.2.0151; WEBSTER JE, 1946, J NEUROSURG, V3, P7, DOI 10.3171/jns.1946.3.1.0007; YASHON D, 1972, American Surgeon, V38, P346	65	71	74	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	1991	29	3					380	384		10.1227/00006123-199109000-00007			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GB934	WOS:A1991GB93400007	1922705				2021-06-18	
J	CERVOSNAVARRO, J; LAFUENTE, JV				CERVOSNAVARRO, J; LAFUENTE, JV			TRAUMATIC BRAIN INJURIES - STRUCTURAL-CHANGES	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	MEETING ON PHARMACOLOGY OF TRAUMATIC BRAIN INJURY	JUN 22-23, 1990	TOLEDO, SPAIN	WORLD FEDERAT NEUROL			LESION-INDUCED SYNAPTOGENESIS; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; SPINAL-CORD; VASCULAR-PERMEABILITY; DEVELOPING RAT; DENTATE GYRUS; AGED RATS; CONTUSION; LAMININ	A host of complications and consequences may follow a contusion or other brain injury of any sort. An appreciation of the temporal evolution of the contusion from a microscopic standpoint is useful to a full understanding of the process by which physical force damages the brain and how the brain reacts to this damage. Some disruptions of the blood brain barrier quite early will result in extracellular edema. The microscopic appearance of an edematous area is usually spongy with numerous vacuoles. The neuropil may appear bubbly, and glial cells may be swollen. If edema has been long standing, the vacuoles may be larger and in fact a small cyst may appear in the white matter. If focal cerebral edema is not present for long periods of time and the underlying cause has been corrected, residual fluid and electrolytes are eventually removed, restoring the neuropil to a normal state, leaving no sign of its presence. However, in longer standing lesions, myelin pallor and some reactive gliosis may remain indefinitely. Neurons may show swelling very early and for a short period of time, which gives way to shrinkage, eosinophilia, and nuclear pyknosis. These changes may be observed at the periphery of lesions for as long as 5 or 6 months after the initial event. Before dissolution, nuclear pyknosis may remain in the tissue for many days and possibly longer, and may even become mineralized in situ (ferruginated neurons) to remain for years. In a traumatic lesion, swollen and ballooned axons may be found in and around the contusion but also at great distances from it (diffuse axonal injury). Axonal ballooning may be observed between 24 and 48 h postinjury and may persist wherever found for many years. Selective axonal calcification has been observed in humans as well as in experimental trauma. At about 7-10 days postinjury increased numbers of astroglia probably are present. Over the ensuing weeks and months, and probably years, astrocytes increase in number and in fibrillary appearance, eventually resulting in a glial scar in and about the injured area. It is thought that this reactive gliosis results in restoration of the blood-brain barrier in the damaged area.	UNIV BASKE COUNTRY,DEPT NEUROSCI,LEIOA,SPAIN	CERVOSNAVARRO, J (corresponding author), FREE UNIV BERLIN,INST NEUROPATHOL,W-1000 BERLIN 33,GERMANY.		Lafuente, Jose-Vicente/O-6395-2014	Lafuente, Jose-Vicente/0000-0001-7246-0987			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, NATO ASI SERIES A, V115, P2; ADLER R, 1981, DEV BIOL, V86, P69, DOI 10.1016/0012-1606(81)90316-X; BALENTINE JD, 1983, SURV SYN PATHOL RES, V2, P184; BALENTINE JD, 1986, J NEUROPATH EXP NEUR, V45, P363, DOI 10.1097/00005072-198605000-00148; BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1982, HEAD INJURY; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; COTMAN CW, 1984, SCIENCE, V225, P1287, DOI 10.1126/science.6382610; CRACCO RQ, 1985, CENTRAL NERVOUS SYST, V31, P331; DELATORRE JC, 1982, BRAIN RES BULL, V9, P545, DOI 10.1016/0361-9230(82)90162-9; EISENMENGER W, 1978, BEITR GERICHTL MED, V26, P281; EVANS JP, 1945, J NEUROSURG, V2, P306, DOI 10.3171/jns.1945.2.4.0306; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GO KG, 1986, NATO ASI SER, V115, P127; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; GRCEVIC N, 1982, RAD JUGOSL AKAD ZNAN, V402, P265; GRONWALL D, 1974, LANCET, V2, P605; GUTH L, 1981, J COMP NEUROL, V203, P297, DOI 10.1002/cne.902030209; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOFF SF, 1982, J COMP NEUROL, V205, P246, DOI 10.1002/cne.902050304; HOFF SF, 1982, J COMP NEUROL, V205, P253, DOI 10.1002/cne.902050305; JELLINGER K, 1977, PATHOLOGY PATHOGENES, V1; JENNETT B, 1982, MANAGEMENT HEAD INJU; KATO T, 1981, BRAIN RES, V212, P393, DOI 10.1016/0006-8993(81)90471-6; KENNADY JC, 1967, PAC MED SURG, V75, P163; Kirkpatrick J B, 1984, Semin Diagn Pathol, V1, P98; KIRKPATRICK JB, 1985, J NEUROPATH EXP NEUR, V44, P268, DOI 10.1097/00005072-198505000-00005; KISHORE PRS, 1982, HEAD INJURY; Kobrine A I, 1975, Surg Neurol, V3, P261; KOBRINE AI, 1977, J NEUROSURG, V46, P489; KRAULAND W, 1982, VERLETZUNGEN INTRAKR; LANGFITT TW, 1966, HEAD INJURY, P172; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LIESI P, 1984, J NEUROSCI RES, V11, P241, DOI 10.1002/jnr.490110304; LINDENBERG R, 1973, GUIDELINES APPLICATI, P420; MANTHORPE M, 1983, BRAIN RES, V267, P47, DOI 10.1016/0006-8993(83)91038-7; MCHEDLISHVILI G, 1986, NATO ASI SERIES A, V115, P295; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; NIETOSAMPEDRO M, 1989, SYNAPTIC PLASTICITY, P407; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; Oehmichen M, 1978, Beitr Gerichtl Med, V36, P291; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; OVERGAARD J, 1974, J NEUROSURG, V41, P532; PETERS G, 1955, HDB SPEZIELLEN PATHO, V13, P363; PETERS G, 1977, APALLIC SYNDROME; PETITO CK, 1982, J NEUROPATH EXP NEUR, V41, P423, DOI 10.1097/00005072-198207000-00005; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PRUSS RM, 1982, DEV BRAIN RES, V2, P19; Ramon y Cajal S, 1928, DEGENERATION REGENER; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; ROGERS SL, 1983, DEV BIOL, V98, P212, DOI 10.1016/0012-1606(83)90350-0; SCHLAEPFER WW, 1979, PROGR NEUROPATHOLOGY, V4, P101; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STURROCK RR, 1982, ADV CELL NEUROBIOL, V3, P3; WE EP, 1980, CIRC RES, V46, P37; WILMES F, 1979, ACTA NEUROPATHOL, V45, P47, DOI 10.1007/BF00691804; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	68	71	72	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL	1991	103			S			S3	S14					12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GF379	WOS:A1991GF37900002	1940963				2021-06-18	
J	LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; EISENBERG, HM				LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; EISENBERG, HM			DISPROPORTIONATELY SEVERE MEMORY DEFICIT IN RELATION TO NORMAL INTELLECTUAL-FUNCTIONING AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG D73,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; BADDELEY A, 1987, NEUROBEHAVIORAL RECO; Benton AL, 1978, MULTILINGUAL APHASIA; BROOKS D N, 1974, Cortex, V10, P224; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUTTERS N, 1985, J CLIN EXP NEUROPSYC, V7, P181, DOI 10.1080/01688638508401252; Butters N, 1980, ALCOHOLIC KORSAKOFFS; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GREEN DM, 1966, SIGNAL DETECTION THE; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; JACOBSON RR, 1987, PSYCHOL MED, V17, P649, DOI 10.1017/S0033291700025885; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Siegel S., 1956, NONPARAMETRIC STAT B; SQUIRE LR, 1986, BEHAV NEUROSCI, V100, P866, DOI 10.1037/0735-7044.100.6.866; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0; WARRINGTON EK, 1978, NEUROPSYCHOLOGIA, V16, P169, DOI 10.1016/0028-3932(78)90104-5; Wechsler D., 1955, MANUAL WECHSLER ADUL; WHITTY CWM, 1977, AMNESIA CLIN PSYCHOL; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	31	71	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	1988	51	10					1294	1301		10.1136/jnnp.51.10.1294			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	Q4621	WOS:A1988Q462100008	3225586	Bronze, Green Published			2021-06-18	
J	FILLEY, CM; CRANBERG, LD; ALEXANDER, MP; HART, EJ				FILLEY, CM; CRANBERG, LD; ALEXANDER, MP; HART, EJ			NEUROBEHAVIORAL OUTCOME AFTER CLOSED HEAD-INJURY IN CHILDHOOD AND ADOLESCENCE	ARCHIVES OF NEUROLOGY			English	Article									KENNEDY MEM HOSP, DEPT NEUROL, BOSTON, MA USA; VET ADM MED CTR JAMAICA PLAIN, DEPT NEUROL, BOSTON, MA 02130 USA; VET ADM MED CTR, BEDFORD, MA USA	FILLEY, CM (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT NEUROL, 4200 E 9TH AVE, DENVER, CO 80262 USA.						ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; Damasio A., 1979, CLIN NEUROPSYCHOLOGY, P360; Flach J, 1972, Scand J Rehabil Med, V4, P9; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, MANAGEMENT HEAD INJU, P80; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P49; LISHMAN WA, 1978, ORGANIC PSYCHIATRY, P191; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MITCHELL DE, 1973, LANCET, V2, P215; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163	31	71	71	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	FEB	1987	44	2					194	198		10.1001/archneur.1987.00520140058018			5	Clinical Neurology	Neurosciences & Neurology	F8054	WOS:A1987F805400016	3813936				2021-06-18	
J	CROMPTON, MR				CROMPTON, MR			BRAINSTEM LESIONS DUE TO CLOSED HEAD INJURY	LANCET			English	Article																Courville CB, 1945, TRAUMA; CROMPTON MR, 1966, LANCET, V2, P938; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FREIDE RL, 1961, ARCH NEUROLOGY, V4, P449; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P591, DOI 10.1001/archneurpsyc.1952.02320230017002; GRASHENKOV NI, 1965, 3 INT C NEUR SURG, P78; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; GURDJIAN ES, 1958, MECHANISMS DIAGNOSIS; JEFFERSON G, 1960, SELECTED PATERS, V11, P526; OPPENHEIMER DR, 1968, J NEUROL NEUROSUR PS, V31, P229; ROSSI GF, 1965, EXCERPTA MED INT  93, P117; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; VONGIERKE HE, 1966, HEAD INJURY C P, P383; WRIGHT RL, 1966, J NEUROSURG, V25, P402, DOI 10.3171/jns.1966.25.4.0402	14	71	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet		1971	1	7701					669	&					0	Medicine, General & Internal	General & Internal Medicine	I9695	WOS:A1971I969500003	4101614				2021-06-18	
J	RINDER, L; OLSSON, Y				RINDER, L; OLSSON, Y			STUDIES ON VASCULAR PERMEABILITY CHANGES IN EXPERIMENTAL BRAIN CONCUSSION .1. DISTRIBUTION OF CIRCULATING FLUORESCENT INDICATORS IN BRAIN AND CERVICAL CORD AFTER SUDDEN MECHANICAL LOADING OF BRAIN	ACTA NEUROPATHOLOGICA			English	Article																	0	71	71	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.		1968	11	3					183	&					0	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	B9000	WOS:A1968B900000001	5709759				2021-06-18	
J	GURDJIAN, ES; WEBSTER, JE; LISSNER, HR				GURDJIAN, ES; WEBSTER, JE; LISSNER, HR			OBSERVATIONS ON THE MECHANISM OF BRAIN CONCUSSION, CONTUSION, AND LACERATION	SURGERY GYNECOLOGY & OBSTETRICS			English	Article																Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DURET H, 1920, TRAUMATISMES CRANIO; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Gurdjian ES, 1944, SURGERY, V16, P381; GURDJIAN ES, 1946, FED P, V5, P1; HADDAD BF, UNPUBLISHED; LeCount ER, 1920, J AMER MED ASSOC, V74, P501, DOI 10.1001/jama.1920.02620080003002; LITTRE A, 1705, HIST ACADEMIE ROYALE, P54; Petit J-L, 1774, TRAITE MALADIES CHIR; POLIS A, 1894, REV CHIR PARIS, V14, P274; POLIS A, 1894, REV CHIR, V14, P645; PUDENZ R, 1943, DEC M ASS RES NERV M; WALKER EA, 1944, J NEUROSURG, V1, P103; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WYCIS HT, 1947, CALIFORNIA NEUROL, V8, P292	16	71	71	0	3	FRANKLIN H MARTIN FOUNDATION	CHICAGO	55 E ERIE ST, CHICAGO, IL 60611	0039-6087			SURG GYNECOL OBSTET	Surg. Gynecol. Obstet.		1955	101	6					680	690					11	Obstetrics & Gynecology; Surgery	Obstetrics & Gynecology; Surgery	WF745	WOS:A1955WF74500004	13274275				2021-06-18	
J	Sun, GY; Simonyi, A; Fritsche, KL; Chuang, DY; Hannink, M; Gu, ZZ; Greenlie, CM; Yao, JK; Lee, JC; Beversdorf, DQ				Sun, Grace Y.; Simonyi, Agnes; Fritsche, Kevin L.; Chuang, Dennis Y.; Hannink, Mark; Gu, Zezong; Greenlie, C. Michael; Yao, Jeffrey K.; Lee, James C.; Beversdorf, David Q.			Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases	PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS			English	Article						Docosahexaenoic acid (DHA); Polyunsaturated fatty acids (PUFA); IPLA(2); Alox 15; Oxylipins Neuroprotectin 1 (NPD1); Resolving; Neuroinflammation; Signaling pathways; Oxidative metabolites; 4-hydoxyhexenal (4-HHE); Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B); Nuclear factor (erythroid-derived 2)-like 2 (Nrf2); Antioxidant response element (ARE); Heme oxygenase-1 (HO-1); Brain-derived neurotropic factor (BDNF); Brain development; Life spectrum	POLYUNSATURATED FATTY-ACIDS; LONG-CHAIN OMEGA-3-FATTY-ACIDS; INDEPENDENT PHOSPHOLIPASE A(2); AUTISM SPECTRUM DISORDERS; PLACEBO-CONTROLLED TRIAL; AMYLOID-BETA PEPTIDE; DIETARY N-3 PUFA; ALZHEIMERS-DISEASE; EICOSAPENTAENOIC ACID; LIPID-PEROXIDATION	Docosahexaenoic acid (DHA), a polyunsaturated fatty acid (PUFA) enriched in phospholipids in the brain and retina, is known to play multi-functional roles in brain health and diseases. While arachidonic acid (AA) is released from membrane phospholipids by cytosolic phospholipase A(2) (cPLA(2)), DHA is linked to action of the Ca2+-independent iPLA2. DHA undergoes enzymatic conversion by 15-lipoxygenase (Alox 15) to form oxylipins including resolvins and neuroprotectins, which are powerful lipid mediators. DHA can also undergo non enzymatic conversion by reacting with oxygen free radicals (ROS), which cause the production of 4-hydoxyhexenal (4-HHE), an aldehyde derivative which can form adducts with DNA, proteins and lipids. In studies with both animal models and humans, there is evidence that inadequate intake of maternal n-3 PUFA may lead to aberrant development and function of the central nervous system (CNS). What is less certain is whether consumption of n-3 PUFA is important in maintaining brain health throughout one's life span. Evidence mostly from non-human studies suggests that DHA intake above normal nutritional requirements might modify the risk/course of a number of diseases of the brain. This concept has fueled much of the present interest in DHA research, in particular, in attempts to delineate mechanisms whereby DHA may serve as a nutraceutical and confer neuroprotective effects. Current studies have revealed ability for the oxylipins to regulation of cell redox homeostasis through the Nuclear factor (erythroid-derived 2)-like 2/Antioxidant response element (Nrf2/ARE) anti-oxidant pathway, and impact signaling pathways associated with neurotransmitters, and modulation of neuronal functions involving brain-derived neurotropic factor (BDNF). This review is aimed at describing recent studies elaborating these mechanisms with special regard to aging and Alzheimer's disease, autism spectrum disorder, schizophrenia, traumatic brain injury, and stroke.	[Sun, Grace Y.; Simonyi, Agnes; Hannink, Mark] Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA; [Fritsche, Kevin L.] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO 65211 USA; [Chuang, Dennis Y.] Univ Hosp Cleveland, Med Ctr, Dept Neurol, Cleveland, OH 44106 USA; [Chuang, Dennis Y.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Gu, Zezong] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65211 USA; [Greenlie, C. Michael] Univ Missouri, Dept Chem, Columbia, MO 65211 USA; [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Med Res Serv, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Lee, James C.] Univ Illinois, Dept Bioengn, Chicago, IL USA; [Beversdorf, David Q.] Univ Missouri, Sch Med, Dept Radiol Neurol & Psychol Sci, Columbia, MO 65211 USA; [Beversdorf, David Q.] Univ Missouri, Sch Med, Thompson Ctr, Radiol, Columbia, MO 65211 USA	Sun, GY (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG044404] Funding Source: NIH RePORTER		Afshordel S, 2015, PROSTAG LEUKOTR ESS, V92, P23, DOI 10.1016/j.plefa.2014.05.008; Ajit D, 2016, NEUROCHEM INT, V97, P49, DOI 10.1016/j.neuint.2016.05.004; Al-Farsi YM, 2013, NUTRITION, V29, P1142, DOI 10.1016/j.nut.2013.03.009; Amminger GP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8934; Amminger GP, 2010, ARCH GEN PSYCHIAT, V67, P146, DOI 10.1001/archgenpsychiatry.2009.192; Anderson R, 2001, J MOL NEUROSCI, V16, P279; Anthonymuthu TS, 2016, BRAIN RES, V1640, P57, DOI 10.1016/j.brainres.2016.02.006; Arsenault D., 2011, PLOS ONE, V6; Bazan NG, 2013, PROSTAG LEUKOTR ESS, V88, P127, DOI 10.1016/j.plefa.2012.08.008; BAZAN N G, 1981, Progress in Lipid Research, V20, P523; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Bazan NG, 2012, EXP NEUROL, V236, P122, DOI 10.1016/j.expneurol.2012.04.007; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bentsen H, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.110; Bentsen H, 2011, BIOL PSYCHIAT, V70, P97, DOI 10.1016/j.biopsych.2011.02.011; Berger GE, 2007, J CLIN PSYCHIAT, V68, P1867, DOI 10.4088/JCP.v68n1206; Bu JY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6906712; Burckhardt M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009002.pub3; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Carabelli B, 2015, MOL NEUROBIOL, V52, P206, DOI 10.1007/s12035-014-8849-8; Cederholm T, 2017, CURR OPIN CLIN NUTR, V20, P104, DOI 10.1097/MCO.0000000000000350; Chalon S, 2006, PROSTAG LEUKOTR ESS, V75, P259, DOI 10.1016/j.plefa.2006.07.005; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Chen CT, 2008, PROSTAG LEUKOTR ESS, V79, P85, DOI 10.1016/j.plefa.2008.09.003; Chen ZH, 2006, FEBS LETT, V580, P479, DOI 10.1016/j.febslet.2005.12.045; Chen ZH, 2005, J BIOL CHEM, V280, P41921, DOI 10.1074/jbc.M508556200; Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677; Chew WS, 2017, NEUROSCIENCE, V340, P91, DOI 10.1016/j.neuroscience.2016.10.037; Chew WS, 2016, MOL NEUROBIOL, V53, P500, DOI 10.1007/s12035-014-9026-9; Chuang DY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0419-0; Cipollina C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/501792; Cipollina C, 2014, BBA-GEN SUBJECTS, V1840, P2299, DOI 10.1016/j.bbagen.2014.02.024; Cipollina C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094836; Condray Ruth, 2011, Front Biosci (Schol Ed), V3, P298, DOI 10.2741/s153; Csala M, 2015, BBA-MOL BASIS DIS, V1852, P826, DOI 10.1016/j.bbadis.2015.01.015; Cunnane SC, 2003, PROG LIPID RES, V42, P544, DOI 10.1016/S0163-7827(03)00038-9; Davis-Bruno K, 2011, BIRTH DEFECTS RES B, V92, P240, DOI 10.1002/bdrb.20311; Fernandes DPD, 2015, NUTR HOSP, V32, P528, DOI 10.3305/nh.2015.32.2.9111; Denis I, 2013, AGEING RES REV, V12, P579, DOI 10.1016/j.arr.2013.01.007; Derosa G, 2012, J CLIN LIPIDOL, V6, P553, DOI 10.1016/j.jacl.2012.02.010; Devassy JG, 2016, ADV NUTR, V7, P905, DOI 10.3945/an.116.012187; du Bois TM, 2005, PROG NEURO-PSYCHOPH, V29, P878, DOI 10.1016/j.pnpbp.2005.04.034; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Dyall SC, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00052; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Eckert GP, 2011, BBA-BIOMEMBRANES, V1808, P236, DOI 10.1016/j.bbamem.2010.10.014; El-Ansary AK, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-63; Emsley R, 2008, PSYCHIAT RES, V161, P284, DOI 10.1016/j.psychres.2007.06.029; Farias J. G., 2016, EXP BIOL MED; Fedorova I, 2009, BEHAV NEUROSCI, V123, P196, DOI 10.1037/a0013801; Fenton WS, 2000, BIOL PSYCHIAT, V47, P8, DOI 10.1016/S0006-3223(99)00092-X; Figueroa JD, 2013, J NEUROTRAUM, V30, P853, DOI 10.1089/neu.2012.2718; Fiol-deRoque MA, 2013, BIOGERONTOLOGY, V14, P763, DOI 10.1007/s10522-013-9461-4; Freeman MP, 2006, J CLIN PSYCHIAT, V67, P1954, DOI 10.4088/JCP.v67n1217; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Gan L, 2014, BBA-MOL BASIS DIS, V1842, P1208, DOI 10.1016/j.bbadis.2013.12.011; Gao B, 2014, CLIN PHARMACOL-ADV A, V6, P19, DOI 10.2147/CPAA.S35078; Gao JQ, 2016, INT J DEV NEUROSCI, V49, P67, DOI 10.1016/j.ijdevneu.2015.11.006; Gatbonton-Schwager TN, 2014, REDOX BIOL, V2, P755, DOI 10.1016/j.redox.2014.04.009; Gharami K, 2015, NEUROCHEM INT, V89, P51, DOI 10.1016/j.neuint.2015.08.014; Green JT, 2008, J LIPID RES, V49, P939, DOI 10.1194/jlr.R700017-JLR200; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Grosso G, 2016, J AFFECT DISORDERS, V205, P269, DOI 10.1016/j.jad.2016.08.011; Guesnet P, 2011, BIOCHIMIE, V93, P7, DOI 10.1016/j.biochi.2010.05.005; Guichardant M, 2006, PROSTAG LEUKOTR ESS, V75, P179, DOI 10.1016/j.plefa.2006.05.006; Guixa-Gonzalez R, 2016, SCI REP-UK, V6, DOI 10.1038/srep19839; Harris WS, 2008, ATHEROSCLEROSIS, V197, P12, DOI 10.1016/j.atherosclerosis.2007.11.008; Harris WS, 2007, PHARMACOL RES, V55, P217, DOI 10.1016/j.phrs.2007.01.013; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hashimoto M, 2006, CLIN EXP PHARMACOL P, V33, P934, DOI 10.1111/j.1440-1681.2006.04467.x; Hashimoto M, 2015, BBA-MOL CELL BIOL L, V1851, P203, DOI 10.1016/j.bbalip.2014.10.009; He Y, 2011, ASN NEURO, V3, P13, DOI 10.1042/AN20100025; Hedelin M, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-38; Heras-Sandoval D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0525-7; Hjorth E, 2013, J ALZHEIMERS DIS, V35, P697, DOI 10.3233/JAD-130131; Hoen WP, 2013, PSYCHIAT RES, V207, P1, DOI 10.1016/j.psychres.2012.09.041; Hong S, 2007, J AM SOC MASS SPECTR, V18, P128, DOI 10.1016/j.jasms.2006.09.002; Hooijmans CR, 2009, NEUROBIOL DIS, V33, P482, DOI 10.1016/j.nbd.2008.12.002; Hooijmans CR, 2007, BRAIN RES, V1181, P93, DOI 10.1016/j.brainres.2007.08.063; Horvath A., 2017, J NUTR; Hosono T, 2015, J ALZHEIMERS DIS, V48, P149, DOI 10.3233/JAD-150341; Huang Y, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-40; Ishikado A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069415; Ishikado A, 2010, BIOCHEM BIOPH RES CO, V402, P99, DOI 10.1016/j.bbrc.2010.09.124; Jacobson TA, 2012, J CLIN LIPIDOL, V6, P5, DOI 10.1016/j.jacl.2011.10.018; James S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007992.pub2; Jiang LH, 2009, J NUTR BIOCHEM, V20, P735, DOI 10.1016/j.jnutbio.2008.07.003; Jones KL, 2013, BEHAV BRAIN RES, V238, P193, DOI 10.1016/j.bbr.2012.10.028; Julvez J, 2016, AM J EPIDEMIOL, V183, P169, DOI 10.1093/aje/kwv195; Kariv-Inbal Z, 2012, J ALZHEIMERS DIS, V28, P667, DOI 10.3233/JAD-2011-111265; KESHAVAN MS, 1994, J PSYCHIATR RES, V28, P239, DOI 10.1016/0022-3956(94)90009-4; Kim HY, 2014, PROG LIPID RES, V56, P1, DOI 10.1016/j.plipres.2014.06.002; Kondo K, 2014, METABOLISM, V63, P930, DOI 10.1016/j.metabol.2014.04.005; Kusunoki C, 2013, BIOCHEM BIOPH RES CO, V430, P225, DOI 10.1016/j.bbrc.2012.10.115; Labrousse VF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036861; Lee LHW, 2012, INT J NEUROPSYCHOPH, V15, P1087, DOI 10.1017/S1461145711001234; Leslie CC, 2015, J LIPID RES, V56, P1386, DOI 10.1194/jlr.R057588; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lim SN, 2013, NEUROBIOL DIS, V51, P104, DOI 10.1016/j.nbd.2012.10.021; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Liu JJ, 2015, BRAIN RES, V1597, P220, DOI 10.1016/j.brainres.2014.11.059; Long EK, 2010, FREE RADICAL BIO MED, V49, P1, DOI 10.1016/j.freeradbiomed.2010.03.015; Luchtman DW, 2013, NEUROPHARMACOLOGY, V64, P550, DOI 10.1016/j.neuropharm.2012.07.019; Lyall K, 2013, AM J EPIDEMIOL, V178, P209, DOI 10.1093/aje/kws433; Mankad D, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0010-7; Matsui Y. K., 2015, SOC NEUR ABSTR, P26; Mazzocchi-Jones D, 2015, BRAIN RES BULL, V111, P69, DOI 10.1016/j.brainresbull.2014.12.010; McEvoy J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068717; McNamara R.K., 2013, CARDIOVASC PSYCHIAT, V2013; McNamara RK, 2016, EARLY INTERV PSYCHIA, V10, P203, DOI 10.1111/eip.12282; Mechelli A., 2016, SCHIZOPHR RES; Medema S, 2016, SCHIZOPHRENIA BULL, V42, P358, DOI 10.1093/schbul/sbv133; Messamore E, 2017, PROG LIPID RES, V66, P1, DOI 10.1016/j.plipres.2017.01.001; Messamore J. K., 2016, OILSEEDS FATS CORPS, V23, pD112; Meyza K. Z., 2017, NEUROSCI BIOBEHAV RE; Meyza KZ, 2013, BEHAV BRAIN RES, V251, P25, DOI 10.1016/j.bbr.2012.07.021; Morgese MG, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6030024; Morris MC, 2005, ARCH NEUROL-CHICAGO, V62, P1849, DOI 10.1001/archneur.62.12.noc50161; Mostafa GA, 2015, BEHAV BRAIN FUNCT, V11, DOI 10.1186/s12993-014-0048-2; Nakagawa F, 2014, BIOCHEM BIOPH RES CO, V443, P991, DOI 10.1016/j.bbrc.2013.12.085; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; Nordmann C, 2014, J NEUROCHEM, V131, P163, DOI 10.1111/jnc.12789; Norris SE, 2015, NEUROBIOL AGING, V36, P1659, DOI 10.1016/j.neurobiolaging.2015.01.002; Ohara K, 2007, PROG NEURO-PSYCHOPH, V31, P469, DOI 10.1016/j.pnpbp.2006.11.013; Oksman M, 2006, NEUROBIOL DIS, V23, P563, DOI 10.1016/j.nbd.2006.04.013; Ooi YP, 2017, PHARMACOPSYCHIATRY, V50, DOI 10.1055/s-0042-109400; Osborne C, 2016, NEUROPHARMACOLOGY, V101, P225, DOI 10.1016/j.neuropharm.2015.09.030; Pan JP, 2011, BRAIN RES, V1412, P18, DOI 10.1016/j.brainres.2011.07.015; Parrott MD, 2015, NEUROBIOL AGING, V36, P90, DOI 10.1016/j.neurobiolaging.2014.08.013; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-6; Patrick RP, 2015, FASEB J, V29, P2207, DOI 10.1096/fj.14-268342; Pawelczyk T, 2016, J PSYCHIATR RES, V73, P34, DOI 10.1016/j.jpsychires.2015.11.013; Perez SE, 2010, J NEUROSCI RES, V88, P1026, DOI 10.1002/jnr.22266; Perica MM, 2011, NUTR CLIN PRACT, V26, P409, DOI 10.1177/0884533611411306; Pietropaolo S, 2014, PSYCHONEUROENDOCRINO, V49, P119, DOI 10.1016/j.psyneuen.2014.07.002; Posar A, 2016, J PEDIATR NEUROSCI, V11, P225, DOI 10.4103/1817-1745.193363; PREMKUMAR N, 1993, J NEUROSCI RES, V35, P321, DOI 10.1002/jnr.490350312; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Pusceddu M. M., 2016, INT J NEUROPSYCHOPHA; Ramanadham S, 2015, J LIPID RES, V56, P1643, DOI 10.1194/jlr.R058701; Rao JS, 2007, MOL PSYCHIATR, V12, P151, DOI 10.1038/sj.mp.4001887; Rao JS, 2007, MOL PSYCHIATR, V12, P36, DOI 10.1038/sj.mp.4001888; Reddy R, 2011, PROSTAG LEUKOTR ESS, V84, P79, DOI 10.1016/j.plefa.2010.12.001; Rey C, 2016, BRAIN BEHAV IMMUN, V55, P249, DOI 10.1016/j.bbi.2015.12.013; Riahi Y, 2010, AM J PHYSIOL-ENDOC M, V299, pE879, DOI 10.1152/ajpendo.00508.2010; Richardson AJ, 2000, EUR NEUROPSYCHOPHARM, V10, P189, DOI 10.1016/S0924-977X(00)00068-7; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Saponetti MS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115780; Scapagnini G, 2011, MOL NEUROBIOL, V44, P192, DOI 10.1007/s12035-011-8181-5; Schaeffer EL, 2005, PSYCHOPHARMACOLOGY, V181, P392, DOI 10.1007/s00213-005-2256-9; Schaeffer EL, 2009, PSYCHOPHARMACOLOGY, V202, P37, DOI 10.1007/s00213-008-1351-0; Schaur RJ, 2015, BIOMOLECULES, V5, P2247, DOI 10.3390/biom5042247; Schlogelhofer M, 2014, EARLY INTERV PSYCHIA, V8, P199, DOI 10.1111/eip.12151; Segawa K, 2014, SCIENCE, V344, P1164, DOI 10.1126/science.1252809; Serhan CN, 2011, CHEM BIOL, V18, P976, DOI 10.1016/j.chembiol.2011.06.008; Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005; Serini S, 2016, CURR ALZHEIMER RES, V13, P123, DOI 10.2174/1567205012666150921101147; Shalini S. M, 2017, MOL NEUROBIOL; Shalini SM, 2016, MOL NEUROBIOL; Shalini SM, 2014, NEUROCHEM INT, V78, P96, DOI 10.1016/j.neuint.2014.08.006; Shelat PB, 2008, J NEUROCHEM, V106, P45, DOI 10.1111/j.1471-4159.2008.05347.x; Sliwinski S, 2006, NEUROENDOCRINOL LETT, V27, P465; Smith T, 2010, AM FAM PHYSICIAN, V82, P338; Solberg DK, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1006-3; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Strokin M, 2007, J NEUROCHEM, V102, P1771, DOI 10.1111/j.1471-4159.2007.04663.x; Sugasini D, 2015, NUTR NEUROSCI, V18, P87, DOI 10.1179/1476830514Y.0000000111; Sumiyoshi T, 2011, PSYCHIAT RES, V186, P23, DOI 10.1016/j.psychres.2010.07.049; Sun GY, 2016, NEUROMOL MED, V18, P241, DOI 10.1007/s12017-016-8411-0; Sun GY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141509; Sun GY, 2014, MOL NEUROBIOL, V50, P6, DOI 10.1007/s12035-014-8662-4; SUN GY, 1968, LIPIDS, V3, P79, DOI 10.1007/BF02530973; SUN GY, 1970, LIPIDS, V5, P1006, DOI 10.1007/BF02533205; Tang MM, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0236-1; Torres M, 2014, BBA-BIOMEMBRANES, V1838, P1680, DOI 10.1016/j.bbamem.2013.12.016; Tremblay ME, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0580-0; Trepanier MO, 2016, EUR J PHARMACOL, V785, P187, DOI 10.1016/j.ejphar.2015.05.045; van de Rest O, 2016, NEUROLOGY, V86, P2063, DOI 10.1212/WNL.0000000000002719; van der Kemp WJM, 2012, SCHIZOPHR RES, V141, P153, DOI 10.1016/j.schres.2012.08.014; Vancassel S, 2001, PROSTAG LEUKOTR ESS, V65, P1, DOI 10.1054/plef.2001.0281; Vandal M, 2014, J NEUROCHEM, V129, P516, DOI 10.1111/jnc.12640; Weiser MJ, 2016, NUTRIENTS, V8, DOI 10.3390/nu8020099; Weiser MJ, 2016, PROSTAG LEUKOTR ESS, V106, P27, DOI 10.1016/j.plefa.2015.10.005; Wellhauser L, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-60; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2015, BBA-MOL BASIS DIS, V1852, P951, DOI 10.1016/j.bbadis.2014.12.005; Yanai Hidekatsu, 2017, J Clin Med Res, V9, P1; Yang XG, 2011, NEUROCHEM INT, V58, P321, DOI 10.1016/j.neuint.2010.12.004; Yao J.K., 2003, ABNORMALITIES FATTY, P193; Yao JK, 2016, SCHIZOPHRENIA BULL, V42, P369, DOI 10.1093/schbul/sbv130; Yao JK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00090; Yao JK, 2011, ANTIOXID REDOX SIGN, V15, P1999, DOI 10.1089/ars.2010.3646; Yavin E, 2001, J MOL NEUROSCI, V16, P229, DOI 10.1385/JMN:16:2-3:229; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang MJ, 2014, J NEUROSCI, V34, P1903, DOI 10.1523/JNEUROSCI.4043-13.2014; Zhang WT, 2016, NEUROBIOL DIS, V91, P37, DOI 10.1016/j.nbd.2016.02.020; Zhang Y, 2016, AM J CLIN NUTR, V103, P330, DOI 10.3945/ajcn.115.124081; Zhu DH, 2006, J NEUROSCI, V26, P11111, DOI 10.1523/JNEUROSCI.3505-06.2006; Zilkha N., 2016, NEUROSCIENCE; Zimmer L, 2000, NEUROSCI LETT, V284, P25, DOI 10.1016/S0304-3940(00)00950-2	201	70	73	6	50	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0952-3278	1532-2823		PROSTAG LEUKOTR ESS	Prostaglandins Leukot. Essent. Fatty Acids	SEP	2018	136				SI		3	13		10.1016/j.plefa.2017.03.006			11	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism	GZ5GK	WOS:000449447000002	28314621				2021-06-18	
J	Glenn, TC; Martin, NA; Horning, MA; McArthur, DL; Hovda, DA; Vespa, P; Brooks, GA				Glenn, Thomas C.; Martin, Neil A.; Horning, Michael A.; McArthur, David L.; Hovda, David A.; Vespa, Paul; Brooks, George A.			Lactate: Brain Fuel in Human Traumatic Brain Injury: A Comparison with Normal Healthy Control Subjects	JOURNAL OF NEUROTRAUMA			English	Article						brain; fuel augmentation; glucose; lactate; mass spectrometry; stable isotopes; TBI	CEREBRAL BLOOD-FLOW; EXERCISE; GLUCOSE; REST; MUSCLE; GLUCONEOGENESIS; ACCLIMATIZATION; METABOLISM; RELEASE; EXTRACTION	We evaluated the hypothesis that lactate shuttling helps support the nutritive needs of injured brains. To that end, we utilized dual isotope tracer [6,6-(2)H2]glucose, that is, D2-glucose, and [3-C-13]lactate techniques involving arm vein tracer infusion along with simultaneous cerebral (arterial [art] and jugular bulb [JB]) blood sampling. Traumatic brain injury (TBI) patients with nonpenetrating brain injuries (n=12) were entered into the study following consent of patients' legal representatives. Written and informed consent was obtained from control volunteers (n=6). Patients were studied 5.7 +/- 2.2 (mean +/- SD) days post-injury; during periods when arterial glucose concentration tended to be higher in TBI patients. As in previous investigations, the cerebral metabolic rate for glucose (CMRgluc, i.e., net glucose uptake) was significantly suppressed following TBI (p<0.001). However, lactate fractional extraction, an index of cerebral lactate uptake related to systemic lactate supply, approximated 11% in both healthy control subjects and TBI patients. Further, neither the CMR for lactate (CMRlac, i.e., net lactate release), nor the tracer-measured cerebral lactate uptake differed between healthy controls and TBI patients. The percentages of lactate tracer taken up and released as (CO2)-C-13 into the JB accounted for 92% and 91% for control and TBI conditions, respectively, suggesting that most cerebral lactate uptake was oxidized following TBI. Comparisons of isotopic enrichments of lactate oxidation from infused [3-C-13]lactate tracer and C-13-glucose produced during hepatic and renal gluconeogenesis (GNG) showed that 75-80% of (CO2)-C-13 released into the JB was from lactate and that the remainder was from the oxidation of glucose secondarily labeled from lactate. Hence, either directly as lactate uptake, or indirectly via GNG, peripheral lactate production accounted for approximate to 70% of carbohydrate (direct lactate uptake+uptake of glucose from lactate) consumed by the injured brain. Undiminished cerebral lactate fractional extraction and uptake suggest that arterial lactate supplementation may be used to compensate for decreased CMRgluc following TBI.	[Glenn, Thomas C.; Martin, Neil A.; McArthur, David L.; Hovda, David A.; Vespa, Paul] Univ Calif Los Angeles, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; [Glenn, Thomas C.; Martin, Neil A.] Univ Calif Los Angeles, Ctr Hlth Sci, Dept Neurosurg, Los Angeles, CA 90095 USA; [Horning, Michael A.; Brooks, George A.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA	Glenn, TC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tglenn@mednet.ucla.edu		Brooks, George A./0000-0002-1389-1629; Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS058489, P01NS058489] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER		AHLBORG G, 1982, J CLIN INVEST, V69, P45, DOI 10.1172/JCI110440; Bergman BC, 2000, AM J PHYSIOL-ENDOC M, V278, pE244; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684; Bergman BC, 2009, J PHYSIOL-LONDON, V587, P2087, DOI 10.1113/jphysiol.2008.168286; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brooks G.A., 1984, COMP PHYSL BIOCH CUR; Brooks GA, 1998, AM J PHYSIOL-REG I, V275, pR1192; BROOKS GA, 1992, J APPL PHYSIOL, V72, P2435; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; BROOKS GA, 1991, J APPL PHYSIOL, V71, P333; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Cahill G J Jr, 1968, Adv Enzyme Regul, V6, P143, DOI 10.1016/0065-2571(68)90011-3; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Emhoff CAW, 2013, J APPL PHYSIOL, V115, P829, DOI 10.1152/japplphysiol.00538.2013; Emhoff CAW, 2013, J APPL PHYSIOL, V114, P297, DOI 10.1152/japplphysiol.01202.2012; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GERTZ EW, 1988, J CLIN INVEST, V82, P2017, DOI 10.1172/JCI113822; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Glenn TC, 2014, J NEUROTRAUMA; HAKIM A M, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P115; Hashimoto T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002915; Henderson GC, 2007, J APPL PHYSIOL, V103, P1604, DOI 10.1152/japplphysiol.00309.2007; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; IOM (Institute of Medicine), 2005, DIET REF INT EN CARB; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; JENSSEN T, 1993, EUR J CLIN INVEST, V23, P448, DOI 10.1111/j.1365-2362.1993.tb00789.x; Johnson ML, 2012, AM J PHYSIOL-REG I, V302, pR143, DOI 10.1152/ajpregu.00402.2011; Johnson ML, 2011, AM J PHYSIOL-REG I, V301, pR769, DOI 10.1152/ajpregu.00206.2011; MAZZEO RS, 1995, AM J PHYSIOL-REG I, V269, pR201; MAZZEO RS, 1986, J APPL PHYSIOL, V60, P232; Messonnier LA, 2013, J APPL PHYSIOL, V114, P1593, DOI 10.1152/japplphysiol.00043.2013; Meyer C, 2002, AM J PHYSIOL-ENDOC M, V282, pE419, DOI 10.1152/ajpendo.00032.2001; Miller BF, 2005, J APPL PHYSIOL, V98, P856, DOI 10.1152/japplphysiol.00753.2004; Miller BF, 2002, J PHYSIOL-LONDON, V544, P963, DOI 10.1113/jphysiol.2002.027128; Miller BF, 2002, AM J PHYSIOL-ENDOC M, V283, pE889, DOI 10.1152/ajpendo.00266.2002; Patel AB, 2014, P NATL ACAD SCI USA, V111, P5385, DOI 10.1073/pnas.1403576111; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Siesjo BK, 1996, ADV NEUROL, V71, P209; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; STANLEY WC, 1986, J APPL PHYSIOL, V60, P1116; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; Trimmer JK, 2001, AM J PHYSIOL-ENDOC M, V281, pE683; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Wilcox R., 2012, INTRO ROBUST ESTIMAT, V1st; Wolfe R.R., 1982, RADIOACTIVE STABLE I; Yuen K.F., 1985, J ROYAL STAT SOC D, V34, P175	56	70	73	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					820	832		10.1089/neu.2014.3483			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700007	25594628	Green Published			2021-06-18	
J	Acosta, SA; Tajiri, N; de la Pena, I; Bastawrous, M; Sanberg, PR; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Tajiri, Naoki; de la Pena, Ike; Bastawrous, Marina; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.			Alpha-Synuclein as a Pathological Link Between Chronic Traumatic Brain Injury and Parkinson's Disease	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article							IN-VIVO; EXPRESSION; MICE; NEURODEGENERATION; PATHOPHYSIOLOGY; OLIGOMERIZATION; ENCEPHALOPATHY; CONSEQUENCES; DEFICITS; RELEASE	The long-term consequences of traumatic brain injury (TBI) are closely associated with the development of histopathological deficits. Notably, TBI may predispose long-term survivors to age-related neurodegenerative diseases, such as Parkinson's disease (PD), which is characterized by a gradual degeneration of the nigrostriatal dopaminergic neurons. However, preclinical studies on the pathophysiological changes in substantia nigra (SN) after chronic TBI are lacking. In the present in vivo study, we examined the pathological link between PD-associated dopaminergic neuronal loss and chronic TBI. Sixty days post-TBI, rats were euthanized and brain tissues harvested. Immunostaining was performed using tyrosine hydroxylase (TH), an enzyme required for the synthesis of dopamine in neurons, -synuclein, a presynaptic protein that plays a role in synaptic vesicle recycling, and major histocompatibility complex II (MHCII), a protein found in antigen presenting cells such as inflammatory microglia cells, all key players in PD pathology. Unbiased stereology analyses revealed significant decrease of TH-positive expression in the surviving dopaminergic neurons of the SN pars compacta (SNpc) relative to sham control. In parallel, increased -synuclein accumulation was detected in the ipsilateral SN compared to the contralateral SN in TBI animals or sham control. In addition, exacerbation of MHCII+ cells was recognized in the SN and cerebral peduncle ipsilateral to injury relative to contralateral side and sham control. These results suggest -synuclein as a pathological link between chronic effects of TBI and PD symptoms as evidenced by significant overexpression and abnormal accumulation of -synuclein in inflammation-infiltrated SN of rats exposed to chronic TBI. J. Cell. Physiol. 230: 1024-1032, 2015. (c) 2014 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.	[Acosta, Sandra A.; Tajiri, Naoki; de la Pena, Ike; Bastawrous, Marina; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Sanberg, Paul R.] Univ S Florida, Off Res & Innovat, Tampa, FL 33612 USA	Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	cborlong@health.usf.edu		dela Pena, Ike/0000-0003-2046-522X	National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01]; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; James and Esther King Foundation for Biomedical Research Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health, National Institute of Neurological Disorders and Stroke;; Contract grant number: 1R01NS071956-01.; Contract grant sponsor: Department of Defense;; Contract grant number: W81XWH-11-1-0634.; Contract grant sponsor: James and Esther King Foundation for Biomedical Research Program.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Amstrong RA, 2003, HISTOPATHOLOGY, V42, P521; Armstrong RA, 2014, J NEURAL TRANSM, V121, P171, DOI 10.1007/s00702-013-1084-z; Auluck PK, 2010, ANNU REV CELL DEV BI, V26, P211, DOI 10.1146/annurev.cellbio.042308.113313; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Chaudhuri KR, 2006, LANCET NEUROL, V5, P235, DOI 10.1016/S1474-4422(06)70373-8; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; Danzer KM, 2011, FASEB J, V25, P326, DOI 10.1096/fj.10-164624; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gaugler MN, 2012, ACTA NEUROPATHOL, V123, P653, DOI 10.1007/s00401-012-0963-y; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jannetta PJ, 2011, NEUROL INT, V3, P24, DOI 10.4081/ni.2011.e7; Karantzoulis S, 2013, NEUROPSYCHOL REV, V23, P350, DOI 10.1007/s11065-013-9243-4; Klein C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a008888; Kokjohn TA, 2013, J NEUROTRAUM, V30, P981, DOI 10.1089/neu.2012.2699; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MAYHEW TM, 1991, EXP PHYSIOL, V76, P639, DOI 10.1113/expphysiol.1991.sp003533; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Protter D, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/829207; Rodrigues TM, 2014, DRUG AGING, V31, P239, DOI 10.1007/s40266-014-0160-x; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Sato H, 2013, REV NEUROSCIENCE, V24, P115, DOI 10.1515/revneuro-2012-0071; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; Siebert H, 2010, J NEUROCHEM, V114, P1007, DOI 10.1111/j.1471-4159.2010.06832.x; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stefanis L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009399; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Su LHJ, 2010, DIS MODEL MECH, V3, P194, DOI 10.1242/dmm.004267; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Ulusoy A, 2013, MOL NEUROBIOL, V47, P484, DOI 10.1007/s12035-012-8329-y; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wakabayashi K, 2007, NEUROPATHOLOGY, V27, P494, DOI 10.1111/j.1440-1789.2007.00803.x; Wan OW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038545; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wong JC, 2013, CRIT REV CL LAB SCI, V50, P103, DOI 10.3109/10408363.2013.844678; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yu S, 2004, NEUROSCI LETT, V367, P34, DOI 10.1016/j.neulet.2004.05.118; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	59	70	70	0	56	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	MAY	2015	230	5					1024	1032		10.1002/jcp.24830			9	Cell Biology; Physiology	Cell Biology; Physiology	CB0FL	WOS:000349301000007	25251017	Green Published, Other Gold			2021-06-18	
J	Baugh, CM; Kiernan, PT; Kroshus, E; Daneshvar, DH; Montenigro, PH; McKee, AC; Stern, RA				Baugh, Christine M.; Kiernan, Patrick T.; Kroshus, Emily; Daneshvar, Daniel H.; Montenigro, Philip H.; McKee, Ann C.; Stern, Robert A.			Frequency of Head-Impact-Related Outcomes by Position in NCAA Division I Collegiate Football Players	JOURNAL OF NEUROTRAUMA			English	Article						American football; mild traumatic brain injury; concussion; college; linemen	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; SPORT-RELATED CONCUSSION; STATES HIGH-SCHOOL; BRAIN-INJURY; PROFESSIONAL FOOTBALL; UNITED-STATES; SUBCONCUSSIVE IMPACTS; EPIDEMIOLOGY; INTERVENTION	Concussions and subconcussive impacts sustained in American football have been associated with short- and long-term neurological impairment, but differences in head impact outcomes across playing positions are not well understood. The American Medical Society for Sports Medicine has identified playing position as a key risk factor for concussion in football and one for which additional research is needed. This study examined variation in head impact outcomes across primary football playing positions in a group of 730 National Collegiate Athletic Association Division I Football Championship Series athletes, using a self-report questionnaire. Although there were no significant differences between position groups in the number of diagnosed concussions during the 2012 football season, there were significant differences between groups in undiagnosed concussions (p=0.008) and "dings" (p<0.001); offensive linemen reported significantly higher numbers than most other positions. Significant differences were found between position groups in the frequencies of several postimpact symptoms, including dizziness (p<0.001), headache (p<0.001), and seeing stars (p<0.001) during the 2012 football season, with offensive linemen reporting significantly more symptoms compared to most other groups. There were also positional differences in frequency of returning to play while symptomatic (p<0.001) and frequency of participating in full-contact practice (p<0.001). Offensive linemen reported having returned to play while experiencing symptoms more frequently and participating in more full-contact practices than other groups. These findings suggest that offensive linemen, a position group that experiences frequent, but low-magnitude, head impacts, develop more postimpact symptoms than other playing positions, but do not report these symptoms as a concussion.	[Baugh, Christine M.] Harvard Univ, Harvard Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Kiernan, Patrick T.; Daneshvar, Daniel H.; Montenigro, Philip H.; McKee, Ann C.; Stern, Robert A.] Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA; [Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Kroshus, Emily] Natl Collegiate Athlet Assoc, Sport Sci Inst, Indianapolis, IN USA; [Daneshvar, Daniel H.] Boston Univ, Sch Med, Dept Behav Neurosci, Boston, MA 02118 USA; [Montenigro, Philip H.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Daneshvar, Daniel H.] Sports Legacy Inst, Boston, MA USA; [McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [McKee, Ann C.; Stern, Robert A.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA	Baugh, CM (corresponding author), Harvard Univ, Harvard Interfac Initiat Hlth Policy, 14 Story St,4th Floor, Cambridge, MA 02138 USA.	cbaugh@g.harvard.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Stern, Robert/0000-0002-5008-077X; Montenigro, Philip/0000-0003-4442-9207; Daneshvar, Daniel/0000-0003-3691-9513	Edmond J. Safra Center for Ethics at Harvard University; NCAA Sports Science Institute; Athena Diagnostics; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	Christine M. Baugh received funding from the Edmond J. Safra Center for Ethics at Harvard University to conduct the larger study from which data for this manuscript was derived. Emily Kroshus receives funding from the NCAA Sports Science Institute as a postdoctoral research fellow. Robert A. Stern is a paid consultant to Athena Diagnostics and receives royalties from Psychological Assessment Resources, Inc. He also provides expert consultation to legal teams involved with NCAA and NFL-related litigation.	[Anonymous], 2013, PAC 12 C EST NEW FOO; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio S. P., 2014, CONCUSSIONS ATHLETIC, P313; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Funk J. R., 2006, ANN P ASS ADV AUTOMO, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Ivy League Ad Hoc Concussion Committee, 2011, REP REG IV LEAG REV; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kroshus E., 2014, ANN BEHAV M IN PRESS; Kroshus E., 2014, CLIN J SPOR IN PRESS; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Mueller F. O., 2002, ANN SURVEY FOOTBALL; National Collegiate Athletic Association, 2014, CONC GUID DIAGN MAN; Nicholas J. A, 1970, FOOTBALL INJURIES, P233; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211	72	70	70	0	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					314	326		10.1089/neu.2014.3582			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700004	25155288	Green Published			2021-06-18	
J	Fann, JR; Bombardier, CH; Vannoy, S; Dyer, J; Ludman, E; Dikmen, S; Marshall, K; Barber, J; Temkin, N				Fann, Jesse R.; Bombardier, Charles H.; Vannoy, Steven; Dyer, Joshua; Ludman, Evette; Dikmen, Sureyya; Marshall, Kenneth; Barber, Jason; Temkin, Nancy			Telephone and In-Person Cognitive Behavioral Therapy for Major Depression after Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; clinical trial; rehabilitation; TBI; behavior	PRIMARY-CARE PATIENTS; QUALITY-OF-LIFE; ANTIDEPRESSANT TREATMENT; PSYCHIATRIC-DISORDERS; RATING-SCALE; SYMPTOMS; OUTCOMES; PSYCHOTHERAPY; SEVERITY; IMPACT	Major depressive disorder (MDD) is prevalent after traumatic brain injury (TBI); however, there is a lack of evidence regarding effective treatment approaches. We conducted a choice-stratified randomized controlled trial in 100 adults with MDD within 10 years of complicated mild to severe TBI to test the effectiveness of brief cognitive behavioral therapy administered over the telephone (CBT-T) (n=40) or in-person (CBT-IP) (n=18), compared with usual care (UC) (n=42). Participants were recruited from clinical and community settings throughout the United States. The main outcomes were change in depression severity on the clinician-rated 17 item Hamilton Depression Rating Scale (HAMD-17) and the patient-reported Symptom Checklist-20 (SCL-20) over 16 weeks. There was no significant difference between the combined CBT and UC groups over 16 weeks on the HAMD-17 (treatment effect=1.2, 95% CI: -1.5-4.0; p=0.37) and a nonsignificant trend favoring CBT on the SCL-20 (treatment effect=0.28, 95% CI: -0.03-0.59; p=0.074). In follow-up comparisons, the CBT-T group had significantly more improvement on the SCL-20 than the UC group (treatment effect=0.36, 95% CI: 0.01-0.70; p=0.043) and completers of eight or more CBT sessions had significantly improved SCL-20 scores compared with the UC group (treatment effect=0.43, 95% CI: 0.10-0.76; p=0.011). CBT participants reported significantly more symptom improvement (p=0.010) and greater satisfaction with depression care (p<0.001), than did the UC group. In-person and telephone-administered CBT are acceptable and feasible in persons with TBI. Although further research is warranted, telephone CBT holds particular promise for enhancing access and adherence to effective depression treatment.	[Fann, Jesse R.; Marshall, Kenneth] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Bombardier, Charles H.; Dyer, Joshua; Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Barber, Jason; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Vannoy, Steven] Univ Massachusetts, Dept Counseling & Sch Psychol, Boston, MA 02125 USA; [Ludman, Evette] Grp Hlth Res Inst, Seattle, WA USA	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.	fann@uw.edu	vannoy, steven/W-2737-2019		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21HD53736]; Department of Education, National Institute on Disability and Rehabilitation Research [H133G070016]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD053736] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health (grant R21HD53736) and the Department of Education, National Institute on Disability and Rehabilitation Research (grant H133G070016). We thank Douglas Weeks at St. Luke's Rehabilitation Institute, Tessa Hart, at Moss Rehabilitation Research Institute, and Thomas Novack at the University of Alabama, Birmingham for assistance with study recruitment.	Armento MEA, 2007, BEHAV THER, V38, P107, DOI 10.1016/j.beth.2006.05.003; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bagby RM, 2004, AM J PSYCHIAT, V161, P2163, DOI 10.1176/appi.ajp.161.12.2163; Baldwin SA, 2009, J CONSULT CLIN PSYCH, V77, P203, DOI 10.1037/a0015235; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Baumeister H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008381.pub2; Baumeister H, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008012.pub3; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; Beltman MW, 2010, BRIT J PSYCHIAT, V197, P11, DOI 10.1192/bjp.bp.109.064675; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Block CK, 2013, BRAIN INJURY, V27, P775, DOI 10.3109/02699052.2013.775487; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Burke BL, 2003, J CONSULT CLIN PSYCH, V71, P843, DOI 10.1037/0022-006X.71.5.843; Busseri MA, 2003, PSYCHOL ASSESSMENT, V15, P193, DOI 10.1037/1040-3590.15.2.193; Christensen AL, 1994, BRAIN INJURY NEUROPS; Cohen RM, 2013, JAMA PSYCHIAT, V70, P343, DOI 10.1001/jamapsychiatry.2013.286; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Dimidjian S, 2011, ANNU REV CLIN PSYCHO, V7, P1, DOI 10.1146/annurev-clinpsy-032210-104535; DOWNHILL JE, 1994, J NERV MENT DIS, V182, P425, DOI 10.1097/00005053-199408000-00001; Dwight-Johnson M, 2011, PSYCHIAT SERV, V62, P936, DOI 10.1176/ps.62.8.pss6208_0936; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fava M, 2003, BIOL PSYCHIAT, V53, P649, DOI 10.1016/S0006-3223(03)00231-2; First Michael B, 2001, USERS GUIDE STRUCTUR; Furukawa TA, 2007, J CLIN PSYCHOPHARM, V27, P531, DOI 10.1097/JCP.0b013e31814f30b1; Furukawa TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035330; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Guy, 1976, ECDEU ASSESSMENT MAN; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard M. R., 2005, COGNITIVE BEHAV THER, P189; Hibbard M. R., 1987, COGNITIVE THERAPY AP, P183; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLLON SD, 1980, COGNITIVE THER RES, V4, P383, DOI 10.1007/BF01178214; Horvath A.O., 1994, WORKING ALLIANCE THE; Horvath A.O., 1986, THER PSYCHOTHERAPEUT, V36, P529; Horvitz-Lennon M, 2003, AM J PSYCHIAT, V160, P720, DOI 10.1176/appi.ajp.160.4.720; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Iosifescu DV, 2007, PSYCHIAT CLIN N AM, V30, P77, DOI 10.1016/j.psc.2006.12.008; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; KUNY S, 1995, PSYCHOPATHOLOGY, V28, P190, DOI 10.1159/000284922; Lavori PW, 2001, BIOL PSYCHIAT, V50, P792, DOI 10.1016/S0006-3223(01)01223-9; Lerner D, 2012, J OCCUP ENVIRON MED, V54, P128, DOI 10.1097/JOM.0b013e31824409d8; Linde JA, 2011, ANN BEHAV MED, V41, P119, DOI 10.1007/s12160-010-9232-2; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Ludman EJ, 2007, J CONSULT CLIN PSYCH, V75, P257, DOI 10.1037/0022-006X.75.2.257; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McGrath CL, 2013, JAMA PSYCHIAT, V70, P821, DOI 10.1001/jamapsychiatry.2013.143; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Miranda J, 2003, HEALTH SERV RES, V38, P613, DOI 10.1111/1475-6773.00136; Mohr DC, 2008, CLIN PSYCHOL-SCI PR, V15, P243, DOI 10.1111/j.1468-2850.2008.00134.x; Montgomery S. A., 1994, EUROPEAN NEUROPSYCHO, V4, P283; Osenbach JE, 2013, DEPRESS ANXIETY, V30, P1058, DOI 10.1002/da.22165; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ricker, 1994, Assessment, V1, P47, DOI 10.1177/1073191194001001007; RINTALA DH, 1986, ARCH PHYS MED REHAB, V67, P118; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simon GE, 2001, ARCH GEN PSYCHIAT, V58, P395, DOI 10.1001/archpsyc.58.4.395; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Simon GE, 2011, J GEN INTERN MED, V26, P698, DOI 10.1007/s11606-011-1679-8; Sirey JA, 2005, PSYCHIAT SERV, V56, P1564, DOI 10.1176/appi.ps.56.12.1564; Smith JL, 2001, MED CARE, V39, P910, DOI 10.1097/00005650-200109000-00002; Stalder-Luthy F, 2013, ARCH PHYS MED REHAB, V94, P1386, DOI 10.1016/j.apmr.2013.02.013; SWEET JJ, 1992, CLIN PSYCHOL REV, V12, P21, DOI 10.1016/0272-7358(92)90090-U; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Tutty S, 2010, BEHAV THER, V41, P229, DOI 10.1016/j.beth.2009.03.002; Wallace ML, 2013, JAMA PSYCHIAT, V70, P1241, DOI 10.1001/jamapsychiatry.2013.1960; Wang PS, 2000, J GEN INTERN MED, V15, P284, DOI 10.1046/j.1525-1497.2000.9908044.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weissman M., 1979, THESIS U PENNSYLVANI; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55; Zimmerman M, 2013, J AFFECT DISORDERS, V150, P384, DOI 10.1016/j.jad.2013.04.028	99	70	70	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2015	32	1					45	57		10.1089/neu.2014.3423			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AX4JX	WOS:000346900100007	25072405	Green Published			2021-06-18	
J	Brines, M; Dunne, AN; van Velzen, M; Proto, PL; Ostenson, CG; Kirk, RI; Petropoulos, IN; Javed, S; Malik, RA; Cerami, A; Dahan, A				Brines, Michael; Dunne, Ann N.; van Velzen, Monique; Proto, Paolo L.; Ostenson, Claes-Goran; Kirk, Rita I.; Petropoulos, Ioannis N.; Javed, Saad; Malik, Rayaz A.; Cerami, Anthony; Dahan, Albert			ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes	MOLECULAR MEDICINE			English	Article							CORNEAL CONFOCAL MICROSCOPY; TRAUMATIC BRAIN-INJURY; LONG-TERM RELIEF; TERTIARY STRUCTURE; TISSUE PROTECTION; HEMORRHAGIC-SHOCK; MIMETIC PEPTIDE; PAIN; SARCOIDOSIS; RECEPTOR	Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subjects were enrolled in this phase 2 study. ARA 290 (4 mg) or placebo were self-administered subcutaneously daily for 28 d and the subjects followed for an additional month without further treatment. No potential safety issues were identified. Subjects receiving ARA 290 exhibited an improvement in hemoglobin A(1c) (Hb A(1c)) and lipid profiles throughout the 56 d observation period. Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group. These observations suggest that ARA 290 may benefit both metabolic control and neuropathy in subjects with type 2 diabetes and deserves continued clinical evaluation.	[Brines, Michael; Dunne, Ann N.; Kirk, Rita I.; Cerami, Anthony] Araim Pharmaceut, Tarrytown, NY 10591 USA; [van Velzen, Monique; Proto, Paolo L.; Dahan, Albert] Leiden Univ, Med Ctr, Dept Anesthesiol, Leiden, Netherlands; [Ostenson, Claes-Goran] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Petropoulos, Ioannis N.; Javed, Saad; Malik, Rayaz A.] Manchester Acad Hlth Sci Ctr, Inst Human Dev, Ctr Diabet & Endocrinol, Manchester, Lancs, England; [Petropoulos, Ioannis N.; Malik, Rayaz A.] Qatar Fdn, Weill Cornell Med Coll Qatar, Doha, Qatar	Brines, M (corresponding author), Araim Pharmaceut, 580 White Plains Rd,Suite 210, Tarrytown, NY 10591 USA.	mbrines@araimpharma.com	Proto, Paolo/AAB-8940-2021; Brinesd, Michael/AAE-6072-2020; van Velzen, Monique/H-7697-2019; Malik, Rayaz/H-9231-2019	Proto, Paolo/0000-0001-9820-6274; Malik, Rayaz/0000-0002-7188-8903; Brines, Michael/0000-0003-4151-4449	Dutch government [FES0908]; Dutch government (Swedish Research Council, ALF); Dutch government (Swedish Diabetes Association)	This work was supported in part by a grant from the Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM, grant no. FES0908, the Swedish Research Council, ALF, and the Swedish Diabetes Association). The authors thank Ferdinand C Breedveld and Geertrui Betgen for invaluable assistance, as well as the subjects and their families for agreeing to participate in this trial.	Ahmet I, 2013, J PHARMACOL EXP THER, V345, P446, DOI 10.1124/jpet.113.202945; Ahmet I, 2011, MOL MED, V17, P194, DOI 10.2119/molmed.2010.00235; Baron R, 2013, P 4 INT C NEUR PAIN; Baron R, 2009, PAIN; Bohr S, 2013, P NATL ACAD SCI USA, V110, P3513, DOI 10.1073/pnas.1214099110; Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024; Brines M, 2008, J INTERN MED, V264, P405, DOI 10.1111/j.1365-2796.2008.02024.x; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines M, 2012, MOL MED, V18, P486, DOI 10.2119/molmed.2011.00414; Collino M, 2014, BRIT J PHARMACOL, V171, P5802, DOI 10.1111/bph.12888; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dahan A, 2013, MOL MED, V19, P334, DOI 10.2119/molmed.2013.00122; Dejager S, 2012, VASC HEALTH RISK MAN, V8, P339, DOI 10.2147/VHRM.S31758; Drent M, 2012, EUR RESPIR J, V40, P255, DOI 10.1183/09031936.00002512; Freynhagen R, 2006, CURR MED RES OPIN, V22, P1911, DOI 10.1185/030079906X132488; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Heij L, 2012, MOL MED, V18, P1430, DOI 10.2119/molmed.2012.00332; Hoeijmakers JG, 2012, NAT REV NEUROL, V8, P369, DOI 10.1038/nrneurol.2012.97; Hoitsma E, 2011, RESP MED, V105, P95, DOI 10.1016/j.rmed.2010.09.014; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; McVicar CM, 2011, DIABETES, V60, P2995, DOI 10.2337/db11-0026; Menichella DM, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-42; Muller C, 2013, DIABETOLOGIA, V56, pS268; Navarro JF, 2005, NEPHROL DIAL TRANSPL, V20, P2601, DOI 10.1093/ndt/gfi155; Niesters M, 2013, EXPERT OPIN ORPHAN D, V1, P77, DOI 10.1517/21678707.2013.719289; Ortmann KLM, 2014, BRAIN BEHAV IMMUN, V41, P144, DOI 10.1016/j.bbi.2014.05.009; Patel NSA, 2011, MOL MED, V17, P883, DOI 10.2119/molmed.2011.00053; Petropoulos IN, 2014, INVEST OPHTH VIS SCI, V55, P2071, DOI 10.1167/iovs.13-13787; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Rolke R, 2006, EUR J PAIN, V10, P77, DOI 10.1016/j.ejpain.2005.02.003; Schmidt RE, 2011, EXP NEUROL, V232, P126, DOI 10.1016/j.expneurol.2011.05.025; Swartjes M, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-13; Swartjes M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071326; Swartjes M, 2011, ANESTHESIOLOGY, V115, P1084, DOI 10.1097/ALN.0b013e31822fcefd; Tavakoli M, 2011, DIABETIC MED, V28, P1261, DOI 10.1111/j.1464-5491.2011.03372.x; Tavakoli M, 2013, DIABETES, V62, P254, DOI 10.2337/db12-0574; Tavakoli M, 2011, JOVE-J VIS EXP, DOI 10.3791/2194; Troosters T, 1999, EUR RESPIR J, V14, P270, DOI 10.1034/j.1399-3003.1999.14b06.x; Woo M, 2014, DIABETES, V63, P2229, DOI 10.2337/db14-0566	44	70	71	0	4	FEINSTEIN INST MED RES	MANHASSET	350 COMMUNITY DR, MANHASSET, NY 11030 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	JUL-DEC	2014	20						658	666		10.2119/molmed.2014.00215			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CE3SV	WOS:000351749900005	25387363	DOAJ Gold, Green Published			2021-06-18	
J	Wang, Y; Wang, H; Tao, Y; Zhang, S; Wang, J; Feng, X				Wang, Y.; Wang, H.; Tao, Y.; Zhang, S.; Wang, J.; Feng, X.			NECROPTOSIS INHIBITOR NECROSTATIN-1 PROMOTES CELL PROTECTION AND PHYSIOLOGICAL FUNCTION IN TRAUMATIC SPINAL CORD INJURY	NEUROSCIENCE			English	Article						spinal cord injury; necrostatin-1; necroptosis; apoptosis; cell protection; physiological function.	OXIDATIVE STRESS; DEATH; HYPOXIA; PATHWAY; KINASE; BRAIN; RATS; STEM	Spinal cord injury (SCI) is a common and serious trauma which lacks efficient treatment. Inhibition of cell death in the trauma area is important for spinal cord protection during this process. In this study, necroptosis inhibitor necrostatin-1 (Nec-1) was used to treat SCI rats, to investigate the role of Nec-1 in the recovery of SCI. Nec-1 was found to reduce lesions, cytokines and reactive oxygen species (ROS), improve pathological conditions and blood supply in the spinal cord trauma area. Further study indicated that Nec-1 could inhibit necroptosis by inhibiting RIP1/3-MLKL recruitment and inhibit apoptosis by inhibiting Caspase 3 and Bax while activating Bcl-2. Ethological performance of SCI rats confirmed improvement and protection of physiological function by Nec-1. Nec-1 as a potential treatment for SCI warrants further study. To our knowledge, this is the first study on the role of Nec-1 in the treatment of traumatic SCI. Our research also found inhibition effects of Nec-1 on apoptosis, not only necroptosis - as reported by most publications. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wang, Y.; Wang, H.; Tao, Y.; Zhang, S.; Wang, J.; Feng, X.] Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Clin Med Coll, Dept Orthoped, Yangzhou 225001, Jiangsu, Peoples R China	Wang, J (corresponding author), Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Clin Med Coll, Dept Orthoped, Yangzhou 225001, Jiangsu, Peoples R China.	0001wjc@sina.com; fxm918spine@126.com		FENG, Xinmin/0000-0001-9287-858X	Research Project Foundation on Social Development of Science and Technology of Yangzhou [YZ2011082]	This study was supported by the Research Project Foundation on Social Development of Science and Technology of Yangzhou (YZ2011082).	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Bryden AM, 2012, J PEDIATR REHAB MED, V5, P287, DOI 10.3233/PRM-2012-00227; Chavez-Valdez R, 2012, NEUROSCIENCE, V219, P192, DOI 10.1016/j.neuroscience.2012.05.002; David Samuel, 2012, Handb Clin Neurol, V109, P485, DOI 10.1016/B978-0-444-52137-8.00030-9; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Goldsmith HS, 2004, NEUROL RES, V26, P586, DOI 10.1179/016164104225017622; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; He YD, 2013, NEUROBIOL DIS, V49, P22, DOI 10.1016/j.nbd.2012.08.014; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Karimi-Abdolrezaee S, 2012, ADV EXP MED BIOL, V760, P53; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Liu P, 2012, SPINAL TRAUMA MAINLA, V37; Liu WM, 2011, J NEUROSCI RES, V89, P791, DOI 10.1002/jnr.22602; Loo DT, 2011, METHODS MOL BIOL, V682, P3, DOI 10.1007/978-1-60327-409-8_1; Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174; Marsala J, 2007, PROG BRAIN RES, V161, P171, DOI 10.1016/S0079-6123(06)61011-X; Moon YJ, 2012, J NEUROSCI RES, V90, P243, DOI 10.1002/jnr.22734; Naujokat C, 2009, ARCH IMMUNOL THER EX, V57, P177, DOI 10.1007/s00005-009-0019-8; Redondo-Castro E, 2013, J NEUROSCI METH, V213, P165, DOI 10.1016/j.jneumeth.2012.12.024; Sacerdote P, 2013, J NEUROIMMUNE PHARM, V8, P202, DOI 10.1007/s11481-012-9428-2; Spitzbarth I, 2012, VET IMMUNOL IMMUNOP, V147, P6, DOI 10.1016/j.vetimm.2012.04.005; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Thapa RJ, 2013, P NATL ACAD SCI USA, V110, pE3109, DOI 10.1073/pnas.1301218110; Ullah N, 2011, NEUROPHARMACOLOGY, V61, P1248, DOI 10.1016/j.neuropharm.2011.06.031; Wang YX, 2013, MOL MED REP, V8, P883, DOI 10.3892/mmr.2013.1579; Wang YX, 2012, BRAIN RES, V1448, P137, DOI 10.1016/j.brainres.2012.02.007; Wang ZY, 2007, CHINESE J PHYSIOL, V50, P211; Xu M, 2011, ACTA PHARMACOL SIN, V32, P1089, DOI 10.1038/aps.2011.50; Xu XS, 2010, BRAIN RES, V1355, P189, DOI 10.1016/j.brainres.2010.07.080; Zhang QL, 2008, INT J IMMUNOPATH PH, V21, P787, DOI 10.1177/039463200802100403	33	70	79	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 25	2014	266						91	101		10.1016/j.neuroscience.2014.02.007			11	Neurosciences	Neurosciences & Neurology	AE8VO	WOS:000334281200009	24561219				2021-06-18	
J	Keightley, ML; Saluja, RS; Chen, JK; Gagnon, I; Leonard, G; Petrides, M; Ptito, A				Keightley, Michelle L.; Saluja, Rajeet Singh; Chen, Jen-Kai; Gagnon, Isabelle; Leonard, Gabriel; Petrides, Michael; Ptito, Alain			A Functional Magnetic Resonance Imaging Study of Working Memory in Youth after Sports-Related Concussion: Is It Still Working?	JOURNAL OF NEUROTRAUMA			English	Article						concussion; fMRI; working memory; youth	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; SCHOOL FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; TEMPORAL WINDOW; WHITE-MATTER; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; WILD BOOTSTRAP; RUGBY PLAYERS	In children, the importance of detecting deficits after mild traumatic brain injury (mTBI) or concussion has grown with the increasing popularity of leisure physical activities and contact sports. Whereas most postconcussive symptoms (PCS) are similar for children and adults, the breadth of consequences to children remains largely unknown. To investigate the effect of mTBI on brain function, we compared working memory performance and related brain activity using blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) in 15 concussed youths and 15 healthy age-matched control subjects. Neuropsychological tests, self-perceived PCS, and levels of anxiety and depression were also assessed. Our results showed that, behaviorally, concussed youths had significantly worse performances on the working memory tasks, as well as on the Rey figure delayed recall and verbal fluency. fMRI results revealed that, compared to healthy children, concussed youths had significantly reduced task-related activity in bilateral dorsolateral prefrontal cortex, left premotor cortex, supplementary motor area, and left superior parietal lobule during performance of verbal and nonverbal working memory tasks. Additionally, concussed youths also showed less activation than healthy controls in the dorsal anterior cingulate cortex, left thalamus, and left caudate nucleus during the nonverbal task. Regression analysis indicated that BOLD signal changes in bilateral dorsolateral prefrontal cortex were significantly correlated with performance such that greater activities in these regions, relative to the control condition, were associated with greater accuracy. Our findings confirmed functional alterations in brain activity after concussion in youths, a result similar to that observed in adults. However, significant differences were noted. In particular, the observation of reduced working memory accuracy suggests that youths may be unable to engage compensatory strategies to maintain cognitive performance after mTBI. This has significant implications for safe return to daily activities, including competitive sport.	[Keightley, Michelle L.; Chen, Jen-Kai] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON M4G 1R8, Canada; [Keightley, Michelle L.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Keightley, Michelle L.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Keightley, Michelle L.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Keightley, Michelle L.] Toronto Rehabil Inst, Toronto, ON, Canada; [Saluja, Rajeet Singh; Chen, Jen-Kai; Leonard, Gabriel; Petrides, Michael; Ptito, Alain] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; [Ptito, Alain] McGill Univ, Ctr Hlth, Dept Psychol, Montreal, PQ H3H 1P3, Canada	Keightley, ML (corresponding author), Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, 150 Kilgour Rd, Toronto, ON M4G 1R8, Canada.	mkeightley@hollandbloorview.ca	Soddu, Andrea/K-7087-2014; Laureys, Steven/A-3349-2011; Meijer, Anna/K-5118-2016	Soddu, Andrea/0000-0001-6833-745X; 	CIHRCanadian Institutes of Health Research (CIHR) [484706]	The authors thank CIHR (grant no. 484706; primary investigator: M. Keightley; coinvestigators: A. Ptito, K. Johnston, and N. Lobaugh) for their financial support of this study as well as the members of the Trauma Program of the Montreal Children's Hospital, McGill University Health Center, for their collaboration.	AFL Community Club, 2013, CONC MAN BOOKL; AFL Community Club, 2011, GUID MAN CONC AUSTR; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 2013, Br J Sports Med, V47, P259; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Boffano P, 2011, J CRANIOFAC SURG, V22, P2053, DOI 10.1097/SCS.0b013e318231988d; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Chen J, 2012, ASIAN PAC J TROP MED, V5, P67, DOI 10.1016/S1995-7645(11)60248-4; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Dimou S, 2013, NEUROSURG REV, V36, P205, DOI 10.1007/s10143-012-0436-8; Dimou S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00500; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Forbes JA, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12288; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gosselin N, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12253; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jung RE, 2009, INTELLIGENCE, V37, P192, DOI 10.1016/j.intell.2008.10.009; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kalsbeek A, 2010, ANN NY ACAD SCI, V1212, P114, DOI 10.1111/j.1749-6632.2010.05800.x; Keightley M. L., 2013, J NEUROTRAUMA, V31; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P581; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Luther N, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417733.09300.04; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medina D, 2006, NEUROBIOL AGING, V27, P663, DOI 10.1016/j.neurobiolaging.2005.03.026; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; National Rugby League, 2013, MAN CONC RUGB LEAG; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Perron AD, 2001, ACAD EMERG MED, V8, P296, DOI 10.1111/j.1553-2712.2001.tb01312.x; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Teel E. F., 2013, CLIN NEUROPHYSIOL, V17, P01044; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Whitcher B, 2008, HUM BRAIN MAPP, V29, P346, DOI 10.1002/hbm.20395; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhu T, 2008, NEUROIMAGE, V40, P1144, DOI 10.1016/j.neuroimage.2008.01.016	112	70	71	0	35	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					437	451		10.1089/NEU.2013.3052			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600242	24070614	Green Published, Bronze			2021-06-18	
J	Tanriverdi, F; De Bellis, A; Ulutabanca, H; Bizzarro, A; Sinisi, AA; Bellastella, G; Paglionico, VA; Dalla Mora, L; Selcuklu, A; Unluhizarci, K; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; De Bellis, Annamaria; Ulutabanca, Halil; Bizzarro, Antonio; Sinisi, Antonio A.; Bellastella, Giuseppe; Paglionico, Vanda Amoresano; Dalla Mora, Liliana; Selcuklu, Ahmed; Unluhizarci, Kursad; Casanueva, Felipe F.; Kelestimur, Fahrettin			A Five Year Prospective Investigation of Anterior Pituitary Function after Traumatic Brain Injury: Is Hypopituitarism Long-Term after Head Trauma Associated with Autoimmunity?	JOURNAL OF NEUROTRAUMA			English	Article						anti-hypothalamus antibodies; anti-pituitary antibodies; autoimmunity; growth hormone; pituitary; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; GH REPLACEMENT THERAPY; ANTIPITUITARY ANTIBODIES; SHEEHANS-SYNDROME; HORMONE; INSUFFICIENCY; ADULTS; NEURONS; RATS	Traumatic brain injury (TBI) has been recently recognized as a common cause of pituitary dysfunction. However, there are not sufficient numbers of prospective studies to understand the natural history of TBI induced hypopituitarism. The aim was to report the results of five years' prospective follow-up of anterior pituitary function in patients with mild, moderate and severe TBI. Moreover, we have prospectively investigated the associations between TBI induced hypopituitarism and presence of anti-hypothalamus antibodies (AHA) and anti-pituitary antibodies (APA). Twenty five patients (20 men, five women) were included who were prospectively evaluated 12 months and five years after TBI, and 17 of them also had a third-year evaluation. Growth hormone (GH) deficiency is the most common pituitary hormone deficit at one, three, and five years after TBI. Although most of the pituitary hormone deficiencies improve over time, there were substantial percentages of pituitary hormone deficiencies at the fifth year (28% GH, 4% adrenocorticotropic hormone [ACTH], and 4% gonadotropin deficiencies). Pituitary dysfunction was significantly higher in strongly AHA- and APA-positive (titers >= 1/16) patients at the fifth year. In patients with mild and moderate TBI, ACTH and GH deficiencies may improve over time in a considerable number of patients but, although rarely, may also worsen over the five-year period. However in severe TBI, ACTH and GH status of the patients at the first year evaluation persisted at the fifth year. Therefore, screening pituitary function after TBI for five years is important, especially in patients with mild TBI. Moreover, close strong associations between the presence of high titers of APA and/or AHA and hypopituitarism at the fifth year were shown for the first time.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Ulutabanca, Halil; Selcuklu, Ahmed] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [De Bellis, Annamaria; Sinisi, Antonio A.; Bellastella, Giuseppe; Paglionico, Vanda Amoresano] Univ Naples 2, Dept Cardiothorac & Resp Sci, Naples, Italy; [Bizzarro, Antonio] Univ Naples 2, Dept Clin & Expt Med & Surg, Naples, Italy; [Dalla Mora, Liliana] Univ Naples 2, Dept Gen Pathol, Naples, Italy; [Casanueva, Felipe F.] Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr		DE BELLIS, Annamaria/0000-0002-0611-4506; DALLA MORA, Liliana/0000-0002-1160-1288			Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; De Bellis A, 2003, J CLIN ENDOCR METAB, V88, P650, DOI 10.1210/jc.2002-021054; De Bellis A, 1999, J CLIN ENDOCR METAB, V84, P3047, DOI 10.1210/jc.84.9.3047; De Bellis A, 2008, EUR J ENDOCRINOL, V158, P147, DOI 10.1530/EJE-07-0647; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Kelestimur F, 2006, CLIN ENDOCRINOL, V64, P667, DOI 10.1111/j.1365-2265.2006.02525.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Kunitomi M, 2002, INT J OBESITY, V26, P361, DOI 10.1038/sj.ijo.0801899; Lamberts SWJ, 1998, LANCET, V352, P127; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Tanriverdi F, 2005, GROWTH HORM IGF RES, V15, P231, DOI 10.1016/j.ghir.2005.03.005; Tanriverdi Fatih, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P131, DOI 10.1586/14737167.6.2.131; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Tanriverdi F, 2010, J NEUROTRAUM, V27, P301, DOI 10.1089/neu.2009.1102; TEASDALE G, 1974, LANCET, V2, P81; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	30	70	72	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	16					1426	1433		10.1089/neu.2012.2752			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	199JB	WOS:000322989500006	23470214				2021-06-18	
J	Pedrocchi, A; Ferrante, S; Ambrosini, E; Gandolla, M; Casellato, C; Schauer, T; Klauer, C; Pascual, J; Vidaurre, C; Gfohler, M; Reichenfelser, W; Karner, J; Micera, S; Crema, A; Molteni, F; Rossini, M; Palumbo, G; Guanziroli, E; Jedlitschka, A; Hack, M; Bulgheroni, M; d'Amico, E; Schenk, P; Zwicker, S; Duschau-Wicke, A; Miseikis, J; Graber, L; Ferrigno, G				Pedrocchi, Alessandra; Ferrante, Simona; Ambrosini, Emilia; Gandolla, Marta; Casellato, Claudia; Schauer, Thomas; Klauer, Christian; Pascual, Javier; Vidaurre, Carmen; Gfoehler, Margit; Reichenfelser, Werner; Karner, Jakob; Micera, Silvestro; Crema, Andrea; Molteni, Franco; Rossini, Mauro; Palumbo, Giovanna; Guanziroli, Eleonora; Jedlitschka, Andreas; Hack, Marco; Bulgheroni, Maria; d'Amico, Enrico; Schenk, Peter; Zwicker, Sven; Duschau-Wicke, Alexander; Miseikis, Justinas; Graber, Lina; Ferrigno, Giancarlo			MUNDUS project: MUltimodal Neuroprosthesis for daily Upper limb Support	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Assistive device; Upper limb support; Neuromuscular electrical stimulation; Wearable exoskeleton; Neurological disorders	POST-ACUTE STROKE; ELECTRICAL-STIMULATION; EYE-TRACKING; INTERFACE; CLASSIFICATION; DESIGN; ROBOT	Background: MUNDUS is an assistive framework for recovering direct interaction capability of severely motor impaired people based on arm reaching and hand functions. It aims at achieving personalization, modularity and maximization of the user's direct involvement in assistive systems. To this, MUNDUS exploits any residual control of the end-user and can be adapted to the level of severity or to the progression of the disease allowing the user to voluntarily interact with the environment. MUNDUS target pathologies are high-level spinal cord injury (SCI) and neurodegenerative and genetic neuromuscular diseases, such as amyotrophic lateral sclerosis, Friedreich ataxia, and multiple sclerosis (MS). The system can be alternatively driven by residual voluntary muscular activation, head/eye motion, and brain signals. MUNDUS modularly combines an antigravity lightweight and non-cumbersome exoskeleton, closed-loop controlled Neuromuscular Electrical Stimulation for arm and hand motion, and potentially a motorized hand orthosis, for grasping interactive objects. Methods: The definition of the requirements and of the interaction tasks were designed by a focus group with experts and a questionnaire with 36 potential end-users. Five end-users (3 SCI and 2 MS) tested the system in the configuration suitable to their specific level of impairment. They performed two exemplary tasks: reaching different points in the working volume and drinking. Three experts evaluated over a 3-level score (from 0, unsuccessful, to 2, completely functional) the execution of each assisted sub-action. Results: The functionality of all modules has been successfully demonstrated. User's intention was detected with a 100% success. Averaging all subjects and tasks, the minimum evaluation score obtained was 1.13 +/- 0.99 for the release of the handle during the drinking task, whilst all the other sub-actions achieved a mean value above 1.6. All users, but one, subjectively perceived the usefulness of the assistance and could easily control the system. Donning time ranged from 6 to 65 minutes, scaled on the configuration complexity. Conclusions: The MUNDUS platform provides functional assistance to daily life activities; the modules integration depends on the user's need, the functionality of the system have been demonstrated for all the possible configurations, and preliminary assessment of usability and acceptance is promising.	[Pedrocchi, Alessandra; Ferrante, Simona; Ambrosini, Emilia; Gandolla, Marta; Casellato, Claudia; Ferrigno, Giancarlo] Politecn Milan, NeuroEngn & Med Robot Lab, NearLab, Dept Elect Informat & Bioengn, Milan, Italy; [Schauer, Thomas; Klauer, Christian] Tech Univ Berlin, Control Syst Grp, Berlin, Germany; [Pascual, Javier; Vidaurre, Carmen] Tech Univ Berlin, Fac Comp Sci, Machine Learning Grp, Berlin, Germany; [Gfoehler, Margit; Reichenfelser, Werner; Karner, Jakob] Vienna Univ Technol, A-1060 Vienna, Austria; [Micera, Silvestro; Crema, Andrea] Ecole Polytech Fed Lausanne, Ctr Neuroprosthet, Translat Neural Engn Lab, CH-1015 Lausanne, Switzerland; [Micera, Silvestro] Scuola Super Sant Anna, BioRobot Inst, Pisa, Italy; [Molteni, Franco; Rossini, Mauro; Palumbo, Giovanna; Guanziroli, Eleonora] Valduce Hosp, Villa Beretta Rehabil Ctr, Costa Masnaga, Lecco, Italy; [Jedlitschka, Andreas; Hack, Marco] Fraunhofer Inst Expt Software Engn, Kaiserslautern, Germany; [Bulgheroni, Maria; d'Amico, Enrico] Ab Acus, Milan, Italy; [Schenk, Peter; Zwicker, Sven; Duschau-Wicke, Alexander; Miseikis, Justinas; Graber, Lina] Hocoma AG, Volketswil, Switzerland	Pedrocchi, A (corresponding author), Politecn Milan, NeuroEngn & Med Robot Lab, NearLab, Dept Elect Informat & Bioengn, Milan, Italy.	alessandra.pedrocchi@polimi.it	Ferrigno, Giancarlo/O-5833-2015; Gandolla, Marta/K-8813-2016; Jedlitschka, Andreas/AAJ-5524-2020; Pedrocchi, Alessandra/A-6634-2012; Schauer, Thomas/AAX-4118-2020; Schauer, Thomas/J-4137-2012; Gandolla, Marta/AAL-8862-2020; Pedrocchi, Alessandra/AAF-2655-2019; Ambrosini, Emilia/R-1371-2016; Ferrante, Simona/K-4122-2016; Micera, Silvestro/AAD-6630-2021	Ferrigno, Giancarlo/0000-0001-5913-9451; Gandolla, Marta/0000-0001-5237-714X; Pedrocchi, Alessandra/0000-0001-9957-2786; Schauer, Thomas/0000-0002-0865-4418; Schauer, Thomas/0000-0002-0865-4418; Gandolla, Marta/0000-0001-5237-714X; Pedrocchi, Alessandra/0000-0001-9957-2786; Ambrosini, Emilia/0000-0002-6527-0779; Ferrante, Simona/0000-0002-7835-1965; casellato, claudia/0000-0002-8729-0391; Gfoehler, Margit/0000-0002-8977-8702; Rossini, Mauro/0000-0002-7670-5758; Vidaurre, Carmen/0000-0003-3740-049X	EU STREP MUNDUS [ICT-2009.7.2 - Accessible, Assistive ICT GA 248326]	The work is supported by the EU STREP MUNDUS grant ICT-2009.7.2 - Accessible and Assistive ICT GA 248326. We would like to acknowledge Axelgaard Manufacturing Ltd for donating us the stimulation electrodes and all the subjects who agreed to participate to the study.	Ambrosini E, 2011, IEEE INT CONF REHABI, V2011; Ambrosini E, 2012, IEEE T NEUR SYS REH, V20, P320, DOI 10.1109/TNSRE.2012.2191574; Ambrosini E, 2011, IEEE ENG MED BIO, P4259, DOI 10.1109/IEMBS.2011.6091057; Ambrosini E, 2011, STROKE, V42, P1068, DOI 10.1161/STROKEAHA.110.599068; Ambrosini E, 2010, ARTIF ORGANS, V34, P663, DOI 10.1111/j.1525-1594.2009.00941.x; Bien Z, 2003, IEEE ASME INT C ADV, P902; Biffi E, 2012, BIOTECHNOL BIOENG, V109, P166, DOI 10.1002/bit.23310; Blankertz B, 2011, NEUROIMAGE, V56, P814, DOI 10.1016/j.neuroimage.2010.06.048; Brose SW, 2010, AM J PHYS MED REHAB, V89, P509, DOI 10.1097/PHM.0b013e3181cf569b; Casellato C, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-49; Cavallaro EE, 2006, IEEE T BIO-MED ENG, V53, P2387, DOI 10.1109/TBME.2006.880883; Cincotti F, 2008, BRAIN RES BULL, V75, P796, DOI 10.1016/j.brainresbull.2008.01.007; Comolli L, 2010, MED ENG PHYS, V32, P339, DOI 10.1016/j.medengphy.2010.01.005; Davidson PR, 2003, CURR OPIN NEUROBIOL, V13, P232, DOI 10.1016/S0959-4388(03)00038-2; Dipietro L, 2003, J REHABIL RES DEV, V40, P179; Driessen BJF, 2001, P I MECH ENG H, V215, P285, DOI 10.1243/0954411011535876; Ferrante S, 2008, EUR J PHYS REHAB MED, V44, P159; Ferrante S, 2012, P 34 ANN INT C IEEE, V2012, P1; Ferrante S, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-47; Gandolla M, 2011, MED ENG PHYS, V33, P1027, DOI 10.1016/j.medengphy.2011.04.005; Herder JL, 2006, J REHABIL RES DEV, V43, P591, DOI 10.1682/JRRD.2006.05.0044; Inmann A, 2004, MED ENG PHYS, V26, P439, DOI 10.1016/j.medengphy.2004.03.002; Janssen T. W. J., 1998, TOP SPINAL CORD INJ, V3, P33; Kilgore K L, 1998, IEEE Trans Rehabil Eng, V6, P424, DOI 10.1109/86.736157; Kinoshita H, 1996, EUR J APPL PHYSIOL, V74, P450; Krantz O, 2012, DISABIL REHABIL-ASSI, V7, P189, DOI 10.3109/17483107.2011.618212; Kuhn A, 2009, MED ENG PHYS, V31, P945, DOI 10.1016/j.medengphy.2009.05.006; Lee EC, 2010, J NEUROSCI METH, V190, P289, DOI 10.1016/j.jneumeth.2010.05.008; Liu YH, 2011, IEEE ENG MED BIO, P7516, DOI 10.1109/IEMBS.2011.6091853; Mele ML, 2012, DISABIL REHABIL-ASSI, V7, P261, DOI 10.3109/17483107.2011.635326; Nef T, 2007, MED BIOL ENG COMPUT, V45, P887, DOI 10.1007/s11517-007-0226-6; Niazi IK, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066009; Popovic DB, 2009, J NEUROSCI METH, V178, P174, DOI 10.1016/j.jneumeth.2008.12.003; Rahman T, 2006, J REHABIL RES DEV, V43, P583, DOI 10.1682/JRRD.2005.04.0070; Riener R, 2005, IEEE T NEUR SYS REH, V13, P380, DOI 10.1109/TNSRE.2005.848628; Schill O, 2011, BIOMED TECH, V56, P35, DOI 10.1515/BMT.2010.056; Sennels S, 1997, IEEE Trans Rehabil Eng, V5, P195, DOI 10.1109/86.593293; Sheffler LR, 2007, MUSCLE NERVE, V35, P562, DOI 10.1002/mus.20758; Sinkjaer T, 2003, MED ENG PHYS, V25, P29, DOI 10.1016/S1350-4533(02)00178-9; Treder MS, 2011, J NEURAL ENG, V8	40	70	71	0	47	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	JUL 3	2013	10								66	10.1186/1743-0003-10-66			20	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	193VE	WOS:000322588800001	23822118	DOAJ Gold, Green Published			2021-06-18	
J	Bigler, ED; Abildskov, TJ; Petrie, J; Farrer, TJ; Dennis, M; Simic, N; Taylor, HG; Rubin, KH; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Bigler, Erin D.; Abildskov, Tracy J.; Petrie, JoAnn; Farrer, Thomas J.; Dennis, Maureen; Simic, Nevena; Taylor, H. Gerry; Rubin, Kenneth H.; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Heterogeneity of Brain Lesions in Pediatric Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						pediatric; traumatic brain injury; magnetic resonance imaging; heterogeneity; hemosiderin; white matter hyperintensities; atrophy	WHITE-MATTER HYPERINTENSITIES; VOXEL-BASED MORPHOMETRY; NEUROPATHOLOGY; DIFFUSION; CHILDREN; ATROPHY; PREVALENCE; DIAGNOSIS	Objective: Magnetic resonance imaging (MRI) provides a method to identify and quantify abnormalities resulting from traumatic brain injury (TBI). MRI abnormalities in children with TBI have not been fully characterized according to the frequency, location, and quantitative measurement of a range of pathologies critical for studies of neuropsychological outcome. Here, we report MRI findings from a large, multicenter study of childhood TBI, the Social Outcomes of Brain Injury in Kids (SOBIK) study, which compared qualitative and quantitative neuroimaging findings in 72 children with complicated mild-to-severe TBI to 52 children with orthopedic injury (OI). Method: Qualitative analyses of MRI scans coded white matter hyperintensities (WMHs), hemosiderin deposits reflecting prior hemorrhagic lesions, regions of encephalomalacia and/or atrophy, and corpus callosum atrophy and traumatic shear lesions. Two automated quantitative analyses were conducted: (a) FreeSurfer methods computed volumes for total brain, white matter (WM), gray matter (GM), corpus callosum, ventricles, amygdala, hippocampus, basal ganglia, and thalamus along with a ventricle-to-brain ratio (VBR); and (b) voxel-based morphometry (VBM) to identify WM, GM, and cerebrospinal fluid. We also examined performance on the Processing Speed Index (PSI) from the Wechsler Intelligence Scale for Children, Fourth Edition, in relation to the above-mentioned neuroimaging variables. Results: WMHs, hemosiderin deposits, and focal areas of encephalomalacia or atrophy were common in children with TBI, were related to injury severity, and were mostly observed within a frontotemporal distribution. Quantitative analyses showed volumetric changes related to injury severity, especially ventricular enlargement and reduced corpus callosum volume. VBM demonstrated similar findings, but, in addition, GM reductions in the inferior frontal, basal forebrain region, especially in the severe TBI group. The complicated mild TBI group showed few differences from the OI group. PSI was significantly associated with global atrophy, as measured by VBR. Conclusion: MRI findings after childhood TBI are diverse and particularly influenced by injury severity, and they involve common features, group heterogeneity, and individual variability.	[Bigler, Erin D.; Abildskov, Tracy J.; Petrie, JoAnn; Farrer, Thomas J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; [Dennis, Maureen; Simic, Nevena] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Dennis, Maureen] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Rubin, Kenneth H.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.] Columbus Childrens Res Inst, Ctr Behav Hlth, Columbus, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Cleveland, OH 44109 USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu	Gerhardt, Cynthia/E-3109-2011; Vannatta, Kathryn/E-4237-2011; Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019; Rubin, Kenneth H/M-5276-2018	Rubin, Kenneth H/0000-0002-2608-2484; Farrer, Thomas J./0000-0001-8092-6214; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R01HD048946, 3R01HD048946-05S1]; Poelman Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Supported by the National Institute of Child Health and Human Development (Grant Nos. 5R01HD048946 and 3R01HD048946-05S1) and the Poelman Foundation. We thank radiologists Barbara Bangert, MD (Cleveland), Jerome Rusin, MD (Columbus), and Susan Blaser, MD (Toronto), who assisted with the overseeing and clinical interpretation of scans.	Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Bendfeldt K, 2012, HUM BRAIN MAPP, V33, P1225, DOI 10.1002/hbm.21279; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 2003, AM J NEURORADIOL, V24, P2066; Bigler ED, 2007, BRAIN INJURY MED PRI, P201; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bruggemann JM, 2009, J CLIN NEUROSCI, V16, P780, DOI 10.1016/j.jocn.2008.08.025; Chen SN, 2009, HUM BRAIN MAPP, V30, P2304, DOI 10.1002/hbm.20669; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Eriksson SH, 2009, HUM BRAIN MAPP, V30, P3351, DOI 10.1002/hbm.20757; Focke NK, 2011, NEUROIMAGE, V56, P1164, DOI 10.1016/j.neuroimage.2011.02.029; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Hartwigsen G, 2010, J COMPUT ASSIST TOMO, V34, P596, DOI 10.1097/RCT.0b013e3181d9c2bb; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Kourtidou P, 2013, J HEAD TRAUMA REHAB, V28, P433, DOI 10.1097/HTR.0b013e3182585d06; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Maxwell WL, 2012, INT J DEV NEUROSCI, V30, P167, DOI 10.1016/j.ijdevneu.2011.12.008; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Muhlau M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029809; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P231, DOI 10.1176/appi.neuropsych.22.2.231; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; TEASDALE G, 1974, LANCET, V2, P81; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wechsler D., 2003, WISC 4 ADM SCORING M; Wechsler D., 2011, WECHLSER ABBREVIATED; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Zhan W, 2009, NEUROIMAGE, V47, pT58, DOI 10.1016/j.neuroimage.2009.02.004	50	70	70	2	29	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2013	27	4					438	451		10.1037/a0032837			14	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	185SC	WOS:000321989600005	23876117				2021-06-18	
J	Tchantchou, F; Zhang, YM				Tchantchou, Flaubert; Zhang, Yumin			Selective Inhibition of Alpha/Beta-Hydrolase Domain 6 Attenuates Neurodegeneration, Alleviates Blood Brain Barrier Breakdown, and Improves Functional Recovery in a Mouse Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ABHD6; neuroinflammation; neuroprotection; traumatic brain injury; 2-arachidonylglycerol	CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE SYNTHASE; ACID AMIDE HYDROLASE; MONOACYLGLYCEROL LIPASE; ENDOCANNABINOID SYSTEM; CANNABINOID RECEPTORS; UP-REGULATION; ACTIVATION; EXPRESSION; PROTECTS	2-arachidonylglycerol (2-AG) is the most abundant endocannabinoid in the central nervous system and is elevated after brain injury. Because of its rapid hydrolysis, however, the compensatory and neuroprotective effect of 2-AG is short-lived. Although inhibition of monoacylglycerol lipase, a principal enzyme for 2-AG degradation, causes a robust increase of brain levels of 2-AG, it also leads to cannabinoid receptor desensitization and behavioral tolerance. Alpha/beta hydrolase domain 6 (ABHD6) is a novel 2-AG hydrolytic enzyme that accounts for a small portion of 2-AG hydrolysis, but its inhibition is believed to elevate the levels of 2-AG within the therapeutic window without causing side effect. Using a mouse model of traumatic brain injury (TBI), we found that post-insult chronic treatment with a selective ABHD6 inhibitor WWL70 improved motor coordination and working memory performance. WWL70 treatment reduced lesion volume in the cortex and neurodegeneration in the dendate gyrus. It also suppressed the expression of inducible nitric oxide synthase and cyclooxygenase-2 and enhanced the expression of arginase-1 in the ipsilateral cortex at 3 and 7 days post-TBI, suggesting microglia/macrophages shifted from M1 to M2 phenotypes after treatment. The blood-brain barrier dysfunction at 3 and 7 days post-TBI was dramatically reduced. Furthermore, the beneficial effects of WWL70 involved up-regulation and activation of cannabinoid type 1 and type 2 receptors and were attributable to the phosphorylation of the extracellular signal regulated kinase and the serine/threonine protein kinase AKT. This study indicates that the fine-tuning of 2-AG signaling by modulating ABHD6 activity can exert anti-inflammatory and neuroprotective effects in TBI.	[Tchantchou, Flaubert; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Zhang, YM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	yumin.zhang@usuhs.edu			Blast Lethality Injury and Research Program [R600-070-00000-00-106109]; Defense Medical Research and Development Program [0130-10-00003-00002]	This work was supported by grants from the Blast Lethality Injury and Research Program (R600-070-00000-00-106109) and the Defense Medical Research and Development Program (0130-10-00003-00002). The authors are grateful to Drs. De-Maw Chuang and Fengshan Yu for careful reading and critical comments on the manuscript. We also acknowledge Ms. Laura Tucker and Dr. Amanda Fu from the Center for Neuroscience and Regenerative Medicine for their help during behavioral tests and CCI surgery.	Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Ay I, 2008, BRAIN RES, V1234, P198, DOI 10.1016/j.brainres.2008.07.121; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Bryan KJ, 2009, FRONT NEUROSCI, P1; Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009; Chanda PK, 2010, MOL PHARMACOL, V78, P996, DOI 10.1124/mol.110.068304; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Dall'Igna OP, 2007, EXP NEUROL, V203, P241, DOI 10.1016/j.expneurol.2006.08.008; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Dauge V, 2001, NEUROPSYCHOPHARMACOL, V25, P690, DOI 10.1016/S0893-133X(01)00291-3; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Di Lorenzo A, 2011, BLOOD, V117, P2284, DOI 10.1182/blood-2010-04-281956; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Diaz-Laviada I, 2005, MINI-REV MED CHEM, V5, P619, DOI 10.2174/1389557054368808; Du HZ, 2011, BRIT J PHARMACOL, V163, P1533, DOI 10.1111/j.1476-5381.2011.01444.x; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frank PG, 2008, AM J PHYSIOL-HEART C, V295, pH926, DOI 10.1152/ajpheart.00779.2008; Galante M, 2009, HUM MOL GENET, V18, P1449, DOI 10.1093/hmg/ddp055; Galve-Roperh I, 2008, CURR PHARM DESIGN, V14, P2279, DOI 10.2174/138161208785740117; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Horne E. A., 2011, SOC NEUR ANN M; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Izzo AA, 2001, BRIT J PHARMACOL, V134, P563, DOI 10.1038/sj.bjp.0704293; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jeong WI, 2008, CELL METAB, V7, P227, DOI 10.1016/j.cmet.2007.12.007; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kan WH, 2008, J APPL PHYSIOL, V105, P1076, DOI 10.1152/japplphysiol.90495.2008; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kunz A, 2007, J NEUROSCI, V27, P7083, DOI 10.1523/JNEUROSCI.1645-07.2007; Kuo HS, 2011, J NEUROSCI, V31, P4137, DOI 10.1523/JNEUROSCI.2592-10.2011; Lee S, 2011, J AM SOC NEPHROL, V22, P317, DOI 10.1681/ASN.2009060615; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liu Y, 2004, J IMMUNOL, V172, P7, DOI 10.4049/jimmunol.172.1.7; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lourbopoulos A, 2011, BRAIN RES, V1390, P126, DOI 10.1016/j.brainres.2011.03.020; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Mangleri RA, 2007, PHARMACOL RES, V56, P360, DOI 10.1016/j.phrs.2007.09.003; Martin-Moreno AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-8; Marrs WR, 2011, J BIOL CHEM, V286, P28723, DOI 10.1074/jbc.M110.202853; Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Molina-Holgado F, 2007, EUR J NEUROSCI, V25, P629, DOI 10.1111/j.1460-9568.2007.05322.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Naidoo V, 2012, NEUROTHERAPEUTICS, V9, P801, DOI 10.1007/s13311-011-0100-y; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Oz M, 2006, PHARMACOL THERAPEUT, V111, P114, DOI 10.1016/j.pharmthera.2005.09.009; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pitkanen A., 2005, DRUG DISCOV TODAY DI, V2, P409, DOI DOI 10.1016/J.DDMEC.2005.11.011; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Savinainen JR, 2012, ACTA PHYSIOL, V204, P267, DOI 10.1111/j.1748-1716.2011.02280.x; Schlosburg JE, 2010, NAT NEUROSCI, V13, P1113, DOI 10.1038/nn.2616; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schneider C, 2009, J NEUROIMMUNOL, V213, P84, DOI 10.1016/j.jneuroim.2009.05.015; Scotter EL, 2010, BRIT J PHARMACOL, V160, P480, DOI 10.1111/j.1476-5381.2010.00735.x; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Soetikno V, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-35; Straiker A, 2009, MOL PHARMACOL, V76, P1220, DOI 10.1124/mol.109.059030; Tanaka K, 2009, NEUROSCI LETT, V462, P235, DOI 10.1016/j.neulet.2009.07.024; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tchantchou F, 2004, NEUROMOL MED, V6, P93, DOI 10.1385/NMM:6:2-3:093; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; van der Poorten D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012841; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200	84	70	71	1	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					565	579		10.1089/neu.2012.2647			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300008	23151067	Green Published			2021-06-18	
J	Rojas, JJ; Deniz, BF; Miguel, PM; Diaz, R; Hermel, EES; Achaval, M; Netto, CA; Pereira, LO				Rojas, Joseane Jimenez; Deniz, Bruna Ferrary; Miguel, Patricia Maidana; Diaz, Ramiro; Hermel, Erica do Espirito-Santo; Achaval, Matilde; Netto, Carlos Alexandre; Pereira, Lenir Orlandi			Effects of daily environmental enrichment on behavior and dendritic spine density in hippocampus following neonatal hypoxia-ischemia in the rat	EXPERIMENTAL NEUROLOGY			English	Article						Neonatal hypoxia-ischemia; Environmental enrichment; Dendritic spine density; Behavior; Neuroprotection	POSTERODORSAL MEDIAL AMYGDALA; TRAUMATIC BRAIN-INJURY; LOCOMOTOR-ACTIVITY; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; MEMORY DEFICITS; NEURONAL DAMAGE; SEX-DIFFERENCES; FIMBRIA-FORNIX; ESTROUS-CYCLE	Hypoxia-ischemia (HI) is the main cause of mortality in the perinatal period and morbidity, in survivors, which is characterized by neurological disabilities. The immature brain is highly susceptible to hypoxicischemic insult and is responsive to environmental stimuli, such as environmental enrichment (EE). Previous results indicate that EE recovered memory deficits in adult rats without reversing hippocampal atrophy related to HI. The aim of this study was to investigate behavioral performance in the open field and rota-rod apparatuses, in object recognition and inhibitory avoidance tasks, as well as dendritic spine density in the hippocampus, in rats undergoing HI and exposed to EE. Seven-day old male rats were submitted to the HI procedure and divided into 4 groups: control maintained in standard environment (CTSE), controls submitted to EE (CTEE), HI in standard environment (HISE) and HI in EE (HIEE). Behavioral and morphological parameters were evaluated 9 weeks after the environmental stimulation. Results indicate impairment in the object recognition task after HI that was recovered by enrichment; however the aversive memory impairment in the inhibitory avoidance task shown by hypoxic-ischemic rats was independent of the environment condition. Hypoxic-ischemic groups showed more crossing responses during the first minute in the open field, when compared to controls, but no differences were found between experimental groups in the rotarod test. Dendritic spine density in the CA1 subfield of the right hippocampus (ipsilateral to the artery occlusion) was decreased after the HI insult, and increased in enriched controls; interestingly enriched HI rats did not differ from CTSE. In conclusion, EE was effective in recovering declarative memory impairment in object recognition and preserved hippocampal dendritic spine density loss after neonatal HI injury. (c) 2012 Elsevier Inc. All rights reserved.	[Rojas, Joseane Jimenez; Diaz, Ramiro; Hermel, Erica do Espirito-Santo; Achaval, Matilde; Netto, Carlos Alexandre; Pereira, Lenir Orlandi] Univ Fed Rio Grande do Sul, ICBS, Programa Posgrad Neurociencias, BR-90046900 Porto Alegre, RS, Brazil; [Rojas, Joseane Jimenez; Deniz, Bruna Ferrary; Miguel, Patricia Maidana; Diaz, Ramiro; Achaval, Matilde; Pereira, Lenir Orlandi] Univ Fed Rio Grande do Sul, ICBS, Dept Ciencias Morfol, BR-90046900 Porto Alegre, RS, Brazil; [Miguel, Patricia Maidana; Netto, Carlos Alexandre] Univ Fed Rio Grande do Sul, ICBS, Dept Bioquim, BR-90046900 Porto Alegre, RS, Brazil	Pereira, LO (corresponding author), ICBS, Rua Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.	lenir.orlandi@ufrgs.br	Silva, Lenir/AAN-7475-2020	Netto, Carlos Alexandre/0000-0002-0596-5667; Maidana Miguel, Patricia/0000-0001-7427-0159; Pereira, Lenir/0000-0001-5541-0697	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); FAPERGSFundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS)	We would like to thank the technical assistance given by Ana Paula Maciel Ornaghi. This work was supported by Brazilian funding agencies: CNPq, CAPES and FAPERGS.	Alvarez VA, 2007, ANNU REV NEUROSCI, V30, P79, DOI 10.1146/annurev.neuro.30.051606.094222; Araki H, 1999, PHYSIOL BEHAV, V66, P263, DOI 10.1016/S0031-9384(98)00293-5; Arteni NS, 2010, BEHAV BRAIN RES, V210, P92, DOI 10.1016/j.bbr.2010.02.015; Arteni NS, 2003, BRAIN RES, V973, P171, DOI 10.1016/S0006-8993(03)02436-3; Baker KB, 2004, BEHAV NEUROSCI, V118, P15, DOI 10.1037/0735-7044.118.1.15; Balduini W, 2000, BRAIN RES, V859, P318, DOI 10.1016/S0006-8993(00)01997-1; Benice T., 2005, NEUR 2005 SAT S WASH; Benson DL, 2012, HIPPOCAMPUS, V22, P954, DOI 10.1002/hipo.20872; BERGER TW, 1980, PHYSIOL PSYCHOL, V8, P155; Bezard E, 2003, J NEUROSCI, V23, P10999; Bindu B, 2007, NEUROSCIENCE, V144, P412, DOI 10.1016/j.neuroscience.2006.09.057; Bona E, 1997, PEDIATR RES, V42, P678, DOI 10.1203/00006450-199711000-00021; Brotto LA, 2000, EUR J PHARMACOL, V402, P87, DOI 10.1016/S0014-2999(00)00491-X; Brown CE, 2008, STROKE, V39, P1286, DOI 10.1161/STROKEAHA.107.498238; Brusco J, 2008, NEUROSCI LETT, V438, P346, DOI 10.1016/j.neulet.2008.04.063; Capasso A, 1996, PHYTOTHER RES, V10, P309, DOI 10.1002/(SICI)1099-1573(199606)10:4&lt;309::AID-PTR850&gt;3.0.CO;2-J; Cassel JC, 1998, NEUROBIOL LEARN MEM, V69, P22, DOI 10.1006/nlme.1997.3807; Chavez D.G., 2008, NEUROSCI LETT, V448, P148; Chen JR, 2009, NEUROSCIENCE, V161, P1104, DOI 10.1016/j.neuroscience.2009.04.022; Cheng HW, 1997, EXP NEUROL, V147, P287, DOI 10.1006/exnr.1997.6618; Clark RE, 2005, CURR OPIN NEUROBIOL, V15, P593, DOI 10.1016/j.conb.2005.08.014; COLEMANMESCHES K, 1995, BRAIN RES, V670, P75, DOI 10.1016/0006-8993(94)01272-J; Coutureau E, 2000, EXP BRAIN RES, V131, P381, DOI 10.1007/s002219900301; de Castilhos J, 2006, BRAIN RES BULL, V69, P131, DOI 10.1016/j.brainresbull.2005.11.013; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Harburger LL, 2007, BEHAV BRAIN RES, V185, P43, DOI 10.1016/j.bbr.2007.07.009; Ikeda T, 2001, BEHAV BRAIN RES, V118, P17, DOI 10.1016/S0166-4328(00)00287-4; Im SH, 2010, NEUROSCIENCE, V169, P259, DOI 10.1016/j.neuroscience.2010.04.038; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; Jadavji NM, 2006, NEUROSCIENCE, V140, P1127, DOI 10.1016/j.neuroscience.2006.03.027; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Jansen EM, 1996, BEHAV BRAIN RES, V78, P189, DOI 10.1016/0166-4328(95)00248-0; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; Kadam SD, 2009, BEHAV BRAIN RES, V197, P77, DOI 10.1016/j.bbr.2008.08.003; Karasev AV, 2010, B EXP BIOL MED+, V149, P677, DOI 10.1007/s10517-010-1022-0; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P209, DOI 10.1007/BF00691854; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; KOELFEN W, 1995, DEV MED CHILD NEUROL, V37, P204; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; KUROIWA T, 1991, BRAIN RES, V563, P33, DOI 10.1016/0006-8993(91)91511-X; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Leuner B, 2003, J NEUROSCI, V23, P659; LEVINE S, 1960, AM J PATHOL, V36, P1; Lippman J, 2005, J NEUROBIOL, V64, P47, DOI 10.1002/neu.20149; LIPSKA BK, 1991, PHARMACOL BIOCHEM BE, V40, P181, DOI 10.1016/0091-3057(91)90342-Y; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; Luine VN, 2011, CURR GERONTOL GERIAT, P1, DOI DOI 10.1016/J.NEUROIMAGE.2013.08.017; Marcuzzo S, 2007, NEUROSCI LETT, V424, P16, DOI 10.1016/j.neulet.2007.07.019; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; MEANEY MJ, 1985, BRAIN RES, V328, P176, DOI 10.1016/0006-8993(85)91340-X; MILESON BE, 1991, NEUROSCI LETT, V128, P71, DOI 10.1016/0304-3940(91)90762-I; Nakamura H, 1999, J NEUROSCI RES, V56, P307; NETTO CA, 1985, BEHAV NEURAL BIOL, V44, P515, DOI 10.1016/S0163-1047(85)91048-9; Nicolelis MAL, 1997, SEMIN NEUROSCI, V9, P24, DOI 10.1006/smns.1997.0103; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Okuda S, 2004, P NATL ACAD SCI USA, V101, P853, DOI 10.1073/pnas.0307803100; Pereira LO, 2007, NEUROBIOL LEARN MEM, V87, P101, DOI 10.1016/j.nlm.2006.07.003; Paxinos G., 2004, RAT BRAIN STEREOTAXI; Pereira LO, 2008, BRAIN RES, V1218, P257, DOI 10.1016/j.brainres.2008.04.010; Pereira LO, 2009, BRAIN RES, V1247, P188, DOI 10.1016/j.brainres.2008.10.017; Pham TM, 2002, PHARMACOL BIOCHEM BE, V73, P167, DOI 10.1016/S0091-3057(02)00783-9; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rasia-Filho AA, 2004, NEUROSCIENCE, V126, P839, DOI 10.1016/j.neuroscience.2004.04.009; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Rodrigues AL, 2004, BRAIN RES, V1002, P94, DOI 10.1016/j.brainres.2003.12.020; Ruan YW, 2009, J NEUROSCI RES, V87, P61, DOI 10.1002/jnr.21816; Schlager GW, 2011, EXP NEUROL, V230, P67, DOI 10.1016/j.expneurol.2010.11.021; SHEN Y, 1991, RESTOR NEUROL NEUROS, V3, P11, DOI 10.3233/RNN-1991-3102; Shimada Masahisa, 1997, Acta Anatomica Nipponica, V72, P545; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Takao K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009460; Ten VS, 2004, STROKE, V35, P2183, DOI 10.1161/01.STR.0000137768.25203.df; Trollmann R, 2009, BRAIN DEV-JPN, V31, P503, DOI 10.1016/j.braindev.2009.03.007; VALLE FP, 1980, B PSYCHONOMIC SOC, V16, P429; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WANG D, 1990, BRAIN RES, V533, P78, DOI 10.1016/0006-8993(90)91798-L; WIDMAN DR, 1990, PHYSIOL BEHAV, V47, P57, DOI 10.1016/0031-9384(90)90042-3; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035; YOUNG RSK, 1986, STROKE, V17, P1313, DOI 10.1161/01.STR.17.6.1313; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	97	70	78	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2013	241						25	33		10.1016/j.expneurol.2012.11.026			9	Neurosciences	Neurosciences & Neurology	095DV	WOS:000315315800004	23219882				2021-06-18	
J	Harris, JL; Yeh, HW; Choi, IY; Lee, P; Berman, NE; Swerdlow, RH; Craciunas, SC; Brooks, WM				Harris, Janna L.; Yeh, Hung-Wen; Choi, In-Young; Lee, Phil; Berman, Nancy E.; Swerdlow, Russell H.; Craciunas, Sorin C.; Brooks, William M.			Altered neurochemical profile after traumatic brain injury: H-1-MRS biomarkers of pathological mechanisms	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						animal models; brain trauma; cell death mechanisms; MR spectroscopy; neurochemistry	PROTON-MAGNETIC-RESONANCE; CORTICAL IMPACT INJURY; VIVO H-1-NMR SPECTROSCOPY; RAT-BRAIN; IN-VIVO; N-ACETYLASPARTATE; TIME-COURSE; ENERGY-METABOLISM; OXIDATIVE STRESS; REGIONAL CHANGES	Specific neurochemicals measured with proton magnetic resonance spectroscopy (H-1-MRS) may serve as biomarkers of pathological mechanism in the brain. We used high field in vivo H-1-MRS to measure a detailed neurochemical profile after experimental traumatic brain injury (TBI) in rats. We characterized neurochemical changes in the contused cortex and the normal-appearing perilesional hippocampus over a time course from 1 hour to 2 weeks after injury. We found significant changes in 19 out of 20 neurochemicals in the cortex, and 9 out of 20 neurochemicals in the hippocampus. These changes provide evidence of altered cellular metabolic status after TBI, with specific compounds proposed to reflect edema, excitotoxicity, neuronal and glial integrity, mitochondrial status and bioenergetics, oxidative stress, inflammation, and cell membrane disruption. Our results support the utility of H-1-MRS for monitoring cellular mechanisms of TBI pathology in animal models, and the potential of this approach for preclinical evaluation of novel therapies. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 2122-2134; doi:10.1038/jcbfm.2012.114; published online 15 August 2012	[Harris, Janna L.; Choi, In-Young; Lee, Phil; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; [Yeh, Hung-Wen] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66160 USA; [Choi, In-Young; Swerdlow, Russell H.; Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA; [Lee, Phil; Swerdlow, Russell H.; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Berman, Nancy E.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Swerdlow, Russell H.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; [Craciunas, Sorin C.] Carol Davila Univ Med, Neurosurg Unit 4, Bagdasar Arseni Hosp, Bucharest, Romania	Harris, JL (corresponding author), Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Mail Stop 1052,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	jharris2@kumc.edu	Brooks, William/AAF-8299-2019	Brooks, William/0000-0001-6227-7636; Lee, Phil/0000-0002-2087-8887	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR000001, P30 HD002528, P30 AG035982, R01 AG031140, R03 NS077852]; University of Kansas; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS077852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG035982, R01AG031140] Funding Source: NIH RePORTER	This study was supported in part by the National Institutes of Health (UL1 TR000001 to Frontiers: The Heartland Institute for Clinical and Translational Research at the University of Kansas Medical Center; P30 HD002528 to the Kansas Intellectual and Developmental Disabilities Research Center; P30 AG035982 to the University of Kansas Alzheimer's Disease Center; R01 AG031140 to Dr Berman; and R03 NS077852 to Dr Swerdlow) and a University of Kansas Lied Endowed Basic Science grant to Dr Brooks. The Hoglund Brain Imaging Center is supported by a generous gift from Forrest and Sally Hoglund.	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Arun P, 2006, J NEUROCHEM, V98, P2034, DOI 10.1111/j.1471-4159.2006.04068.x; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BEHAR KL, 1993, MAGNET RESON MED, V30, P38, DOI 10.1002/mrm.1910300107; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brooks WM, 2010, ARTHRITIS RHEUM-US, V62, P2055, DOI 10.1002/art.27458; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buitrago MM, 2004, NEUROBIOL LEARN MEM, V81, P211, DOI 10.1016/j.nlm.2004.01.001; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Choi IY, 2011, MULT SCLER J, V17, P289, DOI 10.1177/1352458510384010; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Imbrosci B, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/614329; Lei HX, 2009, J CEREBR BLOOD F MET, V29, P811, DOI 10.1038/jcbfm.2009.8; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Moffett J. R., 2006, N ACETYLASPARTATE UN; Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rice ME, 1998, NEUROSCIENCE, V82, P1213; Righi V, 2009, NMR BIOMED, V22, P629, DOI 10.1002/nbm.1377; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Schafer JL., 1997, ANAL INCOMPLETE MULT; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tkac I, 2003, MAGN RESON MED, V50, P24, DOI 10.1002/mrm.10497; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7; Zacharoff L, 2012, J CEREBR BLOOD F MET, V32, P502, DOI 10.1038/jcbfm.2011.157; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhou J, 2005, NAT REV DRUG DISCOV, V4, P1015, DOI 10.1038/nrd1903	51	70	75	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2012	32	12					2122	2134		10.1038/jcbfm.2012.114			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	095QJ	WOS:000315349200006	22892723	Green Published, Other Gold			2021-06-18	
J	Wolf, G; Cifu, D; Baugh, L; Carne, W; Profenna, L				Wolf, George; Cifu, David; Baugh, Laura; Carne, William; Profenna, Leonardo			The Effect of Hyperbaric Oxygen on Symptoms after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						hyperbaric oxygen; post-concussive syndrome; traumatic brain injury	PLACEBO-RESPONSE; MAJOR DEPRESSION; AFGHANISTAN; CONCUSSION; CHECKLIST; THERAPY; IRAQ	In this single-center, double-blind, randomized, sham-controlled, prospective trial at the U. S. Air Force School of Aerospace Medicine, the effects of 2.4 atmospheres absolute (ATA) hyperbaric oxygen (HBO2) on post-concussion symptoms in 50 military service members with at least one combat-related, mild traumatic brain injury were examined. Each subject received 30 sessions of either a sham compression (room air at 1.3 ATA) or HBO2 treatments at 2.4 ATA over an 8-week period. Individual and total symptoms scores on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT (R)) and composite scores on Post-traumatic Disorder Check List-Military Version (PCL-M) were measured just prior to intervention and 6 weeks after completion of intervention. Difference testing of post-intervention means between the sham-control and HBO2 group revealed no significant differences on the PCL-M composite score (t= -0.205, p = 0.84) or on the ImPACT total score (t= -0.943, p = 0.35), demonstrating no significant effect for HBO2 at 2.4 ATA. PCL-M composite scores and ImPACT total scores for sham-control and HBO2 groups revealed significant improvement over the course of the study for both the sham-control group (t = 3.76, p = 0.001) and the HBO2 group (t = 3.90, p = 0.001), demonstrating no significant HBO2 effect. Paired t-test results revealed 10 ImPACT scale scores in the sham-control group improved from pre- to post-testing, whereas two scale scores significantly improved in the HBO2 group. One PCL-M measure improved from pre- to post-testing in both groups. This study showed that HBO2 at 2.4 ATA pressure had no effect on post-concussive symptoms after mild TBI.	[Wolf, George; Baugh, Laura; Profenna, Leonardo] USAF, Sch Aerosp Med, Hyperbar Med Dept, Wilford Hall Ambulatory Surg Ctr, Lackland AFB, TX USA; [Cifu, David] PM&R Program Off, Dept Vet Affairs, Washington, DC USA; [Cifu, David; Carne, William] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Baugh, Laura] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Carne, William] Richmond Def & Vet Brain Injury Ctr, Richmond, VA USA	Cifu, D (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 E Marshall St, Richmond, VA 23298 USA.	dcifu@vcu.edu		Cifu, David/0000-0003-1600-9387	Air Force Medical Support Agency Medical Modernization Directorate; 711th Human Performance Wing for the primary study; U.S. Navy Bureau of Medicine and Surgery; U.S. Army Medical Materiel Development Activity; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-09-2-206]; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	Funding was provided by the Air Force Medical Support Agency Medical Modernization Directorate and the 711th Human Performance Wing for the primary study. The U.S. Navy Bureau of Medicine and Surgery provided contract funding for temporary duty requirements, and the U.S. Army Medical Materiel Development Activity provided funding for end of the study.; Dr. Cifu's efforts were supported, in part, through a Defense Advanced Research Projects Agency grant (N66001-09-2-206) and a contract from the U.S. Army Medical Materiel Development Activity. Dr. Carne's efforts were supported, in part, through contracts from the U.S. Army Medical Materiel Development Activity and the Defense and Veterans Brain Injury Center. The funding sources had no role in the study design, analysis, interpretation of the data, the writing of the paper, or the decision to submit the paper for publication.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bennett M.H., 2004, COCHRANE DB SYST REV, V4; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brunoni AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004824; Cifu D.X., 2011, OVERCOMING POSTDEPOL; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TBI; ECRI Institute, 2006, 1001 ECRI I CLIN; Gesell L.B., 2008, HYPERBARIC OXYGEN TH, V12th; Harch P.G., 2002, P 2 INT S HYP OXYG C; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Health Affairs, 2007, COMMUNICATION; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McDonagh M., 2003, 85 AHRQ; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Naval Sea Systems Command, 2008, SS521AGPRO010 NAV SE; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Stein DJ, 2006, J CLIN PSYCHIAT, V67, P1741, DOI 10.4088/JCP.v67n1111; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; U.S. Department of Veterans Affairs, 2007, PTSD CHECKL PCL; van Ophoven A, 2006, J UROLOGY, V176, P1442, DOI 10.1016/j.juro.2006.06.065; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weaver L.K., 2012, UNDERSEA HY IN PRESS; Wolf E.G., 2012, UNDERSEA HY IN PRESS	30	70	72	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2606	2612		10.1089/neu.2012.2549			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400002	23031217				2021-06-18	
J	Tamashiro, TT; Dalgard, CL; Byrnes, KR				Tamashiro, Tami T.; Dalgard, Clifton Lee; Byrnes, Kimberly R.			Primary Microglia Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Immunology; Issue 66; Neuroscience; Physiology; Molecular Biology; Cell Culture; isolation; microglia; mixed glial cell; traumatic brain injury; neurodegenerative disease	ACTIVATION; GLUTAMATE; INFLAMMATION; MECHANISMS	Microglia account for approximately 12% of the total cellular population in the mammalian brain. While neurons and astrocytes are considered the major cell types of the nervous system, microglia play a significant role in normal brain physiology by monitoring tissue for debris and pathogens and maintaining homeostasis in the parenchyma via phagocytic activity 1,2. Microglia are activated during a number of injury and disease conditions, including neurodegenerative disease, traumatic brain injury, and nervous system infection (3). Under these activating conditions, microglia increase their phagocytic activity, undergo morpohological and proliferative change, and actively secrete reactive oxygen and nitrogen species, pro-inflammatory chemokines and cytokines, often activating a paracrine or autocrine loop (4-6). As these microglial responses contribute to disease pathogenesis in neurological conditions, research focused on microglia is warranted. Due to the cellular heterogeneity of the brain, it is technically difficult to obtain sufficient microglial sample material with high purity during in vivo experiments. Current research on the neuroprotective and neurotoxic functions of microglia require a routine technical method to consistently generate pure and healthy microglia with sufficient yield for study. We present, in text and video, a protocol to isolate pure primary microglia from mixed glia cultures for a variety of downstream applications. Briefly, this technique utilizes dissociated brain tissue from neonatal rat pups to produce mixed glial cell cultures. After the mixed glial cultures reach confluency, primary microglia are mechanically isolated from the culture by a brief duration of shaking. The microglia are then plated at high purity for experimental study. The principle and protocol of this methodology have been described in the literature (7,8). Additionally, alternate methodologies to isolate primary microglia are well described (9-12). Homogenized brain tissue may be separated by density gradient centrifugation to yield primary microglia (12). However, the centrifugation is of moderate length (45 min) and may cause cellular damage and activation, as well as, cause enriched microglia and other cellular populations. Another protocol has been utilized to isolate primary microglia in a variety of organisms by prolonged (16 hr) shaking while in culture (9-11). After shaking, the media supernatant is centrifuged to isolate microglia. This longer two-step isolation method may also perturb microglial function and activation. We chiefly utilize the following microglia isolation protocol in our laboratory for a number of reasons: (1) primary microglia simulate in vivo biology more faithfully than immortalized rodent microglia cell lines, (2) nominal mechanical disruption minimizes potential cellular dysfunction or activation, and (3) sufficient yield can be obtained without passage of the mixed glial cell cultures. It is important to note that this protocol uses brain tissue from neonatal rat pups to isolate microglia and that using older rats to isolate microglia can significantly impact the yield, activation status, and functional properties of isolated microglia. There is evidence that aging is linked with microglia dysfunction, increased neuroinflammation and neurodegenerative pathologies, so previous studies have used ex vivo adult microglia to better understand the role of microglia in neurodegenerative diseases where aging is important parameter. However, ex vivo microglia cannot be kept in culture for prolonged periods of time. Therefore, while this protocol extends the life of primary microglia in culture, it should be noted that the microglia behave differently from adult microglia and in vitro studies should be carefully considered when translated to an in vivo setting.	[Tamashiro, Tami T.; Dalgard, Clifton Lee] Uniformed Serv Univ Hlth Sci, Neurosci Program, Bethesda, MD USA; [Dalgard, Clifton Lee; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA; [Dalgard, Clifton Lee] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA	Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD USA.	kimberly.byrnes@usuhs.mil		Byrnes, Kimberly/0000-0002-7501-7734	intramural program at the Uniformed Services University	Funded by the intramural program at the Uniformed Services University.	Barger SW, 2001, J NEUROCHEM, V76, P846, DOI 10.1046/j.1471-4159.2001.00075.x; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Frank MG, 2006, J NEUROSCI METH, V151, P121, DOI 10.1016/j.jneumeth.2005.06.026; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; HASSAN NF, 1991, CLIN IMMUNOL IMMUNOP, V59, P426, DOI 10.1016/0090-1229(91)90038-C; HASSAN NF, 1991, J LEUKOCYTE BIOL, V50, P86; HASSAN NF, 1991, NEUROSCIENCE, V41, P149, DOI 10.1016/0306-4522(91)90205-3; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Ni Mingwei, 2010, Curr Protoc Toxicol, VChapter 12, DOI 10.1002/0471140856.tx1217s43; Pocock J M, 2001, Prog Brain Res, V132, P555; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528	14	70	72	1	17	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	AUG	2012		66							e3814	10.3791/3814			5	Multidisciplinary Sciences	Science & Technology - Other Topics	V36QC	WOS:000209225000009	22929966	Green Published			2021-06-18	
J	Chen, HC; Fong, TH; Lee, AW; Chiu, WT				Chen, Hsien-Chih; Fong, Tsorng-Harn; Lee, Ai-Wei; Chiu, Wen-Ta			Autophagy Is Activated in Injured Neurons and Inhibited by Methylprednisolone After Experimental Spinal Cord Injury	SPINE			English	Article						autophagy; spinal cord injury; methylprednisolone; transmission electron microscopy; microtubule-associated protein light chain 3	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CELL-DEATH; RAT MODEL; PATHOGENESIS; APOPTOSIS; PATHWAYS; SYSTEM; LC3	Study Design. Experimental, controlled trial, animal study. Objective. To assess autophagy expression after rat spinal cord injury (SCI) and investigate the effect of methylprednisolone treatment on autophagy. Summary of Background Data. Although it is evident that SCI induces necrosis and apoptosis, its relationship to autophagy is uncertain. Autophagy is implicated in various pathological states in the nervous system, such as neurodegenerative diseases, cerebral ischemia, and traumatic brain injury. Up to now, no autophagy expression was evidenced by transmission electronic microscope (TEM) and the autophagy marker, microtubule-associated protein light chain 3 (LC3) in neural tissue after SCI. Methods. Sixty-six Sprague-Dawley rats were used for the experimental procedure. In the SCI group, laminectomy at T9 were performed, followed by impactor contusion of the spinal cord. In the sham group, only a laminectomy was performed without contusion. We used Western blot to analyze LC3 at 2 hours, 4 hours, 1 day, 3 days, and 7 days after SCI. We also investigated the effect of methylprednisolone on autophagy expression of contused spinal cord. Cellular localization and ultrastructural changes after spinal cord injury were compared with those sham-operated rats using immunofluorescent double labeling and TEM, respectively. Data from the Western blot were analyzed using a nonparametric Kruskal-Wallis test with P < 0.05 being considered significant. Results. We detected significantly elevated level of LC3 2 hours after SCI, and then the level declined until 1 week after SCI. Methylprednisolone decreased LC3 expression at 2 hours after SCI. LC3 positive cells were colocalized with neuronal nuclei, but not with glial fibrillary acidic protein. The existence of autophagy and progress of autophagic cell death after SCI were confirmed by TEM. Conclusion. Through observing the enhanced autophagy expression in neurons soon after contusion injury and the inhibitive effect of methylprednisolone treatment, this study demonstrates the characteristics of autophagy expression after SCI and suggests that autophagic cell death may play a role in neuronal death after spinal cord trauma.	[Chen, Hsien-Chih; Chiu, Wen-Ta] Taipei Med Univ, Coll Med, Sch Med, Grad Inst Clin Med, Taipei 11031, Taiwan; [Chen, Hsien-Chih] Chang Gung Mem Hosp, Dept Neurosurg, Keelung, Taiwan; [Chen, Hsien-Chih] Chang Gung Univ, Sch Med, Tao Yuan, Taiwan; [Fong, Tsorng-Harn; Lee, Ai-Wei] Taipei Med Univ, Coll Med, Sch Med, Dept Anat, Taipei 11031, Taiwan	Chiu, WT (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Grad Inst Clin Med, 250 Wuxing St, Taipei 11031, Taiwan.	wtchiu@tmu.edu.tw			Chang Gung Memorial HospitalChang Gung Memorial Hospital	Chang Gung Memorial Hospital grant funds were received to support this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.	Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DUCKER TB, 1994, SPINE, V19, P2281, DOI 10.1097/00007632-199410150-00006; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Gurusamy N, 2009, METHODS MOL BIOL, V559, P95, DOI 10.1007/978-1-60327-017-5_7; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sarkar S, 2008, HUM MOL GENET, V17, P170, DOI 10.1093/hmg/ddm294; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412	28	70	81	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	MAR 15	2012	37	6					470	475		10.1097/BRS.0b013e318221e859			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	912CN	WOS:000301772300016	21587101				2021-06-18	
J	Brainard, LL; Beckwith, JG; Chu, JJ; Crisco, JJ; Mcallister, TW; Duhaime, AC; Maerlender, AC; Greenwald, RM				Brainard, Lindley L.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Crisco, Joseph J.; Mcallister, Thomas W.; Duhaime, Ann-Christine; Maerlender, Arthur C.; Greenwald, Richard M.			Gender Differences in Head Impacts Sustained by Collegiate Ice Hockey Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; BRAIN INJURY; SPORTS; ICE HOCKEY; GENDER; HEAD IMPACT	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; UNITED-STATES; EPIDEMIOLOGY; ACCELERATION; ASSOCIATION; RECOMMENDATIONS; LOCATION	BRAINARD, L. L., J. G. BECKWITH, J. J. CHU, J. J. CRISCO, T. W. MCALLISTER, A. DUHAIME, A. C. MAERLENDER, and R. M. GREENWALD. Gender Differences in Head Impacts Sustained by Collegiate Ice Hockey Players. Med. Sci. Sports Exerc., Vol. 44, No. 2, pp. 297-304, 2012. Purpose: This study aimed to quantify the frequency, magnitude, and location of head impacts sustained by male and female collegiate ice hockey players during two seasons of play. Methods: During two seasons, 88 collegiate athletes (51 females, 37 males) on two female and male National Collegiate Athletic Association varsity ice hockey teams wore instrumented helmets. Each helmet was equipped with six single-axis accelerometers and a miniature data acquisition system to capture and record head impacts sustained during play. Data collected from the helmets were postprocessed to compute linear and rotational accelerations of the head as well as impact location. The head impact exposure data (frequency, location, and magnitude) were then compared between genders. Results: Female hockey players experienced a significantly lower (P < 0.001) number of impacts per athlete exposure than males (females = 1.7 +/- 0.7, males = 2.9 +/- 1.2). The frequency of impacts by location was the same between genders (P > 0.278) for all locations except the right side of the head, where males received fewer impacts than females (P = 0.031). Female hockey players were 1.1 times more likely than males to sustain an impact less than 50g, whereas males were 1.3 times more likely to sustain an impact greater than 100g. Similarly, males were 1.9 times more likely to sustain an impact with peak rotational acceleration greater than 5000 rad.s(-2) and 3.5 times more likely to sustain an impact greater than 10,000 rad.s(-2). Conclusions: Although the incidence of concussion has typically been higher for female hockey players than male hockey players, female players sustain fewer impacts and impacts resulting in lower head acceleration than males. Further study is required to better understand the intrinsic and extrinsic risk factors that lead to higher rates of concussion for females that have been previously reported.	[Brainard, Lindley L.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH 03766 USA; [Crisco, Joseph J.] Brown Univ, Bioengn Lab, Dept Orthoped, Alpert Med Sch, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Mcallister, Thomas W.; Maerlender, Arthur C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA; [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Duhaime, Ann-Christine] Harvard Univ, Sch Med, Boston, MA USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Beckwith, JG (corresponding author), Simbex, 10 Water St,Suite 410, Lebanon, NH 03766 USA.	jbeckwith@simbex.com			National Institute for Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; National Operating Committee on Standards for Athletic Equipment; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The research for this study was supported by the National Institute for Child Health and Human Development at the National Institutes of Health (grant no. R01HD048638) and the National Operating Committee on Standards for Athletic Equipment. Joseph J. Crisco, Richard M. Greenwald, Jeffrey J. Chu, and Simbex have a financial interest in the instruments (HIT System, Sideline Response System (Riddell, Inc.)) that were used to collect the data reported in this study.	Agel J, 2007, J ATHL TRAINING, V42, P249; [Anonymous], 2008, F104507 ASTM INT, P150; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Beckwith JG, 2009, SEVERITY HEAD IMPACT, P1144; Beckwith JG, 2010, 8 WORLD C BRAIN INJ, P446; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gwin J., 2006, J BIOMECH, V39, pS153; Gwin J. T., 2009, J ASTM INT, V6, P1; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McDowell Margaret A, 2005, Adv Data, P1; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; National Committee on Standards for Athletic Equipment, 2006, 08104M04 NOCSAE DOC, P1; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Odelgard B, 1989, ASTM STP, p[1989, 164]; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Piotowski S, 2008, 2008 10 NCAA MENS WO, P178; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Talavage TM, 2010, J NEUROTRAUMA   1001; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; US Department of Labor, TITL 9 ED AM 1972	42	70	70	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2012	44	2					297	304		10.1249/MSS.0b013e31822b0ab4			8	Sport Sciences	Sport Sciences	879FY	WOS:000299316300016	21716150	Green Accepted, Green Published			2021-06-18	
J	Rotaru, H; Stan, H; Florian, IS; Schumacher, R; Park, YT; Kim, SG; Chezan, H; Balc, N; Baciut, M				Rotaru, Horatiu; Stan, Horatiu; Florian, Ioan Stefan; Schumacher, Ralf; Park, Yong-Tae; Kim, Seong-Gon; Chezan, Horea; Balc, Nicolae; Baciut, Mihaela			Cranioplasty With Custom-Made Implants: Analyzing the Cases of 10 Patients	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; CRANIAL DEFECTS; HYDROXYAPATITE CEMENT; RECONSTRUCTION; COMPLICATIONS; CHILDREN; SKULL; IMPROVEMENT; PROSTHESES	Purpose: The aim of this study was to assess quantitatively whether a symmetric reconstruction of the calvaria could be achieved using 3-dimensional (3D) custom-made implants and to examine any complications caused by the cranioplasty. Patients and Methods: Custom-made cranial implants were produced using data obtained from computed tomographic scanning of the defect using computer-aided design and rapid prototyping techniques. Polymethylmethacrylate was used as the reconstruction material and the implant was cast from a silicone rubber mold. These implants were used in 10 patients (9 men and 1 woman) who previously received a craniectomy. The symmetry gained after cranioplasty was quantified by volumetric analysis using 3D reconstructed postoperative computed tomographic imaging. Any complications after cranioplasty also were recorded. Results: The average follow-up was 42.5 months (range, 7 to 85 mo). The esthetic appearance of all patients was much improved. When the volume of the reconstructed right calvaria was compared with the left calvaria, the difference was not statistically significant (P > .05). There were 2 cases of complications. One exhibited a transient seroma collection. Another had a wrinkle formation in the forehead. No infectious episodes or signs of plate rejection were encountered. Conclusions: The custom-made implants for cranioplasty showed a significant improvement in morphology. The implants may be very useful for repairing large and complex-shaped cranial defects. The technique may be useful for the bone reconstruction of other sites. c 2012 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 70:e169-e176, 2012	[Park, Yong-Tae; Kim, Seong-Gon] Gangneung Wonju Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Kangnung 210702, South Korea; [Rotaru, Horatiu] Iuliu Hatieganu Univ Med & Pharm, Dept Craniomaxillofacial Surg, Cluj Napoca, Romania; [Stan, Horatiu; Florian, Ioan Stefan] Iuliu Hatieganu Univ Med & Pharm, Dept Neurosurg, Cluj Napoca, Romania; [Schumacher, Ralf] Univ Appl Sci, Med Addit Mfg Grp, Muttenz, Switzerland; [Chezan, Horea] Iuliu Hatieganu Univ Med & Pharm, Natl Rapid Prototyping Lab, Cluj Napoca, Romania; [Baciut, Mihaela] Iuliu Hatieganu Univ Med & Pharm, Dept Implantol & Maxillofacial Surg, Cluj Napoca, Romania; [Balc, Nicolae] Tech Univ, Dept Mfg Engn, Cluj Napoca, Romania	Kim, SG (corresponding author), Gangneung Wonju Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Kangnung 210702, South Korea.	epker@chol.com	Florian, Ioan Stefan I/D-5934-2016; Kim, Seong-Gon/AAF-7553-2020	Florian, Ioan Stefan I/0000-0001-7127-0946; Kim, Seong-Gon/0000-0001-5088-2732	Romanian Government [5/2010, PN I-PCCE-ID 101]; BioGreen21 ProgramRural Development Administration (RDA) [PJ007170201006]; Rural Development Administration, Suwon, Republic of KoreaRural Development Administration (RDA)	This study was supported by grant 5/2010 from the project New Biocompatible Materials for Personalised Implants made by SLS and SLM (BIOMAPIM) PN I-PCCE-ID 101, financed by the Romanian Government, and grant PJ007170201006 from the BioGreen21 Program, Rural Development Administration, Suwon, Republic of Korea.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chiarini L, 2004, J CRANIO MAXILL SURG, V32, P5, DOI 10.1016/j.jcms.2003.08.005; Dean D, 2003, J CRANIOFAC SURG, V14, P819, DOI 10.1097/00001665-200311000-00002; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Durand J L, 1997, Ann Chir Plast Esthet, V42, P75; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; EUFINGER H, 1995, INT J ORAL MAX SURG, V24, P104, DOI 10.1016/S0901-5027(05)80870-7; Fallahi B, 1999, NEUROL RES, V21, P281, DOI 10.1080/01616412.1999.11740932; Fantini M, 2008, RAPID PROTOTYPING J, V14, P318, DOI 10.1108/13552540810907992; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Gerber N, 2010, IEEE ENG MED BIO, P3357, DOI 10.1109/IEMBS.2010.5627903; Golz T, 2010, J CLIN NEUROSCI, V17, P617, DOI 10.1016/j.jocn.2009.09.005; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Jang ES, 2010, ORAL SURG ORAL MED O, V109, P831, DOI 10.1016/j.tripleo.2009.10.038; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Korinek AM:, 1997, NEUROSURGERY, V41, P1079; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Matic DB, 2004, J CRANIOFAC SURG, V15, P415, DOI 10.1097/00001665-200405000-00012; Mokri B, 2010, HEADACHE, V50, P1206, DOI 10.1111/j.1526-4610.2010.01715.x; Moore K, 2007, ESSENTIAL CLIN ANATO, p[496, 498, 499]; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Rotaru H, 2006, J CRANIO MAXILL SURG, V34, P242, DOI 10.1016/j.jcms.2006.01.005; Sahoo N, 2010, J CRANIOFAC SURG, V21, P79, DOI 10.1097/SCS.0b013e3181c3ba58; Solaro P, 2008, J NEUROSURG SCI, V52, P113; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e; VANPUTTEN MC, 1992, J PROSTHET DENT, V68, P103, DOI 10.1016/0022-3913(92)90294-K; Wong RK, 2011, J CRANIOFAC SURG, V22, P247, DOI 10.1097/SCS.0b013e3181f7b7db; Wulf J, 2005, ST HEAL T, V111, P608	34	70	74	2	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	FEB	2012	70	2					E169	E176		10.1016/j.joms.2011.09.036			8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	889DO	WOS:000300053900009	22260919				2021-06-18	
J	Khuman, J; Zhang, J; Park, J; Carroll, JD; Donahue, C; Whalen, MJ				Khuman, Jugta; Zhang, Jimmy; Park, Juyeon; Carroll, James D.; Donahue, Chad; Whalen, Michael J.			Low-Level Laser Light Therapy Improves Cognitive Deficits and Inhibits Microglial Activation after Controlled Cortical Impact in Mice	JOURNAL OF NEUROTRAUMA			English	Article						cognition; controlled cortical impact; inflammation; low-level laser light therapy; mice; microglia	TRAUMATIC BRAIN-INJURY; LONG-TERM DISABILITY; UNITED-STATES; PROMOTES REGENERATION; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; EMITTING DIODE; WATER MAZE; TNF-ALPHA; IRRADIATION	Low-level laser light therapy (LLLT) exerts beneficial effects on motor and histopathological outcomes after experimental traumatic brain injury (TBI), and coherent near-infrared light has been reported to improve cognitive function in patients with chronic TBI. However, the effects of LLLT on cognitive recovery in experimental TBI are unknown. We hypothesized that LLLT administered after controlled cortical impact (CCI) would improve post-injury Morris water maze (MWM) performance. Low-level laser light (800 nm) was applied directly to the contused parenchyma or transcranially in mice beginning 60-80 min after CCI. Injured mice treated with 60 J/cm(2) (500 mW/cm(2)x2 min) either transcranially or via an open craniotomy had modestly improved latency to the hidden platform (p<0.05 for group), and probe trial performance (p<0.01) compared to non-treated controls. The beneficial effects of LLLT in open craniotomy mice were associated with reduced microgliosis at 48h (21.8 +/- 2.3 versus 39.2 +/- 4.2 IbA-1 + cells/200 x field, p<0.05). Little or no effect of LLLT on post-injury cognitive function was observed using the other doses, a 4-h administration time point and 7-day administration of 60 J/cm(2). No effect of LLLT (60 J/cm(2) open craniotomy) was observed on post-injury motor function (days 1-7), brain edema (24h), nitrosative stress (24h), or lesion volume (14 days). Although further dose optimization and mechanism studies are needed, the data suggest that LLLT might be a therapeutic option to improve cognitive recovery and limit inflammation after TBI.	[Khuman, Jugta; Zhang, Jimmy; Park, Juyeon; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Sch Med, Charlestown, MA 02129 USA; [Khuman, Jugta; Zhang, Jimmy; Park, Juyeon; Donahue, Chad; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Neurosci Ctr, Sch Med, Charlestown, MA 02129 USA; [Carroll, James D.] THOR Photomed Ltd, Chesham, England	Whalen, MJ (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Sch Med, Charlestown, MA 02129 USA.	mwhalen@partners.org	Carroll, James/AAL-1739-2021	Carroll, James/0000-0002-9205-1061	Massachusetts General Hospital Center for the Integration of Medicine and Technology (CIMIT);  [RO1NS047447]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from the Massachusetts General Hospital Center for the Integration of Medicine and Technology (CIMIT) (M.J.W.), and RO1NS047447	Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Konstantinovic LM, 2010, PAIN MED, V11, P1169, DOI 10.1111/j.1526-4637.2010.00907.x; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Lanzafame RJ, 2007, LASER SURG MED, V39, P534, DOI 10.1002/lsm.20519; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3; Lubart R, 2006, PHOTOMED LASER SURG, V24, P532, DOI 10.1089/pho.2006.24.532; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; Moriyama Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P1351, DOI 10.1562/2005-02-28-RA-450; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Rochkind S, 2009, PHOTOMED LASER SURG, V27, P219, DOI 10.1089/pho.2009.9955; de Morais NCR, 2010, PHOTOMED LASER SURG, V28, P227, DOI 10.1089/pho.2008.2422; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Simunovic-Soskic M, 2010, PHOTOMED LASER SURG, V28, P189, DOI 10.1089/pho.2008.2420; Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910; Streifler Jonathan Y, 2007, Harefuah, V146, P373; Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184; Tafur J, 2010, PHOTOMED LASER SURG, V28, P23, DOI 10.1089/pho.2008.2373; Wong SF, 2002, CANCER J, V8, P247, DOI 10.1097/00130404-200205000-00008; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yau JLW, 2002, J NEUROSCI, V22, P1436, DOI 10.1523/JNEUROSCI.22-04-01436.2002; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	53	70	70	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					408	417		10.1089/neu.2010.1745			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300020	21851183	Green Published			2021-06-18	
J	Osman, MM; Lulic, D; Glover, L; Stahl, CE; Lau, T; van Loveren, H; Borlongan, CV				Osman, Mohamed M.; Lulic, Dzenan; Glover, Loren; Stahl, Christine E.; Lau, Tsz; van Loveren, Harry; Borlongan, Cesar V.			Cyclosporine-A as a neuroprotective agent against stroke: Its translation from laboratory research to clinical application	NEUROPEPTIDES			English	Article						Immunosuppressant; Neuroprotection; Cerebral ischemia; Mitochondria; Neurological disorders	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; SPINAL-CORD-INJURY; BRADYKININ RECEPTOR AGONIST; TRANSIENT FOCAL ISCHEMIA; NITRIC-OXIDE SYNTHASE; CEREBRAL-ISCHEMIA; CYCLOPHILIN-D; ADULT RATS; IN-VITRO	Stoke remains a leading cause of death and disability with limited treatment options. Extensive research has been aimed at studying cell death events that accompany stroke and how to use these same cell death pathways as potential therapeutic targets for treating the disease. The mitochondrial permeability transition pore (MPTP) has been implicated as a major factor associated with stroke-induced neuronal cell death. MPTP activation and increased permeability has been shown to contribute to the events that lead to cell death. Cyclosporine A (CsA), a widely used immunosuppressant in transplantation and rheumatic medicine, has been recently shown to possess neuroprotective properties through its ability to block the MPTP, which in turn inhibits neuronal damage. This newfound CsA-mediated neuroprotection pathway prompted research on its use to prevent cell death in stroke and other neurological conditions. Preclinical studies are being conducted in hopes of establishing the safety and efficacy guidelines for CsA use in human trials as a potential neuroprotective agent against stroke. In this review, we provide an overview of the current laboratory and clinical status of CsA neuroprotection. (C) 2011 Elsevier Ltd. All rights reserved.	[Osman, Mohamed M.; Lulic, Dzenan; Glover, Loren; Lau, Tsz; van Loveren, Harry; Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Stahl, Christine E.] MacDill Air Force Base, Dept Aerosp Med, Tampa, FL 33621 USA	Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd,MDC 78, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782	Department of Neurosurgery and Brain Repair; James and Esther King Foundation [1KG01-33966]; Draper Laboratory, Inc. [09KC-05]	This study was supported in part by the Department of Neurosurgery and Brain Repair, the James and Esther King Foundation (1KG01-33966), and the Draper Laboratory, Inc. (09KC-05). C.V.B. is a stockholder and consultant to Maas BiolAB.	Actis GC, 1998, INFLAMM BOWEL DIS, V4, P276, DOI 10.1002/ibd.3780040404; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Akl KF, 2010, SAUDI J KIDNEY DIS T, V21, P957; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baiza-Duran L, 2010, BRIT J OPHTHALMOL, V94, P1312, DOI 10.1136/bjo.2008.150011; Bartus RT, 1996, EXP NEUROL, V142, P14, DOI 10.1006/exnr.1996.0175; Berth-Jones J, 2005, J DERMATOL TREAT, V16, P258, DOI 10.1080/09546630500423914; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; Borlongan CV, 2003, BRAIN RES BULL, V60, P297, DOI 10.1016/S0361-9230(03)00043-1; Borlongan CV, 1999, CELL TRANSPLANT, V8, P153, DOI 10.1177/096368979900800107; Borlongan CV, 2002, BRAIN RES, V956, P211, DOI 10.1016/S0006-8993(02)03474-1; Borlongan CV, 2000, NEUROSCI LETT, V279, P73, DOI 10.1016/S0304-3940(99)00962-3; Borlongan CV, 1998, NEUROSCI RES, V32, P195, DOI 10.1016/S0168-0102(98)00088-1; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Callen JP, 2001, SEMIN CUTAN MED SURG, V20, P58, DOI 10.1053/sder.2001.23100; CHOLONGITAS E, 2010, CLIN TRANSPLANT, DOI DOI 10.1111/J.1399.0012.2010.01321.X; Costantini LC, 1998, NEUROBIOL DIS, V5, P97, DOI 10.1006/nbdi.1998.0185; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dawson VL, 1996, J NEUROSCI, V16, P2479; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Gabryel B, 2009, CELL BIOL INT, V33, P739, DOI 10.1016/j.cellbi.2009.04.006; Gerloni V, 2001, RHEUMATOLOGY, V40, P907, DOI 10.1093/rheumatology/40.8.907; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Goldner FM, 1996, J COMP NEUROL, V372, P283; Hanauer SB, 2004, GASTROENTEROLOGY, V126, P1582, DOI 10.1053/j.gastro.2004.02.071; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hayashi Y, 2005, J NEUROTRAUM, V22, P1267, DOI 10.1089/neu.2005.22.1267; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Hesselink DA, 2004, TRANSPL P, V36, p99S, DOI 10.1016/j.transproceed.2003.12.047; Hui KKW, 2010, J CELL MOL MED, V14, P671, DOI 10.1111/j.1582-4934.2009.00715.x; Ibarra A, 1996, J NEUROTRAUM, V13, P569, DOI 10.1089/neu.1996.13.569; Iida K, 1998, NEUROSCI RES, V30, P185, DOI 10.1016/S0168-0102(97)00128-4; INAMURA T, 1994, J CEREBR BLOOD F MET, V14, P862, DOI 10.1038/jcbfm.1994.108; JAUCH E, 2010, E MED; KAHAN BD, 1993, TRANSPLANT P, V25, P5; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; KHAN M, 2008, IMMUNOPHARMACOLOGY, V1, P87; Leger PL, 2010, EXP NEUROL; Leung AWC, 2008, BBA-BIOENERGETICS, V1777, P946, DOI 10.1016/j.bbabio.2008.03.009; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; Malouitre S, 2010, BIOCHEM J, V425, P137, DOI 10.1042/BJ20090332; MARGARITIS A, 1989, BIOTECHNOL LETT, V11, P765, DOI 10.1007/BF01026093; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marsh JD, 2010, J AM COLL CARDIOL, V56, P683, DOI 10.1016/j.jacc.2009.12.072; MATTSON MP, 2003, IMMUNOSUPRESSANT ANA; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; MINONES J, 1994, LANGMUIR, V10, P1888, DOI 10.1021/la00018a045; Miyata K, 2001, NEUROSCIENCE, V105, P571, DOI 10.1016/S0306-4522(01)00225-1; Muramatsu Y, 2007, BRAIN RES, V1149, P181, DOI 10.1016/j.brainres.2007.02.036; Murozono M, 2004, EUR J PHARMACOL, V498, P115, DOI 10.1016/j.ejphar.2004.06.068; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NOMURA T, 1994, BRAIN RES, V659, P62, DOI 10.1016/0006-8993(94)90863-X; Oger J, 2007, J NEUROL SCI, V259, P74, DOI 10.1016/j.jns.2006.05.073; Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8; PETERSON JW, 1990, STROKE, V21, P133, DOI 10.1161/01.STR.21.1.133; Ramos-Casals M, 2010, JAMA-J AM MED ASSOC, V304, P452, DOI 10.1001/jama.2010.1014; ROMAN ID, 1989, TRANSPLANTATION, V48, P554, DOI 10.1097/00007890-198910000-00003; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SAEED B, 2008, CYCLOSPORIN INDUCED, V19, P439; Santos JB, 2003, EPILEPSIA, V44, P995, DOI 10.1046/j.1528-1157.2003.66302.x; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schinkel AH, 1995, AM J CLIN INVEST, V96, P1698; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Serkova N, 2004, MOL INTERV, V4, P97, DOI 10.1124/mi.4.2.7; Sheehan Jason, 2006, Neurosurg Focus, V20, pE9; Shou Y, 2004, BIOCHEM J, V379, P805, DOI 10.1042/BJ20031107; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; SOKOL PP, 1990, AM J PHYSIOL, V259, pC897; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Thrift AG, 2001, STROKE, V32, P1732, DOI 10.1161/01.STR.32.8.1732; TINDALL RSA, 1987, NEW ENGL J MED, V316, P719, DOI 10.1056/NEJM198703193161205; TRUWIT CL, 1991, AM J NEURORADIOL, V12, P651; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; WAKITA H, 1995, STROKE, V26, P1415, DOI 10.1161/01.STR.26.8.1415; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang XY, 2010, STROKE, V41, P2050, DOI 10.1161/STROKEAHA.110.589051; Wang XY, 2009, J NEUROSCI, V29, P2588, DOI 10.1523/JNEUROSCI.5832-08.2009; WHITE DJG, 1982, IMMUNOL REV, V65, P115, DOI 10.1111/j.1600-065X.1982.tb00430.x; WINDEBANK AJ, 1994, J PHARMACOL EXP THER, V268, P1051; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056	96	70	72	0	26	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179			NEUROPEPTIDES	Neuropeptides	DEC	2011	45	6					359	368		10.1016/j.npep.2011.04.002			10	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	859KN	WOS:000297875400001	21592568				2021-06-18	
J	Topolovec-Vranic, J; Pollmann-Mudryj, MA; Ouchterlony, D; Klein, D; Spence, J; Romaschin, A; Rhind, S; Tien, HC; Baker, AJ				Topolovec-Vranic, Jane; Pollmann-Mudryj, Mary-Ann; Ouchterlony, Donna; Klein, David; Spence, Julie; Romaschin, Alexander; Rhind, Shawn; Tien, Homer C.; Baker, Andrew J.			The Value of Serum Biomarkers in Prediction Models of Outcome After Mild Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Adult; Serum biomarkers; Humans; Mild traumatic brain injury; S100B; Neuron-specific enolase	POST-CONCUSSION SYMPTOMS; NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; EMERGENCY-DEPARTMENT ASSESSMENT; FOLLOW-UP; POSTCONCUSSIVE SYMPTOMS; BIOCHEMICAL MARKERS; PROTEIN S-100B; CT FINDINGS; ACUTE-PHASE	Background: To determine, using a civilian model of mild traumatic brain injury (TBI), the added value of biomarker sampling upon prognostication of outcome at 1 week and 6 weeks postinjury. Methods: The Galveston Orientation and Amnesia test was administered, and blood samples for serum protein S100B and neuron-specific enolase (NSE) were collected from 141 emergency department patients within 4 hours of a suspected mild TBI (mTBI). The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) was administered via telephone 3 days postinjury. Patients were assessed by a physician at 1 week (n = 113; 80%) and 6 weeks (n = 95; 67%) postinjury. Neurocognitive and postural stability measures were also administered at these follow-ups. Results: Levels of S100B and NSE were found to be abnormally elevated in 49% and 65% of patients with TBI, respectively. Sixty-eight percent and 38% of the patients were considered impaired at 1 week and 6 weeks postinjury, respectively. Stepwise logistic regression modeling identified admission Galveston Orientation and Amnesia test score, S100B level, and RPQ score at day 3 postinjury to be predictive of poor outcome at 1 week postinjury (c-statistic 0.877); female gender, loss of consciousness, NSE level, and RPQ score at day 3 postinjury were predictive of poor outcome at 6 weeks postinjury (c-statistic 0.895). The discriminative power of the biomarkers alone was limited. Conclusions: Biomarkers, in conjunction with other readily available determinants of outcome assessed in the acute period after injury, add value in the early prognostication of patients with mTBI. Our findings are consistent with the notion that S100B and NSE point to biological mechanisms underlying poor outcome after mTBI.	[Baker, Andrew J.] St Michaels Hosp, Dept Crit Care, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Topolovec-Vranic, Jane; Pollmann-Mudryj, Mary-Ann; Ouchterlony, Donna] St Michaels Hosp, Trauma & Neurosurg Program, Toronto, ON M5B 1W8, Canada; [Spence, Julie] St Michaels Hosp, Emergency Dept, Toronto, ON M5B 1W8, Canada; [Romaschin, Alexander] St Michaels Hosp, Div Clin Chem, Toronto, ON M5B 1W8, Canada; [Rhind, Shawn] Def Res & Dev Canada, Toronto, ON, Canada; [Tien, Homer C.] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON M4N 3M5, Canada; [Baker, Andrew J.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada	Baker, AJ (corresponding author), St Michaels Hosp, Dept Crit Care, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.ca	Pollmann-Mudryj, Mary Ann/AAC-9047-2019; Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Rhind, Shawn/0000-0003-2300-0620; Pollmann-Mudryj, Mary Ann/0000-0003-2244-8116	Defence Research and Development Canada [W7711-067992]	Supported by Defence Research and Development Canada W7711-067992.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Benton A., 1994, MULTILINGUAL APHASIA; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Fridriksson S, 2001, ACTA NEUROL SCAND, V103, P238; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton RK, 2004, REVISED COMPREHENSIV; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McMinn MR., 1988, CLIN NEUROPSYCHOL, V2, P67, DOI [10.1080/13854048808520087, DOI 10.1080/13854048808520087]; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2009, NEUROSURGERY, V64, P698, DOI 10.1227/01.NEU.0000340978.42892.78; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith A., 1991, SYMBOL DIGIT MODALIT; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; STRAUS E, 2006, COMPENDIUM NEUROPSYC; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tien HCN, 2010, AM J PREV MED, V38, P331, DOI 10.1016/j.amepre.2009.12.012; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x	54	70	73	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71			1			S478	S486		10.1097/TA.0b013e318232fa70			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849GE	WOS:000297112800016	22072007				2021-06-18	
J	Shultz, SR; MacFabe, DF; Foley, KA; Taylor, R; Cain, DP				Shultz, Sandy R.; MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy; Cain, Donald P.			A single mild fluid percussion injury induces short-term behavioral and neuropathological changes in the Long-Evans rat: Support for an animal model of concussion	BEHAVIOURAL BRAIN RESEARCH			English	Article						Fluid percussion injury; Concussion; Neuroinflammation; Axonal injury; Learning and memory; Animal model; Anxiety-like behavior	TRAUMATIC BRAIN-INJURY; ELEVATED PLUS-MAZE; AXONAL INJURY; HEAD-INJURY; WATER MAZE; SYNAPTIC PLASTICITY; SPATIAL NAVIGATION; PERIRHINAL CORTEX; SEX-DIFFERENCES; PROPIONIC-ACID	Brain concussion is a serious public health concern and is associated with short-term cognitive impairments and behavioral disturbances that typically occur in the absence of significant brain damage. The current study addresses the need to better understand the effects of a mild lateral fluid percussion injury on rat behavior and neuropathology in an animal model of concussion. Male Long-Evans rats received either a single mild fluid percussion injury or a sham-injury, and either a short (24 h) or long (4 weeks) post-injury recovery period. After recovery, rats underwent a detailed behavioral analysis consisting of tests for rodent anxiety, cognition, social behavior, sensorimotor function, and depression-like behavior. After testing all rats were sacrificed and brains were examined immunohistochemically with markers for microglia/macrophage activation, reactive astrocytosis, and axonal injury. Injured rats (mean injury force: 1.20 +/- .03 atm) displayed significant short-term cognitive impairments in the water maze and significantly more anxiolytic-like behavior in the elevated-plus maze compared to sham controls. Neuropathological analysis of the brains of injured rats showed an acute increase in reactive astrogliosis and activated microglia in cortex and evidence of axonal injury in the corpus callosum. There were no significant long-term effects on any behavioral or neuropathological measure 4 weeks after injury. These short-term behavioral and neuropathological changes are consistent with findings in human patients suffering a brain concussion, and provide further evidence for the use of a single mild lateral fluid percussion injury to study concussion in the rat. (C) 2011 Elsevier B.V. All rights reserved.	[MacFabe, Derrick F.; Taylor, Roy] Univ Western Ontario, Dept Psychol, Kilee Patchell Evans Autism Res Grp, London, ON, Canada; [Shultz, Sandy R.; Foley, Kelly A.; Cain, Donald P.] Univ Western Ontario, Grad Program Neurosci, London, ON, Canada	Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, 1-52 Thompson St, Williamtown, Vic 3016, Australia.	sshultz@unimelb.edu.au		Shultz, Sandy/0000-0002-2525-8775	Natural Science and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by a grant from the Natural Science and Engineering Research Council (NSERC) to Dr. Donald P. Cain, a scholarship from NSERC to Sandy R. Shultz, and contributions from GoodLife Childrens's Foundation and Round for a Reason Charities to Derrick F. MacFabe. We thank Dr. Richard Sutton and Dr. David Hovda from the UCLA Brain Injury Research Center for their help in LFP training. Additional thanks go to Lisa Tichenoff and Francis Boon for their assistance in the research project.	AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Amagdei A, 2010, INT J DEV NEUROSCI, V28, P105, DOI 10.1016/j.ijdevneu.2009.08.017; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Beiko J, 1997, BEHAV BRAIN RES, V88, P201, DOI 10.1016/S0166-4328(97)02298-5; Beiko J, 2004, BEHAV BRAIN RES, V151, P239, DOI 10.1016/j.bbr.2003.08.019; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bortolato M, 2009, NEUROPSYCHOPHARMACOL, V34, P2746, DOI 10.1038/npp.2009.118; Cain DP, 2006, BEHAV BRAIN RES, V170, P241, DOI 10.1016/j.bbr.2006.02.023; Cain DP, 2003, BRAIN RES, V972, P64, DOI 10.1016/S0006-8993(03)02486-7; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Dringen R, 2005, ANTIOXID REDOX SIGN, V7, P1223, DOI 10.1089/ars.2005.7.1223; Fan LW, 2008, EUR J NEUROSCI, V27, P1475, DOI 10.1111/j.1460-9568.2008.06121.x; Gerber J, 2009, CLIN NEUROPATHOL, V28, P33; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hasenohrl RU, 1998, PHARMACOL BIOCHEM BE, V59, P527, DOI 10.1016/S0091-3057(97)00406-1; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kaut KP, 2001, COGN AFFECT BEHAV NE, V1, P270, DOI 10.3758/CABN.1.3.270; Kim E, 2002, NEUROREHABILITATION, V17, P297; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lindemann S, 2008, PHYSIOL BEHAV, V93, P415, DOI 10.1016/j.physbeh.2007.11.038; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer JS, 2008, ANN NY ACAD SCI, V1139, P151, DOI 10.1196/annals.1432.029; Miu AC, 2006, BEHAV BRAIN RES, V172, P135, DOI 10.1016/j.bbr.2006.05.007; Mochizuki A, 1996, EXP NEUROL, V142, P89, DOI 10.1006/exnr.1996.0181; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Mumby DG, 2000, BEHAV BRAIN RES, V114, P119, DOI 10.1016/S0166-4328(00)00217-5; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wiig KA, 1996, LEARN MEMORY, V3, P313, DOI 10.1101/lm.3.4.313; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Young GB, 2009, ANN NY ACAD SCI, V1157, P32, DOI 10.1111/j.1749-6632.2009.04471.x; Zilka N, 2006, Bratisl Lek Listy, V107, P374	63	70	70	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	OCT 31	2011	224	2					326	335		10.1016/j.bbr.2011.06.012			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	818ZQ	WOS:000294795600014	21704658				2021-06-18	
J	Wang, GH; Jiang, ZL; Li, YC; Li, X; Shi, H; Gao, YQ; Vosler, PS; Chen, J				Wang, Guo-Hua; Jiang, Zheng-Lin; Li, Yong-Cai; Li, Xia; Shi, Hong; Gao, Yan-Qin; Vosler, Peter S.; Chen, Jun			Free-Radical Scavenger Edaravone Treatment Confers Neuroprotection Against Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						edaravone; inflammatory cytokines; neuroprotection; oxidative stress; TBI	CELL-DEATH; ANTIOXIDANT; PATHOPHYSIOLOGY; MICROGLIA; CYTOKINES; MCI-186; TARGETS; DAMAGE	Traumatic brain injury (TBI) is one of the leading causes of neurological disability in young adults. Edaravone, a novel synthetic small-molecule free-radical scavenger, has been shown to have a neuroprotective effect in both animal models of cerebral ischemia and stroke patients; however, the underlying mechanism is poorly understood. In this report, we investigated the potential mechanisms of edaravone treatment in a rat model of TBI. TBI was induced in the right cerebral cortex of male adult rats using Feeney's weight-drop method. Edaravone (0.75, 1.5, or 3 mg/kg) or vehicle (normal saline) was intravenously administered at 2 and 12 h after TBI. Edaravone treatment significantly decreased hippocampal CA3 neuron loss, reduced oxidative stress, and decreased neuronal programmed cell death compared to vehicle treatment. The protective effects of edaravone treatment were also related to the pathology of TBI on non-neuronal cells, as edaravone decreased astrocyte and glial activation. Lastly, edaravone treatment significantly reduced the presence of inflammatory cytokines, cerebral edema, blood-brain barrier (BBB) permeability, and, importantly, neurological deficits following TBI. Our results suggest that edaravone exerts a neuroprotective effect in the rat model of TBI. The likely mechanism is via inhibiting oxidative stress, leading to a decreased inflammatory response and glial activation, and thereby reducing neuronal death and improving neurological function.	[Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA; [Wang, Guo-Hua; Jiang, Zheng-Lin; Li, Xia] Nantong Univ, Inst Naut Med, Dept Neuropharmacol, Nantong 226001, Jiangsu, Peoples R China; [Wang, Guo-Hua; Shi, Hong; Gao, Yan-Qin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China; [Li, Yong-Cai] Peoples Hosp Ningxia, Dept Neurosurg, Ningxia, Peoples R China	Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.	jiangzl@ntu.edu.cn; chenj2@upmc.edu	Gao, Yanqin/I-6790-2016	Gao, Yanqin/0000-0002-4915-9819; Wang, Guohua/0000-0002-4810-8534; Vosler, Peter/0000-0002-7689-5539	Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81000497]; Priority Academic Program Development of Jiangsu Higher Education Institutions; Administration of Science and Technology of Nantong, Jiangsu Province, China [S2010011]; Qing Lan Project of Jiangsu Province, China; Chinese Ministry of Science and TechnologyMinistry of Science and Technology, China; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36736, NS43802, NS45048]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045048, R01NS043802, R01NS036736] Funding Source: NIH RePORTER	This study was supported by the Chinese Natural Science Foundation (Grant 81000497), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Administration of Science and Technology of Nantong, Jiangsu Province, China (Project No. S2010011). Guo-Hua Wang was sponsored by the Qing Lan Project of Jiangsu Province, China. Guo-Hua Wang, Yan-Qin Gao, and Jun Chen are supported by the Special Research Funds from Chinese Ministry of Science and Technology to State Key laboratories. Peter S. Vosler and Jun Chen are also supported by National Institutes of Health Grants NS36736, NS43802, and NS45048.	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; Dohi K, 2007, ANTIOXID REDOX SIGN, V9, P281, DOI 10.1089/ars.2007.9.281; Dohi K, 2006, J NEUROTRAUM, V23, P1591, DOI 10.1089/neu.2006.23.1591; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesser M, 2009, J LIPID RES, V50, P2455, DOI 10.1194/jlr.M900181-JLR200; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Kikuchi K, 2010, MED HYPOTHESES, V75, P583, DOI 10.1016/j.mehy.2010.07.038; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lapchak PA, 2010, EXPERT OPIN PHARMACO, V11, P1753, DOI 10.1517/14656566.2010.493558; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Naritomi Hiroaki, 2010, Drugs R D, V10, P155, DOI 10.2165/11586550-000000000-00000; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Petronilho F, 2010, J SURG RES, V164, P316, DOI 10.1016/j.jss.2009.04.031; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Serrano-Perez MC, 2011, GLIA, V59, P94, DOI 10.1002/glia.21079; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Spickett CM, 2010, FREE RADICAL RES, V44, P1172, DOI 10.3109/10715762.2010.498476; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Tacconi MT, 1998, NEUROCHEM RES, V23, P759, DOI 10.1023/A:1022463527474; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Vosler PS, 2009, STROKE, V40, pS119, DOI 10.1161/STROKEAHA.108.533109; Vosler PS, 2009, EXP NEUROL, V218, P213, DOI 10.1016/j.expneurol.2009.04.032; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; WATANABE T, 1988, PROSTAG LEUKOTR ESS, V33, P81, DOI 10.1016/0952-3278(88)90127-5; Yoshida H, 2006, CNS DRUG REV, V12, P9, DOI 10.1111/j.1527-3458.2006.00009.x; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	70	82	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2123	2134		10.1089/neu.2011.1939			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500013	21732763	Green Published			2021-06-18	
J	Marini, A; Galetto, V; Zampieri, E; Vorano, L; Zettin, M; Carlomagno, S				Marini, Andrea; Galetto, Valentina; Zampieri, Elisa; Vorano, Lorenza; Zettin, Marina; Carlomagno, Sergio			Narrative language in traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						Traumatic brain injury; Narrative analysis; Neurolinguistics; Neuropsychology	CLOSED-HEAD-INJURY; CONNECTED SPEECH; FOLLOW-UP; DISCOURSE; ADULTS; APHASIA; ADOLESCENTS; IMPAIRMENT; ABILITIES; COHESION	Persons with traumatic brain injury (TBI) often show impaired linguistic and/or narrative abilities. The present study aimed to document the features of narrative discourse impairment in a group of adults with TBI. 14 severe TBI non-aphasic speakers (GCS < 8) in the phase of neurological stability and 14 neurologically intact participants were recruited for the experiment. Their cognitive, linguistic and narrative skills were thoroughly assessed. The group of non-aphasic individuals with TBI had normal lexical and grammatical skills. However, they produced narratives with increased errors of cohesion and coherence due to the frequent interruption of ongoing utterances, derailments and extraneous utterances that made their discourse vague and ambiguous. They produced a normal amount of thematic units (i.e. concepts) in their narratives. However, this information was not correctly organized at micro- and macrolinguistic levels of processing. A Principal Component Analysis showed that a single factor accounted for the production of global coherence errors, and the reduction of both propositional density at the utterance level and proportion of words that conveyed information. It is hypothesized that the linguistic deficits observed in the participants with TBI may reflect a deficit at the interface between cognitive and linguistic processing rather than a specific linguistic disturbance. (C) 2011 Elsevier Ltd. All rights reserved.	[Marini, Andrea] Univ Udine, Dipartimento Sci Umane, I-33100 Udine, Italy; [Galetto, Valentina; Zettin, Marina] Ctr Puzzle, Turin, Italy; [Galetto, Valentina; Zettin, Marina] Univ Turin, Dipartimento Psicol, I-10124 Turin, Italy; [Vorano, Lorenza] IMFR Gervasutta, Udine, Italy; [Carlomagno, Sergio] Univ Trieste, Dipartimento Psicol, I-34127 Trieste, Italy; [Marini, Andrea; Zampieri, Elisa] IRCCS E Medea Nostra Famiglia, San Vito Al Tagliamento, Pn, Italy	Marini, A (corresponding author), Univ Udine, Dipartimento Sci Umane, Via Margreth 3, I-33100 Udine, Italy.	andrea.marini@uniud.it	Marini, Andrea/A-1206-2012	Marini, Andrea/0000-0002-6058-3864	IRCCS "E. Medea"	Funding for this study was provided by IRCCS "E. Medea". The IRCCS "E. Medea" had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Caplan D., 1992, LANGUAGE STRUCTURE P; Carlomagno S., 2008, 46 ANN M AC APH TURK; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Ellis C, 2009, NEUROREHABILITATION, V24, P255, DOI 10.3233/NRE-2009-0476; GLOSSER G, 1993, NARRATIVE DISCOURSE; Glosser G., 1990, BRAIN LANG, V40, P67; Haravon A., 1994, DISCOURSE ANAL APPL, P47; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Heaton R., 1993, WISCONSIN CARD SORTI; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Kertesz A., 1982, W APHASIA BATTERY; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; Luzzatti C., 1991, AACHENER APHASIE TES; Marini A, 2005, J PSYCHOLINGUIST RES, V34, P439, DOI 10.1007/s10936-005-6203-z; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2008, SCHIZOPHR RES, V105, P144, DOI 10.1016/j.schres.2008.07.011; Marionnet C, 2011, EXP DERMATOL, V20, P477, DOI 10.1111/j.1600-0625.2011.01265.x; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Peach R. K., 1986, ANN CONV AM SPEECH L; Raven J. C., 1938, PROGR MATRICES PERCE; Reitan R. M, 1992, TRAIL MAKING TEST; SAFFRAN EM, 1989, BRAIN LANG, V37, P440, DOI 10.1016/0093-934X(89)90030-8; SHEWAN CM, 1988, J COMMUN DISORD, V21, P103, DOI 10.1016/0021-9924(88)90001-9; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 2000, BRAIN INJURY, V14, P397; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Thompson CK, 1996, BRAIN LANG, V52, P175, DOI 10.1006/brln.1996.0009; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	40	70	72	1	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	AUG	2011	49	10					2904	2910		10.1016/j.neuropsychologia.2011.06.017			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	820XX	WOS:000294940500012	21723304				2021-06-18	
J	Sorrentino, E; Budohoski, KP; Kasprowicz, M; Smielewski, P; Matta, B; Pickard, JD; Czosnyka, M				Sorrentino, Enrico; Budohoski, Karol P.; Kasprowicz, Magdalena; Smielewski, Peter; Matta, Basil; Pickard, John D.; Czosnyka, Marek			Critical Thresholds for Transcranial Doppler Indices of Cerebral Autoregulation in Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Head injury; Transcranial Doppler; Outcome; Thresholds; Autoregulation index	CEREBROVASCULAR PRESSURE-REACTIVITY; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; VALIDATION; HYPERTENSION; ASSOCIATION; MANAGEMENT; HEMORRHAGE	Transcranial Doppler-derived indices of cerebral autoregulation are related to outcome after TBI. We analyzed our retrospective material to identify thresholds discriminative of outcome for these indices. 248 sedated and ventilated patients after head injury were eligible for the study. The indices of autoregulation derived from transcranial Doppler were calculated as correlation coefficients of blood flow velocity with cerebral perfusion pressure (index Mx) or arterial blood pressure (index Mxa). 2 x 2 tables were created grouping patients according to survival-death or favorable-unfavorable outcomes and varying thresholds for Mx and Mxa. Pearson's chi-square was calculated. Thresholds returning the highest chi-square value were assumed to have the best discriminative value between survival-death and favorable-unfavorable outcomes. Mx and Mxa demonstrated that worse autoregulation is associated with poorer outcome and greater mortality (P = 0.0033 for Mx and P = 0.047 for Mxa). Both indices were more effective for prediction of favorable outcome than mortality. Chi-square for Mx showed a double peak with thresholds at 0.05 and 0.3. Mxa had only one peak at 0.3. Peak chi-square for Mx (11.3) was greater than for Mxa (8.7), indicating that Mx was a better discriminant of outcome than Mxa. We propose that Mx greater than 0.3 indicates definitely disturbed autoregulation and lower than 0.05 good autoregulation. For values between 0.05 and 0.3 the state of autoregulation is uncertain.	[Sorrentino, Enrico; Budohoski, Karol P.; Kasprowicz, Magdalena; Smielewski, Peter; Pickard, John D.; Czosnyka, Marek] Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge CB2 OQQ, England; [Kasprowicz, Magdalena] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, PL-50370 Wroclaw, Poland; [Matta, Basil] Addenbrookes Hosp, Dept Anesthet, Cambridge CB2 OQQ, England	Czosnyka, M (corresponding author), Addenbrookes Hosp, Dept Acad Neurosurg, Hills Rd, Cambridge CB2 OQQ, England.	mc141@medschl.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938; Kasprowicz, Magdalena/0000-0002-2271-7737	National Institute of Health ResearchNational Institute for Health Research (NIHR); Biomedical Research Center; Cambridge University Hospital Foundation Trust; Technology Foresight Challenge Fund [FCA 234/95]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MRC G9439390]; Clifford and Mary Corbridge Trust; Foundation for Polish ScienceFoundation for Polish ScienceEuropean Commission; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This project was supported by the National Institute of Health Research, Biomedical Research Center, Cambridge University Hospital Foundation Trust-Neurosciences Theme and Senior Investigator Awards (JDP), Technology Foresight Challenge Fund (Grant FCA 234/95), MRC Program Grant (MRC G9439390). Clifford and Mary Corbridge Trust (KPB), and Foundation for Polish Science (MK).	Balestreri M, 2005, ACT NEUR S, V95, P25; Brady KM, 2010, ANESTH ANALG, V111, P191, DOI 10.1213/ANE.0b013e3181e054ba; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Castellani G, 2009, NEUROCRIT CARE, V11, P143, DOI 10.1007/s12028-009-9235-7; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 2003, ACT NEUR S, V86, P581; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Immink RV, 2004, CIRCULATION, V110, P2241, DOI 10.1161/01.CIR.0000144472.08647.40; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lewis PM, 2007, ACTA NEUROCHIR, V149, P549, DOI 10.1007/s00701-007-1160-y; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; RANDELCASTILLA L, 2010, J NEUROTRAUM, V27, P1853; Reinhard M, 2010, INTENS CARE MED, V36, P264, DOI 10.1007/s00134-009-1698-7; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2003, ANESTH ANALG, V97, P572, DOI 10.1213/01.ANE.0000070234.17226.B0; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Tzeng YC, 2010, HYPERTENSION, V56, P268, DOI 10.1161/HYPERTENSIONAHA.110.152066	28	70	71	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2011	14	2					188	193		10.1007/s12028-010-9492-5			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	738SY	WOS:000288663800007	21181299				2021-06-18	
J	Zohar, O; Rubovitch, V; Milman, A; Schreiber, S; Pick, CG				Zohar, Ofer; Rubovitch, Vardit; Milman, Anat; Schreiber, Shaul; Pick, Chaim G.			Behavioral consequences of minimal traumatic brain injury in mice	ACTA NEUROBIOLOGIAE EXPERIMENTALIS			English	Article						forced swimming test; Morris water maze; mTBI; passive avoidance; swim T-maze	RIGHT PARIETAL CORTEX; CLOSED-HEAD INJURY; COGNITIVE DEFICITS; MODELS; SENSITIVITY; IMPAIRMENT; PEPTIDE; IMPACT; LESION; DEATH	Victims of minor traumatic brain injury (mTBI), who show no clear morphological brain defects, frequently manifest cognitive, behavioral and emotional difficulties that can be long-lasting. In this paper we present a modified weight drop model used to deliver a closed head minimal traumatic brain injury to mice, which closely mimics real-life injuries and the symptoms observed in mTBI patients. Our choice of impact force does not produce structural damage to the brain and its surrounding tissue (as examined by MRI), any skull fracture, no edema and no evident damage to the blood-brain barrier (BBB). Moreover, our mTBI mice show no abnormal behavior on recovering from the weight drop, or any change in other brain functions such as reflexes, balance, exploration, strength, locomotor activity and swim speed. Since our mTBI model does not produce neurological, motor or sensory damage to the mice, it allows the direct evaluation of mTBI sequelae on the mice behavior and cognitive abilities. Using a variety of cognitive and behavioral tests (Morris water maze, staircase test, passive avoidance test, water T-maze, hot palate, elevated plus maze and forced swimming test) we assessed the short- and long-term sequelae induced by our model. Our results indicate that our closed head mTBI cause profound and long-lasting, irreversible learning and memory impairments, accompanied by a depressive-like behavior in mice that are evident even 90 days post injury. Our results indicate that the closed head mTBI model presented here may be useful in the development of novel therapeutic approaches, such as neuroprotective agents, for mTBI.	[Rubovitch, Vardit; Milman, Anat; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Zohar, Ofer] Johns Hopkins Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD USA; [Schreiber, Shaul] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693; Milman, Anat/0000-0002-8551-4101			Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Badowska-Szalewska E, 2009, ACTA NEUROBIOL EXP, V69, P448; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heinrichs SC, 1996, NEUROSCIENCE, V74, P303, DOI 10.1016/0306-4522(96)00140-6; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lehner M, 2010, ACTA NEUROBIOL EXP, V70, P56; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PICK CG, 1991, BRAIN RES, V566, P295, DOI 10.1016/0006-8993(91)91712-A; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WILLNER P, 1990, PHARMACOL THERAPEUT, V45, P425, DOI 10.1016/0163-7258(90)90076-E; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	44	70	71	0	8	NENCKI INST EXPERIMENTAL BIOLOGY	WARSAW	UL PASTEURA 3, 02-093 WARSAW, POLAND	0065-1400	1689-0035		ACTA NEUROBIOL EXP	Acta Neurobiol. Exp.		2011	71	1					36	45					10	Neurosciences	Neurosciences & Neurology	755ET	WOS:000289910500004	21499325				2021-06-18	
J	Echlin, PS; Tator, CH; Cusimano, MD; Cantu, RC; Taunton, JE; Upshur, REG; Hall, CR; Johnson, AM; Forwell, LA; Skopelja, EN				Echlin, Paul Sean; Tator, Charles H.; Cusimano, Michael D.; Cantu, Robert C.; Taunton, Jack E.; Upshur, Ross E. G.; Hall, Craig R.; Johnson, Andrew M.; Forwell, Lorie A.; Skopelja, Elaine N.			A prospective study of physician-observed concussions during junior ice hockey: implications for incidence rates	NEUROSURGICAL FOCUS			English	Article						concussion; ice hockey; incidence; Canada	PROFESSIONAL FOOTBALL PLAYERS; INJURY SURVEILLANCE SYSTEM; RECURRENT CONCUSSION; SPORTS CONCUSSION; DESCRIPTIVE EPIDEMIOLOGY; COLLEGIATE; RISK; ASSOCIATION; SEASON; STATEMENT	Object. The objective of this study was to measure the incidence of concussion (scaled relative to number of athlete exposures) and recurrent concussion within 2 teams of fourth-tier junior ice hockey players (16-21 years old) during 1 regular season. Methods. A prospective cohort study called the Hockey Concussion Education Project was conducted during 1 junior ice hockey regular season (2009-2010) involving 67 male fourth-tier ice hockey players (mean age 18.2 +/- 1.2 years, range 16-21 years) from 2 teams. Prior to the start of the season, every player underwent baseline assessments using the Sideline Concussion Assessment Tool 2 (SCAT2) and the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT). The study protocol also required players who entered the study during the season to complete baseline SCAT2 and ImPACT testing. If the protocol was not followed, the postinjury test results of a player without true baseline test results would be compared against previously established age and gender group normative levels. Each regular season game was observed by a qualified physician and at least 1 other neutral nonphysician observer. Players who suffered a suspected concussion were evaluated at the game. If a concussion diagnosis was made, the player was subsequently examined in the physician's office for a full clinical evaluation and the SCAT2 and ImPACT were repeated. Based on these evaluations, players were counseled on the decision of when to return to play. Athlete exposure was defined as 1 game played by 1 athlete. Results. Twenty-one concussions occurred during the 52 physician-observed games (incidence 21.5 concussions per 1000 athlete exposures). Five players experienced repeat concussions. No concussions were reported during practice sessions. A concussion was diagnosed by the physician in 19 (36.5%) of the 52 observed games. One of the 5 individuals who suffered a repeat concussion sustained his initial concussion in a regular season game that was not observed by a physician, and as a result this single case was not included in the total of 21 total concussions. This initial concussion of the player was identified during baseline testing 2 days after the injury and was subsequently medically diagnosed and treated. Conclusions. The incidence of game-related concussions (per 1000 athlete exposures) in these fourth-tier ice hockey players was 3.3 times higher than the highest rate previously reported in the literature. This difference may be the result of the use of standardized direct physician observation, diagnosis, and subsequent treatment. The results of this study demonstrate the need for follow-up studies involving larger and more diverse sample groups to reflect generalizability of the findings. These follow-up studies should involve other contact sports (for example football and rugby) and also include the full spectrum of gender, age, and skill levels. (DOI: 10.3171/2010.9.FOCUS10186)	[Echlin, Paul Sean] AIM Hlth Grp Family Med, London, ON, Canada; [Tator, Charles H.; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Taunton, Jack E.] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; [Taunton, Jack E.] Univ British Columbia, Sch Human Kinet, Vancouver, BC V5Z 1M9, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Family, Toronto, ON M5S 1A1, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Community Med, Toronto, ON M5S 1A1, Canada; [Hall, Craig R.] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Dept Physiotherapy, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA	Echlin, PS (corresponding author), 320 Adelaide St, S London, ON N5Z 3L2, Canada.	p_echlinfp@hotmail.com	Cusimano, Michael/X-4059-2019; Johnson, Andrew M/B-2048-2012	Johnson, Andrew M./0000-0002-7269-3016; Upshur, Ross/0000-0003-1128-0557; Cusimano, Michael/0000-0002-9989-0650	Ontario Trillium Foundation; Dr. Tom Pashby Safety Fund; Dave Irwin Foundation for Brain Injury; Canadian Institutes of Health Strategic Teams in Applied Injury Research	This work was funded by the Ontario Trillium Foundation, the Dr. Tom Pashby Safety Fund, and the Dave Irwin Foundation for Brain Injury. The Ontario Neurotrauma Foundation made administrative and facilitative contributions. Dr. Cusimano is funded by the Canadian Institutes of Health Strategic Teams in Applied Injury Research.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Keating P, ESPN MAGAZINE; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Schwarz A, 2009, NY TIMES        1217; SCHWARZ A, 2010, NY TIMES        0628; Shuttleworth-Edwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P479, DOI 10.1016/j.acn.2008.07.002; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	70	70	1	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E4	10.3171/2010.9.FOCUS10186			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900005	21039138				2021-06-18	
J	Hoffman, JM; Bell, KR; Powell, JM; Behr, J; Dunn, EC; Dikmen, S; Bombardier, CH				Hoffman, Jeanne M.; Bell, Kathleen R.; Powell, Janet M.; Behr, James; Dunn, Erin C.; Dikmen, Sureyya; Bombardier, Charles H.			A Randomized Controlled Trial of Exercise to Improve Mood After Traumatic Brain Injury	PM&R			English	Article							DEPRESSION FOLLOWING MILD; PHYSICAL-ACTIVITY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; COGNITIVE FUNCTION; PUBLIC-HEALTH; LIFE-STYLE; FOLLOW-UP; ADULTS; SERTRALINE	Objective: To test the hypothesis that a structured aerobic exercise regimen would decrease the severity of depressive symptoms in people with traumatic brain injury (TBI) who reported at least mild depression severity at baseline. Design: Prospective, randomized, controlled trial. Setting: Community gymnasium. Participants: Subjects with a history of a prior TBI (6 months to 5 years post-injury), recruited from the community. Inclusion criteria included scoring >= 5 on the Patient Health Questionnaire-9. Subjects were excluded if they were non-English speakers, had a medical condition precluding exercise, had suicidal ideation, regularly exercised, or could not use standard aerobic exercise equipment. Intervention: Weekly supervised exercise sessions over a 10-week period consisted of education, warm-up, 30 minutes of aerobic exercise, and cool down. The exercise intensity was adjusted to reach a heart rate goal of 60% of the participant's estimated maximal heart rate. Main Outcome Measurement: Beck Depression Inventory (BDI) comparing exercise to control groups. Post hoc analyses compared groups exercising >= 90 minutes or <90 minutes per week. Results: Between-group comparisons at 10 weeks revealed no difference between groups on the BDI (P = .250). For the groups divided by minutes exercised per week, the high-activity group had significantly better depression scores than those in the low-activity group (P = .033). Conclusions: Although there was no statistically significant difference between the treated and the control group on mood after intervention, those persons with TBI who recounted higher levels of exercise per week also reported less depression and improved sleep, community participation, and overall quality of life. PM R 2010;2:911-919	[Hoffman, Jeanne M.; Bell, Kathleen R.; Powell, Janet M.; Dikmen, Sureyya; Bombardier, Charles H.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dunn, Erin C.] St Pauls Hosp, Eating Disorders Program, Vancouver, BC V6Z 1Y6, Canada; [Behr, James] Orthoped Associates, Spartanburg, SC USA	Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	jeanneh@uw.edu		Bell, Kathleen/0000-0002-0928-2046			Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bell KR, 2008, AM J PHYS MED REHAB, V87, P330, DOI 10.1097/PHM.0b013e318168d092; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borg G., 1998, BORGS PERCEIVED EXER; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Cuijpers P, 2008, J CONSULT CLIN PSYCH, V76, P909, DOI 10.1037/a0013075; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Forsell Y, 2007, DEPRESS ANXIETY, V24, P62, DOI 10.1002/da.20231; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; FRANKLIN BA, 2000, ACSMS GUIDELINES EXE; Freeman MP, 2009, J CLIN PSYCHIAT, V70, P4, DOI 10.4088/JCP.8157su1c.01; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greer TL, 2009, CURR PSYCHIAT REP, V11, P466, DOI 10.1007/s11920-009-0071-4; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/mss.0b013e3180616b27; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hu SX, 2009, BRAIN RES, V1249, P191, DOI 10.1016/j.brainres.2008.10.054; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; King AC, 1998, MED SCI SPORT EXER, V30, P1086, DOI 10.1097/00005768-199807000-00011; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lai SM, 2006, J AM GERIATR SOC, V54, P240, DOI 10.1111/j.1532-5415.2006.00573.x; Lane AM, 2001, J SPORT MED PHYS FIT, V41, P539; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; MARTINSEN EW, 1989, COMPR PSYCHIAT, V30, P324, DOI 10.1016/0010-440X(89)90057-6; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Steptoe A, 2000, PREV MED, V31, P183, DOI 10.1006/pmed.2000.0688; Strohle A, 2009, J NEURAL TRANSM, V116, P777, DOI 10.1007/s00702-008-0092-x; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teychenne M, 2008, PREV MED, V46, P397, DOI 10.1016/j.ypmed.2008.01.009; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Ware JE, 1995, SF 12 SCORE SF 12 PH; Williamson JD, 2009, J GERONTOL A-BIOL, V64, P688, DOI 10.1093/gerona/glp014	65	70	71	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2010	2	10					911	919		10.1016/j.pmrj.2010.06.008			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V23SE	WOS:000208361700006	20970760				2021-06-18	
J	Schwarzbold, ML; Rial, D; De Bem, T; Machado, DG; Cunha, MP; dos Santos, AA; dos Santos, DB; Figueiredo, CP; Farina, M; Goldfeder, EM; Rodrigues, ALS; Prediger, RDS; Walz, R				Schwarzbold, Marcelo L.; Rial, Daniel; De Bem, Tatiana; Machado, Daniele G.; Cunha, Mauricio P.; dos Santos, Alessandra A.; dos Santos, Danubia B.; Figueiredo, Claudia P.; Farina, Marcelo; Goldfeder, Eliane M.; Rodrigues, Ana Lucia S.; Prediger, Rui D. S.; Walz, Roger			Effects of Traumatic Brain Injury of Different Severities on Emotional, Cognitive, and Oxidative Stress-Related Parameters in Mice	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; depression; learning and memory; oxidative stress; traumatic brain injury	GLUTATHIONE-PEROXIDASE ACTIVITY; BEHAVIORAL-TEST BATTERIES; EXPERIMENTAL HEAD-INJURY; FLUID PERCUSSION INJURY; TAIL SUSPENSION TEST; LOCOMOTOR-ACTIVITY; LIPID-PEROXIDATION; CORTICAL IMPACT; IMMATURE BRAIN; DEPRESSION	Cognitive deficits and psychiatric disorders are significant sequelae of traumatic brain injury (TBI). Animal models have been widely employed in TBI research, but few studies have addressed the effects of experimental TBI of different severities on emotional and cognitive parameters. In this study, mice were subjected to weight-drop TBI to induce mild, intermediate, or severe TBI. After neurological assessment, the mice recovered for 10 days, and were then subjected to a battery of behavioral tests, which included open-field, elevated plus-maze, forced swimming, tail suspension, and step-down inhibitory avoidance tests. Oxidative stress-related parameters (nonprotein thiols [NPSH], glutathione peroxidase [GPx], glutathione reductase [GR], and thiobarbituric acid reactive species [TBARS]) were quantified in the cortex and hippocampus at 2 and 24 h and 14 days after TBI, and histopathological analysis was performed 15 days after TBI. Mice subjected to mild TBI showed increased anxiety and depressive-like behaviors, while intermediate and severe TBI induced robust memory deficits. The severe TBI group also displayed increased locomotor activity. Intermediate and severe TBI caused extensive macroscopic and microscopic brain damage, while mild TBI typically had no histological abnormalities. Moreover, a significant increase in TBARS in the ipsilateral cortex and GPx in the ipsilateral hippocampus was observed at 24 h and 14 days, respectively, following intermediate TBI. The current experimental TBI model induced emotional and cognitive changes comparable to sequelae seen in human TBI, and it might therefore represent a useful approach to the study of mechanisms of and new treatments for TBI and related disorders.	[Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas, Dept Clin Med, Hosp Univ, Florianopolis, SC, Brazil; [Rial, Daniel; De Bem, Tatiana; Prediger, Rui D. S.] Univ Fed Santa Catarina, Lab Expt Doencas Neurodegenerat, Dept Farmacol, Florianopolis, SC, Brazil; [Machado, Daniele G.; Cunha, Mauricio P.; dos Santos, Alessandra A.; dos Santos, Danubia B.; Farina, Marcelo; Rodrigues, Ana Lucia S.] Univ Fed Santa Catarina, Dept Bioquim, Florianopolis, SC, Brazil; [Figueiredo, Claudia P.] Univ Fed Santa Catarina, Programa Posgrad Neurociencias, Dept Ciencias Fisiol, Florianopolis, SC, Brazil; [Goldfeder, Eliane M.] Univ Fed Santa Catarina, Dept Ciencias Morfol, Florianopolis, SC, Brazil; [Walz, Roger] Hosp Governador Celso Ramos, Ctr Epilepsia Santa Catarina, Florianopolis, SC, Brazil	Walz, R (corresponding author), Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas, Dept Clin Med, Hosp Univ, 3 Andar,Campus Trindade, Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Prediger, Rui D/C-4036-2013; Machado, Daniele G/C-3953-2013; Santos, Alessandra Antunes dos/F-3484-2019; Rial, Daniel/C-3595-2013; Rial, Daniel/D-3219-2009; Schwarzbold, Marcelo Liborio/J-8960-2014; Prediger, Rui Daniel/AAV-3419-2020; Figueiredo, Claudia P/F-8424-2012; Cunha, Mauricio/J-7135-2013; Walz, Roger/K-9096-2013; Rodrigues, Ana Lucia/P-6869-2015; Farina, Marcelo/AAH-2005-2019	Prediger, Rui D/0000-0002-7547-6463; Rial, Daniel/0000-0002-2079-7331; Prediger, Rui Daniel/0000-0002-7547-6463; Cunha, Mauricio/0000-0002-0269-7521; Walz, Roger/0000-0002-9875-6687; Rodrigues, Ana Lucia/0000-0001-6285-8780; Farina, Marcelo/0000-0001-8255-8515; Figueiredo, Claudia/0000-0001-9467-9891	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Programa de Apoio aos Nucleos de Excelencia (PRONEX), Brazil; Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC), Brazil	This work was supported by grants from the following Brazilian agencies: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Programa de Apoio aos Nucleos de Excelencia (PRONEX), and Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC). M.L.S., D.R., and T.D.B. receive scholarships from CNPq, and C.P.F.from CAPES. M.F., A.L.S.R., R.D.S.P., and R.W.are supported by research fellowships from CNPq.	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; BABCOCK AM, 1993, BRAIN RES, V625, P351, DOI 10.1016/0006-8993(93)91081-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Cunha MP, 2008, PROG NEURO-PSYCHOPH, V32, P1913, DOI 10.1016/j.pnpbp.2008.09.006; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Farina M, 2003, TOXICOLOGY, V184, P179, DOI 10.1016/S0300-483X(02)00576-0; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McArthur R, 2006, PHARMACOL BIOCHEM BE, V84, P436, DOI 10.1016/j.pbb.2006.06.005; McIlwain KL, 2001, PHYSIOL BEHAV, V73, P705, DOI 10.1016/S0031-9384(01)00528-5; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Paylor R, 2006, PHYSIOL BEHAV, V87, P95, DOI 10.1016/j.physbeh.2005.09.002; Pelegrin-Valero C, 2001, REV NEUROLOGIA, V32, P681, DOI 10.33588/rn.3207.2000180; PETRONILHO F, 2009, J SURG RES IN PRESS; PICK CG, 2009, J NEUROTRAU IN PRESS; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rial D, 2009, NEUROSCIENCE, V164, P896, DOI 10.1016/j.neuroscience.2009.09.005; Sartorius N, 1996, BRIT J PSYCHIAT, V168, P38, DOI 10.1192/S0007125000298395; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; WANG D, 1990, BRAIN RES, V533, P78, DOI 10.1016/0006-8993(90)91798-L; Wendel A, 1981, Methods Enzymol, V77, P325; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zomkowski ADE, 2004, BRAIN RES, V1023, P253, DOI 10.1016/j.brainres.2004.07.041	71	70	70	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1883	1893		10.1089/neu.2010.1318			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600012	20649482				2021-06-18	
J	Hancock, M; Tapscott, JL; Hoaken, PNS				Hancock, Megan; Tapscott, Jennifer L.; Hoaken, Peter N. S.			Role of Executive Dysfunction in Predicting Frequency and Severity of Violence	AGGRESSIVE BEHAVIOR			English	Article						executive functioning; violence; Delis-Kaplan Executive Function System; Poisson regression; binary logistic regression	TRAUMATIC BRAIN-INJURY; COUNT DATA; AGGRESSION; CHILDREN; BEHAVIOR; ADOLESCENTS; IMPULSIVITY; PERFORMANCE; PREVALENCE; REGRESSION	The adverse consequences of violence on society are tremendous. The proportion of offenders incarcerated for violent offenses is large, and the cost of keeping these offenders incarcerated is startling. Understanding and treating the causal underpinnings of violent crime is of utmost importance for individuals and society as a whole. Several factors have been identified as potential contributors to violent crime, including cognitive deficits in executive functioning [Hoaken et al., 2007]. To investigate this further, 77 offenders from Fenbrook Institution, a federal facility, were tested on a battery of executive functioning measures. Offenders were found to have broad and pervasive dysfunction in their executive abilities. In addition, specific scores from the battery were found using regression techniques, to predict the frequency and severity of past violent offending but not nonviolent offending. This speaks of the possibility of a new type of correctional rehabilitation program, one that focuses on the rehabilitation of basic executive functions. Aggr. Behav. 36:338-349, 2010. (C) 2010 Wiley-Liss, Inc.	[Hancock, Megan] Univ Western Ontario, Dept Psychol, London, ON N6A 3K7, Canada	Hancock, M (corresponding author), Univ Western Ontario, Dept Psychol, Westminster Hall, London, ON N6A 3K7, Canada.	mhancoc6@uwo.ca			Social Sciences and Humanities Research Council of CanadaSocial Sciences and Humanities Research Council of Canada (SSHRC) [410-2008-2461]	Grant sponsor: Social Sciences and Humanities Research Council of Canada; Grant number: 410-2008-2461.	Andrews D., 2003, LEVEL SERVICE INVENT; Baker SF, 2007, INT J LAW PSYCHIAT, V30, P492, DOI 10.1016/j.ijlp.2007.09.010; Barker ED, 2007, ARCH GEN PSYCHIAT, V64, P592, DOI 10.1001/archpsyc.64.5.592; Baron IS, 2004, CHILD NEUROPSYCHOL, V10, P147, DOI 10.1080/09297040490911140; BORNSTEIN RA, 1990, PSYCHIAT RES, V33, P73, DOI 10.1016/0165-1781(90)90150-4; Broomhall L., 2005, PSYCHIAT PSYCHOL LAW, V12, P367, DOI [DOI 10.1375/PPLT.12.2.367, 10.1375/pplt.12.2.367]; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; BUFKIN JL, 2005, ABUSE, V6, P176; Bureau of Justice Statistics, 2009, NAT CRIM VICT SURV C; Burt SA, 2009, CLIN PSYCHOL REV, V29, P163, DOI 10.1016/j.cpr.2008.12.004; Bushman BJ, 2001, PSYCHOL REV, V108, P273, DOI 10.1037//0033-295X.108.1.273; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Cornell D. G., 1996, CODING GUIDE VIOLENT; Coxe S, 2009, J PERS ASSESS, V91, P121, DOI 10.1080/00223890802634175; Delis DC, 2001, DELISKAPLAN EXECUTIV; Flannery D., 2005, HDB ADOLESCENT BEHAV, P415; Greenfield R, 2007, PSYCHOL REP, V101, P323, DOI 10.2466/PR0.101.1.323-333; Hoaken PNS, 2007, AGGRESSIVE BEHAV, V33, P412, DOI 10.1002/ab.20194; Hoaken PNS, 2003, AGGRESSIVE BEHAV, V29, P15, DOI 10.1002/ab.10023; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Hutchinson MK, 2005, RES NURS HEALTH, V28, P408, DOI 10.1002/nur.20093; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Kashani JH, 1999, J EMOT BEHAV DISORD, V7, P200, DOI 10.1177/106342669900700402; Kaufman A. S., 2004, KAUFMAN BRIEF INTELL; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Marsh NV, 2006, BRAIN INJURY, V20, P61, DOI 10.1080/02699050500110645; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Meloy JR, 2006, AUST NZ J PSYCHIAT, V40, P539, DOI 10.1080/j.1440-1614.2006.01837.x; Miura H, 2009, PSYCHIAT CLIN NEUROS, V63, P161, DOI 10.1111/j.1440-1819.2009.01935.x; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Pliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724; Quinsey V. L., 2006, VIOLENT OFFENDERS AP; Raaijmakers MAJ, 2008, J ABNORM CHILD PSYCH, V36, P1097, DOI 10.1007/s10802-008-9235-7; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; RIDOUT M, 1998, P INT BIOM C CAP TOW, V98, P179; Scarpa A, 2007, CAMB HANDB PSYCHOL, P151; Seguin JR, 2004, J ABNORM PSYCHOL, V113, P603, DOI 10.1037/0021-843X.113.4.603; Serin RC, 2001, TREATING ADULT AND JUVENILE OFFENDERS WITH SPECIAL NEEDS, P249, DOI 10.1037/10390-009; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shunk A.W., 2006, APPL NEUROPSYCHOL, V13, P275, DOI [10.1207/s15324826an1304_9, DOI 10.1207/S15324826AN1304_9, DOI 10.1207/S15324826AN1304_]; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Suchy Y, 2009, ANN BEHAV MED, V37, P106, DOI 10.1007/s12160-009-9097-4; *UCLA AC TECHN SER, 2008, STAT DAT AN EX LOG R; Velligan D I, 1999, Semin Clin Neuropsychiatry, V4, P24; Walters GD, 2007, CRIM JUSTICE BEHAV, V34, P1659, DOI 10.1177/0093854807307030; Webster C. D., 1997, HCR 20 ASSESSING RIS; World Health Organization, 2002, WORLD REP VIOL HLTH; WORTHINGTON A, 2005, EFFECTIVENESS REHABI, P257	50	70	72	2	45	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0096-140X	1098-2337		AGGRESSIVE BEHAV	Aggressive Behav.	SEP-OCT	2010	36	5					338	349		10.1002/ab.20353			12	Behavioral Sciences; Psychology, Multidisciplinary	Behavioral Sciences; Psychology	641MS	WOS:000281131500007	20593426				2021-06-18	
J	Davis, DP; Peay, J; Sise, MJ; Kennedy, F; Simon, F; Tominaga, G; Steele, J; Coimbra, R				Davis, Daniel P.; Peay, Jeremy; Sise, Michael J.; Kennedy, Frank; Simon, Fred; Tominaga, Gail; Steele, John; Coimbra, Raul			Prehospital Airway and Ventilation Management: A Trauma Score and Injury Severity Score-Based Analysis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Educators	NOV 21, 2007	Los Angeles, CA	Natl Assoc EMS Educators		Traumatic brain injury; Head trauma; Oxygenation; Hypocapnia; Air medical; Oxygen; Intubation; Ventilation; Prehospital; Paramedic	ADVANCED LIFE-SUPPORT; ENDOTRACHEAL INTUBATION; MAJOR TRAUMA; BRAIN-INJURY; IMPACT; RESUSCITATION; SURVIVAL; MODERATE; HYPOXIA	Background: Emergent endotracheal intubation (ETI) is considered the standard of care for patients with severe traumatic brain injury (TBI). However, recent evidence suggests that the procedure may be associated with increased mortality, possibly reflecting inadequate training, suboptimal patient selection, or inappropriate ventilation. Objective: To explore prehospital ETI in patients with severe TBI using a novel application of Trauma Score and Injury Severity Score methodology. Methods: Patients with moderate-to-severe TBI (head Abbreviated Injury Scale score 3+) were identified from our county trauma registry. Demographic information, pre-resuscitation vital signs, and injury severity scores were used to calculate a probability of survival for each patient. The relationship between outcome and prehospital ETI, provider type (air vs. ground), and ventilation status were explored using observed survival-predicted survival and the ratio of unexpected survivors/deaths. Results: A total of 11,000 patients were identified with complete data for this analysis. Observed and predicted survivals were similar for both intubated and nonintubated patients. The ratio of unexpected survivors/deaths increased and observed survival exceeded predicted survival for intubated patients with lower predicted survival values. Both intubated and nonintubated patients transported by air medical crews had better outcomes than those transported by ground. Both hypo-and hypercapnia were associated with worse outcomes in intubated but not in nonintubated patients. Conclusions: Prehospital intubation seems to improve outcomes in more critically injured TBI patients. Air medical outcomes are better than predicted for both intubated and nonintubated TBI patients. Iatrogenic hyper- and hypoventilations are associated with worse outcomes.	[Davis, Daniel P.; Peay, Jeremy] Univ Calif San Diego, Dept Emergency Med, San Diego, CA USA; [Sise, Michael J.] Scripps Mercy Hosp, Dept Surg, San Diego, CA USA; [Kennedy, Frank] Sharp Mem Hosp & Rehabil Ctr, Dept Surg, San Diego, CA USA; [Simon, Fred; Tominaga, Gail] Scripps Mem Hosp, Dept Surg, San Diego, CA USA; [Steele, John] Palomar Hosp, Dept Surg, San Diego, CA USA; [Coimbra, Raul] Univ Calif San Diego, Div Trauma, San Diego, CA USA	Davis, DP (corresponding author), 200 W Arbor Dr 8676, San Diego, CA 92103 USA.	davismd@cox.net	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAUER M, 1993, CIRC SHOCK, V40, P187; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Corso CO, 1998, J SURG RES, V80, P210, DOI 10.1006/jsre.1998.5426; Davis DP, 2008, CAN MED ASSOC J, V178, P1171, DOI 10.1503/cmaj.080234; Davis DP, 2007, J TRAUMA, V62, P277, DOI 10.1097/TA.0b013e31802ef4a3; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; FELDMAN J A, 1991, Journal of Emergency Medicine, V9, P465, DOI 10.1016/0736-4679(91)90219-6; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	25	70	71	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2010	69	2					294	300		10.1097/TA.0b013e3181dc6c7f			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	638JN	WOS:000280890800009	20699737				2021-06-18	
J	Cheng, JM; Gu, JW; Ma, YA; Yang, T; Kuang, YQ; Li, BC; Kang, JY				Cheng, Jingmin; Gu, Jianwen; Ma, Yuan; Yang, Tao; Kuang, Yongqin; Li, Bingcang; Kang, Jianyi			Development of a rat model for studying blast-induced traumatic brain injury	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Blast; Traumatic brain injury; Animal model	NEURON-SPECIFIC ENOLASE; MANAGEMENT; CASUALTIES; MARKER	Blast-induced traumatic brain injury (TBI) has been the predominant cause of neurotrauma in current military conflicts, and it is also emerging as a potential threat in civilian terrorism. The etiology of TBI, however, is poorly understood. Further study on the mechanisms and treatment of blast injury is urgently needed. We developed a unique rat model to simulate blast effects that commonly occur on the battlefield. An electric detonator with the equivalent of 400 mg TNT was developed as the explosive source. The detonator's peak overpressure and impulse of explosion shock determined the explosion intensity in a distance-dependent manner. Ninety-six male adult Sprague-Dawley rats were randomly divided into four groups: 5-cm, 7.5-cm, 10-cm, and control groups. The rat was fixed in a specially designed cabin with an adjustable aperture showing the frontal, parietal, and occipital parts of the head exposed to explosion; the eyes, ears, mouth, and nose were protected by the cabin. After each explosion, we assessed the physiologic, neuropathologic, and neurobehavioral consequences of blast injury. Changes of brain tissue water content and neuron-specific enolase (NSE) expression were detected. The results in the 7.5-cm group show that 87% rats developed apnea, limb seizure, poor appetite, and limpness. Diffuse subarachnoid hemorrhage and edema could be seen within the brain parenchyma, which showed a loss of integrity. Capillary damage and enlarged intercellular and vascular space in the cortex, along with a tattered nerve fiber were observed. These findings demonstrate that we have provided a reliable and reproducible blast-induced TBI model in rats. (C) 2010 Elsevier B.V. All rights reserved.	[Cheng, Jingmin; Gu, Jianwen; Ma, Yuan; Yang, Tao; Kuang, Yongqin] Gen Hosp Peoples Liberat Army Chengdu Mil Reg, Dept Neurosurg, Chengdu 610083, Sichuan, Peoples R China; [Li, Bingcang; Kang, Jianyi] Third Mil Med Univ, State Key Lab Trauma, Inst Surg Res,Daping Hosp, Res Inst Traff Med Peoples Liberat Army, Chongqing 400038, Peoples R China	Gu, JW (corresponding author), Gen Hosp Peoples Liberat Army Chengdu Mil Reg, Dept Neurosurg, Chengdu 610083, Sichuan, Peoples R China.	doctor_cjm@163.com; gujianwen5000@yahoo.com.cn; tianfu_47@163.com; yangtao_123@163.com; kuangyongqin_123@163.com; bingcangli_123@163.com; kangjianyi_123@163.com			Chengdu Army Region [Z07002]	This work was supported in part by Key Medical Grant of 11th five years' plan from Chengdu Army Region (No. Z07002).	BELL MK, 2008, MIL MED, V173, P5; Bochicchio GV, 2008, AM SURGEON, V74, P267; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Durak Dilek, 2008, Hong Kong Medical Journal, V14, P489; Eastridge Brian J, 2008, Am J Disaster Med, V3, P301; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; HATFIELD RH, 1992, BRAIN RES, V577, P249, DOI 10.1016/0006-8993(92)90280-M; Kluger Yoram, 2007, Am J Disaster Med, V2, P21; Long JB, 2009, J NEUROTRAUM, V26, P1; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Ramasamy A, 2008, J TRAUMA, V65, P910, DOI 10.1097/TA.0b013e3181848cf6; SHANKER T, 2007, NY TIMES        0602, P1; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vink R, 2003, ACT NEUR S, V86, P257; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	21	70	70	1	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	JUL 15	2010	294	1-2					23	28		10.1016/j.jns.2010.04.010			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	621IZ	WOS:000279571100004	20478573				2021-06-18	
J	Tanriverdi, F; Unluhizarci, K; Kelestimur, F				Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin			Pituitary function in subjects with mild traumatic brain injury: a review of literature and proposal of a screening strategy	PITUITARY			English	Article						Traumatic brain injury; Mild TBI; Pituitary; Hypopituitarism; Growth hormone; Boxing; Sports	ANEURYSMAL SUBARACHNOID HEMORRHAGE; INSULIN TOLERANCE-TEST; ADRENAL INSUFFICIENCY; PROFESSIONAL BOXERS; ACUTE-PHASE; HIGH-RISK; HYPOPITUITARISM; DYSFUNCTION; PREVALENCE; CONCUSSION	Traumatic brain injury (TBI) is an important public health problem all over the world. The level of consciousness of the patients and the severity of the brain injury is commonly evaluated by the Glascow Coma Scale as mild, moderate and severe TBI. When we consider the high frequency of mild TBI (MTBI) among the all TBI patients the burden of the pituitary dysfunction problem in this group could not be ignored. However, one of the most important and still unresolved questions is which patients with MTBI should be screened for hypopituitarism? Another type of head trauma which could be considered as the subgroup of MTBI is sports related chronic repetitive head trauma. Therefore, in this review we will discuss the frequency, characteristics and current management of pituitary dysfunction in patients with MTBI including the subjects exposed to sports related chronic mild head trauma.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr					Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2007, NAT CLIN PRACT ENDOC, V3, P318, DOI 10.1038/ncpendmet0460; [Anonymous], 1999, JAMA, V282, P974; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dokmetas HS, 2000, J CLIN ENDOCR METAB, V85, P3713, DOI 10.1210/jc.85.10.3713; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hillier SL, 1997, BRAIN INJURY, V11, P649; Ives JC, 2007, J ATHL TRAINING, V42, P431; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; Ohhashi G, 2002, BRIT J SPORT MED, V36, P346, DOI 10.1136/bjsm.36.5.346; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powell JW, 2001, J ATHL TRAINING, V36, P307; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schmidt IL, 2003, J CLIN ENDOCR METAB, V88, P4193, DOI 10.1210/jc.2002-021897; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2008, J NEUROTRAUM, V25, P1071, DOI 10.1089/neu.2007.0456; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2007, BRAIN INJURY, V21, P433, DOI 10.1080/02699050701311083; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	42	70	71	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	JUN	2010	13	2					146	153		10.1007/s11102-009-0215-x			8	Endocrinology & Metabolism	Endocrinology & Metabolism	584RS	WOS:000276770900008	20037793				2021-06-18	
J	Wygant, DB; Ben-Porath, YS; Arbisi, PA; Berry, DTR; Freeman, DB; Heilbronner, RL				Wygant, Dustin B.; Ben-Porath, Yossef S.; Arbisi, Paul A.; Berry, David T. R.; Freeman, David B.; Heilbronner, Robert L.			Examination of the MMPI-2 Restructured Form (MMPI-2-RF) Validity Scales in Civil Forensic Settings: Findings from Simulation and Known Group Samples	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						MMPI-2-RF; MMPI-2 Restructured Form; Malingering; Forensic evaluation; Medico-legal	FAKE-BAD SCALE; MALINGERED NEUROCOGNITIVE DYSFUNCTION; PERSONAL-INJURY LITIGANTS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; DEPRESSION; TOMM; PERFORMANCE; VALIDATION; INDICATORS	The current study examined the effectiveness of the MMPI-2 Restructured Form (MMPI-2-RF; Ben-Porath and Tellegen, 2008) over-reporting indicators in civil forensic settings. The MMPI-2-RF includes three revised MMPI-2 over-reporting validity scales and a new scale to detect over-reported somatic complaints. Participants dissimulated medical and neuropsychological complaints in two simulation samples, and a known-groups sample used symptom validity tests as a response bias criterion. Results indicated large effect sizes for the MMPI-2-RF validity scales, including a Cohen's d of .90 for Fs in a head injury simulation sample, 2.31 for FBS-r, 2.01 for F-r, and 1.97 for Fs in a medical simulation sample, and 1.45 for FBS-r and 1.30 for F-r in identifying poor effort on SVTs. Classification results indicated good sensitivity and specificity for the scales across the samples. This study indicates that the MMPI-2-RF over-reporting validity scales are effective at detecting symptom over-reporting in civil forensic settings.	[Wygant, Dustin B.] Eastern Kentucky Univ, Dept Psychol, Richmond, KY 40475 USA; [Ben-Porath, Yossef S.] Kent State Univ, Dept Psychol, Kent, OH 44242 USA; [Arbisi, Paul A.] Univ Minnesota, Dept Psychol, Minneapolis VA Med Ctr, Minneapolis, MN 55455 USA; [Berry, David T. R.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; [Freeman, David B.] Cal Psych FMT, Los Angeles, CA USA; [Heilbronner, Robert L.] Chicago Neuropsychol Grp, Chicago, IL USA	Wygant, DB (corresponding author), Eastern Kentucky Univ, Dept Psychol, 127 Cammack Bldg,521 Lancaster Ave, Richmond, KY 40475 USA.	dustin.wygant@eku.edu					Allen L. M., 1997, COMPUTERIZED ASSESSM; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Archer RP, 2006, FORENSIC USES OF CLINICAL ASSESSMENT INSTRUMENTS, P1; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; Ben-Porath Y. S., 2008, MMPI 2 SYMPTOM VALID; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Crawford EF, 2006, J PERS ASSESS, V86, P217, DOI 10.1207/s15327752jpa8602_11; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Dunn TM, 2003, ARCH CLIN NEUROPSYCH, V18, P121, DOI 10.1016/S0887-6177(01)00188-3; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Green, 2003, WORD MEMORY TEST; Green P., 2004, WORD MEMORY TEST MAN; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; ROGERS R, 1997, CLIN ASSESSMENT MALI, P427; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Sellbom M, 2005, ASSESSMENT, V12, P79, DOI 10.1177/1073191104273515; SELLBOM M, 2008, 2008 SOC PERS ASS AN; Sellbom M, 2008, PSYCHOL ASSESSMENT, V20, P370, DOI 10.1037/a0012952; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Tellegen A, 2008, **DROPPED REF**; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wygant D. B., 2007, THESIS KENT STATE U; Wygant D. B., 2004, 39 ANN S REC DEV MMP; WYGANT DB, 2007, 27 ANN M NAT AC NEUR; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009	40	70	72	2	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2009	24	7					671	680		10.1093/arclin/acp073			10	Psychology, Clinical; Psychology	Psychology	514GU	WOS:000271383200004	19797242	Bronze			2021-06-18	
J	Manesh, KM; Halamek, J; Pita, M; Zhou, J; Tam, TK; Santhosh, P; Chuang, MC; Windmiller, JR; Abidin, D; Katz, E; Wang, J				Manesh, Kalayil Manian; Halamek, Jan; Pita, Marcos; Zhou, Jian; Tam, Tsz Kin; Santhosh, Padmanabhan; Chuang, Min-Chieh; Windmiller, Joshua R.; Abidin, Dewi; Katz, Evgeny; Wang, Joseph			Enzyme logic gates for the digital analysis of physiological level upon injury	BIOSENSORS & BIOELECTRONICS			English	Article						Enzyme logic; Biomarker; Injury; Digital sensor; Optical biosensor; Amperometric biosensor	BIOCHEMICAL LOGIC; HEMORRHAGIC-SHOCK; BRAIN-INJURY; REAL-TIME; NOREPINEPHRINE; DIAGNOSTICS; OPERATIONS; BIOSENSORS; LACTATE; SYSTEM	A biocomputing system composed of a combination of AND/IDENTITY logic gates based on the concerted operation of three enzymes: lactate oxidase, horseradish peroxidase and glucose dehydrogenase was designed to process biochemical information related to pathophysiological conditions originating from various injuries. Three biochemical markers: lactate, norepinephrine and glucose were applied as input signals to activate the enzyme logic system. Physiologically normal concentrations of the markers were selected as logic 0 values of the input signals, while their abnormally increased concentrations, indicative of various injury conditions were defined as logic 1 input. Biochemical processing of different patterns of the biomarkers resulted in the formation of norepi-quinone and NADH defined as the output signals. Optical and electrochemical means were used to follow the formation of the output signals for eight different combinations of three input signals. The enzymatically processed biochemical information presented in the form of a logic truth table allowed distinguishing the difference between normal physiological conditions, pathophysiological conditions corresponding to traumatic brain injury and hemorrhagic shock, and abnormal situations (not corresponding to injury). The developed system represents a biocomputing logic system applied for the analysis of biomedical conditions related to various injuries. We anticipate that such biochemical logic gates will facilitate decision-making in connection to an integrated therapeutic feedback-loop system and hence will revolutionize the monitoring and treatment of injured civilians and soldiers. (C) 2009 Elsevier B.V. All rights reserved.	[Halamek, Jan; Pita, Marcos; Zhou, Jian; Tam, Tsz Kin; Katz, Evgeny] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA; [Manesh, Kalayil Manian; Santhosh, Padmanabhan; Chuang, Min-Chieh; Windmiller, Joshua R.; Abidin, Dewi; Wang, Joseph] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA	Katz, E (corresponding author), Clarkson Univ, Dept Chem & Biomol Sci, 8 Clarkson Ave, Potsdam, NY 13699 USA.	ekatz@clarkson.edu; josephwang@ucsd.edu	Wang, Joseph/C-6175-2011; Pita, Marcos/AAB-9772-2020; Padmanabhan, Santhosh/A-6930-2009; Manesh, KM/A-6877-2010; Tam, Tsz Kin/F-9794-2011	Pita, Marcos/0000-0002-6714-3669; Padmanabhan, Santhosh/0000-0003-2418-5284; 	Office of Naval Research (ONR)Office of Naval Research [N00014-08-1-1202]	This work was supported by Office of Naval Research (ONR Award #N00014-08-1-1202).	ALTURA BM, 1983, HDB SHOCK TRAUMA; Amir L, 2009, J AM CHEM SOC, V131, P826, DOI 10.1021/ja8076704; Astaras A, 2008, HIPPOKRATIA, V12, P10; Baker SP, 1992, THE INJURY FACT BOOK; Baron R, 2006, ANGEW CHEM INT EDIT, V45, P1572, DOI 10.1002/anie.200503314; Credi A, 2007, ANGEW CHEM INT EDIT, V46, P5472, DOI 10.1002/anie.200700879; Curreli M, 2008, IEEE T NANOTECHNOL, V7, P651, DOI 10.1109/TNANO.2008.2006165; de Silva AP, 2007, NAT NANOTECHNOL, V2, P399, DOI 10.1038/nnano.2007.188; Feliciano DV, 2007, TRAUMA; Kline JA, 1997, J MOL CELL CARDIOL, V29, P2465, DOI 10.1006/jmcc.1997.0483; LeonCarrion J, 2006, STUD NEUROPSYCH DEV, P1; Mascini M, 2008, BIOMARKERS, V13, P637, DOI [10.1080/13547500802645905, 10.1080/13547500802645905 ]; Pita M, 2009, SENSOR ACTUAT B-CHEM, V139, P631, DOI 10.1016/j.snb.2009.03.001; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Privman V, 2008, J PHYS CHEM B, V112, P11777, DOI 10.1021/jp802673q; ROSENBERG J, 1961, ANN SURG, V154, P611, DOI 10.1097/00000658-196110000-00011; Shao XG, 2002, PROG CHEM, V14, P37; Simpson ML, 2001, TRENDS BIOTECHNOL, V19, P317, DOI 10.1016/S0167-7799(01)01691-2; Sivan S, 2003, BIOSYSTEMS, V70, P21, DOI 10.1016/S0303-2647(03)00039-X; Stojanovic MN, 2005, BIOELECTRONICS: FROM THEORY TO APPLICATIONS, P427, DOI 10.1002/352760376X.ch14; Strack G, 2008, CHEMBIOCHEM, V9, P1260, DOI 10.1002/cbic.200700762; Strack G, 2008, J AM CHEM SOC, V130, P4234, DOI 10.1021/ja7114713; Tokarev I, 2009, ACS APPL MATER INTER, V1, P532, DOI 10.1021/am800251a; Tomizaki KY, 2007, J AM CHEM SOC, V129, P8345, DOI 10.1021/ja0703067; Unger R, 2006, PROTEINS, V63, P53, DOI 10.1002/prot.20886; Wang J, 2006, BIOSENS BIOELECTRON, V21, P1887, DOI 10.1016/j.bios.2005.10.027; Zhou J, 2009, ACS APPL MATER INTER, V1, P144, DOI 10.1021/am800088d; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7	28	70	70	1	36	ELSEVIER ADVANCED TECHNOLOGY	OXFORD	OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0956-5663			BIOSENS BIOELECTRON	Biosens. Bioelectron.	AUG 15	2009	24	12					3569	3574		10.1016/j.bios.2009.05.019			6	Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical; Electrochemistry; Nanoscience & Nanotechnology	Biophysics; Biotechnology & Applied Microbiology; Chemistry; Electrochemistry; Science & Technology - Other Topics	487MI	WOS:000269278300027	19523809				2021-06-18	
J	Kim, YH; Yoo, WK; Ko, MH; Park, CH; Kim, ST; Na, DL				Kim, Yun-Hee; Yoo, Woo-Kyoung; Ko, Myoung-Hwan; Park, Chang-hyun; Kim, Sung Tae; Na, Duk L.			Plasticity of the Attentional Network After Brain Injury and Cognitive Rehabilitation	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						Traumatic brain injury; Cognitive training; Plasticity; Attentional network; Functional MRI	VISUAL-ATTENTION; SPATIAL ATTENTION; ANTERIOR CINGULATE; FUNCTIONAL-ANATOMY; CORTICAL NETWORK; PARAMETRIC FMRI; NEURAL-NETWORKS; ACTIVATION; DEFICITS; MILD	Background. This study aimed to delineate the cerebral attentional network in patients with traumatic brain injury (TBI) and assess for adaptations in this network in response to a rehabilitation intervention. Methods. Seventeen patients with TBI and 15 healthy subjects underwent functional magnetic resonance imaging (fMRI) using a visuospatial attention task. Ten TBI patients who successfully completed attentional training had a follow-up fMRI. Results. In the TBI patients, fMRI analysis showed more activation in the frontal and temporoparietal lobes, as well as less activation in the anterior cingulated gyrus, SMA, and temporooccipital regions compared to the healthy subjects. Following cognitive training, the TBI patients improved performance of attention tasks accompanied by changes in attentional network activation; the activity of the frontal lobe decreased, whereas activation of the anterior cingulate cortices and precuneus increased. Conclusions. These findings demonstrate the plasticity and training induced redistribution of the visuospatial attentional network in TBI patients.	[Kim, Yun-Hee; Park, Chang-hyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Phys Med & Rehabil,Div Neurorehabil,Stroke &, Seoul 135710, South Korea; [Kim, Sung Tae] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Ctr Imaging Sci,Dept Radiol, Seoul 135710, South Korea; [Na, Duk L.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul 135710, South Korea; [Yoo, Woo-Kyoung] Hallym Univ, Sacred Heart Hosp, Dept Phys & Rehabil Med, Anyang, South Korea; [Ko, Myoung-Hwan] Chonbuk Natl Univ, Sch Med, Res Inst Clin Med, Dept Phys Med & Rehabil, Jeonju, South Korea; [Park, Chang-hyun] Korea Adv Inst Sci & Technol, Dept Phys, Taejon 305701, South Korea	Kim, YH (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Phys Med & Rehabil,Div Neurorehabil,Stroke &, 50 Irwon Dong, Seoul 135710, South Korea.	yunkim@skku.edu	Yoo, Woo-Kyoung/B-6356-2013; Na, Duk Lyul/C-9598-2011; Park, Chang-hyun/I-2217-2016; Kim, Yun Hee/F-4600-2014	Yoo, Woo-Kyoung/0000-0002-1273-0647; Ko, Myoung-Hwan/0000-0002-0566-3677	Korean government (MOST)Ministry of Science and Technology (MOST) KoreaKorean Government [M10644000022-06N440002210]; Korean Health 21 RD Project [A0550079]	This study was supported by a KOSEF grant funded by the Korean government (MOST; Number M10644000022-06N440002210) and a grant of the Korean Health 21 R&D Project (A0550079).	Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Beauchamp MS, 2001, NEUROIMAGE, V14, P310, DOI 10.1006/nimg.2001.0788; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Buckner RL, 1998, P NATL ACAD SCI USA, V95, P891, DOI 10.1073/pnas.95.3.891; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; COHEN JD, 1992, AM J PSYCHOL, V105, P239, DOI 10.2307/1423029; Corbetta M, 2002, J COGNITIVE NEUROSCI, V14, P508, DOI 10.1162/089892902317362029; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Donovan NJ, 2008, NEUROREHAB NEURAL RE, V22, P122, DOI 10.1177/1545968307306239; Downar J, 2000, NAT NEUROSCI, V3, P277; Fletcher PC, 1996, BRAIN, V119, P1587, DOI 10.1093/brain/119.5.1587; Gerardin E, 2000, CEREB CORTEX, V10, P1093, DOI 10.1093/cercor/10.11.1093; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Gitelman DR, 1999, BRAIN, V122, P1093, DOI 10.1093/brain/122.6.1093; Goldstein RZ, 2007, NEUROIMAGE, V35, P194, DOI 10.1016/j.neuroimage.2006.12.004; Habekost T, 2003, NEUROPSYCHOLOGIA, V41, P1171, DOI 10.1016/S0028-3932(03)00018-6; Habekost T, 2007, NEUROPSYCHOLOGIA, V45, P1474, DOI 10.1016/j.neuropsychologia.2006.11.006; Hahn B, 2006, NEUROIMAGE, V32, P842, DOI 10.1016/j.neuroimage.2006.04.177; Hillis AE, 2005, J NEUROSCI, V25, P3161, DOI 10.1523/JNEUROSCI.4468-04.2005; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kincade JM, 2005, J NEUROSCI, V25, P4593, DOI 10.1523/JNEUROSCI.0236-05.2005; Kircher TTJ, 2000, COGNITIVE BRAIN RES, V10, P133, DOI 10.1016/S0926-6410(00)00036-7; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Marois R, 2000, NEURON, V25, P717, DOI 10.1016/S0896-6273(00)81073-9; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Michel J A, 2006, Eura Medicophys, V42, P59; Milham MP, 2003, NEUROIMAGE, V18, P483, DOI 10.1016/S1053-8119(02)00050-2; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Tomasi D, 2004, NEUROIMAGE, V23, P1414, DOI 10.1016/j.neuroimage.2004.07.065; Weissman DH, 2002, NEUROIMAGE, V17, P1266, DOI 10.1006/nimg.2002.1284	55	70	71	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUN	2009	23	5					468	477		10.1177/1545968308328728			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	450JP	WOS:000266397100008	19118131				2021-06-18	
J	Provvidenza, CF; Johnston, KM				Provvidenza, C. F.; Johnston, K. M.			Knowledge transfer principles as applied to sport concussion education	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				CONTINUING MEDICAL-EDUCATION; MULTIPLE INTELLIGENCES; COACH EDUCATION; REFLECTION; GUIDELINES; EXPERIENCE; PLAYERS; RETURN	Objective: To (a) examine knowledge transfer literature and optimal learning needs as applied to healthcare professionals, coaches and student athletes; (b) apply the practice of knowledge transfer to sport concussion education resources; and (c) identify needs and make recommendations for optimising concussion education. Design: Qualitative literature review of knowledge transfer and concussion education literature. Intervention: Pubmed, Medline, Psych Info and Sport Discus databases were reviewed. 52 journal articles, 20 websites and 2 books were reviewed. Results: The methods in which individuals experience optimal learning varies and should be considered when developing effective concussion education strategies. Physician knowledge and performance are impacted by education outreach, interaction and reminder messages. Educational strategies associated with optimal learning for physio and athletic therapists include problem and evidence-based practice, socialisation and peer-assisted learning. From a coaching perspective, research supports the reflective process as a learning modality. Student athletes have strengths and weaknesses in different areas and so perform differently on activities requiring distinct strategies. Knowing the impact of sport concussion resources on knowledge enhancement and modifying attitudes and behaviours toward concussion requires evaluation strategies. Review of concussion resources using the perspective of knowledge transfer and methods for improvement is discussed. Conclusions: Knowledge transfer is a relatively new concept in sports medicine and its influence on enhancing concussion education is not well known. The needs and optimal learning styles of target audiences coupled with evaluation need to be a piece of the overall concussion education puzzle to effectively impact knowledge of and attitudes and behaviours towards sport concussion.	[Johnston, K. M.] Toronto Rehabil Inst, Sport Concuss Program, Sport Concuss Clin, Toronto, ON M5G 2A2, Canada; [Johnston, K. M.] Univ Toronto, Dept Neurosurg, Toronto, ON, Canada	Johnston, KM (corresponding author), Toronto Rehabil Inst, Sport Concuss Program, Sport Concuss Clin, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	johnston.karen@torontorehab.on.ca					Abernathy T., 2001, KNOWLEDGE TRANSFER L; Alexander S., 2001, ED TRAINING, V43, P240, DOI DOI 10.1108/00400910110399247; [Anonymous], 2007, KNOWL TRANSF EXCH; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bales J, 2006, SPORT PSYCHOL, V20, P126, DOI 10.1123/tsp.20.2.126; *CAN BROADC CO, 2006, VID GAM CAN RESH ED; *CAN PAED SOC, 2003, J PAEDIATR CHILD H, V8, P301; Cassidy T, 2006, SPORT PSYCHOL, V20, P145, DOI 10.1123/tsp.20.2.145; *COACH ASS CAN, 2005, SUMM NCCP EV PROJ BL; Coutts J, 2005, 7 CHSRF ANN INV WORK; CURRY L, 1981, CAN MED ASSOC J, V124, P563; CURRY L, 1981, CAN MED ASSOC J, V124, P535; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Federation of American Scientists, 2006, SUMM ED GAM HARN POW; GALLO M, 2007, INTERNET ITS EFFECTS; Gardner H., 1993, MULTIPLE INTELLIGENC; Gardner HowardE., 1983, FRAMES MIND THEORY M; Gilbert WD, 2005, PHYS EDUC-US, V62, P32; Gilbert WD, 2001, J TEACH PHYS EDUC, V21, P16; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Greenhawk J, 1997, EDUC LEADERSHIP, V55, P62; Grimshaw JM, 1998, J ROY SOC MED, V91, P20, DOI 10.1177/014107689809135S06; Grimshaw JM, 2001, MED CARE S2, V39, pII2, DOI DOI 10.1097/00005650-200108002-00002; Gunasekaran A., 2002, IND COMMER TRAIN, V34, P44, DOI DOI 10.1108/00197850210417528; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hall E, 2005, INT J LIFELONG EDUC, V24, P243, DOI 10.1080/02601370500134933; Henning JM, 2006, J ATHL TRAINING, V41, P102; Horton A. S., 2002, Medicine & Science in Sports & Exercise, V34, pS99, DOI 10.1097/00005768-200205001-00551; JONES A, 2008, ADV PHYSIOTHER, P9; Klein P. D., 1997, CANADIAN J ED, V22, P377, DOI DOI 10.2307/1585790; Lindquist I, 2006, PHYSIOTHER RES INT, V11, P129, DOI 10.1002/pri.332; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McMahon SD, 2004, J EXP EDUC, V73, P41, DOI 10.3200/JEXE.71.1.41-52; Mettetal G, 1997, J EDUC RES, V91, P115, DOI 10.1080/00220679709597529; Nelson LJ, 2006, SPORT PSYCHOL, V20, P174, DOI 10.1123/tsp.20.2.174; Newton A, 2005, HLTH RES TRANSFER NE; Popay J, 1998, J ROY SOC MED, V91, P32, DOI 10.1177/014107689809135S08; Reardon R., 2006, RES PRACTICE KNOWLED; Rossiter K, 2008, SOC SCI MED, V66, P130, DOI 10.1016/j.socscimed.2007.07.021; Solomon Patricia, 1994, Physiotherapy Theory and Practice, V10, P45, DOI 10.3109/09593989409036386; Solomon Patricia, 2005, Physiotherapy Theory and Practice, V21, P37, DOI 10.1080/09593980590911499; Stevenson K, 2004, J EVAL CLIN PRACT, V10, P207, DOI 10.1111/j.1365-2753.2003.00479.x; Stewart C, 2006, J PHYS EDUC RECREAT, V77, P34, DOI 10.1080/07303084.2006.10597861; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; *UVA WEBL, HAV RAD TV BROADC BE	52	70	70	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I68	I75		10.1136/bjsm.2009.058180			8	Sport Sciences	Sport Sciences	450YO	WOS:000266438100011	19433428				2021-06-18	
J	Barnes, SRS; Haacke, EM				Barnes, Samuel R. S.; Haacke, E. Mark			Susceptibility-Weighted Imaging: Clinical Angiographic Applications	MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA			English	Article						Susceptibility; Susceptibility-weighted imaging; BOLD; Phase; Venography	BLOOD-OXYGEN SATURATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL-DISEASE; NEAR-INFRARED SPECTROSCOPY; DIFFUSE AXONAL INJURY; IN-VIVO MEASUREMENT; MR-VENOGRAPHY; BRAIN-TUMORS; VENOUS THROMBOSIS; ACUTE STROKE	By combining filtered phase and magnitude information to create a novel and intrinsic source of contrast, susceptibility-weighted imaging (SWI) has shown great promise in clinical angiography and venography. SWI has contributed to new insights into traumatic brain injury, the role of calcification in atherosclerosis, and the possible relationship between blood settling and deep venous thrombosis. A further contribution from SWI to deep venous thrombosis research (and also stroke) involves its application to the noninvasive measurement of oxygen saturation in the brain and in other tissues. Altogether, SWI offers manifold and diverse avenues for further research using angiographic and venographic techniques.	[Haacke, E. Mark] Wayne State Univ, Dept Biomed Engn, MRI Inst Biomed Engn, Detroit, MI 48202 USA; [Barnes, Samuel R. S.] Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA 92350 USA; [Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA	Haacke, EM (corresponding author), Wayne State Univ, Dept Biomed Engn, MRI Inst Biomed Engn, 440 E Ferry St,Unit 2, Detroit, MI 48202 USA.	nmrimaging@aol.com	Barnes, Samuel/B-7673-2013	Barnes, Samuel/0000-0002-1065-8442	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL062983] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [2R01 HL062983-04A2, R01 HL062983-04A2, R01 HL062983] Funding Source: Medline		Akbudak E, 1997, MAGNET RESON MED, V38, P990, DOI 10.1002/mrm.1910380619; Aldington S, 2008, INTERN MED J, V38, P133, DOI 10.1111/j.1445-5994.2007.01597.x; AMERI A, 1992, NEUROL CLIN, V10, P87; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Barth M, 2003, INVEST RADIOL, V38, P409, DOI 10.1097/00004424-200307000-00005; BOOS M, 1996, P 13 ANN SCI M EUR S, P127; BRISMAR B, 1978, ACTA CHIR SCAND, V144, P125; Cannegieter SC, 2006, PLOS MED, V3, P1258, DOI 10.1371/journal.pmed.0030307; Costes F, 1996, J APPL PHYSIOL, V80, P1345; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; de Souza JM, 2008, AM J NEURORADIOL, V29, P154, DOI 10.3174/ajnr.A0748; Du YP, 2008, MAGN RESON MED, V59, P954, DOI 10.1002/mrm.21581; ELANGOVAN IR, 2006, VERIFICATION MAGNETI; Esaki K, 2005, EUR J APPL PHYSIOL, V95, P361, DOI 10.1007/s00421-005-0008-5; Essig M, 2001, RADIOLOGE, V41, P288, DOI 10.1007/s001170050989; Fernandez-Seara MA, 2006, MAGN RESON MED, V55, P967, DOI 10.1002/mrm.20892; Guzman RJ, 2008, J AM COLL CARDIOL, V51, P1967, DOI 10.1016/j.jacc.2007.12.058; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HAACKE EM, 1995, INT J IMAG SYST TECH, V6, P153, DOI 10.1002/ima.1850060204; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; HAACKE EM, 2005, P 13 ANN M ISMRM, P13; Harder SL, 2008, AM J NEURORADIOL, V29, P176, DOI 10.3174/ajnr.A0770; Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96; Hinman JM, 2002, EUR J RADIOL, V41, P147, DOI 10.1016/S0720-048X(01)00365-5; Hu J, 2008, J MAGN RESON IMAGING, V28, P300, DOI 10.1002/jmri.21435; Isbell DC, 2007, J CARDIOV MAGN RESON, V9, P71, DOI 10.1080/10976640600843330; Koopmans PJ, 2008, MAGN RESON MATER PHY, V21, P149, DOI 10.1007/s10334-007-0101-3; Li DB, 1998, MAGNET RESON MED, V39, P685, DOI 10.1002/mrm.1910390503; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; MacDonald MJ, 1999, J APPL PHYSIOL, V86, P687; MAMMEN EF, 2002, CHEST S, V102, pS640; Matsushita T, 2008, ACTA MED OKAYAMA, V62, P159; Mentzel HJ, 2005, PEDIATR RADIOL, V35, P85, DOI 10.1007/s00247-004-1333-2; Pandian DSJ, 2008, J MAGN RESON IMAGING, V28, P727, DOI 10.1002/jmri.21487; PENTECOST MJ, 1994, CIRCULATION, V89, P511, DOI 10.1161/01.CIR.89.1.511; Pinker K, 2007, AM J NEURORADIOL, V28, P1280, DOI 10.3174/ajnr.A0540; Preter M, 1996, STROKE, V27, P243, DOI 10.1161/01.STR.27.2.243; Rauscher A, 2005, MAGNET RESON MED, V54, P87, DOI 10.1002/mrm.20520; Rauscher A, 2003, J MAGN RESON IMAGING, V18, P175, DOI 10.1002/jmri.10346; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Schad LR, 2001, NMR BIOMED, V14, P478, DOI 10.1002/nbm.714; Sedlacik J, 2007, MAGN RESON MED, V58, P1035, DOI 10.1002/mrm.21283; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; SHVARTZ E, 1983, J APPL PHYSIOL, V54, P1673; Somasundaram S, 2008, NEUROL INDIA, V56, P103; SONNENFELD T, 1979, SCAND J CLIN LAB INV, V39, P577, DOI 10.3109/00365517909108836; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; Tan IL, 2000, AM J NEURORADIOL, V21, P1039; Tang PH, 2008, ANN ACAD MED SINGAP, V37, P397; Thomas B, 2008, NEURORADIOLOGY, V50, P105, DOI 10.1007/s00234-007-0316-z; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Vink A, 2002, J VASC SURG, V36, P1194, DOI 10.1067/mva.2002.128300; Warmuth C, 2003, RADIOLOGY, V228, P523, DOI 10.1148/radiol.2282020409; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Wright LB, 2004, RADIOGRAPHICS, V24, P467, DOI 10.1148/rg.242035117; Wycliffe ND, 2004, J MAGN RESON IMAGING, V20, P372, DOI 10.1002/jmri.20130; Wyttenbach R, 2004, CIRCULATION, V110, P1156, DOI 10.1161/01.CIR.0000140672.70862.5B; Xu YB, 2006, MAGN RESON IMAGING, V24, P155, DOI 10.1016/j.mri.2005.10.030; Zimmermann GG, 1997, RADIOLOGY, V204, P769, DOI 10.1148/radiology.204.3.9280257	66	70	83	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1064-9689	1557-9786		MAGN RESON IMAGING C	Magn. Reson. Imaging Clin. N. Am.	FEB	2009	17	1					47	+		10.1016/j.mric.2008.12.002			16	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	445OG	WOS:000266059500005	19364599	Green Accepted			2021-06-18	
J	Kellinghaus, C; Berning, S; Besselmann, M				Kellinghaus, Christoph; Berning, Sascha; Besselmann, Michael			Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy	EPILEPSY & BEHAVIOR			English	Article						Nonconvulsive status epilepticus; Anticonvulsant therapy; Lacosamide	TRAUMATIC BRAIN-INJURY; PARTIAL-ONSET SEIZURES; ORAL LACOSAMIDE; MORTALITY; VALPROATE; DAMAGE	Treatment of status epilepticus usually requires intravenous anticonvulsant therapy. Lacosamide is a novel anticonvulsant drug that is available as infusion solution. We describe a patient with nonconvulsive status epilepticus who was Successfully treated with intravenous lacosamide. (C) 2008 Elsevier Inc. All rights reserved.	[Kellinghaus, Christoph; Berning, Sascha; Besselmann, Michael] Klin Osnabruck, Dept Neurol, D-49076 Osnabruck, Germany	Kellinghaus, C (corresponding author), Klin Osnabruck, Dept Neurol, Finkenhugel 1, D-49076 Osnabruck, Germany.	christoph.kellinghaus@klinikum-os.de					Aminoff MJ, 1998, ARCH NEUROL-CHICAGO, V55, P119, DOI 10.1001/archneur.55.1.119; Ben-Menachem E, 2007, EPILEPSIA, V48, P1308, DOI 10.1111/j.1528-1167.2007.01188.x; Biton V, 2008, EPILEPSIA, V49, P418, DOI 10.1111/j.1528-1167.2007.01317.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Doty P, 2007, NEUROTHERAPEUTICS, V4, P145, DOI 10.1016/j.nurt.2006.10.002; Garnett WR, 2002, ANTIEPILEPTIC DRUGS, P380; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; Knake S, 2008, J NEUROL NEUROSUR PS, V79, P588, DOI 10.1136/jnnp.2007.130260; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Misra UK, 2006, NEUROLOGY, V67, P340, DOI 10.1212/01.wnl.0000224880.35053.26; NAGLER J, 1981, AM J GASTROENTEROL, V76, P495; Peters CNA, 2005, SEIZURE-EUR J EPILEP, V14, P164, DOI 10.1016/j.seizure.2005.01.002; SACHDEO R, 2003, ANN M EFNS HELS; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; Shorvon S, 2008, EPILEPSIA, V49, P1277, DOI 10.1111/j.1528-1167.2008.01706_3.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; YAFFE K, 1993, NEUROLOGY, V43, P895, DOI 10.1212/WNL.43.5.895; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	22	70	74	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	FEB	2009	14	2					429	431		10.1016/j.yebeh.2008.12.009			3	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	412ZB	WOS:000263761600027	19130901				2021-06-18	
J	Ruff, RL; Ruff, SS; Wang, XF				Ruff, Robert L.; Ruff, Suzanne S.; Wang, Xiao-Feng			Improving sleep: Initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						combat; concussion; explosion; headache; mild traumatic brain injury; OIF/OEF; pain; prazosin; PTSD; sleep	ENDURING FREEDOM; PAIN; PRAZOSIN; CLASSIFICATION; NIGHTMARES; MANAGEMENT; SCALE	This was an observational study of a cohort of 126 veterans with mild traumatic brain injury caused by an explosion during deployment in Operation Iraqi Freedom or Operation Enduring Freedom (OIF/OEF); 74 of the 126 veterans had comorbidities including frequent, severe headaches and residual deficits on neurological examination, neuropsychological testing, or both. Of these veterans, 71 had posttraumatic stress disorder and only 5 had restful sleep. We examined whether treatment with sleep hygiene counseling and oral prazosin would improve sleep, headaches, and cognitive performance. Nine weeks after providing sleep counseling and initiating an increasing dosage schedule of prazosin at bedtime, 65 veterans reported restful sleep. Peak headache pain (0-10 scale) decreased from 7.28 +/- 0.27 to 4.08 +/- 0.19 (values presented as mean +/- standard deviation). The number of headaches per month decreased from 12.40 +/- 0.94 to 4.77 +/- 0.34. Montreal Cognitive Assessment scores improved from 24.50 +/- 0.49 to 28.60 +/- 0.59. We found these gains maintained 6 months later. This pilot study suggests that addressing sleep is a good first step in treating posttraumatic headaches in OIF/OEF veterans.	[Ruff, Robert L.] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Neurol Serv, Cleveland, OH USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Suzanne S.] LSCVAMC, Psychol Serv, Cleveland, OH USA; [Wang, Xiao-Feng] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA	Ruff, RL (corresponding author), Louis Stokes Cleveland VA Med Ctr, Neurol Serv, 127W,10701 E Blvd, Cleveland, OH 44106 USA.	robert.ruffl@va.gov	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604	Patient Care Services of the VA	This material was based on work supported by the Patient Care Services of the VA.	Agresti A., 1996, INTRO CATEGORICAL DA; Alberti A, 2006, SLEEP MED REV, V10, P431, DOI 10.1016/j.smrv.2006.03.003; Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Boehnlein James K, 2007, J Psychiatr Pract, V13, P72, DOI 10.1097/01.pra.0000265763.79753.c1; Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; COGGON D, 2002, STAT CLIN PRACTICE; *COMB STRESS CTR C, 2009, W REED ARM I RES PSY; DeLoach LJ, 1998, ANESTH ANALG, V86, P102, DOI 10.1097/00000539-199801000-00020; Dick BD, 2007, ANESTH ANALG, V104, P1223, DOI 10.1213/01.ane.0000263280.49786.f5; Dierks MR, 2007, ANN PHARMACOTHER, V41, P1013, DOI 10.1345/aph.1H588; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; *FORC HLTH PROT RE, POST DEPL HLTH REASS; FRY JM, 1987, MED CLIN N AM, V71, P95, DOI 10.1016/S0025-7125(16)30885-9; Hans G, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-170; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holroyd KA, 2001, JAMA-J AM MED ASSOC, V285, P2208, DOI 10.1001/jama.285.17.2208; Holroyd KA, 2009, PAIN, V143, P213, DOI 10.1016/j.pain.2009.02.019; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Linder Steven L, 2007, Curr Pain Headache Rep, V11, P396, DOI 10.1007/s11916-007-0223-3; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mastin DF, 2006, J BEHAV MED, V29, P223, DOI 10.1007/s10865-006-9047-6; McCrea M, 2008, MILD TRAUMATIC BRAIN; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; PROYINI F, 2006, NEUROL SCI, V27, pS149, DOI DOI 10.1007/S10072-006-0591-1; Rains JC, 2008, CURR NEUROL NEUROSCI, V8, P167, DOI 10.1007/s11910-008-0027-9; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Redline S, 1998, AM J RESP CRIT CARE, V157, P858, DOI 10.1164/ajrccm.157.3.9709042; Roberts RJ, 2008, SCI AM MIND, V19, P51, DOI DOI 10.1038/SCIENTIFICAMERICANMIND1208-50; Roth T, 2007, CNS SPECTRUMS, V12, P1; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Schmader KE, 2007, CLIN J PAIN, V23, P490, DOI 10.1097/AJP.0b013e318065b6c9; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Slone L. B., 2008, WAR ZONE PRACTICAL G; Smith MT, 2007, SLEEP, V30, P494, DOI 10.1093/sleep/30.4.494; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor FB, 2008, BIOL PSYCHIAT, V63, P629, DOI 10.1016/j.biopsych.2007.07.001; Verbeke G., 2000, LINEAR MIXED MODELS; Vgontzas AN, 1999, ANNU REV MED, V50, P387; *W REED ARM I RES, 2009, BATTL TRAIN, V2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WHEALIN JM, 2008, CLIN GUIDE TREATING; Wright KP, 2006, J COGNITIVE NEUROSCI, V18, P508, DOI 10.1162/jocn.2006.18.4.508; Young James A, 2007, Phys Med Rehabil Clin N Am, V18, P145, DOI 10.1016/j.pmr.2006.11.008; ZADIKOFF C, 2007, MOVEMENT DISORD, V23, P297, DOI DOI 10.1002/MDS.21837; Zalewski, 1994, Assessment, V1, P133, DOI 10.1177/1073191194001002003; Zelman DC, 2006, CLIN J PAIN, V22, P681, DOI 10.1097/01.ajp.0000210910.49923.09	54	70	70	0	10	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	9					1071	1084		10.1682/JRRD.2009.05.0062			14	Rehabilitation	Rehabilitation	580JJ	WOS:000276444000002	20437313	Bronze			2021-06-18	
J	Norwood, SH; Berne, JD; Rowe, SA; Villarreal, DH; Ledlie, JT				Norwood, Scott H.; Berne, John D.; Rowe, Stephen A.; Villarreal, David H.; Ledlie, Jon T.			Early Venous Thromhoembolism Prophylaxis With Enoxaparin in Patients With Blunt Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	21st Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 15-19, 2008	Jacksonville, FL	Eastern Assoc Surg Trauma		DVT prophylaxis in traumatic brain injury; Enoxaparin; DVT prophylaxis complications	VENA-CAVA FILTERS; DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; THROMBOEMBOLISM PROPHYLAXIS; FOLLOW-UP; PREVENTION	Objective: To determine the safety of early enoxaparin for venous thromboembolism (VTE) prophylaxis in patients with blunt traumatic brain injury (TBI). Methods: Prospective observational study of patients with TBI who received enoxaparin within 48 hours after admission. Brain computed tomography (0) scans were obtained at the time of admission, at 24 hours, and at variable intervals thereafter based on clinical course. Patients were excluded from the study for intracerebral contusions >= 2 cm. multiple contusions within one brain region, subdural or epidural hematomas >= 8 mm, increased size or number of lesions on follow-up CT, persistent intracranial pressure >20 mm Hg, or neurosurgeon or trauma surgeon reluctance to initiate early pharmacologic VTE prophylaxis. Bleeding complications were defined as CT progression of hemorrhage by Marshall CT Classification or radiologists' report, regardless of any neurologic deterioration. Main outcomes measured were intracranial bleeding complications, discharge Glasgow Outcome Score, and hospital mortality. Results: Five hundred twenty-five patients were studied. Eighteen patients (3.4%) had progressive hemorrhagic CT changes after receiving enoxaparin, 12 of whom had no change in treatment, neurologic status, or outcome. Six patients (1.1%) had a change in treatment or potential outcome, including three who required subsequent craniotomy. Twenty-one patients (4.0%) died, and pharmacologic prophylaxis may have contributed to one death (0.2%). Discharge Glasgow Outcome Scores were 445 (84.8%) good recovery, 19 (3.6%) moderate disability, 36 (6.8%) severe disability, 4 (0.8%) persistent vegetative state, and 21 (4.0%) dead. Conclusion: Enoxaparin should be considered as an option for early VTE prophylaxis in selected patients with blunt TBI. Early enoxaparin should be strongly considered in those patients with TBI with additional high risk traumatic injuries.	[Norwood, Scott H.; Berne, John D.; Rowe, Stephen A.; Villarreal, David H.] E Texas Med Ctr, Trauma Serv, Dept Surg, Tyler, TX 75701 USA; [Ledlie, Jon T.] E Texas Med Ctr, Dept Neurosurg, Tyler, TX 75701 USA	Norwood, SH (corresponding author), E Texas Med Ctr, Trauma Serv, Dept Surg, 1020 E Idel St, Tyler, TX 75701 USA.	snorwo01@msn.com					Aito S, 2002, SPINAL CORD, V40, P300, DOI 10.1038/sj.sc.3101298; Borer DS, 2005, J ORTHOP TRAUMA, V19, P92, DOI 10.1097/00005131-200502000-00004; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GEERTS WH, 1999, THROMB HAEMOST S, V82, P650; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; HUK M, 1998, CRIT CARE MED S, V26, pA47; Imberti D, 2005, J THROMB HAEMOST, V3, P1370, DOI 10.1111/j.1538-7836.2005.01448.x; Kaufman JA, 2007, WORLD J SURG, V31, P251, DOI 10.1007/s00268-006-0292-1; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Rogers FB, 1998, ARCH SURG-CHICAGO, V133, P406, DOI 10.1001/archsurg.133.4.406; Rosenthal D, 2004, J VASC SURG, V40, P958, DOI 10.1016/j.jvs.2004.07.048; Schellong SM, 2007, J THROMB HAEMOST, V5, P1431, DOI 10.1111/j.1538-7836.2007.02570.x; Slavik RS, 2007, J TRAUMA, V62, P1075, DOI 10.1097/TA.0b013e31804fa177; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021	24	70	72	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2008	65	5					1021	1027		10.1097/TA.0b013e31818a0e74			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	372DD	WOS:000260881000010	19001969				2021-06-18	
J	Xiong, Y; Lu, DY; Qu, CS; Goussev, A; Schallert, T; Mahmood, A; Chopp, M				Xiong, Ye; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Schallert, Timothy; Mahmood, Asim; Chopp, Michael			Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice - Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						erythropoietin; mouse; sensorimotor function; spatial learning; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY PERFORMANCE; SUBVENTRICULAR ZONE; NEURONAL APOPTOSIS; MITOCHONDRIAL DYSFUNCTION; ENHANCES NEUROGENESIS; CEREBRAL-ISCHEMIA; PROTECTS NEURONS; RATS; HIPPOCAMPAL	Object. This study was designed to investigate the beneficial effects of recombinant human erythropoietin (rhEPO) treatment of traumatic brain injury (TBI) in mice. Methods. Adult male C57BL/6 mice were divided into 3 groups: 1) the saline group (TBI and saline [13 mice]); 2) EPO group (TBI and rhEPO [12]); and 3) sham group (sham and rhEPO [8]). Traumatic brain injury was induced by controlled cortical impact. Bromodeoxyuridine (100 mg/kg) was injected daily for 10 days, starting 1 day after injury, for labeling proliferating cells. Recombinant human erythropoietin was administered intraperitoneally at 6 hours and at 3 and 7 days post-TBI (5000 U/kg body weight, total dosage 15,000 U/kg). Neurological function was assessed using the Morris water maze and footfault tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemical evaluation. Results. Traumatic brain injury caused tissue loss in the cortex and cell loss in the dentate gyrus (DG) as well as impairment of sensorimotor function (footfault testing) and spatial teaming (Morris water maze). Traumatic brain injury alone stimulated cell proliferation and angiogenesis. Compared with saline treatment, rhEPO significantly reduced lesion Volume in the cortex and cell loss in the DG after TBI and substantially improved recovery of sensorimotor function and spatial learning performance. It enhanced neurogenesis in the injured cortex and the DG. Conclusions. Recombinant human erythropoietin initiated 6 hours post-TBI provided neuroprotection by decreasing lesion volume and cell loss as well as neurorestoration by enhancing neurogenesis, subsequently improving sensorimotor and spatial learning function. It is a promising neuroprotective and neurorestorative agent for TBI and warrants further investigation.	[Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Xiong, Ye; Qu, Changsheng; Goussev, Anton; Mahmood, Asim] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Lu, Dunyue] SUNY Brooklyn, Dept Psychiat, Brooklyn, NY USA	Chopp, M (corresponding author), Henry Ford Hlth Syst, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS52280, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280, P01NS042345] Funding Source: NIH RePORTER	Support for this research was provided by NINDS grants R01 NS52280 (D.L.) and P01 NS42345 (A.M. and M.C.).	Arlotta P, 2003, EXP GERONTOL, V38, P173, DOI 10.1016/S0531-5565(02)00156-0; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Magavi SS, 2000, NATURE, V405, P951; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757	72	70	76	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2008	109	3					510	521		10.3171/JNS/2008/109/9/0510			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	344CX	WOS:000258904400024	18759585	Green Accepted			2021-06-18	
J	Maikos, JT; Qian, Z; Metaxas, D; Shreiber, DI				Maikos, Jason T.; Qian, Zhen; Metaxas, Dimitris; Shreiber, David I.			Finite element analysis of spinal cord injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						biomechanics; finite element analysis; spinal cord injury	MECHANICAL-PROPERTIES; BRAIN-INJURY; LARGE-DEFORMATION; WHITE-MATTER; GRAY-MATTER; IN-VITRO; TISSUE; BARRIER; TRAUMA; IMPACT	A three-dimensional (3D) finite element model (FEM) that simulates the Impactor weight-drop experimental model of traumatic spinal cord injury (SCI) was developed. The model consists of the rat spinal cord, with distinct element sets for the gray and white matter, the cerebrospinal fluid (CSF), the dura mater, a rigid rat spinal column, and a rigid impactor. Loading conditions were taken from the average impact velocities determined from previous parallel weight-drop experiments employing a 2.5-mm-diameter, 10-g rod dropped from either 12.5 or 25 mm. The mechanical properties were calibrated by comparing the predicted displacement of the spinal cord at the impact site to that measured experimentally. Parametric studies were performed to determine the sensitivity of the model to the relevant material properties, loading conditions, and essential boundary conditions, and it was determined that the shear modulus had the greatest influence on spinal cord displacement. Additional simulations were performed where gray and white matter were prescribed different material properties. These simulations generated similar drop trajectories to the homogeneous model, but the stress and strain distributions better matched patterns of acute albumin extravasation across the blood-spinal cord barrier following weight-drop SCI, as judged by a logit analysis. A final simulation was performed where the impact site was shifted laterally by 0.35 mm. The off-center impact had little effect on the rod trajectory, but caused marked shifts in the location of stress and strain contours. Different combinations of parameter values could reproduce the impactor trajectory, which suggests that another experimental measure of the tissue response is required for validation. The FEM can be a valuable tool for understanding the injury biomechanics associated with experimental SCI to identify areas for improvement in animal models and future research to identify thresholds for injury.	[Maikos, Jason T.; Qian, Zhen; Shreiber, David I.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Metaxas, Dimitris] Rutgers State Univ, Dept Comp Sci, Piscataway, NJ 08854 USA	Shreiber, DI (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	shreiber@rci.rutgers.edu		Shreiber, David/0000-0001-8248-419X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR 221744-01] Funding Source: Medline		Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Bilston LE, 1996, ANN BIOMED ENG, V24, P67; BILSTON LE, 1998, INT IRCOBI C BIOM IM; Blight A, 1988, J Am Paraplegia Soc, V11, P26; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Cusick JF, 2002, CLIN BIOMECH, V17, P1, DOI 10.1016/S0268-0033(01)00101-2; Fiford RJ, 2005, J BIOMECH, V38, P1509, DOI 10.1016/j.jbiomech.2004.07.009; Fung Y., 1993, BIOMECHANICS MECH PR; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; HUNG T-K, 1975, Surgical Neurology, V4, P271; Ichihara K, 2003, J NEUROSURG, V99, P278, DOI 10.3171/spi.2003.99.3.0278; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Jin Xin, 2006, Stapp Car Crash J, V50, P637; KEARNEY P A, 1988, Journal of Neurotrauma, V5, P187, DOI 10.1089/neu.1988.5.187; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; KOENIG G, 1977, J NEUROL NEUROSUR PS, V40, P1203, DOI 10.1136/jnnp.40.12.1203; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Maikos JT, 2007, J NEUROTRAUM, V24, P492, DOI 10.1089/neu.2006.0149; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Noble LJ, 1996, J COMP NEUROL, V376, P542; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Scifert Jeffrey, 2002, Pain Physician, V5, P394; SHREIBER D, 1997, J PASSENGERS CARS, V106, P3792; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; Wilcox RK, 2004, EUR SPINE J, V13, P481, DOI 10.1007/s00586-003-0625-9; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; YOGANANDAN N, 1994, J SPINAL DISORD, V7, P420; Young W, 2002, PROG BRAIN RES, V137, P231; Zarzur E, 1996, ARQ NEURO-PSIQUIAT, V54, P455, DOI 10.1590/S0004-282X1996000300015; Zhu Q, 2006, DEV NEUROSCI-BASEL, V28, P388, DOI 10.1159/000094165	47	70	73	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					795	816		10.1089/neu.2007.0423			22	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000007	18627257				2021-06-18	
J	Hanna, WC; Ferri, LE; Fata, P; Razek, T; Mulder, DS				Hanna, Waeel C.; Ferri, Lorenzo E.; Fata, Paola; Razek, Tarek; Mulder, David S.			The current status of traumatic Diaphragmatic injury: Lessons learned from 105 patients over 13 years	ANNALS OF THORACIC SURGERY			English	Article							THORACOABDOMINAL TRAUMA; PENETRATING INJURIES; BLUNT TRAUMA; RUPTURE; HERNIA	Background. Our understanding of traumatic diaphragmatic injury (TDI) is based primarily on outdated retrospective series. We sought to reexamine present day patterns of diagnosis, associated injuries, predictors of mortality, and long-term outcomes of this condition. Methods. A prospectively entered trauma database from the Montreal General Hospital was reviewed for patients admitted with a TDI from 1993 to 2006. Hospital charts were reviewed, and patient characteristics, mechanism of injury, associated injuries, operative management, and postoperative outcomes were recorded. Logistic regression was used to identify predictors for mortality. Results. Identified were 105 patients with TDI consisting of blunt in 37% and penetrating in 63%. Only 23% of TDI were diagnosed on initial chest roentgenogram. External wounds in penetrating TDI cases were found in the abdomen alone in 19%, in the chest alone in 46%, and in both in 35%, which was associated with intraabdominal organ injury in 83%, 55%, and 87%, respectively. Less than half of patients had a diaphragmatic hernia. Lung, chest wall, and thoracic organ injuries were more common in blunt trauma, but there was no significant difference between abdominal injuries in both mechanisms. Overall mortality from TDI was 18%, and there was no difference between blunt and penetrating injury. In blunt trauma, brain injury and an Injury Severity Score (ISS) exceeding 15 were independently associated with increased death. In penetrating trauma, only an ISS exceeding 15 predicted death. Conclusions. Traumatic diaphragmatic injury remains a challenge to diagnose and treat, primarily due to the presence of associated injuries. The high incidence of intraabdominal organ injury, irrespective of the site of penetrating wound, dictates a transabdominal approach for exploration and repair. Severity of associated injuries (ISS) predicts death.	[Ferri, Lorenzo E.] McGill Univ, Montreal Gen Hosp, Ctr Hlth, Div Thorac Surg, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Div Trauma, Montreal, PQ, Canada	Ferri, LE (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Hlth, Div Thorac Surg, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	lorenzo.ferri@muhc.mcgill.ca	Hanna, Wael/AAQ-4976-2021				BEAUCHAMP G, 1984, AM J SURG, V148, P292, DOI 10.1016/0002-9610(84)90240-X; BROOS PLO, 1989, INT SURG, V74, P88; DEMETRIADES D, 1988, BRIT J SURG, V75, P824, DOI 10.1002/bjs.1800750834; EPSTEIN LI, 1968, J TRAUM, V8, P19, DOI 10.1097/00005373-196801000-00003; GRIMES OF, 1974, AM J SURG, V128, P175; Murray JA, 1997, J TRAUMA, V43, P624, DOI 10.1097/00005373-199710000-00010; Murray JA, 1998, J AM COLL SURGEONS, V187, P626, DOI 10.1016/S1072-7515(98)00246-4; OCHSNER MG, 1993, J TRAUMA, V34, P704, DOI 10.1097/00005373-199305000-00013; PAYNE JH, 1982, ARCH SURG-CHICAGO, V117, P18; RODRIGUEZMORALES G, 1986, J TRAUMA, V26, P438, DOI 10.1097/00005373-198605000-00005; Rubikas R, 2001, EUR J CARDIO-THORAC, V20, P53, DOI 10.1016/S1010-7940(01)00753-9; SHAH R, 1995, ANN THORAC SURG, V60, P1444, DOI 10.1016/0003-4975(95)00629-Y; WALDSCHMIDT ML, 1980, J TRAUMA, V20, P587; WARD RE, 1981, J TRAUMA, V21, P35, DOI 10.1097/00005373-198101000-00006	14	70	76	3	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	MAR	2008	85	3					1044	1048		10.1016/j.athoracsur.2007.10.084			5	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	266MZ	WOS:000253441500036	18291194				2021-06-18	
J	Wood, RL; Williams, C				Wood, Rodger Ll.; Williams, Claire			Inability to empathize following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						empathy; emotion; TBI; affective disorder; neuropsychological tests; cognitive flexibility	ECOLOGICAL VALIDITY; EXECUTIVE TESTS; RECOGNITION; IMPAIRMENT; INVENTORY; EMOTION; ABILITY; LESIONS	This study examines: (a) the impact of traumatic brain injury (TBI) on emotional empathy, (b) the relationship between emotional empathy and neuropsychological ability, and (c) the influence of low emotional empathy on measures of affect. Eighty-nine patients completed the Balanced Emotional Empathy Scale (BEES), a number of neuropsychological tests, some of which were ecologically valid tests of executive ability, plus two measures of affect, the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI). The TBI cohort showed a high frequency (60.7%) of low emotional empathy scores compared to the control group (31%). There was no relationship between injury severity and the ability to empathize, or between emotional empathy and neuropsychological performance. There was no evidence to suggest that low scores on affective measures influenced emotional empathy scores. A high proportion of TBI patients lack the ability to empathize, but the deficit does not appear related to any specific cognitive impairment and cannot be predicted by measures of affect.	[Wood, Rodger Ll.; Williams, Claire] Swansea Univ, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Swansea, W Glam, Wales	Wood, RL (corresponding author), Univ Wales Swansea, Sch Human Sci, Dept Psychol, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X			Baron-Cohen S., 1995, MIND BLINDNESS ESSAY; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BISHARA SN, 1992, BRAIN INJURY, V3, P373; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; CICERONE KD, 1983, NEUROPSYCHOLOGIA, V21, P513, DOI 10.1016/0028-3932(83)90007-6; Danziger N, 2006, BRAIN, V129, P2494, DOI 10.1093/brain/awl155; DAVIS JM, 1980, AM J NEURORADIOL, V1, P17; ENDBERG AW, 2004, BRAIN INJURY, V18, P533; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; GRATTAN LM, 1994, NEUROPSY NEUROPSY BE, V7, P251; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Mehrabian A, 1997, AGGRESSIVE BEHAV, V23, P433, DOI 10.1002/(SICI)1098-2337(1997)23:6<433::AID-AB3>3.0.CO;2-H; Mehrabian A, 2000, GENET SOC GEN PSYCH, V126, P133; Mehrabian A., 2000, MANUAL BALANCED EMOT; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; ODDY M, 2003, HDB NEUROLOGICAL REH; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Shallice, 1997, HAYLING BRIXTON TEST; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Wilson BA, 1996, BEHAV ASSESSMENT DYS; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2001, BRAIN DAM B, P3; WOOD RL, 2006, BRAIN INJURY, V20, P1; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P90, DOI 10.1017/S1355617707070129; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	36	70	70	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2008	14	2					289	296		10.1017/S1355617708080326			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	338VJ	WOS:000258537200011	18282326	Bronze			2021-06-18	
J	Andelic, N; Sigurdardottir, S; Brunborg, C; Roe, C				Andelic, Nada; Sigurdardottir, Solrun; Brunborg, Cathrine; Roe, Cecilie			Incidence of hospital-treated traumatic brain injury in the Oslo population	NEUROEPIDEMIOLOGY			English	Article						traumatic brain injury; epidemiology; incidence; case fatality rate	HEAD-INJURY; EPIDEMIOLOGY; MANAGEMENT; NORWAY; MILD; REHABILITATION; MORTALITY; IMPACT	Background: The aim of this prospective, population-based study is to present the incidence of hospital-treated traumatic brain injury (TBI) in Oslo, Norway, and to describe the severity of brain injuries and outcome of the patients' acute medical care. Methods: Data were obtained from hospital admission registers and medical records from May 2005 to May 2006. The initial severity of TBI was measured by the Glasgow Coma Scale. The region is urban with a population of 534,129. Results: The 445 patients identified represent an annual incidence of 83.3/100,000. The median age was 29 years. The male: female ratio was 1.8:1.0. The highest incidence of TBI hospitalizations was found in the elderly males and the youngest children. The most common causes of TBI were falls (51%) and transport accidents (29.7%). Intracranial lesions were found more often in the elderly. The case fatality rate was 2.0/100 hospitalized patients and was highest in the elderly. Conclusions: The incidence of hospital-treated TBI in this study is considerably lower than that found in previous studies from Norway and Scandinavia. Despite the apparent decline in TBI hospitalization rates, our findings should also draw attention to the need for more effective preventive programmes related to falls. Studies that assess long-term consequences of TBI in elderly patients are also needed. Copyright (C) 2008 S. Karger AG, Basel.	[Andelic, Nada; Roe, Cecilie] Ullevaal Univ Hosp, Dept Phys Med & Rehabil, NO-0407 Oslo, Norway; [Brunborg, Cathrine] Ullevaal Univ Hosp, Clin Res Ctr, NO-0407 Oslo, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Nesoddtangen, Norway	Andelic, N (corresponding author), Ullevaal Univ Hosp, Dept Phys Med & Rehabil, NO-0407 Oslo, Norway.	nada.andelic@ulleval.no		Andelic, Nada/0000-0002-3719-4406			Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P199; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kelly DF, 2001, WORLD J SURG, V25, P1179; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; *NORW PUBL ROAD AD, KEY FIG ANN REP 2005; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Stella J, 2001, ANZ J SURG, V71, P665, DOI 10.1046/j.1445-1433.2001.02229.x; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Tieves Kelly S, 2005, WMJ, V104, P22; Tieves KS, 2005, WMJ, V104, P54; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 2005, NORWEGIAN SAFETY FOR; 2006, MMWR MORB MORTAL WKL, V55, P201	32	70	70	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350			NEUROEPIDEMIOLOGY	Neuroepidemiology		2008	30	2					120	128		10.1159/000120025			9	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	280HV	WOS:000254417700008	18334828	Green Published, Bronze			2021-06-18	
J	Bornhofen, C; McDonald, S				Bornhofen, Cristina; McDonald, Skye			Treating deficits in emotion perception following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							FACIAL EXPRESSION; HEAD TRAUMA; SOCIAL-PERCEPTION; RECOGNITION; ADULTS; REHABILITATION; COMMUNICATION; IMPAIRMENTS; REMEDIATION; RECOVERY	The present research aimed to investigate whether social perception deficits commonly experienced in the adult traumatic brain injury (TBI) population can be successfully remediated through cognitive rehabilitation. Twelve outC, patient volunteers (11 male, 1 female; age range 20-57 years) with severe, chronic TBI (mean length of post-traumatic amnesia 121 days, range 58-210 days; mean months post-injury 93.58, range 17-207 months) participated in a randomised controlled trial. Participants were randomly allocated to treatment and waitlist control groups following assessment on a range of emotion perception and psychosocial measures. Treatment comprised 25 hours, across 8 weeks, of a programme specifically designed to address emotion perception which incorporated a variety of remediation techniques shown to be effective with the TBI population. Results indicated that participants significantly improved both in judging basic emotional stimuli when presented in a naturalistic format (i.e., video vignettes) and in making social inferences on the basis of speaker demeanour. This is the first known treatment study dealing with emotion perception deficits in individuals with TBI.	[Bornhofen, Cristina; McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bornhofen, C (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	cristinab@iinet.net.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			Bauminger N, 2002, J AUTISM DEV DISORD, V32, P283, DOI 10.1023/A:1016378718278; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BIRD K, 2001, PSY PROGRAM CONTRAST; BRAUNLINGMCMORROW D, 1986, J REHABIL, V52, P39; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cornelissen K, 2003, J COGNITIVE NEUROSCI, V15, P444, DOI 10.1162/089892903321593153; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Duchaine BC, 2003, PERCEPTION, V32, P827, DOI 10.1068/p5067; EKMAN P, 1994, PSYCHOL BULL, V115, P268, DOI 10.1037/0033-2909.115.2.268; EKMAN P, 1976, FUNDAMENTALS NONVERB; EKMAN P, 1975, UMASKING FACE; Ekman P., 2003, EMOTIONS REVEALED RE; Frommann N, 2003, PSYCHIAT RES, V117, P281, DOI 10.1016/S0165-1781(03)00039-8; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; GILES GM, 1988, BRAIN INJURY, V2, P101; Grattan LM, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P266; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grote I, 2003, J DEV PHYS DISABIL, V15, P281, DOI 10.1023/A:1026317815160; Hefter RL, 2005, NEUROLOGY, V65, P1620, DOI 10.1212/01.wnl.0000184498.16959.c0; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Hughes C, 1996, AM J MENT RETARD, V100, P565; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; Keane J, 2002, NEUROPSYCHOLOGIA, V40, P655, DOI 10.1016/S0028-3932(01)00156-7; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kern RS, 2003, PSYCHOL MED, V33, P433, DOI 10.1017/S0033291702007298; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; Ley P., 1972, QUANTITATIVE ASPECTS; LONGONI F, 2000, Z NEUROPSYCHOL, V11, P250, DOI DOI 10.1024//1016-264X.11.4.250; MCALPINE C, 1992, BEHAV MODIF, V16, P559, DOI 10.1177/01454455920164007; McCandliss BD, 2002, COGN AFFECT BEHAV NE, V2, P89, DOI 10.3758/CABN.2.2.89; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; MCDONALD S, IN PRESS DISABILITY; MCDONALD S, 2003, BRAIN IMPAIR, V4, P36, DOI DOI 10.1375/brim.4.1.36.27032; McKenzie K., 2000, BRIT J LEARN DISABIL, V28, P143; Mehrabian A, 1972, NONVERBAL COMMUNICAT; MEICHENBAUM D, 1973, BEHAV THER, V4, P515, DOI 10.1016/S0005-7894(73)80003-6; MEICHENBAUM D, 1974, PSYCHOTHER-THEOR RES, V11, P103, DOI 10.1037/h0086326; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MORRISON RL, 1981, BEHAV THER, V12, P69, DOI 10.1016/S0005-7894(81)80107-4; Mueser K. T., 1998, HDB SOCIAL FUNCTIONI, P79; O'Reilly MF, 2000, J VOCAT REHABIL, V14, P187; Penn DL, 2000, SCHIZOPHR RES, V46, P217, DOI 10.1016/S0920-9964(00)00005-0; PETERS RD, 1981, AM J MENT DEF, V85, P377; PETERSON L, 1988, MANUAL SOCIAL SKILLS; Pizzamiglio L, 1998, ARCH NEUROL-CHICAGO, V55, P561, DOI 10.1001/archneur.55.4.561; Pleger B, 2003, NEUROSCI LETT, V335, P192, DOI 10.1016/S0304-3940(02)01153-9; Polirstok SR, 2003, TOP LANG DISORD, V23, P146, DOI 10.1097/00011363-200304000-00007; Prigatano G. F., 2005, REHABILITATION TRAUM, P118; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Roudier M, 1998, J NEUROL SCI, V154, P151, DOI 10.1016/S0022-510X(97)00222-0; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spence S.H., 1995, SOCIAL SKILLS TRAINI; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE R, 2002, SYDNEY PSYCHOSOCIAL; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor I, 1997, J APPL BEHAV ANAL, V30, P43, DOI 10.1901/jaba.1997.30-43; Temple E, 2003, P NATL ACAD SCI USA, V100, P2860, DOI 10.1073/pnas.0030098100; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TROWER P, 1980, J CONSULT CLIN PSYCH, V48, P327, DOI 10.1037/0022-006X.48.3.327; van der Gaag M, 2002, SCHIZOPHRENIA BULL, V28, P167, DOI 10.1093/oxfordjournals.schbul.a006919; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winter J, 1999, INT J GERIATR PSYCH, V14, P987; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; YLVISAKER M, 1998, COLLABRATIVE BRAIN I	80	70	72	3	26	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	2008	18	1					22	44		10.1080/09602010601061213			23	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	249HD	WOS:000252218000002	17852760				2021-06-18	
J	Conklin, HM; Salorio, CF; Slomine, BS				Conklin, Heather M.; Salorio, Cynthia F.; Slomine, Beth S.			Working memory performance following paediatric traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; executive function; frontal-subcortical pathways; neurodevelopment; childhood	BEHAVIOR RATING INVENTORY; HUMAN FRONTAL-CORTEX; EXECUTIVE FUNCTION; ACADEMIC-PERFORMANCE; CHILDREN; ADOLESCENTS; RECOVERY; OUTCOMES; SKILLS; COMPREHENSION	Primary objective: The present study investigated working memory ability in children who sustained moderate-to-severe traumatic brain injuries in relation to pre-injury, injury-related and developmental factors. It was hypothesized that there would be a correlation between performance- and rater-based working memory measures; factors predictive of working memory impairment would include earlier age at injury, more severe injury, longer time since injury and poorer overall cognitive functioning; and working memory performance would be significantly impaired when compared to normative populations. Methods and procedures: Working memory was assessed in 62 children using a traditional performance measure (digit span backward) and parent report (Behaviour Rating Inventory of Executive Function (BRIEF)). Main outcomes and results: Contrary to prediction, there was no statistical association between performance- and rater-based measures of working memory. Regression analyses revealed injury severity, time-since-injury, overall cognitive ability and attention span were predictive of working memory performance. As a group, working memory was impaired relative to normative samples on both measures. Conclusions: Performance- and rater-based working memory measures, while not significantly correlated, are both sensitive to acquired cognitive dysfunction following paediatric traumatic brain injury. Demographic and clinical factors may be used to predict cognitive outcomes, educate caregivers and design clinical interventions.	[Conklin, Heather M.] St Jude Childrens Res Hosp, Div Behav Med, Memphis, TN 38105 USA; [Salorio, Cynthia F.; Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Salorio, Cynthia F.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA	Conklin, HM (corresponding author), St Jude Childrens Res Hosp, Div Behav Med, 332 N Lauderdale St, Memphis, TN 38105 USA.	heather.conklin@stjude.org	Conklin, Heather M/N-2696-2018				Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Ayr LK, 2005, J INT NEUROPSYCH SOC, V11, P249, DOI 10.1017/S1355617705050307; Baddeley A. D., 1986, WORKING MEMORY; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Conklin HM, 2007, DEV NEUROPSYCHOL, V31, P103, DOI 10.1207/s15326942dn3101_6; deJonge P, 1996, PERS INDIV DIFFER, V21, P1007, DOI 10.1016/S0191-8869(96)00161-4; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Giedd JN, 2004, ANN NY ACAD SCI, V1021, P77, DOI 10.1196/annals.1308.009; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.1111/j.1467-8624.1987.tb01404.x; GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hanten G, 2003, BRAIN INJURY, V17, P871, DOI 10.1080/02699050210147220; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Moran C, 2005, BRAIN INJURY, V19, P743, DOI 10.1080/02699050500110199; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; RUDEL RG, 1974, NEUROPSYCHOLOGIA, V12, P109, DOI 10.1016/0028-3932(74)90032-3; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; *SPSS INC, 2004, STAT PACK SOC SCI 13; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Verger K, 2000, BRAIN INJURY, V14, P495; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Warschausky S, 1996, ARCH CLIN NEUROPSYCH, V11, P147, DOI 10.1016/0887-6177(95)00004-6; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	73	70	70	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					847	857		10.1080/02699050802403565			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700004	18850343				2021-06-18	
J	Hart, T; Fann, JR; Novack, TA				Hart, Tessa; Fann, Jesse R.; Novack, Thomas A.			The dilemma of the control condition in experience-based cognitive and behavioural treatment research	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; INDUCED MOVEMENT THERAPY; CONTROLLED-TRIAL; REHABILITATION; INTERVENTIONS; PLACEBO; DEPRESSION; PSYCHOTHERAPY; APPROPRIATE; ALLIANCE	Rehabilitation using cognitive and behavioural treatment methods (i.e., experience-based interventions) faces particular challenges in improving its evidence base through rigorous studies such as randomised controlled trials (RCTs). Experience-based treatments are often complex, with multiple "active ingredients" that may be difficult to characterise. In addition to the difficulty in specifying treatment ingredients, experience-based rehabilitation researchers face challenges in designing or selecting appropriate control or comparison conditions to test the efficacy of complex treatments. Based on lessons learned in designing a cognitive-behavioural intervention for anger self-management for people with traumatic brain injury (TBI) for the National Institutes of Health (NIH)-funded TBI Clinical Trials Network, we review the advantages, disadvantages and applications of a variety of control conditions for experience-based interventions. We discuss controls in which active treatments are withheld (no-treatment controls, waitlist controls, and placebo-analogue designs); controls that involve comparison to naturally occurring or devised usual care treatments; and conditions that compare active treatments (dismantling designs, dose controls, and equivalence trials). Recommendations for selecting and developing control groups that maximise both equipoise and participant enrolment/retention are discussed.	[Hart, Tessa] Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; [Hart, Tessa] Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Novack, Thomas A.] Univ Alabama, Dept Rehabil Med, Birmingham, AL USA	Hart, T (corresponding author), Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD042738, R24 HD050836] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836, U01HD042738] Funding Source: NIH RePORTER		Barkauskas VH, 2005, WESTERN J NURS RES, V27, P346, DOI 10.1177/0193945904271446; Baskin TW, 2003, J CONSULT CLIN PSYCH, V71, P973, DOI 10.1037/0022-006X.71.6.973; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Benda M, 1999, VACUUM, V55, P171, DOI 10.1016/S0042-207X(99)00145-1; BORKOVEC TD, 1996, PSYCHOTHERAPY REHABI, V5, P14; BUTLER G, 1991, J CONSULT CLIN PSYCH, V59, P167, DOI 10.1037/0022-006X.59.1.167; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Carroll KM, 1997, J CONSULT CLIN PSYCH, V65, P510, DOI 10.1037/0022-006X.65.3.510; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DEFFENBACHER JL, 1992, J COUNS PSYCHOL, V39, P158, DOI 10.1037/0022-0167.39.2.158; DEVINE E, 2005, ISSUES CHALLENGES CO; Dijkers M, 2002, AM J PHYS MED REHAB, V81, P21, DOI 10.1097/00002060-200201000-00005; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; GESUGENS C, 2006, NEUROPSYCHOL REHABIL, V16, P213; Joyce AS, 2003, J CONSULT CLIN PSYCH, V71, P672, DOI 10.1037/0022-006X.71.4.672; Karlawish JHT, 1998, ARCH NEUROL-CHICAGO, V55, P1420, DOI 10.1001/archneur.55.11.1420; Kupfer DJ, 2002, JAMA-J AM MED ASSOC, V287, P1853, DOI 10.1001/jama.287.14.1853; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Miller SS, 2000, EMERG MED CLIN N AM, V18, P233, DOI 10.1016/S0733-8627(05)70120-6; Mohr DC, 2005, ARCH GEN PSYCHIAT, V62, P1007, DOI 10.1001/archpsyc.62.9.1007; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Olsen DP, 2000, J ADV NURS, V31, P267, DOI 10.1046/j.1365-2648.2000.01301.x; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pyne JM, 2005, PSYCHOL MED, V35, P839, DOI 10.1017/S0033291704003332; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Saks ER, 2002, ETHICS BEHAV, V12, P87, DOI 10.1207/S15327019EB1201_6; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Silverman HJ, 2004, CRIT CARE MED, V32, P852, DOI 10.1097/01.CCM.0000114814.62759.06; Smeets RJEM, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-5; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Sterr A, 2002, ARCH PHYS MED REHAB, V83, P1374, DOI 10.1053/apmr.2002.35108; Strasser DC, 2005, ARCH PHYS MED REHAB, V86, P403, DOI 10.1016/j.apmr.2004.04.046; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; Whitehead WE, 2004, GASTROENTEROLOGY, V126, pS159, DOI 10.1053/j.gastro.2003.10.038; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477	39	70	70	0	17	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	2008	18	1					1	21		10.1080/09602010601082359			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	249HD	WOS:000252218000001	17852761				2021-06-18	
J	Ietswaart, M; Milders, M; Crawford, JR; Currie, D; Scott, CL				Ietswaart, Magdalena; Milders, Maarten; Crawford, John R.; Currie, David; Scott, Clare L.			Longitudinal aspects of emotion recognition in patients with traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						brain damage; affect; facial expression; vocal prosody; recovery	CLOSED-HEAD INJURY; FACIAL EXPRESSIONS; PSYCHOSOCIAL ADJUSTMENT; IMPAIRED RECOGNITION; SOCIAL-BEHAVIOR; SCHIZOPHRENIA; DAMAGE; AMYGDALA; SYSTEMS; LESIONS	Changes in emotional and social behaviour are relatively common following traumatic brain injury (TBI). Impairments in recognising the emotional state of others may underlie some of the problems in social relationships that these patients experience. The few previous studies examining emotion recognition in TBI typically assessed patients once, long after the onset of brain injury, making it difficult to distinguish the direct effect of brain injury from the effects of environmental changes. This study examined 30 patients with TBI shortly after brain injury and 32 orthopaedic control patients on their recognition of emotions expressed in the face and the voice using discrimination and labelling tasks. These patients were followed up 1 year later to examine the longitudinal development of emotion recognition deficits. TBI patients were found to be impaired on emotion recognition compared to the control patients both early after injury and I year later. The fact that impairments in emotion recognition were evident early after TBI and no evidence of recovery over time was found, suggests a direct effect of brain injury. (C) 2007 Elsevier Ltd. All rights reserved.	[Ietswaart, Magdalena] Northumbria Univ, Sch Psychol & Sport Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England; [Milders, Maarten; Crawford, John R.; Scott, Clare L.] Univ Aberdeen, Sch Psychol, Aberdeen AB9 1FX, Scotland; [Currie, David] Grampian Univ Hosp Trust, Dept Neurosurg, Aberdeen, Scotland	Ietswaart, M (corresponding author), Northumbria Univ, Sch Psychol & Sport Sci, Northumberland Bldg, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.	magdalena.ietswaart@unn.ac.uk	Milders, Maarten/C-5560-2008; Crawford, John R/A-4165-2008	Crawford, John R/0000-0003-3403-3428; Ietswaart, Magdalena/0000-0003-4576-9393	Chief Scientist Office [CZH/4/14] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Adolphs R, 2002, EMOTION, V2, P23, DOI 10.1037/1528-3542.2.1.23; Benton A. L., 1983, FACIAL RECOGNITION S; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Bowers D., 1991, FLORIDA AFFECT BATTE; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Ekman P., 1976, PICTURE FACIAL AFFEC; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hooker C, 2002, PSYCHIAT RES, V112, P41, DOI 10.1016/S0165-1781(02)00177-4; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kington JM, 2000, J PSYCHIAT RES, V34, P341, DOI 10.1016/S0022-3956(00)00029-7; LEVIDOW L, 1992, MICROBIAL RELEASES, V1, P55; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; Mueser KT, 1996, J ABNORM PSYCHOL, V105, P271, DOI 10.1037/0021-843X.105.2.271; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Shallice, 1997, HAYLING BRIXTON TEST; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1998, MANUAL WECHSLER ADUL; Weniger G, 2002, CEREB CORTEX, V12, P258, DOI 10.1093/cercor/12.3.258; Wilson, 1991, NATL ADULT READING T; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	70	71	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2008	46	1					148	159		10.1016/j.neuropsychologia.2007.08.002			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	265ME	WOS:000253362300015	17915263				2021-06-18	
J	Lefebvre, H; Cloutier, G; Levert, MJ				Lefebvre, Helene; Cloutier, Genevieve; Levert, Marie Josee			Perspectives of survivors of traumatic brain injury and their caregivers on long-term social integration	BRAIN INJURY			English	Article						brain injuries; community reintegration; qualitative research; psychosocial aspects of illness	COMMUNITY INTEGRATION	Background: Traumatic brain injury (TBI) has damaging impacts on victims and family members' lives and their long-term social integration constitutes a major challenge. Purpose: The objective of the study was to document the repercussions of TBI on victims' long-term social integration (10 years post-trauma) and the contribution made by the services received from the point of view of TBI victims and family caregivers. This article examines the determinants of long-term social integration as well as the impact of TBI on family caregivers. Methods: A qualitative design was used (semi-directed interviews). The sample consisted of 22 individuals who had sustained a moderate or severe TBI and 21 family caregivers. Results: The results show that TBI is an experience that continues to present difficulties, even 10 years after the accident, and that different barriers contribute to this difficulty: not going back to work, depressive episodes, problems in relationships and sequellae. Family caregivers must help TBI victims confront the barriers in their path. Implications: This study adopts a longitudinal perspective to help professionals determine how to intervene with TBI victims and their families. It validates the importance of having clients and family caregivers describe their reality.	[Lefebvre, Helene] Univ Montreal, Fac Nursing, Lucie Bruneau Rehabil Ctr, Res Dept, Montreal, PQ H2H 2N8, Canada	Lefebvre, H (corresponding author), Univ Montreal, Fac Nursing, Lucie Bruneau Rehabil Ctr, Res Dept, 2275 Laurier St E, Montreal, PQ H2H 2N8, Canada.	helene.lefebvre@umontreal.ca					ANGUS DE, 1999, EC BURDEN UNINTENTIO; CARRIER S, 2003, CAN J PSYCHOL, V31, P339; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DUMONT C, 2003, THESIS U MONTREAL MO; Durgin CJ, 2000, J HEAD TRAUMA REHAB, V15, P1195, DOI 10.1097/00001199-200012000-00002; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; FAWCETT G, 2004, MESURES SERVICES SOU; FOUGEYROLLAS P, 2001, CAHIERS MEDICAUX SOC, P101; FOUGEYROLLAS P, 1997, RESEAU INT CIDIH, V9, P6; GADOURY M, 1999, CADRE REFERENCE CLIN; Guba E.G., 1989, 4 GENERATION EVALUAT; HABERMAS J, 1987, THEORIE AGIR COMMUNI, V1, P448; Jillings C., 2001, METASTUDY QUALITATIV; Kaufman SR, 1994, QUALITATIVE METHODS, P123; Kendall E, 2000, DISABIL REHABIL, V22, P435, DOI 10.1080/09638280050045901; Lapierre A., 1997, RECHERCHE QUALITATIV, p309 ; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Lefebvre H, 2004, PARTICIPATION SOCIAL; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1053/apmr.2000.5567; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Miczo N, 2003, QUAL HEALTH RES, V13, P469, DOI 10.1177/1049732302250756; Minnes P, 2001, NEUROREHABILITATION, V16, P3; *MSSS, 2004, POUR VER PART COMM O; NOLTE M, 2000, DISS ABSTR INT B, V60, P4900; *OPHQ, 1999, QUEB INT SOC PERS HA; POUPART J., 1997, RECHERCHE QUALITATIV, P173; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; VANIER M, 1992, SYSTEME EVALUATION G; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004	31	70	70	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					535	543		10.1080/02699050802158243			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300004	18568706				2021-06-18	
J	Mbye, LH; Singh, IN; Sullivan, PG; Springer, JE; Hall, ED				Mbye, L. H.; Singh, I. N.; Sullivan, P. G.; Springer, J. E.; Hall, E. D.			Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog	EXPERIMENTAL NEUROLOGY			English	Article						cyclosporin A; mitochondrial permeability transition; NIM811; oxidative damage; respiratory control ratio; traumatic brain injury	PERMEABILITY TRANSITION; CELL-DEATH; NITRIC-OXIDE; LIPID-PEROXIDATION; OXIDATIVE STRESS; DAMAGE; NEUROPROTECTION; INHIBITION; RATS; AMELIORATION	Following traumatic brain injury (TBI), mitochondrial function becomes compromised. Mitochondrial dysfunction is characterized by intra-mitochondrial Ca2+ accumulation, induction of oxidative damage, and mitochondrial permeability transition (mPT). Experimental studies show that cyclosporin A (CsA) inhibits mPT. However, CsA also inhibits calcineurin. In the present study, we conducted a dose-response analysis of NIM811, a non-calcineurin inhibitory CsA analog, on mitochondrial dysfunction following TBI in mice, and compared the effects of the optimal dose of NIM811 (10 mg/kg i.p.) against an optimized dose of CsA (20 mg/kg i.p.). Male CF-1 mice were subjected to severe TBI utilizing the controlled cortical impact model. Mitochondrial respiration was assessed from animals treated with either NIM811, CsA, or vehicle 15 min post-injury. The respiratory control ratio (RCR) of mitochondria from vehicle-treated animals was significantly (p < 0.01) lower at 3 or 12 h post-TBI, relative to shams. Treatment of animals with either NIM811 or CsA significantly (p < 0.03) attenuated this reduction. Consistent with this finding, both NIM811 and CsA significantly reduced lipid peroxidative and protein nitrative damage to mitochondria at 12 h post-TBI. These results showing the ability of NIM811 to fully duplicate the mitochondrial protective efficacy of CsA supports the conclusion that inhibition of the mPT may be sufficient to explain CsA's protective effects. (C) 2007 Elsevier Inc. All rights reserved.	[Mbye, L. H.; Singh, I. N.; Sullivan, P. G.; Springer, J. E.; Hall, E. D.] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,Room B383 BBSRB, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013; springer, joe/B-2581-2014	springer, joe/0000-0001-9611-8107	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS46566, NS048191] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, R01NS046566] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; FLOYD RA, 1992, ANN NEUROL, V32, P22; Fonagy A, 1999, COMP BIOCHEM PHYS B, V124, P51, DOI 10.1016/S0305-0491(99)00096-6; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Friberg H, 1998, J NEUROSCI, V18, P5151; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; HALL ED, 1993, RES P ARNMD, V71, P81; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; HALLIWELL B, 1993, AM J CLIN NUTR, V57, pS724; Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S, DOI 10.1093/ajcn/57.5.715S; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Jiang H H, 2001, Sheng Li Ke Xue Jin Zhan, V32, P359; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 2006, J NEUROSCI METH, V152, P136, DOI 10.1016/j.jneumeth.2005.08.018; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Muramoto M, 2003, NEUROPHARMACOLOGY, V45, P394, DOI 10.1016/S0028-3908(03)00168-0; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	48	70	73	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2008	209	1					243	253		10.1016/j.expneurol.2007.09.025			11	Neurosciences	Neurosciences & Neurology	253EG	WOS:000252500900030	18022160				2021-06-18	
J	Han, SD; Drake, AI; Cessante, LM; Jak, AJ; Houston, WS; Delis, DC; Filoteo, JV; Bondi, MW				Han, S. Duke; Drake, Angela I.; Cessante, Lynne M.; Jak, Amy J.; Houston, Wes S.; Delis, Dean C.; Filoteo, J. Vincent; Bondi, Mark W.			Apolipoprotein E and traumatic brain injury in a military population: evidence of a neuropsychological compensatory mechanism?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEAD-INJURY; ALZHEIMERS-DISEASE; APOE GENOTYPE; EPSILON 4; E POLYMORPHISM; FMRI EVIDENCE; GENETIC RISK; OLDER-ADULTS; ASSOCIATION; DEPOSITION	Objective: Although research has implicated the apolipoprotein E ( APOE) epsilon- 4 genotype as having a negative effect on neuropsychological outcomes following traumatic brain injury ( TBI), the potentially negative role of the epsilon 4 allele on TBI outcomes has recently been challenged. In light of this debate, the present study served to examine the role of APOE genotype on neuropsychological outcomes approximately 1 month following mild to moderate TBI in a military population. Because of the well documented role of the APOE- epsilon 4 allele in increasing the risk of Alzheimer's disease, we predicted that persons with the APOE- epsilon 4 genotype would display relatively greater deficits in cognition than their non- epsilon 4 counterparts. Methods: 78 participants were consecutively recruited following a mild to moderate TBI and were divided into two groups based on the presence or absence of an APOE epsilon 4 allele. Groups were comparable on demographic characteristics and psychosocial outcomes. Participants were administered a comprehensive neuropsychological battery. Results: Analyses revealed comparable performances on most neuropsychological measures and better performances by epsilon 4 carriers on select measures of attention, executive functioning and episodic memory encoding. Furthermore, differences remained after accounting for the effects of TBI severity. Conclusions: Evidence from these analyses supports current literature refuting the notion of relatively poorer neuropsychological functioning associated with the APOE- epsilon 4 genotype among young adult participants shortly following mild or moderate brain injury. Neuropsychological performance differences by APOE genotype following TBI are discussed in terms of the importance of considering severity of injury, timing of postinjury assessment and possible neurocognitive compensatory mechanisms.	VA San Diego Hlthcare Syst, San Diego, CA 92161 USA	Bondi, MW (corresponding author), VA San Diego Hlthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	mbondi@ucsd.edu	Han/N-1246-2019				Arendt T, 1997, J NEUROSCI, V17, P516; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Beffert U, 1996, ANN NY ACAD SCI, V777, P166, DOI 10.1111/j.1749-6632.1996.tb34415.x; Bondi MW, 2005, NEUROLOGY, V64, P501, DOI 10.1212/01.WNL.0000150885.00929.7E; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; BROOKS D N, 1975, Cortex, V11, P329; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; GRONWALL D, 1975, LANCET, V2, P995; Han SD, 2007, NEUROBIOL AGING, V28, P238, DOI 10.1016/j.neurobiolaging.2005.12.013; Hubacek JA, 2001, NEUROPSYCHOBIOLOGY, V43, P200, DOI 10.1159/000054890; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Katzman R, 1996, NEUROLOGY, V46, P889; KELTIKANGASJARVINEN L, 1993, PSYCHOSOM MED, V55, P155, DOI 10.1097/00006842-199303000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Livingston M G, 1985, Int Rehabil Med, V7, P145; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; NAGY Z, 1995, NEUROSCIENCE, V69, P757, DOI 10.1016/0306-4522(95)00331-C; Nicoll J. A. R., 1995, Neuropathology and Applied Neurobiology, V21, P10; Nicoll J. A. R., 1995, Journal of Neurotrauma, V12, P434; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Papassotiropoulos A, 2004, NEUROBIOL AGING, V25, pS490, DOI 10.1016/S0197-4580(04)81619-1; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Scarmeas N, 2005, J NEUROL NEUROSUR PS, V76, P1440, DOI 10.1136/jnnp.2004.053645; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999	48	70	72	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2007	78	10					1103	1108		10.1136/jnnp.2006.108183			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	211LB	WOS:000249524200016	17287237	Green Published			2021-06-18	
J	Rabinstein, AA				Rabinstein, Alejandro A.			Paroxysmal sympathetic hyperactivity in the neurological intensive care unit	NEUROLOGICAL RESEARCH			English	Article						sympathetic hyperactivity; fever; neurological-neurosurgical ICU; causes; predictors	TRAUMATIC BRAIN-INJURY; AUTONOMIC INSTABILITY; DIENCEPHALIC SEIZURES; DYSAUTONOMIA; STORM	Objective: To assess the incidence and associations of paroxysmal sympathetic hyperactivity (PSH) among febrile patients in the neurological intensive care unit (NICU). Methods: Prospective data collection of consecutive patients admitted to an academic NICU for >48 hours. Fever was defined as body temperature >38.3 degrees C (101.0 degrees F) on at least one measurement for two consecutive days. PSH was defined by the transient presence of four of the following six criteria: fever, tachycardia, hypertension, tachypnea, excessive diaphoresis and extensor posturing or severe dystonia in the absence of other potential causes for these clinical signs. Methods: Ninety-three patients were included. Traumatic brain injury (TBI) was the primary diagnosis in 43 patients (46%). PSH were diagnosed in 17 patients (18%). It occurred in 14/43 patients (33%) with TBI but only 3/50 patients (6%) with other primary disorders (p = 0.01). Patients with PSH were younger (mean age: 35 +/- 14 versus 51 +/- 18 years old in the rest of the population) (p = 0.01), although the difference did not reach statistical significance when only TBI patients were included in the analysis (mean age: 35 +/- 15 years old in TBI patients with PSH versus 46 +/- 19 years old in TBI patients without PSH; p = 0.07). Duration of fever in patients with PSH (mean: 10.5 +/- 7 days; median: 9 days) was significantly longer than in the rest of the population ( mean: 5.1 +/- 3 days) ( p<0.001); the difference remained significant when the analysis was restricted to TBI patients (p = 0.001). Conclusion: Episodes of PSH occur in one- third of TBI patients but are rare in other acute neurological conditions. They are more frequent in younger patients and are associated with prolonged duration of fever.	Univ Miami, Sch Med, Jackson Mem Hosp, Neurosci Intens Care Unit, Miami, FL USA	Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu					Audibert G, 2006, TRANSPLANTATION, V82, P1031, DOI 10.1097/01.tp.0000235825.97538.d5; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Tong CY, 2000, ANESTH ANALG, V91, P1450, DOI 10.1097/00000539-200012000-00028	14	70	84	0	3	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	OCT	2007	29	7					680	682		10.1179/016164107X240071			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	234MJ	WOS:000251167900009	18173907				2021-06-18	
J	Kirshblum, SC; Priebe, MM; Ho, CH; Scelza, WM; Chiodo, AE; Wuermser, LA				Kirshblum, Steven C.; Priebe, Michael M.; Ho, Chester H.; Scelza, William M.; Chiodo, Anthony E.; Wuermser, Lisa-Ann			Spinal cord injury medicine. 3. Rehabilitation phase after acute spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						electric stimulation; gait; rehabilitation; spinal cord injuries	TRAUMATIC BRAIN-INJURY; AUTONOMIC DYSREFLEXIA; SUPPORTED TREADMILL; HEAD-INJURY; PREVENTION	This self-directed learning module highlights the rehabilitation aspects of care for people with traumatic spinal cord injury (SCI). It is part of the chapter on SCI medicine in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation. This article specifically focuses on the formulation of a rehabilitation plan based on functional goals by level of injury. Such a plan includes mobility, activities of daily living, equipment needs, and adjustment issues after injury. The effect of a concomitant brain injury on rehabilitation is discussed. Medical complications seen in the rehabilitation stage such as autonomic dysreflexia, heterotopic ossification, neurogenic bowel, and orthostasis are addressed. Preparation for discharge is crucial to allow for a smooth transition to home. There have been advances in SCI rehabilitation research including in wheelchair technology, functional electric stimulation, and partial body weight-supported ambulation. Overall Article Objective: To describe outcomes and issues that may arise during the rehabilitation phase after spinal cord injury.	Kessler Inst Rehab, Spinal Cord Injury Serv, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH USA; Case Western Reserve Univ, Dept Phys Med & Rehabil, Cleveland, OH 44106 USA; Carolinas Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; Univ Michigan Hosp, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA	Kirshblum, SC (corresponding author), Kessler Inst Rehab, Spinal Cord Injury Serv, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	skirshblum@kessler-rehab.com		Ho, Chester/0000-0002-4238-5506			Algood SD, 2005, ARCH PHYS MED REHAB, V86, P380, DOI 10.1016/j.apmr.2004.05.017; Barbeau H, 2003, NEUROREHAB NEURAL RE, V17, P3, DOI 10.1177/0888439002250442; Bogie KM, 2006, ARCH PHYS MED REHAB, V87, P585, DOI 10.1016/j.apmr.2005.11.020; Boninger ML, 2005, J REHABIL RES DEV, V42, P9, DOI 10.1682/JRRD.2004.08.0103; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DiMarco AF, 2006, AM J RESP CRIT CARE, V173, P1386, DOI 10.1164/rccm.200601-097CR; DiMarco AF, 2006, J SPINAL CORD MED, V29, P95, DOI 10.1080/10790268.2006.11753863; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dobkin BH, 1999, NEUROREHAB NEURAL RE, V13, P157, DOI 10.1177/154596839901300301; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Estrores IM, 2004, J SPINAL CORD MED, V27, P434, DOI 10.1080/10790268.2004.11752233; Field-Fote Edelle C, 2005, J Neurol Phys Ther, V29, P127; KIRSHBLUM S, 2002, SPINAL CORD MED, P275; Kirshblum SC, 2002, ARCH PHYS MED REHAB, V83, P1774, DOI 10.1053/apmr.2002.36070; LINDAN R, 1980, PARAPLEGIA, V18, P285, DOI 10.1038/sc.1980.51; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Massagli TL, 1999, ARCH PHYS MED REHAB, V80, P998, DOI 10.1016/S0003-9993(99)90050-3; Millis SR, 2004, J SPINAL CORD MED, V27, P428, DOI 10.1080/10790268.2004.11752232; *PAR VET AM, 1998, CONS SPIN CORD MED D; *PAR VET AM, 1997, CONS SPIN CORD MED A; *PAR VET AM, 1998, CONS SPIN CORD MED N; *PAR VET AM, 1999, CONS SPIN CORD MED O; PECKHAM PH, 2005, TOP SPINAL CORD INJ, V10, P126; Protas EJ, 2001, ARCH PHYS MED REHAB, V82, P825, DOI 10.1053/apmr.2001.23198; Rosito Olga, 2002, J Spinal Cord Med, V25, P174; Scivoletto G, 2005, ARCH PHYS MED REHAB, V86, P512, DOI 10.1016/j.apmr.2004.05.021; Singh RS, 2003, ARCH PHYS MED REHAB, V84, P1584, DOI 10.1053/S0003-9993(03)00347-2; Smith M, 2002, SPINAL CORD, V40, P11, DOI 10.1038/sj.sc.3101226; Sommer JL, 2004, BRAIN INJURY, V18, P1297, DOI 10.1080/02699050410001672288; Stiens SA, 1997, ARCH PHYS MED REHAB, V78, pS86, DOI 10.1016/S0003-9993(97)90416-0; Stiens SA, 1998, SPINAL CORD, V36, P777, DOI 10.1038/sj.sc.3100702; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; Sumida M, 2001, ARCH PHYS MED REHAB, V82, P391, DOI 10.1053/apmr.2001.19780; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Wernig A, 1998, SPINAL CORD, V36, P744, DOI 10.1038/sj.sc.3100670; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0	38	70	73	0	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2007	88	3		1			S62	S70		10.1016/j.apmr.2006.12.003			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	143FX	WOS:000244706500014	17321851				2021-06-18	
J	Beers, SR; Berger, RP; Adelson, PD				Beers, Sue R.; Berger, Rachel P.; Adelson, P. David			Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children	JOURNAL OF NEUROTRAUMA			English	Article						calcium binding protein; myelin-basic protein; neuron-specific enolase	NEURON-SPECIFIC ENOLASE; POST-CONCUSSION SYMPTOMS; SEVERE HEAD-INJURY; PROTEIN; S-100B; AGE; PREDICTOR; SEVERITY; DAMAGE; ABUSE	Traumatic brain injury (TBI) in infants and toddlers is frequently explained by child abuse. This study compared 6-month outcome in children with inflicted TBI (iTBI) or non-inflicted TBI (nTBI) who were injured before 3 years of age, and assessed the relationship between outcome and serum concentrations of neuron-specific enolase (NSE), S100B, and myelin-basic protein (MBP). Children with iTBI (n = 15) or nTBI (n = 15) of varying severity were assessed 6 months after injury using the Glasgow Outcome Scale (GOS), Vineland Adaptive Behavior Scale (VABS), and an intelligence quotient (IQ) measure. Serum concentrations of NSE, S100B, and MBP were measured soon after injury and every 12 h, for up to 5 days. Groups were matched by ethnicity, gender, socioeconomic status, and injury severity. Student's t-tests, analysis of covariance, or nonparametric tests assessed between-group differences for GOS, IQ, and biomarkers; correlation coefficients assessed relationships between outcome and biochemical markers. Functional and cognitive tests showed significant between-group differences (p <= 0.05); the iTBI group performed more poorly (GOS, 2.00 +/- 1.00 vs. 1.23 +/- 0.60; VABS, 95.92 +/- 14.05 vs. 115.80 +/- 20.02; IQ, 69.00 +/- 20.85 vs. 97.33 +/- 23.66). Significant between-group differences (iTBI vs. nTBI) were found for time to peak NSE (66.48 +/- 53.56 vs. 8.11 +/- 11.58), S100B (43.30 +/- 51.41 vs. 8.21 +/- 8.29), and MBP (77.66 +/- 56.77 vs. 21.63 +/- 28.39). Time to peak concentrations were significantly correlated with outcome measures. Children with iTBI are at risk for poorer outcome. Acute measurement of NSE, S100B, and MBP serum concentrations may provide a quantitative predictor of outcome after TBI in young children. Outcome may be due to the mechanism of iTBI, cumulative effects of unreported TBI, and/or other unidentified risk factors.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat Neurosurg, Pittsburgh, PA 15261 USA	Beers, SR (corresponding author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.	beerssr@upmc.edu	Adelson, David/W-2083-2019		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23 HD 43843-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 38448-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038448] Funding Source: NIH RePORTER		Alexander RC, 2001, CHILD ABUSE MED DIAG, P47; American College of Surgeons, 1997, ADV TRAUM LIF SUPP P; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; BARLOW L, 2004, PEDIAT REHABIL, V7, P195; BAYLEY N, 1993, BAYLEY SCALE INFANT; Beers SR, 2002, AM J PSYCHIAT, V159, P483, DOI 10.1176/appi.ajp.159.3.483; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Huck S. W., 1974, READING STAT RES; IRAZUZTA JE, 1997, CHILD ABUSE NEGL, V21, P69; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lange N, 1997, J R STAT SOC C-APPL, V46, P1, DOI 10.1111/1467-9876.00046; Langlois JA, 2001, TRAUMATIC BRAIN INJU; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; MARKOFF KL, 2003, DEV MED CHILD NEUROL, V45, P497; Perez-Arjona E, 2003, CHILD NERV SYST, V19, P69, DOI 10.1007/s00381-002-0686-9; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Soares HD, 2003, J NEUROTRAUM, V20, P1080; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; *SPSS INC, 1989, SPSS WIND 11 5 0; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; THOMAS DJ, 1984, J NEUROL NEUROSUR PS, V47, P421; Thorndike RL., 1986, STANFORD BINET INTEL, V4; Thurman DJ, 2001, HEAD TRAUMA, P327; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	45	70	70	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					97	105		10.1089/neu.2006.0055			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100009	17263673				2021-06-18	
J	Hardingham, GE				Hardingham, G. E.			Pro-survival signalling from the NMDA receptor	BIOCHEMICAL SOCIETY TRANSACTIONS			English	Article						apoptosis; calcium signalling; cAMP-response element (CRE)-binding protein (CREB); excitotoxicity; neuroprotection; N-methyl-D-aspartate receptor (NMDA receptor)	TRAUMATIC BRAIN-INJURY; NEURODEGENERATION; NEUROPROTECTION; PATHWAYS	Ca2+ influx through the NMDA (N-methyl-D-aspartate) subtype of ionotropic glutamate receptors plays a Jekyll and Hyde role in the mammalian central nervous system. While it mediates excitotoxic death triggered by stroke and other acute trauma, there is growing evidence that physiological levels of NMDA receptor activity promote survival. Understanding the mechanisms that underlie these opposing effects may lead to strategies to selectively block pro-death signalling, which could have considerable clinical benefits.	Univ Edinburgh, Ctr Neurosci Res, Edinburgh EH9 1QH, Midlothian, Scotland	Hardingham, GE (corresponding author), Univ Edinburgh, Ctr Neurosci Res, Summerhall Sq, Edinburgh EH9 1QH, Midlothian, Scotland.	Giles.Hardingham@ed.ac.uk		Hardingham, Giles/0000-0002-7629-5314	Wellcome TrustWellcome TrustEuropean Commission [078178] Funding Source: Medline		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stout AK, 1998, NAT NEUROSCI, V1, P366	14	70	72	0	3	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	0300-5127			BIOCHEM SOC T	Biochem. Soc. Trans.	NOV	2006	34		5				936	938		10.1042/BST0340936			3	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	109EE	WOS:000242289900065	17052231	Green Accepted			2021-06-18	
J	Morris, KP; Forsyth, RJ; Parslow, RC; Tasker, RC; Hawley, CA				Morris, Kevin P.; Forsyth, Robert J.; Parslow, Roger C.; Tasker, Robert C.; Hawley, Carol A.			Intracranial pressure complicating severe traumatic brain injury in children: monitoring and management	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; children; intensive care; intracranial pressure; treatment; monitoring	SEVERE HEAD-INJURY; CARE	Objective: To identify factors associated with the use of intracranial pressure (ICP) monitoring and to establish which ICP-targetted therapies are being used in children with severe traumatic brain injury (TBI) in the United Kingdom. To evaluate current practice against recently published guidelines. Design and setting: Prospective data collection of clinical and demographic information from paediatric and adult intensive care units in the UK and Ireland admitting children (< 16 years) with TBI between February 2001 and August 2003. Results: Detailed clinical information was obtained for 501 children, with information on the use of ICP monitoring available in 445. ICP monitoring was used in only 59% (75/127) of children presenting with an emergency room Glasgow Coma Scale of 8 or below. Large between centre variation was seen in the use of ICP monitoring, independent of severity of injury. There were 86 children who received ICP-targetted therapies without ICP monitoring. Wide between centre variation was found in the use of ICP-targetted therapies and in general aspects of management, such as fluid restriction, the use of muscle relaxants and prophylactic anticonvulsants. Intraventricular catheters are rarely placed (6% of cases); therefore cerebrospinal fluid drainage is seldom used as a first-line therapy for raised ICP. Jugular venous bulb oximetry (4%), brain microdialysis (< 1%) and brain tissue oxygen monitoring (< 1%) are rarely used in current practice. Contrary to published guidelines, moderate to severe hyperventilation is being used without monitoring for cerebral ischaemia. Conclusions: There is an urgent need for greater standardisation of practice across UK centres admitting children with severe TBI.	Diana Princess Wales Hosp, Birmingham BN 6NH, W Midlands, England; Royal Victoria Infirm, Sch Clin Med Sci, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 41P, Tyne & Wear, England; Univ Leeds, Ctr Biostat & Epidemiol, Leeds Inst Genet Hlth & Therapeut, Paediat Epidemiol Grp, Leeds LS2 9JT, W Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin, Cambridge CB2 2QQ, England; Univ Warwick, Sch Med, Div Hlth Community, Coventry CV4 7AL, W Midlands, England	Morris, KP (corresponding author), Diana Princess Wales Hosp, Steelhouse Lane, Birmingham BN 6NH, W Midlands, England.	kevin.morris@bch.nhs.uk	Forsyth, Rob/H-9193-2019; Hawley, Carol/AAG-3830-2019; Parslow, Roger/AAV-1477-2020; Tasker, Robert C/R-5837-2019	Forsyth, Rob/0000-0002-5657-4180; Parslow, Roger/0000-0002-3945-5294; Tasker, Robert/0000-0003-3647-8113			Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MENDELOW AD, 1983, J NEUROSURG, V58, P45, DOI 10.3171/jns.1983.58.1.0045; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Raabe A, 1998, NEUROSURGERY, V43, P306, DOI 10.1097/00006123-199808000-00073; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037	11	70	70	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	OCT	2006	32	10					1606	1612		10.1007/s00134-006-0285-4			7	Critical Care Medicine	General & Internal Medicine	089WF	WOS:000240911500022	16874495				2021-06-18	
J	Carpentier, A; Galanaud, D; Puybasset, L; Muller, JC; Lescot, T; Boch, AL; Riedl, V; Cornu, P; Coriat, P; Dormont, D; Van Effenterre, R				Carpentier, Alexandre; Galanaud, Damien; Puybasset, Louis; Muller, Jean-Charles; Lescot, Thomas; Boch, Anne-Laure; Riedl, Vincent; Cornu, Philippe; Coriat, Pierre; Dormont, Didier; Van Effenterre, Remy			Early morphologic and spectroscopic magnetic resonance in severe traumatic brain injuries can detect "invisible brain stem damage" and predict "vegetative states"	JOURNAL OF NEUROTRAUMA			English	Article						brain stem; diffuse axonal injury; Glasgow Outcome Scale; neurological outcome; spectroscopy; traumatic brain injury; vegetative states	PROTON MR SPECTROSCOPY; DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; COMA; RECOVERY; SCALE	A precise evaluation of the brain damage in the first days of severe traumatic brain injured (TBI) patients is still uncertain despite numerous available cerebral evaluation methods and imaging. In 5-10% of severe TBI patients, clinicians remain concerned with prolonged coma and long-term marked cognitive impairment unexplained by normal morphological T2 star, flair, and diffusion magnetic resonance imaging (MRI). For this reason, we prospectively assessed the potential value of magnetic resonance spectroscopy (MRS) of the brain stem to evaluate the functionality of the consciousness areas. Forty consecutive patients with severe TBI were included. Single voxel proton MRS or the brain stem and morphological MRI of the whole brain were performed at day 17.5 +/- 6.4. Disability Rating Scale and Glasgow Outcome Scale (GOS) were evaluated at 18 months post-trauma. MRS appeared to be a reliable tool in the exploration of brainstem metabolism in TBI. Three different spectra were observed (normal, cholinergic reaction, or neuronal damage) allowing an evaluation of functional damage. MRS disturbances were not correlated with anatomical MRI lesions suggesting that the two techniques are strongly complementarity. In two GOS 2 vegetative patients with normal morphological MRI, MRS detected severe functional damage of the brainstem (NAA/Cr < 1.50) that was described as "invisible brain stem damage." MRI and MRS taken separately could not distinguish patients GOS 3 (n = 7) from GOS 1-2 (n = 11) and GOS 4-5 (n = 20). However, a principal component analysis of combined MRI and MRS data enabled a clear-cut separation between GOS 1-2, GOS 3, and GOS 4-5 patients with no overlap between groups. This study showed that combined MRI and MRS provide a reliable evaluation of patients presenting in deep coma, specially when there are insufficient MRI lesions of the consciousness pathways to explain their status. In the first few days post-trauma metabolic (brainstem spectroscopy) and morphological (T2 star and Flair) MRI studies can predict the long-term neurological outcome, especially the persistent vegetative states and minimally conscious state.	Univ Paris 06, Hop La Pitie Salpetriere, Dept Neurosurg, Paris, France; Univ Paris 06, Hop La Pitie Salpetriere, Dept Neuroradiol, Paris, France; Univ Paris 06, Hop La Pitie Salpetriere, Dept Anesthesiol, Paris, France	Carpentier, A (corresponding author), Univ Paris 06, Hop La Pitie Salpetriere, Dept Nedurochirurg, Batiment Babinski,47-83 Blvd Hop, F-75013 Paris, France.	alexandre.carpentier@lrb.aphp.fr	dormont, didier/B-2175-2012; Dormont, Didier/F-5492-2012				Alessandri B, 2000, NEUROL RES, V22, P705; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Galanaud D, 2003, J NEUROSURG, V98, P269, DOI 10.3171/jns.2003.98.2.0269; Galanaud D, 2001, MAGN RESON MATER PHY, V13, P127, DOI 10.1016/S1352-8661(01)00135-1; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.0.CO;2-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; RANGO M, 1995, MAGNET RESON MED, V33, P595, DOI 10.1002/mrm.1910330503; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010	32	70	76	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2006	23	5					674	685		10.1089/neu.2006.23.674			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	042LJ	WOS:000237529200006	16689669				2021-06-18	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			Oxidative stress modulates Sir2 alpha in rat hippocampus and cerebral cortex	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						hippocampus; neural repair; oxidative stress; Sir2 alpha; vitamin E	DEPENDENT HISTONE DEACETYLASE; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR FOXO3A; TRAUMATIC BRAIN-INJURY; LIFE-SPAN EXTENSION; SATURATED-FAT DIET; CALORIE RESTRICTION; NEUROTROPHIC FACTOR; SACCHAROMYCES-CEREVISIAE; SYNAPTIC PLASTICITY	Silent information regulator 2 (Sir2) helps survival and longevity in lower organisms during challenging situations. We investigated the possibility that Sir2 alpha could be involved with brain plasticity under challenging situations. A diet high in saturated fat and sucrose, which has been shown in rodents to reduce synaptic plasticity and cognition, decreased Sir2 alpha levels in the hippocampus and cerebral cortex, in proportion to an increase in protein oxidation. Vitamin E supplementation normalized, in the hippocampus and cerebral cortex, Sir2 alpha levels that had been reduced by the high-fat diet. Neither the high-fat diet nor vitamin E supplementation affected cerebellar Sir2 alpha. Vitamin E reduced, in the hippocampus, the oxidized nucleic acids that were increased by the high-fat diet. Western blot analysis showed higher contents of Sir2 alpha in the hippocampus and cerebellum than in the cerebral cortex. Sir2 alpha immunostaining was predominantly localized in the mossy fibre system and the dentate gyrus granule layer of the hippocampal formation. The high-fat diet decreased Sir2 alpha immunostaining while vitamin E supplementation reversed these effects. Given that oxidative stress is a subproduct of dysfunctional energy homeostasis, we measured AMP-activated protein kinase (AMPK) to have an indication of the energy status of cells. Hippocampal levels of total and phosphorylated AMPK were reduced after high fat consumption and levels were normalized by vitamin E treatment. The present results show that oxidative stress and energy homeostasis associated with the consumption of the high-fat diet are critical for the regulation of Sir2 alpha, with important implications for mechanisms of neural repair.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45804, NS039522, NS050465] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039522, R01NS045804] Funding Source: NIH RePORTER		Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anekonda TS, 2006, J NEUROCHEM, V96, P305, DOI 10.1111/j.1471-4159.2005.03492.x; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cardozo-Pelaez F, 2000, FREE RADICAL BIO MED, V28, P779, DOI 10.1016/S0891-5849(00)00172-6; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Clayton DA, 2002, J NEUROSCI, V22, P3628; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Guarente L, 2000, GENE DEV, V14, P1021; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; Imai S, 2000, NATURE, V403, P795; Kelly A, 2003, J NEUROSCI, V23, P5354; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lee K, 2005, ENDOCRINOLOGY, V146, P3, DOI 10.1210/en.2004-0968; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu PK, 2001, TRENDS NEUROSCI, V24, P581, DOI 10.1016/S0166-2236(00)01918-4; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Mattson MP, 2003, J NEUROCHEM, V84, P417, DOI 10.1046/j.1471-4159.2003.01586.x; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nunomura A, 1999, J NEUROSCI, V19, P1959; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Rafaeloff-Phail R, 2004, J BIOL CHEM, V279, P52934, DOI 10.1074/jbc.M409574200; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sinclair D, 2005, NAT GENET, V37, P339, DOI 10.1038/ng0405-339; Steffenach HA, 2002, P NATL ACAD SCI USA, V99, P3194, DOI 10.1073/pnas.042700999; Sugaya K, 1996, J NEUROSCI, V16, P3427; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x	52	70	72	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2006	23	10					2573	2580		10.1111/j.1460-9568.2006.04807.x			8	Neurosciences	Neurosciences & Neurology	046LB	WOS:000237812000004	16817860				2021-06-18	
J	Zhong, C; Zhao, XR; Van, KC; Bzdega, T; Smyth, A; Zhou, J; Kozikowski, AP; Jiang, JY; O'Connor, WT; Berman, RF; Neale, JH; Lyeth, BG				Zhong, C; Zhao, XR; Van, KC; Bzdega, T; Smyth, A; Zhou, J; Kozikowski, AP; Jiang, JY; O'Connor, WT; Berman, RF; Neale, JH; Lyeth, BG			NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						gamma-aminobutyric acid; glutamate; metabotropic glutamate receptor; microdialysis; N-acetylaspartylglutamate; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ENERGY-RELATED METABOLITES; GAMMA-AMINOBUTYRIC-ACID; UREA-BASED INHIBITORS; N-ACETYLASPARTYLGLUTAMATE; GROUP-II; CARBOXYPEPTIDASE-II; NEURONAL INJURY; AMINO-ACIDS; EXTRACELLULAR LEVELS	Traumatic brain injury (TBI) produces a rapid and excessive elevation in extracellular glutamate that induces excitotoxic brain cell death. The peptide neurotransmitter N-acetyl-aspartylglutamate (NAAG) is reported to suppress neurotransmitter release through selective activation of presynaptic group II metabotropic glutamate receptors. Therefore, strategies to elevate levels of NAAG following brain injury could reduce excessive glutamate release associated with TBI. We hypothesized that the NAAG peptidase inhibitor, ZJ-43 would elevate extracellular NAAG levels and reduce extracellular levels of amino acid neurotransmitters following TBI by a group II metabotropic glutamate receptor (mGluR)-mediated mechanism. Dialysate levels of NAAG, glutamate, aspartate and GABA from the dorsal hippocampus were elevated after TBI as measured by in vivo microdialysis. Dialysate levels of NAAG were higher and remained elevated in the ZJ-43 treated group (50 mg/kg, i.p.) compared with control. ZJ-43 treatment also reduced the rise of dialysate glutamate, aspartate, and GABA levels. Co-administration of the group II mGluR antagonist, LY341495 (1 mg/kg, i.p.) partially blocked the effects of ZJ-43 on dialysate glutamate and GABA, suggesting that NAAG effects are mediated through mGluR activation. The results are consistent with the hypothesis that inhibition of NAAG peptidase may reduce excitotoxic events associated with TBI.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200030, Peoples R China; Georgetown Univ, Dept Biol, Washington, DC 20057 USA; Univ Coll Dublin, Conway Inst, Appl Neurotherapeut Res Grp, Dublin 2, Ireland; Acenta Discovery Inc, Tucson, AZ USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu	O'Connor, William T./I-7459-2015	O'Connor, William/0000-0003-0082-1119; Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038080, R01NS029995, R01NS045136, R01NS042672] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29995, NS38080, NS45136, NS42672] Funding Source: Medline		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Aronica E, 2003, EUR J NEUROSCI, V17, P2106, DOI 10.1046/j.1460-9568.2003.02657.x; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bischofberger J, 1996, J NEUROPHYSIOL, V76, P2089; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bzdega T, 2004, J NEUROCHEM, V89, P627, DOI 10.1111/j.1471-4159.2004.02361.x; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferraguti F, 2001, EXP BRAIN RES, V137, P1, DOI 10.1007/s002210000633; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HSIAO JK, 1990, J NEUROCHEM, V54, P1449, DOI 10.1111/j.1471-4159.1990.tb01982.x; Jackson PF, 2001, CURR MED CHEM, V8, P949, DOI 10.2174/0929867013372797; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jones CK, 2005, NEUROPHARMACOLOGY, V49, P206, DOI 10.1016/j.neuropharm.2005.05.008; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Koura SS, 1998, ACT NEUR S, V71, P244; Kozikowski AP, 2004, J MED CHEM, V47, P1729, DOI 10.1021/jm0306226; Kozikowski AP, 2001, J MED CHEM, V44, P298, DOI 10.1021/jm000406m; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n; MORARI M, 1994, EUR J PHARMACOL, V256, P23, DOI 10.1016/0014-2999(94)90611-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PARSONS LH, 1994, CRIT REV NEUROBIOL, V8, P189; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PINHEIRO JC, 2000, MIXED EFFECTS MODELS, P11; R DEVELOPMENT CORE TEAM, 2005, R LANG ENV STAT COMP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rong SB, 2002, J MED CHEM, V45, P4140, DOI 10.1021/jm010561g; Sanabria ERG, 2004, J NEUROPHYSIOL, V91, P182, DOI 10.1152/jn.00465.2003; Schweitzer C, 2000, NEUROPHARMACOLOGY, V39, P1700, DOI 10.1016/S0028-3908(99)00265-8; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; SMYTH A, 2005, ACTA NEUROBIOL EXP, V65, P90; SMYTH A, 2005, P MOL MECH NEUR JOIN, P25; Smyth GK, 1996, J ROY STAT SOC B MET, V58, P565; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Wroblewska B, 1998, GLIA, V24, P172, DOI 10.1002/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x; Xi ZX, 2002, J PHARMACOL EXP THER, V300, P162, DOI 10.1124/jpet.300.1.162; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Yamamoto T, 2001, BRAIN RES, V909, P138, DOI 10.1016/S0006-8993(01)02650-6; Yamamoto T, 2001, NEUROSCIENCE, V102, P473, DOI 10.1016/S0306-4522(00)00502-9; Zauner A, 1996, ACT NEUR S, V67, P40; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x; Zhang W, 2002, J NEUROL SCI, V194, P21, DOI 10.1016/S0022-510X(01)00670-0; Zhao ZX, 2001, SOLID STATE SCI, V3, P339, DOI 10.1016/S1293-2558(00)01087-6; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zhou J, 2005, NAT REV DRUG DISCOV, V4, P1015, DOI 10.1038/nrd1903; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	70	70	74	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2006	97	4					1015	1025		10.1111/j.1471-4159.2006.03786.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	036HW	WOS:000237063200010	16606367				2021-06-18	
J	Davis, DP; Douglas, DJ; Smith, W; Sise, MJ; Vilke, GM; Holbrook, TL; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, DP; Douglas, DJ; Smith, W; Sise, MJ; Vilke, GM; Holbrook, TL; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB			Traumatic brain injury outcomes in pre- and post-menopausal females versus age-matched males	JOURNAL OF NEUROTRAUMA			English	Article						estrogen; gender; head trauma; menopause; outcomes; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; NECROSIS-FACTOR-ALPHA; GENDER-DIFFERENCES; SEX-DIFFERENCES; LIPID-PEROXIDATION; HYPOGONADOTROPIC HYPOGONADISM; PROGESTERONE PROTECTS; ESTROUS-CYCLE; HEAD TRAUMA; CELL-DEATH	Gender differences in outcomes from major trauma have been described previously, and exogenous female hormone administration appears to be neuroprotective following traumatic brain injury (TBI). This analysis explored outcomes in pre- and post-menopausal females versus age-matched males. A total of 13,437 patients (n = 3,178 females, it = 10,259 males) with moderate-to-severe TBI (head AIS >= 3) were identified from our county trauma registry. Overall mortality was similar between males and females (22% for both). Logistic regression was used to compare gender outcome differences, with a separate analysis performed for premenopausal (<50 years) versus postmenopausal (>= 50 years) patients, and after stratification by decade of life. No statistically significant difference in outcomes was observed for pre-menopausal females versus males (odds ratio [OR] 1.06; 95% confidence interval [CI] 0.83, 1.35; p = 0.633), but outcomes were significantly better in postmenopausal females versus males (OR 0.63, 95% CI 0.48-0.81, p < 0.001) after adjusting for age, mechanism of injury, Glasgow Coma Scale (GCS), hypotension (SBP <= 90 min Hg), head Abbreviated Injury Score (AIS), and Injury Severity Score (ISS). Stratification by decade of life revealed the gender survival differential inflection point to occur between ages 40-49 (OR 1.06, 95% CI 0.66-1.71, p = 0.798) and ages 50-59 (OR 0.38, 95% CI 0.20-0.74, p = 0.005). In addition, Revised Trauma Score and Injury Severity Score (TRISS) was used to calculate probability of survival (PS); all patients were then stratified by decade of life, and males and females were compared with regard to mean survival differential (outcome PS). The identical pattern of improved outcomes in post-menopausal but not pre-menopausal females versus age-matched males was observed. These data suggest that endogenous female sex hormone production is not neuroprotective.	Univ Calif San Diego, San Diego Emergency Med, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Scripps Mercy Hosp, San Diego, CA USA; San Diego Cty EMS, San Diego, CA USA; Univ Calif San Diego, Div Trauma, San Diego, CA 92103 USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA; Scripps Mem Hosp, San Diego, CA USA; Palomar Hosp, Escondido, CA USA	Davis, DP (corresponding author), Univ Calif San Diego, San Diego Emergency Med, Dept Emergency Med, 200 W Arbor Dr, San Diego, CA 92103 USA.	davismd@cox.net					Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; BARRON WM, 1986, AM J PHYSIOL, V250, pE352; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bujas M, 1997, BRAIN RES BULL, V43, P411, DOI 10.1016/S0361-9230(97)00027-0; Cannon JG, 1998, ANN NY ACAD SCI, V856, P234, DOI 10.1111/j.1749-6632.1998.tb08330.x; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; DAVISON JM, 1984, AM J PHYSIOL, V246, pF105; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; EVANS RW, 1992, NEUROL CLIN, V10, P815; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Gannon CJ, 2002, J AM COLL SURGEONS, V195, P11, DOI 10.1016/S1072-7515(02)01187-0; Garcia EF, 2003, P W PHARMACOL SOC, V46, P54; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Grachev ID, 2000, NEUROIMAGE, V11, P554, DOI 10.1006/nimg.2000.0557; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harukuni I, 2001, BRAIN RES, V900, P137, DOI 10.1016/S0006-8993(01)02278-8; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Jones F S, 1998, N C Med J, V59, P191; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kaldi I, 2004, EUR J OPHTHALMOL, V14, P306, DOI 10.5301/EJO.2008.1363; KIMURA D, 1995, HORM BEHAV, V29, P312, DOI 10.1006/hbeh.1995.1022; Kimura D, 1996, CURR OPIN NEUROBIOL, V6, P259, DOI 10.1016/S0959-4388(96)80081-X; Kimura D, 2003, PSYCHOL REP, V93, P263, DOI 10.2466/PR0.93.5.263-264; Kimura D, 2002, PSYCHOL REP, V91, P1137, DOI 10.2466/PR0.91.7.1137-1142; KIMURA D, 1992, SCI AM, V267, P119; KIMURA D, 1984, PROG BRAIN RES, V61, P423; KIMURA D, 1983, CAN J PSYCHOL, V37, P19, DOI 10.1037/h0080696; Knoferl MW, 2003, CELL IMMUNOL, V222, P27, DOI 10.1016/S0008-8749(03)00081-9; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Landgren BM, 2004, J CLIN ENDOCR METAB, V89, P2763, DOI 10.1210/jc.2003-030824; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; McCauley LD, 1995, J PHARMACOL EXP THER, V275, P1412; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCullough LD, 2003, J NEUROSCI, V23, P8701; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Nunez JL, 2003, ENDOCRINOLOGY, V144, P2350, DOI 10.1210/en.2002-220840; OVTSCHAROFF W, 1992, J COMP NEUROL, V323, P299, DOI 10.1002/cne.903230212; RIVIER C, 1990, ENDOCRINOLOGY, V127, P849; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Russell SH, 2001, J NEUROENDOCRINOL, V13, P296, DOI 10.1046/j.1365-2826.2001.00632.x; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SPINEDI E, 1992, ENDOCRINOLOGY, V131, P2430, DOI 10.1210/en.131.5.2430; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; STACHENFELD N.S., 1998, AM J PHYSIOL, V274, P187; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TABIBZADEH S, 1994, HUM REPROD, V9, P947, DOI 10.1093/oxfordjournals.humrep.a138621; Theas S, 2000, ENDOCRINE, V12, P249, DOI 10.1385/ENDO:12:3:249; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Veliskova J, 2001, ANN NEUROL, V50, P596, DOI 10.1002/ana.1248; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; WILSON MA, 1992, BRAIN RES BULL, V29, P165, DOI 10.1016/0361-9230(92)90022-P; Wilson MA, 1997, LIFE SCI, V60, P1679, DOI 10.1016/S0024-3205(97)00110-0; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	74	70	70	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					140	148		10.1089/neu.2006.23.140			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600003	16503798				2021-06-18	
J	Dohi, K; Satoh, K; Ohtaki, H; Shioda, S; Miyake, Y; Shindo, M; Aruga, T				Dohi, K; Satoh, K; Ohtaki, H; Shioda, S; Miyake, Y; Shindo, M; Aruga, T			Elevated plasma levels of bilirubin in patients with neurotrauma reflect its pathophysiological role in free radical scavenging	IN VIVO			English	Article						bilirubin; heme oxygenase; traumatic brain injury; antioxidant; bioantioxidant potential (BAP); electron spin resonance; ESR; hydroxyl radical	HEME OXYGENASE-1; OXIDATIVE STRESS; SERUM BILIRUBIN; CARBON-MONOXIDE; BRAIN-INJURY; RAT-BRAIN; RISK; ANTIOXIDANT; PEROXYNITRITE; ASSOCIATION	Bilirubin, a powerful endogenous antioxidant, is one of the catabolites of heme oxygenases (HOs). In this study, the plasma bilirubin concentration was measured to establish bilirubin kinesis after traumatic brain injury (TBI). Furthermore, in in vitro studies, the free radical scavenging activity and antioxidant potency of bilirubin was also investigated at various concentrations, including physiological ones. Indirect plasma bilirubin was measured in 25 patients on days 1, 2, 3 and 4 after presentation with TBI, The ability of bilirubin to scavenge the hydroxyl (OH.) and 1,1-diphenyl-2-picrylhyrazyl (DPPH) radicals, and its antioxidant potency, were also analyzed using electron spin resonance (ESR) and the bioantioxidant power (BAP) methods, respectively. Plasma bilirubin levels were significantly higher on days 2, 3 and 4 than on patient admission (day 1; p < 0.05). ESR and BAP results revealed that bilirubin has direct OH. and DPPH radical scavenging activities and potent antioxidant effects in vitro at physiological concentrations. These data indicate that physiological concentrations of bilirubin have antioxidant properties and that it constitutes one of the biological defense mechanisms in neurotrauma patients.	Showa Univ, Sch Med, Dept Crit Care & Emergency Med, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Anat, Tokyo 1428555, Japan	Dohi, K (corresponding author), Showa Univ, Sch Med, Dept Crit Care & Emergency Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kdop@med.showa-u.ac.jp		dohi, kenji/0000-0002-4451-0382	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16591815] Funding Source: KAKEN		Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; BREIMER LH, 1995, CLIN CHEM, V41, P1504; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chin K, 2001, SLEEP, V24, P218, DOI 10.1093/sleep/24.2.218; Clark JE, 2000, BIOCHEM J, V348, P615, DOI 10.1042/0264-6021:3480615; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643; Dani C, 2003, ARCH DIS CHILD-FETAL, V88, pF119, DOI 10.1136/fn.88.2.F119; Dohi K, 2003, ACT NEUR S, V86, P247; Dohi K, 2003, ACT NEUR S, V86, P87; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Hansen TWR, 1999, MOL GENET METAB, V68, P404, DOI 10.1006/mgme.1999.2899; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; HOUKIN K, 2003, CEREBROVASC DIS, V15, P222; Imaizumi Y, 2003, ACT NEUR S, V86, P101; Iwashita A, 2003, J PHARMACOL EXP THER, V307, P961, DOI 10.1124/jpet.103.056572; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; Leinonen JS, 2000, STROKE, V31, P33, DOI 10.1161/01.STR.31.1.33; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; MAINES MD, 1986, J BIOL CHEM, V261, P411; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mayer M, 2000, CLIN CHEM, V46, P1723; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Mihara Y, 2004, HYPOTHERMIA FOR ACUTE BRAIN DAMAGE: PATHOMECHANISM AND PRACTICAL ASPECTS, P94; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; NEUZIL J, 1994, J BIOL CHEM, V269, P16712; Orihara Yoshiyuki, 2003, Leg Med (Tokyo), V5 Suppl 1, pS278; OTSUJI S, 1988, CLIN BIOCHEM, V21, P33, DOI 10.1016/S0009-9120(88)80109-7; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; Siow RCM, 1999, CARDIOVASC RES, V41, P385, DOI 10.1016/S0008-6363(98)00278-8; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Suzuki H, 1999, J CLIN INVEST, V104, P59, DOI 10.1172/JCI5357; Temme EHM, 2001, CANCER CAUSE CONTROL, V12, P887, DOI 10.1023/A:1013794407325; Tomaro ML, 2002, INT J BIOCHEM CELL B, V34, P216, DOI 10.1016/S1357-2725(01)00130-3; Van Hoydonck PGA, 2001, INT J EPIDEMIOL, V30, P1465; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165	44	70	73	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0258-851X	1791-7549		IN VIVO	In Vivo	SEP-OCT	2005	19	5					855	860					6	Medicine, Research & Experimental	Research & Experimental Medicine	951AU	WOS:000230901900007	16097438				2021-06-18	
J	Williams, GP; Robertson, V; Greenwood, KM; Goldie, PA; Morris, ME				Williams, GP; Robertson, V; Greenwood, KM; Goldie, PA; Morris, ME			The high-level mobility assessment tool (HiMAT) for traumatic brain injury. Part 2: Content validity and discriminability	BRAIN INJURY			English	Article; Proceedings Paper	1st Neurological Physiotherapy Conference of the National-Neurology-Group-of-Australian-Physiotherapy-Association	NOV, 2003	Sydney, AUSTRALIA	Natl Neurol Grp Australian Physiotherapy Assoc		brain injuries; rehabilitation; gait disorders; neurologic; outcome assessment	FUNCTIONAL MOBILITY; OBSTACLE COURSE; RASCH ANALYSIS; OLDER-ADULTS; STROKE; BALANCE; MOTOR; STABILITY; OUTCOMES; PROFILE	Primary objectives: (i) To assess the measurement properties of the high-level mobility assessment tool (HiMAT) for people with traumatic brain injury (TBI), (ii) to measure the extent to which the HiMAT is a uni-dimensional, discriminative hierarchical outcome scale. Research design: The content validity was assessed using a three-stage process of investigating internal consistency, factor analysis and Rasch analysis. The uni-dimensionality of the HiMAT items was also tested. Discriminability was investigated by correlating raw and logit scores obtained from Rasch analysis. The study was conducted at a major rehabilitation facility using a convenience sample of 103 adults with TBI. Main outcomes and results: The internal consistency for the high-level items was very high (Cronbach's alpha = 0.99). Principal axis factoring identified several balance items as belonging to a second factor not related to high-level mobility, hence these items were excluded. Rasch analysis identified several misfitting items, such as walking around a figure of eight and stopping from a run, which were also excluded. Logit scores were used to exclude clustered and, therefore, redundant items. Raw scores correlated very highly (r = 0.98) with logit scores, indicating that raw scores provided good discriminability and were suitable for use by clinicians. Conclusion: The HiMAT, which assesses higher-level mobility requirements of people with TBI for return to pre-accident social, leisure and sporting activities, is a uni-dimensional and discriminative scale for quantifying therapy outcomes.	Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; Univ Newcastle, Newcastle, NSW 2308, Australia; La Trobe Univ, Bundoora, Vic 3083, Australia	Williams, GP (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavinw@epworth.org.au	Greenwood, Kenneth M/J-8993-2015	Greenwood, Kenneth M/0000-0002-8420-6588; Williams, Gavin/0000-0003-2758-7473; Morris, Meg/0000-0002-0114-4175			American Psychological Association American Educational Research Association & National Council on Measurement in Education, 1985, STAND ED PSYCH TEST; Badke Mary Beth, 1993, Physiotherapy Canada, V45, P15; Baer HR, 2001, STROKE, V32, P973, DOI 10.1161/01.STR.32.4.973; BERG K, 1989, Physiotherapy Canada, V41, P304; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Brauer S, 1999, Physiother Res Int, V4, P81, DOI 10.1002/pri.155; BREWER K, 1998, PHYSIOTHER CAN, V50, P118; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; CHANG WC, 1995, ARCH PHYS MED REHAB, V76, P934, DOI 10.1016/S0003-9993(95)80070-0; Collen F M, 1991, Int Disabil Stud, V13, P50; DUNCAN P, 1995, DUKE MOBILITY SKILLS; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Duncan PW, 1990, J GERONTOL, V45, P192; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; Granger CV, 1983, GUIDE USE UNIFORM DA; HILL KD, 1996, PHYSIOTHER CAN, P257; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, P3; KORNERBITENSKY N, 1989, ARCH PHYS MED REHAB, V70, P95; Linacre J M, 1999, J Outcome Meas, V3, P103; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Lincoln N, 1979, Physiotherapy, V65, P48; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Means KM, 1996, J REHABIL RES DEV, V33, P413; Means KM, 1996, AM J PHYS MED REHAB, V75, P88, DOI 10.1097/00002060-199603000-00003; Newton RA, 2001, J GERONTOL A-BIOL, V56, pM248, DOI 10.1093/gerona/56.4.M248; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PASTOR MA, 1993, BRAIN, V116, P1177, DOI 10.1093/brain/116.5.1177; PFEIFFER E, 1981, J AM GERIATR SOC, V29, P433, DOI 10.1111/j.1532-5415.1981.tb01744.x; Platt W, 1998, PHYSIOTHER CAN, V50, P47; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Portney LG., 1993, FDN CLIN RES APPL PR, V3rd; ROTHSTEIN JM, 1991, PHYS THER, V71, P589, DOI 10.1093/ptj/71.8.589; ROTHWELL WP, 1985, BRUKER REPORT, V1, P46; SEABY L, 1989, Physiotherapy Canada, V41, P264; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tabachnick B., 2001, USING MULTIVARIATE S; Tang PF, 1998, J GERONTOL A-BIOL, V53, pM140, DOI 10.1093/gerona/53A.2.M140; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; *WHO, 2001, ICF INT CLASS FUNCT; Williams G, 2001, BRAIN INJURY, V15, P831; WILLIAMS G, 2003, DEV HIGH LEVEL MOBIL; Wu M.L., 1998, ACER CONQUEST GEN IT	45	70	70	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2005	19	10					833	843		10.1080/02699050500058711			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800009	16175843				2021-06-18	
J	Kraus, J; Schaffer, K; Ayers, K; Stenehjem, T; Shen, HK				Kraus, J; Schaffer, K; Ayers, K; Stenehjem, T; Shen, HK			Physical complaints, medical service use, and social and employment changes following mild traumatic brain injury - A 6-month longitudinal study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cohort study; epidemiology; mild traumatic brain injury; outcomes; risk estimates	MINOR HEAD-INJURY; ALCOHOL-USE; ACOUSTIC HYPERESTHESIA; SEQUELAE; EMERGENCY; SYMPTOMS; RISK; VALIDATION; DISCHARGE; PATTERNS	Using a prospective, dual-cohort study design in which selected preinjury factors were controlled, we present outcomes of 235 patients in a case cohort and 235 patients in a comparison cohort following emergency-department-diagnosed mild traumatic brain injury (MTBI). Symptoms, medical services use, and social and employment concerns were evaluated 6 months after the injury. After adjusting for preinjury characteristics, headaches, dizziness, vision difficulties, memory or learning problems, and alcohol intolerance were found to occur significantly more often in the MTBI cohort than in the comparison cohort. Problems sleeping, use of prescribed medications, and changes in employment were less likely in the MTBI cohort. Although MTBI is not life threatening, our findings suggest that 6 months after injury persons still have related health problems that require routine medical management.	Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Dept Biostat, Los Angeles, CA 90024 USA; Sharp Mem Hosp & Rehabil Ctr, Trauma Serv, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, Rehabil Ctr, San Diego, CA USA	Kraus, J (corresponding author), Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Dept Epidemiol, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90024 USA.	jfkraus@ucla.edu		SCHAFFER, KATHRYN/0000-0002-3550-1679			ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; BOHNEN N, 1991, BRIT J PSYCHIAT, V159, P860, DOI 10.1192/bjp.159.6.860; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; CHERPITEL CJ, 1995, J STUD ALCOHOL, V56, P83, DOI 10.15288/jsa.1995.56.83; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hungerford DW, 2003, ACAD EMERG MED, V10, P79, DOI 10.1111/j.1553-2712.2003.tb01982.x; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Longabaugh R, 2001, J STUD ALCOHOL, V62, P806, DOI 10.15288/jsa.2001.62.806; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; *SAS I INC, 1999, SAS STAT; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Tellier A, 1999, BRAIN INJURY, V13, P463; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; *WHO COLL CTR TASK, 2004, J REHABIL MED S, V43, P126; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 1997, INT CLASSIFICATION D	57	70	70	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					239	256		10.1097/00001199-200505000-00007			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500007	15908824				2021-06-18	
J	Mathias, JL; Mansfield, KM				Mathias, JL; Mansfield, KM			Prospective and declarative memory problems following moderate and severe traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; prospective memory; declarative memory; memory	CLOSED-HEAD INJURY; ATTENTION; DEFICITS; TIME; PERFORMANCE; PATTERNS; FAILURE; DAMAGE; EVENT; MILD	Primary objective: To examine prospective and declarative memory problems following moderate and severe traumatic brain injury (TBI) and the relationship between prospective memory ( PM) and declarative memory and PM and other cognitive functions. Research design: The performance of persons who suffered a TBI (n=25) was compared with that of a demographically matched control group (n=25). Methods and procedures: Measures of time- and event-based PM, visual and verbal declarative memory, attention and executive functioning were administered to both groups. Main outcome and results: The group with a TBI performed more poorly on event- and time-based PM, verbal declarative memory, certain aspects of attention and executive functioning. The correlations between the measures of PM, declarative memory and the other cognitive tests were all non-significant. Conclusions: Problems with declarative memory, attention, and executive functioning do not adequately account for poorer PM performance following a TBI, suggesting that PM should also be assessed following TBI.	Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia	Mathias, JL (corresponding author), Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia.	jane.mathias@psychology.adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			BADDELEY AD, 1995, HDB MEMORY DISORDERS, P3; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Carmines E.G., 1979, RELIABILITY VALIDITY, V17, P1; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J.D., 1996, PROSPECTIVE MEMORY T, P267; CURRY LM, 1991, PHILADELPHIA HEAD IN; d'Ydewalle G, 1999, EUR J COGN PSYCHOL, V11, P219, DOI 10.1080/713752309; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Heaton R., 1993, WISCONSIN CARD SORTI; Hillier SL, 1997, BRAIN INJURY, V11, P649; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MATHIAS JL, IN PRESS APPL NEUROP; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Schmidt M., 1996, REY AUDITORY VERBAL; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SINNOTT JD, 1989, EVERYDAY COGNITION IN ADULTHOOD AND LATE LIFE, P352; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; TRANEL D, 1995, HDB MEMORY DISORDERS, P27; Vakil E, 2001, J CLIN EXP NEUROPSYC, V23, P207, DOI 10.1076/jcen.23.2.207.1209; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson, 1991, NATL ADULT READING T; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	53	70	72	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					271	282		10.1080/02699050400005028			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400005	15832873				2021-06-18	
J	Chiaravalloti, ND; Hillary, FG; Ricker, JH; Christodoulou, C; Kalnin, AJ; Liu, WC; Steffener, J; Deluca, J				Chiaravalloti, ND; Hillary, FG; Ricker, JH; Christodoulou, C; Kalnin, AJ; Liu, WC; Steffener, J; Deluca, J			Cerebral activation patterns during working memory performance in multiple sclerosis using fMRI	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; ADAPTIVE FUNCTIONAL-CHANGES; RIGHT-HEMISPHERE INVOLVEMENT; CORTICAL ACTIVATION; GLUCOSE-METABOLISM; COGNITIVE FUNCTION; OPTIC NEURITIS; AXONAL INJURY; CORTEX	Working memory deficits are common in Multiple Sclerosis (MS) and have been identified behaviorally in numerous studies. Despite recent advance in functional magnetic resonance imaging (fMRI), few published studies have examined cerebral activations associated with working memory dysfunction in MS. The present study examines brain activation patterns during performance of a working memory task in individuals with clinically definite MS, compared to healthy controls (HC). fMRI was performed using a 1.5 Tesla GE scanner during a modified Paced Auditory Serial Addition Test (mPA-SAT). Participants were 6 individuals with MS with working memory impairment as evidenced on neuropsychological testing, 5 individuals with MS without working memory impairment, and 5 HC Groups were demographically equivalent. Data were analyzed using Statistical Parametric Mapping (SPM99) software, with a stringent significance level (alpha <.005, voxel extent >= 8). Both MS groups and the HC group were able to perform the task, with comparable performance in terms of numbers of correct responses. Activation patterns within the HC and MS not-impaired groups were noted in similar brain regions, consistent with published observations in healthy samples. That is, activations were lateralized to the left hemisphere, involving predominantly frontal regions. In contrast, the MS impaired group showed greater right frontal and right parietal lobe activation, when compared with the HC group. Thus, it appears that working memory dysfunction in MS is associated with altered patterns of cerebral activation that are related to the presence of cognitive impairment, and not solely a function of MS.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA	Deluca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jdeluca@kmrrec.org	Hillary, Frank/AAN-8622-2021	Ricker, Joseph/0000-0003-3415-991X			Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Baddeley A. D., 1986, WORKING MEMORY; Bakshi R, 1998, J NEUROIMAGING, V8, P228, DOI 10.1111/jon199884228; Belger A, 1998, HUM BRAIN MAPP, V6, P14, DOI 10.1002/(SICI)1097-0193(1998)6:1<14::AID-HBM2>3.0.CO;2-O; Blinkenberg M, 1999, NEUROLOGY, V53, P149, DOI 10.1212/WNL.53.1.149; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 1997, J NEUROSCI, V17, P391; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cobble N., 1992, J NEUROL REHABIL, V6, P141; Crosson B, 1999, NEUROPSYCHOLOGY, V13, P171, DOI 10.1037/0894-4105.13.2.171; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DEsposito M, 1996, NEUROPSYCHOLOGY, V10, P51, DOI 10.1037/0894-4105.10.1.51; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Evangelou N, 2000, BRAIN, V123, P1845, DOI 10.1093/brain/123.9.1845; Filippi M, 2002, NEUROIMAGE, V15, P559, DOI 10.1006/nimg.2001.1011; Filippi M, 2002, NEUROIMAGE, V15, P537, DOI 10.1006/nimg.2001.1023; Filippi M, 1999, NEUROLOGY, V53, pS18; Foong J, 1999, J NEUROPSYCH CLIN N, V11, P45, DOI 10.1176/jnp.11.1.45; GOLDBERG E, 1981, BRAIN LANG, V14, P144, DOI 10.1016/0093-934X(81)90072-9; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; GORDON PA, 1994, J REHABIL, V60, P34; GRIGSBY J, 1994, J NEUROL, V241, P125; GRIGSBY J, 1994, ARCH CLIN NEUROPSYCH, V9, P134; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GROSSMAN M, 1994, NEUROPSY NEUROPSY BE, V7, P194; JOHNSON MK, 1992, J COGNITIVE NEUROSCI, V4, P268, DOI 10.1162/jocn.1992.4.3.268; Jonides J, 1998, J NEUROSCI, V18, P5026; Kollias SS, 1996, INT J NEURORADIOL, V2, P450; Lee M, 2000, ANN NEUROL, V47, P606, DOI 10.1002/1531-8249(200005)47:5<606::AID-ANA8>3.3.CO;2-C; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P281, DOI 10.1001/archneur.1988.00520270059021; LYCKE J, 1993, EUR NEUROL, V33, P163, DOI 10.1159/000116926; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MINOSHIMA S, 1993, INT CONGR SER, V1030, P409; Pan J W, 2001, Appl Neuropsychol, V8, P155, DOI 10.1207/S15324826AN0803_4; PAPANICOLAOU AC, 1988, ARCH NEUROL-CHICAGO, V45, P1025, DOI 10.1001/archneur.1988.00520330117020; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Paulesu E, 1996, NEUROIMAGE, V4, P87, DOI 10.1006/nimg.1996.0032; Pelletier J, 2001, ARCH NEUROL-CHICAGO, V58, P105, DOI 10.1001/archneur.58.1.105; Pfefferbaum A, 2001, NEUROIMAGE, V14, P7, DOI 10.1006/nimg.2001.0785; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1989, NEUROLOGY, V39, P161, DOI 10.1212/WNL.39.2.161; Reddy H, 2000, BRAIN, V123, P2314, DOI 10.1093/brain/123.11.2314; Reddy H, 2000, NEUROLOGY, V54, P236, DOI 10.1212/WNL.54.1.236; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Rocca MA, 2002, NEUROLOGY, V58, P866, DOI 10.1212/WNL.58.6.866; Rocca MA, 2002, ANN NEUROL, V51, P330, DOI 10.1002/ana.10120; Roelcke U, 1997, NEUROLOGY, V48, P1566, DOI 10.1212/WNL.48.6.1566; Rombouts SARB, 1998, NEUROLOGY, V50, P1896, DOI 10.1212/WNL.50.6.1896; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rovaris M, 1999, NEUROLOGY, V53, pS40; RUMRILL P, 1996, EMPLOYMENT ISSUES MU; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Salmon E, 1996, BRAIN, V119, P1617, DOI 10.1093/brain/119.5.1617; Seger CA, 2000, NEUROPSYCHOLOGY, V14, P361, DOI 10.1037//0894-4105.14.3.361; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; Staffen W, 2002, BRAIN, V125, P1275, DOI 10.1093/brain/awf125; STEIN DG, 2000, INT HDB NEUROPSYCHOL, P9; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; van Waesberghe JHTM, 1999, NEUROLOGY, V53, pS46; Wechsler D, 1981, WESCHELER ADULT INTE; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Werring DJ, 2000, J NEUROL NEUROSUR PS, V68, P441, DOI 10.1136/jnnp.68.4.441	73	70	72	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN	2005	27	1					33	54		10.1080/138033990513609			22	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	908NM	WOS:000227793700003	15814441				2021-06-18	
J	Prins, ML; Lee, SM; Fujima, LS; Hovda, DA				Prins, ML; Lee, SM; Fujima, LS; Hovda, DA			Increased cerebral uptake and oxidation of exogenous beta HB improves ATP following traumatic brain injury in adult rats	JOURNAL OF NEUROCHEMISTRY			English	Article						alternative substrates; beta-hydroxybutyrate; metabolism; traumatic brain injury	KETONE-BODIES; MONOCARBOXYLATE TRANSPORTER; MITOCHONDRIAL DYSFUNCTION; ENERGY-METABOLISM; CORTICAL CONTUSION; GLUCOSE; NEURONS; ASTROCYTES; HYDROXYBUTYRATE; (CO2)-C-14	There is growing evidence of the brain's ability to increase its reliance on alternative metabolic substrates under conditions of energy stress such as starvation, hypoxia and ischemia. We hypothesized that following traumatic brain injury (TBI), which results in immediate changes in energy metabolism, the adult brain increases uptake and oxidation of the alternative substrate beta-hydroxybutyrate (betaHB). Arterio-venous differences were used to determine global cerebral uptake of betaHB and production of (CO2)-C-14 from [C-14]3-betaHB 3 h after controlled cortical impact (CCI) injury. Quantitative bioluminescence was used to assess regional changes in ATP concentration. As expected, adult sham and CCI animals with only endogenously available betaHB showed no significant increase in cerebral uptake of betaHB or (CO2)-C-14 production. Increasing arterial betaHB concentrations 2.9-fold with 3 h of betaHB infusion failed to increase cerebral uptake of betaHB or (CO2)-C-14 production in adult sham animals. Only CCI animals that received a 3-h betaHB infusion showed an 8.5-fold increase in cerebral uptake of betaHB and greater than 10.7-fold increase in (CO2)-C-14 production relative to sham betaHB-infused animals. The TBI-induced 20% decrease in ipsilateral cortical ATP concentration was alleviated by 3 h of betaHB infusion beginning immediately after CCI injury.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA	Prins, ML (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Room NPI 18-228,Box 957039, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37363, NS30308, NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037363, R01NS027544, P50NS030308] Funding Source: NIH RePORTER		Alberti K G, 1978, Biochem Soc Symp, P163; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BEAVEN MA, 1978, ANAL BIOCHEM, V84, P638, DOI 10.1016/0003-2697(78)90089-1; BRANDT RB, 1984, P SOC EXP BIOL MED, V175, P328; CASADO FJ, 1988, ANAL BIOCHEM, V172, P509, DOI 10.1016/0003-2697(88)90476-9; Chen T, 2000, ACT NEUR S, V76, P359; Cuff MA, 2002, J PHYSIOL-LONDON, V539, P361, DOI 10.1113/jphysiol.2001.014241; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDMOND J, 1987, J NEUROSCI RES, V18, P551, DOI 10.1002/jnr.490180407; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; HAWKINS RA, 1985, AM J PHYSIOL, V248, pC170; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KAWAMATA Y, 1990, J NEUROSURG, V73, P889; KREIS R, 1992, RADIOLOGY, V184, P123, DOI 10.1148/radiology.184.1.1319074; KROGURE K, 1978, BRAIN RES, V154, P273; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; LOPESCARDOZO M, 1986, J NEUROCHEM, V46, P773, DOI 10.1111/j.1471-4159.1986.tb13039.x; MCKENNA MC, 1990, NEUROCHEM RES, V15, P1211, DOI 10.1007/BF01208582; MCKENNA MC, 1986, BIOCHEM J, V237, P47, DOI 10.1042/bj2370047; MCKENNA MC, 1994, DEV NEUROSCI-BASEL, V16, P291, DOI 10.1159/000112122; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; POLLAY M, 1980, J NEUROSCI RES, V5, P163, DOI 10.1002/jnr.490050208; Ritter AM, 1996, J NEUROTRAUM, V13, P473, DOI 10.1089/neu.1996.13.473; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; SATO K, 1995, FASEB J, V9, P651; SHAND JH, 1987, COMP BIOCHEM PHYS A, V87, P583, DOI 10.1016/0300-9629(87)90365-3; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki M, 2002, JPN J PHARMACOL, V89, P36, DOI 10.1254/jjp.89.36; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vannucci RC, 2000, SEMIN PERINATOL, V24, P107, DOI 10.1053/sp.2000.6361; Veech RL, 2001, IUBMB LIFE, V51, P241; Waniewski RA, 1998, J NEUROSCI, V18, P5225; WESTERGAARD N, 1994, J NEUROCHEM, V62, P1727; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU ACH, 1984, J NEUROSCI RES, V11, P351, DOI 10.1002/jnr.490110403; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015	51	70	71	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2004	90	3					666	672		10.1111/j.1471-4159.2004.02542.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	838NQ	WOS:000222720500017	15255945	Bronze			2021-06-18	
J	Weinstock, M; Shoham, S				Weinstock, M; Shoham, S			Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity	JOURNAL OF NEURAL TRANSMISSION			English	Article						bilateral carotid occlusion; cerebral blood flow; cerebral glucose metabolism; cytochrome oxidase; streptozotocin	CHOLINE-ACETYLTRANSFERASE ACTIVITY; NERVE GROWTH-FACTOR; ACETYL-L-CARNITINE; FIMBRIA-FORNIX TRANSECTION; SPATIAL-LEARNING DEFICIT; COMMON CAROTID ARTERIES; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PERMANENT OCCLUSION	Three models are described in rats which attempt to mimic morphological and behavioural pathology of Alzheimer's dementia; intracerebroventricular injection of streptozotocin (STZ), permanent bilateral carotid artery occlusion (2VO) and brain mitochondrial cytochrome oxidase inhibition by sodium azide. Learning and memory are impaired within 4 weeks in all models. This probably involves a reduction in cortical and/or hippocampal cholinergic neurotransmission. STZ causes microglial activation and specific damage to myelinated tracts in the fornix through generation of oxidative stress, thereby disrupting connections between the septum and hippocampus. 2VO results in damage to myelin and CA1 cells in hippocampus and in abnormal processing of APP to beta-amyloid. It is not known if microglial activation and neuronal damage occur after sodium azide administration. Memory and learning can be improved in the STZ and 2VO models by estradiol, melatonin and cholinesterase inhibitors. Antioxidants and neuroprotective agents may also decrease memory deficits by preventing inflammation and neurodegeneration.	Hebrew Univ Jerusalem, Med Ctr, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Herzog Hosp, Dept Res, Jerusalem, Israel	Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Med Ctr, Sch Pharm, Dept Pharmacol, Ein Kerem, IL-91120 Jerusalem, Israel.	martar@cc.huji.ac.il					ARANGO M, 1999, FREE RADICAL BIO MED, V11, P1467; Arnaiz E, 2001, NEUROREPORT, V12, P851, DOI 10.1097/00001756-200103260-00045; Bastar I, 1998, RES COMMUN MOL PATH, V102, P265; Bennett M C, 1992, J Geriatr Psychiatry Neurol, V5, P93; Bennett MC, 1996, J NEUROCHEM, V66, P2606; Bennett MC, 1996, P NATL ACAD SCI USA, V93, P1330, DOI 10.1073/pnas.93.3.1330; Bennett SAL, 2000, NEUROBIOL AGING, V21, P207, DOI 10.1016/S0197-4580(00)00131-7; BLOKLAND A, 1993, PHARMACOL BIOCHEM BE, V44, P491, DOI 10.1016/0091-3057(93)90497-H; BONAVITA E, 1986, INT J CLIN PHARM TH, V24, P511; Braak H, 2000, ANN NY ACAD SCI, V924, P53; Carter J., 2001, Current Molecular Medicine (Hilversum), V1, P733, DOI 10.2174/1566524013363177; Chanvitayapongs S, 1997, NEUROREPORT, V8, P1499, DOI 10.1097/00001756-199704140-00035; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Cholerton B, 2002, DRUG AGING, V19, P405, DOI 10.2165/00002512-200219060-00002; COLTON CA, 1993, ADV NEUROL, V59, P321; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; delaTorre JC, 1997, NEUROSCI LETT, V223, P165, DOI 10.1016/S0304-3940(97)13421-8; DELATORRE JC, 1993, BRAIN RES, V623, P6, DOI 10.1016/0006-8993(93)90003-6; DELATORRE JC, 1992, BRAIN RES, V582, P186, DOI 10.1016/0006-8993(92)90132-S; DELEON MJ, 1983, J CEREBR BLOOD F MET, V3, P391, DOI 10.1038/jcbfm.1983.57; DUFFY PE, 1980, NEUROLOGY, V30, P778, DOI 10.1212/WNL.30.7.778; FOLLI F, 1994, J NEUROSCI, V14, P6412; FROLICH F, 1998, PROGR ALZHEIMERS PAR, P287; Galani R, 2002, NEUROBIOL LEARN MEM, V77, P1, DOI 10.1006/nlme.2000.3998; Gibbs RB, 1998, HORM BEHAV, V34, P98, DOI 10.1006/hbeh.1998.1451; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Grammas P, 2000, NEUROBIOL AGING, V21, P199, DOI 10.1016/S0197-4580(00)00102-0; HAGG T, 1989, BRAIN RES, V505, P29, DOI 10.1016/0006-8993(89)90112-1; HARRELL LE, 1985, NEUROSCIENCE, V15, P359, DOI 10.1016/0306-4522(85)90218-0; HELLWEG R, 1992, J NEUROSCI RES, V31, P479, DOI 10.1002/jnr.490310310; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hollerbach EH, 1998, J COMP NEUROL, V390, P481; HORWOOD N, 1994, VIRCHOWS ARCH, V425, P69; Hoyer S, 1990, Aging (Milano), V2, P245; HOYER S, 1993, PROG NEURO-PSYCHOPH, V17, P199, DOI 10.1016/0278-5846(93)90043-R; Hoyer S, 1996, ANN NY ACAD SCI, V777, P374, DOI 10.1111/j.1749-6632.1996.tb34448.x; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; KALARIA RN, 1992, ANN NEUROL, V32, P583, DOI 10.1002/ana.410320417; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; KIYOSAWA M, 1989, BRAIN, V112, P435, DOI 10.1093/brain/112.2.435; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; Lannert H, 1998, J NEURAL TRANSM, V105, P1045, DOI 10.1007/s007020050111; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; Li X, 1997, NEUROENDOCRINOLOGY, V66, P63, DOI 10.1159/000127221; MASLIAH E, 1994, NEUROSCI LETT, V174, P67, DOI 10.1016/0304-3940(94)90121-X; MAYER G, 1990, BRAIN RES, V532, P95, DOI 10.1016/0006-8993(90)91747-5; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785; Murakami Y, 1997, JPN J PHARMACOL, V75, P443, DOI 10.1254/jjp.75.443; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; NI JW, 1995, BRAIN RES, V673, P290, DOI 10.1016/0006-8993(94)01436-L; NI JW, 1994, BRAIN RES, V653, P231, DOI 10.1016/0006-8993(94)90394-8; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Ohta H, 1997, NEUROSCIENCE, V79, P1039, DOI 10.1016/S0306-4522(97)00037-7; Ouchi Y, 1998, J NUCL MED, V39, P198; Pappas BA, 1996, BRAIN RES, V708, P50, DOI 10.1016/0006-8993(95)01267-2; PIOVESAN P, 1995, INT J DEV NEUROSCI, V13, P13, DOI 10.1016/0736-5748(94)00070-J; PLASCHKE K, 1993, INT J DEV NEUROSCI, V11, P477, DOI 10.1016/0736-5748(93)90021-5; Potkin SG, 2001, INT J NEUROPSYCHOPH, V4, P223, DOI 10.1017/S1461145701002528; Prickaerts J, 1999, BEHAV BRAIN RES, V102, P73, DOI 10.1016/S0166-4328(98)00158-2; Rabey JM, 2000, CLIN NEUROPHARMACOL, V23, P324, DOI 10.1097/00002826-200011000-00005; Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x; Salmon E, 1996, J CEREBR BLOOD F MET, V16, P399, DOI 10.1097/00004647-199605000-00006; SCREMIN OU, 1993, J CEREBR BLOOD F MET, V13, P702, DOI 10.1038/jcbfm.1993.89; Selkirk AB, 1998, PHARM SCI TECHNOL TO, V1, P8, DOI 10.1016/S1461-5347(98)00009-1; Sharma M, 2002, LIFE SCI, V71, P2489, DOI 10.1016/S0024-3205(02)02083-0; Sharma M, 2001, PHARMACOL BIOCHEM BE, V70, P325, DOI 10.1016/S0091-3057(01)00611-6; Shi J, 2000, NEUROBIOL AGING, V21, P357, DOI 10.1016/S0197-4580(00)00119-6; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Small GW, 2000, P NATL ACAD SCI USA, V97, P6037, DOI 10.1073/pnas.090106797; Smith KJ, 1999, BRAIN PATHOL, V9, P69; SPAGNOLI A, 1991, NEUROLOGY, V41, P1726, DOI 10.1212/WNL.41.11.1726; Svendsen O, 1998, SCAND J LAB ANIM SCI, V25, P9; Svensson AL, 1999, NEUROREPORT, V10, P3485, DOI 10.1097/00001756-199911260-00004; TAGLIALATELA G, 1994, EXP GERONTOL, V29, P55, DOI 10.1016/0531-5565(94)90062-0; TAKASU N, 1991, DIABETES, V40, P1141, DOI 10.2337/diabetes.40.9.1141; Tanaka K, 1996, BRAIN RES, V729, P55, DOI 10.1016/0006-8993(96)00400-3; TERWEL D, 1995, EUR J PHARMACOL, V287, P65, DOI 10.1016/0014-2999(95)00475-4; TSUCHIYA M, 1993, EXP BRAIN RES, V95, P1; TSUJIMOTO K, 1995, NEUROSCI LETT, V188, P105, DOI 10.1016/0304-3940(95)11409-P; Ueno M, 2002, J CEREBR BLOOD F MET, V22, P97, DOI 10.1097/00004647-200201000-00012; Valla J, 2001, J NEUROSCI, V21, P4923, DOI 10.1523/JNEUROSCI.21-13-04923.2001; Wakita H, 2002, BRAIN RES, V924, P63, DOI 10.1016/S0006-8993(01)03223-1; Wang LM, 2000, EUR J PHARMACOL, V398, P65, DOI 10.1016/S0014-2999(00)00291-0; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.0.CO;2-Z; Weinstock M, 2001, ANN NY ACAD SCI, V939, P148; WILSON GL, 1984, DIABETOLOGIA, V27, P587, DOI 10.1007/BF00276973; Wong TP, 1999, J NEUROSCI, V19, P2706; Xiao XQ, 2000, NEUROSCI LETT, V286, P155, DOI 10.1016/S0304-3940(00)01088-0; Xiao XQ, 1999, NEUROSCI LETT, V275, P73, DOI 10.1016/S0304-3940(99)00695-3; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649	92	70	73	0	9	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	MAR	2004	111	3					347	366		10.1007/s00702-003-0058-y			20	Clinical Neurology; Neurosciences	Neurosciences & Neurology	803SZ	WOS:000220252100009	14991459				2021-06-18	
J	Karimi-Abdolrezaee, S; Eftekharpour, E; Fehlings, MG				Karimi-Abdolrezaee, S; Eftekharpour, E; Fehlings, MG			Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Caspr; NF200; rat; real-time PCR; western blotting	GATED POTASSIUM CHANNELS; K+ CHANNELS; IN-VITRO; COMPRESSIVE INJURY; EVOKED-POTENTIALS; GLIA INTERACTIONS; CONDUCTION-BLOCK; LOCALIZATION; APOPTOSIS; MYELIN	After spinal cord injury (SCI), surviving white matter axons display axonal dysfunction associated with demyelination and altered K+ channel activity To clarify the molecular basis of posttraumatic axonal pathophysiology after SCI, we investigated the changes in expression and distribution of the axonal K+ channel subunits Kv1.1 and Kv1.2 in spinal cord white matter after in vivo SCI in the rat. Using Western blot analysis, we found an increased expression of Kv1.1 and Kv1.2 at 2 and 6 weeks after SCI. By real-time PCR we observed an increase in Kv1.1 and Kv1.2 mRNA levels 1 day after SCI, which persisted until 6 weeks. Confocal immunohistochemistry showed a markedly dispersed labelling of Kv1.1 and Kv1.2 along the injured axons, in contrast to the tight localization of these channels to the juxtaparanodes of noninjured axons. This redistribution of Kv1.1 and Kv1.2 occurred as early as 1 h postinjury along some injured axons, and persisted at 6 weeks postinjury. In parallel with the redistribution of Kv1.1 and 1.2, contactin-associated protein (Caspr), which is normally confined to a paranodal location, also displayed a more diffuse distribution along the injured spinal cord axons. Our results suggest that the increased expression of Kv1.1 and Kv1.2 proteins is transcriptionally regulated. In contrast, the redistribution of the axonal K+ channel subunits occurs very early postinjury and probably reflects a disruption of the juxtaparanodal axonal region due to physical trauma, as shown by altered localization of Caspr.	Univ Toronto, Krembil Neurosci Ctr, Toronto Western Res Inst, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Krembil Neurosci Ctr, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Hlth Network, Toronto Western Hosp, Room 4W-449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael@uhnres.utoronto.ca		Fehlings, Michael/0000-0002-5722-6364; Eftekharpour, Eftekhar/0000-0002-2849-3754; Karimi-Abdolrezaee, Soheila/0000-0002-0683-2663			Agrawal SK, 1996, J NEUROSCI, V16, P545; Arroyo EJ, 2002, J NEUROSCI, V22, P1726, DOI 10.1523/JNEUROSCI.22-05-01726.2002; BALENTINE JD, 1978, LAB INVEST, V39, P254; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; Bunge R P, 1997, Adv Neurol, V72, P305; BUNGE RP, 1993, ADV NEUROL, V59, P75; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dupree JL, 1999, J CELL BIOL, V147, P1145, DOI 10.1083/jcb.147.6.1145; Edwards L, 2002, J COMP NEUROL, V443, P154, DOI 10.1002/cne.10115; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Eng H, 1999, J NEUROSCI, V19, P1; FEHLINGS MG, 1992, BRAIN RES, V579, P32, DOI 10.1016/0006-8993(92)90738-U; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/0006-8993(96)00667-1; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; Hayes KC, 1997, J NEUROTRAUM, V14, P235, DOI 10.1089/neu.1997.14.235; KARIMIABDOLREZA.S, 2002, J NEUROTRAUM, V19, P566; Kirkpatrick LL, 2001, J NEUROSCI, V21, P2288; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liu XZ, 1997, J NEUROSCI, V17, P5395; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Nashmi R, 2001, BRAIN RES REV, V38, P165, DOI 10.1016/S0165-0173(01)00134-5; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Poliak S, 2001, J NEUROSCI, V21, P7568; Rasband M, 1998, J NEUROSCI, V18, P36; Rasband MN, 2001, J COMP NEUROL, V429, P166, DOI 10.1002/1096-9861(20000101)429:1<166::AID-CNE13>3.0.CO;2-Y; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Schmidt K, 1999, BRAIN RES, V843, P145, DOI 10.1016/S0006-8993(99)01938-1; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Sobko A, 1998, J NEUROSCI, V18, P10398; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; Wrathall JR, 1998, J NEUROSCI, V18, P8780	49	70	70	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2004	19	3					577	589		10.1111/j.0953-816X.2004.03164.x			13	Neurosciences	Neurosciences & Neurology	775WU	WOS:000189084300009	14984408				2021-06-18	
J	Zhao, ZM; Li, HJ; Liu, HY; Lu, SH; Yang, RC; Zhang, QJ; Han, ZC				Zhao, ZM; Li, HJ; Liu, HY; Lu, SH; Yang, RC; Zhang, QJ; Han, ZC			Intraspinal transplantation of CD34+human umbilical cord blood cells after spinal cord hemisection injury improves functional recovery in adult rats	CELL TRANSPLANTATION			English	Article						spinal cord injury; bone marrow stromal cells; human umbilical cord blood cells; transplantation; stem cell plasticity; rats	MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; REPLACEMENT THERAPIES; PROMOTE RECOVERY; IN-VITRO; DIFFERENTIATE; STROKE; ENGRAFTMENT	The present study was designed to compare the functional outcome of the intraspinal transplantation of CD34+ human umbilical cord blood (CB) cells with that of human bone marrow stromal (BMS) cells in adult rats with spinal cord injury. Sixty adult Wistar rats were subjected to left spinal cord hemisection. and then divided into three groups randomly. The control group received an injection of PBS without cells, while the two other groups of rats received a transplantation of 5 x 10(5) CD34+ CB or BMS cells, respectively. Functional outcome was measured using the modified Tarlov score at days 1, 7, 14, 21, and 28 after transplantation. A statistically significant improvement in functional outcome and survival rate in the experimental groups of rats was observed compared with the control group. Rats that received CD34+ CB cells achieved a better improvement in functional score than those that received BMS cells at days 7 and 14 after transplantation. Histological evaluation revealed that bromodeoxyuridine (BrdU)-labeled CD34+ CB and BMS cells survived and migrated into the injured area. Some of these cells expressed galial fibriliary acidic protein (GFAP) or neuronal nuclear antigen (NeuN). Our data demonstrate for the first time that intraspinal transplantation of human CD34+ CB cells provides benefit in function recovery after spinal cord hemisection in rats and suggest that CD34+ CB cells may be an excellent choice of cells as routine starting material of allogenic and autologous transplantations for the treatment of spinal cord injury.	Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Natl Res Ctr Stem Cell Engn & Technol, Tianjin 300020, Peoples R China; Peking Union Med Coll, Tianjin, Peoples R China; Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang, Peoples R China	Han, ZC (corresponding author), Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Natl Res Ctr Stem Cell Engn & Technol, Tianjin 300020, Peoples R China.	tihzch@public.tpt.tj.cn	Han, Zhong Chao/D-7157-2016	Han, Zhong Chao/0000-0002-2687-7682			Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Broxmeyer H E, 1996, Cancer Treat Res, V84, P139; Buzanska L, 2002, J CELL SCI, V115, P2131; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; DENG W, 2001, BIOCHEM BIOPH RES CO, V282, P1418; Diener PS, 1998, J NEUROSCI, V18, P779; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Gage FH, 1998, NATURE, V392, P18; Galvin KA, 2002, MED J AUSTRALIA, V177, P316, DOI 10.5694/j.1326-5377.2002.tb04791.x; Gluckman E, 2001, Rev Clin Exp Hematol, V5, P87, DOI 10.1046/j.1468-0734.2001.00034.x; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Tariq M, 1998, J NEUROTRAUM, V15, P239, DOI 10.1089/neu.1998.15.239; Wickelgren I, 2002, SCIENCE, V297, P178, DOI 10.1126/science.297.5579.178; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zhao Zong-mao, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P484	33	70	88	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2004	13	2					113	122		10.3727/000000004773301780			10	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	813MD	WOS:000220910300003	15129757				2021-06-18	
J	Lu, M; Chen, JL; Lu, DY; Yi, L; Mahmood, A; Chopp, M				Lu, M; Chen, JL; Lu, DY; Yi, L; Mahmood, A; Chopp, M			Global test statistics for treatment effect of stroke and traumatic brain injury in rats with administration of bone marrow stromal cells	JOURNAL OF NEUROSCIENCE METHODS			English	Article						stroke; traumatic brain injury; rat; data analysis; global test	LONGITUDINAL DATA-ANALYSIS; GENERALIZED LINEAR-MODELS; MIDDLE CEREBRAL-ARTERY; CLINICAL-TRIALS; ODDS RATIO; OUTCOMES; OCCLUSION; ISCHEMIA	Because no single test measures disability in rats with middle cerebral artery occlusion/traumatic brain injury (MCAo/TBI), multiple tests are needed to assess the effect of bone marrow stromal cell (MSC) on functional recovery. Testing the treatment effect on each outcome at the 0.05 level without adjusting for multiple outcomes can increase type I error. Therefore, we applied the global test to evaluate a common MSC dose effect on multiple outcomes in two applications: (i) MCAo rats with the MSC dose of zero (BPS), 1 x 10(6) and 3 x 10(6), and (ii) TBI rats with the MSC dose of zero, 1 x 10(6), 2 x 10(6) and 4 x 10(6), administered intravenously at I day after injury. For the MCAo rats, 3 x 10(6) MSCs improved the 14 day functional recovery (P < 0.05) compared to the controls. TBI rats with the MSC dose 4 x 10(6) were improved significantly at I month compared to controls, rats with 1 x 10(6) or 2 x 10(6) MSCs (P < 0.05). The global test on multiple outcomes is more efficient than a single outcome when treatment effects are consistent. The less correlation among the outcomes, the more power and, therefore, the higher efficiency of the global test. We demonstrated that the global test for continuous outcomes could be implemented under careful statistical modeling and proper data transformation. (C) 2003 Elsevier B.V. All rights reserved.	Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Lu, M (corresponding author), Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, 1 Ford Pl,3E, Detroit, MI 48202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038292, P01NS023393, R01NS033627] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL64766] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS23393, R01 NS33627, R01 NS38292] Funding Source: Medline		CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen J., 1983, APPL MULTIPLE REGRES; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Lehmann EL., 1986, TESTING STAT HYPOTHE; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIPSITZ SR, 1991, BIOMETRIKA, V78, P153; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu M, 2001, STAT MED, V20, P1891, DOI 10.1002/sim.841; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; PARK T, 1993, STAT MED, V12, P1723, DOI 10.1002/sim.4780121807; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; *SAS I, 1999, SAS STAT SOFTW; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; WEDDERBURN RWM, 1974, BIOMETRIKA, V61, P439, DOI 10.2307/2334725; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	24	70	89	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	SEP 30	2003	128	1-2					183	190		10.1016/S0165-0270(03)00188-2			8	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	721GD	WOS:000185307900019	12948561				2021-06-18	
J	MacKay, CI; Han, PP; Albuquerque, FC; McDougall, CG				MacKay, CI; Han, PP; Albuquerque, FC; McDougall, CG			Recurrence of a vertebral artery dissecting pseudoaneurysm after successful stent-supported coil embolization: Case report	NEUROSURGERY			English	Article						coil embolization; dissection; pseudoaneurysm; stent; subarachnoid hemorrhage; vertebral artery	TECHNICAL CASE-REPORT; SUBARACHNOID HEMORRHAGE; ENDOVASCULAR TREATMENT; FOLLOW-UP; ANEURYSMS; OCCLUSION; FUSIFORM	OBJECTIVE AND IMPORTANCE: Dissecting aneurysms of the intracranial vertebral artery are increasingly recognized as a cause of subarachnoid hemorrhage. We present a case involving technical success of the stent-supported coil embolization but with recurrence of the dissecting pseudoaneurysm of the intracranial vertebral artery. The implications for the endovascular management of ruptured dissecting pseudoaneurysms of the intracranial vertebral artery are discussed. CLINICAL PRESENTATION: A 36-year-old man with a remote history of head injury had recovered functionally to the point of independent living. He experienced the spontaneous onset of severe head and neck pain, which progressed rapidly to obtundation. A computed tomographic scan of the head revealed subarachnoid hemorrhage centered in the posterior fossa. The patient underwent cerebral angiography, which revealed dilation of the distal left vertebral artery consistent with a dissecting pseudoaneurysm. INTERVENTION: Transfemoral access was achieved under general anesthesia, and two overlapping stents (3 mm in diameter and 14 mm long) were placed to cover the entire dissected segment. Follow-up angiography of the left vertebral artery showed the placement of the stents across the neck of the aneurysm; coil placement was satisfactory, with no residual aneurysm filling. Approximately 6 weeks after the patient's initial presentation, he developed the sudden onset of severe neck pain. A computed tomographic scan showed no subarachnoid hemorrhage, but computed tomographic angiography revealed that the previously treated left vertebral artery aneurysm had recurred. Angiography confirmed a recurrent pseudoaneurysm around the previously placed Guglielmi detachable coils. A test balloon occlusion was performed for 30 minutes. The patient's neurological examination was stable throughout the test occlusion period. Guglielmi detachable coil embolization of the left vertebral artery was then performed, sacrificing the artery at the level of the dissection. After the procedure was completed, no new neurological deficits occurred. On the second day after the procedure, the patient was discharged from the hospital. He was alert, oriented, and able to walk. CONCLUSION: We appreciate the value of preserving a parent vessel when a dissecting pseudoaneurysm of the intracranial vertebral artery ruptures in patients with inadequate collateral blood flow, in patients with disease involving the contralateral vertebral artery, or in patients with both. However, our case represents a cautionary note that patients treated in this fashion require close clinical follow-up. We suggest that parent vessel occlusion be considered the first option for treatment in patients who will tolerate sacrifice of the parent vessel along its diseased segment. In the future, covered stent technology may resolve this dilemma for many of these patients.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ USA	McDougall, CG (corresponding author), Barrow Neurol Inst, Neurosci Publicat, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.						AOKI N, 1990, STROKE, V21, P1628, DOI 10.1161/01.STR.21.11.1628; COSSU M, 1993, NEUROSURGERY, V32, P344, DOI 10.1227/00006123-199303000-00002; ENDO S, 1993, NEUROSURGERY, V33, P732, DOI 10.1227/00006123-199310000-00026; Kurata A, 2001, AM J NEURORADIOL, V22, P11; Lanzino G, 1999, J NEUROSURG, V91, P538, DOI 10.3171/jns.1999.91.4.0538; Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020; Lylyk P, 1998, NEUROSURGERY, V43, P385, DOI 10.1097/00006123-199808000-00132; Lylyk P, 2001, J NEUROSURG, V94, P427, DOI 10.3171/jns.2001.94.3.0427; Malek AM, 2000, J TRAUMA, V48, P143, DOI 10.1097/00005373-200001000-00027; Mizutani T, 1999, NEUROSURGERY, V45, P253, DOI 10.1097/00006123-199908000-00010; MIZUTANI T, 1995, NEUROSURGERY, V36, P905, DOI 10.1227/00006123-199505000-00003; Mizutani T, 2001, J NEUROSURG, V94, P712, DOI 10.3171/jns.2001.94.5.0712; Nakagawa K, 2000, J NEUROSURG, V93, P19, DOI 10.3171/jns.2000.93.1.0019; Phatouros CC, 2000, NEUROSURGERY, V47, P107, DOI 10.1097/00006123-200007000-00023; Redekop G, 1999, NEUROSURGERY, V45, P1258, DOI 10.1097/00006123-199911000-00056; TSUKAHARA T, 1995, NEUROSURGERY, V36, P914, DOI 10.1227/00006123-199505000-00004; Yamaura I, 1999, J NEUROSURG, V90, P853, DOI 10.3171/jns.1999.90.5.0853; Yasui T, 1999, J NEUROSURG, V91, P139, DOI 10.3171/jns.1999.91.1.0139	18	70	77	3	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2003	53	3					754	759		10.1227/01.NEU.0000080065.49651.48			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	718AL	WOS:000185122900047	12943592				2021-06-18	
J	Chiang, MF; Chang, JG; Hu, CJ				Chiang, MF; Chang, JG; Hu, CJ			Association between apolipoprotein E genotype and outcome of traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						apolipoprotein E; genotype; PCR; traumatic brain injury	AMYLOID PROTEIN DEPOSITION; CLOSED-HEAD INJURY; E EPSILON-4 ALLELE; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; APOE GENOTYPE; BETA-PROTEIN; RISK; GENE; POLYMORPHISM	Background. The prognosis of traumatic brain injury is quite variable and not fully explained by the known factors. This study is to examine if the polymorphism of apolipoprotein E (apoE) influences the outcome of traumatic brain injury. Methods. Over a period of twelve months, we prospectively studied 100 patients who sustained traumatic brain injuries and were admitted to our neurosurgical unit. Findings. Nineteen patients were apoE4(+) and 81 patients were apoE4(-). There was no significant difference between apoE4(+) and apoE4(-) groups in the cause of injury (p=0.288), type of brain injury (p=0.983) and choice of treatment (p=0.88). The proportion of patients with a lower GCS (<13), indicating a poor prognosis, was higher in the apoE4(+) group (73.7%) than that in apoE4(-) group (61.7%), although the difference was not significant (p=0.654). Six patients (7.4%) in the apoE4(-) group and 5(26.3%) in the apoE4(+) group had been drinking alcohol at the time of injury (p=0.018). The mean duration of hospital stay for apoE4(+) patients was significantly longer than for apoE4(-) patients (p<0.001). Six months after injury, 10 of 19 patients (52.6%) with apoE4 had an unfavorable outcome (dead, vegetative state, or severe disability) compared with 20 of the 81 (24.1%) patients without apoE4 (p=0.017). The apoE4(+) patients had a significantly longer hospital stay and unfavorable outcomes a er brain injury. Interpretation. This study discloses a significant genetic association between the apoE genotypes and outcomes of traumatic brain injury. Patients with apoE4 allele are more likely to have an unfavorable clinical outcome after brain injury.	Mackay Mem Hosp, Dept Neurosurg, Mackay Jr Coll Nursing, Taipei 104, Taiwan; China Med Coll, Dept Mol Med, Taichung, Taiwan; Taipei Municipal Jen Ai Hosp, Dept Neurol, Taipei, Taiwan	Chiang, MF (corresponding author), Mackay Mem Hosp, Dept Neurosurg, Mackay Jr Coll Nursing, 92 Sec 2,Chung Shan N Rd, Taipei 104, Taiwan.		Chang, Jan-Gowth/C-9544-2009				ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Graham DI, 1999, ACT NEUR S, V73, P89; HIXSON JE, 1990, J LIPID RES, V31, P545; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Hu CJ, 1998, J NEUROL SCI, V157, P158, DOI 10.1016/S0022-510X(98)00052-5; Johansson K, 1997, LANCET, V349, P1143, DOI 10.1016/S0140-6736(97)24016-X; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Katzman R, 1998, NEUROCHEM RES, V23, P369, DOI 10.1023/A:1022461601609; Katzman R, 1996, NEUROLOGY, V46, P889; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	31	70	74	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	AUG	2003	145	8					649	654		10.1007/s00701-003-0069-3			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	719WL	WOS:000185228000010	14520543				2021-06-18	
J	Valera, EM; Berenbaum, H				Valera, EM; Berenbaum, H			Brain injury in battered women	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the International-Society-for-Traumatic-Stress-Studies	DEC 06-09, 2001	NEW ORLEANS, LOUISIANA	Int Soc Traumat Stress Studies			MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; VIOLENCE; RELIABILITY; CONCUSSION; DEPRESSION; SYMPTOMS; SCALES	The goals of the present study were to examine (a) whether battered women in a sample of both shelter and nonshelter women are sustaining brain injuries from their partners and (b) if so, whether such brain injuries are associated with partner abuse severity, cognitive functioning, or psychopathology. Ninety-nine battered women were assessed using neuropsychological, psychopathology, and abuse history measures. Almost three quarters of the sample sustained at least I partner-related brain injury and half sustained multiple partner-related brain injuries. Further, in a subset of women (n = 57), brain injury severity was negatively associated with measures of memory, learning, and cognitive flexibility and was positively associated with partner abuse severity, general distress, anhedonic depression, worry, anxious arousal, and posttraurnatic stress disorder symptomatology.	Univ Illinois, Dept Psychol, Urbana, IL 61801 USA	Valera, EM (corresponding author), Massachusetts Gen Hosp, Dept Pathol, Bldg 149,9th Floor E,13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH011763] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1 F31 MH11763-01A2] Funding Source: Medline		Adjutant General's Office, 1944, ARM IND TEST BATT MA; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bremner JD, 1999, BIOL PSYCHIAT, V45, P797, DOI 10.1016/S0006-3223(99)00009-8; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Campbell JC, 1997, PSYCHIAT CLIN N AM, V20, P353, DOI 10.1016/S0193-953X(05)70317-8; CASCARDI M, 1992, J FAM VIOLENCE, V7, P249, DOI 10.1007/BF00994617; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Cohen J., 1987, STAT POWER ANAL BEHA; Committee on Mild Traumatic Brain Injury and American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P48; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis D. C., 1988, CLIN NEUROPSYCHOL, V2, P88, DOI [10.1080/13854048808520100, DOI 10.1080/13854048808520100]; Diaz-Olavarrieta C, 1999, ARCH NEUROL-CHICAGO, V56, P681, DOI 10.1001/archneur.56.6.681; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dutton M.A., 1992, EMPOWERING HEALING B; First M., 1995, STRUCTURED CLIN INTE; GENNARELLI TA, 1981, ACTA NEUROPATHOL B S, V7, P26; Goodman L.A., 1993, APPL PREVENTATIVE PS, V2, P79, DOI DOI 10.1016/S0962-1849(05)80114-3; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Harway M, 1994, SPOUSE ABUSE ASSESSI; Hawley DA, 2001, J EMERG MED, V21, P317, DOI 10.1016/S0736-4679(01)00401-2; HOUSKAMP BM, 1991, J INTERPERS VIOLENCE, V6, P367, DOI 10.1177/088626091006003008; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Koss M. P., 1994, NO SAFE HAVEN MALE V, P69; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1982, 5 EUR C INT NEUR SOC; MARSHALL LL, 1992, J FAM VIOLENCE, V7, P103, DOI 10.1007/BF00978700; MATARAZZO JD, 1984, J CLIN NEUROPSYCHOL, V6, P351, DOI 10.1080/01688638408401227; Mayberg H, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P177; McGrath E., 1990, WOMEN DEPRESSION RIS; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MEYER TJ, 1990, BEHAV RES THER, V28, P487, DOI 10.1016/0005-7967(90)90135-6; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROURKE SB, 1996, NEUROPSYCHOLOGICAL A, P379; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SMITH DJ, 2001, J EMERG MED, V21, P223; Straus M, 1990, PHYSICAL VIOLENCE AM; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Vitanza S, 1995, Violence Vict, V10, P23; WALKER LEA, 1994, ABUSED WOMAN SURVIVO; WARSHAW C, 2001, PSYCHOL ASPECTS WOME, P477; Wechsler, 1981, WAIS R MANUAL; YOUNGJOHN JR, 1992, CLIN NEUROPSYCHOL, V0006, P00276, DOI DOI 10.1080/13854049208404129	53	70	70	2	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	AUG	2003	71	4					797	804		10.1037/0022-006X.71.4.797			8	Psychology, Clinical	Psychology	703QM	WOS:000184292500018	12924684				2021-06-18	
J	Fan, P; Yamauchi, T; Noble, LJ; Ferriero, DM				Fan, P; Yamauchi, T; Noble, LJ; Ferriero, DM			Age-dependent differences in glutathione peroxidase activity after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cortical impactor; glutathione peroxidase; immature; posttraumatic brain edema	ZINC-SUPEROXIDE-DISMUTASE; PERINATAL HYPOXIA-ISCHEMIA; HEAD-INJURY; TRANSGENIC MICE; ANTIOXIDANT ENZYMES; OXIDATIVE STRESS; REGIONAL VULNERABILITY; LIPID-PEROXIDATION; MOUSE-BRAIN; RAT-BRAIN	Children younger than 4 years old have worse outcome after traumatic brain injury (TBI) compared to older children and adults. This increased susceptibility may in part be due to differences in the response to oxidative stress. We hypothesized that the immature brain does not have an adequate compensatory response to injury from oxidative stress. To begin to address this hypothesis, we first compared the general dimensions and water content in postnatal day 21 (P21) and adult murine brain in the naive state as well as after injury (edema). We examined glutathione peroxidase (GPx) activity in cortical and subcortical regions in P21 and adult murine brain following a controlled cortical impact. Brain dimensions including areas of the mantle and hemispheres were similar in each of these groups. The thickness of the cortical mantle was significantly greater in the immature brain as compared to the mature brain (p = 0.01, respectively). Brain edema was assessed through changes in water content, and the response to oxidative challenge was identified by changes in GPx activity. The P21 brain was similar in vulnerability to posttraumatic brain edema when compared to adult. GPx activity in the adult brain was increased within 24 h post-injury in the cortex, thalamus and hippocampus (ANOVA, p < 0.05), whereas there was no compensatory increase in GPx activity in P21 brain, although baseline levels had reached adult levels developmentally. These findings support our hypothesis and illuminate the important role of oxidative stress after TBI in the immature brain that warrants further study.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Chang Gung Childrens Hosp, Dept Pediat, Taipei, Taiwan	Ferriero, DM (corresponding author), Univ Calif San Francisco, Dept Neurol, Rm C215,521 Parnassus Ave, San Francisco, CA 94143 USA.			FAN, PI-CHUAN/0000-0002-6974-971X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS041256] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 41256] Funding Source: Medline		Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ASPBERG A, 1992, DEV BRAIN RES, V66, P55, DOI 10.1016/0165-3806(92)90139-N; Barzo P, 1997, ACT NEUR S, V70, P119; Bauer R, 1999, EXP TOXICOL PATHOL, V51, P143, DOI 10.1016/S0940-2993(99)80088-8; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BRIZZEE K. R., 1959, GROWTH, V23, P337; BUARD A, 1992, NEUROSCI LETT, V141, P72, DOI 10.1016/0304-3940(92)90337-7; CEBALLOSPICOT I, 1992, MUTAT RES, V275, P281, DOI 10.1016/0921-8734(92)90032-K; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Conti AC, 1998, J NEUROSCI, V18, P5663; Crack PJ, 2001, J NEUROCHEM, V78, P1389, DOI 10.1046/j.1471-4159.2001.00535.x; DAVISON AN, 1968, CONT NEUROLOGY SERIE, V4, P253; DEHAAN JB, 1994, PEDIATR RES, V35, P188, DOI 10.1203/00006450-199402000-00013; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; EAYRS JT, 1959, J ANAT, V93, P385; Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; HADDARA M, 1956, J ANAT, V90, P494; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kempski O, 2001, SEMIN NEPHROL, V21, P303, DOI 10.1053/snep.2001.21665; LAZO O, 1991, J NEUROCHEM, V56, P1343, DOI 10.1111/j.1471-4159.1991.tb11431.x; LEUBA G, 1978, J HIRNFORSCH, V19, P301; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MELLER K, 1968, Z ZELLFORSCH MIK ANA, V92, P217, DOI 10.1007/BF00335649; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Ustun ME, 2001, J TRAUMA, V51, P503; VEXLER ZS, 2000, SEMIN NEONATOL, V6, P99; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	44	70	70	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					437	445		10.1089/089771503765355513			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900004	12803976				2021-06-18	
J	Witol, AD; Webbe, FM				Witol, AD; Webbe, FM			Soccer heading frequency predicts neuropsychological deficits	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						soccer; neuropsychological deficits; soccer heading; injury	TRAUMATIC BRAIN INJURY; COMPUTED-TOMOGRAPHY; FOOTBALL PLAYERS; TEST-PERFORMANCE; CONCUSSION; RECOVERY; SPORTS; MEMORY; IMPAIRMENT; IMPACT	This study investigated the presence of neuropsychological deficits associated with hitting the ball with one's head (heading) during soccer play. A neuro-cognitive test battery was administered to 60 male soccer players, high school, amateur and professional level, and 12 nonplaying control participants. The effects of currently reported heading behavior as well as that of estimated lifetime heading experience on neuropsychological test performance were examined. Players with the highest lifetime estimates of heading had poorer scores on scales measuring attention, concentration, cognitive flexibility and general intellectual functioning. Players' current level of heading was less predictive of neuro-cognitive level. Comparison of individual scores to age-appropriate norms revealed higher probabilities of clinical levels of impairment in players who reported greater lifetime frequencies of heading. Because of the worldwide popularity of the game, continued research is needed to assess the interaction between heading and soccer experience in the development of neuropsychological deficits associated with soccer play. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA	Webbe, FM (corresponding author), Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA.		Webbe, Frank/A-8074-2009	Webbe, Frank/0000-0002-4370-5698			Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; ASHWORTH B, 1985, SCOT MED J, V30, P240, DOI 10.1177/003693308503000413; Barth JT., 1989, MILD HEAD INJURY, P257; Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2001, ATHLET THER TODAY, V6, P28, DOI 10.1123/att.6.1.28; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ekstrand J, 1990, Br J Sports Med, V24, P117; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; FIELDS KB, 1989, PHYSICIAN SPORTSMED, V17, P69, DOI 10.1080/00913847.1989.11709682; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HARRISON D W, 1990, Journal of Emergency Medicine, V8, P21, DOI 10.1016/0736-4679(90)90381-5; Hunt M, 1990, Br J Sports Med, V24, P265; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; KRAUS R, 1983, Z EEGEMG, V14, P209; LAMBERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676; LEHMAN LB, 1988, AM FAM PHYSICIAN, V38, P181; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LUNBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P2483; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MATHEWS WB, 1972, BRIT MED J, V2, P327; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSENBERG SJ, 1984, J CLIN PSYCHOL, V40, P785, DOI 10.1002/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Sandelin J, 1985, Br J Sports Med, V19, P30; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; SMITH MD, 1992, PERCEPT MOTOR SKILL, V75, P955, DOI 10.2466/PMS.75.7.955-961; SMODLAKA VN, 1981, PHYSICIAN SPORTSMED, V9, P100; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spreen O., 1991, COMPENDIUM NEUROPSYC; Taylor L B, 1969, Clin Neurosurg, V16, P269; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; VANDEGEER JP, 1971, INTRO MULTIVARIATE A; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P204; ZACHARY RA, 1985, J CLIN PSYCHOL, V41, P532, DOI 10.1002/1097-4679(198507)41:4<532::AID-JCLP2270410414>3.0.CO;2-D; ZACHARY RA, 1986, SKIPLEY I LIVING SCA	59	70	70	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2003	18	4					397	417	PII S0887-6177(02)00151-8	10.1016/S0887-6177(02)00151-8			21	Psychology, Clinical; Psychology	Psychology	678GA	WOS:000182857100005	14591454				2021-06-18	
J	Suehiro, E; Ueda, Y; Wei, EP; Kontos, HA; Povlishocki, JT				Suehiro, E; Ueda, Y; Wei, EP; Kontos, HA; Povlishocki, JT			Posttraumatic hypothermia followed by slow rewarming protects the cerebral microcirculation	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia with rewarming; pial vaculature; rats; traumatic brain injury; vasoreactivity	SEVERE HEAD-INJURY; CONCUSSIVE BRAIN INJURY; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; CARDIOPULMONARY BYPASS; MODERATE HYPOTHERMIA; PIAL ARTERIOLES; RELAXING FACTOR; CO2 REACTIVITY; CYCLOSPORINE-A	In the clinical and laboratory setting, multiple reports have suggested the efficacy of hypothermia in blunting the damaging consequences of traumatic brain injury (TBI). With the use of posttraumatic hypothermia, it has been recognized that the time of initiation and duration of hypothermia are important variables in determining the degree of neuroprotection provided. Further, it has been recently recognized that the rate of posttraumatic rewarming is an important variable, with rapid rewarming exacerbating neuronal/axonal damage in contrast to slow rewarming which appears to provide enhanced neuroprotection. Although these findings have been confirmed in the brain parenchyma, no information exists for the cerebral microcirculation on the potential benefits of posttraumatic hypothermia followed by either slow or rapid rewarming. In the current communication we assess these issues in the pial circulation using a well-characterized model of TBI. Rats were prepared for the placement of cranial widows for direct assessment of the pial microcirculation prior to and after the induction of impact acceleration injury followed by moderate hypothermia with either subsequent slow or rapid rewarming strategies. The cranial windows allowed for the measurement of pial vessel diameter to assess ACh-dependent and CO2 reactivity in the chosen paradigms. ACh was applied topically to assess ACh-dependent dilation, while CO2 reactivity was assessed by changing the concentration of the inspired gas. Through this approach, it was found that posttraumatic hypothermia followed by slow rewarming maintained normal arteriolar vascular responses in terms of ACh-dependent dilation and CO2 reactivity. In contrast, arterioles subjected to TBI followed by normothermia or hypothermia and rapid rewarming showed impaired vasoreactivity in terms of their ACh-dependent and CO2 responses. This study provides additional evidence of the benefits of posttraumatic hypothermia followed by slow rewarming, demonstrating for the first time that the previously described neuroprotective effects extend to the cerebral microcirculation.	Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA	Povlishocki, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu	Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Golding EM, 2000, J CEREBR BLOOD F MET, V20, P820, DOI 10.1097/00004647-200005000-00008; Irikura K, 1998, J CEREBR BLOOD F MET, V18, P1294, DOI 10.1097/00004647-199812000-00003; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kishi K, 2000, ANESTH ANALG, V91, P140, DOI 10.1097/00000539-200007000-00026; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498; Kontos HA, 1998, AM J PHYSIOL-HEART C, V274, pH974; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Nakamura T, 1998, ACT NEUR S, V71, P85; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; NELSON CW, 1992, AM J PHYSIOL, V271, pH1356; Rehman A, 1997, BRIT J PHARMACOL, V122, P1702, DOI 10.1038/sj.bjp.0701556; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; UEDA Y, 2002, J NEUROTRAUM, V19, P1357; Wagerle LC, 1998, J THORAC CARDIOV SUR, V115, P1047, DOI 10.1016/S0022-5223(98)70404-0; WEI EP, 1992, STROKE, V23, P1623, DOI 10.1161/01.STR.23.11.1623; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Wei EP, 1999, STROKE, V30, P851, DOI 10.1161/01.STR.30.4.851; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262; WEI EP, 2002, J NEUROTRAUM, V19, P1358	46	70	74	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					381	390		10.1089/089771503765172336			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900007	12866817				2021-06-18	
J	Weismer, G; Laures, JS				Weismer, G; Laures, JS			Direct magnitude estimates of speech intelligibility in dysarthria: Effects of a chosen standard	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						speech intelligibility; perceptual scaling; dysarthria	VOWEL ROUGHNESS; QUALITY	Direct magnitude estimation (DME) has been used frequently as a perceptual scaling technique in studies of the speech intelligibility of persons with speech disorders. The technique is typically used with a standard, or reference stimulus, chosen as a good exemplar of "midrange" intelligibility. In several published studies, the standard has been chosen subjectively, usually on the basis of the fixed set expertise of the investigators. The current experiment demonstrates that a of sentence-level utterances, obtained from 4 individuals with dysarthria (2 with Parkinson disease, 2 with traumatic brain injury) as well as 3 neurologically normal speakers, is scaled differently depending on the identity of the standard. Four different standards were used in the main experiment, three of which were judged qualitatively in two independent evaluations to be good exemplars of midrange intelligibility. Acoustic analyses did not reveal obvious differences between these four standards but suggested that the standard with the worst-scaled intelligibility had much poorer voice source characteristics compared to the other three standards. Results are discussed in terms of possible standardization of midrange intelligibility exemplars for DME experiments.	Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Georgia State Univ, Program Commun Disorders, Atlanta, GA 30303 USA	Weismer, G (corresponding author), Univ Wisconsin, Dept Commun Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	weismer@waisman.wisc.edu			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P60DC001409] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC00319, DC01409] Funding Source: Medline		BECK J, 1965, PERCEPT MOTOR SKILL, V21, P151, DOI 10.2466/pms.1965.21.1.151; BECK J, 1961, AM J PSYCHOL, V74, P242, DOI 10.2307/1419409; CHEN MY, 1995, J ACOUST SOC AM, V98, P2443, DOI 10.1121/1.414399; CULLINAN WL, 1963, J SPEECH HEAR RES, V6, P187, DOI 10.1044/jshr.0602.187; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; ENGEN T, 1971, WOODWORTH SCHLOSBERG, P47; Forrest K., 1997, CLIN MANAGEMENT SENS, P63; Gescheider GA., 1976, PSYCHOPHYSICS METHOD; HILLENBRAND J, 1994, J SPEECH HEAR RES, V37, P769, DOI 10.1044/jshr.3704.769; KENT RD, 1989, J SPEECH HEAR DISORD, V54, P482, DOI 10.1044/jshd.5404.482; McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; MILENKOVIC P, 1994, CSPEECH COMPUTER PRO; MONSEN RB, 1983, J SPEECH HEAR DISORD, V48, P286, DOI 10.1044/jshd.4803.286; Poulton E.C., 1989, BIAS QUANTIFYING JUD; POULTON EC, 1968, PSYCHOL BULL, V69, P1, DOI 10.1037/h0025267; Ramig L. O., 1992, INTELLIGIBILITY SPEE, DOI [10.1075/sspcl.1.05ram, DOI 10.1075/SSPCL.1.05RAM]; Samlan R. A., 1995, AM J SPEECH-LANG PAT, V4, P9; SCHIAVETTI N, 1983, J SPEECH HEAR RES, V26, P568, DOI 10.1044/jshr.2604.568; SCHIAVETTI N, 1981, J SPEECH HEAR RES, V24, P441, DOI 10.1044/jshr.2403.441; Schiavetti N, 1992, INTELLIGIBILITY SPEE, P11; SCHIFF ER, 1994, GASTROINTEST DIS TOD, V3, P7; SCHLIESSER HF, 1985, PERCEPT MOTOR SKILL, V61, P1299, DOI 10.2466/pms.1985.61.3f.1299; Southwood M., 1993, J MED SPEECH-LANG PA, V1, P151; Southwood M. H., 1996, J MED SPEECH-LANG PA, V4, P13; Stevens S. S., 1975, PSYCHOPHYSICS INTRO; STEVENS SS, 1956, AM J PSYCHOL, V69, P1, DOI 10.2307/1418112; TONER MA, 1989, J SPEECH HEAR RES, V32, P78, DOI 10.1044/jshr.3201.78; TONER MA, 1990, J SPEECH HEAR RES, V33, P238, DOI 10.1044/jshr.3302.238; TURNER GS, 1995, J SPEECH HEAR RES, V38, P1001, DOI 10.1044/jshr.3805.1001; WEISMER G, 1988, J ACOUST SOC AM, V84, P1281, DOI 10.1121/1.396627; Weismer G, 2001, FOLIA PHONIATR LOGO, V53, P1, DOI 10.1159/000052649; Weismer G., 1992, INTELL SPEECH DISORD, V16, P67; Zraick RI, 2000, J SPEECH LANG HEAR R, V43, P979, DOI 10.1044/jslhr.4304.979	34	70	71	0	5	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	JUN	2002	45	3					421	433		10.1044/1092-4388(2002/033)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	561MH	WOS:000176144200001	12068996				2021-06-18	
J	Stone, JR; Okonkwo, DO; Singleton, RH; Mutlu, LK; Helm, GA; Povlishock, JT				Stone, JR; Okonkwo, DO; Singleton, RH; Mutlu, LK; Helm, GA; Povlishock, JT			Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid beta peptide in traumatic axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						A beta peptide; Alzheimer's Disease; apoptosis; APP; caspase; traumatic axonal injury; traumatic brain injury	DIFFUSE BRAIN-INJURY; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; CYCLOSPORINE-A; WHITE MATTER; DAMAGE; APP; APOPTOSIS; SECRETASE	Immunohistochemical studies demonstrate accumulation of the beta-amyloid precursor protein (APP) within injured axons following traumatic brain injury (TBI). Despite such descriptions, little is known about the ultimate fate of accumulating APP at sites of traumatic axonal injury (TAI). Recently, caspase-3-mediated cleavage of APP and subsequent Abeta deposition was linked to apoptotic neuronal death pathways in hippocampal neurons following ischemic and excitotoxic brain injury. Given that (1) APP is known to accumulate within traumatically injured axons, (2) caspase-3 activation has been demonstrated in traumatic axonal injury (TAI), and (3) recent studies have identified a caspase-3 cleavage site within APP, we initiated the current investigation to determine whether caspase-3-mediated cleavage of APP occurs in TAL We further assessed whether these events were found in relation to Abeta peptide formation. To this end, we employed antibodies targeting APP, the caspase-3-mediated breakdown product of APP proteolysis, and the Abeta peptide. Rats were subjected to impact acceleration TBI (6 h to 10 days survival), and their brains were processed for single-label bright field and multiple double-label immunofluorescent paradigms using the above antibodies. By 12 h postinjury, caspase-3-mediated APP proteolysis (CMAP) was demonstrated within the medial lemniscus (ML) and medial longitudinal fasciculus (MLF) in axons undergoing TAI, identified by their concomitant APP accumulation. Immunoreactivity for CMAP persisted up to 48 h postinjury in the ML and MLF, but was notably reduced by 10 days following injury. Further, CMAP was colocalized with Abeta formation in foci of TAL The current study demonstrates that caspase-3 cleavage of APP occurs in TAI and is associated with formation of Abeta peptide. These findings are of interest given recent epidemiological studies supporting an association between TBI and later risk for AD development.	Univ Virginia, Dept Neurosurg, Charlottesville, VA 22903 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA USA	Stone, JR (corresponding author), Univ Virginia, Dept Neurosurg, Charlottesville, VA 22903 USA.	jrs7r@virginia.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; Barnes NY, 1998, J NEUROSCI, V18, P5869; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BRAMLETT HM, J NEUROPATHOL EXP NE, V596, P1132; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jordan J, 1997, J NEUROCHEM, V68, P1612; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Teramoto N, 1998, J VIROL METHODS, V73, P89, DOI 10.1016/S0166-0934(98)00048-2; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Troy CM, 2000, J NEUROSCI, V20, P1386; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VONBERNHARDI R, 1989, BRAIN RES, V478, P301, DOI 10.1016/0006-8993(89)91510-2; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhang L, 1997, BIOCHEM BIOPH RES CO, V235, P845, DOI 10.1006/bbrc.1997.6698	73	70	71	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					601	614		10.1089/089771502753754073			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900005	12042095				2021-06-18	
J	Miranda, FE; Dennis, JW; Veldenz, HC; Dovgan, PS; Frykberg, ER				Miranda, FE; Dennis, JW; Veldenz, HC; Dovgan, PS; Frykberg, ER			Confirmation of the safety and accuracy of physical examination in the evaluation of knee dislocation for injury of the popliteal artery: A prospective study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	60th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 11-15, 2000	SAN ANTONIO, TX	Amer Assoc Surg Trauma			ARTERIOGRAPHY; TRAUMA; FRACTURES; PATIENT	Background: Knee dislocation, which poses a significant risk for injury of the popliteal artery, prompts many surgeons to evaluate these patients with arteriography routinely. Our hypothesis was that physical examination alone (without arteriography) accurately confirms or excludes surgically significant vascular injuries associated with knee dislocation. Methods: All patients diagnosed with a knee dislocation by an attending orthopedic surgeon between January 1990 and January 2000 were prospectively managed by protocol at our Level I trauma center according to their physical examination. Those with hard signs (active hemorrhage, expanding hematoma, absent pulse, distal ischemia, bruit/thrill) underwent arteriography followed immediately by surgical repair if indicated. Patients with no hard signs (negative physical examination) were admitted for 23 hours, underwent serial physical examination, and then followed as outpatients. Results: There were 35 knee dislocations in 35 patients during this 10-year period. The average age was 31 years; 18 dislocations were on the right knee and 17 were on the left. Two patients died from closed head injuries and multisystem trauma. Eight patients were found to have hard signs (positive physical examination) either at presentation (six patients) or during their hospitalization after reduction of their dislocation (two patients). All eight patients demonstrated a loss of pulses only. Six of these patients showed occlusion of the popliteal artery on arteriography and underwent surgical repair without complication (five vein grafts, one primary repair), one demonstrated spasm of the popliteal artery, and one showed a normal artery that required no treatment. None of the 27 patients with negative physical examination during their hospitalization ever developed limb ischemia, needed an operation for vascular injury, or experienced limb loss. Sixteen patients were available for follow-up (46%). Twelve patients with negative physical examination (44%) were contacted (mean, 13 months; range, 2-35 months), and four of the eight patients with positive physical examination (50%) and surgical repair were contacted (mean, 19 months; range, 6-49 months). None of the patients in either group developed any vascular-related symptoms or suffered from a vascular repair complication over the follow-up interval. Conclusion: This limited series suggests that the presence or absence of an injury of the popliteal artery after knee dislocation can be safely and reliably predicted, with a 94.3% positive predictive value and 100% negative predictive value. Arteriography appears to be unnecessary when physical examination is negative but may avert negative vascular exploration when physical examination is positive. This approach substantially reduces cost and resource use without adverse impact on the patient.	Univ Florida, Hlth Sci Ctr, Dept Surg, Jacksonville, FL 32209 USA	Dennis, JW (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Surg, 653-2 W 8th St, Jacksonville, FL 32209 USA.	james.dennis@jax.ufl.edu					APPLEBAUM R, 1990, AM J SURG, V160, P221, DOI 10.1016/S0002-9610(05)80311-3; Atteberry LR, 1996, J AM COLL SURGEONS, V183, P377; BISHARA RA, 1986, J VASC SURG, V3, P707, DOI 10.1067/mva.1986.avs0030707; Bryan T, 1991, Orthop Rev, V20, P525; BYNOE RP, 1991, J VASC SURG, V14, P346, DOI 10.1016/0741-5214(91)90087-B; DEBAKEY ME, 1946, ANN SURG, V123, P534, DOI 10.1097/00000658-194604000-00005; DENNIS JW, 1990, J VASC SURG, V11, P85; DENNIS JW, 1993, J TRAUMA, V35, P692, DOI 10.1097/00005373-199311000-00007; DOWNS AR, 1986, J VASC SURG, V4, P55; FRYKBERG ER, 1989, J TRAUMA, V29, P577, DOI 10.1097/00005373-198905000-00006; FRYKBERG ER, 1991, SURGERY, V109, P85; Gable DR, 1997, J TRAUMA, V43, P541, DOI 10.1097/00005373-199709000-00029; GOMES AS, 1985, AM J ROENTGENOL, V145, P1249, DOI 10.2214/ajr.145.6.1249; HUGHES CW, 1958, ANN SURG, V147, P555; KAUFMAN SL, 1992, RADIOLOGY, V184, P153, DOI 10.1148/radiology.184.1.1609074; KENDALL RW, 1993, J TRAUMA, V35, P875, DOI 10.1097/00005373-199312000-00013; Melton SM, 1997, ANN SURG, V225, P518, DOI 10.1097/00000658-199705000-00009; Roman P D, 1987, Orthop Rev, V16, P917; ROSE SC, 1988, J TRAUMA, V28, P240, DOI 10.1097/00005373-198802000-00022; SCLAFANI SJA, 1986, RADIOLOGY, V161, P165, DOI 10.1148/radiology.161.1.3763860; TREIMAN GS, 1992, ARCH SURG-CHICAGO, V127, P1056	21	70	74	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2002	52	2					247	251		10.1097/00005373-200202000-00008			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	522XQ	WOS:000173922600012	11834983				2021-06-18	
J	Prasad, MR; Ewing-Cobbs, L; Swank, PR; Kramer, L				Prasad, MR; Ewing-Cobbs, L; Swank, PR; Kramer, L			Predictors of outcome following traumatic brain injury in young children	PEDIATRIC NEUROSURGERY			English	Article						outcome; Glasgow coma scale; Glasgow outcome scale; child abuse; brain injury; children; infants; neuroimaging	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; AGE; RECOVERY; INFANTS; ABUSE; PRESCHOOLERS; MECHANISMS; CHILDHOOD; PROGNOSIS	The relationship between clinical and neuroimaging variables and multiple outcome measures was examined in a longitudinal, prospective study of 60 children less than 6 years of age who sustained either inflicted or noninflicted traumatic brain injury. Hierarchical multiple regression indicated that the modified Glasgow Coma Scale score, the duration of impaired consciousness and the number of intracranial lesions visualized on CT/MRI accounted for a significant amount of the variance in the Glasgow Outcome Scale (GOS), cognitive and motor scores at baseline, 3- and 12-month evaluations. Inflicted brain injury adversely affected both GOS and cognitive outcomes. Pupillary abnormalities were associated with poorer motor outcome. Neither age at injury nor the Injury Severity Score accounted for significant variability in outcomes. Copyright (C) 2002 S. Karger AG, Basel.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA	Prasad, MR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,Suite 2431, Houston, TX 77030 USA.	Mary.R.Prasad@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS29462] Funding Source: Medline		Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; APPELBAUM AS, 1977, J ABNORM CHILD PSYCH, V5, P417, DOI 10.1007/BF00915089; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bayley N., 2006, BAYLEY SCALES INFANT; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HOFFMANPLOTKIN D, 1984, CHILD DEV, V55, P794, DOI 10.1111/j.1467-8624.1984.tb03816.x; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUERSSEN TG, 2001, PEDIAT NEUROSURGERY, P601; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; McCarthy D., 1972, MCCARTHY SCALES CHIL; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; REILLY PL, 1988, CHILD NERV SYST, V4, P30; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Thorndike RL., 1986, STANFORD BINET INTEL, V4; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	45	70	73	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	FEB	2002	36	2					64	74		10.1159/000048355			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	531QN	WOS:000174427100002	11893887				2021-06-18	
J	Schmeer, C; Straten, G; Kugler, S; Gravel, C; Bahr, M; Isenmann, S				Schmeer, C; Straten, G; Kugler, S; Gravel, C; Bahr, M; Isenmann, S			Dose-dependent rescue of axotomized rat retinal ganglion cells by adenovirus-mediated expression of glial cell-line derived neurotrophic factor in vivo	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; GDNF; gene transfer; neurodegeneration; neurotrophic factors; regeneration	OPTIC-NERVE LESION; NEURONS IN-VIVO; ADULT-RATS; GENE-TRANSFER; FACTOR GDNF; DOPAMINERGIC-NEURONS; RET PROTOONCOGENE; MESSENGER-RNA; BRAIN; SURVIVAL	Adult rat retinal ganglion cells undergo degeneration after optic nerve transection. Repeated intraocular injection of glial cell-line derived neurotrophic factor (GDNF) has been shown to be efficient in enhancing retinal ganglion cell survival following optic nerve axotomy. In the present study we evaluated the potential survival-promoting effect of adenovirally administered GDNF on axotomized retinal ganglion cells. A single intravitreal injection [7 x 10(7) plaque-forming units (pfu) or 7 x 10(8) pfu] of an adenoviral vector expressing the rat GDNF gene from a cytomegalovirus promoter enhanced retinal ganglion cell survival 14 days after axotomy by 67 and 125%, respectively, when compared to control animals. Intraocular administration of the vector rescued 12.6 and 23%, respectively, of the retinal ganglion cells which would otherwise have died after axotomy. An increase in retinal GDNF protein and specific virally transduced GDNF mRNA expression was detected following intraocular vector application. Our data support previous findings showing that adenoviral delivery of neurotrophic factors to the vitreous body is a feasible approach for the prevention of axotomy-induced retinal ganglion cell death in vivo and may constitute a relevant strategy for future treatment in traumatic brain injury and ensuing neurodegeneration.	Univ Tubingen, Dept Neurol, Neuroregenerat Lab, D-72076 Tubingen, Germany; Inst Venezolano Invest Cient, Lab Neuroquim, Caracas 1020A, Venezuela; Univ Laval Robert Giffard, Ctr Rech, Beauport, PQ, Canada	Isenmann, S (corresponding author), Univ Tubingen, Dept Neurol, Neuroregenerat Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Baehr, Mathias/K-2188-2014; Isenmann, Stefan/AAJ-3788-2020	Schmeer, Christian/0000-0002-2289-0126			BAHR M, 1991, NEUROREPORT, V2, P581; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CUI Q, 1994, NEUROREPORT, V5, P1882, DOI 10.1097/00001756-199410000-00010; Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978; Eberhardt O, 2000, J NEUROSCI, V20, P9126; Encinas M, 2001, J NEUROSCI, V21, P1464; ESCHWEILER GW, 1993, J NEUROL SCI, V116, P34, DOI 10.1016/0022-510X(93)90086-E; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; Gravel C, 1997, NAT MED, V3, P765, DOI 10.1038/nm0797-765; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Isenmann S, 1997, EXP NEUROL, V147, P28, DOI 10.1006/exnr.1997.6585; Isenmann S, 2001, BRAIN RES, V892, P229, DOI 10.1016/S0006-8993(00)02957-7; Kermer P, 1999, FEBS LETT, V453, P361, DOI 10.1016/S0014-5793(99)00747-4; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7; Kugler S, 2001, MOL CELL NEUROSCI, V17, P78, DOI 10.1006/mcne.2000.0929; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; LE GLS, 1993, SCIENCE, V259, P988; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; Mason I, 1996, MOL CELL NEUROSCI, V8, P112, DOI 10.1006/mcne.1996.0050; Matheson CR, 1997, J NEUROBIOL, V32, P22, DOI 10.1002/(SICI)1097-4695(199701)32:1<22::AID-NEU3>3.0.CO;2-G; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Trupp M, 1997, J NEUROSCI, V17, P3554; VIDALSANZ M, 1988, EXP NEUROL, V102, P92, DOI 10.1016/0014-4886(88)90081-7; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Williams LR, 1996, J PHARMACOL EXP THER, V277, P1140; Yan Q, 1999, J NEUROBIOL, V38, P382, DOI 10.1002/(SICI)1097-4695(19990215)38:3<382::AID-NEU7>3.0.CO;2-5	41	70	71	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2002	15	4					637	643		10.1046/j.1460-9568.2002.01893.x			7	Neurosciences	Neurosciences & Neurology	536HB	WOS:000174693700005	11886444				2021-06-18	
J	McGeorge, P; Phillips, LH; Crawford, JR; Garden, SE; Della Sala, S; Milne, AB; Hamilton, S; Callender, JS				McGeorge, P; Phillips, LH; Crawford, JR; Garden, SE; Della Sala, S; Milne, AB; Hamilton, S; Callender, JS			Using virtual environments in the assessment of executive dysfunction	PRESENCE-TELEOPERATORS AND VIRTUAL ENVIRONMENTS			English	Article							TRAUMATIC BRAIN INJURY; REHABILITATION; REALITY; TECHNOLOGY; MEMORY; PEOPLE; DAMAGE	A study is reported into the role of virtual environments in the assessment of patients with executive dysfunction. Five patients and five matched controls entered the study. The patients did not differ significantly from normative values on the standard executive dysfunction measure, the Behavioural Assessment of the Dysexecutive Syndrome battery (Wilson, Alderman, Burgess, Emslie, & Evans, 1996); however, care staff reported the patients had problems planning. Patients and controls undertook both real and virtual environment multiple-errand planning tasks. The patients completed significantly fewer errands, and produced significantly worse plans than did controls in both the real and virtual environments. There was a significant correlation between performance in the real and virtual environments. The results suggest that virtual environments may provide a valid means of assessing planning impairments and that there may be patients with executive dysfunction (specifically planning deficits) that may not be detected by the currently available standardized tests.	Univ Aberdeen, Dept Psychol, Neuropsychol Res Grp, Old Aberdeen AB24 2UB, Scotland	McGeorge, P (corresponding author), Univ Aberdeen, Dept Psychol, Neuropsychol Res Grp, Old Aberdeen AB24 2UB, Scotland.		Crawford, John R/A-4165-2008; McGeorge, Peter/A-4233-2008; Phillips, Louise H/A-7952-2008	Crawford, John R/0000-0003-3403-3428; Phillips, Louise H/0000-0003-1005-8567; Phillips, Louise/0000-0002-0988-3028			Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; BENTON A L, 1978, Archives of Neurology, V35, P364; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P209, DOI 10.1080/713755574; CRAWFORD JR, 1996, BLACKWELL DICT NEURO, P108; Crawford JR, 1998, COMPREHENSIVE CLIN P, V7, P133; Cromby J. J., 1996, P 1 EUR C DIS VIRT R, P103; Cromby JJ, 1996, J INTELL DISABIL RES, V40, P489, DOI 10.1111/j.1365-2788.1996.tb00659.x; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R. K, 1981, WISCONSIN CARD SORTI; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; PARKER DM, 1992, HDB NEUROPSYCHOLOGIC, P267; Penfield W, 1935, BRAIN, V58, P115, DOI 10.1093/brain/58.1.115; PHILLIPS LH, 1997, GENERATIONS REV J BR, V7, P14; Phillips LH, 1997, Methodology of frontal " and executive function, P191; PONSFORD JL, 1996, RECOVERY TRAUMATIC B; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; ROSE FD, 1994, MED SCI RES, V22, P82; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Tinson D J, 1989, Int Disabil Stud, V11, P45; WEHMAN P, 1996, RECOVERY TRAUMATIC B; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; Wilson B., 1987, BEHAV INATTENTION TE; Wilson B.A., 1996, BADS BEHAV ASSESSMEN; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530	33	70	70	0	12	M I T PRESS	CAMBRIDGE	FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA	1054-7460			PRESENCE-TELEOP VIRT	Presence-Teleoper. Virtual Env.	AUG	2001	10	4					375	383		10.1162/1054746011470235			9	Computer Science, Cybernetics; Computer Science, Software Engineering	Computer Science	492AT	WOS:000172143800004					2021-06-18	
J	Mahone, EM; Koth, CW; Cutting, L; Singer, HS; Denckla, MB				Mahone, EM; Koth, CW; Cutting, L; Singer, HS; Denckla, MB			Executive function in fluency and recall measures among children with Tourette syndrome or ADHD	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	27th Annual Meeting of the International-Neuropsychological-Society	FEB, 1999	BOSTON, MASSACHUSETTS	Int Neuropsychol Soc		Tourette syndrome; executive function; attention deficit/hyperactivity disorder; verbal fluency; verbal learning	DEFICIT HYPERACTIVITY DISORDER; FRONTAL-SUBCORTICAL CIRCUITS; CONTINUOUS PERFORMANCE-TEST; CLOSED-HEAD INJURY; MAGNETIC-RESONANCE; VERBAL FLUENCY; BASAL GANGLIA; WORKING-MEMORY; DESIGN FLUENCY; HEALTHY-ADULTS	This study assessed two relevant aspects of executive dysfunction in children with either Tourette syndrome (TS) or ADHD. Process variables derived from existing neuropsychological measures were used to clarify the executive function construct. Clustering of responses on measures of verbal fluency, figural fluency, and verbal learning was examined to assess strategic response organization. Rule breaks, intrusions, and repetition errors were recorded to assess inhibition errors. No significant differences were found among the three groups (TS, ADHD, and controls) on tasks of response organization (clustering). In our sample, both the ADHD and the TS groups were largely free from executive function impairment. and their performance on thr fluency and list learning tasks was in the average range. There was a significant group difference on one of the disinhibition variables, with both TS and ADHD groups showing significantly more intrusions on verbal list learning trials than controls. When more traditional total score variables were analyzed among the three groups, there were no significant differences; however, analysis of effect size revealed medium-to-large effect sizes for Letter Word Fluency total score differences (ADHD vs. controls), and for Semantic Word Fluency total score differences (ADHD vs. TS), with the ADHD group having weaker performance in both comparisons. Results provide some support for the use and analysis of process variables-particularly those related to inhibition and intrusion errors, in addition to the total score variables when assessing executive function deficits in children with ADHD and TS. While group differences may be found, children with uncomplicated TS should not routinely be considered to have significant executive function impairments, and when deficits are found, they may be attributable to other comorbid disorders.	Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21205 USA; Kennedy Krieger Inst, Dept Dev Cognit Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Mahone, EM (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway,5th Floor TWR, Baltimore, MD 21205 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-24061] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-25806] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALYWARD EH, 1996, J CHILD NEUROL, V11, P112; Barkley R. A., 1997, ADHD NATURE SELF CON; BAUMGARDNER TL, 1996, NEUROLOGY, V47, P1; BAXTER LR, 1993, HDB TOURETTES SYNDRO, P298; BEEBE DW, 2000, J INT NEUROPSYCH SOC, V6, P107; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; CASTRO AM, 1994, PLANT BREEDING, V112, P151, DOI 10.1111/j.1439-0523.1994.tb00663.x; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cornoldi C, 1999, DEV NEUROPSYCHOL, V15, P53; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; De Beni R, 1998, Q J EXP PSYCHOL-A, V51, P305, DOI 10.1080/713755761; Demakis GJ, 1997, PSYCHOL REP, V81, P443; Denckla M.B., 1994, FRAMES REFERENCE ASS, P117; Denckla MB, 1996, DEV NEUROPSYCHOL, V12, P5, DOI 10.1080/87565649609540637; DENCKLA MB, 1997, DEV PREFRONTAL CORTE, P283; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; DUPAUL GJ, 1998, ADHD RATING SCALE, V4; DUPAUL GR, 1991, J CLIN CHILD PSYCHOL, V20, P2425; Elfgren CI, 1998, NEUROPSYCHOLOGIA, V36, P505, DOI 10.1016/S0028-3932(97)00146-2; ELIS D, 1994, CALIFORNIA VERBAL LE; FAHN S, 1993, ARCH NEUROL-CHICAGO, V50, P1013; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; HALL TM, 1991, NUCL MED STATE ART N, P243; Harris E L, 1995, J Int Neuropsychol Soc, V1, P511; Heilman K. M., 1994, NIH C ATT MEM EX FUN; HEILMAN KM, 1991, J CHILD NEUROL S, V6, P76; Heishman SJ, 1999, PSYCHOL ADDICT BEHAV, V13, P227; Hill D, 1999, ARCH CLIN NEUROPSYCH, V14, P692, DOI 10.1016/S0887-6177(99)80139-5; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; Kane H, 1994, World Watch, V7, P33; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levy F, 1997, J PAEDIATR CHILD H, V33, P384; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mahone EM, 1999, ARCH CLIN NEUROPSYCH, V14, P12, DOI 10.1093/arclin/14.1.12; Mataix-Cols D, 1999, J NEUROPSYCH CLIN N, V11, P395, DOI 10.1176/jnp.11.3.395; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; OZONOFF S, 1994, J CHILD PSYCHOL PSYC, V35, P1015, DOI 10.1111/j.1469-7610.1994.tb01807.x; Parkin AJ, 1996, BRAIN COGNITION, V32, P14, DOI 10.1006/brcg.1996.0055; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; Pineda D, 1999, J LEARN DISABIL, V32, P159, DOI 10.1177/002221949903200206; READER MJ, 1994, DEV NEUROPSYCHOL, V10, P493, DOI 10.1080/87565649409540598; RIDDLE MA, 1992, ADV NEUROL, V58, P208; Robert PH, 1998, J INT NEUROPSYCH SOC, V4, P539, DOI 10.1017/S1355617798466025; RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2; Schuerholz LJ, 1997, J CHILD NEUROL, V12, P438, DOI 10.1177/088307389701200705; Schuerholz LJ, 1996, NEUROLOGY, V46, P958, DOI 10.1212/WNL.46.4.958; SCHUERHOLZ LJ, 1998, J CLIN NEUROLOGY, V13, P27; Shucard DW, 1997, NEUROPSYCHOLOGY, V11, P147, DOI 10.1037/0894-4105.11.1.147; SINGER HS, 1993, NEUROLOGY, V43, P950, DOI 10.1212/WNL.43.5.950; SINGER HS, 1994, BRAIN DEV-JPN, V16, P353, DOI 10.1016/0387-7604(94)90122-8; SINGER HS, 1995, J CHILD NEUROL, V10, pS58, DOI 10.1177/08830738950100S112; Spencer T, 1998, J CHILD PSYCHOL PSYC, V39, P1037, DOI 10.1017/S0021963098002984; SUTHERLAND RJ, 1982, GILLES TOURETTE SYND, P311; Troyer AK, 1998, J INT NEUROPSYCH SOC, V4, P137, DOI 10.1017/S1355617798001374; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Turner MA, 1999, J CHILD PSYCHOL PSYC, V40, P189, DOI 10.1017/S0021963098003515; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Varney NR, 1996, ARCH CLIN NEUROPSYCH, V11, P345, DOI 10.1016/0887-6177(95)00015-1; VIC P, 1988, DEV NEUROPSYCHOL, V4, P63; WECHSLER D, 1992, WECHSLER INDIVIDUAL; WOZNIAK JR, 1998, J INT NEUROPSYCH SOC, V4, P42; Yeates KO, 1994, NEUROPSYCHOLOGY, V8, P65, DOI 10.1037/0894-4105.8.1.65; Zimmerman IL, 1997, PERCEPT MOTOR SKILL, V85, P531	68	70	73	0	7	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-4930 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2001	7	1					102	111		10.1017/S1355617701711101			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	427UX	WOS:000168424800010	11253836				2021-06-18	
J	Brookshire, BL; Chapman, SB; Song, J; Levin, HS				Brookshire, BL; Chapman, SB; Song, J; Levin, HS			Cognitive and linguistic correlates of children's discourse after closed bead injury: A three-year follow-up	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						closed head injury; children; discourse	TRAUMATIC BRAIN INJURY; HEAD-INJURY; NARRATIVE DISCOURSE; ADOLESCENTS; CHILDHOOD; COMPREHENSION; IMPAIRMENTS; PERFORMANCE; ADULTHOOD; RECALL	The discourse of 91 children who had sustained severe (n = 68) or mild (n = 23) closed head injury (CHI) was examined at least three years postinjury. The groups' retellings of a narrative story were analyzed according to two domains, information and language. In comparison to the mild CHI group, the severe group produced stories characterized by reduced content and information, impaired organization, fewer words, and less complex sentences. The relationships between discourse production and the groups' performance on measures of language, executive function, memory, and processing speed were examined. Correlations were found between discourse production and general verbal ability including verbal fluency. Correlations were also found for discourse performance and executive function measures associated with problem solving and working memory. Site and extent of lesion were not useful in predicting discourse production. These findings indicate that children who sustain a severe closed head injury during early to middle childhood are at risk for persisting deficits in discourse processing and other cognitive abilities.	Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Callier Ctr Commun Disorders, Dallas, TX 75230 USA	Levin, HS (corresponding author), Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 1333 Moursund Ave,Rm A205, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Baddeley A. D., 1987, WORKING MEMORY; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; DELIS D, 1986, CALIFORNIA VERBAL LE; DENCKLA M B, 1974, Cortex, V10, P186; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DREWE E A, 1975, Cortex, V11, P8; Dunn L., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1998, J CLIN EXPT NEUROPSY, V20, P1; Frederiksen C.H., 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; GRAFMAN J, 1995, TRAUMATIC HEAD INJUR, P235; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HISCOCK M, 1987, BRAIN COGNITION, V6, P24, DOI 10.1016/0278-2626(87)90044-3; Hunt K. W., 1965, 3 NAT COUNC TEACH EN; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT B, 1975, LANCET, V1, P480; JOHNSON DA, 1989, CHILDRENS HEAD INJUR, P96; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; JORDAN FM, 1988, BRAIN INJURY, V2, P175; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; Labov William., 1972, LANGUAGE INNER CITY; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; Mross E. F., 1990, DISCOURSE ABILITY BR, P50; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; Van Dijk T, 1980, MACROSTRUCTURES; Van Dijk T.A., 1983, STRATEGIES DISCOURSE; Van Dijk T. A., 1985, HDB DISCOURSE ANAL; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9	63	70	72	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2000	6	7					741	751		10.1017/S1355617700677019			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	370QG	WOS:000165133300001	11105464				2021-06-18	
J	Bredesen, DE				Bredesen, DE			Apoptosis: Overview and signal transduction pathways	JOURNAL OF NEUROTRAUMA			English	Article						programmed cell death; caspase; physiological cell death; neurodegeneration; neurotrauma	PROGRAMMED CELL-DEATH; KEEPING NEURONS ALIVE; CYTOCHROME-C; BRAIN INJURY; SYMPATHETIC NEURONS; PROTOONCOGENE BCL-2; MOLECULAR CONTROL; GENE-EXPRESSION; CASPASE FAMILY; NEURAL CELLS	Apoptosis is a form of cell death that is driven by an intrinsic cellular suicide program, The roles of apoptosis and other forms of programmed cell death in neural development, maintenance, and disease states are increasingly being recognized and defined, Therapies directed at the apoptotic program have seen at least some degree of success in animal models of neurodegenerative disease, vascular disease, and traumatic CNS injury, This article describes the signal transduction pathways that mediate apoptosis, Broadly speaking, intrinsic and extrinsic pathways for apoptosis activation may be distinguished, as can be cross-talk between these two, These pathways converge on a system of proteases referred to as "capases" (cysteinyl aspartic proteinases), and modulators exist that multimerize, activate, amplify, or inhibit caspases, Activated caspases are the executioners of the apoptotic program, and carry out this function by cleaving specific cellular substrates, Modulation of this process holds promise as a therapeutic approach in neurotrauma.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Bredesen, DE (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12282] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33376, NS35155] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033376, R01NS035155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012282] Funding Source: NIH RePORTER		Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bredesen DE, 1996, NEUROSCIENTIST, V2, P211, DOI 10.1177/107385849600200409; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Bredesen DE, 1996, NEUROSCIENTIST, V2, P181, DOI 10.1177/107385849600200313; BREDESEN DE, 1999, NEURAL NOTES, V70, P31; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Conti AC, 1998, J NEUROSCI, V18, P5663; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frasch SC, 2000, J BIOL CHEM, V275, P23065, DOI 10.1074/jbc.M003116200; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERSHBERGER PA, 1992, J VIROL, V66, P5525, DOI 10.1128/JVI.66.9.5525-5533.1992; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOCKSHIN RA, 1964, J INSECT PHYSIOL, V10, P643, DOI 10.1016/0022-1910(64)90034-4; Lu DC, 2000, NAT MED, V6, P397; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MIYASHITA T, 1995, CELL, V80, P293; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; MYERS KM, 1995, J NEUROCHEM, V65, P2432; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PILAR G, 1976, J CELL BIOL, V68, P339, DOI 10.1083/jcb.68.2.339; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Reed JC, 1999, P NATL ACAD SCI USA, V96, P7614, DOI 10.1073/pnas.96.14.7614; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhong L. T., 1992, Society for Neuroscience Abstracts, V18, P44; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZHONG LT, 1993, MOL BRAIN RES, V19, P353, DOI 10.1016/0169-328X(93)90139-G; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	74	70	76	1	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2000	17	10					801	810		10.1089/neu.2000.17.801			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	364LR	WOS:000089894300002	11063049				2021-06-18	
J	Gaviria, M; Privat, A; d'Arbigny, P; Kamenka, JM; Haton, H; Ohanna, F				Gaviria, M; Privat, A; d'Arbigny, P; Kamenka, JM; Haton, H; Ohanna, F			Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats	BRAIN RESEARCH			English	Article						critical time window; Gacyclidine; N-Methyl-D-aspartate; contusive spinal cord injury; secondary injury; neurochemical cascade	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; GLUTAMATE NEUROTOXICITY; EXTRACELLULAR LEVELS; HYDROXYL RADICALS; IN-VITRO; MECHANISMS; MICRODIALYSIS; RECEPTORS; SECONDARY	The aim of this study was to analyze the optimal time-window for neuroprotection by a novel NMDA antagonist, Gacyclidine, after experimental spinal cord injury, in terms of its functional, histopathological and electrophysiological effects. This molecule has already demonstrated its capacity for reducing the extent of an ischemic lesion and is currently experimented in a clinical trial of spinal cord injury. In this study, the spinal cord of rats was damaged by a contusive method and the animals were treated by saline or 1 mg/kg of Gacyclidine i.v., 10, 30, 60 and 120 min after injury. The time-course of the motor score was evaluated on days 1, 7 and 18 after injury, and somatosensory evoked potentials were determined on day 20. The animals were then killed and the cross-sectional area of the spinal cord (at the epicenter of the injury, above and below the injury), was measured. Walking recovery was better (P<0.0125) in the group treated 10 min after injury than in the untreated injured animals after 18 days of injury. Motor performances were related to the preservation of a larger undamaged area of spinal cord at the level of the injury (P<0.0125). Somatosensory evoked potential amplitudes were also higher in this group. These results confirm that Gacyclidine attenuates spinal cord damage after an experimental spinal cord lesion. Recovery was better within the group treated 10 min after injury compared with the other groups, which certainly confirms that the acute time-course of glutamate release requires rapid pharmacological intervention to achieve good results. (C) 2000 Elsevier Science B.V. All rights reserved.	Ctr PROPARA, Lab Neurophysiol Clin, F-34195 Montpellier, France; Ctr PROPARA, Lab Chirurg Fonct Expt, F-34195 Montpellier, France; USTL, INSERM, U336, F-34095 Montpellier, France; Beaufour Ipsen, Res & Dev, F-75781 Paris, France; ENSCM, CNRS, UPR 1086, F-34296 Montpellier, France; Fac Med Montpellier, Lab Physiopathol Malad Neuromusculaires, F-34000 Montpellier, France	Gaviria, M (corresponding author), Ctr PROPARA, Lab Neurophysiol Clin, Parc Euromed, F-34195 Montpellier, France.	mgaviria@club-internet.fr; manuelgaviri@hotmail.com	Gaviria, Manuel/AAH-4403-2019	Gaviria, Manuel/0000-0001-6106-6538			Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BIRCH PJ, 1988, EUR J PHARMACOL, V151, P313, DOI 10.1016/0014-2999(88)90814-X; BLACK P, 1988, NEUROSURGERY, V22, P51, DOI 10.1227/00006123-198801000-00008; BRESNAHAN JC, 1976, J NEUROL SCI, V28, P521, DOI 10.1016/0022-510X(76)90122-2; CAMERON T, 1990, EXP NEUROL, V109, P214, DOI 10.1016/0014-4886(90)90076-5; Cauquil-Caubere I, 1999, J NEUROSCI RES, V56, P160, DOI 10.1002/(SICI)1097-4547(19990415)56:2<160::AID-JNR5>3.0.CO;2-C; Cauquil-Caubere I, 1998, EUR J MED CHEM, V33, P867, DOI 10.1016/S0223-5234(99)80011-7; CHOI D, 1989, TRENDS NEUROSCI, V11, P21; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Drian MJ, 1999, J NEUROSCI RES, V57, P927, DOI 10.1002/(SICI)1097-4547(19990915)57:6<927::AID-JNR18>3.0.CO;2-C; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; Hebel R., 1986, ANATOMY EMBRYOLOGY L; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; KAMENKA JM, 1982, J MED CHEM, V25, P431, DOI 10.1021/jm00346a019; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; Lancelot E, 1998, BRAIN RES, V809, P294, DOI 10.1016/S0006-8993(98)00942-1; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; Lu YM, 1996, J NEUROSCI, V16, P5457; MAIER CM, 1995, J NEUROCHEM, V65, P652; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANJABI MM, 1988, SPINE, V13, P1365, DOI 10.1097/00007632-198812000-00007; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; PRIVAT A, 1990, ACTUAL CHIM THER, V17, P187; RAINES A, 1988, Journal of Neurotrauma, V5, P151, DOI 10.1089/neu.1988.5.151; Ribotta MGY, 1998, CURR OPIN NEUROL, V11, P647, DOI 10.1097/00019052-199812000-00007; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RONDOUIN G, 1988, NEUROSCI LETT, V91, P199, DOI 10.1016/0304-3940(88)90768-9; Rosenberg LJ, 1999, J NEUROSCI, V19, P464; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SIESJO BK, 1985, BRIT J ANAESTH, V57, P47, DOI 10.1093/bja/57.1.47; SYKOVA E, 1992, PROG BRAIN RES, V94, P47; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Watanabe M, 1998, J NEUROTRAUM, V15, P285, DOI 10.1089/neu.1998.15.285; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	58	70	74	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 25	2000	874	2					200	209		10.1016/S0006-8993(00)02581-6			10	Neurosciences	Neurosciences & Neurology	350NK	WOS:000089107800013	10960605				2021-06-18	
J	Cusick, CP; Gerhart, KA; Mellick, DC				Cusick, CP; Gerhart, KA; Mellick, DC			Participant-proxy reliability in traumatic brain injury outcome research	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; outcomes research; proxy ratings reliability and validity; surveys	QUALITY-OF-LIFE; SIGNIFICANT OTHERS; HEAD-INJURY; FUNCTIONAL STATUS; PATIENT HEALTH; COMMUNITY; SATISFACTION; INDIVIDUALS; RECOVERY; HANDICAP	Objective: To assess reliability between persons with Traumatic Brain Injury (TBT) and their self-selected proxies. Design: Intraclass Correlation Coefficients were used to assess participant-proxy reliability on the Craig Handicap Assessment and Reporting Technique (CHART), the Community Integration Questionnaire (CIQ), and the Functional Independence Measure (FIM). Setting: Participants had been discharged to the community from inpatient rehabilitation between six months and approximately five years prior to the study's beginning. Participants: 204 persons with moderate to severe TBI and their self-selected proxies. Results: Eighty-seven percent of the items on the three instruments exhibited moderate to high intraclass correlation (ICC), with strongest participant-proxy agreement for questions assessing con crete, observable information. Participant-proxy agreement was poorest when assessing cognitive and money management capacity as well as out-of-home activities. Conclusions: For many types of items, participant-proxy reliability is sufficient to merit the use of proxies in TBI outcome research when the participants are allowed to select their own proxy.	Craig Hosp, Rocky Mt Reg Brain Injury Syst, Englewood, CO 80110 USA	Cusick, CP (corresponding author), Craig Hosp, Rocky Mt Reg Brain Injury Syst, 3425 S Clarkson St, Englewood, CO 80110 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B30041] Funding Source: Medline		BLAND JM, 1990, COMPUT BIOL MED, V20, P337, DOI 10.1016/0010-4825(90)90013-F; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; BURTON LA, 1993, J REHABILITATION OCT, P34; CLARRIDGE BR, 1989, MED CARE, V27, P352, DOI 10.1097/00005650-198904000-00003; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GRANGER CV, 1997, ASSESSING MED REHABI; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Long K, 1998, J AM GERIATR SOC, V46, P1103, DOI 10.1111/j.1532-5415.1998.tb06648.x; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; ROTHMAN ML, 1991, MED CARE, V29, P115, DOI 10.1097/00005650-199102000-00004; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; SPRANGERS MAG, 1992, J CLIN EPIDEMIOL, V45, P743, DOI 10.1016/0895-4356(92)90052-O; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WEINBERGER M, 1992, J AM GERIATR SOC, V40, P585, DOI 10.1111/j.1532-5415.1992.tb02107.x; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILSON BA, 1997, J REHABILITATION OUT, V1, P60; World Health Organization, 1980, INT CLASS IMP DIS HA; 1996, GUIDE UNIFORM DATA S	32	70	70	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2000	15	1					739	749		10.1097/00001199-200002000-00012			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	287MX	WOS:000085510800013	10745189				2021-06-18	
J	Leclercq, M; Couillet, J; Azouvi, P; Marlier, N; Martin, Y; Strypstein, E; Rousseaux, M				Leclercq, M; Couillet, J; Azouvi, P; Marlier, N; Martin, Y; Strypstein, E; Rousseaux, M			Dual task performance after severe diffuse traumatic brain injury or vascular prefrontal damage	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; ANTERIOR COMMUNICATING ARTERY; RANDOM NUMBER GENERATION; WORKING-MEMORY; DYSEXECUTIVE SYNDROME; COGNITIVE DEFICITS; DIVIDED ATTENTION; FRONTAL-CORTEX; ANEURYSMS; DISORDERS	The ability to perform two tasks simultaneously is a key function of the central executive of working memory (Baddeley, 1986). This study addressed dual-task performance after diffuse very severe traumatic brain injury (TBI) (mean coma duration = 21 days, mean post-traumatic amnesia = 70 days) or prefrontal damage due to a ruptured aneurysm of the anterior communicating artery (AACA). Mean time since injury was 8 and 16 months in the TBI and the AACA group respectively. A simple visual reaction time and random number generation were used as single and dual tasks. Randomization was self-paced, to control for individual differences in speed. Both patient groups had greater reaction time decrements than controls under the dual-task condition, suggesting a divided attention deficit. In addition, patients with AACA performed significantly poorer in random generation. These results suggest that patients with AACA and with severe TBI suffer from an impairment of the central executive system.	Ctr Neurol William Lennox, Ottignies Louvain Neuve, Belgium; Univ Paris 05, Hop Raymond Poincare, Serv Reeduc Neurol, F-75270 Paris 06, France; Ctr Reeduc Espoir, Lille Hellemmes, France; Hop Swynghedauw, Serv Reeduc Neurol, Lille, France	Azouvi, P (corresponding author), Raymond Poincare Hosp, Dept Neurol Rehabilitat, F-92380 Garches, France.						ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A., 1998, PREFRONTAL CORTEX EX, P9; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brugger P, 1996, NEUROPSYCHOLOGIA, V34, P97, DOI 10.1016/0028-3932(95)00066-6; CHATFIELD C, 1984, ANAL TIME SERIES; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Godefroy O, 1996, BRAIN COGNITION, V30, P155, DOI 10.1006/brcg.1996.0010; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; Godefroy O, 1999, CORTEX, V35, P1, DOI 10.1016/S0010-9452(08)70782-2; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; HARTMAN A, 1992, CLIN REHABIL, V6, P133; HORNE RL, 1982, ARCH GEN PSYCHIAT, V39, P680; Jahanshahi M, 1998, BRAIN, V121, P1533, DOI 10.1093/brain/121.8.1533; Kendall M. G., 1973, TIME SERIES; LAIACONA M, 1989, CORTEX, V25, P261, DOI 10.1016/S0010-9452(89)80042-5; LECLERCQ M, 1990, NORMALISATION 3 EPRE; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Norman D. A., 1980, 99 CHIP U CAL; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; Robertson C, 1996, NEUROPSYCHOLOGIA, V34, P1069, DOI 10.1016/0028-3932(96)00031-0; ROSENBERG S, 1990, PSYCHOL MED, V20, P953, DOI 10.1017/S0033291700036643; Rousseaux M, 1996, REV NEUROL-FRANCE, V152, P678; Rousseaux M, 1996, REV NEUROL, V152, P517; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Shallice T., 1993, ATTENTION SELECTION; SPATT J, 1993, BRAIN COGNITION, V23, P231, DOI 10.1006/brcg.1993.1057; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STENHOUSE LM, 1991, J NEUROL NEUROSUR PS, V54, P909, DOI 10.1136/jnnp.54.10.909; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0	47	70	71	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	3					339	350		10.1076/1380-3395(200006)22:3;1-V;FT339			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	327UB	WOS:000087811000004	10855042				2021-06-18	
J	Ownsworth, TL; McFarland, K				Ownsworth, TL; McFarland, K			Memory remediation in long-term acquired brain injury: two approaches in diary training	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; REAL-LIFE	This study investigated the remediation and assessment of everyday memory impairment in a sample of long-term acquired brain injury (ABI) subjects. The Rivermead Behavioural Memory Test (RBMT) and subtests of the Wechsler Memory Scale-Revised (WMS-R) were selected to measure global memory performance. A memory questionnaire and a daily memory checklist were developed from a review of existing self-report questionnaires. The interrelationships among self-report measures and standardized psychometric tests of memory were examined and the findings suggest that self-report measures may be used to obtain relatively accurate information about everyday memory performance. A baseline across groups' design evaluated the relative effectiveness of two different approaches in training subjects to use a diary to compensate for memory problems. There was a Diary Only (DO) approach, which emphasized compensation based upon task specific learning, and a Diary and Self-instructional Training (DSIT) approach, which taught compensation using higher cognitive skills of self-awarenes and self-regulation. The results obtained show that, during the treatment phase, the DSIT group more consistently made diary entries, reported less memory problems, and made more positive ratings associated with treatment efficacy. The implications arising from the current study are that: (1) the choice of memory assessment procedures need to be guided by the patients' real daily living needs; and (2) an approach based upon self-instructional training has greater ecological validity than an approach that focuses on task specific learning. In general, successful assessment and rehabilitation of memory deficits requires a well-established theoretical basis and sound ecological validity.	Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia	Ownsworth, TL (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	tamarao@psy.uq.edu.au		Ownsworth, Tamara/0000-0003-1835-7094			BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BAUER RM, 1993, CLIN NEUROPSYCHOLOGY, P523; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CICERONE KD, 1991, NEUROPSYCHOLOGY EVER, P271; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Davis AM, 1995, CLIN REHABIL, V9, P238, DOI DOI 10.1177/026921559500900310; GODFREY HP, 1995, FAMILY SUPPORT PROGR; GODFREY HPD, 1987, BRIT J CLIN PSYCHOL, V26, P83, DOI 10.1111/j.2044-8260.1987.tb00735.x; GOLDSTEIN G, 1990, INT HDB BEHAV MODIFI, P139; GORDON WA, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P175; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Herrmann DJ, 1978, PRACTICAL ASPECTS ME, P35; Hersen M., 1990, INT HDB BEHAV MODIFI, P175, DOI DOI 10.1007/978-1-4613-0523-1_9; KEPPEL G, 1991, DESIGN ANAL; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KOLB B, 1992, ADV EXP MED BIOL, V325, P169; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; McNair DM, 1981, PROFILE MOOD STATES; MEICHENBAUM D, 1973, BEHAV THER, V4, P515, DOI 10.1016/S0005-7894(73)80003-6; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SQUIRE LR, 1987, MEMORY BRAIN; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; SUNDERLAND A, 1990, NEUROPSYCHOLOGY EVER, P169; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEBSTER JS, 1983, CLIN NEUROPSYCHOL, V5, P69; WECHSLER O, 1987, WECHSLER MEMORY SCAL; WILSON B, 1989, J CLIN EXPT NEUROPSY, V11, P885; Wilson B.A, 1987, REHABILITATION MEMOR; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; ZENCIUS AH, 1994, PRACTICAL GUIDE HEAD	40	70	70	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1999	13	8					605	626		10.1080/026990599121340			22	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200005	10901689				2021-06-18	
J	Sullivan, TP; Jarvik, JG; Cohen, WA				Sullivan, TP; Jarvik, JG; Cohen, WA			Follow-up of conservatively managed epidural hematomas: Implications for timing of repeat CT	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-of-Neuroradiology	MAY, 1997	TORONTO, CANADA	Amer Soc Neuroradiol			EXTRADURAL HEMATOMAS; NONOPERATIVE MANAGEMENT; NONSURGICAL TREATMENT; HEAD-INJURY; TRAUMA	BACKGROUND AND PURPOSE: Small asymptomatic epidural hematomas (EDHs) are frequently managed nonoperatively with good neurologic outcome. Our goals were to determine the frequency and timing of enlargement of acute traumatic EDHs that are not immediately surgically evacuated as well as to identify factors associated with rehemorrhage. METHODS: Of 252 consecutive patients with acute traumatic EDH who were treated over a 5-year period, 160 were managed nonoperatively. Their CT scans, imaging reports, and medical records were reviewed retrospectively. Parameters analyzed as possible predictors of rehemorrhage during nonoperative management were size of the EDH, presence of an associated fracture, contralateral brain injury, midline shift, coagulopathy, and neurologic and physiological injury as measured by the Revised Trauma Score. We compared discharge disposition as a proxy for neurologic condition at discharge. RESULTS: The EDH enlarged in 37 (23%) of the 160 patients during conservative management. Mean enlargement was 7 mm, and the mean time to enlargement was 8 hours after injury and 5.3 hours after CT diagnosis. EDH enlargement occurred within 36 hours after injury in all cases, Of the parameters analyzed, only a high Revised Trauma Score correlated significantly with EDH rehemorrhage, suggesting that intubation and chemical paralysis may prevent rehemorrhage through the restriction of head movement and the control of blood pressure. The subgroup of patients with rehemorrhage experienced no difference in neurologic outcome despite a higher rate of clinical deterioration, CONCLUSION: EDH enlargement occurs frequently, but early. Repeat imaging with CT is most appropriate within 36 hours after injury.	Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA	Jarvik, JG (corresponding author), Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,357115, Seattle, WA 98195 USA.		Jarvik, Jeffrey/AAL-4292-2021				BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COOPER PR, 1986, NEUROSURGERY, V18, P700; DIROCCO A, 1991, NEURORADIOLOGY, V33, P253, DOI 10.1007/BF00588229; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; FORD LE, 1963, J NEUROSURG, V20, P760, DOI 10.3171/jns.1963.20.9.0760; GEAN AD, 1994, IMAGING HEAD TRAUMA, P107; HAMILTON M, 1992, AM J NEURORADIOL, V13, P853; KAWAKAMI Y, 1990, PEDIATR NEUROL, V6, P112, DOI 10.1016/0887-8994(90)90044-2; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; Lofgren J, 1986, Acta Neurochir Suppl (Wien), V36, P151; MARSHALL LF, 1985, NEUROSURGERY, V16, P606; MAURER JJ, 1965, J NEUROSURG, V23, P63, DOI 10.3171/jns.1965.23.1.0063; MCLAURIN RL, 1964, J NEUROSURG, V21, P364, DOI 10.3171/jns.1964.21.5.0364; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; SAGHER O, 1992, AJNR AM J NEURORADIO, V13, P853; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27	23	70	73	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	1999	20	1					107	113					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	163CQ	WOS:000078385300018	9974064				2021-06-18	
J	Prince, DA; Jacobs, K				Prince, DA; Jacobs, K			Inhibitory function in two models of chronic epileptogenesis	EPILEPSY RESEARCH			English	Article; Proceedings Paper	4th Workshop on the Neurobiology of Epilepsy	JUN 26-28, 1997	ADARE, IRELAND	Amer Epilepsy Soc, Hoechst Marion Roussel, Japan Fdn Neurosci & Mental Health, Novartis Pharmaceutical Corp, Parke-Davis/Div Warner-Lambert Co		epilepsy; neocortex; microgyria; post-traumatic; rat; inhibition	NEURONAL MIGRATION DISORDERS; HIPPOCAMPUS IN-VITRO; SYNAPTIC TRANSMISSION; NEOCORTICAL EPILEPTOGENESIS; EPILEPTIFORM ACTIVITY; DEPENDENT DEPRESSION; TEMPORAL NEOCORTEX; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; CEREBRAL-CORTEX	Although drug-induced disinhibition is a potent method for producing acute epileptogenesis, data with respect to possible disorders of GABAergic inhibitory function in models of chronic epilepsy are incomplete and inconsistent. We examined rat models of cortical post-traumatic epilepsy, and epileptogenic cortical microgyri. Results suggest enhanced rather than decreased inhibitory function in cortical networks in these preparations. In brain slices from epileptogenic chronically isolated cortex, the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) and miniature (m)IPSCs in layer V pyramidal neurons is increased compared to control. In the epileptogenic zone adjacent to the microgyrus, both spontaneous and stimulus-induced IPSCs are larger in amplitude than control, and the frequency of sIPSCs is more dependent upon glutamatergic excitation of interneurons than in control layer V neurons of homotopic cortex. Immunocytochemical studies show that there is enhanced immunoreactivity for several proteins in GABAergic interneurons of chronic cortical isolations, and suggest that there may be sprouting of GABAergic axons in the area of injury. This conclusion is supported by anatomic data showing an approximate doubling of the number of presumed inhibitory synapses on somata of layer V pyramidal neurons. These anatomic findings are consistent with the increased frequency of mIPSCs on these neurons. Inhibition is robust in both of these chronic models of epileptogenesis. Increased inhibitory electrogenesis might be pictured as part of the epileptogenic process, e.g. a mechanism for synchronizing the discharge of pyramidal neurons, or as a compensatory mechanism that might prevent the development of abnormal activities in some cases, or limit the intensity of epileptogenesis in others. (C) 1998 Elsevier Science B.V. All rights reserved.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Prince, DA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.		Jacobs, Kimberle/AAW-7526-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12151, NS07288, NS09806] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012151, P50NS012151] Funding Source: NIH RePORTER		ARAM JA, 1991, J NEUROPHYSIOL, V65, P1034; ASHWOOD TJ, 1986, BRAIN RES, V367, P390, DOI 10.1016/0006-8993(86)91625-2; BABB TL, 1989, J NEUROSCI, V9, P2562; BARKOVICH AJ, 1992, AM J NEURORADIOL, V13, P95; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; Carmignoto G, 1997, J PHYSIOL-LONDON, V498, P153, DOI 10.1113/jphysiol.1997.sp021848; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; DAVENPORT CJ, 1990, EXP NEUROL, V109, P180, DOI 10.1016/0014-4886(90)90072-Z; DEFELIPE J, 1994, BRAIN RES, V657, P150, DOI 10.1016/0006-8993(94)90962-8; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DOMANN R, 1991, EXP BRAIN RES, V83, P683; DVORAK K, 1977, ACTA NEUROPATHOL, V38, P203; ENGEL J, 1995, ADV NEUROL, V67, P157; ESCLAPEZ M, 1997, P NATL ACAD SCI USA, V94, P1; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; GONZALES C, 1992, NEUROSCI LETT, V135, P53, DOI 10.1016/0304-3940(92)90134-S; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; HUMPHREYS P, 1991, J NEUROPATH EXP NEUR, V50, P145, DOI 10.1097/00005072-199103000-00006; Jacobs K. M., 1996, Society for Neuroscience Abstracts, V22, P2102; Jacobs K. M., 1997, Society for Neuroscience Abstracts, V23, P811; Jacobs Kimberle M., 1996, Epilepsia, V37, P77; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; KREINDLER A, 1960, ARCH ITAL BIOL, V98, P10; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059; Marco P, 1997, EXP BRAIN RES, V114, P1, DOI 10.1007/PL00005608; Marco P, 1996, BRAIN, V119, P1327, DOI 10.1093/brain/119.4.1327; MATHERN GW, 1995, J NEUROSCI, V15, P3990; MATSUMOTO H, 1964, EXP NEUROL, V9, P286, DOI 10.1016/0014-4886(64)90025-1; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; NIEOULLON A, 1981, BRAIN RES, V224, P129, DOI 10.1016/0006-8993(81)91122-7; OBENAUS A, 1993, J NEUROSCI, V13, P4470; PALMINI A, 1991, CAN J NEUROL SCI, V18, P580, DOI 10.1017/S0317167100032753; PALMINI A, 1994, EPILEPSIA, V35, pS57, DOI 10.1111/j.1528-1157.1994.tb05989.x; PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602; PERREAULT P, 1992, J NEUROSCI, V12, P104; PRINCE DA, 1978, ANNU REV NEUROSCI, V1, P395, DOI 10.1146/annurev.ne.01.030178.002143; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Prince DA, 1997, CAN J PHYSIOL PHARM, V75, P500, DOI 10.1139/cjpp-75-5-500; PRINCE DA, 1998, ADV NEUROLOGY; PRINCE DA, 1992, NEUROTRANSMITTERS EP, P31; Prince David A., 1996, V72, P1; Purpura D P, 1968, Prog Brain Res, V22, P107; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROMIJN HJ, 1988, EXP NEUROL, V100, P332, DOI 10.1016/0014-4886(88)90112-4; Rosen G. D., 1996, Society for Neuroscience Abstracts, V22, P485; RUTECKI PA, 1987, J NEUROPHYSIOL, V57, P1911; Salin P, 1995, J NEUROSCI, V15, P8234; SEIL FJ, 1994, DEV BRAIN RES, V77, P123, DOI 10.1016/0165-3806(94)90219-4; SLOPER JJ, 1980, BRAIN RES, V198, P204, DOI 10.1016/0006-8993(80)90356-X; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501; WESTENBROEK RE, 1988, J COMP NEUROL, V274, P334, DOI 10.1002/cne.902740304; WHITTINGTON MA, 1994, J PHYSIOL-LONDON, V481, P593, DOI 10.1113/jphysiol.1994.sp020466	63	70	71	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	SEP	1998	32	1-2			SI		83	92		10.1016/S0920-1211(98)00042-4			10	Clinical Neurology	Neurosciences & Neurology	121UX	WOS:000076034000009	9761311				2021-06-18	
J	Inskip, PD; Mellemkjaer, L; Gridley, G; Olsen, JH				Inskip, PD; Mellemkjaer, L; Gridley, G; Olsen, JH			Incidence of intracranial tumors following hospitalization for head injuries (Denmark)	CANCER CAUSES & CONTROL			English	Article						brain neoplasms; Denmark; glioma; head trauma; hemangioblastoma; meningioma	LOS-ANGELES COUNTY; EXPLORATORY CASE-CONTROL; CENTRAL NERVOUS-SYSTEM; BRAIN-TUMORS; RISK-FACTORS; LINDAU DISEASE; TRAUMA; CANCER; MENINGIOMAS; CHILDREN	The incidence of brain and other intracranial tumors following head trauma was evaluated in a cohort of 228,055 Danish residents hospitalized because of concussion, fractured skull, or other head injury between 1977 and 1992 and followed for an average of eight years (maximum, 17 years). Traffic accidents, falls, and sports-related incidents were the usual causes of the injury. Malignant and benign neoplasms were identified by linking the study roster with records of the Danish Cancer Registry for the years 1977 to 1993. This approach precludes differential reporting of injuries by study participants as an explanation for any associations seen. Intracranial tumors of the nervous system occurred more often than expected based on incidence rates for the Danish population; however, most of the excess occurred during the first year after the injury and likely was due to the detection of tumors that were present before the injury occurred. Excluding the first year of follow-up, the standardized incidence ratio (SIR) was 1.15 (95 percent confidence interval [CI] = 0.99-1.32). The same general temporal pattern was seen for the major subtypes of brain tumor as for all types combined. SIRs after the first year were 1.0 for glioma (CI = 0.8-1.2), 1.2 for meningioma (CI = 0.8-1.7), and 0.8 for neurilemmoma (CI = 0.4-1.7). However, hemangioblastoma and hemangioma were more frequent than expected, based on 15 cases (SIR = 2.6, CI = 1.4-4.2). Results indicate that head trauma causes, at most, a small increase in the overall risk of brain tumors during the ensuing 15 years; however, a possible association with intracranial vascular tumors warrants further evaluation.	Texas A&M Univ, Coll Vet Med, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA; NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; Danish Canc Soc, Div Canc Epidemiol, Copenhagen, Denmark	Inskip, PD (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA.			Olsen, Jorgen Helge/0000-0001-9633-5662			ANNEGERS JF, 1979, NEUROSURGERY, V4, P203, DOI 10.1227/00006123-197903000-00001; BRESLOW N.E., 1987, STAT METHODS CANC RE, VII; BUNIN GR, 1994, CANCER EPIDEM BIOMAR, V3, P197; BURCH JD, 1987, J NATL CANCER I, V78, P601; CARPENTER AV, 1987, AM J PUBLIC HEALTH, V77, P1180, DOI 10.2105/AJPH.77.9.1180; CHOI NW, 1970, AM J EPIDEMIOL, V91, P467, DOI 10.1093/oxfordjournals.aje.a121158; CUSHING H, 1962, MENINGIOMAS THEIR CL; *DAN NAT BOARD HLT, 1976, CLASS DIS; Danish National Board of Health, 1981, ACT HOSP CAR SYST; *DANM STAT, 1987, BEF BEV 1985; Gurney JG, 1996, EPIDEMIOLOGY, V7, P485, DOI 10.1097/00001648-199609000-00005; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HOCHBERG F, 1984, NEUROLOGY, V34, P1511, DOI 10.1212/WNL.34.11.1511; HOWE GR, 1989, CANCER RES, V49, P4349; Inskip PD, 1995, EPIDEMIOL REV, V17, P382; KEPES J J, 1989, Neurosurgery (Baltimore), V25, P258; Kleihues P, 1993, HISTOLOGICAL TYPING, V2nd; KLEY N, 1995, GLIA, V15, P297, DOI 10.1002/glia.440150310; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LUDWIN SK, 1984, NATURE, V308, P274, DOI 10.1038/308274a0; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MORANTZ RA, 1978, NEUROSURGERY, V3, P181, DOI 10.1227/00006123-197809000-00009; *NORD MED STAT COM, 1985, NOMESKO PUB, V20; OLSEN JH, 1989, JNCI-J NATL CANCER I, V81, P803, DOI 10.1093/jnci/81.10.803; Parker HL, 1931, J AMER MED ASSOC, V97, P0535, DOI 10.1001/jama.1931.02730080027008; PERLMUTTER I, 1950, SURG GYNECOL OBSTET, V91, P89; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PRESTONMARTIN S, 1980, JNCI-J NATL CANCER I, V65, P67; PRESTONMARTIN S, 1989, CANCER RES, V49, P6137; PRESTONMARTIN S, 1983, J NATL CANCER I, V70, P863; PRESTONMARTIN S, 1989, BRIT J CANCER, V59, P783, DOI 10.1038/bjc.1989.163; RADHAKRISHNAN K, 1995, ANN NEUROL, V37, P67, DOI 10.1002/ana.410370113; Resche F, 1993, Adv Tech Stand Neurosurg, V20, P197; Sargent P, 1929, BRIT J SURG, V17, P84, DOI 10.1002/bjs.1800176508; SCHLEHOFER B, 1992, CANCER, V69, P2541, DOI 10.1002/1097-0142(19920515)69:10<2541::AID-CNCR2820691025>3.0.CO;2-H; STORM HH, 1992, CANC INCIDENCE DENMA; *WHO, 1976, INT CLASS DIS ONC	37	70	73	0	2	KLUWER ACADEMIC PUBL	DORDRECHT	SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0957-5243			CANCER CAUSE CONTROL	Cancer Causes Control	JAN	1998	9	1					109	116		10.1023/A:1008861722901			8	Oncology; Public, Environmental & Occupational Health	Oncology; Public, Environmental & Occupational Health	YV685	WOS:000071852500014	9486470				2021-06-18	
J	Gasquoine, PG				Gasquoine, PG			Postconcussion symptoms	NEUROPSYCHOLOGY REVIEW			English	Article						concussion; head injury; self-reported symptoms; emotional distress; motivation	MILD HEAD-INJURY; POST-CONCUSSIONAL SYMPTOMS; TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DEFICITS; COMPENSATION NEUROSIS; DISORDER; SEQUELAE; AMNESIA; DAMAGE; LONG	Research pertaining to the self-report of symptoms after traumatic brain injury was reviewed. Cognitive, emotional, and motivational factors have more relevance than demographic (except for female sex) and personality factors. Specific neuropsychological deficits in attention and memory have been found in the early stages after head injury of even mild severity. This is unlikely to be the only factor affecting symptom persistence. Exaggeration of cognitive dysfunction occurs in some cases, but appears unrelated to symptom overreport. Increased emotional distress typically accompanies symptom persistence. The psychological reaction of preoccupation with symptoms and emotional distress is not unique to concussion, but also occurs after severe head injury and back injury and relates more to the personal interpretation of the effect of the trauma than to objective indicators of brain injury severity.		Gasquoine, PG (corresponding author), S TEXAS NEUROPSYCHOL,3857 S STAPLES,CORPUS CHRISTI,TX 78411, USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; Benton A. L, 1989, MILD HEAD INJURY, P3; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BRACKSTONE MJ, 1995, INT J REHABILITATION, V1, P37; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FEE CRA, 1988, ARCH EMERG MED, V5, P12; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GENNARELLI TA, 1988, J HEAD TRAUMA REHABI, V1, P23; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [DOI 10.1007/BF02214959, 10.1007/BF02214959]; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; GORMAN WF, 1993, LEGAL NEUROLOGY MALI; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1975, LANCET, V2, P945; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HATHAWAY SR, 1989, MINNESOTA MULTIPHASI, V2; HATHAWAY SR, 1983, MINNESOTA MULTIPHASI; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jennett B, 1989, MILD HEAD INJURY, P23; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Keller L. S., 1991, ASSESSMENT CHRONIC P; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1988, NEUROTRAUMA MED REPO, V2, P1; Lidvall HF, 1974, ACTA NEUROLOGICA S56, V50, P7; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; LONG CJ, 1991, J HEAD INJURY, V2, P18; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1972, LANCET, V2, P580; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nemeth AJ, 1996, ARCH CLIN NEUROPSYCH, V11, P677, DOI 10.1016/S0887-6177(96)80004-7; POPE KS, 1993, MMPI MMPI 2 MMPI A C; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Rimel R. W., 1981, NEUROSURGERY, V9, P35; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; TEASDALE G, 1974, LANCET, V2, P81; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WADDELL G, 1984, SPINE, V9, P209, DOI 10.1097/00007632-198403000-00013; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfson D., 1993, HALSTEAD REITAN NEUR; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	78	70	70	1	11	PLENUM PUBL CORP	NEW YORK	CONSULTANTS BUREAU, 233 SPRING ST, NEW YORK, NY 10013	1040-7308			NEUROPSYCHOL REV	Neuropsychol. Rev.	JUN	1997	7	2					77	85		10.1023/B:NERV.0000005945.58251.c0			9	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	XN256	WOS:A1997XN25600002	9253770				2021-06-18	
J	Chen, SHA; Thomas, JD; Glueckauf, RL; Bracy, OL				Chen, SHA; Thomas, JD; Glueckauf, RL; Bracy, OL			The effectiveness of computer-assisted cognitive rehabilitation for persons with traumatic brain injury	BRAIN INJURY			English	Article							MEMORY-IMPAIRED PATIENTS; RETENTION	This study examined the efficacy of computer-assisted cognitive rehabilitation (CACR) in persons with traumatic brain injury (TBI). Twenty persons with TBI who received hierarchically based CACR following inpatient neurorehabilitation were compared to a group of 20 persons with TBI matched for age, education, days in coma and rime between testing The comparison group received various other therapies including speech therapy and occupational therapy. The difference between pre- and posttreatment neuropsychological test scores was used to measure improvements in the domains of attention, visual spatial ability, memory and problem-solving. CACR and the comparison group showed significant post-treatment gains on the neuropsychological test scores, with CACR making significant gains on 15 measures and the comparison group on seven measures. However, we found no significant differences between the groups on their post-treatment gains. Results from this preliminary study found that, though significant cognitive gains were obtained after CACR, the extent and nature of these gains remains to be shown in controlled, prospective soup studies.	CTR NEUROSCI,INDIANAPOLIS,IN	Chen, SHA (corresponding author), INDIANA UNIV PURDUE UNIV,INDIANAPOLIS,IN 46202, USA.		Chen, SH Annabel/F-3742-2011	Chen, SH Annabel/0000-0002-1540-5516			Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; BENYISHAY Y, 1981, INT J REHABIL RES, V4, P208, DOI 10.1097/00004356-198106000-00012; Bracy O, 1986, PROGRAMS COGNITIVE R; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; BRACY OL, 1985, COGNITIVE REHABILITA, V4, P10; ESON ME, 1978, J NEUROL NEUROSUR PS, V41, P1036, DOI 10.1136/jnnp.41.11.1036; Ethier M, 1989, CANADIAN J REHABILIT, V2, P223; ETHIER M, 1989, CANADIAN J REHABILIT, V3, P7; FINLEY G, 1987, P AM ASSOC CANC RES, V28, P180; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; KENDALL MC, ADV THEORY STATISTIC; KERNER MJ, 1985, COGNITIVE REHABILITA, V3, P36; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; ROSS FL, 1991, AM J OCCUPATIONAL TH, V46, P314; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1989, INTRO COGNITIVE REHA, P5; Wechsler D., 1987, WECHSLER ADULT INTEL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wood R L, 1987, Int Disabil Stud, V9, P149; WOOD RLI, 1990, COGNITIVE REHABILITA; BEHAV RES METHODS IN, V15, P357	29	70	72	0	16	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1997	11	3					197	209					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WL158	WOS:A1997WL15800004	9058001				2021-06-18	
J	Kilaru, S; Garb, J; Emhoff, T; Fiallo, V; Simon, B; Swiencicki, T; Lee, KF				Kilaru, S; Garb, J; Emhoff, T; Fiallo, V; Simon, B; Swiencicki, T; Lee, KF			Long-term functional status and mortality of elderly patients with severe closed head injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	26th Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 01, 1996	GRAND TARGHEE, WY	W Trauma Assoc		elderly; closed head injury; mortality; functional outcome	BRAIN INJURY; TRAUMA; MANAGEMENT; SURVIVAL	Objective: To evaluate long-term clinical outcome of elderly patients with severe closed head injuries, Design: Retrospective study, Patients and methods: All patients older than 65 years of age admitted to a regional trauma center with a diagnosis of closed head injury and an admission Glasgow Coma Scale (GCS) score of 8 or less, Using chi(2) analysis, Student's t test, and multiple logistic regression, we correlated age, sex, mechanism of injury, pupillary reactivity, alcohol and drug use, admission GCS score, Injury Severity Score, Revised Trauma Score, heart rate, and blood pressure to the main outcome measures, i.e. long-term functional outcome and mortality, Results: Among 40 elderly patients who met the criteria, 27% were still alive at the end of 38 +/- 3 month follow-up, Eighty-five percent of patients who were discharged from the hospital were still alive long-term, but did not show significant neurologic improvement, In a univariate analysis, GCS and pupillary reactivity were predictive for long-term functional outcome and mortality, In a multivariate analysis, GCS and heart rate were predictive, All patients with an admission GCS score of 3 died in-hospital, All patients with an admission GCS score of 3 to 7 were either deceased or lived in persistent vegetative or dependent functional states. Conclusions: Elderly patients with severe closed head injuries have high in-hospital mortality, Those who survived the hospital stay had high long-term survival, but did not show significant functional improvement, Prediction of long-term functional status is vital to the trauma care of elderly patients with severe closed head injuries.	BAYSTATE MED CTR,DEPT SURG,TRAUMA GEN SURG SERV,SPRINGFIELD,MA 01199							BULLOCK R, 1995, GUIDLINES MANAGEMENT; CENTURA TA, 1994, SURG CLIN N AM, V74, P163; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; GIBSON RM, 1989, LANCET, V2, P369; GRANGER CV, 1994, GUIDE USE UNIFORM DA; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; JENNETT B, 1975, LANCET, V1, P480; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LAWTON MP, 1990, MILBANK Q, V68, P1, DOI 10.2307/3350075; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; *NATL SAF COUNC, 1992, ACC FACTS; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Ross A M, 1992, J Neurosci Nurs, V24, P88; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	21	70	70	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1996	41	6					957	963		10.1097/00005373-199612000-00003			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VY407	WOS:A1996VY40700003	8970546				2021-06-18	
J	Owings, JT; Bagley, M; Gosselin, R; Romac, D; Disbrow, E				Owings, JT; Bagley, M; Gosselin, R; Romac, D; Disbrow, E			Effect of critical injury on plasma antithrombin activity: Low antithrombin levels are associated with thromboembolic complications	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						antithrombin; deep venous thrombosis; disseminated intravascular coagulation; heparin; thromboembolism prophylaxis; trauma; adult respiratory distress syndrome	DISSEMINATED INTRAVASCULAR COAGULATION; RESPIRATORY-DISTRESS SYNDROME; DEEP VENOUS THROMBOSIS; SEVERE HEAD-INJURY; TRAUMA PATIENTS; III DEFICIENCY; MAJOR TRAUMA; SEPTIC SHOCK; DOUBLE-BLIND; EFFICACY	Objective: Determine whether severe injury results in decreased plasma antithrombin (AT) activity and whether this decreased AT activity is associated with thromboembolic complications. Design: Prospective observational. Subjects: A total of 157 critically injured trauma patients. Methods: Each patient underwent laboratory analysis on arrival to the emergency room at hours 8, 16, 24, and 45, and days 3, 4, 5, and 6. Laboratory analyses included AT, tissue factor pathway inhibitor, protein C, prothrombin fragment 1.2, thrombin-antithrombin complex, and D-dimer, Patients were followed for thromboembolic complications including: deep venous thrombosis (DVT), pulmonary embolus, disseminated intravascular coagulation (DIG) and adult respiratory distress syndrome (ARDS). Results: Mean Injury Severity Score was 23 (+/-11), AT activity fell below normal in 95 (61%) patients; AT activity rose to greater than normal in 51 (32%) patients, Nine (6%) patients developed DVT, two (1%) pulmonary embolus, 13 (8%) DIC and 26 (17%) ARDS. Using logistic regression analysis, low AT levels were a significant predictor of DVT, DIG, and ARDS (p < 0.05). Supranormal AT levels mere associated with closed head injury (p < 0.05), D-dimer levels were inversely correlated with AT (p < 0.05). Conclusions: AT activity was depressed in critically injured patients, Patients with head injury developed supranormal AT activity, The risk factors for AT deficiency mimicked those for thromboembolism. Patients with decreased AT activity were at increased risk for thromboembolic complications. Given heparin's dependence on AT, these data call into question the use of unmonitored heparin thromboembolism prophylaxis.		Owings, JT (corresponding author), UNIV CALIF DAVIS,MED CTR,DEPT SURG,4301 X ST,SACRAMENTO,CA 95817, USA.			Gosselin, Robert/0000-0002-5669-8722			BAUER KA, 1985, J CLIN INVEST, V76, P826, DOI 10.1172/JCI112040; BELL WR, 1994, SEMIN HEMATOL, V31, P19; BLAUHUT B, 1985, THROMB RES, V39, P81, DOI 10.1016/0049-3848(85)90123-9; CAFFERATA HT, 1969, AM J SURG, V118, P221; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; DEMERS C, 1993, THROMB HAEMOSTASIS, V69, P231; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; DIAZCREMADES JM, 1994, INTENS CARE MED, V20, P577, DOI 10.1007/BF01705725; ENDERSON BL, 1991, J TRAUMA, V31, P1240, DOI 10.1097/00005373-199109000-00007; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GEERTS WH, 1995, THROMB HAEMOSTASIS, V73, P973; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HIRSH J, 1989, AM J MED, V87, pS34, DOI 10.1016/0002-9343(89)80529-7; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KILLEWICH LA, 1993, J VASC SURG, V17, P934, DOI 10.1016/0741-5214(93)90043-L; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; LUTERMAN A, 1977, SURGERY, V82, P703; MILLER RS, 1994, J TRAUMA, V37, P442, DOI 10.1097/00005373-199409000-00019; MODIG J, 1983, ACTA ANAESTH SCAND, V27, P369, DOI 10.1111/j.1399-6576.1983.tb01970.x; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; RAPAPORT SI, 1993, WESTERN J MED, V158, P153; RUIZ AJ, 1991, AM J SURG, V162, P159, DOI 10.1016/0002-9610(91)90180-L; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; SEVITT S, 1986, BRIT J SURG, V256, P744; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shackford SR, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; TAYLOR FB, 1988, CIRC SHOCK, V26, P227; VASSAR MJ, 1992, J TRAUMA, V32, P490, DOI 10.1097/00005373-199204000-00014; WESSLER S, 1977, FED PROC, V36, P66; WILLEJORGENSEN P, 1990, SURG GYNECOL OBSTET, V171, P126	34	70	71	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1996	41	3					396	405		10.1097/00005373-199609000-00004			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VH571	WOS:A1996VH57100006	8810955				2021-06-18	
J	Rutledge, R; Lentz, CW; Fakhry, S; Hunt, J				Rutledge, R; Lentz, CW; Fakhry, S; Hunt, J			Appropriate use of the Glasgow Coma Scale in intubated patients: A linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HEAD-INJURED PATIENTS; TRAUMATIC BRAIN INJURY; INTENSIVE-CARE UNIT; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; ACUTE PHYSIOLOGY; RISK-FACTORS; APACHE-II; SEVERITY; RELIABILITY	The Glasgow Coma Scale (GCS) has been shown to be a valuable tool in assessing the neurologic and physiologic status of critically ill patients. Unfortunately, the GCS requires assessment of the verbal response of the patient and this can be blocked by intubation. The purpose of this study was to assess the ability of a regression model based upon the eye and motor components of the GCS to accurately predict the verbal response of the GCS. The primary hypothesis was that the verbal response could be derived from the motor and eye responses of the GCS. Methods: Data were collected prospectively in an intensive care unit computer data base, Patients were divided into training and test data sets. Linear regression was used to derive a model of verbal score from the motor and eye scores of the GCS in the training data set. Correlation between the actual and the predicted verbal scores was calculated. Results: A total of 2,521 GCS assessments were available for analysis. The second order multiple regression model was an accurate predictor of the verbal score (Pearson's Correlation r = 0.9, R(2) = 0.8,p = 0.0001) in 1,463 observations in the training data set. Second Order Multiple Regression Model: Estimated GCS Verbal = (2.3976) + [GCS Motor x (-0.9253)] + [GCS Eye x (-0.9214)] + [(GCS Motor)(2) x (0.2208)] + [(GCS Eye)(2) x (0.2318)] where r = 0.91, R(2) = 0.83, and p = 0.0001. The accuracy of this model was confirmed by comparing the predicted verbal score to the actual verbal score in the test data set (n = 736, r = 0.92, R(2) = 0.85, p = 0.0001) Conclusions: The GCS is a useful tool in the intensive care unit and a critical part of the APACHE II assessment of patient acuity. GCS has been shown to be a useful tool in its own right as a predictor of outcome in the critically ill. Its use is limited with intubation. (See Segatore M, Way C: Heart Lung 21:548, 1992; and Lieh-Lai MW, Theodorou AA, Sarnaik AP, et al: J Pediatr 120:195,1992.) The present study demonstrates that a relatively simple regression model can use the eve and motor components of the GCS to predict the expected verbal component of the GCS, thus allowing the calculation of the GCS sum score in intubated patients.		Rutledge, R (corresponding author), UNIV N CAROLINA,DEPT SURG,CAMPUS BOX 7210,BURNETT WOMACK,CHAPEL HILL,NC 27599, USA.						ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BENESCH CG, 1993, ARCH NEUROL-CHICAGO, V50, P1309, DOI 10.1001/archneur.1993.00540120024008; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chan Betty, 1993, Journal of Emergency Medicine, V11, P579, DOI 10.1016/0736-4679(93)90312-U; ELLIS A, 1992, INTENSIVE CRIT CARE, V8, P4; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; KARKELA J, 1992, CRIT CARE MED, V20, P378; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANGFITT TW, 1983, J NEUROSURG, V48, P673; LANZA DC, 1990, ANN OTO RHINOL LARYN, V99, P38, DOI 10.1177/000348949009900106; LEE H, 1992, CRIT CARE MED, V20, P1555, DOI 10.1097/00003246-199211000-00013; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MARGULIES DR, 1994, AM SURGEON, V60, P387; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; METZ CA, 1993, CRIT CARE MED, V21, P1844, DOI 10.1097/00003246-199312000-00010; NISKANEN M, 1991, CRIT CARE MED, V19, P1465, DOI 10.1097/00003246-199112000-00005; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SANO K, 1994, NEUROL RES, V16, P23; SCHWARTZ ML, 1991, J TRAUMA, V31, P962, DOI 10.1097/00005373-199107000-00013; SEGATORE M, 1992, HEART LUNG, V21, P548; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; TEASDALE G, 1974, LANCET, V2, P81; TERES D, 1982, CRIT CARE MED, V10, P86, DOI 10.1097/00003246-198202000-00004; TUHRIM S, 1991, ANN NEUROL, V29, P658, DOI 10.1002/ana.410290614; TURAZZI S, 1984, ACTA NEUROCHIR, V72, P167, DOI 10.1007/BF01406869; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WOLFGOULD C, 1991, J TROP PEDIATRICS, V38, P290; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169	47	70	72	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1996	41	3					514	522		10.1097/00005373-199609000-00022			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VH571	WOS:A1996VH57100026	8810973				2021-06-18	
J	Breese, CR; DCosta, A; Rollins, YD; Adams, C; Booze, RM; Sonntag, WE; Leonard, S				Breese, CR; DCosta, A; Rollins, YD; Adams, C; Booze, RM; Sonntag, WE; Leonard, S			Expression of insulin-like growth factor-1 (IGF-1) and IGF-binding protein 2 (IGF-BP2) in the hippocampus following cytotoxic lesion of the dentate gyrus	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						colchicine; brain injury; astroglia; neurotrophic factor; microglia	FIBRILLARY ACIDIC PROTEIN; HYPOXIC-ISCHEMIC INJURY; CENTRAL NERVOUS-SYSTEM; I GENE-EXPRESSION; RAT-BRAIN; MESSENGER-RNA; GRANULE CELLS; GLIAL-CELLS; ADULT-RAT; SPREADING DEPRESSION	Receptor binding and gene expression of several members of the IGF gene family were examined in the rat brain following lesion of the hippocampal dentate gyrus granular cells by intradentate colchicine injection. Dentate granular cell loss was accompanied by extensive reactive gliosis in the lesioned hippocampus and damaged overlying cortex, as verified by the increase in GFAP mRNA and BS-P lectin binding. At 4 days post-lesion, I-125-IGF-2 binding was dramatically increased within the lesioned dentate gyrus and damaged overlying cortex, and corresponded temporally and anatomically with increased IGF-BP2 gene expression following the lesion. Increased IGF-BP3 gene expression was only observed in the overlying cortex at 10 days post-lesion, and corresponded with an increase in I-125-IGF-1 binding at the injured surface of the cortex. Type-2 IGF receptor mRNA expression was reduced to background levels in the lesioned dentate gyrus, suggesting that IGF-BP2 was a major component of the observed increase in I-125-IGF-2 binding. In situ hybridization also revealed a prominent increase in IGF-L mRNA expression by 4 days post-lesion, which was localized within the lesioned dentate gyrus and damaged cortical areas, and was shown to be expressed by microglia. While no IGF-S mRNA expression was observed within the CNS, either prior to, or following the lesion, IGF-2 mRNA expression was observed in the choroid plexus, meningeal membranes, and in blood vessel endothelium, providing a potential source for the transport of IGF-2 into the CNS. In the injured CNS, increased IGF-BP2 expression may act to maintain or transport IGF-1 or IGF-2, as well as modulate the local autocrine and paracrine actions of the IGFs. Increased microglial IGF-1 expression following colchicine treatment con elates with the timing of a number of post-traumatic post-traumatic events within the CNS, suggesting that IGF-1 may have a role as a neuroprotectant for surviving neurons and signal for local neuronal sprouting, as well as a role in reactive astrogliosis. (C) 1996 Wiley-Liss, Inc.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL & PSYCHIAT, DENVER, CO 80262 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PHYSIOL & PHARMACOL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT NEUROBIOL & ANAT, WINSTON SALEM, NC 27157 USA; UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT PHARMACOL, LEXINGTON, KY 40536 USA				Booze, Rosemarie/0000-0003-3908-8313; sonntag, William/0000-0003-1850-2407	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA008536, T32AA007464, F31AA005315] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA08536, AA07464-17, AA05315] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG011370] Funding Source: Medline		AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANG LC, 1993, DEV BRAIN RES, V74, P83, DOI 10.1016/0165-3806(93)90086-P; AULETTA M, 1992, J NEUROSCI RES, V31, P14, DOI 10.1002/jnr.490310103; BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BALLARD FJ, 1991, J ENDOCRINOL, V128, P197, DOI 10.1677/joe.0.1280197; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BALLOTTI R, 1987, EMBO J, V6, P3633, DOI 10.1002/j.1460-2075.1987.tb02695.x; BEILHARZ EJ, 1993, MOL BRAIN RES, V18, P209, DOI 10.1016/0169-328X(93)90191-Q; BENVENISTE EN, 1992, CHEM IMMUNOL, V52, P106; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; BONDY CA, 1991, J NEUROSCI, V11, P3442; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; BRADSHAW SL, 1993, ENDOCRINOLOGY, V133, P1767, DOI 10.1210/en.133.4.1767; BREESE CR, 1991, ADV EXP MED BIOL, V293, P449; BREESE CR, 1994, NEUROSCIENCE, V63, P579, DOI 10.1016/0306-4522(94)90551-7; BREESE CR, 1991, NEUR ABTS, V26, P9; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DRUST EG, 1985, BRAIN RES BULL, V14, P9, DOI 10.1016/0361-9230(85)90172-8; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ENBERG G, 1985, ACTA PHYSIOL SCAND, V125, P305, DOI 10.1111/j.1748-1716.1985.tb07720.x; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GARCIAESTRADA J, 1992, BRAIN RES, V592, P343, DOI 10.1016/0006-8993(92)91695-B; GINN SR, 1991, BRAIN RES, V554, P257, DOI 10.1016/0006-8993(91)90198-5; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GIULIAN D, 1985, J CELL BIOL, V101, P2411, DOI 10.1083/jcb.101.6.2411; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GOLDSCHMIDT RB, 1980, P NATL ACAD SCI-BIOL, V77, P3047, DOI 10.1073/pnas.77.5.3047; GOMEZPINILLA F, 1992, NEUROSCIENCE, V49, P771, DOI 10.1016/0306-4522(92)90355-6; GUAN J, 1993, J CEREBR BLOOD F MET, V13, P609, DOI 10.1038/jcbfm.1993.79; GUTHRIE KM, 1995, J COMP NEUROL, V352, P147, DOI 10.1002/cne.903520111; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KANJE M, 1989, BRAIN RES, V486, P396, DOI 10.1016/0006-8993(89)90531-3; KIESS W, 1989, ENDOCRINOLOGY, V124, P1727, DOI 10.1210/endo-124-4-1727; KLEMPT M, 1993, MOL BRAIN RES, V17, P347, DOI 10.1016/0169-328X(93)90021-G; KOMOLY S, 1992, P NATL ACAD SCI USA, V89, P1894, DOI 10.1073/pnas.89.5.1894; KRAIG RP, 1991, J NEUROSCI, V11, P2187; LAPCHAK PA, 1993, NEUROREPORT, V4, P191, DOI 10.1097/00001756-199302000-00019; LAUTERIO TJ, 1992, ADV EXP MED BIOL, V321, P31; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; LEE WH, 1992, MOL CELL NEUROSCI, V3, P36, DOI 10.1016/1044-7431(92)90006-N; LEONARD S, 1993, MOL BRAIN RES, V18, P275, DOI 10.1016/0169-328X(93)90090-C; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LIU X, 1994, MOL CELL NEUROSCI, V5, P418, DOI 10.1006/mcne.1994.1052; LOGAN A, 1992, J NEUROSCI, V12, P3828; MASTERS BA, 1991, REGUL PEPTIDES, V33, P117, DOI 10.1016/0167-0115(91)90207-W; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; MUNDY WR, 1990, NEUROTOXICOLOGY, V11, P539; Nachemson AK, 1990, GROWTH FACTORS, V3, P309, DOI 10.3109/08977199009003673; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; Paxinos G, 1986, RAT BRAIN STEREOTAXI; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; ROBAIN O, 1989, J COMP NEUROL, V285, P274, DOI 10.1002/cne.902850209; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SHEMER J, 1987, J BIOL CHEM, V262, P7693; SONNTAG WE, 1980, ENDOCRINOLOGY, V107, P1875, DOI 10.1210/endo-107-6-1875; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; TANDON P, 1994, NEUROTOXICOLOGY, V15, P513; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	66	70	70	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	JUN 3	1996	369	3					388	404					17	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	UM590	WOS:A1996UM59000005	8743420				2021-06-18	
J	OMMAYA, AK				OMMAYA, AK			HEAD-INJURY MECHANISMS AND THE CONCEPT OF PREVENTIVE MANAGEMENT - A REVIEW AND CRITICAL SYNTHESIS	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, D.C.	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		TRAUMATIC BRAIN INJURY; BIOMECHANICS; CENTRIPETAL THEORY; TADD SYNDROME; VENOSPASM; HEAD INJURY MECHANISMS; PREVENTION	DIFFUSE AXONAL INJURY; NEUROFILAMENT SUBUNITS; CEREBRAL CONCUSSION; BRAIN; DETERIORATE; SECONDARY; HEMATOMA; SPORTS; IMPACT; MILD	Recent advances in head injury research have produced a plethora of useful data coupled with a paucity of conceptual integration across the four ways in which this research is pursued, These research orientations are the epidemiological, biomechanical, basic neuroscientific, and clinicopathologic/therapeutic (including rehabilitation). This overview of the history and current state of the art assumes that biomechanics is the basic science of causation in head injury research and when fully integrated with its counterparts, physiology and pathology, it can serve to overcome our conceptual handicaps, A paradigm integrating biomechanics into the sequence of preventive, protective, acute therapeutic, and rehabilitative interventions will. be described as the concept of preventive management, From this we derive the hypothesized claim that the exact biomechanics and the physiopathologic response at the time of injury (at the macroscopic and microscopic levels) determine the sequence of so-called secondary effects that are conceived as the inexorable delayed manifestations of the primary events and concomitant boundary conditions, Knowledge of these events will enable accurate predictions of the natural history and outcome of head injuries from observations carried out in the early acute phase, Examples to test this claim will be given with particular reference to the two types of traumatic brain injury (TBI) phenomenologically associated with disturbances of consciousness, the onset of which can be either immediate or delayed, The current economics and availability of computational power provide a significant opportunity for the development of selected experimental, physical, and simulated models of head injury on the basis of which the complex neurovascular and nonneural cellular and fluid elements of the nervous system may be accurately modeled. This approach will significantly improve the efficiency and quality of the essential biological and clinical observations and model experiments required to validate the theoretical methods and their predictions.	GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC 20052 USA	OMMAYA, AK (corresponding author), CYBORGAN INC, 8006 GLENBROOK RD, BETHESDA, MD 20814 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; ADAMS JH, 1990, HDB CLIN NEUROLOGY, V13, pCH3; ADVANI SH, 1982, HUMAN BODY DYNAMICS, P3; BLUMBERGS PC, 1967, J NEUROL NEUROSUR PS, V52, P839; BOOCK JR, 1990, P IRCOBI LYON; BRUCE DA, 1983, J NEUROSURG, V54, P285; Cairns H, 1941, BRIT MED J, V1941, P465, DOI 10.1136/bmj.2.4213.465; CHOI SC, 1994, NEUROSURGERY, V81, P169; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DENNYBROWN D, 1941, BRAIN, P64; ENGIN AE, 1970, J BIOMECH, V3, P283, DOI 10.1016/0021-9290(70)90030-8; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; FISHMAN RA, 1993, NEUROLOGY, V43, P609, DOI 10.1212/WNL.43.3_Part_1.609; GADD CW, 1966, 10TH P STAPP CAR CRA; Gennarelli T. A., 1972, 16 STAPP CAR CRASH C, P296; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENNARELLI TA, 1971, 15TH P STAPP CAR CRA; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOLDSMITH W, 1984, BIOMECHANICS IMPACT; GOLDSMITH W, 1966, HEAD INJURY C P; GOLDSMITH W, 1989, AAAM M NEED ANGULAR; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1993, HEAD INJURY; GRONWALL D, 1974, LANCET, V2, P605; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; Gurdjian ES, 1975, IMPACT HEAD INJURY; HAYASHI T, 1969, J FAC ENG U TOKYO B, V30, P117; HAYASHI T, 1969, J FAC ENG U TOKYO, V30, P59; HIGGINS LS, 1967, 11TH STAPP CAR CRASH, P35; Holbourn AHS, 1943, LANCET, V2, P438; HUMAYUN MS, 1987, P SOC NEUROSCI, V2, P137; JANE J, 1982, SEMINARS NEUROLOGIC; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1972, LANCET, V1, P734; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; Levin HS, 1989, MILD HEAD INJURY; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; LINDGREN SO, 1966, ACTA CHIR SCAND S, V360; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MAMELAK AN, 1994, P CNS CHICAGO, P75; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Meaney DF, 1991, THESIS U PENNSYLVANI; MEANEY DF, 1994, UNPUB ULTIMATE FAILU; MEANEY DF, 1994, UNPUB PROPOSED ADSH; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1987, PUBLIC HEALTH REP, V102, P587; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1982, DTNH2282C07247 NAT T; OMMAYA AK, UNPUB HIST HEAD INJU; OMMAYA AK, 1985, IRCOBI P GOTEBERG, P32; Ommaya AK, 1968, J BIOMECH; OMMAYA AK, 1983, DOTHS806434 PUBL; OMMAYA AK, 1966, 10TH P STAPP CAR CRA; Ommaya AK, 1995, PRINCIPLES NUCLEAR M; OMMAYA AK, 1973, PB226828; OMMAYA AK, 1989, SPORTS NEUROLOGY, pCH8; OMMAYA AK, 1969, ACCIDENT PATHOLOGY; OMMAYA AK, 1994, ASTM STP, V1229; OMMAYA AK, 1982, NEUROLOGICAL SURGERY, V4, P1877; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus E., 1994, Society for Neuroscience Abstracts, V20, P421; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; REILLY PL, 1975, LANCET, V2, P375; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTS GW, 1994, LANCET, V342, P863; RUSSELL RW, 1969, HDB CLIN NEUROLOGY, V3, P293; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNIEDER RC, 1973, HEAD NECK INJURIES F; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; VIANO D, 1989, 881708 STAPP CAR CRA; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; 1985, INJURY AM CONTINUING; 1988, INJURY CONTROL REV S	100	70	75	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					527	546		10.1089/neu.1995.12.527			20	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000004	8683604				2021-06-18	
J	THOMSEN, IV				THOMSEN, IV			LATE PSYCHOSOCIAL OUTCOME IN SEVERE TRAUMATIC BRAIN INJURY - PRELIMINARY-RESULTS OF A 3RD FOLLOW-UP-STUDY AFTER 20 YEARS	SCANDINAVIAN JOURNAL OF REHABILITATION MEDICINE			English	Article						SEVERE HEAD INJURY; LATE PSYCHOSOCIAL OUTCOME; BEHAVIORAL DEFICITS; FAMILY RELATIONSHIPS		More than 20 years after severe head injury the preliminary results of the present study indicate that the very late psychosocial outcome differed much in the individual subjects. The most decisive negative factors were severely disturbed behaviour and lack of insight. Improvement many years after injury was, however, possible. During the years the relationship between parent(s) and severely head injured sons often became strained. After the first posttraumatic year or two the patient with severe behavioural deficits must be helped to adopt some other type of living.		THOMSEN, IV (corresponding author), UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT NEUROL,DK-2100 COPENHAGEN,DENMARK.							0	70	71	0	1	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5505			SCAND J REHABIL MED	Scand. J. Rehabil. Med.		1992				26			142	152					11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	KG064	WOS:A1992KG06400014	1488637				2021-06-18	
J	ROCKSWOLD, GL; LEONARD, PR; NAGIB, MG				ROCKSWOLD, GL; LEONARD, PR; NAGIB, MG			ANALYSIS OF MANAGEMENT IN 33 CLOSED HEAD-INJURY PATIENTS WHO TALKED AND DETERIORATED	NEUROSURGERY			English	Article									UNIV MINNESOTA,DEPT NEUROSURG,MINNEAPOLIS,MN 55455	ROCKSWOLD, GL (corresponding author), HENNEPIN CTY MED CTR,DIV NEUROSURG,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.						BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; DIAG FG, 1979, J NEUROSURG, V50, P217; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; REILLY PL, 1975, LANCET, V2, P375; RICHARDS T, 1974, SURGERY, V75, P253; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516	11	70	70	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUL	1987	21	1					51	55		10.1227/00006123-198707000-00010			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	J1313	WOS:A1987J131300009	3614604				2021-06-18	
J	Williams, D; Denny-Brown, D				Williams, D; Denny-Brown, D			Cerebral electrical changes in experimental concussion	BRAIN			English	Article																Adrian ED, 1934, BRAIN, V57, P355, DOI 10.1093/brain/57.4.355; Berger H, 1930, J PSYCHOL NEUROL, V40, P160; COURTNEY JW, 1899, BOSTON M S J, V140, P373; COURTNEY JW, 1899, BOSTON MED SURG J, V140, P397; COURTNEY JW, 1899, BOSTON M S J, V140, P345; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; DENNYBROWN D, 1941, BRAIN, V64; Derbyshire AJ, 1936, AM J PHYSIOL, V116, P577; Dixon KC, 1940, LANCET, V2, P360; Lennox WG, 1938, J NEUROL PSYCHIATRY, V1, P211, DOI 10.1136/jnnp.1.3.211; LOOMIS ALFRED L., 1935, SCIENCE, V81, P597, DOI 10.1126/science.81.2111.597; MARTIN JP, 1939, P ROY SOC MED, V32, P141; TROTTER W, 1923, SYSTEM SURG, V3, P464; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P131, DOI 10.1136/jnnp.4.2.131; WILLIAMS DH, UNPUB	16	70	70	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain		1941	64						223	238		10.1093/brain/64.4.223			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V20IW	WOS:000201375000010					2021-06-18	
J	Shin, JH; Yan, Y; Bai, WB; Xue, YG; Gamble, P; Tian, LM; Kandela, I; Haney, CR; Spees, W; Lee, Y; Choi, M; Ko, J; Ryu, H; Chang, JK; Pezhouh, M; Kang, SK; Won, SM; Yu, KJ; Zhao, JN; Lee, YK; MacEwan, MR; Song, SK; Huang, YG; Ray, WZ; Rogers, JA				Shin, Jiho; Yan, Ying; Bai, Wubin; Xue, Yeguang; Gamble, Paul; Tian, Limei; Kandela, Irawati; Haney, Chad R.; Spees, William; Lee, Yechan; Choi, Minseok; Ko, Jonathan; Ryu, Hangyu; Chang, Jan-Kai; Pezhouh, Maryam; Kang, Seung-Kyun; Won, Sang Min; Yu, Ki Jun; Zhao, Jianing; Lee, Yoon Kyeung; MacEwan, Matthew R.; Song, Sheng-Kwei; Huang, Yonggang; Ray, Wilson Z.; Rogers, John A.			Bioresorbable pressure sensors protected with thermally grown silicon dioxide for the monitoring of chronic diseases and healing processes	NATURE BIOMEDICAL ENGINEERING			English	Article							TEMPERATURE-COEFFICIENT; BIOFLUID BARRIERS; ELECTRONICS; LAYERS; DISSOLUTION; CHALLENGES; ULTRATHIN; TISSUE	Pressures in the intracranial, intraocular and intravascular spaces are clinically useful for the diagnosis and management of traumatic brain injury, glaucoma and hypertension, respectively. Conventional devices for measuring these pressures require surgical extraction after a relevant operational time frame. Bioresorbable sensors, by contrast, eliminate this requirement, thereby minimizing the risk of infection, decreasing the costs of care and reducing distress and pain for the patient. However, the operational lifetimes of bioresorbable pressure sensors available at present fall short of many clinical needs. Here, we present materials, device structures and fabrication procedures for bioresorbable pressure sensors with lifetimes exceeding those of previous reports by at least tenfold. We demonstrate measurement accuracies that compare favourably to those of the most sophisticated clinical standards for non-resorbable devices by monitoring intracranial pressures in rats for 25 days. Assessments of the biodistribution of the constituent materials, complete blood counts, blood chemistry and magnetic resonance imaging compatibility confirm the biodegradability and clinical utility of the device. Our findings establish routes for the design and fabrication of bioresorbable pressure monitors that meet requirements for clinical use.	[Shin, Jiho; Lee, Yechan; Choi, Minseok; Ko, Jonathan; Ryu, Hangyu] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL USA; [Shin, Jiho; Lee, Yechan; Choi, Minseok; Ko, Jonathan; Ryu, Hangyu; Chang, Jan-Kai; Won, Sang Min; Zhao, Jianing] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL USA; [Yan, Ying; Gamble, Paul; MacEwan, Matthew R.; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63130 USA; [Bai, Wubin; Xue, Yeguang; Huang, Yonggang; Rogers, John A.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; [Bai, Wubin; Rogers, John A.] Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Civil & Environm Engn, Evanston, IL 60208 USA; [Tian, Limei] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL USA; [Kandela, Irawati] Northwestern Univ, Dev Therapeut Core, Evanston, IL USA; [Haney, Chad R.] Northwestern Univ, Ctr Adv Mol Imaging, Evanston, IL USA; [Spees, William; Song, Sheng-Kwei] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Biomed Magnet Resonance Lab, St Louis, MO USA; [Spees, William; Song, Sheng-Kwei] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO USA; [Chang, Jan-Kai] Univ Illinois, Dept Mat Sci & Engn, Urbana, IL USA; [Pezhouh, Maryam] Northwestern Univ, Feinberg Sch Med, Northwestern Med, Evanston, IL USA; [Kang, Seung-Kyun] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea; [Won, Sang Min] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL USA; [Yu, Ki Jun] Yonsei Univ, Sch Elect & Elect Engn, Seoul, South Korea; [Zhao, Jianing] Univ Illinois, Dept Mech Sci & Engn, Urbana, IL USA; [Lee, Yoon Kyeung] Seoul Natl Univ, Dept Mat Sci & Engn, Seoul, South Korea; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Elect Engn & Comp Sci, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA	Ray, WZ (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63130 USA.; Rogers, JA (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Elect Engn & Comp Sci, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA.	rayz@wudosis.wustl.edu; jrogers@northwestern.edu	Xue, Yeguang/B-8696-2015; huang, yonggang/O-6236-2019; Huang, Yonggang/B-6998-2009; Bai, Wubin/AAG-2382-2020; Rogers, John/L-2798-2016; Haney, Chad R/A-3909-2008	Xue, Yeguang/0000-0002-1968-5092; Bai, Wubin/0000-0003-2872-5559; Haney, Chad R/0000-0001-5981-2925; Lee, Yoon Kyeung/0000-0001-5160-1015; Tian, Limei/0000-0002-1931-8567; WANG, KE/0000-0003-2004-2745; Lee, Yechan/0000-0002-4744-267X	Ryan Fellowship; Northwestern University International Institute for Nanotechnology; Beckman Institute Postdoctoral Fellowship at UIUC; Cancer Center Support grant (National Cancer Institute) [P30 CA060553]; National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2017M1A2A2048880, NRF-2018M3A7B4071109]; Yonsei University [RMS2 2018-22-0028]; NSFNational Science Foundation (NSF) [1400169, 1534120, 1635443]	J.S. thanks G. Mensing and J. Maduzia at the Micro-Nano-Mechanical Systems Cleanroom (University of Illinois at Urbana-Champaign) for assistance with process development. J. S. acknowledges support from True Phantom Solutions Inc. with the preparation of brain phantoms for MRI compatibility tests. Y.X. acknowledges support from the Ryan Fellowship and the Northwestern University International Institute for Nanotechnology. L.T. acknowledges support from a Beckman Institute Postdoctoral Fellowship at UIUC. I.K. acknowledges support from Cancer Center Support grant no. P30 CA060553 (National Cancer Institute) awarded to the Robert H. Lurie Comprehensive Cancer Center. K.J.Y. acknowledges support from the National Research Foundation of Korea (grant nos. NRF-2017M1A2A2048880 and NRF-2018M3A7B4071109) and Yonsei University Future-leading Research Initiative of 2017 (grant no. RMS2 2018-22-0028). Y.H. acknowledges support from the NSF (grant nos. 1400169, 1534120 and 1635443).	[Anonymous], 2010, POSTCR SUBD PRESS MO; Boutry CM, 2012, PHILOS T R SOC A, V370, P2418, DOI 10.1098/rsta.2011.0439; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Camino G, 2001, POLYMER, V42, P2395, DOI 10.1016/S0032-3861(00)00652-2; Chamis AL, 2001, CIRCULATION, V104, P1029, DOI 10.1161/hc3401.095097; Dunn JF, 2009, MAGN RESON MED, V61, P222, DOI 10.1002/mrm.21803; Fang H, 2016, P NATL ACAD SCI USA, V113, P11682, DOI 10.1073/pnas.1605269113; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Hwang SW, 2015, NANO LETT, V15, P2801, DOI 10.1021/nl503997m; Hwang SW, 2014, ADV MATER, V26, P3905, DOI 10.1002/adma.201306050; Hwang SW, 2012, SCIENCE, V337, P1640, DOI 10.1126/science.1226325; Jiang GQ, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/neuro.20.002.2010; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; KANDA Y, 1982, IEEE T ELECTRON DEV, V29, P64, DOI 10.1109/T-ED.1982.20659; Kang SK, 2016, NATURE, V530, P71, DOI 10.1038/nature16492; Kang SK, 2015, ADV FUNCT MATER, V25, P1789, DOI 10.1002/adfm.201403469; Kang SK, 2014, ADV FUNCT MATER, V24, P4427, DOI 10.1002/adfm.201304293; Lee CH, 2015, ADV FUNCT MATER, V25, P5100, DOI 10.1002/adfm.201502192; Lee G, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700157; Lee YK, 2017, ACS NANO, V11, P12562, DOI 10.1021/acsnano.7b06697; Lee YK, 2017, ACS APPL MATER INTER, V9, P42633, DOI 10.1021/acsami.7b15302; Lund E., 2000, MRS P, V657; Luo MD, 2014, J MICROELECTROMECH S, V23, P4, DOI 10.1109/JMEMS.2013.2290111; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Moghimi SM, 1998, ADV DRUG DELIVER REV, V32, P45, DOI 10.1016/S0169-409X(97)00131-2; National Research Council, 2011, GUIDE CARE USE LAB A, DOI 10.17226/12910; NORTON P, 1978, SOLID STATE ELECTRON, V21, P969, DOI 10.1016/0038-1101(78)90296-4; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Sawyer-Glover AM, 2000, J MAGN RESON IMAGING, V12, P92, DOI 10.1002/1522-2586(200007)12:1<92::AID-JMRI11>3.0.CO;2-7; Sit AJ, 2009, J GLAUCOMA, V18, P272, DOI 10.1097/IJG.0b013e3181862490; Tao H, 2014, P NATL ACAD SCI USA, V111, P17385, DOI 10.1073/pnas.1407743111; Wang Q, 2005, SENSOR ACTUAT A-PHYS, V120, P468, DOI 10.1016/j.sna.2005.01.036; Yu KJ, 2016, NAT MATER, V15, P782, DOI [10.1038/NMAT4624, 10.1038/nmat4624]; Yu L, 2014, SENSORS-BASEL, V14, P20620, DOI 10.3390/s141120620; Zacchetti L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1137-9	37	69	69	23	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2157-846X			NAT BIOMED ENG	Nat. Biomed. Eng	JAN	2019	3	1					37	46		10.1038/s41551-018-0300-4			10	Engineering, Biomedical	Engineering	HG6VH	WOS:000455123800010	30932064		Y	N	2021-06-18	
J	Chou, A; Krukowski, K; Jopson, T; Zhu, PJ; Costa-Mattioli, M; Walter, P; Rosi, S				Chou, Austin; Krukowski, Karen; Jopson, Timothy; Zhu, Ping Jun; Costa-Mattioli, Mauro; Walter, Peter; Rosi, Susanna			Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						brain trauma; memory deficits; translational control; eIF2 alpha; hippocampus	TERM SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; TRANSLATIONAL CONTROL; MOUSE MODEL; HEAD TRAUMA; NEUROINFLAMMATORY RESPONSE; MEMORY STORAGE; UP-REGULATION; RISK-FACTOR; EIF2-ALPHA	Traumatic brain injury (TBI) is a leading cause of long-term neurological disability, yet the mechanisms underlying the chronic cognitive deficits associated with TBI remain unknown. Consequently, there are no effective treatments for patients suffering from the long-lasting symptoms of TBI. Here, we show that TBI persistently activates the integrated stress response (ISR), a universal intracellular signaling pathway that responds to a variety of cellular conditions and regulates protein translation via phosphorylation of the translation initiation factor eIF2 alpha. Treatment with ISRIB, a potent drug-like small-molecule inhibitor of the ISR, reversed the hippocampal-dependent cognitive deficits induced by TBI in two different injury mouse models-focal contusion and diffuse concussive injury. Surprisingly, ISRIB corrected TBI-induced memory deficits when administered weeks after the initial injury and maintained cognitive improvement after treatment was terminated. At the physiological level, TBI suppressed long-term potentiation in the hippocampus, which was fully restored with ISRIB treatment. Our results indicate that ISR inhibition at time points late after injury can reverse memory deficits associated with TBI. As such, pharmacological inhibition of the ISR emerges as a promising avenue to combat head trauma-induced chronic cognitive deficits.	[Chou, Austin; Krukowski, Karen; Jopson, Timothy; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Chou, Austin; Rosi, Susanna] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA; [Krukowski, Karen; Jopson, Timothy; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA; [Krukowski, Karen; Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Zhu, Ping Jun; Costa-Mattioli, Mauro] Baylor Coll Med, Memory & Brain Res Ctr, Dept Neurosci, Houston, TX 77030 USA; [Walter, Peter] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Walter, P (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.; Walter, P (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	peter@walterlab.ucsf.edu; Susanna.Rosi@ucsf.edu		Chou, Austin/0000-0003-4328-5811	Rogers Family Foundation; NIH/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32AG054126, R21AG042016] Funding Source: NIH RePORTER	We thank Dr. Nicole Day for technical expertise in conducting the initial injury and behavioral experiments; Dr. Carmela Sidrauski, Jordan Tsai, and Aditya Anand for help and advice with drug administration; and Dr. Regis Kelly for invaluable feedback on the manuscript. This work was supported by a generous grant from the Rogers Family Foundation (to S.R. and P.W.) and NIH/National Institute on Aging Grant R21AG042016 (to S.R.). P.W. is an Investigator of the Howard Hughes Medical Institute.	Acosta SA, 2017, J CELL PHYSIOL, V232, P665, DOI 10.1002/jcp.25629; Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Bachstetter AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0289-5; Batista G, 2016, ELIFE, V5, DOI 10.7554/eLife.17197; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Buffington SA, 2014, ANNU REV NEUROSCI, V37, P17, DOI 10.1146/annurev-neuro-071013-014100; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Committee on Care and Use of Laboratory Animals, 1996, GUIDE CARE USE LAB A, P85; Costa-Mattioli M, 2007, CELL, V129, P195, DOI 10.1016/j.cell.2007.01.050; Costa-Mattioli M, 2009, NEURON, V61, P10, DOI 10.1016/j.neuron.2008.10.055; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Di Prisco GV, 2014, NAT NEUROSCI, V17, P1073, DOI 10.1038/nn.3754; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Faizi M, 2012, BRAIN BEHAV, V2, P142, DOI 10.1002/brb3.41; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Freeman OJ, 2016, BRAIN RES, V1648, P530, DOI 10.1016/j.brainres.2016.03.029; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Huang W, 2016, ELIFE, V5, DOI 10.7554/eLife.12052; Huang W, 2013, NAT NEUROSCI, V16, P441, DOI 10.1038/nn.3351; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jiang Z, 2010, J NEUROSCI, V30, P2582, DOI 10.1523/JNEUROSCI.3971-09.2010; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Nadif K. N., 2011, NEURON, V72, P300, DOI DOI 10.1016/J.NEUR0N.2011.09.001; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Pasini S, 2015, CELL REP, V11, P183, DOI 10.1016/j.celrep.2015.03.025; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Placzek AN, 2016, ELIFE, V5, P5; Ron D, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013177; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scheper W, 2015, ACTA NEUROPATHOL, V130, P315, DOI 10.1007/s00401-015-1462-8; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sekine Y, 2015, SCIENCE, V348, P1027, DOI 10.1126/science.aaa6986; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Song SJ, 2016, J NEUROSCI RES, V94, P409, DOI 10.1002/jnr.23714; Stern E, 2013, J NEUROSCI, V33, P2517, DOI 10.1523/JNEUROSCI.2322-12.2013; Stoica L, 2011, P NATL ACAD SCI USA, V108, P3791, DOI 10.1073/pnas.1014715108; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhu PJ, 2011, CELL, V147, P1384, DOI 10.1016/j.cell.2011.11.029	72	69	70	0	12	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 1	2017	114	31					E6420	E6426		10.1073/pnas.1707661114			7	Multidisciplinary Sciences	Science & Technology - Other Topics	FC2FR	WOS:000406653300020	28696288	Bronze, Green Published			2021-06-18	
J	Robba, C; Cardim, D; Tajsic, T; Pietersen, J; Bulman, M; Donnelly, J; Lavinio, A; Gupta, A; Menon, DK; Hutchinson, PJA; Czosnyka, M				Robba, Chiara; Cardim, Danilo; Tajsic, Tamara; Pietersen, Justine; Bulman, Michael; Donnelly, Joseph; Lavinio, Andrea; Gupta, Arun; Menon, David K.; Hutchinson, Peter J. A.; Czosnyka, Marek			Ultrasound non-invasive measurement of intracranial pressure in neurointensive care: A prospective observational study	PLOS MEDICINE			English	Article							OPTIC-NERVE SHEATH; TRAUMATIC BRAIN-INJURY; VENTRICULOSTOMY PLACEMENT; HEMORRHAGIC COMPLICATIONS; PULSATILITY INDEX; SINUS THROMBOSIS; DIAMETER; HYPERTENSION; PREDICTION; GUIDELINES	Background The invasive nature of the current methods for monitoring of intracranial pressure (ICP) has prevented their use in many clinical situations. Several attempts have been made to develop methods to monitor ICP non-invasively. The aim of this study is to assess the relationship between ultrasound-based non-invasive ICP (nICP) and invasive ICP measurement in neurocritical care patients. Methods and findings This was a prospective, single-cohort observational study of patients admitted to a tertiary neurocritical care unit. Patients with brain injury requiring invasive ICP monitoring were considered for inclusion. nICP was assessed using optic nerve sheath diameter (ONSD), venous transcranial Doppler (vTCD) of straight sinus systolic flow velocity (FVsv), and methods derived from arterial transcranial Doppler (aTCD) on the middle cerebral artery (MCA): MCA pulsatility index (PIa) and an estimator based on diastolic flow velocity (FVd). A total of 445 ultrasound examinations from 64 patients performed from 1 January to 1 November 2016 were included. The median age of the patients was 53 years (range 37-64). Median Glasgow Coma Scale at admission was 7 (range 3-14), and median Glasgow Outcome Scale was 3 (range 1-5). The mortality rate was 20%. ONSD and FVsv demonstrated the strongest correlation with ICP (R = 0.76 for ONSD versus ICP; R = 0.72 for FVsv versus ICP), whereas PIa and the estimator based on FVd did not correlate with ICP significantly. Combining the 2 strongest nICP predictors (ONSD and FVsv) resulted in an even stronger correlation with ICP (R = 0.80). The ability to detect intracranial hypertension (ICP-20 mm Hg) was highest for ONSD (area under the curve [AUC] 0.91, 95% CI 0.88-0.95). The combination of ONSD and FVsv methods showed a statistically significant improvement of AUC values compared with the ONSD method alone (0.93, 95% CI 0.90-0.97, p = 0.01). Major limitations are the heterogeneity and small number of patients included in this study, the need for specialised training to perform and interpret the ultrasound tests, and the variability in performance among different ultrasound operators. Conclusions Of the studied ultrasound nICP methods, ONSD is the best estimator of ICP. The novel combination of ONSD ultrasonography and vTCD of the straight sinus is a promising and easily available technique for identifying critically ill patients with intracranial hypertension.	[Robba, Chiara; Lavinio, Andrea; Gupta, Arun; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; [Robba, Chiara] Univ Genoa, Dept Neurosci, Genoa, Italy; [Cardim, Danilo; Donnelly, Joseph; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Brain Phys Lab,Dept Clin Neurosci, Cambridge, England; [Tajsic, Tamara] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; [Pietersen, Justine; Bulman, Michael] Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge, England; [Hutchinson, Peter J. A.] Univ Cambridge Hosp, Div Neurosurg, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Robba, C (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England.; Robba, C (corresponding author), Univ Genoa, Dept Neurosci, Genoa, Italy.	kiarobba@gmail.com	Cardim, Danilo Augusto/B-8447-2012; Donnelly, Joseph/N-6803-2019; Donnelly, Joseph/E-9235-2018; Robba, Chiara/AAS-7421-2020	Cardim, Danilo Augusto/0000-0002-9261-1321; Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Pietersen, Justine Mari/0000-0001-8770-3355	NIHR Brain Injury Healthcare Technology Cooperative, Cambridge, UK; Woolf Fisher Scholarship (NZ); National Institute for Health Research Cambridge BRC as a Research Professor of Neurosurgery; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish	DC and MC are partially supported by NIHR Brain Injury Healthcare Technology Cooperative, Cambridge, UK. JD is supported by a Woolf Fisher Scholarship (NZ). PJAH is supported by the National Institute for Health Research Cambridge BRC as a Research Professor of Neurosurgery. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amini A, 2013, AM J EMERG MED, V31, P236, DOI 10.1016/j.ajem.2012.06.025; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bauer DF, 2011, NEUROSURGERY, V69, P255, DOI 10.1227/NEU.0b013e31821a45ba; Binz DD, 2009, NEUROCRIT CARE, V10, P253, DOI 10.1007/s12028-009-9193-0; Budohoski Karol P, 2012, Acta Neurochir Suppl, V114, P121, DOI 10.1007/978-3-7091-0956-4_22; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cardim D, 2016, J NEUROTRAUM, V33, P792, DOI 10.1089/neu.2015.4134; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; de Riva N, 2012, NEUROCRIT CARE, V17, P58, DOI 10.1007/s12028-012-9672-6; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Helmke K, 2000, TRANSPLANTATION, V70, P392, DOI 10.1097/00007890-200007270-00029; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Hosmer D, 1989, APPL LOGISTIC REGRES; Kashif FM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003249; Komut E, 2016, AM J EMERG MED, V34, P963, DOI 10.1016/j.ajem.2016.02.012; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; Ragauskas A, 2012, NEUROLOGY, V78, P1684, DOI 10.1212/WNL.0b013e3182574f50; Ragauskas A, 2014, NEUROL RES, V36, P607, DOI 10.1179/1743132813Y.0000000308; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Robba C, 2016, BRIT J ANAESTH, V117, P783, DOI 10.1093/bja/aew356; Robba C, 2016, ACTA NEUROL SCAND, V134, P4, DOI 10.1111/ane.12527; Robba C, 2017, J NEUROSURG ANESTH, V29, P243, DOI 10.1097/ANA.0000000000000295; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Schmidt B, 1997, STROKE, V28, P2465, DOI 10.1161/01.STR.28.12.2465; Schoser BGH, 1999, J NEUROSURG, V91, P744, DOI 10.3171/jns.1999.91.5.0744; Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087; Strumwasser A, 2011, J SURG RES, V170, P265, DOI 10.1016/j.jss.2011.03.009; VALDUEZA JM, 1995, STROKE, V26, P1196, DOI 10.1161/01.STR.26.7.1196; WARDLAW JM, 1994, J NEUROSURG, V80, P332, DOI 10.3171/jns.1994.80.2.0332; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42	38	69	71	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	JUL	2017	14	7							e1002356	10.1371/journal.pmed.1002356			16	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200026	28742869	DOAJ Gold, Green Published			2021-06-18	
J	Lee, JH; Wei, ZZ; Cao, WY; Won, S; Gu, XH; Winter, M; Dix, TA; Wei, L; Yu, SP				Lee, Jin Hwan; Wei, Zheng Z.; Cao, Wenyuan; Won, Soonmi; Gu, Xiaohuan; Winter, Megan; Dix, Thomas A.; Wei, Ling; Yu, Shan Ping			Regulation of therapeutic hypothermia on inflammatory cytokines, microglia polarization, migration and functional recovery after ischemic stroke in mice	NEUROBIOLOGY OF DISEASE			English	Article						Stroke; Hypothermia; Neurotensin receptor agonist; HPI-201; Inflammation; M1/M2 polarization; Microglia migration; Functional recovery	TRAUMATIC BRAIN-INJURY; PHARMACOLOGICALLY INDUCED HYPOTHERMIA; TRANSIENT CEREBRAL-ISCHEMIA; MILD HYPOTHERMIA; ARTERY-OCCLUSION; CARDIAC-ARREST; POSTISCHEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; INFARCT SIZE; FOCAL MODEL	Stroke is a leading threat to human life and health in the US and around the globe, while very few effective treatments are available for stroke patients. Preclinical and clinical studies have shown that therapeutic hypothermia (TH) is a potential treatment for stroke. Using novel neurotensin receptor 1 (NTR1) agonists, we have demonstrated pharmacologically induced hypothermia and protective effects against brain damages after ischemic stroke, hemorrhage stroke, and traumatic brain injury (TBI) in rodent models. To further characterize the mechanism of TH-induced brain protection, we examined the effect of TH (at +/- 33 degrees C for 6 h) induced by the NTR1 agonist HPI-201 or physical (ice/cold air) cooling on inflammatory responses after ischemic stroke in mice and oxygen glucose deprivation (OGD) in cortical neuronal cultures. Seven days after focal cortical ischemia, microglia activation in the penumbra reached a peak level, which was significantly attenuated by TH treatments commenced 30 min after stroke. The TH treatment decreased the expression of M1 type reactive factors including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta, IL-12, IL-23, and inducible nitric oxide synthase (iNOS) measured by RT-PCR and Western blot analyses. Meanwhile, TH treatments increased the expression of M2 type reactive factors including IL-10, Fizz1, Ym1, and arginase-1. In the ischemic brain and in cortical neuronal/BV2 microglia cultures subjected to OGD, TH attenuated the expression of monocyte chemoattractant protein -1 (MCP-1) and macrophage inflammatory protein-1 alpha(MIP-1 alpha), two key chemokines in the regulation of microglia activation and infiltration. Consistently, physical cooling during OGD significantly decreased microglia migration 16 h after OGD. Finally, TH improved functional recovery at 1, 3, and 7 days after stroke. This study reveals the first evidence for hypothermia mediated regulation on inflammatory factor expression, microglia polarization, migration and indicates that the anti-inflammatory effect is an important mechanism underlying the brain protective effects of a TH therapy. (C) 2016 Elsevier Inc. All rights reserved.	[Lee, Jin Hwan; Wei, Zheng Z.; Cao, Wenyuan; Won, Soonmi; Gu, Xiaohuan; Winter, Megan; Wei, Ling; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Lee, Jin Hwan; Wei, Zheng Z.; Gu, Xiaohuan; Yu, Shan Ping] Atlanta Vet Affairs Med Ctr, Ctr Visual & Neurocognit Rehabil, Atlanta, GA 30033 USA; [Dix, Thomas A.] JT Pharmaceut, Mt Pleasant, SC 29464 USA; [Dix, Thomas A.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29401 USA	Yu, SP (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,WMR Bldg,Suite 620, Atlanta, GA 30322 USA.	spyu@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073378, NS075338, NS085568, NS091585]; VA National Merit grant [RX000666]; American Heart Association Postdoctoral FellowshipAmerican Heart Association [14P0ST20130024, 15POST25680013, 15POST25710112]; NIH S10 grant [1S10 RR025679 01]; O. Wayne Rollins Endowed Chair fund; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR025679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R41NS073378, R21NS075338, R01NS085568, R01NS091585, R44NS073378, R42NS073378] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000666] Funding Source: NIH RePORTER	This work was supported by the NIH grants NS073378, (TD/SPY), NS075338, (LW/SPY), NS085568, (LW), NS091585, (LW) a VA National Merit grant RX000666 (SPY), and American Heart Association Postdoctoral Fellowship, 14P0ST20130024, (SW), 15POST25680013, (JHL), and 15POST25710112, (ZZW). We also acknowledge the Emory Electron Microscope Core supported by NIH S10 grant (1S10 RR025679 01). This study was also supported by the O. Wayne Rollins Endowed Chair fund to SPY.	Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Chen DD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415605114; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Dae MW, 2003, STROKE, V34, P734, DOI 10.1161/01.STR.0000057461.56040.FE; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Fantegrossi WE, 2005, PHARMACOL BIOCHEM BE, V80, P341, DOI 10.1016/j.pbb.2004.12.005; Flugel A, 2001, J CEREBR BLOOD F MET, V21, P69; Frink M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/762840; Gao J., 2016, CELL TRANSPLANT; Gelderblom M, 2012, J CEREBR BLOOD F MET, V32, P835, DOI 10.1038/jcbfm.2011.189; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Gordon R, 2016, NEUROBIOL DIS, V93, P96, DOI 10.1016/j.nbd.2016.04.008; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Guillemette A, 2012, EUR J PAIN, V16, P473, DOI 10.1016/j.ejpain.2011.07.008; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Herz J, 2014, NEUROBIOL DIS, V62, P456, DOI 10.1016/j.nbd.2013.10.022; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; Jiang M. Q, 2016, BRAIN PATHOL; Karaszewski B, 2013, J CEREBR BLOOD F MET, V33, P1083, DOI 10.1038/jcbfm.2013.52; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Lee JH, 2016, STROKE, V47, P1907, DOI 10.1161/STROKEAHA.116.013061; Lee JH, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0575-x; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lyden PD, 2014, INT J STROKE, V9, P117, DOI 10.1111/ijs.12151; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Markarian GZ, 1996, NEUROSURGERY, V38, P542; Mechanic JA, 2009, EUR NEUROPSYCHOPHARM, V19, P466, DOI 10.1016/j.euroneuro.2009.01.004; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Perez-de Puig I, 2013, J CEREBR BLOOD F MET, V33, P1955, DOI 10.1038/jcbfm.2013.155; Phipps MS, 2011, STROKE, V42, P3357, DOI 10.1161/STROKEAHA.111.621425; PIIRONEN IL, 2014, STROKE, V45, P486, DOI DOI 10.1161/STROKEAHA.111.621425; Polderman KH, 2015, CRIT CARE MED, V43, P2191, DOI 10.1097/CCM.0000000000001158; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Schwab S, 1998, ACT NEUR S, V71, P131; Shobha N, 2011, CEREBROVASC DIS, V31, P223, DOI 10.1159/000321893; Skuljec J, 2011, CELL IMMUNOL, V270, P164, DOI 10.1016/j.cellimm.2011.05.001; Sladojevic N, 2014, NEUROBIOL DIS, V67, P57, DOI 10.1016/j.nbd.2014.03.010; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; Stewart CR, 2010, PEDIATR CRIT CARE ME, V11, P109, DOI 10.1097/PCC.0b013e3181b01042; Su YY, 2016, STROKE, V47, P457, DOI 10.1161/STROKEAHA.115.009789; Subramaniam A, 2015, THER HYPOTHERMIA TEM, V5, P13, DOI 10.1089/ther.2014.0019; Sugerman NT, 2009, J NEUROTRAUM, V26, P371, DOI 10.1089/neu.2008.0588; Takami S, 2001, J CEREBR BLOOD F MET, V21, P1430, DOI 10.1097/00004647-200112000-00007; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Wan YH, 2014, J STROKE CEREBROVASC, V23, P2736, DOI 10.1016/j.jstrokecerebrovasdis.2014.06.017; Wang HK, 2008, J NEUROSCI, V28, P1721, DOI 10.1523/JNEUROSCI.4973-07.2008; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; WEI L, 1995, STROKE, V26, P1459, DOI 10.1161/01.STR.26.8.1459; Wei S, 2013, NEUROSCIENCE, V252, P489, DOI 10.1016/j.neuroscience.2013.07.052; Won S, 2015, BRAIN BEHAV IMMUN, V49, P267, DOI 10.1016/j.bbi.2015.06.007; Xiao GG, 2013, EMERG MED J, V30, P91, DOI 10.1136/emermed-2012-201120; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yoshino H, 1997, BRAIN RES, V767, P81, DOI 10.1016/S0006-8993(97)00616-1; ZHANG ZG, 1993, J NEUROL SCI, V117, P240, DOI 10.1016/0022-510X(93)90179-3; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801	81	69	75	2	27	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2016	96						248	260		10.1016/j.nbd.2016.09.013			13	Neurosciences	Neurosciences & Neurology	EC3WX	WOS:000388058900023	27659107	Green Accepted			2021-06-18	
J	Hickman, RA; Faustin, A; Wisniewski, T				Hickman, Richard A.; Faustin, Arline; Wisniewski, Thomas			Alzheimer Disease and Its Growing Epidemic Risk Factors, Biomarkers, and the Urgent Need for Therapeutics	NEUROLOGIC CLINICS			English	Article						Alzheimer disease; Risk factors; Biomarkers; Epidemiology	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA PLAQUES; APOLIPOPROTEIN-E; HEAD-INJURY; A-BETA; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; NATIONAL INSTITUTE; GLOBAL PREVALENCE	Alzheimer disease (AD) represents one of the greatest medical challenges of this century; the condition is becoming increasingly prevalent worldwide and no effective treatments have been developed for this terminal disease. Because the disease manifests at a late stage after a long period of clinically silent neurodegeneration, knowledge of the modifiable risk factors and the implementation of biomarkers is crucial in the primary prevention of the disease and presymptomatic detection of AD, respectively. This article discusses the growing epidemic of AD and antecedent risk factors in the disease process. Disease biomarkers are discussed, and the implications that this may have for the treatment of this currently incurable disease.	[Hickman, Richard A.] NYU, Dept Pathol, Sch Med, Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA; [Faustin, Arline; Wisniewski, Thomas] NYU, Dept Pathol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA; [Faustin, Arline; Wisniewski, Thomas] NYU, Dept Neurol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA; [Wisniewski, Thomas] NYU, Dept Psychiat, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA	Wisniewski, T (corresponding author), NYU, Dept Neurol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA.	Thomas.wisniewski@nyumc.org	Wisniewski, Thomas/Q-6525-2019	Wisniewski, Thomas/0000-0002-3379-8966; Hickman, Richard/0000-0002-8329-6083	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG08051, AG20245, NS073502]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020245, P30AG008051] Funding Source: NIH RePORTER	NIH: AG08051; AG20245; NS073502.	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Alzheimer's Association, 2006, EARL ONS DEM NAT CHA; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; [Anonymous], 1997, Neurobiol Aging, V18, pS1; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Bloudek LM, 2011, J ALZHEIMERS DIS, V26, P627, DOI 10.3233/JAD-2011-110458; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; Brier MR, 2016, NEUROBIOL AGING, V38, P104, DOI 10.1016/j.neurobiolaging.2015.10.025; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Carlson MC, 2008, ALZHEIMERS DEMENT, V4, P324, DOI 10.1016/j.jalz.2008.07.002; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CLINTON J, 1993, NEUROPATH APPL NEURO, V19, P277, DOI 10.1111/j.1365-2990.1993.tb00438.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; Deane R, 2008, CURR PHARM DESIGN, V14, P1601, DOI 10.2174/138161208784705487; Deary IJ, 2004, PSYCHOL AGING, V19, P367, DOI 10.1037/0882-7974.19.2.367; Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Edland SD, 2002, ARCH NEUROL-CHICAGO, V59, P1589, DOI 10.1001/archneur.59.10.1589; Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Engelhart MJ, 2002, NEUROLOGY, V59, P1915, DOI 10.1001/archneur.59.12.1915; Esiri MM, 2007, J PATHOL, V211, P181, DOI 10.1002/path.2089; Esiri MM, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt105; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Fratiglioni L, 2007, J ALZHEIMERS DIS, V12, P11; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Groot C, 2016, AGEING RES REV, V25, P13, DOI 10.1016/j.arr.2015.11.005; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Hartley D, 2015, ALZHEIMERS DEMENT, V11, P700, DOI 10.1016/j.jalz.2014.10.007; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Hellstrom-Lindahl E, 2008, NEUROBIOL AGING, V29, P210, DOI 10.1016/j.neurobiolaging.2006.10.010; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Holtzman DM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006312; Irwin DJ, 2013, JAMA NEUROL, V70, P462, DOI 10.1001/jamaneurol.2013.1933; Iwata N, 2000, NAT MED, V6, P143; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; James OG, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00038; Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Jonsson T, 2012, NATURE, V488, P96, DOI 10.1038/nature11283; Kalaria RN, 2008, LANCET NEUROL, V7, P812, DOI 10.1016/S1474-4422(08)70169-8; Kalaria RN, 2010, NUTR REV, V68, pS74, DOI 10.1111/j.1753-4887.2010.00352.x; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Karch CM, 2015, BIOL PSYCHIAT, V77, P43, DOI 10.1016/j.biopsych.2014.05.006; Kivipelto M, 2001, NEUROLOGY, V56, P1683, DOI 10.1212/WNL.56.12.1683; Kopits IM, 2011, GENET TEST MOL BIOMA, V15, P871, DOI 10.1089/gtmb.2011.0028; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; Langa KM, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0118-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; Leibson C L, 1997, Ann N Y Acad Sci, V826, P422, DOI 10.1111/j.1749-6632.1997.tb48496.x; Luchsinger JA, 2001, AM J EPIDEMIOL, V154, P635, DOI 10.1093/aje/154.7.635; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Neumann PJ, 2012, HEALTH ECON, V21, P238, DOI 10.1002/hec.1704; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Potter Huntington, 2012, Int J Alzheimers Dis, V2012, P489428, DOI 10.1155/2012/489428; Prince M., 2015, WORLD ALZHEIMER REPO; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Prusiner SB, 2013, ANNU REV GENET, V47, P601, DOI 10.1146/annurev-genet-110711-155524; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Rajagopalan P, 2013, NEW ENGL J MED, V369, P1565, DOI 10.1056/NEJMc1306509; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2; Roberts RO, 2010, J ALZHEIMERS DIS, V21, P853, DOI 10.3233/JAD-2010-091597; Rohn TT, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/860959; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Saito S, 2015, CURR ALZHEIMER RES, V12, P507, DOI 10.2174/1567205012666150530202508; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Spinney L, 2014, NATURE, V510, P26, DOI 10.1038/510026a; Stampfer MJ, 2006, J INTERN MED, V260, P211, DOI 10.1111/j.1365-2796.2006.01687.x; Swan GE, 1998, STROKE, V29, P2334, DOI 10.1161/01.STR.29.11.2334; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Toledo JB, 2013, ACTA NEUROPATHOL, V126, P659, DOI 10.1007/s00401-013-1151-4; Turner AJ, 2004, ANN NY ACAD SCI, V1035, P1, DOI 10.1196/annals.1332.001; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Vardarajan BN, 2014, JAMA NEUROL, V71, P315, DOI 10.1001/jamaneurol.2013.5570; Vemuri P, 2010, NEUROLOGY, V75, P143, DOI 10.1212/WNL.0b013e3181e7ca82; Wikler EM, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt206; Wisniewski T, 2015, NEURON, V85, P1162, DOI 10.1016/j.neuron.2014.12.064; Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200; Yang Z, 2013, NEW ENGL J MED, V369, P489, DOI 10.1056/NEJMc1305541	115	69	74	1	23	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2016	34	4					941	+		10.1016/j.ncl.2016.06.009			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EA3YK	WOS:000386545000010	27720002	Green Accepted			2021-06-18	
J	Harrison, EB; Hochfelder, CG; Lamberty, BG; Meays, BM; Morsey, BM; Kelso, ML; Fox, HS; Yelamanchili, SV				Harrison, Emily B.; Hochfelder, Colleen G.; Lamberty, Benjamin G.; Meays, Brittney M.; Morsey, Brenda M.; Kelso, Matthew L.; Fox, Howard S.; Yelamanchili, Sowmya V.			Traumatic brain injury increases levels of miR-21 in extracellular vesicles: implications for neuroinflammation	FEBS OPEN BIO			English	Article						controlled cortical impact; exosomes; microglia; microRNA; neuroinflammation; secondary injury	SPINAL-CORD-INJURY; MICRORNA EXPRESSION; IMMUNE-RESPONSES; INFLAMMATORY RESPONSE; MESSENGER-RNAS; UP-REGULATION; CELL-DEATH; RECEPTOR 7; RATS; NEURONS	Traumatic brain injury (TBI) is an important health concern and effective treatment strategies remain elusive. Understanding the complex multicellular response to TBI may provide new avenues for intervention. In the context of TBI, cell-cell communication is critical. One relatively unexplored form of cell-cell communication in TBI is extracellular vesicles (EVs). These membrane-bound vesicles can carry many different types of cargo between cells. Recently, miRNA in EVs have been shown to mediate neuroinflammation and neuronal injury. To explore the role of EV-associated miRNA in TBI, we isolated EVs from the brain of injured mice and controls, purified RNA from brain EVs, and performed miRNA sequencing. We found that the expression of miR-212 decreased, while miR-21, miR-146, miR-7a, and miR-7b were significantly increased with injury, with miR-21 showing the largest change between conditions. The expression of miR-21 in the brain was primarily localized to neurons near the lesion site. Interestingly, adjacent to these miR-21-expressing neurons were activated microglia. The concurrent increase in miR-21 in EVs with the elevation of miR-21 in neurons, suggests that miR-21 is secreted from neurons as potential EV cargo. Thus, this study reveals a new potential mechanism of cell-cell communication not previously described in TBI.	[Harrison, Emily B.; Hochfelder, Colleen G.; Lamberty, Benjamin G.; Meays, Brittney M.; Morsey, Brenda M.; Fox, Howard S.; Yelamanchili, Sowmya V.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA; [Kelso, Matthew L.] Univ Nebraska Med Ctr, Dept Cellular & Integrat Physiol, Omaha, NE USA; [Hochfelder, Colleen G.] Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA; [Kelso, Matthew L.] Medpace Reference Labs, 5365 Medpace Way, Cincinnati, OH USA	Yelamanchili, SV (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.	syelamanchili@unmc.edu		Harrison, Emily/0000-0002-6934-3875	Nebraska Research Initiative Grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM106397] Funding Source: NIH RePORTER	This work was supported by a Nebraska Research Initiative Grant.	Alexander M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8321; Bellingham SA, 2012, NUCLEIC ACIDS RES, V40, P10937, DOI 10.1093/nar/gks832; Bergman P, 2013, J IMMUNOL, V190, P4066, DOI 10.4049/jimmunol.1200728; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Chaudhuri AD, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00160; Choi DC, 2014, J NEUROSCI, V34, P12725, DOI 10.1523/JNEUROSCI.0985-14.2014; Choudhury NR, 2013, GENE DEV, V27, P24, DOI 10.1101/gad.199190.112; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Crozat K, 2004, P NATL ACAD SCI USA, V101, P6835, DOI 10.1073/pnas.0401347101; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Forsbach A, 2008, J IMMUNOL, V180, P3729, DOI 10.4049/jimmunol.180.6.3729; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hu G, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.114; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Kim AH, 2010, SCHIZOPHR RES, V124, P183, DOI 10.1016/j.schres.2010.07.002; Kraft-Terry SD, 2009, NEURON, V64, P133, DOI 10.1016/j.neuron.2009.09.042; Kuo CY, 2015, INT J ENV RES PUB HE, V12, P4116, DOI 10.3390/ijerph120404116; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lescher J, 2012, J NEUROIMMUNOL, V246, P27, DOI 10.1016/j.jneuroim.2012.02.012; Liu HY, 2015, EXP NEUROL, V269, P202, DOI 10.1016/j.expneurol.2015.04.011; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Montalban E, 2014, NEUROMOL MED, V16, P415, DOI 10.1007/s12017-014-8292-z; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Patz S, 2013, J NEUROTRAUM, V30, P1232, DOI 10.1089/neu.2012.2596; Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Sakai A, 2013, BIOCHEM BIOPH RES CO, V435, P176, DOI 10.1016/j.bbrc.2013.04.089; Sandhir R, 2014, NEUROCHEM INT, V78, P117, DOI 10.1016/j.neuint.2014.09.009; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Sun TY, 2014, J HUAZHONG U SCI-MED, V34, P548, DOI 10.1007/s11596-014-1313-1; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tang Y, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-92; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wanet A, 2012, NUCLEIC ACIDS RES, V40, P4742, DOI 10.1093/nar/gks151; Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0; WHITTEMORE ER, 1993, BRAIN RES, V621, P59, DOI 10.1016/0006-8993(93)90297-Z; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yelamanchili SV, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.56; Yelamanchili SV, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005032; Yelamanchili SV, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-52; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhang ZP, 2010, INT J BIOCHEM CELL B, V42, P367, DOI 10.1016/j.biocel.2009.11.023	60	69	72	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2211-5463			FEBS OPEN BIO	FEBS Open Bio	AUG	2016	6	8					835	846		10.1002/2211-5463.12092			12	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DS8RC	WOS:000381049500005	27516962	DOAJ Gold, Green Published			2021-06-18	
J	Tulsky, DS; Kisala, PA; Victorson, D; Carlozzi, N; Bushnik, T; Sherer, M; Choi, SW; Heinemann, AW; Chiaravalloti, N; Sander, AM; Englander, J; Hanks, R; Kolakowsky-Hayner, S; Roth, E; Gershon, R; Rosenthal, M; Cella, D				Tulsky, David S.; Kisala, Pamela A.; Victorson, David; Carlozzi, Noelle; Bushnik, Tamara; Sherer, Mark; Choi, Seung W.; Heinemann, Allen W.; Chiaravalloti, Nancy; Sander, Angelle M.; Englander, Jeffrey; Hanks, Robin; Kolakowsky-Hayner, Stephanie; Roth, Elliot; Gershon, Richard; Rosenthal, Mitchell; Cella, David			TBI-QOL: Development and Calibration of Item Banks to Measure Patient Reported Outcomes Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						common data elements; clinical research; health-related quality of life; item response theory; patient-reported outcomes; quality of life; traumatic brain injury	QUALITY-OF-LIFE; COMPUTERIZED ADAPTIVE ASSESSMENT; INFORMATION-SYSTEM PROMIS; RESPONSE THEORY; REHABILITATION-MEDICINE; SHORT-FORMS; HEALTH; ISSUES; SCALE; RECOMMENDATIONS	Objective: To use a patient-centered approach or participatory action research design combined with advanced psychometrics to develop a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with traumatic brain injury (TBI). This TBI Quality-of-Life (TBI-QOL) measurement system expands the work of other large PRO measurement initiatives, that is, the Patient-Reported Outcomes Measurement Information System and the Neurology Quality-of-Life measurement initiative. Setting: Five TBI Model Systems centers across the United States. Participants: Adults with TBI. Design: Classical and modern test development methodologies were used. Qualitative input was obtained from individuals with TBI, TBI clinicians, and caregivers of individuals with TBI through multiple methods, including focus groups, individual interviews, patient consultation, and cognitive debriefing interviews. Item pools were field tested in a large multisite sample (n = 675) and calibrated using item response theory methods. Main Outcomes Measures: Twenty-two TBI-QOL item banks/scales. Results: The TBI-QOL consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. Conclusions: The TBI-QOL measurement system has potential as a common data element in TBI research and to enhance collection of health-related quality-of-life and PRO data in rehabilitation research and clinical settings.	[Tulsky, David S.; Kisala, Pamela A.] Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, STAR Hlth Sci Complex,540 S Coll Ave, Newark, DE 19713 USA; [Tulsky, David S.; Chiaravalloti, Nancy; Rosenthal, Mitchell] Kessler Fdn Res Ctr, W Orange, NJ USA; [Bushnik, Tamara] NYU, Langone Med Ctr, New York, NY USA; [Victorson, David; Heinemann, Allen W.; Roth, Elliot; Gershon, Richard; Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Carlozzi, Noelle] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Sherer, Mark; Sander, Angelle M.] TIRR Mem Hermann, Houston, TX USA; [Choi, Seung W.] McGraw Hill Educ CTB, Monterey, CA USA; [Heinemann, Allen W.; Roth, Elliot] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Chiaravalloti, Nancy] Rutgers NJ Univ, Med Ctr, Newark, NJ USA; [Sander, Angelle M.] Baylor Coll Med, Houston, TX 77030 USA; [Englander, Jeffrey; Kolakowsky-Hayner, Stephanie] Santa Clara Valley Med Ctr, Santa Clara, CA USA; [Hanks, Robin] Wayne State Univ, Sch Med, Detroit, MI USA	Tulsky, DS (corresponding author), Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, STAR Hlth Sci Complex,540 S Coll Ave, Newark, DE 19713 USA.	dtulsky@udel.edu	Kolakowsky-Hayner, Stephanie A./I-9858-2019; Heinemann, Allen W./AAI-2790-2021	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Heinemann, Allen W./0000-0003-2782-7326; Tulsky, David/0000-0002-4335-4509; Bushnik, Tamara/0000-0003-3328-257X	National Institute on Disability and Rehabilitation Research [H133G070138, H133A070037, H133A070043, H133A080045, H133A080044, H133A70038]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U2CCA186878] Funding Source: NIH RePORTER	This study was supported by grant nos. H133G070138, H133A070037, H133A070043, H133A080045, H133A080044, and H133A70038 from the National Institute on Disability and Rehabilitation Research.	Bjorner JB, 2007, QUAL LIFE RES, V16, P95, DOI 10.1007/s11136-007-9168-6; Bode RK, 2003, ARCH PHYS MED REHAB, V84, pS52, DOI 10.1053/apmr.2003.50247; Bottari C, 2007, J HEAD TRAUMA REHAB, V22, P26, DOI 10.1097/00001199-200701000-00003; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cella D F, 1995, Oncology (Williston Park), V9, P47; Cella D, 2007, QUAL LIFE RES, V16, P133, DOI 10.1007/s11136-007-9204-6; Cella D, 2011, ARCH PHYS MED REHAB, V92, pS28, DOI 10.1016/j.apmr.2011.01.025; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Choi SW, 2011, J STAT SOFTW, V39, P1; DeWitt EM, 2011, J CLIN EPIDEMIOL, V64, P794, DOI 10.1016/j.jclinepi.2010.10.012; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Eremenco SL, 2005, EVAL HEALTH PROF, V28, P212, DOI 10.1177/0163278705275342; Fries JF, 2009, J RHEUMATOL, V36, P2061, DOI 10.3899/jrheum.090358; Fries JF, 2005, CLIN EXP RHEUMATOL, V23, pS53; Gershon R, 2010, QUAL LIFE RES, V19, P677, DOI 10.1007/s11136-010-9634-4; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kisala Pamela A, 2010, J Appl Meas, V11, P315; Lai JS, 2011, ARCH PHYS MED REHAB, V92, pS20, DOI 10.1016/j.apmr.2010.08.033; Lie HH, 2010, J CLIN EPIDEMIOL, V63, P1169, DOI 10.1016/j.jclinepi.2009.11.021; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741; MESSICK S, 1980, AM PSYCHOL, V35, P1012, DOI 10.1037/0003-066X.35.11.1012; Orlando M, 2003, APPL PSYCH MEAS, V27, P289, DOI 10.1177/0146621603027004004; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PROMIS, 2012, PROMIS INSTR DEV PSY; Quatrano LA, 2011, ARCH PHYS MED REHAB, V92, pS7, DOI 10.1016/j.apmr.2010.08.032; Reeve BB, 2007, QUAL LIFE RES, V16, P175, DOI 10.1007/s11136-007-9190-8; Reeve BB, 2007, QUAL LIFE RES, V16, P1, DOI 10.1007/s11136-007-9220-6; REISE SP, 1990, J EDUC MEAS, V27, P133, DOI 10.1111/j.1745-3984.1990.tb00738.x; Rosenthal M, 2007, HDB REHABILITATION P, P49; Samejima F, 1996, HDB MODERN ITEM RESP, P85, DOI DOI 10.1007/978-1-4757-2691-6_5; Sherer M., 2005, FORENSIC NEUROPSYCHO, P237; Steinberg L, 1996, PSYCHOL METHODS, V1, P81, DOI 10.1037/1082-989X.1.1.81; STOCKING ML, 1983, APPL PSYCH MEAS, V7, P201, DOI 10.1177/014662168300700208; Thissen D, 2007, QUAL LIFE RES, V16, P109, DOI 10.1007/s11136-007-9169-5; Tulsky DS, 2011, ARCH PHYS MED REHAB, V92, pS1, DOI 10.1016/j.apmr.2011.07.202; Varni JW, 2010, J PAIN, V11, P1109, DOI 10.1016/j.jpain.2010.02.005; Velozo CA, 2012, ARCH PHYS MED REHAB, V93, pS154, DOI 10.1016/j.apmr.2012.06.001; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whyte J, 2005, PHYS MED REHABILITAT, P1677; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeatts KB, 2010, J ASTHMA, V47, P295, DOI 10.3109/02770900903426997	49	69	69	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2016	31	1					40	51		10.1097/HTR.0000000000000131			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DK9CN	WOS:000375228000013	25931184	Green Published			2021-06-18	
J	Kabaria, S; Choi, DC; Chaudhuri, AD; Jain, MR; Li, H; Junn, E				Kabaria, Sayan; Choi, Doo Chul; Chaudhuri, Amrita Datta; Jain, Mohit Raja; Li, Hong; Junn, Eunsung			MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						MicroRNA-7; Keap1; Nrf2; MPP; Oxidative stress; Parkinson's disease	1-METHYL-4-PHENYLPYRIDINIUM-INDUCED CELL-DEATH; TRAUMATIC BRAIN-INJURY; HEME OXYGENASE-1 HO-1; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; PARKINSONS-DISEASE; NEURONAL SURVIVAL; PROTECTS; GENE; INDUCTION	Nuclear factor E2-related factor 2 (Nrf2) is a key transcription factor that regulates the expression of a number of antioxidant and detoxifying genes that provide cellular protection against various stressors including reactive oxygen species (ROS). Nrf2 activity is tightly regulated by a cytoplasmic inhibitory protein called Kelch-like ECH-associated protein 1 (Keap1). The mechanism that controls Keap1 expression, however, remains poorly understood. In the present study, we demonstrate that microRNA-7 (miR-7), which is highly expressed in the brain, represses Keap1 expression by targeting the 3'-untranslated region (UTR) of its mRNA in human neuroblastoma cells, SH-SY5Y. Subsequently, this event results in an increased Nrf2 activity, as evidenced by an increase in the expression of its transcriptional targets, heme oxygenase 1 (HO-1) and glutamate-cysteine ligase modifier subunit (GCLM), and an enhanced nuclear localization of Nrf2. In addition, miR-7 decreases the intracellular hydroperoxides level and increases the level of reduced form of glutathione, indicative of oxidative stress relief. We also demonstrate that targeted repression of Keap1 and activation of Nrf2 pathway, in part, underlies the protective effects of miR-7 against 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in SH-SY5Y and differentiated human neural progenitor cells, ReNcell VM. These findings point to a new mechanism by which miR-7 exerts cytoprotective effects by regulating the Nrf2 pathway. (C) 2015 Elsevier Inc. All rights reserved.	[Kabaria, Sayan; Choi, Doo Chul; Chaudhuri, Amrita Datta; Junn, Eunsung] Rutgers Robert Wood Johnson Med Sch, Dept Neurol, Ctr Neurodegenerat & Neuroimmunol Dis, Piscataway, NJ 08854 USA; [Jain, Mohit Raja; Li, Hong] Rutgers New Jersey Med Sch, Ctr Adv Prote Res, Newark, NJ 07103 USA	Junn, E (corresponding author), Rutgers Robert Wood Johnson Med Sch, Dept Neurol, 683 Hoes Lane West,Room 185, Piscataway, NJ 08854 USA.	junneu@rwjms.rutgers.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS070898, P30NS046593]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS046593, R01NS070898] Funding Source: NIH RePORTER	This work was supported by NIH grant NS070898 (E.J), and in part by NIH grant P30NS046593 (H.L).	Ahmad AS, 2006, NEUROSCIENCE, V141, P1703, DOI 10.1016/j.neuroscience.2006.05.035; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Bilen J, 2006, MOL CELL, V24, P157, DOI 10.1016/j.molcel.2006.07.030; Bogdanov M, 2008, BRAIN, V131, P389, DOI 10.1093/brain/awm304; Boudreau RL, 2014, NEURON, V81, P294, DOI 10.1016/j.neuron.2013.10.062; Cao TT, 2005, J NEUROCHEM, V95, P406, DOI 10.1111/j.1471-4159.2005.03377.x; Chaudhuri AD, 2015, J BIOL CHEM, V290, P12425, DOI 10.1074/jbc.M114.625962; Chen HL, 2010, BIOCHEM BIOPH RES CO, V394, P921, DOI 10.1016/j.bbrc.2010.03.076; Chen PC, 2009, P NATL ACAD SCI USA, V106, P2933, DOI 10.1073/pnas.0813361106; Choi DC, 2014, J NEUROSCI, V34, P12725, DOI 10.1523/JNEUROSCI.0985-14.2014; Donato R, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-36; Eacker SM, 2009, NAT REV NEUROSCI, V10, P837, DOI 10.1038/nrn2726; Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Hara H, 2006, J NEUROSCI RES, V84, P860, DOI 10.1002/jnr.20974; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Huang E, 2005, J NEUROSCI RES, V80, P268, DOI 10.1002/jnr.20444; Hwang YP, 2008, FEBS LETT, V582, P2655, DOI 10.1016/j.febslet.2008.06.045; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Junn E, 2012, PHARMACOL THERAPEUT, V133, P142, DOI 10.1016/j.pharmthera.2011.10.002; Junn E, 2009, P NATL ACAD SCI USA, V106, P13052, DOI 10.1073/pnas.0906277106; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Lin Y, 2007, J CEREBR BLOOD F MET, V27, P1010, DOI 10.1038/sj.jcbfm.9600412; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; MacKenzie EL, 2008, FREE RADICAL BIO MED, V44, P1762, DOI 10.1016/j.freeradbiomed.2008.01.031; Maines MD, 1998, J NEUROCHEM, V70, P2057; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Narasimhan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051111; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Satoh T, 2009, BIOCHEM BIOPH RES CO, V380, P298, DOI 10.1016/j.bbrc.2009.01.063; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Wruck CJ, 2007, J NEURAL TRANSM-SUPP, P57; Yu MA, 2011, CELL SIGNAL, V23, P883, DOI 10.1016/j.cellsig.2011.01.014; Zhang JY, 2006, MOL CELL BIOL, V26, P7942, DOI 10.1128/MCB.00700-06; Zielonka J, 2012, CHEM RES TOXICOL, V25, P1793, DOI 10.1021/tx300164j	50	69	74	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC	2015	89						548	556		10.1016/j.freeradbiomed.2015.09.010			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CY4CI	WOS:000366355800050	26453926	Green Accepted			2021-06-18	
J	Maekawa, T; Yamashita, S; Nagao, S; Hayashi, N; Ohashi, Y				Maekawa, Tsuyoshi; Yamashita, Susumu; Nagao, Seigo; Hayashi, Nariyuki; Ohashi, Yasuo		Brain-Hypothermia B-HYPO Study Grp	Prolonged Mild Therapeutic Hypothermia versus Fever Control with Tight Hemodynamic Monitoring and Slow Rewarming in Patients with Severe Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF NEUROTRAUMA			English	Article						cardiac output; cerebral perfusion; therapeutic hypothermia.; intracranial pressure	HOSPITAL CARDIAC-ARREST; MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; EFFICACY; INDUCTION; OUTCOMES; SCALE	Although mild therapeutic hypothermia is an effective neuroprotective strategy for cardiac arrest/resuscitated patients, and asphyxic newborns, recent randomized controlled trials (RCTs) have equally shown good neurological outcome between targeted temperature management at 33 degrees C versus 36 degrees C, and have not shown consistent benefits in patients with traumatic brain injury (TBI). We aimed to determine the effect of therapeutic hypothermia, while avoiding some limitations of earlier studies, which included patient selection based on Glasgow coma scale (GCS), delayed initiation of cooling, short duration of cooling, inter-center variation in patient care, and relatively rapid rewarming. We conducted a multicenter RCT in patients with severe TBI (GCS 4-8). Patients were randomly assigned (2:1 allocation ratio) to either therapeutic hypothermia (32-34 degrees C, n=98) or fever control (35.5-37 degrees C, n=50). Patients with therapeutic hypothermia were cooled as soon as possible for >= 72 h and rewarmed at a rate of <1 degrees C/day. All patients received tight hemodynamic monitoring under intensive neurological care. The Glasgow Outcome Scale was assessed at 6 months by physicians who were blinded to the treatment allocation. The overall rates of poor neurological outcomes were 53% and 48% in the therapeutic hypothermia and fever control groups, respectively. There were no significant differences in the likelihood of poor neurological outcome (relative risk [RR] 1.24, 95% confidence interval [CI] 0.62-2.48, p=0.597) or mortality (RR 1.82, 95% CI 0.82-4.03, p=0.180) between the two groups. We concluded that tight hemodynamic management and slow rewarming, together with prolonged therapeutic hypothermia (32-34 degrees C) for severe TBI, did not improve the neurological outcomes or risk of mortality compared with strict temperature control (35.5-37 degrees C).	[Maekawa, Tsuyoshi] Yamaguchi Univ, Grad Sch Med, Dept Stress & Bioresponse Med, Ube, Yamaguchi 7558505, Japan; [Maekawa, Tsuyoshi; Yamashita, Susumu] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan; [Nagao, Seigo] Kagawa Univ, Fac Med, Dept Neurol Surg, Takamatsu, Kagawa 760, Japan; [Hayashi, Nariyuki] Nihon Univ, Sch Med, Dept Acute Med, Div Emergency & Crit Care Med, Tokyo, Japan; [Ohashi, Yasuo] Univ Tokyo, Fac Med, Sch Integrated Hlth Sci, Tokyo 113, Japan	Maekawa, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Stress & Bioresponse Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	maekawa.tsuyoshi@ymghp.jp	Oksengendler, Boris L/G-1329-2011; Oksengendler, Boris Leonidovich/E-4504-2012	Oksengendler, Boris L/0000-0001-8247-8996; Oksengendler, Boris Leonidovich/0000-0002-6771-293X; dohi, kenji/0000-0002-4451-0382	Japanese Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan [H-14-shinkin-005, H-15-shinkin-001, H-16-shinkin-001]; Japanese Human Science Association	This study was supported by grants from Japanese Ministry of Health, Labour and Welfare (H-14-shinkin-005, H-15-shinkin-001, and H-16-shinkin-001), and the Japanese Human Science Association 2002-2004. We thank Takahiro Kiuchi (Director of the UMIN Centre) and Kiyoshi Ichihara (Yamaguchi University Graduate School of Medicine) for their support. We also thank Kees H Polderman (University of Pittsburgh Medical Center) for reviewing our manuscript and for his valuable suggestions.	Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Eddy VA, 2000, SURG CLIN N AM, V80, P845, DOI 10.1016/S0039-6109(05)70099-2; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2006, STROKE, V37, P1792, DOI 10.1161/01.STR.0000227265.52763.16; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kasaoka S, 2006, MINIMALLY INVASIVE NEUROSURGERY AND MULTIDISCIPLINARY NEUROTRAUMATOLOGY, P335, DOI 10.1007/4-431-28576-8_50; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Nagao K, 2010, CIRC J, V74, P77, DOI 10.1253/circj.CJ-09-0502; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; The Japan Society of Neurotraumatology, 2001, GUID MAN SEV HEAD IN	30	69	71	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					422	429		10.1089/neu.2013.3197			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400002	25099730	Green Published			2021-06-18	
J	Taber, KH; Hurley, RA; Haswell, CC; Rowland, JA; Hurt, SD; Lamar, CD; Morey, RA				Taber, Katherine H.; Hurley, Robin A.; Haswell, Courtney C.; Rowland, Jared A.; Hurt, Susan D.; Lamar, Cory D.; Morey, Rajendra A.			White Matter Compromise in Veterans Exposed to Primary Blast Forces	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffusion tensor imaging (DTI); diffusivity; fractional anisotropy; mild traumatic brain injury (mTBI); military veterans; primary blast; subconcussive blast exposure; white matter	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSION; INTEGRITY; ABNORMALITIES; IMPAIRMENT; CONCUSSION; DEPENDENCE; TESTS; MRI	Objective: Use diffusion tensor imaging to investigate white matter alterations associated with blast exposure with or without acute symptoms of traumatic brain injury (TBI). Participants: Forty-five veterans of the recent military conflicts included 23 exposed to primary blast without TBI symptoms, 6 having primary blast with mild TBI, and 16 unexposed to blast. Design: Cross-sectional case-control study. Main Measures: Neuropsychological testing and diffusion tensor imaging metrics that quantified the number of voxel clusters with altered fractional anisotropy (FA) radial diffusivity, and axial diffusivity, regardless of their spatial location. Results: Significantly lower FA and higher radial diffusivity were observed in veterans exposed to primary blast with and without mild TBI relative to blast-unexposed veterans. Voxel clusters of lower FA were spatially dispersed and heterogeneous across affected individuals. Conclusion: These results suggest that lack of clear TBI symptoms following primary blast exposure may not accurately reflect the extent of brain injury. If confirmed, our findings would argue for supplementing the established approach of making diagnoses based purely on clinical history and observable acute symptoms with novel neuroimaging-based diagnostic criteria that "look below the surface" for pathology.	[Taber, Katherine H.; Hurley, Robin A.; Haswell, Courtney C.; Rowland, Jared A.; Lamar, Cory D.; Morey, Rajendra A.] Mid Atlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA; [Taber, Katherine H.; Hurley, Robin A.; Rowland, Jared A.; Hurt, Susan D.; Lamar, Cory D.] WG Bill Hefner VA Med Ctr, Salisbury, NC 28144 USA; [Taber, Katherine H.] Edward Via Coll Osteopath Med, Div Biomed Sci, Blacksburg, VA USA; [Taber, Katherine H.] Baylor Coll Med, Dept Phys Med, Houston, TX 77030 USA; [Taber, Katherine H.] Baylor Coll Med, Dept Rehabil, Houston, TX 77030 USA; [Hurley, Robin A.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Hurley, Robin A.; Rowland, Jared A.] Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA; [Haswell, Courtney C.; Morey, Rajendra A.] Durham VA Med Ctr, Durham, NC USA; [Haswell, Courtney C.; Morey, Rajendra A.] Duke Univ, Duke UNC Brain Imaging & Anal Ctr, Durham, NC USA; [Morey, Rajendra A.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA	Taber, KH (corresponding author), WG Bill Hefner VA Med Ctr, Res & Educ Serv Line,Mailstop 11M,1601 Brenner Av, Salisbury, NC 28144 USA.	Kather-ine.taber@va.gov	Morey, Rajendra A/P-3079-2018; Taber, Katherine H/B-8260-2011; Rowland, Jared A./AAN-3030-2021	Morey, Rajendra A/0000-0002-6517-6969; Taber, Katherine H/0000-0001-7382-6151; Rowland, Jared A./0000-0002-3655-3411	Department of Defense, Joint Improvised Explosive Device Defeat OrganizationUnited States Department of Defense [51467EGJDO]; Department of Veterans Health Affairs Rehabilitation Research and Development [RX000389-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086885] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000389] Funding Source: NIH RePORTER	This research was supported by a grant from the Department of Defense, Joint Improvised Explosive Device Defeat Organization (51467EGJDO), the Department of Veterans Health Affairs Rehabilitation Research and Development (RX000389-01), and with resources of the Mid-Atlantic Mental Illness Research, Education, and Clinical Center and W. G. (Bill) Hefner VA Medical Center.	Anderson MJ, 2001, AUST NZ J STAT, V43, P75, DOI 10.1111/1467-842X.00156; Bartres-Faz D, 2011, BRAIN TOPOGR, V24, P340, DOI 10.1007/s10548-011-0195-9; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Bochicchio GV, 2008, AM SURGEON, V74, P267; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Duckworth Josh L, 2013, Pathophysiology, V20, P23, DOI 10.1016/j.pathophys.2012.03.001; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Goldstein L.E., 2012, SCI TRANSL MED, V4; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Jensen KB, 2012, P NATL ACAD SCI USA, V109, P15959, DOI 10.1073/pnas.1202056109; Jones DK, 2003, MAGN RESON MED, V49, P7, DOI 10.1002/mrm.10331; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; KENNEDY PE, 1995, J BUS ECON STAT, V13, P85, DOI 10.2307/1392523; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2012, NEUROIMAGE, V61, P324, DOI 10.1016/j.neuroimage.2011.11.006; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Madden DJ, 2004, NEUROIMAGE, V21, P1174, DOI 10.1016/j.neuroimage.2003.11.004; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Mori S., 2005, MRI ATLAS HUMAN WHIT; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Rosen Allyson, 2009, Mil Med, V174, pv; Sams R, 2012, MIL MED, V177, P48, DOI 10.7205/MILMED-D-11-00214; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Wedeen VJ, 2012, SCIENCE, V335, P1628, DOI 10.1126/science.1215280; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; White T, 2013, SCHIZOPHRENIA BULL, V39, P1077, DOI 10.1093/schbul/sbs106; Yeh DD, 2012, WORLD J SURG, V36, P966, DOI 10.1007/s00268-012-1500-9; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Zhuang L, 2010, NEUROIMAGE, V53, P16, DOI 10.1016/j.neuroimage.2010.05.068	52	69	69	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					E15	E25		10.1097/HTR.0000000000000030			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400003	24590156	Green Accepted, Green Published			2021-06-18	
J	Tremblay, S; Henry, LC; Bedetti, C; Larson-Dupuis, C; Gagnon, JF; Evans, AC; Theoret, H; Lassonde, M; De Beaumont, L				Tremblay, Sebastien; Henry, Luke C.; Bedetti, Christophe; Larson-Dupuis, Camille; Gagnon, Jean-Francois; Evans, Alan C.; Theoret, Hugo; Lassonde, Maryse; De Beaumont, Louis			Diffuse white matter tract abnormalities in clinically normal ageing retired athletes with a history of sports-related concussions	BRAIN			English	Article						sports-related concussions; ageing; white matter; neuropsychology	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; TENSOR IMAGING FINDINGS; AXONAL INJURY; ALZHEIMERS-DISEASE; LONG-TERM; IN-VIVO; DEPRESSIVE SYMPTOMS; PROFESSIONAL BOXERS; PREFRONTAL GRAY	Sports-related concussions have been shown to lead to persistent subclinical anomalies of the motor and cognitive systems in young asymptomatic athletes. In advancing age, these latent alterations correlate with detectable motor and cognitive function decline. Until now, the interacting effects of concussions and the normal ageing process on white matter tract integrity remain unknown. Here we used a tract-based spatial statistical method to uncover potential white matter tissue damage in 15 retired athletes with a history of concussions, free of comorbid medical conditions. We also investigated potential associations between white matter integrity and declines in cognitive and motor functions. Compared to an age-and education-matched control group of 15 retired athletes without concussions, former athletes with concussions exhibited widespread white matter anomalies along many major association, interhemispheric, and projection tracts. Group contrasts revealed decreases in fractional anisotropy, as well as increases in mean and radial diffusivity measures in the concussed group. These differences were primarily apparent in fronto-parietal networks as well as in the frontal aspect of the corpus callosum. The white matter anomalies uncovered in concussed athletes were significantly associated with a decline in episodic memory and lateral ventricle expansion. Finally, the expected association between frontal white matter integrity and motor learning found in former non-concussed athletes was absent in concussed participants. Together, these results show that advancing age in retired athletes presenting with a history of sports-related concussions is linked to diffuse white matter abnormalities that are consistent with the effects of traumatic axonal injury and exacerbated demyelination. These changes in white matter integrity might explain the cognitive and motor function declines documented in this population.	[Tremblay, Sebastien] McGill Univ, Montreal Neurol Inst, Integrated Program Neurosci, Montreal, PQ, Canada; [Henry, Luke C.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Bedetti, Christophe; Larson-Dupuis, Camille; Gagnon, Jean-Francois; De Beaumont, Louis] Hop Sacre Coeur, Montreal Res Ctr, Montreal, PQ, Canada; [Larson-Dupuis, Camille; Theoret, Hugo; Lassonde, Maryse] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Gagnon, Jean-Francois] Univ Quebec, Dept Psychol, Montreal, PQ, Canada; [Evans, Alan C.] McGill Univ, McConnell Brain Imaging Ctr, Montreal, PQ, Canada; [Evans, Alan C.] Montreal Neurol Inst, Montreal, PQ, Canada; [Theoret, Hugo; Lassonde, Maryse] Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada; [De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada	De Beaumont, L (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada.	louis.debeaumont@uqtr.ca	Meijer, Anna/K-5118-2016; Evans, Alan C/B-2373-2013	Evans, Alan C/0000-0003-3841-6098; Theoret, Hugo/0000-0002-7458-8797	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); NSERC Alexander Graham Bell Canada Graduate Scholarship	This work was supported by grants to H.T., M.L., and L.D.B. from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). The NSERC Alexander Graham Bell Canada Graduate Scholarship supported S.T.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ardekani S, 2007, MAGN RESON IMAGING, V25, P154, DOI 10.1016/j.mri.2006.09.045; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett IJ, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.03.017; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chua TC, 2008, CURR OPIN NEUROL, V21, P83, DOI 10.1097/WCO.0b013e3282f4594b; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davis SW, 2009, NEUROIMAGE, V46, P530, DOI 10.1016/j.neuroimage.2009.01.068; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; Fjell AM, 2009, CEREB CORTEX, V19, P2001, DOI 10.1093/cercor/bhn232; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Gunning-Dixon FM, 2009, INT J GERIATR PSYCH, V24, P109, DOI 10.1002/gps.2087; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Liu JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059440; Lyttelton O, 2007, NEUROIMAGE, V34, P1535, DOI 10.1016/j.neuroimage.2006.10.041; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madden DJ, 2009, NEUROPSYCHOL REV, V19, P415, DOI 10.1007/s11065-009-9113-2; Malloy P, 2007, CLIN NEUROPSYCHOL, V21, P73, DOI 10.1080/13854040500263583; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Marner L, 2003, J COMP NEUROL, V462, P144, DOI 10.1002/cne.10714; Masliah E, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P91; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nir TM, 2013, NEUROIMAGE-CLIN, V3, P180, DOI 10.1016/j.nicl.2013.07.006; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Salat DH, 1999, ARCH NEUROL-CHICAGO, V56, P338, DOI 10.1001/archneur.56.3.338; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Stricker NH, 2013, J INT NEUROPSYCH SOC, V19, P925, DOI 10.1017/S1355617713000660; Sullivan EV, 2006, CEREB CORTEX, V16, P1030, DOI 10.1093/cercor/bhj045; Sun SW, 2006, NEUROIMAGE, V32, P1195, DOI 10.1016/j.neuroimage.2006.04.212; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wang PN, 2014, HUM BRAIN MAPP, V35, P1529, DOI 10.1002/hbm.22271; Wiest-Daessle N, 2008, LECT NOTES COMPUT SC, V5242, P171, DOI 10.1007/978-3-540-85990-1_21; General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14, DOI 10.1001/jama.2013.281053; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhang Y, 2007, NEUROLOGY, V68, P13, DOI 10.1212/01.wnl.0000250326.77323.01; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066367	96	69	69	1	41	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2014	137		11				2997	3011		10.1093/brain/awu236			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AX2GG	WOS:000346760900022	25186429	Green Published, Bronze			2021-06-18	
J	Naci, L; Cusack, R; Anello, M; Owen, AM				Naci, Lorina; Cusack, Rhodri; Anello, Mimma; Owen, Adrian M.			A common neural code for similar conscious experiences in different individuals	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						fMRI; brain injury; disorders of consciousness	INDEPENDENT COMPONENT ANALYSIS; TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; DETECTING AWARENESS; EXECUTIVE FUNCTIONS; DISORDERS; STATE; INTELLIGENCE; PERFORMANCE; LESIONS	The interpretation of human consciousness from brain activity, without recourse to speech or action, is one of the most provoking and challenging frontiers of modern neuroscience. We asked whether there is a common neural code that underpins similar conscious experiences, which could be used to decode these experiences in the absence of behavior. To this end, we used richly evocative stimulation (an engaging movie) portraying real-world events to elicit a similar conscious experience in different people. Common neural correlates of conscious experience were quantified and related to measurable, quantitative and qualitative, executive components of the movie through two additional behavioral investigations. The movie's executive demands drove synchronized brain activity across healthy participants' frontal and parietal cortices in regions known to support executive function. Moreover, the timing of activity in these regions was predicted by participants' highly similar qualitative experience of the movie's moment-to-moment executive demands, suggesting that synchronization of activity across participants underpinned their similar experience. Thus we demonstrate, for the first time to our knowledge, that a neural index based on executive function reliably predicted every healthy individual's similar conscious experience in response to real-world events unfolding over time. This approach provided strong evidence for the conscious experience of a brain-injured patient, who had remained entirely behaviorally nonresponsive for 16 y. The patient's executive engagement and moment-to-moment perception of the movie content were highly similar to that of every healthy participant. These findings shed light on the common basis of human consciousness and enable the interpretation of conscious experience in the absence of behavior.	[Naci, Lorina; Cusack, Rhodri; Owen, Adrian M.] Univ Western Ontario, Brain & Mind Inst, Dept Psychol, London, ON N6A 5B7, Canada; [Anello, Mimma] Univ Western Ontario, Schulich Sch Med & Dent, London, ON N6A 5B7, Canada	Naci, L (corresponding author), Univ Western Ontario, Brain & Mind Inst, Dept Psychol, London, ON N6A 5B7, Canada.	lorina.clare@gmail.com	Cusack, Rhodri/A-2231-2010; Owen, Adrian M/B-4997-2015; Williams, Jackie/B-3495-2015	Cusack, Rhodri/0000-0002-5234-7415; Naci, Lorina/0000-0001-9630-3978	Canada Excellence Research Chairs programCanada Research Chairs	We are grateful to Leah Sinai for her help with the first movie experiment. This research was supported by the Canada Excellence Research Chairs program.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Barbey AK, 2012, BRAIN, V135, P1154, DOI 10.1093/brain/aws021; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Casali AG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006294; Chennu S, 2013, NEUROIMAGE-CLIN, V3, P450, DOI 10.1016/j.nicl.2013.10.008; Chung CSY, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008391.pub2; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Collette F, 2005, COGNITIVE BRAIN RES, V24, P237, DOI 10.1016/j.cogbrainres.2005.01.023; Cruse D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049933; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Datta Avijit, 2007, Comput Intell Neurosci, P93968, DOI 10.1155/2007/93968; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duncan J, 2010, TRENDS COGN SCI, V14, P172, DOI 10.1016/j.tics.2010.01.004; Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49; Fernandez-Espejo D, 2013, NAT REV NEUROSCI, V14, P801, DOI 10.1038/nrn3608; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hampshire A, 2006, CEREB CORTEX, V16, P1679, DOI 10.1093/cercor/bhj116; Hasson U, 2004, SCIENCE, V303, P1634, DOI 10.1126/science.1089506; Hasson U, 2008, PROJECTIONS, V2, P1, DOI 10.3167/proj.2008.020102; Hasson U, 2010, TRENDS COGN SCI, V14, P40, DOI 10.1016/j.tics.2009.10.011; Kamitani Y, 2005, NAT NEUROSCI, V8, P679, DOI 10.1038/nn1444; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mizuno K, 2012, NEUROPSYCHOLOGIA, V50, P1998, DOI 10.1016/j.neuropsychologia.2012.04.025; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Naci L, 2013, JAMA NEUROL, V70, P1235, DOI 10.1001/jamaneurol.2013.3686; Naci L, 2013, J NEUROSCI, V33, P9385, DOI 10.1523/JNEUROSCI.5577-12.2013; Naci L, 2012, ANN NEUROL, V72, P312, DOI 10.1002/ana.23656; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Owen AM, CONSCIOUSNE IN PRESS; Plum F., 1966, DIAGNOSIS STUPOR COM; Ptak R, 2012, NEUROSCIENTIST, V18, P502, DOI 10.1177/1073858411409051; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sauseng P, 2005, INT J PSYCHOPHYSIOL, V57, P97, DOI 10.1016/j.ijpsycho.2005.03.018; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Soon CS, 2008, NAT NEUROSCI, V11, P543, DOI 10.1038/nn.2112; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Woolgar A, 2010, P NATL ACAD SCI USA, V107, P14899, DOI 10.1073/pnas.1007928107	46	69	70	0	16	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	SEP 30	2014	111	39					14277	14282		10.1073/pnas.1407007111			6	Multidisciplinary Sciences	Science & Technology - Other Topics	AP8SW	WOS:000342350200062	25225384	Green Published, Bronze			2021-06-18	
J	Apolloni, S; Amadio, S; Parisi, C; Matteucci, A; Potenza, RL; Armida, M; Popoli, P; D'Ambrosi, N; Volonte, C				Apolloni, Savina; Amadio, Susanna; Parisi, Chiara; Matteucci, Alessandra; Potenza, Rosa L.; Armida, Monica; Popoli, Patrizia; D'Ambrosi, Nadia; Volonte, Cinzia			Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis	DISEASE MODELS & MECHANISMS			English	Article						ALS; Brilliant Blue G; Microglia; Motor neuron; P2X7	NF-KAPPA-B; PREVENTS ATP EXCITOTOXICITY; P2X(7) RECEPTOR; EXTRACELLULAR ATP; NEUROPATHIC PAIN; RODENT MODELS; MICROGLIA; NEURONS; ACTIVATION; INJURY	In recent years there has been an increasing awareness of the role of P2X7, a receptor for extracellular ATP, in modulating physiopathological mechanisms in the central nervous system. In particular, P2X7 has been shown to be implicated in neuropsychiatry, chronic pain, neurodegeneration and neuroinflammation. Remarkably, P2X7 has also been shown to be a 'gene modifier' in amyotrophic lateral sclerosis (ALS): the receptor is upregulated in spinal cord microglia in human and rat at advanced stages of the disease; in vitro, activation of P2X7 exacerbates pro-inflammatory responses in microglia that have an ALS phenotype, as well as toxicity towards neuronal cells. Despite this detrimental in vitro role of P2X7, in SOD1-G93A mice lacking P2X7, the clinical onset of ALS was significantly accelerated and disease progression worsened, thus indicating that the receptor might have some beneficial effects, at least at certain stages of disease. In order to clarify this dual action of P2X7 in ALS pathogenesis, in the present work we used the antagonist Brilliant Blue G (BBG), a blood-brain barrier permeable and safe drug that has already been proven to reduce neuroinflammation in traumatic brain injury, cerebral ischemia-reperfusion, neuropathic pain and experimental autoimmune encephalitis. We tested BBG in the SOD1-G93A ALS mouse model at asymptomatic, pre-symptomatic and late pre-symptomatic phases of disease. BBG at late pre-onset significantly enhanced motor neuron survival and reduced microgliosis in lumbar spinal cord, modulating inflammatory markers such as NF-kappa B, NADPH oxidase 2, interleukin-1 beta, interleukin-10 and brain-derived neurotrophic factor. This was accompanied by delayed onset and improved general conditions and motor performance, in both male and female mice, although survival appeared unaffected. Our results prove the twofold role of P2X7 in the course of ALS and establish that P2X7 modulation might represent a promising therapeutic strategy by interfering with the neuroinflammatory component of the disease.	[Apolloni, Savina; Parisi, Chiara; D'Ambrosi, Nadia; Volonte, Cinzia] CNR, Cellular Biol & Neurobiol Inst, I-00143 Rome, Italy; [Apolloni, Savina; Amadio, Susanna; Volonte, Cinzia] Santa Lucia Fdn, IRCCS, I-00179 Rome, Italy; [Matteucci, Alessandra; Potenza, Rosa L.; Armida, Monica; Popoli, Patrizia] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy	Volonte, C (corresponding author), CNR, Cellular Biol & Neurobiol Inst, Via Fosso di Fiorano 65, I-00143 Rome, Italy.	cinzia.volonte@cnr.it	parisi, Chiara/K-6330-2016; Apolloni, Savina/N-7695-2019; Amadio, Susanna/K-5580-2016; Volonte, Cinzia/N-6474-2013; Apolloni, Savina/AAH-9502-2020	parisi, Chiara/0000-0003-1350-3929; Apolloni, Savina/0000-0002-5782-1665; Amadio, Susanna/0000-0002-9266-4597; Volonte, Cinzia/0000-0001-7362-8307; MATTEUCCI, Alessandra/0000-0002-8793-3422; D'AMBROSI, Nadia/0000-0002-6646-7653; Potenza, Rosa Luisa/0000-0003-2342-0705	AriSLA-Fondazione Italiana per la Ricerca sulla Sclerosi Laterale Amiotrofica; Ministry of Health [grant PRALS]; Progetto Ministero della Salute Ricerca Corrente Fondazione Santa Lucia: 'Studio molecolare e funzionale dei recettori purinergici P2 nel sistema nervoso e nelle patologie neurodegenerative e neuroinfiammatorie'	This work was supported by AriSLA-Fondazione Italiana per la Ricerca sulla Sclerosi Laterale Amiotrofica co-financed with the support of '5x1000' - Healthcare Research of the Ministry of Health [grant PRALS 2009]; and by Progetto Ministero della Salute Ricerca Corrente Fondazione Santa Lucia: 'Studio molecolare e funzionale dei recettori purinergici P2 nel sistema nervoso e nelle patologie neurodegenerative e neuroinfiammatorie'.	Amadio S, 2011, J NEUROCHEM, V116, P796, DOI 10.1111/j.1471-4159.2010.07025.x; Apolloni S, 2013, HUM MOL GENET, V22, P4102, DOI 10.1093/hmg/ddt259; Apolloni S, 2013, J IMMUNOL, V190, P5187, DOI 10.4049/jimmunol.1203262; Arbeloa J, 2012, NEUROBIOL DIS, V45, P954, DOI 10.1016/j.nbd.2011.12.014; Beers DR, 2011, BRAIN BEHAV IMMUN, V25, P1025, DOI 10.1016/j.bbi.2010.12.008; Bhattacharya A, 2013, BRIT J PHARMACOL, V170, P624, DOI 10.1111/bph.12314; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Butovsky O, 2012, J CLIN INVEST, V122, P3063, DOI 10.1172/JCI62636; Casanovas A, 2008, J COMP NEUROL, V506, P75, DOI 10.1002/cne.21527; Cervetto C, 2013, TOXICOLOGY, V311, P69, DOI 10.1016/j.tox.2013.04.004; Chu KT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-69; D'Ambrosi N, 2009, J IMMUNOL, V183, P4648, DOI 10.4049/jimmunol.0901212; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Gandelman M, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-33; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; He WJ, 2012, BEHAV BRAIN RES, V226, P163, DOI 10.1016/j.bbr.2011.09.015; Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5; Hernandez S, 2010, J NEUROPATH EXP NEUR, V69, P176, DOI 10.1097/NEN.0b013e3181cd3e33; Kairisalo M, 2009, EUR J NEUROSCI, V30, P958, DOI 10.1111/j.1460-9568.2009.06898.x; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kobayashi K, 2011, NEUROSCI LETT, V504, P57, DOI 10.1016/j.neulet.2011.08.058; Li Q, 2011, J BIOL CHEM, V286, P40151, DOI 10.1074/jbc.M111.279711; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lim H, 2013, J BIOL CHEM, V288, P7572, DOI 10.1074/jbc.M112.414904; Ludolph AC, 2010, AMYOTROPH LATERAL SC, V11, P38, DOI 10.3109/17482960903545334; Marden JJ, 2007, J CLIN INVEST, V117, P2913, DOI 10.1172/JCI31265; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Monif M, 2010, INT J BIOCHEM CELL B, V42, P1753, DOI 10.1016/j.biocel.2010.06.021; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Nikodemova M, 2014, NEUROBIOL DIS, V69, P43, DOI 10.1016/j.nbd.2013.11.009; Parisi C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.491; Pelayes DE, 2012, OPHTHALMIC RES, V48, P21, DOI 10.1159/000339845; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Philips T, 2011, LANCET NEUROL, V10, P253, DOI 10.1016/S1474-4422(11)70015-1; Pugazhenthi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069585; Sargsyan SA, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-91; Swarup V, 2011, J EXP MED, V208, P2429, DOI 10.1084/jem.20111313; Takenouchi T, 2010, ARCH IMMUNOL THER EX, V58, P91, DOI 10.1007/s00005-010-0069-y; Thau N, 2012, NEUROBIOL DIS, V47, P248, DOI 10.1016/j.nbd.2012.04.008; Trumbull KA, 2012, NEUROBIOL DIS, V45, P137, DOI 10.1016/j.nbd.2011.07.015; Turner BJ, 2008, PROG NEUROBIOL, V85, P94, DOI 10.1016/j.pneurobio.2008.01.001; Volonte C, 2012, CNS NEUROL DISORD-DR, V11, P705, DOI 10.2174/187152712803581137; Volonte C, 2011, PHARMACOL THERAPEUT, V132, P111, DOI 10.1016/j.pharmthera.2011.06.002; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12; Zhao WH, 2013, J NEUROIMMUNE PHARM, V8, P888, DOI 10.1007/s11481-013-9489-x	50	69	70	0	14	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	1754-8403	1754-8411		DIS MODEL MECH	Dis. Model. Mech.	SEP	2014	7	9					1101	1109		10.1242/dmm.017038			9	Cell Biology; Pathology	Cell Biology; Pathology	AT5TS	WOS:000345005600008	25038061	DOAJ Gold, Green Published			2021-06-18	
J	Xiang, HY; Wheeler, KK; Groner, JI; Shi, JX; Haley, KJ				Xiang, Huiyun; Wheeler, Krista Kurz; Groner, Jonathan Ira; Shi, Junxin; Haley, Kathryn Jo			Undertriage of major trauma patients in the US emergency departments	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							CENTER DESIGNATION; GERIATRIC TRAUMA; UNITED-STATES; FIELD TRIAGE; LEVEL I; SURVIVAL ADVANTAGE; AMERICAN-COLLEGE; BRAIN-INJURY; CENTER CARE; CENTERS	Background: There is evidence that regionalized trauma care and appropriate triage of major trauma patients improve patient outcomes. However, the national rate of undertriage and diagnoses of undertriaged patients are unknown. Methods: We used the 2010 Nationwide Emergency Department Sample to estimate the national rate of undertriage, identify the prevalent diagnoses, and conduct a simulation analysis of the capacity increase required for level I and II trauma centers (TCs) to accommodate undertriaged patients. Undertriaged patients were those with major trauma, injury severity score >= 16, who received definitive care at nontrauma centers (NTCs), or level III TCs. The rate of undertriage was calculated with those receiving definitive care at an NTC center or level III center as a fraction of all major trauma patients. Results: The estimated number of major trauma patient discharges in 2010 was 232448. Level of care was known for 197702 major trauma discharges, and 34.0% were undertriaged in emergency departments (EDs). Elderly patients were at a significantly higher risk of being undertriaged. Traumatic brain injury (TBI) was the most common diagnosis, 40.2% of the undertriaged patient diagnoses. To accommodate all undertriaged patients, level I and II TCs nationally would have to increase their capacity by 51.5%. Conclusions: We found that more than one-third of US ED major trauma patients were undertriaged, and more than 40% of undertriaged diagnoses were TBIs. A significant capacity increase at level I and II TCs to accommodate these patients appears not feasible. (C) 2014 Elsevier Inc. All rights reserved.	[Xiang, Huiyun; Wheeler, Krista Kurz; Groner, Jonathan Ira; Shi, Junxin] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH 43205 USA; [Xiang, Huiyun; Groner, Jonathan Ira] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Groner, Jonathan Ira; Haley, Kathryn Jo] Nationwide Childrens Hosp, Dept Pediat Surg, Trauma Program, Columbus, OH 43205 USA	Xiang, HY (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	Huiyun.Xiang@NationwideChildrens.org	Groner, Jonathan/E-3156-2011; Xiang, Huiyun/E-4335-2011		Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1R03-HS022277]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R03HS022277] Funding Source: NIH RePORTER	Supported by a research grant (Principal investigator: Dr Huiyun Xiang, grant no.: 1R03-HS022277) from the Agency for Healthcare Research and Quality. The authors have no conflicts of interest to report.	American College of Surgeons, 2011, PRER QUEST PRQ; American College of Surgeons Committee on Trauma, 2008, REG TRAUM SYST OPT E; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Centers for Disease Control and Prevention, 2013, NAT CTR INJ PREV CON; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; Committee on Trauma of the American College of Surgeons, 2006, RES OPT CAR INJ PAT; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Finkelstein EA, 2006, ASS INCIDENCE EC BUR; Gage AM, 2012, J AM COLL SURGEONS, V215, P148, DOI 10.1016/j.jamcollsurg.2012.02.025; Garwe T, 2011, J TRAUMA, V70, P1118, DOI 10.1097/TA.0b013e3181e243b8; Gomez D, 2012, J TRAUMA ACUTE CARE, V73, P1288, DOI 10.1097/TA.0b013e318265cec2; Goodmanson NW, 2012, SURGERY, V152, P668, DOI 10.1016/j.surg.2012.08.017; Haas B, 2009, J AM COLL SURGEONS, V208, P28, DOI 10.1016/j.jamcollsurg.2008.09.004; Hsia RY, 2011, ARCH SURG-CHICAGO, V146, P585, DOI 10.1001/archsurg.2010.311; Kohn MA, 2004, ACAD EMERG MED, V11, P1, DOI 10.1197/S1069-656(03)00578-5; Lehmann R, 2009, ARCH SURG-CHICAGO, V144, P853, DOI 10.1001/archsurg.2009.153; Lehmann R, 2009, AM J SURG, V197, P571, DOI 10.1016/j.amjsurg.2008.12.037; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mangram AJ, 2012, J TRAUMA ACUTE CARE, V72, P119, DOI 10.1097/TA.0b013e318241f0ba; Mansouri B, 2013, NEUROL SCI, V34, P1933, DOI 10.1007/s10072-013-1410-0; Mohan D, 2013, J TRAUMA ACUTE CARE, V74, P1541, DOI 10.1097/TA.0b013e31828c3f75; Mohan D, 2011, ARCH SURG-CHICAGO, V146, P786, DOI 10.1001/archsurg.2011.43; Nakamura Y, 2012, ANN EMERG MED, V60, P335, DOI 10.1016/j.annemergmed.2012.04.006; Nathens AB, 2004, J TRAUMA, V56, P173, DOI 10.1097/01.TA.0000056159.65396.7C; Newgard CD, 2013, J TRAUMA ACUTE CARE, V74, P1298, DOI 10.1097/TA.0b013e31828b7848; Pracht EE, 2011, J TRAUMA, V71, P69, DOI 10.1097/TA.0b013e31820e82b7; Rivara FP, 2006, J TRAUMA, V61, P949, DOI 10.1097/01.ta.0000219936.72483.6a; Rogers A, 2012, AM SURGEON, V78, P711; Sasser SM, 2012, CTR DIS CONTROL, V61, P1; Scheetz LJ, 2011, PREHOSP EMERG CARE, V15, P83, DOI 10.3109/10903127.2010.514088; Shifflette VK, 2010, J TRAUMA, V69, P88, DOI 10.1097/TA.0b013e3181e291e9; Staudenmayer KL, 2013, J AM COLL SURGEONS, V217, P569, DOI 10.1016/j.jamcollsurg.2013.06.017; Sugerman DE, 2012, J TRAUMA ACUTE CARE, V73, P1491, DOI 10.1097/TA.0b013e3182782675; Tepas JJ, 2000, J TRAUMA, V48, P581, DOI 10.1097/00005373-200004000-00001; Tourtier JP, 2012, J AM COLL SURGEONS, V215, P740, DOI 10.1016/j.jamcollsurg.2012.08.011; Trooskin SZ, 2004, J TRAUMA, V57, P998, DOI 10.1097/01.TA.0000135349.24414.AE; Utter GH, 2006, J TRAUMA, V60, P529, DOI 10.1097/01.ta.0000204022.36214.9e	41	69	69	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2014	32	9					997	1004		10.1016/j.ajem.2014.05.038			8	Emergency Medicine	Emergency Medicine	AR1AY	WOS:000343312600010	24993680				2021-06-18	
J	Villemagne, VL; Okamura, N				Villemagne, Victor L.; Okamura, Nobuyuki			In vivo tau imaging: Obstacles and progress	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Chronic traumatic encephalopathy; Tau; Tauopathies; Molecular neuroimaging; Neurodegeneration; Radiotracer design	POSITRON-EMISSION-TOMOGRAPHY; PAIRED HELICAL FILAMENTS; BETA-AMYLOID PLAQUES; CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; MOUSE MODEL; A-BETA; COGNITIVE DECLINE; SENILE DEMENTIA	The military conflicts of the last decade have highlighted the growing problem of traumatic brain injury in combatants returning from the battlefield. The considerable evidence pointing at the accumulation of tau aggregates and its recognition as a risk factor in neurodegenerative conditions such as Alzheimer's disease have led to a major effort to develop selective tau ligands that would allow research into the physiopathologic underpinnings of traumatic brain injury and chronic traumatic encephalopathy in military personnel and the civilian population. These tracers will allow new insights into tau pathology in the human brain, facilitating research into causes, diagnosis, and treatment of traumatic encephalopathy and major neurodegenerative dementias, such as Alzheimer's disease and some variants of frontotemporal lobar degeneration, in which tau plays a role. The field of selective tau imaging has to overcome several obstacles, some of them associated with the idiosyncrasies of tau aggregation and others related to radiotracer design. A worldwide effort has focused on the development of imaging agents that will allow selective tau imaging in vivo. Recent progress in the development of these tracers is enabling the noninvasive assessment of the extent of tau pathology in the brain, eventually allowing the quantification of changes in tau pathology over time and its relation to cognitive performance, brain volumetrics, and other biomarkers, as well as assessment of efficacy and patient recruitment for antitau therapeutic trials. (C) 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.	[Villemagne, Victor L.] Austin Hlth, Dept Nucl Med, Melbourne, Vic, Australia; [Villemagne, Victor L.] Austin Hlth, Ctr PET, Melbourne, Vic, Australia; [Villemagne, Victor L.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Okamura, Nobuyuki] Tohoku Univ, Sch Med, Dept Pharmacol, Sendai, Miyagi 980, Japan	Villemagne, VL (corresponding author), Austin Hlth, Dept Nucl Med, Melbourne, Vic, Australia.	victorlv@unimelb.edu.au	Villemagne, Victor/AAC-5406-2019; Okamura, Nobuyuki/C-3541-2017	Okamura, Nobuyuki/0000-0002-5991-7812	Alzheimer Drug Discovery Foundation Research Grant [20101208 AFTD]; National Health and Medical Research Council of Australia Project GrantNational Health and Medical Research Council of Australia [1044361]; National Health and Medical Research Council of Australia Research FellowshipNational Health and Medical Research Council of Australia [1046471]; Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20019006]	This study was supported in part by Alzheimer Drug Discovery Foundation Research Grant (20101208 AFTD), National Health and Medical Research Council of Australia Project Grant 1044361, National Health and Medical Research Council of Australia Research Fellowship 1046471, and the Grant-in-Aid for Scientific Research on Priority Areas "Integrative Brain Research" from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (20019006). The funding sources had no input into the design of this study, the analysis of data, or writing of the manuscript.	Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Agdeppa ED, 2001, J NUCL MED, V42, p65P; Arima K, 2006, NEUROPATHOLOGY, V26, P475, DOI 10.1111/j.1440-1789.2006.00669.x; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Asuni AA, 2007, J NEUROSCI, V27, P9115, DOI 10.1523/JNEUROSCI.2361-07.2007; Barrio J. R., 1999, Journal of Labelled Compounds and Radiopharmaceuticals, V42, pS194; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bolander A, 2012, J MED CHEM, V55, P9170, DOI 10.1021/jm300653b; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Braak H, 1998, J NEURAL TRANSM-SUPP, P127; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Bresjanac M, 2003, J NEUROSCI, V23, P8029; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bugiani O, 2007, NEUROL SCI, V28, P241, DOI 10.1007/s10072-007-0829-6; Cairns NJ, 2009, ARCH NEUROL-CHICAGO, V66, P1557, DOI 10.1001/archneurol.2009.279; Carpenter GM, 2011, P NAT C UND RES 2011; Chen F, 2004, CURR DRUG TARGETS, V5, P503, DOI 10.2174/1389450043345236; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Delacourte A, 2005, FOLIA NEUROPATHOL, V43, P244; Delacourte A, 2002, EXP GERONTOL, V37, P1291, DOI 10.1016/S0531-5565(02)00141-9; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; Delacourte Andre, 2000, Current Opinion in Neurology, V13, P371, DOI 10.1097/00019052-200008000-00002; DELAERE P, 1990, NEUROSCI LETT, V116, P87, DOI 10.1016/0304-3940(90)90391-L; DELAERE P, 1989, ACTA NEUROPATHOL, V77, P645, DOI 10.1007/BF00687893; Dickson DW, 1997, NEUROBIOL AGING, V18, pS21, DOI 10.1016/S0197-4580(97)00065-1; DISCHINO DD, 1983, J NUCL MED, V24, P1030; DUYCKAERTS C, 1990, J NEUROL SCI, V97, P295, DOI 10.1016/0022-510X(90)90226-D; DUYCKAERTS C, 1987, ACTA NEUROPATHOL, V73, P167, DOI 10.1007/BF00693783; Fodero-Tavoletti MT, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt240; Fodero-Tavoletti MT, 2011, BRAIN, V134, P1089, DOI 10.1093/brain/awr038; Giacobini E, 2007, J ALZHEIMERS DIS, V12, P37; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Gotz J, 2010, BBA-MOL BASIS DIS, V1802, P860, DOI 10.1016/j.bbadis.2009.09.008; Gozes I, 2009, CURR ALZHEIMER RES, V6, P455, DOI 10.2174/156720509789207895; Hampel H, 2009, J CLIN PSYCHIAT, V70, P922, DOI 10.4088/JCP.08m04606; HANIHARA T, 1995, NEUROPATH APPL NEURO, V21, P319, DOI 10.1111/j.1365-2990.1995.tb01066.x; Harada R, 2013, EUR J NUCL MED MOL I, V40, P125, DOI 10.1007/s00259-012-2261-2; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hernandez F, 2007, CELL MOL LIFE SCI, V64, P2219, DOI 10.1007/s00018-007-7220-x; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Honson NS, 2007, NEUROBIOL DIS, V28, P251, DOI 10.1016/j.nbd.2007.07.018; Honson NS, 2007, BIOCHEM BIOPH RES CO, V363, P229, DOI 10.1016/j.bbrc.2007.08.166; Jack CR, 2008, BRAIN, V131, P665, DOI 10.1093/brain/awm336; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; JELLINGER K, 1990, KEY TOP BRAIN RES, P61; Jensen JR, 2011, J ALZHEIMERS DIS, V26, P147, DOI 10.3233/JAD-2011-0003; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kemp S.J., 2010, PCT Int. Appl. WO, Patent No. [2010034982 Al 20100401, 2010034982]; Kepe V, 2013, J ALZHEIMERS DIS, V36, P145, DOI 10.3233/JAD-130032; Kepe V, 2010, BRAIN PATHOL, V20, P419, DOI 10.1111/j.1750-3639.2009.00306.x; Klunk WE, 2005, J NEUROSCI, V25, P10598, DOI 10.1523/JNEUROSCI.2990-05.2005; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2007, J NEUROSCI, V27, P6174, DOI 10.1523/JNEUROSCI.0730-07.2007; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kolb H., 2013, ALZHEIMERS DEMENTIA, V9, pP844; Komori T, 1999, BRAIN PATHOL, V9, P663; Kudo Y, 2006, U.S. Patent, Patent No. [7,118,730, 7118730]; Kudo Y, 2010, U.S. Patent Application, Patent No. [2010/0021385, 20100021385]; Laruelle Marc, 2003, Mol Imaging Biol, V5, P363, DOI 10.1016/j.mibio.2003.09.009; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LeVine H, 2010, NEUROBIOL AGING, V31, P542, DOI 10.1016/j.neurobiolaging.2008.05.026; Li XY, 2011, EMBO J, V30, P4825, DOI 10.1038/emboj.2011.376; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; Mandelkow E, 2007, BRAIN PATHOL, V17, P83, DOI 10.1111/j.1750-3639.2007.00053.x; Martin L, 2011, NEUROCHEM INT, V58, P458, DOI 10.1016/j.neuint.2010.12.023; Maruyama M, 2013, NEURON, V79, P1094, DOI 10.1016/j.neuron.2013.07.037; Masters CL, 2005, DEMENTIA, P393; MASTERS CL, 2005, NEURODEGENER DIS, P433; Masters CL, 2006, J NEUROCHEM, V97, P1700, DOI 10.1111/j.1471-4159.2006.03989.x; Matsumura K, 2013, BIOORGAN MED CHEM, V21, P3356, DOI 10.1016/j.bmc.2013.02.054; Matsuoka Y, 2008, J PHARMACOL EXP THER, V325, P146, DOI 10.1124/jpet.107.130526; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Mintun M., 2013, ALZHEIMERS DEMENT, V9, pP842; Mohorko N, 2008, ZDR VESTN, V77, pII35; MUKAETOVALADINSKA EB, 1993, AM J PATHOL, V143, P565; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Nelson LD, 2011, ARCH NEUROL-CHICAGO, V68, P768, DOI 10.1001/archneurol.2011.104; Noda A, 2008, SYNAPSE, V62, P472, DOI 10.1002/syn.20508; Okamura N, 2005, J NEUROSCI, V25, P10857, DOI 10.1523/JNEUROSCI.1738-05.2005; Okamura N, 2014, BRAIN, V137, P1762, DOI 10.1093/brain/awu064; Okamura N, 2013, J NUCL MED, V54, P1420, DOI 10.2967/jnumed.112.117341; Ono M, 2011, ACS CHEM NEUROSCI, V2, P269, DOI 10.1021/cn200002t; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; Pike VW, 2009, TRENDS PHARMACOL SCI, V30, P431, DOI 10.1016/j.tips.2009.05.005; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Price JL, 2009, NEUROBIOL AGING, V30, P1026, DOI 10.1016/j.neurobiolaging.2009.04.002; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Rojo LE, 2010, J ALZHEIMERS DIS, V19, P573, DOI 10.3233/JAD-2010-1262; Rosen RF, 2011, NEUROBIOL AGING, V32, P223, DOI 10.1016/j.neurobiolaging.2009.02.011; Rowe CC, 2007, NEUROLOGY, V68, P1718, DOI 10.1212/01.wnl.0000261919.22630.ea; Schafer KN, 2012, NEUROIMAGE, V60, P1724, DOI 10.1016/j.neuroimage.2012.01.066; Selenica ML, 2007, BRIT J PHARMACOL, V152, P959, DOI 10.1038/sj.bjp.0707471; Sergeant N, 2008, EXPERT REV PROTEOMIC, V5, P207, DOI 10.1586/14789450.5.2.207; Serrano-Pozo A, 2011, AM J PATHOL, V179, P1373, DOI 10.1016/j.ajpath.2011.05.047; Shao X, 2012, ACS MED CHEM LETT, V3, P936, DOI 10.1021/ml300216t; Shin J, 2008, NEUROIMAGE, V43, P236, DOI 10.1016/j.neuroimage.2008.07.022; Shoghi-Jadid K, 2002, AM J GERIAT PSYCHIAT, V10, P24, DOI 10.1176/appi.ajgp.10.1.24; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Small GW, 2006, NEW ENGL J MED, V355, P2652, DOI 10.1056/NEJMoa054625; Small GW, 2002, J MOL NEUROSCI, V19, P323; Smid LM, 2013, J ALZHEIMERS DIS, V36, P261, DOI 10.3233/JAD-122434; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szardenings AK, 2011, US Patent, Patent No. [2011/0182812 A1, 20110182812, 2011/ 0182812 A1]; Taghavi A, 2011, J ALZHEIMERS DIS, V27, P835, DOI 10.3233/JAD-2011-111238; Tago T, 2014, J LABELLED COMPD RAD, V57, P18, DOI 10.1002/jlcr.3133; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Thompson PW, 2009, J NEUROCHEM, V109, P623, DOI 10.1111/j.1471-4159.2009.05996.x; Tolboom N, 2009, J NUCL MED, V50, P191, DOI 10.2967/jnumed.108.056499; Tomiyama T, 2008, ANN NEUROL, V63, P377, DOI 10.1002/ana.21321; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Veitch DP, 2013, CURR ALZHEIMER RES, V10, P907, DOI 10.2174/15672050113109990142; Villemagne VL, 2008, NEUROPSYCHOLOGIA, V46, P1688, DOI 10.1016/j.neuropsychologia.2008.02.008; Villemagne VL, 2008, MOL NEUROBIOL, V38, P1, DOI 10.1007/s12035-008-8019-y; Villemagne VL, 2014, EUR J NUCL MED MOL I, V41, P816, DOI 10.1007/s00259-013-2681-7; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; Villemagne VL, 2012, FUTUR NEUROL, V7, P409, DOI 10.2217/FNL.12.34; Villemagne VL, 2011, ANN NEUROL, V69, P181, DOI 10.1002/ana.22248; Villemagne VL, 2013, ALZHEIMERS DEMENT, V9, pP94; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; Watanabe H, 2012, BIOORG MED CHEM LETT, V22, P5700, DOI 10.1016/j.bmcl.2012.06.086; Wischik C, 2009, J NUTR HEALTH AGING, V13, P367, DOI 10.1007/s12603-009-0046-5; Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Xu SH, 2010, ALZHEIMERS DEMENT, V6, P110, DOI 10.1016/j.jalz.2009.06.002; Zhang B, 2005, P NATL ACAD SCI USA, V102, P227, DOI 10.1073/pnas.0406361102; Zhang W, 2012, J ALZHEIMERS DIS, V31, P601, DOI 10.3233/JAD-2012-120712	132	69	71	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S254	S264		10.1016/j.jalz.2014.04.013			11	Clinical Neurology	Neurosciences & Neurology	CP8GM	WOS:000360130700019	24924676	Other Gold			2021-06-18	
J	Chrisman, SP; Schiff, MA; Chung, SK; Herring, SA; Rivara, FP				Chrisman, Sara P.; Schiff, Melissa A.; Chung, Shana K.; Herring, Stanley A.; Rivara, Frederick P.			Implementation of Concussion Legislation and Extent of Concussion Education for Athletes, Parents, and Coaches in Washington State	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						return to play; education; athletics; concussion; adolescents; legislation	TRAUMATIC BRAIN-INJURY; KNOWLEDGE; SOCCER; IMPACT	Background: Most states in the United States have passed laws regarding concussions, but little is known regarding the implementation of these laws. Hypothesis/Purpose: The purpose of this study was to survey high school coaches 3 years after the passage of a concussion law to evaluate the variation in concussion education and knowledge in the context of this law as well as measure the effects of sport (football vs soccer) and urban versus rural locations. The hypothesis was that concussion education and knowledge would be more extensive in football compared with soccer and in urban locations compared with rural locations. Study Design: Descriptive epidemiology study. Methods: A mixed-methods (paper and online) survey was conducted in 2012 to 2013 on a random sample of public high school football, girls' soccer, and boys' soccer coaches in Washington State, stratified by urban and rural locality. The survey covered the extent of concussion education for coaches, athletes, and parents as well as coaches' concussion knowledge and experience. Results: Of 496 coaches contacted, 270 responded (54.4%). Nearly all coaches answered concussion knowledge questions correctly, and nearly all coaches received education via >= 2 modalities (written, video, slide presentation, test, and in person). Athlete education was less extensive, with 34.7% exposed to >= 2 modalities and 29.5% only signing a concussion information form. Parent education was even more limited, with 16.2% exposed to >= 2 modalities and 57.9% only signing a concussion information form. Significantly more football than soccer coaches gave their athletes an in-person talk about concussions (59.1% vs 39.4%, respectively; P = .002) and provided concussion education to athletes via >= 2 modalities (44.1% vs 29.7%, respectively; P = .02). Concussion education for coaches and parents was similar between sports, and concussion education for all parties was similar in urban and rural localities. Conclusion: Three years after the passage of a concussion law in Washington State, high school football and soccer coaches are receiving substantial concussion education and have good concussion knowledge. Concussion education for athletes and parents is more limited. Football players receive more extensive concussion education than do soccer players. Clinical Relevance: Clinicians should be aware that athletes and parents may not be receiving significant concussion education.	[Chrisman, Sara P.; Schiff, Melissa A.; Chung, Shana K.; Herring, Stanley A.; Rivara, Frederick P.] Univ Washington, Seattle, WA 98104 USA	Chrisman, SP (corresponding author), Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, 325 Ninth Ave,Box 359960, Seattle, WA 98104 USA.	sara.chrisman@seattlechildrens.org		Chrisman, Sara/0000-0001-5373-7223	Public Health Law Research Program of the Robert Wood Johnson Foundation	One or more of the authors has declared the following potential conflict of interest or source of funding: S. A. H. has a nonfinancial role on the medical advisory board for X2 Biosystems, which makes monitors that measure the force of head impacts while playing sports. Support for this study was provided by a grant from the Public Health Law Research Program of the Robert Wood Johnson Foundation.	Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Broglio SP, 2010, J SPORT SCI MED, V9, P418; *CDCP, HEADS CONC YOUTH SPO; Chopp F, 2009, YOUTH SPORTS HEAD IN, V1824; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Ginns P, 2005, LEARN INSTR, V15, P313, DOI 10.1016/j.learninstruc.2005.07.001; Hailu A, 2013, GUIDELINES USING RUR; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Heffler B, 2001, EDUC STUD, V27, P307, DOI 10.1080/03055690120076583; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; National Athletic Trainers' Association, 2009, ATHL TRAIN FILL NEC; National Federation of State High School Associations, CONC SPORTS WHAT YOU; National Football League, ZACK LYST LAW; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Tomei KL, 2012, NEUROSURG FOCUS, V33, pE11; van Merrienboer JJG, 2010, MED EDUC, V44, P85, DOI 10.1111/j.1365-2923.2009.03498.x; Washington Interscholastic Activities Association, CONC MAN GUID	21	69	69	1	29	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2014	42	5					1190	1196		10.1177/0363546513519073			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AG6ZM	WOS:000335567700022	24510067				2021-06-18	
J	Karvellas, CJ; Fix, OK; Battenhouse, H; Durkalski, V; Sanders, C; Lee, WM				Karvellas, Constantine J.; Fix, Oren K.; Battenhouse, Holly; Durkalski, Valerie; Sanders, Corron; Lee, William M.		US Acute Liver Failure Study Grp	Outcomes and Complications of Intracranial Pressure Monitoring in Acute Liver Failure: A Retrospective Cohort Study*	CRITICAL CARE MEDICINE			English	Article						cerebral edema; intracranial pressure monitoring; intracranial hypertension; acute liver failure; acetaminophen; fulminant hepatic failure	FULMINANT HEPATIC-FAILURE; TRAUMATIC BRAIN-INJURY; FACTOR-VII; ENCEPHALOPATHY; MANAGEMENT	Objective: To determine if intracranial pressure monitor placement in patients with acute liver failure is associated with significant clinical outcomes. Design: Retrospective multicenter cohort study. Setting: Academic liver transplant centers comprising the U.S. Acute Liver Failure Study Group. Patients: Adult critically ill patients with acute liver failure presenting with grade III/IV hepatic encephalopathy (n = 629) prospectively enrolled between March 2004 and August 2011. Intervention: Intracranial pressure monitored (n = 140) versus nonmonitored controls (n = 489). Measurements and Main Results: Intracranial pressure monitored patients were younger than controls (35 vs 43 yr, p < 0.001) and more likely to be on renal replacement therapy (52% vs 38%, p = 0.003). Of 87 intracranial pressure monitored patients with detailed information, 44 (51%) had evidence of intracranial hypertension (intracranial pressure > 25 mm Hg) and overall 21-day mortality was higher in patients with intracranial hypertension (43% vs 23%, p = 0.05). During the first 7 days, intracranial pressure monitored patients received more intracranial hypertension-directed therapies (mannitol, 56% vs 21%; hypertonic saline, 14% vs 7%; hypothermia, 24% vs 10%; p < 0.03 for each). Forty-one percent of intracranial pressure monitored patients received liver transplant (vs 18% controls; p < 0.001). Overall 21-day mortality was similar (intracranial pressure monitored 33% vs controls 38%, p = 0.24). Where data were available, hemorrhagic complications were rare in intracranial pressure monitored patients (4 of 56 [7%]; three died). When stratifying by acetaminophen status and adjusting for confounders, intracranial pressure monitor placement did not impact 21-day mortality in acetaminophen patients (p = 0.89). However, intracranial pressure monitor was associated with increased 21-day mortality in nonacetaminophen patients (odds ratio, ~ 3.04; p = 0.014). Conclusions: In intracranial pressure monitored patients with acute liver failure, intracranial hypertension is commonly observed. The use of intracranial pressure monitor in acetaminophen acute liver failure did not confer a significant 21-day mortality benefit, whereas in nonacetaminophen acute liver failure, it may be associated with worse outcomes. Hemorrhagic complications from intracranial pressure monitor placement were uncommon and cannot account for mortality trends. Although our results cannot conclusively confirm or refute the utility of intracranial pressure monitoring in patients with acute liver failure, patient selection and ancillary assessments of cerebral blood flow likely have a significant role. Prospective studies would be required to conclusively account for confounding by illness severity and transplant.	[Karvellas, Constantine J.] Univ Alberta, Div Hepatol, Edmonton, AB, Canada; [Karvellas, Constantine J.] Univ Alberta, Div Crit Care Med, Edmonton, AB, Canada; [Fix, Oren K.] Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA; [Battenhouse, Holly; Durkalski, Valerie] Med Univ S Carolina, Fac Med, Charleston, SC 29425 USA; [Sanders, Corron; Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA	Karvellas, CJ (corresponding author), Univ Alberta, Div Hepatol, Edmonton, AB, Canada.	dean.karvellas@ualberta.ca		Karvellas, Constantine/0000-0002-1555-1089	National Institutes of Health (NIH) (United States Acute Liver Failure Study Group [U.S. ALFSG] - NIH [National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK] [DK U-01 58369]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIDDK/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); NIH (NIDDK)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01-DK58369, U-01 58369]; Medical University of South Carolina; Medical University of South Carolina [U01 DK0583691]; University of Texas Southwestern (UTSW) MCD (NIH) [U-01 58369]; UTSW Medical Center (Anadys); UTSW Medical Center (BMS); UTSW Medical Center (BI); UTSW Medical Center (Gilead); UTSW Medical Center (Merck); UTSW Medical Center (Siemens); UTSW Medical Center (Vertex)Vertex Pharmaceuticals; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK058369, P30DK026743] Funding Source: NIH RePORTER	Dr. Karvellas received support for article research from the National Institutes of Health (NIH) (United States Acute Liver Failure Study Group [U.S. ALFSG] is funded by an NIH grant [National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, DK U-01 58369]). Dr. Fix is employed by University of California San Francisco and received support for article research from NIH. His institution received grant support from NIDDK/NIH. Ms. Battenhouse received support for article research from NIH. Her institution received grant support from NIH (U01-DK58369) and is employed by NIH. Dr. Durkalski is employed by Medical University of South Carolina and received support for article research from NIH. His institution received grant support from the Medical University of South Carolina (funding provided by ALFSG grant U01 DK0583691). Dr. Sanders received support for article research from NIH grant U-01 58369 (from NIDDK). Dr. Lee consulted for Lilly, Novartis, and Pfizer (drug safety review) and received support for article research from NIH. His institution received grant support from University of Texas Southwestern (UTSW) MCD (NIH grant U-01 58369 to UTSW) and UTSW Medical Center (Anadys, BMS, BI, Gilead, Merck, Siemens, Vertex).	Agarwal B, 2012, J HEPATOL, V57, P780, DOI 10.1016/j.jhep.2012.06.020; ATTERBURY CE, 1978, AM J DIG DIS, V23, P398, DOI 10.1007/BF01072921; Bernal W, 1999, EUR J GASTROEN HEPAT, V11, P977, DOI 10.1097/00042737-199909000-00005; Bernal W, 2007, HEPATOLOGY, V46, P1844, DOI 10.1002/hep.21838; Bernal W, 2010, LANCET, V376, P190, DOI 10.1016/S0140-6736(10)60274-7; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; Caldwell SH, 2004, HEPATOLOGY, V39, P592, DOI 10.1002/hep.20123; Conn HO, 1979, HEPATIC COMA SYNDROM; Daas M, 1995, Liver Transpl Surg, V1, P210, DOI 10.1002/lt.500010403; DAVIES MH, 1994, LANCET, V343, P1329, DOI 10.1016/S0140-6736(94)92471-6; Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; Griesdale DEG, 2010, CAN J NEUROL SCI, V37, P43, DOI 10.1017/S031716710000963X; Kamat P, 2012, PEDIATR CRIT CARE ME, V13, pE33, DOI 10.1097/PCC.0b013e31820ac08f; Kasotakis G, 2012, J AM COLL SURGEONS, V214, P950, DOI 10.1016/j.jamcollsurg.2012.03.004; KEAYS RT, 1993, J HEPATOL, V18, P205, DOI 10.1016/S0168-8278(05)80247-8; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Le TV, 2010, NEUROSURGERY, V66, P455, DOI 10.1227/01.NEU.0000365517.52586.A2; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1993, LANCET, V342, P743, DOI 10.1016/0140-6736(93)91736-6; Peck M, 2010, CRIT CARE S1, V14, pP542, DOI DOI 10.1186/cc8774; Polson J, 2005, HEPATOLOGY, V41, P1179, DOI 10.1002/hep.20703; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Stravitz RT, 2012, J HEPATOL, V56, P129, DOI 10.1016/j.jhep.2011.04.020; Vaquero J, 2005, LIVER TRANSPLANT, V11, P1581, DOI 10.1002/lt.20625; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; WARE AJ, 1971, GASTROENTEROLOGY, V61, P877	27	69	69	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2014	42	5					1157	1167		10.1097/CCM.0000000000000144			11	Critical Care Medicine	General & Internal Medicine	AG4IU	WOS:000335383900032	24351370	Green Accepted			2021-06-18	
J	Tanna, T; Sachan, V				Tanna, Tanmay; Sachan, Vatsal			Mesenchymal Stem Cells: Potential in Treatment of Neurodegenerative Diseases	CURRENT STEM CELL RESEARCH & THERAPY			English	Article						Alzheimer's disease (AD); Amyotrophic lateral sclerosis (ALS); Huntington's disease (HD); Mesenchymal stem cells; multiple sclerosis (MS); neurodegenerative diseases; Parkinson's disease (PD)	AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID-BETA DEPOSITION; MARROW STROMAL CELLS; NEURON-LIKE CELLS; ALZHEIMERS-DISEASE; BONE-MARROW; HUNTINGTONS-DISEASE; MULTIPLE-SCLEROSIS; UMBILICAL-CORD; PARKINSONS-DISEASE	Mesenchymal Stem Cells or Marrow Stromal Cells (MSCs) have long been viewed as a potent tool for regenerative cell therapy. MSCs are easily accessible from both healthy donor and patient tissue and expandable in vitro on a therapeutic scale without posing significant ethical or procedural problems. MSC based therapies have proven to be effective in preclinical studies for graft versus host disease, stroke, myocardial infarction, pulmonary fibrosis, autoimmune disorders and many other conditions and are currently undergoing clinical trials at a number of centers all over the world. MSCs are also being extensively researched as a therapeutic tool against neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD) and Multiple Sclerosis (MS). MSCs have been discussed with regard to two aspects in the context of neurodegenerative diseases: their ability to transdifferentiate into neural cells under specific conditions and their neuroprotective and immunomodulatory effects. When transplanted into the brain, MSCs produce neurotrophic and growth factors that protect and induce regeneration of damaged tissue. Additionally, MSCs have also been explored as gene delivery vehicles, for example being genetically engineered to over express glial-derived or brain-derived neurotrophic factor in the brain. Clinical trials involving MSCs are currently underway for MS, ALS, traumatic brain injuries, spinal cord injuries and stroke. In the present review, we explore the potential that MSCs hold with regard to the aforementioned neurodegenerative diseases and the current scenario with reference to the same.	[Tanna, Tanmay; Sachan, Vatsal] Natl Inst Technol, Dept Biotechnol, Warangal 506004, Andhra Pradesh, India	Sachan, V (corresponding author), Natl Inst Technol, Dept Biotechnol, Warangal 506004, Andhra Pradesh, India.	vatsalsac@gmail.com		Tanna, Tanmay/0000-0002-1150-0188			Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Ahmed H, 2014, HUM EXP TOXICOL; Amin EM, 2008, NEUROL RES, V30, P1086, DOI 10.1179/174313208X327955; Ardeshiry Lajimi Abdolreza, 2013, Int J Hematol Oncol Stem Cell Res, V7, P15; Arnold I, J ORTHOPAED RES; Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Auletta JJ, 2012, IMMUNOTHERAPY-UK, V4, P529, DOI [10.2217/IMT.12.41, 10.2217/imt.12.41]; Babaei P, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/369417; Bachoud-Levi AC, 2006, LANCET NEUROL, V5, P303, DOI 10.1016/S1474-4422(06)70381-7; Bachurin SO, 2003, MED RES REV, V23, P48, DOI 10.1002/med.10026; Bae JS, 2013, CURR ALZHEIMER RES, V10, P524; Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841; Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74; Barker RA, 2012, REGEN MED, V7, P26, DOI [10.2217/rme.12.64, 10.2217/RME.12.64]; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Ben-Ami E, 2014, AUTOIMMUN REV, V13, P187, DOI 10.1016/j.autrev.2013.09.007; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Bobkova NV, 2013, B EXP BIOL MED+, V156, P119, DOI 10.1007/s10517-013-2293-z; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; Bonab MM, 2013, ARCH MED RES, V44, P266, DOI 10.1016/j.arcmed.2013.03.007; Bonab MM, 2012, CURR STEM CELL RES T, V7, P407; Bouchez G, 2008, NEUROCHEM INT, V52, P1332, DOI 10.1016/j.neuint.2008.02.003; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Brunt KR, 2012, CAN J PHYSIOL PHARM, V90, P327, DOI [10.1139/Y2012-007, 10.1139/y2012-007]; Burt RK, 2009, LANCET NEUROL, V8, P244, DOI 10.1016/S1474-4422(09)70017-1; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; Chang KA, 2014, NEURODEGENER DIS, V13, P99, DOI 10.1159/000355261; Chapuis S, 2005, MOVEMENT DISORD, V20, P224, DOI 10.1002/mds.20279; Chen Y, 2014, DRUG DISCOV TODAY; Chipman PH, 2012, PROG BRAIN RES, V201, P313, DOI 10.1016/B978-0-444-59544-7.00015-9; Choi CI, 2013, CELL TRANSPLANT, V22, P855, DOI 10.3727/096368912X637019; Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z; CLARKE DJ, 1988, PROG BRAIN RES, V78, P47; Cobo M, 2013, CELL TRANSPLANT, V22, P839, DOI 10.3727/096368912X657404; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Cova L, 2010, STEM CELLS CLONING, V3, P145, DOI 10.2147/SCCAA.S8662; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Dantuma E, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt37; Darlington PJ, 2011, EXPERT REV NEUROTHER, V11, P1295, DOI [10.1586/ERN.11.113, 10.1586/ern.11.113]; Davie CA, 2008, BRIT MED BULL, V86, P109, DOI 10.1093/bmb/ldn013; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; de Munter Johannes P J M, 2014, Parkinsonism Relat Disord, V20 Suppl 1, pS150, DOI 10.1016/S1353-8020(13)70036-1; de Oliveira G., 2013, CELL TRANSPLANT; Deierborg T, 2014, NEURODEGENER DIS, V13, P99; Dey ND, 2010, BEHAV BRAIN RES, V214, P193, DOI 10.1016/j.bbr.2010.05.023; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dezawa M, 2008, MED MOL MORPHOL, V41, P14, DOI 10.1007/s00795-007-0389-0; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Dyson SC, 2011, EXPERT REV NEUROTHER, V11, P831, DOI [10.1586/ERN.11.33, 10.1586/ern.11.33]; Ehnert S, 2009, LANGENBECK ARCH SURG, V394, P985, DOI 10.1007/s00423-009-0546-0; Erba P, 2010, CURR STEM CELL RES T, V5, P153, DOI 10.2174/157488810791268645; Fan XT, 2014, MED RES REV, V34, P957, DOI 10.1002/med.21309; Farge D, 2010, HAEMATOL-HEMATOL J, V95, P284, DOI 10.3324/haematol.2009.013458; Feng ZL, 2009, AM J ALZHEIMERS DIS, V24, P52, DOI 10.1177/1533317508327587; Garcia KO, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00030; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Glavaski-Joksimovic A, 2013, EXP NEUROL, V247, P25, DOI 10.1016/j.expneurol.2013.03.016; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Habisch HJ, 2010, STEM CELLS DEV, V19, P629, DOI 10.1089/scd.2009.0045; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harris VK, 2012, STEM CELL TRANSL MED, V1, P536, DOI 10.5966/sctm.2012-0015; Harrison DM, 2009, ANN INDIAN ACAD NEUR, V12, P283, DOI 10.4103/0972-2327.58279; Hedayatpour A, 2013, CELL J, V15, P142; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Hou ZL, 2013, CELL ADHES MIGR, V7, P404, DOI 10.4161/cam.26941; Ikebe C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/951512; ISACSON O, 1984, NATURE, V311, P458, DOI 10.1038/311458a0; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Jin GZ, 2008, CELL BIOL INT, V32, P1433, DOI 10.1016/j.cellbi.2008.08.014; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Kanno Hiroshi, 2013, World J Stem Cells, V5, P163, DOI 10.4252/wjsc.v5.i4.163; Karussis D, 2013, EXPERT REV NEUROTHER, V13, P567, DOI [10.1586/ERN.13.36, 10.1586/ern.13.36]; Katsuda T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01197; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Keilhoff G, 2006, CELL MOL NEUROBIOL, V26, P1235, DOI 10.1007/s10571-006-9029-9; Khoo MLM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019025; Kim HJ, 2013, EXP BIOL MED, V238, P923, DOI 10.1177/1535370213497173; Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045757; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kitada M, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/873706; Koh SH, 2012, EXP NEUROL, V233, P472, DOI 10.1016/j.expneurol.2011.11.021; Krakora D, 2013, MOL THER, V21, P1602, DOI 10.1038/mt.2013.108; Lanctot KL, 2003, CAN MED ASSOC J, V169, P557; Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399; Lee H, 2007, STEM CELLS, V25, P1931, DOI 10.1634/stemcells.2007-0097; Lee HJ, 2012, NEUROBIOL AGING, V33, P588, DOI 10.1016/j.neurobiolaging.2010.03.024; Lee HJ, 2010, NEUROSCI LETT, V481, P30, DOI 10.1016/j.neulet.2010.06.045; Lee JK, 2009, NEUROSCI LETT, V450, P136, DOI 10.1016/j.neulet.2008.11.059; Lee ST, 2006, MECH AGEING DEV, V127, P432, DOI 10.1016/j.mad.2006.01.022; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; Lescaudron L, 2012, CURR MED CHEM, V19, P6018; Lescaudron L, 2003, INT J NEUROSCI, V113, P945, DOI 10.1080/00207450390207759; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Liang J, 2013, NEUROSCI LETT, V532, P59, DOI 10.1016/j.neulet.2012.11.014; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lu GH, 2012, NEUROREPORT, V23, P513, DOI 10.1097/WNR.0b013e328353fbb4; Lundkvist J, 2001, TRENDS NEUROSCI, V24, P492, DOI 10.1016/S0166-2236(00)01888-9; Ma T, 2013, CELL TRANSPLANT, V22, pS113, DOI 10.3727/096368913X672181; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; Mancardi G, 2008, LANCET NEUROL, V7, P626, DOI 10.1016/S1474-4422(08)70138-8; Mannon PJ, 2011, EXPERT OPIN BIOL TH, V11, P1249, DOI 10.1517/14712598.2011.602967; Marconi S, 2013, NEUROSCIENCE, V248, P333, DOI 10.1016/j.neuroscience.2013.05.034; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Maucksch C, 2013, J CELL BIOCHEM, V114, P754, DOI 10.1002/jcb.24432; Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007; Mazzini L, 2008, J NEUROL SCI, V265, P78, DOI 10.1016/j.jns.2007.05.016; Mazzini L, 2012, PROG BRAIN RES, V201, P333, DOI 10.1016/B978-0-444-59544-7.00016-0; Mazzini L, 2012, CYTOTHERAPY, V14, P56, DOI 10.3109/14653249.2011.613929; Meamar R, 2013, J CLIN NEUROSCI, V20, P1659, DOI 10.1016/j.jocn.2013.04.024; Meininger V, 2000, J NEUROL, V247, P19; Meyerrose T, 2010, ADV DRUG DELIVER REV, V62, P1167, DOI 10.1016/j.addr.2010.09.013; Mitrecic D, 2009, ANAT REC, V292, P1962, DOI 10.1002/ar.20971; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; Naganska E, 2011, FOLIA NEUROPATHOL, V49, P1; Nishimura K, 2013, BIOL PHARM BULL, V36, P171, DOI 10.1248/bpb.b12-00929; Olson SD, 2012, MOL CELL NEUROSCI, V49, P271, DOI 10.1016/j.mcn.2011.12.001; Park HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032847; Park HJ, 2008, J NEUROCHEM, V107, P141, DOI 10.1111/j.1471-4159.2008.05589.x; Pasquini MC, 2010, BIOL BLOOD MARROW TR, V16, P1076, DOI 10.1016/j.bbmt.2010.03.012; Paul G, 2013, BIOCHIMIE, V95, P2246, DOI 10.1016/j.biochi.2013.07.013; Payne NL, 2013, CELL TRANSPLANT, V22, P1409, DOI 10.3727/096368912X657620; Pereira MCL, 2011, STEM CELL REV REP, V7, P1006, DOI 10.1007/s12015-011-9256-4; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pluchino S, 2009, NEUROSCI LETT, V456, P101, DOI 10.1016/j.neulet.2008.03.097; Politis M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-1; PURDON SE, 1994, J PSYCHIATR NEUROSCI, V19, P359; Reekmans K, 2012, REGEN MED, V7, P245, DOI [10.2217/RME.12.5, 10.2217/rme.12.5]; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Rice CM, 2013, LANCET, V382, P1204, DOI 10.1016/S0140-6736(13)61810-3; Rivera FJ, 2012, BIOL RES, V45, P257, DOI 10.4067/S0716-97602012000300007; Rivera FT, 2006, STEM CELLS, V24, P2209, DOI 10.1634/stemcells.2005-0614; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rossignol J, 2014, STEM CELLS, V32, P500, DOI 10.1002/stem.1508; Ryu CH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/696738; Sadan O, 2012, EXP NEUROL, V234, P417, DOI 10.1016/j.expneurol.2011.12.045; Sadan O, 2008, STEM CELLS, V26, P2542, DOI 10.1634/stemcells.2008-0240; Sadan O, 2009, STEM CELLS DEV, V18, P1179, DOI 10.1089/scd.2008.0411; SANBERG PR, 1989, EXP NEUROL, V105, P45, DOI 10.1016/0014-4886(89)90170-2; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554; SH Oh, 2014, CELL TRANSPLANT; Shetty P, 2013, CELL BIOL INT, V37, P167, DOI 10.1002/cbin.10029; Shin JY, 2014, AUTOPHAGY, V10, P32, DOI 10.4161/auto.26508; Siatskas C, 2010, STEM CELL REV REP, V6, P500, DOI 10.1007/s12015-010-9173-y; Silani V, 2004, LANCET, V364, P200, DOI 10.1016/S0140-6736(04)16634-8; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; Snyder BR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009347; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Sorrentino A, 2008, EXP HEMATOL, V36, P1035, DOI 10.1016/j.exphem.2008.03.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; Sugaya K, 2008, J ALZHEIMERS DIS, V15, P241; Sun H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072926; Suzuki M, 2008, MOL THER, V16, P2002, DOI 10.1038/mt.2008.197; Taran R, 2014, J BIOSCIENCES, V39, P157, DOI 10.1007/s12038-013-9409-5; Thomas MG, 2011, TRANSL RES, V157, P56, DOI 10.1016/j.trsl.2010.11.001; Thomsen GM, 2014, EXP NEUROL; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-52; Uccelli A, 2013, MULT SCLER J, V19, P515, DOI 10.1177/1352458512464686; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; Volkmann J, 2009, MOVEMENT DISORD, V24, P1154, DOI 10.1002/mds.22496; Waldau B, 2008, CELL MOL LIFE SCI, V65, P2372, DOI 10.1007/s00018-008-8053-y; Wang MJ, 2006, AM J PHYSIOL-REG I, V291, pR880, DOI 10.1152/ajpregu.00280.2006; WHITEHOUSE PJ, 1983, PSYCHOPHARMACOL BULL, V19, P437; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wu S, 2008, PATHOBIOLOGY, V75, P186, DOI 10.1159/000124979; Xuan AG, 2009, NEUROSCI LETT, V450, P167, DOI 10.1016/j.neulet.2008.12.001; Yan MX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061056; Yang H, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt227; Yun HM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.490; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zavan B, 2010, DISCOV MED, V10, P37; Zhang L, 2012, INT J DEV NEUROSCI, V30, P471, DOI 10.1016/j.ijdevneu.2012.05.006; Zhao CP, 2007, CYTOTHERAPY, V9, P414, DOI 10.1080/14653240701376413; Zhao HB, 2014, CELL BIOL INT, V38, P462, DOI 10.1002/cbin.10217; Zhu JS, 2012, EXP CLIN TRANSPLANT, V10, P492, DOI 10.6002/ect.2011.0197; Zilka N, 2011, NEUROSCIENCE, V193, P330, DOI 10.1016/j.neuroscience.2011.06.088	186	69	72	2	50	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1574-888X	2212-3946		CURR STEM CELL RES T	Curr. Stem Cell Res. Ther.		2014	9	6					513	521		10.2174/1574888X09666140923101110			9	Cell & Tissue Engineering; Cell Biology	Cell Biology	AQ9WV	WOS:000343209600009	25248677				2021-06-18	
J	Azulay, J; Smart, CM; Mott, T; Cicerone, KD				Azulay, Joanne; Smart, Colette M.; Mott, Tasha; Cicerone, Keith D.			A Pilot Study Examining the Effect of Mindfulness-Based Stress Reduction on Symptoms of Chronic Mild Traumatic Brain Injury/Postconcussive Syndrome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; mindfulness; quality of life; rehabilitation; self-efficacy	MEDITATION; INJURY; PROGRAM; ATTENTION; LIFE; INTERVENTION; INDIVIDUALS; SENSITIVITY; COMPLAINTS; QUALITY	Objective: To evaluate the effectiveness of the mindfulness-based stress reduction (MBSR) program tailored to individuals with mild traumatic brain injury (mTBI). Design: A convenience sample recruited from clinical referrals over a 2-year period completed outcome measures pre- and posttreatment intervention. Setting: Post-acute brain injury rehabilitation center within a suburban medical facility. Participants: Twenty-two individuals with mTBI and a time postinjury more than 7 months. Eleven participants were men and 11 were women, ranging in age from 18 to 62 years. Intervention: A 10-week group (with weekly 2-hour sessions) modeled after the MBSR program of Kabat-Zinn, but with modifications designed to facilitate implementation in a population of individuals with brain injury. (The treatment involved enhancement of attentional skills, in addition to increased awareness of internal and external experiences associated with the perspective change of acceptance and nonjudgmental attitude regarding those experiences). Main Outcome Measures: Perceived Quality of Life Scale, Perceived Self-Efficacy Scale, and the Neurobehavioral Symptom Inventory. Secondary measures included neuropsychological tests, a self-report problem-solving inventory, and a self-report measure of mindfulness. Results: Clinically meaningful improvements were noted on measures of quality of life (Cohen d = 0.43) and perceived self-efficacy (Cohen d = 0.50) with smaller but still significant effects on measures of central executive aspects of working memory and regulation of attention. Conclusion: The MBSR program can be adapted for participants with mTBI. Improved performance on measures associated with improved quality of life and self-efficacy may be related to treatment directed at improving awareness and acceptance, thereby minimizing the catastrophic assessment of symptoms associated with mTBI and chronic disability. Additional research on the comparative effectiveness of the MBSR program for people with mTBI is warranted.	[Azulay, Joanne; Smart, Colette M.; Mott, Tasha; Cicerone, Keith D.] JFK Johnson Rehabil Inst, Edison, NJ USA; [Azulay, Joanne; Smart, Colette M.; Mott, Tasha] New Jersey Neurosci Inst, Edison, NJ USA; [Smart, Colette M.] Univ Victoria, Dept Psychol, Victoria, BC, Canada	Azulay, J (corresponding author), 2048 Oak Tree Rd, Edison, NJ 08820 USA.						Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bedard M, 2005, J COGN REHABIL, V23, P8, DOI DOI 10.1080/0963828031000090489; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Chambers R, 2008, COGNITIVE THER RES, V32, P303, DOI 10.1007/s10608-007-9119-0; Chiesa A, 2011, CLIN PSYCHOL REV, V31, P449, DOI 10.1016/j.cpr.2010.11.003; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; D'Zurilla TJ, 2002, SPSI R SOCIAL PROBLE; Delis DC, 2000, CALIFORNIA VERBAL LE; Evans S, 2008, J ANXIETY DISORD, V22, P716, DOI 10.1016/j.janxdis.2007.07.005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; Kabat-Zinn J, 1990, FULL CATASTROPHE LIV; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; KAPLAN KH, 1993, GEN HOSP PSYCHIAT, V15, P284, DOI 10.1016/0163-8343(93)90020-O; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lorig K., 1996, OUTCOME MEASURES HLT; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Rutherford WH, 1989, BRAIN INJURY, V10, P225; Sawechyn JM, J HEAD TRAUMA REHABI, V20, P301; Sayegh A, 2008, J NEUROL NEUROSRG PS, V81, P1; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; Tang YY, 2009, TRENDS COGN SCI, V13, P222, DOI 10.1016/j.tics.2009.01.009; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zylowska L, 2008, J ATTEN DISORD, V11, P737, DOI 10.1177/1087054707308502	58	69	70	2	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					323	331		10.1097/HTR.0b013e318250ebda			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900010	22688212				2021-06-18	
J	Mohan, K; Kecova, H; Hernandez-Merino, E; Kardon, RH; Harper, MM				Mohan, Kabhilan; Kecova, Helga; Hernandez-Merino, Elena; Kardon, Randy H.; Harper, Matthew M.			Retinal Ganglion Cell Damage in an Experimental Rodent Model of Blast-Mediated Traumatic Brain Injury	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						traumatic brain injury; traumatic optic neuropathy; pattern electroretinography; blast injury	AMYLOID PRECURSOR PROTEIN; VISUAL FUNCTION; AXONAL INJURY; MOUSE RETINA; HEAD-INJURY; MILD; EYE	PURPOSE. To evaluate retina and optic nerve damage following experimental blast injury. METHODS. Healthy adult mice were exposed to an overpressure blast wave using a custom-built blast chamber. The effects of blast exposure on retina and optic nerve function and structure were evaluated using the pattern electroretinogram (pERG), spectral domain optical coherence tomography (OCT), and the chromatic pupil light reflex. RESULTS. Assessment of the pupil response to light demonstrated decreased maximum pupil constriction diameter in blast-injured mice using red light or blue light stimuli 24 hours after injury compared with baseline in the eye exposed to direct blast injury. A decrease in the pupil light reflex was not observed chronically following blast exposure. We observed a biphasic pERG decrease with the acute injury recovering by 24 hours postblast and the chronic injury appearing at 4 months postblast injury. Furthermore, at 3 months following injury, a significant decrease in the retinal nerve fiber layer was observed using OCT compared with controls. Histologic analysis of the retina and optic nerve revealed punctate regions of reduced cellularity in the ganglion cell layer and damage to optic nerves. Additionally, a significant upregulation of proteins associated with oxidative stress was observed acutely following blast exposure compared with control mice. CONCLUSIONS. Our study demonstrates that decrements in retinal ganglion cell responses can be detected after blast injury using noninvasive functional and structural tests. These objective responses may serve as surrogate tests for higher CNS functions following traumatic brain injury that are difficult to quantify.	[Mohan, Kabhilan; Kardon, Randy H.; Harper, Matthew M.] Ctr Prevent & Treatment Visual Loss, Iowa City Vet Adm, Iowa City, IA 52242 USA; [Mohan, Kabhilan] Iowa State Univ, Dept Biomed Sci, Ames, IA USA; [Kecova, Helga; Hernandez-Merino, Elena] Iowa State Univ, Dept Vet Clin Sci, Ames, IA USA; [Kardon, Randy H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA	Harper, MM (corresponding author), Ctr Prevent & Treatment Visual Loss, Dept Vet Affairs, 601 Highway 6 W, Iowa City, IA 52242 USA.	kabhilan@gmail.com; matthew.harper@va.gov		Kardon, Randy/0000-0002-3173-7123; Harper, Matthew/0000-0003-3395-2406	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development; Rehabilitation Research and Development Center for Prevention and Treatment of Visual Loss; Rehabilitation Research and Development Career Development Award; RRD Merit Study Award [1I01RX000427-01]; Iowa State University T32 National Institutes of Health Fellowship awardsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Iowa State University Biotechnology Fund; Veterans AffairsUS Department of Veterans Affairs [I01RX000427] Funding Source: NIH RePORTER	Supported by the Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Rehabilitation Research and Development Center for Prevention and Treatment of Visual Loss; a Rehabilitation Research and Development Career Development Award (MMH); an RRD Merit Study Award (1I01RX000427-01); Iowa State University T32 National Institutes of Health Fellowship awards; and The Iowa State University Biotechnology Fund. The authors alone are responsible for the content and writing of the paper.	[Anonymous], 2006, CLIN PRACT GUID REC; Bach M, 2006, INVEST OPHTH VIS SCI, V47, P4881, DOI 10.1167/iovs.05-0875; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gaetz M, 2000, BRAIN INJURY, V14, P815; Goldstein L.E., 2012, SCI TRANSL MED, V4; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Kardon R, 2011, OPHTHALMOLOGY, V118, P376, DOI 10.1016/j.ophtha.2010.06.033; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kretschmer WB, 2011, J ORAL MAXIL SURG, V69, P861, DOI 10.1016/j.joms.2010.05.024; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Mohan K, 2012, VET OPHTHALMOL, V15, P94, DOI 10.1111/j.1463-5224.2012.01034.x; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; Risling M, 2002, FOIR0757SE SWED DEF, P1; SOTA, 2008, STAT ART 9 TRAUM BRA; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Zunic Gordana, 2005, Vojnosanit Pregl, V62, P273, DOI 10.2298/VSP0504273Z	32	69	69	0	12	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404			INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	MAY	2013	54	5					3440	3450		10.1167/iovs.12-11522			11	Ophthalmology	Ophthalmology	173YC	WOS:000321118300042	23620426	Green Published			2021-06-18	
